PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kadhim, MA				Kadhim, MA			Role of genetic background in induced instability	ONCOGENE			English	Article						genetic predisposition; induced genomic instability; radiation; carcinogenesis	INDUCED GENOMIC INSTABILITY; INDUCED CHROMOSOMAL INSTABILITY; HUMAN LYMPHOBLASTOID-CELLS; HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; IONIZING-RADIATION; DNA-DAMAGE; LETHAL MUTATIONS; MAMMALIAN-CELLS; CANCER-PATIENTS	Genomic instability is effectively induced by ionizing radiation. Recently, evidence has accumulated supporting a relationship between genetic background and the radiation-induced genomic instability phenotype. This is possibly due to alterations in proteins responsible for maintenance of genomic integrity or altered oxidative metabolism. Studies in human cell lines, human primary cells, and mouse models have been performed predominantly using high linear energy transfer (LET) radiation, or high doses of low LET radiation. The interplay between genetics, radiation response, and genomic instability has not been fully determined at low doses of low LET radiation. However, recent studies using low doses of low LET radiation suggest that the relationship between genetic background and radiation-induced genomic instability may be more complicated than these same relationships at high LET or high doses of low LET radiation. The complexity of this relationship at low doses of low LET radiation suggests that more of the population may be at risk than previously recognized and may have implications for radiation risk assessment.	MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England		Kadhim, MA (corresponding author), MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England.	m.kadhim@har.mrc.ac.uk						Amundson SA, 1999, RADIAT RES, V152, P225, DOI 10.2307/3580321; An Mi-Young, 2002, J Vet Sci, V3, P213; Ban N, 2002, RADIAT RES, V158, P69, DOI 10.1667/0033-7587(2002)158[0069:CAORIL]2.0.CO;2; Baria K, 2002, INT J RADIAT BIOL, V78, P341, DOI 10.1080/09553000110117359; BAVERSTOCK K, 2003, UNPUB; Bouffler SD, 1996, RADIAT RES, V146, P349, DOI 10.2307/3579467; Boulton E, 2001, INT J RADIAT BIOL, V77, P21, DOI 10.1080/0955300010001880; Chang WP, 1997, LANCET, V350, P330, DOI 10.1016/S0140-6736(97)11056-X; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; *COMM BIOL EFF ION, 1990, EFF EXP LOW LEV ION; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DiMajo V, 1996, RADIAT RES, V146, P81, DOI 10.2307/3579399; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Green LM, 2001, RADIAT RES, V155, P32, DOI 10.1667/0033-7587(2001)155[0032:ROTFCT]2.0.CO;2; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Harper K, 1997, EXP HEMATOL, V25, P263; HOLMBERG K, 1993, MUTAT RES, V286, P321, DOI 10.1016/0027-5107(93)90197-N; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; Honma M, 2000, MOL CARCINOGEN, V28, P203, DOI 10.1002/1098-2744(200008)28:4<203::AID-MC3>3.0.CO;2-1; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kadhim MA, 1998, INT J RADIAT BIOL, V73, P143, DOI 10.1080/095530098142518; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KADHIM MA, 1994, LANCET, V344, P987, DOI 10.1016/S0140-6736(94)91643-8; Kadhim MA, 1999, BRIT J HAEMATOL, V105, P673, DOI 10.1046/j.1365-2141.1999.01428.x; Kadhim MA, 1996, INT J RADIAT BIOL, V69, P167, DOI 10.1080/095530096145995; Kang CM, 2003, RADIAT RES, V159, P312, DOI 10.1667/0033-7587(2003)159[0312:PBFIRE]2.0.CO;2; Lavin MF, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P306; Leger C, 2002, CARCINOGENESIS, V23, P1631, DOI 10.1093/carcin/23.10.1631; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Limoli CL, 2001, BRIT J CANCER, V84, P489, DOI 10.1054/bjoc.2000.1604; Lindholm C, 1999, INT J RADIAT BIOL, V75, P921, DOI 10.1080/095530099139683; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; LORIMORE SA, 1993, INT J RADIAT BIOL, V63, P655, DOI 10.1080/09553009314450851; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MAJOR IR, 1979, BRIT J CANCER, V40, P903, DOI 10.1038/bjc.1979.284; MAJOR IR, 1978, NATURE, V272, P455, DOI 10.1038/272455a0; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; McIlrath J, 2003, INT J RADIAT BIOL, V79, P27, DOI 10.1080/0955300021000038635; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill CE, 1999, CARCINOGENESIS, V20, P2273, DOI 10.1093/carcin/20.12.2273; Okayasu R, 2000, CANCER RES, V60, P4342; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Papworth R, 2001, BRIT J CANCER, V84, P776, DOI 10.1054/bjoc.2000.1692; Plumb M, 1998, INT J RADIAT BIOL, V74, P711, DOI 10.1080/095530098140989; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Rodgers BE, 2001, ENVIRON TOXICOL CHEM, V20, P2830, DOI 10.1002/etc.5620201223; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; Salomaa S, 2002, RADIAT RES, V158, P591, DOI 10.1667/0033-7587(2002)158[0591:SCAITL]2.0.CO;2; Salomaa S, 1998, INT J RADIAT BIOL, V74, P771, DOI 10.1080/095530098141050; Sankaranarayanan K, 2001, HEALTH PHYS, V80, P363, DOI 10.1097/00004032-200104000-00013; Sankaranarayanan K, 2001, RADIAT RES, V156, P648, DOI 10.1667/0033-7587(2001)156[0648:IOCPAR]2.0.CO;2; Schwartz JL, 2001, GENE CHROMOSOME CANC, V30, P236, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1085>3.3.CO;2-7; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Smith L, 2001, P NATL ACAD SCI USA, V98, P13300, DOI 10.1073/pnas.241355098; Smith LE, 1998, MUTAGENESIS, V13, P435, DOI 10.1093/mutage/13.5.435; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2001, INT J RADIAT BIOL, V77, P409, DOI 10.1080/09553000010028476; Weil MM, 2001, ONCOGENE, V20, P4409, DOI 10.1038/sj.onc.1204589; Yu YJ, 2001, CANCER RES, V61, P1820	65	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					6994	6999		10.1038/sj.onc.1206883	http://dx.doi.org/10.1038/sj.onc.1206883			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557803				2022-12-28	WOS:000185903900003
J	Muller, S; Kunkel, P; Lamszus, K; Ulbricht, U; Lorente, GA; Nelson, AM; von Schack, D; Chin, DJ; Lohr, SC; Westphal, M; Melcher, T				Muller, S; Kunkel, P; Lamszus, K; Ulbricht, U; Lorente, GA; Nelson, AM; von Schack, D; Chin, DJ; Lohr, SC; Westphal, M; Melcher, T			A role for receptor tyrosine phosphatase zeta in glioma cell migration	ONCOGENE			English	Article						glioblastoma; custom cDNA array; RNA interference; migration; receptor tyrosine phosphatase zeta; pleiotrophin	ANTIBODY 81C6 TREATMENT; GENE-EXPRESSION; MAMMALIAN-CELLS; TENASCIN-C; BRAIN; ADHESION; ZETA/BETA; BETA; IDENTIFICATION; SUPPRESSION	Glioblastomas (GBM) are the most frequent and malignant human brain tumor type. Typically striking in adulthood, tumor progression is rapid, relentless, and ultimately leads to the patient's death within a year of diagnosis. The identification of transcriptionally regulated genes can lead to the discovery of targets for antibody or small-molecule-mediated therapy, as well as diagnostic markers. We prepared cDNA arrays that are specifically enriched for genes expressed in human brain tumors and pro. led gene expression patterns in 14 individual tumor samples. Out of 25 000 clones arrayed, greater than 200 genes were found transcriptionally induced in glioblastomas compared to normal human brain tissue including the receptor tyrosine phosphatasezeta (RPTPzeta) and one of its ligands, pleiotrophin (Ptn). We confirmed by Northern blot analysis and immunohistochemistry that RPTPzeta is enriched in tumor samples. Knockdown of RPTPzeta by RNA interference studies established a functional role of RPTPzeta in cell migration. Our results suggest a novel function for RPTPzeta in regulating glioblastoma cell motility and point to the therapeutic utility of RPTPzeta as a target for antibody-mediated therapy of brain tumors.	AGY Therapeut Inc, San Francisco, CA 94080 USA; Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany	University of Hamburg	Muller, S (corresponding author), AGY Therapeut Inc, 290 Utah Ave, San Francisco, CA 94080 USA.	sabine@agyinc.com						Adamsky K, 2001, ONCOGENE, V20, P609, DOI 10.1038/sj.onc.1204119; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bigner DD, 1998, J CLIN ONCOL, V16, P2202, DOI 10.1200/JCO.1998.16.6.2202; Brown MT, 1996, CLIN CANCER RES, V2, P963; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Davis FG, 2001, NEURO-ONCOLOGY, V3, P152, DOI 10.1093/neuonc/3.3.152; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dirks PB, 1997, NEUROSURGERY, V40, P1000, DOI 10.1097/00006123-199705000-00025; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gary S C, 2000, Clin Neurosurg, V47, P72; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Huang HT, 2000, CANCER RES, V60, P6868; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Kim CH, 2000, SURG NEUROL, V54, P235, DOI 10.1016/S0090-3019(00)00307-4; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Menon PM, 2000, INT J ONCOL, V17, P683; Oz Buge, 2000, Pathology and Oncolgy Research, V6, P118; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Rhee CH, 1999, ONCOGENE, V18, P2711, DOI 10.1038/sj.onc.1202623; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; WESTPHAL M, 1994, ACTA NEUROCHIR, V126, P17, DOI 10.1007/BF01476489; Zhang H, 1998, J NEUROSCI, V18, P2370	30	101	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6661	6668		10.1038/sj.onc.1206763	http://dx.doi.org/10.1038/sj.onc.1206763			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555979				2022-12-28	WOS:000185799300001
J	Fukuhara, H; Masvuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y				Fukuhara, H; Masvuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y			Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg	ONCOGENE			English	Article						tumor suppressor gene; lung cancer; TSLC1; MPP3; discs large	SEPTATE JUNCTIONS; BINDING INTERFACE; GLYCOPHORIN-C; PDZ DOMAINS; GENE; CANCER; PROTEIN; PROMOTER; FAMILY; HYPERMETHYLATION	We have previously identified the tumor suppressor in lung cancer 1 (TSLC1) gene as a novel tumor suppressor in human non-small cell lung cancer (NSCLC) by functional complementation. TSLC1 encodes a membrane glycoprotein belonging to an immunoglobulin superfamily and participates in cell adhesion. A truncating mutation of the TSLC1 corresponding to its cytoplasmic domain in a primary NSCLC tumor suggests that this domain is important for tumor suppressor activity. Here, we report that TSLC1 directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large (Dlg). This interaction was dependent on the presence of a PDZ-binding motif at the carboxyl terminus of TSLC1. Furthermore, TSLC1 and MPP3 were colocalized at the cell - cell attachment sites in both a low and a high cell density. The MPP3 gene was expressed in normal lung as well as in many tissues examined except for peripheral blood lymphocytes but lost its expression in one of the nine NSCLC cell lines. These results suggest that TSLC1 and MPP3 are involved in the same cascade of cell - cell interaction, and that the disruption of this cascade might lead cells to malignant growth and tumor formation in lung cancer.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Sch Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	National Cancer Center - Japan; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.res.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; BRYANT PJ, 1990, J CELL SCI, P169; FEHON RG, 1994, DEVELOPMENT, V120, P545; FONG KM, 1995, CANCER RES, V55, P4268; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Harris BZ, 2001, J CELL SCI, V114, P3219; Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x; James P, 1996, GENETICS, V144, P1425; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yageta M, 2002, CANCER RES, V62, P5129	29	66	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6160	6165		10.1038/sj.onc.1206744	http://dx.doi.org/10.1038/sj.onc.1206744			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679854				2022-12-28	WOS:000185506200005
J	Chamulitrat, W; Schmidt, R; Tomakidi, P; Stremmel, W; Chunglok, W; Kawahara, T; Rokutan, K				Chamulitrat, W; Schmidt, R; Tomakidi, P; Stremmel, W; Chunglok, W; Kawahara, T; Rokutan, K			Association of gp91phox homolog Nox1 with anchorage-independent growth and MAP kinase-activation of transformed human keratinocytes	ONCOGENE			English	Article						redox-signaling; human gingival keratinocytes; anchorage-independent growth; gp91phox homologs; Nox1	SMOOTH-MUSCLE CELLS; NADPH OXIDASE; IN-VITRO; MALIGNANT TRANSFORMATION; SUPEROXIDE GENERATION; RAS TRANSFORMATION; EPITHELIAL-CELLS; FIBROBLASTS; EXPRESSION; LOCALIZATION	Among five members of the NADPH oxidase (Nox) family, Nox1 confers mitogenic properties and is implicated to participate in the process of cell transformation. We have established two phenotypes of carcinogenesis model by ethanol treatment of human gingival keratinocytes immortalized with E6/E7 oncogenes of human papillomavirus type16: immortalized (EPI) nontransformed cells with epithelium-like morphology and more advanced transformed (FIB) cells with spindle fibroblastic-shape morphology. FIB membranes possessed a 63-kDa Nox1 protein at higher levels and exhibited 2.8-fold higher capability for superoxide and hydroxyl radical generation, compared with EPI membranes. Both EPI and FIB cells expressed more abundant Nox1 protein at a proliferating stage than that at a quiescent confluent phase. Immunofluorescence staining with an anti-Nox1 antibody showed that immunoreactive materials were distributed in the whole interior of both types of cells, while they were preferentially localized in the nuclei of FIB cells. Nuclei isolated from EPI and FIB cells contained a 63 kDa-Nox1 protein. Compared with EPI cells, FIB cells expressed elevated levels of Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase proteins. Furthermore, JNK2 was constitutively phosphorylated in FIB cells. Together, our data strongly implicate Nox1 in redox-mediated signaling related to cellular activation of human keratinocytes at a more advanced stage of transformation.	Univ Heidelberg, Univ Clin Hosp, Dept Gastroenterol & Infect Dis, D-69115 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Dept Appl Tumorvirol, D-69120 Heidelberg, Germany; Univ Heidelberg, Sch Dent, Dept Orthodont, D-69120 Heidelberg, Germany; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand; Univ Tokushima, Sch Med, Dept Nutr, Tokushima 770, Japan	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Mahidol University; Tokushima University	Chamulitrat, W (corresponding author), Univ Heidelberg, Univ Clin Hosp, Dept Gastroenterol & Infect Dis, Bergheimer Str 58, D-69115 Heidelberg, Germany.	Walee_Chamulitrat@med.uni-heidelberg.de		Stremmel, Wolfgang/0000-0002-8545-1753				Aplin AE, 2002, J CELL SCI, V115, P2781; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; Chamulitrat W, 2003, EUR J CELL BIOL, V82, P313, DOI 10.1078/0171-9335-00317; Chamulitrat W, 1999, FREE RADICAL BIO MED, V27, P411, DOI 10.1016/S0891-5849(99)00088-X; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chiu C, 2001, INT J MOL MED, V8, P251; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Goldman R, 1999, BBA-MOL CELL BIOL L, V1438, P349, DOI 10.1016/S1388-1981(99)00066-9; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones RD, 2000, FREE RADICAL BIO MED, V29, P416, DOI 10.1016/S0891-5849(00)00320-8; KUROKI T, 1993, JPN J CANCER RES, V84, P1091, DOI 10.1111/j.1349-7006.1993.tb02806.x; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; PARK NH, 1995, ONCOGENE, V10, P2145; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sashiyama H, 2002, CANCER LETT, V177, P21, DOI 10.1016/S0304-3835(01)00771-6; Schimmel M, 2002, ONCOGENE, V21, P5886, DOI 10.1038/sj.onc.1205740; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yang XL, 1998, MOL CARCINOGEN, V22, P95, DOI 10.1002/(SICI)1098-2744(199806)22:2<95::AID-MC4>3.3.CO;2-Y; Yoshida LS, 2002, BIOCHEM BIOPH RES CO, V296, P1322, DOI 10.1016/S0006-291X(02)02059-4	40	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6045	6053		10.1038/sj.onc.1206654	http://dx.doi.org/10.1038/sj.onc.1206654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955083				2022-12-28	WOS:000185137800013
J	Fei, PW; El-Deiry, WS				Fei, PW; El-Deiry, WS			P53 and radiation responses	ONCOGENE			English	Review						checkpoint; IR; DSB; p53	DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; WILD-TYPE P53; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR P53; IONIZING-RADIATION; MAMMALIAN-CELLS; P53-DEPENDENT APOPTOSIS; GAMMA-IRRADIATION	Cells have evolved elaborate mechanisms (checkpoints) to monitor genomic integrity in order to ensure the high-fidelity transmission of genetic information. Cells harboring defects in checkpoint pathways respond to DNA damage improperly, which in turn may enhance the rate of cancer development. Ionizing radiation (IR) primarily leads to double-strand DNA breaks (DSBs), which activate DNA damage checkpoints to initiate signals ultimately leading to a binary decision between cell death and cell survival. TP53 has been recognized as an important checkpoint protein, functioning mainly through transcriptional control of target genes that influence multiple response pathways and leading to the diversity of responses to IR in mammalian cells. We review how the tumor suppressor P53 is involved in the complex response to IR to enforce the cell's fate to live by inducing the growth arrest coupled to DNA damage repair or to die by inducing irreversible growth arrest or apoptosis. Moreover, recent insights have emerged in our understanding of how P53 modulates radiosensitivity in tissues following IR as well as its role in sensitizing cells to chemo- and radiotherapy. The P53 pathway remains an attractive target for exploitation in the war on cancer.	Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat,Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat,Dept Med, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Appella E, 2000, PATHOL BIOL, V48, P227; Attardi LD, 2000, GENE DEV, V14, P704; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Bae I, 1996, CANCER RES, V56, P840; BAE IS, 1995, CANCER RES, V55, P2387; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Benchimol S, 2001, CELL DEATH DIFFER, V8, P1049, DOI 10.1038/sj.cdd.4400918; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Chiou SH, 2001, J IMMUNOL, V167, P4098, DOI 10.4049/jimmunol.167.7.4098; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DeSimone JN, 2000, RADIAT RES, V153, P131, DOI 10.1667/0033-7587(2000)153[0131:PCCAII]2.0.CO;2; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKHODAIRY KA, 1992, J MICROENCAPSUL, V9, P365, DOI 10.3109/02652049209021251; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fei PW, 2002, CANCER RES, V62, P7316; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GANNON JV, 1991, NATURE, V349, P802; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; HARTWELL D, 1994, IMMUNOL LETT, V43, P15, DOI 10.1016/0165-2478(94)00144-8; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hui T, 2002, NEOPLASIA, V4, P171, DOI 10.1038/sj.neo.7900219; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jeggo PA, 2002, RADIAT PROT DOSIM, V99, P117, DOI 10.1093/oxfordjournals.rpd.a006740; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Jongmans W, 1998, INT J RADIAT BIOL, V74, P287, DOI 10.1080/095530098141438; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Larner JM, 1997, CANCER SURV, V29, P25; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; Liu L, 1999, MOL CELL BIOL, V19, P1202; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MacCallum DE, 1996, ONCOGENE, V13, P2575; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Mallya SM, 1998, INT J RADIAT BIOL, V74, P231, DOI 10.1080/095530098141618; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MCMILLAN TJ, 1994, INT J RADIAT BIOL, V65, P49, DOI 10.1080/09553009414550071; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Michelson R, 1999, NAT CELL BIOL, V1, pE177, DOI 10.1038/15614; MIHARA M, 2003, MOL CELL; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Painter R B, 1985, Kroc Found Ser, V19, P89; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shieh SY, 2000, GENE DEV, V14, P289; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Teyssier F, 1999, B CANCER, V86, P345; TLSTY TD, 2002, CANCER CELL, P2; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Watanabe E, 2002, J BIOMED MATER RES, V62, P540, DOI 10.1002/jbm.10357; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yan T, 2001, CANCER RES, V61, P8290; Yount GL, 1996, CANCER RES, V56, P500; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	159	394	424	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5774	5783		10.1038/sj.onc.1206677	http://dx.doi.org/10.1038/sj.onc.1206677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947385				2022-12-28	WOS:000185086100005
J	Lammering, G; Hewit, TH; Valerie, K; Contessa, JN; Amorino, GP; Dent, P; Schmidt-Ullrich, RK				Lammering, G; Hewit, TH; Valerie, K; Contessa, JN; Amorino, GP; Dent, P; Schmidt-Ullrich, RK			EGFRvIII-mediated radioresistance through a strong cytoprotective response	ONCOGENE			English	Article						radiation; EGFRvIII; EGFR; MAP kinase; PI3 kinase; AKT	GROWTH-FACTOR RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; MAMMARY-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; GLIOMA-CELLS; KINASE; GENE	The constitutively active, truncated epidermal growth factor receptor EGFRvII lacks the ability of EGF binding due to a deletion of the NH2-terminal domain. EGFRvIII confers increased tumorigenicity, is coexpressed with EGFR wild type (wt) in human carcinoma and malignant glioma cells when grown as xenografts, but is not expressed in vitro. The effects of EGFRvIII expression on cellular radiation responses were studied in Chinese hamster ovary (CHO) cells transfected with plasmids expressing EGFRvIII (CHO.EGFRvIII) or EGFRwt (CHO.EGFRwt). CHO cells expressing similar levels of either receptor were employed to define their roles in response to EGF and ionizing radiation. EGF activated EGFRwt with no effect on EGFRvIII. In contrast, a single radiation exposure of 2 Gy resulted in a 2.8- and 4.3-fold increase in Tyr phosphorylation of EGFRwt and EGFRvIII, respectively. Downstream consequences of this radiation-induced activation were examined by inhibiting EGFRwt and EGFRvIII with AG1478 (kinase inhibitor). The radiation-induced 8.5-fold activation of the pro-proliferative mitogen-activated protein kinase and the 3.2-fold stimulation of the antiapoptotic AKT/phosphatidylinositol-3-kinase pathways by EGFRvII far exceeded that in CHO.EGFR wt cells. Thus, based on colony formation and apoptosis assays, EGFRvIII expression conferred a stronger cytoprotective response to radiation than EGFRwt, resulting in relative radioresistance. Therefore, disabling EGFRvIII in addition to EGFRwt needs to be considered in any therapeutic approach aimed at targeting EGFR for tumor cell radiosensitization.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany	Virginia Commonwealth University; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, POB 980058, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA65896, P01 CA72955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Frederick L, 2000, CANCER RES, V60, P1383; Han YC, 1996, CANCER RES, V56, P3859; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965	31	72	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5545	5553		10.1038/sj.onc.1206788	http://dx.doi.org/10.1038/sj.onc.1206788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944901				2022-12-28	WOS:000184865900002
J	Berton, TR; Matsumoto, T; Page, A; Conti, CJ; Deng, CX; Jorcano, JL; Johnson, DG				Berton, TR; Matsumoto, T; Page, A; Conti, CJ; Deng, CX; Jorcano, JL; Johnson, DG			Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues	ONCOGENE			English	Article						BRCA1; Cre-lox; epithelium; E2F1	SUPPRESSOR GENE BRCA1; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; CENTROSOME AMPLIFICATION; MESSENGER-RNA; BREAST; EXPRESSION; P53	The BRCA1 tumor-suppressor protein has been implicated in the regulation of transcription, DNA repair, proliferation, and apoptosis. BRCA1 is expressed in many proliferative tissues and this is at least in part due to E2F-dependent transcriptional control. In this study, inactivation of a conditional murine Brca1 allele was achieved in a variety of epithelial tissues via expression of the Cre recombinase under the control of a keratin 5 (K5) promoter. The K5 Cre:Brca1 conditional knockout mice exhibited modest epidermal hyperproliferation, increased apoptosis, and were predisposed to developing tumors in the skin, the inner ear canal, and the oral epithelium after 1 year of age. Overexpression of the E2F1 transcription factor in K5 Cre:Brca1 conditional knockout mice dramatically accelerated tumor development. In addition, Brca1 heterozygous female mice that had elevated E2F1 expression developed tumors of the reproductive tract at high incidence. These findings demonstrate that in mice Brca1 functions as a tumor suppressor in other epithelial tissues in addition to the mammary gland. Moreover, inactivation of Brca1 is shown to cooperate with deregulation of the Rb-E2F1 pathway to promote tumorigenesis.	Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; CIEMAT, E-28040 Madrid, Spain; NIDDKD, Biochem & Metab Lab, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Johnson, DG (corresponding author), Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	djohnson@sprd1.mdacc.tmc.edu	deng, chuxia/N-6713-2016	Johnson, David/0000-0002-6223-1790; Page, Angustias/0000-0002-0231-8536	NATIONAL CANCER INSTITUTE [T32CA009480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA9480] Funding Source: Medline; NIEHS NIH HHS [U01 ES11047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baldwin RL, 2000, CANCER RES, V60, P5329; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; Esteller M, 2001, CANCER RES, V61, P3225; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hill ADK, 1997, BRIT J SURG, V84, P1334; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Johannsson O, 1999, EUR J CANCER, V35, P1248, DOI 10.1016/S0959-8049(99)00135-5; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Randrianarison V, 2001, CANCER GENE THER, V8, P759, DOI 10.1038/sj.cgt.7700366; Rao VN, 1996, ONCOGENE, V12, P523; Rhei E, 1998, CANCER RES, V58, P3193; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMEDTS F, 1992, AM J PATHOL, V140, P601; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tong D, 2000, INT J CANCER, V88, P319, DOI 10.1002/1097-0215(20001015)88:2<319::AID-IJC27>3.0.CO;2-X; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	74	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5415	5426		10.1038/sj.onc.1206825	http://dx.doi.org/10.1038/sj.onc.1206825			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934101				2022-12-28	WOS:000184735000006
J	Yeh, CT; Lu, SC; Tseng, IC; Lai, HY; Tsao, ML; Huang, SF; Liaw, YF				Yeh, CT; Lu, SC; Tseng, IC; Lai, HY; Tsao, ML; Huang, SF; Liaw, YF			Antisense overexpression of BMAL2 enhances cell proliferation	ONCOGENE			English	Article						hepatocellular carcinoma; BMAL2; antisense; cell cycle; TNF-alpha; caspase-3	DIFFERENTIALLY EXPRESSED GENES; HEPATOCELLULAR-CARCINOMA; HEPATITIS-C; NUCLEAR-LOCALIZATION; IDENTIFICATION; PROTEIN; CLONING; CARCINOGENESIS; MICROARRAY; APOPTOSIS	To identify genes that are frequently downregulated in hepatocellular carcinoma (HCC), a panel of putative underexpressed genes was first established by an in-house cDNA macroarray method. Two different assays, semi-quantitative RT-PCR combined with Northern analysis and customized cDNA microarray analysis, were used to screen through these genes and the results were compared. Several genes, some with unknown function, were confirmed to be downregulated by both the methods. The effect of a downregulated gene, BMAL2, on cell proliferation was examined. Overexpression of antisense BMAL2 RNA in 293EBNA cells resulted in reduced cell cycle time, increased plating efficiency in soft agar, diminished TNF-alpha-induced increment of CPP32/caspase-3 activity, and a reduced proportion of cells in the G2 phase with a concomitantly increased proportion of cells in the S phase. In conclusion, by combining three different methods, we have obtained a panel of frequently down regulated genes in HCC, including BMAL2. Antisense overexpression of BMAL2 enhances cell proliferation.	Chang Gung Mem Hosp, Liver Res Unit, Taipei 10591, Taiwan; Chang Gung Univ, Coll Med, Dept Pathol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Yeh, CT (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	chauting@adm.cgmh.org.tw	Liaw, Yun-Fan/B-4305-2009; Huang, Shiu-Feng Kathy/E-3977-2010; Tseng, I-Chu/C-1936-2013	Tseng, I-Chu/0000-0001-8522-6524				BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; Boige V, 1997, CANCER RES, V57, P1986; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; Gerber AN, 1996, MOL CELL BIOL, V16, P3901; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hung SC, 2001, P NATL ACAD SCI USA, V98, P1865, DOI 10.1073/pnas.031584698; Iizuka N, 2002, CANCER RES, V62, P3939; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V275, P493, DOI 10.1006/bbrc.2000.3248; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Norton JD, 2000, J CELL SCI, V113, P3897; Okabe H, 2001, CANCER RES, V61, P2129; Okano T, 2001, GENES CELLS, V6, P825, DOI 10.1046/j.1365-2443.2001.00462.x; REDDY P, 1986, CELL, V46, P53, DOI 10.1016/0092-8674(86)90859-7; Scuric Z, 1998, HEPATOLOGY, V27, P943, DOI 10.1002/hep.510270408; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; WU GS, 1995, LIFE SCI, V57, P1077, DOI 10.1016/0024-3205(95)02053-L; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yeh CT, 2001, J VIROL, V75, P11017, DOI 10.1128/JVI.75.22.11017-11024.2001; Yeh CT, 1997, J GEN VIROL, V78, P2761, DOI 10.1099/0022-1317-78-11-2761; YEH CT, 1993, P NATL ACAD SCI USA, V90, P6459, DOI 10.1073/pnas.90.14.6459	39	26	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5306	5314		10.1038/sj.onc.1206674	http://dx.doi.org/10.1038/sj.onc.1206674			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917632				2022-12-28	WOS:000184734900010
J	Mayer, F; Stoop, H; Sen, S; Bokemeyer, C; Oosterhuis, JW; Looijenga, LH				Mayer, F; Stoop, H; Sen, S; Bokemeyer, C; Oosterhuis, JW; Looijenga, LH			Aneuploidy of human testicular germ cell tumors is associated with amplification of centrosomes	ONCOGENE			English	Article						germ cell tumors; aneuploidy; centrosomes; STK15	COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA IN-SITU; ENDODERMAL SINUS TUMORS; SPERMATOCYTIC SEMINOMA; MITOTIC KINASE; CHROMOSOMAL INSTABILITY; ALKALINE-PHOSPHATASE; CYTOGENETIC ANALYSIS; CANCER PROGRESSION; FLOW-CYTOMETRY	Testicular germ cell tumors occur in three age groups. Seminomas and nonseminomas of adults, including mature teratomas, and the precursor carcinoma in situ (CIS) are aneuploid. This also holds true for yolk sac tumors of newborn and infants, while the mature teratomas of this age are diploid. In contrast, spermatocytic seminomas occurring in the elderly contain both diploid and polyploid cells. Aneuploidy has been associated with centrosome aberrations, sometimes related to overexpression of STK15. Aneuploidy of non-neoplastic germ cells has been demonstrated in the context of male infertility, a risk factor for the development of seminoma/nonseminoma. We investigated aneuploidy, centrosome aberrations and the role of STK15 in different types of testicular germ cell tumors as well as in normal and disturbed spermatogenesis. The aneuploid seminomas and nonseminomas tumors (including CIS) showed increased numbers of centrosomes, without STK15 amplification or overexpression. Four out of six infantile teratomas had normal centrosomes, the remaining two and an infantile yolk sac tumor showed a heterogeneous pattern of cells with normal or amplified centrosomes. Spermatocytic seminomas had two, four or eight centrosomes. Germ cells in seminiferous tubules with disturbed spermatogenesis shared both aneuploidy and centrosome abnormalities with seminomas/nonseminomas and showed a more intense STK15 staining than those with normal spermatogenesis and CIS. Therefore, aneuploidy of testicular germ cell tumors is associated with amplified centrosomes probably unrelated to STK15.	Dr Daniel Den Hoed Canc Ctr, Pathol Lab Expt Pathooncol, Josophine Nefkens Inst, Erasmus Med Ctr, NL-3000 DR Rotterdam, Netherlands; Med Univ Klin Tubingen, Abt Onkol Hamatol Immunol & Rheumatol, D-72076 Tubingen, Germany; Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Texas System; UTMD Anderson Cancer Center	Looijenga, LH (corresponding author), Dr Daniel Den Hoed Canc Ctr, Pathol Lab Expt Pathooncol, Josophine Nefkens Inst, Erasmus Med Ctr, Bldg Be Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.		Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911				Acar H, 2000, UROL INT, V64, P202, DOI 10.1159/000030531; Burke A, 1993, J UROL PATHOL, V1, P21; CLAUSEN OPF, 1991, CYTOMETRY, V12, P77, DOI 10.1002/cyto.990120111; CUMMINGS OW, 1994, HUM PATHOL, V25, P54, DOI 10.1016/0046-8177(94)90171-6; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; EBLE JN, 1994, HUM PATHOL, V25, P1035, DOI 10.1016/0046-8177(94)90062-0; ELNAGGAR AK, 1992, AM J SURG PATHOL, V16, P611, DOI 10.1097/00000478-199206000-00009; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; FLOYD C, 1988, CANCER-AM CANCER SOC, V61, P409, DOI 10.1002/1097-0142(19880115)61:2<409::AID-CNCR2820610234>3.0.CO;2-6; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GILLIS AJM, 1994, LAB INVEST, V71, P874; GIWERCMAN A, 1993, LANCET, V341, P384, DOI 10.1016/0140-6736(93)90199-Q; GIWERCMAN A, 1992, SCAND J UROL NE S148, V26, P1; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Goepfert TM, 2002, CANCER RES, V62, P4115; Gustafson LM, 2000, LARYNGOSCOPE, V110, P1798; HIGGINS MJ, 1985, CHROMOSOMA, V93, P77, DOI 10.1007/BF01259449; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Jacobsen R, 2000, BMJ-BRIT MED J, V321, P789, DOI 10.1136/bmj.321.7264.789; Jacobsen R, 2000, HUM REPROD, V15, P1958, DOI 10.1093/humrep/15.9.1958; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Lahdetie J, 1997, AM J MED GENET, V71, P115; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOIJENGA LHJ, 1994, LAB INVEST, V71, P490; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; LOOIJENGA LHJ, 1991, LAB INVEST, V64, P113; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; MATOSKA J, 1990, AM J CLIN PATHOL, V94, P89, DOI 10.1093/ajcp/94.1.89; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Moller H, 1999, BMJ-BRIT MED J, V318, P559, DOI 10.1136/bmj.318.7183.559; Mostert M, 2000, LAB INVEST, V80, P1055, DOI 10.1038/labinvest.3780110; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1998, HISTOLOGICAL TYPING; MULLER J, 1987, INT J ANDROL, V10, P147, DOI 10.1111/j.1365-2605.1987.tb00176.x; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Perlman EJ, 2000, J PEDIAT HEMATOL ONC, V22, P100, DOI 10.1097/00043426-200003000-00003; PERLMAN EJ, 1994, PEDIATR PATHOL, V14, P695, DOI 10.3109/15513819409023342; Pihan GA, 2001, CANCER RES, V61, P2212; Robbins WA, 1997, NAT GENET, V16, P74, DOI 10.1038/ng0597-74; Roelofs H, 1999, J PATHOL, V189, P236; ROSAI J, 1969, CANCER-AM CANCER SOC, V24, P103, DOI 10.1002/1097-0142(196907)24:1<103::AID-CNCR2820240114>3.0.CO;2-1; Rosenberg C, 1997, CYTOMETRY, V29, P113, DOI 10.1002/(SICI)1097-0320(19971001)29:2<113::AID-CYTO3>3.0.CO;2-E; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, GENE CHROMOSOME CANC, V23, P286, DOI 10.1002/(SICI)1098-2264(199812)23:4<286::AID-GCC2>3.0.CO;2-6; SCULLY RE, 1961, CANCER-AM CANCER SOC, V14, P788, DOI 10.1002/1097-0142(199007/08)14:4<788::AID-CNCR2820140414>3.0.CO;2-3; SCULLY RE, 1978, TUMORS OVARY MALDEVE, P226; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shi Q, 2000, CYTOGENET CELL GENET, V90, P79, DOI 10.1159/000015668; Stoop H, 2001, LAB INVEST, V81, P919, DOI 10.1038/labinvest.3780302; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; TALERMAN A, 1974, J UROLOGY, V112, P212, DOI 10.1016/S0022-5347(17)59689-5; Tatsuka M, 1998, CANCER RES, V58, P4811; TRUE LD, 1988, AM J SURG PATHOL, V12, P75, DOI 10.1097/00000478-198802000-00001; Van Dyk Q, 2000, HUM REPROD, V15, P1529; vanEchten J, 1995, CANCER GENET CYTOGEN, V85, P133, DOI 10.1016/0165-4608(95)00151-4; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	74	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3859	3866		10.1038/sj.onc.1206469	http://dx.doi.org/10.1038/sj.onc.1206469			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813459				2022-12-28	WOS:000183612000005
J	Nowicki, MO; Pawlowski, P; Fischer, T; Hess, G; Pawlowski, T; Skorski, T				Nowicki, MO; Pawlowski, P; Fischer, T; Hess, G; Pawlowski, T; Skorski, T			Chronic myelogenous leukemia molecular signature	ONCOGENE			English	Article						BCR/ABL; CML; microarrays; gene profiling	ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; BCR/ABL-MEDIATED LEUKEMOGENESIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; PHILADELPHIA-CHROMOSOME; CYCLIN D2; SIGNALING PATHWAYS	To obtain comprehensive information about the genes involved in BCR/ABL-dependent leukemogenesis, samples from 15 chronic myelogenous leukemia (CML) patients and seven normal donors were analysed using a cDNA microarray assay. After subtraction of the artificial, random or cross-hybridization signals, data about 5315 genes have been effectively analysed in all samples. The assay revealed greater than or equal to4-fold difference in the average expression of 263 genes in all CML samples when compared to normal counterparts, with 148 genes being upregulated and 115 being downregulated. Differentially expressed genes include those associated with BCR/ABL-induced abnormalities in signal transduction, gene transactivation, cell cycle, apoptosis, adhesion, DNA repair, differentiation, metabolism and malignant progression. Interestingly, CML-blast crisis cells in peripheral blood differ from those from bone marrow, indicating major changes in gene expression profiles upon entering into the bloodstream. Moreover, BCR/ABL modulates expression of genes, which are involved in regulation of chromosome/chromatin/DNA dynamics during S and M cell cycle phase. Moreover, the ability of CML cells to recognize and respond to a pathogen infection may be compromised. Altogether, this work provides a large body of information regarding gene expression profiles associated with CML and also represents a source of potential targets for CML therapeutics.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; UC Irvine, Coll Med, Dept Pathol, Orange, CA USA; Univ Mainz, Dept Med 3, D-55131 Mainz, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Irvine; Johannes Gutenberg University of Mainz	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Biolife Sci Bldg,Room 419,1900 N 12th St, Philadelphia, PA 19122 USA.			Nowicki, Michal/0000-0002-5807-0007	NCI NIH HHS [CA87300] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AKIYAMA H, 1991, REV INFECT DIS, V13, P815; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Behrens P, 2001, ANTICANCER RES, V21, P2413; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; Deininger MWN, 2001, CANCER RES, V61, P8005; Deininger MWN, 2000, CANCER RES, V60, P2049; Dotti G, 1999, BRIT J HAEMATOL, V105, P163, DOI 10.1111/j.1365-2141.1999.01299.x; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Huang HT, 2000, CANCER RES, V60, P6868; Itoh M, 2001, Rinsho Ketsueki, V42, P209; Janowska-Wieczorek A, 2002, LEUKEMIA, V16, P1160, DOI 10.1038/sj.leu.2402486; Jena N, 2002, CANCER RES, V62, P535; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Maio M, 1998, INT J ONCOL, V13, P305; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Olesen SH, 2001, CARCINOGENESIS, V22, P813, DOI 10.1093/carcin/22.5.813; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pierce A, 2002, ONCOGENE, V21, P3068, DOI 10.1038/sj.onc.1205424; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Soto T, 1999, APPL ENVIRON MICROB, V65, P2020; Tauchi T, 2001, EXP HEMATOL, V29, P356, DOI 10.1016/S0301-472X(00)00673-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vieira SAD, 2001, GENE CHROMOSOME CANC, V32, P353, DOI 10.1002/gcc.1200; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	73	94	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3952	3963		10.1038/sj.onc.1206620	http://dx.doi.org/10.1038/sj.onc.1206620			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813469				2022-12-28	WOS:000183612000015
J	DuHadaway, JB; Du, W; Donover, S; Baker, J; Liu, AX; Sharp, DM; Muller, AJ; Prendergast, GC				DuHadaway, JB; Du, W; Donover, S; Baker, J; Liu, AX; Sharp, DM; Muller, AJ; Prendergast, GC			Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1	ONCOGENE			English	Article						FTI; farnesyltransferase; Ras; RhoB; SV40T antigen; amphiphysin	TUMOR-SUPPRESSOR BIN1; GENE-EXPRESSION; YEAST HOMOLOG; SMALL GTPASE; CELL-CYCLE; KINASE 2; PROTEIN; ACTIN; RAS; MYC	Neoplastic transformation sensitizes many cells to apoptosis. This phenomenon may underlie the therapeutic benefit of many anticancer drugs, but its molecular basis is poorly understood. We have used a selective and potent farnesyltransferase inhibitor (FTI) to probe a mechanism of apoptosis that is peculiarly linked to neoplastic transformation. While nontoxic to untransformed mouse cells, FTI triggers a massive RhoB-dependent, p53-independent apoptosis in mouse cells that are neoplastically transformed. Here we offer evidence that the BAR adapter-encoding tumor suppressor gene Bin1 is required for this transformation-selective death program. Targeted deletion of Bin1 in primary mouse embyro fibroblasts (MEFs) transformed by E1A + Ras did not affect FTI-induced reversion, actin fiber formation, or growth inhibition, but it abolished FTI-induced apoptosis. The previously defined requirement for RhoB in these effects suggests that BinI adapter proteins act downstream or in parallel to RhoB in cell death signaling. The death defect in Bin1 null cells was significant insofar as it abolished FTI efficacy in tumor xenograft assays. p53 deletion did not phenocopy the effects of Bin1 deletion. However, MEFs transformed by SV40 large T antigen + Ras were also resistant to apoptosis by FTI, consistent with other evidence that large T inhibits Bin1-dependent cell death by a p53-independent mechanism. Taken together, the results define a function for Bin1 in apoptosis that is conditional on transformation stress. This study advances understanding of the functions of BAR adapter proteins, which are poorly understood, by revealing genetic interactions with an Rho small GTPase that functions in stress signaling. The frequent losses of Bin1 expression that occur in human breast and prostate cancers may promote tumor progression and limit susceptibility to FTI or other therapeutic agents that exploit the heightened sensitivity of neoplastic cells to apoptosis.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Canc Res Grp, Glenolden, PA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont; The Wistar Institute; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org		Muller, Alexander/0000-0001-7854-6933	NATIONAL CANCER INSTITUTE [R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [CA82222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Balguerie A, 1999, J CELL SCI, V112, P2529; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO;2-Q; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Colwill K, 1999, GENETICS, V152, P881; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Du W, 1999, MOL CELL BIOL, V19, P1831; Du W, 1999, CANCER RES, V59, P4208; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Galderisi U, 1999, J CELL BIOCHEM, V74, P313, DOI 10.1002/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.3.CO;2-Q; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P559, DOI 10.1002/1096-911X(20001201)35:6<559::AID-MPO14>3.3.CO;2-A; Huang HT, 2000, CANCER RES, V60, P6868; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ P, 1998, CELL ADHES COMMUN, V4, P1; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mangues R, 1998, CANCER RES, V58, P1253; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Prendergast GC, 1999, CANCER RES, V59, P5924; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; ZALCMAN G, 1995, ONCOGENE, V10, P1935	53	15	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3578	3588		10.1038/sj.onc.1206481	http://dx.doi.org/10.1038/sj.onc.1206481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789266				2022-12-28	WOS:000183399200008
J	Bristow, RG; Peacock, J; Jang, A; Kim, J; Hill, RP; Benchimol, S				Bristow, RG; Peacock, J; Jang, A; Kim, J; Hill, RP; Benchimol, S			Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53	ONCOGENE			English	Article						p53; sensitivity; MEF; gain of function; metastasis; transformation	OF-FUNCTION MUTATIONS; P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; REPAIR PATHWAYS; CELL-SURVIVAL; MUTANT FORMS; CORE DOMAIN; IN-VITRO; GENE; CHECKPOINT	Tumor cells can acquire aggressive phenotypes secondary to the loss of expression of the wild-type p53 (WTp53) protein or by the gain of function for selected mutant p53 (MTp53) proteins. However, it is unclear as to whether the development of aggressive phenotypes is inter-related. Herein we report the radiosensitivity, chemosensitivity, and in vivo growth characteristics of isogenic p53(-/-) MEF ras-transformants that variably express an MTp53 protein. Initial experiments revealed significant clonal heterogeneity with respect to cellular sensitivity to DNA-damaging agents (i.e. ionizing radiation, ultraviolet radiation, cis-platinum, and methotrexate) within subclones of a pre-existing p53(-/-) MEF cell population. Moreover, this differential sensitivity was also observed within suliclones of p53(-/-) MEF cells transformed with an activated ras allele, suggesting that secondary genetic events and clonal selection, but not cellular transformation per se, may drive the resistance patterns for certain null-p53 tumors. In contrast, uniform resistance was observed following the additional transfection of an MTp53 allele (MTp53pro193) into p53(-/-) MEF transformants and p53(-/-) DP-16 Friend erythroleukemia cells, consistent with a gain of MTp53 function for this allele. Relative tumor growth rate and experimental metastatic ability was not enhanced by MTp53pro193 expression. Our results support the concept that gain of MTp53pro193 function leads to the selection of dominant clones, which may exhibit cellular resistance following cancer therapy.	Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Bristow, RG (corresponding author), Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Radiat Oncol, 610 Univ Ave,Room 5-923, Toronto, ON M5G 2M9, Canada.			Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X; Bristow, Robert/0000-0002-8553-9544				Albor A, 1998, CANCER RES, V58, P2091; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1998, ONCOGENE, V16, P1789, DOI 10.1038/sj.onc.1201935; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gangopadhyay S, 2002, EXP CELL RES, V275, P122, DOI 10.1006/excr.2002.5493; Grant SW, 1998, CANCER DETECT PREV, V22, P185, DOI 10.1046/j.1525-1500.1998.0oa18.x; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HSIAO M, 1994, AM J PATHOL, V145, P702; Illidge TM, 2000, CELL BIOL INT, V24, P621, DOI 10.1006/cbir.2000.0557; Iwamoto KS, 1996, CANCER RES, V56, P3862; Iwanaga Y, 2002, CANCER RES, V62, P2618; KIESER A, 1994, ONCOGENE, V9, P963; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; POWELL SN, 1995, CANCER RES, V55, P1643; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; Roth JA, 2001, ACTA ONCOL, V40, P739; Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sigal A, 2000, CANCER RES, V60, P6788; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; STRANO S, 2002, J BIOL CHEM, V13, P13; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Tang W, 1999, CANCER RES, V59, P2562; Tannock IF, 2001, BRIT J CANCER, V84, P100, DOI 10.1054/bjoc.2000.1538; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wiesmueller Lisa, 2001, Journal of Biomedicine and Biotechnology, V1, P7, DOI 10.1155/S1110724301000043	49	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2960	2966		10.1038/sj.onc.1206405	http://dx.doi.org/10.1038/sj.onc.1206405			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771947				2022-12-28	WOS:000182824800011
J	Maio, M; Coral, S; Fratta, E; Altomonte, M; Sigalotti, L				Maio, M; Coral, S; Fratta, E; Altomonte, M; Sigalotti, L			Epigenetic targets for immune intervention in human malignancies	ONCOGENE			English	Review						DNA methylation; histone acetylation; cancer; immunotherapy; HLA antigens; tumor antigens	CANCER-TESTIS ANTIGENS; CLASS-I ANTIGENS; 5-AZA-2'-DEOXYCYTIDINE DECITABINE TREATMENT; CYTOLYTIC T-LYMPHOCYTES; SQUAMOUS-CELL CARCINOMA; HUMAN GENE MAGE-1; DNA METHYLATION; MYELODYSPLASTIC SYNDROME; MELANOMA-CELLS; HETEROGENEOUS EXPRESSION	Emerging evidences suggest that epigenetic events associated with tumor development and progression, such as deregulated methylation of CpG dinucleotides and aberrant histone acetylation, may impair the immunogenic potential of cancer cells. In fact, DNA hypermethylation and/or histone deacetylation contribute to the absent or downregulated expression of different components of the 'tumor recognition complex' (i.e., HLA class I antigens, cancer/testis antigens and accessory/costimulatory molecules) in solid and hemopoietic human malignancies. However, pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation can modify these epigenetic phenomena, restoring the defective expression of selected components of the 'tumor recognition complex' in cancer cells. These antigenic modi. cations positively modulate the immunogenicity and the immune recognition of cancer cells, making epigenetic drugs attractive agents to design new combined chemoimmunotherapeutic strategies for the treatment of cancer patients.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy	IRCCS Aviano (CRO)	Maio, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occle 12, I-33081 Aviano, Italy.	mmaio@cro.it	Fratta, Elisabetta/J-8707-2016; Sigalotti, Luca/A-5893-2013; altomonte, maresa/G-7734-2011; Sigalotti, Luca/AAC-2926-2020; Coral, Sandra/AAB-9552-2022	Fratta, Elisabetta/0000-0002-7472-8841; Sigalotti, Luca/0000-0003-3362-5026; Sigalotti, Luca/0000-0002-1436-2358; Maio, Michele/0000-0002-0323-6321; Altomonte, Maresa/0000-0001-8021-1921; coral, sandra/0000-0002-1308-3082				ALTOMONTE M, 1993, CANCER RES, V53, P3343; Arnold JM, 2001, BRIT J CANCER, V85, P1351, DOI 10.1054/bjoc.2001.2075; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; BRASSEUR F, 1992, INT J CANCER, V52, P839, DOI 10.1002/ijc.2910520528; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chambost H, 2001, LEUKEMIA, V15, P1769, DOI 10.1038/sj.leu.2402278; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Coral S, 1999, J IMMUNOTHER, V22, P16, DOI 10.1097/00002371-199901000-00003; Coral S, 2002, CLIN CANCER RES, V8, P2690; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; dos Santos NR, 2000, CANCER RES, V60, P1654; EURA M, 1995, INT J CANCER, V64, P304, DOI 10.1002/ijc.2910640504; Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077; Fujie T, 1997, ANN ONCOL, V8, P369, DOI 10.1023/A:1008255630202; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Jungbluth AA, 2000, BRIT J CANCER, V83, P493, DOI 10.1054/bjoc.2000.1291; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Kienstra MA, 2003, HEAD NECK-J SCI SPEC, V25, P457, DOI 10.1002/hed.10223; Kim JJ, 1999, J CLIN INVEST, V103, P869, DOI 10.1172/JCI6024; Li J, 1996, CLIN CANCER RES, V2, P1619; Luo Guorong, 2002, Cancer Immun, V2, P11; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Maio M, 2003, J CLIN ENDOCR METAB, V88, P748, DOI 10.1210/jc.2002-020830; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Mori M, 1996, ANN SURG, V224, P183, DOI 10.1097/00000658-199608000-00011; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; Quillien V, 1997, ANTICANCER RES, V17, P387; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Sandor V, 2002, CLIN CANCER RES, V8, P718; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Soling A, 1999, ANTICANCER RES, V19, P2205; Traversari C, 1999, MINERVA BIOTECNOL, V11, P243; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; WEBER J, 1994, CANCER RES, V54, P1766; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Worm J, 2002, J ORAL PATHOL MED, V31, P443, DOI 10.1034/j.1600-0714.2002.00034.x; Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215; Zuckerman LA, 1998, J IMMUNOL, V160, P3259	54	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6484	6488		10.1038/sj.onc.1206956	http://dx.doi.org/10.1038/sj.onc.1206956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528272				2022-12-28	WOS:000185700700004
J	Ribatti, D; Guidolin, D; Conconi, MT; Nico, B; Baiguera, S; Parnigotto, PP; Vacca, A; Nussdorfer, GG				Ribatti, D; Guidolin, D; Conconi, MT; Nico, B; Baiguera, S; Parnigotto, PP; Vacca, A; Nussdorfer, GG			Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo	ONCOGENE			English	Article						adrenomedullin; angiogenesis; antiangiogenesis; chorioallantoic membrane; Matrigel; vinblastine	MICE LACKING; ANTIANGIOGENESIS; ABNORMALITIES; GROWTH	Adrenomedullin (ADM) is protumorigenic by stimulating tumor cell growth and angiogenesis. In this context, ADM is identified as a novel target for antiangiogenic therapy. In this study, we addressed the possibility that vinblastine (VBL), as demonstrated in other experimental conditions, may act as an angiostatic molecule in the angiogenic response induced by ADM in two assays, such as Matrigel tube formation in vitro and angiogenesis in the chick embryo chorioallantoic membrane (CAM) in vivo. When tested on Matrigel, ADM caused a morphogenetic effect. In fact, endothelial cells spread and aligned with each other to form branching anastomosing tubes with multicentric junctions that gave rise to a meshwork of capillary-like structures. When ADM was administered in the presence of VBL, the capillary-like tubes were interrupted, most cells were spherical, either isolated or aggregated in small clumps. In the CAM assay, ADM induced a strong angiogenic response, which was counteracted by the treatment with VBL. Overall, these observations implicate ADM as a promoter of tumor growth and a possible target for anticancer strategies, such as the use of VBL at very low, nontoxic doses. Nevertheless, the antiangiogenic acitivity of low-dose VBL deserves further investigation, alone or together with other antiangiogenic agents for the treatment of tumors characterized by enhanced angiogenesis.	Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy; Univ Padua, Sch Med, Sect Anat, Dept Human Anat & Physiol, Padua, Italy; Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Sect Internal Med & Clin Oncol, Bari, Italy	Universita degli Studi di Bari Aldo Moro; University of Padua; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Policlin, Dept Human Anat & Histol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022; Baiguera, Silvia/AAC-4738-2022	Vacca, Angelo/0000-0002-4567-8216; Baiguera, Silvia/0000-0002-6669-7061; Guidolin, Diego/0000-0003-2133-3552				Belloni AS, 2001, HISTOL HISTOPATHOL, V16, P1263, DOI 10.14670/HH-16.1263; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; ElHafny B, 1997, BIOCHEM PHARMACOL, V53, P1735, DOI 10.1016/S0006-2952(97)00093-2; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Hague S, 2000, CLIN CANCER RES, V6, P2808; Ishikawa T, 2003, ONCOGENE, V22, P1238, DOI 10.1038/sj.onc.1206207; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Martinez A, 2002, J NATL CANCER I, V94, P1226; Minamino N, 2000, CLIN HEMORHEOL MICRO, V23, P95; Nikitenko LL, 2002, TRENDS PHARMACOL SCI, V23, P101, DOI 10.1016/S0165-6147(00)01983-0; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Presta M, 2002, LEUKEMIA, V16, P1490, DOI 10.1038/sj.leu.2402646; Presta M, 1999, CANCER RES, V59, P2417; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti Domenico, 1999, Neoplasia (New York), V1, P293, DOI 10.1038/sj.neo.7900038; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Vacca A, 2002, J HEMATOTH STEM CELL, V11, P103, DOI 10.1089/152581602753448577; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	20	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6458	6461		10.1038/sj.onc.1206789	http://dx.doi.org/10.1038/sj.onc.1206789			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508526				2022-12-28	WOS:000185535300016
J	Yuan, ZQ; Kent, TS; Weber, TK				Yuan, ZQ; Kent, TS; Weber, TK			Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; DOC-1; differential expression	MISMATCH REPAIR; INSTITUTE WORKSHOP; INSTABILITY; P12(DOC-1); GENES; CARCINOMAS; MUTATIONS; APOPTOSIS; PROFILES	The precise genetic mechanism of malignant transformation in DNA mismatch repair deficient, microsatellite-unstable colorectal cancer (CRC) has yet to be elucidated. We employed cDNA microarray to identify patterns of gene expression among CRC cell lines and to compare directly lines with and without microsatellite instability. This study was undertaken to test the hypothesis that microsatellite-unstable CRC cell lines demonstrate specific patterns of gene expression that differ significantly from those observed among microsatellite-stable CRC. Multiple differential expression patterns were identified. Genes demonstrating differential expression included deleted-in-oral-cancer-1 (DOC-1), a highly conserved growth suppressor. DOC-1 expression correlated with microsatellite status, with significantly decreased expression in microsatellite-unstable cell lines and constitutive expression in microsatellite-stable cell lines. We also observed alterations in the biologic behavior of p12(DOC-1)deficient cell lines, with increased S phase and decreased apoptosis compared to microsatellite-stable (DOC-1+) cell lines. Transfection of p12(DOC-1) into SW48, which lacks p12(DOC-1) expression, resulted in cell cycle and apoptosis profiles similar to other p12(DOC-1)+ cell lines. These results support the hypothesis that microsatellite-unstable CRC is characterized by novel patterns of gene expression different from those associated with microsatellite-stable CRC, and demonstrate that p12(DOC-1) has tumor suppressor potential in colon epithelial cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Surg & Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Surg, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Weber, TK (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Surg & Mol Genet, 1300 Morris Pk Ave,Ullmann 1219, Bronx, NY 10461 USA.	tweber@aecom.yu.edu						Barnetson RA, 2000, INT J COLORECTAL DIS, V15, P83, DOI 10.1007/s003840050237; Boland CR, 1997, HOSP PRACT, V32, P79, DOI 10.1080/21548331.1997.11443598; Boland CR, 1998, CANCER RES, V58, P5248; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278-2391(00)90924-8; Fink D, 1997, BRIT J CANCER, V76, P890, DOI 10.1038/bjc.1997.480; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Harris TM, 2000, NAT BIOTECHNOL, V18, P384, DOI 10.1038/74435; He YDD, 2001, NAT MED, V7, P658, DOI 10.1038/89022; Hegde P, 2001, CANCER RES, V61, P7792; Hu Miaofen, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P326; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368-8375(01)00055-0; Kruschewski M, 2002, CLIN EXP METASTAS, V19, P71, DOI 10.1023/A:1013853224644; Loeb LA, 2001, CANCER RES, V61, P3230; Lynch HT, 1999, J MED GENET, V36, P801; Markowitz S, 2000, BBA-REV CANCER, V1470, pM13, DOI 10.1016/S0304-419X(99)00031-1; Martin L, 1999, EUR J CANCER PREV, V8, pS13; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Notterman DA, 2001, CANCER RES, V61, P3124; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; Sepulveda AR, 1999, AM J GASTROENTEROL, V94, P3034, DOI 10.1016/S0002-9270(99)00509-2; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; Takemasa I, 2001, BIOCHEM BIOPH RES CO, V285, P1244, DOI 10.1006/bbrc.2001.5277; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704	31	33	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6304	6310		10.1038/sj.onc.1206609	http://dx.doi.org/10.1038/sj.onc.1206609			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679870				2022-12-28	WOS:000185506200021
J	Yustein, JT; Xia, L; Kahlenburg, JM; Robinson, D; Templeton, D; Kung, HJ				Yustein, JT; Xia, L; Kahlenburg, JM; Robinson, D; Templeton, D; Kung, HJ			Comparative studies of a new subfamily of human Ste20-like kinases: homodimerization, subcellular localization, and selective activation of MKK3 and p38	ONCOGENE			English	Article						Ste20 kinase; TAO; p38 MAPK	EPIDERMAL-GROWTH-FACTOR; N-TERMINAL KINASE; HEMATOPOIETIC PROGENITOR KINASE-1; SIGNAL-REGULATED KINASE; GERMINAL CENTER KINASE; PROTEIN-KINASE; PAK-FAMILY; MOLECULAR-CLONING; ADAPTER PROTEINS; COILED COILS	The Sterile-20 or Ste20 family of serine/threonine kinases is a group of signaling molecules whose physiological roles within mammalian cells are just starting to be elucidated. Here, in this report we present the characterization of three human Ste20-like kinases with greater than 90% similarity within their catalytic domains that de. ne a novel subfamily of Ste20s. Members of this kinase family include rat thousand and one (TAO1) and chicken KFC ( kinase from chicken). For the lack of a consensus nomenclature in the literature, in this report, we shall call this family hKFC ( for their homology to chicken KFC) and the three members hKFC-A, hKFC-B, and hKFC-C, respectively. These kinases have many similarities including an aminoterminal kinase domain, a serine-rich region, and a coiled-coil configuration within the C-terminus. All three kinases are able to activate the p38 MAP kinase pathway through the specific activation of the upstream MKK3 kinase. We also offer evidence, both theoretical and biochemical, showing that these kinases can undergo self-association. Despite these similarities, these kinases differ in tissue distribution, apparent subcellular localization, and feature structural differences largely within the carboxyl-terminal sequence.	Univ Calif Davis, Med Ctr, Ctr Canc, Sacramento, CA 95817 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of California System; University of California Davis; Case Western Reserve University; Case Western Reserve University; University of Virginia	Kung, HJ (corresponding author), Univ Calif Davis, Med Ctr, Ctr Canc, 4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Templeton, Dennis J/F-7695-2011; Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [U01CA057179, R37CA039207, R01CA057179, R37CA046613, R01CA039207, R01CA046613] Funding Source: NIH RePORTER; NCI NIH HHS [CA39207, CA57179, CA46613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Bost F, 1999, MOL CELL BIOL, V19, P1938; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Endo J, 2000, FEBS LETT, V468, P234, DOI 10.1016/S0014-5793(00)01219-9; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; HATZ P, 1994, J BIOL CHEM, V269, P16802; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	49	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6129	6141		10.1038/sj.onc.1206605	http://dx.doi.org/10.1038/sj.onc.1206605			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679851				2022-12-28	WOS:000185506200002
J	Copland, JA; Luxon, BA; Ajani, L; Maity, T; Campagnaro, E; Guo, HP; LeGrand, SN; Tamboli, P; Wood, CG				Copland, JA; Luxon, BA; Ajani, L; Maity, T; Campagnaro, E; Guo, HP; LeGrand, SN; Tamboli, P; Wood, CG			Genomic profiling identifies alterations in TGF beta signaling through loss of TGF beta receptor expression in human renal cell carcinogenesis and progression	ONCOGENE			English	Article						TGF beta, type III TGF beta receptor, type II TGF beta; receptor, renal cell carcinoma; carcinogenesis; metastasis	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; II RECEPTOR; CARCINOMA; AUTOCRINE; PROLIFERATION; INACTIVATION; BETAGLYCAN; PATTERNS; CULTURE	Renal cell carcinoma (RCC) is a major health issue. Whereas localized disease can be cured surgically, there is no effective therapy for metastatic disease. The development of an effective therapy will require an understanding of the pathways that are important in RCC carcinogenesis and progression. Using genomic profiling of patient-matched tissue, we have identified aberrations in the transforming growth factor beta (TGFbeta) signaling pathway in RCC. We observed loss of type III TGFbeta receptor (TBR3) expression in all RCC samples. This suggests that TBR3 loss is an early event in RCC carcinogenesis and plays a sentinel role in the acquisition of a tumorigenic phenotype. We also observed subsequent loss of type II TGFbeta receptor (TBR2) expression in metastatic RCCs. We propose that loss of TBR3 is necessary for RCC carcinogenesis, and that loss of TBR2 leads to acquisition of a metastatic phenotype. To this end, we have identified a human renal cell carcinoma tine (UMRC6) that is representative of localized, nonmetastatic RCC, reflecting a loss of TBR3, but not TBR2 expression. Another cell line, UMRC3, is highly metastatic, having lost TBR3 and TBR2 expression. We demonstrate functional loss of TGFbeta responsiveness in these cell lines as observed through phenotypic and transcriptional responsiveness to exogenous TGFbeta. Restoring TBR2 and TBR3 expression in UMRC3 cells attenuates cell proliferation, completely restores TGFbeta-mediated transcriptional responses, and completely blocks anchorage independent-growth: while restoration of TBR2 partially restores TGFbeta-mediated signaling. Based on these data, we propose that dysregulation in TGFbeta signaling, through stepwise loss in receptor expression, plays a prominent role in RCC carcinogenesis and progression. In addition, these studies unequivocably demonstrate a link between loss of TBR3 and a human disease.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol & Canc Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Bioinformat Program, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Wood, CG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, Box 446,1515 Holcombe Blvd, Houston, TX 77030 USA.	cgwood@mdanderson.org	Luxon, Bruce A/C-9140-2012	Campagnaro, Erica/0000-0003-3820-3260				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Allander SV, 2001, CANCER RES, V61, P8624; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Boyer AS, 2001, DEV DYNAM, V221, P454, DOI 10.1002/dvdy.1154; Cardillo MR, 2001, ANAL QUANT CYTOL, V23, P109; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Copland JA, 2003, RECENT PROG HORM RES, V58, P25, DOI 10.1210/rp.58.1.25; DEDIR A, 1996, CLIN BIOCHEM, V29, P385; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; DeRisi J, 1996, NAT GENET, V14, P457; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel JD, 1999, UROLOGY, V54, P164, DOI 10.1016/S0090-4295(99)00093-X; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Gilbert RE, 1998, DIABETES, V47, P414, DOI 10.2337/diabetes.47.3.414; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; Hegele A, 2003, UROL RES, V30, P363, DOI 10.1007/s00240-002-0280-3; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kundu SD, 1998, J UROLOGY, V160, P1883, DOI 10.1016/S0022-5347(01)62437-6; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Ramp U, 1997, J UROLOGY, V157, P2345, DOI 10.1016/S0022-5347(01)64778-5; Ramp U, 1997, LAB INVEST, V76, P739; Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Sens DA, 1999, EXP NEPHROL, V7, P344; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Trifillis AL, 1999, EXP NEPHROL, V7, P353; Wogensen L, 1999, DIABETES, V48, P182, DOI 10.2337/diabetes.48.1.182; Wunderlich H, 1998, UROL INT, V60, P205, DOI 10.1159/000030255; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	43	87	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8053	8062		10.1038/sj.onc.1206835	http://dx.doi.org/10.1038/sj.onc.1206835			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970754				2022-12-28	WOS:000185388200021
J	Tashiro, E; Minato, Y; Maruki, H; Asagiri, M; Imoto, M				Tashiro, E; Minato, Y; Maruki, H; Asagiri, M; Imoto, M			Regulation of FGF receptor-2 expression by transcription factor E2F-1	ONCOGENE			English	Article						FGFR-2; cell cycle; promoter; transcription; E2F-1; pRB	FIBROBLAST GROWTH-FACTORS; CYCLIN-E GENE; RETINOBLASTOMA PROTEIN; PROMOTER; RECEPTOR; FAMILY; PRB; TRANSACTIVATION; BINDING; MOUSE	Fibroblast growth factors (FGF) and their receptors play an important role in cell proliferation, angiogenesis and embryonal development. In this study, we show that expression of the FGF receptor-2 (FGFR-2) protein is induced in the mid-to-late G1 phase of the cell cycle in serum-starved mouse NIH3T3 cells released from starvation. Transcription of mouse FGFR-2 was activated by E2F-1. Analysis of various mouse FGFR-2 promoter mutant constructs showed that a sequence located +57/+64 downstream of the transcriptional initiation site, related to the consensus E2F-responsive sequence, is necessary for the activation. The promoter activity of the mouse FGFR-2 gene is also positively regulated by E2F-2 and E2F-3, but not by E2F-4 and E2F-5. Moreover, the E2F-1-induced activation of mouse FGFR-2 gene transcription is suppressed by pRB. Taken together, the results demonstrate that FGFR-2 is a new class of targets for E2F, and expression of mouse FGFR-2 in mid-to-late G1 phase would be mediated, at least in part, by the activation of a pRB/E2F pathway.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 2238522, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 2238522, Japan.			Tashiro, Etsu/0000-0003-4533-623X				AVIVI A, 1992, ONCOGENE, V7, P1957; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Botz J, 1996, MOL CELL BIOL, V16, P3401; DEGREGORI J, 1997, P NATL ACAD SCI USA, V94, P2443; Geng Y, 1996, ONCOGENE, V12, P1173; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; STARK KL, 1991, DEVELOPMENT, V113, P641; Takahashi Y, 2000, GENE DEV, V14, P804; Tashiro E, 2003, CANCER RES, V63, P424; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; ZHANG YH, 1995, ONCOGENE, V10, P2085	23	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5630	5635		10.1038/sj.onc.1206636	http://dx.doi.org/10.1038/sj.onc.1206636			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944911				2022-12-28	WOS:000184865900012
J	Sato, N; Fukushima, N; Maehara, N; Matsubayashi, H; Koopmann, J; Su, GH; Hruban, RH; Goggins, M				Sato, N; Fukushima, N; Maehara, N; Matsubayashi, H; Koopmann, J; Su, GH; Hruban, RH; Goggins, M			SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions	ONCOGENE			English	Article						SPARC; methylation; pancreatic cancer; tumor-stromal interaction	CELL-CYCLE PROGRESSION; SPARC-NULL MICE; GENE-EXPRESSION; NEOPLASTIC PROGRESSION; DUCTAL ADENOCARCINOMA; DESMOPLASTIC RESPONSE; CPG ISLANDS; CANCER; INVASION; PROTEIN	Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biological functions, has been associated with the progression of various cancers. Using microarrays, we previously identified SPARC as one of the genes induced by treatment with a DNA methylation inhibitor in pancreatic cancer cells. We therefore analysed the expression pattern and methylation status of the SPARC gene in pancreatic cancer. Gene expression profiting by oligonucleotide microarray and reverse transcription-PCR analyses demonstrated that SPARC mRNA was expressed in non-neoplastic pancreatic ductal epithelial cells, but was not expressed in a majority of pancreatic cancer cell lines. The loss of SPARC expression was associated with aberrant hypermethylation of its CpG island. Immunohistochemical labeling revealed that the SPARC protein was overexpressed in the stromal fibroblasts immediately adjacent to the neoplastic epithelium in primary pancreatic cancers, but rarely expressed in the cancers themselves. Primary fibroblasts derived from pancreatic cancer strongly expressed SPARC mRNA and secreted SPARC protein into the conditioned media, and treatment of pancreatic cancer cells with exogenous SPARC resulted in growth suppression. SPARC expression in fibroblasts from noncancerous pancreatic tissue was augmented by coculture with pancreatic cancer cells. These findings suggest that SPARC is a frequent target for aberrant methylation in pancreatic cancer and that SPARC expression in fibroblasts adjacent to pancreatic cancer cells is regulated through tumor-stromal interactions.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu		Su, Gloria/0000-0002-5158-6019	NCI NIH HHS [CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Dhanesuan N, 2002, BREAST CANCER RES TR, V75, P73, DOI 10.1023/A:1016536725958; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Fukushima N, 2003, CANCER BIOL THER, V2, P78; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Goggins M, 2000, J SURG ONCOL, V74, P243, DOI 10.1002/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C; HAHN SA, 1995, CANCER RES, V55, P4670; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, CANCER RES, V62, P5351; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P91, DOI 10.1016/S0002-9440(10)64353-2; Jacob K, 1999, CANCER RES, V59, P4453; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Le Bail B, 1999, J PATHOL, V189, P46; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Maehara N, 2001, BRIT J CANCER, V84, P864, DOI 10.1054/bjoc.2000.1682; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; Mok SC, 1996, ONCOGENE, V12, P1895; Paley PJ, 2000, GYNECOL ONCOL, V78, P336, DOI 10.1006/gyno.2000.5894; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Rempel SA, 1999, CLIN CANCER RES, V5, P237; Rosty C, 2002, CANCER RES, V62, P1868; Rosty C, 2002, HEMATOL ONCOL CLIN N, V16, P37, DOI 10.1016/S0889-8588(01)00007-7; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Ryu B, 2001, CANCER RES, V61, P1833; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2002, GASTROENTEROLOGY, V123, P365, DOI 10.1053/gast.2002.34160; SATO N, 2003, IN PRESS CANC RES; Schultz C, 2002, CANCER RES, V62, P6270; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Ueki T, 2001, CANCER RES, V61, P8540; WEWER UM, 1988, AM J PATHOL, V132, P345; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	51	235	248	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5021	5030		10.1038/sj.onc.1206807	http://dx.doi.org/10.1038/sj.onc.1206807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902985				2022-12-28	WOS:000184578900010
J	Ma, Y; Koza-Taylor, PH; DiMattia, DA; Hames, L; Fu, HN; Dragnev, KH; Turi, T; Beebe, JS; Freemantle, SJ; Dmitrovsky, E				Ma, Y; Koza-Taylor, PH; DiMattia, DA; Hames, L; Fu, HN; Dragnev, KH; Turi, T; Beebe, JS; Freemantle, SJ; Dmitrovsky, E			Microarray analysis uncovers retinoid targets in human bronchial epithelial cells	ONCOGENE			English	Article						retinoic acid; bronchial epithelial cells; microarray analysis; retinoic acid resistance	TGF-BETA SUPERFAMILY; FACTOR BINDING PROTEIN-6; LOOP-HELIX PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; ASPARAGINE SYNTHETASE GENE; PLACEBO-CONTROLLED TRIAL; TISSUE TRANSGLUTAMINASE; LUNG-CANCER; TRANSCRIPTION FACTOR; SIGNALING PATHWAY	Retinoids, the natural and synthetic derivatives of vitamin A, have a role in cancer treatment and prevention. There is a need to reveal mechanisms that account for retinoid response or resistance. This study identified candidate all-trans-retinoic acid (RA) target genes linked to growth suppression in BEAS-2B human bronchial epithelial cells. Microarray analyses were performed using Affymetrix arrays. A total of 11 RA-induced species were validated by reverse transcription polymerase chain reaction (RT-PCR), Western or Northern analyses. Three of these species were novel candidate RA-target genes in human bronchial epithelial cells. These included: placental bone morphogenetic protein (PLAB), polyamine oxidase isoform 1 (PAOh1) and E74-like factor 3 (ELF3). Expression patterns were studied in RA-resistant BEAS-2BR1 cells. In BEAS-2B-R1 cells, RA dysregulated the expression of the putative lymphocyte G0/G1 switch gene (G0S2), heme oxygenase 1 (HMOX1), tumor necrosis factor-alpha-induced protein 2 (TNFAIP2), inhibitor of DNA binding 1(Id1), fos-like antigen 1 (FOSL1), transglutaminase 2 (TGM2), asparagine synthetase (ASNS), PLAB, PAOh1 and ELF3, while prominent induction of insulin-like growth-factor-binding protein 6 (IGFBP6) still occurred. In summary, this study identified 11 candidate RA-target genes in human bronchial epithelial cells including three novel species. Expression studies in BEAS-2B-R1 cells indicated that several were directly implicated in RA signaling, since their aberrant expression was linked to RA resistance of human bronchial epithelial cells.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Pfizer Global Res & Dev, Groton, CT 06340 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Pfizer	Dmitrovsky, E (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA087546] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA87546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Clarke PA, 2001, BIOCHEM PHARMACOL, V62, P1311, DOI 10.1016/S0006-2952(01)00785-7; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DELVA L, 1993, BLOOD, V82, P2175; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; Freeman WM, 2000, BIOTECHNIQUES, V29, P1042, DOI 10.2144/00295rv01; Gabbitas B, 1996, J CELL PHYSIOL, V169, P15, DOI 10.1002/(SICI)1097-4652(199610)169:1<15::AID-JCP2>3.0.CO;2-H; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HONGO S, 1990, LEUKEMIA, V4, P708; Kaiser A, 1999, FEBS LETT, V448, P45, DOI 10.1016/S0014-5793(99)00326-9; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; KITAREEWAN S, IN PRESS CANC CHEMOP, V1; Kizaki M, 1996, BLOOD, V87, P725, DOI 10.1182/blood.V87.2.725.bloodjournal872725; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Langenfeld J, 1996, ONCOGENE, V13, P1983; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; Lonardo F, 1999, CANCER RES, V59, P2470; Lonardo F, 2002, CLIN CANCER RES, V8, P54; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Nagy L, 1996, J BIOL CHEM, V271, P4355; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; REDDEL RR, 1988, CANCER RES, V48, P1904; Rusiniak ME, 2000, CANCER RES, V60, P1824; RUSSELL L, 1991, DNA CELL BIOL, V10, P581, DOI 10.1089/dna.1991.10.581; SARMA V, 1992, J IMMUNOL, V148, P3302; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; SPORN MB, 1976, FED PROC, V35, P1332; Sueoka N, 2000, AM J RESP CELL MOL, V23, P297, DOI 10.1165/ajrcmb.23.3.4013; Sueoka N, 1999, CANCER RES, V59, P3838; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Yan ZH, 1996, MOL CELL ENDOCRINOL, V120, P203, DOI 10.1016/0303-7207(96)03826-9; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	59	44	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4924	4932		10.1038/sj.onc.1206728	http://dx.doi.org/10.1038/sj.onc.1206728			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894236				2022-12-28	WOS:000184344600018
J	Taylor, ER; Boner, W; Dornan, ES; Corr, EM; Morgan, IM				Taylor, ER; Boner, W; Dornan, ES; Corr, EM; Morgan, IM			UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein	ONCOGENE			English	Article						HPV; E2; transcription; protein solubility; UV	HUMAN-PAPILLOMAVIRUS TYPE-18; E2 PROTEIN; DNA-DAMAGE; FUNCTIONAL INTERACTION; TRANSCRIPTIONAL ACTIVATOR; BINDING PROTEIN; P53; PROMOTER; CELLS; DEGRADATION	Human papillomaviruses (HPV) are causative agents of human cancers including those of the cervix and also of the head and neck; HPV16 is the most commonly found type in these diseases. The viral E2 protein regulates transcription from the viral genome by interacting with DNA-binding sequences in the HPV transcriptional control region; it also regulates replication by interacting with and recruiting the HPV replication factor El to the viral origin. Therefore, E2 is essential for the viral life cycle. The E2 protein interacts with several proteins involved in the cellular response to DNA damage including p53, TopBP1, and PARP. We therefore set out to establish whether DNA-damaging agents can regulate E2 activity. Here we show that UVB irradiation downregulates transcriptional activity of both HPV16 and HPV8 E2, while hydroxyurea and etoposide do not. This downregulation of E2 activity is independent of p53 function as it occurs in p53 wild type and null cell types as well as in the presence of functional HPV16 E6 that degrades p53. Using stable cell lines expressing E2 we show that this downregulation of E2 function by UVB is due to a reduction of the E2 protein half-life. The identification of the pathway(s) through which UVB downregulates E2 transcriptional activity and protein levels will present a novel target for the treatment of HPV-related diseases.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Morgan, IM (corresponding author), Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	i.morgan@vet.gla.ac.uk						Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Boner W, 2002, J BIOL CHEM, V277, P22297, DOI 10.1074/jbc.M202163200; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Chao SF, 1999, BIOCHEMISTRY-US, V38, P4586, DOI 10.1021/bi982616v; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Mantovani F, 1999, SEMIN CANCER BIOL, V9, P387, DOI 10.1006/scbi.1999.0142; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Ruhland A, 2001, INT J CANCER, V91, P828, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1129&gt;3.0.CO;2-B; SANDERS CM, 1995, VIROLOGY, V211, P418, DOI 10.1006/viro.1995.1424; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; STUBENRAUCH F, 1994, J VIROL, V68, P6959, DOI 10.1128/JVI.68.11.6959-6966.1994; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	47	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4469	4477		10.1038/sj.onc.1206746	http://dx.doi.org/10.1038/sj.onc.1206746			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881703				2022-12-28	WOS:000184054700002
J	Kunapuli, P; Chitta, KS; Cowell, JK				Kunapuli, P; Chitta, KS; Cowell, JK			Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene	ONCOGENE			English	Article						LGI1; tumor suppressor gene; brain tumors; leucine-rich repeat; tumor invasion	MALIGNANT BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; CHROMOSOME-10; HETEROZYGOSITY; PTEN; IDENTIFICATION; PROGRESSION; ASTROCYTOMA; MUTATIONS; REGIONS	The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Jacobs JR, 2000, PROG NEUROBIOL, V62, P475, DOI 10.1016/S0301-0082(00)00016-2; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 2000, PATHOLOGY GENETICS T; Krex D, 2002, ACTA NEUROPATHOL, V103, P255, DOI 10.1007/s004010100463; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MYERS PM, 1997, P NATL ACAD SCI USA, V94, P9502; Papazisis KT, 1997, J IMMUNOL METHODS, V208, P151, DOI 10.1016/S0022-1759(97)00137-3; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; Sasaki H, 2002, CANCER RES, V62, P1790; Somerville RPT, 2000, MAMM GENOME, V11, P622, DOI 10.1007/s0033500101280; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Wang SI, 1997, CANCER RES, V57, P4183	31	55	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3985	3991		10.1038/sj.onc.1206584	http://dx.doi.org/10.1038/sj.onc.1206584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821932				2022-12-28	WOS:000183707600001
J	McKay, TR; Bell, S; Tenev, T; Stoll, V; Lopes, R; Lemoine, NR; McNeish, IA				McKay, TR; Bell, S; Tenev, T; Stoll, V; Lopes, R; Lemoine, NR; McNeish, IA			Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy	ONCOGENE			English	Article						survivin; caspase; ovarian carcinoma; gene therapy	ADENOVIRUS-MEDIATED TRANSFER; CASPASE ACTIVATION; DIRECT INHIBITOR; CANCER-CELLS; IN-VIVO; APOPTOSIS; PROTEIN; DEATH; IAP; PATHWAY	Increased survivin expression is a negative prognostic marker in many tumours, including ovarian cancer. We show here that ovarian carcinoma cells upregulate survivin transcription in response to increased expression of the proapoptotic protein procaspase 3. We have utilized this observation in a combination gene therapy strategy using adenoviral constructs expressing the dominant-negative mutant survivin T34A (Ad Survivin T34A) and procaspase 3 (Ad Caspase 3) in ovarian carcinoma cell lines. Transfection of ovarian carcinoma cells with Ad Survivin T34A induces apoptosis via a caspase 9-mediated pathway that is not affected by cell cycle block prior to G2/M. Ad Survivin T34A-induced apoptosis can be significantly enhanced by cotransfection with Ad Caspase 3, and the combination of Ad Survivin T34A and Ad Caspase 3 leads to a significant increase in survival in a murine intraperitoneal ovarian carcinoma model with some long-term survivors. This suggests that inhibiting endogenous survivin activity while also delivering high levels of procaspase 3 allow proteolytic cleavage and activation of the terminal caspase cascade leading to tumour cell death.	Hammersmith Hosp, Imperial Coll Sch Med, Canc Res UK Mol Oncol Unit, London W12 0NN, England	Cancer Research UK; Imperial College London	McNeish, IA (corresponding author), Hammersmith Hosp, Canc Res UK Mol Oncol Unit, MRC Cyclotron Bldg, London W12 0HS, England.			Tenev, Tencho/0000-0001-8762-1069; McNeish, Iain/0000-0002-9387-7586; McKay, Tristan/0000-0002-9128-9115				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dong Z, 2002, BIOCHEM J, V364, P413, DOI 10.1042/BJ20011431; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ikeguchi M, 2002, ONCOL REP, V9, P1121; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; McNeish IA, 2001, CANCER GENE THER, V8, P308, DOI 10.1038/sj.cgt.7700305; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Shariat SF, 2001, CANCER RES, V61, P2562; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shinoura N, 2000, EXP CELL RES, V256, P423, DOI 10.1006/excr.2000.4848; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Silke J, 2001, J CELL SCI, V114, P1821; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Tenev T, 2001, CELL DEATH DIFFER, V8, P256, DOI 10.1038/sj.cdd.4400808; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wall NR, 2003, CANCER RES, V63, P230; Yamabe K, 1999, GENE THER, V6, P1952, DOI 10.1038/sj.gt.3301041; Yoshitake T, 2000, J MATER SCI LETT, V19, P537, DOI 10.1023/A:1006722205010; Zhao J, 2000, J CELL SCI, V113, P4363; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	46	37	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3539	3547		10.1038/sj.onc.1206417	http://dx.doi.org/10.1038/sj.onc.1206417			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789262	Bronze			2022-12-28	WOS:000183399200004
J	Bader, S; Walker, M; McQueen, HA; Sellar, R; Oei, E; Wopereis, S; Zhu, YH; Peter, A; Bird, AP; Harrison, DJ				Bader, S; Walker, M; McQueen, HA; Sellar, R; Oei, E; Wopereis, S; Zhu, YH; Peter, A; Bird, AP; Harrison, DJ			MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers	ONCOGENE			English	Article						18q21 gene mutations; colon cancer; lung cancer	CPG-BINDING-PROTEIN; HISTONE DEACETYLASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; DROSOPHILA-TRITHORAX; MESSENGER-RNA; ALL-1 GENE; DOMAIN; EXPRESSION; DCC	The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5'-DCC 3'-MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis.	Univ Edinburgh, Mol Med Ctr, Div Pathol, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Life Sci Technol, NL-7500 KB Enschede, Netherlands	University of Edinburgh; University of Edinburgh	Bader, S (corresponding author), Univ Edinburgh, Mol Med Ctr, Div Pathol, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland.	s.bader@ed.ac.uk	McQueen, Heather/AAS-3294-2020	McQueen, Heather/0000-0002-4228-6081; Bird, Adrian/0000-0002-8600-0372; harrison, david/0000-0001-9041-9988				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Carlone DL, 2001, MOL CELL BIOL, V21, P7601, DOI 10.1128/MCB.21.22.7601-7606.2001; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; Fabre M, 1999, INT J CANCER, V81, P799, DOI 10.1002/(SICI)1097-0215(19990531)81:5<799::AID-IJC22>3.3.CO;2-N; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 1999, MOL CELL BIOL, V19, P6415; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Muller-Tidow C, 2001, BRIT J CANCER, V85, P1168, DOI 10.1054/bjoc.2001.2041; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; SHISEKI M, 1994, CANCER RES, V54, P5643; TAKAI K, 1998, CANCER RES, V58, P3700; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	46	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3506	3510		10.1038/sj.onc.1206574	http://dx.doi.org/10.1038/sj.onc.1206574			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776203				2022-12-28	WOS:000183128500018
J	Wu, WC; Shu, XD; Hovsepyan, H; Mosteller, RD; Broek, D				Wu, WC; Shu, XD; Hovsepyan, H; Mosteller, RD; Broek, D			VEGF receptor expression and signaling in human bladder tumors	ONCOGENE			English	Article						VEGF; sphingosine kinase; bladder tumor	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; VASCULAR-PERMEABILITY FACTOR; SPHINGOSINE KINASE; GENE-PRODUCT; IN-VITRO; CELLS; ACTIVATION; CANCER; RAS	Overexpression of vascular endothelial growth factor receptors (VEGFRs) has been reported in a variety of tumor types. Here we find that 11 out of the 14 bladder tumor cell tines examined express one or more VEGF receptors. Analysis of the T24 bladder tumor cell line reveals a functional autocrine loop involving VEGF and the Flk-1 receptor. Blocking VEGF expression in T24 cells results in a decrease in DNA synthesis. The Flk-1 receptor in T24 cells is phosphorylated in response to VEGF-121 or VEGF-165, and an Flk-1 inhibitor blocks VEGF to ERK signaling. We report that VEGF stimulation of T24 cells results in activation of H- and N-Ras and this is dependent on cellular sphingosine kinase I (SPK1) activity. Previously, we found VEGF-induced activation of Ras appears to be independent of a Ras-guanine nucleotide exchange factors (GEFs). Here we report that sphingosine can stimulate Ras-GTPase activating protein (GAP) activity in vitro, and sphingosine-I-phosphate (SPP) can block the stimulatory effects of sphingosine. We present a model where the balance between sphingosine and SPP regulates Ras-GAP activity such that stimulation of SPK1 favors downregulation of Ras-GAP and thereby the activation of Ras proteins. These data highlight a VEGF pathway that may be involved in the survival and proliferation of bladder tumor cells as well as other tumor cell types.	Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California	Broek, D (corresponding author), Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.				NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; BROWN LF, 1993, AM J PATHOL, V143, P1255; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Crew JP, 1997, CANCER RES, V57, P5281; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrer FA, 1999, UROLOGY, V54, P567, DOI 10.1016/S0090-4295(99)00156-9; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; ObergWelsh C, 1997, MOL CELL ENDOCRINOL, V126, P125, DOI 10.1016/S0303-7207(96)03977-9; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Strawn LM, 1996, CANCER RES, V56, P3540; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Veikkola T, 2000, CANCER RES, V60, P203; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	35	127	141	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3361	3370		10.1038/sj.onc.1206285	http://dx.doi.org/10.1038/sj.onc.1206285			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776187				2022-12-28	WOS:000183128500002
J	Ivanov, VN; Bhoumik, A; Ronai, Z				Ivanov, VN; Bhoumik, A; Ronai, Z			Death receptors and melanoma resistance to apoptosis	ONCOGENE			English	Review						melanoma; apoptosis; death receptors; Fas; TNFR-1; TRAIL	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; PROTEIN LIGASE ACTIVITY; FAS-LIGAND; SIGNAL-TRANSDUCTION; DOWN-REGULATION; TNF-ALPHA; C-JUN; TRANSCRIPTIONAL REGULATION	Impaired ability to undergo programmed cell death in response to a wide range of external stimuli acquires melanomas a selective advantage for progression and metastasis as well as their notorious resistance to therapy. Better understanding of mechanisms that govern apoptosis has enabled identification of diverse routes by which melanomas manage to escape stimuli of apoptosis. Changes at genomic, transcriptional and post-translational levels of G-proteins and protein kinases (Ras, B-Raf) and their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL receptors, which play important roles in acquiring melanoma's resistance to apoptosis. Here, we summarize our current understanding of changes that alters the regulation of death receptors during melanoma development.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.	Zeev.ronai@mssm.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA55995, CA559908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [S15CA055995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Aoki K, 2000, MOL THER, V1, P555, DOI 10.1006/mthe.2000.0076; Aragane Y, 2000, J INVEST DERMATOL, V115, P1008, DOI 10.1046/j.1523-1747.2000.00164.x; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Bhoumik A, 2001, CLIN CANCER RES, V7, P331; Bullani RR, 2002, MELANOMA RES, V12, P263, DOI 10.1097/00008390-200206000-00010; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Griffith TS, 1998, J IMMUNOL, V161, P2833; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Herlyn M, 1996, AM J PATHOL, V149, P739; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Hug H, 1997, BIOL CHEM, V378, P1405; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KRASILNIKOV M, 2003, IN PRESS MOL CELL BI; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsui K, 1998, J IMMUNOL, V161, P3469; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Murray PG, 2001, J PATHOL, V194, P158, DOI 10.1002/path.873; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Niu GL, 2001, CANCER RES, V61, P3276; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Soubrane C, 2000, BRIT J DERMATOL, V143, P307, DOI 10.1046/j.1365-2133.2000.03655.x; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thomas WD, 1998, J IMMUNOL, V161, P2195; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Worth LL, 2002, ONCOL REP, V9, P823; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	123	183	191	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3152	3161		10.1038/sj.onc.1206456	http://dx.doi.org/10.1038/sj.onc.1206456			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789291	Green Published			2022-12-28	WOS:000183096600017
J	Russo, G; Claudio, PP; Fu, Y; Stiegler, P; Yu, ZL; Macaluso, M; Giordano, A				Russo, G; Claudio, PP; Fu, Y; Stiegler, P; Yu, ZL; Macaluso, M; Giordano, A			pRB(2)/p130 target genes in non-small lung cancer cells identified by microarray analysis	ONCOGENE			English	Article						lung cancer; Rb2/p130; microarray analysis	NF-KAPPA-B; POLO-LIKE KINASE; NUCLEAR ANTIGEN; CYCLIN D1; DIFFERENTIAL EXPRESSION; IN-VIVO; GROWTH; PROTEIN; CARCINOMA; MYB	The retinoblastoma gene family consisting of RB/p105, p107, and RB2/p130 cooperate to regulate cell-cycle progression through the G1 phase of the cell cycle. Previous data demonstrated an independent role for the reduction or loss of pRb2/p130 expression in the formation and/or progression of lung carcinoma. Rb2/p130 is mutated in a human cell line of lung small cell carcinoma as well as in primary lung tumors. To identify potential pRb2/p130 target genes in an unbiased manner, we have utilized an adenovirus-mediated expression system of pRb2/p130 in a non-small lung cancer cell line to identify specific genes that are regulated by pRb2/p130. Using oligonucleotide arrays, a number of Rb2/p130 downregulated genes were identified and their regulation was confirmed by semiquantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. As a result, 40 genes showed greater than 2.0-fold modi. cation in their expression level after the RB2/p130 viral transduction. In conclusion, coupling adenoviral overexpression with microarray and semiquantitative RT-PCR analyses proved to be a versatile strategy for identifying pRb2/p130 target genes and for better understanding the expression profiles of these genes. Our results may also contribute to identifying novel therapeutic biomarkers in lung carcinoma.	Temple Univ, Coll Sci & Technol, Dept Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Inst Human Pathol & Oncol, I-53100 Siena, Italy; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillofacciali, Naples, Italy; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University of Naples Federico II; Jefferson University; Jefferson University	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Dept Biotechnol, Sbarro Inst Canc Res & Mol Med, 1900 N 12th St,Room 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622				Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 1999, CIRC RES, V85, P1032; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cunningham MD, 2003, BIOCHEM BIOPH RES CO, V300, P403, DOI 10.1016/S0006-291X(02)02863-2; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fathi Z, 1996, J CELL BIOCHEM, P237; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Forslund KO, 2001, EXP CELL RES, V265, P185, DOI 10.1006/excr.2001.5173; GILLETT C, 1994, CANCER RES, V54, P1812; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Hibi K, 1998, CANCER RES, V58, P5690; HOYT RF, 1993, ANAT REC, V236, P15, DOI 10.1002/ar.1092360106; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; KAWAI T, 1994, CANCER, V74, P2468, DOI 10.1002/1097-0142(19941101)74:9<2468::AID-CNCR2820740913>3.0.CO;2-X; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Markey MP, 2002, CANCER RES, V62, P6587; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Milligan SA, 2001, ANTICANCER RES, V21, P39; Minimo C, 1999, PATHOL RES PRACT, V195, P67, DOI 10.1016/S0344-0338(99)80072-7; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Raschella G, 1996, EXP CELL RES, V222, P395, DOI 10.1006/excr.1996.0049; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Reissmann PT, 1999, J CANCER RES CLIN, V125, P61, DOI 10.1007/s004320050243; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Sugita M, 2002, CANCER RES, V62, P3971; Teng DHF, 2001, GENOMICS, V74, P352, DOI 10.1006/geno.2001.6551; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; Volm M, 2000, BRIT J CANCER, V82, P1747; Wiest JS, 1997, J CELL BIOCHEM, P64; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yano T, 1998, LIFE SCI, V64, P229, DOI 10.1016/S0024-3205(98)00558-X; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	60	17	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6959	6969		10.1038/sj.onc.1206866	http://dx.doi.org/10.1038/sj.onc.1206866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534545				2022-12-28	WOS:000185843400019
J	Takeuchi, S; Seriu, T; van Dongen, JJM; Szczepanski, T; Tsukasaki, K; Takeuchi, N; Fermin, AC; Seo, H; Bartram, CR; Koeffler, HP				Takeuchi, S; Seriu, T; van Dongen, JJM; Szczepanski, T; Tsukasaki, K; Takeuchi, N; Fermin, AC; Seo, H; Bartram, CR; Koeffler, HP			Allelotype analysis in relapsed childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						LOH; ALL; 9p; 12p	2 DISTINCT REGIONS; INITIAL DIAGNOSIS; FREQUENT LOSS; LONG ARM; DELETION; ABNORMALITIES; HETEROZYGOSITY; IDENTIFICATION; CHILDREN; TEL	We performed for the first time the allelotype of relapsed childhood acute lymphoblastic leukemia ( ALL). A total of 38 cases were screened for loss of heterozygosity (LOH) using 71 markers. In all, 26 (68%) patients showed LOH on at least one chromosomal arm, indicating that LOH is a frequent event at relapse. The most frequent loss was found on chromosomal arm 9p at the p16/INK4a locus (39%). LOH at the TEL gene locus on chromosomal arm 12p also occurred often (25%). Frequent loss was observed on chromosome arms 4q (20%), 6q (21%), and 17q (20%). Sequential analysis (i.e. samples obtained from both initial diagnosis and relapse) shows that some patients (63%) have the identical LOH status at both phases, suggesting the presence of the same clone. Other samples (37%) showed distinct LOH alterations, indicating clonal evolution at relapse. Despite the heterogeneous and complex changes, some shared LOH loci occurred in these matched samples, suggesting that many of the same tumor-suppressor genes are aberrant at both phases. In summary, novel tumor-suppressor genes on chromosome arms 4q, 6q, and 17q, as well as the p16 and TEL genes, have an important role in the relapse of childhood ALL.	Kochi Med Sch, Dept Med, Nanko Ku, Kochi 7838505, Japan; Heidelberg Univ, Inst Human Genet, D-69120 Heidelberg, Germany; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; L Warynski Silesian Med Acad, Dept Pediat Hematol & Chemotherapy, Zabrze, Poland; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA	Kochi University; Ruprecht Karls University Heidelberg; Erasmus University Rotterdam; Medical University Silesia; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Takeuchi, S (corresponding author), Kochi Med Sch, Dept Med, Nanko Ku, Kochi 7838505, Japan.	takeuti@kochi-ms.ac.jp	van Dongen, Jacques J.M./F-8537-2015	van Dongen, Jacques J.M./0000-0001-7686-0021; Szczepanski, Tomasz/0000-0001-5336-261X; van Dongen, Jacques J.M./0000-0002-3650-7087				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carter TL, 2001, BRIT J HAEMATOL, V113, P323, DOI 10.1046/j.1365-2141.2001.02729.x; Gaynon PS, 1998, CANCER, V82, P1387, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Harrison CJ, 2001, BLOOD REV, V15, P49, DOI 10.1054/blre.2001.0150; HEEREMA NA, 1992, LEUKEMIA, V6, P185; Heerema NA, 1999, BLOOD, V94, P1537; Heerema NA, 2000, CANCER-AM CANCER SOC, V88, P1945, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1945::AID-CNCR25>3.0.CO;2-6; HEIM S, 1988, CANCER RES, V48, P5911; KAMELREID S, 1991, BLOOD, V78, P2973; Kamps WA, 2002, LEUKEMIA, V16, P1099, DOI 10.1038/sj.leu.2402489; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; McLean TW, 1996, BLOOD, V88, P4252; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; RAIMONDI SC, 1993, BLOOD, V81, P2237; Schrappe M, 2000, BLOOD, V95, P3310; SHIKANO T, 1990, LEUKEMIA, V4, P419; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Szczepanski T, 2002, BLOOD, V99, P2315, DOI 10.1182/blood.V99.7.2315; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Takeuchi S, 1998, CANCER RES, V58, P2618; Takeuchi S, 2003, LEUKEMIA, V17, P149, DOI 10.1038/sj.leu.2402727; Takeuchi S, 1997, LEUKEMIA, V11, P1636, DOI 10.1038/sj.leu.2400817; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Takeuchi S, 1999, ONCOGENE, V18, P7387, DOI 10.1038/sj.onc.1203145; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755	29	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6970	6976		10.1038/sj.onc.1206974	http://dx.doi.org/10.1038/sj.onc.1206974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534546				2022-12-28	WOS:000185843400020
J	Luciano, F; Jacquel, A; Colosetti, P; Herrant, M; Cagnol, S; Pages, G; Auberger, P				Luciano, F; Jacquel, A; Colosetti, P; Herrant, M; Cagnol, S; Pages, G; Auberger, P			Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function	ONCOGENE			English	Article						Bim; Erk1/2; proteasome; apoptosis	BCL-2 FAMILY MEMBER; DEPENDENT DEGRADATION; SIGNALING PATHWAY; CELL-SURVIVAL; APOPTOSIS; DEATH; BAD; EXPRESSION; ACTIVATION; INDUCTION	Bim is a proapoptotic member of the Bcl-2 family that shares only the BH3 domain with this family. Three Bim proteins Bim-EL, Bim-L and Bim-S are synthesized from the same transcript. We report here that Bim-EL when phosphorylated by Erk1/2 is rapidly degraded via the proteasome pathway. Using different cellular models we evidence that serine 69 is both necessary and sufficient for Erk1/2-mediated phosphorylation and degradation of Bim-EL. In K562 cells, Phorbol 12-myristate 13-acetate activates Erk1/2 and consequently increases Bim-EL phosphorylation and degradation by the proteasome, resulting in cell survival, while the Bcr-Abl inhibitor imatinib abrogates Bim-EL phosphorylation and degradation and induces caspase activation and apoptosis. We also show that Bim-EL(S69G) promotes apoptosis more efficiently than Bim-EL-WT in K562 cells. Altogether, our findings demonstrate that phosphorylation of Bim-EL by Erk1/2 on serine 69 selectively leads to its proteasomal degradation and therefore represents a new and important mechanism of Bim regulation.	Fac Med, LNC Label, INSERM, U526, F-06107 Nice 02, France; Ctr Antoine Lacassagne, CNRS, UMR 6547, F-06100 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Antoine Lacassagne	Auberger, P (corresponding author), Fac Med, LNC Label, INSERM, U526, 28 Ave Valombrose, F-06107 Nice 02, France.		luciano, frederic/P-6264-2016; Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; AUBERGER, Patrick/G-1491-2013; Jacquel, Arnaud/O-1928-2017; Pages, Gilles/N-7135-2017	luciano, frederic/0000-0001-9253-4998; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Jacquel, Arnaud/0000-0001-5062-8048; Colosetti, Pascal/0000-0002-5848-6053				Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	26	376	386	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6785	6793		10.1038/sj.onc.1206792	http://dx.doi.org/10.1038/sj.onc.1206792			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555991				2022-12-28	WOS:000185799300013
J	Desai, AA; Innocenti, F; Ratain, MJ				Desai, AA; Innocenti, F; Ratain, MJ			Pharmacogenomics: road to anticancer therapeutics nirvana?	ONCOGENE			English	Review						pharmacogenomics; cancer chemotherapy; EGFR; irinotecan; thymidylate synthase	EPIDERMAL-GROWTH-FACTOR; THYMIDYLATE-SYNTHASE GENE; HUMAN UDP-GLUCURONOSYLTRANSFERASES; ACTIVE METABOLITE; REPEATED SEQUENCES; IRINOTECAN CPT-11; COLORECTAL-CANCER; REGULATORY REGION; UGT1A1 PROMOTER; ENHANCER REGION	Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such 'unpredictable' drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of 'individualized' treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.	Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Ratain, MJ (corresponding author), Univ Chicago, Canc Res Ctr, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	mratain@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER; NIGMS NIH HHS [U01GM61393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acuna Gonzalo, 2002, Pharmacogenomics Journal, V2, P327, DOI 10.1038/sj.tpj.6500123; ADAMSON ED, 1981, MOL CELL BIOCHEM, V34, P129, DOI 10.1007/BF02359619; Akaba K, 1998, BIOCHEM MOL BIOL INT, V46, P21; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Ando Y, 2000, CANCER RES, V60, P6921; ARAKI E, 1993, JPN J CANCER RES, V84, P697, DOI 10.1111/j.1349-7006.1993.tb02031.x; Aschele C, 1999, J CLIN ONCOL, V17, P1760, DOI 10.1200/JCO.1999.17.6.1760; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; BRUNO R, 2003, P ASCO, V22; BURCHELL B, 1995, LIFE SCI, V57, P1819, DOI 10.1016/0024-3205(95)02073-R; Burchell B, 1999, J GASTROEN HEPATOL, V14, P960, DOI 10.1046/j.1440-1746.1999.01984.x; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen Z, 2000, ANTICANCER RES, V20, P899; Chi D. D., 1992, Human Molecular Genetics, V1, P135, DOI 10.1093/hmg/1.2.135; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; Chu E, 1999, CANC DRUG DISC DEV, P397; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; CLARK GM, 2003, P ASCO, V22; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Dolnick BJ, 2000, CANCER J, V6, P215; EVANS DAP, 1968, ANN NY ACAD SCI, V151, P723, DOI 10.1111/j.1749-6632.1968.tb11933.x; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Fuchs CS, 2003, J CLIN ONCOL, V21, P807, DOI 10.1200/JCO.2003.08.058; Fukuoka M, 2002, P AN M AM SOC CLIN, V21, p298a; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; GRAU JJ, 2003, P ASCO, V22; GUPTA E, 1994, CANCER RES, V54, P3723; HALEY JD, 1991, J BIOL CHEM, V266, P1746; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; HORIE N, 1995, CELL STRUCT FUNCT, V20, P191, DOI 10.1247/csf.20.191; Huang CS, 2000, PHARMACOGENETICS, V10, P539, DOI 10.1097/00008571-200008000-00007; Humerickhouse R, 2000, CANCER RES, V60, P1189; Innocenti F, 2002, PHARMACOGENETICS, V12, P725, DOI 10.1097/00008571-200212000-00006; Innocenti F, 2002, EUR J CANCER, V38, P639, DOI 10.1016/S0959-8049(01)00434-8; INNOCENTI F, 2003, P ASCO, V22; Innocenti F, 2002, PHARMACOGENOMICS SEA; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Iyer L, 1999, CLIN PHARMACOL THER, V65, P576, DOI 10.1016/S0009-9236(99)70078-0; Iyer L, 1998, CANCER CHEMOTH PHARM, V42, pS31, DOI 10.1007/s002800051077; Iyer L., 2002, Pharmacogenomics Journal, V2, P43, DOI 10.1038/sj.tpj.6500072; Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915; JOHNSTON PG, 1994, J CLIN ONCOL, V12, P2640, DOI 10.1200/JCO.1994.12.12.2640; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KALOW W, 1956, LANCET, V271, P576; KANEDA S, 1987, NUCLEIC ACIDS RES, V15, P1259, DOI 10.1093/nar/15.3.1259; KAWABE S, 2003, P AM SOC CLIN ONCOLO, V22; Kawakami K., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P436; Kohn EC, 1997, J CLIN ONCOL, V15, P1985, DOI 10.1200/JCO.1997.15.5.1985; Korn EL, 2001, J CLIN ONCOL, V19, P265, DOI 10.1200/JCO.2001.19.1.265; Kornmann M, 1997, CANCER LETT, V118, P29, DOI 10.1016/S0304-3835(97)00220-6; KRIS MG, 2002, P ASCO, V21; Leichman CG, 1997, J CLIN ONCOL, V15, P3223, DOI 10.1200/JCO.1997.15.10.3223; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; Liu WQ, 2003, CLIN CANCER RES, V9, P1009; Luo HR, 2002, BIOCHEM GENET, V40, P41, DOI 10.1023/A:1014589105977; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Mandola MV, 2003, CANCER RES, V63, P2898; Marsh S, 2000, Hum Mutat, V16, P528; Marsh S, 2001, INT J ONCOL, V19, P383; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Monaghan G, 1997, PHARMACOGENETICS, V7, P153, DOI 10.1097/00008571-199704000-00010; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; Nagasubramanian R, 2003, ANNU REV MED, V54, P437, DOI 10.1146/annurev.med.54.101601.152352; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; PESTALOZZI BC, 1995, BRIT J CANCER, V71, P1151, DOI 10.1038/bjc.1995.225; Peus D, 1997, J INVEST DERMATOL, V109, P751, DOI 10.1111/1523-1747.ep12340759; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Pullarkat S. T., 2001, Pharmacogenomics Journal, V1, P65; Ratain MJ, 2001, NAT MED, V7, P283, DOI 10.1038/85414; Reardon David A, 2003, Oncology (Williston Park), V17, P9; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALTZ L, 2002, P ASCO, V21; Saltz LB, 2003, P ASCO, V22, p817a; Sampietro M, 1999, HAEMATOLOGICA, V84, P150; Santos A, 2000, CLIN CANCER RES, V6, P2012; Sato H, 1996, LANCET, V347, P557, DOI 10.1016/S0140-6736(96)91266-0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SOONG R, 2003, P ASCO, V22; Stadler WM, 2000, INVEST NEW DRUG, V18, P7, DOI 10.1023/A:1006371512390; Sugatani J, 2002, BIOCHEM BIOPH RES CO, V292, P492, DOI 10.1006/bbrc.2002.6683; Sung T, 2000, BRAIN PATHOL, V10, P249, DOI 10.1111/j.1750-3639.2000.tb00258.x; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Villafranca E, 2001, J CLIN ONCOL, V19, P1779, DOI 10.1200/JCO.2001.19.6.1779	90	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6621	6628		10.1038/sj.onc.1206958	http://dx.doi.org/10.1038/sj.onc.1206958			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528287				2022-12-28	WOS:000185700700019
J	Iyengar, P; Combs, TP; Shah, SJ; Gouon-Evans, V; Pollard, JW; Albanese, C; Flanagan, L; Tenniswood, MP; Guha, C; Lisanti, MP; Pestell, RG; Scherer, PE				Iyengar, P; Combs, TP; Shah, SJ; Gouon-Evans, V; Pollard, JW; Albanese, C; Flanagan, L; Tenniswood, MP; Guha, C; Lisanti, MP; Pestell, RG; Scherer, PE			Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization	ONCOGENE			English	Review						stromal cells; heterotypic signaling; breast cancer; adipocytes; Type VI collagen	HUMAN-BREAST-CANCER; BETA-CATENIN; EPITHELIAL-CELL; GENE-EXPRESSION; ADIPOSE-TISSUE; GROWTH-FACTOR; MALIGNANT-TRANSFORMATION; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MESSENGER-RNA	Mammary epithelial cells are embedded in a unique extracellular environment to which adipocytes and other stromal cells contribute. Mammary epithelial cells are critically dependent on this milieu for survival. However, it remains unknown which adipocyte-secreted factors are required for the survival of the mammary epithelia and what role these adipokines play in the process of ductal carcinoma tumorigenesis. Here, we take a systematic molecular approach to investigate the multiple ways adipocytes and adipokines can uniquely influence the characteristics and phenotypic behavior of malignant breast ductal epithelial cells. Microarray analysis and luciferase reporter assays indicate that adipokines specifically induce several transcriptional programs involved in promoting tumorigenesis, including increased cell proliferation (IGF2, FOS, JUN, cyclin D1), invasive potential (MMP1, ATF3), survival (A20, NFkappaB), and angiogenesis. One of the key changes in the transformed ductal epithelial cells associated with the cell cycle involves the induction of NFkappaB (five-fold) and cyclin D1 (three-fold). We show that by regulating the transcription of these molecules, the synergistic activity of adipocyte-derived factors can potentiate MCF-7 cell proliferation. Furthermore, compared to other stromal cell-secreted factors, the full complement of adipokines shows an unparalleled ability to promote increased cell motility, migration, and the capacity for angiogenesis. Adipocyte-secreted factors can affect tumorigenesis by increasing the stabilization of pro-oncogenic factors such as beta-catenin and CDK6 as a result of a reduction in the gene expression of their inhibitors (i.e. p18). An in vivo coinjection system using 3T3-L1 adipocytes and SUM159PT cells effectively recapitulates the host-tumor interactions in primary tumors. Type VI collagen, a soluble extracellular matrix protein abundantly expressed in adipocytes, is further upregulated in adipocytes during tumorigenesis. It promotes GSK3beta phosphorylation, beta-catenin stabilization, and increased beta-catenin activity in breast cancer cells and may critically contribute towards tumorigenesis when not counterbalanced by other factors.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Radiat Oncol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Univ Notre Dame, Galvin Life Sci Ctr, Notre Dame, IN 46556 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Georgetown University; University of Notre Dame; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Gouon-Evans, Valerie/0000-0001-5424-6573; Shah, Shalin/0000-0002-1622-8443	NATIONAL CANCER INSTITUTE [R01CA094173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [CA94173] Funding Source: Medline; NIDDK NIH HHS [1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achison M, 2001, J BIOL CHEM, V276, P3167, DOI 10.1074/jbc.M007186200; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BATSAKIS JG, 1983, HEAD NECK SURG, V5, P222, DOI 10.1002/hed.2890050307; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berking C, 2001, CANCER RES, V61, P8306; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bickel PE, 2000, BIOTECHNOL GENET ENG, V17, P417, DOI 10.1080/02648725.2000.10648000; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; CASTELLOT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P5597, DOI 10.1073/pnas.79.18.5597; Chamras H, 1998, NUTR CANCER, V32, P59, DOI 10.1080/01635589809514719; Charpentier AH, 2000, CANCER RES, V60, P5977; Cheng YC, 2001, MOL BRAIN RES, V92, P193, DOI 10.1016/S0169-328X(01)00147-4; CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1; Codd JD, 1999, J PATHOL, V187, P549; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cunha GR, 2000, ADV EXP MED BIOL, V480, P93; de la Guardia C, 2001, HEAD NECK-J SCI SPEC, V23, P104; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M; ELLIOTT BE, 1992, INT J CANCER, V51, P416, DOI 10.1002/ijc.2910510314; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FIDLER I, 2001, J NATL CANC I MONOGR, V28, P10; Fidler I J, 2001, Surg Oncol Clin N Am, V10, P257; Fidler IJ, 2001, JNCI-J NATL CANCER I, V93, P1040, DOI 10.1093/jnci/93.14.1040; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen RK, 2000, ENDOCR-RELAT CANCER, V7, P95, DOI 10.1677/erc.0.0070095; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hayward SW, 2001, CANCER RES, V61, P8135; Heber D, 1996, ADV EXP MED BIOL, V399, P41; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Huss FRM, 2001, CELLS TISSUES ORGANS, V169, P361, DOI 10.1159/000047903; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; JOHNSTON PG, 1992, CANCER RES, V52, P6860; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lapointe J, 1996, CANCER RES, V56, P4586; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIOTTA LA, 1983, LAB INVEST, V49, P636; Liu SC, 2000, ORAL ONCOL, V36, P145, DOI 10.1016/S1368-8375(99)00076-7; Matrisian LM, 2001, CANCER RES, V61, P3844; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; McKeon F, 1999, Breast Cancer Res, V1, P8, DOI 10.1186/bcr4; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Brien SN, 1999, BIOCHEM BIOPH RES CO, V259, P695, DOI 10.1006/bbrc.1999.0843; Oh Y, 1997, ENDOCRINE, V7, P111, DOI 10.1007/BF02778076; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Pentecost BT, 1998, J STEROID BIOCHEM, V64, P25, DOI 10.1016/S0960-0760(97)00140-4; Perks CM, 2000, J MAMMARY GLAND BIOL, V5, P75, DOI 10.1023/A:1009519400591; PEYRAT JP, 1988, CANCER RES, V48, P6429; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rahimi N, 1998, IN VITRO CELL DEV-AN, V34, P412; Rasmussen AA, 1998, BREAST CANCER RES TR, V47, P219, DOI 10.1023/A:1005903000777; Ross JS, 2001, ANN NY ACAD SCI, V947, P271; Ruhl M, 1999, J BIOL CHEM, V274, P34361, DOI 10.1074/jbc.274.48.34361; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Shaw LM, 1999, J MAMMARY GLAND BIOL, V4, P367, DOI 10.1023/A:1018766317055; SHERR CJ, 1994, STEM CELLS, V12, P47; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shigeishi H, 2001, PATHOBIOLOGY, V69, P24, DOI 10.1159/000048754; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; Tani M, 1997, GENOMICS, V39, P30, DOI 10.1006/geno.1996.4483; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Wagenaar RA, 2001, CANCER RES, V61, P2097; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Ye S, 2001, CANCER RES, V61, P1296; Zangani D, 1999, EXP CELL RES, V247, P399, DOI 10.1006/excr.1998.4373; Zhang JY, 2001, CLIN EXP IMMUNOL, V125, P3, DOI 10.1046/j.1365-2249.2001.01585.x	105	263	282	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6408	6423		10.1038/sj.onc.1206737	http://dx.doi.org/10.1038/sj.onc.1206737			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508521				2022-12-28	WOS:000185535300011
J	Lui, VWY; Thomas, SM; Zhang, Q; Wentzel, AL; Siegfried, JM; Li, JY; Grandis, JR				Lui, VWY; Thomas, SM; Zhang, Q; Wentzel, AL; Siegfried, JM; Li, JY; Grandis, JR			Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor	ONCOGENE			English	Article						EGFR transactivation; GRPR; G-protein-coupled receptor; TGF-alpha; head and neck cancer	BOMBESIN ANTAGONIST RC-3095; LUNG-CARCINOMA CELLS; SMOOTH-MUSCLE-CELLS; PROSTATE-CANCER; MESSENGER-RNA; NEUROMEDIN-B; EGF RECEPTOR; AUTOCRINE GROWTH; EPITHELIAL-CELLS; PROTEIN-KINASE	Head and neck squamous cell carcinomas (HNSCC) are characterized by upregulation of the epidermal growth factor receptor ( EGFR), where EGFR serves as a potential therapeutic target. We previously reported that a gastrin-releasing peptide/gastrin-releasing peptide receptor (GRP/GRPR) autocrine growth pathway is activated early in HNSCC carcinogenesis. In the present study, we examined the mechanism of EGFR activation by GRP/GRPR in HNSCC proliferation. In HNSCC cells that express elevated levels of both GRPR and EGFR, we found that GRP induced rapid phosphorylation of EGFR as well as p44/42-MAPK activation. Using several EGFR-specific tyrosine kinase inhibitors and cells derived from EGFR knockout mice, we demonstrated that GRP-induced p44/42-MAPK activation was dependent upon EGFR activation. Further investigation demonstrated that cleavage of transforming growth factor-alpha (TGF-alpha) by matrix metalloproteinases mediated GRP-induced MAPK activation. In addition, HNSCC proliferation stimulated by GRP was eliminated upon specific inhibition of EGFR or MEK, and GRP failed to stimulate proliferation in EGFR- deficient cells. These results imply that the mitogenic effects of GRP in HNSCC are mediated by extracellular release of TGF-alpha and require the activation of an EGFR- dependent MEK/MAPK-dependent pathway.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.		Thomas, Sufi Mary/AFR-1642-2022; Lui, Vivian W. Y./I-5458-2016; Thomas, Sufi/O-1487-2018; ZHANG, QING/AGY-7972-2022	Thomas, Sufi Mary/0000-0001-5370-0842; Lui, Vivian W. Y./0000-0001-6918-1573; Thomas, Sufi/0000-0001-5370-0842; ZHANG, QING/0000-0002-6595-8995	NATIONAL CANCER INSTITUTE [R01CA079882, U01CA084968, P50CA090440] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA84968, R01CA79882, P50CA90440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; ALEXANDER RW, 1988, CANCER RES, V48, P1439; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARNEY DN, 1987, CANCER RES, V47, P821; Carroll RE, 2000, CELL GROWTH DIFFER, V11, P385; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Charlesworth A, 1996, ONCOGENE, V12, P1337; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Feldman RI, 1996, MOL PHARMACOL, V50, P1346; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; HALMOS G, 1995, CANCER RES, V55, P280; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; Lango MN, 2002, J NATL CANCER I, V94, P375; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; LIEBOW C, 1994, P NATL ACAD SCI USA, V91, P3804, DOI 10.1073/pnas.91.9.3804; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nagakawa O, 2000, CANCER LETT, V155, P173, DOI 10.1016/S0304-3835(00)00425-0; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; Pansky A, 2000, J AM SOC NEPHROL, V11, P1409, DOI 10.1681/ASN.V1181409; PINSKI J, 1994, BRIT J CANCER, V70, P886, DOI 10.1038/bjc.1994.415; Plonowski A, 2000, INT J CANCER, V88, P652, DOI 10.1002/1097-0215(20001115)88:4<652::AID-IJC21>3.0.CO;2-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rounseville MP, 2000, J MOL ENDOCRINOL, V25, P121, DOI 10.1677/jme.0.0250121; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Santiskulvong C, 2001, AM J PHYSIOL-CELL PH, V281, pC886, DOI 10.1152/ajpcell.2001.281.3.C886; Sharif TR, 1997, MOL CELL ENDOCRINOL, V130, P119, DOI 10.1016/S0303-7207(97)00080-4; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; SIEGFRIED JM, 1998, BIOL LUNG CANC, P317; SORENSON GD, 1982, REGUL PEPTIDES, V4, P59, DOI 10.1016/0167-0115(82)90095-7; Sun BD, 2000, REGUL PEPTIDES, V90, P77, DOI 10.1016/S0167-0115(00)00114-2; Sun BD, 2000, PROSTATE, V42, P295; Szepeshazi K, 1997, P NATL ACAD SCI USA, V94, P10913, DOI 10.1073/pnas.94.20.10913; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	54	75	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6183	6193		10.1038/sj.onc.1206720	http://dx.doi.org/10.1038/sj.onc.1206720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679857				2022-12-28	WOS:000185506200008
J	Gurrola-Diaz, C; Lacroix, J; Dihlmann, S; Becker, CM; Doeberitz, MV				Gurrola-Diaz, C; Lacroix, J; Dihlmann, S; Becker, CM; Doeberitz, MV			Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha 1 subunit in small-cell lung cancer cells	ONCOGENE			English	Article						glycine receptor alpha-1 subunit; GLRA1; NRSF; NRSE; neuroendocrine differentiation; small-cell lung cancer; SCLC; NSCLC	GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-BINDING; REPRESSOR; PROTEIN; IDENTIFICATION; VARIANT; REST4; RAT	Small-cell lung cancer (SCLC) cells express various markers of neuronal differentiation associated with deficient activity of the neuron-restricted silencer factor (NRSF). Here, we characterize mechanisms by which NRSF target genes are upregulated in SCLC and their functional consequences for cell survival. Since the glycine receptor (GlyR) alpha1 subunit gene, GLRA1, contains a sequence motif for NRSF binding (NRSE) within its 5' UTR, it served as a cellular surrogate marker for NRSF activity. Expression of GLRA1 in nontransformed cells is largely restricted to cells in the spinal cord, retina and brain stem. In experiments described here, we detected GLRA1 transcripts in three out of four SCLC-derived cell lines and in three of five biopsy samples obtained from SCLCs. In contrast, no GLRA1 transcripts were found in 10 nonmalignant nor 15 non-small-cell lung cancer biopsies. Consistent with this observation, NRSF-mediated suppression of an expression construct harbouring the NRSE of the GLRA1 (GLRA1 NRSE) gene was impaired in three of four 'classic' SCLC cell lines, whereas exogenous overexpression of NRSF in NRSF-deficient SCLC cell lines reconstituted silencing of the reporter plasmid. The level of NRSF transcripts as well as the level of specifically bound NRSF to the NRSE correlated with the level of GLRA1 transcripts in SCLC cell lines. Splice variants encoding truncated NRSF proteins and expressed in some SCLC did not antagonize the repression of NRSE-containing genes. Most interestingly, reconstitution of NRSF expression induced apoptosis in SCLC cells, suggesting that inhibition of NRSF activity is a crucial step in the carcinogenesis of a subgroup of SCLC.	Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Erlangen Nurnberg, Emil Fischer Ctr, Inst Biochem, D-91054 Erlangen, Germany	Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de		Dihlmann, Susanne/0000-0002-3737-7755; Gurrola-Diaz, Carmen Magdalena/0000-0002-9851-8961				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; CARNEY DN, 1985, CANCER RES, V45, P2913; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coulson JM, 1999, CANCER RES, V59, P5123; Coulson JM, 2000, CANCER RES, V60, P1840; ENZ R, 1995, VISUAL NEUROSCI, V12, P501, DOI 10.1017/S0952523800008403; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Magin A, 2002, NEUROCHEM INT, V40, P195, DOI 10.1016/S0197-0186(01)00091-2; Monani U, 1996, GENOME RES, V6, P1200, DOI 10.1101/gr.6.12.1200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Palm K, 1998, J NEUROSCI, V18, P1280; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; PARKIN DM, 1994, ANTICANCER RES, V14, P277; Quinn JP, 2002, REGUL PEPTIDES, V108, P135, DOI 10.1016/S0167-0115(02)00103-9; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200	25	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5636	5645		10.1038/sj.onc.1206790	http://dx.doi.org/10.1038/sj.onc.1206790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944912				2022-12-28	WOS:000184865900013
J	Yang, G; Thompson, JA; Fang, BL; Liu, JS				Yang, G; Thompson, JA; Fang, BL; Liu, JS			Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer	ONCOGENE			English	Article						siRNA; H-ras; retrovirus; ovarian cancer	SMALL INTERFERING RNA; MAMMALIAN-CELLS; EPITHELIAL TUMORS; STABLE SUPPRESSION; HAIRPIN RNAS; MUTATIONS; ACTIVATION; PROTOONCOGENE; CARCINOMAS; ONCOGENES	To examine the role of H-ras in the development of human ovarian cancer, we used small inhibitory RNA (siRNA) to silence its expression in human ovarian cancer cell lines and assessed the effects of its silencing on proliferation, apoptosis, and tumorgrowth. First, we developed a retrovirus-based delivery system that allowed long-term stable expression of the desired siRNA. Retrovirus-mediated expression of siRNA against green fluorescence protein (GFP) reduced its expression more than 90% in four cancer cell lines. We then constructed three retroviruses that expressed siRNAs targeting the H-rasV(12) mutation (H1/siRNA) or either of two wild-type sequences of the H-ras gene (H2/siRNA and H3/siRNA) and used these retroviruses to infect T80H and SKOV-3 cells. In T80H cells (a genetically transformed human ovarian surface epithelial cell tine whose tumorigenicity depends on H-rasV(12) expression), infection with the H1/siRNA and H2/siRNA, but not with H3/siRNA, decreased T80H proliferation, increased G(0)/G(1) arrest and apoptosis, blocked transformation in vitro, and suppressed tumor growth in nude mice. In SKOV-3 cells (a human ovarian cancer cell line that contains high levels of wild-type H-ras protein but no H-rasV(12) mutation), introduction of the H2/siRNA construct, but not H1/siRNA or H3/siRNA, produced similar effects, demonstrating that the suppression of tumorgrowth by siRNA was sequence-specific. We conclude that H-ras is involved in maintenance of tumorgrowth of human ovarian cancer, and that retrovirus-mediated siRNA expression against H-Pas expression is a powerful toot to dissect ras-signaling pathways and may be used therapeutically against ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cuatrecasas M, 1998, CANCER-AM CANCER SOC, V82, P1088; Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENOMOTO T, 1991, AM J PATHOL, V139, P777; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; ICHIKAWA Y, 1994, CANCER RES, V54, P33; JACQUE JM, 2002, NATURE, V26, P26; LIU J, 2003, UNPUB; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MOK SCH, 1993, CANCER RES, V53, P1489; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Patton SE, 1998, CANCER RES, V58, P2253; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	34	105	128	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5694	5701		10.1038/sj.onc.1206858	http://dx.doi.org/10.1038/sj.onc.1206858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944918				2022-12-28	WOS:000184865900019
J	Pan, W; Datta, A; Adami, GR; Raychaudhuri, P; Bagchi, S				Pan, W; Datta, A; Adami, GR; Raychaudhuri, P; Bagchi, S			P19ARF inhibits the functions of the HPV16 E7 oncoprotein	ONCOGENE			English	Article						ARF; HPV16 E7 oncoprotein; nucleolar localization; E7 relocalization; Rb proteolysis	HUMAN-PAPILLOMAVIRUS TYPE-16; E7 PROTEIN; DNA-REPLICATION; DIFFERENTIAL REGULATION; CARCINOMA-CELLS; GENE; P53; E2F; TRANSFORMATION; KERATINOCYTES	The E7 oncoprotein encoded by high-risk types of human papillomavirus (HPV) plays a significant role in the development of HPV-related cancers. E7 is a potent stimulator of S phase and host DNA replication. These functions of E7 are linked to the deregulation of the Rb family of proteins. For example, E7 binds and induces proteolysis of Rb through the ubiquitin-proteasome pathway. Despite advances in our understanding of E7, reagents that inhibit E7 with promise in therapy have not been developed or identified. Here, we provide evidence that the tumor suppressor ARF can inhibit E7. We show that the expression of ARF causes a relocalization of E7 from the nucleoplasm to the nucleolus. Two distinct regions in ARF overlapping with the MDM2-binding sites are necessary for the relocalization of E7. Furthermore, we show that ARF blocks the proteolysis of Rb induced by E7. In addition, ARF expression inhibits DNA replication induced by E7. Although it is not known whether the endogenous ARF, which is expressed at a low level, interferes with E7, our results suggest that ARF is an effective inhibitor of E7. We speculate that ARF or an ARF-derived molecule might have a significant impact in therapy against HPV-related tumors.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	sbagchi@uic.edu			NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012506] Funding Source: NIH RePORTER; NCI NIH HHS [CA76276] Funding Source: Medline; NIDCR NIH HHS [DE12506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bohl J, 2001, J VIROL, V75, P513, DOI 10.1128/JVI.75.1.513-521.2001; Boyer SN, 1996, CANCER RES, V56, P4620; CHANG FJ, 1991, J ORAL PATHOL MED, V20, P305, DOI 10.1111/j.1600-0714.1991.tb00936.x; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jian YC, 1999, CELL GROWTH DIFFER, V10, P101; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1989, J VIROL, V63, P4417; NEVINS JR, 1992, SCIENCE, V258, P424; QUELLE DE, 1995, CELL, V83, P993; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHILLITOE EJ, 1992, ANN NY ACAD SCI, V660, P286, DOI 10.1111/j.1749-6632.1992.tb21087.x; SHILLITOE EJ, 1994, CANCER GENE THER, V1, P193; STEELE C, 1992, CANCER RES, V52, P4706; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wettergreen MA, 2001, EUR J ORAL SCI, V109, P415, DOI 10.1034/j.1600-0722.2001.00105.x; Zatsepina O, 1997, ONCOGENE, V14, P1137, DOI 10.1038/sj.onc.1200946; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	38	15	16	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5496	5503		10.1038/sj.onc.1206857	http://dx.doi.org/10.1038/sj.onc.1206857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934109				2022-12-28	WOS:000184735000014
J	Willis, AC; Pipes, T; Zhu, JH; Chen, XB				Willis, AC; Pipes, T; Zhu, JH; Chen, XB			p73 can suppress the proliferation of cells that express mutant p53	ONCOGENE			English	Article						p73; p53; p21; cell cycle arrest; apoptosis	INDUCIBLE GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-DAMAGE; TUMOR-SUPPRESSOR; CODON-72 POLYMORPHISM; CYCLE ARREST; HEPATOCELLULAR-CARCINOMA; FUNCTIONAL DOMAINS; CHROMOSOME 1P36.3; COLORECTAL-CANCER	Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. p73, a member of the p53 family, has been found to exhibit activity similar to that of p53, including the ability to induce growth arrest and apoptosis. p53 and p73 have a high percentage of similarity at several domains, including the DNA binding domain. This domain in p53 is the location of missense mutations in many human cancers. Mutant p53, which cannot suppress cell proliferation, has been found to have a dominant-negative activity that inactivates wild-type p53. To determine the effects of mutant p53 on wild-type p73, we have established cell lines expressing both mutant p53 and wild-type p73 in a dual-inducible system. This system expresses mutant p53 in a tetracycline-repressible system and p73beta in an ecdysone-inducible system in a p53-null lung carcinoma parental cell tine. We have found that wild-type p73beta, in the presence of mutant p53, retains the ability to transactivate p21 and suppresses cell growth through induction of both cell cycle arrest and apoptosis. In addition, in cell lines expressing wild-type p53 and wild-type p73beta, we have found that these proteins cooperate to additively transactivate p21 and suppress cell proliferation.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35242 USA.			Amara, Amy/0000-0003-0762-9656	NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Calhoun ES, 2002, CLIN CHEM, V48, P1218; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harvey DM, 1998, CURR OPIN CHEM BIOL, V2, P512; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Robles AI, 2001, CANCER RES, V61, P6660; ROLLEY N, 1995, ONCOGENE, V11, P763; Rossi FMV, 1998, CURR OPIN BIOTECH, V9, P451, DOI 10.1016/S0958-1669(98)80028-1; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; Sambrook J., 2002, MOL CLONING LAB MANU; Saranath D, 2002, GYNECOL ONCOL, V86, P157, DOI 10.1006/gyno.2002.6735; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Shinoura N, 2000, CANCER LETT, V160, P67, DOI 10.1016/S0304-3835(00)00564-4; Sifakis S, 2001, CLIN GENET, V60, P165, DOI 10.1034/j.1399-0004.2001.600301.x; Soulitzis N, 2002, CANCER LETT, V179, P175, DOI 10.1016/S0304-3835(01)00867-9; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sunahara M, 1998, INT J ONCOL, V13, P319; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Toruner GA, 2001, UROL RES, V29, P393; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, PROSTATE, V39, P94; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	76	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5481	5495		10.1038/sj.onc.1206505	http://dx.doi.org/10.1038/sj.onc.1206505			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934108				2022-12-28	WOS:000184735000013
J	West, JT; Wood, C				West, JT; Wood, C			The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression	ONCOGENE			English	Review						Kaposi's sarcoma; KSHV; HHV-8; herpesvirus; transcriptional control; RTA	PRIMARY-EFFUSION LYMPHOMA; READING FRAME 50; PROTEIN-COUPLED RECEPTOR; IMMEDIATE-EARLY GENE; BARR-VIRUS EBV; POLYADENYLATED NUCLEAR-RNA; CREB-BINDING PROTEIN; LYTIC SWITCH PROTEIN; JAK-STAT PATHWAY; RBP-J-KAPPA	The mechanisms that control the replication state, latency versus lytic, of human herpesviruses have been under intense investigations. Here we summarize some of the recent findings that help define such mechanisms for Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV-8). For HHV-8, the viral regulator of transcription activation (RTA) is a key mediator of the switch from latency to lytic gene expression in infected cells. RTA is necessary and sufficient to drive HHV-8 lytic replication and the production of viral progeny. The RTA is an immediate-early gene product, it is the initial activator of expression of a multitude of viral and cellular genes that have been implicated in the replication of HHV-8 and pathogenesis of KS. Interactions of RTA with a number of viral promoters, and with a number of transcription factors or transcriptional co-activators are highlighted. Modulation of transactivation, through alternate RTA-protein, or RTA-promoter interactions, is hypothesisized to participate in the selective tissue tropism and differential pathogenesis observed in KS.	Univ Nebraska, Sch Biol Sci, Nebraska Ctr Virol, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Wood, C (corresponding author), Univ Nebraska, Sch Biol Sci, Nebraska Ctr Virol, 1901 Vine St,E249 Beadle Ctr, Lincoln, NE 68588 USA.	cwood1@unl.edu	Wood, Charles/AAH-4536-2021	Wood, Charles/0000-0002-4256-1530	NATIONAL CANCER INSTITUTE [R01CA075903, R01CA076958] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NCI NIH HHS [CA76958, CA75903] Funding Source: Medline; NCRR NIH HHS [RR15635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Alkan S, 1997, BRIT J HAEMATOL, V96, P412, DOI 10.1046/j.1365-2141.1997.d01-2040.x; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; An JB, 2002, BLOOD, V99, P649, DOI 10.1182/blood.V99.2.649; Aoki Y, 2000, BLOOD, V96, P1599, DOI 10.1182/blood.V96.4.1599.h8001599_1599_1601; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoki Y, 2001, BLOOD, V98, P3042, DOI 10.1182/blood.V98.10.3042; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAINES JD, 1994, J VIROL, V68, P8118, DOI 10.1128/JVI.68.12.8118-8124.1994; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Boshoff C, 2001, ANNU REV MED, V52, P453, DOI 10.1146/annurev.med.52.1.453; BOSHOFF C, 1995, LANCET, V345, P1043; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buonaguro FM, 1996, INT J CANCER, V65, P25, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;25::AID-IJC5&gt;3.0.CO;2-3; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 1998, VIROLOGY, V249, P140, DOI 10.1006/viro.1998.9316; Chang PJ, 2002, J VIROL, V76, P3168, DOI 10.1128/JVI.76.7.3168-3178.2002; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, INFECT AGENT DIS, V5, P215; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chen J, 2001, P NATL ACAD SCI USA, V98, P4119, DOI 10.1073/pnas.051004198; Cohrs RJ, 2001, BRAIN PATHOL, V11, P465, DOI 10.1111/j.1750-3639.2001.tb00415.x; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deng HY, 2000, J GEN VIROL, V81, P3043, DOI 10.1099/0022-1317-81-12-3043; Deng HY, 2002, BLOOD, V100, P1919, DOI 10.1182/blood-2002-01-0015; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; DeWire SM, 2002, J VIROL, V76, P9819, DOI 10.1128/JVI.76.19.9819-9831.2002; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Duan W, 2001, ARCH VIROL, V146, P403, DOI 10.1007/s007050170185; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Giles RH, 1998, TRENDS GENET, V14, P214, DOI 10.1016/S0168-9525(98)01500-5; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; GRUFFAT H, 1990, NUCLEIC ACIDS RES, V18, P6835, DOI 10.1093/nar/18.23.6835; GRUFFAT H, 1994, NUCLEIC ACIDS RES, V22, P1172, DOI 10.1093/nar/22.7.1172; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Gwack Y, 2002, J BIOL CHEM, V277, P6438, DOI 10.1074/jbc.M108289200; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Hall KT, 1999, J VIROL, V73, P9756, DOI 10.1128/JVI.73.12.9756-9763.1999; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Johannsen E, 1996, J VIROL, V70, P4179, DOI 10.1128/JVI.70.6.4179-4183.1996; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kedda MA, 1996, CLIN TRANSPLANT, V10, P429; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1997, JAMA-J AM MED ASSOC, V277, P478, DOI 10.1001/jama.277.6.478; KENNEY S, 1989, J VIROL, V63, P3870, DOI 10.1128/JVI.63.9.3870-3877.1989; KENNEY S, 1989, J VIROL, V63, P3878, DOI 10.1128/JVI.63.9.3878-3883.1989; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lefrere JJ, 1996, J INFECT DIS, V174, P283, DOI 10.1093/infdis/174.2.283; Li H, 2001, J VIROL, V75, P3325, DOI 10.1128/JVI.75.7.3325-3334.2001; Li MT, 1999, J VIROL, V73, P1341, DOI 10.1128/JVI.73.2.1341-1349.1999; Liang YY, 2002, GENE DEV, V16, P1977, DOI 10.1101/gad.996502; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu CQ, 2001, J VIROL, V75, P10933, DOI 10.1128/JVI.75.22.10933-10940.2001; Lukac DM, 1998, VIROLOGY, V252, P304, DOI 10.1006/viro.1998.9486; Lukac DM, 2001, J VIROL, V75, P6786, DOI 10.1128/JVI.75.15.6786-6799.2001; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; MANET E, 1991, NUCLEIC ACIDS RES, V19, P2661, DOI 10.1093/nar/19.10.2661; Manteuffel-Cymborowska M, 1999, ACTA BIOCHIM POL, V46, P77, DOI 10.18388/abp.1999_4185; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Memar OM, 1995, J MOL MED-JMM, V73, P603; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Muralidhar S, 1998, J VIROL, V72, P4980, DOI 10.1128/JVI.72.6.4980-4988.1998; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Neipel F, 1998, J Natl Cancer Inst Monogr, P73; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Nicholas J, 1998, J Natl Cancer Inst Monogr, P79; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; NICHOLAS J, 1988, J VIROL, V62, P3250, DOI 10.1128/JVI.62.9.3250-3257.1988; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Olsen SJ, 1998, AIDS, V12, P1921, DOI 10.1097/00002030-199814000-00024; Osborne J, 1999, HUM IMMUNOL, V60, P921, DOI 10.1016/S0198-8859(99)00083-X; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; QUINLIVAN EB, 1993, NUCLEIC ACIDS RES, V21, P1999, DOI 10.1093/nar/21.8.1999; Raab MS, 1998, J VIROL, V72, P6725, DOI 10.1128/JVI.72.8.6725-6731.1998; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Ragoczy T, 1999, J VIROL, V73, P9858, DOI 10.1128/JVI.73.12.9858-9866.1999; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Reed JA, 1998, BLOOD, V91, P3825, DOI 10.1182/blood.V91.10.3825.3825_3825_3832; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Roan F, 2002, VIROLOGY, V301, P293, DOI 10.1006/viro.2002.1582; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; Sakakibara S, 2001, J VIROL, V75, P6894, DOI 10.1128/JVI.75.15.6894-6900.2001; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Saveliev AK, 2002, VIROLOGY, V299, P301, DOI 10.1006/viro.2002.1561; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Schumann G, 1999, J NEUROCHEM, V73, P2009; Seaman WT, 1999, VIROLOGY, V263, P436, DOI 10.1006/viro.1999.9963; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Song MJ, 2002, J VIROL, V76, P5000, DOI 10.1128/JVI.76.10.5000-5013.2002; Song MJ, 2001, J VIROL, V75, P3129, DOI 10.1128/JVI.75.7.3129-3140.2001; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1999, J VIROL, V73, P4181, DOI 10.1128/JVI.73.5.4181-4187.1999; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Sun R, 1996, P NATL ACAD SCI USA, V93, P11883, DOI 10.1073/pnas.93.21.11883; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; Taylor TJ, 2002, FRONT BIOSCI-LANDMRK, V7, pD752, DOI 10.2741/taylor; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; Wan XY, 1999, J VIROL, V73, P8268, DOI 10.1128/JVI.73.10.8268-8278.1999; Wang S, 2001, ARCH VIROL, V146, P1415, DOI 10.1007/s007050170102; Wang SZ, 2001, J VIROL, V75, P11961, DOI 10.1128/JVI.75.24.11961-11973.2001; Weber-Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353; WeberNordt RM, 1996, BLOOD, V88, P809; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Whitehouse A, 1997, J VIROL, V71, P2550, DOI 10.1128/JVI.71.3.2550-2554.1997; Whitehouse A, 1998, J VIROL, V72, P1967, DOI 10.1128/JVI.72.3.1967-1973.1998; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Wu TT, 2000, J VIROL, V74, P3659, DOI 10.1128/JVI.74.8.3659-3667.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yu YM, 1999, J GEN VIROL, V80, P83, DOI 10.1099/0022-1317-80-1-83; Zalani S, 1996, P NATL ACAD SCI USA, V93, P9194, DOI 10.1073/pnas.93.17.9194; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; Zhu FX, 1999, J VIROL, V73, P5556, DOI 10.1128/JVI.73.7.5556-5567.1999	169	95	99	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5150	5163		10.1038/sj.onc.1206555	http://dx.doi.org/10.1038/sj.onc.1206555			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910252				2022-12-28	WOS:000184615100006
J	Xin, H; Curry, J; Johnstone, RW; Nickoloff, BJ; Choubey, D				Xin, H; Curry, J; Johnstone, RW; Nickoloff, BJ; Choubey, D			Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence	ONCOGENE			English	Article						interferon-inducible IFI 16; prostate; senescence; p21(WAF1); E2F; Rb	NEGATIVE REGULATOR; RETINOBLASTOMA PROTEIN; GENE; EXPRESSION; CELLS; P202; TRANSCRIPTION; IDENTIFICATION; LOCALIZATION; INHIBITION	Recent studies have implicated interferon signaling in the regulation of cellular senescence. However, the role of specific interferon-inducible proteins in cellular senescence remains to be defined. Here we report that IFI 16, an interferon-inducible transcriptional modulator from the p200-protein family, contributes to cellular senescence of prostate epithelial cells. Normal human prostate epithelial cells (PrEC) in culture expressed detectable levels of IFI 16, and the levels increased more than fourfold when cells approached cellular senescence. Consistent with a role of IFI 16 in cellular senescence, human prostate cancer cell lines either did not express IFI 16 or expressed a variant form, which was primarily detected in the cytoplasm of prostate cancer cells and not in the nucleus. Moreover, overexpression of functional IFI 16 in human prostate cancer cell lines inhibited colony formation. Additionally, ectopic expression of IFI 16 in clonal prostate cancer cell lines was associated with a senescence-like phenotype, production of senescence-associated beta-galactosidase (a biochemical marker for cellular senescence), and reduction of S-phase cells in culture. Importantly, upregulation of p21(WAF1) and inhibition of E2F-stimulated transcription accompanied inhibition of cell growth by IFI 16 in prostate cancer cell lines. Collectively, our observations support the idea that increased levels of IFI 16 in PrECs contribute to senescence-associated irreversible cell growth arrest.	Loyola Univ, Stritch Sch Med, Dept Pathol, Med Ctr, Maywood, IL 60153 USA; Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Med Ctr, Maywood, IL 60153 USA; Peter MacCallum Canc Inst, Canc Immunol Program, Trescowthick Res Labs, Melbourne, Vic 3002, Australia	Loyola University Chicago; Loyola University Chicago; Peter Maccallum Cancer Center	Choubey, D (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pathol, Med Ctr, 2160 S 1st Ave,Mail Code 114B, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG022124] Funding Source: NIH RePORTER; NCI NIH HHS [CA69031] Funding Source: Medline; NIAMS NIH HHS [AR47307] Funding Source: Medline; NIA NIH HHS [AG022124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Castro P, 2003, PROSTATE, V55, P30, DOI 10.1002/pros.10204; Certa U, 2001, BRIT J CANCER, V85, P107, DOI 10.1054/bjoc.2001.1865; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Jarrard DF, 1999, CANCER RES, V59, P2957; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Karlsson C, 1996, CANCER RES, V56, P241; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Mori Y, 2001, CANCER RES, V61, P6046; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Untergasser G, 2002, CANCER RES, V62, P6255; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Webber MM, 1997, PROSTATE, V30, P58; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844	51	97	100	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4831	4840		10.1038/sj.onc.1206754	http://dx.doi.org/10.1038/sj.onc.1206754			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894224				2022-12-28	WOS:000184344600006
J	Dallol, A; Krex, D; Hesson, L; Eng, C; Maher, ER; Latif, F				Dallol, A; Krex, D; Hesson, L; Eng, C; Maher, ER; Latif, F			Frequent epigenetic inactivation of the SLIT2 gene in gliomas	ONCOGENE			English	Article						SLIT2; glioma; methylation	TUMOR-SUPPRESSOR GENE; BREAST CANCERS; LATERAL POSITION; DNA METHYLATION; ROBO RECEPTORS; AXON GUIDANCE; HUMAN HOMOLOG; CPG ISLAND; RASSF1A; 3P21.3	The SLIT family of genes consists of large extracellular matrix-secreted and membrane-associated glycoproteins. The Slits (Slit1-3) are ligands for the repulsive guidance receptors, the roho gene family. The Slit-Robo interactions mediate the repulsive cues on axons and growth cones during neural development. In a recent report, we demonstrated that promoter region CpG island of human SLIT2 was frequently hypermethylated in lung, breast and colorectal tumours and the silenced gene transcript suppressed the malignant phenotype in in vitro assays. In this report we undertook epigenetic, genetic and expression analysis of SLIT2 gene in a large series of gliomas and glioma cell lines. Promoter region CpG island of SLIT2 was found to be methylated in 71% (5/7) of glioma cell lines and was unmethylated in five DNA samples from normal brain tissues. The hypermethylation of the SLIT2 promoter region in glioma cell lines correlated with loss of expression and treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated SLIT2 gene expression. In primary gliomas, SLIT2 was methylated in 59% (37/63) of tumours analysed. In addition, SLIT2 expression was downregulated in methylated gliomas relative to unmethylated tumour samples, as demonstrated by quantitative real-time RT-PCR. Loss of heterozygosity analysis revealed that SLIT2 methylated gliomas retained both alleles of a microsatellite marker within 100 kb of the SLIT2 gene at 4p15.2. Exogenous expression of SLIT2 in a glioma cell tine that was heavily methylated for SLIT2 decreased in vitro colony formation. Our data indicate that SLIT2 is frequently inactivated by promoter region CpG island hypermethylation in gliomas and may be a good candidate for a glioma tumour suppressor gene (TSG) located at 4p15.2. Furthermore, our data suggest that a detailed analysis of both the cancer genome and epigenome will be required to identify key TSGs involved in glioma development.	Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England; Tech Univ Dresden, Dept Neurosurg, Univ Klinikum Carl Gustav Carus, D-01307 Dresden, Germany; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Univ Birmingham, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England	University of Birmingham; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.		Krex, Dietmar/E-6833-2014; Hesson, Luke/HDM-0311-2022; Dallol, Ashraf/H-8661-2012; MAHER, EAMONN R/A-9507-2008	Dallol, Ashraf/0000-0002-8803-228X; MAHER, EAMONN R/0000-0002-6226-6918; Eng, Charis/0000-0002-3693-5145				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Burton EC, 2002, CANCER RES, V62, P6205; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; GREGER V, 1994, HUM GENET, V94, P491; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Lo KW, 2001, CANCER RES, V61, P3877; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lusher ME, 2002, CANCER RES, V62, P5906; Morrissey C, 2001, CANCER RES, V61, P7277; Rajagopalan S, 2000, CELL, V103, P1033, DOI 10.1016/S0092-8674(00)00207-5; Simpson JH, 2000, CELL, V103, P1019, DOI 10.1016/S0092-8674(00)00206-3; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031	28	108	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4611	4616		10.1038/sj.onc.1206687	http://dx.doi.org/10.1038/sj.onc.1206687			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881718				2022-12-28	WOS:000184054700017
J	Mao, ZB; Shan, S; Zhu, YY; Yi, X; Zhang, H; Shang, YF; Tong, TJ				Mao, ZB; Shan, S; Zhu, YY; Yi, X; Zhang, H; Shang, YF; Tong, TJ			Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel-like factor	ONCOGENE			English	Article						A33 antigen; GKLF; gene regulation	MONOCLONAL-ANTIBODY A33; ADVANCED COLON-CANCER; COXSACKIE B VIRUSES; GENE-EXPRESSION; INTESTINAL EPITHELIUM; ENDOTHELIAL-CELLS; PHASE I/II; PROMOTER; GROWTH; DIFFERENTIATION	A33 antigen is a membrane-bound protein that is expressed only in intestinal epithelium and in most human colon cancers. Thus, A33 antigen has been explored as a potential therapeutic target for the treatment of colon cancers. However, little is known about the mechanism responsible for the tissue-specific pattern of its expression. In this report, we demonstrate that gut-enriched Kruppel-like factor (GKLF) binds to the promoter region of A33 antigen gene in colonic carcinoma cells and that mutations in the GKLF binding sequence in this region lead to diminished expression of A33 antigen. In addition, the expression of GKLF is linked to the expression of A33 antigen and blocking the expression of GKLF leads to the abolishment of A33 antigen expression. These results suggest that GKLF is a critical regulator in inducing the expression of A33 antigen in intestinal epithelium. While it has been suggested that GKLF is a regulator in inducing cell growth arrest and differentiation of the intestine, our observation that A33 antigen gene is a downstream target for GKLF suggests a more complex and diverse role for GKLF in the gut.	Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Shang, YF (corresponding author), Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.							Abud HE, 2000, MECH DEVELOP, V98, P111, DOI 10.1016/S0925-4773(00)00438-X; Antoniw P, 1996, BRIT J CANCER, V74, P513, DOI 10.1038/bjc.1996.395; Barendswaard EC, 2001, J NUCL MED, V42, P1251; Behr R, 2002, MECH DEVELOP, V115, P167, DOI 10.1016/S0925-4773(02)00127-2; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Catimel B, 1996, J BIOL CHEM, V271, P25664, DOI 10.1074/jbc.271.41.25664; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Chretien I, 1996, EUR J IMMUNOL, V26, P780, DOI 10.1002/eji.1830260409; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johnstone CN, 2002, J BIOL CHEM, V277, P34531, DOI 10.1074/jbc.M204865200; Katevuo K, 1999, J IMMUNOL, V162, P5685; Katz JP, 2002, DEVELOPMENT, V129, P2619; KING DJ, 1995, BRIT J CANCER, V72, P1364, DOI 10.1038/bjc.1995.516; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Sakamoto J, 2000, CANCER CHEMOTH PHARM, V46, pS27, DOI 10.1007/PL00014045; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; WELT S, 1994, J CLIN ONCOL, V12, P1561, DOI 10.1200/JCO.1994.12.8.1561; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	38	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4434	4443		10.1038/sj.onc.1206508	http://dx.doi.org/10.1038/sj.onc.1206508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853980				2022-12-28	WOS:000183978900013
J	Lewis, MD; Roberts, BJ				Lewis, MD; Roberts, BJ			Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein	ONCOGENE			English	Article						VHL; HIF-1 alpha; RCC	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; REGULATE HIF; HYDROXYLATION; DEGRADATION; DISEASE; ALPHA; GENE; CELL; FIBRONECTIN; TRAFFICKING	Mutations in the von Hippel-Lindau (VHL) tumour-suppressor gene result in several forms of cancer. In the present study, we investigated the role of VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/DNES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.		Lewis, Martin/A-3881-2010; Lewis, Martin/A-8489-2008	Lewis, Martin/0000-0002-3332-3776				Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298	22	25	25	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3992	3997		10.1038/sj.onc.1206683	http://dx.doi.org/10.1038/sj.onc.1206683			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821933				2022-12-28	WOS:000183707600002
J	Shonukan, T; Bagayogo, I; McCrea, PD; Chao, M; Hempstead, B				Shonukan, T; Bagayogo, I; McCrea, PD; Chao, M; Hempstead, B			Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin	ONCOGENE			English	Article						fascin; melanoma; migration; NGF; p75(NTR)	NERVE GROWTH-FACTOR; HEPARAN-SULFATE SUBPOPULATIONS; INVASION SELECTED ENHANCEMENT; NF-KAPPA-B; RECEPTOR; P75; BINDING; ACTIVATION; TRK; STIMULATION	Expression of the p75 neurotrophin receptor (p75(NTR)) in primary melanomas is associated with deeply invasive lesions. In turn, there is expression of high levels of neurotrophins at the invasion front of normal tissue adjacent to brain metastases, thus implicating this growth factor-receptor system in melanoma tumorigenesis. The neurotrophins nerve growth factor (NGF) and neurotrophin-3 (NT-3) are potent chemotactic agents for human melanoma cells which express p75(NTR)in vitro. Here we show that the actin-bundling protein fascin specifically interacts with p75(NTR) in an NGF-dependent manner by co-immunoprecipitation and colocalization in melanoma cells that express the two proteins endogenously. In addition, expression of a fascin point mutant at the serine phosphorylation site (serine 39) regulating actin binding abrogates neurotrophin-induced migration. These results suggest a causal role for NGF-mediated dephosphorylation of serine 39 on fascin in mediating actin binding and subsequent melanoma cell migration.	Univ Miami, Sch Med, Dept Med, Div Hematol Oncol,Sylvester Canc Ctr, Miami, FL 33136 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Skirball Inst Biomol Med, Dept Cell Biol, Mol Neurobiol Program, New York, NY 10016 USA	University of Miami; Cornell University; University of Texas System; UTMD Anderson Cancer Center	Shonukan, T (corresponding author), Univ Miami, Sch Med, Dept Med, Div Hematol Oncol,Sylvester Canc Ctr, Pap 110,M-877,1550 NW 10th Ave, Miami, FL 33136 USA.	oshonukan@med.miami.edu		Chao, Moses/0000-0002-6969-3744	NIGMS NIH HHS [R01 GM052112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BRYAN J, 1986, METHOD ENZYMOL, V134, P13; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; Gallo G, 1998, J NEUROSCI, V18, P5403, DOI 10.1523/JNEUROSCI.18-14-05403.1998; Iwamoto S, 1996, J AM ACAD DERMATOL, V35, P725, DOI 10.1016/S0190-9622(96)90728-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P99, DOI 10.1038/jidsymp.1997.19; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Nicolson GL, 1995, CANCER METAST REV, V14, P303, DOI 10.1007/BF00690600; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	28	83	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3616	3623		10.1038/sj.onc.1206561	http://dx.doi.org/10.1038/sj.onc.1206561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789270				2022-12-28	WOS:000183399200012
J	Walters, DK; French, JD; Arendt, BK; Jelinek, DF				Walters, DK; French, JD; Arendt, BK; Jelinek, DF			Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex	ONCOGENE			English	Article						ErbB3; interferon-alpha; multiple myeloma	EPIDERMAL GROWTH-FACTOR; MULTIPLE-MYELOMA; RECEPTOR; INTERLEUKIN-6; ACTIVATION; CARCINOMA; PATHWAYS; LEUKEMIA; THERAPY; CANCER	We have previously demonstrated that the responsiveness of multiple myeloma (MM) cells to interferon-alpha (IFN-alpha) stimulation is variable, with an atypical growth response displayed by some cells. Here we report the ability of IFN-alpha to induce tyrosine phosphorylation of a 180 kDa band in the KAS-6/1 MM cell line, which is growth responsive to IFN-alpha. Further characterization demonstrated that this band corresponds to ErbB3. To our knowledge, this is the first report of ErbB3 expression in a cell type of the hematopoietic lineage. Although ErbB receptors have been shown to crosscommunicate with various other receptors, our results show for the first time that the IFN-alpha: receptor can crosscommunicate with ErbB3. To address the significance of these observations, we transfected ErbB3-negative DP-6 MM cells with ErbB3 and used siRNA to silence ErbB3 in the KAS-6/1 cell line. Although IFN-alpha transactivated ErbB3 in the DP-6 transfectants, it did not confer growth responsiveness to IFN-alpha. Interestingly, silencing ErbB3 expression in the KAS-6/1 cells decreased the overall growth response to IFN-alpha and to interleukin-6. These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Jelinek, DF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA62228, CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA062228, R01CA062228, P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arora T, 1999, J IMMUNOL, V162, P3289; BLADE J, 1991, BRIT J HAEMATOL, V79, P523, DOI 10.1111/j.1365-2141.1991.tb08068.x; BREGMAN MD, 1986, INT J CELL CLONING, V4, P224, DOI 10.1002/stem.5530040401; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; French JD, 2002, LEUKEMIA, V16, P1189, DOI 10.1038/sj.leu.2402516; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JOURDAN M, 1991, J IMMUNOL, V147, P4402; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; SALMON SE, 1991, SEMIN ONCOL, V18, P33; SAWAMURA M, 1992, BRIT J HAEMATOL, V82, P631, DOI 10.1111/j.1365-2141.1992.tb06484.x; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Walters DK, 2002, ANTISENSE NUCLEIC A, V12, P411, DOI 10.1089/108729002321082483; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	23	14	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3598	3607		10.1038/sj.onc.1206512	http://dx.doi.org/10.1038/sj.onc.1206512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789268				2022-12-28	WOS:000183399200010
J	Jourdan, M; Veyrune, JL; De Vos, J; Redal, N; Couderc, G; Klein, B				Jourdan, M; Veyrune, JL; De Vos, J; Redal, N; Couderc, G; Klein, B			A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells	ONCOGENE			English	Article						myeloma; IL-6; apoptosis; Mcl-1	HUMAN MULTIPLE-MYELOMA; INTERLEUKIN-6 TRANSGENIC MICE; BCL-2 FAMILY; B-CELLS; MONOCLONAL-ANTIBODIES; CHROMOSOME 1Q21; PLASMA-CELLS; EXPRESSION; LINES; APOPTOSIS	Interleukin-6 (IL-6) is a major survival factor for malignant plasma cells involved in multiple myeloma. Using an RNase protection assay, we looked for gene expression of 10 anti- and proapoptotic Bcl-2-family proteins in 12 IL-6-dependent human myeloma cell lines (HMCL). A high Mcl-1 gene expression was found in all HMCLs and the other genes were variably expressed. Out of the 10 Bcl-2-family members, only the Mcl-1 gene was regulated by IL-6. Upon starvation of IL-6, Mcl-1 gene expression decreased in association with myeloma cell apoptosis and was upregulated after adding IL-6 again in association with myeloma cell survival. A constitutive Mcl-1 expression was induced with an Mcl-1-GFP retrovirus in two IL-6-dependent HMCLs. The Mcl-1 HMCLs have a marked reduced apoptosis upon IL-6 starvation compared to HMCLs transduced with control GFP retrovirus and may grow without adding IL-6. These data emphasize the major role of Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.	INSERM, U475, F-34197 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34197 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	De Vos, John/A-5703-2010	De Vos, John/0000-0003-1880-4130				Bae J, 2001, APOPTOSIS, V6, P319, DOI 10.1023/A:1011319901057; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; CRAIG RW, 1994, GENOMICS, V23, P457, DOI 10.1006/geno.1994.1523; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; HAMILTON MS, 1991, LEUKEMIA, V5, P768; Harada N, 1998, LEUKEMIA, V12, P1817, DOI 10.1038/sj.leu.2401168; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Keung YK, 1998, CANCER GENET CYTOGEN, V106, P135, DOI 10.1016/S0165-4608(97)00316-6; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 2003, BIOL MULTIPLE MYELOM; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Le Baccon P, 2001, GENE CHROMOSOME CANC, V32, P250, DOI 10.1002/gcc.1189; Liautard J, 1997, CYTOKINE, V9, P233, DOI 10.1006/cyto.1996.0159; LOKHORST HM, 1994, BLOOD, V84, P2269; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; PETTERSSON M, 1992, BLOOD, V79, P495; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; SHIMIZU S, 1989, J EXP MED, V169, P339, DOI 10.1084/jem.169.1.339; Spets H, 1997, BRIT J HAEMATOL, V98, P126, DOI 10.1046/j.1365-2141.1997.1903004.x; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; UCHIYAMA H, 1993, BLOOD, V82, P3712; Westendorf JJ, 1996, LEUKEMIA, V10, P866; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; ZHANG XG, 1994, BLOOD, V83, P3654; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	42	124	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2950	2959		10.1038/sj.onc.1206423	http://dx.doi.org/10.1038/sj.onc.1206423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771946	Green Submitted, Green Accepted			2022-12-28	WOS:000182824800010
J	Zeller, C; Hinzmann, B; Seitz, S; Prokoph, H; Burkhard-Goettges, E; Fischer, J; Jandrig, B; Schwarz, LE; Rosenthal, A; Scherneck, S				Zeller, C; Hinzmann, B; Seitz, S; Prokoph, H; Burkhard-Goettges, E; Fischer, J; Jandrig, B; Schwarz, LE; Rosenthal, A; Scherneck, S			SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer	ONCOGENE			English	Article						breast cancer; LOH analysis; 6q24.3; tumor suppressor genes; SAM; SH3	OVARIAN-CANCER; CELL-LINES; ALLELIC LOSS; IN-SITU; PROTEIN; CARCINOMA; 6Q; IDENTIFICATION; SUSCEPTIBILITY; REGION	Loss of heterozygosity (LOH) and in silico expression analysis were applied to identify genes significantly downregulated in breast cancer within the genomic interval 6q23-25. Systematic comparison of candidate EST sequences with genomic sequences from this interval revealed the genomic structure of a potential target gene on 6q24.3, which we called SAM and SH3 domain containing I (SASH1). Loss of the gene-internal marker D6S311, found in 30% of primary breast cancer, was significantly correlated with poor survival and increase in tumor size. Two SASH1 transcripts of approximately 4.4 and 7.5 kb exist and are predominantly transcribed in the human breast, lung, thyroid, spleen, placenta and thymus. In breast cancer cell tines, SASH1 is only expressed at low levels. SASH1 is downregulated in the majority (74%) of breast tumors in comparison with corresponding normal breast epithelial tissues. In addition, SASH1 is also downregulated in tumors of the lung and thyroid. Analysis of the protein domain structure revealed that SASH1 is a member of a recently described family of SH3/SAM adapter molecules and thus suggests a role in signaling pathways. We assume that SASH1 is a new tumor suppressor gene possibly involved in tumorigenesis of breast and other solid cancers. We were unable to find mutations in the coding region of the gene in primary breast cancers showing LOH within the critical region. We therefore hypothesize that other mechanisms as for instance methylation of the promoter region of SASH1 are responsible for the loss of expression of SASH1 in primary and metastatic breast cancer.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13125 Berlin, Germany; MetaGen Pharmaceut GmbH, D-13347 Berlin, Germany; Robert Roessle Hosp, Dept Med Informat, D-13122 Berlin, Germany; Robert Roessle Hosp, Dept Surg & Surg Oncol, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zeller, C (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, Robert Roessle Str 10, D-13125 Berlin, Germany.	c.zeller@mdc-berlin.de						Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Beer S, 2001, BBA-GENE STRUCT EXPR, V1520, P89, DOI 10.1016/S0167-4781(01)00242-1; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Claudio J, 2001, ONCOGENE, V20, P5373, DOI 10.1038/sj.onc.1204698; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Hofmann W, 2002, INT J CANCER, V97, P472, DOI 10.1002/ijc.1626; Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Pagotto U, 2000, CANCER RES, V60, P6794; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Sachs L, 1992, ANGEW STAT, V7; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Srikantan V, 1999, INT J CANCER, V84, P331, DOI 10.1002/(SICI)1097-0215(19990621)84:3<331::AID-IJC23>3.0.CO;2-J; Stallmach I, 2002, VIRCHOWS ARCH, V440, P77, DOI 10.1007/s004280100523; Theile M, 1996, ONCOGENE, V13, P677; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Uchida T, 2001, BIOCHEM BIOPH RES CO, V288, P137, DOI 10.1006/bbrc.2001.5722; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WURSTERHILL DH, 1984, CANCER GENET CYTOGEN, V13, P303, DOI 10.1016/0165-4608(84)90075-X; YOO HW, 1993, GENOMICS, V15, P21, DOI 10.1006/geno.1993.1005; Zhang YM, 1998, HUM GENET, V103, P727; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	40	107	115	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2972	2983		10.1038/sj.onc.1206474	http://dx.doi.org/10.1038/sj.onc.1206474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771949				2022-12-28	WOS:000182824800013
J	Agazie, YM; Movilla, N; Ischenko, I; Hayman, MJ				Agazie, YM; Movilla, N; Ischenko, I; Hayman, MJ			The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3	ONCOGENE			English	Article						SHP2; FGFR3; transformation; Ras-ERK; PI3K-Akt	TYROSINE-PHOSPHATASE; MULTIPLE-MYELOMA; ACTIVATING MUTATIONS; SIGNAL-TRANSDUCTION; ECTOPIC EXPRESSION; SKELETAL DISORDERS; TUMOR PROGRESSION; KINASE ACTIVATION; STAT ACTIVATION; FGFR3 MUTATIONS	Receptor tyrosine kinases (RTKs) such as the fibroblast growth factor receptor (FGFR) and the epidermal growth factor receptor are overexpressed in a variety of cancers. In addition to overexpression, the FGFRs are found mutated in some cancers. The Src homology 2 domain-containing phosphotyrosine phosphatase (SHP2) is a critical mediator of RTK signaling, but its role in oncogenic RTK-induced cell transformation and cancer development is largely unknown. In the current report, we demonstrate that constitutively activated FGFR3 (K/E-FR3) transforms NIH-3T3 cells, and that SHP2 is a critical mediator of this transformation. Infection of K/E-FR3-transformed 3T3 cells with a retrovirus carrying a dominant-negative mutant of SHP2 (C/S-SHP2) retarded cell growth, reversed the transformation phenotype and inhibited focus-forming ability. Furthermore, treatment of K/E-FR3-transformed NIH-3T3 cells with PD98059 or LY294002, specific inhibitors of MEK and PI3K, respectively, inhibited focus formation. Biochemical analysis showed that K/E-FR3 activates the Ras-ERK and the PI3K signaling pathways, and that the C/SSHP2 mutant suppressed this effect via competitive displacement of interaction of the endogenous SHP2 with FRS2. However, the C/SSHP2 protein did not show any effect on receptor autophosphorylation, FRS2 tyrosine phosphorylation or interaction of Grb2 with K/E-FR3 or FRS2. Together, the results show that K/E-FR3 is transforming and that the Ras-ERK and the PI3K-Akt signaling pathways, which are positively regulated by SHP2, are important for K/E-FR3-induced transformation.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NCI NIH HHS [CA42573, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Chesi M, 2002, CURR OPIN HEMATOL, V9, P288, DOI 10.1097/00062752-200207000-00005; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1611; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; Iseki S, 1997, DEVELOPMENT, V124, P3375; Jang JH, 2001, CANCER RES, V61, P3541; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; Lin HY, 1996, J NEUROSCI, V16, P4579; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; UEKI T, 1995, J PATHOL, V177, P353, DOI 10.1002/path.1711770405; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wilkie AOM, 1996, CURR OPIN NEUROL, V9, P146, DOI 10.1097/00019052-199604000-00016; Wilkie AOM, 1997, AM J MED GENET, V69, P433, DOI 10.1002/(SICI)1096-8628(19970414)69:4<433::AID-AJMG21>3.0.CO;2-N; WILKIE AOM, 1995, J MED GENET, V32, P174, DOI 10.1136/jmg.32.3.174; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; Winterpacht A, 2000, PHYSIOL GENOMICS, V2, P9, DOI 10.1152/physiolgenomics.2000.2.1.9; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	57	65	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6909	6918		10.1038/sj.onc.1206798	http://dx.doi.org/10.1038/sj.onc.1206798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534538				2022-12-28	WOS:000185843400012
J	Schreiner, B; Greten, FR; Baur, DM; Fingerle, AA; Zechner, U; Bohm, C; Schmid, M; Hameister, H; Schmid, RM				Schreiner, B; Greten, FR; Baur, DM; Fingerle, AA; Zechner, U; Bohm, C; Schmid, M; Hameister, H; Schmid, RM			Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes with two independently amplified gene loci	ONCOGENE			English	Article						murine pancreatic tumor cell line; c-Myc and Egfr amplification; p53 deletion; p16(Ink4a) hypermethylation	PROGRESSION MODEL; TRANSGENIC MICE; SOLID TUMORS; AMPLIFICATION; DNA; ADENOCARCINOMA; P16(INK4A); ACTIVATION; DELETIONS; INDUCTION	TGFalpha/p53(+/-) transgenic mice represent a genetically engineered mouse model for pancreatic adenocarcinoma. The tumors develop a characteristic pattern of secondary genetic changes. From one of these tumors, the permanent cell line TD2 was established. Here, we describe in detail the genetic changes by molecular - cytogenetic techniques. The original tumor-specific CGH profile has been retained unchanged. The most characteristic aberration pattern bears chromosome 11. Egfr, localized on proximal chromosome 11, is amplified two to three times and leads to an easily identifiable, stable marker chromosome with a large amplification unit, which is present in each metaphase. The wild-type p53 gene on distal chromosome 11 is lost. The p16(Ink4a) locus on chromosome 4 is hypermethylated. For c-Myc a 15-fold amplification, present in a 1.65 Mb amplification unit, is detected on chromosome 15. Transition between presence in the form of several double minutes, DMs, or a single homogeneously staining region, HSR, was observed for c-Myc. Molecular - cytogenetic analysis of both amplification units show that Egfr amplification and c-Myc amplification represent two alternative modes by which genes get amplified in tumor cells. The expression level of the respective genes was proven by Northern blot analysis. The cell line TD2 represents a valuable in vitro model for pancreatic adenocarcinoma.	Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Univ Wurzburg, Inst Human Genet, D-97074 Wurzburg, Germany; Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany; Univ Ulm, Dept Human Genet, D-89069 Ulm, Germany; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Technical University of Munich; University of Wurzburg; Ulm University; Ulm University; University of California System; University of California San Diego	Schmid, RM (corresponding author), Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany.		Greten, Florian R/AAF-5196-2020; Zechner, Ulrich/G-2116-2010	Greten, Florian R/0000-0002-3928-6080; 				Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Bardeesy N, 2001, SEMIN CANCER BIOL, V11, P201, DOI 10.1006/scbi.2000.0371; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Greten FR, 2002, GASTROENTEROLOGY, V123, P2052, DOI 10.1053/gast.2002.37075; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Steinle AU, 1999, GASTROENTEROLOGY, V116, P420, DOI 10.1016/S0016-5085(99)70140-X; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; WAHL GM, 1989, CANCER RES, V49, P1333; Wang WX, 1999, CLIN CANCER RES, V5, P119; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu YF, 2002, ONCOGENE, V21, P1518, DOI 10.1038/sj.onc.1205208	24	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6802	6809		10.1038/sj.onc.1206836	http://dx.doi.org/10.1038/sj.onc.1206836			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555993				2022-12-28	WOS:000185799300015
J	Senderowicz, AM				Senderowicz, AM			Small-molecule cyclin-dependent kinase modulators	ONCOGENE			English	Review						cell cycle; molecular targets; cyclin-dependent kinases; flavopiridol; UCN-01; CYC202; BMS 387032; drug development	CANCER-CELL-LINES; BREAST-CARCINOMA CELLS; FLAVOPIRIDOL INDUCES APOPTOSIS; HUMAN EPIDERMOID CARCINOMA; SKIN TUMOR-DEVELOPMENT; ACTIVITY IN-VIVO; PROTEIN-KINASE; SELECTIVE INHIBITOR; LUNG-CANCER; ANTITUMOR-ACTIVITY	Aberrations in cell cycle progression occur in the majority of human malignancies. The main pathway affected is the retinoblastoma (Rb) pathway. The tumor suppressor gene Rb is an important component in the G(1)/S transition and its function is abnormal in most human neoplasms. Loss in Rb function occurs by the hyperactivation of the cyclin-dependent kinases (cdk's). Therefore, modulation of cdk's may have an important use for the therapy and prevention of human neoplasms. Efforts to obtain small-molecule cdk modulators yielded two classes of modulators: direct and indirect modulators. Direct cdk modulators are small molecules that specifically target the ATP binding site of cdk's. Examples for this group include. avopiridol, roscovitine and BMS-387032. In contrast, indirect cdk modulators affect cdk function due to modulation of upstream pathways required for cdk activation. Some examples include perifosine, lovastatin, and UCN-01. The first example of a direct small-molecule cdk modulator tested in the clinic,. avopiridol, is a pan-cdk inhibitor that not only promotes cell cycle arrest but also halts transcriptional elongation, promotes apoptosis, induces differentiation, and has antiangiogenic properties. Clinical trials with this agent were performed with at least three different schedules of administration: 1-, 24- and 72-h infusions. The main toxicities for infusions greater than or equal to24-h are secretory diarrhea and proinflammatory syndrome. In addition, patients receiving shorter infusions have nausea/ vomiting and neutropenia. A phase II trial of patients with advanced non-small-cell lung carcinoma using the 72-h infusion every 2 weeks was recently completed. The median overall survival for the 20 patients who received treatment was 7.5 months, a survival similar to that obtained in a randomized trial of four chemotherapy regimens containing platinum analogues in combination with taxanes or gemcitabine, or with gefitinib, a recently approved EGFR inhibitor for the treatment of advanced lung cancer. Based on these encouraging results, a phase III trial comparing standard combination chemotherapy versus combination chemotherapy plus. avopiridol is currently under investigation. The second example of direct small-molecule cdk modulator tested in clinical trials is UCN-01(7-hydroxystaurosporine). UCN-01 has interesting preclinical features: it inhibits Ca2+-dependent PKCs, promotes apoptosis, arrests cell cycle progression at G(1)/S, and abrogates checkpoints upon DNA damage. The first phase I trial of UCN-01 demonstrated a very prolonged half-life. Based on this novel feature, UCN-01 is administered as a 72-h continuous infusion every 4 weeks ( in second and subsequent cycles UCN-01 is administered as a 36-h infusion). Other shorter schedules (i.e. 3 h) are being tested. Dose-limiting toxicities include nausea/vomiting, hypoxemia, and insulin-resistant hyperglycemia. Combination trials with cisplatin and other DNA-damaging agents are being tested. Recently, phase I trials with two novel small-molecule cdk modulators, BMS 387032 and R-Roscovitine (CYC202), have commenced with good tolerability. In summary, novel small-molecule cdk modulators are being tested in the clinic with interesting results. Although these small molecules are directed towards a very prevalent cause of carcinogenesis, we need to test them in advanced clinical trials to determine the future of this class of agents for the prevention and therapy of human malignancies.	NICDR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Senderowicz, AM (corresponding author), NICDR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 212, Bethesda, MD 20892 USA.	sendero@helix.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000706] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1997, CANCER RES, V57, P1495; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Arguello F, 1998, BLOOD, V91, P2482; BARATTE B, 1992, ANTICANCER RES, V12, P873; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BARTKOVA J, 1995, CANCER RES, V55, P949; Bartkova J, 1996, CANCER RES, V56, P5475; BENNETT S, 1999, P AN M AM SOC CLIN, V18, P156; Bible KC, 1996, CANCER RES, V56, P4856; Bible KC, 1997, CANCER RES, V57, P3375; Blanchard JL, 1999, BIOORG MED CHEM LETT, V9, P2537, DOI 10.1016/S0960-894X(99)00431-X; Bonfanti M, 1997, CANCER RES, V57, P1442; Bramson HN, 2001, J MED CHEM, V44, P4339, DOI 10.1021/jm010117d; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brusselbach S, 1998, INT J CANCER, V77, P146; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; BuquetFagot C, 1997, ANTI-CANCER DRUG, V8, P623, DOI 10.1097/00001813-199707000-00011; Busby EC, 2000, CANCER RES, V60, P2108; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Cagnoli M, 1998, GYNECOL ONCOL, V70, P372, DOI 10.1006/gyno.1998.5062; Carlson B, 1999, CANCER RES, V59, P4634; Carlson B. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P424; Carlson BA, 1996, CANCER RES, V56, P2973; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Chien M, 1999, CANCER CHEMOTH PHARM, V44, P81, DOI 10.1007/s002800050948; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEES E, 2000, P AN M AM SOC CLIN, V19, P154; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dermatakis A, 2003, BIOORGAN MED CHEM, V11, P1873, DOI 10.1016/S0968-0896(03)00036-1; Dodo K, 2000, BIOORG MED CHEM LETT, V10, P615, DOI 10.1016/S0960-894X(00)00065-2; Drees M, 1997, CLIN CANCER RES, V3, P273; Driscoll B, 1999, AM J PHYSIOL-LUNG C, V276, pL679, DOI 10.1152/ajplung.1999.276.4.L679; EASTHAM JA, 1995, CANCER RES, V55, P5151; Eicher SA, 1996, CLIN CANCER RES, V2, P1659; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FINGERT HJ, 1988, CANCER RES, V48, P4375; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Fuse E, 1998, CANCER RES, V58, P3248; Gansauge S, 1997, CANCER RES, V57, P1634; Gius DR, 1999, CANCER RES, V59, P2577; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GrayBablin J, 1997, CANCER RES, V57, P604; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hsueh CT, 1998, CLIN CANCER RES, V4, P2201; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Husain A, 1997, CLIN CANCER RES, V3, P2089; Ichimura K, 1996, ONCOGENE, V13, P1065; Innocenti F, 2000, CLIN CANCER RES, V6, P3400; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; JIN XM, 1995, CANCER RES, V55, P3250; Jones CB, 2000, CANCER CHEMOTH PHARM, V45, P252, DOI 10.1007/s002800050037; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Katayose Y, 1997, CANCER RES, V57, P5441; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Kent LL, 1999, BIOCHEM BIOPH RES CO, V260, P768, DOI 10.1006/bbrc.1999.0891; Kerr JS, 1999, ANTICANCER RES, V19, P959; Kim KS, 2002, J MED CHEM, V45, P3905, DOI 10.1021/jm0201520; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Konig A, 1997, BLOOD, V90, P4307; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; KRIS MG, 2002, P AN M AM SOC CLIN, V21, P1166; Lahusen J, 2000, P 20 ANN M AM ASS CA; Lahusen T, 2003, MOL CARCINOGEN, V36, P183, DOI 10.1002/mc.10114; Lane ME, 2001, CANCER RES, V61, P6170; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee HR, 1999, INT J ONCOL, V15, P161; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LOWE SW, 1994, COLD SPRING HARB SYM, V59, P419, DOI 10.1101/SQB.1994.059.01.047; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, CANCER RES, V55, P4818; MARCHETTI A, 1993, CANCER RES, V53, P2846; Masciullo V, 1997, INT J CANCER, V74, P390, DOI 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; Melillo G, 1999, CANCER RES, V59, P5433; Mesguiche V, 2003, BIOORG MED CHEM LETT, V13, P217, DOI 10.1016/S0960-894X(02)00884-3; Mettey Y, 2003, J MED CHEM, V46, P222, DOI 10.1021/jm020319p; MICHALIDES R, 1995, CANCER RES, V55, P975; Misra RN, 2003, BIOORG MED CHEM LETT, V13, P1133, DOI 10.1016/S0960-894X(03)00034-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nugiel DA, 2001, J MED CHEM, V44, P1334, DOI 10.1021/jm0100032; Ortega MA, 2002, BIOORGAN MED CHEM, V10, P2177, DOI 10.1016/S0968-0896(02)00069-X; Park SG, 1996, MOL CELLS, V6, P679; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Patel V, 2002, CLIN CANCER RES, V8, P3549; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Patel V, 2002, CANCER RES, V62, P1401; Pollack IF, 1996, J NEUROSURG, V84, P1024, DOI 10.3171/jns.1996.84.6.1024; ROBERGE M, 1994, CANCER RES, V54, P6115; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Ryu CK, 2000, BIOORG MED CHEM LETT, V10, P461, DOI 10.1016/S0960-894X(00)00014-7; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Sausville EA, 1998, CANCER CHEMOTH PHARM, V42, pS54, DOI 10.1007/s002800051080; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schoepfer J, 2002, J MED CHEM, V45, P1741, DOI 10.1021/jm0108348; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; Schwartz GK, 2002, J CLIN ONCOL, V20, P2157, DOI 10.1200/JCO.2002.08.080; Schwartz GK, 1997, CLIN CANCER RES, V3, P1467; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Senderowicz A M, 2001, Cancer Chemother Biol Response Modif, V19, P165; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 2002, HEMATOL ONCOL CLIN N, V16, P1229, DOI 10.1016/S0889-8588(02)00049-7; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; SENDEROWICZ AM, 1999, P 25 ANN M AM SOC CL; SENDEROWICZ AM, 1998, 10 NAT CANC I EUR OR, P78; SENDEROWICZ AM, 2000, P ANN M AM SOC CLIN; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, CANCER RES, V57, P4029; SHAPIRO G, 1999, P AM SOC CLIN ONC AT, V18; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu E, 1996, ONCOLOGY-BASEL, V53, P494; Sielecki TM, 2001, BIOORG MED CHEM LETT, V11, P1157, DOI 10.1016/S0960-894X(01)00185-8; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; SONODA Y, 1995, ONCOGENE, V11, P2145; Spitz FR, 1996, ANTICANCER RES, V16, P3415; Stadler WM, 2000, J CLIN ONCOL, V18, P371, DOI 10.1200/JCO.2000.18.2.371; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAMURA T, 1999, P AN M AM SOC CLIN, V18, P159; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Tsuchida E, 1997, INT J RADIAT ONCOL, V39, P1153, DOI 10.1016/S0360-3016(97)00549-X; Usuda J, 2000, INT J CANCER, V85, P275, DOI 10.1002/(SICI)1097-0215(20000115)85:2<275::AID-IJC20>3.0.CO;2-5; Walker DH, 1998, CURR TOP MICROBIOL, V227, P149; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang MB, 1998, OTOLARYNG HEAD NECK, V119, P593, DOI 10.1016/S0194-5998(98)70017-8; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WERNER J, 1998, P AM SOC CLIN ONC LO, V17; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Wilson WH, 2000, CLIN CANCER RES, V6, P415; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; Wright J, 1998, Oncology (Williston Park), V12, P1023; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zaharevitz DW, 1999, CANCER RES, V59, P2566; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu GX, 2003, J MED CHEM, V46, P2027, DOI 10.1021/jm0256169; Zhu GX, 2003, BIOORG MED CHEM LETT, V13, P1231, DOI 10.1016/S0960-894X(03)00133-1	185	199	210	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6609	6620		10.1038/sj.onc.1206954	http://dx.doi.org/10.1038/sj.onc.1206954			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528286	Bronze			2022-12-28	WOS:000185700700018
J	Raval, GN; Bharadwaj, S; Levine, EA; Willingham, MC; Geary, RL; Kute, T; Prasad, G				Raval, GN; Bharadwaj, S; Levine, EA; Willingham, MC; Geary, RL; Kute, T; Prasad, G			Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors	ONCOGENE			English	Article						tropomyosin; breast cancer; tumor suppressor; anoikis; biomarker	HUMAN TRK ONCOGENE; CANCER-CELLS; TRANSFORMED PHENOTYPE; EPITHELIAL-CELLS; PROSTATE-CANCER; KINASE; METHYLATION; RECEPTOR; PROTEIN; GROWTH	Suppression of tropomyosins (TMs), a family of actin-binding, microfilament-associated proteins, is a prominent feature of many transformed cells. Yet it is unclear whether downregulation of TMs occur in human tumors. We have investigated the expression of tropomyosin-1 (TM1) in human breast carcinoma tissues by in situ hybridization and immunofluorescence. TM1 mRNA and protein are readily detectable in normal mammary tissue. In contrast, TM1 expression is abolished in the primary human breast tumors. Expression of other TM isoforms, however, is variable among the tumors. The consistent and profound downregulation of TM1 suggests that TM1 may be a novel and useful biomarker of mammary neoplasms. These data also support the hypothesis that suppression of TM1 expression during the malignant conversion of mammary epithelium as a contributing factor of breast cancer. In support of this hypothesis, we show that the ability to suppress malignant growth properties of breast cancer cells is specific to TM1 isoform. Investigations into the mechanisms of TM1-induced tumor suppression reveal that TM1 induces anoikis ( detachment induced apoptosis) in breast cancer cells. Downregulation of TM1 in breast tumors may destabilize microfilament architecture and confer resistance to anoikis, which facilitates survival of neoplastic cells outside the normal microenvironment and promote malignant growth.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Surg Oncol Serv, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Vasc Surg Serv, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Prasad, G (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Surg Oncol Serv, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.							Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Asch HL, 1996, CANCER RES, V56, P4841; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Braverman RH, 1996, ONCOGENE, V13, P537; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; Darzynkiewicz Z, 2001, METHOD CELL BIOL, V66, P69; Dhar S, 2001, CLIN CANCER RES, V7, P3393; Donner K, 2002, NEUROMUSCULAR DISORD, V12, P151, DOI 10.1016/S0960-8966(01)00252-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Franzen B, 1997, ELECTROPHORESIS, V18, P582, DOI 10.1002/elps.1150180341; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Li B, 2001, CANCER RES, V61, P8014; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Lin JLC, 2002, GASTROENTEROLOGY, V123, P152, DOI 10.1053/gast.2002.34154; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Meech SJ, 2001, BLOOD, V98, P1209, DOI 10.1182/blood.V98.4.1209; Michele DE, 2000, J MOL MED, V78, P543, DOI 10.1007/s001090000161; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; Mondy JS, 1997, CIRC RES, V81, P320, DOI 10.1161/01.RES.81.3.320; Nass SJ, 2000, CANCER RES, V60, P4346; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Wang SC, 2001, ONCOGENE, V20, P6960, DOI 10.1038/sj.onc.1204873; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Zhu ZY, 2001, CANCER RES, V61, P1707	50	116	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6194	6203		10.1038/sj.onc.1206719	http://dx.doi.org/10.1038/sj.onc.1206719			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679858				2022-12-28	WOS:000185506200009
J	Goueli, BS; Janknecht, R				Goueli, BS; Janknecht, R			Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor	ONCOGENE			English	Article						E-box; human telomerase reverse transcriptase (hTERT); Myc; transcription; upstream regulatory factor (USF)	FACTOR USF; C-MYC; MEDIATED REGULATION; CATALYTIC SUBUNIT; ACTIVATION; PROMOTER; HTERT; PROTEIN; KINASE; CELLS	Upregulation of human telomerase reverse transcriptase (hTERT) transcription accounts for the immortalization of greater than 85% of all human tumor cells. However, the mechanism whereby hTERT expression is activated remains unresolved. Specifically, recent data challenging the role of Myc/Max in E-box-dependent activation of hTERT expression suggests that other E-box-binding proteins regulate hTERT transcription. Indeed, we now demonstrate that two such proteins, upstream stimulatory factor (USF) 1 and 2, readily associate with two E-boxes in the hTERT promoter in vitro and in vivo primarily as heterodimers, whereas Myc/Max does not. The avid binding of USF1/2 heterodimers to these E-boxes occurs in both hTERT-positive and -negative cells. In contrast, USF1/2 activates the hTERT promoter exclusively in hTERT-positive cells in a manner that is enhanced by the coactivator p300 and attenuated upon inhibiting p38-MAP kinase, a known modulator of USF activity. Collectively, our data indicate that USF binding to the hTERT promoter may be transcriptionally neutral, or even repressive, in nonimmortalized hTERT-negative somatic cells, but stimulatory in hTERT-positive cells where USF1/2 contributes to the acquisition and maintenance of immortality.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Dhaene K, 2000, J PATHOL, V190, P80; Dillner NB, 2002, J BIOL CHEM, V277, P33890, DOI 10.1074/jbc.M204399200; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Ducrest AL, 2001, CANCER RES, V61, P7594; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Goodman RH, 2000, GENE DEV, V14, P1553; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; HORIUCHI K, 1981, CANCER RES, V41, P1488; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Kumari D, 2001, J BIOL CHEM, V276, P4357, DOI 10.1074/jbc.M009629200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Won JJ, 2002, FASEB J, V16, P1943, DOI 10.1096/fj.02-0311fje; Yago M, 2002, FEBS LETT, V520, P40, DOI 10.1016/S0014-5793(02)02757-6	32	95	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8042	8047		10.1038/sj.onc.1206847	http://dx.doi.org/10.1038/sj.onc.1206847			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970752				2022-12-28	WOS:000185388200019
J	Li, YQ; Liu, D; Chen, DS; Kharbanda, S; Kufe, D				Li, YQ; Liu, D; Chen, DS; Kharbanda, S; Kufe, D			Human DF3/MUC1 carcinoma-associated protein functions as an oncogene	ONCOGENE			English	Article						DF3/MUC1; 3Y1 cells; anchorage-independent growth; cellular transformation	BETA-CATENIN; CELL-ADHESION; C-SRC; ANTIGEN; CANCER; DF3	The human DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed by most carcinomas of the breast and other epithelia. The contribution of MUC1 overexpression to the malignant phenotype is, however, not known. In the present studies, we have stably expressed MUC1 in rat 3Y1 fibroblasts. MUC1-positive cells were selected from independent transfections. The results demonstrate that, as found in human carcinomas, MUC1 is expressed on the cell surface and as a complex with P-catenin in the nucleus of the transfectants. Colony formation in soft agar demonstrates that cells expressing MUC1, but not the empty vector, exhibit anchorage-independent growth. The results also show that MUC1 expression confers tumor formation in nude mice. These findings provide the first evidence that MUC1 induces cellular transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; ILEX Prod Inc, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [R01 CA097098, CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kondo K, 1998, CANCER RES, V58, P2014; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGHTENBERG M, 1992, CANCER RES, V52, P223; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; VLERNINCKX K, 1991, CELL, V66, P107; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492	17	168	186	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6107	6110		10.1038/sj.onc.1206732	http://dx.doi.org/10.1038/sj.onc.1206732			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955090	Green Accepted			2022-12-28	WOS:000185137800020
J	Amundson, SA; Bittner, M; Fornace, AJ				Amundson, SA; Bittner, M; Fornace, AJ			Functional genomics as a window on radiation stress signaling	ONCOGENE			English	Article						gene induction; cDNA microarray; cancer cells	FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; IONIZING-RADIATION; TARGET GENES; MALIGNANT-MELANOMA; GENOTOXIC STRESS; DNA-REPAIR; P53; INDUCTION	Exposure to ionizing radiation, as well as other stresses, results in the activation of complex signal transduction pathways, which eventually shape the response of cells and organisms. Some of the important pathways responding to radiation include the ATM/P53 pathway, MAPK cascades and NF-kappaB activation, as well as signaling events initiated at the cell membrane and within the cytoplasm. Alterations in gene expression play roles both as intermediaries in signaling and as downstream effector genes. Differences in cell type, interindividual genetic differences and crosstalk occurring between signaling pathways may help to channel radiation stress signals between cell cycle delay, enhanced DNA repair, and apoptosis. These differences may in turn help determine the likelihood of late effects of radiation exposure, including carcinogenesis and fibrosis. The tools of the postgenomic era enable high-throughput studies of the multiple changes resulting from the interplay of radiation signaling pathways. Gene expression profiling, in particular shows great promise, both in terms of insight into basic molecular mechanisms and for the future hope of biomarker development and individual tailoring of cancer therapy.	NCI, NIH, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Amundson, SA (corresponding author), NCI, NIH, 37 Convent Dr,Bldg 37,Room 6144, Bethesda, MD 20892 USA.	amundson@mail.nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 1999, RADIAT RES, V152, P225, DOI 10.2307/3580321; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Ardekani Ali M, 2002, Expert Rev Mol Diagn, V2, P312, DOI 10.1586/14737159.2.4.312; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chapman K, 2002, BIOCHEM SOC T, V30, P82, DOI 10.1042/BST0300082; Chen XF, 2002, CANCER RES, V62, P1213; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dumic J, 2000, CELL PHYSIOL BIOCHEM, V10, P149, DOI 10.1159/000016345; Eickhoff Holger, 2002, Adv Biochem Eng Biotechnol, V77, P103; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Geffrotin C, 1998, RADIAT RES, V149, P472, DOI 10.2307/3579787; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hallahan DE, 1998, CANCER RES, V58, P5484; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Johnston CJ, 2002, RADIAT RES, V157, P256, DOI 10.1667/0033-7587(2002)157[0256:RIPFEO]2.0.CO;2; Kawai H, 1999, CANCER RES, V59, P6038; Koch-Paiz CA, 2000, BIOTECHNIQUES, V29, P706, DOI 10.2144/00294bm07; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Meyer RG, 2002, EUR J BIOCHEM, V269, P337, DOI 10.1046/j.0014-2956.2001.02658.x; Mori K, 2000, FREE RADICAL RES, V33, P157, DOI 10.1080/10715760000300711; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; Raju U, 1999, RADIAT ONCOL INVESTI, V7, P145, DOI 10.1002/(SICI)1520-6823(1999)7:3<145::AID-ROI2>3.0.CO;2-R; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robles AI, 2001, CANCER RES, V61, P6660; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Sreekumar A, 2001, CANCER RES, V61, P7585; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yacoub A, 2001, INT J RADIAT BIOL, V77, P1067, DOI 10.1080/09553000110069317; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhan QM, 1996, ONCOGENE, V13, P2287; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao WL, 2001, CANCER RES, V61, P5537	52	89	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5828	5833		10.1038/sj.onc.1206681	http://dx.doi.org/10.1038/sj.onc.1206681			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947389				2022-12-28	WOS:000185086100009
J	Ueda, K; Arakawa, H; Nakamura, Y				Ueda, K; Arakawa, H; Nakamura, Y			Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53	ONCOGENE			English	Article						DUSP5; p53; Erk1/2	ACTIVATED PROTEIN-KINASE; P53-DEPENDENT APOPTOSIS; GENE; IDENTIFICATION; PHOSPHATASE; EXPRESSION; MUTATIONS; PHOSPHORYLATION; STIMULATION; GROWTH	Dual-specificity phosphatase 5 (DUSP5), a VH1-Iike enzyme that hydrolyses nuclear substrates phosphorylated on both tyrosine and serine/threonine residues, has a potential role in deactivation of mitogen- or stress-activated protein kinases. Using cDNA-microarray technology, we found that the expression of DUSP5 mRNA was dramatically increased by exogenous p53 in U373MG, a p53-mutant glioblastoma cell line. Transcription of DUSP5 was also remarkably activated by endogenous p53 in response to DNA damage in colon-cancer cells (p53+/+) that contained wild-type p53, but not in p53-/- cells. Chromatin-immunoprecipitation (ChIP) and reporter assays demonstrated that endogenous p53 protein would bind directly to the promoter region of the DUSP5 gene, implying p53-dependent transcriptional activity. Overexpression of DUSP5 suppressed the growth of several types of human cancer cells, in which Erk1/2 was significantly dephosphorylated. If, as the results suggest, DUSP5 is a direct target of p53, it represents a novel mechanism by which p53 might negatively regulate cell-cycle progression by downregulating mitogen- or stress-activated protein kinases.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Furuhata T, 1996, ONCOGENE, V13, P1965; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiizumi M, 2002, CANCER RES, V62, P1246; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Kim TI, 2002, ANN NY ACAD SCI, V973, P241, DOI 10.1111/j.1749-6632.2002.tb04641.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIYASHITA T, 1995, CELL, V80, P293; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ono K, 2000, CANCER RES, V60, P5007; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Shiraishi K, 2000, CANCER RES, V60, P3722; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281; Yoo J, 2002, ARCH PATHOL LAB MED, V126, P1096	31	94	98	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5586	5591		10.1038/sj.onc.1206845	http://dx.doi.org/10.1038/sj.onc.1206845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944906	Bronze			2022-12-28	WOS:000184865900007
J	Cutress, RI; Townsend, PA; Sharp, A; Maison, A; Wood, L; Lee, R; Brimmell, M; Mullee, MA; Johnson, PWM; Royle, GT; Bateman, AC; Packham, G				Cutress, RI; Townsend, PA; Sharp, A; Maison, A; Wood, L; Lee, R; Brimmell, M; Mullee, MA; Johnson, PWM; Royle, GT; Bateman, AC; Packham, G			The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription	ONCOGENE			English	Article						BAG-1; breast cancer; oestrogen; receptor; hormone therapy; survival	HUMAN BREAST-CANCER; APOPTOTIC PROTEIN BAG-1; GENE BAG-1; CELL-LINES; RECEPTOR; EXPRESSION; SURVIVAL; HSC70; BINDS; OVEREXPRESSION	BAG-1 is a multifunctional protein that interacts with a wide range of cellular targets including heat-shock proteins and some nuclear hormone receptors. BAG-1 exists as three major isoforms, BAG-1L, BAG-1M and BAG-1S. BAG-1L contains a nuclear localization signal, which is not present in the other isoforms, and is predominantly localized in the cell nucleus. Here we have investigated the effects of BAG-1 on function of the oestrogen receptor (ER), a key growth control molecule and target for hormonal therapy in breast cancer. We demonstrate that BAG-1L, but not BAG-1S or BAG-1M increased oestrogen-dependent transcription in breast cancer cells. BAG-1L interacted with and stimulated the activity of both ER alpha and beta. Although BAG-1L and ERs colocalize to the nucleus, fusing BAG-1S to an heterologous nuclear localization sequence was not sufficient to stimulate transcription. Consistent with an important effect on receptor function, nuclear BAG-I expression in breast cancers was associated with expression of the progesterone receptor, a transcriptional target of ER(x, and was associated with improved survival in patients treated with hormonal therapy. These data suggest that BAG-1L is an important determinant of ER function in vitro and in human breast cancer.	Univ Southampton, Canc Res UK,Southampton Gen Hosp, Oncol Unit, Canc Sci Div,Sch Med, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Royal S Hants Hosp, Southampton Breast Unit, Southampton SO14 0YG, Hants, England; Southampton Gen Hosp, Dept Pathol, Southampton SO16 6YD, Hants, England	Cancer Research UK; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton	Packham, G (corresponding author), Univ Southampton, Canc Res UK,Southampton Gen Hosp, Oncol Unit, Canc Sci Div,Sch Med, Somers Canc Sci Bldg,Mail Point 824, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018; Townsend, Paul/AAF-8234-2020	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Sharp, Adam/0000-0002-3740-1612; Packham, Graham/0000-0002-9232-5691; Sharp, Adam/0000-0002-3902-0135; Bateman, Adrian/0000-0003-2222-4104; Townsend, Paul/0000-0001-8956-9508	Breast Cancer Now [2001:180] Funding Source: Medline	Breast Cancer Now		*AJM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P2843; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Cato ACB, 2001, J STEROID BIOCHEM, V78, P379, DOI 10.1016/S0960-0760(01)00114-5; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Clarke M, 1998, LANCET, V351, P1451; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cutress RI, 2002, BRIT J CANCER, V87, P834, DOI 10.1038/sj.bjc.6600538; Cutress RI, 2001, J CLIN ONCOL, V19, P3706, DOI 10.1200/JCO.2001.19.16.3706; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Guzey M, 2000, J BIOL CHEM, V275, P40749, DOI 10.1074/jbc.M004977200; Hague A, 2002, J PATHOL, V197, P60, DOI 10.1002/path.1076; Hohfeld J, 1998, BIOL CHEM, V379, P269; HORWITZ KB, 1975, SCIENCE, V189, P726, DOI 10.1126/science.168640; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; KINSEL LB, 1989, CANCER RES, V49, P1052; Knee DA, 2001, J BIOL CHEM, V276, P12718, DOI 10.1074/jbc.M010841200; Kudoh M, 2002, CANCER RES, V62, P1904; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Niyaz Y, 2001, J CELL SCI, V114, P1839; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Shindoh M, 2000, ORAL ONCOL, V36, P444, DOI 10.1016/S1368-8375(00)00025-7; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1998, CANCER RES, V58, P3116; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yamauchi H, 2001, CANCER LETT, V165, P103, DOI 10.1016/S0304-3835(01)00397-4; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1999, EXP CELL RES, V247, P200, DOI 10.1006/excr.1998.4349; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	52	60	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4973	4982		10.1038/sj.onc.1206688	http://dx.doi.org/10.1038/sj.onc.1206688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902980				2022-12-28	WOS:000184578900005
J	Russell, JP; Shinohara, S; Melillo, RM; Castellone, MD; Santoro, M; Rothstein, JL				Russell, JP; Shinohara, S; Melillo, RM; Castellone, MD; Santoro, M; Rothstein, JL			Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors	ONCOGENE			English	Article						autoimmunity; inflammation; inflammatory cytokines; oncogene; RET/PTC; tumor antigen	PAPILLARY THYROID-CARCINOMA; NF-KAPPA-B; CHRONIC LYMPHOCYTIC THYROIDITIS; TUMOR-NECROSIS-FACTOR; CELL-LINE; IMMUNOCYTOCHEMICAL LOCALIZATION; TARGETED EXPRESSION; ONCOGENE ACTIVATION; RET PROTOONCOGENE; TRANSGENIC MICE	Differentiated thyroid carcinomas are the most frequent endocrine neoplasms, but account for few cancer-related deaths. Although the indolent growth of these cancers correlates well with longevity, the biological basis for this good prognosis is not known. In contrast, two of the most frequent autoimmune diseases involve the thyroid suggesting a high propensity for this organ to invoke destructive immunity. Unfortunately, the mechanism linking malignancy and autoimmunity is not clear, although the expression of the oncogenic fusion protein RET/PTC3 (RP3) in both of these disorders may provide a clue. Interestingly, the signaling caused by activated RET kinase involves overlapping pathways and some common to the inflammatory response. Accordingly, we analyzed the function of RP3 and a mutant RP3 molecule to induce proinflammatory pathways in thyroid epithelial cells. Indeed, we find that RP3 alone causes increases in nuclear NF-kappaB activity and secretion of MCP-1 and GM-CSF. Finally, transfer of RP3-expressing thyrocytes into mice in vivo attracted dense macrophage infiltrates, which lead to rapid thyroid cell death. Further, cytokine synthesis and inflammation was largely abrogated by mutation of RP3 Tyr(588); an important protein-binding site for downstream signaling. Together, these studies implicate oncogene-induced cytokine-signaling pathways in a new mechanism linking inflammation with cancer.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Rothstein Kimmel Canc Inst, Philadelphia, PA 19107 USA; Univ Naples Federico II, Fac Med & Chirurg 2, Ctr Endocrinol & Oncol Sperimentale, CNR,Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Rothstein Kimmel Canc Inst, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.	Jay.Rothstein@jefferson.edu	melillo, rosa marina/O-5255-2015; Shinohara, Shogo/H-8976-2019	Shinohara, Shogo/0000-0002-1794-2091; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa Marina/0000-0002-9233-5275	NCI NIH HHS [T32-CA09678, CA-76259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009678, P01CA076259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asakawa H, 1999, ANTICANCER RES, V19, P761; Aust G, 1996, CLIN EXP IMMUNOL, V105, P148, DOI 10.1046/j.1365-2249.1996.d01-726.x; Aust G, 2001, J ENDOCRINOL, V170, P513, DOI 10.1677/joe.0.1700513; Basolo F, 1998, CLIN CANCER RES, V4, P381; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Borrello I, 2002, CYTOKINE GROWTH F R, V13, P185, DOI 10.1016/S1359-6101(01)00034-X; BRAVERMAN LE, 1995, THYROID FUNDAMENTAL; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CRILE G, 1953, CANCER-AM CANCER SOC, V6, P57, DOI 10.1002/1097-0142(195301)6:1<57::AID-CNCR2820060104>3.0.CO;2-D; DAILEY ME, 1955, ARCH SURG-CHICAGO, V70, P291, DOI 10.1001/archsurg.1955.01270080137023; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; Di Pasquale M, 2001, HUM PATHOL, V32, P24, DOI 10.1053/hupa.2001.21138; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOMOTO T, 1990, CANCER, V65, P1971, DOI 10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; Fleischmann A, 1999, SCHWEIZ MED WSCHR, V129, P873; Foo SY, 1999, TRENDS GENET, V15, P229; Fusco A, 2002, AM J PATHOL, V160, P2157, DOI 10.1016/S0002-9440(10)61164-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; KABEL PJ, 1987, ACTA ENDOCRINOL-COP, V115, P42; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kayser L, 1996, AUTOIMMUNITY, V23, P91, DOI 10.3109/08916939608995332; KAYSER L, 1995, AUTOIMMUNITY, V20, P75, DOI 10.3109/08916939509001930; Kebebew E, 2001, WORLD J SURG, V25, P632, DOI 10.1007/s002680020165; KENNEDY RL, 1992, J ENDOCRINOL, V133, P477, DOI 10.1677/joe.0.1330477; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Loh KC, 1999, J CLIN ENDOCR METAB, V84, P458, DOI 10.1210/jc.84.2.458; Ludwig L, 2001, CANCER RES, V61, P4526; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mechler C, 2001, BRIT J CANCER, V85, P1831, DOI 10.1054/bjoc.2001.2187; Nakada T, 1996, INTERNAL MED, V35, P815, DOI 10.2169/internalmedicine.35.815; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Sagartz JE, 1997, LAB INVEST, V76, P307; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Tamimi DM, 2002, INT J SURG PATHOL, V10, P141, DOI 10.1177/106689690201000207; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; YOSHIDA A, 1994, J SURG ONCOL, V55, P104, DOI 10.1002/jso.2930550209; YOSHIDA M, 1992, CANCER RES, V52, P464	59	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4569	4577		10.1038/sj.onc.1206759	http://dx.doi.org/10.1038/sj.onc.1206759			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881713				2022-12-28	WOS:000184054700012
J	Henneke, G; Koundrioukoff, S; Hubscher, U				Henneke, G; Koundrioukoff, S; Hubscher, U			Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation	ONCOGENE			English	Article						replication; cell cycle; Fen1; Cdks; phosphorylation	EUKARYOTIC DNA-REPLICATION; HUMAN FLAP ENDONUCLEASE-1; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CDC2 PHOSPHORYLATION; MOTIF PRESENT; PCNA-BINDING; YEAST; REPAIR; PROTEINS	Cyclin-dependent kinase (Cdk) Cdk1-Cyclin A can phosphorylate Flap endonuclease 1 (Fen1), a key-enzyme of the DNA replication machinery, in late S phase. Cdk1-cyclin A forms a complex in vitro and in vivo with Fen1. Furthermore, Fen1 phosphorylation is detected in vivo and depends upon Cdks activity. As a functional consequence of phosphorylation by Cdk1-Cyclin A in vitro, endo- and exonuclease activities of Fen1 are reduced whereas its DNA binding is not affected. Moreover, phosphorylation of Fen1 by Cdk1-Cyclin A abrogates its proliferating cell nuclear antigen (PCNA) binding thus preventing stimulation of Fen1 by PCNA. Concomitantly, human cells expressing the S187A mutant defective for Cdk1-Cyclin A phosphorylation accumulate in S phase consistent with a failure in cell cycle regulation through DNA replication. Our results suggest a novel regulatory role of Cdks onto the end of S phase by targeting directly a key enzyme involved in DNA replication.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hubscher@vetbio.unizh.ch		Henneke, Ghislaine/0000-0002-2985-5526				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Brosh RM, 2001, EMBO J, V20, P5791; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Dahm K, 2002, ONCOGENE, V21, P7710, DOI 10.1038/sj.onc.1205872; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Fotedar R, 1995, Prog Cell Cycle Res, V1, P73; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Johnston L H, 2000, Prog Cell Cycle Res, V4, P61; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kang HY, 2000, GENETICS, V155, P1055; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Schub O, 2001, J BIOL CHEM, V276, P38076; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	56	83	87	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4301	4313		10.1038/sj.onc.1206606	http://dx.doi.org/10.1038/sj.onc.1206606			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853968				2022-12-28	WOS:000183978900001
J	Steiling, H; Wustefeld, T; Bugnon, P; Brauchle, M; Fassler, R; Teupser, D; Thiery, J; Gordon, JI; Trautwein, C; Werner, S				Steiling, H; Wustefeld, T; Bugnon, P; Brauchle, M; Fassler, R; Teupser, D; Thiery, J; Gordon, JI; Trautwein, C; Werner, S			Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration	ONCOGENE			English	Article						cell cycle; hepatectomy; injury; keratinocyte growth factor; regeneration; steatosis	TARGETED EXPRESSION; TRANSGENIC MICE; DNA-SYNTHESIS; RAT; HEPATOCYTES; PROLIFERATION; MORPHOGENESIS; INITIATION; PROTEIN; FGF	Several growth factors have been suggested to play a crucial role in liver regeneration, but a functional proof is still missing. Since fibroblast growth factors are important for the initiation of mammalian liver development, we determined the roles of these mitogens in liver repair by targeted expression of a dominant-negative fibroblast growth factor receptor (FGFR) in hepatocytes of transgenic mice. The liver of young animals appeared histologically normal, and liver function was not obviously impaired. In aged transgenic mice, the frequency of fatty liver development was strongly increased compared to control animals. Following partial hepatectomy, transgenic mice showed markedly reduced hepatocyte proliferation because of an arrest in the late G(1) phase of the cell cycle. These data demonstrate a key role of FGFR signalling in repair after liver injury.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Novatis Pharma AG, CH-4002 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Klinikum Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Hannover Medical School; Max Planck Society; Leipzig University; Washington University (WUSTL)	Werner, S (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Arora V, 2000, J PHARMACOL EXP THER, V292, P921; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; HU ZY, 1995, CELL GROWTH DIFFER, V6, P1019; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KORHONEN J, 1992, INT J DEV BIOL, V36, P323; Loyer P, 1996, Prog Cell Cycle Res, V2, P37; Ludde T, 2001, ONCOGENE, V20, P5264, DOI 10.1038/sj.onc.1204690; MARSDEN ER, 1992, LAB INVEST, V67, P427; NONOGAKI K, 1995, ENDOCRINOLOGY, V136, P4278, DOI 10.1210/en.136.10.4278; Ornitz DM, 2001, GENOME BIOL, V2; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Senaldi G, 1998, HEPATOLOGY, V27, P1584, DOI 10.1002/hep.510270618; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; SUZUKI M, 1993, FEBS LETT, V328, P17, DOI 10.1016/0014-5793(93)80956-U; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482	27	64	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4380	4388		10.1038/sj.onc.1206499	http://dx.doi.org/10.1038/sj.onc.1206499			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853974				2022-12-28	WOS:000183978900007
J	Crabtree, M; Sieber, OM; Lipton, L; Hodgson, SV; Lamlum, H; Thomas, HJW; Neale, K; Phillips, RKS; Heinimann, K; Tomlinson, IPM				Crabtree, M; Sieber, OM; Lipton, L; Hodgson, SV; Lamlum, H; Thomas, HJW; Neale, K; Phillips, RKS; Heinimann, K; Tomlinson, IPM			Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients	ONCOGENE			English	Article						polyposis; APC; colorectal tumours; two-hit hypothesis	FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL TUMORS; CLUSTER REGION; GENE; PHENOTYPE; GENOTYPE; GERMLINE; PROTEIN	The site of the 'first hit' in the APC tumour suppressor gene determines the type of the 'second hit', both in familial adenomatous polyposis (FAP) and sporadic colorectal tumours. Mutations near codon 1300 are associated with loss of heterozygosity (LOH) of the wild-type allele; other tumours tend to have two protein-truncating mutations. In this study, we have confirmed and refined the LOH-associated region in colorectal FAP: allelic loss in adenomatous polyps tended to occur when the germline mutation lay in the region of the APC gene between the first and second beta-catenin degradation repeats (codons 1285-1378). LOH generally occurred by mitotic recombination, leaving two identical alleles, each encoding a protein with one remaining beta-catenin degradation repeat. For patients with germline mutations that truncated the protein before the first repeat (codon 1264), LOH was very rare and tumours generally acquired a somatic mutation which left two, or less often one, repeats remaining in the protein. In our sample set, patients with germline mutations after the second beta-catenin degradation repeat tended to have undetectable, presumably cryptic, somatic mutations in their polyps. Exceptions to these rules were, however, not uncommon. Although the site of the germline mutation was the strongest determinant of the somatic mutation in FAP tumours and most patients showed no clear tendency to acquire specific types of truncating 'second hit', a minority of patients did have unusual somatic mutation spectra in their polyps. Thus, some individuals may be predisposed to particular types of 'second hit' (for example, frameshift rather than nonsense changes). Overall, disease severity (polyp number) did not vary with individuals' spectrum of somatic APC mutations, providing no clear evidence for modifier genes that influence disease severity in this fashion. Our data are consistent with the hypothesis that there exists an optimal level of beta-catenin signalling in colorectal tumours and that the APC mutation spectrum principally reflects this fact. The association between 'first hits' and 'second hits' at APC is not, however, so strong as to suggest that tumorigenesis only occurs if the genotype is optimum; we suggest 'relaxed' terminology, the 'loose fit' model, to describe this situation.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; St Marks Hosp, Colorectal Canc Unit, Canc Res UK, Harrow HA1 3UJ, Middx, England; Guys Hosp, Dept Clin Genet, London SE1 9RT, England; St Marks Hosp, Polyposis Registry, Harrow HA1 3UJ, Middx, England; Univ Clin, Res Grp Human Genet, Div Med Genet, CH-4031 Basel, Switzerland	Cancer Research UK; Cancer Research UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London	Tomlinson, IPM (corresponding author), Canc Res UK, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Sieber, Oliver/M-9473-2015; Sieber, Oliver/ABA-9211-2021	Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Crabtree MD, 2002, GUT, V51, P420, DOI 10.1136/gut.51.3.420; Debinski HS, 1996, GASTROENTEROLOGY, V110, P1028, DOI 10.1053/gast.1996.v110.pm8612989; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, CANCER RES, V57, P4624; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P2954, DOI 10.1073/pnas.042699199; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Wasan HS, 1998, J PATHOL, V185, P246	16	81	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4257	4265		10.1038/sj.onc.1206471	http://dx.doi.org/10.1038/sj.onc.1206471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833148				2022-12-28	WOS:000183979800012
J	Ehrhardt, H; Fulda, S; Schmid, I; Hiscott, J; Debatin, KM; Jeremias, I				Ehrhardt, H; Fulda, S; Schmid, I; Hiscott, J; Debatin, KM; Jeremias, I			TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappa B	ONCOGENE			English	Article						TRAIL; proliferation; survival; apoptosis resistance; NF-kappa B	HUMAN T-CELLS; ACTIVATION; DEATH; FAS; CONTRIBUTES; EXPRESSION; CASPASE-8; PATHWAYS; PROTEIN; KINASE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cells. Examining primary cells of children with untreated acute leukemia, TRAIL induced apoptosis in 50% of cells, but to our surprise attenuated spontaneous apoptosis in the remaining samples or, most importantly, even mediated proliferation. W e therefore examined tumor cell lines of leukemic and nonleukemic origin with apoptosis resistance towards TRAIL because of absent Caspase-8 or dysfunctional FADD. In all cell lines tested, TRAIL treatment increased cell numbers in average to 163% within 4 days and accelerated doubling time from 24 to 19 h. TRAIL-mediated proliferation was completely abrogated by blockade of NF-kappaB activation using proteasome inhibitors or in RIP-negative, IKKgamma-negative cells or in cells overexpressing dominant-negative IkappaBalpha. Our data describe the biological significance of TRAIL-mediated activation of NF-kappaB in cancer cells resistant to TRAIL-mediated apoptosis: TRAIL leads to an increase in tumor cell count by a prosurvival and possibly mitogenic function. Given the promising therapeutic potential of TRAIL as a novel anticancer drug, TRAIL-mediated survival or proliferation of target cells may restrict its use to apoptosis-sensitive tumors.	Univ Kinderklin, Dept Hematol Oncol, D-89075 Ulm, Germany; Dr Von Haunerschen Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Lady Davis Institute; McGill University	Debatin, KM (corresponding author), Univ Kinderklin, Dept Hematol Oncol, Prittwitzstr 43, D-89075 Ulm, Germany.		Ehrhardt, Harald/L-9007-2018; Jeremias, Irmela/C-6090-2015; Jeremias, Irmela/Q-5934-2019; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Ehrhardt, Harald/0000-0003-4587-1734; Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thilenius ARB, 1997, EUR J IMMUNOL, V27, P1108, DOI 10.1002/eji.1830270510; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x	20	232	253	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3842	3852		10.1038/sj.onc.1206520	http://dx.doi.org/10.1038/sj.onc.1206520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813457				2022-12-28	WOS:000183612000003
J	Ivins, S; Pemberton, K; Guidez, F; Howell, L; Krumlauf, R; Zelent, A				Ivins, S; Pemberton, K; Guidez, F; Howell, L; Krumlauf, R; Zelent, A			Regulation of Hoxb2 by APL-associated PLZF protein	ONCOGENE			English	Article						leukaemia; transcription; repressor; fusion protein; retinoic acid receptor	ACID RECEPTOR-ALPHA; ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER GENE; ACUTE MYELOID-LEUKEMIA; RETINOIC ACID; RAR-ALPHA; DNA-BINDING; POZ-DOMAIN; HISTONE DEACETYLASE; BTB/POZ DOMAIN	The PLZF gene is translocated in a subset of all-trans-retinoic acid resistant acute promyelocytic leukaemia (APL) cases, encodes a DNA binding transcription factor and is expressed highly in haematopoietic progenitor cells as well-developing central nervous system (CNS). The spatially restricted and temporally dynamic pattern of PLZF expression in the developing CNS suggested that it might play a role in the circuitry regulating hindbrain segmentation. We have now identified a PLZF binding site (PLZF-RE) in an enhancer region of Hoxb2 that itself is required for directing high-level expression in rhombomers 3 and 5 of the developing hindbrain. The wild-type r3/r5 enhancer linked to a heterologous promoter was responsive to regulation by PLZF, and this activity was lost in variants containing a mutated PLZF-RE. Compared with the wild-type protein, the binding of the APL-associated reciprocal RARalpha-PLZF fusion to PLZF-RE was much stronger, suggesting that the N-terminal PLZF sequences missing from the fusion may play a role in the regulation of DNA binding. Consistent with this, the N-terminal POZ domain was required for cooperative binding of PLZF to a multimerized PLZF-RE. In the context of the r3/r5 enhancer, the PLZF-RE cooperated for PLZF binding with an additional A/T-rich motif positioned downstream of the PLZF-RE. This A/T motif was previously shown to be essential for the regulation of Hoxb2 expression in r3 and r5 in cooperation with another Kruppel-like zinc finger protein Krox 20. The presence of both the PLZF-RE and the A/T-rich motif was required for a maximal effect of PLZF on a heterologous promoter and was essential in vivo to direct the expression of a lacZ reporter in the chick neural tube. Hence, both PLZF and Krox20 cooperate with a common A/T motif in mediating in vivo activity of the Hoxb2 enhancer. Our findings indicate that Hoxb2 is a direct target for regulation by PLZF in the developing CNS and suggest that deregulation of Hox gene expression may contribute to APL pathogenesis.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Stowers Inst Med Res, Kansas City, MO 64110 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Stowers Institute for Medical Research	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.	a.zelent@icr.ac.uk	Guidez, Fabien/B-3750-2009; Zelent, Arthur/B-3532-2009; Guidez, Fabien/P-4220-2019; Krumlauf, Robb/AAH-5012-2019	Guidez, Fabien/0000-0003-1380-4473; Krumlauf, Robb/0000-0001-9102-7927; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Barrow JR, 1996, DEVELOPMENT, V122, P3817; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Davenne M, 1999, NEURON, V22, P677, DOI 10.1016/S0896-6273(00)80728-X; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MATHEWS CHE, 1991, BLOOD, V78, P2248; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Quaranta MT, 1996, J IMMUNOL, V157, P2462; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Vesque C, 1996, EMBO J, V15, P5383, DOI 10.1002/j.1460-2075.1996.tb00922.x; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	66	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3685	3697		10.1038/sj.onc.1206328	http://dx.doi.org/10.1038/sj.onc.1206328			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802276				2022-12-28	WOS:000183551000003
J	Udtha, M; Lee, SJ; Alam, R; Coombes, K; Huff, V				Udtha, M; Lee, SJ; Alam, R; Coombes, K; Huff, V			Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors	ONCOGENE			English	Article						WT1; c-MYC; Wilms' tumor; cDNA microarray; smooth t-test	SUPPRESSOR GENE WT1; GROWTH-FACTOR; BETA-CATENIN; KIDNEY DEVELOPMENT; TRANSGENIC MICE; PRODUCT; REPRESSION; PROMOTER; RECEPTOR; PROTOONCOGENES	The Wilms' tumor suppressor gene, WT1, functions as a transcriptional regulator that represses or activates the expression of a variety of putative target genes. However, it is not clear which genes are the biological targets of WT1, nor which cellular pathway(s) is critically altered in tumors as a result of WT1 mutation. To investigate in Vivo the role of WT1 as a transcription factor in Wilms' tumors, we used cDNA microarrays to compare the expression of putative WT1 target genes in a set of 15 primary Wilmstumors carrying WT1-inactivating mutations versus a set of 16 tumors with no WT1 mutations. We hypothesized that the expression of direct downstream targets of WT1 that are relevant to tumor development would differ between these two genetically distinct sets of tumors. Using the Atlas Human Cancer 1.2 cDNA arrays to quantitate gene expression in the 31 tumors, we found that the expression of one WT1 putative target gene, c-MYC, statistically significantly differed between the two sets of tumors and was upregulated in WT1-mutant tumors. This increase of relative gene expression for c-MYC was confirmed using real-time reverse transcription-polymerase chain reaction. The differential expression of another putative target gene, EGR1, approached significance and was also upregulated in WT1-mutant tumors. These data, in addition to the coexpression of c-MYC and WT1 in embryonic renal mesenchyme, strongly suggest that c-MYC is a biologically relevant target of WT1 in Wilmstumors.	MD Anderson Canc Ctr, Dept Mol Genet Canc Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Huff, V (corresponding author), MD Anderson Canc Ctr, Dept Mol Genet Canc Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.			Coombes, Kevin/0000-0002-7630-2123	NCI NIH HHS [CA16672, CA78257, CA34936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936, R01CA078257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baggerly KA, 2001, J COMPUT BIOL, V8, P639, DOI 10.1089/106652701753307539; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coombes KR, 2002, J COMPUT BIOL, V9, P655, DOI 10.1089/106652702760277372; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Geick A, 2001, TRANSGENIC RES, V10, P501, DOI 10.1023/A:1013085228119; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GOODYER P, 1995, ONCOGENE, V10, P1125; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEWITT SM, 1995, CANCER RES, V55, P5386; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huff V, 1998, AM J MED GENET, V79, P260, DOI 10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q; Koesters R, 1999, CANCER RES, V59, P3880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maiti S, 2000, CANCER RES, V60, P6288; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NISEN PD, 1986, CANCER RES, V46, P6217; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Zhang XH, 1999, ANTICANCER RES, V19, P1641	36	33	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3821	3826		10.1038/sj.onc.1206597	http://dx.doi.org/10.1038/sj.onc.1206597			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802290				2022-12-28	WOS:000183551000017
J	Li, YJ; Song, RL; Korkola, JE; Archer, MC; Ben-David, Y				Li, YJ; Song, RL; Korkola, JE; Archer, MC; Ben-David, Y			Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis	ONCOGENE			English	Article						mammary carcinogenesis; anoikis; cyclin D1; beta-catenin	INTESTINAL EPITHELIAL-CELLS; BETA-CATENIN; BREAST-CANCER; ACTIVATED RAS; OVEREXPRESSION; EXPRESSION; LINES; GENE; PROGRESSION; ERYTHROLEUKEMIA	To identify genes associated with the resistance of Copenhagen (Cop) rats to mammary carcinogenesis, we infused a retrovirus harboring v-Ha-ras directly into the main mammary ducts of resistant F1 rats from a cross between Cop and susceptible Wistar Furth (WIT) rats. Adenocarcinomas formed in approximately 50% of infused glands. Cell lines derived from these tumors were clonal, but did not share a common viral integration site, suggesting that a high level of v-Ha-ras expression was able to overcome resistance in the F1 rats. Some of the cell lines were able to grow in soft agar, but a significant number did not display anchorage-independent growth. These growth characteristics were independent of v-Ha-ras expression levels. The ability to grow in soft agar was associated with the size of tumors induced by injecting the cells into nude mice, and showed a striking positive association with the expression of cyclin D1. Furthermore, while resistance to anchorage-independent growth was fully overcome by transfection of cyclin D1 in some clones, in the others the effect was partial. A similar pattern of cyclin D1 upregulation and growth in soft agar was also observed when the cells were transfected with an active form of beta-catenin. Hybrid cells from the somatic fusion of an anchorage-dependent to an anchorage-independent clone did not grow in soft agar. These results suggest that while a high expression level of cyclin D1 is necessary for anchorage-independent growth in all clones, it is not sufficient for full growth capacity in soft agar, raising the possibility that the loss of a tumor suppressor gene in the cell lines is required to fully confer anchorage-independent growth. Our anchorage-dependent and independent rat mammary tumor-derived cell lines may recapitulate the resistance and susceptibility of Cop and WF rats, respectively, to mammary carcinogenesis that could facilitate the identification of breast cancer susceptibility genes.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Nutrit Sci, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave,Res Bldg,Room S218, Toronto, ON M4N 3M5, Canada.			, James/0000-0002-0030-6216				Bani MR, 1996, CANCER RES, V56, P3075; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BESTWICK RK, 1985, J VIROL, V56, P660, DOI 10.1128/JVI.56.3.660-664.1985; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; FILMUS J, 1994, ONCOGENE, V9, P3627; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GOULD MN, 1989, GENES SIGNAL TRANSDU, P19; HAN EKH, 1995, ONCOGENE, V10, P953; JIANG W, 1993, ONCOGENE, V8, P3447; Korkola J E, 1999, Breast Cancer Res, V1, P88, DOI 10.1186/bcr18; Korkola JE, 1999, CARCINOGENESIS, V20, P221, DOI 10.1093/carcin/20.2.221; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PRICE JE, 1990, CANCER RES, V50, P717; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; RUDLAND PS, 1986, DEV BIOL, V113, P388, DOI 10.1016/0012-1606(86)90174-0; Russo J, 2000, J MAMMARY GLAND BIOL, V5, P187, DOI 10.1023/A:1026443305758; Shepel LA, 1998, GENETICS, V149, P289; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Teodori L, 2000, IN VITRO CELL DEV-AN, V36, P153; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG BC, 1991, CANCER RES, V51, P5298; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wood GA, 2002, CARCINOGENESIS, V23, P1, DOI 10.1093/carcin/23.1.1; Zhou Q, 2000, BREAST CANCER RES TR, V59, P27, DOI 10.1023/A:1006370603147; Zhou Q, 2001, CANCER LETT, V162, P3, DOI 10.1016/S0304-3835(00)00657-1	37	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3452	3462		10.1038/sj.onc.1206411	http://dx.doi.org/10.1038/sj.onc.1206411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776197				2022-12-28	WOS:000183128500012
J	Lee, SH; Lee, JW; Soung, YH; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ				Lee, SH; Lee, JW; Soung, YH; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ			BRAF and KRAS mutations in stomach cancer	ONCOGENE			English	Article						mutation; BRAF; RAS; stomach cancer; stomach	RAS ONCOGENES; GENE; ACTIVATION; MELANOMA; PATHWAY; TUMORS	Ras proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. BRAF, which encodes a RAF family member in the downstream pathway of RAS, is somatically mutated in a number of human cancers. The activating mutation of BRAF is known to play a role in tumor development. As there have been no data on the BRAF mutation in stomach cancer, we analysed the genomic DNAs from 319 stomach carcinomas for the detection of somatic mutations of BRAF. Overall, we detected BRAF mutations in seven stomach carcinomas (2.2%). Five of the seven BRAF mutations involved Val 599, the previously identified hotspot, but the substituted amino acid (V599M) was different from the most common BRAF mutation (V599E). The remaining two mutations involved a conserved amino acid (D593G). One tumor had both BRAF and KRAS mutations. This is the first report on BRAF mutation in stomach cancer, and the data indicate that BRAF is occasionally mutated in stomach cancer, and suggest that alterations of RAS pathway both by RAS and BRAF mutations contribute to the pathogenesis of stomach cancer.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea	Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.		Yoo, Nam Jin/GNM-9060-2022; kim, Hong Sug/G-2731-2014					Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; BAE JM, 1999, J KOREAN CANC ASS, V30, P1175; BOS JL, 1989, CANCER RES, V49, P4682; Brose MS, 2002, CANCER RES, V62, P6997; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; JIANG W, 1989, ONCOGENE, V4, P923; LEE KH, 1995, CANCER, V75, P2794, DOI 10.1002/1097-0142(19950615)75:12<2794::AID-CNCR2820751203>3.0.CO;2-F; Naoki K, 2002, CANCER RES, V62, P7001; NEUBAUER A, 1994, BLOOD, V83, P1603; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Satyamoorthy K, 2003, CANCER RES, V63, P756; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Smith ML, 2003, LEUKEMIA, V17, P274, DOI 10.1038/sj.leu.2402787; Yuen ST, 2002, CANCER RES, V62, P6451	17	118	127	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6942	6945		10.1038/sj.onc.1206749	http://dx.doi.org/10.1038/sj.onc.1206749			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534542				2022-12-28	WOS:000185843400016
J	Simeone, AM; Broemeling, LD; Rosenblum, J; Tari, AM				Simeone, AM; Broemeling, LD; Rosenblum, J; Tari, AM			HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production	ONCOGENE			English	Article						HER2/neu; 4-HPR (fenretinide); nitric oxide; all-trans retinoic acid; breast cancer	TRANS-RETINOIC ACID; MONOCLONAL-ANTIBODY; PHASE-II; PROGNOSTIC INDICATOR; GROWTH-INHIBITION; SYNTHASE ACTIVITY; TUMOR-CELLS; EXPRESSION; TRASTUZUMAB; FENRETINIDE	The retinoid N-(4-hydroxyphenyl) retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells. We observed a 4.5-fold reduction in 4-HPR- mediated apoptosis in MCF-7 breast cancer cells transfected with HER2/neu (MCF-7/HER2) as compared with the parental MCF-7 (MCF-7/WT) cells. Blocking HER2/neu with trastuzumab (Herceptin(TM)) led to a sixfold increase in 4-HPR- induced apoptosis in HER2/neuoverexpressing cells. These data indicate that HER2/neu reduces the sensitivity of breast cancer cells to 4-HPR. We showed previously that nitric oxide ( NO) is essential for 4-HPR to induce apoptosis in breast cancer cells. The inhibitory effects of the 4-HPR and trastuzumab combination correlated with the amount of NO produced in HER2/neu-overexpressing cells. When a NO synthase ( NOS) inhibitor was used to block NO production, decreased apoptosis by the 4-HPR and trastuzumab combination was observed. Furthermore, 4-HPR-mediated NOSII expression was lower in MCF-7/HER2 than MCF-7/WT cells, but was increased by trastuzumab in HER2/neu-overexpressing cells. Here we report the novel findings that HER2/neu reduces the ability of 4-HPR to induce apoptosis in breast cancer cells, and that one mechanism by which HER2/neu increases the resistance of breast cancer cells to 4-HPR is by decreasing NOSII-mediated NO production.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers,Unit 422, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers,Unit 422, 1515 Holcombe Blvd, Houston, TX 77030 USA.	atari@mdanderson.org						Adami A, 1998, LIFE SCI, V63, P2097, DOI 10.1016/S0024-3205(99)80006-X; Baselga J, 1998, CANCER RES, V58, P2825; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Binder C, 1999, LAB INVEST, V79, P1703; Burke HB, 1998, CANCER-AM CANCER SOC, V82, P874, DOI 10.1002/(SICI)1097-0142(19980301)82:5<874::AID-CNCR11>3.0.CO;2-Y; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colomer R, 2000, CLIN CANCER RES, V6, P2356; COSTA A, 1989, EUR J CANCER CLIN ON, V25, P805, DOI 10.1016/0277-5379(89)90124-7; Decensi A, 2000, J CELL BIOCHEM, P84; DONG ZY, 1994, CANCER RES, V54, P789; DuenasGonzalez A, 1997, MODERN PATHOL, V10, P645; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haffty BG, 1996, INT J RADIAT ONCOL, V35, P751, DOI 10.1016/0360-3016(96)00150-2; Herbert BS, 1999, NUTR CANCER, V34, P121, DOI 10.1207/S15327914NC3402_1; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; Kazmi SMI, 1996, CANCER RES, V56, P1056; LI LM, 1991, CANCER RES, V51, P2531; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mangelsdorf David J., 1994, P319; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Martin JHJ, 2000, ONCOL REP, V7, P219; MEHTA RG, 1991, EUR J CANCER, V27, P138, DOI 10.1016/0277-5379(91)90471-O; MODIANO MR, 1990, INVEST NEW DRUG, V8, P317; MOON RC, 1979, CANCER RES, V39, P1339; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Rao GN, 1999, BREAST CANCER RES TR, V58, P241; Reveneau S, 1999, LAB INVEST, V79, P1215; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Simeone AM, 2002, MOL CANCER THER, V1, P1009; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Tan M, 1997, CANCER RES, V57, P1199; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Tschugguel W, 1999, BREAST CANCER RES TR, V56, P145; Umansky V, 2000, INT J ONCOL, V16, P109; Vakkala M, 2000, CLIN CANCER RES, V6, P2408; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Witters LM, 1997, BREAST CANCER RES TR, V42, P1, DOI 10.1023/A:1005798224288; WRIGHT C, 1989, CANCER RES, V49, P2087; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Yu DH, 1996, ONCOGENE, V13, P1359	61	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6739	6747		10.1038/sj.onc.1206786	http://dx.doi.org/10.1038/sj.onc.1206786			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555987				2022-12-28	WOS:000185799300009
J	Campochiaro, PA; Hackett, SF				Campochiaro, PA; Hackett, SF			Ocular neovascularization: a valuable model system	ONCOGENE			English	Review						VEGF; angiogenesis; angiopoietins; retinopathies; age-related macular degeneration	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; COMBRETASTATIN A-4 PHOSPHATE; RETINAL-PIGMENT EPITHELIUM; RECEPTOR TYROSINE KINASE; VASCULAR-TARGETING AGENT; CHOROIDAL NEOVASCULARIZATION; INTEGRIN ALPHA(V)BETA(3); INCREASED EXPRESSION; FACTOR VEGF	There is no unique formula for angiogenesis. Instead there is a large group of potential participating proteins that interact in complex ways. Depending upon the surrounding cell types and the relative expression levels of angiogenesis-related proteins, the 'angiogenesis cascade' can vary. Therefore, it is valuable to study and compare the role of proteins in several well-characterized vascular beds. The eye provides a useful model system, because it contains several vascular beds sandwiched between avascular tissue. This allows for unequivocal identification and quantitation of new vessels. Retina-specific promoters combined with inducible promoter systems provide a means to regulate the expression of proteins of interest. As a relatively isolated compartment, the eye also provides advantages for gene transfer. By gaining insight regarding the molecular signals involved in various types of ocular angiogenesis, general concepts can emerge that may apply to other settings, including tumor angiogenesis. One concept that has emerged is that despite participation of multiple stimulatory factors for ocular neovascularization, VEGF plays an essential role and interruption of VEGF signaling is an important therapeutic strategy. Another concept is that while most studies have focused on prevention of ocular neovascularization, regression of new vessels is desirable and is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived factor, and angiopoietin-2. Finally, endostatin and angiostatin, which have been sources of controversy because of inconsistent results in tumor models, have been shown to have good efficacy when delivered by gene transfer in models of ocular neovascularization. These results provide leads for new ocular treatments and perspective for evaluation of studies of neovascularization in extraocular tissues.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@inmi.edu			NEI NIH HHS [EY05951, EY12609, P30EY1765] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539; Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083; [Anonymous], 1991, Arch Ophthalmol, V109, P1109; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Chaplin DJ, 1999, ANTICANCER RES, V19, P189; Dark GG, 1997, CANCER RES, V57, P1829; Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498; DAVEL LE, 1985, TRANSPLANTATION, V39, P564, DOI 10.1097/00007890-198505000-00023; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DEUTSCH TA, 1979, AM J OPHTHALMOL, V87, P536, DOI 10.1016/0002-9394(79)90245-9; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; Dowlati A, 2002, CANCER RES, V62, P3408; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Edgren M, 1999, ANTICANCER RES, V19, P869; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931; Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grosios K, 1999, BRIT J CANCER, V81, P1318, DOI 10.1038/sj.bjc.6692174; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; Hazzard TM, 2000, MOL HUM REPROD, V6, P993, DOI 10.1093/molehr/6.11.993; HILL SA, 1993, EUR J CANCER, V29A, P1320, DOI 10.1016/0959-8049(93)90082-Q; Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203; Horsman MR, 1998, INT J RADIAT ONCOL, V42, P895, DOI 10.1016/S0360-3016(98)00299-5; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jones MK, 1999, NAT MED, V5, P1418; Joukov V, 1996, EMBO J, V15, P290; Kawamori T, 1998, CANCER RES, V58, P409; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kukk E, 1996, DEVELOPMENT, V122, P3829; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401; Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959; Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Luna J, 1996, LAB INVEST, V75, P563; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Masferrer JL, 2000, CANCER RES, V60, P1306; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; NAMBU H, 2003, IN PRESS INVEST OPHT; Nicol D, 1997, J UROLOGY, V157, P1482, DOI 10.1016/S0022-5347(01)65028-6; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OSHIMA Y, 2003, UNPUB DIFFERENT EFFE; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299; PETTIT GR, 1989, EXPERIENTIA, V45, P209, DOI 10.1007/BF01954881; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299; Rasmussen H, 2001, Hum Gene Ther, V12, P2029; Reichelt M, 2003, CLIN EXP OPHTHALMOL, V31, P61, DOI 10.1046/j.1442-9071.2003.00602.x; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawaoka H, 1999, LAB INVEST, V79, P1469; Schwartz SD, 2001, INVEST OPHTH VIS SCI, V42, pS522; Seed L, 1940, SURGERY, V7, P696; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346; Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje; Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8; Takano S, 1996, CANCER RES, V56, P2185; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Tozer GM, 1999, CANCER RES, V59, P1626; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; WOODS JA, 1995, BRIT J CANCER, V71, P705, DOI 10.1038/bjc.1995.138; WRIGHT AD, 1969, BRIT MED J, V2, P346, DOI 10.1136/bmj.2.5653.346; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87; Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y; Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475	133	90	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6537	6548		10.1038/sj.onc.1206773	http://dx.doi.org/10.1038/sj.onc.1206773			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528278				2022-12-28	WOS:000185700700010
J	Menard, S; Pupa, SM; Campiglio, M; Tagliabue, E				Menard, S; Pupa, SM; Campiglio, M; Tagliabue, E			Biologic and therapeutic role of HER2 in cancer	ONCOGENE			English	Review						HER2; biological role; prognostic value; predictive value; therapy	EPIDERMAL-GROWTH-FACTOR; POSITIVE BREAST-CANCER; FACTOR RECEPTOR FAMILY; HER-2/NEU GENE AMPLIFICATION; MAMMARY-TUMOR DEVELOPMENT; T-CELL IMMUNITY; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; DNA VACCINATION	Overexpression of the human epidermal growth factor-2 (HER2) oncogene in human breast carcinomas has been associated with a more aggressive course of disease. The reason for this association is still unclear, although it has been suggested to rest in increased proliferation, vessel formation, and/or invasiveness. Alternatively, prognosis may not be directly related to the presence of the oncoprotein on the cell membrane, but instead to the breast carcinoma subset identified by HER2 overexpression and characterized by a peculiar gene expression profile. HER2 has also been associated with sensitivity to anthracyclins and resistance to endocrine therapy, suggesting that tyrosine kinase receptor and hormone receptor pathways represent two major proliferation pathways exclusively active in breast carcinomas, one sensitive to chemotherapeutic drugs and the other to antiestrogens. HER2 currently represents one of the most appropriate targets for specific therapy. Indeed, trastuzumab, a monoclonal antibody directed against the extracellular domain of HER2, is therapeutically active in HER2-positive breast carcinomas. However, a consistent number of HER2-positive tumors is not responsive to HER2-driven therapy, indicating the need for a better understanding of the mechanism of action of this new biological drug in vivo. While preclinical studies suggest antibody-dependent cell cytotoxicity as the major mechanism, determination of NK activity at the time of treatment remains mandatory, especially in patients treated with immunosuppressive drugs. The efficacy of prophylactic vaccination has been fully demonstrated in preclinical models, whereas ongoing studies of active immunotherapy using a variety of vaccination regimens against HER2 in tumor-bearing mice and patients have met with only moderate success.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	sylvie.menard@istitutotumori.mi.it	Tagliabue, Elda/B-9377-2017; Pupa, Serenella/K-6388-2016; menard, sylvie mm/C-7940-2011	Tagliabue, Elda/0000-0001-9877-2903; Pupa, Serenella/0000-0002-4592-6830; 				Allgayer H, 2000, J CLIN ONCOL, V18, P2201, DOI 10.1200/JCO.2000.18.11.2201; Amici A, 2000, GENE THER, V7, P703, DOI 10.1038/sj.gt.3301151; Bocchia M, 2000, HAEMATOLOGICA, V85, P1172; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Burstein HJ, 2003, J CLIN ONCOL, V21, P46, DOI 10.1200/JCO.2003.03.124; Campiglio M, 2003, INT J CANCER, V105, P568, DOI 10.1002/ijc.11113; CAMPIGLIO M, 1994, J CELL BIOCHEM, V55, P409, DOI 10.1002/jcb.240550402; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Cavallo F, 1997, J NATL CANCER I, V89, P1049, DOI 10.1093/jnci/89.14.1049; Cavallo F, 1999, CANCER RES, V59, P414; Cefai D, 1999, INT J CANCER, V83, P393, DOI 10.1002/(SICI)1097-0215(19991029)83:3<393::AID-IJC16>3.0.CO;2-M; Clarke M, 1998, LANCET, V351, P1451; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colombo MP, 1996, CANCER METAST REV, V15, P317, DOI 10.1007/BF00046345; Cooke T, 2001, EUR J CANCER, V37, pS3, DOI 10.1016/S0959-8049(00)00402-0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dakappagari NK, 2000, CANCER RES, V60, P3782; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; De Vecchi R, 1999, CANCER RES, V59, P4471; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DESANTES K, 1992, CANCER RES, V52, P1916; Di Carlo E, 2001, CLIN CANCER RES, V7, p830S; Di Leo A, 2002, CLIN CANCER RES, V8, P1107; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Disis ML, 2002, J CLIN ONCOL, V20, P2624, DOI 10.1200/JCO.2002.06.171; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; DISIS ML, 1994, CANCER RES, V54, P16; Dittmar T, 2002, FASEB J, V16, P1823, DOI 10.1096/fj.02-0096fje; Elledge RM, 1998, CLIN CANCER RES, V4, P7; Esserman LJ, 1999, CANCER IMMUNOL IMMUN, V47, P337, DOI 10.1007/s002620050539; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; FENDLY BM, 1990, CANCER RES, V50, P1550; Finn OJ, 2002, CURR OPIN IMMUNOL, V14, P172, DOI 10.1016/S0952-7915(02)00317-5; Forni G, 2000, CANCER RES, V60, P2571; Foy TM, 2002, SEMIN ONCOL, V29, P53, DOI 10.1053/sonc.2002.34056; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gancberg D, 2002, BREAST CANCER RES TR, V74, P113, DOI 10.1023/A:1016146130767; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Geddert H, 2002, AM J CLIN PATHOL, V118, P60; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Goebel SU, 2002, CANCER RES, V62, P3702; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Haynes NM, 2002, BLOOD, V100, P3155, DOI 10.1182/blood-2002-04-1041; HIEKEN TJ, 1996, P AN M AM SOC CLIN, V15, P113; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj.bjc.6600286; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jager E, 2002, CURR OPIN IMMUNOL, V14, P178, DOI 10.1016/S0952-7915(02)00318-7; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Khan AJ, 2002, CLIN CANCER RES, V8, P540; Kiessling R, 2002, ADV CANCER RES, V85, P101, DOI 10.1016/S0065-230X(02)85004-7; Kim S, 2000, P NATL ACAD SCI USA, V97, P2731, DOI 10.1073/pnas.050588297; Knutson KL, 2001, J CLIN INVEST, V107, P477, DOI 10.1172/JCI11752; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Latif Z, 2002, BJU INT, V89, P5, DOI 10.1046/j.1464-6.2001.01372.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Lollini PL, 2002, CANCER IMMUNOL IMMUN, V51, P409, DOI 10.1007/s00262-002-0293-3; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Masood S, 2002, MICROSC RES TECHNIQ, V59, P102, DOI 10.1002/jemt.10181; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Menard S, 2002, CLIN CANCER RES, V8, P520; Menard S, 2001, ANN ONCOL, V12, P15, DOI 10.1023/A:1011151505425; Menard S, 1996, J CLIN ONCOL, V14, P2407; Menard S, 2001, J CLIN ONCOL, V19, P329, DOI 10.1200/JCO.2001.19.2.329; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Miles DW, 1999, INT J CANCER, V84, P354, DOI 10.1002/(SICI)1097-0215(19990820)84:4<354::AID-IJC4>3.0.CO;2-6; Moliterni A, 2003, J CLIN ONCOL, V21, P458, DOI 10.1200/JCO.2003.04.021; MURTHY SM, 1989, CANCER, V64, P2035, DOI 10.1002/1097-0142(19891115)64:10<2035::AID-CNCR2820641012>3.0.CO;2-L; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagata Y, 1997, J IMMUNOL, V159, P1336; Nakamura H, 2003, INT J CANCER, V103, P61, DOI 10.1002/ijc.10795; Nanni P, 2001, J EXP MED, V194, P1195, DOI 10.1084/jem.194.9.1195; Nanni P, 1999, ANN ONCOL, V10, P261, DOI 10.1023/A:1008304721889; Nicolini G, 1996, J BIOL CHEM, V271, P30290, DOI 10.1074/jbc.271.47.30290; O-charoenrat P, 1999, CLIN EXP METASTAS, V17, P631, DOI 10.1023/A:1006751016860; Ohashi PS, 2002, CURR OPIN IMMUNOL, V14, P744, DOI 10.1016/S0952-7915(02)00406-5; Paik S, 2002, JNCI-J NATL CANCER I, V94, P852, DOI 10.1093/jnci/94.11.852; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; PRESS MF, 1990, ONCOGENE, V5, P953; Pupa SM, 1996, J CLIN ONCOL, V14, P85, DOI 10.1200/JCO.1996.14.1.85; PUPA SM, 1993, CANCER RES, V53, P5864; Pupa SM, 2001, GENE THER, V8, P75, DOI 10.1038/sj.gt.3301360; Rhodes A, 2002, AM J CLIN PATHOL, V118, P408; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Roche PC, 2002, JNCI-J NATL CANCER I, V94, P855, DOI 10.1093/jnci/94.11.855; Ross JA, 1998, INT J CANCER, V78, P26; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Sfondrini L, 2002, FASEB J, V16, P1749, DOI 10.1096/fj.02-0383com; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soule S, 2002, J CLIN PATHOL, V55, P656, DOI 10.1136/jcp.55.9.656; Tagliabue E, 1998, EUR J CANCER, V34, P1982; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; Tagliabue E, 2001, BREAST CANCER RES TR, V70, P155, DOI 10.1023/A:1012955229031; Tan M, 1997, CANCER RES, V57, P1199; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tsavaris N, 2002, BRIT J CANCER, V87, P21, DOI 10.1038/sj.bjc.6600347; Tubbs RR, 2002, ARCH PATHOL LAB MED, V126, P803; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Volpi A, 2000, BREAST CANCER RES TR, V63, P181, DOI 10.1023/A:1006464426977; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Witters L, 2002, ONCOL REP, V9, P1163; Yan J, 2002, CANCER GENET CYTOGEN, V132, P116, DOI 10.1016/S0165-4608(01)00542-8; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	136	306	337	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6570	6578		10.1038/sj.onc.1206779	http://dx.doi.org/10.1038/sj.onc.1206779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528282				2022-12-28	WOS:000185700700014
J	Harnois, T; Constantin, B; Rioux, A; Grenioux, E; Kitzis, A; Bourmeyster, N				Harnois, T; Constantin, B; Rioux, A; Grenioux, E; Kitzis, A; Bourmeyster, N			Differential interaction and activation of Rho family GTPases by p210(bcr-abl) and p190(bcr-abl)	ONCOGENE			English	Article						Bcr-Abl; Rho GTPases; signal transduction	CHRONIC MYELOGENOUS LEUKEMIA; GUANINE-NUCLEOTIDE EXCHANGE; BCR-ABL ONCOPROTEINS; TYROSINE PHOSPHORYLATION; PHILADELPHIA-CHROMOSOME; CELL-LINES; HEMATOPOIETIC-CELLS; RAS TRANSFORMATION; SIGNALING PATHWAY; PROTOONCOGENE VAV	The p210(bcr-abl) and p190(bcr-abl) fusion proteins, respectively responsible for chronic myelogenous leukemia and acute lymphoblastic leukemia, present deregulated tyrosine kinase activity and abnormal localization. The Dbl homology domain of Bcr, activating Rho GTPases, is present in p210(bcr-abl), but absent in p190(bcr-abl). We investigated the interaction of Bcr-Abl chimeras and Rho proteins by coimmunoprecipitation, pull-down experiments and GEF activity measurement. RhoA, Rac1 and Cdc42 interact in vivo with p210(bcr-abl) only. Moreover, the three types of GTPases are activated in vitro and in vivo by p210(bcr-abl). Nevertheless, Rac1 and Cdc42, but not RhoA, are activated by p190(bcr-abl) in vitro and in vivo. Part of this GEF activity of p190(bcr-abl) is probably attributable to p95(vav), which is complexed with both p190(bcr-abl) and p210(bcr-abl) in an activated form. p160(bcr), also in complex with Bcr-Abl, presents no GEF activity in p190(bcr-abl)-expressing cells. These results suggest that differential activation of Rho proteins should play a major role in BcrAbl-induced leukemogenesis.	CHU Poitiers, UPRES EA2622, Lab Genet Cellulaire & Mol, F-86021 Poitiers, France; CNRS, UMR 6558, Lab Biomembranes & Signalisat Cellulaire, F-86022 Poitiers, France	CHU Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Kitzis, A (corresponding author), CHU Poitiers, UPRES EA2622, Lab Genet Cellulaire & Mol, BP 577, F-86021 Poitiers, France.		Constantin, Bruno/AAH-6463-2021	Bourmeyster, Nicolas/0000-0002-9563-5142; Constantin, Bruno/0000-0003-1668-581X; RIOUX BILAN, Agnes/0000-0003-2798-8576				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHENG JC, 1995, CELL GROWTH DIFFER, V6, P139; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Crespo P, 1996, ONCOGENE, V13, P455; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; DRUKER B, 1992, BLOOD, V79, P2215; Eda M, 2001, J CELL SCI, V114, P3273; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hansen MDH, 2001, CURR BIOL, V11, P356, DOI 10.1016/S0960-9822(01)00091-4; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohguchi K, 1997, J BIOL CHEM, V272, P1990, DOI 10.1074/jbc.272.3.1990; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Rudolph MG, 2001, J BIOL CHEM, V276, P23914, DOI 10.1074/jbc.M011600200; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	56	52	56	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6445	6454		10.1038/sj.onc.1206626	http://dx.doi.org/10.1038/sj.onc.1206626			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508524				2022-12-28	WOS:000185535300014
J	Kamel-Reid, S; Zhang, T; Wells, RA				Kamel-Reid, S; Zhang, T; Wells, RA			Expression of NPM-RAR alpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis	ONCOGENE			English	Article						PPAR gamma; apoptosis; NPM-RAR alpha; acute myelogenous leukemia	PROLIFERATOR-ACTIVATED RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN BREAST-CANCER; RETINOID-X-RECEPTOR; PPAR-GAMMA; MONOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; CYTOSINE-ARABINOSIDE; GROWTH-INHIBITION; LUNG-CANCER	We have investigated the effects of acute promyelocytic leukemia (APL) fusion gene NPM-RARalpha on the function of PPARgamma using the monoblastic cell line U937. U937 cells were transduced using a retrovirus carrying NPM-RARalpha. While treatment with the synthetic PPARgamma ligand troglitazone (TG) had no effect on the viability of U937 cells, TG treatment of U937/NPM-RARalpha cells resulted in a dramatic decrease in cell viability, dependent upon both the concentration of TG and the level of expression of NPM-RARalpha. Analysis of the cell cycle pro. le and flow cytometry with annexin V confirmed that these effects of TG were due to induction of apoptosis. Induction of apoptosis was accompanied by caspase-8 and caspase-9 activation, and could be blocked by treatment with the caspase inhibitor Z-VAD-FMK. Cotreatment of U937/NPM-RARalpha cells with all-trans retinoic acid (atRA) abrogated the induction of apoptosis by TG. Induction of apoptosis was seen also in the PML-RARalpha-expressing APL cell line NB4, and in several other atRA-sensitive leukemia cell lines, demonstrating that this effect is limited neither to the monocyte lineage nor to the rare NPM-RARalpha fusion variant. RXRalpha/NPM-RARalpha heterodimers were found to interact directly with a PPARgamma-responsive element in vitro. We conclude that in the presence of X-RARalpha, TG induces cell death due to apoptosis via the caspase pathway. These observations suggest the investigation of PPARgamma ligands as therapeutic agents in acute leukemia.	Univ Toronto, Inst Med Sci, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Wells, RA (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Room 8-209,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rwells@uhnres.utoronto.ca		Kamel-Reid, Suzanne/0000-0002-4386-0292				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Asou H, 1999, INT J ONCOL, V15, P1027; ATSUMI Y, 1986, AM J MED SCI, V292, P152, DOI 10.1097/00000441-198609000-00006; BENITO A, 1995, AM J PATHOL, V146, P481; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chang TH, 2000, CANCER RES, V60, P1129; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fujimura S, 1998, INT J ONCOL, V13, P1263; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Greene M. E., 1995, Gene Expression, V4, P281; HASS R, 1989, EUR J CELL BIOL, V48, P282; Hirase N, 1999, ONCOLOGY-BASEL, V57, P17, DOI 10.1159/000055271; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOISTINEN P, 1991, LEUKEMIA, V5, P704; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Padilla J, 2002, CLIN IMMUNOL, V103, P22, DOI 10.1006/clim.2001.5181; Pizzimenti S, 2002, FREE RADICAL BIO MED, V32, P233, DOI 10.1016/S0891-5849(01)00798-5; Rebel VI, 1999, BLOOD, V93, P2217, DOI 10.1182/blood.V93.7.2217.407a01_2217_2224; RIGBY WFC, 1984, BLOOD, V64, P1110; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; TESTA U, 1994, CANCER RES, V54, P4508; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG C, 1989, LEUKEMIA, V3, P699; YANG GS, 1993, LEUKEMIA, V7, P1012; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	48	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6424	6435		10.1038/sj.onc.1206696	http://dx.doi.org/10.1038/sj.onc.1206696			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508522				2022-12-28	WOS:000185535300012
J	Bernat, A; Avvakumov, N; Mymryk, JS; Banks, L				Bernat, A; Avvakumov, N; Mymryk, JS; Banks, L			Interaction between the HPV E7 oneoprotein and the transcriptional coactivator p300	ONCOGENE			English	Article						HPV; E7; p300 transcriptional coactivation	HUMAN-PAPILLOMAVIRUS TYPE-16; CREB-BINDING-PROTEIN; RETINOBLASTOMA TUMOR-SUPPRESSOR; E6 ONCOPROTEIN; HISTONE ACETYLTRANSFERASES; HUMAN KERATINOCYTES; P53 DEGRADATION; ADENOVIRUS E1A; CELL-GROWTH; E2 PROTEIN	Infection with high-risk human papillomaviruses (HPV) can lead to the development of cervical cancer. This process depends on the interaction of the virus-encoded oncoproteins, E6 and E7, with a variety of host regulatory proteins. As E7 shares both functional and structural similarities with the Adenovirus E1a (Ad E1a) protein, we were interested in investigating the possible interactions between E7 and the transcriptional coactivator p300, since it was originally identified as a target of Ad E1a. Using a variety of assays, we show that E7s from both high- and low-risk HPV types interact with p300. Mutational analysis of E7 maps the site of the interaction to a region spanning the pRb-binding domain and the CKII phosphorylation site. We also map the site of interaction on p300 largely to the CH1 domain. In addition, we demonstrate that the binding between 16E7 and p300 is direct, and can be detected in vivo by coimmunoprecipitation and mammalian two-hybrid assays. Finally, we show that E7 can abolish the p300-mediated E2 transactivation function, suggesting that complex formation between E7 and p300 may contribute to the regulation of E2 transcriptional activity.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Western Ontario, London Reg Canc Ctr, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Physiol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Pharmacol, London, ON N6A 4L6, Canada	International Center for Genetic Engineering & Biotechnology (ICGEB); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Bernat, Agnieszka/0000-0002-1232-4286				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Bernat A, 2002, J GEN VIROL, V83, P829, DOI 10.1099/0022-1317-83-4-829; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DAVIES RC, 1992, J GEN VIROL, V73, P2135, DOI 10.1099/0022-1317-73-8-2135; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kung AL, 2000, GENE DEV, V14, P272; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marcello A, 2000, J VIROL, V74, P9090, DOI 10.1128/JVI.74.19.9090-9098.2000; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Muller A, 2002, J VIROL, V76, P11042, DOI 10.1128/JVI.76.21.11042-11053.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; PIM D, 2001, VIRUSES CELL TRANSFO, P145; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Stubenrauch F, 1998, J VIROL, V72, P1071, DOI 10.1128/JVI.72.2.1071-1077.1998; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wong HK, 1996, J VIROL, V70, P332, DOI 10.1128/JVI.70.1.332-340.1996; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	86	108	112	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7871	7881		10.1038/sj.onc.1206896	http://dx.doi.org/10.1038/sj.onc.1206896			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970734				2022-12-28	WOS:000185388200001
J	Domon-Dell, C; Schneider, A; Moucadel, V; Guerin, E; Guenot, D; Aguillon, S; Duluc, I; Martin, E; Iovanna, J; Launay, JF; Duclos, B; Chenard, MP; Meyer, C; Oudet, P; Kedinger, M; Gaub, MP; Freund, JN				Domon-Dell, C; Schneider, A; Moucadel, V; Guerin, E; Guenot, D; Aguillon, S; Duluc, I; Martin, E; Iovanna, J; Launay, JF; Duclos, B; Chenard, MP; Meyer, C; Oudet, P; Kedinger, M; Gaub, MP; Freund, JN			Cdx1 homeobox gene during human colon cancer progression	ONCOGENE			English	Article						allelic imbalance; genomic rearrangement; gene expression; xenografts	DOWN-REGULATION; COLORECTAL-CANCER; EXPRESSION; CELLS; PATHWAYS	The Cdx1 homeobox gene encodes an intestine-specific transcription factor with a pro-oncogenic function in vitro. Here we have analysed the pattern of Cdx1 in human colon cancer progression. Cdx1 expression remains at a high level in the majority of the polyps and it is even overexpressed in more than one-third of the specimens, consistent with the fact that the gene is an intestine-specific target of oncogenic pathways. However, Cdx1 decreases in one-fifth of the polyps, which is reminiscent of the loss of expression previously reported in the majority of carcinomas. Allelic imbalance analysis demonstrates that the Cdx1 locus located on chromosome 5q is a major site of genomic rearrangement in colorectal cancers, and that the frequency of the rearrangements increases during polyps to carcinoma progression. Allelic imbalance at the Cdx1 locus occurs in relation to, although not invariably in association with, the rearrangements at the APC locus on the same chromosomal arm. Xenografts of primary human colon carcinomas indicate that the level of Cdx1 mRNA correlates with the intensity of allelic imbalance. Together, these data show that Cdx1 exhibits a complex pattern during colorectal cancer progression. Given that Cdx1 has a pro-oncogenic function in vitro, the maintenance of a high level of expression in polyps, and even its overexpression in one-third of the specimens, suggest that this homeobox gene may be an important factor in the process toward malignant transformation during the first steps of tumorigenesis.	INSERM, U381, F-67200 Strasbourg, France; INSERM, Ctr Rech, EMI 0116, F-13009 Marseille, France; Univ Strasbourg, Hop Hautepierre, F-67200 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasburg.fr	Freund, Jean-Noel/R-4383-2016; Domon-Dell, Claire/P-2368-2017; Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; guenot, dominique/R-3355-2016; Guerin, Eric/R-3426-2016; Chenard, Marie-Pierre/O-2373-2016; Iovanna, Juan/M-9805-2017	Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; guenot, dominique/0000-0003-2782-8425; Iovanna, Juan/0000-0003-1822-2237; GUERIN, ERIC/0000-0003-1388-2834; DOMON-DELL, Claire/0000-0002-8445-9593				BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Domon-Dell C, 2002, FEBS LETT, V518, P83, DOI 10.1016/S0014-5793(02)02650-9; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Oh EJ, 2002, INT J ONCOL, V20, P23; Ren P, 2000, AM J PATHOL, V156, P621, DOI 10.1016/S0002-9440(10)64766-9; Schneider A, 2000, CANCER RES, V60, P4617; Schneider A, 2000, AUST NZ J SURG, V70, P587, DOI 10.1046/j.1440-1622.2000.01904.x; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364; Weber JC, 2001, ANN SURG, V234, P795, DOI 10.1097/00000658-200112000-00011	26	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7913	7921		10.1038/sj.onc.1206756	http://dx.doi.org/10.1038/sj.onc.1206756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970739				2022-12-28	WOS:000185388200006
J	Schmidt-Ullrich, RK; Contessa, JN; Lammering, G; Amorino, G; Lin, PS				Schmidt-Ullrich, RK; Contessa, JN; Lammering, G; Amorino, G; Lin, PS			ERBB receptor tyrosine kinases and cellular radiation responses	ONCOGENE			English	Article						ERBB receptors; IGF-IR; proliferation; apoptosis; DNA repair; signal transduction	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; FACTOR-I RECEPTOR; MAMMARY-CARCINOMA CELLS; IONIZING-RADIATION; EGF RECEPTOR; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; ZD1839 IRESSA; INTACT-CELLS	Ionizing radiation induces in autocrine growth-regulated carcinoma and malignant glioma cells powerful cytoprotective responses that confer relative resistance to consecutive radiation exposures. Understanding the mechanisms of these responses should provide new molecular targets for tumor radiosensitization. ERBB and other receptor Tyr kinases have been identified as immediate early response gene products that are activated by radiation within minutes, as by their physiological growth factor ligands, and induce secondary stimulation of cytoplasmic protein kinase cascades. The simultaneous activation of all receptor Tyr kinases and nonreceptor Tyr kinases leads to complex cytoprotective responses including increased cell proliferation, reduced apoptosis and enhanced DNA repair. Since these responses contribute to cellular radioresistance, ERBB1, the most extensively studied ERBB receptor, is examined as a target for tumor cell radiosensitization. The three methods of ERBB1 inhibition include blockade of growth factor binding by monoclonal antibody against the ligand-binding domain, inhibition of the receptor Tyr kinase-mediating receptor activation, and overexpression of a dominant-negative epidermal growth factor receptor-CD533 that lacks the COOH-terminal 533 amino acids and forms nonfunctional heterodimeric complexes with wild-type receptors. All the three approaches enhance radiation toxicity in vitro and in vivo. The different mechanisms of inhibition have contributed to the understanding of cellular responses to radiation, vary in relative effectiveness and pose different challenges for translation.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA; Univ Dusseldorf, Dept Radiat Oncol, Dusseldorf, Germany	Virginia Commonwealth University; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23284 USA.	rullrich@hsc.vcu.edu			NCI NIH HHS [R01CA65896, P01CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Allen LF, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34049; Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; AMORINO GP, 2003, UNPUB J BIOL CHEM; Ang KK, 2002, CANCER RES, V62, P7350; BASERGA R, 1995, CANCER RES, V55, P249; BENTZEN SM, 1991, RADIOTHER ONCOL, V22, P161, DOI 10.1016/0167-8140(91)90019-D; Bernhard EJ, 1998, CANCER RES, V58, P1754; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bonner JA, 2000, J CLIN ONCOL, V18, p47S; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chakravarti A, 2002, CANCER RES, V62, P200; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Durand, 1993, Semin Radiat Oncol, V3, P105, DOI 10.1016/S1053-4296(05)80086-4; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; FOWLER JF, 1991, RADIOTHER ONCOL, V22, P156, DOI 10.1016/0167-8140(91)90017-B; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harari PM, 2001, SEMIN RADIAT ONCOL, V11, P281, DOI 10.1053/srao.2001.26027; Huang SM, 2002, CANCER RES, V62, P4300; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kasid U, 2003, ONCOGENE, V22, P5876, DOI 10.1038/sj.onc.1206700; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kuan CT, 1999, CLIN CANCER RES, V5, P1539; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; LAMMERING G, 2003, IN PRESS ONCOGENE; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Leach JK, 2001, CANCER RES, V61, P3894; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levitzki A, 1997, MED ONCOL, V14, P83, DOI 10.1007/BF02990952; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; McKenna WG, 2003, ONCOGENE, V22, P5866, DOI 10.1038/sj.onc.1206699; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MIKKELSEN RB, 2003, IN PRESS ONCOGENE RE; Milas L, 2000, CLIN CANCER RES, V6, P701; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pietras RJ, 1999, CANCER RES, V59, P1347; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; SHAH BH, 2003, UNPUB J BIOL CHEM; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Solomon B, 2003, INT J RADIAT ONCOL, V55, P713, DOI 10.1016/S0360-3016(02)04357-2; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner BC, 1997, CANCER RES, V57, P3079; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; Wikstrand CJ, 1997, CANCER RES, V57, P4130; Wilkinson JC, 2002, BIOCHEMISTRY-US, V41, P8, DOI 10.1021/bi015839l; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2	81	96	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5855	5865		10.1038/sj.onc.1206698	http://dx.doi.org/10.1038/sj.onc.1206698			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947392				2022-12-28	WOS:000185086100012
J	Amin, HM; Medeiros, LJ; Ma, Y; Feretzaki, M; Das, P; Leventaki, V; Rassidakis, GZ; O'Connor, SL; McDonnell, TJ; Lai, R				Amin, HM; Medeiros, LJ; Ma, Y; Feretzaki, M; Das, P; Leventaki, V; Rassidakis, GZ; O'Connor, SL; McDonnell, TJ; Lai, R			Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma	ONCOGENE			English	Article						anaplastic large cell lymphoma; AG490; STAT; JAK; NPM-ALK	NON-HODGKINS LYMPHOMA; STAT3 ACTIVATION; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SURVIVIN EXPRESSION; SIGNAL TRANSDUCER; HUMAN OVARIAN; PROTEIN; GROWTH; AG490	Signal transducer and activator of transcription 3 (STAT3), normally activated by Janus kinase (JAK) in response to cytokine stimulation, has been shown to have oncogenic potential. In addition to JAK, recent data suggest that STAT3 can also be activated by other proteins such as the aberrant fusion protein, NPM-ALK, which is expressed in a subset of systemic anaplastic large cell lymphoma (ALCL). In this study, we investigated the possible role of JAK in activating STAT3 in ALCL using two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1. At the steady state, JAK3 showed detectable tyrosine phosphorylation by immunoprecipitation. Treatment with AG490, a JAK inhibitor, decreased but did not completely abrogate tyrosine phosphorylation of JAK3 and STAT3 in a concentration-dependent manner. Similar results were obtained using two other inhibitors of JAK3, WHI-P131 and WHI-P154. These biochemical changes were associated with apoptosis in both cell lines that was coupled with activation of caspase 3 and decreased bcl-xL and bcl-2. Cell cycle analysis revealed a decrease in the S phase, which may be attributed to cyclin D3 downregulation and P21(waf1) upregulation. Importantly, the tyrosine kinase activity of NPM-ALK, as assessed by an in vitro assay, decreased with increasing concentrations of AG490. Our findings highlight the importance of JAK3 in activating STAT3 in ALCL, and that NPM-ALK-mediated activation of STAT3 is influenced by the functional status of JAK3.	Univ Texas, MD Anderson Canc Ctr, Dept Histopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lai, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Histopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	raymondmail_65@yahoo.com	Rassidakis, George/V-9553-2019; Leventaki, Vasiliki/N-8175-2018					Alas S, 2001, CANCER RES, V61, P5137; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Delsol G, 2001, WHO CLASSIFICATION T, P230; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4; Eriksen KW, 2001, LEUKEMIA, V15, P787, DOI 10.1038/sj.leu.2402093; Falini B, 1999, BLOOD, V93, P2697; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kirken RA, 2001, TRANSPLANT P, V33, P95, DOI 10.1016/S0041-1345(00)02791-3; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narla RK, 1998, CLIN CANCER RES, V4, P2463; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Pulford K, 2001, CURR OPIN HEMATOL, V8, P231, DOI 10.1097/00062752-200107000-00009; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Turturro F, 2001, ONCOGENE, V20, P4466, DOI 10.1038/sj.onc.1204582; Uckun FM, 1999, CLIN CANCER RES, V5, P2954; Wang LH, 1999, J IMMUNOL, V162, P3897; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	51	104	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5399	5407		10.1038/sj.onc.1206849	http://dx.doi.org/10.1038/sj.onc.1206849			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934099				2022-12-28	WOS:000184735000004
J	Lodygin, D; Yazdi, AS; Sander, CA; Herzinger, T; Hermeking, H				Lodygin, D; Yazdi, AS; Sander, CA; Herzinger, T; Hermeking, H			Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma	ONCOGENE			English	Article						tumour suppressor; basal cell carcinoma; CpG-methylation; keratinocytes; cell cycle	HIGH-FREQUENCY; EARLY EVENT; HYPERMETHYLATION; GENE; INACTIVATION; LEADS	The p53-regulated 14-3-3sigma gene encodes an inhibitor of cell cycle progression essential for senescence and clonal evolution of keratinocytes in vitro. Here we analysed the in vivo expression of 14-3-3sigma protein in several skin diseases, which are characterized by hyperproliferative keratinocytes. Unexpectedly, the 14-3-3sigma protein was expressed at high levels in psoriasis (11 of 11 patients), condylomata acuminata (11/11), actinic keratoses (11/11) and squamous cell carcinomas (SCC) (11/11). However, keratinocytes that had undergone transformation to basal cell carcinoma (BCC) showed partial (10 of 41; 24.4%) or complete (19 of 41; 46.3%) loss of 14-3-3sigma protein expression. BCC (5/5), SCC (6/6) and actinic keratoses (7/7) concomitantly expressed the p53-homolog p63 and 14-3-3sigma at high levels, ruling out potential inhibitory effects of p63 isoforms on 14-3-3sigma transcription as the basis for loss of 14-3-3sigma expression. Of 41 BCC samples isolated by laser-capture microdissection, 28 (68.3%) showed CpG-hypermethylation of the 14-3-3sigma promoter combined with reduced or absent 14-3-3sigma protein levels in 22 cases (78.6%). Since it has been reported that BCC retain wild-type p16(INK4A) and here BCC with CpG-methylation of 14-3-3sigma did not show CpG-methylation of p16(INK4A) (0/17), silencing of 14-3-3sigma may contribute to evasion of senescence in BCC. As experimental removal of 14-3-3sigma sensitizes to DNA damage, silencing of 14-3-3sigma may explain the high efficacy of radiation therapy in the treatment of BCC.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Dept Dermatol, D-80539 Munich, Germany	Max Planck Society; University of Munich	Hermeking, H (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	herme@biochem.mpg.de						Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Li Z, 2002, CANCER RES, V62, P1939; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Saridaki Z, 2000, J INVEST DERMATOL, V115, P719, DOI 10.1046/j.1523-1747.2000.00098.x; Schubert J, 1997, Mund Kiefer Gesichtschir, V1, P44; Tokugawa T, 2002, CANCER RES, V62, P4938; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4	20	72	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5519	5524		10.1038/sj.onc.1206854	http://dx.doi.org/10.1038/sj.onc.1206854			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934112				2022-12-28	WOS:000184735000017
J	Miro-Mur, F; Meiller, A; Haddada, H; May, E				Miro-Mur, F; Meiller, A; Haddada, H; May, E			p73 alpha expression induces both accumulation and activation of wt-p53 independent of the p73 alpha transcriptional activity	ONCOGENE			English	Article						p53; p73 alpha; p73 alpha R292H; recombinant adenovirus; protein stability; transcriptional activity	DNA-DAMAGE; P53-DEPENDENT MANNER; FEEDBACK LOOP; P53 PROTEIN; MCF7 CELLS; P73; APOPTOSIS; P63; DEGRADATION; DELTA-NP73	The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. p73alpha has common activities with p53, such as DNA binding and transactivation, and can thus activate the transcription of p53-responsive genes. Using the adenoviral system, we report that an overexpression of either wt-p73alpha or one of the two transcriptional inactive mutants, DeltaNp73alpha or p73alpha:R292H, induces an accumulation of the endogenous wt-p53 expressed in the three transformed cell lines, SK-N-SH, MCF-7 and U-2OS, without stimulating the p53 gene transcription. p73-mediated accumulation of p53 protein coincides with an increase of p53-target gene expression in cells expressing either wt-p73alpha or the transcriptional inactive mutant p73alphaR292H, but not DeltaNp73alpha: that encodes a dominant-negative mutant of both p73 and p53. The fact that an ectopic expression of p73alpha:R292H leads to both accumulation of p53 and stimulation of p53 target gene expression strongly suggests that p73alpha is able to induce activation of p53. This was confirmed by showing that p73alphaR292H no longer stimulated Waf1/p21 expression in MCF7/R-A1 cells that expressed a transcriptional inactive mutant of p53. We thus conclude that p73alpha: protein was able to both stabilize and activate wt-p53 protein, independent of the p73alpha transcriptional activity.	CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, F-92265 Fontenay Aux Roses, France; Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Inst Gustave Roussy, INSERM, U3652, F-94805 Villejuif, France	CEA; Autonomous University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	May, E (corresponding author), CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, Route Panorama,BP 6, F-92265 Fontenay Aux Roses, France.		Miro-Mur, Francesc A./AAT-3013-2020	Miro-Mur, Francesc A./0000-0003-3936-2693; MEILLER, Anne/0000-0001-5546-3035				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Drane P, 2002, CELL DEATH DIFFER, V9, P527, DOI 10.1038/sj.cdd.4400983; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Levrero M, 2000, J CELL SCI, V113, P1661; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516	24	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5451	5456		10.1038/sj.onc.1206538	http://dx.doi.org/10.1038/sj.onc.1206538			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934105				2022-12-28	WOS:000184735000010
J	Stroh, C; Held, E; Samraj, AK; Schulze-Osthoff, K				Stroh, C; Held, E; Samraj, AK; Schulze-Osthoff, K			Specific inhibition of transcription factor NF-kappa B through intracellular protein delivery of I kappa B alpha by the Herpes virus protein VP22	ONCOGENE			English	Article						NF-kappa B; I kappa B alpha; VP22; protein transduction	BIOLOGICALLY-ACTIVE PROTEINS; GENE-THERAPY; TRANSDUCTION; ACTIVATION; CELLS; EXPRESSION; VIVO; PEPTIDE; TRAFFICKING; DISTINCT	In many cancers, a high constitutive activation of transcription factor NF-kappaB has been implicated in tumor progression and apoptosis resistance, making NF-kappaB an attractive target for cancer therapy. Here, we describe the specific inhibition of NF-kappaB by the intracellular delivery of IkappaBalpha through VP22-mediated protein transduction. The Herpes virus protein VP22 has attracted great attention in gene therapy, because of its ability to migrate from an original expressing cell into surrounding recipient cells, resulting in high levels of protein transduction. To evaluate the use of VP22 as a vehicle for NF-kappaB inhibition, we expressed several versions of VP22-IkappaBalpha fusion proteins in baculovirus, bacteria, and mammalian cells. While we could not detect transcellular migration of different VP22-IkappaBalpha constructs, interestingly, baculovirally expressed VP22-IkappaBalpha was efficiently delivered into cells after exogenous administration. The purified and imported VP22-IkappaBalpha retained its function and efficiently inhibited both constitutive and inducible NF-kappaB activation. We further show that the 34 C-terminal amino acids of VP22 were sufficient for the import property, suggesting also that the ability of intercellular migration and cellular import are not linked to each other. Together, our results demonstrate that recombinant VP22 acts as an efficient vehicle for the exogenous delivery of IkappaBalpha and, moreover, might find applications to block NF-kappaB activation specifically.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, D-4400 Munster, Germany	Heinrich Heine University Dusseldorf; University of Munster	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Held, Jurgen/0000-0003-1130-9727				Aradhya S, 2001, CURR OPIN GENET DEV, V11, P300, DOI 10.1016/S0959-437X(00)00194-5; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Fujihara SM, 2000, J IMMUNOL, V165, P1004, DOI 10.4049/jimmunol.165.2.1004; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Normand N, 2001, J BIOL CHEM, V276, P15042, DOI 10.1074/jbc.M010294200; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Swinney DC, 2002, J BIOL CHEM, V277, P23573, DOI 10.1074/jbc.M200842200; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wills KN, 2001, J VIROL, V75, P8733, DOI 10.1128/JVI.75.18.8733-8741.2001; Wybranietz WA, 2001, GENE THER, V8, P1654, DOI 10.1038/sj.gt.3301564; Wybranietz WA, 1999, J GENE MED, V1, P265; Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	32	20	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5367	5373		10.1038/sj.onc.1206544	http://dx.doi.org/10.1038/sj.onc.1206544			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917639				2022-12-28	WOS:000184734900017
J	Zhong, SP; Goto, H; Inagaki, M; Dong, ZG				Zhong, SP; Goto, H; Inagaki, M; Dong, ZG			Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A	ONCOGENE			English	Article						histone H3; trichostatin A; phosphorylation; acetylation; ultraviolet; MAP kinase	ACTIVATED PROTEIN-KINASE; MITOTIC CHROMOSOME CONDENSATION; B-INDUCED PHOSPHORYLATION; P38 MAP KINASE; GENE ACTIVATION; CYCLIC TETRAPEPTIDE; CHROMATIN STRUCTURE; IN-VITRO; DEACETYLASE; EXPRESSION	Trichostatin A (TSA), a histone deacetylase inhibitor, strongly increases acetylation of the N-terminal tails of histone H3. Many studies have correlated the function of TSA with the hyperacetylation of histone. Although histone H3 is known to be phosphorylated, the effect of acetylation on phosphorylation is not known. Here, we report that in JB6 cells, TSA induces both acetylation at lysine 9 and phosphorylation at serine 28 of histone H3. UVB irradiation, which is known to induce phosphorylation at serine 28, did not significantly affect phosphorylation of histone H3 in TSA-pretreated JB6 cells. In contrast, TSA markedly increased phosphorylation and acetylation of histone H3 in UVB-pretreated JB6 cells. TSA strongly activated MAP kinases. Moreover, PD98059 and SB202190 inhibited TSA-induced phosphorylation but not acetylation of histone H3. Dominant negative mutant ERK2 and dominant negative mutant p38 kinase blocked TSA-stimulated phosphorylation of histone H3 at serine 28. The results indicate that TSA-induced phosphorylation of histone H3 at serine 28 occurs through activation of the MAP kinase pathway and phosphorylated histone H3 is more sensitive to TSA-induced hyperacetylation. The facilitation of phosphorylation and acetylation of histone H3 induced by TSA may play a critical regulatory role in chromatin remodeling and gene expression.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Aichi 4648681, Japan	University of Minnesota System; Aichi Cancer Center	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467	NATIONAL CANCER INSTITUTE [R01CA077646, P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Davie JR, 1999, J CELL BIOCHEM, P141; Davie JR, 1998, J CELL BIOCHEM, P203; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; HONDA BM, 1975, J BIOL CHEM, V250, P8681; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Medina V, 1997, CANCER RES, V57, P3697; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Smalley KSM, 1999, BIOCHEM BIOPH RES CO, V263, P239, DOI 10.1006/bbrc.1999.1351; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	49	45	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5291	5297		10.1038/sj.onc.1206507	http://dx.doi.org/10.1038/sj.onc.1206507			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917630				2022-12-28	WOS:000184734900008
J	Vilchez, RA; Butel, JS				Vilchez, RA; Butel, JS			SV40 in human brain cancers and non-Hodgkin's lymphoma	ONCOGENE			English	Article						SV40; human cancers; brain tumors; non-Hodgkin'slymphoma	LARGE-T-ANTIGEN; HUMAN MESOTHELIAL CELLS; SIMIAN VIRUS 40; DNA-SEQUENCES; SIMIAN-VIRUS-40 SEQUENCES; MOLECULAR-BIOLOGY; HUMAN INFECTIONS; CHOROID-PLEXUS; POLIO VACCINE; HUMAN TUMORS	Simian virus 40 (SV40) is a potent DNA tumor virus that is known to induce primary brain cancers and lymphomas in laboratory animals. SV40 oncogenesis is mediated by the viral large tumor antigen (T-ag), which inactivates the tumor-suppressor proteins p53 and pRb family members. During the last decade, independent studies using different molecular biology techniques have shown the presence of SV40 DNA, T-ag, or other viral markers in primary human brain cancers, and a systematic assessment of the data indicates that the virus is significantly associated with this group of human tumors. In addition, recent large independent studies showed that SV40 T-ag DNA is significantly associated with human non-Hodgkin's lymphoma (NHL). Although the prevalence of SV40 infections in humans is not known, numerous observations suggest that SV40 is a pathogen in the human population today. This review examines the molecular biology, pathology, and clinical data implicating SV40 in the pathogenesis of primary human brain cancers and NHL and discusses future research directions needed to define a possible etiologic role for SV40 in these malignancies.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Butel, JS (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Mail Stop BCM-385,1 Baylor Plaza, Houston, TX 77030 USA.	jbutel@bcm.tmc.edu		Butel, Janet/0000-0002-6876-3245	NATIONAL CANCER INSTITUTE [R21CA096951] Funding Source: NIH RePORTER; NCI NIH HHS [R21CA96951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; American Cancer Society, 2002, CANC FACTS FIG 2002; ARRINGTON AS, 2001, HUMAN POLYOMAVIRUSES, P461; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Butel J S, 1972, Adv Cancer Res, V15, P1, DOI 10.1016/S0065-230X(08)60371-1; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Butel JS, 1999, HUM PATHOL, V30, P1496, DOI 10.1016/S0046-8177(99)90173-9; Cacciotti P, 2002, AM J RESP CELL MOL, V26, P189, DOI 10.1165/ajrcmb.26.2.4673; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Carroll-Pankhurst C, 2001, BRIT J CANCER, V85, P1295, DOI 10.1054/bjoc.2001.2065; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; COE JE, 1975, J NATL CANCER I, V54, P269, DOI 10.1093/jnci/54.1.269; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Engels EA, 2002, INT J CANCER, V101, P348, DOI 10.1002/ijc.10621; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; Fisher SG, 1999, ANTICANCER RES, V19, P2173; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P85; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gerard L, 2001, J ACQ IMMUN DEF SYND, V26, P182, DOI 10.1097/00126334-200102010-00013; GIRARDI AJ, 1962, P SOC EXP BIOL MED, V109, P649, DOI 10.3181/00379727-109-27298; Gomez-Brouchet A, 2001, J CLIN PATHOL, V54, P617, DOI 10.1136/jcp.54.8.617; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; Huang HT, 1999, BRAIN PATHOL, V9, P33; IBELGAUFTS H, 1982, ACTA NEUROPATHOL, V56, P118, DOI 10.1007/BF00690582; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; Jafar S, 1998, J MED VIROL, V54, P276, DOI 10.1002/(SICI)1096-9071(199804)54:4<276::AID-JMV7>3.0.CO;2-1; Jaffe ES, 2001, WHO CLASSIFICATION T; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Kleihues P, 2000, PATHOLOGY GENETICS T; Kouhata T, 2001, J NEUROSURG, V95, P96, DOI 10.3171/jns.2001.95.1.0096; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Lednicky JA, 1999, FRONT BIOSCI, V4, P153; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; Malkin D, 2001, ONCOGENE, V20, P4441, DOI 10.1038/sj.onc.1204583; Martini F, 1996, CANCER RES, V56, P4820; Martini F, 2002, CANCER-AM CANCER SOC, V94, P1037, DOI 10.1002/cncr.10272; Martini F, 1998, INT J CANCER, V78, P669, DOI 10.1002/(SICI)1097-0215(19981209)78:6<669::AID-IJC1>3.0.CO;2-B; MEINKE W, 1979, NEUROLOGY, V29, P1590, DOI 10.1212/WNL.29.12.1590; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; Ohgaki H, 2000, J NATL CANCER I, V92, P495, DOI 10.1093/jnci/92.6.495; Olin P, 1998, DEV BIOL STAND, V94, P227; *PAN AM HLTH ORG, 1960, SCI PUBL, V50; Ries L, 1998, SEER CANC STAT REV 1; Rizzo P, 1999, CHEST, V116, p470S, DOI 10.1378/chest.116.suppl_3.470S; Rizzo P, 1999, CANCER RES, V59, P6103; ROLLISON DE, 2001, HUMAN POLYOMAVIRUSES, P561; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2000, INT J CANCER, V85, P743, DOI 10.1002/(SICI)1097-0215(20000301)85:5<743::AID-IJC24>3.3.CO;2-V; STEWART AM, 1965, LANCET, V2, P789; STRATTON K, 2003, IN PRESS IMMUNIZATIO; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Suzuki S O, 1997, Brain Tumor Pathol, V14, P125, DOI 10.1007/BF02478881; TABUCHI K, 1978, INT J CANCER, V21, P12, DOI 10.1002/ijc.2910210104; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; Vastag B, 2002, JAMA-J AM MED ASSOC, V288, P1337, DOI 10.1001/jama.288.11.1337; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1; Vilchez RA, 2003, LANCET ONCOL, V4, P188, DOI 10.1016/S1470-2045(03)01024-6; Vilchez RA, 2002, J ACQ IMMUN DEF SYND, V29, P109, DOI 10.1097/00042560-200202010-00001; Weggen S, 2000, BRAIN PATHOL, V10, P85; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609; Zhen HN, 1999, CANCER, V86, P2124, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2124::AID-CNCR34>3.0.CO;2-D; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	77	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5164	5172		10.1038/sj.onc.1206547	http://dx.doi.org/10.1038/sj.onc.1206547			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910253				2022-12-28	WOS:000184615100007
J	Liao, GX; Sun, SC				Liao, GX; Sun, SC			Regulation of NF-kappa B2/p100 processing by its nuclear shuttling	ONCOGENE			English	Article						NF-kappa B; p100; protein processing; nuclear localization signal; leptomycin B	NF-KAPPA-B; TRCP UBIQUITIN LIGASE; MICE LACKING; P105; PROTEINS; SIGNAL; PHOSPHORYLATION; PRECURSOR; KINASE; DOMAIN	Processing of the NF-kappaB2 precursor protein p100 to generate p52 is an important step of NF-kappaB regulation. This proteolytic event is tightly regulated by sequences located at the C-terminal portion of p100. Constitutive processing of p100 occurs in certain lymphoma cells due to the loss of its C-terminal regulatory domain, although the underlying mechanisms remain unknown. We show here that the constitutive processing of C-terminal truncation mutants of p100 is associated with their active nuclear translocation. Deletion of the C-terminal death domain of p100 triggers a low, but significant, level of nuclear translocation and processing. Disruption of the ankyrin-repeat domain of p100 further enhances its nuclear shuttling activity, which is again associated with elevated level of processing. More importantly, mutation of the nuclear localization signal (NLS) of p100 abolishes its processing, and this defect can be rescued by fusion of a heterologous NLS to the amino- or carboxyl-terminus of the p100 mutant. These results suggest that nuclear shuttling is a mechanism regulating the processing of NF-kappaB2/p100.	Penn State Univ Hosp, Dept Microbiol & Immunol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ Hosp, Dept Microbiol & Immunol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NCI NIH HHS [1R01 CA94922] Funding Source: Medline; NIAID NIH HHS [1R01 AI45045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Harhaj EW, 1996, ONCOGENE, V12, P2385; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980	37	34	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4868	4874		10.1038/sj.onc.1206761	http://dx.doi.org/10.1038/sj.onc.1206761			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894228				2022-12-28	WOS:000184344600010
J	Span, PN; Tjan-Heijnen, VCG; Manders, P; Beex, LVAM; Sweep, CGJ				Span, PN; Tjan-Heijnen, VCG; Manders, P; Beex, LVAM; Sweep, CGJ			Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer	ONCOGENE			English	Article						cell cycle; prognosis; multivariate study; treatment interaction; tamoxifen	PROGNOSTIC FACTORS; E OVEREXPRESSION; CELL-CYCLE; EXPRESSION; DEREGULATION; SURVIVAL; PROTEIN; KINASE; PROLIFERATION; RISK	Recently, cyclin-E was reported to be the most prominent prognostic factor for breast cancer outcome described so far, even surpassing axillary nodal involvement. Earlier studies on the prognostic value of cyclin-E in breast cancer, however, yielded heterogeneous results. Therefore, we set out to confirm and extend these results by quantitative Taqman RT-PCR of cyclin-E levels in 277 resectable breast cancers. Cyclin-E levels were not associated with relapse-free survival (RFS) or overall survival (OS) in the total cohort of patients, or in the subset of patients without involved lymph nodes that were not treated with adjuvant systemic therapy. Besides several classical clinicopathological factors, the interaction between cyclin-E and adjuvant endocrine therapy (P = 0.01, HR = 3.04, 95% CI: 1.30-7.09) was found to contribute significantly in multivariate analyses. Cyclin-E levels were associated with poor RFS specifically in patients treated with adjuvant endocrine therapy (n = 108, P = 0.001, HR = 4.01, 95% CI: 1.76-9.12), independent of estrogen receptor status. In conclusion, cyclin-E is not a pure prognostic factor in breast cancer, but rather a predictor of failure of endocrine therapy. Differences in literature on the presumed prognostic value of cyclin-E may be due to differences in treatment. Assessment of cyclin-E levels can aid in improving adjuvant treatment selection.	Univ Med Ctr Nijmegen, Dept Chem Endocrinol 530, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Span, PN (corresponding author), Univ Med Ctr Nijmegen, Dept Chem Endocrinol 530, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Span, Paul/G-4710-2012; Sweep, C.G.J./H-8096-2014; Manders, P./L-4501-2015; Span, Paul N./A-3143-2009	Span, Paul/0000-0002-1930-6638; Sweep, C.G.J./0000-0003-1103-3070; 				ALTMAN DG, 1994, J NATL CANCER I, V86, P829, DOI 10.1093/jnci/86.11.829; Altman DG, 1998, BREAST CANCER RES TR, V52, P289, DOI 10.1023/A:1006193704132; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; COX DR, 1972, J R STAT SOC B, V34, P187; Dhillon NK, 2002, ONCOGENE, V21, P4626, DOI 10.1038/sj.onc.1205576; Donnellan R, 2001, HUM PATHOL, V32, P89, DOI 10.1053/hupa.2001.21141; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Foekens JA, 2003, CANCER RES, V63, P337; Harbeck N, 2002, CANCER RES, V62, P4617; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kim HK, 2001, EUR J SURG ONCOL, V27, P464, DOI 10.1053/ejso.2001.1137; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kuhling H, 2003, J PATHOL, V199, P424, DOI 10.1002/path.1322; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076	25	70	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4898	4904		10.1038/sj.onc.1206818	http://dx.doi.org/10.1038/sj.onc.1206818			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894232				2022-12-28	WOS:000184344600014
J	Ko, J; Lee, YH; Hwang, SY; Lee, YS; Shin, SM; Hwang, JH; Kim, J; Kim, YW; Jang, SW; Ryoo, ZY; Kim, IK; Namkoong, SE; Kim, JW				Ko, J; Lee, YH; Hwang, SY; Lee, YS; Shin, SM; Hwang, JH; Kim, J; Kim, YW; Jang, SW; Ryoo, ZY; Kim, IK; Namkoong, SE; Kim, JW			Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization	ONCOGENE			English	Article						HCCR-2; cervical cancer; p53; oncogene	TUMOR-SUPPRESSOR GENES; CELLS; ASSOCIATION; MICROSCOPY; PROTEINS; INVITRO	Basic studies of oncogenesis have demonstrated that either the elevated production of particular oncogene proteins or the occurrence of qualitative abnormalities in oncogenes can contribute to neoplastic cellular transformation. The purpose of this study was to identify unique oncogenes that are differentially expressed in human cancers and characterize their functions in tumorigenesis. To discover new putative oncogenes, the differential display RT-PCR method was applied using normal cervical tissues, cervical cancer cell lines, cervical cancer tissues, and metastatic tissues. We identified a new human cervical cancer oncogene HCCR-2 that was overexpressed in various human tumors including leukemia, lymphoma, and carcinomas of the breast, kidney, ovary, stomach, colon, and uterine cervix. Ectopic expression of HCCR-2 resulted in direct tumorigenic conversions of NIH/3T3 and Rat1 fibroblasts. Nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 formed tumors in 4 weeks. The resultant tumors display characteristics of an epithelial carcinoma. In HCCR-2 transfected NCI-H460 cells and RKO cells, stabilization of the p53 tumor suppressor occurred without genetic mutation and correlated with functional impairment, as indicated by the defective induction of p53-induced p21(WAF1), MDM2, and bax. These results indicate. that HCCR-2 probably represents a new oncogene that is related to tumorigenesis, functioning as a negative regulator of the p53 tumor suppressor.	Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Hanyang Univ, Dept Biochem & Mol Biol, Ansan 425791, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Anat, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Lab Anim Sci, Seoul 137040, South Korea	Catholic University of Korea; University of Ulsan; Yeungnam University; Hanyang University; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Kim, JW (corresponding author), Catholic Univ Korea, Coll Med, Mol Genet Lab, 505 Banpo Dong, Seoul 137040, South Korea.	jinwoo@cmc.cu-k.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					AARONSON SA, 1970, P NATL ACAD SCI USA, V66, P1236, DOI 10.1073/pnas.66.4.1236; AHN KY, 1991, AM J PHYSIOL, V265, pF792; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUICK RN, 1980, CANCER, V45, P1238, DOI 10.1002/1097-0142(19800315)45:5+<1238::AID-CNCR2820451333>3.0.CO;2-R; BUSBYEARLE RMC, 1994, BRIT J CANCER, V69, P732, DOI 10.1038/bjc.1994.138; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; Cooper G.M., 1995, ONCOGENES; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; HUBERT WG, 1993, J VIROL, V67, P2932, DOI 10.1128/JVI.67.5.2932-2937.1993; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575, DOI 10.1152/ajprenal.1996.270.4.F575; Kim JW, 1996, GYNECOL ONCOL, V62, P230, DOI 10.1006/gyno.1996.0221; Leonard C J, 1995, Important Adv Oncol, P33; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PUCHTLER H, 1978, HISTOCHEMISTRY, V57, P177, DOI 10.1007/BF00492078; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	48	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4679	4689		10.1038/sj.onc.1206624	http://dx.doi.org/10.1038/sj.onc.1206624			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879013				2022-12-28	WOS:000184157000009
J	Nozell, S; Wu, YJ; McNaughton, K; Liu, G; Willis, A; Paik, JC; Chen, XB				Nozell, S; Wu, YJ; McNaughton, K; Liu, G; Willis, A; Paik, JC; Chen, XB			Characterization of p73 functional domains necessary for transactivation and growth suppression	ONCOGENE			English	Article						p73; p53 family; apoptosis; cell cycle	KINASE C-ABL; DNA-DAMAGE; P53 FAMILY; APOPTOTIC RESPONSE; TRANSCRIPTIONAL ACTIVITY; P53-RELATED PROTEIN; INDUCE APOPTOSIS; TERMINAL DOMAIN; TARGET GENES; TUMOR-CELLS	p73, a p53 family member, is highly similar to p53 in both structure and function. Like p53, the p73 protein contains an N-terminal activation domain, a DNA-binding domain, a tetramerization domain, and several PXXP motifs. Previously, we and others have shown that some functional domains in p53, such as the DNA-binding and tetramerization domains, are required for inducing both cell cycle arrest and apoptosis whereas others, such as the second activation domain, the proline-rich domain, and the C-terminal basic domain, are only required for inducing apoptosis. To determine the activity of p73 functional domains, we have generated stable inducible cell lines that express p73beta and various mutants deficient in one or more functional domains. We found that in addition to the DNA-binding domain, p73-mediated growth suppression requires the N-terminal activation domain and the tetramerization domain. However, unlike p53, p73-mediated apoptosis does not require the region adjacent to the activation domain or the entire C-terminal region. Interestingly, while the N- or the C-terminal PXXP motifs are dispensable for p73 function, deletion of both the Nand the C-terminal PXXP motifs renders p73 inactive in transactivation. In addition, we found that substitution of two conserved tandem hydrophobic residues with two hydrophilic ones, which can abrogate the activity of the first activation domain in p53, has no effect on p73 transcriptional activity. Together, we showed that the p73 protein has its own unique determinants for transactivation and growth suppression.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		, Gang/0000-0002-6999-7633; Paik, Jason/0000-0002-9075-4679; Amara, Amy/0000-0003-0762-9656; Liu, Gang/0000-0003-2615-131X	NCI NIH HHS [CA 81237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gong JG, 1999, NATURE, V399, P806; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LIN JY, 1995, ONCOGENE, V10, P2387; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schultz J, 1997, PROTEIN SCI, V6, P249; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Takada N, 1999, CANCER RES, V59, P2810; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	52	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4333	4347		10.1038/sj.onc.1206470	http://dx.doi.org/10.1038/sj.onc.1206470			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853970				2022-12-28	WOS:000183978900003
J	Fajas, L; Egler, V; Reiter, R; Miard, S; Lefebvre, AM; Auwerx, J				Fajas, L; Egler, V; Reiter, R; Miard, S; Lefebvre, AM; Auwerx, J			PPAR gamma controls cell proliferation and apoptosis in an RB-dependent manner	ONCOGENE			English	Article						cancer; cell cycle; colon; nuclear receptor; transcription	ACTIVATED RECEPTOR-GAMMA; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; INDUCE APOPTOSIS; DOWN-REGULATION; MOUSE LENS; DIFFERENTIATION; TRANSCRIPTION; INHIBITION; LIGANDS	The nuclear receptor PPARgamma is implicated in the control of cell proliferation and apoptosis. However, the molecular mechanisms by which it controls these processes remain largely elusive. We show here that PPARgamma activation in the presence of the retinoblastoma protein (RB) results in the arrest of cells at the G1 phase of the cell cycle, whereas in the absence of RB, cells accumulate in G2/M, endoreduplicate, and undergo apoptosis. Through the use of HDAC inhibitors and coimmunoprecipitations, we furthermore demonstrate that the effects of RB on PPARgamma-mediated control of the cell cycle and apoptosis depend on the recruitment of histone deacetylase 3 (HDAC3) to PPARgamma. In combination, these data hence demonstrate that the effects of PPARgamma on cell proliferation and apoptosis are dependent on the presence of an RB-HDAC3 complex.	CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.		Coll, Lluis Fajas/C-8567-2014	Fajas, Lluis/0000-0002-1283-9503; Auwerx, Johan/0000-0002-5065-5393; Lefebvre, Anne-Marie/0000-0001-5644-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 P01-DK59820-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Palakurthi SS, 2001, CANCER RES, V61, P6213; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2000, GENE DEV, V14, P1293; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805	31	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4186	4193		10.1038/sj.onc.1206530	http://dx.doi.org/10.1038/sj.onc.1206530			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833141				2022-12-28	WOS:000183979800005
J	Kool, J; Hamdi, M; Cornelissen-Steijger, P; van der Eb, AJ; Terleth, C; van Dam, H				Kool, J; Hamdi, M; Cornelissen-Steijger, P; van der Eb, AJ; Terleth, C; van Dam, H			Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2	ONCOGENE			English	Article						ionizing radiation; ATM; NBS; ATF3; ATF-2	NIJMEGEN BREAKAGE SYNDROME; CELL-CYCLE CHECKPOINT; MAMMALIAN UV RESPONSE; DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; C-JUN INDUCTION; NF-KAPPA-B; ATAXIA-TELANGIECTASIA; GENOTOXIC STRESS; GROWTH-FACTOR	Exposure of human cells to genotoxic agents induces various signaling pathways involved in the execution of stress- and DNA-damage responses. Inappropriate functioning of the DNA-damage response to ionizing radiation (IR) is associated with the human diseases ataxia-telangiectasia (A-T) and Nijmegen Breakage syndrome (NBS). Here, we show that IR efficiently induces Jun/ATF transcription factor activity in normal human diploid fibroblasts, but not in fibroblasts derived from A-T and NBS patients. IR was found to enhance the expression of c-Jun and, in particular, ATF3, but, in contrast to various other stress stimuli, did not induce the expression of c-Fos. Using specific inhibitors, we found that the ATM- and Nibrin1-dependent activation of ATF3 does neither require p53 nor reactive oxygen species, but is dependent on the p38 and JNK MAPkinases. Via these kinases, IR activates ATF-2, one of the transcription factors acting on the atf3 promoter. The activation of ATF-2 by IR resembles ATF-2 activation by certain growth factors, since IR mainly induced the second step of ATF-2 phosphorylation via the stress-inducible MAPkinases, phosphorylation of Thr69. As IR does not enhance ATF-2 phosphorylation in ATM and Nibrin1-deficient cells, both ATF-2 and ATF3 seem to play an important role in the protective response of human cells to IR.	Leiden Univ, Ctr Biomed Genet, Dept Mol Cell Biol, Sect Gene Regulat,Med Ctr, NL-2333 AL Leiden, Netherlands; Leiden Univ, Dept Radiat Genet & Chem Mutagenesis, Med Ctr, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dam, H (corresponding author), Leiden Univ, Ctr Biomed Genet, Dept Mol Cell Biol, Sect Gene Regulat,Med Ctr, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	vdam@lumc.nl		van Dam, Hans/0000-0002-8307-4325				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; COFFER PJ, 1995, ONCOGENE, V11, P561; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Hai T, 1999, GENE EXPRESSION, V7, P321; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KHANNA KK, 1995, ONCOGENE, V11, P609; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Pfeiffer P, 1996, MUTAT RES-REV GENET, V366, P69, DOI 10.1016/S0165-1110(96)90029-9; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamazaki V, 1998, CANCER RES, V58, P2316; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	69	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4235	4242		10.1038/sj.onc.1206611	http://dx.doi.org/10.1038/sj.onc.1206611			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833146				2022-12-28	WOS:000183979800010
J	Waki, T; Tamura, G; Sato, M; Motoyama, T				Waki, T; Tamura, G; Sato, M; Motoyama, T			Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples	ONCOGENE			English	Article						age-related methylation; tumor suppressor gene; autopsy	ABERRANT PROMOTER METHYLATION; CPG-ISLAND METHYLATION; E-CADHERIN GENE; DNA METHYLATION; GASTRIC-CANCER; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; MULTIPLE GENES; HYPERMETHYLATION; P16	Age-related methylation may have the potential to behave as a mutator process. To clarify the physiological consequence of age-related methylation of tumor suppressor and tumor-related genes, we studied promoter methylation status in non-neoplastic cells of various organs obtained at autopsy by methylation-specific PCR. Promoter methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes, which are frequently silenced in certain human malignancies, was studied in non-neoplastic cells of the esophagus, stomach, small and large intestines, liver, pancreas, kidney and lung obtained from 38 Japanese autopsies. The tumor suppressor and tumor-related genes, except APC and RASSF1A, were generally unmethylated in samples obtained from people who were less than 32 years old (n = 11). Methylated promoters were present at variable frequencies in a tissue-specific manner in samples obtained from people who were greater than 42 years old (n = 27), although GSTP1 and hMLH1 methylation was absent or infrequent and lacked tissue specificity. In the majority of organs, the incidence of age-related methylation paralleled the reported methylation incidence in malignant counterparts. Thus, age-related methylation of a different set of genes is thought to constitute a field defect in different organs.	Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585, Japan	Yamagata University	Tamura, G (corresponding author), Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; Belinsky SA, 2002, CANCER RES, V62, P2370; Byun DS, 2001, CANCER RES, V61, P7034; Chan AOO, 2003, GUT, V52, P502, DOI 10.1136/gut.52.4.502; Esteller M, 2001, CANCER RES, V61, P3225; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kang GH, 2001, CANCER RES, V61, P2847; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Nakagawa H, 2001, CANCER RES, V61, P6991; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Paz MF, 2002, CANCER RES, V62, P4519; Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319; To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783; Tokugawa T, 2002, CANCER RES, V62, P4938; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueki T, 2000, CANCER RES, V60, P1835; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8; Yanagawa N, 2002, JPN J CANCER RES, V93, P1107, DOI 10.1111/j.1349-7006.2002.tb01212.x; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	25	152	170	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4128	4133		10.1038/sj.onc.1206651	http://dx.doi.org/10.1038/sj.onc.1206651			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821947				2022-12-28	WOS:000183707600016
J	Llorca, O; Rivera-Calzada, A; Grantham, J; Willison, KR				Llorca, O; Rivera-Calzada, A; Grantham, J; Willison, KR			Electron microscopy and 3D reconstructions reveal that human ATM kinase uses an arm-like domain to clamp around double-stranded DNA	ONCOGENE			English	Article						ATM; electron microscopy reconstruction; DNA repair	DEPENDENT PROTEIN-KINASE; CONFORMATIONAL-CHANGES; ATAXIA-TELANGIECTASIA; BREAST-CANCER; SUSCEPTIBILITY; PURIFICATION; MUTATIONS; BREAKS/; DAMAGE; SITES	The human tumor suppressor gene ataxia telangiectasia mutated (ATM) encodes a 3056 amino-acid protein kinase that regulates cell cycle checkpoints. ATM is defective in the neurodegenerative and cancer predisposition syndrome ataxia-telangiectasia. ATM protein kinase is activated by DNA damage and responds by phosphorylating downstream effectors involved in cell cycle arrest and DNA repair, such as p53, MDM2, CHEK2, BRCA1 and H2AX. ATM is probably a component of, or in close proximity to, the double-stranded DNA break-sensing machinery. We have observed purified human ATM protein, ATM-DNA and ATM-DNA-avidin bound complexes by single-particle electron microscopy and obtained three-dimensional reconstructions which show that ATM is composed of two main domains comprising a head and an arm. DNA binding to ATM induces a large conformational movement of the arm-like domain. Taken together, these three structures suggest that ATM is capable of interacting with DNA, using its arm to clamp around the double helix.	Canc Res UK, Canc Res Inst, Ctr Cell & Mol Biol, Chester Beatty Labs, London SW3 6JB, England; CSIC, Ctr Invest Biol, Madrid 28040, Spain	Cancer Research UK; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Willison, KR (corresponding author), Canc Res UK, Canc Res Inst, Ctr Cell & Mol Biol, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.		Llorca, Oscar/K-1144-2014; Rivera-Calzada, Angel/K-3617-2014; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009	Llorca, Oscar/0000-0001-5705-0699; Rivera-Calzada, Angel/0000-0003-2472-5535; Llorca, Oscar/0000-0001-5705-0699; 				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Concannon P, 2002, NAT GENET, V32, P89, DOI 10.1038/ng0902-89; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Rhodes N, 2001, PROTEIN EXPRES PURIF, V22, P462, DOI 10.1006/prep.2001.1459; Rosano C, 1999, BIOMOL ENG, V16, P5, DOI 10.1016/S1050-3862(99)00047-9; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098	30	45	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3867	3874		10.1038/sj.onc.1206649	http://dx.doi.org/10.1038/sj.onc.1206649			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813460				2022-12-28	WOS:000183612000006
J	Gabet, AS; Mortreux, F; Charneau, P; Riou, P; Duc-Dodon, M; Wu, YL; Jeang, KT; Wattel, E				Gabet, AS; Mortreux, F; Charneau, P; Riou, P; Duc-Dodon, M; Wu, YL; Jeang, KT; Wattel, E			Inactivation of hTERT transcription by Tax	ONCOGENE			English	Article						telomere; telomerase HTLV-1 hTERT oncogene; oncogenegic leukemogenesis	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; COMPARATIVE GENOMIC HYBRIDIZATION; INHIBITS TELOMERASE ACTIVITY; HTLV-1 TAX; P53 GENE; IN-VIVO; BINDING ELEMENT; CANCER CELLS; CYCLE ARREST	Telomerase expression is the hallmark of tumor cells in which this ribonucleoprotein complex preserves chromosome integrity by maintaining telomere length and thereby prevents cell death. However, recent data support a role of the combination of p53 and telomerase inactivation in initiating genetic instability that promotes malignant transformation. Through its pleiotropic effects on infected T-cell metabolism, the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax plays a central role in leukemogenesis. Here, we show that Tax inhibits human telomerase reverse transcriptase (hTERT) transcription, which is the rate-limiting factor of telomerase activity. This inhibitory effect, that occurs in competition with c-Myc through a canonical c-Myc binding site within the hTERT promoter, results in a decreased telomerase activity of Tax-expressing cells. This is the first demonstration of hTERT inhibition by an oncogene. Tax, which is only expressed in preleukemic cells, triggers infected T-cell cycle and keeps these cells cycling while inactivating p53. We propose that, in combination with these effects, h TER T repression by Tax at an early phase of carcinogenesis might contribute to the massive ploidy changes associated with the development of HTLV-1-associated malignancies.	Ctr Leon Berard, CNRS UMR 5537, Unite Oncogenese Viral, F-69373 Lyon 08, France; Inst Pasteur, Grp Virol Mol & Vector, F-75724 Paris, France; Fac Med Lyon Laennec, CNRS UMR 5537, F-69372 Lyon 8, France; NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA; Hop Edouard Herriot, Hematol Serv, F-69437 Lyon 03, France	UNICANCER; Centre Leon Berard; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); CHU Lyon	Wattel, E (corresponding author), Univ Lyon 1, UMR5578 CNRS, Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon 08, France.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; CESARMAN E, 1992, BLOOD, V80, P3205; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; FUJII M, 1991, ONCOGENE, V6, P1023; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; Gauthier LR, 2001, BRIT J CANCER, V84, P631, DOI 10.1054/bjoc.2000.1662; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Horikawa I, 1999, CANCER RES, V59, P826; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; LEE M, J BIOL CHEM, V277, P27748; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NISHIMURA S, 1995, LEUKEMIA, V9, P598; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; REID RL, 1993, ONCOGENE, V8, P3029; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Royer-Leveau C, 2002, J VIROL METHODS, V105, P133, DOI 10.1016/S0166-0934(02)00097-6; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SAKASHITA A, 1992, BLOOD, V79, P477; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 2000, BLOOD, V95, P3939; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Uchida N, 1999, LEUKEMIA RES, V23, P311, DOI 10.1016/S0145-2126(98)00170-2; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	59	71	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3734	3741		10.1038/sj.onc.1206468	http://dx.doi.org/10.1038/sj.onc.1206468			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802280				2022-12-28	WOS:000183551000007
J	Yang, HS; Knies, JL; Stark, C; Colburn, NH				Yang, HS; Knies, JL; Stark, C; Colburn, NH			Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation	ONCOGENE			English	Article						Pdcd4; AP-1; c-Jun; c-Fos; transformation	NF-KAPPA-B; C-JUN; TRANSCRIPTIONAL REGULATION; TRANSFORMATION SUPPRESSOR; CYCLE PROGRESSION; ANTISENSE RNA; EXPRESSION; GENES; PROMOTION; PROTEIN	Transformation suppressor Pdcd4 is downregulated in transformed (Tx) mouse epidermal JB6 RT101 cells relative to transformation-resistant (P-) and susceptible (P+) variants. Whether Pdcd4 downregulation is necessary not only to induce transformation but also to maintain tumor phenotypes has not been determined previously. In the present study, overexpression of Pdcd4 cDNA in stably transfected RT101 cells resulted in 40% fewer anchorage-independent colonies that were smaller in size than the vector control colonies, indicating that elevated Pdcd4 expression is sufficient to suppress tumor phenotype. Transient transfection of Pdcd4 expression plasmid and 4 x AP-1 reporter gene showed that activation of AP-1-dependent transcription was inhibited by Pdcd4 expression in a concentration-dependent manner. In contrast, Pdcd4 did not inhibit serum response element-dependent transcription, indicating specificity. In a Gal4 fusion assay, Pdcd4 specifically inhibited activation of c-Jun and c-Fos activation domains, but did not inhibit activation of JunB, JunD, Fra-1, or Fra-2. Gel mobility shift assay demonstrated that c-Jun is the major component detected in the AP-1 complex in RT101 cells. Previous studies suggested that AP-1 activity is required for maintaining the transformed phenotype in RT101 cells. Thus, Pdcd4 suppresses tumor phenotype by inhibiting AP-1-dependent transcription, possibly through inhibiting c-Jun and c-Fos activation.	Natl Canc Inst, Ctr Canc Res, Gene Regulat Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yang, HS (corresponding author), Natl Canc Inst, Ctr Canc Res, Gene Regulat Sect, Gene Regulat Sect,Bldg 567,Rm 180, Frederick, MD 21702 USA.	hyang@ncifcrf.gov	Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036	NATIONAL CANCER INSTITUTE [Z01BC010026, ZIABC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Colburn N H, 1980, Carcinog Compr Surv, V5, P33; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Hsu TC, 2001, CANCER RES, V61, P4160; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; KAZUMI S, 2002, ONCOGENE, V21, P2181; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; RAPP UR, 1994, ONCOGENE, V9, P3493; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Svitkin YV, 2001, RNA, V7, P1743; TAKAHASHI K, 1986, CANCER RES, V46, P5923; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	42	142	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3712	3720		10.1038/sj.onc.1206433	http://dx.doi.org/10.1038/sj.onc.1206433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802278				2022-12-28	WOS:000183551000005
J	Schraets, D; Lehmann, T; Dingermann, T; Marschalek, R				Schraets, D; Lehmann, T; Dingermann, T; Marschalek, R			MLL-mediated transcriptional gene regulation investigated by gene expression profiling	ONCOGENE			English	Article						MLL; expression profiling; development; differential gene expression	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTO-ONCOPROTEIN MLL; GROWTH-FACTOR-BETA; CELL-LINE; TRANSMEMBRANE-4 SUPERFAMILY; MOUSE EMBRYO; CDNA CLONING; ALL1 GENE; IN-VITRO; BINDING	The human mixed lineage leukemia (MLL) gene is involved in about 50 different chromosomal translocations, associated with the disease phenotype of acute leukemia. However, the normal function of MLL is less understood. Homozygous knockouts of murine Mll were embryonal lethal, while heterozygous disruption led to aberrant hox gene expression associated with skeletal malformations, growth retardation, and impaired hematopoiesis. To understand MLL functions on the molecular level, gene expression profiling experiments were performed with a pair of murine cell lines (MLL+/+ and MLL-/-). Microarray hybridization experiments revealed 197 potential target genes that are differentially expressed, providing new and important clues about MLL functions.	Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Alward WLM, 2000, AM J OPHTHALMOL, V130, P107, DOI 10.1016/S0002-9394(00)00525-0; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Attardi LD, 2000, GENE DEV, V14, P704; Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Cavodeassi F, 2001, DEVELOPMENT, V128, P2847; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Cimino G, 1998, HAEMATOLOGICA, V83, P350; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gopalakrishnan R, 2001, ENDOCRINOLOGY, V142, P4379, DOI 10.1210/en.142.10.4379; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Hanashima C, 2002, J NEUROSCI, V22, P6526; Henkel GW, 2002, INT IMMUNOL, V14, P723, DOI 10.1093/intimm/dxf040; Hosokawa Y, 1999, NEUROSCI RES, V35, P281, DOI 10.1016/S0168-0102(99)00093-0; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Iida K, 1997, DEVELOPMENT, V124, P4627; Irikura VM, 2002, J IMMUNOL, V169, P393, DOI 10.4049/jimmunol.169.1.393; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lochner K, 1996, CANCER RES, V56, P2171; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pasqualetti M, 2001, NAT GENET, V29, P34, DOI 10.1038/ng702; PERRIS R, 1993, DEV DYNAM, V198, P135, DOI 10.1002/aja.1001980207; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Spandorfer SD, 2000, AM J REPROD IMMUNOL, V43, P6, DOI 10.1111/j.8755-8920.2000.430102.x; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Toft DJ, 2001, P NATL ACAD SCI USA, V98, P13055, DOI 10.1073/pnas.231364798; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; YonedaKato N, 1996, ONCOGENE, V12, P265; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	67	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3655	3668		10.1038/sj.onc.1206438	http://dx.doi.org/10.1038/sj.onc.1206438			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789274				2022-12-28	WOS:000183399200016
J	Stoecklin, G; Gross, B; Ming, XF; Moroni, C				Stoecklin, G; Gross, B; Ming, XF; Moroni, C			A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA	ONCOGENE			English	Article						ARE; interleukin-3; MRNA decay; tristetraprolin; zinc-finger protein	INTERLEUKIN-3 MESSENGER-RNA; ACTIVATED PROTEIN-KINASE; MAST-CELLS; DEGRADATION PATHWAY; STABILITY FACTOR; CANCER CELLS; GM-CSF; ELEMENTS; TRISTETRAPROLIN; STABILIZATION	The occurrence of pathologically stable mRNAs of protooncogenes, growth factors and cyclins has been proposed to contribute to experimental and human oncogenesis. In normal resting cells, mRNAs containing an AU-rich element (ARE) in their 3' untranslated region are subjected to rapid degradation. Tristetraprolin (TTP) is an RNA-binding zinc-finger protein that promotes decay of ARE-containing mRNAs. Here we report that TTP acts as a potent tumor suppressor in a v-H-ras-dependent mast cell tumor model, where tumors express abnormally stable interleukin-3 (IL-3) mRNA as part of an oncogenic autocrine loop. Premalignant v-H-ras cells were transfected with TTP and injected into syngeneic mice. TTP expression delayed tumor progression by 4 weeks, and late appearing tumors escaped suppression by loss of TTP. When transfected into a fully established tumor line, TTP reduced cloning efficiency in vitro and growth of the inoculated cells in vivo. Transgenic TTP interfered with the autocrine loop by enhancing the degradation of IL-3 mRNA with concomitant reduction of IL-3 secretion. Our data establish the ARE as an antioncogenic target in a model situation, underline the importance of mRNA stabilization in oncogenesis and show for the first time that tumor suppression can be achieved by interfering with mRNA turnover.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.			Stoecklin, Georg/0000-0001-9284-9834				AGHIB DF, 1990, ONCOGENE, V5, P707; ALGATE PA, 1993, ONCOGENE, V8, P1221; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gouble A, 2002, CANCER RES, V62, P1489; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirsch HH, 1996, GROWTH FACTORS, V13, P99, DOI 10.3109/08977199609034570; HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nabors LB, 2001, CANCER RES, V61, P2154; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROSS HJ, 1991, BLOOD, V77, P1787; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Stoecklin G, 2001, RNA, V7, P1578; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200	44	93	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3554	3561		10.1038/sj.onc.1206418	http://dx.doi.org/10.1038/sj.onc.1206418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789264				2022-12-28	WOS:000183399200006
J	Srinivasan, RS; de Erkenez, AC; Hemenway, CS				Srinivasan, RS; de Erkenez, AC; Hemenway, CS			The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor	ONCOGENE			English	Article						oncogenic fusion proteins; alternative RNA splicing; gene repression; leukemia cell lines	ACUTE MYELOID-LEUKEMIA; DROSOPHILA-TRITHORAX; NUCLEAR-PROTEIN; HUMAN HOMOLOG; MLL; GENE; POLYCOMB; 11Q23; ENL; TRANSLOCATIONS	The mixed lineage leukemia (MLL) gene at chromosome band 11q23 is commonly involved in reciprocal translocations that are detected in acute leukemias. Evidence suggests that the resulting MLL fusion genes contribute to leukemogenesis. AF9 is a common MLL fusion partner in acute myeloid leukemia. The AF9 protein functions as a transcriptional activator in artificial reporter gene assays and a structurally related protein in yeast, ANC1/TFG3, is a component of the SWI/SNF complex. Apart from these observations, little is known about the biologic function of AF9 in mammals. We have found that a recently described transcriptional repressor, BCL-6 corepressor (BCoR), interacts with the carboxy-terminus of AF9. The interaction of AF9 with BCoR has been confirmed by independent in vitro and in vivo protein-binding studies. The BCoR gene is expressed as several alternatively spliced transcripts. AF9 only binds BCoR isoforms that contain a unique 34 aa sequence located in the mid-portion of the protein. In artificial reporter gene assays, a BCoR isoform that binds AF9 efficiently suppresses AF9 transcriptional activity, while a nonbinding isoform does not. These results indicate that different isoforms of BCoR have unique biologic properties and that cell function may be partly determined by the different isoforms that are present within the cell.	Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Mol & Cellular Biol Program, Dept Pediat, New Orleans, LA 70112 USA	Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave,SL-37, New Orleans, LA 70112 USA.	chemenw@tulane.edu			NATIONAL CANCER INSTITUTE [K01CA078318] Funding Source: NIH RePORTER; NCI NIH HHS [CA78318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOWNING JR, 1996, MOL GENETICS THERAPY; Erfurth F, 2000, BLOOD, V96, p700A; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huynh KD, 2000, GENE DEV, V14, P1810; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Joh T, 1996, ONCOGENE, V13, P1945; Kuwada N, 2001, CANCER RES, V61, P2665; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Ono R, 2002, CANCER RES, V62, P333; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUBNITZ JE, 1994, BLOOD, V84, P1747; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; WELCH MD, 1994, MOL BIOL CELL, V5, P617, DOI 10.1091/mbc.5.6.617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	38	63	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3395	3406		10.1038/sj.onc.1206361	http://dx.doi.org/10.1038/sj.onc.1206361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776190				2022-12-28	WOS:000183128500005
J	Carr, KM; Bittner, M; Trent, JM				Carr, KM; Bittner, M; Trent, JM			Gene-expression profiling in human cutaneous melanoma	ONCOGENE			English	Article						gene expression profiling; melanoma	B-CELL LYMPHOMA; MALIGNANT-MELANOMA; HUMAN CANCER; MICROARRAY; PATTERNS; CLASSIFICATION; INTERLEUKIN-2; PREDICTION; RESPONSES; SURVIVAL	Genomic technology presents new and exciting opportunities to study complex human diseases. Several types of genomic analysis are helping to elucidate the biology of important human cancers. One of these, gene expression profiling, provides a more comprehensive view of the consequences of the genetic changes in cancer cells than was previously available. In addition to detailing the expression patterns of thousands of genes simultaneously, this exploding field of research has begun to build a new 'molecular taxonomy' of cancer and to identify novel disease genes for many human cancers, including cutaneous melanoma. Whether this new information will lead to improved treatments and prolonged survival for cancer patients remains to be determined. Here, we review the use of complementary DNA microarray technology to study gene expression patterns in cutaneous melanoma and highlight recent advances concerning the identification of novel melanoma disease-related genes. The fundamentals of microarray technology and analysis have been extensively discussed, and readers are referred to several recent reviews in this area.	Translat Genom Res Inst, Phoenix, AZ USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	Translational Genomics Research Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Trent, JM (corresponding author), TGen, 400 N 5th St,Suite 1600, Phoenix, AZ 85004 USA.							Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DeRisi J, 1996, NAT GENET, V14, P457; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; LOTZE MT, 1986, JAMA-J AM MED ASSOC, V256, P3117, DOI 10.1001/jama.256.22.3117; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Palmantier R, 2001, CANCER RES, V61, P2445; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; RISE LAG, 2001, SEER CANC STAT REV 1, V2001; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang E, 2002, CANCER RES, V62, P3581; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157	30	87	97	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3076	3080		10.1038/sj.onc.1206448	http://dx.doi.org/10.1038/sj.onc.1206448			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789283				2022-12-28	WOS:000183096600008
J	Dazard, JE; Gal, H; Amariglio, N; Rechavi, G; Domany, E; Givol, D				Dazard, JE; Gal, H; Amariglio, N; Rechavi, G; Domany, E; Givol, D			Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer	ONCOGENE			English	Article						microarray; clustering; epidermis; apoptosis; chemokines	B-INDUCED APOPTOSIS; HISTONE H2AX; P53; EXPRESSION; INDUCTION; REPAIR; P63; SUPPRESSION; ONSET; CARCINOGENESIS	To gain insight into the transformation of epidermal cells into squamous carcinoma cells (SCC), we compared the response to ultraviolet B radiation (UVB) of normal human epidermal keratinocytes (NHEK) versus their transformed counterpart, SCC, using biological and molecular profiling. DNA microarray analyses (Affymetrix(R), similar to12 000 genes) indicated that the major group of upregulated genes in keratinocytes fall into three categories: (i) antiapoptotic and cell survival factors, including chemokines of the CXC/CC subfamilies (e.g. IL-8, GRO-1, -2, -3, SCYA20), growth factors (e.g. HB-EGF, CTGF, INSL-4), and proinflammatory mediators (e.g. COX-2, S100A9), (ii) DNA repair-related genes (e.g. GADD45, ERCC, BTG-1, Histones), and (iii) ECM proteases (MMP-1, -10). The major downregulated genes are DeltaNp63 and PUMILIO, two potential markers for the maintenance of keratinocyte stem cells. NHEK were found to be more resistant than SCC to UVB-induced apoptosis and this resistance was mainly because of the protection from cell death by secreted survival factors, since it can be transferred from NHEK to SCC cultures by the conditioned medium. Whereas the response of keratinocytes to UVB involved regulation of key checkpoint genes (p53, MDM2, p21(Cip1), DeltaNp63), as well as antiapoptotic and DNA repair-related genes - no or little regulation of these genes was observed in SCC. The effect of UVB on NHEK and SCC resulted in upregulation of 251 and 127 genes, respectively, and downregulation of 322 genes in NHEK and 117 genes in SCC. To further analyse these changes, we used a novel unsupervised coupled two-way clustering method that allowed the identification of groups of genes that clearly partitioned keratinocytes from SCC, including a group of genes whose constitutive expression levels were similar before UVB. This allowed the identification of discriminating genes not otherwise revealed by simple static comparison in the absence of UVB irradiation. The implication of the changes in gene profile in keratinocytes for epithelial cancer is discussed.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		DOMANY, EYTAN/K-1560-2012					Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Brune Bernhard, 2002, J Environ Pathol Toxicol Oncol, V21, P103; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chazal M, 2002, ONCOGENE, V21, P2652, DOI 10.1038/sj.onc.1205349; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Decraene D, 2002, J BIOL CHEM, V277, P32587, DOI 10.1074/jbc.M111106200; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Garssen J, 2001, CRIT REV IMMUNOL, V21, P359; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greinert R, 2000, PHOTOCHEM PHOTOBIOL, V72, P701, DOI 10.1562/0031-8655(2000)072<0701:TDDOCD>2.0.CO;2; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanson KM, 2002, PHOTOCHEM PHOTOBIOL, V76, P57, DOI 10.1562/0031-8655(2002)076<0057:OAQOUI>2.0.CO;2; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Liefer KM, 2000, CANCER RES, V60, P4016; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Loukinova E, 2001, INT J CANCER, V94, P637, DOI 10.1002/ijc.1514; Martini EMD, 2002, GENETICS, V160, P1375; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Notterman DA, 2001, CANCER RES, V61, P3124; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; Selgrade MK, 2001, PHOTOCHEM PHOTOBIOL, V74, P88, DOI 10.1562/0031-8655(2001)074<0088:DRFUII>2.0.CO;2; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Soehnge Holly, 1997, Frontiers in Bioscience, V2, pD538; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xing PX, 2001, FRONT BIOSCI-LANDMRK, V6, pD1284, DOI 10.2741/Xing; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhao RB, 2000, GENE DEV, V14, P981; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	56	75	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2993	3006		10.1038/sj.onc.1206537	http://dx.doi.org/10.1038/sj.onc.1206537			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771951				2022-12-28	WOS:000182824800015
J	Little, JB				Little, JB			Genomic instability and bystander effects: a historical perspective	ONCOGENE			English	Review						genomic instability; bystander effect; ionizing radiation; clastogenic factors; oxidative stress; gap junction intercellular communication	INDUCED CHROMOSOMAL INSTABILITY; DELAYED REPRODUCTIVE DEATH; SISTER-CHROMATID EXCHANGES; VERY-LOW FLUENCES; X-RAY INDUCTION; IN-VIVO; ALPHA-PARTICLES; INTERCELLULAR COMMUNICATION; HIGH-LET; MICROSATELLITE INSTABILITY	Data have been emerging over the past two decades concerning two phenomena in which important biological effects of ionizing radiation arise in cells that in themselves receive no radiation exposure. In the first, radiation-induced genomic instability, biological effects occur in the progeny of the irradiated cell after many generations of cell division. In the second, radiation-induced bystander effects, they arise in cells that receive no radiation exposure as a consequence of damage signals transmitted from neighboring irradiated cells; transmission may be mediated either by direct intercellular communication through gap junctions, or by factors released into the surrounding medium. In both phenomena, the biological effects appear to be associated with an upregulation of oxidative metabolism. The present paper is designed to review the historical background leading to our current knowledge of these two phenomena, and to indicate some future directions for research that will allow us to assess better their importance in the health effects of exposure to ionizing radiation.	Harvard Univ, Sch Med, Radiobiol Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Little, JB (corresponding author), Harvard Univ, Sch Med, Radiobiol Lab, 665 Huntington Ave, Boston, MA 02115 USA.	jlittle@hsph.harvard.edu						Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; BACQ EM, 1961, FUNDAMENTALS RADIOBI; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Belyakov OV, 1999, INT J RADIAT BIOL, V75, P985, DOI 10.1080/095530099139746; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; Bouffler SD, 2001, RADIAT RES, V155, P345, DOI 10.1667/0033-7587(2001)155[0345:LODTCI]2.0.CO;2; Bouffler SD, 2001, INT J RADIAT BIOL, V77, P995, DOI 10.1080/09553000110069326; Boulton E, 2001, INT J RADIAT BIOL, V77, P21, DOI 10.1080/0955300010001880; BOYCE RP, 1964, P NATL ACAD SCI USA, V51, P293, DOI 10.1073/pnas.51.2.293; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; CHENG KC, 1993, ADV CANCER RES, V60, P121; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DEMEREC M, 1946, COLD SPRING HARB SYM, V11, P38; Deshpande A., 1996, RADIAT RES, V152, P552; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Dugan LC, 2003, RADIAT RES, V159, P301, DOI 10.1667/0033-7587(2003)159[0301:ACIIBE]2.0.CO;2; DUTRILLAUX B, 1997, RADIOPROTECTION, V32, pC431; Emerit I, 1997, MUTAT RES-FUND MOL M, V373, P47, DOI 10.1016/S0027-5107(96)00187-X; Emerit I, 1998, NATO ADV SCI I A-LIF, V296, P375; Evans HH, 2001, RADIAT RES, V156, P259, DOI 10.1667/0033-7587(2001)156[0259:DDEIHL]2.0.CO;2; Fabre F., 1983, CELLULAR RESPONSE DN, P379; FAGUET GB, 1984, CANCER GENET CYTOGEN, V12, P73, DOI 10.1016/0165-4608(84)90010-4; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Fouladi B, 2000, NEOPLASIA, V2, P540, DOI 10.1038/sj.neo.7900107; FRANK JP, 1982, SCIENCE, V216, P307, DOI 10.1126/science.7063888; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; HANAWALT PC, 1977, DNA REPAIR PROCESS, P1; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; HOLMBERG K, 1993, MUTAT RES, V286, P321, DOI 10.1016/0027-5107(93)90197-N; Howell RW, 2002, MICRON, V33, P127, DOI 10.1016/S0968-4328(01)00007-5; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; Iyer R, 2002, RADIAT RES, V157, P3, DOI 10.1667/0033-7587(2002)157[0003:APIIIT]2.0.CO;2; Jamali M, 1996, INT J RADIAT BIOL, V70, P705, DOI 10.1080/095530096144590; JOHNSON PR, 1976, BRIT J CANCER, V33, P370, DOI 10.1038/bjc.1976.61; Kadhim MA, 2001, RADIAT RES, V155, P122, DOI 10.1667/0033-7587(2001)155[0122:LTGIIH]2.0.CO;2; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; Kato Kyozo, 1994, Neurologia Medico-Chirurgica, V34, P339, DOI 10.2176/nmc.34.339; KENNEDY AR, 1984, NATURE, V307, P85, DOI 10.1038/307085a0; KENNEDY AR, 1980, CARCINOGENESIS, V1, P1039, DOI 10.1093/carcin/1.12.1039; KENNEDY AR, 1980, P NATL ACAD SCI-BIOL, V77, P7262, DOI 10.1073/pnas.77.12.7262; KETTMAN J, 1974, EUR J IMMUNOL, V4, P641, DOI 10.1002/eji.1830041002; Lehnert BE, 1997, CANCER RES, V57, P2164; LI CY, 1992, MOL CARCINOGEN, V5, P270, DOI 10.1002/mc.2940050407; LIBER HL, 1983, MUTAT RES, V111, P387, DOI 10.1016/0027-5107(83)90035-0; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2003, RADIAT RES, V159, P262, DOI 10.1667/0033-7587(2003)159[0262:IOTNEJ]2.0.CO;2; LITTLE JB, 1971, INT J RADIAT BIOL RE, V20, P87, DOI 10.1080/09553007114550921; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; Loeb LA, 2001, CANCER RES, V61, P3230; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Lyng FM, 2001, BIOCHEM SOC T, V29, P350; MacDonald D, 2001, INT J RADIAT BIOL, V77, P1023, DOI 10.1080/09553000110073411; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; MARTIN RF, 1981, SCIENCE, V213, P896, DOI 10.1126/science.7256283; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; MENDONCA MS, 1989, RADIAT RES, V119, P387, DOI 10.2307/3577629; Mesnil M, 2000, CANCER RES, V60, P3989; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Nagar S, 2003, CANCER RES, V63, P324; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Nakanishi M, 2001, INT J RADIAT BIOL, V77, P687, DOI 10.1080/095530000110047537; Narayanan PK, 1997, CANCER RES, V57, P3963; NIAS AHW, 1965, INT J RADIAT BIOL RE, V9, P275, DOI 10.1080/09553006514550331; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Okayasu R, 2000, CANCER RES, V60, P4342; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; PAQUETTE B, 1994, CANCER RES, V54, P3173; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; RAJEWSKY K, 1972, EUR J IMMUNOL, V2, P592, DOI 10.1002/eji.1830020622; Redpath JL, 2001, INT J RADIAT BIOL, V77, P1081, DOI 10.1080/09553000110065807; Romney CA, 2001, MOL CARCINOGEN, V32, P118, DOI 10.1002/mc.1071; Romney CA, 2001, MUTAT RES-FUND MOL M, V478, P97, DOI 10.1016/S0027-5107(01)00126-9; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; Sankaranarayanan K, 2001, RADIAT RES, V156, P648, DOI 10.1667/0033-7587(2001)156[0648:IOCPAR]2.0.CO;2; Sawant SG, 2002, RADIAT RES, V157, P361, DOI 10.1667/0033-7587(2002)157[0361:TRIBEF]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; SCOTT D, 1969, CELL TISSUE KINET, V2, P295, DOI 10.1111/j.1365-2184.1969.tb00239.x; SELVANAYAGAM CS, 1995, CANCER RES, V55, P3310; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SINCLAIR WK, 1964, RADIAT RES, V21, P584, DOI 10.2307/3571653; SMYTHE WR, 1994, CANCER RES, V54, P2055; STAMATO T, 1987, SOMAT CELL MOLEC GEN, V13, P57, DOI 10.1007/BF02422299; Suzuki K, 2003, CANCER RES, V63, P936; Syljuasen RG, 2001, RADIAT RES, V155, P215, DOI 10.1667/0033-7587(2001)155[0215:MEIRT]2.0.CO;2; TERZAGHI M, 1976, CANCER RES, V36, P1367; Touraine RL, 1998, GENE THER, V5, P1705, DOI 10.1038/sj.gt.3300784; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Trosko JE, 2001, MUTAT RES-FUND MOL M, V480, P219, DOI 10.1016/S0027-5107(01)00181-6; Ullrich RL, 1999, RADIAT RES, V152, P170, DOI 10.2307/3580090; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Watson GE, 1996, INT J RADIAT BIOL, V69, P175, DOI 10.1080/095530096146002; Watson GE, 2001, INT J RADIAT BIOL, V77, P409, DOI 10.1080/09553000010028476; Whitehouse CA, 2001, RADIAT RES, V156, P467, DOI 10.1667/0033-7587(2001)156[0467:NEFCII]2.0.CO;2; WU JK, 1994, NEUROSURGERY, V35, P1094, DOI 10.1227/00006123-199412000-00012; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Wygoda MR, 1997, CANCER RES, V57, P1699; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699; YAMASAKI H, 1990, PROG CLIN BIOL RES, V340, P153; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798; ZIRKLE RE, 1953, SCIENCE, V117, P487, DOI 10.1126/science.117.3045.487	131	170	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					6978	6987		10.1038/sj.onc.1206988	http://dx.doi.org/10.1038/sj.onc.1206988			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557801				2022-12-28	WOS:000185903900001
J	M'kacher, R; Bennaceur, A; Farace, F; Lauge, A; Plassa, LF; Wittmer, E; Dossou, J; Violot, D; Deutsch, E; Bourhis, J; Stoppa-Lyonnet, D; Ribrag, V; Carde, P; Parmentier, C; Bernheim, A; Turhan, AG				M'kacher, R; Bennaceur, A; Farace, F; Lauge, A; Plassa, LF; Wittmer, E; Dossou, J; Violot, D; Deutsch, E; Bourhis, J; Stoppa-Lyonnet, D; Ribrag, V; Carde, P; Parmentier, C; Bernheim, A; Turhan, AG			Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma	ONCOGENE			English	Article						DNA repair; ATM; P53; mantle cell lymphoma; irradiation	ATAXIA-TELANGIECTASIA GENE; IONIZING-RADIATION; MISSENSE MUTATIONS; C-ABL; ATM; PROTEIN; INACTIVATION; KINASE; PHOSPHORYLATION; P53	Mantle cell lymphomas (MCL) are characterized by their aggressive behavior and poor response to chemotherapy regimens. We report here evidence of increased in vitro radiation sensitivity in two cell lines that we have generated from two MCL patients (UPN1 and UPN2). However, despite their increased radiation sensitivity, UPN2 cells were totally resistant to apoptotic cell death, whereas UPN1 cells underwent massive apoptosis 6 h after irradiation. The frequency of induced chromosomal abnormalities was higher in UPN1 as compared to UPN2. Distinct mechanisms have been found to contribute to this phenotype: a major telomere shortening (UPN1 and UPN2), deletion of one ATM allele and a point mutation in the remaining allele in UPN2, mutation of p53 gene (UPN1 and UPN2) with absence of functional p53 as revealed by functional yeast assays. After irradiation, Ku70 levels in UPN1 increased and decreased in UPN2, whereas in the same conditions, DNA-PKcs protein levels decreased in UPN1 and remained unchanged in UPN2. Thus, irradiation-induced apoptotic cell death can occur despite the nonfunctional status of p53 (UPN1), suggesting activation of a unique pathway in MCL cells for the induction of this event. Overall, our study demonstrates that MCL cells show increased radiation sensitivity, which can be the result of distinct molecular events. These findings could clinically be exploited to increase the dismal response rates of MCL patients to the current chemotherapy regimens.	IGR, INSERM, U362, Translat Res Cell Therapy Lab, Villejuif, France; UPRES EA 27 10, Dept Med, Villejuif, France; UPRES EA 27 10, Dept Biol Clin, Villejuif, France; IGR, Cytogenet & Oncol Genet Lab, Villejuif, France; Inst Curie, Serv Genet Oncol, F-75231 Paris, France; Hop St Louis, Lab Biochim B, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Turhan, AG (corresponding author), IGR, INSERM, U362, Translat Res Cell Therapy Lab, Villejuif, France.	turali@igr.fr		deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; bennaceur griscelli, annelise/0000-0002-3557-4499; TURHAN, Ali/0000-0002-4861-0137				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Behr TM, 2002, CANCER-AM CANCER SOC, V94, P1363, DOI 10.1002/cncr.10307; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOSCH F, 1994, BLOOD, V84, P2726; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238; Campo E, 1999, SEMIN HEMATOL, V36, P115; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; di Fagagna FD, 1999, NAT GENET, V23, P76; Dreyling MH, 1997, CANCER RES, V57, P4608; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gatei M, 2000, CANCER RES, V60, P3299; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Gopal AK, 2002, BLOOD, V99, P3158, DOI 10.1182/blood.V99.9.3158; Hou M, 2001, CLIN CHEM, V47, P519; Iavarone A, 1997, NATURE, V387, P417; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; M'kacher R, 2003, CANCER GENET CYTOGEN, V143, P32, DOI 10.1016/S0165-4608(02)00823-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyer KM, 1999, ONCOGENE, V18, P5795, DOI 10.1038/sj.onc.1202977; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; TOLKSDORF G, 1980, BRIT J CANCER, V41, P168, DOI 10.1038/bjc.1980.27; VERPY E, 1994, P NATL ACAD SCI USA, V91, P1873, DOI 10.1073/pnas.91.5.1873; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Weisenburger DD, 1996, BLOOD, V87, P4483, DOI 10.1182/blood.V87.11.4483.bloodjournal87114483; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	38	33	35	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7905	7912		10.1038/sj.onc.1206826	http://dx.doi.org/10.1038/sj.onc.1206826			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970738				2022-12-28	WOS:000185388200005
J	Nishizawa, M; Kataoka, K; Vogt, PK				Nishizawa, M; Kataoka, K; Vogt, PK			MafA has strong cell transforming ability but is a weak transactivator	ONCOGENE			English	Article						oncogenic transformation; transcriptional; activation; regulatable construct	BZIP TRANSCRIPTION FACTOR; FACTOR C-MAF; V-MAF; ESTROGEN-RECEPTOR; FACTOR NF-E2; GENE; JUN; ONCOGENE; DIFFERENTIATION; FAMILY	The maf oncogene of the avian oncogenic retrovirus AS42 encodes a nuclear bZip protein, v-Maf, that recognizes sequences related to the AP-1 target site. The corresponding cellular protein, c-Maf belongs to a family of related bZip proteins together with MafA and MafB. In this paper, we compare the transactivation and cell transforming abilities of MafA and MafB along with two forms of the c-Maf protein. These proteins induce cellular transformation when expressed in chicken embryo fibroblasts. In reporter assays, MafA is a much less effective transactivator than the other Maf proteins, but unexpectedly shows the strongest activity in cell transformation. Chimeras of MafA and MOB correlate the strong cell transforming ability of MafA with its DNA-binding domain. The DNA-binding domain of MafA is also correlated with weak transactivation. Additional mutagenesis experiments show that transactivation and transformation by MafA are also controlled by phosphorylation of two conserved serine residues in the transactivation domain. Finally, we constructed MafA-estrogen receptor fusion molecules that show tightly hormone-dependent cell transforming ability. These regulatable constructs permit a kinetic characterization of target gene responses and facilitate discrimination between direct and indirect targets.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Scripps Research Institute; Tokyo Institute of Technology	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA78230, CA42564, CA79616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564, R01CA079616, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 2003, IN PRESS ONCOGENE; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Ring BZ, 2000, DEVELOPMENT, V127, P307; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	38	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7882	7890		10.1038/sj.onc.1206526	http://dx.doi.org/10.1038/sj.onc.1206526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970735				2022-12-28	WOS:000185388200002
J	Henshall, SM; Afar, DEH; Rasiah, KK; Horvath, LG; Gish, K; Caras, I; Ramakrishnan, V; Wong, M; Jeffry, U; Kench, JG; Quinn, DI; Turner, JJ; Delprado, W; Lee, CS; Golovsky, D; Brenner, PC; O'Neill, GF; Kooner, R; Stricker, PD; Grygiel, JJ; Mack, DH; Sutherland, RL				Henshall, SM; Afar, DEH; Rasiah, KK; Horvath, LG; Gish, K; Caras, I; Ramakrishnan, V; Wong, M; Jeffry, U; Kench, JG; Quinn, DI; Turner, JJ; Delprado, W; Lee, CS; Golovsky, D; Brenner, PC; O'Neill, GF; Kooner, R; Stricker, PD; Grygiel, JJ; Mack, DH; Sutherland, RL			Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer	ONCOGENE			English	Article						ZnT4; prostate cancer; zinc transporter; oligonucleotide microarrray; hyperplasia	FUNCTIONAL-CHARACTERIZATION; MONOCLONAL-ANTIBODY; CONFERS RESISTANCE; GERMLINE MUTATIONS; EPITHELIAL-CELLS; GENE; CLONING; MICROARRAYS; THERAPY; TISSUE	We have utilized oligonucleotide microarrays to identify novel genes of potential clinical and biological importance in prostate cancer. RNA from 74 prostate cancers and 164 normal body samples representing 40 different tissues were analysed using a customized Affymetrix GeneChip(R) oligonucleotide microarray representative of over 90% of the expressed human genome. The gene for the zinc transporter ZnT4 was one of several genes that displayed significantly higher expression in prostate cancer compared to normal tissues from other organs. A polyclonal antipeptide antibody was used to demonstrate ZnT4 expression in the epithelium of all 165 elements of benign and 326 elements of localized prostate cancers examined and in nine of 10 advanced prostate cancer specimens by immunohistochemistry. Interestingly, decreased intensity of ZnT4 immunoreactivity occurred in the progression from benign to invasive localized prostate cancer and to metastatic disease. Immunofluorescence analysis and surface biotinylation studies of cells expressing ZnT4 localised the protein to intracellular vesicles and to the plasma membrane. These findings are consistent with a role for ZnT4 in vesicular transport of zinc to the cell membrane and potentially in efflux of zinc in the prostate.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Eos Biotechnol, Genom Res, San Francisco, CA 94080 USA; St Vincents Hosp, Dept Anat Pathol, Darlinghurst, NSW 2010, Australia; Douglass Hanly Moir Pathol, N Ryde, NSW 2113, Australia; Royal Prince Alfred Hosp, Dept Anat Pathol, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Pathol, Camperdown, NSW 2050, Australia; St Vincents Hosp, Dept Urol, Darlinghurst, NSW 2010, Australia; St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of Sydney; University of Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	r.sutherland@garvan.org.au	Quinn, David/N-3730-2019; Quinn, David I/F-4343-2015; Sutherland, Robert L/A-8378-2008	Quinn, David/0000-0002-1411-0417; Quinn, David I/0000-0002-1411-0417; Caras, Ingrid/0000-0002-8902-808X; Turner, Jennifer/0000-0001-5550-3375; Horvath, Lisa/0000-0001-6842-9223; Kench, James Geoffrey/0000-0001-8687-4988; Lee, C. Soon/0000-0003-1058-5826				Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Feng P, 2000, MOL UROL, V4, P31; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Liang JY, 1999, PROSTATE, V40, P200; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MCMAHON RJ, 1998, J NUTR, V128; MCNEAL JE, 1997, HISTOLOGY PATHOLOGIS; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Quinn DI, 2001, J CLIN ONCOL, V19, P3692, DOI 10.1200/JCO.2001.19.16.3692; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202	28	85	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6005	6012		10.1038/sj.onc.1206797	http://dx.doi.org/10.1038/sj.onc.1206797			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955079				2022-12-28	WOS:000185137800009
J	Ivanisevic, L; Banerjee, K; Saragovi, HU				Ivanisevic, L; Banerjee, K; Saragovi, HU			Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75	ONCOGENE			English	Article						receptor; neurotrophin; cross-regulation; ligand; Trk; signal transduction	NERVE GROWTH-FACTOR; NF-KAPPA-B; NEUROTROPHIN SIGNAL-TRANSDUCTION; CULTURED HIPPOCAMPAL-NEURONS; HIGH-AFFINITY; FUNCTIONAL INTERACTIONS; HUMAN NEUROBLASTOMAS; FACTOR-BINDING; P75(NTR); CELLS	The neurotrophins neurotrophin-3 (NT-3), brain-derived growth factor (BDNF) and nerve growth factor (NGF) bind to the p75 receptor, but each neurotrophin also binds a more selective Trk receptor (e.g. TrkA-NGF and TrkC-NT-3). The biochemical signals following engagement of either Trk or p75 with ligands are well understood, but long-term biological outcomes (trophic, proapoptotic or differentiative) remain unclear because they are cell/tissue specific. For example, Trk receptors are usually trophic but when overexpressed they can be proapoptotic in neuroblastomas and medulloblastomas. We hypothesized that coexpression of Trk and p75 receptors may lead to cross-regulation of signals and different biological outcomes; and used receptor-selective ligands to study cross-regulation by these receptors. We show that in the absence of Trk activation, expression of TrkC is permissive of p75 trophic and differentiation signals induced by p75 ligands, whereas expression of TrkA abolishes trophic and differentiation signals induced by p75 ligands. In contrast, in the presence of Trk activation, p75 ligands can regulate TrkA-mediated survival and TrkC-mediated differentiation. Therefore, a complex homeostasis of p75-selective and Trk-selective signals may determine the fate of cells expressing both receptors.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Oncol Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St 1320, Montreal, PQ H3G 1Y6, Canada.	Uri@pharma.mcgill.ca						Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Baskey JC, 2002, J NEUROCHEM, V80, P501, DOI 10.1046/j.0022-3042.2001.00730.x; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; Dechant G, 1997, J NEUROSCI, V17, P5281; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hirata H, 2001, GLIA, V36, P245, DOI 10.1002/glia.1113; Ito H, 2003, J NEUROSCI RES, V72, P211, DOI 10.1002/jnr.10564; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kramer K, 1997, EUR J CANCER, V33, P2090, DOI 10.1016/S0959-8049(97)00210-4; Kuner P, 1998, J NEUROSCI RES, V54, P465, DOI 10.1002/(SICI)1097-4547(19981115)54:4<465::AID-JNR4>3.0.CO;2-T; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Lachyankar MB, 2003, J NEUROSCI RES, V71, P157, DOI 10.1002/jnr.10480; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roux PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/jbc.M011520200; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Sarmiere PD, 2001, MOL CELL NEUROSCI, V18, P320, DOI 10.1006/mcne.2001.1021; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Urdiales JL, 1998, J NEUROSCI, V18, P6767; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yan CH, 2002, MOL PHARMACOL, V61, P710, DOI 10.1124/mol.61.4.710; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5677	5685		10.1038/sj.onc.1206864	http://dx.doi.org/10.1038/sj.onc.1206864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944916				2022-12-28	WOS:000184865900017
J	Johnson, TR; Stone, K; Nikrad, M; Yeh, T; Zong, WX; Thompson, CB; Nesterov, A; Kraft, AS				Johnson, TR; Stone, K; Nikrad, M; Yeh, T; Zong, WX; Thompson, CB; Nesterov, A; Kraft, AS			The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells	ONCOGENE			English	Article						PS-341; TRAIL; Bax; Bcl-2; apoptosis	CYTOCHROME-C RELEASE; FACTOR-KAPPA-B; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; TUMOR-CELLS; DRUG-RESISTANCE; LIGAND TRAIL; DEATH; ACTIVATION; RECEPTOR	We demonstrate that PS-341, a small molecule inhibitor of the proteasome, markedly sensitizes resistant prostate, colon, and bladder cancer cells to TNF-like apoptosis-inducing ligand (TRAIL)-induced apoptosis irrespective of Bcl-xL overexpression. PS-341 treatment by itself does not affect the levels of Bax, Bak, caspases 3 and 8, c-Flip or FADD, but elevates levels of TRAIL receptors DR4 and DR5. This increase in receptor protein levels is associated with the ubiquitination of the DR5 protein. When PS-341 is combined with TRAIL, the levels of activated caspase 8 and cleaved Bid are substantially increased. In Bax-negative TRAIL-resistant HC-4 colon cancer cells, the combination of PS-341 and TRAIL overcomes the block to activation of the mitochondrial pathway and causes SMAC and cytochrome c release followed by apoptosis. Similarly, murine embryonic fibroblasts lacking Bax undergo apoptosis when exposed to the combination of PS-341 and TRAIL; however, fibroblasts lacking Bak are significantly resistant. Taken together, these findings indicate that PS-341 enhances TRAIL-induced apoptosis by increasing the cleavage of caspase 8, causing Bak-dependent release of mitochondrial proapoptotic proteins.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Penn, Dept Med Canc Biol & Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Pennsylvania; Pennsylvania Medicine	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.	Andrew.Kraft@UCHSC.edu	高, 雨莉/HGU-8187-2022					Adams J, 1999, CANCER RES, V59, P2615; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Cusack JC, 2001, CANCER RES, V61, P3535; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hao CH, 2001, CANCER RES, V61, P1162; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hideshima T, 2001, CANCER RES, V61, P3071; Hietakangas V, 2003, MOL CELL BIOL, V23, P1278, DOI 10.1128/MCB.23.4.1278-1291.2003; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lacour S, 2001, CANCER RES, V61, P1645; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2000, CANCER RES, V60, P847; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pawlowski JE, 2000, ANTICANCER RES, V20, P4243; Racke MM, 2002, J NEUROCHEM, V80, P1039, DOI 10.1046/j.0022-3042.2002.00787.x; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; van Bokhoven A, 2001, CANCER RES, V61, P6340; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; van Kerkhof P, 2001, BIOCHEM SOC T, V29, P488, DOI 10.1042/BST0290488; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	161	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4953	4963		10.1038/sj.onc.1206656	http://dx.doi.org/10.1038/sj.onc.1206656			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902978				2022-12-28	WOS:000184578900003
J	Napolitano, G; Mazzocco, A; Fraldi, A; Majello, B; Lania, L				Napolitano, G; Mazzocco, A; Fraldi, A; Majello, B; Lania, L			Functional inactivation of Cdk9 through oligomerization chain reaction	ONCOGENE			English	Article						Cdk9; OCR; P-TEFb; coiled-coil domain; PML	P-TEFB KINASE; C-TERMINAL DOMAIN; HUMAN CYCLIN T1; HIV-1 TAT; IN-VIVO; TRANSCRIPTIONAL ELONGATION; DEPENDENT TRANSCRIPTION; TAK/P-TEFB; ACTIVATION; RECRUITMENT	The oligomerization chain reaction (OCR) strategy is a recently described technique for inactivation of target proteins that function as homoassociate complexes. This novel strategy is based on the fusion of self-associating coiled-coil (CC) domain of the nuclear factor promyelocytic leukemia (PML) to target proteins. Here, we present the successful application of the OCR strategy for inactivation of the heterodimeric Cdk9/cyclin T1 complex. Cyclin T1/Cdk9 (P-TEFb) complex is a positive regulator of gene transcription, whose function is underlined by the ability to phosphorylate the carboxyl-terminal domain (CTD) of the RNA polymerase II conferring productive transcript elongation. Fusion of the CC domain to Cdk9 leads to the formation of high molecular complexes to which the endogenous cyclin T1 is recruited. The CC-Cdk9 chimera effectively inhibits HIV-1 Tat activation, whose transcription activity is exquisitely dependent upon cyclin T1/Cdk9 function. Furthermore, expression of CC-Cdk9 protein inhibits cell proliferation, as shown by colony-formation assay. Collectively, our findings add further support to the OCR strategy for functional inactivation of hetero-associated factors such as the Cdk9/cyclin T1 complex, and highlight a putative function of Cdk9 in cell growth control.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy	University of Naples Federico II	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lania@unina.it	Fraldi, Alessandro/AAB-2243-2021	Fraldi, Alessandro/0000-0002-7795-0720; Majello, Barbara/0000-0003-2789-3585; Napolitano, Giuliana/0000-0002-1637-6016				ALONSO A, 1992, J VIROL, V66, P4617, DOI 10.1128/JVI.66.7.4617-4621.1992; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Contegno F, 2002, P NATL ACAD SCI USA, V99, P1865, DOI 10.1073/pnas.042460299; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Herrmann CH, 2001, J CELL SCI, V114, P1491; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marcello A, 2001, J BIOL CHEM, V276, P39220, DOI 10.1074/jbc.M104830200; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Napolitano G, 2002, J CELL PHYSIOL, V192, P209, DOI 10.1002/jcp.10130; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sausville EA, 2002, TRENDS MOL MED, V8, pS32, DOI 10.1016/S1471-4914(02)02308-0; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	34	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4882	4888		10.1038/sj.onc.1206785	http://dx.doi.org/10.1038/sj.onc.1206785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894230	Bronze			2022-12-28	WOS:000184344600012
J	Syken, J; Macian, F; Agarwal, S; Rao, A; Munger, K				Syken, J; Macian, F; Agarwal, S; Rao, A; Munger, K			TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells	ONCOGENE			English	Article						tumor suppressor; apoptosis; DnaJ protein; T cells	ESCHERICHIA-COLI DNAJ; T-CELL; MOLECULAR CHAPERONES; ATPASE ACTIVITY; UP-REGULATION; EXPRESSION; APOPTOSIS; PROTEIN; GENE; SUBSETS	We previously described two human DnaJ proteins, hTid-1(L) and hTid-1(S), which are derived from alternative splicing of the TID1 gene, the human homologue of the Drosophila tumor suppressor lethal(2) tumorous imaginal discs, and showed that hTid-1(L) promoted while hTid-1(S) antagonized apoptosis. There are two subsets of helper T cells, Th1 and Th2, of which Th2 cells are significantly less prone to apoptosis induced by stimulation through the T-cell receptor. This apoptotic process is known as activation-induced cell death (AICD). The molecular basis for the differential susceptibility of Th1 and Th2 cells to AICD is not known. Here we show that the antiapoptotic variant, Tid-1(S), is selectively induced in murine Th2 cells following activation. Expression of a dominant-negative mutant of hTid-1(S) in a Th2 cell line strikingly enhanced activation of caspase 3 in response to CD3 stimulation, and caused the cells to become sensitive to AICD. Hence, the accumulation of Tid-1(S) in Th2 cells following activation represents a novel mechanism that may contribute to the induction of apoptosis resistance during the activation of Th2 cells.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,D2-544A, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Macian, Fernando/0000-0003-2666-035X; Munger, Karl/0000-0003-3288-9935				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Carter LL, 1998, J IMMUNOTHER, V21, P181, DOI 10.1097/00002371-199805000-00003; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P1256, DOI 10.1038/sj.cdd.4401102; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P101, DOI 10.1038/sj.cdd.4400984; Li-Weber M, 2002, J CLIN INVEST, V110, P681, DOI [10.1172/JCI0215073, 10.1172/JCI200215073]; Lohman BL, 1998, J VIROL, V72, P7815, DOI 10.1128/JVI.72.10.7815-7821.1998; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; WALL D, 1994, J BIOL CHEM, V269, P5446; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	41	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4636	4641		10.1038/sj.onc.1206569	http://dx.doi.org/10.1038/sj.onc.1206569			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879007				2022-12-28	WOS:000184157000003
J	Edwards, SJ; Hananeia, L; Eccles, MR; Zhang, YF; Braithwaite, AW				Edwards, SJ; Hananeia, L; Eccles, MR; Zhang, YF; Braithwaite, AW			The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions	ONCOGENE			English	Article						p53; proline domain; apoptosis	WILD-TYPE P53; DNA-DAMAGE; TUMOR-SUPPRESSOR; DROSOPHILA P53; GROWTH ARREST; CELLS; HOMOLOG; IDENTIFICATION; TRANSCRIPTION; PROMOTERS	The N-terminal proline-rich domain of human p53 has been shown to be important for the induction of apoptosis. However, the corresponding region in mouse and other species is not highly conserved and has been less well studied. In this paper, we have characterized mutants with deletions in this region of mouse p53. Our results demonstrate that deletions in the proline-rich domain have varying effects on function ranging from no effect to severe impairment of cell death activity, depending on precisely which residues are deleted. We also show that the mutants differ in their ability to transactivate different p53 target promoters. Although we have been able to obtain mutants selectively impaired for apoptosis, our data are not generally consistent with this region being a functional domain. The data are more consistent with the interpretation that the region influences function by altering local protein structure which may affect promoter discrimination.	Univ Otago, Dept Pathol, Dunedin Sch Med, Dunedin, New Zealand	University of Otago	Edwards, SJ (corresponding author), Univ Otago, Dept Pathol, Dunedin Sch Med, Box 913, Dunedin, New Zealand.		Eccles, Michael Roger/AAF-7878-2020	Eccles, Michael Roger/0000-0002-6824-8761; Edwards, Sara/0000-0002-3468-1217				Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hansen RS, 1996, ONCOGENE, V13, P995; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; JACKSON P, 1993, ONCOGENE, V8, P589; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; PERREM K, 1995, ONCOGENE, V11, P1299; Prives C, 1999, J PATHOL, V187, P112; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SOUSSI T, 1990, ONCOGENE, V5, P945; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	24	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4517	4523		10.1038/sj.onc.1206726	http://dx.doi.org/10.1038/sj.onc.1206726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881708				2022-12-28	WOS:000184054700007
J	Alonso, MM; Asumendi, A; Villar, J; Gil, MJ; Martinez-Merino, V; Encio, IJ; Migliaccio, M				Alonso, MM; Asumendi, A; Villar, J; Gil, MJ; Martinez-Merino, V; Encio, IJ; Migliaccio, M			New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells	ONCOGENE			English	Article						antineoplastic drugs; apoptosis; CCRF-CEM; reactive oxygen species; caspase-8	CERVICAL-CARCINOMA CELLS; JURKAT LEUKEMIA-CELLS; CYTOCHROME-C; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; DEATH; MITOCHONDRIA; CANCER; CHEMOTHERAPY; INVOLVEMENT; DIARYLSULFONYLUREAS	In this work, we describe the process of cell death induced by a series of new benzo(b)thiophenesulphonamide 1,1-dioxide derivatives (BTS) that have been selected as candidate antineoplastic drugs. Human leukaemic CCRF-CEM cells incubated with BTS undergo a typical apoptotic process that includes cell shrinkage, phosphatidylserine translocation to the cell surface, mitochondrial dysfunction, caspase activation, chromatin condensation and internucleosomal DNA degradation. Mitochondrial alterations included dissipation of the mitochondrial membrane potential, oxidation of the phospholipid cardiolipin, release of cytochrome c and uncoupling of the mitochondrial respiratory chain, leading to a decrease of the intracellular ATP pool. Activation of caspase-8, -9 and -3 takes place during BTS-induced apoptosis. Either the addition of the specific caspase-8 inhibitor Z-IETD-fmk, or the overexpression of the antiapoptotic protein Bcl-2 significantly prevented BTS-induced apoptosis, suggesting the involvement of both caspase-8-regulated and mitochondria-dependent signalling pathways in this process. BTS induce a significant increase in the production and accumulation of intracellular reactive oxygen species (ROS) that can be observed within minutes after drug addition. Moreover, cytochrome c release, caspase-3 activation and cell death can be completely abrogated by a previous incubation with the antioxidant N-acetyl-cysteine. These results suggest that ROS are essential mediators in BTS-induced apoptosis.	Univ Publ Navarra, Dept Hlth Sci, Pamplona 31008, Spain; Univ Basque Country, Dept Cell Biol, Leioa 31006, Spain; Univ Publ Navarra, Dept Appl Chem, Pamplona 31013, Spain	Universidad Publica de Navarra; University of Basque Country; Universidad Publica de Navarra	Migliaccio, M (corresponding author), Univ Publ Navarra, Dept Hlth Sci, Avd Baranain S-N, Pamplona 31008, Spain.	marco.migliaccio@una.varra.es	Martinez-Merino, Victor/K-5177-2014; Alonso, Marta M/AAI-9457-2020; Asumendi, Aintzane/ABF-7001-2021	Martinez-Merino, Victor/0000-0002-1873-0699; Alonso, Marta M/0000-0002-7520-7351; Encio, Ignacio/0000-0003-1732-1989; Asumendi, Aintzane/0000-0002-2156-2323				Alonso MM, 2001, BRIT J CANCER, V85, P1400, DOI 10.1054/bjoc.2001.2083; Boutonnat J, 2000, CYTOMETRY, V42, P50, DOI 10.1002/(SICI)1097-0320(20000215)42:1<50::AID-CYTO8>3.3.CO;2-3; BOZOLLA JJ, 1992, ELECT MICROSCOPY; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; COTTER TG, 1992, ANTICANCER RES, V12, P773; Ferreira CG, 2000, CANCER RES, V60, P7133; Green D R, 1994, Important Adv Oncol, P37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HOWBERT JJ, 1990, J MED CHEM, V33, P2393, DOI 10.1021/jm00171a013; Huschtscha LI, 1996, BRIT J CANCER, V73, P54, DOI 10.1038/bjc.1996.10; Keller JN, 1998, J NEUROSCI, V18, P687; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Koren R, 2000, J STEROID BIOCHEM, V73, P105, DOI 10.1016/S0960-0760(00)00068-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTINEZMERINO V, 2000, Patent No. 0063202; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Oridate N, 1995, J CELL BIOCHEM, P80; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SOSINSKI J, 1993, BIOCHEM PHARMACOL, V45, P2135, DOI 10.1016/0006-2952(93)90027-T; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Umansky V, 2000, J CELL BIOCHEM, V78, P578, DOI 10.1002/1097-4644(20000915)78:4<578::AID-JCB7>3.0.CO;2-A; Umansky V, 2001, EXP CELL RES, V265, P274, DOI 10.1006/excr.2001.5188; Zamai L, 2001, CYTOMETRY, V44, P57, DOI 10.1002/1097-0320(20010501)44:1<57::AID-CYTO1082>3.3.CO;2-F; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	40	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3759	3769		10.1038/sj.onc.1206435	http://dx.doi.org/10.1038/sj.onc.1206435			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802283				2022-12-28	WOS:000183551000010
J	Goldberg, Z				Goldberg, Z			Clinical implications of radiation-induced genomic instability	ONCOGENE			English	Article						radiation; genomic instability; clinical implications	INDUCED CHROMOSOMAL INSTABILITY; BONE-MARROW CELLS; BREAST-CANCER; HODGKINS-DISEASE; NO EVIDENCE; RADIOTHERAPY; THERAPY; LUNG; RADIOSENSITIVITY; SUSCEPTIBILITY	Radiation-induced genomic instability encompasses a range of measurable end points such as chromosome destabilization, sister chromatid exchanges, gene mutation and amplification, late cell death and aneuploidy, all of which may be causative factors in the development of clinical disease, including carcinoma. Clinical implications of genomic instability can be broadly grouped into two main areas: as a marker for increased cancer risk/early detection, and as a consequence of radiation therapy (IR) that may be causative of, or a strong marker for, the induction of a therapy-induced second malignancy. Research in human populations has been limited, but broadly encompasses three populations: those exposed to alpha-particle irradiation, those with a cancer diagnosis who were examined for lymphocyte sensitivity to IR as a biomarker for risk of cancer induction, and those who successfully completed radiation therapy for an index cancer and who were examined for the induction of a second malignancy. This review examines each of those populations in turn and offers some potential future research directions to better elucidate the role of radiation-induced genomic instability in clinical disease.	Univ Calif Davis, Ctr Canc, Dept Radiat Oncol, Sacramento, CA 95817 USA	University of California System; University of California Davis	Goldberg, Z (corresponding author), Univ Calif Davis, Ctr Canc, Dept Radiat Oncol, 4501 X St,Ste G-126, Sacramento, CA 95817 USA.							Al-Maghrabi J, 2001, MODERN PATHOL, V14, P1252, DOI 10.1038/modpathol.3880471; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Buchholz TA, 2001, INT J RADIAT ONCOL, V49, P533, DOI 10.1016/S0360-3016(00)01502-9; Chronowski GM, 2003, INT J RADIAT ONCOL, V55, P36, DOI 10.1016/S0360-3016(02)03915-9; Colleu-Durel S, 2001, ONCOL REP, V8, P1001; Dann EJ, 2001, BEST PRACT RES CL HA, V14, P119, DOI 10.1053/beha.2000.0119; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Dorr Wolfgang, 2002, J Radiol Prot, V22, pA117, DOI 10.1088/0952-4746/22/3A/321; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Finette BA, 2000, SCIENCE, V288, P514, DOI 10.1126/science.288.5465.514; Hande MP, 2003, AM J HUM GENET, V72, P1162, DOI 10.1086/375041; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; HSU TC, 1991, CANCER EPIDEM BIOMAR, V1, P83; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KADHIM MA, 1994, LANCET, V344, P987, DOI 10.1016/S0140-6736(94)91643-8; Kryscio A, 2001, INT J RADIAT BIOL, V77, P1087, DOI 10.1080/09443000110070289; Leith CP, 1999, BLOOD, V94, P1086; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Liu D, 2002, INT J CANCER, V102, P366, DOI 10.1002/ijc.10726; Matheson JB, 2002, RADIOTHER ONCOL, V65, P159, DOI 10.1016/S0167-8140(02)00135-4; Pickles T, 2002, RADIOTHER ONCOL, V65, P145, DOI 10.1016/S0167-8140(02)00307-9; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Schmidberger H, 2001, INT J RADIAT ONCOL, V50, P857, DOI 10.1016/S0360-3016(01)01521-8; Scott D, 1999, INT J RADIAT BIOL, V75, P1, DOI 10.1080/095530099140744; Siantar CLH, 2001, MED PHYS, V28, P1322, DOI 10.1118/1.1381551; Tawn EJ, 2000, MUTAT RES-GEN TOX EN, V465, P45, DOI 10.1016/S1383-5718(99)00210-7; Watson GE, 1996, INT J RADIAT BIOL, V69, P175, DOI 10.1080/095530096146002; Whitehouse CA, 2001, RADIAT RES, V156, P467, DOI 10.1667/0033-7587(2001)156[0467:NEFCII]2.0.CO;2; WHITEHOUSE CA, 2001, RAD RES 1, V156, P7587; Zablotska LB, 2003, CANCER, V97, P1404, DOI 10.1002/cncr.11214; Zhang HF, 2000, INT J ONCOL, V17, P399	32	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7011	7017		10.1038/sj.onc.1206990	http://dx.doi.org/10.1038/sj.onc.1206990			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557805				2022-12-28	WOS:000185903900005
J	Fonsatti, E; Altomonte, M; Nicotra, MR; Natali, PG; Maio, M				Fonsatti, E; Altomonte, M; Nicotra, MR; Natali, PG; Maio, M			Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels	ONCOGENE			English	Review						angiogenesis; CD105; endoglin; endothelial cells; soluble CD105; transforming growth factor	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; HUMAN SOLID TUMORS; CELL LUNG-CANCER; ENDOTHELIAL-CELLS; BINDING-PROTEIN; RECEPTOR-COMPLEX; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROVESSEL DENSITY; BREAST-CARCINOMA	Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -beta receptor complex and is involved in vascular development and remodelling. Quanti. cation of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to have prognostic significance in selected neoplasias. In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy; CNR, Ist Biol & Patol Mol, I-00156 Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, Immunol Lab, I-00158 Rome, Italy	IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Maio, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occle 12, I-33081 Aviano, Italy.	mmaio@cro.it	altomonte, maresa/G-7734-2011	coral, sandra/0000-0002-1308-3082; Maio, Michele/0000-0002-0323-6321; Altomonte, Maresa/0000-0001-8021-1921				Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Akagi K, 2002, SURGERY, V131, pS109, DOI 10.1067/msy.2002.119361; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Balza E, 2001, INT J CANCER, V94, P579, DOI 10.1002/ijc.1505; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bredow S, 2000, EUR J CANCER, V36, P675, DOI 10.1016/S0959-8049(99)00335-4; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brewer CA, 2000, OBSTET GYNECOL, V96, P224, DOI 10.1016/S0029-7844(00)00864-4; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Calabro L, 2003, J CELL PHYSIOL, V194, P171, DOI 10.1002/jcp.10200; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Cho SK, 2001, BLOOD, V98, P3635, DOI 10.1182/blood.V98.13.3635; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Cowan PJ, 2003, XENOTRANSPLANTATION, V10, P223, DOI 10.1034/j.1399-3089.2003.01140.x; Dales JP, 2003, AM J CLIN PATHOL, V119, P374, DOI 10.1309/1KF54L6RB625556W; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; Fonsatti E, 2000, CLIN CANCER RES, V6, P2037; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Graulich W, 1999, GENE, V227, P55, DOI 10.1016/S0378-1119(98)00585-X; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; HENRIKSEN R, 1995, LAB INVEST, V73, P213; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Jonker L, 2002, MECH DEVELOP, V110, P193, DOI 10.1016/S0925-4773(01)00562-7; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Kumar S, 1999, CANCER RES, V59, P856; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, INT J CANCER, V89, P122, DOI 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; LOPARDO C, 1997, LEUCOCYTE TYPING, V6, P711; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; Maier JAM, 1997, ANTI-CANCER DRUG, V8, P238, DOI 10.1097/00001813-199703000-00004; Maio M, 2001, FRONT BIOSCI-LANDMRK, V6, pD776, DOI 10.2741/Maio; Matsuno F, 1999, CLIN CANCER RES, V5, P371; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Nettelbeck DM, 2001, MOL THER, V3, P882, DOI 10.1006/mthe.2001.0342; OCONNELL PJ, 1992, CLIN EXP IMMUNOL, V90, P154; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pierelli L, 2001, LEUKEMIA LYMPHOMA, V42, P1195, DOI 10.3109/10428190109097744; Pruneri G, 2002, BRIT J HAEMATOL, V118, P817, DOI 10.1046/j.1365-2141.2002.03654.x; Pruneri G, 2003, BRIT J HAEMATOL, V120, P695, DOI 10.1046/j.1365-2141.2003.04133.x; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Rajkumar SV, 2002, J HEMATOTH STEM CELL, V11, P33, DOI 10.1089/152581602753448522; Rius C, 1998, BLOOD, V92, P4677; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; ROKHLIN OW, 1995, J IMMUNOL, V154, P4456; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Savontaus MJ, 2002, GENE THER, V9, P972, DOI 10.1038/sj.gt.3301747; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Schimming R, 2002, HEAD NECK-J SCI SPEC, V24, P151, DOI 10.1002/hed.10040; Seon BK, 1997, CLIN CANCER RES, V3, P1031; Seon BK, 2002, INT J CANCER, V99, P310, DOI 10.1002/ijc.10378; Tabata M, 1999, INT J CANCER, V82, P737, DOI 10.1002/(SICI)1097-0215(19990827)82:5<737::AID-IJC18>3.3.CO;2-#; Takahashi N, 2001, CLIN CANCER RES, V7, P524; Takahashi N, 2001, CANCER RES, V61, P7846; Tanaka F, 2001, CLIN CANCER RES, V7, P3410; Tanaka F, 2003, LUNG CANCER-J IASLC, V39, P289, DOI 10.1016/S0169-5002(02)00534-2; Tanaka F, 2002, CANCER RES, V62, P7124; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; van den Driesche S, 2003, CARDIOVASC RES, V58, P20, DOI 10.1016/S0008-6363(02)00852-0; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; WANG JM, 1994, J NATL CANCER I, V86, P386, DOI 10.1093/jnci/86.5.386; WANG JM, 1993, INT J CANCER, V54, P363, DOI 10.1002/ijc.2910540303; Wikstrom P, 2002, PROSTATE, V51, P268, DOI 10.1002/pros.10083; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	88	201	227	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6557	6563		10.1038/sj.onc.1206813	http://dx.doi.org/10.1038/sj.onc.1206813			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528280				2022-12-28	WOS:000185700700012
J	Macaluso, M; Paggi, MG; Giordano, A				Macaluso, M; Paggi, MG; Giordano, A			Genetic and epigenetic alterations as hallmarks of the intricate road to cancer	ONCOGENE			English	Review						cell transformation; cancer development and progression	METASTASIS SUPPRESSOR GENE; CELL-CYCLE CONTROL; DNA METHYLATION; HISTONE DEACETYLASE; HUMAN-BREAST; TRANSCRIPTIONAL REPRESSION; P53; EXPRESSION; PROTEIN; FAMILY	Despite the clonal origin of most tumors, their tremendous heterogeneity suggests that cancer progression springs from the combined forces of both genetic and epigenetic events, which produce variant clonal populations, together with the selective pressures of the microenvironment, which promote growth and, perhaps, dissemination of variants with a specific set of characteristics. Although the importance of genetic mutations in cancer has long been recognized, the role of epigenetic events has been suggested more recently. This review focuses on the genetic and epigenetic molecular mechanisms involved in cancer onset and progression, and discusses the possibility of new strategies in the development of anticancer treatments.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Palermo, Dept Oncol, Sect Mol Oncol, Reg Reference Ctr Biomol Characterizat Neoplasm &, Palermo, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Rome, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.	giordano@temple.edu	Paggi, Marco G./K-3494-2018; Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Aplin AE, 1998, PHARMACOL REV, V50, P197; Bartkova J, 1996, CANCER RES, V56, P5475; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CINTI C, 2000, EMERGING THER TARGET, V4, P765; Cornelius LA, 1998, J IMMUNOL, V161, P6845; De Luca A, 2003, CANCER RES, V63, P1430; Ding HF, 2002, ANN MED, V34, P451, DOI 10.1080/078538902321012405; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Duensing S, 2001, CANCER RES, V61, P2356; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Frank SA, 2003, CURR BIOL, V13, pR261, DOI 10.1016/S0960-9822(03)00195-7; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; GAN DD, 2003, IN PRESS J EXP CLIN; Gatenby RA, 2003, NATURE, V421, P321, DOI 10.1038/421321a; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; HAJES JJ, 2001, CURR OPIN GENE DEV, V11, P124; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; JEN J, 1994, CANCER RES, V54, P6353; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KALEBIC T, 2003, ANN ACAD SCI, V293, P278; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Konopka G, 2003, CURR MOL MED, V3, P73, DOI 10.2174/1566524033361609; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lee JH, 1997, CANCER RES, V57, P2384; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Meijer L, 1995, Prog Cell Cycle Res, V1, P351; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Muegge K, 2003, ANN NY ACAD SCI, V983, P55, DOI 10.1111/j.1749-6632.2003.tb05962.x; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Newcomb EW, 2000, HUM PATHOL, V31, P115, DOI 10.1016/S0046-8177(00)80207-5; OHTA M, 1994, CANCER RES, V54, P5269; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Paggi MG, 2001, CANCER RES, V61, P4651; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Russo A, 2001, CANCER, V92, P294, DOI 10.1002/1097-0142(20010715)92:2<294::AID-CNCR1322>3.0.CO;2-9; RUSSO A, 2003, IN PRESS ENCY HUM GE; Saikawa Y, 2001, JPN J CANCER RES, V92, P1102, DOI 10.1111/j.1349-7006.2001.tb01065.x; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Sarkar S, 2000, CANCER RES, V60, P3862; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297; Skubitz Amy P N, 2002, Cancer Treat Res, V107, P305; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Stewart CL, 2001, J NEURO-ONCOL, V51, P183, DOI 10.1023/A:1010615822317; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sutherland JE, 2003, ANN NY ACAD SCI, V983, P151, DOI 10.1111/j.1749-6632.2003.tb05970.x; TEMPIACALIERA AA, 2002, J SURG ONCOL, V9, P668; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Toyota M, 2002, J GASTROENTEROL, V37, P97, DOI 10.1007/BF03326425; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; von Willebrand M, 2003, CANCER RES, V63, P1420; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yasui W, 2003, ANN NY ACAD SCI, V983, P220, DOI 10.1111/j.1749-6632.2003.tb05977.x; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zini N, 2001, J CELL PHYSIOL, V189, P34, DOI 10.1002/jcp.1135; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	98	73	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6472	6478		10.1038/sj.onc.1206955	http://dx.doi.org/10.1038/sj.onc.1206955			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528270				2022-12-28	WOS:000185700700002
J	Cantile, M; Cindolo, L; Napodano, G; Altieri, V; Cillo, C				Cantile, M; Cindolo, L; Napodano, G; Altieri, V; Cillo, C			Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas	ONCOGENE			English	Article						HOX gene network; HOX C locus; chromosome 12q13; bladder cancer	HUMAN-MELANOMA; MUTANT MICE; EXPRESSION; CANCER; HOMEOBOX; PATTERN; HOXD-11; IDENTIFICATION; AMPLIFICATION; ORGANIZATION	Bladder carcinogenesis remains unclear despite the identification of chemical, environmental and genetic factors. It has recently been reported that the chromosomal region 12q13-q15, containing crucial cancer genes such as MDM2, CDK4 and GLI, is amplified in bladder cancer. In the same region are also located the genes of the locus HOX C, flanked by keratin genes whose protein product may be a prognostic marker of bladder cancer. The HOX genes constitute a network of transcription factors controlling embryonal development and play an important role in crucial adult eukaryotic cell functions. The molecular organization of this 39-gene network is unique in the genome and probably acts by regulating phenotypical cell identity. We have analysed the expression of the whole HOX gene network in pairs of normal tumour bladder and in tumoral biopsies. Comparison between normal urothelium and bladder tumour has identified dramatic variations of expression in a block of three genes (HOX C4, HOX C5 and HOX C6) localized in the HOX C locus on the chromosome 12q13 and in the paralogous group 11 HOX genes, involved during normal development in the formation of the urogenital system. These data suggest a key involvement of the HOX gene network, and especially the locus C, in bladder cancer.	Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, I-80131 Naples, Italy; Univ Naples Federico II, Sch Med, Dept Urol, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Cillo, C (corresponding author), Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, Via S Pansini 5, I-80131 Naples, Italy.	clecillo@unina.it	Cindolo, Luca/Q-8342-2016	Vincenzo, Altieri/0000-0002-1321-2817; Cantile, Monica/0000-0001-7840-3369				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Adshead JM, 1999, BJU INT, V83, P1039; AKAM M, 1987, DEVELOPMENT, V101, P1; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Cantile M, 2003, EUR J CANCER, V39, P257, DOI 10.1016/S0959-8049(02)00599-3; Cantile M, 2003, J CELL PHYSIOL, V194, P225, DOI 10.1002/jcp.10210; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christoph F, 1999, INT J CANCER, V84, P169, DOI 10.1002/(SICI)1097-0215(19990420)84:2<169::AID-IJC13>3.0.CO;2-F; CILLO C, 1994, INVAS METAST, V14, P38; Cillo C, 1996, INT J CANCER, V66, P692, DOI 10.1002/(SICI)1097-0215(19960529)66:5<692::AID-IJC18>3.0.CO;2-6; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; CILLO C, 1995, INT J ONCOL, V7, P1145; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; CILLO C, 1995, P 86 AACR; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DEKKER EJ, 1992, DEVELOPMENT, P195; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; FUJIMOTO K, 1992, CANCER RES, V52, P1393; Gazzaniga P, 2001, CLIN CANCER RES, V7, P4288; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Gromova I, 1999, ELECTROPHORESIS, V20, P241, DOI 10.1002/(SICI)1522-2683(19990201)20:2<241::AID-ELPS241>3.3.CO;2-1; Hostikka SL, 1998, MECH DEVELOP, V70, P133, DOI 10.1016/S0925-4773(97)00182-2; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MOLL R, 1988, AM J PATHOL, V132, P123; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nocito A, 2001, INT J CANCER, V94, P1, DOI 10.1002/ijc.1385; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reed SI, 1997, CANCER SURV, V29, P7; Sandberg AA, 2002, AM J MED GENET, V115, P173, DOI 10.1002/ajmg.10693; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Shinohara N, 2002, UROL RES, V30, P273, DOI 10.1007/s00240-002-0275-0; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 2001, CANCER RES, V61, P4514; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; UICC/AJCC, 1997, TNM CLASS MAL TUM; Wada T, 2000, CLIN CANCER RES, V6, P610; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YOON SJ, 1994, GENOMICS, V24, P502, DOI 10.1006/geno.1994.1659	55	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6462	6468		10.1038/sj.onc.1206808	http://dx.doi.org/10.1038/sj.onc.1206808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508527				2022-12-28	WOS:000185535300017
J	Eason, DD; LeBron, C; Coppola, D; Moscinski, LC; Livingston, S; Sutton, ET; Blanck, G				Eason, DD; LeBron, C; Coppola, D; Moscinski, LC; Livingston, S; Sutton, ET; Blanck, G			Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1	ONCOGENE			English	Article						CD30; lymphoma; interferon regulatory factor-1	LARGE-CELL LYMPHOMA; TRANSCRIPTION FACTOR IRF-1; REED-STERNBERG CELLS; KAPPA-B ACTIVATION; HUMAN-IMMUNODEFICIENCY-VIRUS; CDKN2 MTS1/P16(INK4A) GENE; NITRIC-OXIDE SYNTHASE; NATURAL-KILLER-CELLS; CD4(+) T-CELLS; FACTOR-I IRF-1	Human lymphomas continue to represent a major challenge in oncology, and in particular occur at very high frequencies in AIDS patients. We report here the development of a CD30+ lymphoproliferative disease in mice lacking the proapoptotic transcription factor, interferon regulatory factor-1. These mice most closely represent a model of human anaplastic large-cell lymphoma (ALCL). This mouse model of lymphoma will likely be useful in understanding the development of ALCL and in understanding the development of other closely related CD30+ forms of lymphoma, such as CD30+ Hodgkin's disease and CD30+ cutaneous T-cell lymphoma. This mouse model will also be useful in testing therapies for different forms of CD30+ lymphoma, in particular anti-CD30-based therapies.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Publ Hlth, Dept Environm & Occupat Hlth, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Bd MDC7, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012		NCI NIH HHS [R01-CA81497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; ANAGNOSTOPOULOS I, 1990, AM J PATHOL, V137, P1317; ANDREESEN R, 1984, BLOOD, V63, P1299; Annunziata CM, 2000, BLOOD, V96, P2841; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BARTETT M, 1996, ONCOGENE, V12, P1873; BASHIR MS, 1992, CLIN EXP IMMUNOL, V88, P543; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CARBONE A, 1991, CANCER, V68, P842, DOI 10.1002/1097-0142(19910815)68:4<842::AID-CNCR2820680429>3.0.CO;2-E; CHADBURN A, 1993, CANCER, V72, P3078, DOI 10.1002/1097-0142(19931115)72:10<3078::AID-CNCR2820721033>3.0.CO;2-F; Chan WC, 2001, HEMATOL ONCOL, V19, P1; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; DELPRETE G, 1995, IMMUNOL TODAY, V16, P76, DOI 10.1016/0167-5699(95)80092-1; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Eason DD, 2001, J IMMUNOL, V166, P1041, DOI 10.4049/jimmunol.166.2.1041; Foss HD, 1996, BLOOD, V88, P4005, DOI 10.1182/blood.V88.10.4005.bloodjournal88104005; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Galon J, 1999, J IMMUNOL, V162, P7256; Gardner LJ, 2001, ARCH PATHOL LAB MED, V125, P1036; GONZALEZCLEMENTE JM, 1991, AIDS, V5, P751, DOI 10.1097/00002030-199106000-00017; GRUSS HJ, 1994, BLOOD, V83, P2045; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERBST H, 1989, LEUKEMIA RES, V13, P103, DOI 10.1016/0145-2126(89)90134-3; Heyman M, 1996, LEUKEMIA, V10, P909; Hobart M, 1997, J IMMUNOL, V158, P4260; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; HSU PL, 1990, CANCER RES, V50, P350; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kumanishi T, 1996, JPN J CANCER RES, V87, P691, DOI 10.1111/j.1349-7006.1996.tb00279.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; McElligott DL, 1997, J IMMUNOL, V159, P4180; Mir SS, 2000, BLOOD, V96, P4307; MIURA I, 1992, CANCER RES, V52, P1322; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moller MB, 2000, LEUKEMIA, V14, P898, DOI 10.1038/sj.leu.2401761; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nosari A, 1996, BRIT J HAEMATOL, V95, P508, DOI 10.1046/j.1365-2141.1996.d01-1940.x; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; OHMORI Y, 1995, J IMMUNOL, V154, P5235; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Ransom DT, 1996, HEAD NECK-J SCI SPEC, V18, P248; Salkowski CA, 1996, J IMMUNOL, V156, P3107; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; Sugimura J, 1997, PATHOL INT, V47, P79; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Telford WG, 1997, CELL IMMUNOL, V182, P125, DOI 10.1006/cimm.1997.1228; Uchida T, 1998, LEUKEMIA LYMPHOMA, V29, P27, DOI 10.3109/10428199809058379; UCHIDA T, 1995, BLOOD, V86, P2724, DOI 10.1182/blood.V86.7.2724.bloodjournal8672724; UDAYACHANDER M, 1983, BRIT J CANCER, V48, P717, DOI 10.1038/bjc.1983.255; WENDTNER CM, 1995, CANCER RES, V55, P4157; WIDGREN S, 1985, PATHOL RES PRACT, V180, P563, DOI 10.1016/S0344-0338(85)80025-X; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	77	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6166	6176		10.1038/sj.onc.1206563	http://dx.doi.org/10.1038/sj.onc.1206563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679855				2022-12-28	WOS:000185506200006
J	Bai, YQ; Miyake, S; Iwai, T; Yuasa, Y				Bai, YQ; Miyake, S; Iwai, T; Yuasa, Y			CDX2, a homeobox transcription factor, upregulates transcription of the p21/WAF1/CIP1 gene	ONCOGENE			English	Article						CDX2; transcription; p21/WAF1/CIP1	HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; HOMEODOMAIN PROTEIN CDX2; CYCLIN-DEPENDENT KINASES; INTESTINAL METAPLASIA; CELL-LINE; P21(WAF1/CIP1) GENE; ECTOPIC EXPRESSION; DNA-REPLICATION; TRANSGENIC MICE; DOWN-REGULATION	The CDX2 homeobox transcription factor plays key roles in intestinal development and homeostasis. CDX2 is downregulated during colorectal carcinogenesis, whereas overexpression of CDX2 results in growth inhibition and differentiation of colon carcinoma and intestinal cells. However, the means by which CDX2 functions remain poorly understood. p21/WAF1/CIP1 is one of the cyclin-dependent kinase inhibitors. In addition to its role in cell cycle control, p21 plays critical roles in differentiation and tumor suppression. The overlapping in both the expression and function of CDX2 and p21 in the small intestine and colon strongly suggests a link between these two genes. By means of luciferase reporter and electrophoretic mobility shift assays, we show here that CDX2 transactivated and physically interacted with the promoter of p21 in a p53-independent manner. Moreover, overexpression of CDX2 increased the mRNA expression of p21 in HT-29 colon carcinoma cells, as demonstrated by reverse transcription-polymerase chain reaction. These data suggest that p21 is a transcriptional target of CDX2. Our results may thus provide a new mechanism underlying the functions of CDX2.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Surg, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Yuasa, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bukholm IK, 2000, VIRCHOWS ARCH, V436, P224, DOI 10.1007/s004280050034; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; EE HC, 1995, AM J PATHOL, V147, P586; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; HARPER JW, 1993, CELL, V75, P805; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JAMES R, 1994, J BIOL CHEM, V269, P15229; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Polyak K, 1996, AM J PATHOL, V149, P381; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; van Wering HM, 2002, J BIOL CHEM, V277, P27659, DOI 10.1074/jbc.M203645200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	86	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7942	7949		10.1038/sj.onc.1206634	http://dx.doi.org/10.1038/sj.onc.1206634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970742				2022-12-28	WOS:000185388200009
J	Johansson, EM; Kannius-Janson, M; Bjursell, G; Nilsson, J				Johansson, EM; Kannius-Janson, M; Bjursell, G; Nilsson, J			The p53 tumor suppressor gene is regulated in vivo by nuclear factor 1-C2 in the mouse mammary gland during pregnancy	ONCOGENE			English	Article						p53; NF1-C2; NF1-A1; mammary gland; development; transcriptional regulation	ESTER LIPASE GENE; HUMAN BREAST-TUMORS; CELL-LINE K562; TRANSCRIPTION FACTOR; WILD-TYPE; KAPPA-B; HA-RAS; EXPRESSION; DIFFERENTIATION; PROMOTER	The p53 tumor suppressor protein plays an important role in preventing cancer development by arresting or killing potential tumor cells. Downregulated p53 levels, or mutations within the p53 gene, leading to the loss of p53 activity, are found in many breast carcinomas. Here we demonstrate that the p53 gene is transcriptionally upregulated in the normal mouse mammary gland at midpregnancy. We show that the specific isoform nuclear factor 1-C2 (NF1-C2) plays an important role in this activation. Functional mutation of the NF1-binding site in the mouse p53 promoter resulted in a reduction of the gene expression to less than 30% in mammary epithelial cells. By the use of two powerful techniques, chromatin immunoprecipitation and oligonucleotide decoy, we verify the importance of NF1-C2 in p53 gene activation in vivo. These findings demonstrate a broader role for NF1-C2 in the mammary gland at midpregnancy, beyond its earlier reported activation of milk protein genes. We also demonstrate that NF1-A1 proteins are produced in the mouse mammary gland. However, due to their lower affinity to the NF1-binding site, these proteins are not involved in the transcriptional upregulation of p53 at midpregnancy. This paper constitutes the first report demonstrating the importance of NF1 proteins in the p53 gene activation in the mouse mammary gland. It is also the first time that p53 gene activation is coupled to a specific, endogenously expressed NF1 isoform.	Dept CMB Mol Biol, S-40530 Gothenburg, Sweden		Johansson, EM (corresponding author), Dept CMB Mol Biol, Box 462, S-40530 Gothenburg, Sweden.	Eva.Johansson@molbio.gu.se	Kannius Janson, Marie/M-3052-2015; Nilsson, Jeanette/M-3051-2015					Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Balint E, 1996, CANCER RES, V56, P1648; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Bengtsson SHM, 2002, BIOCHEM J, V365, P481, DOI 10.1042/BJ20020223; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; COLES C, 1992, CANCER RES, V52, P5291; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Kane R, 2000, ADV EXP MED BIOL, V480, P117; Kannius-Janson M, 1998, BIOCHEM J, V336, P577, DOI 10.1042/bj3360577; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Lidberg U, 1998, J BIOL CHEM, V273, P31417, DOI 10.1074/jbc.273.47.31417; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; NEBL G, 1994, J BIOL CHEM, V269, P7371; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada S, 1999, BIOCHEM J, V342, P189, DOI 10.1042/0264-6021:3420189; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Saifudeen Z, 2002, J CLIN INVEST, V109, P1021, DOI 10.1172/JCI200213972; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; STRANGE R, 1992, DEVELOPMENT, V115, P49; Stromqvist M, 1997, ARCH BIOCHEM BIOPHYS, V347, P30, DOI 10.1006/abbi.1997.0307; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	45	18	19	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6061	6070		10.1038/sj.onc.1206884	http://dx.doi.org/10.1038/sj.onc.1206884			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955085				2022-12-28	WOS:000185137800015
J	Schmidt-Ullrich, RK				Schmidt-Ullrich, RK			Molecular targets in radiation oncology - Overview	ONCOGENE			English	Editorial Material						DNA damage; cell survival; signal transduction			Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23284 USA.								0	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 1	2003	22	37					5730	5733		10.1038/sj.onc.1206662	http://dx.doi.org/10.1038/sj.onc.1206662			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947382				2022-12-28	WOS:000185086100002
J	Figueroa, C; Vojtek, AB				Figueroa, C; Vojtek, AB			Akt negatively regulates translation of the ternary complex factor Elk-1	ONCOGENE			English	Article						Elk-1; Sap1a; Akt/PKB; translational control; Ets; cross-talk	PROTEIN-KINASE-B; C-FOS TRANSCRIPTION; EPITHELIAL-CELLS; RAS; DIFFERENTIATION; EXPRESSION; PATHWAY; BINDING; MOUSE; PHOSPHORYLATION	Cross-talk between signaling pathways plays an important role in regulation of cell growth, differentiation, survival, and death. Here, we show that Akt regulates the Elk-1 transcription factor, independent of its negative regulation of Raf kinases. Using a constitutively active Mek1 to bypass the regulation of Raf by Akt, we find that the Elk-1 and Sap1a proteins are dramatically decreased in the presence of activated Akt. Akt catalytic activity is required. Also, Mek-dependent activation of a TCF (Etk-1/Sap-1a)-dependent c-fos reporter is decreased by activated Akt. Neither the level of Elk-1 mRNA nor the stability of the Elk-1 protein is altered by activated Akt. Instead, the rate of incorporation of labeled methionine into Elk-1 protein is decreased in the presence of Akt. In addition, the level of the Elk-1 protein but not GFP is significantly decreased in the presence of activated Akt, when GFP is expressed from an IRES element in a bicistronic message with Elk-1. We conclude that Akt negatively regulates translation of the Elk-1 mRNA. A coding region determinant that maps within the first 279 nts of the Elk-1 message is necessary and sufficient for Akt-mediated regulation of Elk-1.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Figueroa-Romero, Claudia/0000-0001-7546-4190				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Guan KL, 2000, J BIOL CHEM, V275, P27354; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JUN T, 1999, SCI STKE, P10591; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARTI A, 1994, ONCOGENE, V9, P1213; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Preston GA, 2000, CELL DEATH DIFFER, V7, P215, DOI 10.1038/sj.cdd.4400637; Preston GA, 1996, MOL CELL BIOL, V16, P211; Rich KA, 1997, J NEUROBIOL, V32, P593, DOI 10.1002/(SICI)1097-4695(19970605)32:6<593::AID-NEU5>3.0.CO;2-V; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sheng HM, 2001, CANCER RES, V61, P2670; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; VOJTEK AB, 1993, J CELL SCI, V105, P777; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5554	5561		10.1038/sj.onc.1206496	http://dx.doi.org/10.1038/sj.onc.1206496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944902				2022-12-28	WOS:000184865900003
J	Calissano, M; Latchman, DS				Calissano, M; Latchman, DS			Functional interaction between the small GTP-binding protein Rin and the N-terminal of Brn-3a transcription factor	ONCOGENE			English	Article						Brn-3a; Pou; Rin; RAS yeast two hybrid	GENE-EXPRESSION; NEURONAL CELLS; DOMAIN; ACTIVATION; FAMILY; SUBFAMILY; OUTGROWTH; GANGLION; DISTINCT	Brn-3a is a transcription factor belonging to the class IV of POU domain transcription factors. It is expressed throughout the peripheral nervous system but especially in postmitotic sensory neurons of dorsal root ganglia. Brn-3a is known to regulate different genes involved in neuronal differentiation and survival. It has been shown that some of these genes require the N-terminal domain of Brn-3a in order to be activated and this effect is observed only in neurons suggesting that it may require a neuronal-specific cofactor. In order to identify this putative factor(s) we screened a cDNA library via a variant of the original yeast two-hybrid system. By using the N-terminal of Brn-3a as the bait, we have repeatedly isolated a protein named Rin, an incompletely characterized small GTP-binding protein expressed only in neurons. In this work, we describe the evidence for a functional interaction between Brn-3a and Rin and demonstrate the role of Rin in modulating the activation of the Brn-3a regulated egr-1 promoter by the N-terminal domain of Brn-3a.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Calissano, M (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	m.calissano@ich.ucl.ac.uk			Telethon [487/B] Funding Source: Medline	Telethon(Fondazione Telethon)		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; PATEL G, 1992, ONCOGENE, V7, P283; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1999, MOL BRAIN RES, V74, P117, DOI 10.1016/S0169-328X(99)00271-5; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Spencer ML, 2002, J BIOL CHEM, V277, P17605, DOI 10.1074/jbc.M111400200; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445	27	8	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5408	5414		10.1038/sj.onc.1206635	http://dx.doi.org/10.1038/sj.onc.1206635			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934100				2022-12-28	WOS:000184735000005
J	Mulloy, R; Salinas, S; Philips, A; Hipskind, RA				Mulloy, R; Salinas, S; Philips, A; Hipskind, RA			Activation of cyclin D1 expression by the ERK5 cascade	ONCOGENE			English	Article						MEK5; ERK1/2; NF kappa B; CRE; CCL-39 cells; breast cancer	NF-KAPPA-B; HUMAN BREAST-CANCER; CAMP-RESPONSIVE ELEMENT; C-JUN PROMOTER; GROWTH-FACTOR; BINDING PROTEIN; TRANSCRIPTION FACTOR-2; KINASE; GENE; CELLS	Transcriptional activation of the cyclin D1 gene is a key step in cell proliferation. Accordingly, cyclin D1 overexpression is frequently an early step in neoplastic transformation, particularly in mammary epithelium. Numerous studies have linked elevated cyclin D1 promoter activity to a sustained activation of the ERK1/2 cascade. Here we show that the ERK5 cascade, a distinct mitogen-induced MAPK pathway, can also drive cyclin D1 expression. In CCL39 cells, serum induces a strong, prolonged peak of ERK1/2 and ERK5 phosphorylation, and subsequently elevates cyctin D1 mRNA and protein levels. Overexpression of constitutively active MEK5 and wt ERK5 induces a cyclin D1 reporter gene (D1-973-luciferase) at least as well as constitutively active MEK1. Activation is blocked by kinase-dead mutants of ERK5 and ERK2, respectively. Mutation of the CRE at -50 in the cyclin D1 promoter decreases activation by the ERK5 but not the ERK1/2 cascade. Importantly, expression of kinase-dead ERK5 diminishes endogenous cyclin D1 protein induction by serum in CCL39 cells and the breast cancer cell lines MCF-7 and HS579. These data identify the cyclin D1 gene as a novel target of the ERK5 cascade, an observation with important implications in cancers involving cyclin D1 deregulation.	Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Hipskind, RA (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	hipskind@soleil.igm.cnrs-mop.fr	Salinas, Sara/O-1150-2019; PHILIPS, Alexandre/AAB-6047-2020; Salinas, Sara/O-1856-2013	Salinas, Sara/0000-0003-4492-2093; Salinas, Sara/0000-0003-4492-2093				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BRUNET A, 1994, ONCOGENE, V9, P3379; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HERBER, 1994, ONCOGENE, V9, P2105; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; LAVOIE J, J BIOL CHEM, V271, P20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	46	75	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5387	5398		10.1038/sj.onc.1206839	http://dx.doi.org/10.1038/sj.onc.1206839			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934098				2022-12-28	WOS:000184735000003
J	Chen, Y; Kramer, DL; Li, FZ; Porter, CW				Chen, Y; Kramer, DL; Li, FZ; Porter, CW			Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells	ONCOGENE			English	Article						survivin; apoptosis; DENSPM; IAP; ML-IAP; polyamines; siRNA	CYTOCHROME-C; BACULOVIRAL-INHIBITOR; CANCER-CELLS; IAP PROTEINS; LUNG-CANCER; PHASE-I; SURVIVIN; FAMILY; IDENTIFICATION; EXPRESSION	We have previously shown that the clinically relevant polyamine analog N-1,N-11-diethylnorspermine (DENSPM) causes rapid apoptosis in human melanoma SK-MEL-28 cells via a series of events that include mitochondrial release of cytochrome c and activation of the caspase cascade. Upstream to these events, DENSPM downregulates polyamine biosynthesis and potently upregulates polyamine catabolism at the level of spermidine/spermine All-acetyltransferase (SSAT). In searching for downstream effectors that either contribute to or abrogate the apoptotic response, we observed that DENSPM treatment of SK-MEL-28 cells for 30 h led to cytosolic release of Smac/Diablo, a mitochondrial protein known to bind and inhibit the function of inhibitor of apoptosis proteins (IAPs). Subsequently, we found that DENSPM markedly lowered survivin and ML-IAP protein (but not XIAP) levels by 18 h via an apparently Smac/Diablo-independent pathway. Proteasome inhibitors fully prevented survivin and ML-IAP protein loss as well as apoptosis, suggesting that the proteasome-mediated degradation of survivin and ML-IAP is causally linked to the cellular outcome. We also observed that structural analogs of DENSPM which differentially induced SSAT and apoptosis lowered survivin and ML-IAP levels in a manner that correlated with enzyme activity. The linkage between IAPs and SSAT was more directly established by the finding that selective prevention of SSAT induction by small interfering RNA prevented survivin and ML-IAP loss as well as apoptosis during DENSPM treatment. Among the melanoma cell lines (SK-MEL-28, MALME-3M, A375 and LOX), survivin degradation correlated temporally with the onset of DENSPM induced apoptosis or growth inhibition. By contrast, ML-IAP degradation occurred only during rapid apoptosis seen in SK-MEL-28 cells. These data suggest a sequence of events whereby DENSPM induction of SSAT leads to loss of IAP proteins and a more fulminate apoptotic response. The findings implicate survivin and ML-IAP as important determinants of polyamine analog drug action in melanoma cells.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA022153] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-22153, CA-16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Chen Y, 2001, CANCER RES, V61, P6437; CHEN Y, 2003, IN PRESS CANC RES; CHEN Y, 2003, UNPUB MOL PHARM; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Creaven PJ, 1997, INVEST NEW DRUG, V15, P227, DOI 10.1023/A:1005827231849; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kramer DL, 2001, CANCER RES, V61, P7754; Kramer DL, 1999, CANCER RES, V59, P1278; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Olie RA, 2000, CANCER RES, V60, P2805; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Streiff RR, 2001, INVEST NEW DRUG, V19, P29, DOI 10.1023/A:1006448516938; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Tamm I, 1998, CANCER RES, V58, P5315; Tanaka K, 2000, CLIN CANCER RES, V6, P127; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao J, 2000, J CELL SCI, V113, P4363	39	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4964	4972		10.1038/sj.onc.1206725	http://dx.doi.org/10.1038/sj.onc.1206725			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902979				2022-12-28	WOS:000184578900004
J	Molton, SA; Todd, DE; Cook, SJ				Molton, SA; Todd, DE; Cook, SJ			Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3 '-kinase (PI3K) pathway is inhibited	ONCOGENE			English	Article						apoptosis; Bcl-2; JNK; MEKK1; PI3K; PKB	KAPPA-B KINASE; FORKHEAD TRANSCRIPTION FACTOR; PROGRAMMED CELL-DEATH; BCL-2 FAMILY MEMBER; PROTEIN-KINASE; FAS LIGAND; SIGNAL-TRANSDUCTION; MAP KINASES; MEK KINASE; NH2-TERMINAL KINASE	c-Jun N-terminal kinase (JNK) is activated when cells are exposed to noxious stimuli. The role of JNK in apoptosis is subject to considerable debate; for example, JNK activation may promote or inhibit apoptosis depending on the cell type and stimulus involved. These conflicting results have arisen in part because few studies have successfully separated JNK activation from the primary stress-induced damage or from other stress-induced signalling pathways. Here we describe a conditional mutant, DeltaMEKK1:ER*, which allows selective activation of the JNK cascade in the absence of any cellular stress. Activation of DeltaMEKK1:ER* in CC139 fibroblasts resulted in the rapid and sustained activation of JNK without activating ERK or p38 or promoting IkappaBalpha phosphorylation. Activation of AMEKK1:ER* caused a reversible halt in cell growth but failed to induce apoptosis. In contrast, treatment of cells with LY294002, to inhibit phosphoinositide 3-kinase (PI3K), caused downregulation of Bcl-2 and Mcl-1 and allowed AMEKK1:ER* to elicit a robust apoptotic response characterized by activation of Bax and caspases. This PI3K-inhibitable, JNK-induced death response was not impeded, but actually accelerated, by cycloheximide. This suggests that JNK-induced activation of Bax and cell death does not require the upregulation of pro-death genes such as Bim or FasL, but rather proceeds through preexisting components. However, if the PI3K cell survival pathway is not inhibited, even sustained activation of JNK exerts no overt proapoptotic effect in CC139 cells.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England.				Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ADLER V, 1992, J BIOL CHEM, V267, P17001; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Levresse V, 2000, J NEUROSCI RES, V62, P799; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	62	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4690	4701		10.1038/sj.onc.1206692	http://dx.doi.org/10.1038/sj.onc.1206692			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879014				2022-12-28	WOS:000184157000010
J	Konduri, SD; Srivenugopal, KS; Yanamandra, N; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Ali-Osman, F; Kondraganti, S; Lakka, SS; Rao, JS				Konduri, SD; Srivenugopal, KS; Yanamandra, N; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Ali-Osman, F; Kondraganti, S; Lakka, SS; Rao, JS			Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells	ONCOGENE			English	Article						TFPI-2; 5 '-CpG methylation; gliomas; methyl CpG-group binding protein; historic deacetylation; gene silencing; epigenetic mechanisms; proteinase inhibitor	HISTONE DEACETYLASE INHIBITION; IN-VITRO; TRANSCRIPTIONAL REPRESSOR; PROTEASE INHIBITOR; CANCER-CELLS; CDNA CLONING; GENE; DNA; MATRIX; EXPRESSION	We have shown previously that the tissue factor pathway inhibitor-2 (TFPI-2), a broad range proteinase inhibitor, is highly expressed in low-grade gliomas, but, minimally expressed or undetectable in glioblastomas, and that enforced expression of this gene reduces the invasive properties of brain tumor cells. Here, we examined the role of promoter methylation as a mechanism of TFPI-2 gene silencing. In SNB19 glioblastoma cells, which have no detectable TFPI-2 expression, 5-aza-2'-deoxycytidine (5aC), an inhibitor of DNA methyltransferase, induced TFPI-2 mRNA in a dose-dependent manner. Trichostatin A (TSA), the histone deacetylase (HDAC) inhibitor, by itself, was more efficient than 5aC in inducing TFPI-2 transcripts, and the 5aC + TSA combination resulted in highly synergistic reactivation of the gene, both at the transcript and protein levels. In Hs683 glioma cells, which express the TFPI-2 gene at high levels, transfection of the in vitro methylated TFPI-2 promoter constructs resulted in a drastic decrease of promoter activity compared to the unmethylated promoter. Further, the methylation-specific PCR in SNB19 and Hs683 cells showed that TFPI-2 gene repression was closely linked with methylation of the CpG islands in the promoter. Finally, the chromatin immunoprecipitation assays in SNB19 cells showed that the methylated and repressed TFPI-2 promoter was associated with the methyl-CpG binding protein 2 (MeCP2), and that gene reactivation resulted in the loss of MeCP2 from this site. These studies establish that TFPI-2 is transcriptionally silenced through promoter methylation in SNB19 cells.	Univ Illinois, Coll Med, Program Canc Biol, Peoria, IL 61656 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Neuropathol, Peoria, IL USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zymogenet Inc.; University of New Mexico; University of New Mexico's Health Sciences Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.ed						BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Esteller M, 2001, CANCER RES, V61, P3225; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; McQueen HA, 1998, GENOME RES, V8, P621, DOI 10.1101/gr.8.6.621; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; RAO JS, 1993, CANCER RES, V53, P2208; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Yang XW, 2001, CANCER RES, V61, P7025	31	61	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4509	4516		10.1038/sj.onc.1206695	http://dx.doi.org/10.1038/sj.onc.1206695			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881707				2022-12-28	WOS:000184054700006
J	Soares, P; Trovisco, V; Rocha, AS; Lima, J; Castro, P; Preto, A; Maximo, V; Botelho, T; Seruca, R; Sobrinho-Simoes, M				Soares, P; Trovisco, V; Rocha, AS; Lima, J; Castro, P; Preto, A; Maximo, V; Botelho, T; Seruca, R; Sobrinho-Simoes, M			BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC	ONCOGENE			English	Article						BRAF; RET/PTC; thyroid; papillary carcinoma	THYROID-TUMORS; CARCINOMA; CANCER; GENE; ONCOGENES; MELANOMA	Rearrangement of RET proto-oncogene is the major event in the etiopathogenesis of papillary thyroid carcinoma (PTC). We report a high prevalence of BRAF(V599E) mutation in sporadic PTC and in PTC-derived cell lines. The BRAF(V599E) mutation was detected in 23 of 50 PTC (46%) and in three of four PTC-derived cell lines. The prevalence of the BRAF(V599E) mutation in PTC is the highest reported to date in human carcinomas, being only exceeded by melanoma. PTC with RET/PTC rearrangement as well as the TPC-1 cell line (the only one harboring RET/PTC rearrangement) did not show the BRAF(V599E) mutation. BRAF(V599E) mutation was not detected in any of 23 nodular goiters, 51 follicular adenomas and 18 follicular carcinomas. A distinct mutation in BRAF (codon K600E) was detected in a follicular adenoma. Activating mutations in RAS genes were detected in 15% of FA, 33% of FTC and 7% of PTC. BRAF(V599E) mutation did not coexist with alterations in any of the RAS genes in any of the tumors. These results suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC. The BRAF(V599E) mutation appears to be an alternative event to RET/PTC rearrangement rather than to RAS mutations, which are rare in PTC. BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET/PTC activation.	IPATIMUP, P-4200465 Oporto, Portugal; Hosp Sao Joao, Dept Pathol, Oporto, Portugal; Fac Med Porto, Dept Pathol, Oporto, Portugal	Sao Joao Hospital; Universidade do Porto	Sobrinho-Simoes, M (corresponding author), IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.		Preto, Ana/H-8112-2012; Sobrinho-Simões, Manuel/J-8290-2013; Lima, Jorge/J-5975-2013; seruca, raquel/F-8187-2011; Castro, Patricia/J-8537-2013; Maximo, Valdemar/E-7480-2011; Soares, Paula/B-6054-2008	Preto, Ana/0000-0002-7302-0630; Lima, Jorge/0000-0001-7780-0901; Maximo, Valdemar/0000-0002-8631-8356; Soares, Paula/0000-0001-9607-6998; Castro, Patricia/0000-0001-9588-9065; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Oliveira Botelho, Tiago/0000-0002-2456-8421; Seruca, Raquel/0000-0002-8851-4166				Brose MS, 2002, CANCER RES, V62, P6997; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; KOVACS K, 1991, FUNCTIONAL ENDOCRINE; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Ludwig L, 2001, CANCER RES, V61, P4526; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Naoki K, 2002, CANCER RES, V62, P7001; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, NATURE, V417, P906, DOI 10.1038/417906a; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; ROSAI J, 1992, TUMORS THYROID GLAND; Soares P, 1998, J PATHOL, V185, P71; Soares P, 1997, EUR J CANCER, V33, P293, DOI 10.1016/S0959-8049(96)00457-1; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Yuen ST, 2002, CANCER RES, V62, P6451	20	498	522	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4578	4580		10.1038/sj.onc.1206706	http://dx.doi.org/10.1038/sj.onc.1206706			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881714				2022-12-28	WOS:000184054700013
J	Zhuang, SG; Ouedraogo, GD; Kochevar, IE				Zhuang, SG; Ouedraogo, GD; Kochevar, IE			Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases	ONCOGENE			English	Article						apoptosis; epidermal growth factor receptor; caspase; keratinocyte; protein phosphatase; singlet oxygen	RABBIT SKELETAL-MUSCLE; REVERSIBLE INACTIVATION; ULTRAVIOLET-LIGHT; OXIDATIVE STRESS; EGF RECEPTOR; APOPTOSIS; CLEAVAGE; INHIBITION; INDUCTION; ACID	Downregulation of survival signaling pathways contributes to the cytotoxicity of reactive oxygen species (ROS) and may underlie certain therapies for hyperproliferative diseases. We have investigated the role of singlet oxygen, an ROS formed by photosensitization, in the regulation of survival signaling via the epidermal growth factor receptor (EGFR). Exposure of human keratinocytes to singlet oxygen resulted in rapid loss of EGFR, which was not blocked by either inhibition of receptor internalization or by interrupting the major proteolytic pathways (proteasome, lysosome or calpain). However, pretreatment with a caspase-3 inhibitor, DEVD-FMK, inhibited EGFR degradation. Caspase-3 cleavage was detected as early as 5 min after singlet oxygen treatment, and recombinant active caspase-3 completely cleaved EGFR in a keratinocyte membrane fraction. The singlet oxygen-induced loss of EGFR was accompanied by dephosphorylation of EGFR as well as of Akt and extracellular signal-regulated kinase 1/2 (ERK)1/2. Singlet oxygen-induced protein dephosphorylation was not dependent on activation of caspase-3. In contrast, inhibition of protein phosphatases (PPs) with okadaic acid completely blocked dephosphorylation of EGFR, ERK1/2 and Akt as well as degradation of EGFR. These results indicate that the oxidative stress produced by singlet oxygen rapidly disrupts EGFR-mediated signaling by decreasing both the protein level and its phosphorylation. These responses depended on intertwined activation of caspase-3 and PPs.	Harvard Univ, Sch Med, Wellman Labs Photomed, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Sch Med, Wellman Labs Photomed, Massachusetts Gen Hosp, WEL-224,55 Fruit St, Boston, MA 02114 USA.	kochevar@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030755] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad N, 2001, ONCOGENE, V20, P2314, DOI 10.1038/sj.onc.1204313; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; Boulougouris P, 2001, ANTICANCER RES, V21, P2769; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hunter I, 2001, J BONE MINER RES, V16, P466, DOI 10.1359/jbmr.2001.16.3.466; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; KATOH S, 1994, BIOL PHARM BULL, V17, P1003; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; LASKIN JD, 1986, P NATL ACAD SCI USA, V83, P8211, DOI 10.1073/pnas.83.21.8211; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Lin CP, 2000, EXP CELL RES, V259, P351, DOI 10.1006/excr.2000.4979; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scheving LA, 1998, AM J PHYSIOL-CELL PH, V274, pC1363, DOI 10.1152/ajpcell.1998.274.5.C1363; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Yarden Y, 2001, EUR J CANCER, V37, pS3; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501	60	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4413	4424		10.1038/sj.onc.1206604	http://dx.doi.org/10.1038/sj.onc.1206604			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853978				2022-12-28	WOS:000183978900011
J	Avvakumov, N; Torchia, J; Mymryk, JS				Avvakumov, N; Torchia, J; Mymryk, JS			Interaction of the HPV E7 proteins with the pCAF acetyltransferase	ONCOGENE			English	Article						human papillomavirus; E7; pCAF; acetyltransferase; transcription	HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRAL ONCOPROTEIN E1A; CREB-BINDING PROTEIN/P300; DNA-DAMAGE; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL ACTIVATION; P300/CBP-ASSOCIATED FACTOR; SACCHAROMYCES-CEREVISIAE	Most cervical carcinomas express the E6 and E7 proteins of a high-risk human papillomavirus (HPV). These proteins affect growth control by interfering with the functions of cell regulatory proteins, promoting oncogenic transformation. A key target of E7 is the tumor suppressor protein pRb, which directly interacts with E7. However, binding to additional cellular regulatory proteins is clearly required for oncogenesis, as mutants of E7 have been identified that bind to pRb, yet fail to transform efficiently. Here we demonstrate the interaction of the HPV 6, 16 and 18 E7 proteins with the pCAF acetyltransferase, which has been reported to function as a coactivator for a variety of transcription factors including p53. Mutation of a highly conserved leucine residue within the zinc finger region of HPV 16 E7 disrupts binding to pCAF and also impairs transformation and transcriptional activation. HPV 16 E7 interacts with the acetyltransferase domain of pCAF, and reduces its acetyltransferase activity in vitro. Our analysis of the interaction between the pCAF acetyltransferase and E7 provides new insight into the mechanisms by which the E7 oncoproteins can alter cellular gene expression and growth.	Univ Western Ontario, Dept Microbiol & Immunol, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Oncol, London Reg Canc Ctr, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Mymryk, JS (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London Reg Canc Ctr, London, ON N6A 4L6, Canada.	jmymryk@uwo.ca						BANKS L, 1990, ONCOGENE, V5, P1383; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brehm A, 1999, MOL CELL BIOL, V19, P2635; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Bryant LA, 2000, J VIROL, V74, P7230, DOI 10.1128/JVI.74.16.7230-7237.2000; CARTER JJ, 1991, VIROLOGY, V182, P513, DOI 10.1016/0042-6822(91)90592-Y; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KAWABATA H, 2001, J BIOL CHEM; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Massimi P, 1997, VIROLOGY, V227, P255, DOI 10.1006/viro.1996.8315; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Roberts SM, 1997, GENETICS, V147, P451; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Scolnick DM, 1997, CANCER RES, V57, P3693; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 1996, ONCOGENE, V12, P213	57	89	91	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3833	3841		10.1038/sj.onc.1206562	http://dx.doi.org/10.1038/sj.onc.1206562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813456				2022-12-28	WOS:000183612000002
J	George, A; Morse, HC; Justice, MJ				George, A; Morse, HC; Justice, MJ			The homeobox gene Hex induces T-cell-derived lymphomas when overexpressed in hematopoietic precursor cells	ONCOGENE			English	Article						Hex; retroviral transduction; T-cell lymphoma	LEUKEMIC HEMATOPOIESIS; EXPRESSION; DIFFERENTIATION; MOUSE; PROTEIN; MICE; PRH; TRANSFORMATION; ACTIVATION; ZEBRAFISH	Proviral insertions at the viral insertion site Lvis1 occur frequently in B- and T-cell leukemias and lymphomas in AKXD mice and activate two nearby genes, the divergent homeobox gene Hex and the kinesin-related spindle protein gene Eg5. To determine whether Hex misexpression results in the altered differentiation or neoplastic transformation of hematopoietic lineages, we have transplanted mice with bone marrow cells transduced with retrovirus containing the Hex coding region. High levels of Hex expression in hematopoietic precursor cells inhibit contribution to mature blood cell lineages by these precursors. Hex bone marrow transplant recipient mice also develop hematologic neoplasms that appear to originate in the bone marrow. The tumors have clonal rearrangements of the TCR locus, are Thy1(+), and are CD4(+)CD8(+), CD4(-)CD8(-), or mixed, indicating tumor origin from a precursor T-cell population. Tumors in transplant mice contain clonal and transcriptionally active Hex proviral insertions, demonstrating a causal role for Hex misexpression in the onset of these neoplasms. Our results demonstrate that Hex can act as a T lineage oncogene when misexpressed in hematopoietic precursor cells.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, MD PhD Program, Houston, TX 77030 USA; NIAID, Immunopathol Lab, NIH, Rockville, MD USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu		Morse, Herbert/0000-0002-9331-3705	NATIONAL CANCER INSTITUTE [R01CA063229, R29CA063229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [CA63229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Bogue CW, 2003, P NATL ACAD SCI USA, V100, P556, DOI 10.1073/pnas.0236979100; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; GOLDFARB AN, 1994, LEUKEMIA LYMPHOMA, V12, P157, DOI 10.3109/10428199409059586; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1994, GENE THER, V1, P136; Ho CY, 1999, CURR BIOL, V9, P1131, DOI 10.1016/S0960-9822(99)80485-0; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jayaraman PS, 2000, LEUKEMIA RES, V24, P1023, DOI 10.1016/S0145-2126(00)00072-2; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Keng VW, 2000, BIOCHEM BIOPH RES CO, V276, P1155, DOI 10.1006/bbrc.2000.3548; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Liao W, 2000, DEVELOPMENT, V127, P4303; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Mack DL, 2002, IMMUNOLOGY, V107, P444, DOI 10.1046/j.1365-2567.2002.01523.x; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; SAWYERS CL, 2001, MOL BASIS BLOOD DIS; Schaefer LK, 2001, J BIOL CHEM, V276, P43074, DOI 10.1074/jbc.M102552200; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3	37	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6764	6773		10.1038/sj.onc.1206822	http://dx.doi.org/10.1038/sj.onc.1206822			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555989				2022-12-28	WOS:000185799300011
J	Krum, SA; Womack, JE; Lane, TF				Krum, SA; Womack, JE; Lane, TF			Bovine BRCA1 shows classic responses to genotoxic stress but low in vitro transcriptional activation activity	ONCOGENE			English	Article						breast and ovarian cancer; RNA polymerase II; phosphorylation; DNA repair; BRCT; GAL4UAS	MURINE BRCA1; EMBRYONIC LETHALITY; OVARIAN-CANCER; CELL-CYCLE; GENE; PHOSPHORYLATION; BREAST; EXPRESSION; KINASE; DOMAIN	Human BRCA1 has a genetically demonstrated role in DNA repair, and has been proposed to act as a transcriptional activator in a limited number of specialized settings. To gain insight into biologically conserved functional motifs, we isolated an ortholog of BRCA1 from cattle (Bos taurus). The predicted protein product shows 72.5% sequence identity with the human protein and conservation of amino acids involved in BRCA1 structure and function. Although the bovine C-terminus is truncated by seven amino acids as compared to human, bovine BRCA1 protein exhibited a similar cell cycle-regulated nuclear expression pattern. Expression was characteristically low and diffuse in the nucleus of G1/G0 cells, followed by increasing BRCA1-positive nuclear speckles in late S phase and G2/M phase cells. Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents. Consistent with evidence from studies of human BRCA1, bovine BRCA1 was shown to interact with RNA polymerase II in vivo, an activity that was mapped to the C-terminal domain (CTD) (bBRCA(1364-1849)). Interestingly, when tested in the GAL4 transcriptional activation assay, full-length bovine and human BRCA1 lacked any ability to act as transcriptional activators and the CTD of bovine BRCA1 had five-fold lower activity when compared to the more acidic human C-terminus. These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress. In addition, bovine BRCA1 binds the RNA polymerase II holoenzyme, but this interaction lacks significant ability to correctly orient or recruit RNA polymerase II for transcription in the classic GAL4 transcriptional activation system.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, 10833 LeConte Ave, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Texas A&M Univ, College Stn, TX 77843 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Texas A&M University System; Texas A&M University College Station; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lane, TF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, 10833 LeConte Ave, Los Angeles, CA 90095 USA.	tlane@mednet.ucla.edu	Krum, Susan A./D-7282-2013	Krum, Susan A./0000-0002-6414-6397; Lane, Timothy F./0000-0002-0210-970X	NIGMS NIH HHS [GM07185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADKISON LR, 1988, CYTOGENET CELL GENET, V47, P155, DOI 10.1159/000132536; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Band MR, 2000, GENOME RES, V10, P1359, DOI 10.1101/gr.145900; BARENDSE W, 1991, CYTOGENET CELL GENET, V58, P2123; Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935; Benuck ML, 1999, J BIOL CHEM, V274, P25419, DOI 10.1074/jbc.274.36.25419; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown MA, 1996, ONCOGENE, V12, P2507; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HORT Y, 1995, GENOMICS, V26, P77, DOI 10.1016/0888-7543(95)80085-Z; Hu YF, 2000, J BIOL CHEM, V275, P40910, DOI 10.1074/jbc.C000607200; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Lane TF, 2000, ONCOGENE, V19, P4085, DOI 10.1038/sj.onc.1203760; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mixon M, 2000, ONCOGENE, V19, P5237, DOI 10.1038/sj.onc.1203905; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; O'Brien KA, 1999, BIOCHEM BIOPH RES CO, V260, P658, DOI 10.1006/bbrc.1999.0892; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang YP, 1998, GENOME RES, V8, P731, DOI 10.1101/gr.8.7.731; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	58	12	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6032	6044		10.1038/sj.onc.1206515	http://dx.doi.org/10.1038/sj.onc.1206515			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955082				2022-12-28	WOS:000185137800012
J	Liang, Y; Mirnics, ZK; Yan, CH; Nylander, KD; Schor, NF				Liang, Y; Mirnics, ZK; Yan, CH; Nylander, KD; Schor, NF			Bcl-2 mediates induction of neural differentiation	ONCOGENE			English	Article						neural differentiation; TrkA; nerve growth factor; Bcl-2; DNA microarray	NERVE GROWTH-FACTOR; NEURONATIN MESSENGER-RNA; EXPRESSION; APOPTOSIS; RECEPTOR; DEATH; CELLS; POTENTIATION; PATHWAYS; SIGNALS	Bcl-2 is an antiapoptotic protein expressed in a wide variety of cell types. We have found that overexpression of bcl-2 in PC12 neural crest tumor cells leads to increased expression of neural differentiation-associated genes and decreased expression of proliferation-related genes. Culture growth rate decreases as well. Overexpression of bcl-2 also leads to increased expression of TrkA and increased phosphorylation of signal transductants in, albeit not specific for, the TrkA-MEK-ERK pathway. Blocking of NGF-mediated signaling through TrkA prevents Bcl-2-associated expression changes in differentiation-associated genes, raising the possibility that Bcl-2 mediates induction of neural differentiation through TrkA/NGF signaling.	Univ Pittsburgh, Div Child Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schor, NF (corresponding author), Univ Pittsburgh, Div Child Neurol, 3705 5th Ave, Pittsburgh, PA 15213 USA.			Schor, Nina/0000-0002-3817-7376; Korade, Zeljka/0000-0002-8690-4507				Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Cortazzo M, 1996, CANCER RES, V56, P1199; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Grellier P, 1998, CANCER RES, V58, P1670; Hamada S, 2001, NEUROSCI RES, V41, P207, DOI 10.1016/S0168-0102(01)00281-4; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; JOSEPH R, 1995, BRAIN RES, V690, P92, DOI 10.1016/0006-8993(95)00621-V; Joseph R, 1996, BRAIN RES, V738, P32, DOI 10.1016/0006-8993(96)00768-8; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Liang Y, 2002, MOL PHARMACOL, V61, P142, DOI 10.1124/mol.61.1.142; Mani S, 2001, MOL CELL NEUROSCI, V17, P54, DOI 10.1006/mcne.2000.0931; Middleton G, 1998, J NEUROSCI, V18, P3344; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; Rong YP, 2002, ACTA BIOCH BIOPH SIN, V34, P411; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Suzuki A, 1998, BRAIN RES, V801, P59, DOI 10.1016/S0006-8993(98)00523-X; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Yan CH, 2002, CANCER RES, V62, P4867; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	24	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5515	5518		10.1038/sj.onc.1206844	http://dx.doi.org/10.1038/sj.onc.1206844			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934111				2022-12-28	WOS:000184735000016
J	Mohan, S; Burk, RD				Mohan, S; Burk, RD			von Hippel-Lindau protein complex is regulated by cell density	ONCOGENE			English	Article						VHL; cell density; cell-cell contact	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR EXPRESSION; DEPENDENT REGULATION; SOMATIC MUTATIONS; RENAL-CARCINOMA; VHL; PRODUCT; BINDING; UBIQUITINATION; HEMANGIOBLASTOMAS	Mutations in the von Hippel-Lindau (VHL) gene are involved in the VHL family cancer syndrome and sporadic renal cell carcinoma. Previous studies indicated that VHL-induced growth arrest required high cell density and growth on extracellular matrix. In the present study, VHL protein (pVHL) levels were observed to be dramatically increased in cells grown to high cell density compared to cells grown at low cell density. Reverse transcription-polymerase chain reaction and Northern blot analysis indicated that VHL mRNA levels were equivalent in sparse and dense cells. The pVHL was rapidly degraded when cell-cell contact was disturbed by trypsinization or EDTA release. Treatment of cells with a proteasome inhibitor blocked the degradation of pVHL. Using a set of VHL deletions fused to GFP, a cell density-dependent region (CDDR) was identified and localized to the c-terminus of pVHL. In addition, other members of the VBC protein complex also showed a cell density-dependent regulation similar to pVHL. Cell density regulation of VHL did not require elongin binding and density-dependent regulation of other VBC components was not dependent on pVHL. In addition, hypoxia inducible factor-2alpha protein levels were elevated in sparse cells with low levels of pVHL and reduced or absent in confluent cells containing abundant VHL. These results indicate that pVHL levels and thus function are tightly regulated by cell-cell signaling. In addition, care must be taken when interpreting studies of VHL function and subcellular localization of cells grown at subconfluent conditions.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Burk, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Marion Bessin Liver Res Ctr, Ullmann Bldg,Rm 515,1300 Morris Pk Ave, Bronx, NY 10461 USA.	burk@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA085412] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSLER K, 1994, J CELL PHYSIOL, V159, P331, DOI 10.1002/jcp.1041590216; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kojima N, 2000, BIOCHEM BIOPH RES CO, V277, P152, DOI 10.1006/bbrc.2000.3635; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lindon C, 2001, DEV BIOL, V240, P574, DOI 10.1006/dbio.2001.0435; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Singh RK, 1996, CELL GROWTH DIFFER, V7, P397; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298	41	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5270	5280		10.1038/sj.onc.1206592	http://dx.doi.org/10.1038/sj.onc.1206592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917628				2022-12-28	WOS:000184734900006
J	Shai, R; Shi, T; Kremen, TJ; Horvath, S; Liau, LM; Cloughesy, TF; Mischel, PS; Nelson, SF				Shai, R; Shi, T; Kremen, TJ; Horvath, S; Liau, LM; Cloughesy, TF; Mischel, PS; Nelson, SF			Gene expression profiling identifies molecular subtypes of gliomas	ONCOGENE			English	Article						glioblastoma; gene expression profiling; microarray; glioma	DELTA-CATENIN; CLASSIFICATION; MICROARRAY; PREDICTION; PROTEIN; COMPLEX; TUMORS; RNA	Identification of distinct molecular subtypes is a critical challenge for cancer biology. In this study, we used Affymetrix high-density oligonucleotide arrays to identify the global gene expression signatures associated with gliomas of different types and grades. Here, we show that the global transcriptional profiles of gliomas of different types and grades are distinct from each other and from the normal brain. To determine whether our data could be used to uncover molecular subtypes without prior knowledge of pathologic type and grade, we performed K-means clustering analysis and found evidence for three clusters with the aid of multidimensional scaling plots. These clusters corresponded to glioblastomas, lower grade astrocytomas and oligodendrogliomas (P<0.00001). A predictor constructed from the 170 genes that are most differentially expressed between the subsets correctly identified the type and grade of all samples, indicating that a relatively small number of genes can be used to distinguish between these molecular subtypes. These results further define molecular subsets of gliomas which may potentially be used for patient stratification, and suggest potential targets for treatment.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biostat, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurosurg, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurol, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Cloughesy, Timothy Francis/AGV-1013-2022; Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114; Kremen, Thomas/0000-0003-1643-4869; , Tao/0000-0001-5489-2655; Liau, Linda/0000-0002-4053-0052	NCI NIH HHS [U01 CA88127] Funding Source: Medline; NINDS NIH HHS [K08NS43147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS043147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; De Luca A, 2003, CANCER RES, V63, P1430; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-84858-7_7; Hastie T, 2001, GENOME BIOL, V2; Her C, 2003, CANCER RES, V63, P865; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kaufmann L., 1990, FINDING GROUPS DATA; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lal A, 2002, CANCER RES, V62, P3335; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Ljubimova JY, 2001, CANCER RES, V61, P5601; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; McCusker D, 1997, GENOMICS, V45, P362, DOI 10.1006/geno.1997.4948; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Najib S, 2002, J CELL BIOCHEM, V86, P99, DOI 10.1002/jcb.10198; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rickman DS, 2001, CANCER RES, V61, P6885; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sallinen SL, 2000, CANCER RES, V60, P6617; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tanahashi N, 1998, BIOCHEM BIOPH RES CO, V243, P229, DOI 10.1006/bbrc.1997.7892; Venables W., 2013, MODERN APPL STAT S, V53, P86; Yano T, 2002, MOL ASPECTS MED, V23, P345, DOI 10.1016/S0098-2997(02)00011-0; Zhang W, 2002, BRAIN PATHOL, V12, P87	37	228	236	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4918	4923		10.1038/sj.onc.1206753	http://dx.doi.org/10.1038/sj.onc.1206753			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894235				2022-12-28	WOS:000184344600017
J	Rodrigues, S; Attoub, S; Nguyen, QD; Bruyneel, E; Rodrigue, CM; Westley, BR; May, FEB; Thim, L; Mareel, M; Emami, S; Gespach, C				Rodrigues, S; Attoub, S; Nguyen, QD; Bruyneel, E; Rodrigue, CM; Westley, BR; May, FEB; Thim, L; Mareel, M; Emami, S; Gespach, C			Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells	ONCOGENE			English	Article						HER-CD533; EGFRvIIl; Iressa; src; TXA2-R; bile acids	EPIDERMAL-GROWTH-FACTOR; PLATELET-ACTIVATING-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR INVASION; EPITHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER	Trefoil peptides (TFFs) are now considered as scatter factors, proinvasive and angiogenic agents acting through cyclooxygenase-2 (COX-2)- and thromboxane A2 receptor (TXA2-R)-dependent signaling pathways. As expression and activation levels of the epidermal growth factor receptor (EGFR) predict the metastatic potential of human colorectal cancers, the purpose of this study was to establish whether the EGF receptor tyrosine kinase (EGFR-TK) contributes to cellular invasion induced by TFFs in kidney and colonic cancer cells. Both the dominant negative form of the EGFR (HER-CD533) and the EGFR-TK inhibitor ZD1839 (Iressa) abrogated cellular invasion induced by pS2, spasmolytic polypeptide (SP) and the src oncogene, but not by ITF and the TXA2-R. Similarly, EGFR-TK inhibition by ZD1839 reversed the invasive phenotype promoted by the constitutively activated form of the EGFR (EGFRvIII) and the EGFR agonists transforming growth factor alpha (TGFalpha), amphiregulin and EGF. We also provide evidence that TFFs, EGFRvIII, and TGFalpha trigger common proinvasive pathways using the P13'-kinase and Rho/Rho- kinase cascades. These findings identify the EGFR-TK as a key signaling element for pS2- and SP-mediated cellular invasion. It is concluded that although pS2, SP and ITF belong to the same family of inflammation- and cancer-associated regulatory peptides, they do not control identical signaling networks.	Hop St Antoine, INSERM, U482, Signal Transduct & Cellular Funct Diabet & Digest, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Newcastle Univ, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Newcastle University - UK; Novo Nordisk	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, Signal Transduct & Cellular Funct Diabet & Digest, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; CHINERY R, 1995, FEBS LETT, V357, P50, DOI 10.1016/0014-5793(94)01297-E; CHINERY R, 1995, CLIN SCI, V88, P401, DOI 10.1042/cs0880401; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DANTE R, 1994, LAB INVEST, V71, P188; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; Hoffmann W, 2002, INT REV CYTOL, V213, P147; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jacoby RF, 1996, CANCER RES, V56, P710; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Lal A, 2002, CANCER RES, V62, P3335; Lalani EN, 1999, LAB INVEST, V79, P537; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Maurizi M, 1996, BRIT J CANCER, V74, P1253, DOI 10.1038/bjc.1996.525; May FEB, 1997, J PATHOL, V182, P404; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; Moasser MM, 2001, CANCER RES, V61, P7184; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; ROSAM AC, 1986, NATURE, V319, P54, DOI 10.1038/319054a0; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SAITO Y, 1997, BACTERIAL TOXINS TOO, P85; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Taupin D, 1996, LAB INVEST, V75, P25; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; THEISINGER B, 1991, EUR J CANCER, V27, P770, DOI 10.1016/0277-5379(91)90186-H; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tong WM, 1998, BRIT J CANCER, V77, P1792, DOI 10.1038/bjc.1998.298; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; VAN BT, 1995, NATURE, V376, P781; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang DG, 1998, J CELL PHYSIOL, V177, P387, DOI 10.1002/(SICI)1097-4652(199812)177:3<387::AID-JCP2>3.3.CO;2-C; Wheeler M, 2001, MOL CELL BIOL, V21, P6660, DOI 10.1128/MCB.21.19.6660-6667.2001; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Williams R, 1996, J CELL SCI, V109, P63; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; Xie H, 1998, J CELL SCI, V111, P615; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YANG LJ, 1993, J BIOL CHEM, V268, P3739; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yoon JH, 2002, GASTROENTEROLOGY, V122, P985, DOI 10.1053/gast.2002.32410; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	98	50	50	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4488	4497		10.1038/sj.onc.1206685	http://dx.doi.org/10.1038/sj.onc.1206685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881705				2022-12-28	WOS:000184054700004
J	Bierie, B; Nozawa, M; Renou, JP; Shillingford, JM; Morgan, F; Oka, T; Taketo, MM; Cardiff, RD; Miyoshi, K; Wagner, KU; Robinson, GW; Hennighausen, L				Bierie, B; Nozawa, M; Renou, JP; Shillingford, JM; Morgan, F; Oka, T; Taketo, MM; Cardiff, RD; Miyoshi, K; Wagner, KU; Robinson, GW; Hennighausen, L			Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation	ONCOGENE			English	Article						beta-catenin; cell identity; transdifferentiation; neoplasia; prostate	HAIR FOLLICLE MORPHOGENESIS; SIGNALING PATHWAYS; STEM-CELLS; DIFFERENTIATION; EXPRESSION; GENE; PREGNANCY; EPIDERMIS; DELETION; GROWTH	The Wnt/beta-catenin signaling pathway is critical for normal mammalian development, the specification of epidermal cells and neoplastic transformation of intestinal epithelium. However, precise molecular information regarding cell-specific responses to beta-catenin signaling has been limited. This question was addressed using a mouse model in which exon 3 of the beta-catenin gene was deleted in several cell types with loxP-mediated recombination utilizing a Cre transgene under control of the mouse mammary tumor virus-long terminal repeat (MMTV-LTR). The stabilization of beta-catenin in prostate epithelium resulted in hyperplasias and extensive transdifferentiation into epidermal-like structures, which expressed keratins 1 and 6, filaggrin, loricrin and involucrin. The cell-specific loss of NKCC1 protein and reduced nuclear Stat5a is further suggestive of a loss of prostate epithelial characteristics. In addition to the prostate, hyperplasias and squamous metaplasias were detected in epithelia of the epididymis, vas deferens, coagulating gland, preputial gland and salivary gland. However, and in contrast to a recent study, no lesions reminiscent of high-grade prostate intraepithelial neoplasia were detected. Since beta-catenin was activated in several cell types and impinged upon the viability of these mice, it was not possible to evaluate the cumulative effect over more than 3 months. To assess long-term consequences of beta-catenin activation, mutant and control prostate tissues were transplanted into the mammary fat pads of wild-type males. Notably, squamous metaplasias, intra-acinous hyperplasia and possible neoplastic transformation were observed after a total of 18 weeks of beta-catenin stimulation. This suggests that the transdifferentiation into squamous metaplasias is an early response of endoderm-derived cells to beta-catenin, and that the development of intra-acinous hyperplasias or neoplastic foci is a later event.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; INRA, Jouy En Josas, France; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Univ Tokushima, Dept Biochem, Sch Dent, Tokushima 7708504, Japan; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr, Omaha, NE USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Kyoto University; University of California System; University of California Davis; Tokushima University; University of Nebraska System; University of Nebraska Medical Center	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.	hennighausen@nih.gov	Wagner, Kay-Uwe/B-6044-2009; Robinson, Gertraud/I-2136-2012	Hennighausen, Lothar/0000-0001-8319-9841; Miyoshi, Keiko/0000-0001-6910-4172; Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTATTER T, 1985, J HISTOCHEM CYTOCHEM, V33, P415, DOI 10.1177/33.5.2580881; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; BARRESI G, 1984, VIRCHOWS ARCH A, V403, P59, DOI 10.1007/BF00689338; Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647; Brault V, 2001, DEVELOPMENT, V128, P1253; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; de Lau W, 2001, NAT GENET, V28, P3, DOI 10.1038/88233; DEOME KB, 1959, CANCER RES, V19, P515; Fischer DF, 1998, NUCLEIC ACIDS RES, V26, P5288, DOI 10.1093/nar/26.23.5288; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Li XF, 1999, J BIOL CHEM, V274, P27249, DOI 10.1074/jbc.274.38.27249; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nevalainen MT, 2000, LAB INVEST, V80, P993, DOI 10.1038/labinvest.3780105; Niemann C, 2002, DEVELOPMENT, V129, P95; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Polakis P, 2000, GENE DEV, V14, P1837; REESE JH, 1992, PROSTATE, V20, P73, DOI 10.1002/pros.2990200109; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P563, DOI 10.1210/me.16.3.563; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; Voeller HJ, 1998, CANCER RES, V58, P2520; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Widelitz RB, 2000, DEV BIOL, V219, P98, DOI 10.1006/dbio.1999.9580	53	108	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3875	3887		10.1038/sj.onc.1206426	http://dx.doi.org/10.1038/sj.onc.1206426			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813461				2022-12-28	WOS:000183612000007
J	Boya, P; Gonzalez-Polo, RA; Poncet, D; Andreau, K; Vieira, HLA; Roumier, T; Perfettini, JL; Kroemer, G				Boya, P; Gonzalez-Polo, RA; Poncet, D; Andreau, K; Vieira, HLA; Roumier, T; Perfettini, JL; Kroemer, G			Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine	ONCOGENE			English	Article						Bax; Bcl-2; cell death; lysosomes; mitochondria	CELL-DEATH; GLYCOPROTEIN COMPLEX; CYTOCHROME-C; BCL-2; BAX; P53; TRANSLOCATION; CHLOROQUINE; DYSFUNCTION; ACTIVATION	Hydroxychloroquine (HCQ) is a lysosomotropic amine with cytotoxic properties. Here, we show that HCQ induces signs of lysosomal membrane permeabilization (LMP), such as the decrease in the lysosomal pH gradient and the release of cathepsin B from the lysosomal lumen, followed by signs of apoptosis including caspase activation, phosphatidylserine exposure, and chromatin condensation with DNA loss. HCQ also induces mitochondrial membrane permeabilization (MMP), as indicated by the insertion of Bax into mitochondrial membranes, the conformational activation of Bax within mitochondria, the release of cytochrome c from mitochondria, and the loss of the mitochondrial transmembrane potential. To determine the molecular order among these events, we introduced inhibitors of LMP (bafilomycin A(1)), MMP (Bcl-X-L, wild-type Bcl-2, mitochondrion-targeted Bcl-2, or viral mitochondrial inhibitor of apoptosis from cytomegalovirus), and caspases (Z-VAD.fmk) into the system. Our data indicate that caspase-independent MMP is rate-limiting for LMP-mediated caspase activation. Mouse embryonic fibroblasts lacking the expression of both Bax and Bak are resistant against hydroxychloroquine-induced apoptosis. Such Bax(-/-) Bak(-/-) cells manifest normal LMP, yet fail to undergo MMP and subsequent cell death. The data reported herein indicate that LMP does not suffice to trigger caspase activation and that Bax/Bak-dependent MMP is a critical step of LMP-induced cell death.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Poncet, Delphine A/A-7190-2016; González-Polo, Rosa A./I-6076-2016; Kroemer, Guido/AAY-9859-2020; PERFETTINI, Jean-Luc/N-4699-2017; Vieira, Helena/AAZ-9562-2021; KROEMER, Guido/B-4263-2013; Boya, Patricia/P-8345-2019; Boya, Patricia/K-2911-2014	Poncet, Delphine A/0000-0003-0446-5262; González-Polo, Rosa A./0000-0002-0163-2953; PERFETTINI, Jean-Luc/0000-0002-2427-2604; KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X; Andreau, Karine/0000-0002-9773-0733; Vieira, Helena/0000-0001-9415-3742				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; BOYA P, IN PRESS; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai JH, 2001, J IMMUNOL, V166, P6914, DOI 10.4049/jimmunol.166.11.6914; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; Munafo DB, 2001, J CELL SCI, V114, P3619; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	52	310	317	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3927	3936		10.1038/sj.onc.1206622	http://dx.doi.org/10.1038/sj.onc.1206622			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813466				2022-12-28	WOS:000183612000012
J	Kim, TY; Jong, HS; Song, SH; Dimtchev, A; Jeong, SJ; Lee, JW; Kim, TY; Kim, NK; Jung, M; Bang, YJ				Kim, TY; Jong, HS; Song, SH; Dimtchev, A; Jeong, SJ; Lee, JW; Kim, TY; Kim, NK; Jung, M; Bang, YJ			Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells	ONCOGENE			English	Article						DLC-1; methylation; histone deacetylation; gastric cancer	HISTONE DEACETYLASE INHIBITOR; DNA METHYLATION; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; RECEPTOR GENE; SP1 SITES; ACTIVATION; CHROMATIN; PROMOTER	DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma. However, little is known about the genetic status and the expression of this gene in gastric cancer. In this study, Northern and Southern analysis showed that seven of nine human gastric cancer cell lines did not express DLC-1 mRNA, but contained the DLC-1 gene. To identify the mechanism of the loss of DLC-1 mRNA expression in these cell lines, we investigated the methylation status of DLC-1 gene by using methylation-specific PCR (MSP) and Southern blot, and found that five of seven DLC-1 nonexpressing gastric cancer cell lines were methylated in the DLC-1 CpG island. Treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) induced DLC-1 mRNA expression in the gastric cancer cell lines that have the methylated alleles. Studies using SNU-601 cell line with methylated DLC-1 alleles revealed that nearly all CpG sites within DLC-1 CpG island were methylated, and that the in vitro methylation of the DLC-1 promoter region is enough to repress DLC-1 mRNA expression, regardless of the presence of transcription factors capable of inducing this gene. In all, 29 of 97 (30%) primary gastric cancers were also shown to be methylated, demonstrating that methylation of the DLC-1 CpG island is not uncommon in gastric cancer. In addition, we demonstrated that DLC-1 mRNA expression was induced, and an increase in the level of acetylated H3 and H4 was detected by the treatment with trichostatin A (TSA) in two DLC-1 nonexpressing cell lines that have the unmethylated alleles. Taken together, the results of our study suggest that the transcriptional silencing of DLC-1, by epigenetic mechanism, may be involved in gastric carcinogenesis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Canc Epigenet, Canc Res Inst, Seoul 110744, South Korea; Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA	Seoul National University (SNU); Seoul National University (SNU); Georgetown University	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Lee, Jung Weon/F-9149-2012; Bang, Yung Jue/J-2759-2012; Kim, Tae-You/J-2750-2012; Lee, Jung Weon/AAC-1146-2020	Bang, Yung Jue/0000-0001-6000-4597; Lee, Jung Weon/0000-0003-2722-8200; KIM, TAI YOUNG/0000-0001-8086-2476				Baffa R, 2000, CLIN CANCER RES, V6, P1372; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; EMI M, 1992, CANCER RES, V52, P5368; Euer N, 2002, ANTICANCER RES, V22, P733; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jong HS, 1999, CANCER, V86, P559, DOI 10.1002/(SICI)1097-0142(19990815)86:4<559::AID-CNCR3>3.0.CO;2-4; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493; Kurimoto F, 2001, INT J MOL MED, V8, P89; MORII N, 1993, J BIOL CHEM, V268, P27160; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng IOL, 2000, CANCER RES, V60, P6581; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; Sondak VK, 2001, CANCER GENET CYTOGEN, V131, P97, DOI 10.1016/S0165-4608(01)00539-8; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Stirzaker C, 1997, CANCER RES, V57, P2229; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tsutsumi S, 2002, CANCER RES, V62, P4484; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wistuba II, 1999, CANCER RES, V59, P1973; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	48	97	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3943	3951		10.1038/sj.onc.1206573	http://dx.doi.org/10.1038/sj.onc.1206573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813468				2022-12-28	WOS:000183612000014
J	Levine, JJ; Stimson-Crider, KM; Vertino, PM				Levine, JJ; Stimson-Crider, KM; Vertino, PM			Effects of methylation on expression of TMS1/ASC in human breast cancer cells	ONCOGENE			English	Article						DNA methylation; methyltransferase; apoptosis; ASC; gene regulation; transcription	RECRUITMENT DOMAIN PROTEIN; DNA METHYLATION; CPG ISLAND; GENE; TRANSCRIPTION; REPRESSION; PROMOTER; HYPERMETHYLATION; LEUKEMIA; COMPLEX	Gene silencing associated with aberrant methylation of promoter region CpG islands is one mechanism in which tumor suppressor genes are inactivated in human cancers. Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1) (also called ASC), which is aberrantly methylated and silenced in human breast cancers. To further investigate the mechanism of TMS1 silencing, we defined the transcription initiation site and detailed the DNA methylation pattern of the TMS1 CpG island in normal breast epithelial cells, breast cancer cell lines, and primary tumors. We find that in normal cells, the TMS1 CpG island lies within a 1.2kb unmethylated domain, the 5' boundary of which is in close proximity to the transcription initiation site. In breast cancer cell lines, this boundary appeared to be unstable in that methylation tended to accumulate in the 5' end of the CpG island relative to normal epithelial cells. In contrast, the 3' methylation boundary remained intact. Gene silencing was not correlated with the methylation of specific CpG sites nor the inability to transactivate the TMS1 promoter, but was correlated with the percentage of alleles in the population exhibiting dense methylation across the entire CpG island. Using 5-aza-deoxycytidine to reactivate TMS1 in methylated and silent cell lines, and a cassette methylation strategy to determine the impact of methylation on different parts of the promoter, we find that demethylation of a small region immediately surrounding the transcription start site is critical to TMS1 expression. Our data support the idea that gene silencing and dense methylation are tightly coupled events that affect individual chromosomal copies of TMS1 in an all-or-none manner. The transition to this stably repressed state may be facilitated by spreading of methylation into the proximal promoter and direct effects of methylation on TMS1 transcription.	Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Vertino, PM (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365-B Clifton Rd NE,Room B5119, Atlanta, GA 30322 USA.	pvertin@emory.edu		Crider, Krista/0000-0001-6997-5955	NCI NIH HHS [1R01 CA77337] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conway KE, 2000, CANCER RES, V60, P6236; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Dammann R, 2001, CANCER RES, V61, P3105; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Han L, 2001, MOL CELL BIOL, V21, P3416, DOI 10.1128/MCB.21.10.3416-3424.2001; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kass Stefan U., 1993, Biochemical Society Transactions, V21, p9S; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kinoshita H, 2000, CANCER RES, V60, P3623; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Mann JR, 2000, CRIT REV EUKAR GENE, V10, P241; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; McConnell BB, 2000, CANCER RES, V60, P6243; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WANG L, 2002, J BIOL CHEM, V17, P17; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	40	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3475	3488		10.1038/sj.onc.1206430	http://dx.doi.org/10.1038/sj.onc.1206430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776200				2022-12-28	WOS:000183128500015
J	Joerges, C; Kuntze, I; Herzinge, T				Joerges, C; Kuntze, I; Herzinge, T			Induction of a caffeine-sensitive S-phase cell cycle checkpoint by psoralen plus ultraviolet A radiation	ONCOGENE			English	Article						cell cycle; keratinocytes; psoralens; replication checkpoint; ultraviolet radiation	DNA-DAMAGE CHECKPOINT; INTERSTRAND CROSS-LINKS; IRRADIATED HELA-CELLS; ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASES; G(1)/S TRANSITION; MAMMALIAN-CELLS; G(2) CHECKPOINT; PROTEIN-KINASE	Induction of interstrand crosslinks (ICLs) in chromosomal DNA is considered a major reason for the antiproliferative effect of psoralen plus ultraviolet A ( PUVA). It is unclear as to whether PUVA-induced cell cycle arrest is caused by ICLs mechanically stalling replication forks or by triggering cell cycle checkpoints. Cell cycle checkpoints serve to maintain genomic stability by halting cell cycle progression to prevent replication of damaged DNA templates or segregation of broken chromosomes. Here, we show that HaCaT keratinocytes treated with PUVA arrest with S-phase DNA content. Cells that had completed DNA replication were not perturbed by PUVA and passed through mitosis. Cells treated with PUVA during G1-phase continued traversing G1 until arresting in early S-phase. PUVA induced rapid phosphorylation of the Chk1 checkpoint kinase at Ser345 and a concomitant decrease in Cdc25A levels. Chk1 phosphorylation, decrease of Cdc25 A levels and S-phase arrest were abolished by caffeine, demonstrating that active checkpoint signaling rather than passive mechanical blockage by ICLs causes the PUVA-induced replication arrest. Overexpression of Cdc25A only partially overrode the S-phase arrest, suggesting that additional signaling events implement PUVA-induced S-phase arrest.	Univ Munich, Klin & Poliklin Dermatol & Allergol, D-80337 Munich, Germany	University of Munich	Herzinge, T (corresponding author), Univ Munich, Klin & Poliklin Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany.	Thomas.Herzinger@lrz.uni-muenchen.de						Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; COHEN SR, 1981, J INVEST DERMATOL, V76, P409, DOI 10.1111/1523-1747.ep12520956; DEANDRADE HHR, 1989, MOL GEN GENET, V217, P419; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Gaspprro F. P., 1988, PSORALEN DNA PHOTOBI, V1, P5; GUNTHER EJ, 1995, CANCER RES, V55, P1283; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HAMLIN JL, 1992, BIOESSAYS, V14, P651, DOI 10.1002/bies.950141002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Liu QH, 2000, GENE DEV, V14, P1448; LJUNGGREN B, 1980, J INVEST DERMATOL, V74, P59, DOI 10.1111/1523-1747.ep12514621; Luftl M, 1998, J INVEST DERMATOL, V111, P399, DOI 10.1046/j.1523-1747.1998.00316.x; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MENIEL V, 1995, MUTAT RES-FUND MOL M, V329, P121, DOI 10.1016/0027-5107(95)00023-C; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; VARGA JM, 1982, CANCER RES, V42, P2223; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	58	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6119	6128		10.1038/sj.onc.1206613	http://dx.doi.org/10.1038/sj.onc.1206613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679850				2022-12-28	WOS:000185506200001
J	Kalinina, OA; Kalinin, SA; Polack, EW; Mikaelian, I; Panda, S; Costa, RH; Adami, GR				Kalinina, OA; Kalinin, SA; Polack, EW; Mikaelian, I; Panda, S; Costa, RH; Adami, GR			Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions	ONCOGENE			English	Article						FoxM1B; hepatocytes; cell proliferation; diethylnitrosamine; adenoma; hepatocelluar carcinoma	TRANSFORMING-GROWTH-FACTOR; TRANSCRIPTION FACTOR TRIDENT; LIVER-REGENERATION; FACTOR-ALPHA; S-PHASE; C-MYC; CARBON-TETRACHLORIDE; TUMOR PROGRESSION; HEPATOCYTE ENTRY; GENE-EXPRESSION	Increased hepatic expression of the Forkhead transcription factor FoxM1B in adult mice accelerates hepatocyte proliferation after partial hepatectomy, while in hepatocytes in intact liver the transgenic (Tg) protein is inactive and has no effect on proliferation. To investigate the influence of FoxM1B on liver tumor formation, we examined the effect of sustained enrichment of FoxM1B in the hepatocytes of mice treated with a diethylnitrosamine (DEN)/phenobarbital tumor induction protocol. Tg enrichment of FoxM1B in hepatocytes did not increase the proliferation rate in normal liver tissue even when the protein was localized to the nucleus. However, it did cause an increase in the proliferation rate and size of preneoplastic and early neoplastic lesions, although having no effects on the total numbers of these lesions. As tumors progressed to hepatocellular carcinomas, the additional Tg FoxM1B protein had no effect on cell proliferation, and there was no increase in tumor burden compared to wild-type animals. This suggests that the artificial enrichment of FoxM1B in the liver, which has been suggested as a gene therapy protocol for liver dysfunction with aging, may not be tumorigenic in that organ.	Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA; Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Coll Vet Med, Vet Diagnost Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Dept Vet Pathobiol, Urbana, IL 61802 USA; Jackson Lab, Dept Pathol, Bar Harbor, ME 04609 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Jackson Laboratory; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Adami, GR (corresponding author), Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, 801 S Paulina St,M-C 838, Chicago, IL 60612 USA.		Kalinin, Sergey/E-7741-2013		NATIONAL CANCER INSTITUTE [R01CA085529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85529-05] Funding Source: Medline; NIDDK NIH HHS [R01 DK 54687-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; Birner P, 2001, AM J PATHOL, V158, P1991, DOI 10.1016/S0002-9440(10)64670-6; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCHER NL, 1997, LIVER REGENERATION C; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Cowen T, 2001, TRENDS GENET, V17, P109, DOI 10.1016/S0168-9525(00)02214-9; Deane NG, 2001, CANCER RES, V61, P5389; DRAGANI TA, 1986, CANCER LETT, V31, P171, DOI 10.1016/0304-3835(86)90008-X; Factor VM, 1997, HEPATOLOGY, V26, P1434; Fausto N, 1993, Prog Liver Dis, V11, P115; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; FRY M, 1984, J CELL PHYSIOL, V118, P225, DOI 10.1002/jcp.1041180302; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Isenberg JS, 1997, CARCINOGENESIS, V18, P1511, DOI 10.1093/carcin/18.8.1511; Ito T, 1998, HISTOCHEM CELL BIOL, V110, P589, DOI 10.1007/s004180050321; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kaestner KH, 2000, GENE DEV, V14, P142; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; KOIKE K, 1995, J GEN VIROL, V76, P3031, DOI 10.1099/0022-1317-76-12-3031; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; LEE GH, 1992, CANCER RES, V52, P5162; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MILLS JJ, 1997, LIVER REGENERATION C; Okabe H, 2001, CANCER RES, V61, P2129; PERAINO C, 1981, CARCINOGENESIS, V2, P463, DOI 10.1093/carcin/2.5.463; Pierce RH, 2002, AM J PATHOL, V160, P1555, DOI 10.1016/S0002-9440(10)61101-7; Pitot HC, 1996, J CANCER RES CLIN, V122, P257, DOI 10.1007/BF01261401; Pitot HC, 2001, LANCET, V358, P859, DOI 10.1016/S0140-6736(01)06038-X; PUGH TD, 1983, CANCER RES, V43, P1261; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1997, LIVER REGENERATION C, P257; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SANTONIRUGIU E, 1998, LIVER GROWTH REPAIR, P100; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SELL S, 1991, CANCER RES, V51, P1278; TAMANO S, 1994, CARCINOGENESIS, V15, P1791, DOI 10.1093/carcin/15.9.1791; TAUB R, 1997, LIVER REGENERATION C; Teh MT, 2002, CANCER RES, V62, P4773; Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; WEBBER EM, 1994, AM J PATHOL, V145, P398; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	60	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6266	6276		10.1038/sj.onc.1206640	http://dx.doi.org/10.1038/sj.onc.1206640			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679865				2022-12-28	WOS:000185506200016
J	Wang, SW; Yan-Neale, Y; Fischer, D; Zeremski, M; Cai, R; Zhu, J; Asselbergs, F; Hampton, G; Cohen, D				Wang, SW; Yan-Neale, Y; Fischer, D; Zeremski, M; Cai, R; Zhu, J; Asselbergs, F; Hampton, G; Cohen, D			Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line	ONCOGENE			English	Article						HDAC1; HDAC inhibitor; RhoB; expression profile; transcription regulation	GROWTH-FACTOR-BETA; BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION; GERANYLGERANYLATED RHOB; DNA-DAMAGE; GENE RHOB; NF-Y; CANCER; TUMOR	The dynamic balance between histone acetylation and deacetylation plays a significant role in the regulation of gene transcription. Much of our current understanding of this transcriptional control comes from the use of HDAC inhibitors such as trapoxin A (TPX), which leads to hyperacetylated histone, alters local chromatin architecture and transcription and results in tumor cell death. In this study, we treated tumor cells with TPX and HDAC1 antisense oligonucleotides, and analysed the transcriptional consequences of HDAC inhibition. Among other genes, the small GTPase RhoB was found to be significantly upregulated by TPX and repressed by HDAC1. The induction of RhoB by HDAC inhibition was mediated by an inverted CCAAT box in the RhoB promoter. Interestingly, measurement of RhoB transcription in similar to130 tumor-derived cell lines revealed low expression in almost all of these samples, in contrast to RhoA and RhoC. Accumulating evidence indicates that the small GTPase Rho proteins are involved in a variety of important processes in cancer, including cell transformation, survival, invasion, metastasis and angiogenesis. This study for the first time demonstrates a link between HDAC inhibition and RhoB expression and provides an important insight into the mechanisms of HDAC-mediated transcriptional control and the potential therapeutic benefit of HDAC inhibition.	Novartis Pharmaceut Corp, Dept Funct Genom, Summit, NJ 07901 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Novartis; Novartis	Cohen, D (corresponding author), Novartis Pharmaceut Corp, Dept Funct Genom, Summit, NJ 07901 USA.		Asselbergs, Folkert W./ABD-6752-2021	Asselbergs, Folkert W./0000-0002-1692-8669				Adnane J, 2002, CLIN CANCER RES, V8, P2225; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BUTLER LM, 2002, P NATL ACAD SCI USA, V20, P20; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Du W, 1999, CANCER RES, V59, P5492; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jones PL, 2001, J BIOL CHEM, V276, P8807, DOI 10.1074/jbc.C000879200; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu L, 1999, MOL CELL BIOL, V19, P1202; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; van Golen KL, 2000, CANCER RES, V60, P5832; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Welsh JB, 2001, CANCER RES, V61, P5974; Yoshioka K, 1999, CANCER RES, V59, P2004; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	45	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6204	6213		10.1038/sj.onc.1206653	http://dx.doi.org/10.1038/sj.onc.1206653			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679859				2022-12-28	WOS:000185506200010
J	McJilton, MA; Van Sikes, C; Wescott, GG; Wu, DQ; Foreman, TL; Gregory, CW; Weidner, DA; Ford, OH; Lasater, AM; Mohler, JL; Terrian, DM				McJilton, MA; Van Sikes, C; Wescott, GG; Wu, DQ; Foreman, TL; Gregory, CW; Weidner, DA; Ford, OH; Lasater, AM; Mohler, JL; Terrian, DM			Protein kinase C epsilon interacts with Bax and promotes survival of human prostate cancer cells	ONCOGENE			English	Article						apoptosis; LNCaP; CWR22; recurrent prostate cancer; phorbol ester; Bcl-2	ESTER-INDUCED APOPTOSIS; N-TERMINAL KINASE; PHORBOL ESTER; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; SIGNALING COMPLEXES; EPITHELIAL-CELLS; LINE LNCAP; ANDROGEN; ACTIVATION; EXPRESSION	Prostatic glandular epithelial cells express protein kinase Cepsilon (PKCepsilon), an oncoprotein that coordinately disrupts the reactivation of the tumor suppressor Rb, derepressess transcriptional elongation of the c-myc oncogene, and propagates survival signals in LNCaP cells. Since the activation of such a program may contribute to the progression of human prostate cancer, a proteomic analysis was performed to gain a more global perspective on the signaling network that PKCepsilon might be capable of engaging in prostate cancer cells. Using CWR22 xenografts, we identified at least 18 different structural, signaling, and stress-related proteins that associated with PKCepsilon, including an interaction with the proapoptotic protein Bax that was novel to recurrent CWR22 tumors. An investigation into the biological significance of the PKCepsilon association with Bax provided the first evidence of an inverse relationship between endogenous levels of PKCepsilon and susceptibility of prostate cancer cells to the apoptotic effects of phorbol esters. Western blot and antisense experiments demonstrated that CWR-R1 cells expressed moderate levels of PKCepsilon and relied on this protein to survive in the presence of phorbol esters, while the apoptosis normally induced by phorbol esters in PKCepsilon-deficient LNCaP cells was dependent on the presence of Bax. Forced expression of PKCepsilon in LNCaP cells was sufficient to confer a significant resistance to phorbol esters and this resistance was associated with an inhibition of phorbol ester-induced Bax conformational rearrangements that are important for Bax oligomerization, mitochondrial integration, and cytochrome c release. Considered in their entirety, our data suggest that an association of PKCepsilon with Bax may neutralize apoptotic signals propagated through a mitochondrial death-signaling pathway.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA; Univ N Carolina, Dept Lab Med & Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Div Urol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Terrian, DM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 600 Moye Blvd, Greenville, NC 27858 USA.			Weidner, Douglas/0000-0003-1397-1757	NCI NIH HHS [P01 CA77739, R01 CA256058] Funding Source: Medline; NICHD NIH HHS [U54 HD35041] Funding Source: Medline; NIEHS NIH HHS [ES8397] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Engedal N, 2001, PROSTATE, V46, P289, DOI 10.1002/1097-0045(20010301)46:4<289::AID-PROS1035>3.0.CO;2-K; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gao WH, 2001, J CELL SCI, V114, P2855; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gregory CW, 1999, ENDOCRINOLOGY, V140, P2372, DOI 10.1210/en.140.5.2372; Gregory CW, 2001, J ANDROL, V22, P537; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Montalvo L, 2002, LIFE SCI, V71, P2257, DOI 10.1016/S0024-3205(02)02016-7; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Qiao LX, 2001, BIOORG MED CHEM LETT, V11, P955, DOI 10.1016/S0960-894X(01)00097-X; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Song CX, 2002, AM J PHYSIOL-HEART C, V282, pH1166, DOI 10.1152/ajpheart.00830.2001; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Wu DQ, 2002, CANCER RES, V62, P2423; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zhao X, 2001, UROLOGY, V57, P860, DOI 10.1016/S0090-4295(01)00946-3; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	46	96	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7958	7968		10.1038/sj.onc.1206795	http://dx.doi.org/10.1038/sj.onc.1206795			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970744				2022-12-28	WOS:000185388200011
J	Nishizawa, M; Fu, SL; Kataoka, K; Vogt, PK				Nishizawa, M; Fu, SL; Kataoka, K; Vogt, PK			Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation	ONCOGENE			English	Article						regulatable transcription; chimeric protein; dimerization	AP-1 TRANSCRIPTION FACTORS; DNA-BINDING DOMAIN; V-JUN; C-JUN; GROWTH-FACTOR; ONCOGENIC TRANSFORMATION; EMBRYO FIBROBLASTS; ESTROGEN-RECEPTOR; DIRECT TARGET; IN-VIVO	We have constructed artificial AP-1 proteins containing elements derived from yeast GCN4 and from the herpes simplex virus activator VP16. These proteins can only homodimerize but do not heterodimerize, and lacking significant homology to Jun outside the DNA-binding domain, they are largely unaffected by proteins that modulate Jun. Constructs in which the transactivation domain of GCN4 is replaced by that of VP16 induce oncogenic transformation in cultures of chicken embryo fibroblasts. The availability of transforming VP16-GCN4 fusion proteins permits an evaluation of downstream target genes, based on the hypothesis that transformation-relevant targets should be common between Jun and the artificial AP-1 proteins. In a pilot study, we examined the expression of several Jun target genes in cells transformed by the VP16-GCN4 fusions and found that some of the Jun targets are not upregulated by the GCN4-derived transforming construct, suggesting that their upregulation in Jun-transformed cells is not essential for cell transformation. We have further constructed a regulatable GCN4-VP16 protein that will permit a kinetic characterization of target gene responses and will facilitate discrimination between direct and indirect targets.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Scripps Research Institute; Tokyo Institute of Technology	Vogt, PK (corresponding author), Natl Yang Ming Univ, Inst Tradit Med, 155 Sec 2,Li Nong St, Taipei 112, Taiwan.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R01CA079616, R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA79616, CA78230, CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1994, ONCOGENE, V9, P791; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	51	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7931	7941		10.1038/sj.onc.1206527	http://dx.doi.org/10.1038/sj.onc.1206527			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970741				2022-12-28	WOS:000185388200008
J	Stampfer, MR; Garbe, J; Nijjar, T; Wigington, D; Swisshelm, K; Yaswen, P				Stampfer, MR; Garbe, J; Nijjar, T; Wigington, D; Swisshelm, K; Yaswen, P			Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines	ONCOGENE			English	Article						immortal transformation; telomerase; telomeres; TGF beta; genomic instability; conversion; p53	HUMAN BREAST-CANCER; MUTANT P53-INDUCED IMMORTALIZATION; HUMAN-PAPILLOMAVIRUS TYPE-16; CARCINOMA IN-SITU; HUMAN FIBROBLASTS; TUMOR-CELLS; EXPRESSION; GENE; TRANSFORMATION; PROTEIN	We describe novel effects of p53 loss on immortal transformation, based upon comparison of immortally transformed human mammary epithelial cell (HMEC) lines lacking functional p53 with closely related p53(+) lines. Our previous studies of p53(+) immortal HMEC lines indicated that overcoming the stringent replicative senescence step associated with critically short telomeres (agonescence), produced indefinite lifespan lines that maintained growth without immediately expressing telomerase activity. These telomerase(-) 'conditionally immortal' HMEC underwent an additional step, termed conversion, to become fully immortal telomerase( +) lines with uniform good growth. The very gradual conversion process was associated with slow heterogeneous growth and high expression of the cyclin-dependent kinase inhibitor p57(Kip2). We now show that p53 suppresses telomerase activity and is necessary for the p57 expression in early passage p53(+) conditionally immortal HMEC lines, and that p53(-/-) lines exhibit telomerase reactivation and attain full immortality much more rapidly. A p53-inhibiting genetic suppressor element introduced into early passages of a conditionally immortal telomerase(-) p53(+) HMEC line led to rapid induction of hTERT mRNA, expression of telomerase activity, loss of p57 expression, and quick attainment of uniform good growth. These studies indicate that derangements in p53 function may impact malignant progression through direct effects on the conversion process, a potentially rate-limiting step in HMEC acquisition of uniform unlimited growth potential. These studies also provide evidence that the function of p53 in suppression of telomerase activity is separable from its cell cycle checkpoint function.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle	Stampfer, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 70A1118, Berkeley, CA 94720 USA.				NCI NIH HHS [CA24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bednarek AK, 1997, CLIN CANCER RES, V3, P11; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Bunz F, 2002, CANCER RES, V62, P1129; Cao YA, 1997, CANCER RES, V57, P5584; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; CLARK R, 1988, CANCER RES, V48, P4689; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Done SJ, 1998, CANCER RES, V58, P785; FINER MH, 1994, BLOOD, V83, P43; Gao QS, 1996, CANCER RES, V56, P3129; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gollahon LS, 1996, ONCOGENE, V12, P715; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HERMAN JG, 1995, CANCER RES, V55, P4525; Iacopetta B, 1998, CLIN CANCER RES, V4, P1597; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nijjar T, 1999, CANCER RES, V59, P5112; Nonet GH, 2001, CANCER RES, V61, P1250; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shpitz B, 1999, BREAST CANCER RES TR, V58, P65, DOI 10.1023/A:1006394209922; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 2001, ADV CELL AGING GERON, V8, P103; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890	57	55	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5238	5251		10.1038/sj.onc.1206667	http://dx.doi.org/10.1038/sj.onc.1206667			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917625				2022-12-28	WOS:000184734900003
J	Shao, GZ; Zhou, RL; Zhang, QY; Zhang, Y; Liu, JJ; Rui, JA; Wei, X; Ye, DX				Shao, GZ; Zhou, RL; Zhang, QY; Zhang, Y; Liu, JJ; Rui, JA; Wei, X; Ye, DX			Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma	ONCOGENE			English	Article						LAPTM4B; hepatocellular carcinoma; differential expression; promoter analysis	HEPATITIS-B-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; MESSENGER-RNA OVEREXPRESSION; CYCLIN D1 OVEREXPRESSION; MEMBRANE-PROTEIN; C-MET; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; P53 MUTATION; CELL-LINES	Lysosomal-associated protein transmembrane-4 beta (LAPTM4B), a novel gene upregulated in hepatocellular carcinoma (HCC), was cloned using fluorescence differential display, RACE, and RT-PCR. It contains seven exons and encodes a 35-kDa protein with four putative transmembrane regions. Both the N- and C-termini of the protein are proline-rich, and may serve as potential ligands for the SH3 domain. Immunohistochemical analysis localized the protein predominantly to intracellular membranes. Northern blot showed that the LAPTM4B mRNAs were remarkably upregulated in HCC (87.3%) and correlated inversely with differentiation status. LAPTM4B was also overexpressed in many HCC-derived cell tines. It was also highly expressed in fetal livers and certain adult normal tissues including the heart, skeletal muscle, testis, and ovary. Promoter function assays showed a distinct difference in the gene's activities between BEL7402 and HLE cell lines, suggesting that the transcription factors responsible for regulation of the gene in the two cell lines are different, and that possible negative regulatory cis-elements may exist upstream of the promoter region. It was demonstrated that the N-terminus of LAPTM4B was essential for survival of the cells. Cells harboring the full-length LAPTM4B cDNA expression clone displayed a slightly increased efficiency in colony formation. These results suggest that LAPTM4B is a potential protooncogene, whose overexpression is involved in carcinogenesis and progression of HCC. In normal cells, it may also play important roles such as regulation of cell proliferation and survival.	Peking Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Beijing 100083, Peoples R China; Beijing Union Med Coll Hosp, Dept Basic Surg, Beijing 100032, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Zhou, RL (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	rlzhou@mail.bjmu.edu.cn						Adra CN, 1996, GENOMICS, V35, P328, DOI 10.1006/geno.1996.0364; Anthony PP, 2001, HISTOPATHOLOGY, V39, P109, DOI 10.1046/j.1365-2559.2001.01188.x; Arii S, 1996, HEPATOLOGY, V24, P316; BEGUM NA, 1995, HEPATOLOGY, V22, P1447, DOI 10.1002/hep.1840220518; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Cabrita MA, 1999, CANCER RES, V59, P4890; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; Deane NG, 2001, CANCER RES, V61, P5389; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Fujimoto Y, 1998, J GASTROENTEROL, V33, P368, DOI 10.1007/s005350050098; GRAZIANO P, 2001, GENE, V276, P73; GRIGIONI WF, 1995, HEPATOLOGY, V21, P1543, DOI 10.1016/0270-9139(95)90457-3; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; HE J, 2003, IN PRESS J PEKING U, V35; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 2002, BIOCHEM J, V365, P721, DOI 10.1042/BJ20020205; Hogue DL, 1999, J BIOL CHEM, V274, P12877, DOI 10.1074/jbc.274.18.12877; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; KENMOCHI K, 1987, LIVER, V7, P18; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4; Liu J.J., 2000, J BEIJING MED U, V32, P411; Liu JJ, 2000, CHINESE MED J-PEKING, V113, P881; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Masumoto N, 2002, GENE, V291, P169, DOI 10.1016/S0378-1119(02)00593-0; Nakakura EK, 2000, ONCOLOGY-NY, V14, P1085; Ozaki I, 2000, CANCER RES, V60, P6519; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; Pineau P, 2000, J HEPATOL, V33, P152, DOI 10.1016/S0168-8278(00)80172-5; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Radford KJ, 1997, J IMMUNOL, V158, P3353; TANG ZY, 1995, CHINESE MED J-PEKING, V108, P568; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wu BY, 1996, CHINESE MED J-PEKING, V109, P922; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; YEH FS, 1989, CANCER RES, V49, P2506; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652	49	137	154	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5060	5069		10.1038/sj.onc.1206832	http://dx.doi.org/10.1038/sj.onc.1206832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902989				2022-12-28	WOS:000184578900014
J	Mulholland, NM; Soeth, E; Smith, CL				Mulholland, NM; Soeth, E; Smith, CL			Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation	ONCOGENE			English	Article						histone deacetylase; transcription; chromatin; mouse mammary tumor virus	TUMOR VIRUS PROMOTER; LONG TERMINAL REPEAT; GLUCOCORTICOID-RECEPTOR; DEACETYLASE INHIBITORS; GENE-EXPRESSION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; SODIUM-BUTYRATE; N-COR; ACTIVATION	Increased histone acetylation has been associated with activated gene transcription and decreased acetylation with repression. However, there is a growing number of genes known, which are downregulated by histone deacetylase (HDAC) inhibitors through unknown mechanisms. This study examines the mechanism by which the mouse mammary tumor virus (MMTV) promoter is repressed by the HDAC inhibitor, trichostatin A (TSA). We find that this repression is transcriptional in nature and that it occurs in the presence and absence of glucocorticoids. TSA decreases MMTV transcription at a rapid rate, reaching maximum in 30-60 min. In contrast with previous reports, the repression does not correlate with an inhibition of glucocorticoid-induced nuclease hypersensitivity or NF1-binding at the MMTV promoter. Surprisingly, TSA does not induce sizable increases in histone acetylation at the MMTV promoter nor does it inhibit histone deacetylation, which accompanies deactivation of the glucocorticoid-activated MMTV promoter. Repression of MMTV transcription by TSA does not depend on the chromatin organization of the promoter because a transiently transfected MMTV promoter construct with a disorganized nucleoprotein structure was also repressed by TSA treatment. Mutational analysis of the MMTV promoter indicates that repression by TSA is mediated through the TATA box region. These results suggest a novel mechanism that involves acetylation of nonhistone proteins necessary for basal transcription.	NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; George Washington Univ, Dept Genet, Washington, DC 20052 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Smith, CL (corresponding author), NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bldg 41,Room B608,41 Library Dr,MSC 5055, Bethesda, MD 20892 USA.	smithcat@exchange.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DeRubertis F, 1996, NATURE, V384, P589; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HONG L, 1993, J BIOL CHEM, V268, P305; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kim SY, 2003, J VIROL, V77, P3394, DOI 10.1128/JVI.77.6.3394-3401.2003; Koyama Y, 2000, BLOOD, V96, P1490, DOI 10.1182/blood.V96.4.1490.h8001490_1490_1495; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lambert JR, 1998, J BIOL CHEM, V273, P32708, DOI 10.1074/jbc.273.49.32708; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MCKNIGHT SL, 1982, COLD SPRING HARB SYM, V47, P945; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOYER ML, 1993, J BIOL CHEM, V268, P22933; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PIERCE J, 1993, J VIROL, V67, P415, DOI 10.1128/JVI.67.1.415-424.1993; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; VanLint C, 1996, GENE EXPRESSION, V5, P245; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200	61	46	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4807	4818		10.1038/sj.onc.1206722	http://dx.doi.org/10.1038/sj.onc.1206722			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894222				2022-12-28	WOS:000184344600004
J	Miething, C; Grundler, R; Fend, F; Hoepfl, J; Mugler, C; von Schilling, C; Morris, SW; Peschel, C; Duyster, J				Miething, C; Grundler, R; Fend, F; Hoepfl, J; Mugler, C; von Schilling, C; Morris, SW; Peschel, C; Duyster, J			The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model	ONCOGENE			English	Article						NPM-ALK; mouse model; tyrosine kinase; lymphoma	LARGE-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE DISEASE; MULTIPLE-MYELOMA; RAPID INDUCTION; TYROSINE KINASE; V-MYC; MICE	A t(2;5) (p23;q35) chromosomal translocation can be found in a high percentage of anaplastic large-cell lymphomas (ALCL). This genetic abnormality leads to the expression of the NPM-ALK fusion protein, which encodes a constitutively active tyrosine kinase that plays a causative role in lymphomagenesis. Employing a modified infection/transplantation protocol utilizing an MSCV-based vector, we were able to reproducibly induce two phenotypically different lymphoma-like diseases dependent on the retroviral titers used. The first phenotype presented as a polyclonal histiocytic malignancy of myeloid/macrophage origin with a short latency period of 3-4 weeks. Clinically, the diseased mice showed rapidly progressive wasting, lymphadenopathy and pancytopenia. Mice displaying the second phenotype developed monoclonal B-lymphoid tumors with a longer latency of approximately 12-16 weeks, primarily involving the spleen and the bone marrow, with less extensive lymph node but also histologically evident extranodal organ infiltration by large immature plasmoblastic cells. The described retroviral mouse model will be useful to analyse the role of NPM-ALK in lymphomagenesis in vivo and may contribute to the development of new treatment options for NPM-ALK induced malignancies.	Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; Tech Univ Munich, Dept Pathol, D-8000 Munich, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Technical University of Munich; University of Munich; Technical University of Munich; St Jude Children's Research Hospital	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Trogerstr 32, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA069129] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA69129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Cheuk W, 2000, AM J SURG PATHOL, V24, P1537, DOI 10.1097/00000478-200011000-00010; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 1999, BLOOD, V93, P2697; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; HAWLEY RG, 1994, GENE THER, V1, P136; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Mason DY, 1998, CANCER RES, V58, P1057; Million RP, 2000, BLOOD, V96, P664; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Parker JR, 2001, PEDIATR DEVEL PATHOL, V4, P397, DOI 10.1007/s10024001-0004-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Potter M, 1999, INT IMMUNOL, V11, P1059, DOI 10.1093/intimm/11.7.1059; POTTER M, 1986, CURR TOP MICROBIOL, V132, P40; Rawat R, 2000, BLOOD, V96, P3514; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Stein H, 2000, BLOOD, V96, P3681; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Tu YP, 2000, CANCER RES, V60, P6763; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang W, 2001, IEEE CONTR SYST MAG, V21, P84, DOI 10.1109/37.898794; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	38	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4642	4647		10.1038/sj.onc.1206575	http://dx.doi.org/10.1038/sj.onc.1206575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879008				2022-12-28	WOS:000184157000004
J	Park, JI; Lee, MG; Cho, KC; Park, BJ; Chae, KS; Byun, DS; Ryu, BK; Park, YK; Chi, SG				Park, JI; Lee, MG; Cho, KC; Park, BJ; Chae, KS; Byun, DS; Ryu, BK; Park, YK; Chi, SG			Transforming growth factor-beta 1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappa B, JNK, and Ras signaling pathways	ONCOGENE			English	Article						IL-6; TGF-beta 1; Smad; nuclear factor-kappa B; c-Jun; prostate cancer	GROWTH-FACTOR-BETA; MESSENGER-RNA STABILITY; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; TGF-BETA; GENE-EXPRESSION; TERMINAL KINASE; NEUROENDOCRINE DIFFERENTIATION; IL-6 FUNCTIONS; RICH ELEMENTS	Transforming growth factor (TGF)-beta1 acts as a potent growth inhibitor of prostate epithelial cells, and aberrant function of its receptor type I and II correlates with tumor aggressiveness. However, intracellular and serum TGF-beta1 levels are elevated in prostate cancer patients and further increased in patients with metastatic carcinoma, suggesting the oncogenic switch of TGF-beta1 role in prostate tumorigenesis. Recently, we reported the mitogenic conversion of TGF-beta1 effect by oncogenic Ha-Ras in prostate cancer cells. Here, we show that TGF-beta1 activates interleukin (IL)-6, which has been implicated in the malignant progression of prostate cancers, via multiple signaling pathways including Smad2, nuclear factor-kappaB (NF-kappaB), JNK, and Ras. TGF-beta1-induced IL-6 gene expression was strongly inhibited by DN-Smad2 but not by DN-Smad3 while it was further activated by wild-type Smad2 transfection. IL-6 activation by TGF-beta1 was accompanied by nuclear translocation of NF-kappaB, which was blocked by the p38 inhibitors SB202190 and SB203580 or by IkappaBalphaDeltaN transfection, indicating the crucial role for the p38-NF-kappaB signaling in TGF-beta1 induction of IL-6. TGF-beta1 activated c-Jun phosphorylation, and IL-6 induction by TGF-beta1 was severely impeded by DN-c-Jun and DN-JNK or AP-1 inhibitor curcumin, showing that the JNK-c-Jun-AP-1 signaling plays a pivotal role in TGF-beta1 stimulation of IL-6. It was also found that the Ras-Raf-MEK1 cascade is activated by TGF-beta1 and participates in the TGF-beta1 induction of IL-6 in an AP-1-dependent manner. Cotransfection assays demonstrated that TGF-beta1 stimulation of IL-6 results from the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK-c-Jun-AP-1, or Ras-Raf-MEK1 cascades. In addition, a time course IL-6 decay revealed that mRNA stability of IL-6 is modestly increased by TGF-beta1, indicating that TGF-beta1 also regulates IL-6 at the post-transcriptional level. Intriguingly, IL-6 inactivation restored the sensitivity to TGF-beta1-mediated growth arrest and apoptosis, suggesting that elevated IL-6 in advanced prostate tumors might act as a resistance factor against TGF-beta1. Collectively, our data demonstrate that IL-6 expression is stimulated by tumor-producing TGF-beta1 in human prostate cancer cells through multiple signaling pathways including Smad2, p38, JNK, and Ras, and enhanced expression of IL-6 could contribute to the oncogenic switch of TGF-beta1 role for prostate tumorigenesis, in part by counteracting its growth suppression function.	Kyung Hee Univ, Dept Pathol, Coll Med, Seoul 130701, South Korea; Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Kyung Hee University; Korea University	Chi, SG (corresponding author), Kyung Hee Univ, Dept Pathol, Coll Med, Seoul 130701, South Korea.	sgchi@khu.ac.kr	park, jaeil/AAS-5894-2021	PARK, JAE-IL/0000-0002-0737-2654				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akira S, 1992, Semin Cancer Biol, V3, P17; Asschert JGW, 1999, INT J CANCER, V82, P244, DOI 10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO;2-N; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Barrack ER, 1997, PROSTATE, V31, P61; BORSELLINO N, 1995, CANCER RES, V55, P4633; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN PH, 1994, ONCOGENE, V9, P791; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chi SG, 1997, CLIN CANCER RES, V3, P1889; Chung TDK, 2000, PROSTATE, V42, P1; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; EASTHAM JA, 1995, LAB INVEST, V73, P628; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 2000, BONE, V26, P249, DOI 10.1016/S8756-3282(99)00275-6; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1996, CANCER RES, V56, P44; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mazzarelli P, 1998, J NEUROIMMUNOL, V87, P185, DOI 10.1016/S0165-5728(98)00110-6; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Montero L, 1999, CANCER RES, V59, P5286; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nabors LB, 2001, CANCER RES, V61, P2154; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Oka M, 1996, CANCER RES, V56, P2776; Okamoto M, 1997, CANCER RES, V57, P141; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; Park BJ, 2000, CANCER RES, V60, P3031; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riggins GJ, 1997, CANCER RES, V57, P2578; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Sehgal I, 1996, CANCER RES, V56, P3359; Seymour JF, 1997, AM J MED, V102, P21; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; St-Arnaud Rene, 1998, Frontiers in Bioscience, V3, pD838; Stearns ME, 1999, CLIN CANCER RES, V5, P711; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TRUONG LD, 1993, HUM PATHOL, V24, P4, DOI 10.1016/0046-8177(93)90055-L; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yakymovych I, 2002, BIOCHEMISTRY-US, V41, P11000, DOI 10.1021/bi025936u; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	83	164	171	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4314	4332		10.1038/sj.onc.1206478	http://dx.doi.org/10.1038/sj.onc.1206478			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853969				2022-12-28	WOS:000183978900002
J	Kulaeva, OI; Draghici, S; Tang, L; Kraniak, JM; Land, SJ; Tainsky, MA				Kulaeva, OI; Draghici, S; Tang, L; Kraniak, JM; Land, SJ; Tainsky, MA			Epigenetic silencing of multiple interferon pathway genes after cellular immortalization	ONCOGENE			English	Article						senescence; immortalization; interferon gene silencing; LI-Fraumeni syndrome	LI-FRAUMENI-SYNDROME; INDUCIBLE NEGATIVE REGULATOR; HUMAN-CELLS; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; DNA METHYLATION; EPITHELIAL-CELLS; CPG ISLAND; CANCER; EXPRESSION	Abrogating cellular senescence is a necessary step in the formation of a cancer cell. Promoter hypermethylation is an epigenetic mechanism of gene regulation known to silence gene expression in carcinogenesis. Treatment of spontaneously immortal Li-Fraumeni fibroblasts with 5-aza-2'-deoxycytidine (5AZA-dC), an inhibitor of DNA methyltransferase (DNMT), induces a senescence-like state. We used microarrays containing 12 558 genes to determine the gene expression pro. le associated with cellular immortalization and also regulated by 5AZA-dC. Remarkably, among 85 genes with methylation-dependent downregulation (silencing) after immortalization, 39 (46%) are known to be regulated during interferon signaling, a known growth-suppressive pathway. This work indicates that gene silencing may be associated with an early event in carcinogenesis, cellular immortalization.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Tainsky, MA (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, 110 Warren Ave, Detroit, MI 48201 USA.		Studitskaia, Olga/D-8551-2014; Draghici, Sorin/B-3074-2013	Studitskaia, Olga/0000-0001-5417-9964; Draghici, Sorin/0000-0002-0786-8377; Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P30CA022453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bechter OE, 2002, EXP HEMATOL, V30, P26, DOI 10.1016/S0301-472X(01)00760-3; Bender CM, 1998, CANCER RES, V58, P95; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Dessain SK, 2000, CANCER RES, V60, P537; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duncan EL, 2000, BIOGERONTOLOGY, V1, P103, DOI 10.1023/A:1010000132671; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FAIRWEATHER NF, 1987, INFECT IMMUN, V55, P2541, DOI 10.1128/IAI.55.11.2541-2545.1987; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Harada M, 2001, J IMMUNOTHER, V24, P323, DOI 10.1097/00002371-200107000-00008; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Liang G, 2002, CANCER RES, V62, P961; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; Mori Y, 2001, CANCER RES, V61, P6046; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Wen Y, 2001, CANCER RES, V61, P7142; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	49	112	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4118	4127		10.1038/sj.onc.1206594	http://dx.doi.org/10.1038/sj.onc.1206594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821946				2022-12-28	WOS:000183707600015
J	Senchenko, V; Liu, J; Braga, E; Mazurenko, N; Loginov, W; Seryogin, Y; Bazov, I; Protopopov, A; Kisseljov, FL; Kashuba, V; Lerman, MI; Klein, G; Zabarovsky, ER				Senchenko, V; Liu, J; Braga, E; Mazurenko, N; Loginov, W; Seryogin, Y; Bazov, I; Protopopov, A; Kisseljov, FL; Kashuba, V; Lerman, MI; Klein, G; Zabarovsky, ER			Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas	ONCOGENE			English	Article						quantitative real-time PCR; human chromosome 3p; tumor suppressor genes; NotI linking clone; loss of heterozygosity; cervical carcinoma	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; LUNG-CANCER; 3P DELETIONS; SHORT ARM; INTRAEPITHELIAL NEOPLASIA; EPIGENETIC INACTIVATION; ALLELIC LOSS; HETEROZYGOSITY; FREQUENT	We report chromosome 3p deletion mapping of 32 cervical carcinoma (CC) biopsies using 26 microsatellite markers located in frequently deleted 3p regions to detect loss of heterozygosity and homozygous loss. In addition, two STS markers (NLJ-003 and NL3-001) located in the 3p21.3 telomeric (3p21.3T) and 3p21.3 centromeric (3p21.3C) regions, respectively, were used for quantitative real-time PCR as TaqMan probes. We show that quantitative real-time PCR is reliable and sensitive and allows discriminating between 0, 1 and 2 marker copies per human genome. For the first time, frequent (five of 32 cases, i.e. 15.6%) homozygous deletions were demonstrated in CCs in both 3p21.3T and 3p21.3C regions. The smallest region homozygously deleted in 3p21.3C was located between D3S1568 (CACNA2D2 gene) and D3S4604 (SEMA3F gene) and contains 17 genes previously defined as lung cancer candidate Tumor suppressor genes (TSG(s)). The smallest region homozygously deleted in 3p21.3T was flanked by D3S1298 and NL1-024 (D3S4285), excluding DLEC1 and MYD88 as candidate TSGs involved in cervical carcinogenesis. Overall, this region contains five potential candidates, namely GOLGA4, APRG1, ITGA9, HYA22 and VILL, which need to be analysed. The data showed that aberrations of either NLJ-003 or NL3-001 were detected in 29 cases (90.6%) and most likely have a synergistic effect (P<0.01). The study also demonstrated that aberrations in 3p21.3 were complex and in addition to deletions, may involve gene amplification as well. The results strongly suggest that 3p21.3T and 3p21.3C regions harbor genes involved in the origin and/or development of CCs and imply that those genes might be multiple TSG(s).	Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; Russian State Genet Ctr, Moscow 113545, Russia; Russian Acad Med Sci, Blokhin Canc Res Ctr, Moscow 115478, Russia; NCI, Canc Causing Genes Sect, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Karolinska Institutet; Research Center of Biotechnology RAS; Russian Academy of Sciences; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Senchenko, Vera N/C-8992-2014; Loginov, Vytaliy/J-9738-2018; Braga, Eleonora A./P-5574-2016; Kashuba, Vladimir/AAO-7742-2020; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017	Senchenko, Vera N/0000-0002-3119-515X; Loginov, Vytaliy/0000-0003-2668-8096; Kashuba, Vladimir I/0000-0001-9416-8282; Bazov, Igor/0000-0003-4388-1656; Braga, Eleonora/0000-0001-5188-4094	PHS HHS [N01-C0-56000] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; ANGELONI D, 2001, SOURCEBOOK ASBESTOS, V23, P169; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Boulay JL, 1999, BIOTECHNIQUES, V27, P228, DOI 10.2144/99272bm03; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Braga E. A., 1997, Molekulyarnaya Biologiya (Moscow), V31, P985; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cairns JP, 1998, CLIN CANCER RES, V4, P441; Chiang PW, 1999, CLIN CANCER RES, V5, P1381; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; de Nooij-van Dalen AG, 1998, GENE CHROMOSOME CANC, V21, P30, DOI 10.1002/(SICI)1098-2264(199801)21:1<30::AID-GCC5>3.0.CO;2-9; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Fouret PJ, 1998, PATHOBIOLOGY, V66, P306, DOI 10.1159/000028038; Guo ZM, 2000, INT J CANCER, V86, P518, DOI 10.1002/(SICI)1097-0215(20000515)86:4<518::AID-IJC12>3.0.CO;2-Y; Guo ZM, 1998, ANTICANCER RES, V18, P707; Guo ZM, 2001, MODERN PATHOL, V14, P54, DOI 10.1038/modpathol.3880256; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Helland A, 2000, INT J CANCER, V88, P217; Herzog CR, 2001, MOL CARCINOGEN, V30, P159, DOI 10.1002/mc.1024; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Kashuba VI, 1999, GENE, V239, P259, DOI 10.1016/S0378-1119(99)00411-4; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kisseljov F, 1996, INT J CANCER, V69, P484, DOI 10.1002/(SICI)1097-0215(19961220)69:6<484::AID-IJC12>3.3.CO;2-G; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Larson AA, 1997, CANCER RES, V57, P4082; Larson AA, 1997, CANCER RES, V57, P4171; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lerman MI, 2000, CANCER RES, V60, P6116; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; LIVAK KJ, 1995, PCR METH APPL, V4, P357; MANTEL N, 1967, CANCER RES, V27, P209; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Mazurenko N, 1999, ONCOL REP, V6, P859; Muller CY, 1998, J NATL CANCER I, V90, P433, DOI 10.1093/jnci/90.6.433; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Protopopov A, 2003, CANCER RES, V63, P404; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; Rader JS, 1996, ONCOGENE, V13, P2737; SAMOYLOVA EV, 1995, INT J CANCER, V61, P337, DOI 10.1002/ijc.2910610311; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Varella-Garcia M, 1998, CANCER RES, V58, P4701; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1997, CANCER RES, V57, P3154; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	52	51	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2984	2992		10.1038/sj.onc.1206429	http://dx.doi.org/10.1038/sj.onc.1206429			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771950				2022-12-28	WOS:000182824800014
J	Li, G; Kalabis, J; Xu, XW; Meier, F; Oka, M; Bogenrieder, T; Herlyn, M				Li, G; Kalabis, J; Xu, XW; Meier, F; Oka, M; Bogenrieder, T; Herlyn, M			Reciprocal regulation of MelCAM and AKT in human melanoma	ONCOGENE			English	Article						AKT; MelCAM; melanoma; survival; signaling	PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE-AKT PATHWAY; CELL-ADHESION MOLECULES; GROWTH-FACTOR; TUMOR-GROWTH; TYROSINE PHOSPHORYLATION; VASCULOGENIC MIMICRY; MALIGNANT-MELANOMA; ESTROGEN-RECEPTOR; E-CADHERIN	Alteration in the expression of invasion/ metastasis-related melanoma cell adhesion molecule (MelCAM) is strongly associated with the acquisition of malignancy by human melanoma. However, little is known about the molecular and biochemical mechanisms that regulate the expression and function of MelCAM, or its downstream signaling transduction. In this study, we show that there is a reciprocal regulation loop between AKT and MelCAM. Pharmacological inhibition of AKT in human melanoma cell lines substantially reduced the expression of MelCAM. Overexpression of constitutively active AKT upregulated the levels of MelCAM in melanoma cell lines, whereas expression of a dominant-negative PI-3 kinase downregulated MelCAM. On the other hand, overexpression of MelCAM activated endogenous AKT and inhibited proapoptotic protein BAD in melanoma cells, leading to increased survival under stress conditions. Constitutive activation of AKT was observed in most melanoma cell lines and tumor samples of different progression stages. These data link AKT activation with MelCAM expression, and implicate that intervention of MelCAM-AKT signaling axis in melanoma is a potential therapeutical approach.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Kobe Univ, Sch Med, Dept Dermatol, Kobe, Hyogo 6500017, Japan	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; Kobe University	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA080999, R01CA076674, R01CA047159, P30CA010815, P01CA025874] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80999, CA-76674, CA-47159, CA-25874, CA-10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; ARMSTRONG PB, 1989, CRIT REV BIOCHEM MOL, V24, P119, DOI 10.3109/10409238909086396; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2001, CANCER RES, V61, P3250; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; JOHNSON JP, 1992, INT J CLIN LAB RES, V22, P69, DOI 10.1007/BF02591399; JOHNSON JP, 1993, MELANOMA RES, V3, P337, DOI 10.1097/00008390-199310000-00006; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LEHMANN JM, 1987, CANCER RES, V47, P841; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Li G, 2001, CANCER RES, V61, P3819; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mills L, 2002, CANCER RES, V62, P5106; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Oka M, 2000, J INVEST DERMATOL, V115, P699, DOI 10.1046/j.1523-1747.2000.00095.x; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ries LAG, 2000, CANCER-AM CANCER SOC, V88, P2398, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Rummel MM, 1996, CANCER RES, V56, P2218; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, AM J PATHOL, V145, P837; SHIH IM, 1994, CANCER RES, V54, P2514; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sun M, 2001, CANCER RES, V61, P5985; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waldmann V, 2002, MELANOMA RES, V12, P45, DOI 10.1097/00008390-200202000-00007; Waldmann V, 2001, ARCH DERMATOL RES, V293, P368, DOI 10.1007/s004030100236; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xie SH, 1997, CANCER RES, V57, P2295	67	65	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6891	6899		10.1038/sj.onc.1206819	http://dx.doi.org/10.1038/sj.onc.1206819			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534536				2022-12-28	WOS:000185843400010
J	Moon, C; Soria, JC; Jang, SJ; Lee, J; Hoque, MO; Sibony, M; Trink, B; Chang, YS; Sidransky, D; Mao, L				Moon, C; Soria, JC; Jang, SJ; Lee, J; Hoque, MO; Sibony, M; Trink, B; Chang, YS; Sidransky, D; Mao, L			Involvement of aquaporins in colorectal carcinogenesis	ONCOGENE			English	Article						aquaporin; in situ hybridization; RT-PCR; colon cancer; carcinogenesis	WATER CHANNELS; PERMEABILITY; EXPRESSION; GENE	Aquaporins (AQPs) are important in controlling water permeability. As AQP1 is known as a serum-responsive gene, we hypothesized that AQP expression may be involved in the development of human cancer. By reverse transcriptase-polymerase chain reaction analysis, expression of AQPs 1, 3, and 5 was found in seven colon and colorectal cancer cell lines. Western blot analysis confirmed their expression in four of these cell lines. In situ hybridization demonstrated that during colorectal carcinogenesis, the expression of AQPs 1 and 5 was induced in early-stage disease ( early dysplasia) and maintained through the late stages of colon cancer development. Expression of AQPs 1 and 5 was maintained even in metastatic lesions in the liver. These findings demonstrate that the expression of several AQPs is found in tumor cells and is associated with an early stage of colorectal cancer development. These novel observations suggest that multiple AQP expression may be advantageous to tumorigenesis, which may lead to a better understanding of colorectal carcinogenesis.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehans Canc Ctr, Baltimore, MD 21205 USA; Inst Gustave Roussy, Dvi Canc Med, F-94805 Villejuif, France; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Hosp Tenon, APHP, Dept Pathol, F-75020 Paris, France	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Moon, C (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	cmoon5@jhmi.edu	Mao, Li/C-7570-2011; Soria, Jean-Charles/F-3619-2014	Mao, Li/0000-0001-7263-3358; Hoque, Mohammad Obaidul/0000-0001-6701-9978; Chang, Yoon Soo/0000-0003-3340-4223	NCI NIH HHS [P50 CA96784-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA096784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; Ma TH, 1999, J PHYSIOL-LONDON, V517, P317, DOI 10.1111/j.1469-7793.1999.0317t.x; Marples D, 2000, LANCET, V355, P1571, DOI 10.1016/S0140-6736(00)02209-1; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; MOON C, 1995, GENOMICS, V30, P354, DOI 10.1006/geno.1995.0029; MOON C, 1993, J BIOL CHEM, V268, P15772; MOON C, 1997, AM J PHYSIOL-CELL PH, V273, pC1562; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512; Splinter PL, 2003, J BIOL CHEM, V278, P6268, DOI 10.1074/jbc.M212079200; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	23	158	199	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6699	6703		10.1038/sj.onc.1206762	http://dx.doi.org/10.1038/sj.onc.1206762			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555983				2022-12-28	WOS:000185799300005
J	Nickoloff, BJ; Osborne, BA; Miele, L				Nickoloff, BJ; Osborne, BA; Miele, L			Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents	ONCOGENE			English	Review						Notch; cancer; leukemia; therapeutic targets; signalling	NF-KAPPA-B; INTRACELLULAR DOMAIN; ACTIVATED NOTCH1; HUMAN HOMOLOG; STEM-CELLS; NEOPLASTIC TRANSFORMATION; INHIBITS DIFFERENTIATION; INDUCED APOPTOSIS; DENDRITIC CELLS; LEUKEMIA CELLS	Notch signaling controls cell fate decisions including during development and stem cell renewal and differentiation in many postnatal tissues. Increasing evidence suggests that the Notch signaling network is frequently deregulated in human malignancies and that genetic or pharmacological manipulation of Notch signaling is a novel potential strategy for the treatment of human neoplasms. This review article summarizes the most recent preclinical and clinical evidence linking Notch signaling to cancer, delineates questions that remain unanswered and explores potential biopharmacological strategies to manipulate Notch signaling in vivo.	Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Loyola Univ, Dept Pathol, Chicago, IL 60611 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Chicago, IL 60611 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; Loyola University Chicago; University of Massachusetts System; University of Massachusetts Amherst; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Miele, L (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, 833 S Wood St,M-C 865,Room 335, Chicago, IL 60612 USA.	lmiele@uic.edu		Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [R01CA084065, P01CA059327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016690] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84065-01, P01 CA59327] Funding Source: Medline; NIA NIH HHS [R01 AG 16690] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Anderson AC, 2001, CURR OPIN GENET DEV, V11, P554, DOI 10.1016/S0959-437X(00)00232-X; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Blair SS, 1996, SCIENCE, V271, P1822, DOI 10.1126/science.271.5257.1822; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; CHATURVEDI V, 2003, IN PRESS J INVEST DE; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Engel I, 2002, P NATL ACAD SCI USA, V99, P11322, DOI 10.1073/pnas.162373999; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fortini ME, 2000, NATURE, V406, P357, DOI 10.1038/35019233; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Gailani M R, 1999, Adv Dermatol, V14, P261; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Gartel AL, 2002, MOL CANCER THER, V1, P639; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hendrix MJC, 2002, CANCER RES, V62, P665; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hubmann R, 2002, BLOOD, V99, P3742, DOI 10.1182/blood.V99.10.3742; Ikeya T, 1999, DEVELOPMENT, V126, P4455; Ingles-Esteve J, 2001, J BIOL CHEM, V276, P44873, DOI 10.1074/jbc.M104703200; Ishii H, 2001, RHEUMATOL INT, V21, P10, DOI 10.1007/s002960100119; Izon DJ, 2002, CURR OPIN IMMUNOL, V14, P192, DOI 10.1016/S0952-7915(02)00321-7; Jang MS, 2000, CURR OPIN MOL THER, V2, P55; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Jehn BM, 1999, J IMMUNOL, V162, P635; Johnson J, 2001, MECH DEVELOP, V109, P355, DOI 10.1016/S0925-4773(01)00523-8; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kortschak RD, 2001, DEV GENES EVOL, V211, P350; Krebs LT, 2000, GENE DEV, V14, P1343; Kumano K, 2001, BLOOD, V98, P3283, DOI 10.1182/blood.V98.12.3283; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lewis J, 1998, NATURE, V393, P304, DOI 10.1038/30597; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; MAINE EM, 1995, MOL PHYLOGENET EVOL, V4, P139, DOI 10.1006/mpev.1995.1014; Matsuno K, 2002, DEVELOPMENT, V129, P1049; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Miele L., 2000, Journal of Investigative Dermatology, V114, P758; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mizuguchi T, 2001, J CELL PHYSIOL, V189, P106, DOI 10.1002/jcp.1136; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mori S, 2003, DEV GROWTH DIFFER, V45, P7, DOI 10.1046/j.1440-169X.2003.00670.x; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nakazawa M, 2001, ARTHRITIS RHEUM-US, V44, P1545, DOI 10.1002/1529-0131(200107)44:7<1545::AID-ART278>3.0.CO;2-Q; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ohishi K, 2002, J CLIN INVEST, V110, P1165, DOI 10.1172/JCI200216167; Ohishi K, 2002, INT J HEMATOL, V75, P449, DOI 10.1007/BF02982106; Ohishi K, 2001, BLOOD, V98, P1402, DOI 10.1182/blood.V98.5.1402; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Osborne BA, 2000, CURR OPIN IMMUNOL, V12, P301, DOI 10.1016/S0952-7915(00)00091-1; Parks AL, 2000, DEVELOPMENT, V127, P1373; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; QIN JZ, 2003, IN PRESS J INVEST DE; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Rosenfield RL, 2000, HORM RES, V54, P269, DOI 10.1159/000053270; Royet J, 1998, EMBO J, V17, P7351, DOI 10.1093/emboj/17.24.7351; Ruiz-Hidalgo MJ, 1999, INT J ONCOL, V14, P777; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Suzuki T, 2000, INT J ONCOL, V17, P1131; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Wang WL, 2002, J BIOL CHEM, V277, P21723, DOI 10.1074/jbc.M202224200; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weijzen S, 2002, J IMMUNOL, V169, P4273, DOI 10.4049/jimmunol.169.8.4273; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wilson A, 2000, J IMMUNOL, V165, P5397, DOI 10.4049/jimmunol.165.10.5397; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000; Zlobin A., 2000, Current Pharmaceutical Biotechnology, V1, P83, DOI 10.2174/1389201003379013	136	251	292	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6598	6608		10.1038/sj.onc.1206758	http://dx.doi.org/10.1038/sj.onc.1206758			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528285				2022-12-28	WOS:000185700700017
J	Russo, G; Zegar, C; Giordano, A				Russo, G; Zegar, C; Giordano, A			Advantages and limitations of microarray technology in human cancer	ONCOGENE			English	Review						microarray; proteomics; human cancer	GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; LASER-CAPTURE MICRODISSECTION; COMPLEMENTARY-DNA MICROARRAY; BENIGN PROSTATIC HYPERPLASIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; EPITHELIAL OVARIAN-CANCER; URINARY-BLADDER CANCER; CDNA MICROARRAY; BREAST-CANCER	Cancer is a highly variable disease with multiple heterogeneous genetic and epigenetic changes. Functional studies are essential to understanding the complexity and polymorphisms of cancer. The final deciphering of the complete human genome, together with the improvement of high throughput technologies, is causing a fundamental transformation in cancer research. Microarray is a new powerful tool for studying the molecular basis of interactions on a scale that is impossible using conventional analysis. This technique makes it possible to examine the expression of thousands of genes simultaneously. This technology promises to lead to improvements in developing rational approaches to therapy as well as to improvements in cancer diagnosis and prognosis, assuring its entry into clinical practice in specialist centers and hospitals within the next few years. Predicting who will develop cancer and how this disease will behave and respond to therapy after diagnosis will be one of the potential benefits of this technology within the next decade. In this review, we highlight some of the recent developments and results in microarray technology in cancer research, discuss potentially problematic areas associated with it, describe the eventual use of microarray technology for clinical applications and comment on future trends and issues.	Temple Univ, Dept Biotechnol, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Dept Biotechnol, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, 1900 N 12th St,Room 333, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Agrawal D, 2002, J NATL CANCER I, V94, P513; Ahr A, 2002, LANCET, V359, P131, DOI 10.1016/S0140-6736(02)07337-3; Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Barlund M, 2000, CANCER RES, V60, P5340; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; BATTIFORA H, 1986, LAB INVEST, V55, P244; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Belbin TJ, 2002, CANCER RES, V62, P1184; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Best C J, 2001, Expert Rev Mol Diagn, V1, P53, DOI 10.1586/14737159.1.1.53; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Brail LH, 1999, MUTAT RES-GENOMICS, V406, P45, DOI 10.1016/S1383-5726(98)00009-0; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Bubendorf L, 1999, CANCER RES, V59, P803; Bull JH, 2001, BRIT J CANCER, V84, P1512, DOI 10.1054/bjoc.2001.1816; Caldas C, 2002, NATURE, V415, P484, DOI 10.1038/415484a; Celis JE, 2000, FEBS LETT, V480, P2, DOI 10.1016/S0014-5793(00)01771-3; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Collins FS, 1999, NAT GENET, V21, P2, DOI 10.1038/4425; Devilard E, 2002, ONCOGENE, V21, P3095, DOI 10.1038/sj.onc.1205418; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Fejzo MS, 2001, AM J PATHOL, V159, P1645, DOI 10.1016/S0002-9440(10)63011-8; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gariboldi M, 2003, CANCER RES, V63, P1871; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gordon GJ, 2002, CANCER RES, V62, P4963; Granjeaud S, 1999, BIOESSAYS, V21, P781, DOI 10.1002/(SICI)1521-1878(199909)21:9<781::AID-BIES10>3.0.CO;2-2; Graves DJ, 1999, TRENDS BIOTECHNOL, V17, P127, DOI 10.1016/S0167-7799(98)01241-4; Han HY, 2002, CANCER RES, V62, P2890; Hanash S, 2003, NAT BIOTECHNOL, V21, P37, DOI 10.1038/nbt0103-37; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hedenfalk IA, 2002, ADV CANCER RES, V84, P1, DOI 10.1016/S0065-230X(02)84001-5; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hippo Y, 2002, CANCER RES, V62, P233; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Ismail RS, 2000, CANCER RES, V60, P6744; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Khan J, 1998, CANCER RES, V58, P5009; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6; Kodadek T, 2001, CHEM BIOL, V8, P105, DOI 10.1016/S1074-5521(00)90067-X; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kudoh K, 2000, CANCER RES, V60, P4161; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Leethanakul C, 2003, ORAL ONCOL, V39, P248, DOI 10.1016/S1368-8375(02)00107-0; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Luo J, 2001, CANCER RES, V61, P4683; Luo J, 2002, PROSTATE, V51, P189, DOI 10.1002/pros.10087; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Meldrum D, 2000, GENOME RES, V10, P1288, DOI 10.1101/gr.157400; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Niemeyer CM, 1999, ANGEW CHEM INT EDIT, V38, P2865, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2865::AID-ANIE2865>3.0.CO;2-F; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Ono K, 2000, CANCER RES, V60, P5007; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; RUSSO G, 2003, IN PRESS ONCOGENE; Sallinen SL, 2000, CANCER RES, V60, P6617; Sawiris GP, 2002, CANCER RES, V62, P2923; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Senior K, 1999, MOL MED TODAY, V5, P326, DOI 10.1016/S1357-4310(99)01536-1; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shridhar V, 2001, CANCER RES, V61, P5895; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 2001, J NATL CANCER I, V93, P1141, DOI 10.1093/jnci/93.15.1141; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stratowa C, 2001, INT J CANCER, V91, P474, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1078>3.0.CO;2-C; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2001, CANCER RES, V61, P7388; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; von Eggeling F, 2000, BIOTECHNIQUES, V29, P1066; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Xu JC, 2001, CANCER RES, V61, P1563; Zhou M, 2002, AM J SURG PATHOL, V26, P926, DOI 10.1097/00000478-200207000-00012	123	182	188	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 29	2003	22	42					6497	6507		10.1038/sj.onc.1206865	http://dx.doi.org/10.1038/sj.onc.1206865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528274				2022-12-28	WOS:000185700700006
J	Evans, JR; Mitchell, SA; Spriggs, KA; Ostrowski, J; Bomsztyk, K; Ostarek, D; Willis, AE				Evans, JR; Mitchell, SA; Spriggs, KA; Ostrowski, J; Bomsztyk, K; Ostarek, D; Willis, AE			Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo	ONCOGENE			English	Article						c-myc; translation; internal ribosome entry; IRES; poly (rC) binding proteins	NUCLEAR RIBONUCLEOPROTEIN-K; SITE-MEDIATED TRANSLATION; DOMAIN PROTEINS; HNRNP K; INITIATION; IRES; REGION; ONCOGENE; LEADS; GENE	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment and c-Myc translation can be initiated by cap-independent as well as cap-dependent mechanisms. In contrast to the process of cap-dependent initiation, the trans-acting factor requirements for cellular internal ribosome entry are poorly understood. Here, we show that members of the poly (rC) binding protein family, poly (rC) binding protein 1 (PCBP1), poly (rC) binding protein 2 (PCBP2) and hnRNPK were able to activate the IRES in vitro up to threefold when added in combination with upstream of N-ras and unr-interacting protein. The interactions of PCBP1, PCBP2 and hnRNPK with c-myc-IRES-RNA were shown to be specific by ultraviolet crosslinking analysis and electrophoretic mobility shift assays, while immunoprecipitation of the three proteins using specific antibodies followed by reverse transcriptase-polymerase chain reaction showed that they were able to bind c-myc mRNA. c-myc-IRES-mediated translation from the reporter vector was stimulated by cotransfection of plasmids encoding PCBP1, PCBP2 and hnRNPK. Interestingly, the mutated version of the c-myc IRES that is prevalent in patients with multiple myeloma bound hnRNPK more efficiently in vitro and was stimulated by hnRNPK to a greater extent in vivo.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Washington, Seattle, WA 98195 USA; Univ Halle Wittenberg, Dept Biochem, D-06210 Halle An Der Saale, Germany	University of Leicester; University of Washington; University of Washington Seattle; Martin Luther University Halle Wittenberg	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	aew5@le.ac.uk		Ostareck, Dirk/0000-0001-9406-7190; Ostrowski, Jerzy/0000-0003-1363-3766; Willis, Anne/0000-0002-1470-8531				Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; BLACK DL, 1998, ELECTROPHORETIC MOBI; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Gamarnik AV, 1997, RNA, V3, P882; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Jopling CL, 2001, ONCOGENE, V20, P2664, DOI 10.1038/sj.onc.1204404; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Lomakin IB, 2000, MOL CELL BIOL, V20, P6019, DOI 10.1128/MCB.20.16.6019-6029.2000; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Ostrowski J, 2002, J BIOL CHEM, V277, P6303, DOI 10.1074/jbc.M110267200; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; Pilipenko EV, 2000, GENE DEV, V14, P2028; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Walter BL, 1999, RNA, V5, P1570, DOI 10.1017/S1355838299991483; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515	43	177	187	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8012	8020		10.1038/sj.onc.1206645	http://dx.doi.org/10.1038/sj.onc.1206645			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970749				2022-12-28	WOS:000185388200016
J	Kim, YK; Han, JW; Woo, YN; Chun, JK; Yoo, JY; Cho, EJ; Hong, SY; Lee, HY; Lee, YW; Lee, HW				Kim, YK; Han, JW; Woo, YN; Chun, JK; Yoo, JY; Cho, EJ; Hong, SY; Lee, HY; Lee, YW; Lee, HW			Expression of p21WAF1/Cip1 through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinasePKC epsilon signaling pathway	ONCOGENE			English	Article						historic deacetylase inhibitor; apicidin; p21(WAF1/Cip1); PI 3-kinase; PKC epsilon	KINASE-C-EPSILON; HUMAN P21(WAF1/CIP1) GENE; GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; TRICHOSTATIN-A; INDUCTION; PROMOTER; P53; CHROMATIN	We previously reported that the activation of p21(WAF1/Cip1) transcription by histone deacetylase inhibitor apicidin was mediated through Sp1 sites and pointed to the possible participation of protein kinase C (PKC). In this study, we investigated the role and identity of the specific isoforms of PKC involved and identified phosphatidylinositol 3-kinase (PI 3-kinase) as an upstream effector in HeLa cells. Using an isoform-specific pharmacological inhibitor of PKC, a PKCepsilon dominant-negative mutant, and antisense oligonucleotide to inhibit PKCepsilon specifically, we found that among PKC isoforms, PKCepsilon was required for the p21(WAF1/Cip1) expression by apicidin. In addition to PKCepsilon, PI 3-kinase appeared to participate in the activation of p21(WAF1/Cip1) promoter by apicidin, since inactivation of PI 3-kinase either by transient expression of dominant-negative mutant of PI 3-kinase or its specific inhibitors, LY294002 and wortmannin, attenuated the activation of p21(WAF1/Cip1) promoter and p21(WAF1/Cip1) protein expression by apicidin. Furthermore, membrane translocation of PKCepsilon in response to apicidin was blocked by the PI 3-kinase inhibitor, indicating the role of PI 3-kinase as an upstream molecule of PRO: in the p21(WAF1/Cip1) promoter activation by apicidin. However, the p21(WAF1/Cip1) expression by apicidin appeared to be independent of the histone hyperacetylation, since apicidin-induced histone hyperacetylation of p21(WAF1/Cip1) promoter region was not affected by inhibition of PI 3-kinase and PKC, suggesting that the chromatin remodeling through the histone hyperacetylation alone might not be sufficient for the expression of p21(WAF1/Cip1) by apicidin. Taken together, these results suggest that the PI 3-kinase-PKCepsilon signaling pathway plays a pivotal role in the expression of the p21(WAF1/Cip1) by apicidin.	Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea; Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, South Korea; Konyang Univ, Coll Med, Dept Pharmacol, Nonsan 320711, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; Seoul National University (SNU)	Lee, HW (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea.	hylee@skku.ac.kr	Cho, Eun-Jung/AAR-1785-2020	Cho, Eun-Jung/0000-0002-6610-5329				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; CHEDID M, 1994, ONCOGENE, V9, P3021; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinos E, 1998, MOL BRAIN RES, V56, P118, DOI 10.1016/S0169-328X(98)00036-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LI YJ, 1995, ONCOGENE, V10, P599; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Petrovics G, 2002, ARCH BIOCHEM BIOPHYS, V397, P217, DOI 10.1006/abbi.2001.2640; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rivero JA, 1998, BIOCHEM BIOPH RES CO, V248, P664, DOI 10.1006/bbrc.1998.9041; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sowa Y, 1999, CANCER RES, V59, P4266; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TOKER A, 1994, J BIOL CHEM, V269, P32358; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	63	48	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6023	6031		10.1038/sj.onc.1206875	http://dx.doi.org/10.1038/sj.onc.1206875			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955081				2022-12-28	WOS:000185137800011
J	Krause, DR; Jonnalagadda, JC; Gatei, MH; Sillje, HHW; Zhou, BB; Nigg, EA; Khanna, K				Krause, DR; Jonnalagadda, JC; Gatei, MH; Sillje, HHW; Zhou, BB; Nigg, EA; Khanna, K			Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1	ONCOGENE			English	Article						ATM; NBS1; checkpoints; DNA damage; Chk1; TLK	S-PHASE CHECKPOINT; CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; PROTEIN-KINASE; HUMAN ASF1; GENE; ACTIVATION; PATHWAYS; REPAIR	The human Tousled-like kinases 1 and 2 (TLK) have been shown to be active during S phase of the cell cycle. TLK activity is rapidly suppressed by DNA damage and by inhibitors of replication. Here we report that the signal transduction pathway, which leads to transient suppression of TLK activity after the induction of double-strand breaks (DSBs) in the DNA, is dependent on the presence of a functional ataxia-telangiectasia-mutated kinase (ATM). Interestingly, we have discovered that rapid suppression of TLK activity after low doses of ultraviolet (UV) irradiation or aphidicolin-induced replication block is also ATM-dependent. The nature of the signal that triggers ATM-dependent downregulation of TLK activity after UVC and replication block remains unknown, but it is not due exclusively to DSBs in the DNA. We also demonstrate that TLK suppression is dependent on the presence of a functional Nijmegan Breakage Syndrome protein (NBS1). ATM-dependent phosphorylation of NBS1 is required for the suppression of TLK activity, indicating a role for NBS1 as an adaptor or scaffold in the ATM/TLK pathway. ATM does not phosphorylate TLK directly to regulate its activity, but Chk1 does phosphorylate TLK1 GST-fusion proteins in vitro. Using Chk1 siRNAs, we show that Chk1 is essential for the suppression of TLK activity after replication block, but that ATR, Chk2 and BRCA1 are dispensable for TLK suppression. Overall, we propose that ATM activation is not linked solely to DSBs and that ATM participates in initiating signaling pathways in response to replication block and UV-induced DNA damage.	Queensland Inst Med Res, Canc & Cell Biol Div, Signal Transduct Lab, 300 Herston Rd, Herston, Qld 4029, Australia; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Incyte Genom Inc, Newark, DE 19714 USA	QIMR Berghofer Medical Research Institute; Max Planck Society; DuPont; Incyte	Krause, DR (corresponding author), Queensland Inst Med Res, Canc & Cell Biol Div, Signal Transduct Lab, 300 Herston Rd, Herston, Qld 4029, Australia.	darrenk@qimr.edu.au		Khanna, Kum Kum/0000-0001-8650-5381; nigg, erich/0000-0003-4835-5719				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GATEI M, 2003, J BIOL CHEM; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Jackson JR, 2000, CANCER RES, V60, P566; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Li Y, 2001, ONCOGENE, V20, P726, DOI 10.1038/sj.onc.1204147; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu B, 2002, CANCER RES, V62, P4588; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZDZIENICKA MZ, 1989, CANCER RES, V49, P1481; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, CANCER RES, V62, P1598	48	58	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5927	5937		10.1038/sj.onc.1206691	http://dx.doi.org/10.1038/sj.onc.1206691			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955071				2022-12-28	WOS:000185137800001
J	Rippe, V; Drieschner, N; Meiboom, M; Escobar, HM; Bonk, U; Belge, G; Bullerdiek, J				Rippe, V; Drieschner, N; Meiboom, M; Escobar, HM; Bonk, U; Belge, G; Bullerdiek, J			Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas	ONCOGENE			English	Article						2p21 aberrations; thyroid adenomas; THADA; fusion gene	CYTOGENETIC FINDINGS; TUMORS; TRANSLOCATION; 19Q13	Thyroid adenomas belong to the cytogenetically best investigated human epithelial tumors. Cytogenetic studies of about 450 benign lesions allow one to distinguish between different cytogenetic subgroups. Two chromosomal regions, that is, 19q13 and 2p21, are frequently rearranged in these tumors. Although 2p21 aberrations only account for about 10% of the benign thyroid tumors with clonal cytogenetic deviations, 2p21 rearrangements belong to the most common cytogenetic rearrangements in epithelial tumors due to the high frequency of these benign lesions. The 2p21 breakpoint region recently has been delineated to a region of 450 kbp, but the gene affected by the cytogenetic rearrangements still has escaped detection. Positional cloning and 3' RACE-PCR allowed us to clone that gene which we will refer to as thyroid adenoma associated (THADA) gene. In cells from two thyroid adenomas characterized by translocations t(2;20;3) (p21;q11.2;p25) and t(2;7)(p21;p15), respectively, we performed 3'-RACE-PCRs and found two fusions of THADA with a sequence derived from chromosome band 3p25 or with a sequence derived from chromosome band 7p15. The THADA gene spans roughly 365 kbp and, based on preliminary results, encodes a death receptor-interacting protein.	Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany; Cent Hosp Bremen Nord, Inst Pathol, Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, Leobener Str ZHG, D-28359 Bremen, Germany.	bullerdiek@uni-breinen.de	Rippe, Volkhard/I-1927-2013; Murua Escobar, Hugo/A-1294-2012	Rippe, Volkhard/0000-0001-8758-6013; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTNITZKE S, 1989, CANCER GENET CYTOGEN, V39, P65, DOI 10.1016/0165-4608(89)90230-6; BELGE G, 1992, CELL BIOL INT REP, V16, P339, DOI 10.1016/S0309-1651(06)80139-6; Belge G, 1998, CANCER GENET CYTOGEN, V101, P42, DOI 10.1016/S0165-4608(97)00057-5; Belge G, 2001, CYTOGENET CELL GENET, V93, P48, DOI 10.1159/000056947; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Bol S, 2001, CYTOGENET CELL GENET, V95, P189, DOI 10.1159/000059344; Bol S, 1999, CANCER GENET CYTOGEN, V114, P75, DOI 10.1016/S0165-4608(99)00028-X; BONDESON L, 1989, CANCER, V64, P680, DOI 10.1002/1097-0142(19890801)64:3<680::AID-CNCR2820640319>3.0.CO;2-I; BULLERDIEK J, 1987, CANCER GENET CYTOGEN, V24, P205, DOI 10.1016/0165-4608(87)90100-2; DALCIN P, 1992, CANCER GENET CYTOGEN, V60, P99, DOI 10.1016/0165-4608(92)90244-3; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; Rippe V, 1999, GENE CHROMOSOME CANC, V26, P229, DOI 10.1002/(SICI)1098-2264(199911)26:3<229::AID-GCC7>3.0.CO;2-J; TEYSSIER JR, 1990, CANCER GENET CYTOGEN, V50, P249, DOI 10.1016/0165-4608(90)90184-C	16	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6111	6114		10.1038/sj.onc.1206867	http://dx.doi.org/10.1038/sj.onc.1206867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955091				2022-12-28	WOS:000185137800021
J	McKenna, WG; Muschel, RJ; Gupta, AK; Hahn, SM; Bernhard, EJ				McKenna, WG; Muschel, RJ; Gupta, AK; Hahn, SM; Bernhard, EJ			The RAS signal transduction pathway and its role in radiation sensitivity	ONCOGENE			English	Article						RAS; EGFR; AKT; signal transduction; radiation sensitivity	MAP KINASE ACTIVATION; TUMOR-CELL LINES; H-RAS; FARNESYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC RADIOSENSITIVITY; CERVICAL-CARCINOMA; SMALL GTPASES; CANCER CELLS; NECK-CANCER	RAS has been shown to increase radiation resistance. Upstream and downstream pathways from RAS could thus be targets for manipulation of radiosensitivity. EGFR expression and AKT phosphorylation are also associated with the response to radiation. A retrospective study evaluating EGFR and AKT in patients treated with multimodality therapy found a significant association between P-AKT and treatment failure. Moreover, these data are strengthened by in vitro studies showing that inhibition of EGFR, RAS, PI3K, and AKT radiosensitized cancer cell lines. We have previously shown that PI3K is a mediator of RAS-induced radiation resistance. We now suggest that EGFR, which is upstream of PI3K, may also mediate resistance through a common pathway. In addition to EGFR and RAS, PTEN can also regulate the PI3K pathway. Identifying a common signal for EGFR, RAS, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control.	Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19103 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19103 USA	University of Pennsylvania; University of Pennsylvania	McKenna, WG (corresponding author), Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19103 USA.	mckenna@xrt.upenn.edu	BERNHARD, ERIC/HIU-0025-2022		NCI NIH HHS [P01 CA 75138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ader I, 2002, ONCOGENE, V21, P5998, DOI 10.1038/sj.onc.1205746; Arase Y, 2000, BIOCHEM BIOPH RES CO, V267, P33, DOI 10.1006/bbrc.1999.1857; Barabasi A.-L., 2002, LINKED NEW SCI NETWO, P256; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bernhard EJ, 2000, CANCER RES, V60, P6597; BERNHARD EJ, 2000, PRENYLTRANSFERASE IN; Bonner JA, 2000, J CLIN ONCOL, V18, p47S; Brognard J, 2001, CANCER RES, V61, P3986; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Cataldi A, 2001, CELL SIGNAL, V13, P369, DOI 10.1016/S0898-6568(01)00147-4; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; Delmas C, 2002, INT J CANCER, V100, P43, DOI 10.1002/ijc.10439; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Edwards E, 2002, CANCER RES, V62, P4671; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; GIRINSKY T, 1993, INT J RADIAT ONCOL, V25, P3, DOI 10.1016/0360-3016(93)90137-K; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Grana TM, 2002, CANCER RES, V62, P4142; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gupta AK, 2001, METHOD ENZYMOL, V333, P284; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hahn SM, 2002, CLIN CANCER RES, V8, P1065; HAHN SMK, 2000, CLIN CANCER RES, V8, P1065; Harari PM, 2002, SEMIN RADIAT ONCOL, V12, P21, DOI 10.1053/srao.2002.34865; Harari PM, 2001, INT J RADIAT ONCOL, V49, P427, DOI 10.1016/S0360-3016(00)01488-7; HENDERSON L, 2002, DISAPPOINTING IRESSA; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Klapper LN, 2000, ADV CANCER RES, V77, P25; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MCKENNA WG, 1990, CANCER RES, V50, P97; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; McKenna WG, 2002, SEMIN RADIAT ONCOL, V12, P27, DOI 10.1053/srao.2002.34866; Milas L, 2000, CLIN CANCER RES, V6, P701; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Pastan Ira, 2002, Curr Opin Investig Drugs, V3, P1089; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rait A, 2000, BIOCONJUGATE CHEM, V11, P153, DOI 10.1021/bc990106n; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Russell JS, 2002, CANCER RES, V62, P2318; Russell JS, 1999, CANCER RES, V59, P5239; Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO;2-8; Sheridan M T, 1997, Radiat Oncol Investig, V5, P180, DOI 10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.3.CO;2-Z; SHIN DM, 1994, CANCER RES, V54, P3153; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thomssen C, 2001, ANTI-CANCER DRUG, V12, pS19, DOI 10.1097/00001813-200112004-00004; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; WEST CML, 1991, LANCET, V338, P818, DOI 10.1016/0140-6736(91)90700-Y; WEST CML, 1995, INT J RADIAT ONCOL, V31, P841, DOI 10.1016/0360-3016(94)00508-7; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Workman P, 2001, CURR CANCER DRUG TAR, V1, P33, DOI 10.2174/1568009013334269; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	83	113	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5866	5875		10.1038/sj.onc.1206699	http://dx.doi.org/10.1038/sj.onc.1206699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947393				2022-12-28	WOS:000185086100013
J	Beniston, RG; Campo, MS				Beniston, RG; Campo, MS			Quercetin elevates p27(Kip1) and arrests both primary and HPV16 E6/E7 transformed human keratinocytes in G1	ONCOGENE			English	Article						HFK; HPV E6/E7; quercetin; cell cycle; p27(Kip1)	HUMAN-PAPILLOMAVIRUS DNA; CELL-CYCLE; GASTRIC-CANCER; BRACKEN FERN; E7; PROTEIN; PTAQUILOSIDE; DEGRADATION; APOPTOSIS; P53	Our previous work with primary bovine fibroblasts demonstrated that quercetin, a potent mutagen found in high levels in bracken fern (Pteridium aquilinum), arrested cells in G1 and G2/M, in correlation with p53 activation. The expression of bovine papillomavirus type 4 (BPV-4) E7 overcame this arrest and lead to the development of tumorigenic cells lines (Beniston et al., 2001). Given the possible link between papillomavirus infection, bracken fern in the diet and cancer of the upper gastrointestinal (GI) tract in humans, we investigated whether a similar situation would occur in human cells transformed by human papillomavirus type 16 (HPV-16) oncoproteins. Quercetin arrested primary human foreskin keratinocytes in G1. Arrest was linked to an elevation of the cyclin-dependent kinase inhibitor (cdki) p27(Kip1). Expression of the HPV16 E6 and E7 oncoproteins in transformed cells failed to abrogate cell cycle arrest. GI arrest in the transformed cells was also linked to an increase of p27(Kip1) with a concomitant reduction of cyctin E-associated kinase activity. This elevation of p27(Kip1) was due not only to increased protein half-life, but also to increased mRNA transcription.	Univ Glasgow, Sch Vet, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Campo, MS (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Garscube Estate, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk						Alonso-Amelot ME, 2001, INT J CANCER, V91, P252, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1028&gt;3.0.CO;2-; AlonsoAmelot ME, 1996, NATURE, V382, P587, DOI 10.1038/382587a0; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; BJELDANES LF, 1977, SCIENCE, V197, P577, DOI 10.1126/science.327550; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAIRNEY M, 1995, CARCINOGENESIS, V16, P1997, DOI 10.1093/carcin/16.8.1997; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; CHANG FJ, 1990, INT J CANCER, V45, P21, DOI 10.1002/ijc.2910450106; Choi JA, 2001, INT J ONCOL, V19, P837; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; COOPER K, 1995, J PATHOL, V175, P273, DOI 10.1002/path.1711750304; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Villiers EM, 1999, INT J CANCER, V81, P225, DOI 10.1002/(SICI)1097-0215(19990412)81:2&lt;225::AID-IJC10&gt;3.0.CO;2-0; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; FAZAL F, 1990, CARCINOGENESIS, V11, P2005, DOI 10.1093/carcin/11.11.2005; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GALPIN OP, 1990, BRIT J CANCER, V61, P737, DOI 10.1038/bjc.1990.165; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hirayama T., 1979, NUTR CANCER, V1, P67; HIRONO I, 1987, J NATL CANCER I, V79, P1143; ISHIDATE M, 1988, MUTAT RES, V195, P151, DOI 10.1016/0165-1110(88)90023-1; Iwashita K, 2000, BIOSCI BIOTECH BIOCH, V64, P1813, DOI 10.1271/bbb.64.1813; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; JACKSON ME, 1995, DNA TUMOUR VIRUSES O; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; JONES DL, 1921, GENE DEV, P11; LIANG Y, 2002, NAT MED, V10, P1163; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marliere CA, 2000, BRACKEN FERN TOXICIT, V4, P144; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MATOBA M, 1987, MUTAGENESIS, V2, P419, DOI 10.1093/mutage/2.6.419; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; Plaumann B, 1996, ONCOGENE, V13, P1605; Potter DM, 2000, BRIT J CANCER, V83, P914, DOI 10.1054/bjoc.2000.1368; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rong Y, 2000, ANTICANCER RES, V20, P4339; Sano T, 2002, PATHOL INT, V52, P375, DOI 10.1046/j.1440-1827.2002.01359.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SORSDAHL K, 1994, CANCER DETECT PREV, V18, P179; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suzuk L, 1996, CANCER-AM CANCER SOC, V78, P704; SUZUKI S, 1991, JPN J CANCER RES, V82, P1061, DOI 10.1111/j.1349-7006.1991.tb01757.x; Syrjanen KJ, 2002, J CLIN PATHOL, V55, P721, DOI 10.1136/jcp.55.10.721; TOGAWA K, 1994, GASTROENTEROLOGY, V107, P128, DOI 10.1016/0016-5085(94)90070-1; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; VILLALOBOSSALAZ.J, 1995, BRACKEN ENV ISSUE, P102; Yamashita N, 2000, FREE RADICAL RES, V33, P623, DOI 10.1080/10715760000301141; Zehbe I, 1999, ONCOGENE, V18, P2201, DOI 10.1038/sj.onc.1202549; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	66	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5504	5514		10.1038/sj.onc.1206848	http://dx.doi.org/10.1038/sj.onc.1206848			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934110	Green Accepted			2022-12-28	WOS:000184735000015
J	Fehrmann, F; Laimins, LA				Fehrmann, F; Laimins, LA			Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation	ONCOGENE			English	Review						HPV; cervical cancer; Oncoproteins; E6; E7; E5	RETINOBLASTOMA TUMOR-SUPPRESSOR; GROWTH-FACTOR RECEPTOR; E6 PROTEINS TARGET; HUMAN KERATINOCYTES; TYPE-16 E6; TELOMERASE ACTIVATION; E7 ONCOPROTEIN; E5 GENE; DEPENDENT ACTIVATION; ADENOVIRUS E4-ORF1	Human papillomavirus (HPV) infections play a crucial role in the pathogenesis of cervical neoplasia. Insights into the mechanisms by which HPV infection can, in a small numbers of cases, result in malignancy, comes from the observation that three proteins encoded by high-risk genital HPVs, E6, E7 and to a lesser extent E5, target factors that control the cell cycle and proliferation These interactions result in abrogation of cell cycle control, chromosomal alterations, telomerase activation, and eventual cell immortalization. In this review, we discuss the functions of E6, E7, and E5 proteins that are most relevant to the malignant progression of HPV-transformed cells.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Laimins, LA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	l-laimins@northwestern.edu						ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Villiers E M, 1994, Curr Top Microbiol Immunol, V186, P1; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIPAOLO JA, 1989, ONCOGENE, V4, P395; Doorbar J, 1997, VIROLOGY, V238, P40, DOI 10.1006/viro.1997.8768; DOORBAR J, 1991, NATURE, V352, P824, DOI 10.1038/352824a0; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; FRATTINI MG, 1994, VIROLOGY, V204, P799, DOI 10.1006/viro.1994.1596; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Howley PM, 2001, VIROLOGY, P2197; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Laimins LA, 1996, SEMIN VIROL, V7, P305, DOI 10.1006/smvy.1996.0038; LAMBERT PF, 1991, J VIROL, V65, P3417, DOI 10.1128/JVI.65.7.3417-3420.1991; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Lepik D, 2000, J VIROL, V74, P4688, DOI 10.1128/JVI.74.10.4688-4697.2000; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Ozbun MA, 2002, J VIROL, V76, P11291, DOI 10.1128/JVI.76.22.11291-11300.2002; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1992, ONCOGENE, V7, P27; Reddel RR, 1998, BIOESSAYS, V20, P977, DOI 10.1002/(SICI)1521-1878(199812)20:12<977::AID-BIES3>3.0.CO;2-E; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; Stubenrauch F, 1998, J VIROL, V72, P8115, DOI 10.1128/JVI.72.10.8115-8123.1998; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thomas JT, 2001, J VIROL, V75, P7564, DOI 10.1128/JVI.75.16.7564-7571.2001; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; VANOORTMARSSEN GJ, 1995, INT J EPIDEMIOL, V24, P300; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	119	178	197	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5201	5207		10.1038/sj.onc.1206554	http://dx.doi.org/10.1038/sj.onc.1206554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910257				2022-12-28	WOS:000184615100011
J	Israel, BF; Kenney, SC				Israel, BF; Kenney, SC			Virally targeted therapies for EBV-associated malignancies	ONCOGENE			English	Article						EBV; malignancy; therapeutics	EPSTEIN-BARR-VIRUS; IMMEDIATE-EARLY GENE; CYTOTOXIC T-LYMPHOCYTES; LATENTLY INFECTED-CELLS; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; LYTIC CYCLE; HODGKINS-DISEASE; BRLF1 PROMOTER; BZLF1 PROMOTER	In Epstein-Barr virus (EBV)-positive lymphomas, the presence of the EBV genome in virtually all tumor cells, but very few normal cells, suggests that novel, EBV-targeted therapies could be used to treat these malignancies. In this paper, we review a variety of different approaches currently under development that specifically target EBV-infected cells for destruction. EBV-based strategies for treating cancer include prevention of viral oncogene expression, inducing loss of the EBV episome, the purposeful induction of the lytic form of EBV infection, and enhancing the host immune response to virally encoded antigens.	Univ N Carolina, Dept Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kenney, SC (corresponding author), Univ N Carolina, Dept Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	shann@med.unc.edu			NCI NIH HHS [R01-CA66519, R01-CA58853] Funding Source: Medline; NIAID NIH HHS [K23-AI51200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058853, R01CA066519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI051200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370; Ambinder RF, 1996, SEMIN CANCER BIOL, V7, P217, DOI 10.1006/scbi.1996.0029; BENSASSON SA, 1981, INT J CANCER, V28, P131, DOI 10.1002/ijc.2910280204; Binne UK, 2002, J VIROL, V76, P10282, DOI 10.1128/JVI.76.20.10282-10289.2002; Bollard CM, 2002, BLOOD, V99, P3179, DOI 10.1182/blood.V99.9.3179; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Bryant H, 2002, J VIROL, V76, P10290, DOI 10.1128/JVI.76.20.10290-10298.2002; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; Chang LK, 2000, NUCLEIC ACIDS RES, V28, P3918, DOI 10.1093/nar/28.20.3918; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; Chapman ALN, 2001, CANCER RES, V61, P6219; Chatila T, 1997, J VIROL, V71, P6560, DOI 10.1128/JVI.71.9.6560-6567.1997; CHEN CY, 1995, HUM GENE THER, V6, P1467, DOI 10.1089/hum.1995.6.11-1467; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; Chodosh J, 1998, J INFECT DIS, V177, P1194, DOI 10.1086/515290; Chua D, 2001, INT J CANCER, V94, P73, DOI 10.1002/ijc.1430; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Connors TA, 1995, GENE THER, V2, P702; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; DAIBATA M, 1994, VIROLOGY, V198, P446, DOI 10.1006/viro.1994.1056; Darr CD, 2001, J VIROL, V75, P6135, DOI 10.1128/JVI.75.13.6135-6142.2001; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DAVIES AH, 1991, J VIROL, V65, P6838, DOI 10.1128/JVI.65.12.6838-6844.1991; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; FAGGIONI A, 1986, SCIENCE, V232, P1554, DOI 10.1126/science.3012779; Falk KI, 1999, ARCH VIROL, V144, P2219, DOI 10.1007/s007050050636; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; Feng WH, 2002, J VIROL, V76, P10951, DOI 10.1128/JVI.76.21.10951-10959.2002; Feng WH, 2002, CANCER RES, V62, P1920; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; Franken M, 1996, NAT MED, V2, P1379, DOI 10.1038/nm1296-1379; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gahn B, 2001, INT J CANCER, V93, P706, DOI 10.1002/ijc.1396; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Gottschalk S, 2001, BLOOD, V97, P835, DOI 10.1182/blood.V97.4.835; Gradoville L, 2002, J VIROL, V76, P5612, DOI 10.1128/JVI.76.11.5612-5626.2002; Grinstein S, 2002, CANCER RES, V62, P4876; Gruffat H, 2002, EMBO REP, V3, P141, DOI 10.1093/embo-reports/kvf031; Gutierrez MI, 1996, CANCER RES, V56, P969; HARDWICK JM, 1988, J VIROL, V62, P2274, DOI 10.1128/JVI.62.7.2274-2284.1988; Hirai H, 1997, BIOCHEM BIOPH RES CO, V241, P112, DOI 10.1006/bbrc.1997.7776; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Judde JG, 1996, HUM GENE THER, V7, P647, DOI 10.1089/hum.1996.7.5-647; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kenney S, 1998, HUM GENE THER, V9, P1131, DOI 10.1089/hum.1998.9.8-1131; KIEFF E, 2001, FIELDS VIROLOGY, V2, P2397; KIEFF E, 2001, FIELDS VIROLOGY, V2, P2343; Kim SH, 1997, J NEURO-ONCOL, V33, P189, DOI 10.1023/A:1005764324900; Kraus RJ, 2001, J VIROL, V75, P867, DOI 10.1128/JVI.75.2.867-877.2001; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Li JH, 2002, CANCER RES, V62, P171; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; Meij P, 2002, INT J CANCER, V99, P93, DOI 10.1002/ijc.10309; Mentzer S J, 2001, Transpl Infect Dis, V3, P177, DOI 10.1034/j.1399-3062.2001.003003177.x; Mentzer SJ, 1998, BLOOD CELL MOL DIS, V24, P114, DOI 10.1006/bcmd.1998.0178; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MONTALVO EA, 1995, J VIROL, V69, P4158, DOI 10.1128/JVI.69.7.4158-4165.1995; Moore SM, 2001, ANTIMICROB AGENTS CH, V45, P2082, DOI 10.1128/AAC.45.7.2082-2091.2001; Murono S, 2000, CANCER RES, V60, P2555; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Putnam DA, 1996, AM J HEALTH-SYST PH, V53, P151; Ragoczy T, 1998, J VIROL, V72, P7978, DOI 10.1128/JVI.72.10.7978-7984.1998; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Robertson K D, 1995, Curr Top Microbiol Immunol, V194, P145; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; Rooney C M, 1998, J Natl Cancer Inst Monogr, P89; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; Roskrow MA, 1998, BLOOD, V91, P2925, DOI 10.1182/blood.V91.8.2925.2925_2925_2934; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; Slobod KS, 2000, LANCET, V356, P1493, DOI 10.1016/S0140-6736(00)02879-8; Speck SH, 1997, TRENDS MICROBIOL, V5, P399, DOI 10.1016/S0966-842X(97)01129-3; Su Z, 2001, EUR J IMMUNOL, V31, P947, DOI 10.1002/1521-4141(200103)31:3<947::AID-IMMU947>3.0.CO;2-M; Sugawara Y, 2000, SCAND J GASTROENTERO, V35, P981, DOI 10.1080/003655200750023075; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; TIBERGHIEN P, 1994, J LEUKOCYTE BIOL, V56, P203, DOI 10.1002/jlb.56.2.203; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang YCJ, 1997, VIROLOGY, V227, P323, DOI 10.1006/viro.1996.8326; Westphal EM, 2000, CANCER RES, V60, P5781; Westphal EM, 2000, CANCER GENE THER, V7, P97, DOI 10.1038/sj.cgt.7700102; Westphal EM, 1999, CANCER RES, V59, P1485; Wildner O, 1999, CANCER RES, V59, P5233; ZALANI S, 1992, J VIROL, V66, P7282, DOI 10.1128/JVI.66.12.7282-7292.1992; Zalani S, 1997, J VIROL, V71, P3268, DOI 10.1128/JVI.71.4.3268-3274.1997; ZALANI S, 1995, J VIROL, V69, P3816, DOI 10.1128/JVI.69.6.3816-3823.1995; Zalani S, 1996, P NATL ACAD SCI USA, V93, P9194, DOI 10.1073/pnas.93.17.9194; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZURHAUSEN H, 1978, NATURE, V272, P373	99	82	85	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5122	5130		10.1038/sj.onc.1206548	http://dx.doi.org/10.1038/sj.onc.1206548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910249				2022-12-28	WOS:000184615100003
J	Matsuoka, M				Matsuoka, M			Human T-cell leukemia virus type I and adult T-cell leukemia	ONCOGENE			English	Article						ATL; HTLV-I; tax; cytotoxic T cell; leukemogenesis; retrovirus	NF-KAPPA-B; HORMONE-RELATED PROTEIN; BLOOD MONONUCLEAR-CELLS; NON-HODGKIN-LYMPHOMA; HTLV-I; TAX PROTEIN; INFECTED CELLS; NUCLEAR-FACTOR; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR	Human T-cell leukemia virus type I (HTLV-I) causes adult T-cell leukemia (ATL) in about 5% of carriers after a long latent period. After its infection, HTLV-I promotes the clonal proliferation of HTLV-I infected cells in vivo by actions of encoded viral proteins, including Tax. However, leukemic cells frequently lack the expression of Tax by the genetic and epigenetic changes of HTLV-I provirus, suggesting that Tax is not always necessary after transformation. Alternatively, ATL cells without Tax protein could escape from the host immune system since Tax is the major target of cytotoxic lymphocytes. During the latent period, alterations of host genome accumulate, finally leading to onset of ATL.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Matsuoka, M (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.			Matsuoka, Masao/0000-0002-0473-754X				AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Arisawa K, 2002, CANCER CAUSE CONTROL, V13, P657, DOI 10.1023/A:1019511224501; Arisawa K, 2000, INT J CANCER, V85, P319, DOI 10.1002/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO;2-B; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BLATTNER WA, 1994, ADULT TCELL LEUKEMIA, P4; Borg A, 1996, BRIT J HAEMATOL, V94, P713, DOI 10.1046/j.1365-2141.1996.02338.x; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; CESARMAN E, 1992, BLOOD, V80, P3205; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Ding W, 2001, J VIROL, V75, P7672, DOI 10.1128/JVI.75.16.7672-7682.2001; Etoh K, 1999, INT J CANCER, V81, P859, DOI 10.1002/(SICI)1097-0215(19990611)81:6<859::AID-IJC4>3.0.CO;2-K; Etoh K, 1997, CANCER RES, V57, P4862; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361; GREENBERG SJ, 1990, BLOOD, V76, P911; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Hasegawa H, 2000, BLOOD, V95, P30; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HIMES SR, 1993, ONCOGENE, V8, P3189; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561; Hoshida Y, 2001, INT J CANCER, V91, P869, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1125>3.0.CO;2-N; Iga M, 2002, J INFECT DIS, V185, P691, DOI 10.1086/339002; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KANNAGI M, 1991, INT IMMUNOL, V3, P761, DOI 10.1093/intimm/3.8.761; KATSUKI T, 1987, JPN J CANCER RES, V78, P639; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; MATSUOKA M, 2002, LEUKEMIA, P705; Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mori N, 1999, BLOOD, V93, P2360; MURAOKA O, 1993, IMMUNOL LETT, V37, P159, DOI 10.1016/0165-2478(93)90026-X; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; NIITSU Y, 1988, BLOOD, V71, P263; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Nosaka K, 2000, CANCER RES, V60, P1043; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1557::AID-CNCR5>3.0.CO;2-H; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; SAKASHITA A, 1992, BLOOD, V79, P477; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1994, ADULT T CELL LEUKEMI, P22; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAJIMA K, 1994, ADULT TCELL LEUKEMIA, P9; Takaori-Kondo A, 1998, BLOOD, V91, P4747, DOI 10.1182/blood.V91.12.4747.412k41_4747_4751; Takatsuki T., 1977, 16 INT C HEM AMST, P73; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tamiya S, 1998, BLOOD, V91, P3935; TOBINAI K, 1991, LEUKEMIA RES, V15, P837, DOI 10.1016/0145-2126(91)90468-9; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Tsukasaki K, 2001, CANCER RES, V61, P3770; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; VILLIGER PM, 1991, J IMMUNOL, V146, P550; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307; Wodarz D, 2001, P ROY SOC B-BIOL SCI, V268, P1215, DOI 10.1098/rspb.2001.1608; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x; YAMAGUCHI K, 1994, LEUKEMIA, V8, P1708; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	96	144	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5131	5140		10.1038/sj.onc.1206551	http://dx.doi.org/10.1038/sj.onc.1206551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910250				2022-12-28	WOS:000184615100004
J	Hastak, K; Gupta, S; Ahmad, N; Agarwal, MK; Agarwal, ML; Mukhtar, H				Hastak, K; Gupta, S; Ahmad, N; Agarwal, MK; Agarwal, ML; Mukhtar, H			Role of p53 and NF-kappa B in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells	ONCOGENE			English	Article						epigallocatechin-3-gallate; prostate cancer; p53; NF-kappa B; Bax; Bcl-2; caspases; apoptosis	TEA CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE; CYCLE ARREST; GROWTH-INHIBITION; GREEN; ACTIVATION; EXPRESSION; PHOSPHORYLATION; GALLATE; FAMILY; GENES	We have recently shown that oral consumption of green tea polyphenols inhibits prostate carcinogenesis in transgenic mouse model of prostate cancer and suggested that induction of apoptosis in prostate cancer cells is responsible for these effects. Much of the chemopreventive effects of green tea are attributed to its major polyphenolic constituent (-) epigallocatechin-3-gallate (EGCG). In the present study, we report that EGCG-induced apoptosis in human prostate carcinoma LNCaP cells is mediated via modulation of two related pathways: (a) stabilization of p53 by phosphorylation on critical serine residues and p14(ARF)-mediated downregulation of murine double minute 2(MDM2) protein, and (b) negative regulation of NF-kappaB activity, thereby decreasing the expression of the proapoptotic protein Bcl-2. EGCG-induced stabilization of p53 caused an upregulation in its transcriptional activity, thereby resulting in activation of its downstream targets p21/WAF1 and Bax. Thus, EGCG had a concurrent effect on two important transcription factors p53 and NF-kappaB, causing a change in the ratio of Bax/Bcl-2 in a manner that favors apoptosis. This altered expression of Bcl-2 family members triggered the activation of initiator capsases 9 and 8 followed by activation of effector caspase 3. Activation of the caspases was followed by poly (ADP-ribose) polymerase cleavage and induction of apoptosis. Taken together, the data indicate that EGCG induces apoptosis in human prostate carcinoma cells by shifting the balance between pro- and antiapoptotic proteins in favor of apoptosis.	Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Cleveland Clin, Dept Mol Biol, Learner Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Jim & Eillen Dicke Res Lab, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; University Hospitals of Cleveland	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159/000068711; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Otsuka T, 1998, LIFE SCI, V63, P1397, DOI 10.1016/S0024-3205(98)00406-8; Pianetti S, 2002, CANCER RES, V62, P652; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TOHYAMA M, 1999, BIOL CHEM, V274, P8531; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2001, NATURE, V412, P865, DOI 10.1038/35091170; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weisburger JH, 1999, P SOC EXP BIOL MED, V220, P271, DOI 10.1046/j.1525-1373.1999.d01-46.x; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	44	254	279	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4851	4859		10.1038/sj.onc.1206708	http://dx.doi.org/10.1038/sj.onc.1206708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894226				2022-12-28	WOS:000184344600008
J	Rosner, M; Hofer, K; Kubista, M; Hengstschlager, M				Rosner, M; Hofer, K; Kubista, M; Hengstschlager, M			Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38	ONCOGENE			English	Article						TSC1; TSC2; tuberin; hamartin; tuberous sclerosis; cell cycle; cell size	SCLEROSIS GENE-2 PRODUCT; C-MYC; EMBRYONIC LETHALITY; GENETIC-CONTROL; KINASE-ACTIVITY; TUBERIN; HAMARTIN; GROWTH; IDENTIFICATION; ACTIVATION	TSC1 and TSC2 are responsible for the tumor suppressor gene syndrome tuberous sclerosis (TSC). Mammalian TSC genes have been shown to be involved in cell cycle regulation. Recently, in Drosophila, these data have been confirmed and TSC genes have further been demonstrated to affect cell size control. Here we provide supporting data for the fact that the latter function is conserved in mammals. Human TSC1 and TSC2 trigger mammalian cell size reduction and a dominant-negative TSC2 mutant induces increased size. These effects occur in all cell cycle phases, are dependent on the activity of the phosphoinositide-3-kinase and are abolished by co-overexpression of a dominant-negative Akt mutant. Two independent naturally occurring and disease-causing mutations within the TSC2 gene eliminate tuberin's capacity to affect cell size control, emphasizing the relevance of this function for the development of the disease. The same mutations have earlier been shown not to affect tuberin's antiproliferative capacity. That the consequences of modulated TSC gene expression on cell proliferation and on cell size can be assigned to separable functions is further supported by two findings: A mutation within the TSC1 gene, earlier shown to still harbor anti-proliferative effects, was found to eliminate the cell size regulating functions. An important mammalian cell size regulator, c-Myc, was found to inhibit tuberin's antiproliferative capacity, but to have no effects on tuberin-dependent cell size control. To obtain further mechanistical insights, microarray screens for genes involved in TSC1- or TSC2-mediated cell size effects were performed. Antisense experiments revealed that the so observed regulation of the FK506-binding protein, FKBP38, plays a role in TSC gene-dependent cell size regulation. These data provide new insights into mammalian cell size regulation and allow a better understanding of the function of human TSC genes.	Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@akh-wien.ac.at	Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwan KM, 2002, GENESIS, V32, P49, DOI 10.1002/gene.10068; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Mak BC, 2003, J BIOL CHEM, V278, P5947, DOI 10.1074/jbc.C200473200; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2002, J NEUROPATH EXP NEUR, V61, P154, DOI 10.1093/jnen/61.2.154; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Montagne J, 2001, Sci STKE, V2001, ppe36, DOI 10.1126/stke.2001.105.pe36; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	66	85	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4786	4798		10.1038/sj.onc.1206776	http://dx.doi.org/10.1038/sj.onc.1206776			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894220				2022-12-28	WOS:000184344600002
J	Song, LX; Turkson, J; Karras, JG; Jove, R; Haura, EB				Song, LX; Turkson, J; Karras, JG; Jove, R; Haura, EB			Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells	ONCOGENE			English	Article						STAT proteins; lung cancer; Src; IL-6; HGF; EGF receptor; tyrosine kinase inhibitors	EPIDERMAL-GROWTH-FACTOR; LUNG-CANCER; CONSTITUTIVE ACTIVATION; SRC KINASES; FACTOR-I; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; FACTOR-ALPHA; INHIBITOR; APOPTOSIS	Overexpression of receptor tyrosine kinases including the epidermal growth factor receptor (EGF-R) as well as nonreceptor tyrosine kinases, such as Src, have been implicated in the formation of human lung cancers. In addition, cytokines like interleukin-6 (IL-6) have been demonstrated to modulate lung cancer cell growth and elevated levels of IL-6 have been shown to be an adverse prognostic factor for patients with lung cancer. Despite a large body of evidence pointing to their potential importance, few direct studies into the role of signal transducers and activators of transcription (STAT) pathways in human lung cancer have been undertaken. Here we demonstrate that multiple nonsmall cell lung cancer cell lines demonstrate constitutive Stat3 DNA-binding activity. Stat3 DNA-binding activity is specifically upregulated by the addition of epidermal growth factor (EGF), IL-6, and hepatocyte-derived growth factor (HGF). Furthermore, the stimulation of Stat3 DNA-binding activity by EGF requires the activity of EGF-R tyrosine kinase as well as Src-kinase, while the upregulation of Stat3 activity by IL-6 or HGF requires only Src-kinase activity. Treatment of A549 lung cancer cells with PD180970 or SU6656, both pharmacological inhibitors of Src-kinase, resulted in reduced Src and Stat3 activity, cell cycle arrest in G2, and reduced viability of cells accompanied by induction of apoptosis. Treatment of Stat3-positive A549 and H358 cells with antisense Stat3 oligonucleotides results in complete loss of Stat3 DNA-binding activity and apoptosis, while Stat3-positive H1299 cells remained healthy. Finally, an adenoviral vector expressing a dominant-negative Stat3 isoform results in loss of Stat3 DNA-binding activity, apoptosis, and reduced cellular viability. These results demonstrate a role of Stat3 in transducing survival signals downstream of tyrosine kinases such as Src, EGF-R, and c-Met, as well as cytokines such as IL-6, in human nonsmall cell lung cancers.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Isis Pharmaceuticals Inc	Haura, EB (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, MRC3 E,Room 3056,12902 Magnolia Dr, Tampa, FL 33612 USA.	hauraeb@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [P01CA082533] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI W, 1995, BRIT MED J, V311, P899; ANKRAPP DP, 1993, CANCER RES, V53, P3399; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman, 1999, Cancer Control, V6, P615; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Brognard J, 2001, CANCER RES, V61, P3986; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Carbone DP, 1997, SEMIN ONCOL, V24, P388; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Doucet C, 2000, ONCOGENE, V19, P5898, DOI 10.1038/sj.onc.1203933; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fang K, 1999, INT J CANCER, V81, P471; FAVONI RE, 1994, INT J CANCER, V56, P858, DOI 10.1002/ijc.2910560618; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hallek M, 1997, EXP HEMATOL, V25, P1367; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hitt DC, 2000, MOL BIOTECHNOL, V14, P197, DOI 10.1385/MB:14:3:197; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kawai T, 1997, LAB INVEST, V77, P431; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kopantzev Y, 2002, ONCOGENE, V21, P6791, DOI 10.1038/sj.onc.1205815; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1998, CANCER RES, V58, P4660; LEE M, 1992, JNCI-J NATL CANCER I, V13, P117; Lei WD, 1998, BIOCHEM BIOPH RES CO, V245, P939, DOI 10.1006/bbrc.1998.8552; Lei WD, 1999, ANTICANCER RES, V19, P221; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Ling YH, 2000, ANTICANCER RES, V20, P693; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Martin F, 1999, CYTOKINE, V11, P80, DOI 10.1006/cyto.1998.0398; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Moasser MM, 1999, CANCER RES, V59, P6145; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Norman P, 2001, Curr Opin Investig Drugs, V2, P428; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; RABIASZ GJ, 1992, BRIT J CANCER, V66, P254, DOI 10.1038/bjc.1992.253; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RUSCH V, 1993, CANCER RES, V53, P2379; Rusch V, 1997, CLIN CANCER RES, V3, P515; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; Siegfried JM, 1997, CANCER RES, V57, P433; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Takahashi T, 1999, CIRC RES, V85, P884; TAKANAMI I, 1995, J SURG ONCOL, V58, P40, DOI 10.1002/jso.2930580109; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; YANAGAWA H, 1995, BRIT J CANCER, V71, P1095, DOI 10.1038/bjc.1995.212; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	89	315	347	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4150	4165		10.1038/sj.onc.1206479	http://dx.doi.org/10.1038/sj.onc.1206479			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833138				2022-12-28	WOS:000183979800002
J	Atlas, E; Bojanowski, K; Mehmi, I; Lupu, R				Atlas, E; Bojanowski, K; Mehmi, I; Lupu, R			A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity	ONCOGENE			English	Article						HRG; mutants; drug resistance; doxorubicin; estrogen dependence; antiestrogen resistance; breast cancer	TOPOISOMERASE-II; GROWTH-FACTOR; ESTROGEN-RECEPTOR; EXPRESSION; APOPTOSIS; INDUCTION; ONCOGENE; LINE; DIFFERENTIATION; PROLIFERATION	Heregulin (HRG) is an activator of the erbB2-, erbB3- and erB4-(erbB-2/3/4) signaling pathway. Transfection of full-length HRG cDNA into the estrogen (E2)-dependent cell line MCF-7 promoted an invasive E2-independent phenotype, as well as persistent activation of the erbB-2/3/4 receptors. Moreover, HRG expression in MCF-7 cells renders the cells sensitive to the topoisomerase 11 inhibitor doxorubicin (Doxo). In an attempt to dissociate the tumorigenic effect of HRG from the sensitizing effect to chemotherapy, we constructed a structural deletion mutant of HRG. Transfection of the deletion mutant of HRG described in this study (HRG/M) into MCF-7 cells resulted in the dissociation of the tumor-promoting activity of HRG from the sensitization to Doxo, that is, although the cells did not become more aggressive or E2-independent they became more sensitive to Doxo. HRG/M was unable to autophosphorylate the erbB receptors and did not affect the level of MAPK phosphorylation. Furthermore, the intracellular localization of the protein was different from that of the full-length protein. Our data show that the HRG/M sequences are sufficient to sensitize MCF-7 cells to Doxo, and provide evidence that this sensitization is independent of erbB2 activation.	Northwestern Univ, Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA	Northwestern University	Lupu, R (corresponding author), Northwestern Univ, Evanston NW Healthcare Res Inst, 1001 Univ Pl,2650 Ridge Ave, Evanston, IL 60201 USA.							Alper O, 2000, INT J CANCER, V88, P566, DOI 10.1002/1097-0215(20001115)88:4<566::AID-IJC8>3.0.CO;2-D; Aoyama M, 1998, BIOCHEM J, V336, P727, DOI 10.1042/bj3360727; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Harris LN, 2001, CLIN CANCER RES, V7, P1497; Hijazi MM, 2000, INT J ONCOL, V17, P629; Keir M, 2000, STEM CELLS, V18, P422, DOI 10.1634/stemcells.18-6-422; Krane IM, 1996, ONCOGENE, V12, P1781; Lessor T, 1998, J CELL BIOCHEM, V70, P587, DOI 10.1002/(SICI)1097-4644(19980915)70:4<587::AID-JCB14>3.0.CO;2-E; Li WL, 1996, ONCOGENE, V12, P2473; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Matsumoto Y, 1999, J NEURO-ONCOL, V45, P37, DOI 10.1023/A:1006346624083; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Talukder AH, 2000, CANCER RES, V60, P276; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2000, CANCER RES, V60, P5603; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; Xiong SB, 2001, CANCER RES, V61, P1727	27	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3441	3451		10.1038/sj.onc.1206410	http://dx.doi.org/10.1038/sj.onc.1206410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776196				2022-12-28	WOS:000183128500011
J	Dang, DT; Chen, XM; Feng, J; Torbenson, M; Dang, LH; Yang, VW				Dang, DT; Chen, XM; Feng, J; Torbenson, M; Dang, LH; Yang, VW			Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity	ONCOGENE			English	Article						Kruppel-like factor 4; tumorigenecity; RKO; colorectal cancer	ZINC-FINGER PROTEIN; CARCINOMA CELLS; GENE-EXPRESSION; IN-VIVO; TRANSCRIPTION; DIFFERENTIATION; GROWTH; GKLF; PROLIFERATION; PROGRESSION	Kruppel-like factor 4 (KLF4) is a zinc-finger-containing transcription factor, the expression of which is enriched in the postmitotic cells of the intestinal epithelium. KLF4 is a target gene of the tumor suppressor adenomatous polyposis coli (APC). We sought to determine the role of KLF4 in suppressing the tumorigenecity of RKO colon cancer cells, which do not express KLF4. We utilized an established system in RKO cells, in which an inducible promoter controls expression of KLF4. Four independent assays were used to assess the effects of KLF4 induction on tumor cells. We find that KLF4 overexpression reduces colony formation, cell migration and invasion, and in vivo tumorigenecity. The mechanism of action of KLF4 does not involve apoptosis. These findings, along with our previous findings that KLF4 induces G1/S arrest, suggest that KLF4 is a cell cycle checkpoint protein that can reduce tumorigenecity of colon cancer cells.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Johns Hopkins University; Emory University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Emory University	Dang, DT (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 720 Rutland Ave,Ross 918, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, K08DK059970] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197, R01 CA084197-04, CA84197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230-06, DK52230, DK59970, K08 DK059970, R01 DK052230] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Behr R, 2002, MECH DEVELOP, V115, P167, DOI 10.1016/S0925-4773(02)00127-2; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Katz JP, 2002, DEVELOPMENT, V129, P2619; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Luo J, 2002, PROSTATE, V51, P189, DOI 10.1002/pros.10087; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; Rigas A, 2002, CANCER INVEST, V20, P657, DOI 10.1081/CNV-120002491; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Suh E, 1996, MOL CELL BIOL, V16, P619; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	31	133	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3424	3430		10.1038/sj.onc.1206413	http://dx.doi.org/10.1038/sj.onc.1206413			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776194	Green Accepted			2022-12-28	WOS:000183128500009
J	Hendrix, MJC; Seftor, EA; Hess, AR; Seftor, REB				Hendrix, MJC; Seftor, EA; Hess, AR; Seftor, REB			Molecular plasticity of human melanoma cells	ONCOGENE			English	Article						melanoma; plasticity; vasculogenic mimicry; VE-cadherin; EphA2	HUMAN UVEAL MELANOMA; VASCULOGENIC MIMICRY; ENDOTHELIAL SURVIVAL; VE-CADHERIN; STEM-CELLS; ANGIOGENESIS; EXPRESSION; GENE; LAMININ-5; ADHESION	The molecular analysis of tumors, such as melanoma, has benefited significantly from microarray technology that can facilitate the classification of tumors based on the differential expression of genes. The data summarized in this review describe the molecular profile of aggressive cutaneous and uveal melanoma cells as that of multiple phenotypes similar to a pluripotent, embryonic-like stem cell. A noteworthy example of the plasticity of the aggressive melanoma cell phenotype is demonstrated by the ability of these tumor cells to engage in vasculogenic mimicry and neovascularization. A review of the current evidence demonstrating important cellular and molecular determinants of melanoma vasculogenic mimicry is presented. In addition, novel signaling pathways are discussed, involving VE-cadherin, EphA2, FAK, and PI 3-kinase, which promote cell migration, invasion, and matrix remodeling. The observations summarized in this review describe some of the key molecular events that regulate the process of melanoma vasculogenic mimicry and identify new signal transduction pathways that can serve as putative targets for therapeutic intervention.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of Iowa	Hendrix, MJC (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Holden Comprehens Canc Ctr, Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.				NATIONAL CANCER INSTITUTE [R01CA088043, R01CA059702, T32CA079445, R01CA080318, R37CA059702] Funding Source: NIH RePORTER; NCI NIH HHS [CA80318, CA88043-02S1, CA79445-03, CA59702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Clarijs R, 2002, INVEST OPHTH VIS SCI, V43, P912; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; D'Amour KA, 2002, NAT MED, V8, P213, DOI 10.1038/nm0302-213; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hendrix MJC, 2002, CANCER RES, V62, P665; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2001, CANCER RES, V61, P3250; HESS AR, 2002, THESIS U IOWA IOWA C, P1; HESS AR, 2002, CANCER RES, V43, P36; Holden C, 2002, SCIENCE, V296, P2126, DOI 10.1126/science.296.5576.2126; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; Kemler R, 1992, Semin Cell Biol, V3, P149; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Khan J, 1998, CANCER RES, V58, P5009; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kumar R, 1998, IN VIVO, V12, P27; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Maniotis AJ, 2002, LAB INVEST, V82, P1031, DOI 10.1097/01.LAB.0000024362.12721.67; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Rak J, 1996, CANCER METAST REV, V15, P231, DOI 10.1007/BF00437476; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Seftor REB, 2001, CANCER RES, V61, P6322; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Vogel G, 2002, SCIENCE, V295, P1989, DOI 10.1126/science.295.5562.1989; Warso MA, 2001, CLIN CANCER RES, V7, P473; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	45	178	199	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3070	3075		10.1038/sj.onc.1206447	http://dx.doi.org/10.1038/sj.onc.1206447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789282				2022-12-28	WOS:000183096600007
J	Streit, M; Detmar, M				Streit, M; Detmar, M			Angiogenesis, lymphangiogenesis, and melanoma metastasis	ONCOGENE			English	Review						VEGF; FGF; LYVE-1; VEGF-C	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; INCREASES TUMOR-GROWTH; LYMPH-NODE METASTASIS; IN-SITU HYBRIDIZATION; MALIGNANT-MELANOMA; FACTOR EXPRESSION; FACTOR-C; TRANSFORMED PHENOTYPE; INHIBIT ANGIOGENESIS	The induction of angiogenesis is a critical point in the development of most human tumors - including melanomas. Some of the earliest studies in the field of tumor angiogenesis showed that transplantation of human melanoma fragments into the hamster cheek pouch stimulated blood vessel growth. Since then, numerous studies have demonstrated that human melanomas also induce angiogenesis. The prognostic importance of the degree of melanoma vascularization, however, has remained controversial. Elevated expression of several angiogenic factors, including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8, has been detected in primary cutaneous melanomas, and the importance of these mediators in promoting melanoma angiogenesis and metastasis has been confirmed in tumor xenotransplant models. Based upon these findings, several clinical trials of angiogenesis inhibitors have been initiated in human melanoma patients and are currently underway. Recent experimental evidence indicates that tumor-associated lymphangiogenesis also plays an important role in mediating tumor spread to regional lymph nodes. These observations have important implications for prognosis and treatment of human melanomas.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Dermatol, Charlestown, MA 02129 USA; Berlex Biosci, Richmond, CA 94804 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Detmar, M (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410, R01CA091861] Funding Source: NIH RePORTER; NCI NIH HHS [CA69184, CA91861, CA86410] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Ahmed NU, 1997, MELANOMA RES, V7, P299, DOI 10.1097/00008390-199708000-00004; BARNHILL RL, 1993, AM J PATHOL, V143, P99; Barnhill RL, 1996, BRIT J DERMATOL, V135, P898, DOI 10.1046/j.1365-2133.1996.d01-1092.x; BARNHILL RL, 1992, LAB INVEST, V67, P331; Bayer-Garner IB, 1999, MODERN PATHOL, V12, P770; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; BUSAM KJ, 1995, AM J PATHOL, V147, P1049; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARNOCHAN P, 1991, BRIT J CANCER, V64, P102, DOI 10.1038/bjc.1991.250; Cascinelli N, 2000, EXP DERMATOL, V9, P439, DOI 10.1034/j.1600-0625.2000.009006439.x; Claffey KP, 1996, CANCER RES, V56, P172; DADRAS SS, 2003, IN PRESS AM J PATHOL; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; Detmar M, 2002, J EXP MED, V196, P713, DOI 10.1084/jem.20021346; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Dreau D, 2000, ONCOL RES, V12, P241; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eisen T, 2000, BRIT J CANCER, V82, P812, DOI 10.1054/bjoc.1999.1004; Erhard H, 1997, MELANOMA RES, V7, pS19; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; Graeven U, 2001, CANCER RES, V61, P7282; Graeven U, 1999, J CANCER RES CLIN, V125, P621, DOI 10.1007/s004320050325; GRAHAM CH, 1994, AM J PATHOL, V145, P510; Grant SW, 1998, CANCER DETECT PREV, V22, P185, DOI 10.1046/j.1525-1500.1998.0oa18.x; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann A, 1999, CANCER RES, V59, P1578; Hawighorst T, 2001, EMBO J, V20, P2631, DOI 10.1093/emboj/20.11.2631; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hendrix MJC, 2002, CANCER RES, V62, P665; Huang SY, 1996, CLIN CANCER RES, V2, P1969; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; HUBLER WR, 1976, CANCER, V38, P187, DOI 10.1002/1097-0142(197607)38:1<187::AID-CNCR2820380129>3.0.CO;2-D; Hwu WJ, 2002, J CLIN ONCOL, V20, P2610, DOI 10.1200/JCO.2002.09.034; Hwu WJ, 2000, ONCOLOGY-NY, V14, P25; Ilmonen S, 1999, MELANOMA RES, V9, P273; Karpanen T, 2001, CANCER RES, V61, P1786; Kashani-Sabet M, 2002, J CLIN ONCOL, V20, P1826, DOI 10.1200/JCO.2002.07.082; Kumar CC, 2001, CANCER RES, V61, P2232; Kusters B, 2002, CANCER RES, V62, P341; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li YW, 2002, J EXP MED, V195, P1575, DOI 10.1084/jem.20020072; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; Lode HN, 1999, P NATL ACAD SCI USA, V96, P1591, DOI 10.1073/pnas.96.4.1591; Luca M, 1997, AM J PATHOL, V151, P1105; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marcoval J, 1997, J CUTAN PATHOL, V24, P212, DOI 10.1111/j.1600-0560.1997.tb01583.x; Miao WM, 2001, CANCER RES, V61, P7830; Mihm M C Jr, 1975, Semin Oncol, V2, P105; Min HY, 1996, CANCER RES, V56, P2428; Morin MJ, 2000, ONCOGENE, V19, P6574, DOI 10.1038/sj.onc.1204102; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Naglich JG, 2001, CANCER RES, V61, P8480; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V114, P373; Plum SM, 2000, VACCINE, V19, P1294, DOI 10.1016/S0264-410X(00)00210-3; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; POTGENS AJG, 1995, AM J PATHOL, V146, P197; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Rak J, 2002, CANCER RES, V62, P1931; REED JA, 1994, AM J PATHOL, V144, P329; Reiher FK, 2002, INT J CANCER, V98, P682, DOI 10.1002/ijc.10247; Rofstad EK, 2000, CANCER RES, V60, P4932; Rofstad EK, 2002, BRIT J CANCER, V86, P301, DOI 10.1038/sj.bjc.6600052; Saeki H, 1999, J IMMUNOL, V162, P2472; Salven P, 1997, BRIT J CANCER, V76, P930, DOI 10.1038/bjc.1997.486; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Seftor REB, 2001, CANCER RES, V61, P6322; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; SRIVASTAVA A, 1986, EUR J CANCER CLIN ON, V22, P1205, DOI 10.1016/0277-5379(86)90322-6; St Croix B, 2000, SCIENCE, V289, P1197; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; STENZINGER W, 1983, EUR J CANCER CLIN ON, V19, P649, DOI 10.1016/0277-5379(83)90181-5; Straume O, 1999, INT J ONCOL, V15, P595; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Straume O, 2001, AM J PATHOL, V159, P223, DOI 10.1016/S0002-9440(10)61688-4; Streit M, 2002, CANCER RES, V62, P2004; Ugurel S, 2001, J CLIN ONCOL, V19, P577, DOI 10.1200/JCO.2001.19.2.577; Vlaykova T, 1999, MELANOMA RES, V9, P59, DOI 10.1097/00008390-199902000-00008; WARREN BA, 1966, LAB INVEST, V15, P464; Weninger W, 1996, LAB INVEST, V75, P647; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Wild R, 2000, BRIT J CANCER, V83, P1077, DOI 10.1054/bjoc.2000.1439; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Yu JL, 2002, CANCER RES, V62, P1838; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	110	174	280	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3172	3179		10.1038/sj.onc.1206457	http://dx.doi.org/10.1038/sj.onc.1206457			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789293				2022-12-28	WOS:000183096600019
J	Widlund, HR; Fisher, DE				Widlund, HR; Fisher, DE			Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival	ONCOGENE			English	Article						MITF; melanoma; development; melanocyte; survival	WAARDENBURG SYNDROME TYPE-2; CREST-DERIVED MELANOCYTES; WNT SIGNALING PATHWAY; NEURAL-CREST; TYROSINASE GENE; BETA-CATENIN; MITF GENE; HIRSCHSPRUNG-DISEASE; MALIGNANT-MELANOMA; POLYCYSTIC KIDNEY	The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate. This basic-helix-loop-helix-leucine-zipper (bHLHzip) protein is critical for melanocyte cell-fate choice during commitment from pluripotent precursor cells in the neural crest. Its role in differentiation pathways has been highlighted by its potent transcriptional and lineage-specific regulation of the three major pigment enzymes: tyrosinase, Tyrp1, and Dell as well as other pigmentation factors. However, the cellular functions of MITF seem to be wider than differentiation and celt-fate pathways alone, since melanocytes and melanoma cells appear to require an expression of this factor. Here, we discuss the transcriptional networks in which MITF is thought to reside and describe signaling pathways in the cell which impinge on MITF. Accumulating evidence supports the notion that MITF is involved in survival pathways during normal development as well as during neoplastic growth of melanoma.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Fisher, DE (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	David_Fisher@dfci.harvard.edu		Widlund, Hans/0000-0002-7506-2447	NIAMS NIH HHS [AR43369] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; AROCA P, 1993, J BIOL CHEM, V268, P25650; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; BUNSAM KJ, 2001, AM J SURG PATHOL, V25, P197; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Fuchs S, 2001, MOL MED, V7, P115, DOI 10.1007/BF03401945; FULLER BB, 1987, J BIOL CHEM, V262, P4024; GANSS R, 1994, J BIOL CHEM, V269, P29808; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; Goding CR, 2000, GENE DEV, V14, P1712; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; Hou L, 2000, DEVELOPMENT, V127, P5379; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jin EJ, 2001, DEV BIOL, V233, P22, DOI 10.1006/dbio.2001.0222; KAMADA S, 1995, CANCER RES, V55, P354; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; Lister JA, 1999, DEVELOPMENT, V126, P3757; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MALEK ZAA, 1985, CANCER RES, V45, P4735; MAYER TC, 1979, J EXP ZOOL, V210, P81, DOI 10.1002/jez.1402100109; McCallion AS, 2001, PIGM CELL RES, V14, P161, DOI 10.1034/j.1600-0749.2001.140305.x; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Nakamura M, 2002, J DERMATOL SCI, V28, P1, DOI 10.1016/S0923-1811(01)00158-X; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Polakis P, 2000, GENE DEV, V14, P1837; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 2001, NEURON, V30, P15, DOI 10.1016/S0896-6273(01)00259-8; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUSSELL LB, 1979, GENETICS, V92, pS153; Saito H, 2002, J BIOL CHEM, V277, P28787, DOI 10.1074/jbc.M203719200; Salti GI, 2000, CANCER RES, V60, P5012; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Steingrimsson E, 1996, EMBO J, V15, P6280, DOI 10.1002/j.1460-2075.1996.tb01018.x; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080	88	285	297	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3035	3041		10.1038/sj.onc.1206443	http://dx.doi.org/10.1038/sj.onc.1206443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789278				2022-12-28	WOS:000183096600003
J	Cui, XJ; Lazard, Z; Zhang, P; Hopp, TA; Lee, AV				Cui, XJ; Lazard, Z; Zhang, P; Hopp, TA; Lee, AV			Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2	ONCOGENE			English	Article						breast cancer; IGFs; IRS-2; phosphorylation; progesterone; R5020	ESTROGEN PLUS PROGESTIN; REPLACEMENT THERAPY; FACTOR-I; EXPRESSION; KINASE; IRS-1; GENE; ACTIVATION; PATHWAYS; INHIBIT	Both progesterone and the insulin-like growth factors (IGFs) are critically involved in mammary gland development and also in breast cancer progression. How ever, how the progesterone and IGF signaling pathways interact with each other to regulate breast cancer cell growth remains unresolved. In this study, we investigated progesterone regulation of IGF signaling components in breast cancer cells. We found that insulin receptor substrate-2 (IRS-2) levels were markedly induced by progesterone and the synthetic progestin R5020 in MCF-7 and other progesterone receptor (PR) positive breast cancer cell lines, whereas IRS-1 and the IGF-I receptor were not induced. The antiprogestin RU486 blocked the R5020 effect on IRS-2 expression. Ectopic expression of either PR-A or PR-B in C4-12 breast cancer cells (estrogen receptor and PR negative) showed that progestin upregulation of IRS-2 was mediated specifically by PR-B. The IRS-2 induction by R5020 occurred via an increase of IRS-2 mRNA levels. Further more, progestin treatment prior to IGF-I stimulation resulted in higher tyrosine-phosphorylated IRS-2 levels, increased binding of IRS-2 to Grb-2 and the PI3K regulatory subunit p85, and correspondingly enhanced ERK and Akt activation, as compared with IGF-I-only conditions. Taken together, our data suggest that IRS-2 may play an important role in crosstalk between progesterone and the IGFs in breast cancer cells.	Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine	Lee, AV (corresponding author), Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA.	avlee@breastcenter.tmc.edu		Lee, Adrian/0000-0001-9917-514X	NATIONAL CANCER INSTITUTE [R01CA094118] Funding Source: NIH RePORTER; NCI NIH HHS [CA94118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASERGA R, 1995, CANCER RES, V55, P249; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chang Q, 2002, CANCER RES, V62, P6035; Dupont J, 2001, J CLIN PATHOL-MOL PA, V54, P149, DOI 10.1136/mp.54.3.149; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LeRoith D, 1996, BAILLIERE CLIN ENDOC, V10, P49, DOI 10.1016/S0950-351X(96)80298-9; Lin VCL, 1999, CLIN CANCER RES, V5, P395; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Oesterreich S, 2001, CANCER RES, V61, P5771; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	27	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6937	6941		10.1038/sj.onc.1206803	http://dx.doi.org/10.1038/sj.onc.1206803			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534541				2022-12-28	WOS:000185843400015
J	Krutilina, RI; Smirnova, AN; Mudrak, OS; Pleskach, NM; Svetlova, MP; Oei, SL; Yau, PM; Bradbury, EM; Zalensky, AO; Tomilin, NV				Krutilina, RI; Smirnova, AN; Mudrak, OS; Pleskach, NM; Svetlova, MP; Oei, SL; Yau, PM; Bradbury, EM; Zalensky, AO; Tomilin, NV			Protection of internal (TTAGGG)n repeats in Chinese hamster cells by telomeric protein TRF1	ONCOGENE			English	Article						internal telomeric repeats; instability; TRF1; wortmannin; tankyrase 1	DOUBLE-STRAND BREAK; ATM-DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE RESPONSE; END-JOINING FACTORS; OVARY CELLS; CHROMOSOMAL INSTABILITY; L1 ENDONUCLEASE; MAMMALIAN-CELLS; TTAGGG REPEATS	Chinese hamster cells have large interstitial ( TTAGGG) bands (ITs) which are unstable and should be protected by an unknown mechanism. Here, we expressed in Chinese hamster V79 cells green fluorescent protein (GFP)-tagged human TRF1, and found that a major fraction of GFP-TRF1 bound to ITs is diffusionally mobile. This fraction strongly decreases after treatment of cells with wortmannin, a protein kinase inhibitor, and this drug also increases the frequency of chromosome aberrations. Ionizing radiation does not induce detectable translocation of GFP-TRF1 to the sites of random double-strand breaks visualized using antibodies against histone gamma-H2AX. TRF1 is known to be eliminated from telomeres by overexpression of tankyrase 1 which induces TRF1 poly(ADP-ribosyl) ation. We transfected V79 cells by plasmid encoding tankyrase 1 and found that the frequency of chromosome rearrangements is increased in these cells independently of their treatment by IR. Taken together, our results suggest that TRF1 is involved in sequence-specific protection of internal nontelomeric (TTAGGG) n repeats.	Russian Acad Sci, Inst Cytol, Lab Chromosome Stabil, St Petersburg 194064, Russia; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Free University of Berlin; University of California System; University of California Davis; United States Department of Energy (DOE); Los Alamos National Laboratory	Tomilin, NV (corresponding author), Russian Acad Sci, Inst Cytol, Lab Chromosome Stabil, St Petersburg 194064, Russia.		Smirnova, Alexandra/Y-9941-2019; Pleskach, Nadezhda/AAE-9290-2021	Smirnova, Alexandra/0000-0002-8911-8827; Yau, Peter/0000-0002-1984-185X; Krutilina, Raisa/0000-0002-2118-4019	NICHD NIH HHS [5R01-HD39830-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039830] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Allio T, 2000, MUTAT RES-FUND MOL M, V453, P5, DOI 10.1016/S0027-5107(00)00030-0; ALVAREZ L, 1993, GENE CHROMOSOME CANC, V8, P8, DOI 10.1002/gcc.2870080103; Azzalin CM, 2001, CHROMOSOMA, V110, P75, DOI 10.1007/s004120100135; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bertoni L, 1996, MAMM GENOME, V7, P853, DOI 10.1007/s003359900250; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Cost GJ, 2001, NUCLEIC ACIDS RES, V29, P573, DOI 10.1093/nar/29.2.573; Day JP, 1998, CARCINOGENESIS, V19, P259, DOI 10.1093/carcin/19.2.259; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Faravelli M, 2002, GENE, V283, P11, DOI 10.1016/S0378-1119(01)00877-0; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fernandez JL, 1998, CYTOGENET CELL GENET, V82, P195, DOI 10.1159/000015098; FERNANDEZ JL, 1995, CHROMOSOME RES, V3, P281, DOI 10.1007/BF00713065; FLINT J, 1994, AM J HUM GENET, V55, P505; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Gineitis AA, 2000, J CELL BIOL, V151, P1591, DOI 10.1083/jcb.151.7.1591; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kilburn AE, 2001, MOL CELL BIOL, V21, P126, DOI 10.1128/MCB.21.1.126-135.2001; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kishi S, 2002, J BIOL CHEM, V277, P7420, DOI 10.1074/jbc.M111365200; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Krutilina RI, 2001, BIOCHEM BIOPH RES CO, V280, P471, DOI 10.1006/bbrc.2000.4143; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 2001, RADIAT RES, V156, P642, DOI 10.1667/0033-7587(2001)156[0642:TROAIT]2.0.CO;2; RADMAN M, 1991, BIOCHIMIE, V73, P357, DOI 10.1016/0300-9084(91)90101-6; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Simi S, 1998, MUTAT RES-FUND MOL M, V397, P229, DOI 10.1016/S0027-5107(97)00217-0; SLIJEPCEVIC P, 1995, CYTOGENET CELL GENET, V69, P87, DOI 10.1159/000133944; Slijepcevic P, 1996, CHROMOSOMA, V104, P596, DOI 10.1007/s004120050152; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Sprung CN, 1999, P NATL ACAD SCI USA, V96, P6781, DOI 10.1073/pnas.96.12.6781; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tomilin NV, 2001, RADIAT RES, V156, P347, DOI 10.1667/0033-7587(2001)156[0347:VOFNSO]2.0.CO;2; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zalensky AO, 1997, EXP CELL RES, V232, P29, DOI 10.1006/excr.1997.3482; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	69	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6690	6698		10.1038/sj.onc.1206745	http://dx.doi.org/10.1038/sj.onc.1206745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555982				2022-12-28	WOS:000185799300004
J	Bogenrieder, T; Herlyn, M				Bogenrieder, T; Herlyn, M			Axis of evil: molecular mechanisms of cancer metastasis	ONCOGENE			English	Review						microenvironment; adhesion; migration; integrins; cadherins; ephrins	HEPARAN-SULFATE PROTEOGLYCANS; MATRIX-METALLOPROTEINASE INHIBITORS; GAP JUNCTIONAL COMMUNICATION; PLASMINOGEN-ACTIVATOR SYSTEM; CELL-SURFACE PROTEOLYSIS; HUMAN-MALIGNANT MELANOMA; HUMAN ENDOTHELIAL-CELLS; E-CADHERIN EXPRESSION; INDUCED UP-REGULATION; HUMAN BREAST-CANCER	Although the genetic basis of tumorigenesis may vary greatly between different cancer types, the cellular and molecular steps required for metastasis are similar for all cancer cells. Not surprisingly, the molecular mechanisms that propel invasive growth and metastasis are also found in embryonic development, and to a less perpetual extent, in adult tissue repair processes. It is increasingly apparent that the stromal microenvironment, in which neoplastic cells develop, profoundly influences many steps of cancer progression, including the ability of tumor cells to metastasize. In carcinomas, the influences of the microenvironment are mediated, in large part, by bidirectional interactions ( adhesion, survival, proteolysis, migration, immune escape mechanisms lymph-/angiogenesis, and homing on target organs) between epithelial tumor cells and neighboring stromal cells, such as fibroblasts as well as endothelial and immune cells. In this review, we summarize recent advances in understanding the molecular mechanisms that govern this frequently lethal metastatic progression along an axis from primary tumor to regional lymph nodes to distant organ sites. Affected proteins include growth factor signaling molecules, chemokines, cell - cell adhesion molecules (cadherins, integrins) as well as extracellular proteases ( matrix metalloproteinases). We then discuss promising new therapeutic approaches targeting the microenvironment. We note, however, that there is still too little knowledge of how the many events are coordinated and integrated by the cancer cell, with conspiratorial help by the stromal component of the host. Before drug development can proceed with a legitimate chance of success, significant gaps in basic knowledge need to be filled.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA025874, R01CA047159] Funding Source: NIH RePORTER; NCI NIH HHS [CA-25874, CA-47159] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Anfosso F, 2001, J BIOL CHEM, V276, P1564, DOI 10.1074/jbc.M007065200; Barth AIM, 2002, BIOESSAYS, V24, P771, DOI 10.1002/bies.10152; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bissell MJ, 1999, AM J PATHOL, V155, P675, DOI 10.1016/S0002-9440(10)65164-4; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Bogenrieder T, 2002, CRIT REV ONCOL HEMAT, V44, P1, DOI 10.1016/S1040-8428(01)00196-2; BOGENRIEDER T, IN PRESS CUTANEOUS M; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Cameron MD, 2000, CANCER RES, V60, P2541; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chambers A F, 2001, Surg Oncol Clin N Am, V10, P243; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; Clohisy DR, 2003, CANCER-AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gruss C, 2001, CURR OPIN ONCOL, V13, P117, DOI 10.1097/00001622-200103000-00006; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbeck Nadia, 2002, Clin Breast Cancer, V3, P196, DOI 10.3816/CBC.2002.n.023; Hartmann A, 1999, CANCER RES, V59, P1578; Hegerfeldt Y, 2002, CANCER RES, V62, P2125; HERLYN M, 1991, LAB INVEST, V65, P262; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Homey B, 2002, NAT REV IMMUNOL, V2, P175, DOI 10.1038/nri748; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerr JS, 2002, EXPERT OPIN INV DRUG, V11, P1765, DOI 10.1517/13543784.11.12.1765; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2001, CANCER RES, V61, P3819; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liotta LA, 2003, NAT GENET, V33, P10, DOI 10.1038/ng0103-10; Liu SH, 2000, CANCER RES, V60, P6061; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Luo J, 1999, CANCER RES, V59, P3552; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747; McKenzie E, 2000, BIOCHEM BIOPH RES CO, V276, P1170, DOI 10.1006/bbrc.2000.3586; Moschos SJ, 2002, ONCOLOGY-BASEL, V63, P317, DOI 10.1159/000066230; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; MUNDY GR, 1995, CLIN ORTHOP RELAT R, P34; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Naumov GN, 2002, CANCER RES, V62, P2162; Naumov GN, 2001, SEMIN CANCER BIOL, V11, P271, DOI 10.1006/scbi.2001.0382; Nesbit M, 2001, J IMMUNOL, V166, P6483, DOI 10.4049/jimmunol.166.11.6483; Nielsen BS, 1996, LAB INVEST, V74, P168; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; Pezzella F, 2001, HISTOPATHOLOGY, V39, P551, DOI 10.1046/j.1365-2559.2001.01027.x; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; PYKE C, 1991, AM J PATHOL, V138, P1059; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rasmussen AA, 1998, BREAST CANCER RES TR, V47, P219, DOI 10.1023/A:1005903000777; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; Schaider H, 2003, INT J CANCER, V103, P335, DOI 10.1002/ijc.10775; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sheng SJ, 2001, CANCER METAST REV, V20, P287, DOI 10.1023/A:1015539612576; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, AM J PATHOL, V151, P745; Sood AK, 2002, J SOC GYNECOL INVEST, V9, P2, DOI 10.1016/S1071-5576(01)00147-2; Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5; Sporn MB, 1997, ANN NY ACAD SCI, V833, P137, DOI 10.1111/j.1749-6632.1997.tb48599.x; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Sun JX, 2001, CANCER RES, V61, P2276; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Uno F, 2001, CANCER RES, V61, P7855; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 2001, BIOCHIMIE, V83, P831, DOI 10.1016/S0300-9084(01)01318-9; Vogt T, 1998, CLIN CANCER RES, V4, P791; Wandel E, 2000, EXP DERMATOL, V9, P34, DOI 10.1034/j.1600-0625.2000.009001034.x; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wong CW, 2002, AM J PATHOL, V161, P749, DOI 10.1016/S0002-9440(10)64233-2; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	142	475	506	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6524	6536		10.1038/sj.onc.1206757	http://dx.doi.org/10.1038/sj.onc.1206757			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528277				2022-12-28	WOS:000185700700009
J	Ischenko, I; Petrenko, O; Gu, HH; Hayman, MJ				Ischenko, I; Petrenko, O; Gu, HH; Hayman, MJ			Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase	ONCOGENE			English	Article						V-SEA; Gab2; transformation	MACROPHAGE-STIMULATING PROTEIN; CELL ANTIGEN RECEPTOR; GROWTH-FACTOR; DOCKING SITE; C-MET; EPITHELIAL MORPHOGENESIS; GENE-PRODUCT; ONCOPROTEIN; ACTIVATION; PATHWAY	Transformation of fibroblasts by V-SEA involves activation of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways. Effector proteins that are key mediators of the ERK and PI3K pathways, namely Grb2, the tyrosine phosphatase, SHP2 and PI3K, interact with the two phosphotyrosines found in the bidentate motif in the carboxy-terminal region of V-SEA. Genetic analysis demonstrated that while Y557 was a primary binding site and thus activator of the PI3K-Akt pathway, Y564 also contributed to the activation of this pathway. Y564 was located within a Grb2-binding motif, this raised the possibility that a protein that associated with Grb2 might be important for this PI3K activation. The scaffolding proteins Gab1 and/or Gab2 were candidates for this role. In this report, we demonstrate that V-SEA preferentially interacts with Gab2. Furthermore by using Gab2 null fibroblasts, we demonstrate that Gab2 is essential for fibroblast transformation by V-SEA. Using mutant forms of Gab2, we show that activation of the PI3K-Akt pathway via Gab2 is required for V-SEA-induced transformation. However, efficient fibroblast transformation also requires the SHP2 interaction site on Gab2.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pratt JC, 2000, J IMMUNOL, V165, P4158, DOI 10.4049/jimmunol.165.8.4158; RONSIN C, 1993, ONCOGENE, V8, P1195; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Suda Toshio, 1997, Leukemia (Basingstoke), V11, P451; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, J BIOL CHEM, V269, P29943	35	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6311	6318		10.1038/sj.onc.1206742	http://dx.doi.org/10.1038/sj.onc.1206742			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508511				2022-12-28	WOS:000185535300001
J	Ji, P; Diederichs, S; Wang, WB; Boing, S; Metzger, R; Schneider, PM; Tidow, N; Brandt, B; Buerger, H; Bulk, E; Thomas, M; Berdel, WE; Serve, H; Muller-Tidow, C				Ji, P; Diederichs, S; Wang, WB; Boing, S; Metzger, R; Schneider, PM; Tidow, N; Brandt, B; Buerger, H; Bulk, E; Thomas, M; Berdel, WE; Serve, H; Muller-Tidow, C			MALAT-1, a novel noncoding RNA, and thymosin beta 4 predict metastasis and survival in early-stage non-small cell lung cancer	ONCOGENE			English	Article						metastasis; non-small cell lung cancer; subtractive hybridization; prognostic parameter; thymosin beta 4; MALAT-1	GENE-EXPRESSION; IDENTIFICATION; CHEMOTHERAPY; CARCINOMA; GROWTH; MAP; ADENOCARCINOMA; INVASION; MOTILITY; REVEALS	Early-stage non-small cell lung cancer (NSCLC) can be cured by surgical resection, but a substantial fraction of patients ultimately dies due to distant metastasis. In this study, we used subtractive hybridization to identify gene expression differences in stage I NSCLC tumors that either did or did not metastasize in the course of disease. Individual clones (n = 225) were sequenced and quantitative RT-PCR verified overexpression in metastasizing samples. Several of the identified genes (eIF4A1, thymosin beta4 and a novel transcript named MALAT-1) were demonstrated to be significantly associated with metastasis in NSCLC patients (n = 70). The genes' association with metastasis was stage- and histology specific. The Kaplan-Meier analyses identified MALAT-1 and thymosin beta4 as prognostic parameters for patient survival in stage I NSCLC. The novel MALAT-1 transcript is a noncoding RNA of more than 8000 nt expressed from chromosome 11q13. It is highly expressed in lung, pancreas and other healthy organs as well as in NSCLC. MALAT-1 expressed sequences are conserved across several species indicating its potentially important function. Taken together, these data contribute to the identification of early-stage NSCLC patients that are at high risk to develop metastasis. The identification of MALAT-1 emphasizes the potential role of noncoding RNAs in human cancer.	Univ Munster, Dept Med Hematol Oncol, D-48129 Munster, Germany; Univ Cologne, Dept Visceral & Vasc Surg, D-5000 Cologne 41, Germany; Univ Munster, Inst Lab Med & Clin Chem, D-48129 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, D-48129 Munster, Germany	University of Munster; University of Cologne; University of Munster; University of Munster	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med Hematol Oncol, Domagkstr 3, D-48129 Munster, Germany.		Müller-Tidow, Carsten/O-7207-2018; Müller-Tidow, Carsten CMT/B-5257-2014; Diederichs, Sven/J-6237-2012	Müller-Tidow, Carsten/0000-0002-7166-5232; Brandt, Burkhard/0000-0003-3681-3049; Diederichs, Sven/0000-0001-7901-4752				Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brem R, 2001, ANTICANCER RES, V21, P1731; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; CHENCHIK A, 1998, GENE CLONING ANAL RT, P305; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; FIDLER IJ, 1990, CANCER RES, V50, P6130; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; HESKETH R, 1997, ONCOGENE TUMOUR SUPR; Hibi K, 1998, CANCER RES, V58, P5690; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Li X, 1996, GENOMICS, V32, P388, DOI 10.1006/geno.1996.0133; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nagamachi Y, 1998, CANCER LETT, V127, P203, DOI 10.1016/S0304-3835(98)00039-1; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RASIO D, 1995, CANCER RES, V55, P3988; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; Shimizu K, 2000, GENOMICS, V65, P113, DOI 10.1006/geno.2000.6154; Sorenson S, 2001, ACTA ONCOL, V40, P327; Souquet PJ, 2001, LUNG CANCER-J IASLC, V34, pS155, DOI 10.1016/S0169-5002(01)00361-0; Ukena D, 2001, LUNG CANCER-J IASLC, V33, pS25, DOI 10.1016/S0169-5002(01)00299-9; URA H, 1989, CANCER RES, V49, P4615; van Asseldonk M, 2000, GENOMICS, V66, P35, DOI 10.1006/geno.2000.6194; Weston WM, 1999, J BIOL CHEM, V274, P13698, DOI 10.1074/jbc.274.19.13698; Xu GC, 2000, CHINESE MED J-PEKING, V113, P617; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	36	1673	1827	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8031	8041		10.1038/sj.onc.1206928	http://dx.doi.org/10.1038/sj.onc.1206928			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970751				2022-12-28	WOS:000185388200018
J	Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC				Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC			Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway	ONCOGENE			English	Article						IL-4; androgen receptor; PSA; prostate cancer	STIMULATORY FACTOR-I; JAK-3 JANUS KINASE; CANCER CELLS; GENE-EXPRESSION; IL-4 RECEPTOR; PROTEIN; PHOSPHORYLATION; INSULIN; IGE; ACQUISITION	Androgen receptor (AR) plays an important role in the development and progression of prostate cancer upon the action of androgen through the binding of the androgen-responsive elements (AREs) on the target genes. Abnormal activation of the AR by nonandrogen has been implicated in the progression of androgen-independent prostate cancer. The levels of interleukin-4 (IL-4) are significantly elevated in sera of patients with hormone refractory prostate cancer. The potential role of IL-4 on the activation of AR was investigated in prostate cancer cells. IL-4 enhances AR-mediated prostate-specific antigen (PSA) expression and ARE-containing gene activity through activation of the AR in the androgen ablation condition in human prostate cancer cells. The AR can also be sensitized by IL-4 and activated by significantly lower levels of androgen (10 pm of R1881) in prostate cancer cells. IL-4 enhances nuclear translocation of AR and increases binding of the AR to the ARE in LNCaP prostate cancer cells. Blocking of the Akt pathway by an Akt-specific inhibitor LY294002 abrogates IL-4-induced PSA expression and AR signaling. These results demonstrate that IL-4 enhances PSA expression through activation of the AR and Akt signaling pathways in LNCaP prostate cancer cells. Understanding IL-4-induced signaling leading to abnormal activation of AR will provide insights into the molecular mechanisms of androgen-independent progression of prostate cancer cells.	Roswell Pk Canc Inst, Dept Med Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA; Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA	Roswell Park Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gao, AC (corresponding author), Roswell Pk Canc Inst, Dept Med Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA90271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrack ER, 1996, MT SINAI J MED, V63, P403; Chen TS, 2000, CANCER RES, V60, P2132; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Godoy-Tundidor S, 2002, CLIN CANCER RES, V8, P2356; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; ISAACS JT, 1994, VITAM HORM, V49, P433; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Murata T, 1996, J IMMUNOL, V156, P2972; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pang S, 1997, CANCER RES, V57, P495; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; UEDA T, 2001, J BIOL CHEM, V19, P19; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Wen Y, 2000, CANCER RES, V60, P6841; Wise GJ, 2000, J UROLOGY, V164, P722, DOI 10.1016/S0022-5347(05)67289-8; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	36	61	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7981	7988		10.1038/sj.onc.1206735	http://dx.doi.org/10.1038/sj.onc.1206735			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970746				2022-12-28	WOS:000185388200013
J	Dent, P; Yacoub, A; Fisher, PB; Hagan, MP; Grant, S				Dent, P; Yacoub, A; Fisher, PB; Hagan, MP; Grant, S			MAPK pathways in radiation responses	ONCOGENE			English	Review						signal transduction; kinase; phospatase; receptor; autocrine ligand; RAS	ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; SIGNAL-REGULATED KINASE; RECEPTOR TYROSINE KINASES; SQUAMOUS CARCINOMA-CELLS; DOSE IONIZING-RADIATION; MALIGNANT GLIOMA-CELLS; MEK-DEPENDENT PATHWAY; OVARIAN-CANCER CELLS	Within the last 15 years, multiple new signal transduction pathways within cells have been discovered. Many of these pathways belong to what is now termed 'the mitogen-activated protein kinase (MAPK) superfamily.' These pathways have been linked to the growth factor-mediated regulation of diverse cellular events such as proliferation, senescence, differentiation and apoptosis. Based on currently available data, exposure of cells to ionizing radiation and a variety of other toxic stresses induces simultaneous compensatory activation of multiple MAPK pathways. These signals play critical roles in controlling cell survival and repopulation effects following irradiation, in a cell-type-dependent manner. Some of the signaling pathways activated following radiation exposure are those normally activated by mitogens, such as the 'classical' MAPK (also known as the ERK) pathway. Other MAPK pathways activated by radiation include those downstream of death receptors and procaspases, and DNA-damage signals, including the JNK and P38 MAPK pathways. The expression and release of autocrine growth factor ligands, such as (transforming growth factor alpha) and TNF-alpha, following irradiation can also enhance the responses of MAPK pathways in cells and, consequently, of bystander cells. Thus, the ability of radiation to activate MAPK signaling pathways may depend on the expression of multiple growth factor receptors, autocrine factors and Ras mutation. Enhanced basal signaling by proto-oncogenes such as K-/H-/N-RAS may provide a radioprotective and growth-promoting signal. In many cell types, this may be via the PI3K pathway; in others, this may occur through nuclear factor-kappa B or multiple MAPK pathways. This review will describe the enzymes within the known MAPK signaling pathways and discuss their activation and roles in cellular radiation responses.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ, Dept Urol & Pathol, New York, NY 10032 USA	Virginia Commonwealth University; Columbia University	Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	pdent@hsc.vcu.edu			NCI NIH HHS [CA72955, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088906, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahmed MM, 2001, AM J CLIN ONCOL-CANC, V24, P500, DOI 10.1097/00000421-200110000-00017; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Assefa Z, 1999, BIOCHEM BIOPH RES CO, V261, P641, DOI 10.1006/bbrc.1999.1090; Baba I, 2000, CANCER RES, V60, P6886; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; Ching TT, 2001, J BIOL CHEM, V276, P43932, DOI 10.1074/jbc.M105159200; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cuello M, 2001, CANCER RES, V61, P4892; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Grana TM, 2002, CANCER RES, V62, P4142; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Guan KL, 2000, J BIOL CHEM, V275, P27354; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hayakawa J, 2000, CANCER RES, V60, P5988; HAYSTEAD CMM, 1993, FEBS LETT, V317, P12, DOI 10.1016/0014-5793(93)81481-E; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holbrook N J, 1996, EXS, V77, P273; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kato K, 2001, CELL STRESS CHAPERON, V6, P16, DOI 10.1379/1466-1268(2001)006<0016:PKICSS>2.0.CO;2; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Leach JK, 2001, CANCER RES, V61, P3894; Lee H, 2001, CANCER RES, V61, P4467; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Maizels ET, 2001, MOL ENDOCRINOL, V15, P716, DOI 10.1210/me.15.5.716; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; McKinstry R, 2002, CANCER BIOL THER, V1, P243, DOI 10.4161/cbt.75; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Meyer RG, 2002, EUR J BIOCHEM, V269, P337, DOI 10.1046/j.0014-2956.2001.02658.x; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Munster PN, 2002, CANCER RES, V62, P3132; Nakazato M, 2002, PEDIATR INT, V44, P177, DOI 10.1046/j.1328-8067.2001.01516.x; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Park JS, 1999, MOL BIOL CELL, V10, P4231, DOI 10.1091/mbc.10.12.4231; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Qiao L, 2002, CANCER BIOL THER, V1, P168, DOI 10.4161/cbt.64; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Russell JS, 2002, CANCER RES, V62, P2318; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schlesinger TK, 2002, J BIOL CHEM, V277, P10283, DOI 10.1074/jbc.M106885200; SCHLESINGER TK, 1998, BIOSCIENCE, V3, pD1181; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shao RP, 2001, CANCER RES, V61, P7413; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038/sj.cdd.4401050; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; SUY S, 2001, 48 RAD RES SOC M, V155, P125; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Taher MM, 2000, PHOTOCHEM PHOTOBIOL, V71, P455, DOI 10.1562/0031-8655(2000)071<0455:ROTPAM>2.0.CO;2; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Vrana JA, 1999, RADIAT RES, V151, P559, DOI 10.2307/3580032; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Warenius HM, 1996, RADIAT RES, V146, P485, DOI 10.2307/3579548; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2; Yacoub A, 2001, INT J RADIAT BIOL, V77, P1067, DOI 10.1080/09553000110069317; YAN MH, 1994, NATURE, V372, P798; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	210	500	538	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5885	5896		10.1038/sj.onc.1206701	http://dx.doi.org/10.1038/sj.onc.1206701			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947395				2022-12-28	WOS:000185086100015
J	Haga, N; Fujita, N; Tsuruo, T				Haga, N; Fujita, N; Tsuruo, T			Mitochondrial aggregation precedes cytochrome c 1release from mitochondria during apoptosis	ONCOGENE			English	Article						apoptosis; mitochondria; aggregation; cytochrome c; laser scanning cytometer	CELL-DEATH; ROCK-I; RELEASE; ACTIVATION; CASPASE-2; CLEAVAGE; PROTEIN; BCL-2; BAX; REQUIREMENT	Mitochondria play a central role in apoptotic signaling pathways. Upon exposure to apoptotic stimuli, mitochondria release cytochrome c to the cytoplasm and activate caspase cascade leading to cell death. However, the events upstream of cytochrome c release are not fully understood. Here, we quantitate mitochondrial aggregation in situ using a novel laser scanning cytometry technique and reveal that mitochondria aggregate during apoptosis in a budding-like shape. The quantitative analysis reveals that mitochondrial aggregation is not inhibited by caspase-3 inhibitor ZEVD. Furthermore, bcl-x(L) transfection cannot suppress mitochondrial aggregation. However, overexpression of bcl-x(L) inhibits cytochrome c release from mitochondria. Therefore, mitochondrial aggregation is an event upstream of cytochrome c release during apoptosis. This mitochondrial aggregation was not observed in human leukemia H9 cells where apoptosis occurs in a mitochondria-independent fashion. Our studies imply that changes in the localization of mitochondria participate in the regulation of apoptosis through cytochrome c release.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferreira CG, 2000, CANCER RES, V60, P7133; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Haga N, 1998, INT J CANCER, V76, P86, DOI 10.1002/(SICI)1097-0215(19980330)76:1<86::AID-IJC14>3.0.CO;2-E; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	36	73	76	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5579	5585		10.1038/sj.onc.1206576	http://dx.doi.org/10.1038/sj.onc.1206576			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944905				2022-12-28	WOS:000184865900006
J	Block, TM; Mehta, AS; Fimmel, CJ; Jordan, R				Block, TM; Mehta, AS; Fimmel, CJ; Jordan, R			Molecular viral oncology of hepatocellular carcinoma	ONCOGENE			English	Review						hepatocellular carcinoma; liver cancer; hepatitis B; hepatitis C	HEPATITIS-C VIRUS; ACTIVATED PROTEIN-KINASE; OXIDATIVE DNA-DAMAGE; NONSTRUCTURAL 5A PROTEIN; DOUBLE-STRANDED-RNA; N-TERMINAL KINASE; B-VIRUS; ENDOPLASMIC-RETICULUM; CORE PROTEIN; X PROTEIN	Hepatocellular carcinoma (HCC) is the fifth most common cancer, but the third leading cause of cancer death, in the world, with more than 500000 fatalities annually. The major etiology of HCC/liver cancer in people is hepatitis B virus (HBV), followed by hepatitis C virus infection (HCV), although nonviral causes also play a role in a minority of cases. Recent molecular studies confirm what was suspected: that HCC tissue from different individuals have many phenotypic differences. However, there are clearly features that unify HCC occurring in a background of viral hepatitis B and C. HCC due to HBV and HCV may be an indirect result of enhanced hepatocyte turnover that occurs in an effort to replace infected cells that have been immunologically attacked. Viral functions may also play a more direct role in mediating oncogenesis. This review considers the molecular and cellular mechanisms involved in primary hepatocellular carcinoma, using a viral perspective.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Jefferson Ctr Biomed Res, Doylestwon, PA 18901 USA; St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63106 USA	Jefferson University; Saint Louis University	Block, TM (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Jefferson Ctr Biomed Res, 700 E Butler Ave, Doylestwon, PA 18901 USA.	tim.block@mail.tju.edu						Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Cerny A, 1999, HEPATOLOGY, V30, P595, DOI 10.1002/hep.510300312; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1995, SPRINGER SEMIN IMMUN, V17, P261, DOI 10.1007/BF00196169; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; Collins AR, 1999, BIOESSAYS, V21, P238, DOI 10.1002/(SICI)1521-1878(199903)21:3<238::AID-BIES8>3.0.CO;2-3; den Boon JA, 2001, J VIROL, V75, P12370, DOI 10.1128/JVI.75.24.12370-12381.2001; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; El-Serag HB, 2001, HEPATOLOGY, V33, P62, DOI 10.1053/jhep.2001.21041; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Evans AA, 1998, CANCER EPIDEM BIOMAR, V7, P559; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flint M, 1999, J GEN VIROL, V80, P1943, DOI 10.1099/0022-1317-80-8-1943; FORNS X, 1999, TRENDS CELL; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GASS JN, 2002, J BIOL CHEM; Gerotto M, 1999, J VIROL, V73, P7241, DOI 10.1128/JVI.73.9.7241-7247.1999; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Guidotti LG, 2002, J VIROL, V76, P2617, DOI 10.1128/JVI.76.6.2617-2621.2002; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; HSU HC, 1993, CANCER RES, V53, P4691; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873; HURLIMANN J, 1991, AM J SURG PATHOL, V15, P280, DOI 10.1097/00000478-199103000-00008; ISRAEL J, 1989, MAGN RESON IMAGING, V7, P629, DOI 10.1016/0730-725X(89)90531-6; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Jordan R, 2002, VIROLOGY, V295, P10, DOI 10.1006/viro.2002.1370; Kakimi K, 2001, J IMMUNOL, V167, P6701, DOI 10.4049/jimmunol.167.12.6701; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kinoshita T, 2002, BBA-MOL CELL RES, V1592, P303, DOI 10.1016/S0167-4889(02)00323-3; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Kladney RD, 2002, VIROLOGY, V301, P236, DOI 10.1006/viro.2002.1523; Lee WM, 2001, J VIROL, V75, P2097, DOI 10.1128/JVI.75.5.2097-2106.2001; Liang T. Jake, 2000, Annals of Internal Medicine, V132, P296; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; MacKenzie JM, 2001, J VIROL, V75, P10787, DOI 10.1128/JVI.75.22.10787-10799.2001; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Menne S, 1999, NAT MED, V5, P1125, DOI 10.1038/13445; Menne S, 2002, J VIROL, V76, P1769, DOI 10.1128/JVI.76.4.1769-1780.2002; Montalto G, 2002, ANN NY ACAD SCI, V963, P13, DOI 10.1111/j.1749-6632.2002.tb04090.x; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229; Nejjari M, 2002, HEPATOLOGY, V36, P418, DOI 10.1053/jhep.2002.34611; Park KS, 2002, INT J CANCER, V97, P261, DOI 10.1002/ijc.1585; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Preikschat P, 2002, HEPATOLOGY, V35, P466, DOI 10.1053/jhep.2002.30698; Rehermann B, 1996, J CLIN INVEST, V97, P1655, DOI 10.1172/JCI118592; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHLESINGER MJ, 1982, J BIOL CHEM, V257, P9887; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Sekine S, 2002, ONCOGENE, V21, P5906, DOI 10.1038/sj.onc.1205756; Shackel NA, 2002, AM J PATHOL, V160, P641, DOI 10.1016/S0002-9440(10)64884-5; SHIMODA R, 1994, CANCER RES, V54, P3171; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Steel LF, 2001, DIS MARKERS, V17, P179, DOI 10.1155/2001/963023; STEEL LF, 2003, IN PRESS PROTEOMIC; STEVENS RG, 1994, INT J CANCER, V56, P364, DOI 10.1002/ijc.2910560312; Sumida Y, 2000, J HEPATOL, V33, P616, DOI 10.1034/j.1600-0641.2000.033004616.x; Sun JR, 2001, J VIROL, V75, P11992, DOI 10.1128/JVI.75.24.11992-11998.2001; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Tai PC, 2002, VIROLOGY, V292, P44, DOI 10.1006/viro.2001.1239; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Tennant Bud C., 1994, P1455; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Webster G, 2001, MOL IMMUNOL, V38, P467, DOI 10.1016/S0161-5890(01)00082-7; Webster GJM, 2000, HEPATOLOGY, V32, P1117, DOI 10.1053/jhep.2000.19324; Weiland F, 1999, J GEN VIROL, V80, P1157, DOI 10.1099/0022-1317-80-5-1157; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Wu CG, 2002, FASEB J, V16, P1665, DOI 10.1096/fj.02-0074fje; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Xu ZC, 1997, J VIROL, V71, P7387, DOI 10.1128/JVI.71.10.7387-7392.1997; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yu LR, 2000, ELECTROPHORESIS, V21, P3058, DOI 10.1002/1522-2683(20000801)21:14<3058::AID-ELPS3058>3.0.CO;2-U; Zhou TL, 1997, CANCER RES, V57, P2749; Zhu NL, 2001, VIROLOGY, V283, P178, DOI 10.1006/viro.2001.0896; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	117	396	429	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5093	5107		10.1038/sj.onc.1206557	http://dx.doi.org/10.1038/sj.onc.1206557			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910247				2022-12-28	WOS:000184615100001
J	Tkach, V; Tulchinsky, E; Lukanidin, E; Vinson, C; Bock, E; Berezin, V				Tkach, V; Tulchinsky, E; Lukanidin, E; Vinson, C; Bock, E; Berezin, V			Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility	ONCOGENE			English	Article						c-Fos; Fra-1; Fra-2; cell locomotion	TRANSCRIPTION FACTOR AP-1; DNA-BINDING; TRANSFORMATION; ACTIVATION; MIGRATION; INTERACTS; INVASION; GENE; JUN; AP1	The AP-1 transcription factor is composed of members of the Fos, Jun and ATF families, and plays a key role in tumor progression. We investigated whether Fos proteins regulate cell motility, and if so, whether this capacity is related to their transactivation potential. Two cell tines with different expression profiles of AP-1 were employed focusing on the Fos-family members c-Fos, Fra-1 and Fra-2. Transactivation motifs are found in c-Fos, but not in Fra-1 or Fra-2. The adenocarcinoma CSML0 cells display a low motility and do not express Fra-1 or Fra-2, and only very little c-Fos. In contrast, the fibroblastoid L929 cells express both Fra-1 and Fra-2, but no c-Fos, and these cells display a high motility. Transfection with Fra-1 or c-Fos, but not with Fra-2, strongly enhanced the motility of CSML0 cells. The effect of Fra-1 required the presence of the N-terminal domain of this protein. Conversely, transfection with a Fos dominant-negative mutant or with anti-sense fra-1 or fra-2, strongly reduced the motility of L929 cells. Changes in cell motility correlated with the morphological appearance and the degree of contact with the substratum. We conclude that Fos proteins have distinct roles in the regulation of cell motility.	Univ Copenhagen, Panum Inst, Prot Lab,Inst Mol Pathol, Sch Med, DK-2200 Copenhagen N, Denmark; Danish Canc Soc, Dept Mol Cell Biol, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; NCI, Met Lab, NIH, Bethesda, MD 20892 USA	University of Copenhagen; Danish Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Berezin, V (corresponding author), Univ Copenhagen, Panum Inst, Prot Lab,Inst Mol Pathol, Sch Med, Blegdamsvej 3C,Bld 6-2, DK-2200 Copenhagen N, Denmark.	berezin@plab.ku.dk	Tulchinsky, Eugene/ABD-7070-2021		NATIONAL CANCER INSTITUTE [Z01BC005271, ZIABC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrektsen T, 2001, MOL PHARMACOL, V59, P567, DOI 10.1124/mol.59.3.567; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Dunn G A, 1983, Agents Actions Suppl, V12, P14; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P236; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lepekhin EA, 2001, METH MOL B, V161, P85; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Walmod PS, 1998, CELL MOTIL CYTOSKEL, V40, P220; Walmod PS, 2001, METH MOL B, V161, P59; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	29	60	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5045	5054		10.1038/sj.onc.1206570	http://dx.doi.org/10.1038/sj.onc.1206570			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902987				2022-12-28	WOS:000184578900012
J	Kichina, JV; Rauth, S; Das Gupta, TK; Gudkov, AV				Kichina, JV; Rauth, S; Das Gupta, TK; Gudkov, AV			Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53	ONCOGENE			English	Article						melanoma; p53; Ing1; tumor suppressor; transactivation	TUMOR-SUPPRESSOR P33(ING1); MALIGNANT-MELANOMA; TYROSINASE GENE; MUTANT P53; IN-VITRO; EXPRESSION; LINES; MUTATIONS; MDM2; PROTEIN	Malignant melanomas are frequently characterized by elevated levels of wild-type p53, suggesting that p53 function could be suppressed by a mechanism different from p53 mutation. We analysed the functionality of the p53-signaling pathway in a panel of seven human melanoma cell lines consisting of one p53-deficient line, two lines with mutant p53, and four lines expressing wildtype p53. Only lines with wild-type p53 were characterized by elevated levels of endogenous p21, high activity of p53-responsive reporters and accumulation of p53 in response to genotoxic stress, common properties of functional p53. The presence of wild-type p53 was associated with depletion or loss of p14(ARF) and p16 expression. The levels of p33(ING1b) and p24(ING1c), two major products of Ing1 locus and putative coregulators of p53, were elevated in all cell lines tested; however, ectopic expression of either ING1 isoform had no effect on cell proliferation. All lines retained expression of Apaf-1, and all but one remained sensitive to ectopic expression of retrovirus-transduced p53. Our data indicate that regardless of abnormally high levels of p53 in melanomas, their p53 remains competent in transactivation of its targets, and, if highly overexpressed, capable of growth inhibition. Hence, the p53 pathway in malignant melanomas can be considered for pharmacological targeting and anticancer gene therapy.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Gudkov, Andrei/0000-0003-2548-0154; Das Gupta, Tapas K./0000-0001-6437-6320	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; *ACS, 2002, CANC FACTS FIG 2002; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Bae I, 1996, CANCER RES, V56, P840; Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Campos EI, 2002, BRIT J DERMATOL, V146, P574, DOI 10.1046/j.1365-2133.2002.04641.x; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GALLION HH, 1995, CANCER, V76, P1992, DOI 10.1002/1097-0142(19951115)76:10+<1992::AID-CNCR2820761315>3.0.CO;2-U; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kichina J, 1996, PIGM CELL RES, V9, P85, DOI 10.1111/j.1600-0749.1996.tb00094.x; Leung KM, 2002, CANCER RES, V62, P4890; Loggini B, 2001, TUMORI, V87, P179, DOI 10.1177/030089160108700313; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Mehta RR, 2002, MELANOMA RES, V12, P27, DOI 10.1097/00008390-200202000-00005; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MONTANO X, 1994, ONCOGENE, V9, P1455; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ragnarsson-Olding BK, 2002, MELANOMA RES, V12, P453, DOI 10.1097/00008390-200209000-00007; Rass K, 2001, HISTOCHEM J, V33, P459, DOI 10.1023/A:1014472314354; RAUTH S, 1994, IN VITRO CELL DEV-AN, V30A, P79, DOI 10.1007/BF02631396; RAUTH S, 1994, ANTICANCER RES, V14, P2457; RAUTH S, 1993, SOMAT CELL MOLEC GEN, V19, P285, DOI 10.1007/BF01233076; RENZING J, 1995, ONCOGENE, V10, P1865; Salti GI, 2001, MELANOMA RES, V11, P99, DOI 10.1097/00008390-200104000-00003; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Sunamura Makoto, 2002, J Hepatobiliary Pancreat Surg, V9, P32, DOI 10.1007/s005340200002; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; YAMAMOTO M, 1993, VIRCHOWS ARCH A, V422, P127, DOI 10.1007/BF01607164; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4911	4917		10.1038/sj.onc.1206741	http://dx.doi.org/10.1038/sj.onc.1206741			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894234				2022-12-28	WOS:000184344600016
J	Charvet, C; Alberti, I; Luciano, F; Jacquel, A; Bernard, A; Auberger, P; Deckert, M				Charvet, C; Alberti, I; Luciano, F; Jacquel, A; Bernard, A; Auberger, P; Deckert, M			Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases	ONCOGENE			English	Article						FOXO3a; transcription; cleavage; caspase; Fas; apoptosis	SERUM RESPONSE FACTOR; RECEPTOR-INDUCED APOPTOSIS; INDUCED CELL-DEATH; SIGNALING COMPLEX; FACTOR FKHR-L1; FACTOR FKHRL1; FAS LIGAND; T-CELLS; PROTEIN; DOWNSTREAM	Forkhead family transcription factors are critical regulators of cell cycle progression and apoptosis in hematopoietic cells. Here, we show that FOXO3a (also known as FKHRL1) is a new substrate of caspase-3-like proteases during apoptosis in T lymphocytes. FOXO3a was cleaved in vivo by caspases in leukemic Jurkat cells following engagement of Fas (CD95) receptor, staurosporine, and etoposide treatment, but not following engagement of CD99, a caspase-independent cell death inducer. Caspase-mediated cleavage of FOXO3a was also observed in CD4 +. peripheral T cells subjected to activation-induced cell death. The expression of the death adapter FADD and caspase-8 was required for Fas-induced FOXO3a cleavage, but activation of survival pathways by overexpression of FLICE-inhibitory protein or phorbol myristate acetate treatment prevented it. FOXO3a was cleaved in vitro by caspase-3-like proteases at the consensus sequence DELD(304)A, releasing the N-terminal DNA-binding domain of FOXO3a from its C-terminal transactivating domain. Whereas full-length FOXO3a enhanced Forkhead response element-dependent transcription and apoptosis in Jurkat cells, both fragments were inactive to promote gene activation and cell death. In contrast, a caspase-resistant FOXO3a mutant exhibited enhanced transcriptional and proapoptotic activities. Together, these results indicate that the proteolytic cleavage of FOXO3a by caspases may represent a novel regulatory mechanism of FOXO3a activity during death receptors signaling.	Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France; Fac Med Nice, INSERM, U526, IFR50, F-06107 Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Deckert, M (corresponding author), Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France.		luciano, frederic/P-6264-2016; Deckert, Marcel/T-3566-2019; Jacquel, Arnaud/O-1928-2017; AUBERGER, Patrick/G-1491-2013; Jacquel, Arnaud/AAJ-4760-2021; Deckert, Marcel/M-4998-2016	luciano, frederic/0000-0001-9253-4998; Deckert, Marcel/0000-0003-2094-559X; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Jacquel, Arnaud/0000-0001-5062-8048; 				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Noraz N, 2000, J BIOL CHEM, V275, P15832, DOI 10.1074/jbc.M908568199; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ravi R, 1998, CANCER RES, V58, P882; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	41	61	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4557	4568		10.1038/sj.onc.1206778	http://dx.doi.org/10.1038/sj.onc.1206778			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881712				2022-12-28	WOS:000184054700011
J	Zhang, XH; Ma, L; Enkemann, SA; Pledger, WJ				Zhang, XH; Ma, L; Enkemann, SA; Pledger, WJ			Role of Gadd45 alpha in the density-dependent G1 arrest induced by p27(Kip1)	ONCOGENE			English	Article						Gadd45 alpha; p27(Kip1); culture density	MESSENGER-RNA EXPRESSION; KINASE INHIBITOR; GROWTH ARREST; MAMMALIAN-CELLS; P53-REGULATED PROTEIN; T-LYMPHOCYTES; MICE LACKING; GENES; TRANSCRIPTION; FIBROBLASTS	p27(Kip1), an inhibitor of cyclin-dependent kinases, is an important regulator of cell cycle progression. We have previously shown that p27(Kip1) inhibits the G0 to S transition when ectopically expressed in p27-47 mouse fibroblasts arrested at high but not low densities. In the study described here, we identify Gadd45alpha, a member of the growth arrest- and DNA damage-inducible family of proteins, as a potential mediator of the density-dependent effects of p27(Kip1) on cell proliferation. Gadd45alpha mRNA and protein were more abundant in p27-47 cells arrested at high densities than at low densities. Amounts of both decreased and remained low when cells arrested at high densities were exposed to mitogens in the absence, but not in the presence, of ectopically expressed p27(Kip1). Importantly, enforced expression of Gadd45alpha prevented density-arrested mouse fibroblasts from initiating DNA synthesis in response to mitogens. We suggest that amounts of Gadd45alpha above a certain threshold are growth inhibitory and that such amounts are achieved in cells arrested at high but not low densities. For cultures arrested at high densities, the resumption of cell cycle traverse requires a sustained reduction in Gadd45alpha abundance, a process that is induced by mitogens and inhibited by p27(Kip1).	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA67370] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kettenhofen R, 2001, CELL SIGNAL, V13, P787, DOI 10.1016/S0898-6568(01)00198-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miskimins R, 2002, J NEUROSCI RES, V67, P100, DOI 10.1002/jnr.10080.abs; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	52	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4166	4174		10.1038/sj.onc.1206599	http://dx.doi.org/10.1038/sj.onc.1206599			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833139				2022-12-28	WOS:000183979800003
J	Coppo, P; Dusanter-Fourt, I; Millot, G; Nogueira, MM; Dugray, A; Bonnet, ML; Mitjavila-Garcia, MT; Le Pesteur, D; Guilhot, F; Vainchenker, W; Sainteny, F; Turhan, AG				Coppo, P; Dusanter-Fourt, I; Millot, G; Nogueira, MM; Dugray, A; Bonnet, ML; Mitjavila-Garcia, MT; Le Pesteur, D; Guilhot, F; Vainchenker, W; Sainteny, F; Turhan, AG			Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells	ONCOGENE			English	Article						BCR-ABL; STAT3; embryonic stem cells	CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; CHRONIC MYELOID-LEUKEMIA; SIGNAL TRANSDUCERS; KINASE-ACTIVITY; SELF-RENEWAL; IN-VIVO; GENE; EXPRESSION; BCR/ABL	BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia (CML) arises in a primitive hematopoietic stem cell with both differentiation and self-renewal ability. To study the phenotypic effects of BCR-ABL in a clonal in vitro self-renewal and differentiation model, we have introduced BCR-ABL in the ES cell line CCE. The major effect of BCR-ABL expression was the persistence of primitive morphology of ES cells despite LIF deprivation, correlated with a constitutive activation of STAT3, the major self-renewal factor of ES cells, but no evidence of activation of STAT5. The enforced expression of BCR-ABL in an ES cell line, engineered to express a tetracycline-inducible dominant-negative form of a STAT3, triggered ES cell differentiation with an increased generation of hematopoietic cells expressing erythroid and megakaryocytic phenotypes. RT-PCR analysis for Oct4, Brachyury and beta-globin expression confirmed a delay of differentiation in BCR-ABL expressing clones, which could be entirely reversed upon activation of the dominant-negative form of STAT3. To study the possible relevance of STAT3 activation by BCR-ABL in human CML, Western blot analyses performed on the CD34+ cells, purified from CML patients at different stages of their disease, also demonstrated increased levels of STAT3 proteins phosphorylated both on tyrosine and serine residues. These results represent to our knowledge the first functional link between BCR-ABL oncogene and a self-renewal in the context of ES cells through constitutive activation of STAT3. Thus, the BCR-ABL embryonic stem cell model that we developed as well as the results obtained in human CML samples suggests a role for STAT3 in the pathogenesis of human CML.	Inst Gustave Roussy, INSERM, U362, Translat Res Cell Therapy Lab, F-94805 Villejuif, France; Hop Cochin, ICGM, INSERM, U363, F-75674 Paris, France; Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France; CHU Poitiers, Dept Oncol & Cell Therapy, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; UNICANCER; Gustave Roussy; CHU Poitiers	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, Translat Res Cell Therapy Lab, PR-1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dusanter-Fourt, Isabelle/P-4558-2017; Mitjavila-Garcia, Maria Teresa/L-8909-2018	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Nogueira, Maria Manuela/0000-0002-8353-1979; Guilhot, Francois/0000-0001-7222-487X; Vainchenker, William/0000-0003-4705-202X; TURHAN, Ali/0000-0002-4861-0137				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUGRAY A, 2001, LEUKEMIA, V14, P662; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4102	4110		10.1038/sj.onc.1206607	http://dx.doi.org/10.1038/sj.onc.1206607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821944				2022-12-28	WOS:000183707600013
J	Hollander, MC; Poola-Kella, S; Fornace, AJ				Hollander, MC; Poola-Kella, S; Fornace, AJ			Gadd34 functional domains involved in growth suppression and apoptosis	ONCOGENE			English	Article						Gadd34; PEG-3; apoptosis	DAMAGE-INDUCIBLE GENE; DNA-DAMAGE; PROTEIN GADD34; ARREST; INTERACTS; SEQUENCE; SIGNALS; PEG-3; CELLS	Gadd34 (also known as MyD116) was originally described as a growth arrest and DNA damage-inducible gene. Increased expression of Gadd34 was subsequently found to correlate with apoptosis, and forced overexpression of the protein leads to apoptosis. Gadd34 protein modulates protein phosphatase type 1 activity through both direct binding to the protein, as well as through binding to other proteins that also modulate phosphatase activity. In addition, Gadd34 has a region of homology with the herpes simplex virus type 1 ICP34.5 protein that is involved in the prevention of apoptosis in infected cells. Recently it was reported that a novel rat Gadd34-related gene, PEG-3, was upregulated in transformed cells, and that forced expression of this gene led to increased tumorigenic potential of cells implanted into nude mice and increased angiogenesis of these tumors. We have found, however, that PEG-3 does not exist in normal rat cells, which have a single diploid complement of Gadd34. Sequence analysis of the rat Gadd34 gene and comparison with PEG-3 indicates that PEG-3 is most likely a mutant of Gadd34 that perhaps arose as a result of transformation. This finding suggests that truncated Gadd34 may interfere with normal Gadd34 function in transfected cells. However, human Gadd34 lacking the viral homology domain does not interfere with normal Gadd34-induced apoptosis in cultured cells. This suggests that viral similarity sequences may be required for Gadd34-mediated functions other than apoptosis.	NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hollander, MC (corresponding author), NCI, Basic Res Lab, NIH, Bldg 37,Room 6144, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Adler HT, 1999, MOL CELL BIOL, V19, P7050; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Hasegawa T, 2000, J CELL BIOCHEM, V77, P596, DOI 10.1002/(SICI)1097-4644(20000615)77:4<596::AID-JCB7>3.0.CO;2-K; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; WU DY, 2002, J BIOL CHEM	20	33	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3827	3832		10.1038/sj.onc.1206567	http://dx.doi.org/10.1038/sj.onc.1206567			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813455				2022-12-28	WOS:000183612000001
J	Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC				Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC			Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro	ONCOGENE			English	Article						Dupuytren's contracture; fibromatosis; beta-catenin; extracellular matrix	TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; E-CADHERIN; CONTRACTURE; COMPLEX; CANCER; FIBROMATOSIS; ABNORMALITIES; ASSOCIATION; INHIBITION	Dupuytren's disease (DD) is a superficial fibromatosis of the hand. Although the molecular mechanisms responsible for this disease are unknown, recent studies suggest that beta-catenin may be a key factor involved in fibromatosis. In this study, we analysed the in vivo and in vitro expression levels of beta-catenin in DD, using surgical specimens and primary cell lines. Although no somatic mutations (exon 3) of beta-catenin were detected, Western blot analysis revealed high levels of beta-catenin in diseased palmar fascia, and low to undetectable levels of beta-catenin in patient-matched normal palmar fascia. Immunohistochemistry analysis showed high levels of beta-catenin expression within the disease fascia, as well as cytoplasmic and nuclear accumulations of the protein. Immunoprecipitation of beta-catenin from seven patient lesions showed the protein to be tyrosine phosphorylated. Lastly, Western analysis of three patient-matched (disease and normal fascia) primary cell cultures showed significantly elevated levels of beta-catenin in disease cells cultured in three-dimensional collagen lattices. This is the first extensive in vivo and in vitro characterization of beta-catenin in DD, and the first to suggest that the extracellular matrix may play an important role in modulating beta-catenin stability in DD.	Univ Western Ontario, Hand & Upper Limb Ctr, Cell & Mol Biol Lab, London, ON, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Surg, London, ON, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Howard, JC (corresponding author), St Josephs Hlth Care, Hand & Upper Limb Ctr, Cell & Mol Biol Lab, 268 Grosvenor St, London, ON N6A 4V2, Canada.							Abraham SC, 2002, HUM PATHOL, V33, P39, DOI 10.1053/hupa.2002.30196; AN HS, 1988, J HAND SURG-AM, V13A, P872, DOI 10.1016/0363-5023(88)90262-6; ARAFA M, 1992, J HAND SURG-BRIT EUR, V17B, P221, DOI 10.1016/0266-7681(92)90095-J; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BONNICI AV, 1992, J HAND SURG-BRIT EUR, V17B, P349, DOI 10.1016/0266-7681(92)90128-O; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; Burge P, 1999, HAND CLIN, V15, P63; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cheon SS, 2002, P NATL ACAD SCI USA, V30, P30; Dal Cin P, 1999, CANCER GENET CYTOGEN, V108, P137, DOI 10.1016/S0165-4608(98)00126-5; De Wever I, 2000, MODERN PATHOL, V13, P1080, DOI 10.1038/modpathol.3880200; Dupuytren B, 1834, LANCET, V2, P222; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Gudmundsson KG, 2002, J CLIN EPIDEMIOL, V55, P5, DOI 10.1016/S0895-4356(01)00413-9; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Kloen P, 1999, BRIT J PLAST SURG, V52, P629, DOI 10.1054/bjps.1999.3187; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhn MA, 2002, J SURG RES, V103, P146, DOI 10.1006/jsre.2001.6350; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; MCFARLANE RM, 1991, J HAND SURG-AM, V16A, P775, DOI 10.1016/S0363-5023(10)80134-0; MIKKELSEN OA, 1978, HAND, V10, P1, DOI 10.1016/S0072-968X(78)80019-9; Mikkelsen OA, 1999, J HAND SURG-BRIT EUR, V24B, P515, DOI 10.1054/jhsb.1999.0229; Montgomery E, 2001, MODERN PATHOL, V14, P695, DOI 10.1038/modpathol.3880374; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NOBLE J, 1992, J HAND SURG-BRIT EUR, V17B, P71, DOI 10.1016/0266-7681(92)90015-T; NOBLE J, 1984, J BONE JOINT SURG BR, V66, P322, DOI 10.1302/0301-620X.66B3.6725338; Polakis P, 2000, GENE DEV, V14, P1837; Rayan GM, 1999, HAND CLIN, V15, P87; Ross DC, 1999, HAND CLIN, V15, P53; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SERGOVICH FR, 1983, NEW ENGL J MED, V308, P162; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SKOOG T, 1960, PLAST RECONSTR SURG, V31, P258; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WURSTERHILL DH, 1988, AM J HUM GENET, V43, P285	43	47	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3680	3684		10.1038/sj.onc.1206415	http://dx.doi.org/10.1038/sj.onc.1206415			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802275				2022-12-28	WOS:000183551000002
J	David, MD; Bertoglio, J; Pierre, J				David, MD; Bertoglio, J; Pierre, J			Functional characterization of IL-13 receptor alpha 2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression	ONCOGENE			English	Article						cytokine receptors; gene regulation; transcription factors; cytokines; keratinocytes	MESSENGER-RNA; HUMAN B; HUMAN MONOCYTES; GAMMA-CHAIN; INTERLEUKIN-13; PROTEIN; CLONING; CELLS; ACTIVATION; BINDING	Interleukin (IL)-4 and IL-13 are two structurally and functionally related cytokines that have overlapping but also distinct biological activities. One of the components of the IL-13 receptor, the alpha2 chain (IL-13Ralpha2), has been reported to downregulate the cell responsiveness to IL-13, without affecting IL-4 signaling. Here, we report that TNFalpha synergizes with either IL-4 or IL-13 in inducing the IL-13Ralpha2 chain at both the mRNA and protein levels in the HaCaT human keratinocyte cell line. Further studies by 5'RACE identified as yet undescribed exonic sequences of the IL-13Ralpha2 5'UTR, provided evidence for the expression of alternatively spliced IL-13Ralpha2 transcripts and defined the transcription start of the IL-13Ralpha2 gene. A 1.5 kb region upstream of the first exon of the IL-13Ralpha2 gene displayed basal promoter activity when inserted in a reporter plasmid and transiently transfected in HaCaT cells. This promoter activity was further increased in response to IL-4 and IL-13. Furthermore, by electrophoretic mobility shift assay and site-directed mutagenesis, we showed that the IL-4/IL-13-induced promoter activity depended upon a positively acting STAT6 response element. Finally, TNFalpha was shown to potentiate IL-4/IL-13-induced IL-13Ralpha2 promoter activity when the same reporter construct was studied in stably but not in transiently transfected cells. These results suggest that the synergistic effect of TNFalpha on IL-4/IL-13-induced IL-13Ralpha2 expression is dependent upon chromatin re-modeling events.	Fac Pharm Chatenay Malabry, U461, INSERM, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm Chatenay Malabry, U461, INSERM, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	josiane.pierre@cep.u-psud.fr	David, Muriel/F-9592-2012	David, Muriel/0000-0003-1392-2701				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Debinski W, 1999, INT J ONCOL, V15, P481; Debinski W, 1999, CLIN CANCER RES, V5, P985; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Feng NP, 1998, LAB INVEST, V78, P591; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo DQ, 1998, J IMMUNOL, V160, P2742; Guo JA, 1997, GENOMICS, V42, P141, DOI 10.1006/geno.1997.4628; Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575, DOI 10.1002/jlb.66.4.575; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613; Kambayashi T, 1996, CELL IMMUNOL, V171, P153, DOI 10.1006/cimm.1996.0186; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Pesu M, 2002, J BIOL CHEM, V277, P38254, DOI 10.1074/jbc.M201427200; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang JG, 1997, J BIOL CHEM, V272, P9474	43	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3386	3394		10.1038/sj.onc.1206352	http://dx.doi.org/10.1038/sj.onc.1206352			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776189				2022-12-28	WOS:000183128500004
J	Ruivenkamp, C; Hermsen, M; Postma, C; Klous, A; Baak, J; Meijer, G; Demant, P				Ruivenkamp, C; Hermsen, M; Postma, C; Klous, A; Baak, J; Meijer, G; Demant, P			LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21	ONCOGENE			English	Article						PTPRJ; colorectal cancer; LOH; CGH; 18q12-21	MOUSE	Recently, the gene PTPRJ (protein tyrosine phosphatase receptor type J) was identified as the candidate gene for the mouse colon cancer susceptibility locus Scc1. Its human homologue PTPRJ is frequently deleted in several cancer types, including colorectal cancer. To elucidate the role of PTPRJ loss in different stages of colorectal cancer and in its pathways of progression, we expanded the previously published comparative genomic hybridization results with novel data on loss of heterozygosity (LOH) at the PTPRJ locus. We identified a strong association between the LOH of PTPRJ and the loss of chromosomal region 18q12-21 (P=0.009). This observation is specific for progressed colorectal adenomas, suggesting that an interaction between LOH of PTPRJ and loss of 18q12-21 may be involved in the development of a more progressed form of adenomas.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands	Netherlands Cancer Institute; Vrije Universiteit Amsterdam	Demant, P (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	P.demant@nki.nl						Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen MAJA, 1996, HUM PATHOL, V27, P342, DOI 10.1016/S0046-8177(96)90106-9; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MOEN CJA, 1992, ONCOGENE, V7, P563; Moustakas A, 2001, J CELL SCI, V114, P4359; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243	9	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3472	3474		10.1038/sj.onc.1206246	http://dx.doi.org/10.1038/sj.onc.1206246			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776199				2022-12-28	WOS:000183128500014
J	Knauf, JA; Ouyang, B; Croyle, M; Kimura, E; Fagin, JA				Knauf, JA; Ouyang, B; Croyle, M; Kimura, E; Fagin, JA			Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKC epsilon in PCCL3 thyroid cells	ONCOGENE			English	Article						thyroid; protein kinase C; phospholipase C gamma; apoptosis; RET/PTC	PROTEIN-KINASE-C; GENE-EXPRESSION; RET ACTIVATION; CANCER; RAS; APOPTOSIS; ONCOGENE; GROWTH; TRANSLOCATION; INVOLVEMENT	Most papillary thyroid carcinomas (PTC) have an isozyme-specific reduction of protein kinase C (PKC)epsilon, which occurs through a post-transcriptional mechanism. Here, we test whether the oncoprotein RET/PTC could be responsible for this effect, since RET/PTC rearrangements are quite prevalent in PTC and RET/PTC activates PLCgamma, an upstream modulator of PKCs. At 3 h after induction of RET/PTC1 or RET/PTC3 expression, there was evidence of PKCepsilon activation. Activation was restricted to PKCepsilon, as acute expression of RET/PTC did not change the subcellular distribution of other PKC isozymes expressed in PCCL3 cells. Prolonged RET/PTC expression (2-6 days) produced an isozyme-specific change in PKCepsilon subcellular localization and a decrease in total PKCepsilon levels. The expression of RET/PTC3(Y541F), which does not interact with PLCgamma, but signals normally through other RET effectors, had no effect on PKCepsilon distribution at any of the time points examined. However, downregulation of total PKCepsilon levels was only partially prevented by expression of RET/PTCY541F. Cells with decreased PKCepsilon following prolonged expression of RET/ PTC were relatively resistant to doxorubicin-induced apoptosis. Based on our previous observation that PCCL3 cells expressing a dominant-negative PKCepsilon are also markedly resistant to apoptosis, we propose that selective downregulation of PKCepsilon following prolonged RET/ PTC activation promotes cell survival and clonal expansion.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knauf, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Mail Locat 0547, Cincinnati, OH 45267 USA.	Jeffrey.Knauf@UC.EDU	Croyle, Maria/L-4586-2019; Kimura, Edna/D-7334-2012	Croyle, Maria/0000-0003-0809-901X; Kimura, Edna/0000-0001-8403-4459	NATIONAL CANCER INSTITUTE [R29CA050706, R01CA050706, R01CA072597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002781] Funding Source: NIH RePORTER; NCI NIH HHS [CA50706, CA72597] Funding Source: Medline; NIDDK NIH HHS [K01DK02781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Borrello MG, 1995, ONCOGENE, V11, P2419; CACACE AM, 1993, ONCOGENE, V8, P2095; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Kim MJ, 2000, EXP MOL MED, V32, P101, DOI 10.1038/emm.2000.18; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Knauf JA, 2002, J CLIN ENDOCR METAB, V87, P2150, DOI 10.1210/jc.87.5.2150; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Maddens S, 2002, BLOOD, V100, P1294, DOI 10.1182/blood.V100.4.1294.h81602001294_1294_1301; Marks F, 1995, MUTAT RES-FUND MOL M, V333, P161, DOI 10.1016/0027-5107(95)00142-5; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, FASEB J, V12, P35; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Neri LM, 2002, MOL BIOL CELL, V13, P947, DOI 10.1091/mbc.01-02-0086; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; Ohmori T, 1998, CELL GROWTH DIFFER, V9, P345; Plo I, 2001, ONCOGENE, V20, P6752, DOI 10.1038/sj.onc.1204877; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Zhuang SG, 1997, BIOCHEM BIOPH RES CO, V240, P273, DOI 10.1006/bbrc.1997.7474	44	14	16	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6830	6838		10.1038/sj.onc.1206829	http://dx.doi.org/10.1038/sj.onc.1206829			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534528				2022-12-28	WOS:000185843400002
J	Biroccio, A; Leonetti, C; Zupi, G				Biroccio, A; Leonetti, C; Zupi, G			The future of antisense therapy: combination with anticancer treatments	ONCOGENE			English	Review						antisense; molecular targets; proliferation; apoptosis; combination therapy	PROTEIN-KINASE-A; RI-ALPHA-SUBUNIT; BREAST-CANCER CELLS; C-MYC EXPRESSION; HUMAN-MELANOMA CELLS; BCL-XL EXPRESSION; FIBROBLAST-GROWTH-FACTOR; INHIBITS TUMOR-GROWTH; IN-VIVO ACTIVITIES; PROSTATE-CANCER	The current direction in cancer research is rational drug design, which is based on the evidence that transformed cells are characterized by alterations of genes devoted to the regulation of both cell proliferation and apoptosis. A variety of approaches have been carried out to develop new agents selective for cancer cells. Among these, antisense oligonucleotides (ASOs) are one of such class of new agents able to inhibit specifically the synthesis of a particular cancer-associated protein by binding to protein-encoding RNA, thereby preventing RNA function. In the past decade, several ASOs have been developed and tested in preclinical and clinical studies. Many have shown convincing in vitro reduction in target gene expression and promising activity against a wide variety of tumors. However, because of the multigenic alterations of tumors, the use of ASOs as single agents does not seem to be effective in the treatment of malignancies. Antisense therapy that interferes with signaling pathways involved in cell proliferation and apoptosis are particularly promising in combination with conventional anticancer treatment. An overview of the progress of ASOs used in combination therapy is provided.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro 156, I-00158 Rome, Italy.	zupi@ifo.it	Biroccio, Annamaria/B-2861-2018; Leonetti, Carlo/B-2860-2018	Biroccio, Annamaria/0000-0003-3198-3532; Leonetti, Carlo/0000-0002-3526-7827				Agrawal S, 2002, INT J ONCOL, V21, P65; Agrawal S, 1998, ANTISENSE NUCLEIC A, V8, P135, DOI 10.1089/oli.1.1998.8.135; Akie K, 2000, ANTISENSE NUCLEIC A, V10, P243, DOI 10.1089/108729000421420; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3; Balaji KC, 1997, UROLOGY, V50, P1007, DOI 10.1016/S0090-4295(97)00390-7; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Biroccio A, 2003, MOL PHARMACOL, V63, P632, DOI 10.1124/mol.63.3.632; Biroccio A, 2002, J BIOL CHEM, V277, P43763, DOI 10.1074/jbc.M207684200; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; Boggs RT, 1997, ANTISENSE NUCLEIC A, V7, P461, DOI 10.1089/oli.1.1997.7.461; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; Carroll JS, 2002, CANCER RES, V62, P3126; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chi KN, 2000, BREAST CANCER RES TR, V63, P199, DOI 10.1023/A:1017371013487; Cho YS, 2003, CLIN CANCER RES, V9, P1171; ChoChung YS, 1997, P ASSOC AM PHYSICIAN, V109, P23; Citro G, 1998, CANCER RES, V58, P283; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cotter FE, 1997, HEMATOL ONCOL, V15, P3, DOI 10.1002/(SICI)1099-1069(199702)15:1<3::AID-HON583>3.0.CO;2-S; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Dang CV, 1999, MOL CELL BIOL, V19, P1; DelBufalo D, 1996, BRIT J CANCER, V74, P387, DOI 10.1038/bjc.1996.370; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Funato T, 2001, ONCOL REP, V8, P807; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; GELMON K, 2001, P AACR NCI EORT TARG; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; GRIFFIN CA, 1985, CANCER RES, V45, P272; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUANG Y, 1995, MOL MED, V1, P647, DOI 10.1007/BF03401605; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Itano Y, 1996, J NEUROCHEM, V67, P131; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Knapp DC, 2003, ANTI-CANCER DRUG, V14, P39, DOI 10.1097/00001813-200301000-00006; Koller E, 2000, TRENDS PHARMACOL SCI, V21, P142, DOI 10.1016/S0165-6147(00)01448-6; Konopleva M, 2000, BLOOD, V95, P3929; Lebedeva I, 2000, CANCER RES, V60, P6052; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 2001, CANCER GENE THER, V8, P459, DOI 10.1038/sj.cgt.7700326; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Miller P. S., 1992, Antisense RNA and DNA., P241; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Miyake H, 2000, CANCER RES, V60, P2547; Miyake H, 2001, CLIN CANCER RES, V7, P4245; Miyake H, 2000, INT J CANCER, V86, P855, DOI 10.1002/(SICI)1097-0215(20000615)86:6<855::AID-IJC15>3.3.CO;2-#; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Pakunlu RI, 2003, PHARMACEUT RES, V20, P351, DOI 10.1023/A:1022687617318; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Simoes-Wust AP, 2000, INT J CANCER, V87, P582, DOI 10.1002/1097-0215(20000815)87:4<582::AID-IJC19>3.0.CO;2-P; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Smith JB, 1998, ADV EXP MED BIOL, V451, P17; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, MOL CELL BIOCHEM, V195, P25, DOI 10.1023/A:1006990231186; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; Steiner MS, 1998, HUM GENE THER, V9, P747, DOI 10.1089/hum.1998.9.5-747; Stewart DA, 2002, NUCLEIC ACIDS RES, V30, P2565, DOI 10.1093/nar/30.11.2565; Stewart DA, 2001, NUCLEIC ACIDS RES, V29, P4052, DOI 10.1093/nar/29.19.4052; Supino R, 2001, EUR J CANCER, V37, P2247, DOI 10.1016/S0959-8049(01)00268-4; Tanabe K, 2003, INT J ONCOL, V22, P875; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; Thompson MA, 1998, CANCER RES, V58, P5168; Tortora G, 2000, INT J CANCER, V88, P804, DOI 10.1002/1097-0215(20001201)88:5<804::AID-IJC19>3.0.CO;2-Z; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Tortora G, 2000, CLIN CANCER RES, V6, P2506; Tortora G, 2000, ANN ONCOL, V11, P777, DOI 10.1023/A:1008390206250; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vilenchik M, 2002, CANCER RES, V62, P2175; VLASSOV VV, 1994, BBA-REV BIOMEMBRANES, V1197, P95, DOI 10.1016/0304-4157(94)90001-9; WACHECK V, 2002, NUCL ACID DRUG DEV, V12, P359; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; Wang H, 2002, INT J ONCOL, V21, P73; Wang H, 2001, CLIN CANCER RES, V7, P3613; WATSON PH, 1991, CANCER RES, V51, P3996; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a; YOKOZAKI H, 1993, CANCER RES, V53, P868; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; Zellweger T, 2002, CLIN CANCER RES, V8, P3276; Zellweger T, 2001, NEOPLASIA, V3, P360, DOI 10.1038/sj.neo.7900174; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	117	63	74	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6579	6588		10.1038/sj.onc.1206812	http://dx.doi.org/10.1038/sj.onc.1206812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528283				2022-12-28	WOS:000185700700015
J	Tonini, T; Rossi, F; Claudio, PP				Tonini, T; Rossi, F; Claudio, PP			Molecular basis of angiogenesis and cancer	ONCOGENE			English	Review						angiogenesis; proangiogenic factors; antiangiogenic factors	ENDOTHELIAL GROWTH-FACTOR; BINDING COMPETITIVE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1; HUMAN NEUROBLASTOMA-CELLS; FACTOR GENE-TRANSCRIPTION; TUMOR ANGIOGENESIS; IN-VIVO; SIGNAL-TRANSDUCTION; SOLID TUMORS; CARDIOVASCULAR DEVELOPMENT	Angiogenesis is a term that describes the formation of new capillaries from a pre-existing vasculature. This process is very important in physiologic conditions because it helps healing injured tissues, and in female populations it helps forming the placenta after fertilization and reconstructs the inside layer of the uterus after menstruation. Angiogenesis is the result of an intricate balance between proangiogenic and antiangiogenic factors and is now very well recognized as a powerful control point in tumor development. In this particular environment, the. ne modulation among proangiogenic and antiangiogenic factors is disrupted, leading to inappropriate vessels growth. In this review, we discuss the molecular basis of angiogenesis during tumor growth and we also illustrate some of the molecules that are involved in this angiogenic switch.	Temple Univ, Dept Biotechnol, Philadelphia, PA 19122 USA; Univ Naples 2, Dipartimento Pediat, Naples, Italy; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillofacciali, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli; University of Naples Federico II	Claudio, PP (corresponding author), Temple Univ, Dept Biotechnol, 1900 N 12th St,Room 333, Philadelphia, PA 19122 USA.	claudio@temple.edu	Claudio, Pier Paolo/AAW-7282-2021	Claudio, Pier Paolo/0000-0001-7790-1622; Rossi, Francesca/0000-0003-2879-6277				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Baish JW, 2000, CANCER RES, V60, P3683; Bhushan M, 2002, BRIT J DERMATOL, V147, P418, DOI 10.1046/j.1365-2133.2002.05003.x; Breit S, 2000, CANCER RES, V60, P4596; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Buschmann I, 2000, J PATHOL, V190, P338, DOI 10.1002/(SICI)1096-9896(200002)190:3<338::AID-PATH594>3.0.CO;2-7; Carmeliet P, 1999, NATURE, V401, P657, DOI 10.1038/44304; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Casanova ML, 2002, CANCER RES, V62, P3402; Charvat S, 1999, ANTICANCER RES, V19, P557; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; Dulak J, 2003, ANTIOXID REDOX SIGN, V5, P123, DOI 10.1089/152308603321223612; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1988, AM J PATHOL, V133, P95; Eberhard A, 2000, CANCER RES, V60, P1388; EHRMANN RL, 1968, J NATL CANCER I, V41, P1329; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Gamble J, 1999, ENDOTHELIUM-NEW YORK, V7, P23, DOI 10.3109/10623329909165309; Gastl G, 1997, ONCOLOGY-BASEL, V54, P177; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; Hong YK, 2000, CLIN CANCER RES, V6, P3354; HORI A, 1991, CANCER RES, V51, P6180; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jiang BH, 1997, CANCER RES, V57, P5328; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Juczewska M, 1997, Rocz Akad Med Bialymst, V42 Suppl 1, P86; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim YM, 2000, CANCER RES, V60, P5410; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Lahm H, 1996, BIOCHEM BIOPH RES CO, V220, P334, DOI 10.1006/bbrc.1996.0406; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lingen MW, 1998, CANCER RES, V58, P5551; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Majewski S, 1996, J INVEST DERMATOL, V106, P1114, DOI 10.1111/1523-1747.ep12340161; Malonne H, 1999, CLIN EXP METASTAS, V17, P1, DOI 10.1023/A:1026443925807; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MINCHENKO A, 1994, LAB INVEST, V71, P374; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Pluda JM, 1997, SEMIN ONCOL, V24, P203; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Ruiter D J, 1993, Behring Inst Mitt, P258; Ryan CJ, 2000, DRUG AGING, V17, P249, DOI 10.2165/00002512-200017040-00001; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Scappaticci FA, 2001, MOL THER, V3, P186, DOI 10.1006/mthe.2000.0243; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SONOBE MH, 1991, ONCOGENE, V6, P1531; Stack MS, 1999, BIOCHEM J, V340, P77, DOI 10.1042/0264-6021:3400077; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taraboletti G, 2000, FASEB J, V14, P1674; Taraboletti G, 1997, CELL GROWTH DIFFER, V8, P471; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Werner H, 2000, MOL GENET METAB, V71, P315, DOI 10.1006/mgme.2000.3044; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Wouters BG, 2003, SEMIN RADIAT ONCOL, V13, P31, DOI 10.1053/srao.2003.50004; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47	100	231	277	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6549	6556		10.1038/sj.onc.1206816	http://dx.doi.org/10.1038/sj.onc.1206816			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528279				2022-12-28	WOS:000185700700011
J	Kopitz, J; Andre, S; von Reitzenstein, C; Versluis, K; Kaltner, H; Pieters, RJ; Wasano, K; Kuwabara, I; Liu, FT; Cantz, M; Heck, AJR; Gabius, HJ				Kopitz, J; Andre, S; von Reitzenstein, C; Versluis, K; Kaltner, H; Pieters, RJ; Wasano, K; Kuwabara, I; Liu, FT; Cantz, M; Heck, AJR; Gabius, HJ			Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells	ONCOGENE			English	Article						apoptosis; cell growth; galectin; ganglioside; mass spectrometry; neuroblastoma	CARBOHYDRATE-BINDING PROTEINS; TOXIN B-SUBUNIT; MEMBRANE GANGLIOSIDE SIALIDASE; ADHERENS JUNCTION PROTEIN; ANIMAL LECTINS; ENDOGENOUS LECTINS; MASS-SPECTROMETRY; PLASMA-MEMBRANE; TUMOR BIOLOGY; HUMAN GLIOMAS	The extracellular functions of galectin-7 (p53-induced gene 1) are largely unknown. On the surface of neuroblastoma cells (SK-N-MC), the increased GM(1) density, a result of upregulated ganglioside sialidase activity, is a key factor for the switch from proliferation to differentiation. We show by solid-phase and cell assays that the sugar chain of this ganglioside is a ligand for galectin-7. In serum-supplemented proliferation assays, galectin-7 reduced neuroblastoma cell growth without the appearance of features characteristic for classical apoptosis. The presence of galectin-3 blocked this effect, which mechanistically resembles that of galectin-1. By virtue of carbohydrate binding, galectin-7 thus exerts neuroblastoma growth control similar to galectin-1 despite their structural differences. In addition to p53-linked proapoptotic activity intracellularly, galectin-7, acting as a lectin on the cell surface, appears to be capable of reducing cancer cell proliferation in susceptible systems.	Univ Heidelberg Klinikum, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Munich, Tierarztliche Fak, Inst Physiol Chem, D-80539 Munich, Germany; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Med Chem, NL-3508 TB Utrecht, Netherlands; Kyushu Univ, Fac Med, Dept Anat & Cell Biol, Fukuoka 8120054, Japan; Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA	Ruprecht Karls University Heidelberg; University of Munich; Utrecht University; Utrecht University; Utrecht University; Kyushu University; University of California System; University of California Davis	Kopitz, J (corresponding author), Univ Heidelberg Klinikum, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	juergen_kopitz@med.uni-heidelberg.de	Pieters, Roland J/A-9254-2008; Heck, Albert/D-7098-2011; Liu, FU-TONG/A-5749-2019	Pieters, Roland J/0000-0003-4723-3584; Heck, Albert/0000-0002-2405-4404; Liu, FU-TONG/0000-0002-3354-1001; Gabius, Hans-Joachim/0000-0003-3467-3900; Andre, Sabine/0000-0003-0850-0432; Kaltner, Herbert/0000-0003-4680-8411				AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Ahmad N, 2002, CAN J CHEM, V80, P1096, DOI 10.1139/V02-162; Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Andre S, 2000, PHARMACEUT RES, V17, P985, DOI 10.1023/A:1007535506705; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Andre S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W; Andre S, 1997, BIOCONJUGATE CHEM, V8, P845, DOI 10.1021/bc970164d; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Borriello A, 2002, HAEMATOLOGICA, V87, P196; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; Camby I, 2002, J NEUROPATH EXP NEUR, V61, P585, DOI 10.1093/jnen/61.7.585; Camby I, 2001, BRAIN PATHOL, V11, P12; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Dobo A, 2001, ANAL CHEM, V73, P4763, DOI 10.1021/ac010713f; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; Gabius HJ, 2000, NATURWISSENSCHAFTEN, V87, P108, DOI 10.1007/s001140050687; GABIUS HJ, 1990, ANAL BIOCHEM, V189, P91, DOI 10.1016/0003-2697(90)90050-J; GABIUS HJ, 1987, CANCER INVEST, V5, P39, DOI 10.3109/07357908709020305; Gabius HJ, 2002, BBA-GEN SUBJECTS, V1572, P165, DOI 10.1016/S0304-4165(02)00306-9; Gabius HJ, 2001, BIOCHIMIE, V83, P659, DOI 10.1016/S0300-9084(01)01311-6; Gabius HJ, 2001, ANAT HISTOL EMBRYOL, V30, P3, DOI 10.1046/j.1439-0264.2001.00305.x; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GABIUS S, 1990, BIOCHEM BIOPH RES CO, V169, P239, DOI 10.1016/0006-291X(90)91459-6; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Giudicelli V, 1997, GLYCOBIOLOGY, V7, pR8; Gunnersen JM, 2000, GLIA, V32, P146, DOI 10.1002/1098-1136(200011)32:2<146::AID-GLIA40>3.3.CO;2-V; Hadari YR, 2000, J CELL SCI, V113, P2385; Hakamori S, 1998, ACTA ANAT, V161, P79; Hippo Y, 2001, CANCER RES, V61, P889; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; Hirabayashi J, 1997, TRENDS GLYCOSCI GLYC, V9, P1; Horie H, 2000, NEUROSCI RES, V38, P131, DOI 10.1016/S0168-0102(00)00142-5; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Itzkowitz SH, 1997, GASTROENTEROLOGY, V113, P2003; Kaltner H, 1998, ACTA ANAT, V161, P162; Kayser K, 2001, J PATHOL, V193, P175, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH772>3.0.CO;2-T; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; Kitanaka C, 2002, J NATL CANCER I, V94, P358; KOHNKEGODT B, 1989, BIOCHEMISTRY-US, V28, P6531, DOI 10.1021/bi00442a001; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; LIU FT, 2000, LECTINS PATHOLOGY, P51; Lu JX, 1997, MOL CARCINOGEN, V20, P204, DOI 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Nangia-Makker P, 2000, CANCER METAST REV, V19, P51, DOI 10.1023/A:1026540129688; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; OHANNESIAN DW, 1997, GLYCOSCIENCES STATUS, P459; OUTENREATH RL, 1992, J NEUROCYTOL, V21, P788, DOI 10.1007/BF01237904; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POWELL JT, 1984, BIOCHEM J, V223, P769, DOI 10.1042/bj2230769; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; Rappl G, 2002, LEUKEMIA, V16, P840, DOI 10.1038/sj.leu.2402438; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; Reuter G, 1999, CELL MOL LIFE SCI, V55, P368, DOI 10.1007/s000180050298; Rodighiero C, 2001, J BIOL CHEM, V276, P36939, DOI 10.1074/jbc.M104245200; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; ROFF CF, 1983, J BIOL CHEM, V258, P657; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Sato M, 2002, J BIOCHEM, V131, P255, DOI 10.1093/oxfordjournals.jbchem.a003096; SHAPER NL, 2000, CARBOHYDRATES CHEM 2, P175; Simmons DA, 2002, BIOCHEMISTRY-US, V41, P1906, DOI 10.1021/bi011697j; Solis D, 2001, CELLS TISSUES ORGANS, V168, P5, DOI 10.1159/000016802; Timmons PM, 1999, INT J DEV BIOL, V43, P229; van den Bremer ETJ, 2002, PROTEIN SCI, V11, P1738, DOI 10.1110/ps.0200502; van Dongen WD, 2000, ANALYST, V125, P583, DOI 10.1039/a907957b; Varela PF, 1999, J MOL BIOL, V294, P537, DOI 10.1006/jmbi.1999.3273; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vrasidas I, 2001, EUR J ORG CHEM, V2001, P4685; Wasano K, 1999, J HISTOCHEM CYTOCHEM, V47, P75, DOI 10.1177/002215549904700108; Wollina U, 2002, J CANCER RES CLIN, V128, P103, DOI 10.1007/s00432-001-0304-3; WOO HJ, 1991, J BIOL CHEM, V266, P18419; Wu AM, 2002, BIOCHEM J, V367, P653, DOI 10.1042/BJ20020600; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yamaoka K., 1993, LECTINS GLYCOBIOLOGY, P492	95	131	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6277	6288		10.1038/sj.onc.1206631	http://dx.doi.org/10.1038/sj.onc.1206631			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679866				2022-12-28	WOS:000185506200017
J	Yin, XY; Giap, C; Lazo, JS; Prochownik, EV				Yin, XY; Giap, C; Lazo, JS; Prochownik, EV			Low molecular weight inhibitors of Myc-Max interaction and function	ONCOGENE			English	Article						mad; bHLH proteins; leucine zipper proteins; yeast two-hybrid assay	C-MYC; ORNITHINE-DECARBOXYLASE; DNA-BINDING; ID PROTEINS; GENE; EXPRESSION; GROWTH; APOPTOSIS; TARGET; CELLS	c-Myc is helix - loop - helix - leucine zipper (HLH-ZIP) oncoprotein that is frequently deregulated in human cancers. In order to bind DNA, regulate target gene expression, and function in a biological context, c-Myc must dimerize with another HLH - ZIP protein, Max. A large number of c-Myc target genes have been identified, and many of the encoded proteins are transforming. Such functional redundancy, however, complicates therapeutic strategies aimed at inhibiting any single target gene product. Given this consideration, we have instead attempted to identify ways by which c-Myc itself could be effectively disabled. We have used a yeast two-hybrid approach to identify low-molecular-weight compounds that inhibit c-Myc - Max association. All of the compounds prevented transactivation by c-Myc - Max heterodimers,inhibited cell cycle progression, and prevented the in vitro growth of fibroblasts in a c-Myc-dependent manner. Several of the compounds also inhibited tumor growth in vivo. These results show that the yeast two-hybrid screen is useful for identifying compounds that can be exploited in mammalian cells. More specifically, they provide a means by which structural analogs, based upon these first-generation Myc-Max inhibitors, can be developed to enhance antitumor efficacy.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu			NATIONAL CANCER INSTITUTE [U01CA052995, U19CA052995] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [P12 CA52995] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bai C, 1996, METHOD ENZYMOL, V273, P331; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guo QM, 2000, CANCER RES, V60, P5922; Hasskarl J, 2002, CANCER BIOL THER, V1, P91, DOI 10.4161/cbt.50; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; KIMURA S, 1995, CANCER RES, V55, P1379; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wechsler DS, 1997, CANCER RES, V57, P4905; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	47	330	351	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6151	6159		10.1038/sj.onc.1206641	http://dx.doi.org/10.1038/sj.onc.1206641			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679853				2022-12-28	WOS:000185506200004
J	Zhang, ZQ; Wang, Y; Lantry, LE; Kastens, E; Liu, GJ; Hamilton, AD; Sebti, SM; Lubet, RA; You, M				Zhang, ZQ; Wang, Y; Lantry, LE; Kastens, E; Liu, GJ; Hamilton, AD; Sebti, SM; Lubet, RA; You, M			Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf	ONCOGENE			English	Article						farnesyltransferase inhibitor; lung cancer; chemoprevention; A/J mice; transgenic mice; P53; Ink4a/Arf	GERANYLGERANYLTRANSFERASE-I INHIBITORS; PROTEIN TRANSFERASE INHIBITOR; TRANSGENIC MICE; TUMOR-GROWTH; RAS; MOUSE; CARCINOMAS; MUTATION; PATHWAY; MAMMARY	Mutations in the Kras2 gene are seen in both human and mouse lung adenocarcinomas. The protein product (p21(ras)) encoded by the Kras2 gene must be post-translationally modified at a terminal CAAX motif in order to be biologically active. In this study, we systematically investigated the chemopreventive efficacy of two different farnesyltransferase inhibitors (FTIs): one is a peptidomimetic (FTI-276) and the other is an imidazole (L778 - 123). Both FTIs are designed to inhibit the posttranslational modi. cation of p21ras proteins with a terminal CAAX motif. In a complete chemoprevention study, where the inhibitor was administered before carcinogen was given, and throughout the study, FTI-276 treatment significantly reduced both the tumor multiplicity by 41.7% (P<0.005), and the total tumor volume by 79.4% (P<0.0001). In the late treatment study, where mice were treated with an inhibitor 12 to 20 weeks after carcinogen administration, FTI-276 treatment resulted in a 60% reduction in tumor multiplicity and 58% reduction in tumor volume. Next, we examined the chemopreventive efficacy of a new FTI, L-778,123, on lung tumor development in A/J mice and transgenic mice with a dominant-negative p53 mutation and/or heterozygous deletion of Ink4a/Arf. Treatment of mice with L-778,123 for a period of 10 weeks from 20 weeks to 30 weeks post carcinogen initiation resulted in an similar to50% decrease in tumor multiplicity in wild-type mice and mice with a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/Arf tumor suppressor genes. Interestingly, tumor volume was decreased similar to50% in wildtype mice and in mice with an Ink4a/Arf heterozygous deletion, while tumor volume was decreased similar to75% in animals with a dominant-negative p53 and in mice with both a p53 mutation and heterozygous deletion of Ink4a/ Arf. This result suggests that FTI exhibited a significantly (P<0.05) more efficacious chemopreventive effect in animals with alterations of p53 and Ink4a/ Arf as contrasted with wild-type mice. Thus, FTIs are potent lung chemopreventive agents in both A/J mice and transgenic mice harboring a dominant-negative p53 and heterozygous deletion of Ink4a/Arf. In fact, L-778,123 is more effective in inhibiting primary lung progression in mice with a p53 mutation and/or an Ink4a/Arf deletion than in wild-type animals.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA; Yale Univ, Dept Chem, New Haven, CT USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Drug Discovery Program, Tampa, FL USA; NCI, Chemoprevent Agent Dev Res Grp, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Yale University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, R01CA78797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BOS JL, 1989, CANCER RES, V49, P4682; Brassard DL, 2002, EXP CELL RES, V273, P138, DOI 10.1006/excr.2001.5440; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIBA I, 1990, ONCOGENE, V5, P1603; Crespo NC, 2002, CELL DEATH DIFFER, V9, P702, DOI 10.1038/sj.cdd.4401023; Du W, 1999, MOL CELL BIOL, V19, P1831; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Gu WZ, 1999, EUR J CANCER, V35, P1394, DOI 10.1016/S0959-8049(99)00132-X; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herzog CR, 1996, ONCOGENE, V13, P1885; Herzog CR, 1997, J CELL BIOCHEM, P49; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lantry LE, 2000, CARCINOGENESIS, V21, P113, DOI 10.1093/carcin/21.1.113; Lantry LE, 2000, EXP LUNG RES, V26, P773, DOI 10.1080/01902140150216819; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lubet RA, 2000, EXP LUNG RES, V26, P581, DOI 10.1080/01902140150216684; Mangues R, 1998, CANCER RES, V58, P1253; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; McDoniels-Silvers AL, 2001, EXP LUNG RES, V27, P297, DOI 10.1080/019021401300054064; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Minna JD, 1989, CANCER PRINCIPLES PR, P591; NAGASU T, 1995, CANCER RES, V55, P5310; Omer CA, 2000, CANCER RES, V60, P2680; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; RODENHUIS S, 1992, CANCER RES, V52, pS2665; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; SELLERS TA, 1992, CANCER RES, V52, pS2694; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; XU HJ, 1991, CANCER RES, V51, P2735; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725	42	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6257	6265		10.1038/sj.onc.1206630	http://dx.doi.org/10.1038/sj.onc.1206630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679864				2022-12-28	WOS:000185506200015
J	Gales, C; Sanchez, D; Poirot, M; Pyronnet, S; Buscail, L; Cussac, D; Pradayrol, L; Fourmy, D; Silvente-Poirot, S				Gales, C; Sanchez, D; Poirot, M; Pyronnet, S; Buscail, L; Cussac, D; Pradayrol, L; Fourmy, D; Silvente-Poirot, S			High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor	ONCOGENE			English	Article						CCK2R; constitutively active mutant; gastrin; cancer; nude mice	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; ORNITHINE DECARBOXYLASE; KAPOSIS-SARCOMA; B RECEPTOR; STRUCTURAL INSTABILITY; CELL-TRANSFORMATION; B/GASTRIN RECEPTOR; ASPARTIC-ACID; ACTIVATION	The cholecystokinin 2 receptor (CCK2R) increases proliferation of normal and neoplastic gastrointestinal cells and activates various mitogenic signaling pathways when stimulated by gastrin. To study the incidence of permanent activation of this receptor in tumorigenicity, a constitutively active mutant was generated by replacing residue Glu151 in the conserved E/DRY motif by Ala. Expression of the E151A-CCK2R mutant in NIH-3T3 cells causes ligand-independent activation of phospholipase C and ornithine decarboxylase, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of this mutant was associated with dramatic alteration of NIH-3T3 cell morphology, enhanced cell proliferation and invasion. Moreover, injection of cells expressing E151A-CCK2R in nude mice resulted in the development of large and rapidly growing tumors. By contrast, none of these effects was observed with cells expressing the wildtype CCK2R, indicating that the tumorigenic properties of the E151A-CCK2R mutant is the result of its constitutive activation. To date, this is the first report that provides evidence for the high tumorigenic effect of a constitutively active CCK2R mutant, thus raising a potential role of the CCK2R in human cancer.	Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, INSERM, U531, F-31403 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31403 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Silvente-Poirot, S (corresponding author), Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	poirot_s@icr.fnclcc.fr	Fourmy, Daniel/AAE-3703-2019; Cussac, Daniel/AAP-1544-2020; Pyronnet, Stéphane/P-2419-2014; Poirot, Sandrine/D-5448-2017; Poirot, Marc/C-7613-2009; Poirot, Marc/K-3551-2012	Fourmy, Daniel/0000-0001-9910-4827; Poirot, Marc/0000-0002-5711-6624; Poirot, Marc/0000-0002-5711-6624; GALES, Celine/0000-0002-4938-1583; Cussac, Daniel/0000-0002-7227-898X; Silvente-Poirot, Sandrine/0000-0003-2245-9069				ALBINI A, 1987, CANCER RES, V47, P3239; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Auvinen M, 1997, CANCER RES, V57, P3016; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Burger M, 1999, J IMMUNOL, V163, P2017; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ding WQ, 2002, CANCER RES, V62, P947; Estep RD, 2003, J VIROL, V77, P1738, DOI 10.1128/JVI.77.3.1738-1746.2003; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; Morin D, 1998, FEBS LETT, V441, P470, DOI 10.1016/S0014-5793(98)01585-3; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pagliocca A, 2002, AM J PHYSIOL-GASTR L, V283, pG292, DOI 10.1152/ajpgi.00056.2002; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Reubi JC, 1997, CANCER RES, V57, P1377; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; TODISCO A, 1995, J BIOL CHEM, V270, P28337; WANG SA, 1998, AM J PHYSIOL, V274, pG607; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	50	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6081	6089		10.1038/sj.onc.1206823	http://dx.doi.org/10.1038/sj.onc.1206823			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955087				2022-12-28	WOS:000185137800017
J	Trempat, P; Villalva, C; Laurent, G; Armstrong, F; Delsol, G; Dastugue, N; Brousset, P				Trempat, P; Villalva, C; Laurent, G; Armstrong, F; Delsol, G; Dastugue, N; Brousset, P			Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec	ONCOGENE			English	Article						chronic myeloid leukaemia; STI-571/Glivec; PDGFRA	GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; IMATINIB MESYLATE; DERMATOFIBROSARCOMA PROTUBERANS; BCR; STI571; INHIBITOR; EFFICACY; PDGFRA	Two cases of atypical chronic myeloid leukaemia (CML) carrying the t(4;22)(q12;q11) translocation involving the breakpoint cluster region (BCR) and platelet-derived growth factor a receptor (PDGFRA) genes have been recently characterized. We report a third case of atypical CML with the same translocation but with a distinct breakpoint fusing BCR exon 1 with PDGFRA exon 13. The patient had a clinical presentation of CML with progressive transformation in B-cell acute lymphoblastic leukaemia. The involvement of PDGFRA led us to treat the patient with the small organic compound imatinib mesylate/STI571 (Glivec) that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors. The patient subsequently achieved a rapid clinical and molecular response clearly demonstrating, for the first time, that Glivec is active against PDGFRA in vivo. Therefore, our study expands the list of Glivec targets and has direct biological and also clinical implications.	Purpan Hosp, Ctr Physiopathol Toulouse Purpan, INSERM, U563, Toulouse, France; Purpan Hosp, Dept Pathol, Toulouse, France; Purpan Hosp, Dept Haematol, Toulouse, France; Purpan Hosp, Dept Cytogenet, Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU de Toulouse; CHU de Toulouse	Brousset, P (corresponding author), CHU Purpan, INSERM, Anat Pathol Lab, U563, F-31059 Toulouse, France.							Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Magnusson MK, 2002, BLOOD, V100, P1088, DOI 10.1182/blood-2002-01-0165; Maki RG, 2002, INT J CANCER, V100, P623, DOI 10.1002/ijc.10535; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Petzer AL, 2002, BRIT J HAEMATOL, V117, P623, DOI 10.1046/j.1365-2141.2002.03523.x; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; Thijsen SFT, 1999, LEUKEMIA, V13, P1646, DOI 10.1038/sj.leu.2401565; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7	15	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5702	5706		10.1038/sj.onc.1206543	http://dx.doi.org/10.1038/sj.onc.1206543			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944919				2022-12-28	WOS:000184865900020
J	Gatza, ML; Watt, JC; Marriott, SJ				Gatza, ML; Watt, JC; Marriott, SJ			Cellular transformation by the HTLV-I tax protein, a jack-of-all-trades	ONCOGENE			English	Review						tax; HTLV-I; cell cycle; DNA repair; cellular transformation	VIRUS TYPE-I; WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; ONCOGENE PRODUCT TAX; TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; RECEPTOR GENE-EXPRESSION; LEUKEMIA-VIRUS; TYPE-1 TAX; DNA-REPAIR	The human T-cell leukemia virus type I (HTLV-I) is an oncogenic retrovirus that is responsible for adult T-cell leukemia and a neurological disease, HTLV-I-associated myelopathy/tropical spastic paraparesis. HTLV-I encodes an oncogenic protein, Tax, which affects a variety of cellular functions prompting it to be referred to as a jack-of-all trades. The ability of Tax to both transcriptionally regulate cellular gene expression and to functionally inactivate proteins involved in cell-cycle progression and DNA repair provide the basis for Tax-mediated transformation and leukemogenesis. This review will concentrate on the effects of Tax on the dysregulation of the G(1)/S and G(2)/M checkpoints as well as the suppression of DNA damage repair leading to cellular transformation.	Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Interdept Program Cell & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	susanm@bcm.tmc.edu		Gatza, Michael/0000-0001-6796-7791	NCI NIH HHS [CA-09197, CA-77371] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1996, ONCOGENE, V12, P1645; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016/S0168-1702(01)00286-6; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CESARMAN E, 1992, BLOOD, V80, P3205; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Haller K, 2000, AIDS RES HUM RETROV, V16, P1683, DOI 10.1089/08892220050193146; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA T, 1990, CANCER GENET CYTOGEN, V49, P157, DOI 10.1016/0165-4608(90)90137-Y; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lemoine FJ, 2001, DIS MARKERS, V17, P129, DOI 10.1155/2001/263567; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MIYAMOTO K, 1983, CANCER-AM CANCER SOC, V52, P471, DOI 10.1002/1097-0142(19830801)52:3<471::AID-CNCR2820520316>3.0.CO;2-E; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; NIITSU Y, 1988, BLOOD, V71, P263; Nilsen H, 2001, CARCINOGENESIS, V22, P987, DOI 10.1093/carcin/22.7.987; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PARRY JM, 1987, MUTAT RES, V181, P267, DOI 10.1016/0027-5107(87)90104-7; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; REID RL, 1993, ONCOGENE, V8, P3029; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; ROWLEY JD, 1984, HUMAN T CELL LEUKEMI, P85; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SAKASHITA A, 1992, BLOOD, V79, P477; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SAXINGER W, 1984, SCIENCE, V225, P1473, DOI 10.1126/science.6089348; Schmaltz B, 2000, GNOMON, V72, P633; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Slattery JP, 1999, GENOME RES, V9, P525; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; THOMSON EJ, 1988, MUTAGENESIS, V3, P415, DOI 10.1093/mutage/3.5.415; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; YAMADA Y, 1983, BLOOD, V61, P192; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	159	68	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5141	5149		10.1038/sj.onc.1206549	http://dx.doi.org/10.1038/sj.onc.1206549			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910251				2022-12-28	WOS:000184615100005
J	Khalili, K; Del Valle, L; Otte, J; Weaver, M; Gordon, J				Khalili, K; Del Valle, L; Otte, J; Weaver, M; Gordon, J			Human neurotropic polyomavirus, JCV, and its role in careinogenesis	ONCOGENE			English	Article						PML; oncogene; cancer; brain	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CENTRAL-NERVOUS-SYSTEM; PRIMITIVE NEUROECTODERMAL TUMORS; HUMAN PAPOVAVIRUS JC; VIRUS-DNA SEQUENCES; BASIC-PROTEIN GENE; FETAL GLIAL-CELLS; LARGE T-ANTIGENS; TRANSGENIC MICE; BRAIN-TUMORS	A number of recent studies have reported the detection of the ubiquitous human polyomavirus, JC virus (JCV), in samples derived from several types of neural as well as non-neural human tumors. The human neurotropic JCV was first identified as the etiologic agent of the fatal demyelinating disease, progressive multifocal leukoencephalopathy, which usually occurs in individuals with defects in cell-mediated immunity, including AIDS. However, upon mounting evidence of the oncogenic potential of the viral regulatory protein, T-antigen, and JCV's oncogenecity in a broad range of animal models, studies were initiated to determine its potential involvement in human carcinogenesis. Initially, the most frequently observed tumors in rodent models, including medulloblastoma, astrocytoma, glioblastoma, and other neural-origin tumors were analysed. These studies were followed by analysis of non-neural tumors such as colorectal carcinomas. In a subset of each tumor type examined, JC viral genomic DNA sequences could be detected by PCR and confirmed by Southern blot hybridization or direct sequencing. In a smaller subset of the tumors, the expression of T-antigen was observed by immunohistochemical analysis. Owing to the established functions of T-antigen including its ability to interact with tumor suppressor proteins such as Rb and p53, and its ability to influence chromosomal stability, potential mechanisms of JCV T-antigen-mediated cellular dysregulation are discussed. Further, as increasing evidence suggests that T-antigen is not required for maintenance of a transformed phenotype, a hit-and-run model for T-antigen-induced transformation is proposed.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				AKATANI K, 1994, J MED VIROL, V43, P13, DOI 10.1002/jmv.1890430104; Arrington AS, 2001, HUMAN POLYOMAVIRUSES; ASSOULINE JG, 1991, J VIROL, V65, P1002, DOI 10.1128/JVI.65.2.1002-1006.1991; ATWOOD WJ, 1992, VIROLOGY, V190, P716, DOI 10.1016/0042-6822(92)90909-9; BARONVANEVERCOOREN A, 1992, LAB INVEST, V66, P39; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Bofill-Mas S, 2001, J VIROL, V75, P10290, DOI 10.1128/JVI.75.21.10290-10299.2001; Boldorini R, 1998, J NEUROVIROL, V4, P242, DOI 10.3109/13550289809114524; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BRUN A, 1984, CANCER, V53, P1714, DOI 10.1002/1097-0142(19840415)53:8<1714::AID-CNCR2820530816>3.0.CO;2-T; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; CORALLINI A, 2001, HUMAN POLYOMAVIRUSES; Darbinyan A, 2002, ONCOGENE, V21, P5574, DOI 10.1038/sj.onc.1205744; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P3332; Del Valle L, 2002, NEUROLOGY, V58, P895, DOI 10.1212/WNL.58.6.895; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; Devireddy LR, 1996, J MED VIROL, V49, P205; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Enam S, 2002, CANCER RES, V62, P7093; Franks RR, 1996, ONCOGENE, V12, P2573; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Frye S, 1997, J VIROL METHODS, V63, P81, DOI 10.1016/S0166-0934(96)02117-9; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Hara K, 1998, J VIROL, V72, P5335, DOI 10.1128/JVI.72.7.5335-5342.1998; KITAMURA T, 1994, J CLIN MICROBIOL, V32, P2359, DOI 10.1128/JCM.32.10.2359-2363.1994; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lazutka JR, 1996, CANCER LETT, V109, P177, DOI 10.1016/S0304-3835(96)04448-5; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LYNCH KJ, 1994, VIROLOGY, V204, P819, DOI 10.1006/viro.1994.1600; MAJOR EO, 1987, J VIROL, V61, P1435, DOI 10.1128/JVI.61.5.1435-1441.1987; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MAJOR EO, 1989, J NEUROPATH EXP NEUR, V48, P425, DOI 10.1097/00005072-198907000-00004; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MATSUDA M, 1987, JNCI-J NATL CANCER I, V79, P585; MOLENAAR WM, 1994, CRIT REV ONCOL HEMAT, V17, P1, DOI 10.1016/1040-8428(94)90036-1; MONACO MCG, 1998, J VIROL, P9918; NAGASHIMA K, 1984, AM J PATHOL, V116, P455; Neel JV, 1996, P NATL ACAD SCI USA, V93, P2690, DOI 10.1073/pnas.93.7.2690; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; Ricciardiello L, 2000, GASTROENTEROLOGY, V119, P1228, DOI 10.1053/gast.2000.19269; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RICHARDSON E, 1961, NEW ENGL J MED, V265, P815, DOI 10.1056/NEJM196110262651701; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Shinohara T, 1997, VIROLOGY, V228, P269, DOI 10.1006/viro.1996.8409; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; VACANTE DA, 1989, VIROLOGY, V170, P353, DOI 10.1016/0042-6822(89)90425-X; Walker D L, 1983, Prog Clin Biol Res, V105, P99; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WOODRUFF JM, 2000, PATHOLOGY GENETICS T; WROBLEWSKA Z, 1980, ARCH VIROL, V65, P141, DOI 10.1007/BF01317325; ZURHEIN GM, 1979, NATL CANCER I MONOGR, V51, P205	71	123	126	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5181	5191		10.1038/sj.onc.1206559	http://dx.doi.org/10.1038/sj.onc.1206559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910255				2022-12-28	WOS:000184615100009
J	Kauppila, S; Maaty, WSA; Chen, P; Tomar, RS; Eby, MT; Chapo, J; Chew, S; Rathore, N; Zachariah, S; Sinha, SK; Abrams, JM; Chaudhary, PM				Kauppila, S; Maaty, WSA; Chen, P; Tomar, RS; Eby, MT; Chapo, J; Chew, S; Rathore, N; Zachariah, S; Sinha, SK; Abrams, JM; Chaudhary, PM			Eiger and its receptor, Wengen, comprise a TNF-like system in Drosophila	ONCOGENE			English	Article						Eiger; Wengen; Darth; TNF; apoptosis; JNK; dTRAF2	SUPERFAMILY; ACTIVATION; KINASE; DEATH; PROTEINS; BINDING; PATHWAY; MEMBER; REAPER; EMBRYO	In mammals, members of the tumor necrosis factor (TNF) family play an important role in the regulation of cellular proliferation, differentiation and programmed cell death. We describe isolation and characterization of an orthologous ligand/receptor axis in Drosophila. The ligand, designated Eiger, is a type II membrane glycosylated protein, which can be cleaved at residue 145 and released from the cell surface as a soluble factor, thereby representing the first potential cytokine to be described in Drosophila. Eiger exists in two alternatively spliced isoforms, Eiger long (Eiger-L) and Eiger short (Eiger-s), both of which are expressed throughout development and in the adult. We also describe the isolation and characterization of a novel Drosophila member of the TNF receptor family, designated Wengen, which is a type I membrane protein that can physically interact with the recently described TRAF2 homolog dTRAF2. Both Eiger and Wengen are expressed in distinctive patterns during embryogenesis and Eiger is responsive to genotoxic stress. Forced expression of Eiger-L, Eiger-s or Wengen, caused apoptotic cell death which could be rescued by caspase inhibitors or the JNK phosphatase Puckered. In addition, Eiger-induced cell killing was attenuated by RNAi-mediated suppression of Wengen. Our results illustrate that Eiger and Wengen represent proximal components of an evolutionarily conserved TNF-like signaling pathway in Drosophila.	Univ Texas, Hamon Ctr Therapeut Oncol Res, SW Med Ctr, Dallas, TX 75390 USA; Univ Texas, Div Hematol Oncol, SW Med Ctr, Dallas, TX 75390 USA; Univ Texas, Dept Cell Biol, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas, Hamon Ctr Therapeut Oncol Res, SW Med Ctr, Dallas, TX 75390 USA.		Chaudhary, Preet/E-1970-2018		NIA NIH HHS [R01 AG12466] Funding Source: Medline; NIDCR NIH HHS [1R01 DE015189-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Baker SJ, 1996, ONCOGENE, V12, P1; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Shen BH, 2001, P NATL ACAD SCI USA, V98, P8596, DOI 10.1073/pnas.141235698; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stathopoulos A, 2002, CELL, V111, P687, DOI 10.1016/S0092-8674(02)01087-5; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	20	126	133	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4860	4867		10.1038/sj.onc.1206715	http://dx.doi.org/10.1038/sj.onc.1206715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894227				2022-12-28	WOS:000184344600009
J	He, JQ; Xu, HG; Xu, XX; Hall, RA				He, JQ; Xu, HG; Xu, XX; Hall, RA			Cell cycle-dependent phosphorylation of Disabled-2 by cdc2	ONCOGENE			English	Article						tumor suppressor; cdk; receptor; cancer; kinase; phosphatase	EPITHELIAL OVARIAN-CANCER; TUMOR-SUPPRESSOR GENE; PROTEIN-PHOSPHORYLATION; BINDING PARTNER; PROSTATE-CANCER; OKADAIC ACID; MYOSIN-VI; DOC-2/DAB2; KINASE; MOUSE	Disabled-2 (Dab2; also known as p96 and DOC-2) is a signal transduction protein that has been implicated in the control of cell growth. Dab2 is known to be a phosphoprotein, but little is known about the kinases that phosphorylate Dab2. We have found that Dab2 phosphorylation is markedly increased during the mitosis phase of the cell cycle. This phosphorylation is blocked by roscovitine, a selective inhibitor of cyclin-dependent kinases. Dab2 robustly coimmunoprecipitates from cells with the cyclin-dependent kinase cdc2, and purified cdc2 can phosphorylate purified Dab2 fusion proteins in vitro on multiple sites. Cellular phosphorylation of Dab2 by cdc2 promotes the association of Dab2 with Pir1 a peptidylprolyl isomerase that regulates the rate of Dab2 dephosphorylation. These findings reveal that Dab2 is differentially phosphorylated during the cell cycle by cdc2 and provide a potential feedback mechanism by which Dab2 inhibition of cell growth and proliferation may be regulated.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Fox Chase Canc Ctr, Ovarian Canc Program, Div Med Sci, Philadelphia, PA 19111 USA	Emory University; Fox Chase Cancer Center	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5113 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.			Hall, Randy/0000-0002-8318-8728	NCI NIH HHS [R01-CA-75389, R01-CA-79716] Funding Source: Medline; NHLBI NIH HHS [R01-HL-64713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHETTY KTV, 1995, J NEUROCHEM, V64, P2681; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; SUGANUMA M, 1990, CANCER RES, V50, P3521; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wang SC, 2001, ONCOGENE, V20, P6960, DOI 10.1038/sj.onc.1204873; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	38	31	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4524	4530		10.1038/sj.onc.1206767	http://dx.doi.org/10.1038/sj.onc.1206767			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881709				2022-12-28	WOS:000184054700008
J	Kurosu, T; Fukuda, T; Miki, T; Miura, O				Kurosu, T; Fukuda, T; Miki, T; Miura, O			BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells	ONCOGENE			English	Article						BCL6; apoptosis; chemotherapeutic reagents; reactive oxygen species; etoposide	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; TRANSCRIPTIONAL REPRESSOR; PROTOONCOGENE BCL-6; EXPRESSION; DEATH; LAZ3; DIFFERENTIATION; TRANSLOCATIONS	Chromosomal translocations and somatic mutations occurring in the 5' noncoding region of the BCL6 gene, encoding a transcriptional repressor, are most frequent genetic abnormalities associated with non-Hodgkin B-cell lymphoma and result in deregulated expression of BCL6. However, the significance of deregulated expression of BCL6 in lymphomagenesis and its effect on clinical outcomes of lymphoma patients have remained elusive. In the present study, we established Daudi and Raji B-cell lymphoma cell lines that overexpress BCL6 or its mutant, BCL6-Ala333/343, in which serine residues required for degradation through the proteasome pathway in B-cell receptor-stimulated cells are mutated. BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6. BCL6-Ala333/343 was not degraded after etoposide treatment and strongly inhibited apoptosis. In these lymphoma cell lines, etoposide increased the generation of reactive oxygen species (ROS) and reduced mitochondria membrane potential, both of which were inhibited by the antioxidant N-acetyl-L-cysteine (NAC). NAC also inhibited apoptosis. Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents. These results raise the possibility that deregulated expression of BCL6 may endow lymphoma cells with resistance to chemotherapeutic reagents, most likely by enhancing the antioxidant defense systems.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Miura, Osamu/0000-0002-0981-3054				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Barrans SL, 2002, BRIT J HAEMATOL, V117, P322, DOI 10.1046/j.1365-2141.2002.03435.x; BASTARD C, 1994, BLOOD, V83, P2423; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chabner B.A., 2001, CANC CHEMOTHERAPY BI, V3rd; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kojima S, 2001, DEVELOPMENT, V128, P57; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	39	82	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4459	4468		10.1038/sj.onc.1206755	http://dx.doi.org/10.1038/sj.onc.1206755			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881702				2022-12-28	WOS:000184054700001
J	Peng, YH; Li, CG; Chen, LH; Sebti, S; Chen, JD				Peng, YH; Li, CG; Chen, LH; Sebti, S; Chen, JD			Rescue of mutant p53 transcription function by ellipticine	ONCOGENE			English	Article						p53; ellipticine; rescue; conformation; mutant	ELLIPTINIUM ACETATE; ACTIVATION FUNCTION; MDM2; CANCER; PHASE; DNA; RESTORATION; MUTATIONS; STABILITY; DATABASE	The p53 tumor suppressor is frequently inactivated in tumors by point mutations in the DNA-binding domain, resulting in loss of sequence-specific DNA binding and transcription function. We present evidence that ellipticine can restore the transactivation function of several transfected p53 mutants (175 H, 248W, 249S, 273 H, 281G), resulting in the induction of p53-responsive genes (p21(WAF1), MDM2) and activation of a p53-responsive luciferase reporter. Ellipticine also activates mutant p53 function in tumor cells expressing endogenous 194F, 233L, 241F, and 273C mutants. Treatment with ellipticine alters mutant p53 reactivity to conformation-sensitive Pab1620 and Pab240 antibodies and increases its sequence-specific DNA-binding activity in vivo. Finally, ellipticine activates mutant p53 and induces p21(WAF1) and MDM2 expression in nude mouse tumor xenografts. These results demonstrate that ellipticine can restore transcription function to mutant p53. This property may contribute to the selectivity of ellipticine-derived compounds against tumor cell lines expressing mutant p53.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu						ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; BUZDAR AU, 1990, ONCOLOGY, V47, P101; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOUYETTE A, 1982, EUR J CANCER CLIN ON, V18, P1285, DOI 10.1016/0277-5379(82)90130-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KATTAN J, 1994, AM J CLIN ONCOL-CANC, V17, P242, DOI 10.1097/00000421-199406000-00013; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Ohnishi T, 1999, RADIAT RES, V151, P498, DOI 10.2307/3579838; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; ROUESSE J, 1993, EUR J CANCER, V29A, P856, DOI 10.1016/S0959-8049(05)80424-1; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shi LM, 1998, MOL PHARMACOL, V53, P241, DOI 10.1124/mol.53.2.241; Soong R, 1996, HUM PATHOL, V27, P1050, DOI 10.1016/S0046-8177(96)90282-8; Sugikawa E, 2001, ANTICANCER RES, V21, P2671; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	35	119	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4478	4487		10.1038/sj.onc.1206777	http://dx.doi.org/10.1038/sj.onc.1206777			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881704				2022-12-28	WOS:000184054700003
J	Renou, JP; Bierie, B; Miyoshi, K; Cui, YZ; Djiane, J; Reichenstein, M; Shani, M; Hennighausen, L				Renou, JP; Bierie, B; Miyoshi, K; Cui, YZ; Djiane, J; Reichenstein, M; Shani, M; Hennighausen, L			Identification of genes differentially expressed in mouse mammary epithelium transformed by an activated beta-catenin	ONCOGENE			English	Article						mammary gland; beta-catenin; transdifferentiation; metaplasia; microarrays Mammochip	LYSOSOMAL CYSTEINE PROTEASES; CRE RECOMBINASE; DEPENDENT EXPRESSION; GLAND INVOLUTION; BREAST-CANCER; HAMSTER CELLS; CATHEPSIN-L; PROTEIN; SPECIFICITY; ADIPOCYTES	beta-Catenin is an executor of Wnt signaling and it can control cell fate and specification. Deletion of exon 3 from the endogenous beta-catenin gene in differentiating mammary alveolar epithelium of the mouse results in the generation of an activated protein that lacks amino acids 5-80. This is accompanied by a loss of mammary epithelial differentiation and a transdifferentiation process to squamous metaplasias. To further understand the molecular process of transdifferentiation, the expression of genes in mammary tissue was profiled in the absence and presence of activated of beta-catenin. Microarrays were generated that carry about 8500 cDNA clones with approximately 6000 obtained from mammary tissue. Mutant tissues, which had undergone either partial (TD1) or complete (TD2) squamous transdifferentiation, were compared with wild-type mammary tissue. Four groups of genes were identified. Group I contained genes whose expression was induced in both mutant tissues. Groups 2 and 3 contained genes that were active preferentially in TD2 and TD1, respectively. Group 4 contained genes suppressed in both samples. Using this approach, known and unknown genes activated in the transdifferentiation process were identified. A new 20 kDa protein (PANE1) induced upon transdifferentiation was nuclear in nonconfluent cells and cytoplasmic in confluent or dividing cells. Lastly, stabilization of beta-catenin resulted in the retention of differentiated epithelium upon involution and altered activities of several proteases in transdifferentiated mammary epithelium.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; INRA, Jouy En Josas, France; Univ Tokushima, Dept Biochem, Sch Dent, Tokushima 770, Japan; Agr Res Org, Volcani Ctr, IL-50250 Bet Dagan, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Tokushima University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.			Miyoshi, Keiko/0000-0001-6910-4172; Hennighausen, Lothar/0000-0001-8319-9841; Reichenstein, Moshe/0000-0003-4957-004X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; CALABRO MA, 1982, LIPIDS, V17, P397, DOI 10.1007/BF02535218; Campana WM, 1999, BBA-GEN SUBJECTS, V1427, P392, DOI 10.1016/S0304-4165(99)00036-7; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DUFOUR E, 1988, BIOSCIENCE REP, V8, P185, DOI 10.1007/BF01116463; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Larsen LB, 1996, J DAIRY RES, V63, P119, DOI 10.1017/S0022029900031599; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; LYNCH CJ, 1993, AM J PHYSIOL, V265, pC234, DOI 10.1152/ajpcell.1993.265.1.C234; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; McMurtrie EB, 1997, GENOMICS, V45, P623, DOI 10.1006/geno.1997.4959; McTernan PG, 2002, J CLIN ENDOCR METAB, V87, P2407, DOI 10.1210/jc.87.5.2407; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Park DS, 2001, J BIOL CHEM, V276, P48389, DOI 10.1074/jbc.M108210200; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Polakis P, 2000, GENE DEV, V14, P1837; Rossman TG, 1997, MUTAT RES-REV MUTAT, V386, P307, DOI 10.1016/S1383-5742(97)00013-6; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Sol-Church K, 2000, BBA-GENE STRUCT EXPR, V1491, P289, DOI 10.1016/S0167-4781(00)00030-0; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	33	28	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4594	4610		10.1038/sj.onc.1206596	http://dx.doi.org/10.1038/sj.onc.1206596			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881717				2022-12-28	WOS:000184054700016
J	Matteucci, E; Modora, S; Simone, M; Desiderio, MA				Matteucci, E; Modora, S; Simone, M; Desiderio, MA			Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency	ONCOGENE			English	Article						hepatocyte growth factor; apoptosis; hypoxia-inducible factor-1; ornithine decarboxylase; caspases	ORNITHINE-DECARBOXYLASE; TRANSDUCTION PATHWAYS; FACTOR PROTECTS; HEPG2 HEPATOMA; FACTOR 1-ALPHA; CYTOCHROME-C; RECEPTOR; DEATH; INVOLVEMENT; SURVIVAL	Two hepatocarcinoma cell lines, the Hepa-1 wild-type (c1c7) and the beta-subunit mutated (c4) lacking hypoxia-inducible factor-1 (HIF-1) activity, were differentially susceptible to apoptosis by hepatocyte growth factor (HGF). The c4 cells were 40% apoptotic 48 h after HGF treatment. On the contrary, the wild-type c1c7 cells showed modest signs of apoptosis only at 72 h. The revertant vT{2} cells, consisting of c4 cells stably transfected with HIF-1b expression vector, behaved as the parental cells. To understand the mechanisms of this different sensitivity, we examined a panel of genes involved in apoptosis: ornithine decarboxylase, c-Myc and p53 protein levels progressively decreased while JNK1, caspase 8 and 3 activities persistently increased in c4 cells undergoing apoptosis. Distinct time-related events in c1c7 cells were the transient activations of JNK1 and caspase 8 followed by the accumulation of ODC and c-Myc proteins. The proapoptotic effect of HGF in c4 hepatocarcinoma cells seems to be related to HIF-1 deficiency with loss of cytoprotective and signalling functions. This may contribute to the triggering of the extrinsic pathway consisting in caspase 8 activation, which in turn causes BID cleavage and cytochrome c release. The effector caspase 3 is also activated.	Univ Milan, Sch Med, Inst Gen Pathol, I-20133 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, Flow Cytometry Unit, I-20157 Milan, Italy	University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Desiderio, MA (corresponding author), Univ Milan, Sch Med, Inst Gen Pathol, Via L Mangiagalli 31, I-20133 Milan, Italy.	a.desiderio@unimi.it	Desiderio, Maria Alfonsina/M-8870-2016	Desiderio, Maria Alfonsina/0000-0002-9894-9462				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Akakura N, 2001, CANCER RES, V61, P6548; Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bendinelli P, 1996, FEBS LETT, V398, P193, DOI 10.1016/S0014-5793(96)01228-8; Bowers DC, 2000, CANCER RES, V60, P4277; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Grassilli E, 1998, BIOCHEM BIOPH RES CO, V250, P293, DOI 10.1006/bbrc.1998.9291; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Katoh O, 1998, CANCER RES, V58, P5565; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Mar PK, 1995, MOL CARCINOGEN, V14, P240, DOI 10.1002/mc.2940140404; Matteucci E, 2001, J CELL PHYSIOL, V186, P387, DOI 10.1002/1097-4652(2000)9999:9999<000::AID-JCP1033>3.0.CO;2-8; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Semenza GL, 2000, GENE DEV, V14, P1983; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tacchini L, 2000, EXP CELL RES, V256, P272, DOI 10.1006/excr.2000.4824; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	46	38	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4062	4073		10.1038/sj.onc.1206519	http://dx.doi.org/10.1038/sj.onc.1206519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821940				2022-12-28	WOS:000183707600009
J	Orend, G; Huang, WT; Olayioye, MA; Hynes, NE; Chiquet-Ehrismann, R				Orend, G; Huang, WT; Olayioye, MA; Hynes, NE; Chiquet-Ehrismann, R			Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4	ONCOGENE			English	Article						fibronectin; tenascin-C; syndecan-4; cell cycle; cdk2; FAK	FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; HEPARIN-BINDING; MAMMARY-GLAND; RHO GTPASES; INTEGRIN; EXPRESSION; P27(KIP1); GROWTH	Tenascin-C is an adhesion-modulatory extracellular matrix protein that is predominantly expressed during embryonic development, wound healing and in tumor stroma. Here we report that anchorage-dependent human, rat and mouse fibroblasts adhere poorly and fail to proliferate on pure tenascin-C. This was due to a significant reduction of cyclin-dependent kinase 2 (cdk2) activity, resulting from elevated expression and association of the cdk inhibitors (CKIs) p21Cip1 and p27Kip1. To analyse the effect of tenascin-C on fibronectin-mediated adhesion, cells were plated on a mixed. bronectin/tenascin-C substratum. Compared to fibronectin alone, cell spreading and adhesion signaling were compromised, as determined by delayed phosphorylation kinetics of focal adhesion kinase (FAK). Despite the presence of growth factors, these cells remained arrested in the G1 phase of the cell cycle. In contrast to cells plated on pure tenascin-C, cdk2activity appeared to be inhibited independently of CKIs. Interestingly, overexpression of the transmembrane proteoglycan syndecan-4 restored cell spreading, adhesion signaling and DNA replication on the fibronectin/tenascin-C substratum. A similar rescue was observed using a recombinant peptide that spans the syndecan-4-binding site in fibronectin. This indicates that tenascin-C causes cell cycle arrest and cdk2 inactivation by interfering with fibronectin-syndecan-4 interactions. We therefore propose that syndecan-4 signaling plays a central role in the control of cellular proliferation of anchorage-dependent fibroblasts.	Novartis Forschungsstiftung, Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Orend, G (corresponding author), Univ Basel, Inst Biochem & Genet, Vesalgasse 1, CH-4051 Basel, Switzerland.		Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195				Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Denhez F, 2002, J BIOL CHEM, V277, P12270, DOI 10.1074/jbc.M110291200; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Garcion E, 2001, DEVELOPMENT, V128, P2485; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOULD VE, 1990, CELL DIFFER DEV, V32, P409, DOI 10.1016/0922-3371(90)90057-4; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hauzenberger D, 1999, EUR J IMMUNOL, V29, P1435, DOI 10.1002/(SICI)1521-4141(199905)29:05<1435::AID-IMMU1435>3.0.CO;2-N; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Huang WT, 2001, CANCER RES, V61, P8586; HYNES RO, 1994, CURR OPIN GENET DEV, V4, P569, DOI 10.1016/0959-437X(94)90074-D; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kalembeyi I, 1997, INT J DEV BIOL, V41, P569; Kuzumaki T, 1997, BIOCHEM BIOPH RES CO, V238, P169, DOI 10.1006/bbrc.1997.7267; Landry R, 2001, CELL GROWTH DIFFER, V12, P497; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Mackie EJ, 1999, J CELL SCI, V112, P3847; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Orend G, 2000, EXP CELL RES, V261, P104, DOI 10.1006/excr.2000.5041; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VAN AL, 1997, GENE DEV, V11, P2295; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vollmer G, 1997, CRIT REV ONCOL HEMAT, V25, P187, DOI 10.1016/S1040-8428(97)00004-8; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; YOUNG SL, 1994, DEV BIOL, V161, P615, DOI 10.1006/dbio.1994.1057; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	55	71	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3917	3926		10.1038/sj.onc.1206618	http://dx.doi.org/10.1038/sj.onc.1206618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813465				2022-12-28	WOS:000183612000011
J	Huang, S; Qu, LK; Cuddihy, AR; Ragheb, R; Taya, Y; Koromilas, AE				Huang, S; Qu, LK; Cuddihy, AR; Ragheb, R; Taya, Y; Koromilas, AE			Protein kinase inhibitor 2-aminopurine overrides multiple genotoxic stress-induced cellular pathways to promote cell survival	ONCOGENE			English	Article						2-aminopurine; p53; DNA damage; protein phosphorylation; cell cycle control; apoptosis	DOUBLE-STRANDED-RNA; DAMAGE-INDUCED PHOSPHORYLATION; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; ENHANCED PHOSPHORYLATION; P53; CHECKPOINT; ATR	2-Aminopurine (2-AP) is an adenine analog shown to cause cells to bypass chemical- and radiation-induced cell cycle arrest through as-yet unidentified mechanisms. 2-AP has also been shown to act as a kinase inhibitor. Tumor suppressor p53 plays an important role in the control of cell cycle and apoptosis in response to genotoxic stress. We were interested in examining the effect of 2-AP on p53 phosphorylation and its possible consequences on checkpoint control in cells subjected to various forms of DNA damage. Here, we show that 2-AP suppresses p53 phosphorylation in response to gamma radiation, adriamycin, or ultraviolet treatment. This is partly explained by the ability of the kinase inhibitor to inhibit ATM or ATR activities in vitro and impair ATM- or ATR-dependent p53 phosphorylation in vivo. However, 2-AP is also capable of inhibiting p53 phosphorylation in cells deficient in ATM, DNA-PK, or ATR suggesting the existence of multiple pathways by which this kinase inhibitor modulates p53 activation. Biologically, the 2AP-mediated inhibition of p53 stabilization enables wildtype p53-containing cells to bypass adriamycin-induced G(2)/M arrest. In the long term, however, 2-AP facilitates cells to resist DNA damage-induced cell death independently, of p53.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol & Med, Montreal, PQ H3A 2T5, Canada; Natl Inst Canc Res, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ H3A 2T5, Canada	McGill University; Lady Davis Institute; McGill University; McGill University; National Cancer Center - Japan; McGill University	Koromilas, AE (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada.	antonis.koromilas@mcgill.ca		Cuddihy, Andrew/0000-0002-9898-0443				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Araki R, 1999, CANCER RES, V59, P3543; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brown EJ, 2000, GENE DEV, V14, P397; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carrier F, 1998, BIOCHEM PHARMACOL, V55, P853, DOI 10.1016/S0006-2952(97)00592-3; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 2000, GENE DEV, V14, P278; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	52	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3721	3733		10.1038/sj.onc.1206490	http://dx.doi.org/10.1038/sj.onc.1206490			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802279				2022-12-28	WOS:000183551000006
J	Hayward, NK				Hayward, NK			Genetics of melanoma predisposition	ONCOGENE			English	Article						CDKN2A; CDK4; ARF; MC1R; pigmentation; penetrance	CDKN2A GERMLINE MUTATIONS; CUTANEOUS MALIGNANT-MELANOMA; S-TRANSFERASE M1; PRONE FAMILIES; NERVOUS-SYSTEM; PANCREATIC ADENOCARCINOMA; RECEPTOR POLYMORPHISMS; MULTIPLE MELANOMAS; HAPLOTYPE ANALYSIS; DYSPLASTIC NEVI	Predisposition to melanoma is genetically heterogeneous. Two high penetrance susceptibility genes, CDKN2A and CDK4, have so far been identified and mapping is ongoing to localize and identify others. With the advent of a catalogue of millions of potential DNA polymorphisms, attention is now also being focused on identification of genes that confer a more modest contribution to melanoma risk, such as those encoding proteins involved in pigmentation, DNA repair, cell growth and differentiation or detoxification of metabolites. One such pigmentation gene, MC1R, has not only been found to be a low penetrance melanoma gene but has also been shown to act as a genetic modifier of melanoma risk in individuals carrying CDKN2A mutations. Most recently, an environmental agent, ultraviolet radiation, has also been established as a modifier of melanoma risk in CDKN2A mutation carriers. Hence, melanoma is turning out to be an excellent paradigm for studying gene-gene and gene-environment interactions.	Queensland Inst Med Res, Herston, Qld 4029, Australia	QIMR Berghofer Medical Research Institute	Hayward, NK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4029, Australia.	nickH@qimr.edu.au	hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	hayward, nicholas k/0000-0003-4760-1033; 				*AIHW AICR, 1999, AIHW CANC SER; Aitken J, 1999, JNCI-J NATL CANCER I, V91, P446, DOI 10.1093/jnci/91.5.446; Armstrong BK, 1996, CANC EPIDEMIOLOGY PR, P1282; Auroy S, 2001, GENE CHROMOSOME CANC, V32, P195, DOI 10.1002/gcc.1183; AZIZI E, 1995, CANCER, V76, P1571, DOI 10.1002/1097-0142(19951101)76:9<1571::AID-CNCR2820760912>3.0.CO;2-6; Bahuau M, 1998, CANCER RES, V58, P2298; Bahuau M, 1997, ANN GENET-PARIS, V40, P78; Bastiaens M, 2001, HUM MOL GENET, V10, P1701, DOI 10.1093/hmg/10.16.1701; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; BLISS JM, 1995, INT J CANCER, V62, P367, DOI 10.1002/ijc.2910620402; Borg A, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260; Borg A, 1996, CANCER RES, V56, P2497; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; CHENEVIXTRENCH G, 1995, CARCINOGENESIS, V16, P1655, DOI 10.1093/carcin/16.7.1655; Ciotti P, 1996, NEW ENGL J MED, V334, P469; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Della Torre G, 2001, BRIT J CANCER, V85, P836; DOLZAN V, 1995, CARCINOGENESIS, V16, P2675, DOI 10.1093/carcin/16.11.2675; Easton DF, 1997, AM J HUM GENET, V61, P120, DOI 10.1086/513891; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Ghiorzo P, 1999, INT J CANCER, V83, P441, DOI 10.1002/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO;2-R; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; Grammatico P, 2001, MELANOMA RES, V11, P447, DOI 10.1097/00008390-200110000-00002; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Harding RM, 2000, AM J HUM GENET, V66, P1351, DOI 10.1086/302863; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; Hashemi J, 2000, CANCER RES, V60, P6864; Hayward N, 2000, Curr Oncol Rep, V2, P300, DOI 10.1007/s11912-000-0022-z; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hutchinson PE, 2000, CLIN CANCER RES, V6, P498; Ichii-Jones F, 1998, J INVEST DERMATOL, V111, P218, DOI 10.1046/j.1523-1747.1998.00287.x; Iscovich J, 2002, INT J CANCER, V98, P42, DOI 10.1002/ijc.10155; Kanetsky PA, 2002, AM J HUM GENET, V70, P770, DOI 10.1086/339076; Kanetsky PA, 2001, CANCER EPIDEM BIOMAR, V10, P509; KAUFMAN DK, 1993, NEUROLOGY, V43, P1728, DOI 10.1212/WNL.43.9.1728; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 2001, INT J CANCER, V95, P388, DOI 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6; LAFUENTE A, 1995, BRIT J CANCER, V72, P324, DOI 10.1038/bjc.1995.332; Lal G, 2000, GENE CHROMOSOME CANC, V27, P358, DOI 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O; Lal G, 2000, CANCER RES, V60, P409; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MacKie RM, 1998, J INVEST DERMATOL, V111, P269, DOI 10.1046/j.1523-1747.1998.00267.x; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; Metzelaar-Blok JAW, 2001, INVEST OPHTH VIS SCI, V42, P1951; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Moskaluk C A, 1998, Hum Mutat, V12, P70; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2002, CANCER RES, V62, P875; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; PETTY EM, 1993, AM J HUM GENET, V53, P96; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Ries LA, 2002, SEER CANC STAT REV 1; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sauroja I, 2000, GENE CHROMOSOME CANC, V28, P404, DOI 10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P; Shahbazi M, 2002, LANCET, V359, P397, DOI 10.1016/S0140-6736(02)07600-6; SHANLEY SM, 1995, CARCINOGENESIS, V16, P2003, DOI 10.1093/carcin/16.8.2003; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sinilnikova OM, 1999, INT J CANCER, V82, P325; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Strange RC, 1999, PHARMACOGENETICS, V9, P269, DOI 10.1097/00008571-199906000-00001; Sturm RA, 1998, BIOESSAYS, V20, P712, DOI 10.1002/(SICI)1521-1878(199809)20:9<712::AID-BIES4>3.0.CO;2-I; Sturm RA, 2001, GENE, V277, P49, DOI 10.1016/S0378-1119(01)00694-1; Sun S, 1997, INT J CANCER, V73, P531, DOI 10.1002/(SICI)1097-0215(19971114)73:4<531::AID-IJC13>3.0.CO;2-C; Tsao H, 2000, ARCH DERMATOL, V136, P1118, DOI 10.1001/archderm.136.9.1118; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; Whiteman DC, 1997, J NATL CANCER I, V89, P1460, DOI 10.1093/jnci/89.19.1460; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; Yakobson E, 2000, EUR J HUM GENET, V8, P590, DOI 10.1038/sj.ejhg.5200505; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Youl P, 2002, INT J CANCER, V98, P92, DOI 10.1002/ijc.10117; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97; 1992, CANC INCIDENCE 5 CON, P871	91	223	230	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3053	3062		10.1038/sj.onc.1206445	http://dx.doi.org/10.1038/sj.onc.1206445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789280				2022-12-28	WOS:000183096600005
J	Aoyagi, M; Higashino, F; Yasuda, M; Takahashi, A; Sawada, Y; Totsuka, Y; Kohgo, T; Sano, H; Kobayashi, M; Shindoh, M				Aoyagi, M; Higashino, F; Yasuda, M; Takahashi, A; Sawada, Y; Totsuka, Y; Kohgo, T; Sano, H; Kobayashi, M; Shindoh, M			Nuclear export of adenovirus E4orf6 protein is necessary for its ability to antagonize apoptotic activity of BH3-only proteins	ONCOGENE			English	Article						E4orf6; adenovirus; nuclear export; BH-3 only protein; BNIP3; Bik	BCL-2 FAMILY; EARLY REGION-4; PERMEABILITY TRANSITION; 55-KILODALTON PROTEIN; DNA-REPLICATION; TUMOR-ANTIGEN; BH3 DOMAIN; CELL-DEATH; P53; GENE	The adenovirus E4orf6 is a viral oncoprotein known to cooperate with the E1A gene product in transforming primary murine cells. It has been shown to inhibit the apoptotic activities of p53 and p73 through direct binding to these proteins. Here, we demonstrate that the adenovirus E4orf6 protein inhibits apoptosis mediated by BNIP3 and Bik, which are BH3-only proteins of the Bcl-2 family. This activity was not mediated by p53 and p73 because E4orf6 had the same effect on the apoptosis in Saos-2 cells that do not express p53-related genes. It was also ascertained that E4orf6 could change the mitochondrial localization of BNIP3 and Bik. A mutant lacking the nuclear export signal of E4orf6 failed to inhibit apoptosis and to translocate BNIP3 protein from the mitochondria. Moreover, it was also established that E4orf6 was able to interact with BNIP3 and Bik. In BNIP3 protein, the region required for the interaction included the transmembrane domain, which is required for the localization of BNIP3 to the mitochondria. These results suggest that E4orf6 is exported from the nucleus to the cytoplasm, enabling it to interact with BH3-only proteins, eventually leading to the inhibition of apoptotic activity.	Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Kita Ku, Sapporo, Hokkaido 0608586, Japan; Hokkaido Univ, Grad Sch Dent Med, Dept Oral Hlth Sci, Kita Ku, Sapporo, Hokkaido 0608586, Japan; Hokkaido Inst Publ Hlth, Dept Biol, Sapporo, Hokkaido 0600819, Japan; Hokkaido Univ, Sch Med, Inst Med Genet, Div Canc Pathobiol, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Higashino, F (corresponding author), Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Kita Ku, N13,W7, Sapporo, Hokkaido 0608586, Japan.	fhigashi@den.hokudai.ac.jp	Higashino, Fumihiro/F-8510-2012; Sano, Hidehiko/A-4802-2012; Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823; Takahashi, Akiko/0000-0003-1904-7645				BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Fischer N, 1999, FEBS LETT, V447, P311, DOI 10.1016/S0014-5793(99)00313-0; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MIYASHITA T, 1995, CELL, V80, P293; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	43	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6919	6927		10.1038/sj.onc.1206743	http://dx.doi.org/10.1038/sj.onc.1206743			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534539				2022-12-28	WOS:000185843400013
J	Momparler, RL				Momparler, RL			Cancer epigenetics	ONCOGENE			English	Review						DNA methylation; histone deacetylation; gene actuation; 5-aza-2 ' deoxycytidine; cancer chemotherapy	HISTONE DEACETYLASE INHIBITION; E-CADHERIN EXPRESSION; ACID RECEPTOR-BETA; DNA METHYLATION; CPG-ISLAND; ANTINEOPLASTIC ACTION; HUMAN BREAST; LUNG-CANCER; 5-AZA-2'-DEOXYCYTIDINE DECITABINE; PROMOTER HYPERMETHYLATION	Aberrant DNA methylation of the promoter region is a key mechanism for inactivation of genes that suppress tumorigenesis. Genes that are involved in every step of tumor formation can be silenced by this mechanism. Inhibitors of DNA methylation, such as 5-azadeoxycytidine (5AZA), can reverse this epigenetic event suggesting a potential use in cancer therapy. The structure of chromatin can also play an important role with respect to the regulation of gene expression. Chromatin containing hypoacetylated lysines in histones has a compact structure that is repressive for transcription. Inhibitors of histone deacetylase (HDAC) can convert chromatin to an open structure and activate certain genes that inhibit tumor growth. These HDAC inhibitors also have potential in cancer therapy. A 'cross-talk' between DNA methylation and histone deacetylation can occur and work in concert to silence gene expression. The molecular mechanism involves the attachment of a methylated CpG binding protein (MBP) to the methylated promoters and its recruitment of HDAC to form a complex that suppresses transcription. These two epigenetic modi. cations represent an interesting target for therapeutic intervention using 5AZA and HDAC inhibitors. These agents in combination have been shown to produce a synergistic reactivation of tumor suppressor genes and an enhanced antineoplastic effect against tumor cells, and should be investigated as a novel form of epigenetic therapy for cancer.	Univ Montreal, Hop St Justine, Ctr Rech, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada	Universite de Montreal	Momparler, RL (corresponding author), Univ Montreal, Hop St Justine, Ctr Rech, Dept Pharmacol, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	richard.l.momparler@umontreal.ca	Momparler, Richard/AAU-6945-2020	Momparler, Richard/0000-0002-9186-6269				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; Boivin AJ, 2002, ANTI-CANCER DRUG, V13, P869, DOI 10.1097/00001813-200209000-00013; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fahrner JA, 2002, CANCER RES, V62, P7213; Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; GRAFF JR, 1995, CANCER RES, V55, P5195; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P277, DOI 10.1016/0163-7258(85)90052-X; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Momparler RL, 2001, LUNG CANCER, V34, pS111; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nguyen CT, 2002, CANCER RES, V62, P6456; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Palmisano WA, 2000, CANCER RES, V60, P5954; Paz MF, 2003, CANCER RES, V63, P1114; PINTO A, 1993, LEUKEMIA, V7, P51; Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789; Qian XLC, 1997, CANCER RES, V57, P3672; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RIVARD GE, 1981, LEUKEMIA RES, V5, P453, DOI 10.1016/0145-2126(81)90116-8; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Shaker S, 2003, LEUKEMIA RES, V27, P437, DOI 10.1016/S0145-2126(02)00222-9; Shi HD, 2002, CANCER RES, V62, P3214; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621	58	228	247	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6479	6483		10.1038/sj.onc.1206774	http://dx.doi.org/10.1038/sj.onc.1206774			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528271				2022-12-28	WOS:000185700700003
J	Malcolm, T; Ettehadieh, E; Sadowski, I				Malcolm, T; Ettehadieh, E; Sadowski, I			Mitogen-responsive expression of RhoB is regulated by RNA stability	ONCOGENE			English	Article						RhoB; RNA stability; immediate early gene; growth factor inducible; AU-rich element	P38 MAP KINASE; CYCLOOXYGENASE-2 MESSENGER-RNA; EPIDERMAL-GROWTH-FACTOR; GTP-BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION; TYROSINE KINASE; GENE-EXPRESSION; CELL-GROWTH; C-FOS	The small GTPase-encoding gene RhoB is strongly induced as part of the immediate early response of serum-stimulated. broblasts. In this report, we have characterized the mechanism for growth factor responsiveness of RhoB in Rat-2. broblasts. By Northern blotting and ribonuclease protection, we observed low or barely detectable levels of RhoB mRNA in quiescent cells, but expression was transiently induced in response to serum stimulation, such that the mRNA peaked within 30 min and then declined over the next hour. Analysis of the rat promoter revealed cis-elements conserved with the mouse and human genes, including a pair of CEBP sites near the transcriptional start site. However, in contrast to the analysis of RNA, RhoB promoter fusions were constitutively expressed in quiescent cells in transient transfections, and were unaffected by serum. Similarly, stable RhoB promoter integrants were highly expressed in quiescent cells, and growth factor caused a slight decrease in activity. This indicates that growth factor-inducible RhoB expression cannot be mediated by transcriptional activation. We then examined decay of the RhoB mRNA and found that serum caused significant stabilization. Additionally, fusion of the 30 RhoB untranslated region (UTR) to a constitutively expressed reporter gene caused serum and growth factor as well as DNA damage-inducible expression. These observations are consistent with the view that RhoB mRNA is produced constitutively but its abundance is controlled in response to growth factors, and other signals including DNA damage, by stabilization through elements within the 3' UTR.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Sadowski, I (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bell B, 1996, ONCOGENE, V13, P2687; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, MOL CELL BIOL, V19, P1831; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Leng E, 2002, J BIOMED SCI, V9, P59, DOI 10.1007/BF02256579; Li QDQ, 2001, INT J MOL MED, V7, P187; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; RIERA FC, 1984, SOMAT CELL MOLEC GEN, V10, P123, DOI 10.1007/BF01534901; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; ZALCMAN G, 1995, ONCOGENE, V10, P1935	40	10	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6142	6150		10.1038/sj.onc.1206638	http://dx.doi.org/10.1038/sj.onc.1206638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679852				2022-12-28	WOS:000185506200003
J	Elsasser, A; Franzen, M; Kohlmann, A; Weisser, M; Schnittger, S; Schoch, C; Reddy, VA; Burel, S; Zhang, DE; Ueffing, M; Tenen, DG; Hiddemann, W; Behre, G				Elsasser, A; Franzen, M; Kohlmann, A; Weisser, M; Schnittger, S; Schoch, C; Reddy, VA; Burel, S; Zhang, DE; Ueffing, M; Tenen, DG; Hiddemann, W; Behre, G			The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner	ONCOGENE			English	Article						AML1-ETO; c-jun; JNK1; AML; myeloid	COLONY-STIMULATING FACTOR; N-TERMINAL KINASE; HA-RAS GENE; TRANSCRIPTION FACTOR; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; LINEAGE COMMITMENT; DOWN-REGULATION; DNA-BINDING; CELLS	Overexpression of proto-oncogene c-jun and constitutive activation of the Jun N-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process. However, c-jun expression and the role of the JNK signaling pathway have not been investigated in primary acute myeloid leukemia (AML) cells with frequently observed balanced rearrangements such as t(8;21). In the present study, we report elevated c-jun mRNA expression in AML patient bone marrow cells with t(8;21), t(15;17) or inv(16), and a high correlation in mRNA expression levels of AML1-ETO and c-jun within t(8;21)-positive AML patient cells. In myeloid U937 cells, c-jun mRNA and protein expression increase upon inducible expression of AML1-ETO. AML1-ETO transactivates the human c-jun promoter through the proximal activator protein (AP-1) site by activating the JNK pathway. Overexpression of JNK-inhibitor JIP-1 and chemical JNK inhibitors reduce the transactivation capacity of AML1-ETO on the c-jun promoter and the proapoptotic function of AML1-ETO in U937 cells. An autocrine mechanism involving granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor (G-CSF-R) might participate in AML1-ETO mediated JNK-signaling, because AML1-ETO induces G-CSF and G-CSF-R expression, and G-CSF-R-neutralizing antibodies reduce AML1-ETO-induced JNK phosphorylation. These data suggest a model in which AML1-ETO induces protooncogene c-jun expression via the proximal AP-1 site of the c-jun promoter in a JNK-dependent manner.	Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Scripps Res Inst, La Jolla, CA USA; Tech Univ, Inst Human Genet, D-81377 Munich, Germany; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Scripps Research Institute; Technical University of Munich; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NCI NIH HHS [CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Baumann MA, 2001, AM J HEMATOL, V68, P99, DOI 10.1002/ajh.1160; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BRADBURY D, 1992, LEUKEMIA, V6, P562; Braess J, 2001, BRIT J HAEMATOL, V113, P975, DOI 10.1046/j.1365-2141.2001.02866.x; Brandstetter T, 1998, INT J CANCER, V75, P847, DOI 10.1002/(SICI)1097-0215(19980316)75:6<847::AID-IJC6>3.0.CO;2-V; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han ZN, 1999, J PHARMACOL EXP THER, V291, P124; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katayama N, 1998, AM J HEMATOL, V58, P31, DOI 10.1002/(SICI)1096-8652(199805)58:1<31::AID-AJH6>3.0.CO;2-1; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KUROKAWA M, 1995, ONCOGENE, V11, P833; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SPINNER DM, 1995, INT J CANCER, V63, P423, DOI 10.1002/ijc.2910630321; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330	50	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5646	5657		10.1038/sj.onc.1206673	http://dx.doi.org/10.1038/sj.onc.1206673			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944913				2022-12-28	WOS:000184865900014
J	Leaner, VD; Kinoshita, I; Birrer, MJ				Leaner, VD; Kinoshita, I; Birrer, MJ			AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets	ONCOGENE			English	Article						cJun; JunB; JunD; transcriptional targets	ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER CELLS; C-JUN; PROTEIN-KINASE; V-JUN; RAT-1A CELLS; EXPRESSION; CAVEOLIN-1; FOS; GENE	To investigate the role of individual Jun proteins in cell growth and transformation, we have used a doxycycline-inducible retroviral vector to regulate their expression in rat fibroblasts. AP-1 complexes enriched with cJun and JunB result in morphological alterations and anchorage-independent cell growth consistent with a transformation-like phenotype, whereas complexes enriched with JunD had an antiproliferative effect. These results suggest that genes regulated by both cJun and JunB are potentially involved in transformation and that they can be distinguished from those regulated by AP-1 complexes containing JunD. To identify genes regulated by cJun and JunB that may have a role in anchorage-independent growth, we investigated differential gene expression by each of the Jun family members using the Affymetrix Rat oligonucleotide microarray, RG_U34A containing approximately 8000 genes. Differentially regulated genes were identified and grouped for correlation with regulation by the different Jun proteins. A total of 33 candidate genes were found to be differentially regulated by both cJun and JunB and not by JunD. These genes have roles in cell metabolism, growth, signal transduction, migration and adhesion. We validated the differential regulation by cJun and JunB of 10 candidate genes by Northern blot analysis. Of these, eight were further characterized as potential direct targets of AP-1 regulation based on Northern blot results showing differential regulation that correlate with cJun expression. Our results show that inducible cJun and JunB expression result in anchorage-independent growth of Rat1a cells, distinct from JunD-expressing cells. This model system and a functional genomic approach enabled us to differentiate AP-1-regulated genes involved in transformation from AP-1-regulated genes known as bystander genes. This approach significantly reduces the number of bystanders and allows for the targeting of genes specifically involved in transformation.	NCI, Cell & Canc Biol Dept, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, NIH, 9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.							ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; HIRAI SI, 1990, ONCOGENE, V5, P39; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Li LK, 2001, CANCER RES, V61, P4386; LIM AL, 1994, MATRIX BIOL, V14, P21, DOI 10.1016/0945-053X(94)90026-4; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MELLSTROM B, 1991, ONCOGENE, V6, P1959; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; NARANJO JR, 1991, ONCOGENE, V6, P223; Nishitani Junko, 2002, Cellular and Molecular Biology Online Papers, V48, pOL331; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 2002, MOL CLONING LAB MANU; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Thepot D, 2000, DEVELOPMENT, V127, P143; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wilson E, 2002, ATHEROSCLEROSIS, V162, P289, DOI 10.1016/S0021-9150(01)00718-3; Zarka TA, 2003, INT J GYNECOL CANCER, V13, P240, DOI 10.1136/ijgc-00009577-200303000-00024; Zhong Y, 2001, CLIN CANCER RES, V7, P1683	55	44	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5619	5629		10.1038/sj.onc.1206644	http://dx.doi.org/10.1038/sj.onc.1206644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944910				2022-12-28	WOS:000184865900011
J	Mulholland, DJ; Read, JT; Rennie, PS; Cox, ME; Nelson, CC				Mulholland, DJ; Read, JT; Rennie, PS; Cox, ME; Nelson, CC			Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis	ONCOGENE			English	Article						androgen receptor; prostate cancer; coactivator; Tcf signaling; beta-catenin	TRANSCRIPTIONAL ACTIVITY; PROSTATE-CANCER; HORMONE-RECEPTORS; ACTIVATION; PROTEIN; PATHWAY; COMPLEX; GROWTH; TRANSLOCATION; COACTIVATORS	Recent reports suggest that the beta-catenin-T-cell factor (Tcf) (BCT) signaling pathway is important in the progression of prostate cancer. Evidence suggests that the androgen receptor (AR) can repress BCT-mediated transcription both in prostate cancer and colon cancer cells (Chesire and Isaacs, 2002). In this study, we validate such findings and show that repression of BCT signaling is facilitated by competition between the AR and Tcf. Measurements of the Tcf transcriptional reporter (TOPFLASH) indicated that AR+DHT-mediated repression can inhibit BCT transcription in the presence of WT and exogenous activating beta-catenin (Delta1-130bp). Transient transfections in SW480 cells (APC(mut/mut)) showed that this mode of repression is functionally independent of APC-mediated beta-catenin ubiquitination. Using a recently developed red flourescent protein (HcRed), we demonstrate novel observations about the nuclear distribution of Tcf. Furthermore, with the use of red (HeRed-AR and HcRed-Tcf) and green fusion proteins (beta-catenin-EGFP), we provide morphological evidence of a reciprocal balance of nuclear beta-catenin-EGFP (BC-EGFP). By cotransfecting in LNCaP prostate tumor cells and using quantitative imaging software, we demonstrated a 62.0% colocalization of HcRed-AR and BC-EGFP in the presence of DHT and 63.3% colocalization of HcRed-Tcf/BC-EGFP in the absence of DHT. Costaining for activated RNA Pol II (phosphoserine 2) and HcRed-Tcf suggested that Tcf foci contain transcriptional 'hotspots' validating that these sites have the capacity for transcriptional activity. Given this apparent androgen-dependent competition for nuclear BC-EGFP, we chose to assess our hypothesis by in vivo and in vitro binding assays. SW480 cells transiently transfected with an AR expression construct, treated with DHT and immunoprecipitated for Tcf showed less associated beta-catenin when compared to Tcf precipitates from untreated cells. Furthermore, by treating cells with DHT+Casodex, we were able to abrogate the androgen-sensitive AR/beta-catenin interaction, in addition to relieving transcriptional repression of the TOPFLASH reporter. In vitro binding assays, with increasing amounts of AR(S35), resulted in decreased Tcf(S35) association with immunoprecipitated recombinant beta-catenin-HIS. These data suggest that in steady-state conditions, AR has the ability to compete out Tcf binding for beta-catenin. Finally, using SW480 cells, we show that AR-mediated repression of the BCT pathway has implications for cell cycle progression and in vitro growth. Using FACs analysis, we observed a 26.1% increase in accumulation of cells in the G1 phase of the cell cycle, while in vitro growth assays showed a 35% reduction in viable cells transfected with AR+DHT treatment. Together, our data strongly suggest that a reciprocal balance of nuclear beta-catenin facilitates AR-mediated repression of BCT-driven transcription and cell growth.	Jack Bell Res, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Mulholland, DJ (corresponding author), Jack Bell Res, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada.							Barker N, 2000, ADV CANCER RES, V77, P1; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Cairns P, 1997, CANCER RES, V57, P4997; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Catalano MG, 2000, INT J CANCER, V86, P325, DOI 10.1002/(SICI)1097-0215(20000501)86:3<325::AID-IJC4>3.0.CO;2-G; Chen RH, 2001, CANCER RES, V61, P4445; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Davies MA, 1999, CANCER RES, V59, P2551; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; GLEAVE M, 1991, CANCER RES, V51, P3753; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Knop M, 2002, BIOTECHNIQUES, V33, P592, DOI 10.2144/02333rr02_11819a; Knudsen KE, 1999, CANCER RES, V59, P2297; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rivera OJ, 2003, MOL ENDOCRINOL, V17, P128, DOI 10.1210/me.2002-0165; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Shtutman Michael, 2002, Cancer Research, V62, P5947; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87	37	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5602	5613		10.1038/sj.onc.1206802	http://dx.doi.org/10.1038/sj.onc.1206802			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944908				2022-12-28	WOS:000184865900009
J	Sharpless, NE; Kannan, K; Xu, J; Bosenberg, MW; Chin, LD				Sharpless, NE; Kannan, K; Xu, J; Bosenberg, MW; Chin, LD			Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo	ONCOGENE			English	Article						melanoma; RAS	GERMLINE MUTATION; TUMOR SUPPRESSION; RAS; P16(INK4A); P53; P19(ARF); GENE; SUSCEPTIBILITY; INACTIVATION; FIBROBLASTS	Deletion of the INK4a/ARF locus at 9p21 is detected with high frequency in human melanoma. Within a short genomic distance, this locus encodes several proteins with established tumor-suppressor roles in a broad spectrum of cancer types. Several lines of evidence support the view that p10(INKa4) and p19(ARF) exert the tumor-suppressor activities of this locus, although their relative importance in specific cancer types such as melanoma has been less rigorously documented on the genetic level. Here, we exploit a well-defined mouse model of RAS-induced melanomas to examine the impact of germline p16(INK4a) or p19(ARF) nullizygosity on melanoma formation. We demonstrate that loss of either Ink4a/Arf product can cooperate with RAS activation to produce clinically indistinguishable melanomas. In line with the common phenotypic end point, we further show that RAS+ p16(INK4a)-/- melanomas sustain somatic inactivation of p19(ARF)-p53 and, correspondingly, that RAS+ p19(ARF)-/- melanomas experience high-frequency loss of p16(INK4a). These genetic studies provide definitive proof that p16(INK4a), and p19(ARF) cooperate to suppress the development of melanoma in vivo.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Dermatol, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Chin, LD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu		Sharpless, Norman/0000-0001-7078-9455				Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flores JF, 1996, CANCER RES, V56, P5023; GLENDENING JM, 1995, CANCER RES, V55, P5531; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Groth A, 2000, J BIOL CHEM, V275, P27473; Herlyn M, 1996, AM J PATHOL, V149, P739; HERMAN JG, 1995, CANCER RES, V55, P4525; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N	29	70	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5055	5059		10.1038/sj.onc.1206809	http://dx.doi.org/10.1038/sj.onc.1206809			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902988				2022-12-28	WOS:000184578900013
J	Higuchi, E; Chandraratna, RAS; Hong, WK; Lotan, R				Higuchi, E; Chandraratna, RAS; Hong, WK; Lotan, R			Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype	ONCOGENE			English	Article						ALL-trans retinoic acid; tazarotene-induced gene 3; head and neck cancer; lung cancer	RECEPTOR-SELECTIVE RETINOIDS; INDUCIBLE GENE; RAS MUTATIONS; CANCER CELLS; EXPRESSION; DIFFERENTIATION; CLONING; GROWTH; ALPHA; BETA	Retinoids can regulate the proliferation and differentiation of various tumor cells. It is thought that nuclear retinoid receptors mediate these effects by regulating gene transcription. The identity of specific retinoid target genes is only beginning to be unraveled. One candidate for mediating retinoid-induced growth suppression is the novel class II tumor suppressor gene tazarotene-induced gene 3 (TIG3). We examined the constitutive and all-trans retinoic acid (ATRA)-inducible expression of TIG3 mRNA in five head and neck squamous cell carcinoma (HNSCC) and five nonsmall cell lung carcinoma (NSCLC) cell tines to determine whether it is associated with their responsiveness to ATRA. The expression patterns of retinoic acid receptor beta (RARbeta), another putative retinoid-inducible tumor suppressor gene, were also examined. The constitutive TIG3 expression was high in one HNSCC cell line and two NSCLC cell tines, and moderate to very low in the other cells. Some RARbeta-expressing cells had either low or undetectable TIG3 levels and vice versa. ATRA (1 mum; 48 h) increased TIG3 mRNA in 4/5 HNSCCs and 3/5 NSCLCs and RARbeta mRNA in some of the same cell lines, but also in cells that did not show TIG3 induction. TIG3 mRNA was induced by ATRA between 6 and 12 h in most of the responsive cells. ATRA concentrations required for TIG3 induction ranged from 1 to 500 nM depending on the cell line. The pan-RAR antagonists AGN193109 and the RARalpha antagonist Ro 41-5253 blocked TIG3 induction by ATRA. ATRA suppressed anchorage-independent colony formation in most cells that had a high or moderate constitutive or induced TIG3 expression level. In contrast, RARbeta mRNA expression pattern was not correlated with sensitivity to ATRA. These results suggest that TIG3 is regulated by ATRA via retinoid receptors in certain aerodigestive tract cancer cells, and its induction by ATRA is associated with the suppression of anchorage-independent growth.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Allergan Pharmaceut Inc, Irvine, CA 92623 USA	University of Texas System; UTMD Anderson Cancer Center; AbbVie; Allergan	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA16672, P01 CA52051, U19 CA68437] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437, P30CA016672, P01CA052051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; AOUDJIT F, 1995, CELL GROWTH DIFFER, V6, P515; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Casanova B, 2001, LEUKEMIA, V15, P1521, DOI 10.1038/sj.leu.2402243; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Deucher A, 2000, INT J ONCOL, V17, P1195; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Dressler D, 2002, INT J ONCOL, V20, P897; Duvic M, 2000, CLIN CANCER RES, V6, P3249; Gudas Lorraine J., 1994, P443; HAJNAL A, 1994, ONCOGENE, V9, P479; Hong Waun Ki, 1994, P597; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huang SL, 2002, ANTICANCER RES, V22, P799; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mangelsdorf David J., 1994, P319; Mao M, 1996, P NATL ACAD SCI USA, V93, P5910, DOI 10.1073/pnas.93.12.5910; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moon Richard C., 1994, P573; MORONI MC, 1993, MECH DEVELOP, V44, P139, DOI 10.1016/0925-4773(93)90063-4; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; Oridate N, 1996, ONCOGENE, V12, P2019; Oridate N, 1996, IN VITRO CELL DEV-AN, V32, P192; REISS M, 1992, ONCOL RES, V4, P349; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Sun SY, 1997, CANCER RES, V57, P4931; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wan HS, 2001, CANCER RES, V61, P556; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	40	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4627	4635		10.1038/sj.onc.1206235	http://dx.doi.org/10.1038/sj.onc.1206235			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879006				2022-12-28	WOS:000184157000002
J	Sreenivasan, Y; Sarkar, A; Manna, SK				Sreenivasan, Y; Sarkar, A; Manna, SK			Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation	ONCOGENE			English	Article						NF-kappa B; araC; apoptosis; phosphatase; p65	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYELOID-LEUKEMIA CELLS; TNF-INDUCED ACTIVATION; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; MULTIDRUG-RESISTANCE; LIPID-PEROXIDATION	Nuclear transcription factor kappa B (NF-kappaB) has been shown both to block apoptosis and to promote cell proliferation, and hence has been considered an important target for anticancer drug development. The pyrimidine analogue cytosine arabinoside (araC) is among the most effective agents used in the treatment of acute leukemia, and we demonstrate in this study that its chemotherapeutic activity may be mediated by its inhibition of NF-kappaB. We found that in Jurkat cells, although tumor necrosis factor (TNF), araC, or ceramide induced NF-kappaB, the induction was only transient in the case of araC. In both HuT-78 and serum-activated LPS-stimulated Jurkat (SA-LPS/Jkt) cells that expressed NF-kappaB, TNF or ceramide treatments did not affect the NF-kappaB expression whereas araC downregulated it. AraC, but not TNF or ceramide was able to induce apoptosis in these cells as detected by assays for lipid peroxidation, reactive oxygen intermediates generation, caspase activation, cytotoxicity, Bcl-2 degradation, and DNA fragmentation. AraC also potentiated apoptosis mediated by cis-platin, etoposide, or taxol in these cells. AraC was able to induce protein phosphatases (PP) 2A and 2B-A, and phosphorylation of p65 subunit of NF-kappaB in the HuT-78 and SA-LPS/Jkt cells was downregulated by araC treatment. Furthermore, calyculin A, a specific phospho-serine/phospho-threonine phosphatase inhibitor, protected HuT-78 and SA-LPS/Jkt cells from araC-mediated NF-kappaB downregulation and apoptosis. These observations collectively suggest that araC induces apoptosis in NF-kappaB-expressing cells by dephosphorylating the p65 subunit of NF-kappaB.	Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Manna, SK (corresponding author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.	manna@www.cdfd.org.in						Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY WT, 1994, ADV CLIN CHEM, V31, P1, DOI 10.1016/S0065-2423(08)60332-7; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRACH MA, 1992, BLOOD, V79, P728; BRACH MA, 1992, MOL PHARMACOL, V41, P60; Braess J, 1999, BRIT J HAEMATOL, V105, P388, DOI 10.1111/j.1365-2141.1999.01338.x; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Izban KF, 2000, HUM PATHOL, V31, P1482, DOI 10.1053/hupa.2000.20370; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; KHARBANDA S, 1994, MOL PHARMACOL, V46, P67; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V162, P1510; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nutku E, 2001, J IMMUNOL, V167, P1039, DOI 10.4049/jimmunol.167.2.1039; Perez C, 1997, J CELL SCI, V110, P337; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUGANUMA M, 1990, CANCER RES, V50, P3521; Terada R, 2002, HEPATO-GASTROENTEROL, V49, P1545; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; VAN AD, 1996, SCIENCE, V274, P787; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829	52	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4356	4369		10.1038/sj.onc.1206486	http://dx.doi.org/10.1038/sj.onc.1206486			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853972				2022-12-28	WOS:000183978900005
J	Matushansky, I; Radparvar, F; Skoultchi, AI				Matushansky, I; Radparvar, F; Skoultchi, AI			CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells	ONCOGENE			English	Article						cyclin-dependent kinase 6; PU. 1; erythroleukemia; proliferation; differentiation	CYCLIN-DEPENDENT KINASE-6; PU.1 TRANSCRIPTION FACTOR; ERYTHROLEUKEMIA-CELLS; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; FRIEND-ERYTHROLEUKEMIA; EXPRESSION; GENE; DISRUPTION; REGULATORS	Cell proliferation and differentiation are highly coordinated during normal development. Many tumor cells exhibit both uncontrolled proliferation and a block to terminal differentiation. To understand the mechanisms coordinating these two processes, we have investigated the relation between cyclin-dependent kinase (CDK) activities and the block to differentiation in murine erythroleukemia (MEL) cells. We found that CDK6 (but not CDK4) is rapidly downregulated as MEL cells are induced to re-enter erythroid differentiation and that maintenance of CDK6 (but not CDK4) activity by transfection blocks differentiation. Moreover, we found that PU.1, an Ets transcription factor that is oncogenic in erythroid cells and also can block their differentiation, controls the synthesis of CDK6 mRNA. These results suggest a mechanism for coupling proliferation and the block to differentiation in these leukemic cells through the action of an oncogenic transcription factor (PU.1) on a key cell cycle regulator (CDK6). Our findings suggest that studying the relative roles of CDK6 and CDK4 in other types of malignant cells will be important in designing approaches for cell cycle inhibition and differentiation therapy in cancer.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Skoultchi, AI (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	skoultch@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R37CA016368, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [5R37CA16368, 2P30CA13330] Funding Source: Medline; NIA NIH HHS [5T32AG00194] Funding Source: Medline; NIGMS NIH HHS [5T32GM07288-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; Easton J, 1998, CANCER RES, V58, P2624; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; LEVENSON R, 1979, J CELL BIOL, V82, P715, DOI 10.1083/jcb.82.3.715; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARKS PA, 1987, ANN NY ACAD SCI, V511, P246, DOI 10.1111/j.1749-6632.1987.tb36252.x; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Senderowicz AM, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	34	70	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4143	4149		10.1038/sj.onc.1206484	http://dx.doi.org/10.1038/sj.onc.1206484			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833137				2022-12-28	WOS:000183979800001
J	Nishimura, N; Furukawa, Y; Sutheesophon, K; Nakamura, M; Kishi, K; Okuda, K; Sato, Y; Kano, Y				Nishimura, N; Furukawa, Y; Sutheesophon, K; Nakamura, M; Kishi, K; Okuda, K; Sato, Y; Kano, Y			Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c	ONCOGENE			English	Article						STI571; ETV6/ARG; cell cycle arrest; p18/INK4c	ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; INK4 FAMILY; APOPTOSIS; DIFFERENTIATION; P18(INK4C); EXPRESSION; PROTEIN; FUSION	ARG is a tyrosine kinase closely related to ABL, which is oncogenic when fused to the transcriptional repressor ETV6 (ETS translocation variant 6). In this study, we investigated the growth-inhibitory effect of STI571 (signal transduction inhibitor number 571) on ETV6/ARG-expressing cells and its molecular mechanisms using HT93A, a cell line derived from a patient with AML-M3 carrying t(1;12). STI571 effectively suppressed overall tyrosyl phosphorylation of intracellular proteins including ETV6/ARG fusion protein, as well as the growth of HT93A cells with an IC50 of 200 nM. The growth inhibition was primarily because of cell cycle arrest at G1 phase when cells were treated with 100 nm STI571 for 48 h, and apoptosis was induced after longer exposure (72 h) or by a higher dose (1000 nM). STI571 increased the amount of p18/INK4c after 2 h of culture, when the cell cycle pattern was not yet affected, but not that of other CDK inhibitors (CKI). p18/INK4c was more abundant in G1-enriched fractions than in S- and G2/M-enriched fractions of STI571-treated HT93A cells, suggesting that the upregulation of p18/INK4c expression correlates with the cell cycle arrest. Treatment of HT93A cells with antisense oligonucleotides against the Ink4c gene abrogated the growth inhibition by STI571. These results suggest that leukemogenesis by an aberrant ARG kinase involves the suppression of p18/INK4c, which is ubiquitously expressed and considered the major CKI in hematopoietic stem cells. STI571 can be an effective drug for the treatment of leukemias with deregulated ARG kinase activity.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minamikachi, Tochigi 3290498, Japan; Tokai Univ, Sch Med, Dept Hematol & Rheumatol, Kanagawa 2591193, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kyoto 6020841, Japan; Int Med Ctr Japan, Div Mol Cytogenet, Tokyo 1620052, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Tokai University; Kyoto Prefectural University of Medicine; National Center for Global Health & Medicine - Japan; Tochigi Prefectural Cancer Center	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minamikachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Iijima Y, 2000, BLOOD, V95, P2126; Iijima Y, 2002, ONCOGENE, V21, P4374, DOI 10.1038/sj.onc.1205544; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; KRUSH GD, 1986, SCIENCE, V234, P1545; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; PEREGO R, 1991, ONCOGENE, V6, P1899; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; SAIJO M, 1994, FEBS LETT, V340, P181, DOI 10.1016/0014-5793(94)80133-9; Schiffer CA, 2001, SEMIN ONCOL, V28, P34, DOI 10.1016/S0093-7754(01)90101-0; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Toba K, 1998, EXP HEMATOL, V26, P135; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	37	26	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4074	4082		10.1038/sj.onc.1206498	http://dx.doi.org/10.1038/sj.onc.1206498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821941				2022-12-28	WOS:000183707600010
J	Ongusaha, PP; Ouchi, T; Kim, KT; Nytko, E; Kwak, JC; Duda, RB; Deng, CX; Lee, SW				Ongusaha, PP; Ouchi, T; Kim, KT; Nytko, E; Kwak, JC; Duda, RB; Deng, CX; Lee, SW			BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest	ONCOGENE			English	Article						BRCA1; p53; senescence; microarray; DNA damage	DNA-DAMAGE RESPONSE; TRANSCRIPTIONAL ACTIVATION; P53; CHECKPOINT; CYCLE; GADD45; PHOSPHORYLATION; REPAIR; CELLS; EXPRESSION	The tumor suppressor protein BRCA1 has been shown to enhance p53 transcription, whereas activated p53 represses BRCA1 transcription. To further understand the functional interaction of these proteins, we investigated the role of BRCA1 in p53-induced phenotypes. We found that BRCA1 when subjected to forced expression acts synergistically with wild-type p53, resulting in irreversible growth arrest, as shown by VhD mouse fibroblast cells expressing a temperature-sensitive mutant of p53. Furthermore, reintroduction of both BRCA1 and p53 into BRCA1(-/-)/p53(-/-) mouse embryonic fibroblasts markedly increased the senescence phenotype compared to that induced by Ill alone. In particular, we found that BRCA1 expression attenuated p53-mediated cell death in response to gamma-irradiation. Moreover, microarray screening of 11 000 murine genes demonstrated that a set of genes upregulated by p53 is enhanced by coexpression of BRCA1 and p53, suggesting that BRCA1 and p53 exert a promoter selectivity leading to a specific phenotype. Taken together, our results provide evidence that BRCA1 is involved in p53-mediated growth suppression rather than apoptosis.	Harvard Univ, Inst Med, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee, SW (corresponding author), Harvard Univ, Inst Med, Sch Med, Room 921,4 Blackfan Circle, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu	deng, chuxia/N-6713-2016		NCI NIH HHS [CA85214, CA80058, CA78356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085214, R01CA078356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee EYHP, 2002, CELL CYCLE, V1, P178, DOI 10.4161/cc.1.3.121; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang SC, 2001, CANCER RES, V61, P2838; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3749	3758		10.1038/sj.onc.1206439	http://dx.doi.org/10.1038/sj.onc.1206439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802282				2022-12-28	WOS:000183551000009
J	Oshiro, MM; Watts, GS; Wozniak, RJ; Junk, DJ; Munoz-Rodriguez, JL; Domann, FE; Futscher, BW				Oshiro, MM; Watts, GS; Wozniak, RJ; Junk, DJ; Munoz-Rodriguez, JL; Domann, FE; Futscher, BW			Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression	ONCOGENE			English	Article						methylation; p53; tumor suppressor; azacytidine; breast cancer; maspin	HUMAN BREAST CARCINOMAS; CLONAL CHROMOSOME-ABNORMALITIES; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; CELL-LINES; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; BINDING PROTEIN; MASPIN GENE; CANCER	p53 is an important transcriptional regulator that is frequently mutated in cancer. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters. Despite the transcriptional repression of these genes by aberrant DNA methylation, restoration of p53 resulted in the partial reactivation of both genes. This reactivation is a result of wt p53 binding to its consensus DNA-binding sites within the MASPIN and DSC3 promoters, stimulating histone acetylation, and enhancing chromatin accessibility of their promoters. Interestingly, wt p53 alone did not affect the methylation status of either promoter, suggesting that p53 itself can partially overcome the repressive barrier of DNA methylation. Pharmacologic inhibition of DNA methylation with 5-aza-2'-deoxycytidine in combination with restoration of wt p53 status resulted in a synergistic reactivation of these genes to near-normal levels. These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells.	Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Iowa; University of Iowa	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.		Rodríguez, Jose Manuel JMMR Muñoz/A-7323-2016	Rodríguez, Jose Manuel JMMR Muñoz/0000-0002-4688-6420; Domann, Frederick/0000-0002-0489-2179; Junk, Damian/0000-0002-9251-3799	NCI NIH HHS [P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan J, 1998, CANCER RES, V58, P5009; Klus GT, 2001, INT J ONCOL, V19, P169; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Seftor REB, 1998, CANCER RES, V58, P5681; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Streuli CH, 2002, BREAST CANCER RES, V4, P137, DOI 10.1186/bcr437; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhao RB, 2000, GENE DEV, V14, P981; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	44	78	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3624	3634		10.1038/sj.onc.1206545	http://dx.doi.org/10.1038/sj.onc.1206545			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789271				2022-12-28	WOS:000183399200013
J	Dranoff, G				Dranoff, G			GM-CSF-secreting melanoma vaccines	ONCOGENE			English	Article						GM-CSF; melanoma; cancer vaccine; tumor antigen	COLONY-STIMULATING FACTOR; T-CELL RESPONSES; TUMOR-INFILTRATING LYMPHOCYTES; MHC CLASS-I; DENDRITIC CELLS; IMMUNE-RESPONSES; CANCER ANTIGENS; NKT CELLS; CTLA-4; SPECIFICITY	The development of biochemical and genetic schemes to characterize cancer antigens led to the recognition that malignant melanoma frequently evokes a host response. While the generation of brisk T-cell infiltrates in early stage disease is correlated with prolonged survival, host reactions in most cases are insufficient to impede tumor progression. One variable that may limit the potency of the host response against nascent melanoma is the mixture of cytokines present in the tumor microenvironment. In a murine melanoma model, we identified granulocyte-macrophage colony stimulating factor (GM-CSF) as the most potent molecule for augmenting tumor immunity following gene transfer into melanoma cells. Vaccination with irradiated melanoma cells engineered to secrete GMCSF enhances host responses through improved tumor antigen presentation by recruited dendritic cells and macrophages. Melanoma-specific CD4(+) and CD8(+) T-cells, CD1d-restricted NKT-cells, and antibodies mediate tumor rejection. Initial testing of this immunization strategy in patients with metastatic melanoma revealed the consistent induction of cellular and humoral antitumor responses that provoked the extensive necrosis of distant metastases without significant toxicity.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dranoff, G (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Dana 510E,44 Binney St, Boston, MA 02115 USA.	glenn_dranoff@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA074886, P01CA039542] Funding Source: NIH RePORTER; NCI NIH HHS [CA39542, CA74886] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5; Doyle AM, 2001, J EXP MED, V194, P893, DOI 10.1084/jem.194.7.893; DRANOFF G, 1995, ADV IMMUNOL, V58, P417, DOI 10.1016/S0065-2776(08)60624-0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FORNI G, 1988, CANCER METAST REV, V7, P289, DOI 10.1007/BF00051371; FORNI G, 1985, J IMMUNOL, V134, P1305; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hodi FS, 2002, P NATL ACAD SCI USA, V99, P6919, DOI 10.1073/pnas.102025999; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Mach N, 2000, CURR OPIN IMMUNOL, V12, P571, DOI 10.1016/S0952-7915(00)00144-8; Mach N, 2000, CANCER RES, V60, P3239; Mihm MC, 1996, LAB INVEST, V74, P43; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Murtaza A, 1999, INT IMMUNOL, V11, P407, DOI 10.1093/intimm/11.3.407; OLD LJ, 1981, CANCER RES, V41, P361; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Pulendran B, 1997, J IMMUNOL, V159, P2222; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; Reilly RT, 2001, CANCER RES, V61, P880; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Shen ZH, 1997, J IMMUNOL, V158, P2723; SHENK T, 1996, FIELDS VIROLOGY, P2111; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; Soiffer R, 1998, P NATL ACAD SCI USA, V95, P13141, DOI 10.1073/pnas.95.22.13141; SUPEK F, 1994, J BIOL CHEM, V269, P24102; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; YAMAGUCHI H, 1990, P NATL ACAD SCI USA, V87, P3333, DOI 10.1073/pnas.87.9.3333; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; Zeng G, 2001, P NATL ACAD SCI USA, V98, P3964, DOI 10.1073/pnas.061507398	51	133	147	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3188	3192		10.1038/sj.onc.1206459	http://dx.doi.org/10.1038/sj.onc.1206459			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789295				2022-12-28	WOS:000183096600021
J	Ramirez-Montagut, T; Turk, MJ; Wolchok, JD; Guevara-Patino, JA; Houghton, AN				Ramirez-Montagut, T; Turk, MJ; Wolchok, JD; Guevara-Patino, JA; Houghton, AN			Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity	ONCOGENE			English	Article						cancer; differentiation; germ cell	CYTOLYTIC T-LYMPHOCYTES; PHASE-I TRIAL; INFILTRATING LYMPHOCYTES; MALIGNANT-MELANOMA; FC-RECEPTORS; DIFFERENTIATION ANTIGEN; SURFACE-ANTIGENS; GD3 GANGLIOSIDE; BETA-CATENIN; CELL	Cancer cells express self-antigens that are weakly recognized by the immune system. Even though responses against autologous cells are difficult to induce, the immune system is still able to mount a response against cancer. The discovery of the molecular identity of antigens that are recognized by the immune system of melanoma patients has led to the elucidation of tumor immunity at a cellular and molecular level. Multiple pathways in both the priming and effector phases of melanoma rejection have been described. Animal models' active immunotherapies for melanoma show a requirement for the cellular compartment of the immune system in the priming phase, primarily CD4 + T cells. More diverse elements are required for the effector phase, including components from the innate immune system (macrophages, complement and/or natural killer cells) and from the adaptive immune system (CD8 + T cells and B cells). Minor differences in amino-acid sequences of antigens must determine the particular mechanisms involved in tumor rejection. Since the immune system contains T and B cells that recognize and reject autologous cells, a consequence of tumor immunity is potential autoimmunity. There are distinct pathways for tumor immunity and autoimmunity. The requirements for autoimmunity at the priming phase seem to be CD4 + /IFN-gamma dependent while the effector mechanisms are alternative and redundant. Vitiligo (autoimmune hypopigmentation) can be mediated by T cells, FcgammaR + macrophages and/or complement.	Cornell Univ, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Houghton, AN (corresponding author), Cornell Univ, Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.		Guevara, Jose/AAD-6707-2020					ALBINO AP, 1992, ONCOGENE, V7, P2315; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; BOYSE EA, 1969, ANNU REV GENET, V3, P269, DOI 10.1146/annurev.ge.03.120169.001413; Castelli C, 1998, EUR J IMMUNOL, V28, P1143; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chiari R, 2000, CANCER RES, V60, P4855; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Colella TA, 2000, J EXP MED, V191, P1221, DOI 10.1084/jem.191.7.1221; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; DISIS ML, 1994, CANCER RES, V54, P16; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; HAMILTON WB, 1993, INT J CANCER, V53, P566, DOI 10.1002/ijc.2910530407; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; Hawkins WG, 2000, SURGERY, V128, P273, DOI 10.1067/msy.2000.107421; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; HOUGHTON AN, 1980, P NATL ACAD SCI-BIOL, V77, P4260, DOI 10.1073/pnas.77.7.4260; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Jager E, 1999, INT J CANCER, V84, P506, DOI 10.1002/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6; Jager E, 2000, J EXP MED, V191, P625, DOI 10.1084/jem.191.4.625; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kurnick JT, 2001, J IMMUNOL, V167, P1204, DOI 10.4049/jimmunol.167.3.1204; Lewis JJ, 2000, INT J CANCER, V87, P391, DOI 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K; Li K, 1998, CANCER IMMUNOL IMMUN, V47, P32, DOI 10.1007/s002620050501; LIVINGSTON PO, 1994, J CLIN ONCOL, V12, P1036, DOI 10.1200/JCO.1994.12.5.1036; Lloyd K. O., 1991, CANCER BIOL, V2, P421; Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647; Lucas S, 2000, INT J CANCER, V87, P55, DOI 10.1002/1097-0215(20000701)87:1<55::AID-IJC8>3.3.CO;2-A; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MATTES MJ, 1983, INT J CANCER, V32, P717, DOI 10.1002/ijc.2910320610; Moreau-Aubry A, 2000, J EXP MED, V191, P1617, DOI 10.1084/jem.191.9.1617; Naftzger C, 1996, P NATL ACAD SCI USA, V93, P14809, DOI 10.1073/pnas.93.25.14809; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; Ramirez-Montagut T, 2000, CLIN EXP IMMUNOL, V119, P11, DOI 10.1046/j.1365-2249.2000.01089.x; RITTER G, 1991, INT J CANCER, V48, P379, DOI 10.1002/ijc.2910480312; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; Takechi Y, 1996, CLIN CANCER RES, V2, P1837; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; Trcka J, 2002, IMMUNITY, V16, P861, DOI 10.1016/S1074-7613(02)00327-8; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Wolchok J D, 2001, Cancer Immun, V1, P9; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yamshchikov G, 2001, CLIN CANCER RES, V7, p909S; Zeng G, 2000, J IMMUNOL, V165, P1153, DOI 10.4049/jimmunol.165.2.1153	55	69	89	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3180	3187		10.1038/sj.onc.1206462	http://dx.doi.org/10.1038/sj.onc.1206462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789294				2022-12-28	WOS:000183096600020
J	Zhang, XQ; Kondrikov, D; Yuan, TC; Lin, FF; Hansen, J; Lin, MF				Zhang, XQ; Kondrikov, D; Yuan, TC; Lin, FF; Hansen, J; Lin, MF			Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen ablation; neuroendocrine differentiation; receptor protein tyrosine phosphatase alpha; ERK/MAPK	MAP KINASE CASCADES; NERVE GROWTH-FACTOR; ACID-PHOSPHATASE; NEURONAL DIFFERENTIATION; REGULATED KINASE; TUMOR-CELLS; PC12 CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SUSTAINED ACTIVATION; STIMULATES GROWTH	The neuroendocrine (NE) cells represent the third cell population in the normal prostate. Results of several clinical studies strongly indicate that the NE cell population is greatly increased in prostate carcinomas during androgen ablation therapy that correlates with hormone-refractory growth and poor prognosis. However, the mechanism of NE cell enrichment in prostate carcinoma remains an enigma. We investigated the molecular mechanism by which androgen-sensitive C-33 LNCaP human prostate cancer cells become NE-like cells in an androgen-reduced environment, mimicking clinical phenomenon. In the androgen-depleted condition, androgen-sensitive C-33 LNCaP cells gradually acquired the NE-like morphology and expressed an increased level of neuron-specific enolase (NSE), a classical marker of neuronal cells. Several NE-like subclone cells were established. Biochemical characterizations of these subclone cells showed that receptor-type protein-tyrosine phosphatase alpha (RPTPalpha) is elevated and ERK is constitutively activated, several folds higher than that in parental cells. In androgen-depleted condition, PD98059, an MEK inhibitor, could efficiently block not only the activation of ERK, but also the acquisition of the NE-like morphology and the elevation of NSE in C-33 LNCaP cells. In RPTPa cDNA-transfected C-33 LNCaP cells, ERK was activated and NSE was elevated. In those cells in the presence of PD98059, the ERK activation and NSE elevation were abolished, following a dose-response fashion. Additionally, in constitutively active MEK mutant cDNA-transfected C-33 LNCaP cells, ERK was activated and NSE level was elevated, and cells obtained the NE-like phenotype. Our data collectively indicated that RPTPa signaling via ERK is involved in the NE transdifferentiation of androgen-sensitive C-33 LNCaP human prostate cancer cells in the androgen-depleted condition.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Dept Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu			NCI NIH HHS [CA88184, CA72274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088184, R01CA072274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; ABRAHAMSSON PA, 1989, PROSTATE, V14, P71, DOI 10.1002/pros.2990140109; Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; ALMAGRO UA, 1986, ARCH PATHOL LAB MED, V110, P916; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOLOGNA M, 1989, CANCER, V63, P1714; Bonkhoff H, 1998, PROSTATE, P18; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Chen TS, 1999, CANCER RES, V59, P213; COCKETT ATK, 1993, UROLOGY, V42, P512, DOI 10.1016/0090-4295(93)90260-H; COHEN RJ, 1991, BRIT J UROL, V68, P258, DOI 10.1111/j.1464-410X.1991.tb15318.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; di Sant'Agnese PA, 1998, PROSTATE, P74; Di Sant'Agnese PA, 1998, UROLOGY, V51, P121, DOI 10.1016/S0090-4295(98)00064-8; Diaz M, 1998, PROSTATE, P32; diSantAgnese PA, 1996, CANCER, V78, P357, DOI 10.1002/(SICI)1097-0142(19960715)78:2<357::AID-CNCR27>3.0.CO;2-U; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; FUKUDA M, 1995, ONCOGENE, V11, P239; Gioeli D, 1999, CANCER RES, V59, P279; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IWAMURA M, 1994, UROLOGY, V43, P675, DOI 10.1016/0090-4295(94)90183-X; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jongsma J, 2000, CANCER RES, V60, P741; Kim J, 2002, CANCER RES, V62, P1549; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Lin MF, 2000, CELL BIOL INT, V24, P681, DOI 10.1006/cbir.2000.0433; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Noordzij MA, 1996, AM J PATHOL, V149, P859; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Ruokonen M, 1996, BIOCHEM BIOPH RES CO, V218, P794, DOI 10.1006/bbrc.1996.0141; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shen R, 1997, Urol Oncol, V3, P67, DOI 10.1016/S1078-1439(97)00039-2; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; TARLE M, 1994, PROSTATE, V24, P143, DOI 10.1002/pros.2990240308; TETU B, 1987, CANCER, V59, P1803, DOI 10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X; Theodorescu D, 1997, CANCER, V80, P2109, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2109::AID-CNCR10>3.0.CO;2-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; vanInzen WG, 1996, DEV BRAIN RES, V91, P304, DOI 10.1016/0165-3806(95)00186-7; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Zelivianski S, 2000, MOL CELL BIOCHEM, V208, P11, DOI 10.1023/A:1007010304194; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zelivianski S, 2001, BBA-MOL CELL RES, V1539, P28, DOI 10.1016/S0167-4889(01)00087-8; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1994, J BIOL CHEM, V269, P23302; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	86	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6704	6716		10.1038/sj.onc.1206764	http://dx.doi.org/10.1038/sj.onc.1206764			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555984				2022-12-28	WOS:000185799300006
J	Reddy, MN; Tang, LY; Lee, TL; Shen, CKJ				Reddy, MN; Tang, LY; Lee, TL; Shen, CKJ			A candidate gene for Drosophila genome methylation	ONCOGENE			English	Article						DNA methylation; Drosophila cells; enzyme	DNA METHYLATION; DE-NOVO; METHYLTRANSFERASES; MELANOGASTER; DNMT3A	Like vertebrates, the genome of Drosophila melanogaster also contains methylated cytosines. However, the enzyme( s) responsible for this methylation has been elusive. By DNA transfection and sodium bisulfite sequencing, we show here that overexpression of dDnmt2, which is the only expressed and cloned Drosophila protein consisting of motifs conserved among the DNA cytosine methyltransferases, results in genomic DNA methylation of Drosophila S2 cells. The data provide the first evidence for dDnmt2 being one candidate gene encoding the Drosophila DNA methyltransferase(s).	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.		shen, Che-Kun James/L-1343-2015					Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	15	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6301	6303		10.1038/sj.onc.1206650	http://dx.doi.org/10.1038/sj.onc.1206650			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679869				2022-12-28	WOS:000185506200020
J	Kanazawa, S; Soucek, L; Evan, G; Okamoto, T; Peterlin, BM				Kanazawa, S; Soucek, L; Evan, G; Okamoto, T; Peterlin, BM			c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis	ONCOGENE			English	Article						c-Myc; P-TEFb; CycT1; apoptosis; proliferation; transcription	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; ELONGATION; TAT; TRANSFORMATION; PROGRESSION; ACTIVATION; MUTATIONS; INTERACTS; NETWORK	c-Myc promotes cellular proliferation, sensitizes cells to apoptosis and prevents differentiation. It binds cyclin T1 structurally and functionally from the positive transcription elongation factor b (P-TEFb). The cyclin-dependent kinase 9 (Cdk9) in P-TEFb then phosporylates the C-terminal domain of RNA polymerase II, which is required for the transition from initiation to elongation of eukaryotic transcription. Inhibiting P-TEFb blocks the transcription of its target genes as well as cellular proliferation and apoptosis induced by c-Myc.	Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Nagoya City Univ, Sch Med, Dept Mol Genet, Nagoya, Aichi 467, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Nagoya City University	Peterlin, BM (corresponding author), Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, Box 0703,3rd & Parnassus Ave, San Francisco, CA 94143 USA.		Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019	Soucek, Laura/0000-0002-4750-7971; 				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; EBERHARDY SR, 2002, J BIOL CHEM; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lis JT, 2000, GENE DEV, V14, P792; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	26	132	138	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5707	5711		10.1038/sj.onc.1206800	http://dx.doi.org/10.1038/sj.onc.1206800			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944920				2022-12-28	WOS:000184865900021
J	Sirri, V; Leibovitch, MP; Leibovitch, SA				Sirri, V; Leibovitch, MP; Leibovitch, SA			Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain	ONCOGENE			English	Article						MRF4; rhabdomyosarcoma; transactivation domain; differentiation	KINASE-ACTIVITY; GENE; EXPRESSION; TRANSCRIPTION; INHIBITION; P38	Rhabdomyosarcoma (RMS) has deregulated proliferation and is blocked in the differentiation program despite Myf-5, MyoD and myogenin expression. Here we show that ectopic expression of MRF4, which is not subject to an autoregulatory pathway but regulated by the other MRFs protein family, induces growth arrest and terminal differentiation in RD cells. Deletion mapping identified a positive-acting C-terminal domain in MRF4 as the mediator of transcriptional activity, revealing a conserved motif with helix III in MyoD previously found to initiate expression of endogenous skeletal muscle genes. By using chimeric MyoD/MRF4 proteins, we observe that the G terminal motif of MRF4 rescues MyoD activity in RD cells. Moreover, comparative induction of muscle-specific genes following activation of MyoD, through the expression of a constitutively activated MKK6 either in the absence or presence of MRF4, shows that MyoD and MRF4 can differently regulate muscle genes expression. Together, these results demonstrate that the MRF4 G terminus functions as specification as well as activation domain in tumor cells. They provide a basis to identify gene products necessary for b-HLH-mediated differentiation versus tumor progression.	Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leibovitch, SA (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94800 Villejuif, France.	leibovit@igr.fr						Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; DIAZ P, 1992, CANCER RES, V52, P6431; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Knudsen ES, 1998, CANCER RES, V58, P2042; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; Meedel TH, 1997, DEVELOPMENT, V124, P1711; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Puri PL, 2000, GENE DEV, V14, P574; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Rawls A, 1998, DEVELOPMENT, V125, P2349; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	25	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5658	5666		10.1038/sj.onc.1206690	http://dx.doi.org/10.1038/sj.onc.1206690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944914				2022-12-28	WOS:000184865900015
J	Martin, J; Hunt, SL; Dubus, P; Sotillo, R; Nehme-Pelluard, F; Magnuson, MA; Parlow, AF; Malumbres, M; Ortega, S; Barbacid, M				Martin, J; Hunt, SL; Dubus, P; Sotillo, R; Nehme-Pelluard, F; Magnuson, MA; Parlow, AF; Malumbres, M; Ortega, S; Barbacid, M			Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number	ONCOGENE			English	Article						adenohypophysis; cell cycle regulation; cell proliferation; gene-targeted mice; pancreatic beta cells	RETINOBLASTOMA PROTEIN; CYCLIN D1; INHIBITORS; DEFICIENT; GROWTH; EXPRESSION; ROLES; LIFE; MASS; E2F	Lack of Cdk4 expression in mice leads to insulin-deficient diabetes and female infertility owing to a reduced number of pancreatic beta cells and prolactin-producing pituitary lactotrophs, respectively. Cdk4 null mice display also reduced body and organ size. Here, we show that Cdk4 is essential for the postnatal proliferation of pancreatic beta cells but not for embryonic neogenesis from ductal epithelial cells. Re-expression of endogenous Cdk4 in beta cells and in the pituitary gland of Cdk4 null mice restores cell proliferation and results in fertile and normoglycemic animals, thus, demonstrating that the proliferation defects in these cellular populations are cell autonomous because of the lack of Cdk4 expression. However, these mice remain small in size, indicating that this phenotype is not because of pancreatic- or pituitary-mediated endocrine defects. This phenotype is a consequence of reduced cell numbers rather than reduced cell size. Thus, mammalian Cdk4 is not only involved in controlling proliferation of specific cell types but may play a wider role in establishing homeostatic cell numbers.	Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid 28029, Spain; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Bordeaux 2, F-33076 Bordeaux, France; Vanderbilt Univ, Med Ctr N CCC 3322, Nashville, TN 37232 USA; Harbor UCLA Med Ctr, Res & Educ Inst, Natl Hormone & Peptide Program, Torrance, CA 90509 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); UDICE-French Research Universities; Universite de Bordeaux; Vanderbilt University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Ortega, S (corresponding author), Ctr Nacl Invest Oncol, Mol Oncol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	s.ortega@cnio.es	Magnuson, Mark/AAY-7172-2021; Malumbres, Marcos/E-8834-2011; Holt, Janet E/B-2415-2013; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Malumbres, Marcos/0000-0002-0829-6315; Magnuson, Mark A/0000-0002-8824-6499; Sotillo, Rocio/0000-0002-0855-7917; Dubus, Pierre/0000-0003-1803-4711				Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reed SI, 1997, CANCER SURV, V29, P7; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	34	103	109	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5261	5269		10.1038/sj.onc.1206506	http://dx.doi.org/10.1038/sj.onc.1206506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917627				2022-12-28	WOS:000184734900005
J	Tognon, M; Corallini, A; Martini, F; Negrini, M; Barbanti-Brodano, G				Tognon, M; Corallini, A; Martini, F; Negrini, M; Barbanti-Brodano, G			Oncogenic transformation by BK virus and association with human tumors	ONCOGENE			English	Review						BK virus; T antigen; transformation; oncogenesis; human tumors	LARGE-T-ANTIGEN; HARVEY-RAS ONCOGENE; HUMAN-BRAIN-TUMORS; HUMAN POLYOMAVIRUS-BK; HUMAN PAPOVA-VIRUS; POLYMERASE CHAIN-REACTION; ENDOTHELIAL GROWTH-FACTOR; EMBRYONIC KIDNEY-CELLS; JC VIRUS; EARLY REGION	BK virus (BKV), a human polyomavirus closely related to JC virus and Simian Virus 40, is ubiquitous in human populations worldwide. After primary infection, BKV establishes a lifelong latent infection in many organs. BKV transforms rodent cells to the neoplastic phenotype and is highly oncogenic in rodents. This review considers the oncogenic potential of BKV in humans and its possible involvement in human tumors. BKV sequences and T antigen (Tag) are detected in several types of human neoplasms, although the viral load is generally low, with less than one copy of the viral genome per cell. The possible causative role of BKV in human oncogenesis rests on the ability of BKV Tag to inactivate the functions of tumor suppressor proteins p53 and pRB family as well as on its ability to induce chromosomal aberrations in human cells. A 'hit and run' mechanism and secretion of paracrine growth factors by BKV Tag-positive cells, recruiting into proliferation neighboring and distant cells, are discussed as possible BKV pathogenic elements in human oncogenesis.	Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, I-44100 Ferrara, Italy; Univ Ferrara, Dept Morphol & Embryol, Sect Histol & Embryol, I-44100 Ferrara, Italy; Univ Ferrara, Interdept Ctr Canc Res, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara; University of Ferrara	Barbanti-Brodano, G (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920				ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; AZZI A, 1994, BONE MARROW TRANSPL, V14, P235; Barbanti-Brodano G, 1987, Antibiot Chemother (1971), V38, P113; Barbanti-Brodano G, 1998, ADV VIRUS RES, V50, P69, DOI 10.1016/S0065-3527(08)60806-4; BARBANTIBRODANO G, 1988, AIDS ASS CANC AFRICA, P175; Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; BECK GR, 1998, HUMAN TUMOR VIRUSES, P51; Bofill-Mas S, 2001, J VIROL, V75, P10290, DOI 10.1128/JVI.75.21.10290-10299.2001; BOUCK N, 1978, P NATL ACAD SCI USA, V75, P2473, DOI 10.1073/pnas.75.5.2473; Bratt G, 1999, AIDS, V13, P1071, DOI 10.1097/00002030-199906180-00010; BROWN P, 1975, AM J EPIDEMIOL, V102, P331, DOI 10.1093/oxfordjournals.aje.a112169; Cacciotti P, 2002, AM J RESP CELL MOL, V26, P189, DOI 10.1165/ajrcmb.26.2.4673; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CALOS MP, 1980, CELL, V20, P579, DOI 10.1016/0092-8674(80)90305-0; CAPUTO A, 1983, J MED VIROL, V12, P37, DOI 10.1002/jmv.1890120105; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; CHENCINER N, 1980, P NATL ACAD SCI-BIOL, V77, P975, DOI 10.1073/pnas.77.2.975; CHOO KB, 1993, VIROLOGY, V193, P1042; CORALLINI A, 1991, CANCER J - FRANCE, V4, P24; CORALLINI A, 1982, ARCH VIROL, V73, P243, DOI 10.1007/BF01318078; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CORALLINI A, 1988, J GEN VIROL, V69, P2671, DOI 10.1099/0022-1317-69-10-2671; CORALLINI A, 1987, CANCER RES, V47, P6671; CORALLINI A, 1977, J NATL CANCER I, V59, P1561, DOI 10.1093/jnci/59.5.1561; CORALLINI A, 1978, J NATL CANCER I, V61, P875; Corallini A, 2001, HUMAN POLYOMAVIRUSES, P431; COSTA T, 1976, J NATL CANCER I, V56, P863; Cubukcu-Dimopulo O, 2000, AM J SURG PATHOL, V24, P145, DOI 10.1097/00000478-200001000-00019; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEMATTEI M, 1994, J INFECT DIS, V169, P1175; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; Dolei A, 2000, J GEN VIROL, V81, P1967, DOI 10.1099/0022-1317-81-8-1967; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DOUGHERTY RM, 1976, J NATL CANCER I, V57, P395, DOI 10.1093/jnci/57.2.395; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELSNER C, 1992, VIROLOGY, V191, P72, DOI 10.1016/0042-6822(92)90167-N; FIORI M, 1976, P NATL ACAD SCI USA, V73, P4662, DOI 10.1073/pnas.73.12.4662; Flaegstad T, 1999, CANCER RES, V59, P1160; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; Geetha D, 2002, TRANSPLANTATION, V73, P1933, DOI 10.1097/00007890-200206270-00015; GOUDSMIT J, 1982, J MED VIROL, V10, P91, DOI 10.1002/jmv.1890100203; GROSSI MP, 1981, INTERVIROLOGY, V15, P10, DOI 10.1159/000149209; GROSSI MP, 1982, J GEN VIROL, V63, P369; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; HAUKLAND HH, 1992, INT J CANCER, V51, P79, DOI 10.1002/ijc.2910510116; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Imperiale MJ, 2001, ONCOGENE, V20, P7917, DOI 10.1038/sj.onc.1204916; ISRAEL MA, 1978, VIROLOGY, V90, P187, DOI 10.1016/0042-6822(78)90302-1; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; Kim JYH, 2002, NEURO-ONCOLOGY, V4, P165, DOI 10.1093/neuonc/4.3.165; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lednicky JA, 1999, FRONT BIOSCI, V4, P153; LEE YY, 1994, ONCOGENE, V9, P1655; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; LOEKEN MR, 1992, J VIROL, V66, P2551, DOI 10.1128/JVI.66.4.2551-2555.1992; MacKenzie J, 1999, BRIT J CANCER, V81, P898, DOI 10.1038/sj.bjc.6690783; MARTIN RG, 1979, CELL, V17, P635, DOI 10.1016/0092-8674(79)90271-X; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MONINI P, 1995, DNA TUMOR VIRUSES ON, P51; NAKASHATRI H, 1988, J VIROL, V62, P4613; NEGRINI M, 1990, J GEN VIROL, V71, P2731, DOI 10.1099/0022-1317-71-11-2731; Nickeleit V, 2000, NEW ENGL J MED, V342, P1309, DOI 10.1056/NEJM200005043421802; NOSS G, 1984, ARCH VIROL, V81, P41, DOI 10.1007/BF01309295; NOSS G, 1981, ARCH VIROL, V69, P239, DOI 10.1007/BF01317339; OCONNELL K, 1991, AM J PATHOL, V139, P743; PADGETT BL, 1976, PROG MED VIROL, V22, P1; PAGNANI M, 1988, INT J CANCER, V42, P405, DOI 10.1002/ijc.2910420317; PAGNANI M, 1986, J VIROL, V59, P500, DOI 10.1128/JVI.59.2.500-505.1986; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PATER MM, 1980, VIRUSES NATURALLY OC, P329; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; Pietropaolo V, 1998, J MED VIROL, V56, P372, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;372::AID-JMV14&gt;3.0.CO;2-4; PORTOLANI M, 1985, MICROBIOLOGICA, V8, P59; PORTOLANI M, 1978, J GEN VIROL, V38, P369, DOI 10.1099/0022-1317-38-2-369; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Reploeg MD, 2001, CLIN INFECT DIS, V33, P191, DOI 10.1086/321813; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RUNDELL K, 1981, J VIROL, V37, P1090, DOI 10.1128/JVI.37.3.1090-1093.1981; SHAH KV, 1976, P SOC EXP BIOL MED, V153, P180, DOI 10.3181/00379727-153-39506; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Shivakumar CV, 1996, ONCOGENE, V13, P323; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stoner GL, 2002, AM J KIDNEY DIS, V39, P1102, DOI 10.1053/ajkd.2002.32795; TAKEMOTO KK, 1979, J VIROL, V29, P1177, DOI 10.1128/JVI.29.3.1177-1185.1979; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; UCHIDA S, 1979, J NATL CANCER I, V63, P119; VANDERNOORDAA J, 1986, J GEN VIROL, V67, P1485, DOI 10.1099/0022-1317-67-7-1485; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; Vastag B, 2002, JAMA-J AM MED ASSOC, V288, P1337, DOI 10.1001/jama.288.11.1337; Volter C, 1997, VIROLOGY, V237, P389, DOI 10.1006/viro.1997.8772; Waheed I, 1999, CANCER RES, V59, P6068; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WATANABE S, 1979, J VIROL, V32, P934, DOI 10.1128/JVI.32.3.934-942.1979; WATANABE S, 1982, INT J CANCER, V29, P583, DOI 10.1002/ijc.2910290515; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; WOLD WSM, 1978, P NATL ACAD SCI USA, V75, P454, DOI 10.1073/pnas.75.1.454; Zambrano A, 2002, ONCOGENE, V21, P5725, DOI 10.1038/sj.onc.1205692; zur Hausen H, 1994, Curr Top Microbiol Immunol, V186, P131; Zur Hausen H, 2001, ONCOGENE, V20, P7820, DOI 10.1038/sj.onc.1204958	114	114	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5192	5200		10.1038/sj.onc.1206550	http://dx.doi.org/10.1038/sj.onc.1206550			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910256				2022-12-28	WOS:000184615100010
J	Jandt, E; Denner, K; Kovalenko, M; Ostman, A; Bohmer, FD				Jandt, E; Denner, K; Kovalenko, M; Ostman, A; Bohmer, FD			The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion	ONCOGENE			English	Article						protein-tyrosine phosphatase; DEP-1; growth factor; cell migration; cell-matrix adhesion	SRC FAMILY KINASES; PDGF BETA-RECEPTOR; SITE-SELECTIVE DEPHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; IN-VIVO; CD148; ACTIVATION; CHEMOTAXIS; PHOSPHORYLATION	Density-enhanced protein-tyrosine phosphatase-1 (DEP-1 also CD148) is a transmembrane molecule with a single intracellular PTP domain. It has recently been proposed to function as a tumor suppressor. We have previously shown that DEP-1 dephosphorylates the activated platelet-derived growth factor (PDGF) beta-receptor in a site-selective manner (Kovalenko et al. (2000). J. Biol. Chem. 275, 16219-16226). We analysed cell lines with inducible DEP-1 expression for cellular functions of DEP-1. Several aspects of PDGFbeta-receptor signaling were negatively affected by DEP-1 expression. These include PDGF-stimulated activation of inositol trisphosphate formation, Erk1/2, p21Ras, and Src. Activation of receptor-associated phosphoinositide-3 kinase activity and of Akt/PKB were weakly attenuated at early time points of stimulation. Inhibition of PDGF-stimulated signaling depended on DEP-1 catalytic activity. Importantly, DEP-1 inhibited PDGF-stimulated cell migration. The catalytically inactive DEP-1 C1239S variant enhanced cell migration and PDGF-stimulated Erk1/2 activation, suggesting a dominant negative interference with endogenous DEP-1. In contrast to cell migration, cell-substrate adhesion was promoted by active DEP-1 and delayed or suppressed by DEP-1 C1239S, correlating with positive effects of DEP-1 on adhesion-stimulated Src kinase. We propose that negative regulation of growth-factor stimulated cell migration and promotion of cell-matrix adhesion may be related to the function of DEP-1 as tumor suppressor.	Univ Jena, Res Unit Mol Cell Biol, Fac Med, D-07747 Jena, Germany; Ludwig Inst Canc Res, Uppsala Branch, S-75123 Uppsala, Sweden	Friedrich Schiller University of Jena; Ludwig Institute for Cancer Research	Bohmer, FD (corresponding author), Univ Jena, Res Unit Mol Cell Biol, Fac Med, Drackendorfer Str 1, D-07747 Jena, Germany.							ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Chiarugi P, 2002, J CELL SCI, V115, P2219; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Hundt M, 1997, EUR J IMMUNOL, V27, P3532, DOI 10.1002/eji.1830271255; Iuliano R, 2003, CANCER RES, V63, P882; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Keane MM, 1996, CANCER RES, V56, P4236; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; KOVALENKO M, 1994, CANCER RES, V54, P6106; Mahboobi S, 2002, J MED CHEM, V45, P1002, DOI 10.1021/jm010988n; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schraven B, 2000, J BIOL REG HOMEOS AG, V14, P220; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	51	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4175	4185		10.1038/sj.onc.1206652	http://dx.doi.org/10.1038/sj.onc.1206652			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833140				2022-12-28	WOS:000183979800004
J	Stearns, ME; Hu, YJ; Wang, M				Stearns, ME; Hu, YJ; Wang, M			IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R alpha chain in human primary prostate cancer cell lines	ONCOGENE			English	Article						IL-10; IL-10R; IL-10E1; primary prostate tumor lines; tyrosine phosphorylation; green fluorescent protein tagged IL-10E1; TIMP-1	EPIDERMAL-GROWTH-FACTOR; CYTOKINE RECEPTORS; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; EPITHELIAL-CELLS; INTERLEUKIN-10; ACTIVATION; STAT; BINDING; EXPRESSION	Interleukin 10 (IL-10) stimulates rapid nuclear translocation and binding of a 22 kDa protein, termed interleukin 10 enhancer I (IL-10E1), to a novel enhancer element (i.e. HTE-1) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene to upregulate TIMP-1 expression. IL10-E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein. In this paper, the studies showed that two tyrosine residues (Tyr(446) and Tyr(496)) located in the cytoplasmic domain of the IL-10R alpha chain were required for receptor function, and for phosphorylation and activation of IL-10E1. Immunoprecipitation studies revealed that 12 amino-acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitate IL-10E1 and blocked figand-dependent IL-10E1 phosphorylation in a cell-free system. In contrast, peptides containing serine substitutions for Tyr(446) and Tyr(496), and tyrosine-phosphorylated peptides containing TNT 2-10 or Tyr(252/259) did not prevent IL-10E1 activation or signaling. To confirm these observations in vivo, fusion protein constructs were made between a modified form of green fluorescent protein or GFP and the intact IL-10E1 protein (IL-10E1-MmGFP) and n-terminal peptides of the IL-10E1 protein (i.e. nt-nls-MmGFP and mutant sequences identified as nt-nls mC61-MmGFP and nt-nis mY57/mY62-MmGFP peptides). Confocal microscopy revealed that IL-10 triggered transport to the nucleus of IL-10E1-MmGFP, nt-nls-MmGFP, and nt-nls mC61-MmGFP by 10-30 min in HPCA-10a (human prostrate cancer cells; derived from Gleason sum 10 tumor tissue) cells. IL-10 failed to induce nuclear translocation of the mY57/mY62-MmGFP peptides with point mutations of the two tyrosine groups. Coinjection of nt-nls-MmGFP with the IL-10R Tyr(446) and Tyr(496) amino-acid residues completely blocked ligand signaling. Coinjection of peptides containing either serine substitutions for Tyr(446) and Tyr(496) or Tyr(230) and Tyr(252/259) failed to block nt-nls-MmGFP signaling. The data demonstrate that IL-10E1 is directly recruited to the ligand-activated IL-10R by binding to specific phosphotyrosine groups which control tyrosine phosphorylation of the LIM domain of the IL-10E1 protein (i.e. Y57/Y62 groups) and IL-10E1 activation.	Drew Univ, Coll Med, Dept Pathol & Lab, Philadelphia, PA 19102 USA		Stearns, ME (corresponding author), Drew Univ, Coll Med, Dept Pathol & Lab, MS 435,15th & Vine Sts, Philadelphia, PA 19102 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bright RK, 1997, CANCER RES, V57, P995; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P744; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LACRAZ S, 1993, CLIN INVESTIGATOR, V90, P382; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIU Y, 1994, J IMMUNOL, V152, P1821; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; PEEHL DM, 1994, CELL TISSUE RES, V277, P11, DOI 10.1007/BF00303075; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 1989, MOL CLONING, pA1; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEARNS M, 1995, ONCOL RES, V7, P173; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang M, 1996, ONCOL RES, V8, P303; Wang M, 2002, CANCER BIOL THER, V1, P556, DOI 10.4161/cbt.1.5.222; Wang M, 1998, ONCOL RES, V10, P219; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3781	3791		10.1038/sj.onc.1206579	http://dx.doi.org/10.1038/sj.onc.1206579			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802285				2022-12-28	WOS:000183551000012
J	King, KE; Ponnamperuma, RM; Yamashita, T; Tokino, T; Lee, LA; Young, MF; Weinberg, WC				King, KE; Ponnamperuma, RM; Yamashita, T; Tokino, T; Lee, LA; Young, MF; Weinberg, WC			Delta Np63 alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes	ONCOGENE			English	Article						Delta Np63 alpha; p63; p53 homologues; keratinocytes; epidermal differentiation	SQUAMOUS-CELL CARCINOMAS; P53 GENE DOSAGE; MALIGNANT PROGRESSION; P53-RELATED PROTEIN; SPONTANEOUS TUMORS; P63 EXPRESSION; CORE DOMAIN; P73; HOMOLOG; APOPTOSIS	DeltaNp63 is overexpressed in squamous carcinomas where it is associated with proliferation and is believed to enhance cell growth by blocking p53-mediated transactivation. In normal epithelium, DeltaNp63alpha protein expression is abundant in basal cells and decreases with differentiation. To explore the biological consequences of DeltaNp63alpha overexpression in relation to squamous carcinogenesis, we evaluated its effect on normal squamous differentiation and p53 transactivation function in keratinocytes. Forced overexpression of DeltaNp63alpha in primary murine keratinocytes in vitro inhibits morphological differentiation induced by elevated extracellular [Ca2+], abrogates Ca2+-induced growth arrest, and blocks expression of maturation-specific proteins keratin 10 and filaggrin. This suggests that DeltaNp63 overexpression in squamous carcinomas may serve to maintain the basal cell phenotype and promote cell survival. DeltaNp63alpha blocks transactivation of p53 responsive reporter constructs mediated by endogenous or exogenous p53 at 17 h postinfection, as expected. However, at 41 h, when p53-mediated transactivation is diminished, DeltaNp63alpha: enhances transactivation of these reporter constructs by 2.2-12-fold over control. Maximal DeltaNp63alpha-induced transactivation requires intact p53 responsive elements, but is independent of cellular p53 status. This positive transcriptional function of DeltaNp63alpha appears to be cell-type specific, as it is not observed in primary dermal fibroblasts or Saos-2 cells. These findings support DeltaNp63alpha as a master regulator of keratinocyte differentiation, and suggest a novel function of this protein in the maintenance of epithelial homeostasis.	US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Sapporo Med Univ, Sch Med, Sapporo, Hokkaido 0608556, Japan; Univ Colorado, Sch Med, Denver, CO 80262 USA; Denver Hlth Med Ctr, Denver, CO 80262 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); Sapporo Medical University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Weinberg, WC (corresponding author), US FDA, Ctr Biol Evaluat & Res, 29 Lincoln Dr,HFM-564,Bldg 29B,Room 3NN04, Bethesda, MD 20892 USA.		Weinberg, Wendy/A-8920-2009; Tokino, Takashi/AAI-9887-2021	Young, Marian F/0000-0003-0929-8854	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bamberger C, 2001, FEBS LETT, V501, P121, DOI 10.1016/S0014-5793(01)02643-6; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dellavalle RP, 2001, J DERMATOL SCI, V27, P82, DOI 10.1016/S0923-1811(01)00105-0; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Glickman JN, 2001, HUM PATHOL, V32, P1157, DOI 10.1053/hupa.2001.28951; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Liefer KM, 2000, CANCER RES, V60, P4016; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Reis JS, 2002, J CUTAN PATHOL, V29, P517, DOI 10.1034/j.1600-0560.2002.290902.x; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shimada A, 1999, CANCER RES, V59, P2781; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	128	133	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3635	3644		10.1038/sj.onc.1206536	http://dx.doi.org/10.1038/sj.onc.1206536			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789272				2022-12-28	WOS:000183399200014
J	La Sala, D; Macaluso, M; Trimarchi, C; Giordano, A; Cinti, C				La Sala, D; Macaluso, M; Trimarchi, C; Giordano, A; Cinti, C			Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb/p130 complexes	ONCOGENE			English	Article						multidrug resistance; apoptosis; p53-independent pathways; pRb2/p130; p73; osteosarcoma	TUMOR-SUPPRESSOR; IN-VIVO; RETINOBLASTOMA PROTEIN; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; P-GLYCOPROTEIN; DNA-BINDING; P53; P73; E2F	Mechanisms underlying multidrug resistance (MDR), one of the major causes of cancer treatment failure, are still poorly understood. We selected the osteosarcoma MDR HosDXR150 cell line by culturing Hos cells in the presence of increasing doxorubicin doses and showed that it is crossresistant to vinblastine. Similarly to the Hos parental cell line, HosDXR150 cells present mutated p53, functionally inactivated pRb/p105 and wild-type pRb2/p130. Owing to p53 mutation, MDR-1 gene, codifying for P-glycoprotein, is upregulated. Evasion of apoptosis in HosDXR150 cells is only partially explained by drug extrusion because of P-glycoprotein overexpression. Analysis of gene expression level profiles showed that parental cell line undergoes apoptosis through an E2F1/p73-dependent pathway while its resistant variant evades it. This result can be explained by the presence of distinct E2Fs-pRb2/p130 complexes on the p73 promoter. Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.	IOR, CNR, ITOI, Unit Bologna, I-40136 Bologna, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19107 USA; CNR, Inst Neurosci, I-56100 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR)	Cinti, C (corresponding author), IOR, CNR, ITOI, Unit Bologna, Via Barbiano 1-10, I-40136 Bologna, Italy.	cinti@area.bo.cnr.it	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369				An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Cinti C, 2000, ONCOGENE, V19, P5098, DOI 10.1038/sj.onc.1203848; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dou Q. Ping, 1998, Frontiers in Bioscience, V3, pD419; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gorlick R, 1999, J CLIN ONCOL, V17, P2781, DOI 10.1200/JCO.1999.17.9.2781; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HANSEN MF, 1991, CLIN ORTHOP RELAT R, P237; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lavia P, 1999, BIOESSAYS, V21, P221; LIN XH, 1994, CANCER RES, V54, P2751; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; NGUYEN KT, 1994, ONCOL RES, V6, P71; Oda Y, 2000, ONCOL REP, V7, P859; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PARK DJ, 1994, ONCOGENE, V9, P1899; Pucci B, 2002, ONCOGENE, V21, P5897, DOI 10.1038/sj.onc.1205750; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; SERRA M, 1993, ANTICANCER RES, V13, P323; Shnyder SD, 1998, BRIT J CANCER, V78, P757, DOI 10.1038/bjc.1998.573; Sigal A, 2000, CANCER RES, V60, P6788; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strauss BE, 1995, BIOCHEM BIOPH RES CO, V217, P825, DOI 10.1006/bbrc.1995.2846; STRAUSS BE, 1995, BIOCHEM BIOPH RES CO, V217, P333, DOI 10.1006/bbrc.1995.2781; Takahashi Y, 2000, GENE DEV, V14, P804; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zini N, 2001, J CELL PHYSIOL, V189, P34, DOI 10.1002/jcp.1135	47	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3518	3529		10.1038/sj.onc.1206487	http://dx.doi.org/10.1038/sj.onc.1206487			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789260				2022-12-28	WOS:000183399200002
J	Oikawa, S; Murakami, K; Kawanishi, S				Oikawa, S; Murakami, K; Kawanishi, S			Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis	ONCOGENE			English	Article						DNA damage; homocysteine; 8-oxo-7, 8-dihydro-2 '-deoxyguanosine; hydrogen peroxide; singlet oxygen	TOTAL PLASMA HOMOCYSTEINE; NESTED CASE-CONTROL; SINGLET OXYGEN; HORDALAND HOMOCYSTEINE; HYDROGEN-PEROXIDE; COLORECTAL-CANCER; STRANDED-DNA; RISK-FACTORS; MALE SMOKERS; FOLATE	Homocysteine is considered to be an important risk factor for cancer as well as cardiovascular diseases. To clarify whether homocysteine has potential carcinogenicity, we investigated formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), which is known to be correlated with the incidence of cancer, induced by homocysteine in human cultured cell lines. Homocysteine increased the amount of 8-oxodG in human leukemia cell line HL-60, whereas the amount of 8-oxodG in its hydrogen peroxide (H2O2)-resistant clone HP100 was not increased. We investigated the mechanism for oxidative DNA damage by homocysteine using P-32-labeled DNA fragments obtained from human tumor suppressor genes and a protooncogene. There were two mechanisms by which homocysteine caused DNA damage in the presence of Cu(II). A low concentration of homocysteine (20 muM) frequently induced piperidine-labile sites at thymine residues, whereas a high concentration of homocysteine (100 muM) resulted in damage principally to guanine residues. Catalase inhibited DNA damage by 20 muM homocysteine, indicating the participation of H2O2, but was ineffective in preventing DNA damage by 100 muM homocysteine. Experiments using a singlet oxygen probe showed that 100 muM homocysteine enhanced chemiluminescence intensity in deuterium oxide more than that in H2O. These results indicated that the metal-dependent DNA damage through H2O2 is likely to be a more relevant mechanism for homocysteine carcinogenicity.	Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan	Mie University	Kawanishi, S (corresponding author), Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan.							Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; Blom HJ, 1998, AM J CLIN NUTR, V67, P188, DOI 10.1093/ajcn/67.2.188; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; CHUMAKOV P, 1990, X54156 EMBL DAT LIB; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P317, DOI 10.1016/0003-9861(91)90366-Q; DIZDAROGLU M, 1990, BIOCHEMISTRY-US, V29, P8447, DOI 10.1021/bi00488a035; El-Khairy L, 1999, AM J CLIN NUTR, V70, P1016; EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M; Fenech M, 1998, CARCINOGENESIS, V19, P1163, DOI 10.1093/carcin/19.7.1163; Fenech MF, 1997, CARCINOGENESIS, V18, P1329, DOI 10.1093/carcin/18.7.1329; Glynn SA, 1996, CANCER EPIDEM BIOMAR, V5, P487; Gray RG, 2000, LANCET, V355, P1588; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; Hall DB, 1998, BIOCHEMISTRY-US, V37, P15933, DOI 10.1021/bi981750c; HALL RD, 1989, J BIOL CHEM, V264, P7900; Heijmans BT, 1999, EUR J HUM GENET, V7, P197, DOI 10.1038/sj.ejhg.5200283; Huschtscha LI, 1998, CANCER RES, V58, P3508; ITO K, 1993, J BIOL CHEM, V268, P13221; Kark JD, 1999, ANN INTERN MED, V131, P321, DOI 10.7326/0003-4819-131-5-199909070-00002; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASUGAI I, 1992, LEUKEMIA RES, V16, P173, DOI 10.1016/0145-2126(92)90129-U; Kato I, 1999, BRIT J CANCER, V79, P1917, DOI 10.1038/sj.bjc.6690305; KAWANISHI S, 1991, BIOCHEMISTRY-US, V30, P3069, DOI 10.1021/bi00226a013; KAWANISHI S, 1986, J BIOL CHEM, V261, P6090; Langman LJ, 1999, CRIT REV CL LAB SCI, V36, P365, DOI 10.1080/10408369991239231; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; LINDIG BA, 1980, J AM CHEM SOC, V102, P5590, DOI 10.1021/ja00537a030; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; Martinez ME, 1999, CANCER RES, V59, P5181; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; Miller H, 2000, BIOCHEMISTRY-US, V39, P1029, DOI 10.1021/bi991789x; Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Oikawa S, 1998, BBA-GENE STRUCT EXPR, V1399, P19, DOI 10.1016/S0167-4781(98)00092-X; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PRYOR WA, 1978, BIOCHEM BIOPH RES CO, V81, P498, DOI 10.1016/0006-291X(78)91562-0; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schneede J, 2000, SEMIN THROMB HEMOST, V26, P263, DOI 10.1055/s-2000-8471; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEVILLA MD, 1987, BIOCHEM BIOPH RES CO, V144, P1037, DOI 10.1016/S0006-291X(87)80068-2; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Stevenson C, 1999, CHEM RES TOXICOL, V12, P38, DOI 10.1021/tx980158l; Stolzenberg-Solomon RZ, 1999, JNCI-J NATL CANCER I, V91, P535, DOI 10.1093/jnci/91.6.535; Tada-Oikawa S, 2000, METHOD ENZYMOL, V319, P331; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; Theophanides T, 2002, CRIT REV ONCOL HEMAT, V42, P57, DOI 10.1016/S1040-8428(02)00007-0; Thomson SW, 2000, NUTRITION, V16, P411, DOI 10.1016/S0899-9007(00)00284-7; TUITE EM, 1993, J PHOTOCH PHOTOBIO B, V21, P103, DOI 10.1016/1011-1344(93)80173-7; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298	58	63	65	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3530	3538		10.1038/sj.onc.1206440	http://dx.doi.org/10.1038/sj.onc.1206440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789261				2022-12-28	WOS:000183399200003
J	Dupin, E; Le Douarin, NM				Dupin, E; Le Douarin, NM			Development of melanocyte precursors from the vertebrate neural crest	ONCOGENE			English	Article						neural crest; quail; chick; embryo; pigment cell; stem cell factor; endothelin 3	ENDOTHELIN-B RECEPTOR; C-KIT ANTIBODY; STEEL FACTOR; AVIAN EMBRYO; COAT COLOR; IN-VITRO; MONOCLONAL-ANTIBODY; CLONAL ANALYSIS; CELLS; DIFFERENTIATION	Pigment cells that differentiate in the vertebral skin arise from the neural crest (NC), a transitory structure formed at the dorsal borders of the neural plate and which gives rise to migratory cells of multiple fates. How NC cells become committed to the melanocytic lineage and what factors control the survival, proliferation and differentiation of melanocyte precursors remain largely unknown. These issues are of great importance for understanding the mechanisms of several pigment cell pathologies including melanomas. Recent in vivo and in vitro analyses of the fate of single NC cells have indicated that multipotent cells yield melanocyte precursors that become spatially and temporally segregated from other, non melanogenic, NC-derived cell types. The proper development of subsets of NC precursors is governed by environmental local cytokines acting in a paracrine manner. The conjunction of recent studies in mammals and birds reviewed here focuses on the action of endothelin 3 in controlling both the emergence and the maintenance of the NC-derived melanocyte phenotype.	CNRS, Lab Embryol Cellulaire & Mol, UMR 7128, F-94736 Nogent Sur Marne, France	Centre National de la Recherche Scientifique (CNRS)	Le Douarin, NM (corresponding author), CNRS, Lab Embryol Cellulaire & Mol, UMR 7128, 49 Bis Ave Belle Gabrielle, F-94736 Nogent Sur Marne, France.		Dupin, Elisabeth/X-8757-2019	Dupin, Elisabeth/0000-0003-0287-0256				ABO T, 1981, J IMMUNOL, V127, P1024; Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; BAROFFIO A, 1991, DEVELOPMENT, V112, P301; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; COHEN AM, 1975, DEV BIOL, V46, P262, DOI 10.1016/0012-1606(75)90104-9; COULY GF, 1993, DEVELOPMENT, V117, P409; Dupin E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/pnas.97.14.7882; DUPIN E, 1995, DEV BIOL, V168, P529, DOI 10.1006/dbio.1995.1100; DUPIN E, 2003, P NATL AC SCI US APR; ERICKSON CA, 1992, DEV BIOL, V151, P251, DOI 10.1016/0012-1606(92)90231-5; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Galli SJ, 1993, ADV IMMUNOL, P1, DOI DOI 10.1016/S0065-2776(08)60508-8; Greenstein-Baynash A., 1994, CELL, V79, P1277; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; ITO K, 1993, DEV BIOL, V157, P517, DOI 10.1006/dbio.1993.1154; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; KITAMURA K, 1992, DEVELOPMENT, V114, P367; LAHAV R, 1994, DIFFERENTIATION, V58, P133; Lahav R, 1998, P NATL ACAD SCI USA, V95, P14214, DOI 10.1073/pnas.95.24.14214; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; Le Douarin N.M., 1982, NEURAL CREST; Le Douarin NM, 1999, NEURAL CREST, V2; Lecoin L, 1998, P NATL ACAD SCI USA, V95, P3024, DOI 10.1073/pnas.95.6.3024; LECOIN L, 1998, MOL BASIS EPITHELIAL, P131; MORRISONGRAHAM K, 1993, DEV BIOL, V159, P346, DOI 10.1006/dbio.1993.1246; MURPHY M, 1992, DEV BIOL, V153, P396, DOI 10.1016/0012-1606(92)90124-Y; Nataf V, 1998, MECH DEVELOP, V73, P217, DOI 10.1016/S0925-4773(98)00048-3; NATAF V, 1993, EXP CELL RES, V207, P171, DOI 10.1006/excr.1993.1177; Nataf V, 2000, PIGM CELL RES, V13, P172, DOI 10.1034/j.1600-0749.2000.130309.x; Nataf V, 1996, P NATL ACAD SCI USA, V93, P9645, DOI 10.1073/pnas.93.18.9645; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; REID K, 1995, DEV BIOL, V169, P568, DOI 10.1006/dbio.1995.1170; Reid K, 1996, DEVELOPMENT, V122, P3911; REITH AD, 1991, GENOME ANAL, V3, P10; RICHARDSON MK, 1993, DEV BIOL, V157, P348, DOI 10.1006/dbio.1993.1140; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; SIEBERBLUM M, 1989, SCIENCE, V243, P1608, DOI 10.1126/science.2564699; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Stone JG, 1997, J CELL SCI, V110, P1673; TEILLET M-A, 1971, Annales d'Embryologie et de Morphogenese, V4, P95; TEILLET MA, 1970, CR ACAD SCI D NAT, V270, P3095; VINCENT M, 1983, DEV BRAIN RES, V9, P235, DOI 10.1016/0165-3806(83)90058-5; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x; Yoshida H, 1996, DEVELOPMENT, V122, P1207; YOSHIDA H, 1993, DEV GROWTH DIFFER, V35, P209	53	131	148	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3016	3023		10.1038/sj.onc.1206460	http://dx.doi.org/10.1038/sj.onc.1206460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789276				2022-12-28	WOS:000183096600001
J	Tucker, MA; Goldstein, AM				Tucker, MA; Goldstein, AM			Melanoma etiology: where are we?	ONCOGENE			English	Review						melanoma; epidemiology; nevi; genetic epidemiology	CUTANEOUS MALIGNANT-MELANOMA; DYSPLASTIC NEVUS SYNDROME; SUN-PROTECTION BEHAVIORS; MULTICENTER CASE-CONTROL; CDK4 GERMLINE MUTATIONS; DANISH CASE-CONTROL; MELANOCYTIC NEVI; RISK-FACTORS; CDKN2A MUTATIONS; PRONE FAMILIES	Melanoma incidence rates are rising rapidly, particularly in older men. Older men are also more likely to have thick melanomas, which confer high mortality and morbidity. The reasons for the rate of increase are not known; increasing sun and UV exposure, however, is the major hypothesized explanation. In the past several years, two major susceptibility genes for melanoma, CDKN2A and CDK4, have been identified, but the two genes together account for a minority of familial melanoma. Other high-risk susceptibility genes are being sought actively. Genetic epidemiologic studies suggest that penetrance of each of the two identified genes is altered by other factors, either genetic or environmental. Epidemiologic studies have also identified other major host factors important in the development of melanoma. In European, North American, and Australian populations, the presence of clinically identified dysplastic nevi confers greatly increased risk of melanoma. A new measure of sun exposure, based on individual residential history, confers substantially increased risk of melanoma. Recent surveys of sun behavior in the US reveal extensive sunburning and use of tanning beds in adolescents and adults. Sun protective behaviors are not as prevalent as in Australia, where population rates of melanoma are stabilizing.	NCI, DCEG, Genet Epidemiol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tucker, MA (corresponding author), NCI, DCEG, Genet Epidemiol Branch, Execut Plaza S 7122,6120 Execut Blvd, Bethesda, MD 20892 USA.	tuckerp@mail.nih.gov	Tucker, Margaret A/B-4297-2015					Aitken J, 1999, JNCI-J NATL CANCER I, V91, P446, DOI 10.1093/jnci/91.5.446; AITKEN JF, 1994, AM J EPIDEMIOL, V140, P961, DOI 10.1093/oxfordjournals.aje.a117203; Ang CG, 1998, MELANOMA RES, V8, P459, DOI 10.1097/00008390-199810000-00011; [Anonymous], 2003, SURVEILLANCE EPIDEMI; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P518; Auroy S, 2001, GENE CHROMOSOME CANC, V32, P195, DOI 10.1002/gcc.1183; BALE SJ, 1986, AM J HUM GENET, V38, P188; BARNHILL RL, 1992, DERMATOLOGY, V184, P2, DOI 10.1159/000247489; Bastuji-Garin S, 2002, BRIT J DERMATOL, V146, P24, DOI 10.1046/j.1365-2133.146.s61.9.x; Bataille V, 2000, JNCI-J NATL CANCER I, V92, P457, DOI 10.1093/jnci/92.6.457; Bataille V, 1998, BRIT J CANCER, V77, P505, DOI 10.1038/bjc.1998.81; BERAL V, 1977, BRIT J CANCER, V50, P681; Bergenmar M, 2001, CANCER NURS, V24, P341, DOI 10.1097/00002820-200110000-00002; BERGMAN W, 1992, CYTOGENET CELL GENET, V59, P161, DOI 10.1159/000133232; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; BISHOP JAN, 1994, MELANOMA RES, V4, P199, DOI 10.1097/00008390-199408000-00001; BLISS JM, 1995, INT J CANCER, V62, P367, DOI 10.1002/ijc.2910620402; Borg A, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260; Borg A, 1996, CANCER RES, V56, P2497; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Breitbart M, 1997, ACTA DERM-VENEREOL, V77, P374; Brenner AV, 2002, AM J EPIDEMIOL, V156, P353, DOI 10.1093/aje/kwf045; Buller DB, 2002, ARCH DERMATOL, V138, P771, DOI 10.1001/archderm.138.6.771; Bulliard JL, 2000, INT J EPIDEMIOL, V29, P416, DOI 10.1093/ije/29.3.416; CHAUDRA V, 2001, MELANOMA RES, V11, pS143; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Clark WH, 1998, HUM PATHOL, V29, P8, DOI 10.1016/S0046-8177(98)90384-7; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLEMENTE C, 1991, HUM PATHOL, V22, P313, DOI 10.1016/0046-8177(91)90078-4; Cokkinides VE, 2002, PEDIATRICS, V109, P1124, DOI 10.1542/peds.109.6.1124; Darlington S, 2002, J AM ACAD DERMATOL, V46, P715, DOI 10.1067/mjd.2002.120931; Davis KJ, 2002, PEDIATRICS, V110, P27, DOI 10.1542/peds.110.1.27; Dwyer T, 2000, MELANOMA RES, V10, P387, DOI 10.1097/00008390-200008000-00011; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; English DR, 1998, CANCER EPIDEM BIOMAR, V7, P857; Fears TR, 2002, CANCER RES, V62, P3992; FORD D, 1995, INT J CANCER, V62, P377, DOI 10.1002/ijc.2910620403; Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955; GARBE C, 1994, J INVEST DERMATOL, V102, P700, DOI 10.1111/1523-1747.ep12374298; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; Geller AC, 2002, PEDIATRICS, V109, P1009, DOI 10.1542/peds.109.6.1009; Ghiorzo P, 1999, INT J CANCER, V83, P441, DOI 10.1002/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO;2-R; Giles GG, 1996, BMJ-BRIT MED J, V312, P1121; Goldstein AM, 2000, CANCER EPIDEM BIOMAR, V9, P889; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Goldstein AM, 2002, MELANOMA RES, V12, P51, DOI 10.1097/00008390-200202000-00008; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; HALPERN AC, 1993, J INVEST DERMATOL, V100, pS346, DOI 10.1038/jid.1993.61; HALPERN AC, 1993, J AM ACAD DERMATOL, V29, P51, DOI 10.1016/0190-9622(93)70151-I; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HARRISON SL, 1994, LANCET, V344, P1529, DOI 10.1016/S0140-6736(94)90348-4; Harrison SL, 1999, ARCH DERMATOL, V135, P47, DOI 10.1001/archderm.135.1.47; HARTGE P, 1995, CANCER EPIDEM BIOMAR, V4, P37; Hashemi J, 1999, MELANOMA RES, V9, P21, DOI 10.1097/00008390-199902000-00004; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HOLLY EA, 1983, JNCI-J NATL CANCER I, V70, P827; Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KAMB A, 1994, GENET, P22; Kanetsky PA, 2001, CANCER EPIDEM BIOMAR, V10, P509; Karagas MR, 2002, BRIT J CANCER, V86, P1085, DOI 10.1038/sj.bjc.6600196; Karlsson P, 2000, ACTA DERM-VENEREOL, V80, P335; KEFFORD R, 2002, ONCOLOGY, V3, P653; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Kelly JW, 1997, MED J AUSTRALIA, V167, P191, DOI 10.5694/j.1326-5377.1997.tb138843.x; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; KOPF AW, 1986, JAMA-J AM MED ASSOC, V256, P1915; Kwan  T Y, 2000, J Cutan Med Surg, V4, P58; Lamberg L, 2002, JAMA-J AM MED ASSOC, V287, P2201, DOI 10.1001/jama.287.17.2201; Landi MT, 2002, JNCI-J NATL CANCER I, V94, P94, DOI 10.1093/jnci/94.2.94; Landi MT, 1999, ARCH DERMATOL, V135, P1554, DOI 10.1001/archderm.135.12.1554; Landi MT, 2001, BRIT J CANCER, V85, P1304, DOI 10.1054/bjoc.2001.2029; LEE JS, 1998, P 1998 ASCO ANN M LO, V17, pA514; Lucci A, 2001, J SURG RES, V97, P179, DOI 10.1006/jsre.2001.6146; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MACKIE RM, 1989, LANCET, V2, P487; MACKIE RM, 1982, BRIT J DERMATOL, V107, P621, DOI 10.1111/j.1365-2133.1982.tb00519.x; MacKie RM, 2002, LANCET, V360, P587, DOI 10.1016/S0140-6736(02)09779-9; Mansson-Brahme E, 2002, ACTA ONCOL, V41, P138, DOI 10.1080/028418602753669508; Mantelli M, 2002, AM J MED GENET, V107, P214, DOI 10.1002/ajmg.10137; Marks R, 2002, RECENT RESULTS CANC, V160, P113; Marrett LD, 2001, INT J CANCER, V92, P457, DOI 10.1002/ijc.1203; McGregor B, 1999, GENET EPIDEMIOL, V16, P40, DOI 10.1002/(SICI)1098-2272(1999)16:1<40::AID-GEPI4>3.3.CO;2-T; Milne E, 2002, AM J EPIDEMIOL, V155, P739, DOI 10.1093/aje/155.8.739; Newton Bishop Julia A., 2000, Journal of Investigative Dermatology, V114, P28; NORDLUND JJ, 1985, CANCER RES, V45, P1855; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; OSTERLIND A, 1988, INT J CANCER, V42, P821, DOI 10.1002/ijc.2910420603; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Pfahlberg A, 2001, BRIT J DERMATOL, V144, P471, DOI 10.1046/j.1365-2133.2001.04070.x; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Puig S, 1997, HUM GENET, V101, P359, DOI 10.1007/s004390050642; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruiz A, 1999, J MED GENET, V36, P490; Saraiya M, 2002, AM J PREV MED, V23, P91, DOI 10.1016/S0749-3797(02)00461-0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stierner U, 1992, Melanoma Res, V1, P367; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Tucker MA, 2002, CANCER, V94, P3192, DOI 10.1002/cncr.10605; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; Vasen HFA, 2000, INT J CANCER, V87, P809, DOI 10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.3.CO;2-L; Wachsmuth RC, 2001, J INVEST DERMATOL, V117, P348, DOI 10.1046/j.0022-202x.2001.01415.x; Weinstock MA, 1997, ARCH DERMATOL, V133, P953, DOI 10.1001/archderm.133.8.953; Weinstock MA, 2000, ANN BEHAV MED, V22, P286, DOI 10.1007/BF02895664; WHITE E, 1994, AM J EPIDEMIOL, V139, P857, DOI 10.1093/oxfordjournals.aje.a117092; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Youl P, 2002, INT J CANCER, V98, P92, DOI 10.1002/ijc.10117; Zanetti R, 2001, MELANOMA RES, V11, P551, DOI 10.1097/00008390-200112000-00001; Zhu G, 1999, AM J HUM GENET, V65, P483, DOI 10.1086/302494; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	122	185	193	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3042	3052		10.1038/sj.onc.1206444	http://dx.doi.org/10.1038/sj.onc.1206444			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789279				2022-12-28	WOS:000183096600004
J	Andreozzi, F; Melillo, RM; Carlomagno, F; Oriente, F; Miele, C; Fiory, F; Santopietro, S; Castellone, MD; Beguinot, F; Santoro, M; Formisano, P				Andreozzi, F; Melillo, RM; Carlomagno, F; Oriente, F; Miele, C; Fiory, F; Santopietro, S; Castellone, MD; Beguinot, F; Santoro, M; Formisano, P			Protein kinase C alpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase	ONCOGENE			English	Article						protein kinase C; tyrosine; phorbol; oncogene; thyroid; familial; papillary; signaling; carcinoma	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN; PHOSPHORYLATION; RAS; PROTOONCOGENE; PATHWAYS; MUSCLE; DELTA	We have studied the role of protein kinase C (PKC) in signaling of the RET tyrosine kinase receptor. By using a chimeric receptor (E/R) in which RET kinase can be tightly controlled by the addition of epidermal growth factor (EGF), we have found that RET triggering induces a strong increase of PKCalpha, PKCdelta and PKCzeta activity and that PKCalpha, not PKCdelta and PKCzeta, forms a ligand-dependent protein complex with E/R. We have identified tyrosine 1062 in the RET carboxyl-terminal tail as the docking site for PKCalpha. Block of PKC activity by bisindolytmaleimide or chronic phorbol esters treatment decreased EGF-induced serine/threonine phosphorylation of E/R, while it caused a similarly sized increase of EGF-induced E/R tyrosine kinase activity and mitogenic signaling. Conversely, acute phorbol esters treatment, which promotes PKC activity, increased the levels of E/R serine/threonine phosphorylation and significantly decreased its phosphotyrosine content. A threefold reduction of tyrosine phosphorylation levels of the constitutively active RET/MEN2A oncoprotein was observed upon coexpression with PKCalpha. We conclude that RET binds to and activates PKCalpha. PKCalpha, in turn, causes RET phosphorylation and downregulates RET tyrosine kinase and downstream signaling, thus functioning as a negative feedback loop to modulate RET activity.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via S Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; melillo, rosa marina/O-5255-2015; Andreozzi, Francesco/J-4073-2018; ORIENTE, Francesco/J-6652-2018	MELILLO, Rosa Marina/0000-0002-9233-5275; Formisano, Pietro/0000-0001-7020-6870; Andreozzi, Francesco/0000-0001-9375-1513; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; De Vita G, 2000, CANCER RES, V60, P3727; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Iwashita T, 1996, ONCOGENE, V12, P481; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Ponder BAJ, 1999, CANCER RES, V59, p1736S; PREISS J, 1986, J BIOL CHEM, V261, P8597; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; Seedorf K, 1995, ANN NY ACAD SCI, V766, P459, DOI 10.1111/j.1749-6632.1995.tb26694.x; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	36	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2942	2949		10.1038/sj.onc.1206475	http://dx.doi.org/10.1038/sj.onc.1206475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771945				2022-12-28	WOS:000182824800009
J	Tutt, A; Connor, F; Bertwistle, D; Kerr, P; Peacock, J; Ross, G; Ashworth, A				Tutt, A; Connor, F; Bertwistle, D; Kerr, P; Peacock, J; Ross, G; Ashworth, A			Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity	ONCOGENE			English	Article							HOMOLOGY-DIRECTED REPAIR; CENTROSOME AMPLIFICATION; BREAST-CANCER; MUTATION; P53; INSTABILITY; MICE; RECOMBINATION; MAINTENANCE; DEFICIENT	Carriers of mutations in the BRCA2 gene are at a highly elevated risk of breast and other cancers. The BRCA2 gene encodes a very large protein thought to play a role in DNA repair. To examine the effect of mutation of BRCA2 on sensitivity to ionizing radiation, we used a previously described mouse model system (Brca2(Tr)) in which the Brca2 open reading frame is truncated. Mouse embryo fibroblasts carrying this mutation have a proliferative defect, which we show here can be substantially rescued by genetic ablation of p53. Proliferating Brca2(Tr/Tr)/p53(-/-) cells, like Brca2(Tr/Tr) cells, show genomic instability. We used the clonogenic survival assay, which depends on the ability of cells to proliferate, to examine the cell cycle dependence of radiation sensitivity of Brca2(Tr/Tr)/p53(-/-) compared to p53(-/-) and wild-type cells. This showed that the Brca2 mutation had little effect on cells irradiated in quiescence but sensitized proliferating cells to ionizing radiation on a p53(-/-) background. These results suggest that the major role of Brca2 in mediating cell survival after irradiation is in the S and G(2) phases of the cell cycle.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.			Tutt, Andrew/0000-0001-8715-2901				Bertwistle D, 1997, CANCER RES, V57, P5485; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gretarsdottir S, 1998, CANCER RES, V58, P859; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Steel G. G., 1997, BASIC CLIN RADIOBIOL, P40; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	19	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2926	2931		10.1038/sj.onc.1206522	http://dx.doi.org/10.1038/sj.onc.1206522			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771943				2022-12-28	WOS:000182824800007
J	Sigurdson, AJ; Jones, IM				Sigurdson, AJ; Jones, IM			Second cancers after radiotherapy: any evidence for radiation-induced genomic instability?	ONCOGENE			English	Article						second primary cancer; radiation therapy; genomic instability; chromosomal instability; review	DNA-REPAIR GENES; THERAPY-RELATED LEUKEMIA; HODGKINS-DISEASE; IONIZING-RADIATION; LUNG-CANCER; P53 MUTATIONS; SOLID TUMORS; MICROSATELLITE INSTABILITY; CHROMOSOMAL-ABERRATIONS; MARROW TRANSPLANTATION	Do second primary cancers in humans arise from radiation-induced somatic genomic instability after radiotherapy for the first malignancy? The amount of truly pertinent human information on this issue is sparse, leading to the conclusion that we cannot confirm or refute that instability induction by radiation is involved. However, the in vitro findings of radiation-induced genomic instability through bystander effects or increased mutation rates in cell progeny of apparently normal but irradiated cells are provocative and their transferability to human in vivo biology deserves further investigation. We describe possible animal and human studies to stimulate ideas, but the collaborative commitment of multiple large institutions to tumor tissue procurement and retrieval will be essential. In addition, detecting the temporal progression of genomic instability and identifying the salient genetic events as being radiation-induced will be pivotal. Execution of some of the studies suggested is not possible now, but applying next-generation methods could bring the concepts to fruition. As nearly one in 10 cancer diagnoses are second (or higher) malignancies, it is important to understand the contribution of radiotherapy to second cancer induction and pursue well-coordinated efforts to determine the role of induced genomic instability.	NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Sigurdson, AJ (corresponding author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, 6120 Execut Blvd,EPS 7092,MSC 7238, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01CP010131, ZIACP010131] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P259; Backlund MG, 2001, CANCER RES, V61, P6577; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Bauchinger M, 1998, MUTAT RES-FUND MOL M, V404, P89, DOI 10.1016/S0027-5107(98)00098-0; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; BenYehuda D, 1996, BLOOD, V88, P4296; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; BERWICK M, 2002, BIOMARKERS ENV ASS D, P84; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BOICE JD, 1988, RADIAT RES, V116, P3, DOI 10.2307/3577477; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr JD, 1996, CANC EPIDEMIOLOGY PR, P319; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; Brat DJ, 1999, AM J PATHOL, V154, P1431, DOI 10.1016/S0002-9440(10)65397-7; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Chen Z, 2002, AM J MED GENET, V115, P130, DOI 10.1002/ajmg.10689; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; de Vathaire F, 1999, ARCH INTERN MED, V159, P2713, DOI 10.1001/archinte.159.22.2713; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Finnon P, 1999, INT J RADIAT BIOL, V75, P1215, DOI 10.1080/095530099139368; Friedberg EC, 2003, DNA REPAIR, V2, P501, DOI 10.1016/S1568-7864(03)00005-3; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Gilbert ES, 2003, RADIAT RES, V159, P161, DOI 10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Horiike S, 1999, LEUKEMIA, V13, P1235, DOI 10.1038/sj.leu.2401466; Inskip PD, 1999, MULTIPLE PRIMARY CANCERS, P91; KALDOR JM, 1992, INT J CANCER, V52, P677, DOI 10.1002/ijc.2910520502; KLEINERMAN RA, 1990, RADIAT RES, V123, P93, DOI 10.2307/3577663; Kodama Y, 2001, RADIAT RES, V156, P337, DOI 10.1667/0033-7587(2001)156[0337:SCAIAB]2.0.CO;2; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MENDELSOHN ML, 1995, MODELING BIOL EFFECT, P185; Mertens F, 2000, CANCER GENET CYTOGEN, V116, P89, DOI 10.1016/S0165-4608(99)00105-3; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Platz EA, 2000, INT J RADIAT BIOL, V76, P955, DOI 10.1080/09553000050050963; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Shoshan Y, 2000, J NEUROPATH EXP NEUR, V59, P614, DOI 10.1093/jnen/59.7.614; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; Tarkkanen M, 2001, CANCER, V92, P1992, DOI 10.1002/1097-0142(20011001)92:7<1992::AID-CNCR1719>3.0.CO;2-2; Travis LB, 2000, JNCI-J NATL CANCER I, V92, P1165, DOI 10.1093/jnci/92.14.1165; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; TUCKER JD, 1993, INT J RADIAT BIOL, V64, P27, DOI 10.1080/09553009314551081; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1991, CANCER RES, V51, P2885; Ullrich RL, 1998, INT J RADIAT BIOL, V74, P747, DOI 10.1080/095530098141023; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Yu YJ, 2001, CANCER RES, V61, P1820; Zablotska LB, 2003, CANCER, V97, P1404, DOI 10.1002/cncr.11214	61	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7018	7027		10.1038/sj.onc.1206989	http://dx.doi.org/10.1038/sj.onc.1206989			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557806				2022-12-28	WOS:000185903900006
J	Mikula, M; Gotzmann, J; Fischer, ANM; Wolschek, MF; Thallinger, C; Schulte-Hermann, R; Beug, H; Mikulits, W				Mikula, M; Gotzmann, J; Fischer, ANM; Wolschek, MF; Thallinger, C; Schulte-Hermann, R; Beug, H; Mikulits, W			The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis	ONCOGENE			English	Article						c-Fos; hepatocytes; cell death; tumour suppressor	GROWTH-FACTOR-BETA; CELL-CYCLE PROGRESSION; LIVER-REGENERATION; TRANSGENIC MICE; E-CADHERIN; HA-RAS; MOUSE DEVELOPMENT; MESSENGER-RNA; AP-1 COMPLEX; IN-VIVO	Hepatocytes adopt an invasive and metastatic phenotype caused by the cooperation of transforming growth factor (TGF)-beta and oncogenic Ha-Ras. In the initial phase of this process, c-Fos is rapidly induced by TGF-beta, but then decreases to undetectable levels. Here, we investigated the functional implications of c-Fos activation and its contribution to hepatocellular tumorigenesis. By employing conditional c-Fos expression, we observed that continuous activation of c-Fos and consequently AP-1 activity leads to depolarization of differentiated murine epithelial hepatocytes. Most remarkably, this change in morphology was associated with inhibition of proliferation and induction of cell death. Coexpression of antiapoptotic Bcl-X-L or scavenging of reactive oxygen species was sufficient to prevent the c-Fos-mediated phenotype. In contrast, the cooperation of c-Fos with oncogenic Ha-Ras or a Ras mutant selectively activating the MAPK pathway even enhanced c-Fos-induced effects. Showing the negative role in hepatocellular tumorigenesis, c-Fos repressed oncogenic Ras-driven anchorage-independent growth in vitro and strongly suppressed tumour formation in vivo. Taken together, we demonstrate that c-Fos modulates plasticity of epithelial hepatocytes and acts tumour suppressive in neoplastic hepatocytes by stimulating cell cycle inhibition and cell death.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Vienna Gen Hosp, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mikulits, W (corresponding author), Univ Vienna, Inst Canc Res, Borschke Gasse 8A, A-1090 Vienna, Austria.		Mikulits, Wolfgang/AAH-4043-2021	Mikula, Mario/0000-0001-5782-0681; Gotzmann, Josef/0000-0001-6392-2115; Mikulits, Wolfgang/0000-0003-4612-7106				Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARMICHAEL J, 1987, CANCER RES, V47, P936; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Garcia EJ, 2002, APPL IMMUNOHISTO M M, V10, P210, DOI 10.1097/00022744-200209000-00004; Germain S, 2000, GENE DEV, V14, P435; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Hu L, 1996, J IMMUNOL, V157, P3804; ITO N, 1991, CANCER RES, V51, P4080; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kieslinger M, 2000, GENE DEV, V14, P232; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; MARTI A, 1994, ONCOGENE, V9, P1213; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; Nakai S, 2002, INT J ONCOL, V20, P769; Nakopoulou L, 1999, PATHOL RES PRACT, V195, P19, DOI 10.1016/S0344-0338(99)80089-2; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Papadopoulos MC, 1998, EUR J NEUROSCI, V10, P1252, DOI 10.1046/j.1460-9568.1998.00134.x; Pistoi S, 1996, FASEB J, V10, P819, DOI 10.1096/fasebj.10.8.8666158; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qin LF, 2001, HUM PATHOL, V32, P778, DOI 10.1053/hupa.2001.27105; Rahmani M, 1999, J HEPATOL, V30, P916, DOI 10.1016/S0168-8278(99)80148-2; Ravazoula P, 2002, ANTICANCER RES, V22, P1799; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MJ, 1992, BLOOD, V79, P2107; Sok J, 1999, MOL CELL BIOL, V19, P495; Spagnoli FM, 1998, J CELL BIOL, V143, P1101, DOI 10.1083/jcb.143.4.1101; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	82	56	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6725	6738		10.1038/sj.onc.1206781	http://dx.doi.org/10.1038/sj.onc.1206781			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555986				2022-12-28	WOS:000185799300008
J	Rimoldi, V; Reversi, A; Taverna, E; Rosa, P; Francolini, M; Cassoni, P; Parenti, M; Chini, B				Rimoldi, V; Reversi, A; Taverna, E; Rosa, P; Francolini, M; Cassoni, P; Parenti, M; Chini, B			Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains	ONCOGENE			English	Article						caveolin; oxytocin receptor; MAPK; EGFR; p21	GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; LIPID RAFTS; PROTEIN-KINASE; CELL-GROWTH; TYROSINE KINASE; EGF RECEPTOR; INHIBITION; PATHWAY; ENDOCYTOSIS	We have recently shown that oxytocin inhibits cell proliferation when the vast majority of oxytocin receptors are excluded from caveolin-1-enriched microdomains, and that, on the contrary, it has a mitogenic effect when the receptors are targeted to these plasma membrane domains. In this study, we investigated whether the receptors located inside and outside caveolar microdomains initiate different signalling pathways and how this may lead to opposite effects on cell proliferation. Our data indicate that, depending on their localization, oxytocin receptors transactivate EGFR and activate ERK1/2 using different signalling intermediates. The final outcome is a different temporal pattern of EGFR and ERK1/2 phosphorylation, which is more persistent when the receptors are located outside caveolar microdomains and inhibit cell growth, and very transient when they are located in caveolar microdomains and stimulate cell growth. Finally, only the activation of receptors located outside caveolar microdomains correlates with the activation of the cell cycle inhibitor p21(WAF1/CIP1), thus suggesting that the antiproliferative OTR effects may, in this case, be achieved by a sustained activation of EGFR and MAPK leading to the induction of this cell cycle regulator.	CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; Univ Milan, Dept Pharmacol, I-20122 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; Univ Milano Bicocca, Dept Expt & Environm Med & Med Biotechnol, Monza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin; University of Milano-Bicocca	Chini, B (corresponding author), CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, Via Vanvitelli 32, I-20129 Milan, Italy.	B.Chini@csfic.mi.cnr.it	Cassoni, Paola/I-8544-2018; taverna, elena/O-8180-2014; Rimoldi, Valeria/AAB-4865-2020; Taverna, Elena/AFW-4935-2022	taverna, elena/0000-0002-2430-4725; Rimoldi, Valeria/0000-0002-5598-3986; Chini, Bice/0000-0002-1686-284X; FRANCOLINI, MAURA/0000-0002-3126-1575; Rosa, Patrizia/0000-0002-2590-6955; Reversi, Alessandra/0000-0002-9934-5636				Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Breton C, 2002, J CLIN ENDOCR METAB, V87, P1415, DOI 10.1210/jc.87.3.1415; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Copland JA, 1999, ENDOCRINOLOGY, V140, P4371, DOI 10.1210/en.140.9.4371; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Jakus J, 1996, ONCOGENE, V12, P2369; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MOORE JJ, 1988, ENDOCRINOLOGY, V123, P1771, DOI 10.1210/endo-123-4-1771; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sanborn BM, 2001, EXP PHYSIOL, V86, P223, DOI 10.1113/eph8602179; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301; USHIOFUKAI M, 2001, J BIOL CHEM, V3, P3; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Xie W, 1997, ANTICANCER RES, V17, P2627	44	97	100	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6054	6060		10.1038/sj.onc.1206612	http://dx.doi.org/10.1038/sj.onc.1206612			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955084				2022-12-28	WOS:000185137800014
J	Criswell, T; Leskov, K; Miyamoto, S; Luo, GB; Boothman, DA				Criswell, T; Leskov, K; Miyamoto, S; Luo, GB; Boothman, DA			Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation	ONCOGENE			English	Review						DNA damage sensors; ionizing radiation (IR); NF-kappa B; p53; signal transduction; SP1	NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA EXPRESSION; IMMEDIATE-EARLY GENES; TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; C-JUN EXPRESSION; WILD-TYPE; GAMMA-IRRADIATION	Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (less than or equal to 2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-kappaB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.	Case Western Reserve Univ, Dept Radiat Oncol, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Program Mol Basis Dis, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol & Biochem, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Genet, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Ireland Comprehens Canc Ctr, 10900 Euclid Ave,BRB 326 E, Cleveland, OH 44106 USA.	dab30@po.cwru.edu	Boothman, David/Q-7776-2019; Leskov, Konstantin S/J-2339-2017	Leskov, Konstantin S/0000-0001-6201-5660	NCI NIH HHS [CA-83196-05, R01 CA078530, CA-77474-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078530, R01CA077474, R01CA083196] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEYAMA K, 1995, FEBS LETT, V364, P298, DOI 10.1016/0014-5793(95)00412-3; Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Ahn JY, 2000, CANCER RES, V60, P5934; ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Araki R, 1999, CANCER RES, V59, P3543; Ashburner BP, 1999, CANCER RES, V59, P5456; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Bae I, 1996, CANCER RES, V56, P840; BAE IS, 1995, CANCER RES, V55, P2387; Baeuml H, 1997, FREE RADICAL RES, V27, P127, DOI 10.3109/10715769709097846; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Bertagna A, 2001, THROMB HAEMOSTASIS, V85, P837; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Burger H, 1998, INT J RADIAT ONCOL, V41, P415, DOI 10.1016/S0360-3016(98)00065-0; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1992, J BIOL CHEM, V267, P1345; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen XF, 2002, CANCER RES, V62, P1213; Choi EK, 2001, INT J RADIAT ONCOL, V49, P397, DOI 10.1016/S0360-3016(00)01485-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; Davis TW, 1998, CONT CANC RES, P223; Davis TW, 1998, CANCER RES, V58, P767; Didelot C, 2001, INT J RADIAT ONCOL, V51, P1354, DOI 10.1016/S0360-3016(01)02608-6; Durand RE, 2001, METHOD CELL BIOL, V64, P211; Eichholtz-Wirth H, 2000, APOPTOSIS, V5, P255, DOI 10.1023/A:1009656513307; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fei PW, 2002, CANCER RES, V62, P7316; Finch JS, 2002, J CANCER RES CLIN, V128, P3, DOI 10.1007/s00432-001-0298-x; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 2001, CANCER RES, V61, P7369; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fornace Albert J Jr, 2002, Mil Med, V167, P13; Gault N, 2002, RADIAT RES, V157, P249, DOI 10.1667/0033-7587(2002)157[0249:PSIITG]2.0.CO;2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; Goldwasser F, 1999, ANTICANCER RES, V19, P3167; Grana TM, 2002, CANCER RES, V62, P4142; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; Hallahan DE, 1998, CANCER RES, V58, P5484; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HALLAHAN DE, 1991, INT J RADIAT ONCOL, V21, P1677, DOI 10.1016/0360-3016(91)90352-5; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; Hallahan DE, 1996, INT J RADIAT ONCOL, V36, P355, DOI 10.1016/S0360-3016(96)00327-6; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HIGO H, 1989, TERATOGEN CARCIN MUT, V9, P191, DOI 10.1002/tcm.1770090402; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda N, 2002, J RADIAT RES, V43, P283, DOI 10.1269/jrr.43.283; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIHARA H, 1993, RADIAT RES, V133, P321, DOI 10.2307/3578216; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; Jackson SP, 1996, CANCER SURV, V28, P261; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin Y, 1996, CARCINOGENESIS, V17, P873, DOI 10.1093/carcin/17.4.873; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kawai H, 1999, CANCER RES, V59, P6038; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KICK G, 1995, CANCER RES, V55, P2373; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Mayo LD, 1997, CANCER RES, V57, P5013; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Meyer RG, 2002, EUR J BIOCHEM, V269, P337, DOI 10.1046/j.0014-2956.2001.02658.x; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; NEL AE, 1994, J IMMUNOL, V152, P4347; Nenoi M, 2001, CANCER RES, V61, P5885; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Novotny V, 1998, NUCLEIC ACIDS RES, V26, P5480, DOI 10.1093/nar/26.23.5480; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; PRASAD AV, 1995, RADIAT RES, V143, P263, DOI 10.2307/3579212; Prives C, 1999, J PATHOL, V187, P112; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JS, 2002, CANCER RES, V62, P2318; Russell JS, 2002, MOL BIOL CELL, V13, P3431, DOI 10.1091/mbc.E02-05-0252; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; RYSECK RP, 1991, ONCOGENE, V6, P533; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shao RP, 2001, CANCER RES, V61, P7413; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; Stavridi ES, 2001, CANCER RES, V61, P7030; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Takahashi T, 1997, HUM GENE THER, V8, P827, DOI 10.1089/hum.1997.8.7-827; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; Wang Y, 2000, GENE DEV, V14, P927; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Weichselbaum RR, 2002, LANCET ONCOL, V3, P665, DOI 10.1016/S1470-2045(02)00900-2; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLOSCHAK GE, 1990, RADIAT RES, V124, P183, DOI 10.2307/3577864; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhao HC, 2000, CANCER RES, V60, P6276; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou DH, 1999, RADIAT RES, V151, P703, DOI 10.2307/3580209; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047; Zhou H, 2000, J BIOL CHEM, V275, P22868, DOI 10.1074/jbc.M909273199	204	205	209	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5813	5827		10.1038/sj.onc.1206680	http://dx.doi.org/10.1038/sj.onc.1206680			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947388				2022-12-28	WOS:000185086100008
J	Powell, SN; Kachnic, LA				Powell, SN; Kachnic, LA			Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation	ONCOGENE			English	Article						breast cancer; BRCA genes; tumor suppressor genes; DNA repair; ionizing radiation; homologous recombination; DNA replication	FAMILIAL BREAST-CANCER; TRANSCRIPTION-COUPLED REPAIR; SUSCEPTIBILITY GENE BRCA1; POLYMERASE-II HOLOENZYME; OVARIAN-CANCER; DAMAGE RESPONSE; CHROMOSOMAL BREAKS; DIRECTED REPAIR; PROTEIN-KINASE; S-PHASE	Inheritance of one defective copy of either of the two breast cancer susceptibility genes, BRCA1 and BRCA2, predisposes individuals to breast and ovarian cancers. Current progress in determining the function of these genes suggests that they participate in a common pathway to facilitate orderly homologous recombination and thereby maintain genomic integrity. As a consequence of this defect in homologous recombination, tumors that arise in BRCA carriers are likely to be more sensitive to ionizing radiation. This review summarizes recent investigations about the nature of the defect in DNA repair, and highlights the unanswered questions about the tumor suppressor paradox of BRCA genes. The unsolved mystery is the other genetic changes that must occur to turn a BRCA-deficient cell from a nonviable cell into a tumor cell capable of endless growth.	Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Boston Med Ctr, Dept Radiat Oncol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Boston Medical Center	Powell, SN (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 302,100 Blossom St, Boston, MA 02114 USA.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2000, BIOESSAYS, V22, P728; Dibiase SJ, 2000, CANCER RES, V60, P1245; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Futamura M, 2000, CANCER RES, V60, P1531; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hakem R, 1998, J MAMMARY GLAND BIOL, V3, P431, DOI 10.1023/A:1018792200700; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Le Page F, 2000, CANCER RES, V60, P5548; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; Paakkonen K, 2001, GENET EPIDEMIOL, V20, P239, DOI 10.1002/1098-2272(200102)20:2<239::AID-GEPI6>3.0.CO;2-Y; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Powell SN, 2002, MOL CELL, V10, P1262, DOI 10.1016/S1097-2765(02)00789-X; Satagopan JM, 2001, CANCER EPIDEM BIOMAR, V10, P467; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu X, 2000, Science, V289, P11; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	76	250	259	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 1	2003	22	37					5784	5791		10.1038/sj.onc.1206678	http://dx.doi.org/10.1038/sj.onc.1206678			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947386				2022-12-28	WOS:000185086100006
J	Tomar, RS; Matta, H; Chaudhary, PM				Tomar, RS; Matta, H; Chaudhary, PM			Use of adeno-associated viral vector for delivery of small interfering RNA	ONCOGENE			English	Article						AAV; siRNA; RNAi; RNA interference	GENE-EXPRESSION; STABLE SUPPRESSION	Post-transcriptional gene silencing by small interfering RNAs (siRNAs) is rapidly becoming a powerful tool for genetic analysis of mammalian cells. Delivery of siRNA into mammalian cells is usually achieved via the transfection of double-stranded oligonucleotides or plasmids encoding RNA polymerase III promoter-driven small hairpin RNA. Recently, retroviral vectors have been used for siRNA delivery, which overcome the problem of poor transfection efficiency seen with the plasmid-based systems. However, retroviral vectors have several limitations, such as the need for active cell division for gene transduction, oncogenic potential, low titers and gene silencing. In this report, we have adapted a commercially available adenoassociated virus (AAV) vector for siRNA delivery into mammalian cells. We demonstrate the ability of this modified vector to deliver efficiently siRNA into HeLa S3 cells and downregulate p53 and caspase 8 expression. Our results suggest that AAV-based vectors are efficient vectors for the delivery of siRNA into mammalian cells. Based on the known ability of these vectors to infect both dividing and nondividing cells, their use as a therapeutic tool for the delivery of siRNA deserves further study.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	preet.chaudhary@utsouthwestern.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stilwell JL, 2003, BIOTECHNIQUES, V34, P148, DOI 10.2144/03341dd01; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599	17	144	192	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5712	5715		10.1038/sj.onc.1206733	http://dx.doi.org/10.1038/sj.onc.1206733			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944921				2022-12-28	WOS:000184865900022
J	Pignatelli, M; Cocca, C; Santos, A; Perez-Castillo, A				Pignatelli, M; Cocca, C; Santos, A; Perez-Castillo, A			Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line	ONCOGENE			English	Article						BRCA1; PPAR gamma; regulation	PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SUBCELLULAR-LOCALIZATION; PROMOTER REGION; SPORADIC BREAST; OVARIAN-CANCER; INHIBITION; COMPLEX; DIFFERENTIATION; TRANSCRIPTION	BRCA1 has been linked to the genetic susceptibility of a majority of familial breast and ovarian cancers. Several lines of evidence indicate that BRCA1 is a tumor suppressor and its expression is downregulated in sporadic breast and ovarian cancer cases. Therefore, the identification of genes involved in the regulation of BRCA1 gene expression might lead to new insights into the pathogenesis and treatment of these tumors. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily that has well-established roles in the regulation of adipocyte development and glucose homeostasis. More recently, it has been shown that ligands of PPARgamma have a potent antitumorigenic activity in breast cancer cells. In the present study we have found that two distinct ligands of PPARgamma; 15-deoxy-Delta-(12,14)-prostaglandin J(2). (15dPG-J(2)) and rosiglitazone, increase the levels of BRCA1 protein in human MCF-7 breast cancer cells. Immunofluorescence microscopy analysis showed that, after treatment with 15dPG-J(2), the BRCA1 protein is mainly localized in the nucleus. Functional analysis by transient transfection of different 5'-flanking region fragments, as well as gel mobility shift assays and mutagenic analysis, suggests that the effects of 15dPG-J(2) and rosiglitazone are mediated through a functional DR1 located between the nucleotides -241 and -229, which is a canonical PPARgamma type response element. Our data suggest that PPARgamma is a crucial gene regulating BRCA1 gene expression and might therefore be important for the BRCA1 regulatory pathway involved in the pathogenesis of sporadic breast and ovarian cancer.	Univ Autonoma Madrid, Inst Invest Biomed, CSIC, E-28049 Madrid, Spain; Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Med, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Perez-Castillo, A (corresponding author), Univ Buenos Aires, Dept Radioisotopos, Fac Farm & Bioquim, RA-1053 Buenos Aires, DF, Argentina.		Santos, Angel/K-3744-2014; Perez-Castillo, Ana/A-9505-2015; izadi, emad/M-1118-2019	Santos, Angel/0000-0002-7551-8483; Perez-Castillo, Ana/0000-0002-2632-5853				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808; Pignatelli M, 2001, J CELL SCI, V114, P4117; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	30	47	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5446	5450		10.1038/sj.onc.1206824	http://dx.doi.org/10.1038/sj.onc.1206824			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934104	Bronze			2022-12-28	WOS:000184735000009
J	Chakraborty, S; Sinha, KK; Senyuk, V; Nucifora, G				Chakraborty, S; Sinha, KK; Senyuk, V; Nucifora, G			SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo	ONCOGENE			English	Article						AML1; SUV39H1; methylation; repression; Runt domain; EMSA	TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CBF-BETA-SMMHC; BINDING; ACETYLATION; GENE; HETEROCHROMATIN; PROTEIN; DOMAIN	Acute myeloid leukemia 1 (AML1) belongs to a family of DNA-binding proteins highly conserved through evolution. AML1 regulates the expression of several hematopoietic genes and is essential for murine fetal liver hematopoiesis. We report here that the histone methyltransferase SUV39H1, a mammalian ortholog of the Drosophila melanogaster SU(VAR) 3-9, forms complex with AML1. SUV39H1 methylates lysine 9 of the histone protein H3 leading to the formation of the high-affinity binding site on chromatin for proteins of the heterochromatin protein 1 family (HP1). The interaction of AML1 with SUV39H1 requires the N-terminus of AML1 where the Runt domain is located. Binding of AML1 to SUV39H1 abrogates the transactivating and DNA-binding properties of AML1 and dissociates the net-like nuclear structure of AML1. It has been reported that AML1 is capable of interaction with histone acetyl transferases (CBP, p300, and MOZ) and with component of the histone deacetylase complex (Sin3), and that the interaction with these coregulators affects the strength of AML1 in promoter regulation. Our data suggest that other enzymes are also involved in gene regulation by AML1 activity by modulating the affinity of AML1 for DNA.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,M-C 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu		Sinha, Kislay/0000-0002-6978-4611	NATIONAL CANCER INSTITUTE [R01CA096448, R01CA072675] Funding Source: NIH RePORTER; NCI NIH HHS [CA72675, CA96448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barton K, 2000, BIOESSAYS, V22, P214, DOI 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; El-Osta A, 2001, BIOCHEM BIOPH RES CO, V289, P733, DOI 10.1006/bbrc.2001.6023; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Polanowska J, 2001, ONCOGENE, V20, P4115, DOI 10.1038/sj.onc.1204514; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI 10.1016/S0006-291X(02)03021-8; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	44	57	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5229	5237		10.1038/sj.onc.1206600	http://dx.doi.org/10.1038/sj.onc.1206600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917624				2022-12-28	WOS:000184734900002
J	Greenbaum, L; Katcoff, DJ; Dou, HY; Gozlan, Y; Malik, Z				Greenbaum, L; Katcoff, DJ; Dou, HY; Gozlan, Y; Malik, Z			A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells	ONCOGENE			English	Article						PBGD; nuclear-localization; RanBPM; porphyrin	PROTOPORPHYRIN-IX ACCUMULATION; INDUCED PORPHYRIN FLUORESCENCE; PHOTODYNAMIC THERAPY; CLINICAL-EXPERIENCE; TRANSFORMED-CELLS; BASIC PRINCIPLES; REGULATORY ROLE; IN-VITRO; CANCER; TRANSPORT	Porphobilinogen deaminase (PBGD) is a rate-limiting enzyme of the heme biosynthesis pathway, whose level is elevated in various human tumors. PBGD was observed in both nuclear and cytoplasmic fractions of C6 glioma cells by immunostaining. During mitosis, chromatids were intensely stained for PBGD in comparison to the interphase chromatin. Using the yeast two-hybrid system, we identified RanBPM, the nuclear Ran-binding protein, as an interacting partner of PBGD. During butyrate-induced differentiation of C6, both nuclear and cytoplasmic PBGD levels declined as did Ran protein and its nucleotide exchange factor RCC1. N,N'-hexamethylene bis-acetamide-dependent differentiation resulted in an increase of the cytoplasmic PBGD, whereas nuclear PBGD, Ran protein and RCC1 remained unchanged. mRNA levels of PBGD remained unchanged during stimulation with both butyrate and N,N'-hexamethylene bis-acetamide. The enzymatic activity of PBGD and protoporphyrin IX synthesis in C6 cells were dependent on the differentiation induction agent. We conclude that PBGD possibly has a nuclear role in addition to its cytosolic enzymatic activity required for heme synthesis, which is related to cell transformation and differentiation.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Malik, Z (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.							ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; ARCANGELI A, 1987, J CELL PHYSIOL, V132, P387, DOI 10.1002/jcp.1041320302; ARCANGELI A, 1993, P NATL ACAD SCI USA, V90, P5858, DOI 10.1073/pnas.90.12.5858; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P5542, DOI 10.1073/pnas.88.13.5542; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; CHUANMAO Z, 1999, J CELL SCI, V112, P2453; Dot J, 2002, NEUROREPORT, V13, P1083, DOI 10.1097/00001756-200206120-00022; Gibson SL, 1998, BRIT J CANCER, V77, P235, DOI 10.1038/bjc.1998.39; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Greenbaum L, 2002, BRIT J CANCER, V86, P1006, DOI 10.1038/sj.bjc.6600173; Hinnen P, 1998, BRIT J CANCER, V78, P679, DOI 10.1038/bjc.1998.559; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KENNEDY JC, 1990, J PHOTOCH PHOTOBIO B, V6, P143, DOI 10.1016/1011-1344(90)85083-9; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; LOUIE GV, 1992, NATURE, V359, P33, DOI 10.1038/359033a0; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; McLintock Lorna A, 2002, Hematology, V7, P189, DOI 10.1080/1024533021000013906; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Orenstein A, 2000, DERMATOL SURG, V26, P765, DOI 10.1046/j.1524-4725.2000.00056.x; ORENSTEIN A, 1995, CANCER LETT, V93, P227, DOI 10.1016/0304-3835(95)03814-D; Orenstein A, 1998, LASER MED SCI, V13, P112, DOI 10.1007/s101030050063; ORENSTEIN A, 1996, LASERS LIFE SCI, V7, P1; Ortel B, 1998, BRIT J CANCER, V77, P1744, DOI 10.1038/bjc.1998.292; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; Ponka P, 1997, BLOOD, V89, P1; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; Sazer S, 2000, J CELL SCI, V113, P1111; SCHOENFELD N, 1988, BIOCHEM MED METAB B, V40, P213, DOI 10.1016/0885-4505(88)90121-1; SEGOVIA J, 1994, J NEUROCHEM, V63, P1218; Stepp H, 1998, ENDOSCOPY, V30, P379, DOI 10.1055/s-2007-1001287; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Tunstall RG, 2002, BRIT J CANCER, V87, P246, DOI 10.1038/sj.bjc.6600460; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5221	5228		10.1038/sj.onc.1206723	http://dx.doi.org/10.1038/sj.onc.1206723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917623				2022-12-28	WOS:000184734900001
J	Le Bras, M; Bensaad, K; Soussi, T				Le Bras, M; Bensaad, K; Soussi, T			Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway	ONCOGENE			English	Article						p53 tumour suppressor gene; p53 gene family; apoptosis; phylogenetic studies; fugu rubripes; data mining	TUMOR-SUPPRESSOR; DNA-DAMAGE; CELL-CYCLE; MDM2; GENE; IDENTIFICATION; P73; EXPRESSION; HOMOLOG; PROTEIN	The p53 tumour suppressor gene belongs to a small family of related proteins that includes two other members, p63 and p73. Phylogenetic and functional studies suggest that p63 and p73 are ancient genes that have essential roles in normal development, whereas p53 seems to have evolved more recently to prevent cell transformation. In mammalian cells, a plethora of proteins have been found to specifically regulate p53 activity. The genome of the fish Fugu rubripes has been recently published. It is the second vertebrate genome for which the entire sequence is now available. Phylogenetic studies are essential in order to analyse and define signalling pathways important for cell cycle regulation. The presence or absence of a critical member in any pathway can shed light about the evolution of these pathways. The Fugu genome databank has been analysed for several members of the p53 network, including p53, p63 and p73. A good conservation of the network that regulates p53 stability and apoptosis has been found. We also discovered that some cofactors that cooperate with p53 for apoptosis are also well conserved and belong to multigene families not detected in the human genome.	Inst Curie, Lab Genotoxciol Tumeurs, F-75005 Paris, France; Univ Paris 06, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.	Thierry.Soussi@curie.fr		soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Cachot J, 1998, COMP BIOCHEM PHYS C, V120, P351, DOI 10.1016/S0742-8413(98)00039-5; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; DEFROMENTEL CC, 1992, GENE, V112, P241, DOI 10.1016/0378-1119(92)90383-Z; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gilley J, 2001, ONCOGENE, V20, P7447, DOI 10.1038/sj.onc.1204933; Goodman RH, 2000, GENE DEV, V14, P1553; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kostic C, 2000, ONCOGENE, V19, P3978, DOI 10.1038/sj.onc.1203747; Krause MK, 1997, GENE, V189, P101, DOI 10.1016/S0378-1119(96)00841-4; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; VERGAMASCHI D, 2003, NAT GENET, V33, P162; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu WP, 2001, ONCOGENE, V20, P5554, DOI 10.1038/sj.onc.1204679; Zhao RB, 2000, GENE DEV, V14, P981	61	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5082	5090		10.1038/sj.onc.1206424	http://dx.doi.org/10.1038/sj.onc.1206424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902991				2022-12-28	WOS:000184578900016
J	Mathur, M; Das, S; Samuels, HH				Mathur, M; Das, S; Samuels, HH			PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration	ONCOGENE			English	Article						PSF-TFE3; TFE3; PSF-A; renal cell carcinoma; endosomes; cell transformation	SPLICING FACTOR PSF; HISTONE DEACETYLASE COMPLEX; NUCLEAR HORMONE-RECEPTORS; LOOP-HELIX PROTEINS; GENE-EXPRESSION; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; RNA INTERFERENCE; FUSION PARTNER; BREAST-CANCER	Papillary renal cell carcinomas are associated with chromosomal translocations involving the helix-loop-helix leucine-zipper region of the TFE3 gene on the X chromosome. These translocations lead to the expression of TFE3 chimeras of PRCC, RCC17, NonO and PSF (PTB-associated splicing factor). In this study, we explored the role of PSF-TFE3 fusion protein in mediating cell transformation. Unlike wild-type TFE3 or PSF, which are nuclear proteins, PSF-TFE3 is not a nuclear protein and is targeted to the endosomal compartment. Although PSF-TFE3 has no effect on the nuclear localization of wild-type PSF, it sequesters wildtype TFE3 as well as p53 in the extranuclear compartment leading to functionally null p53 and TFE3 cells. In UOK-145 papillary renal carcinoma cells, which endogenously express PSF-TFE3, siRNA complementary to the PSF-TFE3 fusion junction leads to a reduction in PSF-TFE3 and redistribution of endogenous TFE3 and p53 from the cytoplasmic compartment to the nucleus. Our results indicate that PSF-TFE3 acts through a novel mechanism, and exports TFE3, p53 and possibly other factors from the nucleus to the cytoplasm for degradation leading to the transformed phenotype. Thus, PSF-TFE3 is a promising target for the treatment for a subset of renal cell carcinomas.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Samuels, HH (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, R37DK016636] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIAMS NIH HHS [AR02083] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Akhmedov AT, 2000, NUCLEIC ACIDS RES, V28, P3022, DOI 10.1093/nar/28.16.3022; Angelo LS, 2002, CANCER RES, V62, P932; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glukhova L, 1998, GENE CHROMOSOME CANC, V22, P171, DOI 10.1002/(SICI)1098-2264(199807)22:3<171::AID-GCC2>3.3.CO;2-K; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Heimann P, 2001, CANCER RES, V61, P4130; Hsueh C, 2002, MODERN PATHOL, V15, P606, DOI 10.1038/modpathol.3880573; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Li DS, 1999, MOL CELL BIOL, V19, P7191; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mahajan MA, 2002, MOL CELL BIOL, V22, P6883, DOI 10.1128/MCB.22.19.6883-6894.2002; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; ODA H, 1995, CANCER RES, V55, P658; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Qi JS, 1999, MOL CELL BIOL, V19, P864; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REITER RE, 1993, CANCER RES, V53, P3092; Rosenberger U, 2002, J CELL BIOCHEM, V86, P394, DOI 10.1002/jcb.10233; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1280, DOI 10.1210/en.143.4.1280; Simon JP, 2000, METHODS, V20, P437, DOI 10.1006/meth.2000.0957; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Tian G, 1999, MOL CELL BIOL, V19, P2946; Urban RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE794, DOI 10.1152/ajpendo.00174.2002; vandenBerg E, 1997, CANCER GENET CYTOGEN, V95, P103, DOI 10.1016/S0165-4608(96)00289-0; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	46	26	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5031	5044		10.1038/sj.onc.1206643	http://dx.doi.org/10.1038/sj.onc.1206643			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902986				2022-12-28	WOS:000184578900011
J	Salvatori, L; Pallante, P; Ravenna, L; Chinzari, P; Frati, L; Russo, MA; Petrangeli, E				Salvatori, L; Pallante, P; Ravenna, L; Chinzari, P; Frati, L; Russo, MA; Petrangeli, E			Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site	ONCOGENE			English	Article						oestrogens; SERMs; oestrogen receptor; Sp1; EGF receptor; gene expression	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; DEOXYRIBONUCLEIC-ACID; THYROID-HORMONE; ACTIVATION; PROMOTER; ANTIESTROGENS; IDENTIFICATION; TRANSCRIPTION; PHYTOESTROGENS	Through the analysis of the transient expression of the luciferase reporter gene in HeLa cells, an evaluation has been made of the transcriptional activity of oestrogens and of selective oestrogen receptor (ER) modulators (SERMs), mediated by the alpha and beta isoforms of the ER, on the epidermal growth factor receptor gene promoter. Oestrogen-activated ERbeta presents a lower transcriptional activity compared with ERalpha, probably due to structural differences in the AF-1 regions of the receptors. Also SERMs induce different responses depending on the receptor isoform bound. Indeed, the phyto-oestrogens, genistein and daidzein, act as weak agonists of the oestrogenic activity via ERalpha, but as full agonists when bound to ERbeta. The synthetic SERM 40H-tamoxifen, on the other hand, displays an opposite behaviour since it exerts a full agonist action through ERalpha, but acts as a full antagonist via ERbeta. As we have previously shown for ERalpha, an ERbeta/Sp1 functional synergism has also been highlighted, by means of gel mobility shift assays. Moreover, our results show that the sensitivity of target tissues to oestrogens and SERMs can be affected by coexpression of ERs, depending on the formation of appropriate levels of homo- and heterodimers, thus providing a useful approach to predict the effects of hormonal treatment.	CNR, Ist Biol & Patol Mol, I-00137 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, I-86077 Pozzilli, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; IRCCS Neuromed	Salvatori, L (corresponding author), CNR, Ist Biol & Patol Mol, Viale Marx N 43, I-00137 Rome, Italy.	luisa.salvatori@ibpm.cnr.it	Salvatori, Luisa/AAK-9365-2021; Frati, Luigi/ABI-7437-2020; Pallante, Pierlorenzo/AAX-8758-2020					BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; DEWET JR, 1987, CELL, V54, P313; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; Maniatis T., 1982, MOL CLONING; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Moore DD, 1995, GLOB MOB SURV; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NEAL DE, 1985, LANCET, V1, P366; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Salvatori L, 2000, ENDOCRINOLOGY, V141, P2266, DOI 10.1210/en.141.6.2266; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; van den Wijngaard A, 2000, MOL ENDOCRINOL, V14, P623, DOI 10.1210/me.14.5.623; Yarden RI, 1996, ENDOCRINOLOGY, V137, P2739, DOI 10.1210/en.137.7.2739; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936	36	40	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4875	4881		10.1038/sj.onc.1206784	http://dx.doi.org/10.1038/sj.onc.1206784			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894229				2022-12-28	WOS:000184344600011
J	Shin, HJ; Baek, KH; Jeon, AH; Kim, SJ; Jang, KL; Sung, YC; Kim, CM; Lee, CW				Shin, HJ; Baek, KH; Jeon, AH; Kim, SJ; Jang, KL; Sung, YC; Kim, CM; Lee, CW			Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation	ONCOGENE			English	Article							CYCLIN-A; KINETOCHORE LOCALIZATION; APOPTOSIS; KINASE; BUBR1; MITOSIS	Histone modification through acetylation and deacetylation is a key process in transcription, DNA replication, and chromosome segregation. During mitosis, histones are highly acetylated and chromatin is condensed. Here, we investigate the mechanistic involvement of histone deacetylase (HDAC) activity in the regulation of mitotic checkpoint activation. Inhibition of HDAC activity was found to cause the improper kinetochore localization of the mitotic checkpoint proteins, and to prolong mitotic arrest, and thus to lead to chromosomal instability due to aberrant exit from the mitotic cell cycle arrest. In addition, treatment with HDAC inhibitor attenuated the activations of p38 and ERK kinases, and increased the expression levels of cIAP-1, suggesting that the observed increased adaptation and chromosomal instability induced by inhibiting HDAC activity might be directly connected with the activations of cell survival and/or antiapoptotic signals. Moreover, the treatment of cells with mitotic defects with HDAC inhibitor increased their susceptibility to chromosomal instability. These results support the notion that HDAC activity plays an important role in the regulation of mitotic checkpoint activation, and thus the aberrant control of HDAC activity contributes to chromosomal instability.	Natl Canc Ctr, Res Inst, Goyang 411764, Gyeonggi Do, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang, South Korea; Pusan Natl Univ, Dept Microbiol, Pusan 609735, South Korea	National Cancer Center - Korea (NCC); Pohang University of Science & Technology (POSTECH); Pusan National University	Lee, CW (corresponding author), Natl Canc Ctr, Res Inst, Goyang 411764, Gyeonggi Do, South Korea.	cwlee@ncc.re.kr		Lee, Chang-Woo/0000-0002-0943-1646				Amato SF, 1998, CANCER RES, V58, P241; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Lieu CH, 1998, CELL GROWTH DIFFER, V9, P767; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1	26	73	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3853	3858		10.1038/sj.onc.1206502	http://dx.doi.org/10.1038/sj.onc.1206502			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813458				2022-12-28	WOS:000183612000004
J	Barnes, H; Ackermann, EJ; van der Geer, P				Barnes, H; Ackermann, EJ; van der Geer, P			v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1	ONCOGENE			English	Article						phosphorylation; kinase; PTB domain; signal transduction	DENSITY-LIPOPROTEIN RECEPTOR; GROWTH-FACTOR; C-SRC; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; FAMILY KINASES; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; PP60C-SRC	We recently observed that the LDL receptor-related protein 1 (LRP-1) is tyrosine phosphorylated in v-Src-transformed cells. Using a GST-fusion protein containing the cytoplasmic domain of LRP-1, we show that LRP-1 is a direct substrate for v-Src in vitro. To study LRP-1 phosphorylation in vivo, we constructed an LRP-1 mini-receptor composed of the beta chain linked at the aminoterminus to a Myc epitope (Myc-LRPbeta). When expressed together with v-Src, Myc-LRPbeta becomes phosphorylated on tyrosine. Of the four tyrosine residues present in the cytoplasmic domain of LRP-1, only Tyr 63 is phosphorylated by v-Src in vivo or in vitro. Using fibroblasts deficient in Src, Yes and Fyn, we were able to show that there are multiple kinases present in the cell that can phosphorylate LRP-1. Tyrosine-phosphorylated LRP-1 associates with Shc, a PTB and SH2 domain containing signaling protein that is involved in the activation of Ras. Binding of the purified Shc PTB domain to Tyr 63 containing peptides shows that the interaction between LRP-1 and She is direct. We found that DAB, a PTB domain containing signaling protein that is involved in signaling by LDL receptor-related proteins in the nervous system, did not bind to full-length LRP-1. Our observations suggest that LRP-1 may be involved in normal and malignant signal transduction through a direct interaction with Shc adaptor proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Neurogenet Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego	van der Geer, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	geer@ucsd.edu			NATIONAL CANCER INSTITUTE [R29CA078629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA78629] Funding Source: Medline; NIDDK NIH HHS [DK 07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Gellner K, 1999, GENOME RES, V9, P251; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lai KMV, 2000, GENE DEV, V14, P1132; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; NIMPF J, 1994, J BIOL CHEM, V269, P212; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3589	3597		10.1038/sj.onc.1206504	http://dx.doi.org/10.1038/sj.onc.1206504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789267				2022-12-28	WOS:000183399200009
J	Rosell, R; Scagliotti, G; Danenberg, KD; Lord, RVN; Bepler, G; Novello, S; Cooc, J; Crino, L; Sanchez, JJ; Taron, M; Boni, C; De Marinis, F; Tonato, M; Marangolo, M; Gozzelino, F; Di Costanzo, F; Rinaldi, M; Salonga, D; Stephens, C				Rosell, R; Scagliotti, G; Danenberg, KD; Lord, RVN; Bepler, G; Novello, S; Cooc, J; Crino, L; Sanchez, JJ; Taron, M; Boni, C; De Marinis, F; Tonato, M; Marangolo, M; Gozzelino, F; Di Costanzo, F; Rinaldi, M; Salonga, D; Stephens, C			Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer	ONCOGENE			English	Article						NSCLC; gene expression; beta-tubulin III; RRM1; stathmin	BETA-TUBULIN GENE; CHROMOSOME SEGMENT 11P15.5; PHASE-III; RIBONUCLEOTIDE REDUCTASE; CARCINOMA-CELLS; PLUS CISPLATIN; ONCOLOGY-GROUP; PACLITAXEL; EXPRESSION; GEMCITABINE	Non-small-cell lung cancer patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. The identification and implementation of predictive genetic markers of response-specific cytotoxic drugs is a priority of current research and future trials. In this study, we have used quantitative PCR to analyse expression of beta-tubulin III, stathmin, RRM1, COX-2 and GSTP1 in mRNA isolated from paraffin-embedded tumor biopsies of 75 nonsmall-cell lung cancer patients treated as part of a large randomized trial. In total, 22 patients were treated with gemcitabine/cisplatin, 25 with vinorelbine/cisplatin and 28 with paclitaxel/carboplatin. There were no differences in clinical characteristics and transcript levels in the pretreatment biopsies according to treatment arm. Patients with low beta-tubulin III levels had better response in the paclitaxel/carboplatin arm (P = 0.05), and those with low RRM1 levels showed a tendency to better response in the gemcitabine/cisplatin arm. Time to progression was influenced by beta-tubulin III (P = 0.03) and stathmin (P = 0.05) levels in the vinorelbine/cisplatin arm, and there was a tendency toward correlation between beta-tubulin III levels and time to progression in the paclitaxel/carboplatin arm. RRM1 levels influenced time to progression (P = 0.05) and even more so, survival (P = 0.0028) in the gemcitabine/cisplatin arm. The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival.	Hosp Germans Trias & Pujol, Dept Oncol, Med Oncol Serv, Barcelona 08916, Spain; Univ Turin, Dept Clin & Biol Sci, Turin, Italy; Response Genet, Los Angeles, CA 90033 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA; Bellaria Hosp, Dept Oncol, Bologna, Italy; Autonomous Univ Madrid, E-28049 Madrid, Spain; Santa Maria Nuova Hosp, Dept Oncol, Reggio Emilia, Italy; Forlanini Hosp, Dept Oncol, Rome, Italy; Policlin Hosp, Perugia, Italy; Santa Maria delle Croci Hosp, Ravenna, Italy; Infermi Hosp, Biella, Italy; S Maria Hosp Terni, Terni, Italy; Regina Elena Inst Canc Res, Dept Oncol, I-00161 Rome, Italy	Hospital Germans Trias i Pujol; University of Turin; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; AUSL di Bologna; Autonomous University of Madrid; IRCCS Arcispedale S. Maria Nuova; Azienda Ospedaliera San Camillo-Forlanini; Hospital of Rimini; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Rosell, R (corresponding author), Hosp Germans Trias & Pujol, Dept Oncol, Med Oncol Serv, Ctra Canyet S-N, Barcelona 08916, Spain.		novello, silvia/K-6335-2016; de Marinis, Filippo/AAR-2826-2020	Lord, Reginald V N/0000-0001-7475-492X				Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; Bepler G, 1999, GENOMICS, V55, P164, DOI 10.1006/geno.1998.5659; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bol DK, 2002, CANCER RES, V62, P2516; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Cardenal F, 1999, J CLIN ONCOL, V17, P12, DOI 10.1200/JCO.1999.17.1.12; Crino L, 1999, J CLIN ONCOL, V17, P3522, DOI 10.1200/JCO.1999.17.11.3522; Crino L, 1997, J CLIN ONCOL, V15, P297, DOI 10.1200/JCO.1997.15.1.297; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goan YG, 1999, CANCER RES, V59, P4204; GOTO S, 1995, CANCER RES, V55, P4297; HARBOTTLE A, 2002, CANC HDB, P1347; He LF, 2001, MOL CANCER THER, V1, P3; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Iancu C, 2000, CANCER RES, V60, P3537; Iwata T, 2002, MOL BRAIN RES, V102, P105, DOI 10.1016/S0169-328X(02)00187-0; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Kelley MJ, 2001, J NATL CANCER I, V93, P1886, DOI 10.1093/jnci/93.24.1886; LECHEVALIER T, 1994, J CLIN ONCOL, V12, P360, DOI 10.1200/JCO.1994.12.2.360; Li M, 2001, INT J CANCER, V93, P218, DOI 10.1002/ijc.1322; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; MONZO M, 2002, J NATL CANCER I, V94, P61; Nicoletti MI, 2001, CLIN CANCER RES, V7, P2912; Nishio K, 2001, CANCER, V91, P1494, DOI 10.1002/1097-0142(20010415)91:8<1494::AID-CNCR1157>3.0.CO;2-7; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Ramsey SD, 2002, J NATL CANCER I, V94, P291, DOI 10.1093/jnci/94.4.291; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Sale S, 2002, MOL CANCER THER, V1, P215; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; SCAGLIOTTI GV, 2001, P AN M AM SOC CLIN, V20, pA308; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P11, DOI 10.1016/S0169-5002(01)00291-4; Wozniak AJ, 1998, J CLIN ONCOL, V16, P2459, DOI 10.1200/JCO.1998.16.7.2459; Zhao BH, 2001, ONCOGENE, V20, P8154, DOI 10.1038/sj.onc.1205027	42	169	194	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3548	3553		10.1038/sj.onc.1206419	http://dx.doi.org/10.1038/sj.onc.1206419			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789263				2022-12-28	WOS:000183399200005
J	del Rincon, SV; Rousseau, C; Samanta, R; Miller, WH				del Rincon, SV; Rousseau, C; Samanta, R; Miller, WH			Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway	ONCOGENE			English	Article						retinoic acid; IRS-1; IGF; AKT; breast cancer	BREAST-CANCER CELLS; INSULIN-RECEPTOR SUBSTRATE-1; FACTOR-I RECEPTOR; FACTOR-BINDING PROTEIN-3; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC IMPLICATIONS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; CYCLIN D1	In the MCF-7 breast cancer cell line, insulin-like growth factors (IGFs) are known to elicit antiproliferative actions via the insulin receptor substrate-1 (IRS-1)/PI 3-kinase/AKT pathway. All-trans retinoic acid (RA) is a potent inhibitor of MCF-7 cell proliferation, but the mechanism by which growth regulation is achieved remains unclear. We investigated the effects of RA on the regulation of the IGF-IR and its key signaling elements: IRS-1, IRS-2, and SHC. Treatment of MCF-7 cells with RA caused a significant reduction in IRS-1 protein and tyrosine phosphorylation levels at a concentration and time consistent with RA-mediated growth inhibition. IRS-1 regulation is selective, as RA did not influence IRS-2 or SHC levels. Downstream signaling events were also selectively reduced, as RA abrogated IGF-I-stimulated AKT activation but did not alter erk1/2 activation. To confirm the importance of IRS-1 regulation by RA, we examined the response to RA in MCF-7 cells overexpressing IGF-IR and IRS-1. RA resistance was observed in MCF-7 cells overexpressing IRS-I but not IGF-IR. This suggests that RA-mediated growth inhibition requires the selective downregulation of IRS-1 and AKT. Therapeutic agents targeting the IRS-1/PI 3-kinase/AKT pathway may enhance the cytostatic effects of RA in breast cancer, since overexpression of IRS-1 and AKT have been reported in primary breast tumors.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Miller, WH (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.							Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allen LF, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34049; Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; ANZANO MA, 1994, CANCER RES, V54, P4614; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Chang Q, 2002, CANCER RES, V62, P6035; CULLEN KJ, 1990, CANCER RES, V50, P48; DE LUCA LM, 1991, FASEB J, V5, P2924; DeVente JE, 1996, J BIOL CHEM, V271, P32276, DOI 10.1074/jbc.271.50.32276; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dragnev K H, 2000, Oncologist, V5, P361, DOI 10.1634/theoncologist.5-5-361; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Guruswamy S, 2001, JNCI-J NATL CANCER I, V93, P516, DOI 10.1093/jnci/93.7.516; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; JONES PF, 1991, NATURE, V376, P599; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; LI XS, 1994, EXP CELL RES, V211, P68, DOI 10.1006/excr.1994.1060; Li YW, 2002, CLIN CANCER RES, V8, P2369; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Moon RC, 1997, BREAST CANCER RES TR, V46, P181, DOI 10.1023/A:1005995925246; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Rosenauer A, 1998, CANCER RES, V58, P5110; Rozen F, 1999, INT J ONCOL, V15, P589; RUBIN M, 1994, CANCER RES, V54, P6549; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Salerno M, 1999, INT J CANCER, V81, P299; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; SPORN MB, 1994, RETINOIDS BIOL CHEM, P573; Straker SM, 2001, REV ENGL STUD, V52, P1; Sueoka N, 1999, CANCER RES, V59, P3838; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Taouis M, 1998, MOL CELL ENDOCRINOL, V137, P177, DOI 10.1016/S0303-7207(97)00245-1; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Torrisi R, 2001, DRUGS, V61, P909, DOI 10.2165/00003495-200161070-00002; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Wang Q, 2000, CANCER RES, V60, P2040; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Xie SP, 1997, J ENDOCRINOL, V154, P495, DOI 10.1677/joe.0.1540495; Xie SP, 1999, EUR J CANCER, V35, P1717, DOI 10.1016/S0959-8049(99)00200-2; Yakes FM, 2002, CANCER RES, V62, P4132; Yoshida H, 1996, CANCER RES, V56, P2945; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	74	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3353	3360		10.1038/sj.onc.1206485	http://dx.doi.org/10.1038/sj.onc.1206485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776186	Green Submitted			2022-12-28	WOS:000183128500001
J	Reliene, R; Schiestl, RH				Reliene, R; Schiestl, RH			Mouse models for induced genetic instability at endogenous loci	ONCOGENE			English	Review						genetic instability; homologous recombination; DNA deletions; in vivo; mouse; mutagenicity test	EYED UNSTABLE MUTATION; RETINAL-PIGMENT EPITHELIUM; PRADER-WILLI SYNDROME; INDUCED INTRACHROMOSOMAL RECOMBINATION; CREST-DERIVED MELANOCYTES; LACZ TRANSGENIC MICE; MAMMALIAN SPOT-TEST; SEVERE HEMOPHILIA-A; ATM-DEFICIENT MICE; DNA DOUBLE-STRAND	Exposure to environmental factors and genetic predisposition of an individual may lead individually or in combination to various genetic diseases including cancer. These diseases may be a consequence of genetic instability resulting in large-scale genomic rearrangements, such as DNA deletions, duplications, and translocations. This review focuses on mouse assays detecting genetic instability at endogenous loci. The frequency of DNA deletions by homologous recombination at the pink-eyed unstable ( pun) locus is elevated in mice with mutations in ATM, Trp53, Gadd45, and WRN genes and after exposure to carcinogens. Other quantitative in vivo assays detecting loss of heterozygosity events, such as the mammalian spot assay, Dlb-1 mouse and Aprt mouse assays, are also reviewed. These in vivo test systems may predict hazardous effects of an environmental agent and/or genetic predisposition to cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Environm Hlth, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Schiestl, RH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, 650 Charles E Young Dr S, Los Angeles, CA 90024 USA.		Reliene, Ramune/AAK-3492-2021		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009519, K02ES000299] Funding Source: NIH RePORTER; NIEHS NIH HHS [KO2 ES00299, R01 ES09519] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; Aubrecht J, 1999, CARCINOGENESIS, V20, P2229, DOI 10.1093/carcin/20.12.2229; AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; BARTSCH H, 1980, IARC SCI PUBL, V27, P179; Bishop AJR, 2000, CANCER RES, V60, P395; Bishop AJR, 2001, CARCINOGENESIS, V22, P641, DOI 10.1093/carcin/22.4.641; Bishop AJR, 2000, MUTAT RES-FUND MOL M, V457, P31, DOI 10.1016/S0027-5107(00)00118-4; BISHOP AJR, 2003, IN PRESS; BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; Brennan RJ, 1997, MUTAT RES-FUND MOL M, V381, P251, DOI 10.1016/S0027-5107(97)00201-7; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V397, P271, DOI 10.1016/S0027-5107(97)00225-X; BRENNAN RJ, 1994, MUTAT RES, V308, P159, DOI 10.1016/0027-5107(94)90151-1; Brennan RJ, 1997, MUTAGENESIS, V12, P215, DOI 10.1093/mutage/12.4.215; Brennan RJ, 1999, MUTAT RES-FUND MOL M, V430, P37, DOI 10.1016/S0027-5107(99)00118-9; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; Brooks RA, 1999, CARCINOGENESIS, V20, P109, DOI 10.1093/carcin/20.1.109; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; CALABRETTA B, 1982, NATURE, V296, P219, DOI 10.1038/296219a0; Carls N, 1999, CARCINOGENESIS, V20, P2351, DOI 10.1093/carcin/20.12.2351; CARLS N, 1994, MUTAT RES, V320, P293, DOI 10.1016/0165-1218(94)90082-5; CASSIDY SB, 1989, AM J HUM GENET, V44, P806; CATTANACH BM, 1971, CHEMICAL MUTAGENS PR, V2, P535; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; DAVIDSON GE, 1977, ARCH TOXICOL, V38, P99, DOI 10.1007/BF00293667; DEFLORA S, 1984, MUTAT RES, V133, P161, DOI 10.1016/0165-1110(84)90016-2; DEKOK AJ, 1983, MUTAT RES, V120, P81, DOI 10.1016/0165-7992(83)90147-1; DELACHAPELLE A, 1981, HUM GENET, V57, P253, DOI 10.1007/BF00278938; DESERRES FJ, 1981, EVALUATION SHORT TER; Douglas GR, 1999, ENVIRON MOL MUTAGEN, V34, P190, DOI 10.1002/(SICI)1098-2280(1999)34:2/3<190::AID-EM18>3.0.CO;2-#; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; FAHRIG R, 1977, ARCH TOXICOL, V38, P87, DOI 10.1007/BF00293666; FAHRIG R, 1975, MOL GEN GENET, V138, P309, DOI 10.1007/BF00264800; FAHRIG R, 1993, ENVIRON HEALTH PERSP, V101, P257, DOI 10.2307/3431735; FAN YJ, 1995, INT J RADIAT BIOL, V68, P177, DOI 10.1080/09553009514551081; Galli A, 1998, GENETICS, V149, P1235; GALLI A, 1995, MOL GEN GENET, V248, P301, DOI 10.1007/BF02191597; Galli A, 1996, MUTAT RES-GENET TOX, V370, P209, DOI 10.1016/S0165-1218(96)00078-X; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; GRASSI G, 1994, CIRCULATION, V90, P248, DOI 10.1161/01.CIR.90.1.248; IVERSON F, 1991, IARC SCI PUBL, V108, P5; Jalili T, 1998, CANCER RES, V58, P2633; Ji YG, 2000, GENOME RES, V10, P597, DOI 10.1101/gr.10.5.597; Kamsler A, 2001, CANCER RES, V61, P1849; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KONG Y, 1992, CELL MOL BIOL, V38, P263; KURIHARA S, 1995, CARDIOLOGY, V86, P102, DOI 10.1159/000176848; Lebel M, 2002, CARCINOGENESIS, V23, P213, DOI 10.1093/carcin/23.1.213; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LEVIN DE, 1982, P NATL ACAD SCI-BIOL, V79, P7445, DOI 10.1073/pnas.79.23.7445; Liang L, 2000, ENVIRON MOL MUTAGEN, V35, P150, DOI 10.1002/(SICI)1098-2280(2000)35:2<150::AID-EM10>3.3.CO;2-S; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; LYON MF, 1992, P NATL ACAD SCI USA, V89, P6968, DOI 10.1073/pnas.89.15.6968; Mazzarella R, 1998, GENOME RES, V8, P1007, DOI 10.1101/gr.8.10.1007; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P5135, DOI 10.1073/pnas.72.12.5135; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MORRISON V, 1994, MUTAGENESIS, V9, P367, DOI 10.1093/mutage/9.4.367; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; Naylor JA, 1996, BLOOD, V87, P3255, DOI 10.1182/blood.V87.8.3255.bloodjournal8783255; Nelis E, 1996, EUR J HUM GENET, V4, P25; Niwa O, 1996, J RADIAT RES, V37, P217, DOI 10.1269/jrr.37.217; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Noda Y, 2002, MUTAT RES-GEN TOX EN, V513, P205, DOI 10.1016/S1383-5718(01)00313-8; OLEARY LM, 1991, AM J IND MED, V20, P17, DOI 10.1002/ajim.4700200103; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; Peter Y, 2001, EMBO J, V20, P1538, DOI 10.1093/emboj/20.7.1538; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1987, J THEOR BIOL, V127, P381, DOI 10.1016/S0022-5193(87)80136-4; Provost GS, 1996, ENVIRON MOL MUTAGEN, V28, P342, DOI 10.1002/(SICI)1098-2280(1996)28:4<342::AID-EM7>3.0.CO;2-D; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; PURCHASE IFH, 1978, BRIT J CANCER, V37, P873, DOI 10.1038/bjc.1978.132; Redhead NJ, 1996, HUM GENE THER, V7, P1491, DOI 10.1089/hum.1996.7.13-1491; RELIENE R, IN PRESS GENETIC REC; ROSEMBLAT S, 1994, P NATL ACAD SCI USA, V91, P12071, DOI 10.1073/pnas.91.25.12071; RUSSELL LB, 1977, ARCH TOXICOL, V38, P75; RUSSELL LB, 1957, GENETICS, V42, P161; RUSSELL LB, 1981, MUTAT RES, V86, P355, DOI 10.1016/0165-1110(81)90011-7; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SANKARANARAYANAN K, 1991, MUTAT RES, V258, P3, DOI 10.1016/0165-1110(91)90027-S; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SCHIESTL RH, 1989, MUTAT RES, V224, P427, DOI 10.1016/0165-1218(89)90067-0; SCHIESTL RH, 1988, GENETICS, V119, P237; Schiestl RH, 1997, P NATL ACAD SCI USA, V94, P4576, DOI 10.1073/pnas.94.9.4576; SCHIESTL RH, 1989, NATURE, V337, P285, DOI 10.1038/337285a0; SCHIESTL RH, 1989, CARCINOGENESIS, V10, P1445, DOI 10.1093/carcin/10.8.1445; SCHIESTL RH, 1994, SCIENCE, V266, P1573, DOI 10.1126/science.7985029; Schiestl RH, 1997, CANCER RES, V57, P4378; SCHLAGER G, 1967, GENETICS, V57, P319; SCHMID CW, 1989, CHROMOSOMES EUKARYOT, V1, P3; SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B; SEARLE AG, 1977, ARCH TOXICOL, V38, P105, DOI 10.1007/BF00293668; SHAVERWALKER PM, 1995, P NATL ACAD SCI USA, V92, P11470, DOI 10.1073/pnas.92.25.11470; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; STRAKOWSKI SM, 1987, LANCET, V2, P1458; STYLES JA, 1985, MUTAT RES, V154, P183, DOI 10.1016/0165-1110(85)90017-X; Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681; TAO KS, 1993, ENVIRON MOL MUTAGEN, V22, P293, DOI 10.1002/em.2850220419; Turker MS, 1999, CANCER RES, V59, P4781; van Delft JHM, 1998, MUTAT RES-GEN TOX EN, V415, P85, DOI 10.1016/S1383-5718(98)00063-1; Van Sloun PPH, 1998, NUCLEIC ACIDS RES, V26, P4888, DOI 10.1093/nar/26.21.4888; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; Wijnhoven SWP, 2003, CARCINOGENESIS, V24, P139, DOI 10.1093/carcin/24.1.139; WINTON DJ, 1990, CANCER RES, V50, P7992; WINTON DJ, 1989, MUTAGENESIS, V4, P404, DOI 10.1093/mutage/4.5.404; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WISE CA, 1993, AM J HUM GENET, V53, P853; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	123	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7000	7010		10.1038/sj.onc.1206904	http://dx.doi.org/10.1038/sj.onc.1206904			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557804				2022-12-28	WOS:000185903900004
J	Berretta, M; Cinelli, R; Martellotta, F; Spina, M; Vaccher, E; Tirelli, U				Berretta, M; Cinelli, R; Martellotta, F; Spina, M; Vaccher, E; Tirelli, U			Therapeutic approaches to AIDS-related malignancies	ONCOGENE			English	Review						AIDS; HIV infection; malignancies; treatment; HAART	HUMAN-IMMUNODEFICIENCY-VIRUS; NON-HODGKINS-LYMPHOMA; SQUAMOUS INTRAEPITHELIAL LESIONS; COLONY-STIMULATING FACTOR; STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-PAPILLOMAVIRUS INFECTION; ITALIAN COOPERATIVE GROUP; PRIMARY EFFUSION LYMPHOMA	The introduction of highly active antiretroviral therapy ( HAART) has changed dramatically the landscape of HIV disease. Deaths from AIDS-related diseases have been reduced by 75% since protease inhibitor therapy and combination antiretroviral therapy came into use in late 1995. While KS is declining, the situation for non-Hodgkin's lymphoma is more complex with a reduced incidence of primary central nervous system lymphoma, but a relatively stability in the number of patients developing systemic NHL. AIDS related NHL appears not to be markedly decreased by the introduction of HAART and it is the greatest therapeutic challenge in the area of AIDS oncology. The emphasis has now shifted to cure while maintaining vigilance regarding the unique vulnerability of HIV-infected hosts. Furthermore, also for the prolongation of the survival expectancy of these patients, other non AIDS-defining tumors, such as Hodgkin's disease, anal and head and neck, lung and testicular cancer, and melanoma have been recently reported with increased frequency in patients with HIV infection.	Natl Canc Inst, Div Med Oncol A, Ctr Riferimento Oncol, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Tirelli, U (corresponding author), Natl Canc Inst, Div Med Oncol A, Ctr Riferimento Oncol, Via Pedemontana Occle 12, I-33081 Aviano, PN, Italy.	utirelli@cro.it	Berretta, Massimiliano/S-5853-2019; Spina, Michele/ABE-6014-2020; Martellotta, Ferdinando/ABE-2332-2020	Berretta, Massimiliano/0000-0002-9837-9148; Spina, Michele/0000-0001-6576-8182; Martellotta, Ferdinando/0000-0002-5646-0036				Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; ANDRIEU JM, 1993, ANN ONCOL, V4, P635, DOI 10.1093/oxfordjournals.annonc.a058617; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARRON BA, 1971, CANCER, V27, P978, DOI 10.1002/1097-0142(197104)27:4<978::AID-CNCR2820270433>3.0.CO;2-2; BERNARDI D, 1995, J CLIN ONCOL, V13, P2705, DOI 10.1200/JCO.1995.13.11.2705; Biggar RJ, 1996, HEMATOL ONCOL CLIN N, V10, P997, DOI 10.1016/S0889-8588(05)70380-4; BOIOCCHI M, 1993, AM J PATHOL, V142, P33; CARBONE A, 1995, AM J CLIN PATHOL, V103, P561; Carbone A, 1997, BRIT J HAEMATOL, V97, P515, DOI 10.1046/j.1365-2141.1997.00064.x; CARTER PS, 1995, BRIT J SURG, V82, P473, DOI 10.1002/bjs.1800820414; CDC, 1993, MMWR-MORBID MORTAL W, V41, P1; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P83; *CDC, 1986, MMWR-MORBID MORTAL W, V35, P334; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CONANT M, 1999, 6 C RETR OPP INF CHI; Dal Maso L, 2003, LANCET ONCOL, V4, P110, DOI 10.1016/S1470-2045(03)00983-5; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DEASI J, 1999, CANCER, V86, P1840; Delecluse HJ, 1997, BLOOD, V89, P1413, DOI 10.1182/blood.V89.4.1413; EMILIE D, 1994, BLOOD, V84, P2472; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ERRANTE D, 1994, CANCER-AM CANCER SOC, V73, P437, DOI 10.1002/1097-0142(19940115)73:2<437::AID-CNCR2820730232>3.0.CO;2-2; Errante D, 1999, ANN ONCOL, V10, P189, DOI 10.1023/A:1008338915945; FICARRA G, 1998, ORAL SURG ORAL MED O, V66, P550; Franceschi S, 1999, INT J CANCER, V83, P481, DOI 10.1002/(SICI)1097-0215(19991112)83:4<481::AID-IJC8>3.3.CO;2-X; Franceschi S, 1998, BRIT J CANCER, V78, P966, DOI 10.1038/bjc.1998.610; FRAZER IH, 1986, LANCET, V2, P657; FRUCHTER RG, 1994, AM J OBSTET GYNECOL, V171, P531, DOI 10.1016/0002-9378(94)90294-1; Gabarre J, 1996, BONE MARROW TRANSPL, V18, P1195; Gabarre J, 2000, LANCET, V355, P1071, DOI 10.1016/S0140-6736(00)02041-9; Gaidano G, 1998, AM J PATHOL, V152, P623; Gates AE, 2002, ONCOLOGY-NY, V16, P441; GILL PS, 1989, AM J MED, V87, P57, DOI 10.1016/S0002-9343(89)80483-8; GILL PS, 1992, AIDS, V6, P1477, DOI 10.1097/00002030-199212000-00009; Gill PS, 1996, J CLIN ONCOL, V14, P2353, DOI 10.1200/JCO.1996.14.8.2353; GISSELBRECHT C, 1993, AM J MED, V95, P188, DOI 10.1016/0002-9343(93)90259-R; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Goldie SJ, 1999, JAMA-J AM MED ASSOC, V281, P1822, DOI 10.1001/jama.281.19.1822; HARRIS NL, 1994, BLOOD, V84, P1361; Hoffman R, 1999, INT J RADIAT ONCOL, V44, P127, DOI 10.1016/S0360-3016(98)00528-8; Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630; International Agency for Research and Cancer (IARC), 1996, HUM IMM VIR HUM T CE, V67; KAPLAN L, 1986, CANCER TREAT REP, V70, P1121; Kaplan LD, 1997, NEW ENGL J MED, V336, P1641, DOI 10.1056/NEJM199706053362304; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KAPLAN LD, 1991, J CLIN ONCOL, V9, P929, DOI 10.1200/JCO.1991.9.6.929; KAPLAN LD, 1998, P AN M AM SOC CLIN, V17, P185; KLEIN RS, 1994, J INFECT DIS, V170, P1404, DOI 10.1093/infdis/170.6.1404; Koblin BA, 1996, AM J EPIDEMIOL, V144, P916, DOI 10.1093/oxfordjournals.aje.a008861; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; Krishnan A, 2001, BLOOD, V98, P3857, DOI 10.1182/blood.V98.13.3857; Krown SE, 1997, J CLIN ONCOL, V15, P3085, DOI 10.1200/JCO.1997.15.9.3085; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Levine AM, 2000, J ACQ IMMUN DEF SYND, V24, P444; LEVINE AM, 1991, HEMATOL ONCOL CLIN N, V5, P331, DOI 10.1016/S0889-8588(18)30445-3; Levine AM, 2001, EUR J CANCER, V37, P1288, DOI 10.1016/S0959-8049(01)00109-5; LEVINE AM, 1993, JNCI-J NATL CANCER I, V85, P1382, DOI 10.1093/jnci/85.17.1382; Little RF, 2000, CURR OPIN ONCOL, V12, P438, DOI 10.1097/00001622-200009000-00009; LOBO DV, 1992, ARCH DERMATOL, V128, P623, DOI 10.1001/archderm.128.5.623; LYTER DW, 1998, INT ACQUIRED IMMUNE, V17, P13; MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X; MAIMAN M, 1991, OBSTET GYNECOL, V78, P84; MANDELBLATT JS, 1992, AIDS, V6, P173, DOI 10.1097/00002030-199202000-00005; MAZZA P, 1992, EUR J HAEMATOL, V49, P1; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Melbye M, 1996, INT J CANCER, V68, P559, DOI 10.1002/(SICI)1097-0215(19961127)68:5<559::AID-IJC1>3.0.CO;2-Y; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mitsuyasu Ronald T., 1993, Current Opinion in Oncology, V5, P835, DOI 10.1097/00001622-199309000-00011; Molina A, 2000, CANCER-AM CANCER SOC, V89, P680, DOI 10.1002/1097-0142(20000801)89:3<680::AID-CNCR25>3.3.CO;2-N; Nasti G, 2003, J CLIN ONCOL, V21, P2876, DOI 10.1200/JCO.2003.10.162; Northfelt DW, 1996, HEMATOL ONCOL CLIN N, V10, P1177, DOI 10.1016/S0889-8588(05)70392-0; Oksenhendler E, 1998, AM J HEMATOL, V57, P266, DOI 10.1002/(SICI)1096-8652(199803)57:3<266::AID-AJH25>3.0.CO;2-7; Palefsky J M, 1998, J Natl Cancer Inst Monogr, P15; Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004; PALEFSKY JM, 1995, CANCER EPIDEM BIOMAR, V4, P415; PALEFSKY JM, 1991, CANCER RES, V51, P1014; Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194; Palefsky JM, 2000, SEMIN ONCOL, V27, P471; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; Peddada AV, 1997, INT J RADIAT ONCOL, V37, P1101, DOI 10.1016/S0360-3016(96)00596-2; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; RAPHAEL M, 1991, ARCH PATHOL LAB MED, V115, P15; Ratner L, 2001, J CLIN ONCOL, V19, P2171, DOI 10.1200/JCO.2001.19.8.2171; Re A, 2002, BLOOD, V100, p649A; REE HJ, 1991, CANCER-AM CANCER SOC, V67, P1614, DOI 10.1002/1097-0142(19910315)67:6<1614::AID-CNCR2820670624>3.0.CO;2-#; REMICK SC, 1993, J CLIN ONCOL, V11, P1691, DOI 10.1200/JCO.1993.11.9.1691; RUBIO R, 1994, CANCER-AM CANCER SOC, V73, P2400, DOI 10.1002/1097-0142(19940501)73:9<2400::AID-CNCR2820730925>3.0.CO;2-C; Said JW, 1997, SEMIN DIAGN PATHOL, V14, P48; SAVILLE MW, 1995, LANCET, V346, P26, DOI 10.1016/S0140-6736(95)92654-2; SERRAINO D, 1992, ANN ONCOL, V3, P595, DOI 10.1093/oxfordjournals.annonc.a058283; SPARANO J, 1999, 3 ANN AIDS MAL C BET; SPARANO J, 1998, 2 NAT AIDS MAL C BET; Sparano JA, 1996, J CLIN ONCOL, V14, P3026, DOI 10.1200/JCO.1996.14.11.3026; Spina M, 2003, AIDS, V17, P137, DOI 10.1097/00002030-200301030-00024; Spina M, 2002, BLOOD, V100, P1984, DOI 10.1182/blood-2002-03-0989; Spina M, 1999, ANN ONCOL, V10, P87; Spina M, 1999, ANN ONCOL, V10, P1271, DOI 10.1023/A:1008390028330; Spina Michele, 1999, Current Opinion in Oncology, V11, P522, DOI 10.1097/00001622-199911000-00015; STELZER KJ, 1993, INT J RADIAT ONCOL, V27, P1057, DOI 10.1016/0360-3016(93)90523-X; Straus David J., 1997, Current Opinion in Oncology, V9, P450, DOI 10.1097/00001622-199709050-00009; Straus DJ, 1998, J CLIN ONCOL, V16, P3601, DOI 10.1200/JCO.1998.16.11.3601; Tan Benjamin, 1997, Current Opinion in Oncology, V9, P455, DOI 10.1097/00001622-199709050-00010; Tavio M, 1996, CANCER-AM CANCER SOC, V77, P2117; Tirelli U, 1992, Ann Oncol, V3 Suppl 4, P69; Tirelli U, 1996, CANCER-AM CANCER SOC, V77, P2127, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2127::AID-CNCR25>3.0.CO;2-W; TIRELLI U, 1995, J CLIN ONCOL, V13, P373, DOI 10.1200/JCO.1995.13.2.373; Tirelli U, 2001, CANC TREAT, V104, P247; TIRELLI U, 1995, J CLIN ONCOL, V13, P1758, DOI 10.1200/JCO.1995.13.7.1758; Tirelli U, 2002, CRIT REV ONCOL HEMAT, V41, P299, DOI 10.1016/S1040-8428(01)00165-2; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Tirelli U, 2000, AIDS, V14, P1675, DOI 10.1097/00002030-200008180-00001; TIRELLI U, 1999, 3 ANN AIDS MAL C BET; Toschi E, 2002, ANTI-CANCER DRUG, V13, P977, DOI 10.1097/00001813-200211000-00001; Tulpule A, 1999, BLOOD REV, V13, P147, DOI 10.1054/blre.1999.0112; Turoglu HT, 1998, CLIN NUCL MED, V23, P446, DOI 10.1097/00003072-199807000-00010; Vaccher E, 1996, J CLIN ONCOL, V14, P2217, DOI 10.1200/JCO.1996.14.8.2217; Vaccher E, 2001, CANCER-AM CANCER SOC, V91, P155, DOI 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B; van Besien K, 1998, BLOOD, V91, P1178, DOI 10.1182/blood.V91.4.1178; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; VICIANA P, 1998, INT C AIDS, V12, P1150; WALSH C, 1993, J ACQ IMMUN DEF SYND, V6, P265; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591	124	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6646	6659		10.1038/sj.onc.1206771	http://dx.doi.org/10.1038/sj.onc.1206771			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528290				2022-12-28	WOS:000185700700022
J	Fukushima, T; Suzuki, S; Mashiko, M; Ohtake, T; Endo, Y; Takebayashi, Y; Sekikawa, K; Hagiwara, K; Takenoshita, S				Fukushima, T; Suzuki, S; Mashiko, M; Ohtake, T; Endo, Y; Takebayashi, Y; Sekikawa, K; Hagiwara, K; Takenoshita, S			BRAF mutations in papillary carcinomas of the thyroid	ONCOGENE			English	Article						BRAF; RAS; papillary carcinoma of the thyroid; follicular carcinoma of the thyroid; MAP kinase pathway	MOLECULAR-GENETICS; ACTIVATION; ONCOGENES	BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene were detected with varying frequencies in several cancers, notably more than 60% in melanoma. We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway. BRAF mutations were detected exclusively in papillary carcinomas ( 40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas. NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. No mutations were found in KRAS or HRAS. Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.	Fukushima Med Univ, Dept Surg, Fukushima 9601295, Japan; Saitama Med Sch, Dept Resp Med, Moroyama, Saitama 3500495, Japan	Fukushima Medical University; Saitama Medical University	Fukushima, T (corresponding author), Fukushima Med Univ, Dept Surg, 1 Hikarigaoka, Fukushima 9601295, Japan.							Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Lazzereschi D, 1997, J EXP CLIN CANC RES, V16, P325; Learoyd DL, 2000, WORLD J SURG, V24, P923, DOI 10.1007/s002680010164; Ledent C, 1991, Thyroidology, V3, P97; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; Naoki K, 2002, CANCER RES, V62, P7001; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sugg SL, 1999, SURGERY, V125, P46, DOI 10.1067/msy.2099.92118; Yuen ST, 2002, CANCER RES, V62, P6451	12	237	249	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6455	6457		10.1038/sj.onc.1206739	http://dx.doi.org/10.1038/sj.onc.1206739			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508525				2022-12-28	WOS:000185535300015
J	Stewart, RA; Li, DM; Huang, H; Xu, T				Stewart, RA; Li, DM; Huang, H; Xu, T			A genetic screen for modifiers of the lats tumor suppressor gene identifies C-terminal Src kinase as a regulator of cell proliferation in Drosophila	ONCOGENE			English	Article						CSK; LATS; SRC; tissue size; cell proliferation; genetic modifier	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; BREAST-CANCER CELLS; FAMILY KINASES; NEGATIVE REGULATION; EYE DEVELOPMENT; HUMAN HOMOLOG; MICE LACKING; CSK; GROWTH	Disrupting mechanisms that control cell proliferation, cell size and apoptosis can cause changes in animal and tissue size and contribute to diseases such as cancer. The LATS family of serine/threonine kinases control tissue size by regulating cell proliferation and function as tumor suppressor genes in both Drosophila and mammals. In order to understand the role of lats in size regulation, we performed a genetic modifier screen in Drosophila to identify components of the lats signaling pathway. Mutations in the Drosophila homolog of C-terminal Src kinase (dcsk) were identified as dominant modifiers of both lats gain-of-function and loss-of-function phenotypes. Homozygous dcsk mutants have enlarged tissue phenotypes similar to lats and FACS and immunohistochemistry analysis of these tissues revealed that dcsk also regulates cell proliferation during development. Animals having mutations in both dcsk and lats display cell overproliferation phenotypes more severe than either mutant alone, demonstrating these genes function together in vivo to regulate cell numbers. Furthermore, homozygous dcsk phenotypes can be partially suppressed by overexpression of lats, indicating that lats is a downstream mediator of dcsk function in vivo. Finally, we show that dCSK phosphorylates LATS in vitro at a conserved C-terminal tyrosine residue, which is critical for normal LATS function in vivo. Taken together, these results demonstrate a role for dCSK in regulating cell numbers during development by inhibiting cell proliferation and suggest that lats is one of the mediators of the dcsk phenotype.	Howard Hughes Med Inst, Dept Genet, New Haven, CT 06536 USA; Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA; Yale Univ, Dept Genet, Sch Med, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Howard Hughes Med Inst, Dept Genet, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.		Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOUGERET C, 1993, ONCOGENE, V8, P1241; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cooper JA, 1996, CELL GROWTH DIFFER, V7, P1435; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAY BA, 1994, DEVELOPMENT, V120, P2121; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; Huang H, 1999, DEVELOPMENT, V126, P5365; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Li G, 2002, DEVELOPMENT, V129, P4159; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Lu XY, 1999, DEV BIOL, V208, P233, DOI 10.1006/dbio.1999.9196; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; McCartney BM, 2000, DEVELOPMENT, V127, P1315; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oldham S, 2000, PHILOS T R SOC B, V355, P945, DOI 10.1098/rstb.2000.0630; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Spradling AC, 1999, GENETICS, V153, P135; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stamenovic D, 1999, J THEOR BIOL, V201, P63, DOI 10.1006/jtbi.1999.1014; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Treisman JE, 1998, CURR TOP DEV BIOL, V39, P119, DOI 10.1016/S0070-2153(08)60454-8; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Wolff Tanya, 1993, P1277; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065	68	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6436	6444		10.1038/sj.onc.1206820	http://dx.doi.org/10.1038/sj.onc.1206820			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508523				2022-12-28	WOS:000185535300013
J	Miller, CT; Chen, G; Gharib, TG; Wang, H; Thomas, DG; Misek, DE; Giordano, TJ; Yee, J; Orringer, MB; Hanash, SM; Beer, DG				Miller, CT; Chen, G; Gharib, TG; Wang, H; Thomas, DG; Misek, DE; Giordano, TJ; Yee, J; Orringer, MB; Hanash, SM; Beer, DG			Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas	ONCOGENE			English	Article						CRK; lung adenocarcinomas; differentiation; quantitative 2-D protein	ADAPTER PROTEIN CRK; CELL-MIGRATION; PROTEOMIC ANALYSIS; SIGNALING PATHWAY; KINASE ACTIVATION; GROWTH-FACTOR; SURVIVAL; CANCER; PHOSPHORYLATION; MEMBRANE	The C-CRK gene, cellular homolog of the avian v-crk oncogene, encodes two alternatively spliced adaptor signaling proteins, CRKI (28kDa) and CRKII (40kDa). Both CRKI and CRKII have been shown to activate kinase signaling and anchorage-independent growth in vitro and CRKI transformed cells readily form tumors in nude mice. Affymetrix oligonucleotide arrays were used to analyse 86 lung adenocarcinomas and 10 uninvolved lung tissues. C-CRK mRNA expression was increased in more advanced (stage III versus stage I), larger (T2-4 versus T-1), and poorly differentiated tumors and in tumors from patients demonstrating poor survival (P = 0.00034). An overlapping series of 93 lung adenocarcinomas (64 stage I and 29 stage III) and 10 uninvolved lung specimens were measured for quantitative differences in CRKI and CRKII protein levels using 2-D PAGE. CRK protein spots were identified using mass spectrometry and 2-D Western blotting. A significant increase in levels of the CRKI oncoprotein and the phosphorylated isoform of CRKII was observed in tumors (P < 0.05). No difference in protein level was evident between stages. Concordant with mRNA expression, CRKI and CRKII were increased in poorly differentiated tumors (P < 0.05). CRK immunohistochemical analysis of tumor tissue arrays using the same tumor series also demonstrated increased abundance of nuclear and cytoplasmic CRK in more proliferative tumors (P < 0.05). This study provides the first quantitative analysis of discrete CRKI and CRKII protein isoforms in human lung tumors and provides evidence that the C-CRK proto-oncogene may foment a more aggressive phenotype in lung cancers.	Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.		Chen, Guoan/J-9140-2018	Chen, Guoan/0000-0001-5608-6761; Giordano, Thomas/0000-0003-0641-8873	NATIONAL CANCER INSTITUTE [R01CA085953] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA-85953] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Chen GA, 2002, CLIN CANCER RES, V8, P2298; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Colby TV, 1995, AFIP ATLAS TUMOR PAT, V13; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fry WA, 1999, CANCER, V86, P1867, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9; Gharib TG, 2002, NEOPLASIA, V4, P440, DOI 10.1038/sj.neo.7900257; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hughes SJ, 1997, CANCER RES, V57, P5571; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KUICK RD, 1987, ELECTROPHORESIS, V8, P199, DOI 10.1002/elps.1150080405; KUICK RD, 1991, ELECTROPHORESIS, V12, P736, DOI 10.1002/elps.1150121007; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller JR, 1997, DEV BIOL, V192, P310, DOI 10.1006/dbio.1997.8739; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; WILLIAMS DE, 1981, J THORAC CARDIOV SUR, V82, P70; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	37	65	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7950	7957		10.1038/sj.onc.1206529	http://dx.doi.org/10.1038/sj.onc.1206529			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970743				2022-12-28	WOS:000185388200010
J	Haffty, BG; Glazer, PM				Haffty, BG; Glazer, PM			Molecular markers in clinical radiation oncology	ONCOGENE			English	Review						molecular markers; radiation sensitivity; radiation oncology	SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; CYCLIN D1 OVEREXPRESSION; DNA MISMATCH REPAIR; RECURRENCE FOLLOWING LUMPECTOMY; BCL-2 PROTEIN EXPRESSION; PREDICT TUMOR RESPONSE; EARLY LARYNGEAL-CANCER; WILD-TYPE P53	Radiation therapy plays a critical role in the management of a majority of patients diagnosed with cancer. Identification of factors that help predict which patients are at risk for relapse within the irradiated field remains an active area of investigation. Although conventional clinical and pathologic factors have been helpful in identifying risk and guiding clinical decision-making for both local and systemic management, there is clearly a need to identify additional prognostic markers, which can aid in refining our treatment strategies and improving outcomes. A substantial amount of research efforts have been devoted to identifying molecular markers for prognostic and therapeutic strategies. The recent emergence of a powerful armamentarium of molecular tools has resulted in rapid expansion of our fund of knowledge and understanding of the molecular biology underlying tumor behavior and response. While a majority of these efforts have been focused on risk factors for metastatic disease and survival, there is a rapidly growing body of literature focused on molecular factors associated with radiation resistance and locoregional failure. In this review, we summarize recent advances and the available literature evaluating molecular markers as they relate to radiation sensitivity of solid tumors. Literature regarding the potential application of expression of genes related to apoptosis, angiogenesis, cell cycle, DNA repair and growth factors will be reviewed. Some of the basic biology and laboratory evidence demonstrating how the marker relates to radiation response and available correlative clinical studies employing these markers as prognostic tools are presented. The majority of molecular markers that have potential clinical significance with respect to radiation sensitivity and local control will be highlighted.	Dept Therapeut Radiol, New Haven, CT 06520 USA		Haffty, BG (corresponding author), Dept Therapeut Radiol, HRT 133,333 Cedar St, New Haven, CT 06520 USA.	bruce.haffty@yale.edu	Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560				Aebersold DM, 2000, INT J RADIAT ONCOL, V48, P17, DOI 10.1016/S0360-3016(00)00573-3; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Agrup M, 2000, BREAST CANCER RES TR, V63, P23, DOI 10.1023/A:1006498721508; Akervall JA, 1997, CANCER, V79, P380; Alcalde RE, 1997, ONCOLOGY, V54, P324; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Alsner J, 2001, RADIOTHER ONCOL, V59, P179, DOI 10.1016/S0167-8140(01)00301-2; Artese L, 2001, ANTICANCER RES, V21, P689; Barker FG, 2001, INT J RADIAT ONCOL, V51, P410, DOI 10.1016/S0360-3016(01)01609-1; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartelink H, 2001, INT J RADIAT ONCOL, V49, P311, DOI 10.1016/S0360-3016(00)01499-1; Bartelink H, 2000, RADIOTHER ONCOL, V55, P217, DOI 10.1016/S0167-8140(99)00055-9; Beatrice F, 1998, ANTICANCER RES, V18, P4737; BEGG AC, 1995, INT J RADIAT ONCOL, V32, P1539, DOI 10.1016/0360-3016(95)00261-V; Begg AC, 1999, RADIOTHER ONCOL, V50, P13, DOI 10.1016/S0167-8140(98)00147-9; Bellacosa A, 1996, CLIN CANCER RES, V2, P175; Bjork-Eriksson T, 2000, INT J RADIAT ONCOL, V46, P13, DOI 10.1016/S0360-3016(99)00373-9; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Bova RJ, 1999, CLIN CANCER RES, V5, P2810; Bradford CR, 1999, HEMATOL ONCOL CLIN N, V13, P777, DOI 10.1016/S0889-8588(05)70092-7; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; Caminero MJ, 1996, ARCH OTOLARYNGOL, V122, P769; Carr JA, 2000, ARCH SURG-CHICAGO, V135, P1469, DOI 10.1001/archsurg.135.12.1469; Chakravarti A, 2002, CANCER RES, V62, P200; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Ciancio G, 1997, TRANSPLANT P, V29, P2878, DOI 10.1016/S0041-1345(97)00716-1; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Condon LT, 2002, INT J CANCER, V100, P472, DOI 10.1002/ijc.10503; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Corvo R, 2000, INT J RADIAT ONCOL, V47, P57, DOI 10.1016/S0360-3016(00)00416-8; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Danic D, 1999, J LARYNGOL OTOL, V113, P538; Davis TW, 1998, CANCER RES, V58, P767; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Dijkema IM, 2000, ORAL ONCOL, V36, P54, DOI 10.1016/S1368-8375(99)00051-2; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; Edstrom S, 2001, LARYNGOSCOPE, V111, P124, DOI 10.1097/00005537-200101000-00022; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elkhuizen PHM, 1999, INT J RADIAT ONCOL, V45, P73, DOI 10.1016/S0360-3016(99)00158-3; Elsaleh H, 2000, RADIOTHER ONCOL, V56, P239, DOI 10.1016/S0167-8140(00)00184-5; Esteva FJ, 2002, SEMIN RADIAT ONCOL, V12, P319, DOI 10.1053/srao.2002.35251; Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973; Ferrandina G, 2002, BRIT J CANCER, V87, P1145, DOI 10.1038/sj.bjc.6600578; Fink D, 1996, CANCER RES, V56, P4881; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Formenti SC, 2002, INT J RADIAT ONCOL, V52, P397, DOI 10.1016/S0360-3016(01)02655-4; Fritzell JA, 1997, CANCER RES, V57, P5143; Gaffney DK, 2001, AM J CLIN ONCOL-CANC, V24, P443, DOI 10.1097/00000421-200110000-00006; Gaffney DK, 2001, INT J RADIAT ONCOL, V49, P1213, DOI 10.1016/S0360-3016(00)01583-2; Gallo O, 1999, INT J CANCER, V84, P573, DOI 10.1002/(SICI)1097-0215(19991222)84:6<573::AID-IJC6>3.0.CO;2-R; Gasparini G, 1995, CLIN CANCER RES, V1, P1375; Gasparini G, 1998, INT J ONCOL, V12, P1117; Geng L, 2001, CANCER RES, V61, P2413; Gong JG, 1999, NATURE, V399, P806; Gorski DH, 1999, CANCER RES, V59, P3374; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1998, INT J ONCOL, V13, P375; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Haffty BG, 1996, INT J RADIAT ONCOL, V35, P751, DOI 10.1016/0360-3016(96)00150-2; Haffty BG, 2002, SEMIN RADIAT ONCOL, V12, P329, DOI 10.1053/srao.2002.35252; Harari PM, 2002, SEMIN RADIAT ONCOL, V12, P21, DOI 10.1053/srao.2002.34865; Harari PM, 2001, SEMIN RADIAT ONCOL, V11, P281, DOI 10.1053/srao.2001.26027; Harari PM, 2001, INT J RADIAT ONCOL, V49, P427, DOI 10.1016/S0360-3016(00)01488-7; Harima Y, 2000, CANCER, V88, P132, DOI 10.1002/(SICI)1097-0142(20000101)88:1<132::AID-CNCR18>3.3.CO;2-8; Hassan AB, 2002, ANN ONCOL, V13, P349, DOI 10.1093/annonc/mdf096; Homer JJ, 2001, CLIN OTOLARYNGOL, V26, P498, DOI 10.1046/j.1365-2273.2001.00512.x; Huang S M, 2001, Cancer Chemother Biol Response Modif, V19, P339; Huang SM, 2002, CANCER RES, V62, P4300; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Izzo JG, 1998, ONCOGENE, V17, P2313, DOI 10.1038/sj.onc.1202153; Jackel MC, 2000, LARYNGOSCOPE, V110, P1339; JARES P, 1994, CANCER RES, V54, P4813; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; Kasid U, 2001, EXP BIOL MED, V226, P624, DOI 10.1177/153537020222600706; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kim YB, 2002, CANCER, V95, P531, DOI 10.1002/cncr.10684; Kishi K, 2000, CANCER RES, V60, P1326; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; Koelbl O, 2001, INT J RADIAT ONCOL, V49, P147, DOI 10.1016/S0360-3016(00)01356-0; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Linderholm B, 1999, BRIT J CANCER, V81, P727, DOI 10.1038/sj.bjc.6690755; Linderholm B, 2000, J CLIN ONCOL, V18, P1423, DOI 10.1200/JCO.2000.18.7.1423; Linderholm B, 2000, INT J CANCER, V89, P51, DOI 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.3.CO;2-#; Liu LL, 1996, CANCER RES, V56, P5375; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Martin JMC, 1999, CANCER RES, V59, P1134; McKenna WG, 2002, SEMIN RADIAT ONCOL, V12, P27, DOI 10.1053/srao.2002.34866; Michalides RJAM, 1997, ARCH OTOLARYNGOL, V123, P497; Milas L, 2002, INT J RADIAT ONCOL, V52, P514, DOI 10.1016/S0360-3016(01)02693-1; Milas L, 2001, SEMIN RADIAT ONCOL, V11, P290, DOI 10.1053/srao.2001.26018; Mineta H, 1998, BRIT J CANCER, V78, P1084, DOI 10.1038/bjc.1998.632; MIYAGUCHI M, 1993, EUR ARCH OTO-RHINO-L, V249, P478; Miyaguchi M, 1998, ACTA OTO-LARYNGOL, V118, P428; Moonen L, 2001, INT J RADIAT ONCOL, V49, P1305, DOI 10.1016/S0360-3016(00)01503-0; Mukherjee G, 2001, INT J GYNECOL CANCER, V11, P187, DOI 10.1046/j.1525-1438.2001.01014.x; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; Narayana A, 2000, INT J RADIAT ONCOL, V46, P21, DOI 10.1016/S0360-3016(99)00348-X; Nicholson RI, 2002, ANN NY ACAD SCI, V963, P104, DOI 10.1111/j.1749-6632.2002.tb04101.x; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Nogueira CP, 1998, LARYNGOSCOPE, V108, P345, DOI 10.1097/00005537-199803000-00007; Obata A, 2000, INT J CANCER, V89, P187, DOI 10.1002/(SICI)1097-0215(20000320)89:2<187::AID-IJC14>3.0.CO;2-V; Overgaard J, 2000, ACTA ONCOL, V39, P327, DOI 10.1080/028418600750013096; Pai HH, 1998, INT J RADIAT ONCOL, V41, P37, DOI 10.1016/S0360-3016(98)00025-X; PENTOPOULOS AJ, 2002, P ANN ASCO M, V19; Peretz S, 2002, RADIAT RES, V158, P174, DOI 10.1667/0033-7587(2002)158[0174:IREPAM]2.0.CO;2; Piccart M, 2001, ONCOLOGY-BASEL, V61, P73, DOI 10.1159/000055405; Pierce L, 2002, SEMIN RADIAT ONCOL, V12, P352, DOI 10.1053/srao.2002.35254; PIERCE LJ, 1994, INT J RADIAT ONCOL, V28, P395, DOI 10.1016/0360-3016(94)90063-9; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Pignataro L, 1998, J CLIN ONCOL, V16, P3069, DOI 10.1200/JCO.1998.16.9.3069; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; Pollack A, 1997, CLIN CANCER RES, V3, P1823; Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1200/JCO.2002.09.094; Pyo H, 2001, CLIN CANCER RES, V7, P2998; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; RaybaudDiogene H, 1997, J CLIN ONCOL, V15, P1030, DOI 10.1200/JCO.1997.15.3.1030; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reitmair AH, 1997, CANCER RES, V57, P3765; Reynolds TY, 1996, CANCER RES, V56, P5754; Ringberg A, 2001, EUR J CANCER, V37, P1514, DOI 10.1016/S0959-8049(01)00165-4; Ritter MA, 2002, INT J RADIAT ONCOL, V53, P574, DOI 10.1016/S0360-3016(02)02781-5; Rockwell S, 2001, Novartis Found Symp, V240, P133; Rockwell S, 2001, NOVART FDN SYMP, V240, P142; Saunders ME, 1999, CLIN CANCER RES, V5, P2455; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shintani S, 2000, CANCER LETT, V154, P71, DOI 10.1016/S0304-3835(00)00376-1; Shintani S, 2001, INT J CANCER, V96, P159, DOI 10.1002/ijc.1014.abs; Silvestri R, 1996, J NATL CANCER I, V88, P1499, DOI 10.1093/jnci/88.20.1499; Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639; Silvestrini R, 1997, INT J CANCER, V74, P122, DOI 10.1002/(SICI)1097-0215(19970220)74:1<122::AID-IJC20>3.0.CO;2-G; Silvestrini R, 1993, Recent Results Cancer Res, V127, P71; SILVESTRINI R, 1993, INT J CANCER, V54, P231, DOI 10.1002/ijc.2910540212; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Silvestrini R, 2000, ANN ONCOL, V11, P259, DOI 10.1023/A:1008323722156; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sittel C, 2000, LARYNGOSCOPE, V110, P1012, DOI 10.1097/00005537-200006000-00024; Slamon Dennis, 1999, Cancer Control, V6, P7; Smith BD, 1999, RADIAT ONCOL INVEST, V7, P125, DOI 10.1002/(SICI)1520-6823(1999)7:3<125::AID-ROI1>3.0.CO;2-W; Smith BD, 2000, J CLIN ONCOL, V18, P2046, DOI 10.1200/JCO.2000.18.10.2046; Stackhouse MA, 1998, INT J RADIAT ONCOL, V42, P817, DOI 10.1016/S0360-3016(98)00330-7; Streffer JR, 2002, J NEURO-ONCOL, V56, P43, DOI 10.1023/A:1014448721327; Taylor D, 1999, HUM PATHOL, V30, P1221, DOI 10.1016/S0046-8177(99)90041-2; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Tsai ST, 1998, ANTICANCER RES, V18, P2849; Turner BC, 1997, CANCER RES, V57, P3079; Turner BC, 2000, INT J RADIAT ONCOL, V47, P1169, DOI 10.1016/S0360-3016(00)00525-3; Turner BC, 2000, CANCER-AM CANCER SOC, V88, P1091, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1091::AID-CNCR21>3.0.CO;2-Y; Unal OF, 1999, J LARYNGOL OTOL, V113, P446, DOI 10.1017/S0022215100144184; Uno M, 2001, INT J CANCER, V94, P474, DOI 10.1002/ijc.1493; Vaisman A, 1998, CANCER RES, V58, P3579; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; WALTER MA, 1991, ANN OTO RHINOL LARYN, V100, P523, DOI 10.1177/000348949110000701; Wang SC, 2001, SEMIN ONCOL, V28, P115, DOI 10.1016/S0093-7754(01)90289-1; Wang YL, 2001, CANCER RES, V61, P8211; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; Wen QH, 1996, LARYNGOSCOPE, V106, P884, DOI 10.1097/00005537-199607000-00019; Wilson GD, 1998, ANTICANCER RES, V18, P4801; WILSON GD, 1995, BRIT J CANCER, V71, P1248, DOI 10.1038/bjc.1995.241; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; Wood NB, 1997, LARYNGOSCOPE, V107, P827, DOI 10.1097/00005537-199706000-00019; Wouters BG, 1999, ONCOGENE, V18, P6540, DOI 10.1038/sj.onc.1203053; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Xia F, 2002, SEMIN RADIAT ONCOL, V12, P296, DOI 10.1053/srao.2002.35250; Yoo SS, 2000, INT J CANCER, V90, P22, DOI 10.1002/(SICI)1097-0215(20000220)90:1<22::AID-IJC3>3.0.CO;2-T; ZATTERSTROM UK, 1991, HEAD NECK-J SCI SPEC, V13, P477, DOI 10.1002/hed.2880130603; Zellars RC, 2000, J CLIN ONCOL, V18, P1906, DOI 10.1200/JCO.2000.18.9.1906; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 1999, CANCER RES, V59, P3021	183	44	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5915	5925		10.1038/sj.onc.1206704	http://dx.doi.org/10.1038/sj.onc.1206704			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947398				2022-12-28	WOS:000185086100018
J	Moghal, N; Sternberg, PW				Moghal, N; Sternberg, PW			Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans	ONCOGENE			English	Article						LET-23; EGF; ErbB; activation; inhibition; structure	EPIDERMAL-GROWTH-FACTOR; C-ELEGANS; VULVAR DEVELOPMENT; CRYSTAL-STRUCTURE; MAP KINASE; SWISS-MODEL; CELL FATES; GENE; PROTEIN; ENCODES	Negative regulation of ErbB/EGFR signalling pathways is important for normal development and the prevention of cancer. In a genetic screen to uncover mechanisms that negatively regulate ErbB signalling in Caenorhabditis elegans, we isolated a second-site mutation (sy621) that promotes the activity of a gain-of-function allele (sa62gf) of the let-23 (EGF) receptor tyrosine kinase. We show that activation by the sa62 mutation (C359Y) likely results from a break in the conserved disulphide-bonded eighth module at the junction of CR1 and L2. The sy621 mutation causes a G270E change in the third disulphide-bonded module of CR1, and causes no phenotype on its own, but cooperates with the sa62 mutation to. promote receptor activity. Although both sa62 single- and double-mutant receptors can function in the absence of ligand, they can be further activated by ligand. Our results support the current model for ligand-induced dimerization based on the recent crystal structures of HER3 and the EGFR, and provide more evidence for the generation of distinctly activated ErbB family members through mutation.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Moghal, N (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	nmoghal@caltech.edu						Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; BRENNER S, 1974, GENETICS, V77, P71; Chang C, 2000, EMBO J, V19, P3283, DOI 10.1093/emboj/19.13.3283; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; FERGUSON EL, 1985, GENETICS, V110, P17; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Greenwald Iva, 1997, Cold Spring Harbor Monograph Series, V33, P519; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Katz WS, 1996, MOL CELL BIOL, V16, P529; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yarden Y, 2001, EUR J CANCER, V37, pS3; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	54	7	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5471	5480		10.1038/sj.onc.1206648	http://dx.doi.org/10.1038/sj.onc.1206648			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934107				2022-12-28	WOS:000184735000012
J	Han, BG; Dong, ZZ; Liu, Y; Chen, Q; Hashimoto, K; Zhang, JT				Han, BG; Dong, ZZ; Liu, Y; Chen, Q; Hashimoto, K; Zhang, JT			Regulation of constitutive expression of mouse PTEN by the 5 '-untranslated region	ONCOGENE			English	Article						PTEN; IRES; promoter; 5 '-UTR	INTERNAL RIBOSOME ENTRY; LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR GENE; LONG TERMINAL REPEAT; MESSENGER-RNA; GROWTH-FACTOR; TRANSLATION INITIATION; TRANSCRIPTIONAL ACTIVATION; PROMOTER METHYLATION; NEGATIVE REGULATION	PTEN tumor suppressor serves as a major negative regulator of survival signaling mediated by PI3 kinase/ AKT/protein kinase B pathway, and is inactivated in various human tumors. Elucidation of mechanisms responsible for PTEN expression is important for providing insight into strategies to control the loss of PTEN expression in human cancers. Although recent studies suggested that p53 and Egr-1 can modulate induced PTEN expression, the mechanism responsible for ubiquitous constitutive expression of PTEN remains elusive. PTEN mRNA contains a highly conserved and GC-rich 5-untranslated region (5'-UTR). Recently, it has been shown that the long 5'-UTR sequences of several growth-regulated mRNAs contain promoters that can generate mRNAs with shorter 5'-UTRs. In this paper, we tested whether the 5'-UTR sequence of mouse PTEN contains a promoter that is responsible for constitutive expression of PTEN. We found that the long 5'-UTR sequence of mouse PTEN severely inhibits translation of PTEN and a heterologous gene firefly luciferase. Deletion of the most 5'-UTR sequence would enhance translation efficiency 100-fold. We also showed that the 5'-UTR sequence of mouse PTEN does not have an internal ribosome entry site (IRES) that can mediate cap-independent initiation of translation. Instead, we found that the 5'-UTR sequence of mouse PTEN contains a strong promoter that drives the production of a transcript with shorter 5'-UTRs, which can be translated with higher efficiency. This promoter was mapped to the region between -551 and -220 bases upstream of the translation start codon. Cotransfection analysis using Drosophila SL2 cells showed that Sp1 is one of the major transcription factors that can constitutively activate this promoter. Two endogenous PTEN transcripts with 5'-UTRs of 193 and 109 bases were found in DU145 and H226 cell lines. Based on these observations, we conclude that the PTEN expression may be regulated at both transcriptional and translational levels, and that the 5'-UTR sequence of PTEN contains a promoter that is responsible for constitutive PTEN expression.	Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Walther Canc Inst, Indianapolis, IN 46202 USA; Natl Inst Infect Dis, Tokyo, Japan	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; National Institute of Infectious Diseases (NIID)	Zhang, JT (corresponding author), Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015		NCI NIH HHS [CA64539] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Li G, 2002, DEVELOPMENT, V129, P4159; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mutter GL, 2001, AM J PATHOL, V158, P1895, DOI 10.1016/S0002-9440(10)64656-1; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Ross AH, 2001, NEUROSCIENTIST, V7, P278, DOI 10.1177/107385840100700404; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Suzuki Y, 2000, GENOMICS, V64, P286, DOI 10.1006/geno.2000.6076; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	49	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5325	5337		10.1038/sj.onc.1206783	http://dx.doi.org/10.1038/sj.onc.1206783			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917634				2022-12-28	WOS:000184734900012
J	Montigiani, S; Muller, R; Kontermann, RE				Montigiani, S; Muller, R; Kontermann, RE			Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F	ONCOGENE			English	Article						E2F; phage display; inhibitor of DNA binding; peptidomimetics; tat; cell cycle; apoptosis	RETINOBLASTOMA GENE-PRODUCT; MULTIPLE ANTIGEN PEPTIDE; TRANSCRIPTION FACTOR; FUNCTIONALLY ANTAGONIZE; CYCLE REGULATION; MAMMALIAN-CELLS; FAMILY MEMBERS; PROTEIN; REPRESSOR; DP-1	We have isolated several peptides from random peptide phage display libraries that specifically recognize the cell cycle regulatory transcription factor E2F and inhibit DNA binding of E2F/DP heterodimers (E2F-1, E2F-2, E2F-3, E2F-4 or EM-5, and DP-1). The inhibitory efficiency could be strongly enhanced by generating branched tetravalent molecules. To analyse the biological consequences of peptide-mediated E2F inhibition, we fused two of these branched molecules to a cell-penetrating peptide derived from the HTV-Tat protein. Incubation of human tumor cells with these branched Tat-containing peptides led to an inhibition of cell proliferation and induction of apoptosis. These results provide new insights into the function of E2F and further validate E2F as a potential therapeutic target in proliferative diseases.	Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Kontermann, Roland E./F-9263-2014; Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				AHLBORG N, 1995, J IMMUNOL METHODS, V179, P269, DOI 10.1016/0022-1759(94)00328-T; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FURUKAWA Y, 2002, J BIOL CHEM, V30, P30; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Loughran O, 2002, CURR BIOL, V12, pR377, DOI 10.1016/S0960-9822(02)00876-X; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Santoni-Rugiu E, 2002, ONCOGENE, V21, P6498, DOI 10.1038/sj.onc.1205828; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zwicker J, 1995, Prog Cell Cycle Res, V1, P91; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4943	4952		10.1038/sj.onc.1206495	http://dx.doi.org/10.1038/sj.onc.1206495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902977				2022-12-28	WOS:000184578900002
J	Ling, MT; Wang, XH; Ouyang, XS; Xu, KX; Tsao, SW; Wong, YC				Ling, MT; Wang, XH; Ouyang, XS; Xu, KX; Tsao, SW; Wong, YC			Id-1 expression promotes cell survival through activation of NF-kappa B signalling pathway in prostate cancer cells	ONCOGENE			English	Article						Id-1; prostate cancer; NF-kappa B; TNF alpha; apoptosis	LOOP-HELIX PROTEIN; CHEMOTHERAPY-INDUCED APOPTOSIS; SENESCENT HUMAN FIBROBLASTS; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; EPITHELIAL-CELLS; GROWTH; CARCINOMA; INDUCTION	The growth-promoting effect of Id-1 (inhibitor of differentiation/DNA binding) has been demonstrated in a number of human cancers. However, the mechanisms responsible for its action are not clear. In this study, we report that in prostate cancer cells, Id-1 promotes cell survival through activation of nuclear factor-kappaB (NF-kappaB) signalling pathway. After stable expression of Id-1 protein in LNCaP cells, we found that the Id-1 transfectants showed increased resistance to apoptosis induced by TNFalpha through inactivation of Bax and caspase 3. In addition, in the LNCaP cells expressing ectopic Id-1 protein, we also observed increased NF-kappaB transactivation activity and nuclear translocation of the p65 and p50 proteins, which was accompanied by upregulation of their downstream effectors Bcl-xL and ICAM-1. These results indicate that the Id-1-induced antiapoptotic effect may be via NF-kappaB signalling transduction pathway in these cells. In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis. Our results strongly suggest that Id-1 may be one of the upstream regulators of NF-kappaB and activation of NF-kappaB signalling pathway, may be essential for Id-1 induced cell proliferation through protection against apoptosis. Our findings also suggest a potential therapeutic strategy in which inactivation of Id-1 may lead to sensitization of prostate cancer cells to chemotherapeutic drug-induced apoptosis.	Univ Hong Kong, Canc Biol Grp, Dept Anat, Lab Block,Fac Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Cent Lab, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wong, YC (corresponding author), Univ Hong Kong, Canc Biol Grp, Dept Anat, Lab Block,Fac Med, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Tsao, George/C-4422-2009					Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Hara E, 1996, DEV GENET, V18, P161; HARA E, 1994, J BIOL CHEM, V269, P2139; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kim BY, 2002, ONCOGENE, V21, P4490, DOI 10.1038/sj.onc.1205547; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kleeff J, 1998, CANCER RES, V58, P3769; Langlands K, 2000, CANCER RES, V60, P5929; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Lin CQ, 2000, CANCER RES, V60, P1332; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Polsky D, 2001, CANCER RES, V61, P6008; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; Schindl M, 2001, CANCER RES, V61, P5703; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wilson JW, 2001, CANCER RES, V61, P8803; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	52	142	147	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4498	4508		10.1038/sj.onc.1206693	http://dx.doi.org/10.1038/sj.onc.1206693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881706				2022-12-28	WOS:000184054700005
J	Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D				Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D			Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax	ONCOGENE			English	Article						apoptosis; IFN alpha; Bak; Bax; Bcl-2	CHRONIC LYMPHOCYTIC-LEUKEMIA; DRUG-INDUCED APOPTOSIS; MULTIPLE-MYELOMA; CYTOCHROME-C; CONFORMATIONAL-CHANGES; BH3-ONLY PROTEINS; OLIGOMERIZES BAK; UP-REGULATION; DEATH; MITOCHONDRIA	We have recently reported that the cytokine interferon-alpha (IFNalpha), commonly used in the treatment of cancer, induced a caspase-dependent apoptosis in tumor cell lines. The signaling mechanisms involved have not been defined. Here, we show that both proapoptotic Bcl-2 family members Bak and Bax were activated by IFNalpha, strictly in correlation with the induction of apoptosis. Using double stainings, we demonstrated that Bak was activated prior to cytochrome c (cyt c) release and caspase-3 activation, whereas activated Bax was only found in cells with released cyt c, mitochondrial depolarization, as well as activated caspase-3. Furthermore, IFNalpha-induced activation of Bak, and to a large extent also of Bax, was dependent on caspase activity. With the use of a panel of specific caspase inhibitors we found, however, that none of caspases-1 to -10 were responsible for this activation. Neither was the Ca2+-dependent protease calpain nor the stress-activated p38 SAPK pathway significantly involved. Overexpression of Bcl-2 blocked apoptosis induced by IFNalpha totally abolished Bak activation, as well as decreased the amount of activated Bax. We conclude that IFNalpha induces Bak and Bax activation via distinct mechanisms involving an unknown protease, and that their activation is regulated by Bcl-2.	Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, R8-03, S-17176 Stockholm, Sweden.			Panaretakis, Theocharis/0000-0001-5754-6950; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bradbury DA, 1997, LEUKEMIA LYMPHOMA, V24, P221, DOI 10.3109/10428199709039010; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Consoli U, 2002, BRIT J HAEMATOL, V116, P774, DOI 10.1046/j.0007-1048.2002.03344.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Grander D, 2000, ACTA ONCOL, V39, P801, DOI 10.1080/028418600750063532; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Ludwig H, 2000, ACTA ONCOL, V39, P815; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Raza A, 2000, LEUKEMIA RES, V24, P63, DOI 10.1016/S0145-2126(99)00152-6; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; SANGFELT O, 1995, INT J CANCER, V63, P190, DOI 10.1002/ijc.2910630207; Smalley RV, 2001, LEUKEMIA, V15, P1118, DOI 10.1038/sj.leu.2402161; Strander H, 1996, BIOTHERAPY, V8, P213, DOI 10.1007/BF01877207; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	37	69	72	4	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4543	4556		10.1038/sj.onc.1206503	http://dx.doi.org/10.1038/sj.onc.1206503			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881711				2022-12-28	WOS:000184054700010
J	Szynal, M; Cleuter, Y; Beskorwayne, T; Bagnis, C; Van Lint, C; Kerkhofs, P; Burny, A; Martiat, P; Griebel, P; Van den Broeke, A				Szynal, M; Cleuter, Y; Beskorwayne, T; Bagnis, C; Van Lint, C; Kerkhofs, P; Burny, A; Martiat, P; Griebel, P; Van den Broeke, A			Disruption of B-cell homeostatic control mediated by the BLV-Tax oncoprotein: association with the upregulation of Bcl-2 and signaling through NF-kappa B	ONCOGENE			English	Article						B-cell transformation; tax; complex retrovirus; BLV; Bcl-2; NF-kappa B	BOVINE LEUKEMIA-VIRUS; HTLV-I TAX; TYPE-1 TAX; GENE-EXPRESSION; GERMINAL CENTER; RAS ONCOGENE; PROTEIN; APOPTOSIS; ACTIVATION; TRANSCRIPTION	Transactivating proteins associated with complex oncoretroviruses including human T-cell leukemia virus-1 (HTLV-1) and bovine leukemia virus (BLV) mediate transformation using poorly understood mechanisms. To gain insight into the processes that govern tumor onset and progression, we have examined the impact of BLV-Tax expression on ovine B-cells, the targets of BLV in experimentally infected sheep, using B-cell clones that are dependent on CD154 and gamma(c)-common cytokines. Tax was capable of mediating progression of B-cells from cytokine dependence to cytokine independence, indicating that the transactivator can over-ride signaling pathways typically controlled by cytokine receptor activation in B-cells. When examined in the presence of both CD154 and interleukin-4, Tax had a clear supportive role on B-cell growth, with an impact on B-cell proliferation, cell cycle phase distribution, and survival. Apoptotic B-cell death mediated by growth factor withdrawal, physical insult, and NF-kappaB inhibition was dramatically reduced in the presence of Tax. Furthermore, the expression of Tax was associated with higher Bcl-2 protein levels, providing rationale for the rescue signals mediated by the transactivator. Finally, Tax expression in B-cells led to a dramatic increase of nuclear RelB/p50 and p50/p50 NF-kappaB dimers, indicating that cellular signaling through NF-kappaB is a major contributory mechanism in the disruption of B-cell homeostasis. Although Tax is involved in aspects of pathogenesis that are unique to complex retroviruses, the viral strategies associated with this transactivating oncoprotein may have wide-ranging effects that are relevant to other B-cell malignancies.	Inst Jules Bordet, Lab Expt Hematol, B-1000 Brussels, Belgium; Vet Infect Dis Org, Saskatoon, SK S7H 5E3, Canada; Etab Francais Sang, F-13009 Marseille, France; IBMM, B-6041 Gosselies, Belgium; Coda Cerva, B-1180 Brussels, Belgium	Institut Jules Bordet; University of Saskatchewan; Universite Libre de Bruxelles	Van den Broeke, A (corresponding author), Inst Jules Bordet, Lab Expt Hematol, 121 Blvd Waterloo, B-1000 Brussels, Belgium.	anne_vandenbroeke@compuserve.com						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Badran BM, 2002, J BIOL CHEM, V277, P47136, DOI 10.1074/jbc.M206330200; Bagnis C, 1997, CANCER GENE THER, V4, P5; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BURNY A, 1994, SYMP SOC GEN MICROBI, V51, P213; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; Feinman R, 1999, BLOOD, V93, P3044; FELBER B K, 1989, New Biologist, V1, P318; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Griebel P, 1999, INT IMMUNOL, V11, P1139, DOI 10.1093/intimm/11.7.1139; Griebel PJ, 2000, J IMMUNOL METHODS, V237, P19, DOI 10.1016/S0022-1759(99)00247-1; HAAS L, 1992, J VIROL, V66, P6223, DOI 10.1128/JVI.66.10.6223-6225.1992; HAURY M, 1993, ONCOGENE, V8, P1257; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Horwitz BH, 1999, J IMMUNOL, V162, P1941; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Keller SA, 2000, BLOOD, V96, P2537; Kerkhofs P, 1998, J VIROL, V72, P2554, DOI 10.1128/JVI.72.3.2554-2559.1998; Kettmann R., 1994, The retroviridae: Volume 3, P39; Kirshenbaum LA, 2000, CLIN INVEST MED, V23, P322; Kistler B, 1998, J IMMUNOL, V160, P2308; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAMMERICKX M, 1988, LEUKEMIA, V2, P103; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; MOTYKA B, 1995, IMMUNOLOGY, V84, P383; MURAKAMI K, 1994, AM J VET RES, V55, P72; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Porter LA, 2000, BLOOD, V95, P2645; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Reyes RA, 1998, VIROLOGY, V242, P184, DOI 10.1006/viro.1998.9029; Richardson JH, 1997, BLOOD, V89, P3303, DOI 10.1182/blood.V89.9.3303; Rovnak J, 1999, J VIROL, V73, P8890, DOI 10.1128/JVI.73.10.8890-8897.1999; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmaltz B, 2000, GNOMON, V72, P633; SchwartzCornil I, 1997, J GEN VIROL, V78, P153, DOI 10.1099/0022-1317-78-1-153; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Stone DM, 2000, J GEN VIROL, V81, P971, DOI 10.1099/0022-1317-81-4-971; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Twizere JC, 2000, J VIROL, V74, P9895, DOI 10.1128/JVI.74.21.9895-9902.2000; Van den Broeke A, 1999, J VIROL, V73, P1054, DOI 10.1128/JVI.73.2.1054-1065.1999; Van den Broeke A, 2001, J VIROL, V75, P1095, DOI 10.1128/JVI.75.3.1095-1103.2001; Van Den Broeke Anne, 1997, P2127; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; Vernau W, 1997, VET PATHOL, V34, P222, DOI 10.1177/030098589703400307; Wagner EF, 1998, J IMMUNOL, V161, P1123; Warren WD, 1999, MOL IMMUNOL, V36, P31, DOI 10.1016/S0161-5890(98)00114-X; Watanabe T, 1997, INT J HEMATOL, V66, P257; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	75	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4531	4542		10.1038/sj.onc.1206546	http://dx.doi.org/10.1038/sj.onc.1206546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881710	Bronze			2022-12-28	WOS:000184054700009
J	Derry, JJ; Prins, GS; Ray, V; Tyner, AL				Derry, JJ; Prins, GS; Ray, V; Tyner, AL			Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells	ONCOGENE			English	Article						prostate cancer; BRK; Sik; tyrosine kinase; Sam68; PTK6	GASTROINTESTINAL-TRACT; GROWTH-FACTORS; SAM68; CANCER; EXPRESSION; RNA; BRK; PHOSPHORYLATION; INHIBITION; SUBSTRATE	Breast tumor kinase (BRK) is an intracellular tyrosine kinase expressed in differentiating epithelial cells of the gastrointestinal tract and skin, and in several epithelial cancers including carcinomas of the breast and colon. We examined expression of BRK and its mouse ortholog Src-related intestinal kinase (Sik) in prostate tissues and detected it in the nuclei of normal luminal prostate epithelial cells. BRK localization was then examined in 58 human prostate biopsy samples representing various grades of prostate cancer. While nuclear localization of BRK was present in well-differentiated tumors, it was absent in poorly differentiated tumors. However localization of Sam68, a nuclear substrate of BRK/Sik, was unaltered in all prostate tumors examined. Consistent with these results, nuclear BRK was detected in the more differentiated androgen-responsive LNCaP human prostate cancer cell line that is poorly tumorigenic in host animals, but it was primarily cytoplasmic in the undifferentiated androgen-unresponsive PC3 prostate cancer cell line that forms aggressive tumors. While PC3 cells expressed higher levels of endogenous BRK than LNCaP cells, BRK was less active in these cells. Our data suggest that BRK plays a role in differentiation of prostate epithelial cells. Altered BRK localization and/or activity may provide a prognostic indicator for prostate tumor progression and be a potential target for therapeutic intervention.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Urol, Chicago, IL 60607 USA; Provident Hosp Cook Cty, Dept Pathol, Chicago, IL 60615 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIDDK NIH HHS [R01 DK040890, DK44525, R01 DK044525-09, R01 DK044525] Funding Source: Medline; PHS HHS [40890] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK040890, R01DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hellawell GO, 2002, BJU INT, V89, P230, DOI 10.1046/j.1464-4096.2001.001067.x; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KAIGHN ME, 1979, INVEST UROL, V17, P16; LEE ST, 1993, ONCOGENE, V8, P3403; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; Llor X, 1999, CLIN CANCER RES, V5, P1767; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9	29	103	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4212	4220		10.1038/sj.onc.1206465	http://dx.doi.org/10.1038/sj.onc.1206465			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833144				2022-12-28	WOS:000183979800008
J	Ho, SM; Lau, KM; Mok, SCH; Syed, V				Ho, SM; Lau, KM; Mok, SCH; Syed, V			Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells	ONCOGENE			English	Article						cDNA microarray; hormonal carcinogenesis; gene expression; GTPase activating protein (rap1GAP); neogenin; restin	REED-STERNBERG CELLS; HEAT-SHOCK PROTEINS; LUTEINIZING-HORMONE; CDNA MICROARRAY; CALORIC RESTRICTION; HODGKINS-DISEASE; BREAST-CANCER; RNA HELICASES; RECEPTOR; GONADOTROPINS	Epidemiological data have implicated the pituitary gonadotropin follicle stimulating hormone (FSH) as both a risk factor for and a protective agent against epithelial ovarian cancer. Yet, little is known about how this hormone could play such opposing roles in ovarian carcinogenesis. Complementary DNA microarrays containing 2400 named genes were used to examine FSH-induced gene expression changes in ovarian cancer (OC) and immortalized normal human ovarian surface epithelial (HOSE) cell lines. Two-way t-statistics analyses of array data identified two distinct sets of FSH-regulated genes in HOSE and in established OC cell lines established from patients (OVCA cell tines). Among the HOSE cell lines, FSH increased expression of 57% of the 312 genes and downregulated 43%. In contrast, FSH diminished expression of 92% of the 177 genes in the OVCA cell lines. All but 18 of the genes affected by FSH in HOSE cell lines were different from those altered in OVCA cell lines. Among the 18 overlapping genes, nine genes exhibited the same direction of change following FSH challenge, while the other nine showed discordance in response between HOSE and OVCA cell tines. The FSH-induced differential expression of seven out of nine genes was confirmed by real-time RT-PCR. Gene-specific antisense otigonuleotides (ODNs) were used to inhibit the expression of genes encoding GTPase activating protein (rap1GAP), neogenin, and restin in HOSE and OVCA cells. Antisense ODNs to neogenin and restin, but not an antisense ODN to rap1GAP, were effective in inhibiting OVCA cell growth, diminishing proliferating cell nuclear antigen expression, and increasing caspase 3 activities. Furthermore, the ODN to rap1GAP was further shown to be ineffective in altering migration properties of OVCA cell lines. HOSE cell proliferation was not affected by treatment with any of the antisense ODNs. In summary, gene profiling data reveal for the first time that FSH may exert different biological actions on OVCA cells than on HOSE cells, by differential regulation of a set of putative oncogenes/tumor suppressors. Specifically, neogenin and restin were found to exhibit proproliferation/survival action on OC cells.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol & Physiol, Worcester, MA 01605 USA; Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Syed, V (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, 364 Plantat St,5th Floor, Worcester, MA 01605 USA.	Viqar.Syed@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ala-Fossi SL, 1999, ANTICANCER RES, V19, P4289; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Conroy SE, 1996, BRIT J CANCER, V74, P717, DOI 10.1038/bjc.1996.427; Cramer DW, 1998, FERTIL STERIL, V70, P371, DOI 10.1016/S0015-0282(98)00153-8; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; Emons G, 1996, CANCER, V78, P1452; ERICKSON GF, 1994, ENDOCRINOLOGY, V134, P1365, DOI 10.1210/en.134.3.1365; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P67, DOI 10.1007/BF00666207; GILLETT WR, 1991, HUM REPROD, V6, P645, DOI 10.1093/oxfordjournals.humrep.a137398; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; Halperin R, 1999, INT J GYNECOL CANCER, V9, P502, DOI 10.1046/j.1525-1438.1999.99075.x; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HEIZISOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926; HILLIKER C, 1994, CYTOGENET CELL GENET, V65, P172, DOI 10.1159/000133625; Hofstra LS, 1999, ANTICANCER RES, V19, P3627; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Hough CD, 2001, CANCER RES, V61, P3869; Ismail RS, 2000, CANCER RES, V60, P6744; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Ivarsson K, 2001, HUM REPROD, V16, P18, DOI 10.1093/humrep/16.1.18; Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee HM, 2001, MECH AGEING DEV, V122, P355, DOI 10.1016/S0047-6374(00)00254-2; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Mandai M, 1997, EUR J CANCER, V33, P1501, DOI 10.1016/S0959-8049(97)00166-4; MARIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Mukherjee A, 1998, MOL ENDOCRINOL, V12, P785, DOI 10.1210/me.12.6.785; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Ono K, 2000, CANCER RES, V60, P5007; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Shridhar V, 2001, CANCER RES, V61, P5895; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang C, 2000, J PHARMACOL EXP THER, V294, P287; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wani MA, 1997, SOMAT CELL MOLEC GEN, V23, P123, DOI 10.1007/BF02679971; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WERA S, 1994, BIOCHEM J, V311, P17; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zheng WX, 1996, AM J PATHOL, V148, P47; Zheng WX, 2000, GYNECOL ONCOL, V76, P80, DOI 10.1006/gyno.1999.5628	68	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4243	4256		10.1038/sj.onc.1206437	http://dx.doi.org/10.1038/sj.onc.1206437			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833147	Bronze			2022-12-28	WOS:000183979800011
J	Sacco, A; Siepi, F; Crescenzi, M				Sacco, A; Siepi, F; Crescenzi, M			HPV E7 expression in skeletal muscle cells distinguishes initiation of the postmitotic state from its maintenance	ONCOGENE			English	Article						cell cycle reactivation; terminal differentiation; papillomavirus; postmitotic state; retinoblastoma protein	PAPILLOMAVIRUS TYPE-16 E7; TERMINALLY DIFFERENTIATED CELLS; A GENE-EXPRESSION; CYCLIN-A; RETINOBLASTOMA PROTEIN; CELLULAR-DIFFERENTIATION; MYOGENIC DIFFERENTIATION; KINASE-ACTIVITY; DNA-SYNTHESIS; S-PHASE	The E7 oncogene is an essential tool used by papillomaviruses to interfere with the cell cycle and cellular differentiation. We investigated the effects of E7 expression on both cellular functions in skeletal muscle cells, a terminally differentiating system. When expressed in myoblasts, E7 impaired differentiation only partially, but allowed continuation of DNA synthesis during and after differentiation. Surprisingly, E7 expression in terminally differentiated myotubes could not reactivate DNA synthesis even though the oncogene bound the retinoblastoma protein, reduced its levels, and increased E2F transcriptional activity. Despite the high cyclin E protein levels induced by E7, the myotubes remained devoid of cyclin E-associated kinase activity. Enforcement of such activity in the presence of E7 brought myotubes into S phase. These results show that E7, unlike other DNA tumor-virus oncogenes, cannot reactivate the cell cycle in postmitotic myotubes. In contrast, E7 allows significant differentiation to occur in the presence of persisting DNA synthesis. These observations distinguish E7 from other functionally related oncogenes and bear significance for the understanding of the natural life cycle of human papillomaviruses. The fact that E7 alone inhibits the initiation but not the maintenance of the postmitotic state indicates that the mechanisms underlying these two functions are at least partially distinct.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Crescenzi, M (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Crescenzi, Marco/J-3603-2018	Crescenzi, Marco/0000-0003-0156-1494	Telethon [GP0293Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; BIGNAMI M, 1988, ONCOGENE, V2, P509; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Chien WM, 2002, J VIROL, V76, P2964, DOI 10.1128/JVI.76.6.2964-2972.2002; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; ENDO T, 1989, UCLA S MOL CELL BIOL, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; MAIONE R, 1992, ONCOGENE, V7, P85; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pajalunga D, 1999, ONCOGENE, V18, P5054, DOI 10.1038/sj.onc.1202897; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Puri PL, 1998, CANCER RES, V58, P1325; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Tedesco D, 1997, J VIROL, V71, P2217, DOI 10.1128/JVI.71.3.2217-2224.1997; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	43	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4027	4034		10.1038/sj.onc.1206353	http://dx.doi.org/10.1038/sj.onc.1206353			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821937				2022-12-28	WOS:000183707600006
J	Chen, YH; Zheng, Y; Foster, DA				Chen, YH; Zheng, Y; Foster, DA			Phospholipase D confers rapamycin resistance in human breast cancer cells	ONCOGENE			English	Article						phospholipase D; rapamycin; mTOR	GROWTH-FACTOR RECEPTOR; PHOSPHATIDIC-ACID; V-SRC; MAMMALIAN TARGET; DEPENDENT ACTIVATION; SIGNALING PATHWAY; TRANSFORMED-CELLS; RAT FIBROBLASTS; PROTEIN; KINASE	mTOR (mammalian target of rapamycin) is a protein kinase that regulates cell cycle progression and cell growth. Rapamycin is a highly specific inhibitor of mTOR in clinical trials for the treatment of breast and other cancers. mTOR signaling was reported to require phosphatidic acid (PA), the metabolic product of phospholipase D (PLD). PLD, like mTOR, has been implicated in survival signaling and the regulation of cell cycle progression. PLD activity is frequently elevated in breast cancer. We have investigated the effect of rapamycin on breast cancer cell lines with different levels of PLD activity. MCF-7 cells, with relatively low levels of PLD activity, were highly sensitive to the growth-arresting effects of rapamycin, whereas MDA-MB-231 cells, with a 10-fold higher PLD activity than MCF-7 cells, were highly resistant to rapamycin. Elevating PLD activity in MCF-7 cells led to rapamycin resistance; and inhibition of PLD activity in MDA-MB-231 cells increased rapamycin sensitivity. Elevated PLD activity in MCF-7 cells also caused rapamycin resistance for S6 kinase phosphorylation and serum-induced Myc expression. These data implicate mTOR as a critical target for survival signals generated by PLD and suggest that PLD levels in breast cancer could be a valuable indicator of the likely efficacy of rapamycin treatment.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.				NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Tsai EM, 2001, CANCER RES, V61, P8390; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	50	157	163	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3937	3942		10.1038/sj.onc.1206565	http://dx.doi.org/10.1038/sj.onc.1206565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813467				2022-12-28	WOS:000183612000013
J	Paterlini-Brechot, P; Saigo, K; Murakami, Y; Chami, M; Gozuacik, D; Mugnier, C; Lagorce, D; Brechot, C				Paterlini-Brechot, P; Saigo, K; Murakami, Y; Chami, M; Gozuacik, D; Mugnier, C; Lagorce, D; Brechot, C			Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene	ONCOGENE			English	Article						Hepatitis B Virus; insertional mutagenesis; hepatocellular carcinoma; hTERT	HUMAN COLORECTAL CARCINOMAS; CELLS-IN-VITRO; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGETS; HUMAN GENOME; INTEGRATION; ACTIVATION; RECEPTOR; DNA; PROTEIN	Integration of Hepatitis B Virus (HBV) DNA into liver cell DNA has been well established, but its implication in liver carcinogenesis is still being debated. In particular, insertion of the viral genome into cellular genes has been viewed as a rare event. By using HBV-Alu PCR, we have now isolated, from nine hepatocellular carcinomas, nine HBV-DNA integration sites showing that the viral genome mutates key regulatory cellular genes: neurotropic tyrosin receptor kinase 2 (NTRK2) gene, IL-1R-associated kinase 2 (IRAK2) gene, p42 mitogen-activated protein kinase 1 (p42MAPK1) gene, inositol 1,4,5-triphosphate receptor type 2 (IP3R2) gene, inositol 1,4,5-triphosphate receptor (IP3R) type 1 (IP3R1) gene, alpha 2,3 sialyltransferase (ST3GAL VI or SITA) gene, thyroid hormone uncoupling protein (TRUP) gene, EMX2-like gene, and human telomerase reverse transcriptase (hTERT) gene. This result brings to 15 the total number of genes targeted by HBV in a study of 22 human liver cancers. Overall, we found that both the inositol 1,4,5-triphosphate receptor gene and the telomerase gene were targeted by HBV in two different tumors. Thus, HBV frequently targets cellular genes involved in cell signalling and some of them may be preferential targets of the viral integration.	Hop Necker Enfants Malad, INSERM, Pasteur Unit 370, Fac Med Necker, F-75015 Paris, France; Chiba Univ, Dept Surg 2, Sch Med, Chiba 2608670, Japan; Hop Necker Enfants Malad, Dept Biostat & Med Informat, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Chiba University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Hop Necker Enfants Malad, INSERM, Pasteur Unit 370, Fac Med Necker, F-75015 Paris, France.	paterlini@necker.fr	Devrim, Gozuacik/C-3330-2008; Chami, Mounia/S-6471-2019	Devrim, Gozuacik/0000-0001-7739-2346; Chami, Mounia/0000-0003-1498-7187; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Fourel G, 1994, PRIMARY LIVER CANC E, P89; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; GRAEF E, 1994, ONCOGENE, V9, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAYNE GS, 1982, NATURE, V21, P209; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROBINSON WS, 1987, HEPATOLOGY, V7, pS64, DOI 10.1002/hep.1840070712; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schneider F, 2001, CANCER RES, V61, P4605; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shibayama E, 1996, AM J PATHOL, V148, P1807; Sugimoto T, 2001, JPN J CANCER RES, V92, P152, DOI 10.1111/j.1349-7006.2001.tb01077.x; TAHARA H, 1995, CANCER RES, V55, P2734; Tu H, 2001, CANCER RES, V61, P7803; Urashima T, 1997, J HEPATOL, V26, P771, DOI 10.1016/S0168-8278(97)80241-3; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wang YX, 2000, INT J ONCOL, V16, P757; Weber G, 1996, ANTICANCER RES, V16, P3271; YU C, 2002, 93 ANN M AM ASS CANC, V43; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	40	226	235	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3911	3916		10.1038/sj.onc.1206492	http://dx.doi.org/10.1038/sj.onc.1206492			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813464				2022-12-28	WOS:000183612000010
J	Fleury-Feith, J; Lecomte, C; Renier, A; Matrat, M; Kheuang, L; Abramowski, V; Levy, F; Janin, A; Giovannini, M; Jaurand, MC				Fleury-Feith, J; Lecomte, C; Renier, A; Matrat, M; Kheuang, L; Abramowski, V; Levy, F; Janin, A; Giovannini, M; Jaurand, MC			Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours	ONCOGENE			English	Article						asbestos; NF2; mesothelioma; hemizygous mice	HUMAN-MALIGNANT MESOTHELIOMA; FACTOR SCATTER FACTOR; NEUROFIBROMATOSIS TYPE-2; SUPPRESSOR GENES; FISCHER-344 RATS; VITREOUS FIBERS; MINERAL FIBERS; INTRAPERITONEAL; GROWTH; TOXICITY	Biallelic NF2 gene inactivation is frequently found in human malignant mesothelioma. In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in mesothelioma developed in mice presenting a heterozygous mutation of the Nf2 gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres. Asbestos-exposed Nf2(KO3/+) mice developed tumoural ascites and mesothelioma at a higher frequency than their wild-type (WT) counterparts (P<0.05). Six out of seven mesothelioma cell lines established from neoplastic ascitic fluids of Nf2(KO3/+) mice exhibited loss of the WT Nf2 allele and no neurofibromatosis type 2 protein expression was found in these cells. The res its show the importance of the NF2 gene in mesothelial oncogenesis, the potential association of asbestos exposure and tumour suppressor gene inactivation, and suggest that NF2 gene mutation may be a susceptibility factor to asbestos.	Univ Paris 12, INSERM EMI 99 09, Fac Med, F-94010 Creteil, France; Hop Tenon, Serv Histol Biol Tumorale, F-75020 Paris, France; Ctr Hosp Intercommunal, Serv Pathol Professionelles, F-94010 Creteil, France; Fdn Jean Dasset, INSERM U434, CEPH, F-75010 Paris, France; Univ Paris 07, Pathol Lab, ERM 220 INSERM, Hop St Louis, F-75010 Paris, France; Univ Paris 07, ERM 220 INSERM, Pathol Lab, Hop St Louis, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jaurand, MC (corresponding author), Univ Paris 12, INSERM EMI 99 09, Fac Med, 8 Rue Gen Sarrail, F-94010 Creteil, France.		JAURAND, MARIE-CLAUDE/S-3538-2017	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; Matrat, Mireille/0000-0001-9252-2612; Boulange-Lecomte, Celine/0000-0002-2461-7473				Adachi S, 2001, IND HEALTH, V39, P168, DOI 10.2486/indhealth.39.168; ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; ASPLUND T, 1994, CANCER RES, V54, P4516; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; CRAIGHEAD JE, 1994, LUNG BIOL HEALTH DIS, V78, P79; Cullen RT, 2000, INHAL TOXICOL, V12, P959; Cullen RT, 2000, J APPL TOXICOL, V20, P49, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<49::AID-JAT627>3.0.CO;2-L; DAVIS JMG, 1991, INT J EXP PATHOL, V72, P263; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; Giovannini M, 2000, GENE DEV, V14, P1617; GOODGLICK LA, 1986, CANCER RES, V46, P5558; Grander D, 1998, MED ONCOL, V15, P20, DOI 10.1007/BF02787340; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; HANSTEEN IL, 1993, CANCER GENET CYTOGEN, V70, P94, DOI 10.1016/0165-4608(93)90174-K; Harvey P, 1996, J PATHOL, V180, P389; HESTERBERG TW, 1993, FUND APPL TOXICOL, V20, P464, DOI 10.1006/faat.1993.1057; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Kociok N, 1999, CANCER GENET CYTOGEN, V111, P71, DOI 10.1016/S0165-4608(98)00221-0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lechner JF, 1997, ENVIRON HEALTH PERSP, V105, P1061, DOI 10.2307/3433510; Lee YCG, 2002, AM J RESP CRIT CARE, V165, P88, DOI 10.1164/ajrccm.165.1.2104006; MAST RW, 1995, INHAL TOXICOL, V7, P425, DOI 10.3109/08958379509015208; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MOALLI PA, 1987, AM J PATHOL, V128, P426; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; POTT F, 1987, EXP PATHOL-JENA, V32, P129, DOI 10.1016/S0232-1513(87)80044-0; Pylkkanen L, 2002, ONCOL REP, V9, P955; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; Roller M, 1997, ENVIRON HEALTH PERSP, V105, P1253, DOI 10.2307/3433542; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shibuya M, 1999, CANCER CHEMOTH PHARM, V43, pS72, DOI 10.1007/s002800051102; SMITH DM, 1987, ANN OCCUP HYG, V31, P731, DOI 10.1093/annhyg/31.4B.731; SUZUKI Y, 1984, ENVIRON RES, V35, P277, DOI 10.1016/0013-9351(84)90136-1; Unfried K, 1997, ENVIRON HEALTH PERSP, V105, P1103, DOI 10.2307/3433516; Vaslet CA, 2002, TOXICOL SCI, V68, P331, DOI 10.1093/toxsci/68.2.331; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364; 2001, J O REPUBLIQUE  0608, P9094	41	71	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3799	3805		10.1038/sj.onc.1206593	http://dx.doi.org/10.1038/sj.onc.1206593			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802287				2022-12-28	WOS:000183551000014
J	Kawasaki, H; Komai, K; Nakamura, M; Yamamoto, E; Ouyang, ZF; Nakashima, T; Morisawa, T; Hashiramoto, A; Shiozawa, K; Ishikawa, H; Kurosaka, M; Shiozawa, S				Kawasaki, H; Komai, K; Nakamura, M; Yamamoto, E; Ouyang, ZF; Nakashima, T; Morisawa, T; Hashiramoto, A; Shiozawa, K; Ishikawa, H; Kurosaka, M; Shiozawa, S			Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis	ONCOGENE			English	Article						c-Fos; AP-1; wee1; rheumatoid arthritis; tumor-like characteristic	C-FOS; PROTEIN-KINASE; CYCLIN-B; ARTHRITIS; EXPRESSION; P34CDC2; PHASE; PHOSPHORYLATION; PROLIFERATION; INFLAMMATION	Wee1 kinase downregulates the M-phase promoting factor, a complex of cdc2 and cyclin B kinase, that controls mitotic cell division. We isolated human wee1 kinase gene promoter and found that it contained one AP-1-binding motif in its promoter region (5'-CGAGTCA-3'; -823/-817), through which wee1 kinase gene was directly transactivated by c-Fos/AP-1. In rheumatoid synovial cells, wee1 kinase was increased in conjunction with the increase of c-Fos/AP-1 and the substrate of wee1, cdc2, was phosphorylated. The amount of wee1 and c-Fos and the phosphorylation of cdc2 were decreased after treatment of the cells with an inhibitor of AP-1, curcumin. A significant proportion of cultured synovial cells of the patients with rheumatoid arthritis, but not those of osteoarthritis, shifted to a tetraploid (4C) state upon long-term culture. Thus, human wee1 kinase gene is directly transactivated by and increased in association with c-Fos/AP-1, and rheumatoid synovial cells over-expressing these genes go into aberrant mitosis.	Kobe Univ, FHS Sch Med, Dept Rheumatol, Suma Ku, Kobe, Hyogo 6540142, Japan; Kobe Univ Hosp, Div Rheumat Dis, Kobe, Hyogo 6500017, Japan; Konan Kakogawa Hosp, Dept Rheumatol, Kakogawa 6758545, Japan; Kobe Univ Hosp, Dept Orthoped Surg, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University; Kobe University	Shiozawa, S (corresponding author), Kobe Univ, FHS Sch Med, Dept Rheumatol, Suma Ku, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.		Komai, Koichiro/L-1633-2019; Shiozawa, Shunichi/W-2992-2019	Komai, Koichiro/0000-0003-0015-5283; 				AICHER WK, 1994, J IMMUNOL, V152, P5940; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Asahara H, 1997, ARTHRITIS RHEUM, V40, P912, DOI 10.1002/art.1780400520; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Fassbender HG, 1998, ARCH ORTHOP TRAUM SU, V117, P2, DOI 10.1007/BF00703430; FASSBENDER HG, 1984, ARTHRITIS RHEUM, V27, P956, DOI 10.1002/art.1780270819; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; HUNG TS, 1995, CANC LETT, V96, P1; Jacobs RA, 1995, CLIN EXP RHEUMATOL, V13, P717; KAKER SS, 1994, CANC LETT, V87, P85; Kawasaki H, 1999, INT IMMUNOL, V11, P1873, DOI 10.1093/intimm/11.12.1873; Kawasaki H, 2001, EMBO J, V20, P4618, DOI 10.1093/emboj/20.16.4618; KUROKI Y, 1993, J RHEUMATOL, V20, P422; KUROKI Y, 1994, CLIN EXP IMMUNOL, V95, P536; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Pope RM, 1999, CLIN IMMUNOL, V91, P271, DOI 10.1006/clim.1999.4723; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schaser K, 1996, Verh Dtsch Ges Pathol, V80, P276; Secchiero P, 1998, BLOOD, V92, P1685, DOI 10.1182/blood.V92.5.1685.417k30_1685_1696; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHIOZAWA S, 1983, ARTHRITIS RHEUM-US, V26, P472, DOI 10.1002/art.1780260404; SHIOZAWA S, 1992, J IMMUNOL, V148, P3100; Shiozawa S, 1997, J CLIN INVEST, V99, P1210, DOI 10.1172/JCI119277; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TRABANDT A, 1992, RHEUMATOL INT, V12, P53, DOI 10.1007/BF00300977; Wakisaka S, 1998, ANN RHEUM DIS, V57, P487, DOI 10.1136/ard.57.8.487; Yamanishi Y, 2001, RHEUM DIS CLIN N AM, V27, P355, DOI 10.1016/S0889-857X(05)70206-4; Zhang Y, 1996, J BIOL CHEM, V271, P4266	35	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6839	6844		10.1038/sj.onc.1206903	http://dx.doi.org/10.1038/sj.onc.1206903			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534529				2022-12-28	WOS:000185843400003
J	Zhang, YJ; Finegold, MJ; Porteu, F; Kanteti, P; Wu, MX				Zhang, YJ; Finegold, MJ; Porteu, F; Kanteti, P; Wu, MX			Development of T-cell lymphomas in E mu-IEX-1 mice	ONCOGENE			English	Article						IEX-1; antiapoptosis; T-cell lymphoma; transgenic mice	IMMEDIATE-EARLY GENE; NF-KAPPA-B; P53 TUMOR-SUPPRESSOR; EARLY-RESPONSE GENE; TRANSGENIC MICE; PROTEIN EXPRESSION; IEX-1; APOPTOSIS; SURVIVAL; BCL-2	Inhibition of apoptosis or abnormal cell survival can result in tumorigenesis by facilitating the insurgence of various mutations. Immediate-early response gene X-1 (IEX-1), protects T cells from apoptosis induced by the ligation of Fas or the T-cell receptor (TCR)/CD3 complex in Emu-IEX-1 mice that direct the gene expression in both T and B cell lineages under the control of the Emu enhancer. Consistent with a biased effect of IEX-1 towards T cells, Emu-IEX-1 mice selectively developed T-cell lymphomas in the spleen, when they aged, which may be associated with increased levels of IEX-1 phosphorylation in T cells compared to B cells. The lymphomas were single positive (CD4(+)CD8(-), CD4(-)CD8(+)), double positive (CD4(+)CD8(-)), or double negative (CD4(-)CD8(-)) T cells. They resulted from aberrantly clonal expansions of T cells expressing a specific TCR, as suggested by the TCR repertoire analysis using a panel of monoclonal antibodies recognizing TCR Vbeta chain, as well as by TCR beta gene rearrangements. The study provides, for the first time, unambiguous evidence of the oncogenic potential of IEX-1 in a cell-specific manner. The animal model may help our understanding of peripheral T-cell lymphoma development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Boston Univ, Med Ctr, Dept Mol & Cell Biol, Boston, MA 02118 USA; Inst Cochin Genet Mol, Dept Hematol, INSERM, U567,CNRS,UMR 8104, F-75014 Paris, France; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	Baylor College of Medicine; Boston University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wu, MX (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, 50 Blossom St,Wellman 224, Boston, MA 02114 USA.		PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045003] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; CHARLES CH, 1993, ONCOGENE, V8, P797; Chuang PI, 2002, BLOOD, V99, P3350, DOI 10.1182/blood.V99.9.3350; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; Kondratyev AD, 1996, CANCER RES, V56, P1498; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; PEZZELLA F, 1990, LANCET, V336, P1510, DOI 10.1016/0140-6736(90)93216-C; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; SEITE P, 1993, LEUKEMIA, V7, P410; STRASSER A, 1993, ONCOGENE, V8, P1; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; WU MX, 1995, P NATL ACAD SCI USA, V92, P1525, DOI 10.1073/pnas.92.5.1525; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	37	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6845	6851		10.1038/sj.onc.1206707	http://dx.doi.org/10.1038/sj.onc.1206707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534530				2022-12-28	WOS:000185843400004
J	Boerner, JL; Danielsen, AJ; Lovejoy, CA; Wang, Z; Juneja, SC; Faupel-Badger, JM; Darce, JR; Maihle, NJ				Boerner, JL; Danielsen, AJ; Lovejoy, CA; Wang, Z; Juneja, SC; Faupel-Badger, JM; Darce, JR; Maihle, NJ			Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis	ONCOGENE			English	Article						EGFR/ErbB; v-ErbB; Grb2; caldesmon	GROWTH-FACTOR RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; HUMAN BREAST-CANCER; TYROSINE KINASES; V-ERBB; TRANSFORMED-CELLS; C-ERBB; ADAPTER PROTEINS; TUMOR-CELLS; SH3 DOMAINS	Mutations within members of the EGF/ErbB receptor family frequently release the oncogenic potential of these receptors, resulting in the activation of downstream signaling events independent of ligand regulatory constraints. We previously have demonstrated that the signal transduction events originating from S3-v-ErbB, a ligand-independent, oncogenic EGF receptor mutant, are qualitatively distinct from the ligand-dependent mitogenic signaling pathways associated with the wild-type EGF receptor. Specifically, expression of S3-v-ErbB in primary fibroblasts results in anchorage-independent growth, increased invasive potential, and the formation of a transformation-specific phosphoprotein signaling complex, all in a Ras-independent manner. Here we demonstrate the transformation-specific interaction between two components of this complex: the adaptor protein Grb2 and the cytoskeletal regulatory protein caldesmon. This interaction is mediated via both the amino-terminal SH3 and central SH2 domains of Grb2, and the aminoterminal (myosin-binding) domain of caldesmon. Expression of a dominant- negative Grb2 deletion mutant, which lacks the carboxy-terminal SH3 domain, in. broblasts expressing S3-v-ErbB results in a reduction in phosphoprotein complex formation, the loss of anchorage-independent growth, and a reduction in invasive potential. Together, these results demonstrate a Ras-independent role for Grb2 in modulating cytoskeletal function during ligand-independent EGF receptor-mediated transformation, and provide further support for the hypothesis that ligand-independent oncogenic signaling is qualitatively distinct from ligand-dependent mitogenic signaling by the EGF receptor.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Maihle, NJ (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.			Faupel-Badger, Jessica/0000-0001-9729-3660; Juneja, Subhash/0000-0002-8536-5724	NATIONAL CANCER INSTITUTE [R01CA079808] Funding Source: NIH RePORTER; NCI NIH HHS [CA79808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALBINI A, 1987, CANCER RES, V47, P3239; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Boerner JL, 2003, EXP CELL RES, V284, P111, DOI 10.1016/S0014-4827(02)00096-4; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; Boerner JL, 2000, J CELL SCI, V113, P935; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CONNOLLY DC, 1994, J VIROL, V68, P6804, DOI 10.1128/JVI.68.10.6804-6810.1994; DALY RJ, 1994, ONCOGENE, V9, P2723; DAmbrosio C, 1996, ONCOGENE, V12, P371; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; Goncharova EA, 2001, FEBS LETT, V497, P113, DOI 10.1016/S0014-5793(01)02445-0; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; Klapper LN, 2000, ADV CANCER RES, V77, P25; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; RAINES MA, 1988, J VIROL, V62, P2437, DOI 10.1128/JVI.62.7.2437-2443.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; TANAKA J, 1993, J CELL SCI, V104, P595; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Wang Z, 1999, J BIOL CHEM, V274, P33807, DOI 10.1074/jbc.274.47.33807; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113	47	9	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6679	6689		10.1038/sj.onc.1206830	http://dx.doi.org/10.1038/sj.onc.1206830			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555981				2022-12-28	WOS:000185799300003
J	Remenyik, E; Wikonkal, NM; Zhang, WG; Paliwal, V; Brash, DE				Remenyik, E; Wikonkal, NM; Zhang, WG; Paliwal, V; Brash, DE			Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones	ONCOGENE			English	Article						Rag1; knockout; sunburn cells; apoptosis; epidermal thickness; immune surveillance	MOUSE SKIN CARCINOGENESIS; EARLY ADAPTIVE RESPONSES; ULTRAVIOLET-IRRADIATION; PERSISTENT HYPERPLASIA; INDUCED APOPTOSIS; HAIRLESS MICE; LYMPHOCYTES-T; P53 MUTATIONS; NKT CELLS; CANCER	Chronic irradiation of human or murine epidermis with ultraviolet B (UVB) induces clones of p53-mutant keratinocytes. Clones precede and parallel the induction of carcinomas, suggesting that they are an early stage of UVB carcinogenesis. In the absence of UVB, these clones rapidly regress. For UVB-induced murine skin tumors and papillomas, regression is known to involve antigen-specific immunity. To determine whether antigen-specific immunity influences the creation, expansion, or regression of p53-mutant clones, we studied Rag1 knockout mice deficient in the recombination activating gene 1 required for development of B, alphabetaT, gammadeltaT, and natural killer T cells. Since tissue homeostasis could affect proliferation or persistence of clones, we also examined the effect of Rag1 on UVB-induced hyperplasia and apoptosis. Mice were irradiated with UVB daily for 7-11 weeks to create p53-mutant clones, and then retained in the absence of UV. After UV ended, epidermal thickness decreased and p53-mutant clones observed in the epidermal sheets regressed, with no significant differences between Rag1(-/-) and wild type. During the initial chronic UVB irradiation, increasing irradiation time increased both the number and size of p53-mutant clones, with no significant difference between genotypes. We conclude that antigen-specific immunity is not involved in the initiation, expansion, or acute regression of p53-mutant clones.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT USA; Yale Univ, Yale Canc Ctr, New Haven, CT USA; Univ Debrecen, Med & Hlth Sci Ctr, Dept Dermatol, H-4012 Debrecen, Hungary; Semmelweis Univ, Sch Med, Dept Dermatol, H-1085 Budapest, Hungary	Yale University; Yale University; Yale University; University of Debrecen; Semmelweis University	Brash, DE (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,HRT 309, New Haven, CT 06520 USA.	douglas.brash@yale.edu		Zhang, Wengeng/0000-0002-1000-4692	NATIONAL CANCER INSTITUTE [R01CA078735] Funding Source: NIH RePORTER; NCI NIH HHS [CA78735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS EJ, 1971, J NATL CANCER I, V47, P653; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1998, CANCER SURV, V32, P69; BURNS FJ, 1976, CANCER RES, V36, P1422; Carnaud C, 1999, J IMMUNOL, V163, P4647; Daugelat S, 1996, IMMUNOL LETT, V50, P81, DOI 10.1016/0165-2478(96)02523-0; DAYNES RA, 1981, J INVEST DERMATOL, V77, P77, DOI 10.1111/1523-1747.ep12479260; DEFABO EC, 1979, PHOTOCHEM PHOTOBIOL, V30, P385, DOI 10.1111/j.1751-1097.1979.tb07372.x; DEGRUIJL FR, 1993, CANCER RES, V53, P53; FISHER MS, 1977, P NATL ACAD SCI USA, V74, P1688, DOI 10.1073/pnas.74.4.1688; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; KRIPKE ML, 1974, J NATL CANCER I, V53, P1333, DOI 10.1093/jnci/53.5.1333; KRIPKE ML, 1976, J NATL CANCER I, V57, P211, DOI 10.1093/jnci/57.1.211; Lu YP, 1999, CANCER RES, V59, P4591; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moodycliffe AM, 2000, NAT IMMUNOL, V1, P521, DOI 10.1038/82782; NOONAN FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P801, DOI 10.1111/j.1751-1097.1990.tb08685.x; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Rebel H, 2001, CANCER RES, V61, P977; Ren ZP, 1996, ONCOGENE, V12, P765; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; STRICKLAND PT, 1987, CANCER RES, V47, P6294; STRICKLAND PT, 1986, ENVIRON HEALTH PERSP, V68, P131, DOI 10.2307/3430257; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; TODA KI, 1986, J CLIN LAB IMMUNOL, V20, P129; Ullrich SE, 2000, BIOCHEMICAL MODULATION OF SKIN REACTIONS, P281; Ullrich SE, 2002, FRONT BIOSCI-LANDMRK, V7, pD684, DOI 10.2741/ullrich; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6369	6376		10.1038/sj.onc.1206657	http://dx.doi.org/10.1038/sj.onc.1206657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508517				2022-12-28	WOS:000185535300007
J	Matsuzawa-Watanabe, Y; Inoue, J; Semba, K				Matsuzawa-Watanabe, Y; Inoue, J; Semba, K			Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1	ONCOGENE			English	Article						tumor-suppressor gene; transcription factor; gonad; sex determination	SEX-DETERMINING REGION; DNA-BINDING; SUPPRESSOR GENE; EXPRESSION; PROTEIN; CHROMOSOME; VARIANTS; SEQUENCE; SOX9	The Wilms' tumor 1 (WT1) and sex-determining region of the Y chromosome (SRY) genes are essential for development of the mammalian gonads and mutations in these genes are associated with gonadal dysgenesis in humans. The SRY gene encodes a transcription factor with one high-mobility group (HMG) box as a DNA-binding domain. WT1 encodes a transcription factor that contains four contiguous C2H2-type zinc-finger motifs as a DNA/RNA binding or protein-protein interaction domain. Here we report that WT1 binds to and acts synergistically with SRY to activate transcription from a promoter containing SRY-binding sites. This interaction is mediated by the WT1 zinc-finger domain and the SRY HMG box. WT1 mutants associated with Denys-Drash syndrome (DDS), which is characterized by Wilms' tumor, pseudohermaphroditism, and nephropathy, fail to interact with SRY. Wildtype WT1 is recruited to SRY-binding sites in an SRY-dependent manner, whereas DDS mutants are not recruited as efficiently. These results suggest that WT1 forms a complex with SRY to regulate transcription and that this WT1-SRY interaction is important in testis development.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Semba, K (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ksemba@ims.u-tokyo.ac.jp						ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Hanley NA, 1999, MECH DEVELOP, V87, P175, DOI 10.1016/S0925-4773(99)00123-9; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; KENT J, 1995, ONCOGENE, V11, P1781; Kim J, 1999, MOL CELL BIOL, V19, P2289; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; McElreavey K, 1999, AM J MED GENET, V89, P176, DOI 10.1002/(SICI)1096-8628(19991229)89:4<176::AID-AJMG2>3.0.CO;2-B; Moore AW, 1999, DEVELOPMENT, V126, P1845; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Semba K, 1996, GENE, V175, P167, DOI 10.1016/0378-1119(96)00143-6; Shimamura R, 1997, CLIN CANCER RES, V3, P2571; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398	38	38	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7900	7904		10.1038/sj.onc.1206717	http://dx.doi.org/10.1038/sj.onc.1206717			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970737				2022-12-28	WOS:000185388200004
J	Nath, N; Wang, S; Betts, V; Knudsen, E; Chellappan, S				Nath, N; Wang, S; Betts, V; Knudsen, E; Chellappan, S			Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases	ONCOGENE			English	Article						Fas; p38; E2F1; cyclins; cdk	S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; CELL-PROLIFERATION; RB/E2F PATHWAY; E2F PROTEINS; EXPRESSION; ACTIVATION; BINDING	Inactivation of the retinoblastoma (Rb) tumor suppressor protein is essential for the G1/S transition during mammalian cell cycle progression. Although Rb is inactivated by phosphorylation by cyclins D and E and their associated kinases during cell cycle progression, we find that Rb is inactivated upon apoptotic stimulation by Fas through the mediation of p38 kinase, independent of cyclins and cyclin-dependent kinases (cdks). Inactivation by p38 kinase coincided with increased phosphorylation of Rb leading to dissociation of E2F and increased transcriptional activity; such p38-mediated changes in Rb function occurred only during Fas stimulation but not mitogenic progression. p38 kinase targets Rb preferentially and had minimal effects on p107 and had no effect on p130 function. We also find that phosphorylation site mutants of Rb (PSM7LP and PSM9-Rb) that cannot be inactivated by cdks can be targeted by Fas and p38 kinase, suggesting that Rb inactivation by these kinases is biochemically and functionally distinct. It appears that Rb inactivation is achieved by different kinase cascades in response to mitogenic and apoptotic signals.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chellappan, S (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nath N, 1999, J IMMUNOL, V162, P5351; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Takahashi Y, 2000, GENE DEV, V14, P804; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang HL, 2000, CLIN CANCER RES, V6, P1579	50	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5986	5994		10.1038/sj.onc.1206843	http://dx.doi.org/10.1038/sj.onc.1206843			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955077				2022-12-28	WOS:000185137800007
J	McBride, WH; Iwamoto, KS; Syljuasen, R; Pervan, M; Pajonk, F				McBride, WH; Iwamoto, KS; Syljuasen, R; Pervan, M; Pajonk, F			The role of the ubiquitin/proteasome system in cellular responses to radiation	ONCOGENE			English	Review						proteasome; ubiquitin; DNA repair; cell cycle arrest; apoptosis	NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; MULTICATALYTIC PROTEINASE COMPLEX; DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; NUCLEOTIDE EXCISION-REPAIR; CEREBELLAR GRANULE NEURONS; HUMAN ENDOTHELIAL-CELLS; MULTIPLE-MYELOMA CELLS	In the last few years, the ubiquitin(Ub)/proteasome system has become increasingly recognized as a controller of numerous physiological processes, including signal transduction, DNA repair, chromosome maintenance, transcriptional activation, cell cycle progression, cell survival, and certain immune cell functions. This is in addition to its more established roles in the removal of misfolded, damaged, and effete proteins. This review examines the role of the Ub/proteasome system in processes underlying the classical effects of irradiation on cells, such as radiation-induced gene expression, DNA repair and chromosome instability, oxidative damage, cell cycle arrest, and cell death. Furthermore, recent evidence suggests that the proteasome is a redox-sensitive target for ionizing radiation and other oxidative stress signals. In other words, the Ub/proteasome system may not simply be a passive player in radiation-induced responses, but may modulate them. The extent of the modulation will be influenced by the functional and structural diversity that is expressed by the system. Cell types vary in the Ub/proteasome structures they possess and the level at which they function, and this changes as they go from the normal to the cancerous condition. Cancer-related functional changes within the Ub/proteasome system may therefore present unique targets for cancer therapy, especially when targeting agents are used in combination with radio- or chemotherapy. The peptide boronic acid compound PS-341, which was designed to inhibit proteasome chymotryptic activity, is in clinical trials for the treatment of solid and hematogenous tumors. It has shown some efficacy on its own and in combination with chemotherapy. Preclinical studies have shown that PS-341 will also potentiate the cytotoxic effects of radiation therapy. In addition, other drugs in common clinical use have been shown to affect proteasome function, and their activities may be valuably reconsidered from this perspective.	Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Radiol Univ Clin, Dept Radiat Oncol, D-79098 Freiburg, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Danish Cancer Society; University of Freiburg	McBride, WH (corresponding author), Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA.	mcbride@radonc.ucla.edu	Pajonk, Frank/E-4247-2010		NCI NIH HHS [CA-87887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEYAMA K, 1995, FEBS LETT, V364, P298, DOI 10.1016/0014-5793(95)00412-3; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Arnold J, 2002, BIOESSAYS, V24, P1060, DOI 10.1002/bies.10179; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Beetz A, 1997, INT J RADIAT BIOL, V72, P33, DOI 10.1080/095530097143518; BEHRENDS U, 1994, 42ND ANN M RAD RES S, P164; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bobba A, 2002, FEBS LETT, V515, P8, DOI 10.1016/S0014-5793(02)02231-7; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; BROSKI AP, 1994, TRANSPLANTATION, V57, P582; Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X; Bush KT, 1997, J BIOL CHEM, V272, P9086; Bussell K, 2001, NAT REV MOL CELL BIO, V2, P875, DOI 10.1038/35103057; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7; Carthew RW, 2000, CURR BIOL, V10, pR532, DOI 10.1016/S0960-9822(00)00587-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; Cheson BD, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.34878; CHIANG CS, 1993, RADIOTHER ONCOL, V29, P60, DOI 10.1016/0167-8140(93)90174-7; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; CohenFix O, 1997, CURR OPIN CELL BIOL, V9, P800, DOI 10.1016/S0955-0674(97)80080-4; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Costelli P, 2002, CYTOKINE, V19, P1, DOI 10.1006/cyto.2002.1036; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; Daino K, 2002, RADIAT RES, V157, P478, DOI 10.1667/0033-7587(2002)157[0478:EIOCPA]2.0.CO;2; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; DEWEY WC, 1971, RADIAT RES, V47, P672, DOI 10.2307/3573359; DEWEY WC, 1972, RADIAT RES, V52, P373, DOI 10.2307/3573575; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Eisen V, 1977, Agents Actions Suppl, V2, P99; EKJKOVA E, 2002, EMBO REP, V3, P219; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Finkielstein CV, 2002, J BIOL CHEM, V277, P38476, DOI 10.1074/jbc.M206184200; Fittkau M, 2001, J CANCER RES CLIN, V127, P96, DOI 10.1007/s004320000174; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FONTANA A, 1982, J IMMUNOL, V129, P2413; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; Fukuchi K, 2002, BIOCHEM BIOPH RES CO, V293, P120, DOI 10.1016/S0006-291X(02)00198-5; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Garber K, 2002, J NATL CANCER I, V94, P550; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gaugler MH, 1997, INT J RADIAT BIOL, V72, P201, DOI 10.1080/095530097143428; GILLETTE EL, 1970, RADIOLOGY, V96, P639, DOI 10.1148/96.3.639; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Gorski DH, 1999, CANCER RES, V59, P3374; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 2000, BIOGERONTOLOGY, V1, P31, DOI 10.1023/A:1010037908060; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; Hayashi T, 2000, J BIOL CHEM, V275, P5238, DOI 10.1074/jbc.275.7.5238; Heckmann M, 1998, EXP CELL RES, V238, P148, DOI 10.1006/excr.1997.3826; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hildebrandt G, 1998, STRAHLENTHER ONKOL, V174, P580, DOI 10.1007/BF03038296; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoffmann C, 2001, AIDS, V15, P2119, DOI 10.1097/00002030-200111090-00007; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hong JH, 1997, MOL BRAIN RES, V48, P223, DOI 10.1016/S0169-328X(97)00095-8; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; HONG JH, 1994, INT J RADIAT ONCOL, V30, pS315; Hosoi Y, 2001, INT J CANCER, V96, P270, DOI 10.1002/ijc.1030; Hu J, 2002, EUR J NEUROSCI, V16, P1409, DOI 10.1046/j.1460-9568.2002.02218.x; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; ICHIHARA A, 1993, ADV ENZYME REGUL, V33, P173; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishii K, 1997, NEUROSCI LETT, V228, P17, DOI 10.1016/S0304-3940(97)00347-9; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; IWAMOTO KS, 1992, RAD RES, V118; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jaster R, 1999, BBA-GENE STRUCT EXPR, V1446, P308, DOI 10.1016/S0167-4781(99)00095-0; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Johnston CJ, 2002, RADIAT RES, V157, P256, DOI 10.1667/0033-7587(2002)157[0256:RIPFEO]2.0.CO;2; Joiner MC, 2001, INT J RADIAT ONCOL, V49, P379, DOI 10.1016/S0360-3016(00)01471-1; Joiner MC, 1999, CR ACAD SCI III-VIE, V322, P167, DOI 10.1016/S0764-4469(99)80040-7; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; KANAYAMA H, 1991, CANCER RES, V51, P6677; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuckelkorn U, 2000, BIOL CHEM, V381, P1017, DOI 10.1515/BC.2000.125; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Kumeda SI, 1999, ANTICANCER RES, V19, P3961; L'Allemain G, 2002, B CANCER, V89, P29; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Lebbe C, 1998, AIDS, V12, pF45, DOI 10.1097/00002030-199807000-00002; Lee MH, 2001, J NEUROCHEM, V78, P32, DOI 10.1046/j.1471-4159.2001.00416.x; Lee RT, 2001, CIRC RES, V88, P262, DOI 10.1161/01.RES.88.3.262; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Liao Yu-Pei, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P480; Liu QH, 2000, GENE DEV, V14, P1448; Locke JE, 2002, INT J RADIAT BIOL, V78, P493, DOI [10.1080/095530002317577312, 10.1080/09553000110120355]; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; Lu XH, 2001, ARCH BIOCHEM BIOPHYS, V387, P163, DOI 10.1006/abbi.2001.2270; LuHesselmann J, 1997, RADIAT RES, V148, P531, DOI 10.2307/3579728; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Luo GJ, 2000, AM J PHYSIOL-REG I, V278, pR749, DOI 10.1152/ajpregu.2000.278.3.R749; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Macagno A, 2001, EUR J IMMUNOL, V31, P3271, DOI 10.1002/1521-4141(200111)31:11<3271::AID-IMMU3271>3.0.CO;2-2; Machiels BM, 1997, CYTOMETRY, V28, P243; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Martin JMC, 1999, CANCER RES, V59, P1134; Masuda T, 2002, CANCER RES, V62, P3819; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; McBride William H, 2002, Mil Med, V167, P66; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Mimnaugh EG, 2000, BIOCHEM PHARMACOL, V60, P1343, DOI 10.1016/S0006-2952(00)00455-X; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORTH RJ, 1984, ADV IMMUNOL, V35, P89, DOI 10.1016/S0065-2776(08)60575-1; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pajonk F, 2001, RADIAT RES, V156, P447, DOI 10.1667/0033-7587(2001)156[0447:TPICBA]2.0.CO;2; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Pajonk F, 2002, AIDS, V16, P1195, DOI 10.1097/00002030-200205240-00020; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Pajonk F, 2000, INT J RADIAT BIOL, V76, P1691; Pajonk F, 2001, RADIOTHER ONCOL, V59, P203, DOI 10.1016/S0167-8140(01)00311-5; Pajonk F, 2002, CANCER RES, V62, P5230; PAJONK F, 2001, RADIOTHER ONCOL, P191; Pallares-Trujillo J, 2000, MED HYPOTHESES, V54, P565, DOI 10.1054/mehy.1999.0895; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; Patel S, 1998, ACTA ONCOL, V37, P475, DOI 10.1080/028418698430430; Pervan M, 2001, AM J CLIN ONCOL-CANC, V24, P481, DOI 10.1097/00000421-200110000-00013; Pervan Milena, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P666; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Piccinini M, 2001, BIOCHEM J, V356, P835, DOI 10.1042/0264-6021:3560835; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Ponnappan U, 1999, CELL IMMUNOL, V192, P167, DOI 10.1006/cimm.1998.1418; Poon RYC, 1997, CANCER RES, V57, P5168; Pritts T, 2002, AM J SURG, V183, P372, DOI 10.1016/S0002-9610(02)00812-7; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roedel F, 2002, INT J RADIAT BIOL, V78, P711, DOI 10.1080/09553000210137671; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Sadekova S, 1997, INT J RADIAT BIOL, V72, P653, DOI 10.1080/095530097142807; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sawada H, 2002, P NATL ACAD SCI USA, V99, P1223, DOI 10.1073/pnas.032389499; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schultz ES, 2002, J EXP MED, V195, P391, DOI 10.1084/jem.20011974; Scully R, 2001, EXP CELL RES, V264, P67, DOI 10.1006/excr.2000.5132; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shah SA, 2002, SURGERY, V131, P595, DOI 10.1067/msy.2002.121890; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; SIERRARIVERA E, 1993, RADIAT RES, V135, P40, DOI 10.2307/3578394; Sijts A, 2002, MOL IMMUNOL, V39, P165, DOI 10.1016/S0161-5890(02)00099-8; Sijts AJAM, 2000, J IMMUNOL, V164, P4500, DOI 10.4049/jimmunol.164.9.4500; Soldatenkov VA, 1997, CANCER RES, V57, P3881; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sun Y, 2002, CANCER RES, V62, P2875; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Trott KR, 1999, RADIOTHER ONCOL, V51, P197, DOI 10.1016/S0167-8140(99)00066-3; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2001, CURR BIOL, V11, pR834, DOI 10.1016/S0960-9822(01)00498-5; Vugmeyster Y, 2002, MOL IMMUNOL, V39, P431, DOI 10.1016/S0161-5890(02)00123-2; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wojcik C, 1996, EUR J CELL BIOL, V70, P172; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; Wu HM, 2002, AM J RESP CELL MOL, V27, P234, DOI 10.1165/ajrcmb.27.2.4792; Wu HM, 2002, FEBS LETT, V526, P101, DOI 10.1016/S0014-5793(02)03151-4; Wu LW, 1999, BLOOD CELL MOL DIS, V25, P20, DOI 10.1006/bcmd.1999.0223; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yamaguchi R, 2000, EXP CELL RES, V261, P271, DOI 10.1006/excr.2000.5053; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zaiss DMW, 2002, P NATL ACAD SCI USA, V99, P14344, DOI 10.1073/pnas.212257299; Zhang F, 2002, EXP CELL RES, V281, P190, DOI 10.1006/excr.2002.5670; ZHANG JS, 1994, CHINESE MED J-PEKING, V107, P653; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou XY, 2002, CANCER RES, V62, P1598	282	110	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5755	5773		10.1038/sj.onc.1206676	http://dx.doi.org/10.1038/sj.onc.1206676			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947384				2022-12-28	WOS:000185086100004
J	Zalcenstein, A; Stambolsky, P; Weisz, L; Muller, M; Wallach, D; Goncharov, TM; Krammer, PH; Rotter, V; Oren, M				Zalcenstein, A; Stambolsky, P; Weisz, L; Muller, M; Wallach, D; Goncharov, TM; Krammer, PH; Rotter, V; Oren, M			Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	ONCOGENE			English	Article						p53; apoptosis; CD 95; Fas/APO-1; repression	APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; WILD-TYPE; CD95 APO-1/FAS; IONIZING-RADIATION; OF-FUNCTION; HUMAN MDR1; ACTIVATION; SUPPRESSOR; FAS	Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which probably confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the CD95 (Fas/APO-1) gene, encoding a death receptor implicated in a variety of apoptotic responses. Moderate (40-50%) downregulation of CD95 mRNA and surface protein expression by mutant p53 correlates with partial protection against CD95-dependent cell death. Excess mutant p53 represses the transcriptional activity of the CD95 promoter, with the extent of repression varying among different tumor-associated p53 mutants. Furthermore, mutant p53 protein binds the CD95 promoter in vitro, in a region distinct from the one implicated in tight interactions of the CD95 gene with witd-type p53. Hence, the CD95 promoter is likely to be a direct target for downregulation by mutant p53. This activity of mutant p53 may contribute to its gain of function effects in oncogenesis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Univ Hosp, Dept Internal Med 4, D-69115 Heidelberg, Germany; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Weizmann Institute of Science; Ruprecht Karls University Heidelberg; Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ)	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Martina, Mueller-Schilling/R-4162-2016	Oren, Moshe/0000-0003-4311-7172				Albor A, 1998, CANCER RES, V58, P2091; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Boldrini L, 2001, ONCOGENE, V20, P6632, DOI 10.1038/sj.onc.1204727; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; O'Connor L, 2000, CANCER RES, V60, P1217; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peled A, 1996, CANCER RES, V56, P2148; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Spence CL, 2000, METHODS MOL BIOL, V147, P25; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STRAUSS BE, 1995, BIOCHEM BIOPH RES CO, V217, P333, DOI 10.1006/bbrc.1995.2781; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volkmann M, 2001, J MOL MED-JMM, V79, P594, DOI 10.1007/s001090100244; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	55	97	101	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5667	5676		10.1038/sj.onc.1206724	http://dx.doi.org/10.1038/sj.onc.1206724			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944915				2022-12-28	WOS:000184865900016
J	Di Bacco, A; Gill, G				Di Bacco, A; Gill, G			The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor	ONCOGENE			English	Article						cell proliferation; mannose-6-phosphate receptor; NTERA-2; tumor suppressor	EMBRYONAL CARCINOMA-CELLS; MANNOSE 6-PHOSPHATE; RETINOIC ACID; NEURONAL DIFFERENTIATION; PERINATAL LETHALITY; UROKINASE RECEPTOR; GENE-EXPRESSION; TGF-ALPHA; IGF-II; ACTIVATION	Secreted proteins and their cognate receptors are implicated in a myriad of activities that regulate cell proliferation, differentiation, and development. CREG, a cellular repressor of E1A-stimulated genes, is a secreted glycoprotein that antagonizes cellular transformation by E1A and ras. We have previously shown that CREG expression is induced very early during differentiation of pluripotent cells and, even in the absence of other inducers, CREG promotes neuronal differentiation of human teratocarcinoma NTERA-2 cells. Here we show that ectopic expression of CREG in NTERA-2 cells results in a delay of the G1/S phase transition of the cell cycle and growth inhibition. We show that CREG binds directly to the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) dependent on CREG glycosylation. The M6P/IGF2R is a tumor suppressor that functions to control cell growth through interactions with multiple ligands. By analysing CREG activity in cells lacking M6P/IGF2R expression, we show that this receptor is required for CREG-induced growth inhibition. These studies reveal that CREG inhibits cell growth dependent on the M6P/IGF2R and suggest that interactions between CREG and a well-characterized tumor suppressor may contribute to regulation of proliferation and differentiation in multiple lineages.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.							ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hankins GR, 1996, ONCOGENE, V12, P2003; Ikushima H, 2000, P NATL ACAD SCI USA, V97, P8439, DOI 10.1073/pnas.97.15.8439; Jadot M, 1999, J BIOL CHEM, V274, P21104, DOI 10.1074/jbc.274.30.21104; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Journet A, 2000, ELECTROPHORESIS, V21, P3411, DOI 10.1002/1522-2683(20001001)21:16<3411::AID-ELPS3411>3.0.CO;2-M; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kunita R, 2002, GENOMICS, V80, P456, DOI 10.1006/geno.2002.6857; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Lorenzo K, 2000, CANCER RES, V60, P4070; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Ma XY, 2002, BLOOD, V100, P833, DOI 10.1182/blood.V100.3.833; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Piquemal D, 2002, GENOMICS, V80, P361, DOI 10.1006/geno.2002.6836; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Veal E, 2000, ONCOGENE, V19, P2120, DOI 10.1038/sj.onc.1203529; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wang SN, 1997, CANCER RES, V57, P2543; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Xie S., 2002, MED SCI MONIT INT ME, V8, P293, DOI [10.3390/ijms21186968, DOI 10.3390/IJMS21186968]	53	72	76	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5436	5445		10.1038/sj.onc.1206670	http://dx.doi.org/10.1038/sj.onc.1206670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934103				2022-12-28	WOS:000184735000008
J	Young, LS; Murray, PG				Young, LS; Murray, PG			Epstein-Barr virus and oncogenesis: from latent genes to tumours	ONCOGENE			English	Review						Epstein-Barr virus; latent genes; lymphoma; carcinoma	MEMBRANE-PROTEIN 1; NF-KAPPA-B; BURKITT-LYMPHOMA CELLS; REED-STERNBERG CELLS; LYMPHOEPITHELIOMA-LIKE CARCINOMA; RECEPTOR-ASSOCIATED FACTOR-1; CLASSICAL HODGKINS-DISEASE; ENCODED NUCLEAR ANTIGEN; HERPES-TYPE VIRUS; NASOPHARYNGEAL CARCINOMA	Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus associated with the development of both lymphoid and epithelial tumours. As a common virus infection, EBV appears to have evolved to exploit the process of B cell development to persist as a life-long asymptomatic infection. However, the virus can contribute to oncogenesis as evidenced by its frequent detection in certain tumours, namely Burkitt's lymphoma (BL), post-transplant B cell lymphomas, Hodgkin's disease (HD) and nasopharyngeal carcinoma (NPC), and by its unique ability to efficiently transform resting B cells in vitro into permanently growing lymphoblastoid cell lines (LCLs). These transforming effects are associated with the restricted expression of EBV genes such that only a subset of so-called latent virus proteins are expressed in virus infected tumours and in LCLs. Distinct forms of EBV latency are manifest in the different tumours and these appear to be a vestige of the pattern of latent gene expression used by the virus during the establishment of persistent infection within the B cell pool. This review summarises our current knowledge of EBV latent gene function and how this relates to the role of the virus in the aetiology of different tumours.	Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.		Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ALLAN GJ, 1992, J GEN VIROL, V73, P1547, DOI 10.1099/0022-1317-73-6-1547; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; Armstrong AA, 1998, LEUKEMIA, V12, P1272, DOI 10.1038/sj.leu.2401097; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Brink AATP, 2000, J PATHOL, V191, P400, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH658&gt;3.0.CO;2-G; BROOKS LA, 1993, J VIROL, V67, P3182, DOI 10.1128/JVI.67.6.3182-3190.1993; BURKITT D, 1962, Br Med J, V2, P1019; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Chen HL, 1999, BLOOD, V93, P3026, DOI 10.1182/blood.V93.9.3026; Chiang AKS, 1996, INT J CANCER, V68, P285, DOI 10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y; Cho YG, 2001, P NATL ACAD SCI USA, V98, P1224, DOI 10.1073/pnas.98.3.1224; Clarke CA, 2001, CANCER-AM CANCER SOC, V91, P1579, DOI 10.1002/1097-0142(20010415)91:8<1579::AID-CNCR1169>3.0.CO;2-L; CLEMENS MJ, 1994, BIOCHIMIE, V76, P770, DOI 10.1016/0300-9084(94)90081-7; COATES PJ, 1991, J PATHOL, V164, P291, DOI 10.1002/path.1711640404; Dadmanesh F, 2001, HISTOPATHOLOGY, V38, P54, DOI 10.1046/j.1365-2559.2001.01055.x; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DECAMPOSLIMA PO, 1993, INT J CANCER, V53, P856, DOI 10.1002/ijc.2910530525; Dotti G, 2000, TRANSPLANTATION, V69, P827; Durkop H, 1999, BLOOD, V93, P617, DOI 10.1182/blood.V93.2.617.402k14_617_623; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Flavell KJ, 2001, BRIT J CANCER, V85, P350, DOI 10.1054/bjoc.2001.1872; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; FUJII T, 1993, ACTA PATHOL JAPON, V43, P107; Galetsky SA, 1997, INT J CANCER, V73, P786, DOI 10.1002/(SICI)1097-0215(19971210)73:6&lt;786::AID-IJC2&gt;3.0.CO;2-Z; Gan YJ, 2002, AM J PATHOL, V160, P781, DOI 10.1016/S0002-9440(10)64900-0; GERBER P, 1972, LANCET, V2, P988; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; Glavina-Durdov M, 2001, BRIT J CANCER, V84, P1227, DOI 10.1054/bjoc.2001.1774; Gonzalez-Moles MA, 2002, LARYNGOSCOPE, V112, P482, DOI 10.1097/00005537-200203000-00014; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Grinstein S, 2002, CANCER RES, V62, P4876; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; Gulley ML, 1996, HUM PATHOL, V27, P20, DOI 10.1016/S0046-8177(96)90133-1; GUTENSOHN N, 1980, SEMIN ONCOL, V7, P92; HATZUBAI A, 1987, INT J CANCER, V40, P358, DOI 10.1002/ijc.2910400313; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; Herbst H, 1996, BLOOD, V87, P2918, DOI 10.1182/blood.V87.7.2918.bloodjournal8772918; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; Huang D P, 1978, IARC Sci Publ, P315; HUEN DS, 1995, ONCOGENE, V10, P549; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; IMAI S, 1994, P NATL ACAD SCI USA, V88, P4766; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; JIANG WQ, 1991, EXP CELL RES, V197, P314, DOI 10.1016/0014-4827(91)90438-Z; Johannessen I, 2000, BRIT J HAEMATOL, V109, P600, DOI 10.1046/j.1365-2141.2000.02066.x; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KHANNA R, 1994, INT IMMUNOL, V6, P639, DOI 10.1093/intimm/6.4.639; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Knox PG, 1996, VIROLOGY, V215, P40, DOI 10.1006/viro.1996.0005; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; LEVINE PH, 1971, CANCER-AM CANCER SOC, V27, P416, DOI 10.1002/1097-0142(197102)27:2<416::AID-CNCR2820270227>3.0.CO;2-W; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; Longnecker R, 2000, ADV CANCER RES, V79, P175, DOI 10.1016/S0065-230X(00)79006-3; MACMAHON B, 1966, CANCER RES, V26, P1189; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER G, 1974, J INFECT DIS, V130, P187, DOI 10.1093/infdis/130.2.187; Moghaddam A, 1997, SCIENCE, V276, P2030, DOI 10.1126/science.276.5321.2030; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MURRAY PG, 1992, J PATHOL, V166, P1, DOI 10.1002/path.1711660102; Murray PG, 2001, J PATHOL, V194, P158, DOI 10.1002/path.873; Nelson BP, 2000, AM J SURG PATHOL, V24, P375, DOI 10.1097/00000478-200003000-00006; NERI A, 1991, BLOOD, V77, P1092; Nerurkar AY, 2000, ANN ONCOL, V11, P475, DOI 10.1023/A:1008363805242; NIEDOBITEK G, 1992, AM J PATHOL, V140, P879; NIEDOBITEK G, 1995, BLOOD, V86, P659, DOI 10.1182/blood.V86.2.659.bloodjournal862659; Niedobitek G, 2000, J PATHOL, V191, P394, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH651&gt;3.0.CO;2-0; Niedobitek G, 1997, NONHODGKINS LYMPHOMA, P309; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; Panousis CG, 1997, J VIROL, V71, P4752, DOI 10.1128/JVI.71.6.4752-4760.1997; Parker GA, 1996, ONCOGENE, V13, P2541; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; Qui K., 1997, INT J CANCER, V71, P155; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Razzouk BI, 1996, J INFECT DIS, V173, P529, DOI 10.1093/infdis/173.3.529; RICKINSON AB, 1992, CANCER SURV, V13, P53; RICKINSON AB, 1984, CELL IMMUNOL, V87, P646, DOI 10.1016/0008-8749(84)90032-7; Rivailler P, 2002, J VIROL, V76, P12055, DOI 10.1128/JVI.76.23.12055-12068.2002; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Robertson E.S, 1997, EPSTEINBARR VIRUS RE, V4, P143; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Sakai T, 1998, J VIROL, V72, P6034, DOI 10.1128/JVI.72.7.6034-6039.1998; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 1999, J VIROL, V73, P4767, DOI 10.1128/JVI.73.6.4767-4775.1999; SHIBATA D, 1992, AM J PATHOL, V140, P769; SHIBATA D, 1991, AM J PATHOL, V139, P469; Shimakage M, 2002, HUM PATHOL, V33, P608, DOI 10.1053/hupa.2002.129786; Shin WS, 1996, AM J CLIN PATHOL, V105, P174; SILINS SL, 1994, VIROLOGY, V202, P16, DOI 10.1006/viro.1994.1317; SPECK SH, 1989, ADV VIRAL ONCOL, V8, P133; Staratschek-Jox A, 2000, AM J PATHOL, V156, P209, DOI 10.1016/S0002-9440(10)64721-9; STRAUCH B, 1974, LANCET, V1, P234; Sugawara Y, 1999, VIROLOGY, V256, P196, DOI 10.1006/viro.1999.9619; Sugiura M, 1996, BRIT J CANCER, V74, P625, DOI 10.1038/bjc.1996.412; SUZUKI T, 1995, J EXP MED, V182, P477, DOI 10.1084/jem.182.2.477; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; TOCZYSKI DP, 1994, P NATL ACAD SCI USA, V91, P3463, DOI 10.1073/pnas.91.8.3463; TOKUNAGA M, 1993, AM J PATHOL, V143, P1250; UCCINI S, 1990, INT J CANCER, V46, P581, DOI 10.1002/ijc.2910460405; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Vo QN, 2002, J CLIN PATHOL, V55, P669, DOI 10.1136/jcp.55.9.669; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WEINBERG E, 1993, AM J CLIN PATHOL, V99, P195, DOI 10.1093/ajcp/99.2.195; WEISS LM, 1991, AM J PATHOL, V139, P1259; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WU TC, 1990, INT J CANCER, V46, P801, DOI 10.1002/ijc.2910460509; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; Young LS, 1999, BIOCHEM SOC T, V27, P807, DOI 10.1042/bst0270807; YU MC, 1986, CANCER RES, V46, P956; YUEN ST, 1994, AM J SURG PATHOL, V18, P1158, DOI 10.1097/00000478-199411000-00010; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	155	387	411	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5108	5121		10.1038/sj.onc.1206556	http://dx.doi.org/10.1038/sj.onc.1206556			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910248				2022-12-28	WOS:000184615100002
J	Omoto, Y; Eguchi, H; Yamamoto-Yamaguchi, Y; Hayashi, S				Omoto, Y; Eguchi, H; Yamamoto-Yamaguchi, Y; Hayashi, S			Estrogen receptor (ER) beta 1 and ER beta cx/beta 2 inhibit ER alpha function differently in breast cancer cell line MCF7	ONCOGENE			English	Article						estrogen receptor alpha; estrogen receptor beta; estrogen receptor beta cx; breast cancer; cDNA microarray	FACTOR-BINDING-PROTEINS; MESSENGER-RNA; CATHEPSIN-D; EXPRESSION PATTERNS; WILD-TYPE; GROWTH; PROLIFERATION; GENE; ISOFORMS; CLONING	Estrogen receptor (ER) alpha plays an important role in the proliferation and progression of breast cancer. In order to explore the function of wild-type ERbeta (ERbeta1) and its variant form, ERbetacx/beta2, stable transformants of ERalpha-positive breast cancer MCF7 cells with ERbeta1 or ERbetacx/ beta2 expression vector were established. Constitutive expression of ERbeta1 or ERbetacx/beta2 reduced the S phase population of the cell cycle in dish culture and the number of colonies in an anchorage-independent assay. DNA-protein complexes of ERE with nuclear extracts from ERbeta1 transformants were observed in the electrophoretic mobility shift assay, while no complex was observed for ERbetacx/beta2 transformants. Reporter gene assay using estrogen-responsive element (ERE)-luciferase showed less responsiveness to estrogen in these transformants compared with parental cells. Endogenous mRNA expression of two known estrogen-responsive genes, cathepsin D and IGFBP4, was weakly induced by estrogen in ERbeta1 and ERbetacx/beta2 transformants compared with parental cells. A comprehensive gene expression analysis using our custom-made cDNA microarray showed that MCF7 and ERbeta1 transformants had a similar gene expression profile, whereas ERbetacx/beta2 showed a distinct profile from others. These results indicate that ERbeta1 and ERbetacx/beta2 inhibit ERalpha function differently in MCF7 cells.	Saitama Canc Ctr, Div Endocrinol, Res Inst, Ina, Saitama 3620806, Japan		Hayashi, S (corresponding author), Hiroshima Univ, Dept Mol Epidemiol, Grad Sch Biomed Sci, Minami Ku, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan.							Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; BTIST G, 1986, J BIOL CHEM, V261, P15544; Chu S, 2000, J CLIN ENDOCR METAB, V85, P1200, DOI 10.1210/jc.85.3.1200; Clarke M, 1998, LANCET, V351, P1451; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Eguchi H, 2000, CELL DEATH DIFFER, V7, P439, DOI 10.1038/sj.cdd.4400675; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; Fujimura T, 2001, BIOCHEM BIOPH RES CO, V289, P692, DOI 10.1006/bbrc.2001.6038; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Honma Y, 1999, BRIT J CANCER, V80, P96, DOI 10.1038/sj.bjc.6690327; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; JENSEN EV, 1980, CANCER-AM CANCER SOC, V46, P2759, DOI 10.1002/1097-0142(19801215)46:12+<2759::AID-CNCR2820461402>3.0.CO;2-7; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1999, CANCER RES, V59, P1175; Leygue E, 1998, CANCER RES, V58, P3197; Locker GY, 1998, CANCER TREAT REV, V24, P221, DOI 10.1016/S0305-7372(98)90051-2; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Omoto Y, 2002, EUR J CANCER, V38, P380, DOI 10.1016/S0959-8049(01)00383-5; Omoto Y, 2000, Breast Cancer, V7, P27, DOI 10.1007/BF02967184; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Omoto Y, 2001, CANCER LETT, V163, P207, DOI 10.1016/S0304-3835(00)00680-7; OWENS PC, 1993, BIOCHEM BIOPH RES CO, V193, P467, DOI 10.1006/bbrc.1993.1647; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Peng B, 2003, J MOL ENDOCRINOL, V30, P13, DOI 10.1677/jme.0.0300013; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PRATT SE, 1993, CANCER RES, V53, P5193; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Saji S, 2002, CANCER RES, V62, P4849; Speirs V, 1999, CANCER RES, V59, P5421; Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P903, DOI 10.1093/nar/27.3.903; TOI M, 1992, CANCER RES, V52, P275; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; Vladusic EA, 2000, ONCOL REP, V7, P157; Vladusic EA, 1998, CANCER RES, V58, P210	48	110	114	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5011	5020		10.1038/sj.onc.1206787	http://dx.doi.org/10.1038/sj.onc.1206787			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902984				2022-12-28	WOS:000184578900009
J	Bohm, M; Sawicka, K; Siebrasse, JP; Brehmer-Fastnacht, A; Peters, R; Klempnauer, KH				Bohm, M; Sawicka, K; Siebrasse, JP; Brehmer-Fastnacht, A; Peters, R; Klempnauer, KH			The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA	ONCOGENE			English	Article						Pdcd4; nuclear export signals; RNA-binding; Myb target gene	INITIATION-FACTOR 4G; EUKARYOTIC TRANSLATION; QUALITY-CONTROL; C-MYB; EXPORT; GENE; CRM1; IDENTIFICATION; PROMOTER; MESSAGE	The Pdcd4 gene has originally been isolated in a search for genes that are activated in cells undergoing apoptosis. Independent of these studies, the Pdcd4 gene has been implicated in the suppression of tumor-promoter-mediated transformation of keratinocytes and as a downstream target of Myb in hematopoietic cells. The Pdcd4 protein has weak homology to the eucaryotic translation initiation factor eIF4G and has been shown to interact with certain translation initiation factors. To explore the molecular function of the Pdcd4 protein, we have studied its subcellular localization. We show that the Pdcd4 protein is a predominantly nuclear protein under normal growth conditions and that it is exported from the nucleus by a leptomycin B-sensitive mechanism upon serum withdrawal. The protein contains two nuclear export signals, one of which is very potent. In addition, we demonstrate that the Pdcd4 protein has RNA-binding activity and that the sequences involved in RNA-binding are located in the amino-terminal part of the protein. Taken together, our data raise the possibility that Pdcd4 is involved in some aspect of nuclear RNA metabolism in addition to its suspected role in protein translation.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Munster, Inst Med Biophys, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Peters, Reiner/E-7352-2011	Sawicka, Kirsty/0000-0003-4195-6327				Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Lykke-Andersen J, 2001, CURR BIOL, V11, pR88, DOI 10.1016/S0960-9822(01)00036-7; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHI K, 1994, J BIOL CHEM, V269, P6320; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Schell T, 2002, GENOME BIOL, V3; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Westhof E, 1999, CURR OPIN STRUC BIOL, V9, P293, DOI 10.1016/S0959-440X(99)80039-6; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x	29	83	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4905	4910		10.1038/sj.onc.1206710	http://dx.doi.org/10.1038/sj.onc.1206710			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894233				2022-12-28	WOS:000184344600015
J	Hayes, SA; Huang, XK; Kambhampati, S; Platanias, LC; Bergan, RC				Hayes, SA; Huang, XK; Kambhampati, S; Platanias, LC; Bergan, RC			p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion	ONCOGENE			English	Article						p38 MAP kinase; transforming growth factor beta; Smad; cell adhesion; prostate cancer	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TGF-BETA; SIGNAL-TRANSDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; INDUCED PHOSPHORYLATION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; CARCINOMA CELLS	Transforming growth factor beta (TGFbeta) regulates cell adhesion, proliferation, and differentiation in a variety of cells. Smad proteins are receptor-activated transcription factors that translocate to the nucleus in response to TGFbeta. We demonstrate here that TGFbeta increases cell adhesion in metastatic PC3-M prostate cancer cells. TGFbeta treatment of PC3-M cells leads to nuclear translocation of R-Smad proteins. We show that Smad proteins are necessary, but not sufficient, for TGFbeta-mediated cell adhesion. After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3. Finally, we show that Smad3 is phosphorylated by p38 MAP kinase in vitro. These findings implicate crosstalk between the MAP kinase and Smad signaling pathways in TGFbeta's regulation of cell adhesion in human prostate cells. This represents a mechanism by which the pleiotropic effects of TGFbeta may be channeled to modulate cell adhesion.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA077816, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000260] Funding Source: NIH RePORTER; NCI NIH HHS [CA9407, CA77816, CA90386] Funding Source: Medline; NIA NIH HHS [T32 AG00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bakin AV, 2002, J CELL SCI, V115, P3193; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brodin G, 1999, CANCER RES, V59, P2731; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsing AY, 1996, CANCER RES, V56, P5146; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1996, CANCER RES, V56, P44; Kostenuik PJ, 1997, CLIN EXP METASTAS, V15, P41; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Latil A, 1999, PROSTATE, V40, P225, DOI 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MOORADIAN DL, 1990, CANCER RES, V50, P273; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Olsson N, 2001, CELL SIGNAL, V13, P483, DOI 10.1016/S0898-6568(01)00176-0; Ozen M, 2000, ANTICANCER RES, V20, P1905; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schnaper HW, 1998, PEDIATR NEPHROL, V12, P790, DOI 10.1007/s004670050550; Sehgal I, 1996, CANCER RES, V56, P3359; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; VERMA A, 2001, J BIOL CHEM, V31, P31; Wagers AJ, 2000, J IMMUNOL, V165, P5011, DOI 10.4049/jimmunol.165.9.5011; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Yamamoto T, 2001, J CELL BIOCHEM, V82, P591, DOI 10.1002/jcb.1179; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	72	48	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4841	4850		10.1038/sj.onc.1206730	http://dx.doi.org/10.1038/sj.onc.1206730			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894225				2022-12-28	WOS:000184344600007
J	Maliekal, TT; Antony, ML; Nair, A; Paulmurugan, R; Karunagaran, D				Maliekal, TT; Antony, ML; Nair, A; Paulmurugan, R; Karunagaran, D			Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer	ONCOGENE			English	Article						Smads; TGF-beta; cervical cancer; SQRT-PCR	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMA; TGF-BETA; TUMOR-SUPPRESSOR; JUVENILE POLYPOSIS; COLORECTAL-CANCER; PANCREATIC-CANCER; DPC4 EXPRESSION; II GENE; RECEPTOR	Mutations in Smads, intermediates of transforming growth factor-beta signaling, are known to contribute to the loss of sensitivity to transforming growth factor-beta, a common feature of many neoplastic cells. However, not much information is available on Smad alterations in cervical cancer and so we probed, for the first time, for alterations in Smad 2 and Smad 4 genes using human cervical cancer cell lines and human cervical tissue samples. Using PCR/reverse transcription-PCR, single-stranded conformation polymorphism analysis and DNA sequencing, we observed a deletion of 'G' in the L3 loop (crucial in Smad-receptor interaction) in C-33A cells, and an insertion of 'A' in codon 122 (loss of MH2 domain) from a cervical tumor sample, both of which caused frame shift and pretermination in Smad 2. In addition, a G/A transition at 31 bp upstream-nontranslated regions of exon 8 of Smad 4 was found in Bu 25TK cells. Smad 2 expression was less in some of the cervical tumor samples than that of nonmalignant samples and six cancer samples showed C-terminal deletions that abolish Smad 2 phosphorylation sites. The loss of expression of Smad 4 found in some cervical tumor samples was due to transcription loss rather than deletion of the gene. Our results highlight an important role for Smad 2 and Smad 4 in human cervical tumors.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Antony, Marie Lue/AAB-3952-2019; Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Paulmurugan, Ramasamy/0000-0001-7155-4738; Maliekal, Tessy/0000-0002-7311-7950				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barabas E, 2001, BRAZ J MED BIOL RES, V34, P1271, DOI 10.1590/S0100-879X2001001000006; Barbera VM, 2000, BBA-MOL BASIS DIS, V1502, P283, DOI 10.1016/S0925-4439(00)00054-5; Bevan S, 1999, GUT, V45, P406, DOI 10.1136/gut.45.3.406; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Costentin L, 2002, PANCREATOLOGY, V2, P17, DOI 10.1159/000049443; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dellas A, 1999, CANCER RES, V59, P3475; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, CANCER RES, V56, P490; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hilgers W, 2000, GENE CHROMOSOME CANC, V27, P353, DOI 10.1002/(SICI)1098-2264(200004)27:4<353::AID-GCC3>3.3.CO;2-X; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kaneko H, 1998, ACTA HAEMATOL-BASEL, V99, P187, DOI 10.1159/000040837; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Lohmann DR, 1996, AM J HUM GENET, V58, P940; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muliokandov MR, 1996, CANCER RES, V56, P197; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Nguyen HN, 1999, SEMIN SURG ONCOL, V16, P217, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<217::AID-SSU4>3.0.CO;2-U; Osawa H, 2000, INT J ONCOL, V17, P723; Patel SA, 2002, AM J SURG PATHOL, V26, P1071, DOI 10.1097/00000478-200208000-00014; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Schutte M, 1996, CANCER RES, V56, P2527; Tanaka S, 2000, BRIT J CANCER, V82, P1557; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uchida K, 1996, CANCER RES, V56, P5583; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Xie W, 2002, CANCER RES, V62, P497	42	46	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4889	4897		10.1038/sj.onc.1206806	http://dx.doi.org/10.1038/sj.onc.1206806			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894231				2022-12-28	WOS:000184344600013
J	Dunfield, LD; Nachtigal, MW				Dunfield, LD; Nachtigal, MW			Inhibition of the antiproliferative effect of TGF beta by EGF in primary human ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; TGF beta; EGF; p15(INK4B)	GROWTH-FACTOR-BETA; SIGNAL-TRANSDUCTION; SURFACE EPITHELIUM; GENE-MUTATIONS; RECEPTOR; SMAD7; IDENTIFICATION; EPIDEMIOLOGY; ANTAGONIST; CARCINOMA	The majority of ovarian cancers (OCs) arise from the ovarian surface epithelium (OSE). Proliferation of the OSE can be regulated by a number of autocrine and paracrine factors, including transforming growth factor beta (TGFbeta). Defects in the TGFbeta signaling pathway have been implicated in a number of cancers, including ovarian. We previously found that the TGFbeta signaling pathway is intact and functional in primary human OC cells, and that these cells stop growing in response to TGFbeta. Ovarian cancer cells in vivo are exposed to TGFbeta, yet continue to proliferate, therefore, mechanisms must exist to inhibit TGFbeta signaling contributing to uncontrolled cellular proliferation. Numerous signaling pathways converge with the TGFbeta pathway to modulate its effects, including signaling induced by epidermal growth factor (EGF). We hypothesized that EGF can modulate TGFbeta signaling and contribute to uncontrolled cellular proliferation of OC cells. Our results show that EGF abrogates the antiproliferative effect of TGFbeta. EGF does not modulate TGFbeta signaling by inhibiting receptor-activated Smad (R-Smad) phosphorylation or nuclear translocation. Rather, EGF decreases TGFbeta-induced mRNA expression of the cell cycle regulator, p15(INK4B), contributing to decreased sensitivity of OC cells to the antiproliferative effect of TGFbeta.	Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 1X5, Canada	Dalhousie University	Nachtigal, MW (corresponding author), Dalhousie Univ, Dept Pharmacol, 5850 Coll St, Halifax, NS B3H 1X5, Canada.	Mark.Nachtigal@Dal.ca		Nachtigal, Mark/0000-0003-3291-8628				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; Chen T, 2001, CANCER RES, V61, P4679; Daly M, 1998, SEMIN ONCOL, V25, P255; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dunfield LD, 2002, ENDOCRINOLOGY, V143, P1174, DOI 10.1210/en.143.4.1174; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HURTEAU J, 1994, CANCER, V74, P93, DOI 10.1002/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Lynch MA, 1998, CANCER RES, V58, P4227; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Riggins GJ, 1997, CANCER RES, V57, P2578; Scully RE, 1995, J CELL BIOCHEM, P208; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TORTOLEROLUNA G, 1994, OBSTET GYN CLIN N AM, V21, P1; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VIGNE JL, 1994, BIOL REPROD, V51, P1213, DOI 10.1095/biolreprod51.6.1213; Wang D, 2000, CANCER RES, V60, P4507; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	26	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4745	4751		10.1038/sj.onc.1206617	http://dx.doi.org/10.1038/sj.onc.1206617			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879019				2022-12-28	WOS:000184157000015
J	Soejima, K; Fang, WZ; Rollins, BJ				Soejima, K; Fang, WZ; Rollins, BJ			DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras	ONCOGENE			English	Article						DNA methyltransferase; tumor suppressor; lung cancer	TUMOR-SUPPRESSOR GENE; HISTONE DEACETYLASE COMPLEX; HUMAN CANCER-CELLS; CYTOSINE-5 METHYLTRANSFERASES; RENAL-CARCINOMA; LUNG-CANCER; IMMUNODEFICIENCY SYNDROME; HUMAN FIBROBLASTS; CPG METHYLATION; STEM-CELLS	Transcriptional silencing of tumor suppressor genes in association with DNA methylation contributes to malignant transformation. However, the specific DNA methyltransferases that initiate this process are unknown. Here we show that a de novo DNA methyltransferase, DNMT3b, substantially contributes to the oncogenic phenotype in a lung cancer model. Normal human bronchial epithelial (NHBE) cells expressing telomerase, SV40 large T antigen, and activated Ras were immortal, formed colonies in soft agar, and expressed DNMT3b. Antisense suppression of DNMT3b prevented soft agar growth. Furthermore, mouse embryo fibroblasts expressing T antigen and Ras formed soft agar colonies and large tumors, but fibroblasts from Dnmt3b(-/-) mice did not grow in soft agar and were much less tumorigenic in vivo. The tumor suppressor genes, FHIT, TSLC1, and RASSF1A were downregulated in transformed NHBE cells, and antisense DNMT3b treatment resulted in re-expression of FHIT and TSLC1. While expression of TSCL1 correlated with methylation of CpG dinucleotides in its promoter region, the expression of FHIT did not, suggesting that DNMT3b may silence genes by several mechanisms including direct DNA methylation or recruitment of proteins that modify chromatin. Regardless of mechanism, our data indicate that DNMT3b plays an important role in transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rollins, BJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, M430,44 Binney St, Boston, MA 02115 USA.	barrett_rollins@dfci.harvard.edu	Soejima, Kenzo/T-9878-2019	Soejima, Kenzo/0000-0001-9749-995X				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan MF, 2000, CURR TOP MICROBIOL, V249, P75; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GREGER V, 1994, HUM GENET, V94, P491; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Pradhan S, 1998, NUCLEIC ACIDS RES, V26, P1214, DOI 10.1093/nar/26.5.1214; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIOS M, 1990, J CELL PHYSIOL, V145, P434, DOI 10.1002/jcp.1041450307; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAKAI T, 1991, AM J HUM GENET, V48, P880; SHAPIRO GI, 1995, CANCER RES, V55, P505; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Tanaka H, 1998, CANCER RES, V58, P3429; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	57	80	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4723	4733		10.1038/sj.onc.1206510	http://dx.doi.org/10.1038/sj.onc.1206510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879017				2022-12-28	WOS:000184157000013
J	Krasilnikov, M; Ivanov, VN; Dong, J; Ronai, Z				Krasilnikov, M; Ivanov, VN; Dong, J; Ronai, Z			ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis	ONCOGENE			English	Article						ERK; PI3K; STAT; melanoma; apoptosis	PERIPHERAL-BLOOD CELLS; KAPPA-B ACTIVATION; CONSTITUTIVE ACTIVATION; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; MAP KINASE; C-JUN; INHIBITION; INTERFERON	Signal transducers and activators of transcription (STAT) proteins nuclear translocation and transcriptional activity are regulated by diverse protein kinases in response to extracellular stimuli by cytokines, growth factors and stress. Using two melanoma-derived cell lines that exhibit marked differences in basal activities of MAPKs and PI3K-AKT, we studied changes both in STAT activities and in their sensitization to apoptosis. Activating mutations of B-RAF (T1796A) and impaired expression of PTEN are detected in LU1205, but not in FEMX melanoma cells, and are reflected in high basal levels of expression and activities of MAPKs and PI3K-AKT. Treatment with either PD98059 (PD) or LY294002 (LY), the pharmacological inhibitors of MEK-ERK and PI3K, respectively, markedly increased GAS-Luc activity in LU1205, but not in FEMX cells. Tyrosine phosphorylation of STAT3/5 and of JAK2 also increased upon treatment of LU1205 cells with either PD or LY, suggesting that constitutive active MAPK and PI3K signals inhibit tyrosine phosphorylation of JAK/STATs. Treatment of FEMX and LU1205 with PD sensitized the cells to apoptosis, albeit by TNFalpha and TRAIL death cascades, respectively, indicating that additional yet distinct targets are affected by each signaling pathway. Indeed, the combination of LY and PD treatment synergistically increased the apoptosis of LU1205 and FEMX cells. Overall, whereas PI3K and MAPK downregulate JAK-STAT signaling, additional targets are affected by these kinases and sensitizes melanoma to apoptosis via distinct death cascades.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NN Blochin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Krasil'nikov, Mikhail/R-6938-2019; Ivanov, Vladimir N/A-3081-2008	Krasil'nikov, Mikhail/0000-0002-5902-7633; Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brose MS, 2002, CANCER RES, V62, P6997; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chai SK, 1997, J IMMUNOL, V159, P4720; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Edwards E, 2002, CANCER RES, V62, P4671; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kim HJ, 1999, MOL CELL BIOL, V19, P6323; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Ozes ON, 1999, NATURE, V401, P82; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719	49	111	112	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4092	4101		10.1038/sj.onc.1206598	http://dx.doi.org/10.1038/sj.onc.1206598			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821943	Green Published			2022-12-28	WOS:000183707600012
J	Penengo, L; Rubin, C; Yarden, Y; Gaudino, G				Penengo, L; Rubin, C; Yarden, Y; Gaudino, G			c-Cbl is a critical modulator of the Ron tyrosine kinase receptor	ONCOGENE			English	Article						c-Cbl; Grb2; Ron; ubiquitylation	MACROPHAGE-STIMULATING PROTEIN; GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; BINDING DOMAIN; RING FINGER; ACTIVATION; PHOSPHORYLATION; MET; PROTOONCOGENE; REGULATOR	Ron, the receptor tyrosine kinase (RTK) for the macrophage stimulating protein (MSP), activates multiple signaling pathways by recruiting several positive regulators to a multifunctional docking site. Here we show that stimulation by MSP also recruits a negative regulator, the c-Cbl ubiquitin ligase, to the multifunctional docking site as well as to a juxtamembrane tyrosine autophosphorylation site. c-Cbl recruitment to these two sites results in polyubiquitylation of Ron molecules, which are subsequently sorted for endocytosis and degradation. Both the phosphotyrosine binding domain of c-Cbl and its RING domain are essential for downregulation of Ron. Although Ron and c-Cbl are found also in physical complexes that include Grb2, these associations are insufficient for productive ubiquitylation of Ron. Our results shed light on the mechanism of receptor desensitization mediated by c-Cbl and its binding partner Grb2.	Univ Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; Weizmann Inst Sci, Dept Biol Sci, IL-76100 Rehovot, Israel	University of Eastern Piedmont Amedeo Avogadro; Weizmann Institute of Science	Gaudino, G (corresponding author), Univ Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy.		YARDEN, YOSEF/K-1467-2012	PENENGO, Lorenza/0000-0001-7888-4473				Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 1998, J IMMUNOL, V161, P4950; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	36	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3669	3679		10.1038/sj.onc.1206585	http://dx.doi.org/10.1038/sj.onc.1206585			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802274				2022-12-28	WOS:000183551000001
J	Kunapuli, P; Somerville, R; Still, IH; Cowell, JK				Kunapuli, P; Somerville, R; Still, IH; Cowell, JK			ZNF198 protein, involved in rearrangement in myeloproliferative disease, forms complexes with the DNA repair-associated HHR6A/6B and RAD18 proteins	ONCOGENE			English	Article						ZNF198; myeloproliferative disease; post replication repair; RAD6; RAD18	UBIQUITIN-CONJUGATING ENZYME; GROWTH-FACTOR RECEPTOR-1; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; DISORDER FUSES; YEAST RAD6; GENE RAD6; TRANSLOCATION; CHROMOSOME-13; BINDING	A highly specific t(8;13)(p11;q12) translocation has been consistently identified in bone marrow cells from patients with an atypical myeloproliferative disease that is associated with peripheral blood eosinophila and T- or B-cell leukemias. In all patients analysed to date, the translocation event results in a chimeric gene in which the atypical zinc-finger domain of ZNF198 is fused to the N-terminal end of the catalytic domain of the FGFR1 receptor tyrosine kinase. To understand more about the consequences of this rearrangement we have investigated the normal function of the ZNF198 gene. Using yeast two-hybrid analysis we identified HHR6 as a protein binding partner an confirmed this using immunoprecipitation studies. The ZNF198/FGFRI fusion protein also binds to HHR6. We demonstrate here that the human RAD18 is also present in the ZNF198/HHR6 protein complex, although it does not coimmunoprecipitate with the fusion kinase. Cells expressing the fusion kinase gene show a marked increased sensitivity to UVB irradiation, suggesting that it acts in a dominant-negative way to affect DNA repair. These observations support the idea that ZNF198, through its interaction with HHR6 and RAD18, may be involved in the DNA repair process.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA	Roswell Park Cancer Institute; Cleveland Clinic Foundation	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA076167] Funding Source: NIH RePORTER; NCI NIH HHS [CA76167, P30 CA16056-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRUZZO LV, 1992, AM J SURG PATHOL, V16, P236, DOI 10.1097/00000478-199203000-00003; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BAUMANN H, 2003, IN PRESS J BIOL CHEM; Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; Shekhar MPV, 2002, CANCER RES, V62, P2115; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SMEDLEY D, 1999, NEOPLASIA, V1, P249; Still IH, 1997, BLOOD, V90, P3136, DOI 10.1182/blood.V90.8.3136; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; van der Laan R, 2000, GENOMICS, V69, P86, DOI 10.1006/geno.2000.6220; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847	29	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3417	3423		10.1038/sj.onc.1206408	http://dx.doi.org/10.1038/sj.onc.1206408			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776193				2022-12-28	WOS:000183128500008
J	Oosterhoff, JK; Penninkhof, F; Brinkmann, AO; Grootegoed, JA; Blok, LJ				Oosterhoff, JK; Penninkhof, F; Brinkmann, AO; Grootegoed, JA; Blok, LJ			REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells	ONCOGENE			English	Article						REPS2; POB1; prostate cancer; internalization; EGF signalling	RAL-BINDING PROTEIN-1; CLATHRIN-MEDIATED ENDOCYTOSIS; PUTATIVE EFFECTOR PROTEIN; GTPASE; IDENTIFICATION; INVOLVEMENT; PATHWAYS; COMPLEX; RLIP76; GENES	During progression of prostate cancer, cellular changes occur, leading to a transition from androgen-dependent to androgen-independent growth. One aspect of this transition is a switch from androgens to growth factors, like epidermal growth factor (EGF), as primary regulators of proliferation. We examined the involvement of REPS2/POB1 in this process. REPS2/POB1 is an EH domain-containing protein, reported to be involved in signalling via RatBP1 and to play a role in endocytosis of EGF receptors. Furthermore, the protein is relatively highly expressed in androgen-dependent as compared to androgen-independent human prostate cancer cell lines and xenografts. Next to the known REPS2/POB1 protein, an open reading frame encoding REPS2/POB1, with 139 additional amino-acid residues at the NH2-terminus, was cloned and found to be expressed in prostate cancer cells. Overexpression, by transient transfection, of both forms of REPS2/POB1 in prostate cancer cell lines, induced apoptosis within 48 h. At shorter time intervals after transfection, signalling towards a TPA response element luciferase reporter was found to be inhibited. From these experiments, it is concluded that REPS2/POB1, through its influence on the Ral signalling pathway, is involved in growth factor signalling. Decreased expression of REPS2/POB1 during progression of prostate cancer may therefore result in loss of control of growth factor signalling and consequently in loss of control of cell proliferation.	Erasmus Univ, Erasmus MC, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Blok, LJ (corresponding author), Erasmus Univ, Erasmus MC, Dept Reprod & Dev, POB 1738, NL-3000 DR Rotterdam, Netherlands.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chang GTG, 1997, CANCER RES, V57, P4075; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JANSSEN T, 1995, PROSTATE, V27, P277, DOI 10.1002/pros.2990270507; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Osada M, 1999, MOL CELL BIOL, V19, P6333; Park SH, 1995, ONCOGENE, V11, P2349; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Russell PJ, 1998, CLIN CHEM, V44, P705; VANSTEENBRUGGE GJ, 1991, J STEROID BIOCHEM, V40, P207, DOI 10.1016/0960-0760(91)90184-7; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086	23	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2920	2925		10.1038/sj.onc.1206397	http://dx.doi.org/10.1038/sj.onc.1206397			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771942				2022-12-28	WOS:000182824800006
J	Chan, ASW; Tsui, WY; Chen, X; Chu, KM; Chan, TL; Chan, ASY; Li, R; So, S; Yuen, ST; Leung, SY				Chan, ASW; Tsui, WY; Chen, X; Chu, KM; Chan, TL; Chan, ASY; Li, R; So, S; Yuen, ST; Leung, SY			Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma	ONCOGENE			English	Article						ID4; hMLH1; microarray; promoter methylation; gastric adenocarcinoma	LOOP-HELIX PROTEINS; ISLAND METHYLATOR PHENOTYPE; GENE-EXPRESSION; MICROSATELLITE INSTABILITY; CANCER; TRANSCRIPTION; CARCINOMAS; HMLH1; CPG; MECHANISM	Promoter hypermethylation has become apparent as a common mechanism of gene silencing in cancer. Based on our published microarray expression data, we noticed a prominent downregulation of ID4 in gastric adenocarcinoma. The dense 5' CpG island covering the previously mapped upstream promoter of ID4 has prompted us to relate its downregulation to promoter hypermethylation. ID proteins are distinct members in the helix-loop-helix family of transcriptional regulators, which modulate various key developmental processes. Emerging data have suggested the involvement of ID genes in tumorigenesis. In this study using bisulfite genomic sequencing, we have found hypermethylation of ID4 promoter in most gastric cancer cell lines and 30% of primary tumors. This correlated with decreased level of ID4 expression. Restoration of ID4 expression in various gastric cancer cell lines was achieved by treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine, which at times required the synergistic action of the histone deacetylase inhibitor trichostatin A, but not with trichostatin A alone. Re-expression was accompanied by the corresponding ID4 promoter demethylation. Furthermore, we have found significant association of ID4 promoter methylation with hMLH1 promoter methylation (P = 0.008) and microsatellite instability (P = 0.006). Overall, our results have shown that transcriptional silencing of ID4 is related to the aberrant methylation of its promoter in gastric cancer. The significant association of ID4 and hMLH1 promoter hypermethylation suggested that ID4 may also be among the genes being targeted in the CpG island methylator phenotype tumorigenic pathway.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Stanford University; University of Hong Kong	Yuen, ST (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Chu, Kent/C-4251-2009; Yuen, Siu/K-6311-2014; Chan, Agnes/C-4477-2009; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				Arnold JM, 2001, BRIT J CANCER, V84, P352, DOI 10.1054/bjoc.2000.1620; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deleu S, 2002, EXP CELL RES, V279, P62, DOI 10.1006/excr.2002.5589; Deng GR, 1999, CANCER RES, V59, P2029; Jen Y, 1996, DEV DYNAM, V207, P235; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7; Kleeff J, 1998, CANCER RES, V58, P3769; Leung SY, 1999, BRIT J CANCER, V79, P582, DOI 10.1038/sj.bjc.6690092; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Leung SY, 1999, CANCER RES, V59, P159; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Wilson JW, 2001, CANCER RES, V61, P8803; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	33	81	94	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6946	6953		10.1038/sj.onc.1206799	http://dx.doi.org/10.1038/sj.onc.1206799			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534543				2022-12-28	WOS:000185843400017
J	Hornstein, I; Mortin, MA; Katzav, S				Hornstein, I; Mortin, MA; Katzav, S			DroVav, the Drosophila melanogaster homologue of the mammalian Vav proteins, serves as a signal transducer protein in the Rac and DER pathways	ONCOGENE			English	Article						Vav; Rac; cytoskeleton; RNAi; Drosophila	T-CELL-RECEPTOR; NUCLEOTIDE EXCHANGE FACTOR; CYTOSKELETAL REORGANIZATION; GDP/GTP EXCHANGE; SH2 DOMAIN; ACTIVATION; FAMILY; EGF; JNK; RHO	Mammalian Vav signal transducer proteins couple receptor tyrosine kinase signals to the activation of the Rho/Rac GTPases, leading to cell differentiation and/or proliferation. The unique and complex structure of mammalian Vav proteins is preserved in the Drosophila melanogaster homologue, DroVav. We demonstrate that DroVav functions as a guanine-nucleotide exchange factor (GEF) for DRac. Drosophila cells overexpressing wildtype (wt) DroVav exhibited a normal morphology. However, overexpression of a truncated DroVav mutant ( that functions as an oncogene when expressed in NIH3T3 cells) results in striking changes in the actin cytoskeleton, resembling those usually visible following Rac activation. Dominant-negative DRac abrogated these morphological changes, suggesting that the effect of the truncated DroVav mutant is mediated by activation of DRac. In Drosophila cells, we find that stimulation of the Drosophila EGF receptor (DER) increases tyrosine phosphorylation of DroVav, which in turn associates with tyrosine-phosphorylated DER. In addition, the following results imply that DroVav participates in downstream DER signalling, such as ERK phosphorylation: ( a) overexpression of DroVav induces ERK phosphorylation; and (b) 'knockout' of DroVav by RNA interference blocks ERK phosphorylation induced by DER stimulation. Unlike mammalian Vav proteins, DroVav was not found to induce Jnk phosphorylation under the experimental circumstances tested in fly cells. The se results establish the role of DroVav as a signal transducer that participates in receptor tyrosine kinase pathways and functions as a GEF for the small RhoGTPase, DRac.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Katzav, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel.	katzav@cc.huji.ac.il	Mortin, Mark A/B-4251-2008					Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOURBON HM, 2000, MECH DEVELOP, V110, P71; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dekel I, 2000, FEBS LETT, V472, P99, DOI 10.1016/S0014-5793(00)01413-7; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Golembo M, 1999, GENE DEV, V13, P158, DOI 10.1101/gad.13.2.158; Golembo M, 1996, DEVELOPMENT, V122, P223; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; HORNSTEIN I, 2003, IN PRESS CELL SIGNAL; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; KATZAV S, 1995, ONCOGENE, V11, P1079; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kranewitter WJ, 1999, FEBS LETT, V455, P123, DOI 10.1016/S0014-5793(99)00857-1; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moller A, 2001, J BIOL CHEM, V276, P20022, DOI 10.1074/jbc.M011139200; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Rebay I, 2002, DEV BIOL, V251, P1, DOI 10.1006/dbio.2002.0806; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rivera J, 2001, INT ARCH ALLERGY IMM, V124, P137, DOI 10.1159/000053692; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schuebel KE, 1996, ONCOGENE, V13, P363; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Settleman J, 2001, DEV CELL, V1, P321, DOI 10.1016/S1534-5807(01)00053-3; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Sotillos S, 2000, DEVELOPMENT, V127, P5427; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WU J, 1995, MOL CELL BIOL, V15, P4337; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	75	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6774	6784		10.1038/sj.onc.1207027	http://dx.doi.org/10.1038/sj.onc.1207027			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555990				2022-12-28	WOS:000185799300012
J	Cattaneo, M; Orlandini, S; Beghelli, S; Moore, PS; Sorio, C; Bonora, A; Bassi, C; Talamini, G; Zamboni, G; Orlandi, R; Menard, S; Bernardi, LR; Biunno, I; Scarpa, A				Cattaneo, M; Orlandini, S; Beghelli, S; Moore, PS; Sorio, C; Bonora, A; Bassi, C; Talamini, G; Zamboni, G; Orlandi, R; Menard, S; Bernardi, LR; Biunno, I; Scarpa, A			SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo	ONCOGENE			English	Article						pancreas; adenocarcinoma; SEL1L; DPC4/Smad4; TGF beta-pathway	C-ELEGANS SEL-1; NEGATIVE REGULATOR; NEOPLASTIC TRANSFORMATION; HUMAN HOMOLOG; NOTCH-GENE; DPC4 GENE; CELLS; INHIBITION; CANCER; PROLIFERATION	Recent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness. To investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo. In 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival. However, immunohistochemical reactivity for Sel1L and Dpc4/Smad4 was concordant in 69% of cases (chi(2) test P < 0.004). Overexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4. When implanted in nude mice, Suit-2-SEL1L-overexpressing clones displayed a considerably reduced rate of tumor growth. Thus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma. Moreover, our data provide evidence that SEL1L has an impact on the expression of genes involved in regulation of cellular growth, possibly through the TGF-beta signaling pathway.	Univ Verona, Dept Pathol, I-37134 Verona, Italy; CNR, Inst Biomed Technol, Milan, Italy; Univ Verona, Dept Surg & Gastroenterol Sci, I-37100 Verona, Italy; Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Univ Milan, Ctr Excellence, I-20122 Milan, Italy	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Verona; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan	Scarpa, A (corresponding author), Univ Verona, Dept Pathol, Str Grazie 8, I-37134 Verona, Italy.	ida.biunno@ltb.cnr.it; aldo.scarpa@univr.it	Giuseppe, Zamboni/L-6029-2019; Moore, Patrick/GVR-8294-2022; Sorio, Claudio/F-2764-2018; scarpa, aldo/K-6832-2016; Orlandi, Rosaria/C-1182-2017; menard, sylvie mm/C-7940-2011	Giuseppe, Zamboni/0000-0001-7428-4673; Sorio, Claudio/0000-0003-2739-4014; scarpa, aldo/0000-0003-1678-739X; Orlandi, Rosaria/0000-0002-0533-9041; SALVIA, Roberto/0000-0002-3514-8473; /0000-0002-1866-5866; , IDA_2/0000-0002-1068-4763				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Biunno I, 2000, HUM GENET, V106, P227, DOI 10.1007/s004390051032; Biunno I, 1997, GENOMICS, V46, P284, DOI 10.1006/geno.1997.5018; Biunno Ida, 2002, OMICS A Journal of Integrative Biology, V6, P187, DOI 10.1089/153623102760092788; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cattaneo M, 2001, DNA CELL BIOL, V20, P1, DOI 10.1089/10445490150504648; Cattaneo M, 2000, INT J BIOL MARKER, V15, P26, DOI 10.1177/172460080001500105; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; Donoviel DB, 1998, MECH DEVELOP, V78, P203, DOI 10.1016/S0925-4773(98)00146-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Furue M, 2001, BIOCHEM BIOPH RES CO, V282, P745, DOI 10.1006/bbrc.2001.4633; Grant B, 1997, DEVELOPMENT, V124, P637; Grant B, 1996, GENETICS, V143, P237; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harada Y, 1999, J HUM GENET, V44, P330, DOI 10.1007/s100380050171; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kloppel G, 2000, WHO CLASSIFICATION T, P219; Kudawara I, 2001, EUR J CANCER, V37, P1703, DOI 10.1016/S0959-8049(01)00185-X; Lei JY, 1996, ONCOGENE, V13, P2459; Liu QY, 1996, CANCER RES, V56, P1155; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; Orlandi R, 2002, CANCER RES, V62, P567; Orlandi R, 2002, INT J BIOL MARKER, V17, P104, DOI 10.1177/172460080201700205; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Rooke HM, 2001, PATHOLOGY, V33, P73; Rozenblum E, 1997, CANCER RES, V57, P1731; Scarpa A, 2002, VIRCHOWS ARCH, V440, P155, DOI 10.1007/s00428-001-0569-6; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; THOMPSON EA, 1989, CANCER RES, V49, pS2259; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612	43	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6359	6368		10.1038/sj.onc.1206665	http://dx.doi.org/10.1038/sj.onc.1206665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508516				2022-12-28	WOS:000185535300006
J	Heckman, CA; Wheeler, MA; Boxer, LM				Heckman, CA; Wheeler, MA; Boxer, LM			Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; C/EBP	NF-KAPPA-B; ACUTE MYELOID-LEUKEMIA; BINDING PROTEIN-BETA; TRANSCRIPTION FACTOR; C-MYB; NEGATIVE REGULATOR; GENE PROMOTER; CREB PROTEINS; ALPHA; DIFFERENTIATION	In follicular lymphomas with the t(14;18) translocation, there is increased expression of the bcl-2 gene, which is dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy-chain gene enhancers. We found that t(14;18) lymphomas expressed C/EBPalpha, which is not normally expressed in B lymphocytes. Expression of C/EBPalpha increased bcl-2 expression, and two regions of the bcl-2 P2 promoter that mediated this effect were identified. C/EBPbeta was also able to increase bcl-2 promoter activity through these sites. The 5' site was GC-rich and did not contain a C/EBP consensus sequence; however, C/EBP was observed to interact with this site both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. The 3' region contained the Cdx site, which mediates the effect of A-Myb on the bcl-2 promoter. In vivo binding studies revealed that C/EBP interacted with this region of the bcl-2 promoter as well. Decreased expression of C/EBP factors due to targeting of their transcripts by siRNA molecules resulted in downregulation of Bcl-2 protein. We conclude that C/EBPalpha and C/EBPbeta contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Chen XN, 1997, BLOOD, V90, P156; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COOPER CL, 1994, J IMMUNOL, V153, P5049; Dearth LR, 2001, J CELL BIOCHEM, V82, P357, DOI 10.1002/jcb.1167; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tenen DG, 2001, LEUKEMIA, V15, P688, DOI 10.1038/sj.leu.2402088; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	32	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7891	7899		10.1038/sj.onc.1206639	http://dx.doi.org/10.1038/sj.onc.1206639			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970736				2022-12-28	WOS:000185388200003
J	Muratovska, A; Zhou, CM; He, SJ; Goodyer, P; Eccles, MR				Muratovska, A; Zhou, CM; He, SJ; Goodyer, P; Eccles, MR			Paired-box genes are frequently expressed in cancer and often required for cancer cell survival	ONCOGENE			English	Article						PAX genes; siRNA; cell survival; tumor	HUMAN FETAL KIDNEY; HUMAN PAX6 GENE; TRANSCRIPTION FACTOR; ALVEOLAR RHABDOMYOSARCOMA; WILMS-TUMOR; APOPTOSIS; MUTATIONS; CARCINOMA; PROTEIN; ONCOGENE	The paired-box (PAX) genes encode a family of nine well-characterized paired-box transcription factors, with important roles in development and disease. Although PAX genes are primarily expressed in the embryo, constitutive expression promotes tissue hyperplasia. Rare tumor-specific mutations of PAX genes implicate an oncogenic role, and persistent PAX expression characterizes several tumors. Yet, a cancer-wide analysis of PAX gene expression to investigate a general role for PAX genes has not been performed. We analysed the pattern and requirement for PAX gene expression in a panel of common cancer cell lines. Very frequent PAX gene expression was identified in tumor cell lines, including lymphoma, breast, ovarian, lung, and colon cancer. In addition, the PAX2 gene was frequently expressed in a panel of 406 common primary tumor tissues. Apoptosis was rapidly induced in ovarian and bladder cancer cell lines following RNA interference to silence PAX2 expression, despite concomitant TP53 and/or HRAS mutations. These data suggest that PAX genes are frequently expressed in cancer, and that endogenous PAX gene expression is required for the growth and survival of cancer cells.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Pediat, Westmount, PQ H3Z 2Z3, Canada	University of Otago; McGill University	Eccles, MR (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin, New Zealand.			Filipovska, Aleksandra/0000-0002-6998-8403				BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Bouchard M, 2000, DEVELOPMENT, V127, P3703; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; ECCLES MR, 1995, AM J PATHOL, V146, P40; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FABBRO D, 1994, CANCER RES, V54, P4744; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GNARRA JR, 1995, CANCER RES, V55, P4092; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Morrison AM, 1998, BLOOD, V92, P3865, DOI 10.1182/blood.V92.10.3865.422k01_3865_3878; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; Murer L, 2002, NEPHRON, V91, P588, DOI 10.1159/000065017; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Scholl FA, 2001, CANCER RES, V61, P823; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Steinbach JP, 2001, INT J CANCER, V93, P459, DOI 10.1002/ijc.1371; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; STUART ET, 1995, CLIN CANCER RES, V1, P207; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torban E, 2000, AM J PATHOL, V157, P833, DOI 10.1016/S0002-9440(10)64597-X; van Raamsdonk CD, 2000, DEVELOPMENT, V127, P5439; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811	50	194	209	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7989	7997		10.1038/sj.onc.1206766	http://dx.doi.org/10.1038/sj.onc.1206766			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970747				2022-12-28	WOS:000185388200014
J	Kolesnick, R; Fuks, Z				Kolesnick, R; Fuks, Z			Radiation and ceramide-induced apoptosis	ONCOGENE			English	Review						radiation; ceramide; sphingomyelin; sphingomyelinase; apoptosis	PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; ACID SPHINGOMYELINASE GENE; DAMAGE-INDUCED APOPTOSIS; STRESS-INDUCED APOPTOSIS; FIBROBLAST-GROWTH-FACTOR; NIEMANN-PICK DISEASE; GH3 PITUITARY-CELLS; NEUTRAL SPHINGOMYELINASE; IONIZING-RADIATION	Ceramide is a sphingolipid that acts as a second messenger in ubiquitous, evolutionarily conserved, signaling systems. Emerging data suggest that radiation acts directly on the plasma membrane of several cell types, activating acid sphingomyelinase, which generates ceramide by enzymatic hydrolysis of sphingomyelin. Ceramide then acts as a second messenger in initiating an apoptotic response via the mitochondrial system. Radiation-induced DNA damage can also initiate ceramide generation by activation of mitochondrial ceramide synthase and de novo synthesis of ceramide. In some cells and tissues, BAX is activated downstream of ceramide, regulating commitment to the apoptotic process via release of mitochondrial cytochrome c. Genetic and pharmacologic studies in vivo showed that radiation targets the acid sphingomyelinase apoptotic system of microvascular endothelial cells in the lungs, intestines and brain, as well as in oocytes, to initiate the pathogenesis of tissue damage. Regulated ceramide metabolism may produce metabolites, such as sphingosine 1-phosphate, shown to signal antiapoptosis, thus controlling the intensity of the apoptotic response and constituting a mechanism for radiation sensitivity or resistance. An improved understanding of this signaling system may offer new opportunities for the modulation of radiation effects in the treatment of cancer.	Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Lab Signal Transduct, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Fuks, Z (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	fuksz@mskcc.org		Kolesnick, Richard/0000-0002-1686-6162				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Allan-Yorke J, 1998, J VIROL, V72, P2316, DOI 10.1128/JVI.72.3.2316-2322.1998; Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bohler T, 1997, PEDIATR INFECT DIS J, V16, P754, DOI 10.1097/00006454-199708000-00005; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chmura SJ, 2000, CLIN CANCER RES, V6, P737; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; Chmura SJ, 2001, SEMIN RADIAT ONCOL, V11, P338, DOI 10.1053/srao.2001.26019; Chmura SJ, 1996, CANCER RES, V56, P2711; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Decaudin D, 1997, CANCER RES, V57, P62; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; Fuks Z, 1995, Important Adv Oncol, P19; Fuks Z, 1995, Cancer J Sci Am, V1, P62; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Garzotto M, 1999, CANCER RES, V59, P5194; Garzotto M, 1998, CANCER RES, V58, P2260; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins Erich, 2002, Subcell Biochem, V36, P229; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1992, INT J RADIAT ONCOL, V24, P687, DOI 10.1016/0360-3016(92)90715-T; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Huwiler A, 2001, FASEB J, V15, P7; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kimura K, 1999, CANCER RES, V59, P1606; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; LEE H, 2003, UNPUB; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano J, 2001, J BIOL CHEM, V276, P442, DOI 10.1074/jbc.M006353200; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Pena LA, 2000, CANCER RES, V60, P321; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rodriguez-Lafrasse C, 2002, INT J CANCER, V101, P589, DOI 10.1002/ijc.10652; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Yan F, 2001, CANCER RES, V61, P963; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	110	361	392	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5897	5906		10.1038/sj.onc.1206702	http://dx.doi.org/10.1038/sj.onc.1206702			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947396				2022-12-28	WOS:000185086100016
J	Dolle, L; El Yazidi-Belkoura, I; Adriaenssens, E; Nurcombe, V; Hondermarck, H				Dolle, L; El Yazidi-Belkoura, I; Adriaenssens, E; Nurcombe, V; Hondermarck, H			Nerve growth factor overexpression and autocrine loop in breast cancer cells	ONCOGENE			English	Article						breast cancer; nerve growth factor; autocrine stimulation; cellular growth	STROMAL CELLS; RECEPTORS; EXPRESSION; PROLIFERATION; NEUROTROPHINS; SURVIVAL; RELEASE	We show here that nerve growth factor (NGF), the canonical neurotrophic factor, is synthesized and released by breast cancer cells. High levels of NGF transcript and protein were detected in breast cancer cells by reverse transcription-PCR, Western blotting, ELISA assay and immunohistochemistry. Conversely, NGF production could not be detected in normal breast epithelial cells at either the transcriptional or protein level. Confocal analysis indicated the presence of NGF within classical secretion vesicles. Breast cancer cell-produced NGF was biologically active, as demonstrated by its ability to induce the neuronal differentiation of embryonic neural precursor cells. Importantly, the constitutive growth of breast cancer cells was strongly inhibited by either NGF-neutralizing antibodies or K-252a, a pharmacological inhibitor of NGF receptor TrkA, indicating the existence of an NGF autocrine loop. Together, our data demonstrate the physiological relevance of NGF in breast cancer and its potential interest as a marker and therapeutic target.	Univ Sci & Technol Lille, UPRES EA 1033, F-59655 Villeneuve Dascq, France; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	Universite de Lille - ISITE; Universite de Lille; University of Queensland	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, UPRES EA 1033, IFR 118,Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	El Yazidi-Belkoura, Ikram/AAE-8805-2022; Dollé, Laurent/H-4612-2014; Malwad, Govind V/F-4682-2010	EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Chiarenza A, 2001, CANCER RES, V61, P3002; Clemow DB, 1998, AM J PHYSIOL-REG I, V275, pR1279, DOI 10.1152/ajpregu.1998.275.4.R1279; Colomer R, 2001, CANCER INVEST, V19, P49, DOI 10.1081/CNV-100000074; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; El Yazidi-Belkoura I, 2003, J BIOL CHEM, V278, P16952, DOI 10.1074/jbc.M300631200; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; HATTORI A, 1993, J BIOL CHEM, V268, P2577; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; Le Bourhis X., 2000, BREAST CANC RES TREA, V1722, P1; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Moller JC, 1998, J NEUROSCI RES, V51, P463, DOI 10.1002/(SICI)1097-4547(19980215)51:4<463::AID-JNR6>3.0.CO;2-A; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; SMALL DH, 1995, J NEUROSCI, V15, P144; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	37	98	121	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5592	5601		10.1038/sj.onc.1206805	http://dx.doi.org/10.1038/sj.onc.1206805			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944907				2022-12-28	WOS:000184865900008
J	Praml, C; Savelyeva, L; Schwab, M				Praml, C; Savelyeva, L; Schwab, M			Aflatoxin B-1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells	ONCOGENE			English	Article						AFAR; AKR7; 1p; aflatoxin B1 aldehyde reductase; detoxication; chemoprevention	ALDO-KETO REDUCTASE; HUMAN NEUROBLASTOMA-CELLS; RAT-LIVER; SUPERFAMILY; EXPRESSION; MEMBER; CANCER; CLONING; B-1; SELENIUM	Alterations of the distal portion of the short arm of chromosome 1 (1p) are among the earliest abnormalities of human colorectal tumours. Recently, we have cloned the Aflatoxin B, aldehyde reductase (AFAR) gene from a smallest region of overlapping deletion that is frequently (48%) hemizygously deleted in sporadic colorectal cancer. AFAR is expressed in a broad range of tissues. Its closely related rat protein is the major factor conferring resistance of rats towards aflatoxin B-1-induced liver carcinogenesis. Here, we have identified cDNAs covering two additional human AFAR-related genes localized in close proximity to the previously described AFAR at 1p35-36. We have analysed their structure and tissue-related expression. One of them, AFAR3, carries a Selenocysteine-Insertion Element (SECIS)-like structure that during translation may recode an in-frame TGA-stop codon to a selenocysteine. Two additional AFAR-pseudogenes are localized at Xq25 and 1p12, respectively. AFAR exon sequences share an identity of DNA and amino acids of more than 78%. Also large blocks of intronic sequences can be up to 98.6% identical. Knowledge of the AFAR genes and their structure will be essential in genetic and functional studies, where discrimination of the genes and proteins is a prerequisite for evaluating their individual functions.	Deutsch Krebsforschungszentrum, Div Tumour Genet B030, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Tumour Genet B030, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.schwab@dkfz.de						Almeida RMA, 1996, MYCOPATHOLOGIA, V133, P23, DOI 10.1007/BF00437095; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHEN J, 1982, J NUTR, V112, P324, DOI 10.1093/jn/112.2.324; CLARK LC, 1995, J NATL CANCER I, V87, P473, DOI 10.1093/jnci/87.7.473; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350; ELLIS EM, 1995, BIOCHEM J, V312, P535, DOI 10.1042/bj3120535; GARLAND M, 1994, NATURAL ANTIOXIDANTS, P263; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Hengstler JG, 1999, DRUG METAB REV, V31, P917, DOI 10.1081/DMR-100101946; Hinshelwood A, 2002, FEBS LETT, V523, P213, DOI 10.1016/S0014-5793(02)02982-4; Houlston RS, 2000, J MED GENET, V37, P161, DOI 10.1136/jmg.37.3.161; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; JUDAH DJ, 1993, BIOCHEM J, V292, P13, DOI 10.1042/bj2920013; Kelly VP, 2002, BIOCHEM J, V366, P847, DOI 10.1042/BJ20020342; Kelly VP, 2000, BIOCHEM J, V348, P389, DOI 10.1042/0264-6021:3480389; Key SCS, 1997, VIROLOGY, V234, P147, DOI 10.1006/viro.1997.8647; Knight LP, 1999, CARCINOGENESIS, V20, P1215, DOI 10.1093/carcin/20.7.1215; Kozma E, 2002, J BIOL CHEM, V277, P16285, DOI 10.1074/jbc.M110808200; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MARNETT LJ, 1994, CANCER METAST REV, V13, P303, DOI 10.1007/BF00666100; McLeod R, 1997, CANCER RES, V57, P4257; NEWBERNE PM, 1969, CANCER RES, V29, P236; Nishi N, 2000, ENDOCRINOLOGY, V141, P3194, DOI 10.1210/en.141.9.3194; Praml C, 1998, CANCER RES, V58, P5014; PRAML C, 1995, ONCOGENE, V11, P1357; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; TUDEK B, 1989, CANCER RES, V49, P1236; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	11	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4765	4773		10.1038/sj.onc.1206684	http://dx.doi.org/10.1038/sj.onc.1206684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879023				2022-12-28	WOS:000184157000019
J	Rangatia, J; Vangala, RK; Singh, SM; Zada, AAP; Elsasser, A; Kohlmann, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G				Rangatia, J; Vangala, RK; Singh, SM; Zada, AAP; Elsasser, A; Kohlmann, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G			Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBP alpha DNA binding via leucine zipper domain interaction	ONCOGENE			English	Article						C/EBP alpha; c-Jun; AML	TRANSCRIPTION-FACTOR; PROTEIN-ALPHA; BCR-ABL; GRANULOCYTIC DIFFERENTIATION; LINEAGE COMMITMENT; DOWN-REGULATION; PU.1; MUTATIONS; REGULATOR; GENE	Transcription factor C/EBPalpha induces normal myeloid differentiation, inactivation of C/EBPalpha leads to a differentiation block in acute myeloid leukemias (AML), and overexpression of C/EBPalpha results in ANIL growth arrest and differentiation. Recent reports suggest that C/EBPalpha is activated or inactivated via protein-protein interactions. We previously reported that C/EBPalpha needs to inactivate the proto-oncogene c-Jun via leucine zipper domain interaction in order to induce granulocytic differentiation. We, therefore, hypothesized that c-Jun expression might be elevated in AML and subsequently inactivate C/EBPalpha. In fact, compared to normal bone marrow mononuclear cells, c-Jun expression is increased in AML patient samples (Affymetrix expression microarray analysis, n = 166). c-Jun binds to C/EBPalpha via the leucine zipper domains and prevents C/EBPalpha from DNA binding. Inactivation of C/EBPalpha by c-Jun is necessary for c-Jun to induce proliferation because c-Jun-induced proliferation can be prevented by ectopic overexpression of C/EBPalpha. The dominant-negative 30-kDa C/EBPalpha protein, found in AML, fails to downregulate c-Jun mRNA expression in AML patient samples. Thus, our data suggest a model for AML in which c-Jun promotes proliferation and prevents differentiation by inhibiting C/EBPalpha DNA binding via leucine zipper domain interaction. It might depend on the expression levels of C/EBPalpha and c-Jun, if inhibition of C/EBPalpha by c-Jun or if inhibition of c-Jun by C/EBPalpha is more predominant: proliferation versus differentiation; AML versus normal myeloid development.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; GSF Res Ctr, Munich, Germany; Harvard Univ, Sch Med, Inst Med, Boston, MA USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.			Tenen, Daniel/0000-0002-6423-3888				Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; ELSAESSER A, 2003, IN PRESS ONCOGENE; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; MILLER M, 2003, J BIOL CHEM     0210; MIZUKI M, 2002, BLOOD           1205; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2002, BLOOD, V100, P2717, DOI 10.1182/blood-2002-03-0990; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; van Waalwijk van Doorn-Khosravani SB, 2002, HEMATOL J, V3, P324; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	31	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4760	4764		10.1038/sj.onc.1206664	http://dx.doi.org/10.1038/sj.onc.1206664			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879022				2022-12-28	WOS:000184157000018
J	Modena, P; Testi, MA; Facchinetti, F; Mezzanzanica, D; Radice, MT; Pilotti, S; Sozzi, G				Modena, P; Testi, MA; Facchinetti, F; Mezzanzanica, D; Radice, MT; Pilotti, S; Sozzi, G			UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines	ONCOGENE			English	Article						EWS; sarcoma; ovarian carcinoma; hinge protein; mitochondrial complex III	CYTOCHROME-C OXIDOREDUCTASE; 17-KDA SUBUNIT-VI; YEAST UBIQUINOL; COMPLEX; EXPRESSION; MUTATIONS; DELETION; SITE	We previously reported the identification of a novel zinc-finger gene, designated ZSG, fused to Ewing sarcoma gene (EWS) by a submicroscopic paracentric inversion of 22q12 in a small round cell sarcoma presenting a translocation t(1;22)(p34;q12). We report here the molecular cloning and characterization of the breakpoint in 1p34, which encompasses the gene coding for mitochondrial Hinge protein ubiquinol-cytochrome C reductase hinge gene (UQCRH). All the three breakpoints, two on 22q12 and one in 1p34, interrupt different genes: EWS, ZSG and UQCRH. We determined the genomic structure of UQCRH, characterized its splicing variants and identified a transcribed processed pseudogene. The analysis of UQCRH expression in normal tissues and cancer cell lines revealed absent expression of UQCRH in two ovarian and one breast cancer cell lines and reduced expression in a further breast carcinoma cell line. CpG island methylation upstream exon 1 was detected in all the three cell lines with absent expression. Moreover, treatment with demethylating agent 5-azacytidine restored UQCRH expression in OAW42 ovarian cancer cells. These data provide preliminary evidence of the inactivation of UQCRH gene in cancer either by structural rearrangements or epigenetic mechanisms.	Ist Nazl Tumori, Unit Mol Cytogenet, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Unit Mol Therapies, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Sozzi, G (corresponding author), Ist Nazl Tumori, Unit Mol Cytogenet, Via G Venezian 1, I-20133 Milan, Italy.		sozzi, gabriella/G-8259-2011; Mezzanzanica, Delia/C-2607-2017; Testi, Maria Adele/D-6994-2017	sozzi, gabriella/0000-0001-9360-6914; Mezzanzanica, Delia/0000-0002-9664-6871; Testi, Maria Adele/0000-0002-9462-0336				Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jones DH, 1997, BIOTECHNIQUES, V23, P132, DOI 10.2144/97231rr01; KIM CH, 1983, J BIOL CHEM, V258, P3543; KIM CH, 1989, BIOCHEMISTRY-US, V28, P1439, DOI 10.1021/bi00430a002; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; LIU AY, 1993, CANCER RES, V53, P2460; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MUKAI K, 1985, J BIOCHEM-TOKYO, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; Okazaki M, 1998, BIOCHEM BIOPH RES CO, V243, P131, DOI 10.1006/bbrc.1997.7979; Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352; Santiard-Baron D, 1999, EXP NEUROL, V158, P206, DOI 10.1006/exnr.1999.7076; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849	20	15	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4586	4593		10.1038/sj.onc.1206472	http://dx.doi.org/10.1038/sj.onc.1206472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881716				2022-12-28	WOS:000184054700015
J	Pirkmaier, A; Dow, R; Ganiatsas, S; Waring, P; Warren, K; Thompson, A; Hendley, J; Germain, D				Pirkmaier, A; Dow, R; Ganiatsas, S; Waring, P; Warren, K; Thompson, A; Hendley, J; Germain, D			Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma	ONCOGENE			English	Article						MMTV; D-type cyclins; squamous differentiation	ESTROGEN-RECEPTOR; BREAST CANCERS; P27(KIP1); PROLIFERATION; ACTIVATION; GLAND; TRANSDIFFERENTIATION; DIFFERENTIATION; SEQUESTRATION; PROGRESSION	The three human D-type cyclins, cyclin D1, D2 and D3 share the ability to bind to and activate cdk4 and 6. MMTV-cyclin D1 transgenic mice develop mainly adenocarcinoma, while MMTV-cyclin D2 mice show a lack of alveologenesis during pregnancy and only develop carcinoma at low frequency. The effect of cyclin D3 overexpression in mammary glands remains hitherto unknown. We generated MMTV-cyclin D3 transgenic mice and report here that they develop exclusively squamous cell carcinoma. We show that although cyclin D3 transgene expression was detected early in puberty, postnatal development and mammary gland proliferation were normal in virgin animals. In contrast, multiparous mice develop multiple foci of abnormal growth that correspond to various stages of squamous metaplasia. Therefore, our results support a role for cyclin D3 in squamous differentiation. In addition, we found that p16 expression during involution is abolished, while p27 expression increased in MMTV-cyclin D3 mice, two modifications that have been reported in the other MMTV-D-type cyclin transgenic models. Our observations indicate that despite biochemical redundancy in vitro and in vivo, D-type cyclins promote distinct oncogenic pathways.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.							Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Evron E, 2001, CANCER RES, V61, P2782; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Gadd M, 2001, CANCER RES, V61, P8811; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Kong G, 2002, ONCOGENE, V21, P7214, DOI 10.1038/sj.onc.1205895; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; TOYASHIMA H, 1994, CELL, V78, P67; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	31	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4425	4433		10.1038/sj.onc.1206488	http://dx.doi.org/10.1038/sj.onc.1206488			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853979				2022-12-28	WOS:000183978900012
J	Rutter, JL; Goldstein, AM; Davila, MR; Tucker, MA; Struewing, JP				Rutter, JL; Goldstein, AM; Davila, MR; Tucker, MA; Struewing, JP			CDKN2A point mutations D153spl(c.457G > T) and IVS2+1G > T result in aberrant splice products affecting both p16(INK4a) and p14(ARF)	ONCOGENE			English	Article						melanoma; RT-PCR; alternate reading frame; cryptic splice site	CELL-CYCLE ARREST; PRONE FAMILIES; MELANOMA; P19(ARF); GENE; INHIBITION; LOCUS; MDM2; P53	The CDKN2A gene, which encodes the proteins p16(INK4a) and p14(ARF), is located on chromosome 9p21. Germline mutations at this locus increase susceptibility to cutaneous malignant melanoma (CMM). In general, missense and nonsense mutations are primarily responsible for defective p16(INK4a) and possibly p14(ARF) protein function and account for similar to20% of inherited CMM cases. We report a G>T transversion mutation in the last nucleotide of exon 2, affecting the aspartic acid residue at position 153 of CDKN2A-p16(INK4a) in a proband with melanoma. If splicing were unaffected, this mutation would change Asp to Tyr. RT-PCR analysis, however, revealed that this mutation, which we have termed D153spl(c.457G>T), and a previously described mutation at the next nucleotide, IVS2 + 1G > T, result in identical aberrant splicing affecting both p16(INK4a) and p14(ARF). The two main alternate splice products for each of the two normal transcripts includes a 74 bp deletion in exon 2, revealing a cryptic splice site, and the complete skipping of exon 2. The dual inactivation of p16(INK4a), and p14(ARF) may contribute to the CMM in these families.	NCI, Lab Populat Genet, NIH, DHHS,Ctr Canc Res, Bethesda, MD 20892 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Struewing, JP (corresponding author), NCI, Lab Populat Genet, NIH, DHHS,Ctr Canc Res, Bldg 41,Room D702,41 Library Dr,MSC 5060, Bethesda, MD 20892 USA.		Struewing, Jeffery P/C-3221-2008; Tucker, Margaret A/B-4297-2015; Struewing, Jeffery P/I-7502-2013	Struewing, Jeffery P/0000-0002-4848-3334; Rutter, Joni/0000-0002-6502-2361				Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Goldstein AM, 2001, ARCH DERMATOL, V137, P1493; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; Moskaluk C A, 1998, Hum Mutat, V12, P70; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pesole G, 1999, NUCLEIC ACIDS RES, V27, P188, DOI 10.1093/nar/27.1.188; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	21	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4444	4448		10.1038/sj.onc.1206564	http://dx.doi.org/10.1038/sj.onc.1206564			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853981				2022-12-28	WOS:000183978900014
J	Mirza, A; Wu, Q; Wang, LQ; McClanahan, T; Bishop, WR; Gheyas, F; Ding, W; Hutchins, B; Hockenberry, T; Kirschmeier, P; Greene, JR; Liu, SX				Mirza, A; Wu, Q; Wang, LQ; McClanahan, T; Bishop, WR; Gheyas, F; Ding, W; Hutchins, B; Hockenberry, T; Kirschmeier, P; Greene, JR; Liu, SX			Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression	ONCOGENE			English	Article						p53; transcription; microarray; chromatin immunoprecipitation; bioinformatics	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; INHIBITS TRANSCRIPTION; PROMOTER; REPRESSION; ACTIVATION; EXPRESSION; ELEMENT; TRANSACTIVATION	The temporal gene expression profile during the entire process of apoptosis and cell cycle progression in response to p53 in human ovarian cancer cells was explored with cDNA microarrays representing 33 615 individual human genes. A total of 1501 genes (4.4%) were found to respond to p53 (approximately 80% of these were repressed by p53) using 2.5-fold change as a cutoff. It was anticipated that most of p53 responsive genes resulted from the secondary effect of p53 expression at late stage of apoptosis. To delineate potential p53 direct and indirect target genes during the process of apoptosis and cell cycle progression, microarray data were combined with global p53 DNA-binding site analysis. Here we showed that 361 out of 1501 p53 responsive genes contained p53 consensus DNA-binding sequence(s) in their regulatory region, approximately 80% of which were repressed by p53. This is the first time that a large number of p53-repressed genes have been identified to contain p53 consensus DNA-binding sequence(s) in their regulatory region. Hierarchical cluster analysis of these genes revealed distinct temporal expression patterns of transcriptional activation and repression by p53. More genes were activated at early time points, while more repressed genes were found after the onset of apoptosis. A small-scale quantitative chromatin immunoprecipitation analysis indicated that in vivo p53-DNA interaction was detected in eight out of 10 genes, most of which were repressed by p53 at the early onset of apoptosis, suggesting that a portion of p53 target genes in the human genome could be negatively regulated by p53 via sequence-specific DNA binding. The approaches and genes described here should aid the understanding of global gene regulatory network of p53.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res Dept, Kenilworth, NJ 07033 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Schering Plough Corp, Res Inst, Biostat Grp, Kenilworth, NJ 07033 USA; Canji Inc, San Diego, CA 92121 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd,K-15-4 4600, Kenilworth, NJ 07033 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaluzova M, 2000, BBA-GENE STRUCT EXPR, V1491, P20, DOI 10.1016/S0167-4781(00)00015-4; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P525, DOI 10.1146/annurev.physiol.60.1.525; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; Wu Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhao RB, 2000, GENE DEV, V14, P981	40	142	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3645	3654		10.1038/sj.onc.1206477	http://dx.doi.org/10.1038/sj.onc.1206477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789273				2022-12-28	WOS:000183399200015
J	Wu, H; Goel, V; Haluska, FG				Wu, H; Goel, V; Haluska, FG			PTEN signaling pathways in melanoma	ONCOGENE			English	Article						PTEN; melanoma; signaling	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR GENE; PRIMARY CUTANEOUS MELANOMA; ENDOMETRIAL CANCER-CELLS; MALIGNANT-MELANOMA; PTEN/MMAC1 GENE; PROSTATE-CANCER; PHOSPHATASE-ACTIVITY; COWDEN-DISEASE; ALLELIC LOSS	Phosphatase and tensin homolog deleted in from chromosome ten (PTEN), initially also known as mutated in multiple advanced cancers or TGF-beta-regulated and epithelia cell-enriched phosphatase, is a tumor suppressor gene that is mutated in a large fraction of human melanomas. A broad variety of human cancers carry PTEN alterations, including glioblastomas, endometrial, breast, thyroid and prostate cancers. The PTEN protein has at least two biochemical functions: it has both lipid phosphatase and protein phosphatase activity. The lipid phosphatase activity of PTEN decreases intracellutar PtdIns(3,4,5)P-3 level and downstream Akt activity. Cell-cycle progression is arrested at G1/S, mediated at least partially through the upregutation of the cyclin-dependent kinase inhibitor p27. In addition, agonist-induced apoptosis is mediated by PTEN, through the upregulation of proapoptotic machinery involving caspases and BID, and the downregulation of antiapoptotic proteins such as Bcl2. The protein phosphatase activity of PTEN is apparently less central to its involvement in tumorigenesis. It is involved in the inhibition of focal adhesion formation, cell spreading and migration, as well as the inhibition of growth factor-stimulated MAPK signaling. Therefore, the combined effects of the loss of PTEN lipid and protein phosphatase activity may result in aberrant cell growth and escape from apoptosis, as well as abnormal cell spreading and migration. In melanoma, PTEN loss has been mostly observed as a late event, although a dose-dependent loss of PTEN protein and function has been implicated in early stages of tumorigenesis as well. In addition, loss of PTEN and oncogenic activation of RAS seem to occur in a reciprocal fashion, both of which could cooperate with CDKN2A loss in contribution to melanoma tumorigenesis.	Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Haluska, FG (corresponding author), Massachusetts Gen Hosp, Dept Hematol Oncol, GRJ1021,55 Fruit St, Boston, MA 02114 USA.	haluska.frank@mgh.harvard.edu						Adachi J, 1999, J NEUROSURG, V91, P822, DOI 10.3171/jns.1999.91.5.0822; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Boni R, 1998, MELANOMA RES, V8, P300; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Cheyney IW, 1999, CANCER RES, V59, P2318; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Dahia PLM, 1997, CANCER RES, V57, P4710; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Flores JF, 1996, CANCER RES, V56, P5023; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FUJITA N, 2002, J BIOL CHEM, V31, P31; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Gottschalk AR, 2001, CANCER RES, V61, P2105; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guldberg P, 1997, CANCER RES, V57, P3660; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Herbst RA, 1999, ARCH DERMATOL RES, V291, P567, DOI 10.1007/s004030050456; HERBST RA, 1994, CANCER RES, V54, P3111; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Ikeda T, 2000, ONCOL REP, V7, P567; ISSHIKI K, 1993, CANCER GENET CYTOGEN, V69, P108; Ittmann M, 1996, CANCER RES, V56, P2143; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kurose K, 1998, JPN J CANCER RES, V89, P842, DOI 10.1111/j.1349-7006.1998.tb00638.x; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lilja JF, 2001, ANTICANCER RES, V21, P1969; LIU L, 1995, ONCOGENE, V11, P405; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; MOELLING K, 2002, J BIOL CHEM, V4, P4; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Mohiuddin I, 2002, ANN SURG ONCOL, V9, P310, DOI 10.1007/BF02573071; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; PARMITER AH, 1988, CANCER GENET CYTOGEN, V30, P313, DOI 10.1016/0165-4608(88)90200-2; Penninger JM, 2001, SCIENCE, V294, P2116, DOI 10.1126/science.1067931; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poetsch M, 2002, CANCER GENET CYTOGEN, V132, P20, DOI 10.1016/S0165-4608(01)00509-X; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reifenberger J, 2000, VIRCHOWS ARCH, V436, P487, DOI 10.1007/s004280050477; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Saida T, 2001, J DERMATOL SCI, V26, P1, DOI 10.1016/S0923-1811(01)00085-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tsao H, 2000, CANCER RES, V60, P1800; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967; Yamada KM, 2001, J CELL SCI, V114, P2375; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhu XY, 2001, CANCER RES, V61, P4569	85	314	335	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3113	3122		10.1038/sj.onc.1206451	http://dx.doi.org/10.1038/sj.onc.1206451			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789288				2022-12-28	WOS:000183096600013
J	Gurbuxani, S; Schmitt, E; Cande, C; Parcellier, A; Hammann, A; Daugas, E; Kouranti, I; Spahr, C; Pance, A; Kroemer, G; Garrido, C				Gurbuxani, S; Schmitt, E; Cande, C; Parcellier, A; Hammann, A; Daugas, E; Kouranti, I; Spahr, C; Pance, A; Kroemer, G; Garrido, C			Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor	ONCOGENE			English	Article						HSP70; AIF; apoptosis; nuclear import	CYTOCHROME-C; GLYCOPROTEIN COMPLEX; SELECTIVE DEPLETION; CELL-DEATH; PROTEIN; ACTIVATION; CASPASES; AIF	Heat shock protein 70 ( HSP70) can inhibit apoptosis by neutralizing and interacting with apoptosis-inducing factor (AIF), a mitochondrial. avoprotein that translocates upon apoptosis induction to the nucleus, via the cytosol. Here, we show that only members of the HSP70 family interact with AIF. Systematic deletion mapping revealed the existence of three distinct functional regions in the AIF protein: ( 1) a region between amino acids 150 and 228 that binds HSP70, ( 2) a domain between residues 367 and 459 that includes a nuclear localization sequence (NLS) and ( 3) a C-terminal domain beyond residue 567 required for its chromatin-condensing activity. Deletion of the 150 - 268 domain completely abolished HSP70 binding and facilitated the nuclear import of AIF, resulting in a gain-of-function phenotype with enhanced AIF-mediated chromatin condensation as compared to wild-type AIF. This gain-of-function phenotype was observed in wild-type control cells ( which express low but significant levels of HSP70), yet was lost when AIFD150-268 was introduced into HSP70 knockout cells, underscoring the functional importance of the AIF - HSP70 interaction. Altogether, our data demonstrate that AIF inhibition by HSP70 involves cytosolic retention of AIF. Moreover, it appears that endogenous HSP70 protein levels are sufficiently elevated to modulate the lethal action of AIF.	Fac Med & Pharm Dijon, INSERM, U517, F-21033 Dijon, France; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Amgen Inc, Amgen Ctr, Mammalian Genom, Thousand Oaks, CA 91320 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Amgen; University of Cambridge	Garrido, C (corresponding author), Fac Med & Pharm Dijon, INSERM, U517, 7 Blvd Jeanne Darc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Kroemer, Guido/AAY-9859-2020; Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022; KROEMER, Guido/B-4263-2013; Pance, Alena/AAH-2878-2021	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Pance, Alena/0000-0002-9017-2644; DAUGAS, Eric/0000-0001-7256-7979				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Courchesne PL, 1998, ELECTROPHORESIS, V19, P956, DOI 10.1002/elps.1150190611; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gurbuxani S, 2001, ONCOGENE, V20, P7478, DOI 10.1038/sj.onc.1204948; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Munster PN, 2001, CLIN CANCER RES, V7, P2228; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836	30	230	243	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6669	6678		10.1038/sj.onc.1206794	http://dx.doi.org/10.1038/sj.onc.1206794			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555980				2022-12-28	WOS:000185799300002
J	Claus, R; Lubbert, M				Claus, R; Lubbert, M			Epigenetic targets in hematopoietic malignancies	ONCOGENE			English	Review						DNA methylation; chromatin; myeloid leukemia; myelodysplastic syndromes	DE-NOVO METHYLATION; RISK MYELODYSPLASTIC SYNDROME; ACUTE PROMYELOCYTIC LEUKEMIA; RECRUIT HISTONE DEACETYLASE; KINASE INHIBITOR P15(INK4B); ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; CPG ISLAND; PROMOTER METHYLATION; HYPOMETHYLATING AGENT	Frequent genetic alterations in hematopoietic neoplasias ( chromosomal translocations, point mutations, etc.) have provided biologic targets for the development of effective novel therapies. A rapidly increasing body of knowledge provides evidence also for multiple epigenetic alterations in these disorders, which can complement or even precede genetic aberrations. Gene inactivation ('silencing') of tumor suppressor and growth inhibitory genes (e.g. the cyclin-dependent kinase inhibitors p16, p15, p21) is frequently mediated by DNA methylation of gene promoters. The acetylation state of histones ( functionally linked to the DNA methylation state by the methylcytosine binding protein 2, recruiting histone deacetylases) provides a second major epigenetic silencing mechanism. Therapeutic reversal strategies are being developed for acute leukemias, myelodysplastic syndromes and malignant lymphomas. Since the discovery of the DNA methyltransferase (Dnmt) inhibitory activity of two azanucleosides (5-azacytidine, 5-aza-2'-deoxycytidine/ decitabine) even at doses with minimal nonhematologic toxicity, both have been clinically studied in several myeloid neoplasias, particularly in elderly patients unable to tolerate aggressive treatment. Further development of agents counteracting aberrant methylation is directed at more targeted approaches, for example, antisense molecules against Dnmts. Histone deacetylases (HDACs) can be inhibited by numerous compounds ( sodium phenylbutyrate, valproic acid, novel compounds such as depsipeptide), which have entered the clinical arena in similar indications as Dnmt inhibitors. Impressive effects of HDAC inhibition in acute promyelocytic leukemia models (PML/RARA expression) translate the finding of HDAC recruitment by this chimeric transcription factor to its target genes. The recent discovery of recruitment by PML/RARA also of Dnmt activity to the retinoic acid receptor-beta promoter makes it an interesting candidate for Dnmt inhibitors. Studies combining a 're-expressor' strategy with inhibitors of Dnmts and HDACs are underway. Thus, resensitization to biological agents such as retinoids, colony-stimulating factors and other differentiation inducers may be envisioned.	Univ Freiburg, Med Ctr, Dept Internal Med 1, Div Hematol Oncol, D-79106 Freiburg, Germany	University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Dept Internal Med 1, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	Luebbert@mm11.ukl.uni-freiburg.de	Claus, Rainer/AAZ-5606-2020	Claus, Rainer/0000-0003-2617-8766				Aoki E, 2000, LEUKEMIA, V14, P586, DOI 10.1038/sj.leu.2401719; Au WY, 2003, BRIT J HAEMATOL, V120, P1062, DOI 10.1046/j.1365-2141.2003.04194.x; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Batova A, 1997, CANCER RES, V57, P832; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; BAYLIN SB, 1986, CANCER RES, V46, P2917; BAYLIN SB, 1987, BLOOD, V70, P412; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Camacho LH, 2001, BLOOD, V98, p460A; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen H, 2002, CHINESE MED J-PEKING, V115, P987; Chim CS, 2002, HEMATOL ONCOL, V20, P167, DOI 10.1002/hon.694; Chim CS, 2001, J CLIN ONCOL, V19, P2033, DOI 10.1200/JCO.2001.19.7.2033; CLAUS R, 2003, UNPUB; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Fan Hongtao, 2000, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V8, P271; Garber K, 2002, J NATL CANCER I, V94, P874; Garcia MJ, 2002, AM J PATHOL, V161, P1007, DOI 10.1016/S0002-9440(10)64261-7; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gore SD, 2001, CLIN CANCER RES, V7, P2330; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 1997, CANCER RES, V57, P837; Hoshino K, 2002, BRIT J HAEMATOL, V117, P531, DOI 10.1046/j.1365-2141.2002.03451.x; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JP, 2001, BLOOD, V98, p594A; ISSA JP, 1997, LEUKEMIA S1, V11, P7; Issa JPJ, 1997, CANCER RES, V57, P1678; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; JAHANGEER S, 1982, BIOCHEM BIOPH RES CO, V108, P1434, DOI 10.1016/S0006-291X(82)80067-3; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; KUNDGEN A, 2003, LEUK RES S1, V27, pS104; Leone G, 2002, HAEMATOLOGICA, V87, P1324; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lubbert M, 2002, BLOOD, V100, p268B; Lubbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Martinez-Delgado B, 1998, LEUKEMIA, V12, P937, DOI 10.1038/sj.leu.2401009; Melki JR, 1999, CANCER RES, V59, P3730; Miller CB, 2001, BLOOD, V98, p622A; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Najfeld V, 2002, BLOOD, V100, p97A; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nguyen TT, 2000, BLOOD, V95, P2990, DOI 10.1182/blood.V95.9.2990.009k08_2990_2992; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1988, CANCER LETT, V39, P185, DOI 10.1016/0304-3835(88)90103-6; PINTO A, 1984, LANCET, V2, P867; Preisler HD, 2001, LEUKEMIA, V15, P1589, DOI 10.1038/sj.leu.2402211; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; RICHEL DJ, 1991, BRIT J CANCER, V64, P144, DOI 10.1038/bjc.1991.258; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Sakashita K, 2001, J CLIN INVEST, V108, P1195, DOI 10.1172/JCI200113030; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Shaker S, 2003, LEUKEMIA RES, V27, P437, DOI 10.1016/S0145-2126(02)00222-9; Shen LL, 2002, BLOOD, V100, P3432, DOI 10.1182/blood-2002-07-1990; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Sun BD, 2001, CANCER RES, V61, P6931; Teofili L, 2001, BLOOD, V98, P495, DOI 10.1182/blood.V98.2.495; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 1999, CANCER RES, V59, P4535; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; WAHLFORS J, 1992, BLOOD, V80, P2074; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Wijermans PW, 1997, LEUKEMIA, V11, P1, DOI 10.1038/sj.leu.2400526; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942	92	173	183	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6489	6496		10.1038/sj.onc.1206814	http://dx.doi.org/10.1038/sj.onc.1206814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528273				2022-12-28	WOS:000185700700005
J	Mitra, RS; Zhang, ZC; Henson, BS; Kurnit, DM; Carey, TE; D'Silva, NJ				Mitra, RS; Zhang, ZC; Henson, BS; Kurnit, DM; Carey, TE; D'Silva, NJ			Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form	ONCOGENE			English	Article						rap1; nucleus; regulation; carcinoma	BINDING PROTEINS; HUMAN-PLATELETS; MYOGENIC DIFFERENTIATION; GOLGI-COMPLEX; GROWTH-FACTOR; MAP KINASE; ACTIVATION; TRANSFORMATION; ASSOCIATION; INHIBITION	We recently showed that rap1 regulates growth and proliferation in normal keratinocytes, which provoked us to investigate its expression and regulation in malignant cells. Rap1 is variably expressed in whole cell lysates of squamous cell carcinoma (SCC) cell lines. Immunoblot analysis of nuclear and cytosolic fractions and immunohistochemistry revealed that in addition to cytoplasmic expression, SCC cells also exhibit prominent punctate rap1 expression in the nucleus. This unexpected nuclear distribution was confirmed by the evaluation of human oral cancer specimens by immunohistochemistry, which showed both nuclear and cytoplasmic localization. Cytoplasmic rap1 expression was observed mostly in large differentiated cells, whereas nuclear localization was found in morphologically less differentiated cells. Quantitative reverse transcriptase polymerase chain reaction and Northern blot analysis showed that both rap1A and rap1B are expressed in SCC cell lines although rap1B signals are more prominent. Transfection with enhanced GFP-tagged constitutively active and inactive forms of rap1B demonstrated that the active GTP-bound form translocates to the nucleus whereas inactive rap1B(GDP) is retained in the cytoplasm, much of which is in a perinuclear distribution. Furthermore, growth factors induce nuclear translocation of rap1 in oral cancer cells. This novel discovery that active, GTP-bound rap1 translocates to the nucleus makes it only the second of over 100 small GTP-binding proteins to be identified in the nucleus, and the striking prominence of rap1 expression in the nucleus of SCC cells suggests that activated rap1 plays a role in the malignant process.	Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Otolaryngol, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA.		D'Silva, Nisha J/B-4734-2013	Carey, Thomas/0000-0002-5202-7518	NCI NIH HHS [1 P50 CA97248] Funding Source: Medline; NIDCR NIH HHS [DE00452-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Carey TE, 1994, ATLAS HUMAN TUMOR CE, P79; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; D'Silva NJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1667, DOI 10.1152/ajpcell.1998.274.6.C1667; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; JORDAN, 1997, J CAN DENT ASS, V63, P517; Jordan RC, 1997, J CAN DENT ASSOC, V63, P521; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PIZON V, 1994, J CELL SCI, V107, P1661; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Pizon V, 1996, EUR J CELL BIOL, V69, P224; QIAO J, 2002, J BIOL CHEM, V8, P8; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SCHNEFEL S, 1992, Cellular Physiology and Biochemistry, V2, P77, DOI 10.1159/000154628; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WAGNER ACC, 1994, AM J PHYSIOL, V266, pG1, DOI 10.1152/ajpgi.1994.266.1.G1; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YA, 2002, MOL CELL NEUROSCI, V19, P430, DOI 10.1006/mcne.2001.1076; Zou CP, 1999, DIFFERENTIATION, V64, P123, DOI 10.1046/j.1432-0436.1999.6420123.x	39	61	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6243	6256		10.1038/sj.onc.1206534	http://dx.doi.org/10.1038/sj.onc.1206534			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679863				2022-12-28	WOS:000185506200014
J	Zhang, J; Choi, Y; Mavromatis, B; Lichtenstein, A; Li, WQ				Zhang, J; Choi, Y; Mavromatis, B; Lichtenstein, A; Li, WQ			Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway	ONCOGENE			English	Article						Akt/PKB; multiple myeloma; PI3K inhibitors; PTEN; signal transduction	ACTIVATED PROTEIN-KINASE; MULTIPLE-MYELOMA; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CELL-LINE; 3-KINASE; INSULIN; APOPTOSIS; RESPONSES	We recently reported that internal deletion of PTEN tumor suppressor gene in OPM2 and Delta47 myeloma lines led to high Akt activation. Re-expression of PTEN induced strong apoptosis and growth inhibition. To understand the biologic importance of the phosphatidylinositol 3 kinase (PI3K)/Akt activation affected by PTEN deletion, we analysed apoptosis and growth inhibition by applying PI3K inhibitors to myeloma lines and by expressing Akt constructs. The PI3K inhibitors preferentially suppressed PTEN-null myeloma growth to those expressing PTEN, indicating that PI3K activation is more critical for growth and survival of those lines with PTEN mutations than others expressing a functional PTEN gene. Since PTEN- null myeloma lines exhibited much stronger Akt activation than PTEN- expressing cells in response to insulin-like growth factor I stimulation, we determined whether Akt could be responsible for PI3K-mediated cell survival and growth of PTEN- null myeloma lines. Expression of an active Akt, but not its kinase dead mutant, reversed wortmannin- and dexamethasone-induced apoptosis and growth inhibition in PTEN- null myeloma lines, suggesting that Akt lies downstream of PI3K for PTEN- null myeloma survival and dexamethasone resistance. In summary, we have provided evidence that PTEN- null myeloma cells are stringently dependent on the PI3K/Akt activation for cell survival. These results may provide a basis to treat myeloma patients with PI3K and Akt inhibitors.	Georgetown Univ, Med Ctr, Sch Med, Lombardi Canc Ctr,Dept Oncol, Washington, DC 20057 USA; W LA VA Med Ctr, Dept Med, Los Angeles, CA USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA	Georgetown University; UCLA Jonsson Comprehensive Cancer Center	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Sch Med, Lombardi Canc Ctr,Dept Oncol, Box 571469,New Res Bldg,E407,3970 Reservoir Rd NW, Washington, DC 20057 USA.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Desikan K R, 1999, Curr Opin Hematol, V6, P216, DOI 10.1097/00062752-199907000-00004; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feinman R, 1997, HEMATOL ONCOL CLIN N, V11, P1, DOI 10.1016/S0889-8588(05)70412-3; Gado K, 2001, HAEMATOLOGICA, V86, P227; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jelinek DF, 1997, J IMMUNOL, V159, P487; Jelinek DF, 1999, HEMATOL ONCOL CLIN N, V13, P1145, DOI 10.1016/S0889-8588(05)70117-9; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kyle RA, 2001, ONCOLOGIST, V6, P119, DOI 10.1634/theoncologist.6-2-119; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Nishimoto N, 1997, HEMATOL ONCOL CLIN N, V11, P159, DOI 10.1016/S0889-8588(05)70421-4; Ogawa M, 2000, CANCER RES, V60, P4262; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YJ, 2002, CANCER RES, V62, P5027; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tu YP, 2000, CANCER RES, V60, P6763; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	36	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6289	6295		10.1038/sj.onc.1206718	http://dx.doi.org/10.1038/sj.onc.1206718			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679867				2022-12-28	WOS:000185506200018
J	Quintanilla, M; Ramirez, JR; Perez-Gomez, E; Romero, D; Velasco, B; Letarte, M; Lopez-Novoa, JM; Bernabeu, C				Quintanilla, M; Ramirez, JR; Perez-Gomez, E; Romero, D; Velasco, B; Letarte, M; Lopez-Novoa, JM; Bernabeu, C			Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis	ONCOGENE			English	Article						endoglin; TGF-beta; keratinocyte; tumor progression	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; VASCULAR ENDOTHELIAL-CELLS; BINDING-PROTEIN ENDOGLIN; TRANSFORMING GROWTH-FACTOR-BETA-1; CHEMICAL CARCINOGENESIS; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES; SPINDLE CARCINOMAS; TUMOR PROGRESSION	Endoglin is an integral membrane glycoprotein primarily expressed in the vascular endothelium, but also found on macrophages and stromal cells. It binds several members of the transforming growth factor (TGF)-beta family of growth factors and modulates TGF-beta(1)-dependent cellular responses. However, it lacks cytoplasmic signaling motifs and is considered as an auxiliary receptor for TGF-beta. We show here that endoglin is expressed in mouse and human epidermis and in skin appendages, such as hair follicles and sweat glands, as determined by immunohistochemistry. In normal interfollicular epidermis, endoglin was restricted to basal keratinocytes and absent in differentiating cells of suprabasal layers. Follicular expression of endoglin was high in hair bulb keratinocytes, but decreased in parts distal from the bulb. To address the role of endoglin in skin carcinogenesis in vivo, Endoglin heterozygous mice were subjected to long-term chemical carcinogenesis treatment. Reduction in endoglin had a dual effect during multistage carcinogenesis, by inhibiting the early appearance of benign papillomas, but increasing malignant progression to highly undifferentiated carcinomas. Our results are strikingly similar to those previously reported for transgenic mice overexpressing TGF-beta(1) in the epidermis. These data suggest that endoglin might attenuate TGF-beta(1) signaling in normal epidermis and interfere with progression of skin carcinogenesis.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp Gomez Ulla, Dept Anat Patol, Madrid 28047, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Hosp Sick Children, Blood & Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Salamanca, Fac Med, Dept Fisiol & Farmacol, Salamanca 37007, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Salamanca	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mquintanilla@iib.uam.es	Bernabeu, Carmelo/L-3226-2014; Pérez-Gómez, Eduardo/GYA-5856-2022; Perez-gomez, Eduardo/F-5906-2015; Lopez-Novoa, Jose M/A-3672-2008; Quintanilla, Miguel/K-9293-2017; Bernabeu, Carmelo/P-4662-2019	Bernabeu, Carmelo/0000-0002-1563-6162; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Perez-gomez, Eduardo/0000-0003-0160-5565; Bernabeu, Carmelo/0000-0002-1563-6162; Lopez-Novoa, Jose M./0000-0002-6211-7269; Quintanilla, Miguel/0000-0002-2124-7657				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bodey B, 1998, ANTICANCER RES, V18, P2701; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BUCHMANN A, 1991, CANCER RES, V51, P4097; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; JINDAL SK, 1995, BIOL REPROD, V52, P1027, DOI 10.1095/biolreprod52.5.1027; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; Kumar S, 1999, CANCER RES, V59, P856; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; Rich JN, 2001, MICROSC RES TECHNIQ, V52, P363, DOI 10.1002/1097-0029(20010215)52:4<363::AID-JEMT1021>3.3.CO;2-6; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Takahashi N, 2001, CANCER RES, V61, P7846; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhang HW, 1996, J IMMUNOL, V156, P565	70	41	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5976	5985		10.1038/sj.onc.1206841	http://dx.doi.org/10.1038/sj.onc.1206841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955076	Green Submitted			2022-12-28	WOS:000185137800006
J	Huang, L; Snyder, AR; Morgan, WF				Huang, L; Snyder, AR; Morgan, WF			Radiation-induced genomic instability and its implications for radiation carcinogenesis	ONCOGENE			English	Article						ionizing radiation; chromosome instability; chromosome breakage syndromes; epigenetic factors	STRAND BREAK REPAIR; DELAYED CHROMOSOMAL INSTABILITY; IONIZING-RADIATION; DNA-REPAIR; IN-VIVO; CLASTOGENIC FACTORS; INTERCELLULAR COMMUNICATION; OXIDATIVE STRESS; BRCA2; CELLS	Radiation-induced genomic instability is characterized by an increased rate of genetic alterations including cytogenetic rearrangements, mutations, gene amplifications, transformation and cell death in the progeny of irradiated cells multiple generations after the initial insult. Chromosomal rearrangements are the best-characterized end point of radiation-induced genomic instability, and many of the rearrangements described are similar to those found in human cancers. Chromosome breakage syndromes are defined by chromosome instability, and individuals with these diseases are cancer prone. Consequently, chromosomal instability as a phenotype may underlie some fraction of those changes leading to cancer. Here we attempt to relate current knowledge regarding radiation-induced chromosome instability with the emerging molecular information on the chromosome breakage syndromes. The goal is to understand how genetic and epigenetic factors might influence the onset of chromosome instability and the role of chromosomal instability in carcinogenesis.	Univ Maryland, Grad Program Human Genet, Baltimore, MD 21201 USA; Univ Maryland, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Mol & Cell Biol Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Huang, L (corresponding author), Univ Maryland, Grad Program Human Genet, 655 W Baltimore St, Baltimore, MD 21201 USA.	lhuan001@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA073924, R01CA083872] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83872, CA73924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Coleman WB, 1999, ANTICANCER RES, V19, P4645; Cui X, 1999, MUTAT RES-DNA REPAIR, V434, P75, DOI 10.1016/S0921-8777(99)00010-5; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Day JP, 1998, CARCINOGENESIS, V19, P259, DOI 10.1093/carcin/19.2.259; Duker NJ, 2002, AM J MED GENET, V115, P125, DOI 10.1002/ajmg.10688; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; EMERIT I, 1982, HUM GENET, V61, P65, DOI 10.1007/BF00291336; EMERIT I, 1990, METHOD ENZYMOL, V186, P555; EMERIT I, 1995, HUM GENET, V96, P14, DOI 10.1007/BF00214180; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Griffin CS, 2000, INT J RADIAT BIOL, V76, P963, DOI 10.1080/09553000050050972; Hickson ID, 2001, BIOCHEM SOC T, V29, P201, DOI 10.1042/0300-5127:0290201; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hollander MC, 2002, ONCOGENE, V21, P6228, DOI 10.1038/sj.onc.1205774; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kadhim MA, 1996, INT J RADIAT BIOL, V69, P167, DOI 10.1080/095530096145995; Kaplan MI, 1998, RADIAT RES, V150, P382, DOI 10.2307/3579656; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P4048; Limoli CL, 1997, CANCER RES, V57, P5557; Limoli CL, 2000, INT J RADIAT BIOL, V76, P1599, DOI 10.1080/09553000050201082; Limoli CL, 1999, RADIAT RES, V151, P677, DOI 10.2307/3580206; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; MORGAN WF, 1988, MOL CELL BIOL, V8, P4204, DOI 10.1128/MCB.8.10.4204; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nagar S, 2003, CANCER RES, V63, P324; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Okayasu R, 2000, CANCER RES, V60, P4342; PAQUETTE B, 1994, CANCER RES, V54, P3173; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; SHAHAM M, 1980, CYTOGENET CELL GENET, V27, P155, DOI 10.1159/000131476; Stewart G, 2002, MOL CELL, V10, P2, DOI 10.1016/S1097-2765(02)00580-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Taylor AMR, 2001, BEST PRACT RES CL HA, V14, P631, DOI 10.1053/beha.2001.0158; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Wojcik A, 1996, RADIAT RES, V145, P119, DOI 10.2307/3579165; Wright EG, 1998, INT J RADIAT BIOL, V74, P681, DOI 10.1080/095530098140943; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Yu YJ, 2001, CANCER RES, V61, P1820	81	166	177	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5848	5854		10.1038/sj.onc.1206697	http://dx.doi.org/10.1038/sj.onc.1206697			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947391				2022-12-28	WOS:000185086100011
J	Logarajah, S; Hunter, P; Kraman, M; Steele, D; Lakhani, S; Bobrow, L; Venkitaraman, A; Wagner, S				Logarajah, S; Hunter, P; Kraman, M; Steele, D; Lakhani, S; Bobrow, L; Venkitaraman, A; Wagner, S			BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation	ONCOGENE			English	Article						mammary epithelium; differentiation; breast cancer; BCL-6; STAT	GERMINAL-CENTER FORMATION; TRANSCRIPTIONAL REPRESSOR; TERMINAL DIFFERENTIATION; ALPHA-6-BETA-4 INTEGRIN; GENE; PROTEIN; INFLAMMATION; PHOSPHORYLATION; MORPHOGENESIS; SUPPRESSION	Appropriately timed proliferation, differentiation and apoptosis are essential to the normal functions of the mammary epithelium. Here, we report that the transcription factor BCL-6 is expressed in mammary epithelium in nonpregnant animals as well as during early pregnancy. When overexpressed in the nontransformed EpH4 mammary epithelial cell line, BCL-6 prevents the STAT-driven expression of the milk protein beta-casein and duct formation, and prevents apoptosis. Consistent with an antiapoptotic function, we demonstrate that BCL-6 is expressed in 68% of histologically high-grade ductal breast carcinomas, which are clinically the most aggressive. BCL-6 has previously been characterized as a regulator of B lymphocyte growth and development, but our work identifies a novel role for it in mammary epithelial differentiation, which may also implicate it in carcinogenesis.	Univ Cambridge, Dept Med, Wellcome Trust Immunol Unit, Cambridge CB2 2SP, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robbins Breast Canc Res Ctr, London SW3 6JB, England; Univ Cambridge, Dept Pathol, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XZ, England	University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Wagner, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, Hammersmith Campus,Du Cane Rd, London W12 ONN, England.		Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760; Wagner, Simon/0000-0002-8914-0370; Kraman, Matthew/0000-0002-5040-0067; Hunter, Patricia/0000-0002-6224-0654				Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Bajalica-Lagercrantz S, 1998, BIOCHEM BIOPH RES CO, V247, P357, DOI 10.1006/bbrc.1998.8551; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Kanazawa N, 1997, PATHOL INT, V47, P600, DOI 10.1111/j.1440-1827.1997.tb04548.x; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	27	64	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5572	5578		10.1038/sj.onc.1206689	http://dx.doi.org/10.1038/sj.onc.1206689			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944904				2022-12-28	WOS:000184865900005
J	Nagano, H; Noguchi, T; Inagaki, K; Yoon, S; Matozaki, T; Itoh, H; Kasuga, M; Hayashi, Y				Nagano, H; Noguchi, T; Inagaki, K; Yoon, S; Matozaki, T; Itoh, H; Kasuga, M; Hayashi, Y			Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma	ONCOGENE			English	Article						tyrosine phosphatase; cell migration; dedifferentiation; hepatoma	FOCAL ADHESION KINASE; CELL INVASION; HUMAN LUNG; EXPRESSION; RECEPTOR; GROWTH; GENE; LIVER; OVEREXPRESSION; AMPLIFICATION	SAP-1 (stomach cancer-associated protein tyrosine phosphatase-1) is a transmembrane-type protein tyrosine phosphatase that has been implicated as a negative regulator of integrin-mediated signaling. The potential role of this enzyme in hepatocarcinogenesis has now been investigated by examining its expression in 32 surgically excised human hepatocellular carcinoma (HCC) specimens. Both immunohistochemical and immunoblot analyses revealed that normal liver tissue, as well as tissue affected by chronic hepatitis or cirrhosis, contained substantial amounts of SAP-1. The expression level of SAP-1 in 75% of well-differentiated HCCs was similar to or higher than that observed in the surrounding non-cancerous tissue. In contrast, the abundance of SAP-1 in 85.7% of moderately differentiated HCCs and in all poorly differentiated HCCs was greatly reduced compared with that in the adjacent tissue. Indeed, SAP-1 was almost undetectable in 83.3% of poorly differentiated HCCs. Furthermore, expression of recombinant SAP-1 in two highly motile human HCC cell lines resulted in a change in morphology and a marked reduction in both migratory activity and growth rate. In conclusion, these results indicate that SAP-1 expression is downregulated during the dedifferentiation of human HCC, and that this downregulation may play a causal role in disease progression.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Biomed Informat, Div Surg Pathol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Kobe University; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVRIES L, 1991, FEBS LETT, V282, P285; DOI I, 1975, GANN, V66, P385; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKUTA S, 1994, J GASTROENTEROL, V29, P727, DOI 10.1007/BF02349278; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; KAMEDA T, 1990, CANCER RES, V50, P8002; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Keane MM, 1996, CANCER RES, V56, P4236; KIM SR, 1995, J GASTROEN HEPATOL, V10, P498, DOI 10.1111/j.1440-1746.1995.tb01338.x; KITAMURA T, 1995, JPN J CANCER RES, V86, P811, DOI 10.1111/j.1349-7006.1995.tb03090.x; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Morita Y, 1997, HEPATOLOGY, V25, P856, DOI 10.1002/hep.510250412; NISHIDA N, 1993, CANCER RES, V53, P368; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; Ojakian GK, 2001, J CELL SCI, V114, P941; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palmer HJ, 1999, J BIOL CHEM, V274, P11424, DOI 10.1074/jbc.274.16.11424; ROGLER CE, 1992, SEMIN LIVER DIS, V12, P265, DOI 10.1055/s-2007-1007398; Saito S, 1996, BIOCHEM BIOPH RES CO, V227, P406, DOI 10.1006/bbrc.1996.1520; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAHARA H, 1995, CANCER RES, V55, P2734; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Tamura M, 1999, CANCER RES, V59, P442; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101	41	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4656	4663		10.1038/sj.onc.1206588	http://dx.doi.org/10.1038/sj.onc.1206588			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879010				2022-12-28	WOS:000184157000006
J	Weber, A; Langhanki, L; Sommerer, F; Markwarth, A; Wittekind, C; Tannapfel, A				Weber, A; Langhanki, L; Sommerer, F; Markwarth, A; Wittekind, C; Tannapfel, A			Mutations of the BRAF gene in squamous cell carcinoma of the head and neck	ONCOGENE			English	Article						squamous cell carcinoma of the head and neck; BRAF; KRAS2	RAS MUTATIONS; ACTIVATION; TUMORIGENESIS; FREQUENCY; PATHWAY; CANCER; KINASE; LIVER; P53	The RAF/MEK/ERK (MAPK) signal transduction cascade is an important mediator of a number of cellular fates including growth, proliferation and survival. The BRAF gene, one of the human isoforms of RAF, is activated by oncogenic RAS, leading to cooperative effects in cells responding to growth factor signals. This study was performed to elucidate a possible function of BRAF in squamous cell carcinoma of the head and neck (HNSCC). Mutations of BRAF and KRAS2 were evaluated in 89 HNSCC and corresponding normal mucosa by direct DNA sequencing analyses after microdissection. The results obtained were correlated with histopathological variables. Activating BRAF missense mutations were identified in 3/89 HNSCC (3%). KRAS2 mutations were found in five out of 89 (6%) HNSCC examined. There were no mutations of KRAS2 and BRAF in non-neoplastic mucosa. We failed to observe a correlation between BRAF or KRAS2 mutations and histopathological factors. Our data indicate that BRAF gene mutations are relatively rare events in HNSCC. Although uncommon, BRAF mutations may identify a subset of patients with HNSCC sensitive to targeted therapy.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Univ Leipzig, Dept Otorhinolaryngol Head & Neck Surg, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.							Brose MS, 2002, CANCER RES, V62, P6997; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Hoa M, 2002, CANCER RES, V62, P7154; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Naoki K, 2002, CANCER RES, V62, P7001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pindborg JJ, 1997, HISTOLOGICAL TYPING; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Shanmugaratnam K, 1991, HISTOLOGICAL TYPING; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 2001, EUR ARCH OTO-RHINO-L, V258, P83, DOI 10.1007/s004050000303; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Weber CK, 2001, CANCER RES, V61, P3595; Xu J, 1998, CANCER-AM CANCER SOC, V83, P204, DOI 10.1002/(SICI)1097-0142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q; Yuen ST, 2002, CANCER RES, V62, P6451	25	99	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4757	4759		10.1038/sj.onc.1206705	http://dx.doi.org/10.1038/sj.onc.1206705			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879021				2022-12-28	WOS:000184157000017
J	Knauf, JA; Kuroda, H; Basu, S; Fagin, JA				Knauf, JA; Kuroda, H; Basu, S; Fagin, JA			RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase	ONCOGENE			English	Article						thyroid; RET/PTC; differentiation; RAS; MEK	TISSUE-SPECIFIC EXPRESSION; RECEPTOR TYROSINE KINASE; SODIUM/IODIDE SYMPORTER GENE; TRANSCRIPTION FACTOR PAX8; PAPILLARY CARCINOMAS; EPITHELIAL-CELLS; AUTOPHOSPHORYLATION SITES; ONCOGENE ACTIVATION; UPSTREAM ENHANCER; MAMMALIAN-CELLS	Constitutive activation of the RET proto-oncogene in papillary thyroid carcinomas results from rearrangements linking the promoter(s) and N-terminal domains of unrelated genes to the C-terminus of RET tyrosine kinase (RET/PTC). RET/PTC expression has been demonstrated to inhibit transcription of thyroid-specific genes. To study the signal transduction pathways responsible for this, we generated PCCL3 thyroid cells with doxycycline-inducible expression of RET/PTC3, RET/PTC3(Y541F), or PTC2/PDZ. Acute expression of RET/PTCY541F appropriately interacted with She, an intermediate in the activation of the Ras pathway, but failed to activate PLCgamma. By contrast, PTC2/PDZ failed to bind She, but interacted normally with PLCgamma. Acute expression of RET/PTC3 or RET/PTC3Y541F, but not PTC2/PDZ, inhibited TSH-induced Tg and NIS expression, suggesting that activation of Shc-Ras, but not PLCgamma, is required for RET/PTC-induced dedifferentiation. Accordingly, acute expression of H-Ras(V12) or of a constitutively active MEK1 also blocked TSH-induced expression of Tg and NIS. Moreover, MEK inhibitors restored Tg and NIS levels. In conclusion, activation of the Ras/Raf/MEK/MAPK pathway through She mediates RET/PTC-induced thyroid cell dedifferentiation. This suggests that inhibition of this pathway may promote redifferentiation in poorly differentiated thyroid carcinomas with constitutive activation of either Ras or RET/PTC.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knauf, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Mail Locat 0547, Cincinnati, OH 45267 USA.			Knauf, Jeffrey/0000-0003-4456-8792	NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002781] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA050706, R01 CA072597, CA72597, CA50706] Funding Source: Medline; NIDDK NIH HHS [KO1DK02781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bounacer A, 1997, BIOCHIMIE, V79, P619, DOI 10.1016/S0300-9084(97)82012-3; Chun JT, 2001, EXP CLIN ENDOCR DIAB, V109, P23, DOI 10.1055/s-2001-11021; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FABBRO D, 1994, CANCER RES, V54, P4744; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ITO T, 1993, CANCER RES, V53, P2940; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 1998, RECENT RES CANCER, V154, P265; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mascia A, 2002, J ENDOCRINOL, V172, P163, DOI 10.1677/joe.0.1720163; Medina DL, 2000, THYROID, V10, P295, DOI 10.1089/thy.2000.10.295; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Nikiforov YE, 1997, CANCER RES, V57, P1690; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Powell DJ, 1998, CANCER RES, V58, P5523; Puxeddu E, 2001, ENDOCRIN METAB CLIN, V30, P493, DOI 10.1016/S0889-8529(05)70196-1; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Santoro M, 2000, BRIT J CANCER, V82, P315, DOI 10.1054/bjoc.1999.0921; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Schmitt TL, 2002, THYROID, V12, P273, DOI 10.1089/10507250252949388; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Trapasso F, 1999, EUR J ENDOCRINOL, V140, P447, DOI 10.1530/eje.0.1400447; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	55	130	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4406	4412		10.1038/sj.onc.1206602	http://dx.doi.org/10.1038/sj.onc.1206602			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853977				2022-12-28	WOS:000183978900010
J	Boehden, GS; Akyuz, N; Roemer, K; Wiesmuller, L				Boehden, GS; Akyuz, N; Roemer, K; Wiesmuller, L			p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair	ONCOGENE			English	Article						genome stability; homologous recombination; p53; transcriptional transactivation; tumor suppression	BASE EXCISION-REPAIR; DNA-POLYMERASE BETA; MUTANT P53; REPLICATION FIDELITY; GENOMIC INTEGRITY; PROMOTER REGION; MISMATCH REPAIR; RECOMBINATION; PROTEIN; GENE	The tumor suppressor p53 transcriptionally transactivates cellular target genes that are implicated in growth control, apoptosis, and DNA repair. However, several studies involving p53 core domain mutants suggested that regulatory functions in recombinative repair do not require transcriptional transactivation and are separable from growth-regulation and apoptosis. Leu22 and Trp23 within the transactivation domain of human p53 play a critical role in binding basal components of the transcription machinery and, therefore, in the transactivation activity of p53. To further delineate whether p53 target genes are involved in recombination regulation, we ectopically expressed p53(22Q,23S) in p53-negative cell lines, which carry reporter systems for different homology-directed double-strand break (DSB) repair events. Like wild-type p53, p53(22Q,23S) efficiently downregulated homologous recombination on two chromosomally integrated substrates without affecting exchange on a substrate for the compound pathway of gene conversion and nonhomologous end joining. Only upon lowering the p53 protein to DNA substrate ratio by several orders of magnitude, we noticed a weak defect of a p53 transactivation domain mutant in DSB repair assays. In conclusion, molecular interactions of p53 within the N-terminal domain are not required to restrain DNA recombination, but might contribute to this genome stabilizing function.	Univ Ulm, Frauenklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Saarland, Dept Virol, D-66421 Homburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg; Saarland University	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.	Lisa.Wiesmueller@medizin.uni-ulm.de						Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bogliolo M, 2000, ONCOGENE, V19, P5781, DOI 10.1038/sj.onc.1203951; Botuyan MVE, 1997, FOLD DES, V2, P331, DOI 10.1016/S1359-0278(97)00047-3; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doetsch PW, 2001, PROG NUCLEIC ACID RE, V68, P29; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Mahdi T, 1998, BIOL CHEM, V90, P15; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Reichenberger S, 1998, EUR J BIOCHEM, V251, P81, DOI 10.1046/j.1432-1327.1998.2510081.x; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Schaffner DL, 1996, LAB INVEST, V74, P1005; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SOUSSI T, 1993, NOUV REV FR HEMATOL, V35, P33; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Theis S, 1997, INT J CANCER, V71, P858; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	56	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4111	4117		10.1038/sj.onc.1206632	http://dx.doi.org/10.1038/sj.onc.1206632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821945				2022-12-28	WOS:000183707600014
J	Ziegert, C; Wentzensen, N; Vinokurova, S; Kisseljov, F; Einenkel, J; Hoeckel, M; Doeberitz, MV				Ziegert, C; Wentzensen, N; Vinokurova, S; Kisseljov, F; Einenkel, J; Hoeckel, M; Doeberitz, MV			A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques	ONCOGENE			English	Article						human papillomavirus (HPV); E6-E7 oncogenes; integration; viral-cellular fusion transcripts; HPV splicing; homologous recombination	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; PHYSICAL STATE; MOLECULAR ANALYSIS; HIGH-RISK; CANCER; SEQUENCES; CARCINOGENESIS; INSTABILITY; DNA	Persistent infections with high-risk human papillomaviruses (HPVs) induce dysplastic lesions of the lower genital tract. Some of these lesions eventually progress to invasive cancers, particularly of the uterine cervix. In many advanced preneoplastic cervical lesions and most derived carcinomas, HPV genomes are found to be integrated into the host cell chromosomes. Although HPV integration seems to play an important role in the progression of cervical dysplasia, the underlying mechanisms are still unclear. To investigate the pathogenic role of genomic integration of HPV genomes in greater detail, we analysed integration sites of HPV16 and 18 genomes in 21 anogenital precancerous and cancerous lesions using a ligation-mediated chain reaction (DIPS) and the recently described amplification of papilloma virus oncogene transcripts (APOT) assay. On the genomic level, only singular integration events were observed in individual neoplastic cell clones. At many integration sites, a short overlap between HPV and genomic sequences was observed, suggesting that the integration of HPV genomes is mediated by nonhomologous sequence-specific recombination. APOT analysis revealed that the majority of integrated HPV genomes was actively transcribed. These data suggest that in the progression of cervical preneoplasia to invasive carcinomas, integration of viral genomes occurs only at single or few chromosomal loci in a given cell clone. Disruption of cellular genes might support malignant transformation in rare cases; however, it is not a pathogenic prerequisite. The main function of HPV integration seems to be the stabilization of oncogene transcription.	Heidelberg Univ, Inst Mol Pathol, Dept Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Blokhin Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	mvkd@aol.com	Einenkel, Jens/B-3772-2014; von Knebel Doeberitz, Magnus/D-2372-2016; Wentzensen, Nicolas/AAG-8522-2019	Einenkel, Jens/0000-0003-4254-667X; von Knebel Doeberitz, Magnus/0000-0002-0498-6781; 				BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BULLOCK P, 1984, J MOL BIOL, V174, P55, DOI 10.1016/0022-2836(84)90365-6; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Choo KB, 1996, J MED VIROL, V49, P15, DOI 10.1002/(SICI)1096-9071(199605)49:1<15::AID-JMV3>3.3.CO;2-4; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Doeberitz MV, 2002, EUR J CANCER, V38, P2229, DOI 10.1016/S0959-8049(02)00462-8; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DURST M, 1986, BANBURY REPORT, V21, P273; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kalantari M, 2001, DIAGN MOL PATHOL, V10, P46, DOI 10.1097/00019606-200103000-00008; Klaes R, 1999, CANCER RES, V59, P6132; LEHN H, 1988, J GEN VIROL, V69, P187, DOI 10.1099/0022-1317-69-1-187; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; Van Tine B. A., 2001, V106, P381; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	29	120	128	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3977	3984		10.1038/sj.onc.1206629	http://dx.doi.org/10.1038/sj.onc.1206629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813471				2022-12-28	WOS:000183612000017
J	Hoare, K; Hoare, S; Smith, OM; Kalmaz, G; Small, D; May, WS				Hoare, K; Hoare, S; Smith, OM; Kalmaz, G; Small, D; May, WS			Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling	ONCOGENE			English	Article						embryonic stem (ES) cells; nonreceptor protein tyrosine kinase (NRPTK); apoptosis; Ras; green fluorescent protein (GFP)	EMBRYONIC STEM-CELLS; HEMATOPOIETIC-CELLS; GTPASE ACTIVITY; GROWTH-FACTOR; PROTEIN-KINASES; MOUSE EMBRYOS; SH2 DOMAINS; IN-VITRO; BINDING; TRANSDUCTION	Kinase of embryonic stem cells (Kos1), a nonreceptor protein tyrosine kinase (NRPTK), was identified and cloned from differentiating murine embryonic stem cells. Kos1 is localized on mouse chromosome 11 that corresponds to human chromosome 17p13.1 and is homologous to Tnk1, Ack1 and Ack2, making it a new member of the Ack family of NRPTKs. Kos1 is a ubiquitously expressed 47-kDa protein with autotyrosine kinase activity that is developmentally regulated during embryogenesis. Kos1 is also upregulated following IL3 withdrawal from factor-dependent murine NSF/N1.H7 cells that undergo apoptosis, suggesting a role in growth inhibition. Stable overexpression of Kos1 inhibits growth of NIH 3T3 cells, while the kinase-dead Kos1(CN) promotes cell growth in both liquid culture and soft agar. In addition, forced expression of Kos1 inhibits Ras activity in an indirect mechanism that results in the downregulation of the Ras-Raf1-MAPK growth pathway. Furthermore, overexpression of Kos1 in NCI-H82 lung cancer cells that express oncogenic Ha-Ras(G12V) inhibits cell growth under reduced serum (0.5%) conditions in close association with the upregulation of the Ras inhibitor, Rap1A. Collectively, these data support a negative regulatory role for Kos1 in regulating the Ras-Raf1-MAPK growth pathway by a mechanism that requires its autotyrosine kinase activity.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Johns Hopkins Univ, Sch Med, Dept Oncol & Pediat, Baltimore, MD 21287 USA	State University System of Florida; University of Florida; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd, Gainesville, FL 32610 USA.			Small, Donald/0000-0002-3072-243X	NCI NIH HHS [CA44649] Funding Source: Medline; NHLBI NIH HHS [HL5408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Avraham H, 2000, J HEMATOTH STEM CELL, V9, P425, DOI 10.1089/152581600419080; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hoehn GT, 1996, ONCOGENE, V12, P903; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sambrook J., 1989, MOL CLONING, pA1; SATOH T, 1995, METHOD ENZYMOL, V255, P149; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; Sem KP, 2002, MOL CELL BIOL, V22, P3685, DOI 10.1128/MCB.22.11.3685-3697.2002; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1995, SCIENCE, V267, P1701; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILES MV, 1991, DEVELOPMENT, V111, P259; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516; YANG JJ, 1998, MOL CELL BIOL, V17, P3850; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200	68	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3562	3577		10.1038/sj.onc.1206480	http://dx.doi.org/10.1038/sj.onc.1206480			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789265				2022-12-28	WOS:000183399200007
J	Steinman, RA; Wentzel, A; Lu, YL; Stehle, C; Grandis, JR				Steinman, RA; Wentzel, A; Lu, YL; Stehle, C; Grandis, JR			Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2	ONCOGENE			English	Article						Stat3 (signal transducer and activator of; transcription-2) cdk2; confluence; cyclin-dependent; kinase; protein transduction	GROWTH IN-VIVO; KINASE INHIBITOR P27(KIP1); CARCINOMA-CELLS; PLASMA-MEMBRANE; NECK-CANCER; TGF-ALPHA; HEAD; DIFFERENTIATION; APOPTOSIS; PROTEIN	The signal transducing protein Stat3 activates gene transcription in cells in response to multiple cytokines. Constitutive activation of Stat3 has been observed in solid tumors including head and neck squamous cell carcinoma. Stat3 activation in cancer has been associated with autocrine stimulatory loops and is believed to convey a growth advantage to cells. We now demonstrate ligand-independent activation of Stat3 by high cell density in multiple cancer cell lines. Activation of Stat3 is associated with anti proliferative rather than proliferative conditions. Interference with cdk2 activity upregulates Stat3 phosphorylation and Stat3-directed DNA-binding activity. Our data supports a model in which Stat3 activity is partially suppressed by cdk2 in growing cells and derepressed upon cell confluence.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Steinman, RA (corresponding author), Hillman Canc Ctr, Suite 2,18 UPCI Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.				NCI NIH HHS [R01CA77308] Funding Source: Medline; NHLBI NIH HHS [R01HL65172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman RS, 2000, ADV EXP MED BIOL, V480, P129; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Dimanche-Boitrel MT, 1998, INT J CANCER, V77, P796, DOI 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z; Endo S, 2000, GENE THER, V7, P1906, DOI 10.1038/sj.gt.3301315; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garrido C, 1997, CANCER RES, V57, P2661; Gaulin JF, 2000, J BIOL CHEM, V275, P16658, DOI 10.1074/jbc.275.22.16658; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; LI L, 2002, J BIOL CHEM, V21, P21; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Steinman RA, 1999, LEUKEMIA, V13, P54, DOI 10.1038/sj.leu.2401253; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Wang S, 1999, J GASTROINTEST SURG, V3, P200, DOI 10.1016/S1091-255X(99)80034-1; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Xie B, 2001, J BIOL CHEM, V276, P19512, DOI 10.1074/jbc.M009063200; Yaroslavskiy BB, 2001, MOL MED, V7, P49, DOI 10.1007/BF03401838; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	42	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3608	3615		10.1038/sj.onc.1206523	http://dx.doi.org/10.1038/sj.onc.1206523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789269				2022-12-28	WOS:000183399200011
J	Bastian, BC				Bastian, BC			Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer	ONCOGENE			English	Article						melanoma; Spitz nevus; genetics; regression; minimal residual disease	SKIN-CANCER; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SPITZ NEVI; RAS; MUTATIONS; CELLS; DIAGNOSIS; APOPTOSIS; TELOMERE	Analysis of DNA copy number changes using comparative genomic hybridization in melanocytic neoplasms has revealed distinct patterns of chromosomal aberrations between benign melanocytic nevi and melanoma. Whereas the vast majority of melanoma expresses chromosomal aberrations, blue nevi, congenital nevi, and most Spitz nevi typically show no aberrations. A subset of Spitz nevi shows an isolated gain of chromosome 11p, an aberration pattern not observed in melanoma. These Spitz nevi frequently harbor mutations in the HRAS gene located on this chromosomal arm. Comparisons among melanoma types showed that melanomas of the palms, soles, and subungual sites can be distinguished by the presence of multiple gene amplifications that arise very early in their progression. About 50% of these amplifications are found at the cyclin D1 locus. By contrast, amplifications are significantly less frequent in other cutaneous melanoma types and if present arise late in progression. The frequent amplifications in melanomas on acral sites allowed the detection of single basal melanocytes with gene amplifications in the histologically normal appearing skin immediately adjacent to a melanoma. These "field cells" represent subtle melanoma in situ and are likely to represent minimal residual disease that can lead to local recurrences if not excised with safety margins. The high frequency of chromosomal aberrations in melanomas and their relative absence in nevi could indicate that melanocytes of melanomas went through telomeric crisis, whereas melanocytes in nevi did not. Such a scenario would suggest that replicative senescence is a tumor-suppressive mechanism in melanocytic neoplasia. It might also explain part of the phenomenon of regression commonly seen in melanoma. Genomic analysis is a powerful tool to obtain insight in the progression of melanocytic neoplasms with potential clinical applications for classification and detection of minimal residual melanoma.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Dermatol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Dept Pathol, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Bastian, BC (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Dept Dermatol, 2340 Sutter St,Rm S434, San Francisco, CA 94115 USA.	bastian@cc.ucsf.edu		Bastian, Boris/0000-0003-1836-6062				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barnhill RL, 1999, HUM PATHOL, V30, P513, DOI 10.1016/S0046-8177(99)90193-4; Bastian BC, 2000, CANCER RES, V60, P1968; Bastian BC, 1999, J INVEST DERMATOL, V113, P1065, DOI 10.1046/j.1523-1747.1999.00787.x; Bastian BC, 1998, CANCER RES, V58, P2170; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; BASTIAN BC, IN PRESS AM J PATHOL; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Brash DE, 1998, CANCER SURV, V32, P69; BRODEUR GM, 1998, GENETIC BASIS HUMAN; Clark W. H., 1990, PATHOLOGY SKIN, P729; DeDavid M, 1997, J AM ACAD DERMATOL, V36, P409, DOI 10.1016/S0190-9622(97)80217-4; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; Glover MT, 1997, LANCET, V349, P398, DOI 10.1016/S0140-6736(97)80015-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herlyn M, 1996, AM J PATHOL, V149, P739; JEN J, 1994, CANCER RES, V54, P5523; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Kageshita T, 1999, AM J PATHOL, V154, P745, DOI 10.1016/S0002-9440(10)65321-7; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Pathak S, 2000, INT J ONCOL, V17, P1219; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; SAUTER ER, IN PRESS CANC RES, V1, P20; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Straten P, 1996, J CLIN INVEST, V98, P279, DOI 10.1172/JCI118790; vanElsas A, 1996, AM J PATHOL, V149, P883; Veenhuizen KCW, 1997, J PATHOL, V182, P266, DOI 10.1002/(SICI)1096-9896(199707)182:3<266::AID-PATH812>3.0.CO;2-#; WEINBERG RA, 1989, CANCER RES, V49, P3713; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	80	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3081	3086		10.1038/sj.onc.1206463	http://dx.doi.org/10.1038/sj.onc.1206463			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789284				2022-12-28	WOS:000183096600009
J	Tellez, C; Bar-Eli, M				Tellez, C; Bar-Eli, M			Role and regulation of the thrombin receptor (PAR-1) in human melanoma	ONCOGENE			English	Review						AP-2; angiogenesis; malignant melanoma; metastasis; thrombin receptor	TRANSCRIPTION FACTOR AP-2; PROTEASE-ACTIVATED RECEPTOR-1; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; DNA-BINDING; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; BREAST-CANCER; TISSUE FACTOR; E-CADHERIN	To determine treatment strategies and predict the clinical outcome of patients with melanoma it is important to understand the etiology of this disease. Recently, there has been some insight into molecular basis of melanoma including identification of a few of the regulatory factors and genes involved in this disease. For instance, the transcription factor AP-2 plays a tumor suppressor-like role in melanoma progression by regulating genes involved in tumor growth and metastasis. Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2. Increasing evidence demonstrates that the thrombin receptor (protease-activated receptor-1, PAR-1) plays a major role in tumor invasion and contributes to the metastatic phenotype of human melanoma. This review focuses on the role of the thrombin receptor in melanoma and its regulation by AP-2. We show that loss of AP-2 expression in metastatic melanoma cells correlates with overexpression of the thrombin receptor. Our analysis of AP-2/Sp1 complexes within the regulatory region of the thrombin receptor demonstrates that AP-2 binds the proximal 3' region of the promoter and diminishes PAR-1 expression. Levels of AP-2 and Sp1 proteins in a panel of melanoma cell lines demonstrated a marked decrease in the ratio of AP-2/ Sp1, a decrease that correlated with overexpression of PAR-1 in metastatic melanoma cells. We propose that loss of AP-2 results in increased expression of the thrombin receptor, which subsequently contributes to the metastatic phenotype of melanoma by upregulating the expression of adhesion molecules, proteases, and angiogenic molecules.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,173, Houston, TX 77030 USA.	mbareli@mdanderson.org			NCI NIH HHS [CA76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Brach MA, 1996, CYTOKINES MOL THER, V2, P81; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Cucina A, 1999, J SURG RES, V82, P61, DOI 10.1006/jsre.1998.5514; De Simone G, 1999, BIOPOLYMERS, V51, P19, DOI 10.1002/(SICI)1097-0282(1999)51:1<19::AID-BIP4>3.0.CO;2-G; Degen SJF, 1998, CRIT REV EUKAR GENE, V8, P203, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.60; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ESUMI N, 1991, CANCER RES, V51, P4549; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FISCHER EG, 1995, CANCER RES, V55, P1629; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Goding CR, 2000, GENE DEV, V14, P1712; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kaufmann R, 1997, CANCER, V80, P2068, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEBEAU B, 1994, CANCER, V74, P38, DOI 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LIU CY, 1979, J BIOL CHEM, V254, P421; Liu YN, 2001, CANCER LETT, V169, P173, DOI 10.1016/S0304-3835(01)00504-3; Luca MR, 1998, HISTOL HISTOPATHOL, V13, P1225, DOI 10.14670/HH-13.1225; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; Ornstein DL, 2001, INT J HEMATOL, V73, P157, DOI 10.1007/BF02981932; Ornstein DL, 1999, HAEMOSTASIS, V29, P48; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Rudroff C, 1998, PANCREAS, V16, P189, DOI 10.1097/00006676-199803000-00013; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Senger DR, 1996, AM J PATHOL, V149, P293; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; TAPPARELLI C, 1993, TRENDS PHARMACOL SCI, V14, P366, DOI 10.1016/0165-6147(93)90095-2; THORNES RD, 1994, J CANCER RES CLIN, V120, pS32, DOI 10.1007/BF01377122; Turner BC, 1998, CANCER RES, V58, P5466; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOJTUKIEWICZ MZ, 1993, INT J CANCER, V54, P793, DOI 10.1002/ijc.2910540514; WOJTUKIEWICZ MZ, 1992, THROMB RES, V68, P233, DOI 10.1016/0049-3848(92)90081-K; WOJTUKIEWICZ MZ, 1990, AM J CLIN PATHOL, V93, P516, DOI 10.1093/ajcp/93.4.516; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; YOSHIDA E, 1994, CANCER RES, V54, P3300; ZACHARSKI LR, 1995, THROMB HAEMOSTASIS, V73, P793; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	101	104	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3130	3137		10.1038/sj.onc.1206453	http://dx.doi.org/10.1038/sj.onc.1206453			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789289				2022-12-28	WOS:000183096600015
J	Milosevic, J; Hoffarth, S; Huber, C; Schuler, M				Milosevic, J; Hoffarth, S; Huber, C; Schuler, M			The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases	ONCOGENE			English	Article						Bcl-2; apoptosis; DNA damage; Bax caspases	CYTOCHROME-C RELEASE; TRIGGERS APOPTOSIS; CELL-DEATH; BAX; PATHWAYS; FAMILY; REQUIREMENT; CLEAVAGE; MEMBER; APAF1	Apoptosis induced by DNA-damaging agents or radiation mainly proceeds through death receptor-independent caspase activation. The release of mitochondrial apoptogenic proteins, such as cytochrome c, into the cytoplasm leading to Apaf1-dependent activation of caspase-9 is a key event in this pathway. The permeability of the mitochondrial outer membrane is regulated by the various pro- and antiapoptotic Bcl-2 family proteins, and it is thought that DNA damage triggers apoptosis through the downregulation of antiapoptotic Bcl-2. Using murine embryonic fibroblasts (MEF) deficient and proficient in Apaf1, we show that DNA-damaging agents and radiation lead to a decline in Bcl-2 protein only in wt MEF, but not in apaf1(-/-) MEF, which are defective in the activation of effector caspases and apoptosis. In contrast, the induction of proapoptotic Noxa, the activation of Bax, the cytoplasmic release of cytochrome c, as well as a drop of the mitochondrial transmembrane potential DeltaPsi(m) are equally observed in wt and apaf1(-/-) MEF following DNA damage. Moreover, the loss of Bcl-2 protein occurring in wt MEF can be prevented by caspase inhibition. Hence, the activation of proapoptotic Bcl-2 family proteins rather than the downregulation of antiapoptotic Bcl-2 mediates the primary signal in the DNA damage-induced release of mitochondrial apoptogenic proteins in MEF.	Johannes Gutenberg Univ Mainz, Dept Med 3, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Gene Therapy Lab, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Schuler, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 3, Bldg 302, D-55101 Mainz, Germany.	m.schuler@3-med.klinik.uni-mainz.de						Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHEN M, 1995, CANCER RES, V55, P991; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	32	23	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6852	6856		10.1038/sj.onc.1206716	http://dx.doi.org/10.1038/sj.onc.1206716			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534531				2022-12-28	WOS:000185843400005
J	Loo, JCY; Liu, L; Hao, AH; Gao, LZ; Agatep, R; Shennan, M; Summers, A; Goldstein, AM; Tucker, MA; Deters, C; Fusaro, R; Blazer, K; Weitzel, J; Lassam, N; Lynch, H; Hogg, D				Loo, JCY; Liu, L; Hao, AH; Gao, LZ; Agatep, R; Shennan, M; Summers, A; Goldstein, AM; Tucker, MA; Deters, C; Fusaro, R; Blazer, K; Weitzel, J; Lassam, N; Lynch, H; Hogg, D			Germline splicing mutations of CDKN2A predispose to melanoma	ONCOGENE			English	Article						splice site mutations; melanoma; genetic predisposition	HAPLOTYPE ANALYSIS; PRONE FAMILIES; P16(INK4A); FOUNDER	Coding mutations of the CDKN2A gene on chromosome 9p21 cosegregate with 25-60% of familial melanoma cases, but there remains a number of 9p21-linked kindreds that lack germline coding mutations of CDKN2A. W e sequenced CDKN2A exons 1alpha, 2, 3, and the adjacent intronic regions in 167 melanoma-prone families ( at least two affected first-degree relatives), and detected four splice site variations, three of which cosegregate with the disease. RT-PCR experiments verified that these three variants, including an AGgt to ATgt mutation that demonstrates a founder effect, do affect splicing. While an exon 1alpha splice donor site mutation incompletely abolishes splicing, the correctly spliced mRNA yields a protein (Q50P) that cannot effectively interact with CDK4. We also performed RT-PCR on mRNA from 16 melanoma-prone kindreds to search for cryptic splice sites deep within introns, but identified no splice variants. Meanwhile, we screened 139 affected families using allele specific PCR for the recently discovered IVS2-105A >G mutation, but found only one family that possesses this alteration. We conclude that splice site mutations do predispose to disease in a subset of melanoma-prone kindreds. Characterization of additional splice site variants and other noncoding alterations of CDKN2A should allow us to detect a wider range of mutations in at-risk patients.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; City Hope Comprehens Canc Ctr, Dept Clin Canc Genet, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; N York Gen Hosp, Dept Genet, Toronto, ON M2K 1E1, Canada	University of Toronto; University of Toronto; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Creighton University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; North York General Hospital	Hogg, D (corresponding author), Univ Toronto, Dept Med Biophys, Room 7368,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.hogg@utoronto.ca	Blazer, Kathleen/ABC-8530-2021; Tucker, Margaret A/B-4297-2015	Loo, Joanne Chung Yan/0000-0001-8429-6109				Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Colitt R, 1999, LAT TRADE, V7, P22; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hogg D, 1998, J Cutan Med Surg, V2, P172; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Liu L, 1997, GENE CHROMOSOME CANC, V19, P52, DOI 10.1002/(SICI)1098-2264(199705)19:1<52::AID-GCC8>3.3.CO;2-S; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MacKie RM, 1998, J INVEST DERMATOL, V111, P269, DOI 10.1046/j.1523-1747.1998.00267.x; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Moskaluk C A, 1998, Hum Mutat, V12, P70; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUTTER JL, IN PRESS ONCOGENE; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shennan MG, 2000, ONCOGENE, V19, P1849, DOI 10.1038/sj.onc.1203507	27	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6387	6394		10.1038/sj.onc.1206736	http://dx.doi.org/10.1038/sj.onc.1206736			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508519				2022-12-28	WOS:000185535300009
J	Habraken, Y; Jolois, O; Piette, J				Habraken, Y; Jolois, O; Piette, J			Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappa B activation by camptothecin and X-ray	ONCOGENE			English	Article						NF-kappa B; double-strand breaks; BRCA1; NBS; ATLD; MMR	NIJMEGEN BREAKAGE SYNDROME; DNA MISMATCH REPAIR; ATM-DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; TOPOISOMERASE-I; MRE11 COMPLEX; DAMAGE; PROTEIN; KINASE; CANCER	Camptothecin (CPT) and X-ray (XR) generate double-strand breaks (DSB) that can be processed by homologous or nonhomologous recombination. We studied the participation of proteins involved in recombination pathways and cell cycle control in the signal transduction between DNA damage and NF-kappaB. Cells harbouring mutated NBS, hMRE11, BRCA1 or MLH1 were analysed. NBS- and hMRE11-deficient cells present a classical kinetic of NF-kappaB induction after camptothecin treatment. When DSB are generated by XR, NBS-deficient cells exhibit a delayed and strongly reduced level of NF-kappaB induction, whereas the hMRE11 mutated cells do not induce NF-kappaB at all. This indicates an important role of the hMRE11/hRAD50/NBS complex in the signal transduction initiated by XR. In HCC1937 cells that express a truncated version of BRCA1, XR induces a very rapid and transient NF-kappaB activation, whereas CPT leads to a delayed activation suggesting that BRCA1 modulates the transduction pathways in different manners after these two stresses. Finally, we found that a proficient MMR pathway is essential to the NF-kappaB activation after both CPT and XR. These results indicate that DSB originating from XR or CPT do not induce NF-kappaB in a unique way. MMR participates in both cascades, whereas the hMRE11/hRAD50/NBS trimer is specifically involved in the response elicited by XR.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Inst Anat L3, Ctr Immunol, Lab Human Histol, B-4020 Liege, Belgium	University of Liege; University of Liege	Habraken, Y (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	Yvette.Habraken@ulg.ac.be						AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2000, MUTAGENESIS, V15, P281, DOI 10.1093/mutage/15.3.281; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Habraken Y, 2001, BIOCHEM PHARMACOL, V62, P603, DOI 10.1016/S0006-2952(01)00709-2; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jacob S, 2001, CANCER RES, V61, P6555; Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KOI M, 1994, CANCER RES, V54, P4308; KRAAKMANVANDERZ.M, 1999, MUTAT RES, V434, P127; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; WU X, 2000, SCIENCE, V289, pA11; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	44	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6090	6099		10.1038/sj.onc.1206893	http://dx.doi.org/10.1038/sj.onc.1206893			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955088				2022-12-28	WOS:000185137800018
J	Marcoux, N; Vuori, K				Marcoux, N; Vuori, K			EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2	ONCOGENE			English	Article						adhesion; cytoskeleton; integrin; kinase; signaling	GROWTH-FACTOR RECEPTORS; GUANOSINE TRIPHOSPHATASES; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; FAMILY PROTEINS; RHO FAMILY; CELL-CYCLE; INTEGRINS; PHOSPHORYLATION; KINASE	Organization of the actin cytoskeleton in eucaryotic cells is controlled by small GTPases of the Rho family. Rac becomes activated by growth factor stimulation and integrin-mediated cell adhesion to extracellular matrix and is known to have a crucial role in lamellipodia formation, cell spreading and migration. At present, the intracellular pathways that connect cell surface receptors to Rac activation are poorly characterized. It has been reported previously that integrin-mediated cell attachment induces activation of the EGF receptor (EGFR) in the absence of EGF. We demonstrate here that this activation is instrumental for integrin-dependent Rac activation. Thus, we found that cells in which EGFR activity had been inhibited failed to spread and form lamellipodia on fibronectin. Failure to spread coincided with inhibition of adhesion-induced GTP loading of Rac and also with inhibition of the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Subsequent studies demonstrated that an activated form of PI 3-kinase restored Rac GTP loading in the presence of EGFR inhibition, while a dominant-negative form of PI 3-kinase blocked Rac GTP loading in fibronectin-adherent cells. Our further functional studies identified Vav2, a known exchange factor for Rac, as a crucial downstream component in EGFR- and PI 3-kinase-dependent Rac activation upon integrin-mediated cell adhesion. Our results provide a mechanistic insight into integrin-dependent Rac activation, and identify a novel role for EGFR, PI 3-kinase and Vav2 in this pathway.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@burnham.org						Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6	34	80	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6100	6106		10.1038/sj.onc.1206712	http://dx.doi.org/10.1038/sj.onc.1206712			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955089				2022-12-28	WOS:000185137800019
J	Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Nakajima, A; Shimamoto, T; Ohyashiki, JH; Ohyashiki, K				Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Nakajima, A; Shimamoto, T; Ohyashiki, JH; Ohyashiki, K			Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways	ONCOGENE			English	Article						telomerase inhibition; ATM; telomere dysfunction	ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN TUMOR-CELLS; ATAXIA-TELANGIECTASIA; CATIONIC PORPHYRINS; CATALYTIC SUBUNIT; CANCER-CELLS; IN-VITRO; CHECKPOINT; GROWTH	The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. In order to determine whether G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), might have effects on telomere dynamics and to evaluate the clinical utility, we assessed the effects of telomestatin on BCR-ABL-positive human leukemia cells. We found that treatment with telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines OM9;22 and K562, resulting in telomere shortening. Inhibition of telomerase activity by telomestatin disrupts' telomere maintenance and ultimately results in telomere dysfunction. Telomestatin completely suppressed the plating efficiency of K562 cells at 1 muM; however, telomestatin had less effects on BFU-Es and CFU-GMs colony formation from normal bone marrow CD34-positive cells. Enhanced chemosensitivity toward imatinib and chemotherapeutic agents was also observed in telomestatin-treated K562 cells. Further, the combination of telomestatin plus imatinib more: effectively inhibited hematopoietic colony formation by primary human chronic myelogenous leukemia. cells. Last, telomestatin induced the activation of ATM and Chk2, and subsequently increased the expression of, p21(CIP1) and p27(KIP1). These results demonstrate that telomere dysfunction induced by telomestatin activates the ATM-dependent DNA damage response. We conclude that telomerase inhibitors combined with the use, of imatinib and other chemotherapeutic agents may be very useful for the treatment of human leukemia.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan	Tokyo Medical University; University of Tokyo; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.		Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blackburn EH, 1995, TELOMERES; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chaves-Dias C, 2001, J IMMUNOL, V166, P6647, DOI 10.4049/jimmunol.166.11.6647; Chehab NH, 2000, GENE DEV, V14, P278; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hisatomi H, 1999, INT J ONCOL, V14, P727; Izbicka E, 1999, CANCER RES, V59, P639; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM MY, 2002, J AM CHEM SOC, V123, P1262; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; OHYASHIKI K, 1993, LEUKEMIA, V7, P1034; Perry, 1999, Expert Opin Investig Drugs, V8, P1981, DOI 10.1517/13543784.8.12.1981; Sachsinger J, 2001, CANCER RES, V61, P5580; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shi DF, 2001, J MED CHEM, V44, P4509, DOI 10.1021/jm010246u; Shieh SY, 2000, GENE DEV, V14, P289; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 2002, CLIN CANCER RES, V8, P3341; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	47	179	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5338	5347		10.1038/sj.onc.1206833	http://dx.doi.org/10.1038/sj.onc.1206833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917635				2022-12-28	WOS:000184734900013
J	Ng, CC; Arakawa, H; Fukuda, S; Kondoh, H; Nakamura, Y				Ng, CC; Arakawa, H; Fukuda, S; Kondoh, H; Nakamura, Y			p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21(WAF1)	ONCOGENE			English	Article						p53RFP; p53-inducible gene; IBR domain	CYCLIN-DEPENDENT KINASES; P53-DEPENDENT APOPTOSIS; UBIQUITIN LIGASE; BINDING-SITE; HUMAN CANCER; PROTEASOME; DEGRADATION; GENES; PATHWAY; P21	The mechanisms by which p53 prevents development of cancer are much more complicated than previously thought. Under normal conditions, p53 is involved in cell-cycle arrest, apoptosis, DNA repair, and inhibition of angiogenesis; it also promotes degradation of proteins through transcriptional regulation of certain target genes. Here we report the isolation of a novel transcriptional target of p53, designated p53RFP (p53-inducible RING-finger protein), whose product has E3 ubiquitin ligase activity. Its expression was negatively correlated to that of p21(WAF1) protein; p53RFP is likely to play a role in the regulation of this protein, probably through interaction with, and ubiquitination of, p21(WAF1). p53RFP appears to represent the second known example, the first being MDM2, of an E3 ubiquitin ligase as a p53 target. Our results further suggest that p53 might regulate the stability of p21(WAF1) through transcriptional regulation of p53RFP, and this feature may represent a novel mechanism for a p53-dependent cell-cycle checkpoint.	Univ Tokyo, Mol Med Lab, Ctr Human Genet, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	University of Tokyo; Osaka University	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genet, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	NG, CHING CHING/B-9221-2010; Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Matsuda N, 2001, J CELL SCI, V114, P1949; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao RB, 2000, GENE DEV, V14, P981	27	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4449	4458		10.1038/sj.onc.1206586	http://dx.doi.org/10.1038/sj.onc.1206586			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853982				2022-12-28	WOS:000183978900015
J	Morelli, C; Garofalo, C; Bartucci, M; Surmacz, E				Morelli, C; Garofalo, C; Bartucci, M; Surmacz, E			Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; insulin receptor substrate; proteasome degradation; cell survival; breast cancer	GROWTH-FACTOR-I; HUMAN PANCREATIC-CANCER; HUMAN SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3-OH KINASE; MEDIATED DEGRADATION; DOWN-REGULATION; 26S PROTEASOME; IRS-2 GENE	In breast cancer cells, 17-beta-estradiol (E2) upregulates the expression of insulin receptor substrate 1 (IRS-1), a molecule transmitting insulin-like growth factor-I (IGF-I) signals through the PI-3K/Akt survival pathways. The stimulation of IRS-1 by E2 has been documented on the transcriptional level. Here we studied whether the expression of estrogen receptor (ER)-alpha affects IRS molecules post-transcriptionally. We used ER-alpha-negative MDA-MB-231 breast cancer cells and MDA-MB-231 cells with re-expressed ER-alpha. In MDA-MB-231 cells cultured under serum-free conditions, IRS-1 and IRS-2 were degraded through the 26S proteasome and calpain pathways. Re-expression of ER-alpha in MDA-MB-231 cells correlated with enhanced stability of IRS molecules. This effect coincided with significantly reduced ubiquitination of IRS-1 and IRS-2, but did not involve increased IRS-1 and IRS-2 transcription. The interference of ER-alpha with IRS-1 and IRS-2 turnover could rely on the competition for common degradation pathways, as in MDA-MB-231/ER cells, ER-alpha processing was blocked by proteasome and calpain inhibitors. Notably, a fraction of the cytosolic ER-alpha colocalized and coprecipitated with IRS-1 and IRS-2, indicating a possible common destination for these proteins. The stabilization of IRS-1 in MDA-MB-231/ER cells was paralleled by the upregulation of the IRS-1/Akt/GSK-3 pathway and improved survival in the presence of IGF-I, whereas IRS-2 was not involved in IGF-I signaling.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Fac Pharm, Postgrad Sch Clin Pathol, I-87030 Commenda Di Rende, Italy	Jefferson University; University of Calabria	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.		Garofalo, Cecilia/B-3834-2017; Morelli, Catia/AAE-1886-2019	Garofalo, Cecilia/0000-0001-5334-8930; Morelli, Catia/0000-0002-9407-0805				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aguirre V., 2000, CURRENT OPIN ENDOCRI, V7, P1, DOI [10.1097/00060793-200002000-00001, DOI 10.1097/00060793-200002000-00001]; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; Ashok BT, 2001, INT J MOL MED, V8, P385; Bartucci M, 2001, CANCER RES, V61, P6747; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Dupont J, 1999, J ENDOCRINOL, V162, P67, DOI 10.1677/joe.0.1620067; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Guvakova MA, 1997, CANCER RES, V57, P2606; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kornmann M, 1998, CANCER RES, V58, P4250; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Powzaniuk MA, 2001, J IMMUNOL, V167, P242, DOI 10.4049/jimmunol.167.1.242; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Richards RG, 2001, ENDOCRINOLOGY, V142, P3842, DOI 10.1210/en.142.9.3842; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Salerno M, 1999, INT J CANCER, V81, P299; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shiba E, 1996, ANTICANCER RES, V16, P773; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SMITH LK, 1993, BIOCHEM BIOPH RES CO, V196, P767, DOI 10.1006/bbrc.1993.2315; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Spector SA, 1999, J SURG RES, V83, P32, DOI 10.1006/jsre.1998.5553; Sun M, 2001, CANCER RES, V61, P5985; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	57	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4007	4016		10.1038/sj.onc.1206436	http://dx.doi.org/10.1038/sj.onc.1206436			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821935				2022-12-28	WOS:000183707600004
J	Okumura, T; Shimada, Y; Imamura, M; Yasumoto, S				Okumura, T; Shimada, Y; Imamura, M; Yasumoto, S			Neurotrophin receptor p75(NTR) characterizes human esophageal keratinocyte stem cells in vitro	ONCOGENE			English	Article						p75(NTR); stem cells; esophagus; keratinocytes; integrin beta 1; integrin beta 4	NERVE GROWTH-FACTOR; TRANSIT AMPLIFYING CELLS; HUMAN EPITHELIAL-CELLS; EPIDERMAL-CELLS; TELOMERASE ACTIVITY; SURFACE PHENOTYPE; HUMAN-SKIN; INTEGRIN; FOLLICLE; EXPRESSION	We report here that human esophageal keratinocyte stem cells are characterized by the expression of the low-affinity neurotrophin receptor p75(NTR) and differentially expressed cell adhesion molecules, the beta1 and beta4 integrins. The candidate stem cells could be fractionated from keratinocytes as a minor cell subset by means of immunocytochemical cell sorting based on the different levels of expression of these cell surface molecules. Flow cytometric analysis revealed that this minor cell subset retained a relatively slow-cycling phenotype in vitro. These cells expressed low levels of involucrin and cytokeratin 13, indicating that the p75(NTR)-positive cell subset is immature relative to the other predominant subpopulations coexpressing beta1 integrin at higher levels. The p75(NTR)-positive cell subset was crucial for achieving longevity and the greatest output of keratinocytes comprising all distinguishable subpopulations in vitro. This process was associated with self-renewal and self-amplification of the p75(NTR)-positive cell subset. These findings strongly implicate p75(NTR) as a stem cell marker, which will be valuable for prospectively investigating stem cell regulation in association with different biological processes including neoplastic transformation of regenerative epithelia.	Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol & Oncol, Asahi Ku, Yokohama, Kanagawa 2410815, Japan; Kyoto Univ, Grad Sch Med, Dept Surg & Surg Basic Sci, Kyoto, Japan	Kanagawa Prefectural Cancer Center; Kyoto University	Yasumoto, S (corresponding author), Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol & Oncol, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 2410815, Japan.	yasumoto@gancen.asahi.yokohama.jp						ALBARWARI SE, 1976, INT J RADIAT BIOL, V30, P201, DOI 10.1080/09553007614550981; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; HALL PA, 1989, DEVELOPMENT, V106, P619; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kaur P, 2000, J INVEST DERMATOL, V114, P413, DOI 10.1046/j.1523-1747.2000.00884.x; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kunimura C, 1998, ONCOGENE, V17, P187, DOI 10.1038/sj.onc.1201916; Lako M, 2002, J CELL SCI, V115, P3967, DOI 10.1242/jcs.00060; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Miller Stanley J., 1997, P331, DOI 10.1016/B978-012563455-7/50012-X; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Ohta Y, 1997, JPN J CANCER RES, V88, P644, DOI 10.1111/j.1349-7006.1997.tb00432.x; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Pincelli C, 2000, J DERMATOL SCI, V22, P71, DOI 10.1016/S0923-1811(99)00065-1; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1988, J CELL SCI, P45; Price J, 2001, CURR OPIN NEUROBIOL, V11, P564, DOI 10.1016/S0959-4388(00)00250-6; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Seery JP, 2002, J CELL SCI, V115, P1783; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Yasumoto S, 1996, ONCOGENE, V13, P433	34	101	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4017	4026		10.1038/sj.onc.1206525	http://dx.doi.org/10.1038/sj.onc.1206525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821936	Green Submitted			2022-12-28	WOS:000183707600005
J	Burgermeister, E; Tencer, L; Liscovitch, M				Burgermeister, E; Tencer, L; Liscovitch, M			Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells	ONCOGENE			English	Article						cancer; caveolin; differentiation; peroxisome proliferator-activated receptor-gamma; transcriptional regulation; multidrug resistance	HUMAN BREAST-CANCER; ONCOGENICALLY TRANSFORMED-CELLS; ANCHORAGE-INDEPENDENT GROWTH; HUMAN PROSTATE-CANCER; D7S522 LOCUS 7Q31.1; MAP KINASE CASCADE; GENE-EXPRESSION; IN-VIVO; PPAR-GAMMA; TERMINAL DIFFERENTIATION	Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a nuclear receptor for eicosanoids that promotes differentiation of human epithelial and mesenchymal cells in vitro and in vivo. PPARgamma was proposed as a target for drug-induced differentiation therapy of cancer. Caveolin-1 is a constituent of plasma membrane caveolae in epithelial cells that is often downregulated upon oncogenic transformation. Caveolin-1 has growth-inhibitory activities and its disruption is sufficient to induce transformation in fibroblasts. Herein we have tested the hypothesis that caveolins are transcriptional target genes for PPARgamma. In human HT-29 colon carcinoma cells, thiazolidinedione PPARgamma ligands increased the levels of caveolin-1 and caveolin-2 proteins two to fivefold in a concentration-dependent manner within 24 h. In human MCF-7 breast adenocarcinoma cells, nonthiazolidinedione PPARgamma ligands elevated caveolin-2 protein three to fourfold, while the thiazoli-dinediones were less effective. Caveolin-1 mRNA levels were found to be upregulated by PPARgamma ligands already after 3 h in both the cell lines. Ectopic expression of a dominant-negative PPARgamma construct attenuated ligand-induced upregulation of caveolins in both HT-29 and HEK-293T cells, indicating that ligand action is mediated by PPARgamma. Ligand-treated MCF-7 cells exhibited a differentiated phenotype, as evinced by analysis of cell-specific differentiation markers: protein levels of maspin were elevated and perinuclear lipid droplets accumulated. In contrast, in HT-29 cells, caveolin expression was not correlated with differentiation. Interestingly, PPARgamma partially cofractionated in lipid rafts and could be coimmunoprecipitated from cell lysates with caveolin-1, indicating that PPARgamma and caveolin-1 may coexist in a complex. Our data indicate that PPARgamma participates in the regulation of caveolin gene expression in human carcinoma cells and suggest that caveolin-1 may mediate some of the phenotypic changes induced by this nuclear receptor in cancer cells. These findings may have potentially important functional implications in the context of cancer differentiation therapy and multidrug resistance.	Weizmann Inst Sci, Dept Biochem Regulat, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Biochem Regulat, POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bagnoli M, 2000, ONCOGENE, V19, P4754, DOI 10.1038/sj.onc.1203839; Bender FC, 2000, CANCER RES, V60, P5870; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Fiucci G, 2000, INT J CANCER, V85, P882, DOI 10.1002/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fra AM, 1999, GENOMICS, V56, P355, DOI 10.1006/geno.1998.5723; Fra AM, 2000, GENE, V243, P75, DOI 10.1016/S0378-1119(99)00559-4; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kilgore MW, 1997, MOL CELL ENDOCRINOL, V129, P229, DOI 10.1016/S0303-7207(97)04057-4; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kubota T, 1998, CANCER RES, V58, P3344; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Li LK, 2001, CANCER RES, V61, P4386; Li WP, 2001, J CELL SCI, V114, P1397; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Matveev S, 1999, J LIPID RES, V40, P1647; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Pignatelli M, 2001, J CELL SCI, V114, P4117; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Samid D, 2000, CLIN CANCER RES, V6, P933; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tahir SA, 2001, CANCER RES, V61, P3882; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Wu YF, 2003, J BIOL CHEM, V278, P8637, DOI 10.1074/jbc.M210910200; Yamamoto M, 1999, LIFE SCI, V64, P1349, DOI 10.1016/S0024-3205(99)00070-3; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4	66	91	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3888	3900		10.1038/sj.onc.1206625	http://dx.doi.org/10.1038/sj.onc.1206625			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813462				2022-12-28	WOS:000183612000008
J	Suzuki, A; Kusakai, G; Kishimoto, A; Lu, J; Ogura, T; Esumi, H				Suzuki, A; Kusakai, G; Kishimoto, A; Lu, J; Ogura, T; Esumi, H			ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation	ONCOGENE			English	Article						ARK5; Akt; cell survival; caspase 8; HepG2	TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE; GLUCOSE STARVATION; SIGNALING COMPLEX; TUMOR-CELLS; B-CELLS; AKT; INVOLVEMENT; TOLERANCE; SURVIVAL	AMPK is a serine/threonine protein kinase family and we recently identified a novel member, ARK5. The activation of ARK5 is triggered by Akt, and ARK5 induces tumor cell survival during nutrient starvation. In the current study, we investigated the mechanisms of induction of cell survival by ARK5. Human hepatoma HepG2 cells undergo necrotic cell death within 24 h after the start of glucose starvation, and the cell death signaling has been found to be mediated by death-receptor-independent activation of caspase 8. When HepG2 cells were transfected with ARK5 expression vector and subjected to several cell death stimuli, ARK5 was found to suppress cell death by glucose starvation, TRAIL, and TNF-alpha, but not by ultraviolet irradiation, camptothecin, or doxorubicin. Western blotting analysis revealed that both TRAIL and glucose starvation induced Bid cleavage and FLIP degradation following caspase 8 activation in a time-dependent manner, and ARK5 overexpression clearly delayed Bid cleavage, FLIP degradation, and caspase 8 activation. On the basis of the results of this study, we report that cell survival induced by ARK5 is, at least in part, due to inhibition of caspase 8 activation.	Natl Canc Ctr, Res Inst E, Invest Treatment Div, Chiba 2778577, Japan	National Cancer Center - Japan	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Invest Treatment Div, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Hasegawa J, 1996, CANCER RES, V56, P1713; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Izuishi K, 2000, CANCER RES, V60, P6201; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, ONCOGENE, V12, P2045; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266	45	73	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6177	6182		10.1038/sj.onc.1206899	http://dx.doi.org/10.1038/sj.onc.1206899			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679856				2022-12-28	WOS:000185506200007
J	Moreno-Bueno, G; Rodriguez-Perales, S; Sanchez-Estevez, C; Hardisson, D; Sarrio, D; Prat, J; Cigudosa, JC; Matias-Guiu, X; Palacios, J				Moreno-Bueno, G; Rodriguez-Perales, S; Sanchez-Estevez, C; Hardisson, D; Sarrio, D; Prat, J; Cigudosa, JC; Matias-Guiu, X; Palacios, J			Cyclin D1 gene (CCND1) mutations in endometrial cancer	ONCOGENE			English	Article						endometrial carcinoma; cyclin D1 expression; cyclin D1 mutation	BETA-CATENIN; IN-SITU; EXPRESSION; AMPLIFICATION; CARCINOMAS; PHOSPHORYLATION; ABNORMALITIES; PROTEIN; PATHWAY	Cyclin D1 is frequently overexpressed in human neoplasias by gene rearrangement and amplification, but no mutations in the CCND1 gene have so far been reported. However, in vitro mutagenesis of CCND1 has shown that substitutions affecting threonine 286 residue produced cyclin D1 nuclear accumulation, by interfering with protein degradation and induced neoplastic transformation in murine fibroblasts. To test whether similar genetic changes may occur in vivo, we analysed a series of 60 endometrioid endometrial carcinomas (EECs) for cyclin D1 expression and gene amplification by immunohistochemistry and FISH, respectively. Two of 17 carcinomas showing cyclin D1 expression in more than 5% of neoplastic cells, but without gene amplification, were found to harbor single-base substitutions in CCND1 that changed proline 287 into threonine and serine, respectively. Both cases expressed cyclin D1 in more than 50% of neoplastic cells. Additionally, seven tumors with cyclin D1 overexpression of an independent series of 59 EECs were also analysed, and a 12-bp in-frame deletion that eliminated amino acids 289-292 was detected in one case with cylin D1 expression in more than 50% of neoplastic cells. In contrast, no mutations of the CCND1 gene were detected in a set of breast carcinomas with cyclin D1 overexpression without gene amplification. In summary, our data indicate that mutations of CCND1, which probably render the protein insensitive to degradation, represent a previously unreported mechanism of cyclin D1 overexpression in human tumors in vivo.	CNIO, Mol Pathol Programme, Lab Breast & Gynaecol Canc, Melchor Fernandez Almagro 3, Madrid 28029, Spain; CNIO, Biotechnol Programme, Cytogenet Unit, Madrid 28029, Spain; Hosp Univ La Paz, Dept Pathol, Madrid 28029, Spain; Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08025, Spain; Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Lleida 25198, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Hospital of Santa Creu i Sant Pau; Universitat de Lleida; University Hospital Arnau de Vilanova	Palacios, J (corresponding author), CNIO, Mol Pathol Programme, Lab Breast & Gynaecol Canc, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	jpalacios@cnio.es	Hardisson, David/AAN-3833-2020; Rodriguez-Perales, Sandra/T-7667-2017; SARRIO, DAVID/Y-8903-2019; Corominas, Joan Prat/C-6420-2011; Cigudosa, Juan C/E-4105-2016; matias-guiu, xavier/C-3039-2009; Hardisson, David/E-2832-2010; Palacios, Jose/AAV-3765-2020; Moreno-Bueno, Gema/K-9354-2016; Hardisson, David/A-6259-2011; Prat, Jaime/G-4679-2011	Rodriguez-Perales, Sandra/0000-0001-7221-3636; matias-guiu, xavier/0000-0002-7201-6605; Hardisson, David/0000-0002-2183-3699; Moreno-Bueno, Gema/0000-0002-5030-6687; Sarrio, David/0000-0003-4886-8290				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Campo E, 1999, SEMIN HEMATOL, V36, P115; Cao QJ, 2002, INT J GYNECOL PATHOL, V21, P147, DOI 10.1097/00004347-200204000-00007; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Hoechtlen-Vollmar W, 2000, BRIT J HAEMATOL, V109, P30, DOI 10.1046/j.1365-2141.2000.02007.x; Kaltz-Wittmer C, 2000, LAB INVEST, V80, P1455, DOI 10.1038/labinvest.3780152; Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nikaido T, 1996, CANCER, V78, P1248, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.3.CO;2-U; Quddus MR, 2002, ARCH PATHOL LAB MED, V126, P459; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Schmitz MJ, 2000, GYNECOL ONCOL, V77, P439, DOI 10.1006/gyno.2000.5814; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Simpson JF, 1997, AM J PATHOL, V151, P161; Soslow RA, 2000, INT J GYNECOL PATHOL, V19, P329, DOI 10.1097/00004347-200010000-00006; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Tsuda H, 2000, BRIT J CANCER, V82, P675; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257	23	87	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6115	6118		10.1038/sj.onc.1206868	http://dx.doi.org/10.1038/sj.onc.1206868			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955092				2022-12-28	WOS:000185137800022
J	Rothenberger, S; Burns, K; Rousseaux, M; Tschopp, J; Bron, C				Rothenberger, S; Burns, K; Rousseaux, M; Tschopp, J; Bron, C			Ubiquitination of the Epstein-Barr virus-encoded latent membrane protein 1 depends on the integrity of the TRAF binding site	ONCOGENE			English	Article						LMP1; ubiquitin; TRAF3; lipid rafts	LIPID RAFTS; SIGNAL-TRANSDUCTION; PROTEIN; CELLS; DEGRADATION; LMP1; TRANSFORMATION; RECOGNITION; ASSOCIATION; ACTIVATION	The latent membrane protein 1 (LMP1) encoded by the Epstein-Barr virus functions as a constitutively activated receptor of the tumor necrosis factor receptor family. LMP1 is a short-lived protein that is ubiquitinated and degraded by the proteasome. We have previously shown that LMP1 recruits the adapter protein tumor necrosis factor receptor-associated factor 3 (TRAF3) to lipid rafts. To test if TRAFs are involved in LMP1's ubiquitination, we have mutated the LMP1 CTAR1 site that has been identified as a TRAF binding site. We show that the CTAR1 mutant (CTAR1(-)) is expressed after transfection at a similar level to wild-type LMP1, and behaves as wild-type LMP1 with respect to membrane localization. However, CTAR1(-) does not bind TRAF3. We demonstrate that ubiquitination of CTAR1(-) is significantly reduced when compared to wild-type LMP1. In addition, the expression of wild-type LMP1 induces the ubiquitination, an effect that is significantly reduced when the CTAR1(-) is expressed. Taken together, our results suggest that TRAF proteins are involved in the ubiquitination of LMP1, and that their binding to LMP1 may facilitate their own ubiquitination.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Rothenberger, S (corresponding author), Univ Lausanne, Inst Biochem, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Sylvia.RothenbergerAubert@ib.unil.ch		Rothenberger, Sylvia/0000-0001-8633-2994				Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chung JY, 2002, J CELL SCI, V115, P679; Ciechanover A, 2000, J CELL BIOCHEM, P40; Clausse B, 1997, VIROLOGY, V228, P285, DOI 10.1006/viro.1996.8380; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Rothenberger S, 2002, CELL MOL LIFE SCI, V59, P171, DOI 10.1007/s00018-002-8413-y; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Strous GJ, 1999, J CELL SCI, V112, P1417; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	31	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5614	5618		10.1038/sj.onc.1206497	http://dx.doi.org/10.1038/sj.onc.1206497			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944909				2022-12-28	WOS:000184865900010
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Aprile, A; Inga, A; Tada, M; Menichini, P; Abbondandolo, A; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Aprile, A; Inga, A; Tada, M; Menichini, P; Abbondandolo, A; Fronza, G			Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	ONCOGENE			English	Article						P73 beta; P53 mutants; yeast; functional assay	WILD-TYPE P53; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; GENE FAMILY; P73; MUTATIONS; P63	p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors. The large majority of p53 mutations observed in tumors are missense mutations. The p73 gene, encoding a protein with significant sequence similarity to p53, expresses multiple transcription-competent spliced variants, or transcription-incompetent forms (i.e. DeltaNp73). It was clearly shown that p73 transactivation from a p53-responsive promoter is inhibited by some tumor-derived p53 mutants in eucaryotic cells. In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta. We determined the ability of a panel of 61 p53 mutants to inhibit p73beta activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter. By analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors. The influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interfere with p73beta was also studied. Two sets of polymorphic variants (R and P) for 14 mutants were constructed and analysed. In all cases, the R/P 72 polymorphism was phenotypically irrelevant. In conclusion, our results suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.	Natl Canc Res Inst IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Insubria, Dept Struct & Funct Biol, Human Genet Lab, Varese, Italy; Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido, Japan; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy	University of Insubria; Hokkaido University; University of Genoa	Fronza, G (corresponding author), Natl Canc Res Inst IST, Mutagenesis Lab, Lgo R Benzi 10, I-16132 Genoa, Italy.		Monti, Paola/Y-1118-2019; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019; Campomenosi, Paola/C-9729-2011; Menichini, Paola/K-9422-2016; Ciribilli, Yari/K-2751-2018	Monti, Paola/0000-0002-1978-4998; Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X; Campomenosi, Paola/0000-0002-8853-1134; Ciribilli, Yari/0000-0001-9231-379X; Menichini, Paola/0000-0003-0057-6184				Agami R, 1999, NATURE, V399, P809; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Prives C, 1999, J PATHOL, V187, P112; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Tada M, 2001, CARCINOGENESIS, V22, P515, DOI 10.1093/carcin/22.3.515; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	39	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5252	5260		10.1038/sj.onc.1206511	http://dx.doi.org/10.1038/sj.onc.1206511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917626	Green Published			2022-12-28	WOS:000184734900004
J	Gong, LJ; Li, YW; Nedeljkovic-Kurepa, A; Sarkar, FH				Gong, LJ; Li, YW; Nedeljkovic-Kurepa, A; Sarkar, FH			Inactivation of NF-kappa B by genistein is mediated via Akt signaling pathway in breast cancer cells	ONCOGENE			English	Article						genistein; NF-kappa B; Akt; breast cancer cells	INDUCED APOPTOSIS; LEUKEMIA-CELLS; UP-REGULATION; CYCLE ARREST; BETA-CATENIN; IN-VITRO; KINASE; ACTIVATION; INHIBITION; INDUCTION	Genistein, a natural isoflavonoid found in soybean products, has been proposed to be associated with a lower rate of breast cancer in Asian women. Studies from our laboratory and others have shown that genistein can induce apoptosis by regulating the expression of apoptosis-related genes in breast cancer cells. However, the precise molecular mechanism(s) by which genistein induces apoptotic cell death is not clear. In order to investigate such mechanism, we tested the role of Akt and NF-kappaB in genistein-treated MDA-MB-231 breast cancer cells. We found that inhibition of cell growth and induction of apoptosis by genistein are partly mediated through the downregulation of Akt and NF-kappaB pathways. Gel shift assay showed that NF-kappaB DNA-binding activity in MDA-MB-231 cells transfected with Akt cDNA was induced, suggesting that there is a cross-talk between NF-kappaB and Akt signaling pathway. Moreover, we found that genistein could abrogate EGF and Akt induced NF-kappaB activation. From these results, we conclude that the inactivation of NF-kappaB by genistein in MDA-MB-231 breast cancer cells is partly mediated via Akt pathway, which could be useful for rational design of strategies for the prevention and/or treatment of breast cancer.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Hudson Webber Canc Res Ctr 715,Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Hudson Webber Canc Res Ctr 715,Dept Pathol, 110 E Warren, Detroit, MI 48201 USA.	fsarkar@med.wayne.edu			NCI NIH HHS [CA83695-O1A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083695] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alhasan SA, 1999, NUTR CANCER, V34, P12, DOI 10.1207/S15327914NC340102; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bradlow HL, 2002, ANN NY ACAD SCI, V963, P247; Brownson DM, 2002, J NUTR, V132, p3482S, DOI 10.1093/jn/132.11.3482S; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; Chen M, 2000, Biostatistics, V1, P293, DOI 10.1093/biostatistics/1.3.293; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; Dale TC, 1998, BIOCHEM J, V329, P209; Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Fotsis T, 1997, CANCER RES, V57, P2916; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIRAYAMA T, 1978, PREV MED, V7, P173, DOI 10.1016/0091-7435(78)90244-X; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650; Li YW, 1999, INT J ONCOL, V15, P525; Li YW, 2002, CLIN CANCER RES, V8, P2369; Lian FR, 1998, NUTR CANCER, V31, P184, DOI 10.1080/01635589809514701; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; MILLER AB, 1977, CANCER-AM CANCER SOC, V39, P2704, DOI 10.1002/1097-0142(197706)39:6<2704::AID-CNCR2820390657>3.0.CO;2-G; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Ozes ON, 1999, NATURE, V401, P82; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6; Shao ZM, 1998, CANCER RES, V58, P4851; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; VAN AD, 1996, SCIENCE, V274, P787; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	49	199	207	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4702	4709		10.1038/sj.onc.1206583	http://dx.doi.org/10.1038/sj.onc.1206583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879015				2022-12-28	WOS:000184157000011
J	Losa, JH; Cobo, CP; Viniegra, JG; Lobo, VJSA; Cajal, SRY; Sanchez-Prieto, R				Losa, JH; Cobo, CP; Viniegra, JG; Lobo, VJSA; Cajal, SRY; Sanchez-Prieto, R			Role of the p38 MAPK pathway in cisplatin-based therapy	ONCOGENE			English	Article						p38 MAPK; cisplatin; phosphorylation resistance; p38 MAPK gamma/ERK6; p38 MAPK delta/SAPK4	ACTIVATED PROTEIN-KINASE; SQUAMOUS-CELL CARCINOMAS; C-ABL ACTIVATION; INDUCED APOPTOSIS; CANCER-CELLS; UV-RADIATION; GENOTOXIC STRESS; TRANS ISOMER; CYCLE ARREST; CROSS-LINKS	p38 MAPK has been implicated in the response to cancer therapy. To determine whether the activation of p38 MAPK could be specific to cancer therapy, we investigated the activation of p38 MAPK in response to several chemotherapeutic agents, such as cisplatin, doxorubicin and taxol in several human cell lines. Activation of p38 MAPK was measured after exposure to several chemotherapeutic agents, using specific phosphoantibodies. Only cisplatin was able to activate p38 MAPK in all the cell lines tested. Furthermore, other platinum compounds such as transplatin and platinum (IV) chloride can induce activation of p38 MAPK. The kinetics of this activation is a key event in the biological role of p38 MAPK in response to cisplatin, as we conclude from the differences observed after treatment with transplatin and cisplatin. The p38 MAPK activation is independent of the origin or genetic alterations of the cell lines and seems to be mediated through both upstream activators MKK6 and MKK3. Although the isoforms alpha/beta are mainly activated, we also demonstrated that other members of the p38 MAPK family were susceptible to activation by cisplatin when they were overexpressed in 293 T. Finally, pretreatment with specific inhibitors (SB 203580 and SKF 86002) induces a resistant phenotype in response to cisplatin. Furthermore, low activation of this SAPK pathway correlates with a resistant phenotype as demonstrated in our experimental model of head and neck cancer. Therefore, we conclude that the p38 MAPK pathway is a specific target for cisplatin-based therapy with clinical implications.	Hosp Univ Puerta de Hierro, Unidad Patol Mol, Madrid 28035, Spain	Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Hosp Univ Puerta de Hierro, Unidad Patol Mol, C San Martin de Porres 4, Madrid 28035, Spain.		Sanchez-Prieto, Ricardo/B-6877-2008; Ramon y Cajal, Santiago/H-4955-2016; Javier, Hernandez Losa/C-1173-2008; Sanchez-Prieto, Ricardo/AAY-4271-2021; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Prieto, Ricardo/AAZ-7221-2021	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Ramon y Cajal, Santiago/0000-0002-3867-1390; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; 				Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Asselin E, 2001, CANCER RES, V61, P1862; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BOUDVILLAIN M, 1995, NUCLEIC ACIDS RES, V23, P2381, DOI 10.1093/nar/23.13.2381; Brognard J, 2001, CANCER RES, V61, P3986; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; CUMMINGS J, 1993, ANN ONCOL, V4, P533, DOI 10.1093/oxfordjournals.annonc.a058584; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Hayakawa J, 2000, CANCER RES, V60, P5988; Hortobagyi GN, 1999, SEMIN ONCOL, V26, P32; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lippert B, 1996, MET IONS BIOL SYST, V33, P105; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NOMURA M, 2001, J BIOL CHEM, V11, P11; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Patel V, 1997, INT J CANCER, V73, P551, DOI 10.1002/(SICI)1097-0215(19971114)73:4<551::AID-IJC16>3.0.CO;2-C; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sodhi A, 2000, CANCER RES, V60, P4873; Trimmer EE, 1999, ESSAYS BIOCHEM, V34, P191, DOI 10.1042/bse0340191; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu ZP, 2000, TOXICOL APPL PHARM, V168, P200, DOI 10.1006/taap.2000.9033; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	54	145	151	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3998	4006		10.1038/sj.onc.1206608	http://dx.doi.org/10.1038/sj.onc.1206608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821934				2022-12-28	WOS:000183707600003
J	Dammann, R; Schagdarsurengin, U; Liu, LM; Otto, N; Gimm, O; Dralle, H; Boehm, B; Pfeifer, GP; Hoang-Vu, C				Dammann, R; Schagdarsurengin, U; Liu, LM; Otto, N; Gimm, O; Dralle, H; Boehm, B; Pfeifer, GP; Hoang-Vu, C			Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma	ONCOGENE			English	Article						pancreatic adenocarcinoma; neuroendocrine pancreatic tumor; pancreatitis; methylation; RASSF1; K-ras; p16	TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION; CANCER CELL-LINES; EPIGENETIC INACTIVATION; ULCERATIVE-COLITIS; CLINICAL-FEATURES; DNA METHYLATION; BREAST CANCERS; LUNG; ADENOCARCINOMA	Recently, we have characterized the Ras association domain family 1A gene (RASSF1A) at the segment 3p21.3, which is frequently lost in variety of human cancers and epigenetically inactivated in many types of primary tumors, such as lung, breast, kidney, prostate and thyroid carcinomas. Here, we investigated the methylation status of the RASSF1A CpG island promoter in the pathogenesis of pancreatic cancer. RASSF1A hypermethylation was detected in 29 out of 45 (64%) primary adenocarcinomas, in 10 out of 12 (83%) endocrine tumors and in eight out of 18 (44%) pancreatitis samples. In seven out of eight pancreas cancer cell lines, RASSF1A was silenced and was retranscribed after treatment with 5-aza-2'-deoxycytidine. Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancreatitis and in 63% of pancreas cancer cell lines. K-ras mutations were detected in 16 out of 45 (36%) primary adenocarcinomas. Pancreatic adenocarcinomas with K-ras mutation have significantly less RASSF1A methylation and vice versa (P = 0.001, X-2 test). In conclusion, our data indicate that inactivation of the RASSF1A gene is a frequent event in pancreatic cancer and suggest an inverse correlation between RASSF1A silencing and K-ras activation.	Univ Halle Wittenberg, Inst Humangenet & Med Biol, AG Tumorgenet, Fak Med, D-06097 Halle Saale, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Klin & Poliklin Allgemein Viszeral & Gefasschirur, D-06097 Halle Saale, Germany; Univ Ulm, Dept Internal Med, Div Endocrinol, D-89070 Ulm, Germany	Martin Luther University Halle Wittenberg; City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg; Ulm University	Dammann, R (corresponding author), Univ Halle Wittenberg, Inst Humangenet & Med Biol, AG Tumorgenet, Fak Med, Magdeburger Str 2, D-06097 Halle Saale, Germany.		Schagdarsurengin, Undraga/AAH-4312-2020; Dralle, Henning/ABD-4454-2020; Boehm, Bernhard Otto/F-8750-2015; Schagdarsurengin, Undraga/AAH-4346-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938; 	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahuja N, 1998, CANCER RES, V58, P5489; Barghom A, 2001, J PATHOL, V194, P451, DOI 10.1002/path.886; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chan AOO, 2003, ONCOGENE, V22, P924, DOI 10.1038/sj.onc.1206123; Chang MC, 2001, J FORMOS MED ASSOC, V100, P352; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Furuya N, 1997, GASTROENTEROLOGY, V113, P593, DOI 10.1053/gast.1997.v113.pm9247481; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gunzburg WH, 2001, TRENDS MOL MED, V7, P30, DOI 10.1016/S1471-4914(00)01865-7; HAHN SA, 1995, CANCER RES, V55, P4670; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hruban R H, 1998, J Hepatobiliary Pancreat Surg, V5, P383, DOI 10.1007/s005340050062; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hsieh CJ, 1998, CANCER RES, V58, P3942; Issa JPJ, 2001, CANCER RES, V61, P3573; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Kwong J, 2002, CLIN CANCER RES, V8, P131; Laghi L, 2002, ONCOGENE, V21, P4301, DOI 10.1038/sj.onc.1205533; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Moore PS, 2001, AM J PATHOL, V158, P317, DOI 10.1016/S0002-9440(10)63971-5; Muscarella P, 1998, CANCER RES, V58, P237; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Perugini RA, 1998, CRIT REV EUKAR GENE, V8, P377, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.70; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Sato T, 2000, HEPATO-GASTROENTEROL, V47, P875; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schutte M, 1997, CANCER RES, V57, P3126; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; TADA M, 1991, CANCER, V67, P634, DOI 10.1002/1097-0142(19910201)67:3<634::AID-CNCR2820670318>3.0.CO;2-7; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wilentz RE, 2000, AM J PATHOL, V156, P1641, DOI 10.1016/S0002-9440(10)65035-3; Yamamoto H, 2001, CANCER RES, V61, P3139; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	51	134	155	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3806	3812		10.1038/sj.onc.1206582	http://dx.doi.org/10.1038/sj.onc.1206582			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802288				2022-12-28	WOS:000183551000015
J	Mimori, K; Shiraishi, T; Mashino, K; Sonoda, H; Yamashita, K; Yoshinaga, K; Masuda, T; Utsunomiya, T; Alonso, MA; Inoue, H; Mori, M				Mimori, K; Shiraishi, T; Mashino, K; Sonoda, H; Yamashita, K; Yoshinaga, K; Masuda, T; Utsunomiya, T; Alonso, MA; Inoue, H; Mori, M			MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway	ONCOGENE			English	Article						T-lymphocyte maturation associated protein; (MAL); esophageal cancer; Fas; apoptosis; motility; tumorigenicity	DARBY CANINE KIDNEY; POLYMERASE-CHAIN-REACTION; HUMAN T-LYMPHOCYTES; APICAL TRANSPORT; CELL-LINES; JUVENILE NEPHRONOPHTHISIS; PROTEIN; MEMBRANE; CARCINOMA; DELETIONS	We isolated the MAL (T-lymphocyte maturation associated protein) gene from differentially expressed products of esophageal epithelium relative to esophageal carcinoma tissues. The Mal protein has been demonstrated as being a component of the protein machinery for apical transport in epithelial polarized cells. In this study, we describe the reduced expression of MAL in all 39 cases of esophageal carcinoma tested and 60 other human carcinomas. MAL gene transcription was induced in three out of 13 esophageal carcinoma cell lines by treatment with the demethylating agent 5-aza-2'-deoxycytidine (DAC), and in nine additional cell lines by simultaneous treatment with trichostatin A, an inhibitor of deacetylation, and DAC. We established a stable MAL gene transfectant whose expression was regulated by subcutaneous doxycycline injection in nude mice. Tumor growth was suppressed in cells expressing TE3-MAL compared with TE3 parent cells or cells not expressing TE3-MAL with doxycycline injection (20mug/body) (P<0.01). Additionally, the TE3-MAL transfectant cells exhibited decreased cellular motility, a G1/S transition block and increased levels of apoptosis, concomitant with increased expression of Fas receptor in vitro. The apoptotic staining in MALexpressing tumors was confirmed by TUNEL assay. Therefore, we conclude that expression of MAL was frequently decreased or diminished in gastrointestinal tract cancers, and that Mal expression confers reduced tumorigenicity in vivo to tumor TE3 cells through the induction of apoptosis via the Fas signaling pathway.	Kyushu Univ, Med Inst Bioregulat, Dept Surg, Beppu, Oita 8740838, Japan; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid, Spain; CSIC, Madrid, Spain	Kyushu University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC)	Mori, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Surg, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.		Alonso, Miguel A/J-3945-2016; Mashino, Kohjiro/AAW-7923-2020	Alonso, Miguel A/0000-0002-7001-8826; Mimori, Koshi/0000-0003-3897-9974				Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Konrad M, 1996, HUM MOL GENET, V5, P367, DOI 10.1093/hmg/5.3.367; Martin-Belmonte F, 2001, J BIOL CHEM, V276, P49337, DOI 10.1074/jbc.M106882200; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; Martin-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033; Matsuyama A, 2001, CANCER RES, V61, P5714; Millan J, 1997, BIOCHEM J, V321, P247, DOI 10.1042/bj3210247; Millan J, 1998, EUR J IMMUNOL, V28, P3675, DOI 10.1002/(SICI)1521-4141(199811)28:11<3675::AID-IMMU3675>3.3.CO;2-X; Mimori K, 1997, BRIT J CANCER, V76, P531, DOI 10.1038/bjc.1997.420; Mori M, 1996, ANN SURG, V224, P183, DOI 10.1097/00000658-199608000-00011; MORI M, 1995, CANCER RES, V55, P3417; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Puertollano R, 2001, MOL BIOL CELL, V12, P1869, DOI 10.1091/mbc.12.6.1869; Saunier S, 2000, AM J HUM GENET, V66, P778, DOI 10.1086/302819; Shibata K, 1999, CANCER RES, V59, P1096; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shiraishi T, 1998, INT J CANCER, V79, P175, DOI 10.1002/(SICI)1097-0215(19980417)79:2<175::AID-IJC13>3.3.CO;2-P; SUGIMACHI K, 1988, BRIT J SURG, V75, P1115, DOI 10.1002/bjs.1800751122; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; Wadler S, 1999, ANAL BIOCHEM, V267, P24, DOI 10.1006/abio.1998.2890	27	68	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3463	3471		10.1038/sj.onc.1206378	http://dx.doi.org/10.1038/sj.onc.1206378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776198				2022-12-28	WOS:000183128500013
J	Bartusel, T; Klempnauer, KH				Bartusel, T; Klempnauer, KH			Transactivation mediated by B-Myb is dependent on TAF(II)250	ONCOGENE			English	Article						B-Myb; TAF(II)250; ts13; transactivation	CELL-CYCLE PROGRESSION; V-MYB; ACETYLTRANSFERASE ACTIVITY; SYNERGISTIC ACTIVATION; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; KINASE-ACTIVITY; MIM-1 GENE; C/EBP-BETA; A-MYB	B-Myb is a highly conserved member of the Myb family of transcription factors, which has been implicated in cell cycle regulation. B-Myb is expressed in most proliferating cells and its activity is highly regulated around the G1/S-phase border of the cell cycle. It is generally assumed that B-Myb regulates the expression of genes that are crucial for cell proliferation; however, the identity of these genes, the molecular mechanisms by which B-Myb stimulates their expression and the involvement of other proteins have not been sufficiently clarified. We have employed the hamster cell line ts13 as a tool to demonstrate a functional link between B-Myb and the coactivator TAF(II)250, a key component of the transcriptional machinery which itself is essential for cell proliferation. ts13 cells express a point-mutated version of TAFI,250 whose intrinsic histone acetyl transferase activity is temperature sensitive. Transactivation of Myb-responsive reporter genes by B-Myb is temperature-dependent in ts13 cells but not in ts13 cells, which have been rescued by transfection with an expression vector for wild-type TAF(II)250. Furthermore, B-Myb and TAF(II)250 can be coprecipitated, suggesting that both proteins are present in a complex. The formation of this complex is dependent on the DNA-binding domain of B-Myb and not on its transactivation domain. Taken together, these observations provide the first evidence that the coactivator TAF(II)250 is involved in the activation of Myb responsive promoters by B-Myb. The finding that B-Myb transactivation is dependent on a key coactivator involved in cell cycle control is consistent with and strengthens the idea that B-Myb plays a crucial role as a transcription factor in proliferating cells.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Horstmann S, 2000, ONCOGENE, V19, P5428, DOI 10.1038/sj.onc.1203937; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEVAILLARD T, 1997, J BIOL CHEM, V272, P30651; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Siegert JL, 2000, ONCOGENE, V19, P5703, DOI 10.1038/sj.onc.1203966; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Sitzmann J, 1996, ONCOGENE, V12, P1889; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wassarman DA, 2001, J CELL SCI, V114, P2895; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	53	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2932	2941		10.1038/sj.onc.1206494	http://dx.doi.org/10.1038/sj.onc.1206494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771944				2022-12-28	WOS:000182824800008
J	Duda, DG; Sunamura, M; Lefter, LP; Furukawa, T; Yokoyama, T; Yatsuoka, T; Abe, T; Inoue, H; Motoi, F; Egawa, S; Matsuno, S; Horii, A				Duda, DG; Sunamura, M; Lefter, LP; Furukawa, T; Yokoyama, T; Yatsuoka, T; Abe, T; Inoue, H; Motoi, F; Egawa, S; Matsuno, S; Horii, A			Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells	ONCOGENE			English	Article						SMAD4; invasion; angiogenesis; TGF-beta; ETS-1	TRANSCRIPTION FACTOR ETS-1; VASCULAR ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; CANCER-CELLS; DUCTAL TUMORIGENESIS; EXPRESSION; ANGIOGENESIS; APOPTOSIS; SUPPRESSION; CARCINOMA	SMAD4 is a critical cofactor in signal transduction pathways activated in response to transforming growth factor-beta (TGF-beta)-related ligands, regulating cell growth and differentiation. The roles played by SMAD4 inactivation in tumours highlighted it as a tumour-suppressor gene. However, restoration of the TGF-beta antiproliferative pathway following SMAD4 gene transfer in null-tumour cell lines is controversial. Herein, we report the inhibitory effects of SMAD4 on pancreatic tumour invasion and angiogenesis. Adenoviral transfer of this gene in a panel of SMAD4 homozygous-deleted human pancreatic tumour cell lines restored SMAD4 protein expression and function. Although it did not affect proliferation significantly in vitro, SMAD4 inhibited in vivo tumour growth in immunodeficient mice. In this xenograft setting, differential suppression of tumour growth in vivo was mediated, at least in part, through downregulation of vascular endothelial growth factor and expression of gelatinases. We documented the reduced invasion and angiogenesis histologically and by intravital microscopy, and gained mechanistic insight at the messenger and protein level. Finally, we found a negative reciprocal regulation between SMAD4 and ETS-1. ETS-1 is considered a marker for tumour invasion. Upon SMAD4 deletion, we detected high expression levels of ETS-1 in pancreatic tumour cells, suggesting the shift of the pancreatic tumour toward an invasive phenotype.	Tohoku Univ, Grad Sch Med, Div Gastroenterol Surg, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Grad Sch Med, Dept Mol Pathol, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Sunamura, M (corresponding author), 1-1 Seiryomachi,Aoba Ku, Sendai, Miyagi 9808574, Japan.	msun-thk@umin.ac.jp	Lefter, Liviu Paul/A-2395-2009; Duda, Dan G/H-8523-2014; Horii, Akira/AAW-2839-2021; Egawa, Shinichi/S-4055-2019; Furukawa, Toru/AAF-5596-2021	Duda, Dan G/0000-0001-7065-8797; Horii, Akira/0000-0002-3967-3291; Egawa, Shinichi/0000-0002-1115-4932; Furukawa, Toru/0000-0002-1083-2324				Attiga FA, 2000, CANCER RES, V60, P4629; Behrens P, 2001, INT J MOL MED, V8, P149; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bramhall SR, 1997, INT J PANCREATOL, V21, P1; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Davidson B, 2001, CLIN CANCER RES, V7, P551; Duda DG, 2000, CANCER RES, V60, P1111; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Eskinazi R, 1998, GASTROENTEROLOGY, V114, P1211, DOI 10.1016/S0016-5085(98)70427-5; Fink SP, 2001, CANCER RES, V61, P256; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fukushige S, 1998, CANCER RES, V58, P4222; Furukawa T, 1996, AM J PATHOL, V148, P1763; Inoue H, 2001, GENE CHROMOSOME CANC, V31, P295, DOI 10.1002/gcc.1147; Ito T, 1998, MODERN PATHOL, V11, P209; Itoh T, 1998, CANCER RES, V58, P1048; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jiang YF, 2000, BLOOD, V95, P3945; JIAO SS, 1993, BIO-TECHNOL, V11, P497, DOI 10.1038/nbt0493-497; Kita D, 2001, CANCER RES, V61, P7985; Kondo E, 1999, J BIOCHEM-TOKYO, V125, P818; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lefter LP, 2002, GENE CHROMOSOME CANC, V34, P234, DOI 10.1002/gcc.10060; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nishikawa A, 2000, GYNECOL ONCOL, V79, P256, DOI 10.1006/gyno.2000.5944; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Ramachandra M, 2002, CANCER RES, V62, P6045; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; St Croix B, 2000, SCIENCE, V289, P1197; Sun CL, 2001, ONCOL REP, V8, P89; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Valter MM, 1999, CANCER RES, V59, P5608; Vlaykova T, 1997, INT J CANCER, V74, P326, DOI 10.1002/(SICI)1097-0215(19970620)74:3<326::AID-IJC16>3.0.CO;2-9; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wilentz RE, 2000, CANCER RES, V60, P2002; Yang X, 1999, DEVELOPMENT, V126, P1571; Yatsuoka T, 2000, AM J GASTROENTEROL, V95, P2080	48	85	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6857	6864		10.1038/sj.onc.1206751	http://dx.doi.org/10.1038/sj.onc.1206751			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534532				2022-12-28	WOS:000185843400006
J	Shah, K; Tang, Y; Breakefield, X; Weissleder, R				Shah, K; Tang, Y; Breakefield, X; Weissleder, R			Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo	ONCOGENE			English	Article						TRAIL; bioluminescence; apoptosis	ANTITUMOR-ACTIVITY; GENE-TRANSFER; LIGAND TRAIL; APO-2 LIGAND; CANCER; DEATH; VECTORS; THERAPY; APO2L/TRAIL; RECEPTORS	Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) has been shown to induce apoptosis in neoplastic cells. While many previous studies have been performed in cell culture, the delivery and efficiency of TRAIL variants in vivo is less well established. Using dual substrate/reporter bioluminescence imaging (Fluc: firefly luciferase - luciferin and Rluc: Renilla luciferase - coelenterazine), we tested the efficacy of TRAIL using replication deficient herpes simplex virus (HSV) type 1 amplicon vectors in gliomas. The cDNA for complete TRAIL and the extracellular domain of TRAIL (aa 114 - 281) were cloned into HSV amplicons and packaged into helper virus-free vectors. Both forms of TRAIL induced similar degrees of apoptosis in human glioma cells (Gli36) in culture within 24 h of infection with TRAIL amplicon vectors. Growth of tumors stably transfected with Fluc (Gli36fluc(+)) was readily monitored in vivo by bioluminescence imaging following luciferin administration. HSV amplicon vectors bearing the genes for TRAIL and Rluc injected directly into Gli36fluc(+)-expressing subcutaneous gliomas revealed peak Rluc activity 36 h after intratumoral injection as determined by coelenterazine injection followed by imaging. TRAIL-treated gliomas regressed in size over a period of 4 weeks as compared to the mock-injected gliomas. These results show the efficacy of vector delivered TRAIL in treating tumors in vivo and offer a unique way to monitor both gene delivery and efficacy of TRAIL-induced apoptosis in tumors in vivo in real time by dual enzyme substrate (Rluc/Fluc) imaging.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Mol Neurogenet Unit, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Shah, K (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Bldg 149,13th St,Room 5421, Charlestown, MA 02129 USA.	kshah@helix.mgh.har-vard.edu		/0000-0003-0828-4143	NCI NIH HHS [CA6924, R24-CA92782, P50 CA86335] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA092782, R01CA086335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; BOVIATSIS EJ, 1994, GENE THER, V1, P323; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Di X, 1997, J EXP CLIN CANC RES, V16, P389; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Fraefel C, 2000, ADV VIRUS RES, V55, P425, DOI 10.1016/S0065-3527(00)55011-8; Fulci G, 2003, FRONT BIOSCI-LANDMRK, V8, pE346, DOI 10.2741/976; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 2001, MOL THER, V4, P257, DOI 10.1006/mthe.2001.0439; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kagawa S, 2001, CANCER RES, V61, P3330; KASHIMA T, 1995, J NEUROPATH EXP NEUR, V54, P23, DOI 10.1097/00005072-199501000-00003; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Luker GD, 2002, J VIROL, V76, P12149, DOI 10.1128/JVI.76.23.12149-12161.2002; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pulkkanen KJ, 2001, CANCER GENE THER, V8, P529, DOI 10.1038/sj.cgt.7700342; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Saeki Y, 2001, MOL THER, V3, P591, DOI 10.1006/mthe.2001.0294; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Tjuvajev JG, 2002, J NUCL MED, V43, P1072; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701	40	102	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6865	6872		10.1038/sj.onc.1206748	http://dx.doi.org/10.1038/sj.onc.1206748			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534533				2022-12-28	WOS:000185843400007
J	Syed, V; Ho, SM				Syed, V; Ho, SM			Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL	ONCOGENE			English	Article						caspases; Fas; Fas ligand; caspase-8; hormonal carcinogenesis; ovarian neoplasm	TUMOR-NECROSIS-FACTOR; LIGAND EXPRESSION; UP-REGULATION; MONOCLONAL-ANTIBODY; ENDOMETRIAL CANCER; IMMUNE PRIVILEGE; RECEPTOR; RISK; ACTIVATION; CARCINOMA	Progesterone (P4) has been implicated as a protective factor for epithelial ovarian cancers, yet little is known about its mechanism of action. We previously reported that pregnancy-equivalent doses of P4 inhibited the growth of normal and malignant human ovarian surface epithelial (HOSE) cells. Here, we investigated how P4-induced cell death in two immortalized normal (HOSE 642, HOSE 12-12) and two malignant (OVCA 429, OVCA 432) HOSE cell lines. The exposure of HOSE or OVCA cell cultures to 10(-6) m P4 induced time-dependent increases in early and late apoptotic cells and activation of caspase-8 and -3, but not that of caspase-9. A general caspase inhibitor Z-VAD effectively blocked the P4-induced cell death in a dose-dependent manner. Comparable levels of Fas mRNA and protein were expressed in HOSE and OVCA cell lines, and these levels were unaffected by P4. In contrast, levels of FasL mRNA and protein were higher in OVCA cells than in HOSE cells. Interestingly, the hormone enhanced levels of FasL mRNA and protein in HOSE cells, but lowered their levels in OVCA cells. The exposure of HOSE or OVCA cells to an activating anti-Fas antibody induced cell loss, whereas treatment of cells with a blocking anti-FasL antibody reduced the P4-induced cell loss. Cotreatment of cells with the activating anti-Fas antibody and P4 produced additive effects on cell loss. These results reveal for the first time that P4 induces apoptosis in HOSE and OVCA cells via activation of a caspase-8-initiated Fas/FasL signaling pathway. They also demonstrate differential P4-regulation of FasL expression between HOSE and OVCA cells.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol & Physiol, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Rm 504,Lazare Res Bldg,364 Plantat St,5th Floor, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [R03CA091250, R01CA094221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline; NIDDK NIH HHS [P30 DK32520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; ADAMI HO, 1995, LANCET, V345, P789, DOI 10.1016/S0140-6736(95)90666-5; Akhmedkhanov A, 2001, ANN NY ACAD SCI, V943, P296, DOI 10.1111/j.1749-6632.2001.tb03811.x; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bennett MW, 2001, J CLIN PATHOL, V54, P598, DOI 10.1136/jcp.54.8.598; Bennett MW, 1998, J IMMUNOL, V160, P5669; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Das H, 2000, BRIT J CANCER, V82, P1682; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ghahremani M, 1998, GYNECOL ONCOL, V70, P275, DOI 10.1006/gyno.1998.5091; Gratas C, 1998, CANCER RES, V58, P2057; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Hayakawa A, 2002, APOPTOSIS, V7, P107, DOI 10.1023/A:1014302212321; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Keane MM, 1996, CANCER RES, V56, P4791; Lambe M, 1999, LANCET, V353, P1941, DOI 10.1016/S0140-6736(99)02000-0; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Munakata S, 2000, BRIT J CANCER, V82, P1446, DOI 10.1054/bjoc.1999.1073; Murdoch WJ, 2002, REPRODUCTION, V123, P743, DOI 10.1530/rep.0.1230743; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Pinkoski MJ, 2000, CURR OPIN GENET DEV, V10, P114, DOI 10.1016/S0959-437X(99)00048-9; Reimer T, 2000, CANCER RES, V60, P822; Riman T, 1998, CLIN ENDOCRINOL, V49, P695, DOI 10.1046/j.1365-2265.1998.00577.x; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; Sampalo A, 2000, BLOOD, V96, P3168; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; Selam B, 2001, BIOL REPROD, V65, P979, DOI 10.1095/biolreprod65.4.979; Song J, 2002, MOL HUM REPROD, V8, P447, DOI 10.1093/molehr/8.5.447; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Ungefroren H, 1998, CANCER RES, V58, P1741; Van Haaften-Day C, 2003, HUM PATHOL, V34, P74, DOI 10.1053/hupa.2003.7; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang S, 2003, GYNECOL ONCOL, V88, P108, DOI 10.1016/S0090-8258(02)00008-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6883	6890		10.1038/sj.onc.1206828	http://dx.doi.org/10.1038/sj.onc.1206828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534535				2022-12-28	WOS:000185843400009
J	Altomonte, M; Fonsatti, E; Visintin, A; Maio, M				Altomonte, M; Fonsatti, E; Visintin, A; Maio, M			Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?	ONCOGENE			English	Review						HLA class II; MHC class II; signaling; immunotherapy; melanoma; monoclonal antibodies	MHC CLASS-II; SQUAMOUS-CELL CARCINOMA; HUMAN-LEUKOCYTE ANTIGEN; TUMOR-NECROSIS-FACTOR; BARE LYMPHOCYTE SYNDROME; DR EXPRESSION; PROGNOSTIC-SIGNIFICANCE; SIGNAL-TRANSDUCTION; BREAST-CARCINOMA; IFN-GAMMA	Intracellular signals, delivered in professional antigen-presenting cells following the engagement of major histocompatibility complex(MHC) class II molecules, activate a variety of cellular functions that also contribute to efficient antigen presentation. As far as human malignancies, the signaling ability of human leukocyte antigens (HLA) class II molecules is a rather well-characterized event in hematologic tumors; in contrast, very limited evidences are available in solid neoplasias of different histotypes that may constitutively express HLA class II antigens. Among solid malignancies, a significant proportion of human cutaneous melanomas have been shown to express HLA class II molecules, and cutaneous melanoma undoubtedly represents a 'model disease' to investigate tumor immunobiology, to unveil the molecular basis underlying the interactions between neoplastic cells and host's immune system, and ultimately to set up new bio-immunotherapeutic approaches. Upcoming preclinical evidences unveil a signaling potential of HLA-DR antigens expressed on melanoma cells, and suggest for the clinical implication of HLA class II molecules as novel therapeutic targets. Therefore, in this review, we will focus on the emerging role of HLA class II antigens as intracellular signal transducing elements in neoplastic cells of the melanocytic lineage, emphasizing their foreseeable role in targeted therapy of human melanoma and potentially of HLA class II antigens-positive tumors of different histology.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy	IRCCS Aviano (CRO)	Altomonte, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occ 12, I-33081 Aviano, Italy.	maltomonte@cro.it	altomonte, maresa/G-7734-2011	coral, sandra/0000-0002-1308-3082; Maio, Michele/0000-0002-0323-6321; Altomonte, Maresa/0000-0001-8021-1921				ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; Altomonte M, 1999, J CELL PHYSIOL, V179, P251, DOI 10.1002/(SICI)1097-4652(199906)179:3<251::AID-JCP2>3.3.CO;2-G; ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; ALTOMONTE M, 2003, IN PRESS J CELL PHYS; ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BARTEK J, 1987, BRIT J CANCER, V56, P727, DOI 10.1038/bjc.1987.278; BERNARD D, 1984, CLIN EXP IMMUNOL, V56, P215; Bernsen MR, 2003, BRIT J CANCER, V88, P424, DOI 10.1038/sj.bjc.6600703; Brasanac D, 1999, NEOPLASMA, V46, P173; BRUNNER CA, 1991, EUR J CANCER, V27, P411, DOI 10.1016/0277-5379(91)90374-M; Byrne SN, 2003, CANCER IMMUNOL IMMUN, V52, P396, DOI 10.1007/s00262-003-0380-0; CABRERA T, 1995, SCAND J IMMUNOL, V41, P398, DOI 10.1111/j.1365-3083.1995.tb03584.x; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chang Eun-Sook, 1995, Journal of Korean Medical Science, V10, P334; CHIA CP, 1994, J IMMUNOL, V153, P3398; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; CONCHA A, 1991, CANCER BIOL, V2, P47; Coral S, 1997, CELL GROWTH DIFFER, V8, P581; Dechant M, 2002, BLOOD, V100, P4574, DOI 10.1182/blood-2002-03-0687; ESTEBAN F, 1989, INT J CANCER, V43, P436, DOI 10.1002/ijc.2910430316; Feinmesser M, 2000, J CLIN PATHOL, V53, P286, DOI 10.1136/jcp.53.4.286; Garban F, 1998, EXP HEMATOL, V26, P874; GLEW SS, 1992, CANCER RES, V52, P4009; Goodwin BL, 2001, CELL GROWTH DIFFER, V12, P327; GUTIERREZ J, 1987, EXP CLIN IMMUNOGENET, V4, P144; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; Heike M, 1996, J IMMUNOL, V156, P2205; HILDERS CGJM, 1995, GYNECOL ONCOL, V57, P366, DOI 10.1006/gyno.1995.1156; HILTON DA, 1990, CANCER, V66, P1154, DOI 10.1002/1097-0142(19900915)66:6<1154::AID-CNCR2820660613>3.0.CO;2-3; HOUCK JR, 1990, ARCH OTOLARYNGOL, V116, P1181; HURLIMANN J, 1985, INT J CANCER, V35, P753, DOI 10.1002/ijc.2910350610; Ioachim E, 2000, HISTOL HISTOPATHOL, V15, P721, DOI 10.14670/HH-15.721; Ishigami S, 1998, ONCOLOGY-BASEL, V55, P65, DOI 10.1159/000011837; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KORETZ K, 1989, INT J CANCER, V44, P816, DOI 10.1002/ijc.2910440512; Kunihiro M, 1998, ONCOLOGY-BASEL, V55, P326, DOI 10.1159/000011870; Laufer TM, 1997, J IMMUNOL, V159, P5914; LAZARIS AC, 1995, DIS COLON RECTUM, V38, P739, DOI 10.1007/BF02048033; Lazzaro B, 2001, APPL IMMUNOHISTO M M, V9, P234, DOI 10.1097/00022744-200109000-00007; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Lu Y, 1997, IMMUNOL CELL BIOL, V75, P325, DOI 10.1038/icb.1997.50; LUCIN K, 1994, PATHOL RES PRACT, V190, P1134; MA XC, 1994, ACTA ONCOL, V33, P187, DOI 10.3109/02841869409098403; MAIO M, 1989, INT J CANCER, V44, P554, DOI 10.1002/ijc.2910440330; MARSDEN S, 2000, HIST EUROPEAN HOUSIN, P26; MATTIJSSEN V, 1991, INT J CANCER, P95; MOLLER P, 1989, AM J PATHOL, V135, P73; MORITA M, 1995, J SURG ONCOL, V59, P233, DOI 10.1002/jso.2930590407; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; NATALI PG, 1983, CANCER RES, V43, P660; NORHEIMANDERSEN S, 1993, BRIT J CANCER, V68, P80; Ostmeier H, 2001, BRIT J DERMATOL, V145, P203, DOI 10.1046/j.1365-2133.2001.04335.x; Ostmeier H, 1999, CANCER-AM CANCER SOC, V85, P2391, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I; PEREZ M, 1986, J IMMUNOGENET, V13, P247; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; ROGNUM TO, 1983, BRIT J CANCER, V48, P543, DOI 10.1038/bjc.1983.227; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SADANAGA N, 1994, CANCER-AM CANCER SOC, V74, P586, DOI 10.1002/1097-0142(19940715)74:2<586::AID-CNCR2820740209>3.0.CO;2-4; Saito T, 1997, CANCER LETT, V115, P121, DOI 10.1016/S0304-3835(97)04754-X; SCHICK MR, 1993, J IMMUNOL, V151, P4090; SCHOLL PR, 1994, IMMUNOL TODAY, V15, P418, DOI 10.1016/0167-5699(94)90271-2; SCHWAB M, 2000, PATHOLOGY GENETICS T, P153; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Stockmeyer B, 2002, BRIT J HAEMATOL, V118, P959, DOI 10.1046/j.1365-2141.2002.03722.x; STPIERRE Y, 1989, J IMMUNOL, V143, P808; Sumiyoshi K, 1999, ONCOL REP, V6, P301; Szollosi J, 1996, J IMMUNOL, V157, P2939; TARAMELLI D, 1986, CANCER RES, V46, P433; Tatsumi T, 2003, CLIN CANCER RES, V9, P947; Ting JPY, 1997, J IMMUNOL, V159, P5457; Trieb K, 1998, PATHOL RES PRACT, V194, P679, DOI 10.1016/S0344-0338(98)80126-X; Truman JP, 1996, CELL IMMUNOL, V172, P149, DOI 10.1006/cimm.1996.0227; Truman JP, 1996, EXP HEMATOL, V24, P1409; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623; VANDUINEN SG, 1988, CANCER RES, V48, P1019; Vora AR, 1997, BRIT J CANCER, V76, P836, DOI 10.1038/bjc.1997.472; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; Westerheide SD, 1997, J IMMUNOL, V158, P4812; WINTZER HO, 1990, BRIT J CANCER, V62, P289, DOI 10.1038/bjc.1990.280; Yazawa T, 1999, J PATHOL, V187, P191, DOI 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8; Yazawa T, 1993, APPL IMMUNOHISTO M M, V1, P289; ZUK JA, 1988, J PATHOL, V155, P301, DOI 10.1002/path.1711550405; ZUK JA, 1987, J PATHOL, V152, P275, DOI 10.1002/path.1711520406	94	39	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6564	6569		10.1038/sj.onc.1206960	http://dx.doi.org/10.1038/sj.onc.1206960			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528281				2022-12-28	WOS:000185700700013
J	Surmacz, E				Surmacz, E			Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor	ONCOGENE			English	Review						insulin-like growth factor receptor; anti-cancer drugs; antibodies; tyrosine kinase inhibitors; antisense; triple helix; dominant-negative mutants	BREAST-CANCER-CELLS; DOMINANT-NEGATIVE MUTANT; TYROSINE KINASE INHIBITORS; CHRONIC MYELOID-LEUKEMIA; IGF-I; TUMOR-GROWTH; ANTISENSE RNA; DOWN-REGULATION; TRASTUZUMAB HERCEPTIN; TRANSFORMED PHENOTYPE	Neoplastic transformation is often related to abnormal activation of growth factor receptors and their signaling pathways. The concept of targeting specific tumorigenic receptors and/or signaling molecules has been validated by the development and successful clinical application of drugs acting against the epidermal growth factor receptor 2 (HER2/neu, Erb2), the epidermal growth factor receptor 1 ( EGFR, HER1), the Brc-Abl kinase, the platelet-derived growth factor receptor, and c-kit. This review will focus on the next promising therapeutic target, the insulin-like growth factor I receptor ( IGF-IR). IGF-IR has been implicated in a number of neoplastic diseases, including several common carcinomas. From a pharmaceutical standpoint, of particular importance is that IGF-IR appears to be required for many transforming agents ( genetic, viral, chemical) to act, but is not obligatory for the function of normal adult cells. The tumorigenic potential of IGF-IR is mediated through its antiapoptotic and transforming signaling, and in some cases through induction of prometastatic pathways. Preclinical studies demonstrated that downregulation of IGF-IR reversed the neoplastic phenotype and sensitized cells to antitumor treatments. The strategies to block IGF-IR function employed anti-IGF-IR antibodies, small-molecule inhibitors of the IGF-IR tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small inhibitory RNA, triple helix, dominant-negative mutants, and various compounds reducing ligand availability. The experience with these strategies combined with the knowledge gained with current anti-growth factor receptor drugs should streamline the development of anti-IGF-IR therapeutics.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.	eva.surmacz@mail.tju.edu						Adachi Y, 2002, GASTROENTEROLOGY, V123, P1191, DOI 10.1053/gast.2002.36023; Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Andrews DW, 2001, J CLIN ONCOL, V19, P2189, DOI 10.1200/JCO.2001.19.8.2189; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; Bartucci M, 2001, CANCER RES, V61, P6747; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Baserga Renato, 1998, P269; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; Butler AA, 1998, CANCER RES, V58, P3021; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Coppola D, 1999, CANCER RES, V59, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Druckmann R, 2002, MATURITAS, V41, pS65; Druker BJ, 2002, EUR J CANCER, V38, pS70, DOI 10.1016/S0959-8049(02)80606-2; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 1997, CANCER RES, V57, P4667; Dunn SE, 2001, CANCER RES, V61, P1367; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Fry DW, 2003, EXP CELL RES, V284, P131, DOI 10.1016/S0014-4827(02)00095-2; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Guo N, 2003, GROWTH HORM IGF RES, V13, P44, DOI 10.1016/S1096-6374(02)00121-1; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hailey J, 2002, MOL CANCER THER, V1, P1349; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Hernandez-Boluda JC, 2002, DRUG TODAY, V38, P601, DOI 10.1358/dot.2002.38.9.696536; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hongo A, 1996, ONCOGENE, V12, P1231; Hongo A, 1998, CANCER RES, V58, P2477; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; KALEBIC T, 1994, CANCER RES, V54, P5531; Kalebic T, 1998, INT J CANCER, V76, P223, DOI 10.1002/(SICI)1097-0215(19980413)76:2<223::AID-IJC9>3.0.CO;2-Z; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Lee CT, 1996, CANCER RES, V56, P3038; Lee CT, 2003, CANCER GENE THER, V10, P57, DOI 10.1038/sj.cgt.7700524; Levitzki A, 2002, EUR J CANCER, V38, pS11, DOI 10.1016/S0959-8049(02)80598-6; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; LI SL, 1993, BIOCHEM BIOPH RES CO, V196, P92, DOI 10.1006/bbrc.1993.2220; Liu YM, 1998, CANCER RES, V58, P570; Long L, 1998, CANCER RES, V58, P3243; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Muller M, 1998, INT J CANCER, V77, P567, DOI 10.1002/(SICI)1097-0215(19980812)77:4<567::AID-IJC16>3.0.CO;2-3; Nakamura K, 2000, CANCER RES, V60, P760; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OCONNOR R, 1998, ADV BIOCHEM ENG BIOT, V62, P138; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Pavelic J, 2002, MOL MED, V8, P149, DOI 10.1007/BF03402007; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 2001, CLIN CANCER RES, V7, P2134; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2003, CANCER RES, V63, P627; Scharf JG, 2001, J CLIN PATHOL-MOL PA, V54, P138, DOI 10.1136/mp.54.3.138; Scotlandi K, 1998, CANCER RES, V58, P4127; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Seely BL, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-15; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Trojan LA, 2002, ACTA BIOCHIM POL, V49, P979; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zia F, 1996, J CELL BIOCHEM, P269; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	110	124	141	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6589	6597		10.1038/sj.onc.1206772	http://dx.doi.org/10.1038/sj.onc.1206772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528284				2022-12-28	WOS:000185700700016
J	Xu, QY; Karouji, Y; Kobayashi, M; Ihara, S; Konishi, H; Fukui, Y				Xu, QY; Karouji, Y; Kobayashi, M; Ihara, S; Konishi, H; Fukui, Y			The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma	ONCOGENE			English	Article						PI3-kinase; signet-ring cell carcinoma; cell-cell contact; p38 MAP kinase; MUC1	ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; EXPRESSION; ADHESION; STRESS; FAMILY; PHOSPHORYLATION; IDENTIFICATION; DOWNSTREAM; DYNAMICS	Signet-ring cell carcinoma is classified in poorly differentiated adenocarcinoma with an aggressive nature and a poor prognosis. We have shown that the activation of PI 3-kinase in highly differentiated adenocarcinomas induces loss of cell-cell contact and formation of vacuoles, giving phenotypes similar to those of signet-ring cell lines. SB203580, a potent p38 MAP kinase inhibitor, blocked this transition, and expression of an active form of MKK6 (MKK6DA), an activator of p38 MAP kinase, gave effects similar to those induced by expression of the active form of PI 3-kinase (BD110), although formation of large vacuoles was not induced. Activation of MKK3, another activator of p38 MAP kinase, was activated in native signet-ring carcinoma cell lines. Anchorage-independent growth of signet-ring cell lines was inhibited by LY294002 or SB203580. These results suggest that p38 MAP kinase is functioning downstream of PI 3-kinase in signaling of the malignant phenotype. Secretion of mucins was enhanced in BD110-expressing cells, but not in MKK6DA-expressing cells, suggesting that secretion of mucins is independent of the MKK6-p38 MAP kinase cascade. Thus, there may be at least two pathways, p38 MAP kinase-dependent and -independent, which are involved in regulation of cell-cell contact and the protein secretion system, respectively.	Univ Tokyo, Fac Agr & Life Sci, Grad Sch Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Fukui, Y (corresponding author), Univ Tokyo, Fac Agr & Life Sci, Grad Sch Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ayfukui@mail.ecc.u-tokyo.ac.jp	Fukui, Yasuhisa/E-8806-2010					AKIYAMA S, 1988, JPN J SURG, V18, P438, DOI 10.1007/BF02471470; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUANE GB, 1985, ACTA CYTOL, V29, P211; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; Gavet O, 1998, J CELL SCI, V111, P3333; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; Guay J, 1997, J CELL SCI, V110, P357; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kobayashi M, 2003, ONCOGENE, V22, P1294, DOI 10.1038/sj.onc.1206256; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Maeno Y, 1999, AM J PATHOL, V154, P1323, DOI 10.1016/S0002-9440(10)65385-0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Tahara E, 1989, Gan To Kagaku Ryoho, V16, P2149; vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMAMOTO R, 1990, VIRCHOWS ARCH B, V59, P26, DOI 10.1007/BF02899383; Yonezawa S, 1997, PATHOL INT, V47, P813, DOI 10.1111/j.1440-1827.1997.tb03713.x; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5537	5544		10.1038/sj.onc.1206796	http://dx.doi.org/10.1038/sj.onc.1206796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944900				2022-12-28	WOS:000184865900001
J	Argani, P; Lui, MY; Couturier, J; Bouvier, R; Fournet, JC; Ladanyi, M				Argani, P; Lui, MY; Couturier, J; Bouvier, R; Fournet, JC; Ladanyi, M			A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23)	ONCOGENE			English	Article						chromosome translocation; carcinoma; pediatric; kidney	SOFT PART SARCOMA; CELL CARCINOMA; TFE3 GENE; NUCLEAR-LOCALIZATION; TUBEROUS SCLEROSIS; CLATHRIN; PRCC; ALK; KINASE; IMMUNOREACTIVITY	A distinctive subset of renal carcinomas is associated with Xp11.2 translocations and resulting TFE3 gene fusions (PRCC-TFE3, PSF-TFE3, NONO-TFE3, ASPL-TFE3), encoding related aberrant transcription factors. We report the cloning of a novel clathrin heavy-chain gene (CLTC)-TFE3 gene fusion resulting from a t(X;l7)(p11.2;q23) in a renal carcinoma arising in a 14-year-old boy. The fusion transcript joined the 5' exons of CLTC on chromosome band 17q23 to the 3' exons of TFE3. CLTC encodes a major subunit of clathrin, a multimeric protein on cytoplasmic organelles, and is a known recurrent fusion partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors. The predicted CLTC-TFE3 product retains the nuclear localization and DNA-binding domains of TFE3, but lacks the multimerization domain of CLTC. The present renal tumor demonstrated morphologic and immunohistochemical features of both PRCC-TFE3 and ASPL-TFE3 carcinomas, including strong nuclear immunoreactivity for the TFE3 C-terminal and only minimal expression of epithelial proteins. However, unlike most renal carcinomas, it also focally expressed melanocytic proteins. The present report highlights the promiscuity of certain genes involved in chromosomal translocations. Further analysis of the shared features of CLTC and other TFE3 fusion partners may shed light on the essential biology of TFE3 fusion proteins.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Inst Curie, F-75248 Paris 05, France; Hop Edouard Herriot, F-69437 Lyon 3, France; Hop St Justine, Montreal, PQ H3T 1C5, Canada	Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CHU Lyon; Universite de Montreal	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Room S-801,1275 York Ave, New York, NY 10021 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019		NCI NIH HHS [R01CA95785] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095785] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Avery AK, 2000, AM J SURG PATHOL, V24, P203, DOI 10.1097/00000478-200002000-00006; Bjornsson J, 1996, AM J PATHOL, V149, P1201; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Cools J, 2002, GENE CHROMOSOME CANC, V34, P354, DOI 10.1002/gcc.10033; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Heimann P, 2001, CANCER RES, V61, P4130; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Ladanyi M, 2000, AM J PATHOL, V157, P341, DOI 10.1016/S0002-9440(10)64545-2; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Pea M, 1998, AM J SURG PATHOL, V22, P180, DOI 10.1097/00000478-199802000-00005; PEROT C, 2003, IN PRESS CANC GENET; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Smith CJ, 1999, TRENDS CELL BIOL, V9, P335, DOI 10.1016/S0962-8924(99)01631-1; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	28	201	213	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5374	5378		10.1038/sj.onc.1206686	http://dx.doi.org/10.1038/sj.onc.1206686			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917640				2022-12-28	WOS:000184734900018
J	Guerra, B; Issinger, OG; Wang, JYJ				Guerra, B; Issinger, OG; Wang, JYJ			Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2	ONCOGENE			English	Article						protein kinase CK2; Chk1; protein phosphorylation	DNA-DAMAGE CHECKPOINT; KAPPA-B-ALPHA; CRYSTAL-STRUCTURE; CASEIN KINASE-2; CELL-CYCLE; CK2-BETA SUBUNIT; FISSION YEAST; PHOSPHORYLATION; PROLIFERATION; ADAPTATION	Protein kinase CK2 is a serine/threonine protein kinase involved in various aspects of cellular regulation. The regulatory beta-subunit of CK2 exerts a central role not only in mediating formation of tetrameric CK2 complexes but also as a docking partner for several protein kinases. In this study, CK2beta is found to interact with the human cell cycle checkpoint kinase Chk1. The Chk1-interacting region of CK2beta is localized at the C-terminus and the complex between CK2beta and Chk1 is devoid of the catalytic CK2alpha-subunit. The interaction between CK2beta and Chk1 leads to an increase in the Cdc25C phosphorylation activity of Chk1. The screening of several cell lines has revealed that the association between CK2beta and Chk1 also occurs in vivo at a different degree. Collectively, these studies confirm the implication of the regulatory beta-subunit of protein kinase CK2 in cell cycle regulation and identify a novel mechanism for the activation of Chk1 protein kinase.	Univ Calif San Diego, Div Biol Sci 0322, La Jolla, CA 92093 USA; Univ So Denmark, Inst Biochem & Mol Biol, DK-5230 Odense, Denmark	University of California System; University of California San Diego; University of Southern Denmark	Guerra, B (corresponding author), Univ Calif San Diego, Div Biol Sci 0322, La Jolla, CA 92093 USA.			Guerra, Barbara/0000-0003-1136-2413	NCI NIH HHS [R01 CA043054, CA43054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Liu QH, 2000, GENE DEV, V14, P1448; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Takai H, 2000, GENE DEV, V14, P1439; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	28	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4933	4942		10.1038/sj.onc.1206721	http://dx.doi.org/10.1038/sj.onc.1206721			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902976				2022-12-28	WOS:000184578900001
J	Lindstrom, MS; Wiman, KG				Lindstrom, MS; Wiman, KG			Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts	ONCOGENE			English	Article						p14ARF; p53; Myc; E2F1; phosphorylation; apoptosis; caffeine; RNA interference	CELL-CYCLE ARREST; C-MYC; DNA-DAMAGE; TUMOR SUPPRESSION; P53-DEPENDENT APOPTOSIS; RADIOSENSITIZING AGENT; TRANSCRIPTION FACTOR; INDUCED SENESCENCE; ONCOGENIC STRESS; NUCLEAR EXPORT	p19ARF is induced in response to oncogene activation or during cellular senescence in mouse embryo fibroblasts, triggering p53-dependent and p53-independent cell cycle arrest and apoptosis. We have studied the involvement of human p14ARF as a regulator of p53 activity in normal human skin fibroblasts (NHFs) or WI38 lung embryonic fibroblasts expressing conditional Myc or E2F1 estrogen receptor fusion proteins. Both Myc and E2F1 activation rapidly induced p53 phosphorylation at Ser-15, p53 protein accumulation, and upregulation of the p53 target genes MDM2 and p21. Activation of E2F1 induced p14ARF mRNA and protein levels. In contrast, Myc activation did not induce any significant increase in p14ARF mRNA or protein levels in neither NHFs nor WI38 fibroblasts within 48 h. Myc and E2F1 induced p53 and cell cycle arrest even after silencing of p14ARF using short-interfering RNA. Treatment with the ATM/ATR kinase inhibitor caffeine prevented p53 accumulation upon activation of Myc or E2F1. Our results indicate that p53 phosphorylation, but not p14ARF, plays a major role for the induction of p53 in response to Myc and E2F1 activation in normal human fibroblasts.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@mtc.ki.se	Wiman, Klas/AAB-8399-2021; Lindström, Mikael S/AAA-1451-2019	Wiman, Klas/0000-0002-7113-524X; Lindström, Mikael S/0000-0003-1148-8497				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deplanque G, 2000, BRIT J CANCER, V83, P346, DOI 10.1054/bjoc.2000.1259; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hashemi J, 2002, CANCER LETT, V180, P211, DOI 10.1016/S0304-3835(02)00027-7; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lee C, 2000, CLIN CHIM ACTA, V295, P141, DOI 10.1016/S0009-8981(00)00201-1; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	91	64	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4993	5005		10.1038/sj.onc.1206659	http://dx.doi.org/10.1038/sj.onc.1206659			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902982				2022-12-28	WOS:000184578900007
J	Xin, H; Pramanik, R; Choubey, D				Xin, H; Pramanik, R; Choubey, D			Retinoblastoma (Rb) protein upregulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth	ONCOGENE			English	Article						interferon-inducible p202; cell cycle; cell survival; Rb; JunD/AP-1	NIH 3T3 CELLS; C-JUN; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSION; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; INDUCED APOPTOSIS; P202; DIFFERENTIATION; INHIBITION	Studies have indicated that ectopic expression of p202, an interferon (IFN)-inducible retinoblastoma (Rb)-binding protein, in cultured cells retards cell proliferation and modulates cell survival. Consistent with a role of p202 in cell cycle regulation, levels of p202 increase in cells arrested in the G(0)/G(1) phase of cell cycle after withdrawal of serum growth factors. However, a role for p202 in cell growth arrest remains to be defined. Moreover, it remains unclear how levels of p202 are upregulated during the cell growth arrest. Here, we report that Rb upregulates expression of Ifi202 gene. We found that basal as well as IFN-induced levels of p202 were significantly higher in wild-type (Rb+/+) mouse embryonic fibroblasts (MEFs) than isogenic Rb-/- MEFs. Consistent with the regulation of Ifi202 gene by Rb, expression of functional Rb, but not a pocket mutant of it, stimulated the activity of a reporter whose expression was driven by the 5'-regulatory region of Ifi202 gene. Importantly, the stimulation by Rb was dependent, in part, on a JunD/AP-1 DNA-binding site present in the 5-regulatory region of the Ifi202 gene. Moreover, basal levels of p202 were significantly higher in wild-type (JunD(+/+)) than isogenic JunD(-/-) MEFs. Additionally, we found that increased expression of p202 potentiated the Rb-mediated inhibition of cell growth and mutations in the Rb-binding motif (LxCxE) of p202 significantly reduced cell survival. Together, our observations support the idea that the transcriptional activation of Ifi202 gene by Rb/JunD may be important for the regulation of cell growth and survival.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA	Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1,Mail Code 114B, Maywood, IL 60153 USA.		Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Berry DE, 1996, ONCOGENE, V12, P1809; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; Grander D, 1997, EUR J HAEMATOL, V59, P129; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAMEL PA, 1992, ONCOGENE, V7, P693; HAPUT Y, 1995, ONCOGENE, V10, P1563; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Li H, 2001, ARCH BIOCHEM BIOPHYS, V394, P1, DOI 10.1006/abbi.2001.2518; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Min W, 1996, MOL CELL BIOL, V16, P359; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang J, 1997, CANCER RES, V57, P351; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Xin H, 2003, J CELL BIOCHEM, V88, P191, DOI 10.1002/jcb.10372; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	59	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4775	4785		10.1038/sj.onc.1206780	http://dx.doi.org/10.1038/sj.onc.1206780			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894219				2022-12-28	WOS:000184344600001
J	Chen, DY; Xu, LG; Chen, L; Li, LX; Zhai, ZH; Shu, HB				Chen, DY; Xu, LG; Chen, L; Li, LX; Zhai, ZH; Shu, HB			NIK is a component of the EGF/heregulin receptor signaling complexes	ONCOGENE			English	Article						NIK; EGF; Grb7; NF-kappa B; signaling	NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; LYMPHOTOXIN-BETA-RECEPTOR; FOCAL ADHESION KINASE; SRC HOMOLOGY 2; ADAPTER PROTEIN; INTERACTING PROTEIN; BINDING-PROTEIN; GRB7 FAMILY; ACTIVATION	Nuclear factor kappaB-inducing kinase (NIK) is a member of the MAP kinase kinase kinase family that was first identified as a component of the TNF-R1-induced NF-kappaB activation pathway (TNF, tumor necrosis factor; nuclear factor kappaB, NF-kappaB). Gene knockout study, however, suggests that NIK is dispensable for TNF-R1- but required for lymphotoxin-beta receptor-induced NF-kappaB activation. A NIK kinase inactive mutant is a potent inhibitor of NF-kappaB activation triggered by various stimuli, suggesting that NIK is involved in a broad range of NF-kappaB activation pathways. To unambiguously identify signaling pathways that NIK participates in, we screened antibody arrays for proteins that are associated with NIK. This effort identified ErbB4, one of the EGF/heregulin receptors, and Grb7, an adapter protein associated with ErbB4 (ErbB, epidermal growth factor receptor family protein; EGF, epidermal growth factor; Grb, growth factor receptor bound). Coimmunoprecipitation experiments demonstrated that NIK interacted with Grb7, as well as Grb10 and Grb14, but not Grb2. Domain mapping experiments indicated that the central GM domain of Grb7 was sufficient for its interaction with NIK. Coimmunoprecipitation experiments also indicated that Grb7 and NIK could be simultaneously recruited into signaling complexes of all known EGF/heregulin receptors, including EGFR, ErbB2, ErbB3, and ErbB4. In reporter gene assays, NIK could potentiate Grb7, ErbB2/ErbB4, and EGF-induced NF-kappaB activation. A NIK kinase inactive mutant could block ErbB2/ErbB4 and EGF-induced NF-kappaB activation. Moreover, EGF/heregulin receptors activated NF-kappaB in wild-type, but not NIK-/- embryonic fibroblasts. Our findings suggest that NIK is a component of the EGF/heregulin receptor signaling complexes and involved in NF-kappaB activation triggered by these receptors.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49992-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akiyama N, 1997, CANCER RES, V57, P3548; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; JANES PW, 1997, J BIOL CHEM, V274, P30896; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; OOI J, 1995, ONCOGENE, V10, P1621; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	41	32	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4348	4355		10.1038/sj.onc.1206532	http://dx.doi.org/10.1038/sj.onc.1206532			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853971				2022-12-28	WOS:000183978900004
J	Baron, V; De Gregorio, G; Krones-Herzig, A; Virolle, T; Calogero, A; Urcis, R; Mercola, D				Baron, V; De Gregorio, G; Krones-Herzig, A; Virolle, T; Calogero, A; Urcis, R; Mercola, D			Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo	ONCOGENE			English	Article						prostate cancer; Egr-1; antisense oligonucleotide; TRAMP mouse	TRANSCRIPTION FACTOR EGR-1; GROWTH-FACTOR; ANTISENSE OLIGONUCLEOTIDES; GENE-EXPRESSION; UP-REGULATION; INVOLVEMENT; INDUCTION; APOPTOSIS; BINDING; PROTEIN	Transcription factor early growth response-1 (Egr-1) is a crucial regulator of cell growth, differentiation and survival. Several observations suggest that Egr-1 is growth promoting in prostate cancer cells and that blocking its function may impede cancer progression. To test this hypothesis, we developed phosphorothioate antisense oligonucleotides that efficiently inhibit Egr-1 expression without altering the expression of other family members Egr-2, Egr-3 and Egr-4. In TRAMP mouse-derived prostate cancer cell lines, our optimal antisense oligonucleotide decreased the expression of the Egr-1 target gene transforming growth factor-beta1 whereas a control oligonucleotide had no effect, indicating that the antisense blocked Egr-1 function as a transcription factor. The antisense oligonucleotide deregulated cell cycle progression and decreased proliferation of the three TRAMP cell lines by an average of 54+/-3%. Both colony formation and growth in soft agar were inhibited by the antisense oligonucleotide. When TRAMP mice were treated systemically for 10 weeks, the incidence of palpable tumors at 32 weeks of age in untreated mice or mice injected with the control scramble oligonucleotide was 87%, whereas incidence of tumors in antisense-Egr-1-treated mice was significantly reduced to 37% (P=0.026). Thus, Egr-1 plays a functional role in the transformed phenotype and may represent a valid target for prostate cancer therapy.	Sidnet Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Ricovero & Cura Carattere Sci, I-86077 Pozzilli, Italy; Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Baron, V (corresponding author), Sidnet Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	vbaron@skcc.org; danmercola@skcc.org	mercola, dan/L-4182-2013; calogero, antonella/U-5418-2019; Virolle, Thierry/E-5838-2016	mercola, dan/0000-0002-0281-9840; calogero, antonella/0000-0002-3322-2916	NATIONAL CANCER INSTITUTE [R01CA084107, R01CA076173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76173, CA 84107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8; BERUBE NG, 1994, CANCER RES, V54, P3077; Bost F, 2000, METHOD ENZYMOL, V314, P342; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Eid MA, 1998, CANCER RES, V58, P2461; Foster BA, 1997, CANCER RES, V57, P3325; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gousseva N, 2001, J CELL BIOCHEM, V81, P523, DOI 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, CANCER RES, V55, P5054; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; Jackson MW, 2002, CANCER RES, V62, P854; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kroon ME, 2001, J CELL SCI, V114, P825; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; McMenamin ME, 1999, CANCER RES, V59, P4291; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nishi H, 2002, CANCER RES, V62, P827; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Okada M, 2001, FASEB J, V15, P2757, DOI 10.1096/fj.01-0490fje; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; Russell PJ, 1998, CLIN CHEM, V44, P705; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	48	90	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4194	4204		10.1038/sj.onc.1206560	http://dx.doi.org/10.1038/sj.onc.1206560			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833142				2022-12-28	WOS:000183979800006
J	Snijders, AM; Nowee, ME; Fridlyand, J; Piek, JMJ; Dorsman, JC; Jain, AN; Pinkel, D; van Diest, PJ; Verheijen, RHM; Albertson, DG				Snijders, AM; Nowee, ME; Fridlyand, J; Piek, JMJ; Dorsman, JC; Jain, AN; Pinkel, D; van Diest, PJ; Verheijen, RHM; Albertson, DG			Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in Fallopian tube carcinoma	ONCOGENE			English	Article						array CGH; CCNE1; AKT2; fallopian tube cancer	CYCLIN-E GENE; OVARIAN-CANCER; C-MYC; SOLID TUMORS; AMPLIFICATION; OVEREXPRESSION; ONCOGENE; MICROARRAYS; CDK2; AKT2	Fallopian tube carcinoma (FTC) is a rare, poorly studied and aggressive cancer, associated with poor survival. Since tumorigenesis is related to the acquisition of genetic changes, we used genome-wide array comparative genomic hybridization to analyse copy number aberrations occurring in FTC in order to obtain a better understanding of FTC carcinogenesis and to identify prognostic events and targets for therapy. We used arrays of 2464 genomic clones, providing similar to 1.4 Mb resolution across the genome to map genomic DNA copy number aberrations quantitatively from 14 FTC onto the human genome sequence. All tumors showed a high frequency of copy number aberrations with recurrent gains on 3q, 6p, 7q, 8q, 12p, 17q, 19 and 20q, and losses involving chromosomes 4, 5q, 8p, 16q, 17p, 18q and X. Recurrent regions of amplification included 1p34, 8p11-q11, 8q24, 12p, 17p13, 17q12-q21, 19p13, 19q12-q13 and 19q13. Candidate, known oncogenes mapping to these amplicons included CMYC (8q24), CCNE1 (19q12-q21) and AKT2 (19q13), whereas PIK3CA and KRAS, previously suggested to be candidate driver genes for amplification, mapped outside copy number maxima on 3q and 12p, respectively. The FTC were remarkably homogeneous, with some recurrent aberrations occurring in more than 70% of samples, which suggests a stereotyped pattern of tumor evolution.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; VU Univ, Dept Obstet & Gynaecol, Med Ctr, Amsterdam, Netherlands; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; VU Univ, Dept Pathol, Med Ctr, Amsterdam, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; Vrije Universiteit Amsterdam	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.		Piek, Jurgen Martinus Johannes/AAX-2108-2021	Piek, Jurgen Martinus Johannes/0000-0002-0487-0631	NATIONAL CANCER INSTITUTE [R01CA083040, R33CA094407] Funding Source: NIH RePORTER; NCI NIH HHS [CA83040, CA94407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Aziz S, 2001, GYNECOL ONCOL, V80, P341, DOI 10.1006/gyno.2000.6095; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Caduff RF, 1998, AM J SURG PATHOL, V22, P319, DOI 10.1097/00000478-199803000-00006; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Chung TKH, 2000, GYNECOL OBSTET INVES, V49, P47, DOI 10.1159/000010212; DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HELLSTROM AC, 1994, INT J GYNECOL CANCER, V4, P408, DOI 10.1046/j.1525-1438.1994.04060408.x; Heselmeyer K, 1998, INT J GYNECOL PATHOL, V17, P245, DOI 10.1097/00004347-199807000-00009; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Karhu R, 1997, CYTOMETRY, V28, P198, DOI 10.1002/(SICI)1097-0320(19970701)28:3<198::AID-CYTO3>3.0.CO;2-A; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Knight SJL, 2000, AM J HUM GENET, V67, P320, DOI 10.1086/302998; Leeper K, 2002, GYNECOL ONCOL, V87, P52, DOI 10.1006/gyno.2002.6779; Lin L, 2000, CANCER RES, V60, P7021; Manavi M, 1998, GYNECOL ONCOL, V71, P165, DOI 10.1006/gyno.1998.5084; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; MIZUUCHI H, 1995, CANCER, V76, P86, DOI 10.1002/1097-0142(19950701)76:1<86::AID-CNCR2820760112>3.0.CO;2-L; MONK BJ, 1994, AM J OBSTET GYNECOL, V171, P1193, DOI 10.1016/0002-9378(94)90131-7; Pere H, 1998, CANCER RES, V58, P4274; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SNIJDERS AM, 2003, IN PRESS ONCOGENE; SolinasToldo S, 1996, CANCER RES, V56, P3803; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sun PC, 2001, GENOMICS, V75, P17, DOI 10.1006/geno.2001.6587; Wang ZR, 1999, EXP MOL PATHOL, V66, P140, DOI 10.1006/exmp.1999.2259; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zweemer RP, 2000, GYNECOL ONCOL, V76, P45, DOI 10.1006/gyno.1999.5623; Zweemer RP, 2001, LAB INVEST, V81, P1363, DOI 10.1038/labinvest.3780350	39	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4281	4286		10.1038/sj.onc.1206621	http://dx.doi.org/10.1038/sj.onc.1206621			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833150				2022-12-28	WOS:000183979800014
J	Chamboredon, S; Briggs, J; Vial, E; Hurault, J; Galvagni, F; Oliviero, S; Bos, T; Castellazzi, M				Chamboredon, S; Briggs, J; Vial, E; Hurault, J; Galvagni, F; Oliviero, S; Bos, T; Castellazzi, M			v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3	ONCOGENE			English	Article						cell transformation; v-Jun; Sp1; Sp3; SPARC; primary chick embryo fibroblasts	CHICK-EMBRYO FIBROBLASTS; EXTRACELLULAR-MATRIX PROTEIN; C-JUN; TRANSCRIPTION FACTOR; NEOPLASTIC PROGRESSION; TRANSFORMING ACTIVITY; CELL-TRANSFORMATION; IN-VIVO; EXPRESSION; CANCER	Transformation of chick embryo fibroblasts by the v-Jun oncoprotein correlates with a downregulation of the extracellular matrix protein SPARC and repression of the corresponding mRNA. Repression of SPARC contributes to the oncogenic process by facilitating tumor development in vivo. A proximal promoter fragment, designated -124/+16, is responsible for high constitutive activity of the SPARC gene and is the target of repression by v-Jun. In this paper, using electrophoretic mobility shift and pull-down assays in vitro, and transient transfections and chromatin immunoprecipitation assays in Sp1/3-deficient Drosophila SL2 cells and in chick embryo fibroblasts, we show that (i) Sp1 and/or Sp3 is required for constitutive activation of SPARC transcription, by binding directly to the GGA-rich -92/-57 fragment; and (ii) v-Jun does not bind -124/+16 directly, but binds to the GGA-rich fragment indirectly, most likely through a physical interaction with Sp1/3. Moreover, a transactivation-proficient v-Jun derivative, designated v-Jun/cebp/glz, which cannot bind Jun DNA motifs anymore and cannot heterodimerize, is still capable of downregulating SPARC efficiently. Taken together, these data strongly suggest that v-Jun downregulates SPARC through the formation of a DNA-Sp1/3-v-Jun, chromatin-associated complex.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France; Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Eastern Virginia Medical School; University of Siena	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.	marc.castellazzi@ens-lyon.fr	Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X				Acloque H, 2001, MECH DEVELOP, V103, P79, DOI 10.1016/S0925-4773(01)00336-7; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Jacob K, 1999, CANCER RES, V59, P4453; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mok SC, 1996, ONCOGENE, V12, P1895; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEL L, 1995, ONCOGENE, V10, P495; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422	50	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4047	4061		10.1038/sj.onc.1206713	http://dx.doi.org/10.1038/sj.onc.1206713			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821939				2022-12-28	WOS:000183707600008
J	Alpy, F; Boulay, A; Moog-Lutz, C; Andarawewa, KL; Degot, S; Stoll, I; Rio, MC; Tomasetto, C				Alpy, F; Boulay, A; Moog-Lutz, C; Andarawewa, KL; Degot, S; Stoll, I; Rio, MC; Tomasetto, C			Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors	ONCOGENE			English	Article						erbB-2; MLN64; MENTHO; StAR; Sp1	HIGHLY EXPRESSED GENES; PROTEIN STAR; ESOPHAGEAL-CARCINOMA; CHROMOSOMAL DOMAINS; DNA AMPLIFICATION; FACTOR RECEPTOR; IN-VITRO; FAMILY; GENOME; REVEALS	MLN64, is invariably coamplified and coexpressed with erbB-2 in breast cancers. The human MLN64 and ERBB2 genes are positioned at less than 50 kb from each other, on chromosome 17q12. To understand the molecular basis of MLN64 overexpression in cancer, the genomic region containing the MLN64 and ERBB2 genes was isolated and mapped. The two genes, DARPP32 and Telethonin, flanking MLN64 respectively on its centromeric and telomeric sides, although coamplified, are not over-expressed in breast cancer cells, indicating that gene amplification is not sufficient to allow overexpression. The MLN64 minimal promoter was isolated and found to be a housekeeping gene promoter containing four potential Sp1 binding elements. Using Sp1-deficient Drosophila SL2 cells, MLN64 promoter activity was induced in a dose-dependent manner by exogenous Sp1 addition. Furthermore, mutation of each individual Sp1 element resulted in a significant decrease in reporter gene activity, indicating that all the Sp1 binding elements are functional and act together to promote gene expression. Since the ERBB2 promoter is also positively regulated by Sp1, this study indicates that MLN64 and ERBB2 genes share common transcriptional controls together with a physical link on chromosome 17q. We speculate that, in addition to the oncogenic potential of erbB-2 overexpression, the unbalanced action of MLN64 contributes to the poor clinical outcome of breast tumors bearing this amplified region.	Univ Louis Pasteur Strasbourg 1, CNRS INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tomasetto, C (corresponding author), IGBMC, Dept Mol Pathol, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, France.		Alpy, Fabien/ABD-5893-2020; MOOG-LUTZ, Christel/F-1975-2011; Alpy, Fabien/H-8941-2016; Tomasetto, Catherine Laure/J-2783-2014	Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848				Alpy F, 2002, J BIOL CHEM, V277, P50780, DOI 10.1074/jbc.M208290200; Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bates NP, 1997, J MAMMARY GLAND BIOL, V2, P153, DOI 10.1023/A:1026303814855; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blumenthal T, 2002, NATURE, V417, P851, DOI 10.1038/nature00831; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; CHEN YY, 1994, ONCOGENE, V9, P2269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Foster KW, 2000, CANCER RES, V60, P6488; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hyman E, 2002, CANCER RES, V62, P6240; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Kauraniemi P, 2001, CANCER RES, V61, P8235; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Mayerhofer A, 1999, J CLIN ENDOCR METAB, V84, P257, DOI 10.1210/jc.84.1.257; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soury E, 2001, IMMUNOGENETICS, V53, P634, DOI 10.1007/s00251-001-0374-z; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 1997, CANCER RES, V57, P28; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	52	23	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3770	3780		10.1038/sj.onc.1206500	http://dx.doi.org/10.1038/sj.onc.1206500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802284				2022-12-28	WOS:000183551000011
J	Ferber, MJ; Montoya, DP; Yu, C; Aderca, I; McGee, A; Thorland, EC; Nagorney, DM; Gostout, BS; Burgart, LJ; Boix, L; Bruix, J; McMahon, BJ; Cheung, TH; Chung, TKH; Wong, YF; Smith, DI; Roberts, LR				Ferber, MJ; Montoya, DP; Yu, C; Aderca, I; McGee, A; Thorland, EC; Nagorney, DM; Gostout, BS; Burgart, LJ; Boix, L; Bruix, J; McMahon, BJ; Cheung, TH; Chung, TKH; Wong, YF; Smith, DI; Roberts, LR			Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers	ONCOGENE			English	Article						hepatitis B virus; human papillomavirus; telomerase reverse transcriptase; hepatocellular carcinoma; cervical cancer; viral integration	RESTRICTION-SITE PCR; COMMON FRAGILE SITES; HEPATOCELLULAR-CARCINOMA; DNA INTEGRATION; CELL-LINES; MYC GENES; ACTIVATION; TYPE-16; SEQUENCE; REGION	Chronic infections with the hepatitis B virus (HBV) and high-risk human papillomaviruses (HPVs) are important risk factors for hepatocellular carcinoma (HCC) and cervical cancer (CC), respectively. HBV and HPV are DNA viruses that almost invariably integrate into the host genome in invasive tumors. The viral integration sites occur throughout the genome, leading to the presumption that there are no preferred sites of integration. A number of viral integrations have been shown to occur within the vicinity of important cancer-related genes. In studies of HBV-induced HCC and HPV-induced CC, we have identified two HBV and three HPV integrations into the human telomerase reverse transcriptase (hTERT) gene. Detailed characterization of the integrations revealed that four integrations occurred within the hTERT promoter and upstream region and the fifth integration occurred in intron 3 of the hTERT gene. None of the integrations altered the hTERT coding sequence and all resulted in juxtaposition of viral enhancers near hTERT, with potential activation of hTERT expression. Our work supports the hypothesis that the sites of oncogenic viral integration are nonrandom and that genes at the sites of viral integration may play important roles in carcinogenesis.	Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin, Div Gastroenterol & Gen Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Obstet & Gynaecol, Rochester, MN 55905 USA; Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA; Univ Barcelona, IMD Hosp Clin, BCLC Grp Liver Unit, Barcelona 08036, Spain; Alaska Native Med Ctr, Anchorage, AK 99508 USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Barcelona; Alaska Native Medical Center; Chinese University of Hong Kong; Prince of Wales Hospital	Roberts, LR (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA.			CHUNG, Tony/0000-0002-6362-8546; Bruix, Jordi/0000-0002-9826-0753; Roberts, Lewis/0000-0001-7885-8574	NATIONAL CANCER INSTITUTE [R01CA048031, K08CA082862] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031, CA82862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CHOO KB, 1995, CANCER LETT, V93, P249, DOI 10.1016/0304-3835(95)03817-G; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DEJEAN A, 1990, MOL BIOL MED, V7, P213; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horikawa I, 1999, CANCER RES, V59, P826; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kalantari M, 1998, INT J GYNECOL PATHOL, V17, P146, DOI 10.1097/00004347-199804000-00009; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kozuka T, 2000, JPN J CANCER RES, V91, P271, DOI 10.1111/j.1349-7006.2000.tb00941.x; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Sarkar G, 1993, PCR Methods Appl, V2, P318; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Shera KA, 2001, J VIROL, V75, P12339, DOI 10.1128/JVI.75.24.12339-12346.2001; Smola-Hess S, 2001, J GEN VIROL, V82, P2335, DOI 10.1099/0022-1317-82-10-2335; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Waris G, 2002, J VIROL, V76, P2721, DOI 10.1128/JVI.76.6.2721-2729.2002; Weber KL, 1998, BIOTECHNIQUES, V25, P415, DOI 10.2144/98253st02; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187	34	145	167	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3813	3820		10.1038/sj.onc.1206528	http://dx.doi.org/10.1038/sj.onc.1206528			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802289				2022-12-28	WOS:000183551000016
J	Aldred, MA; Morrison, C; Gimm, O; Hoang-Vu, C; Krause, U; Dralle, H; Jhiang, S; Eng, C				Aldred, MA; Morrison, C; Gimm, O; Hoang-Vu, C; Krause, U; Dralle, H; Jhiang, S; Eng, C			Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas	ONCOGENE			English	Article						follicular thyroid cancer; microarray analysis	LONG ARM; TUMORS; MUTATIONS; CANCER; HETEROZYGOSITY; PAPILLARY; INSTABILITY; EXPRESSION; DELETIONS; SUGGESTS	Peroxisome proliferator-activated receptor gamma (PPARgamma) has previously been implicated in the pathogenesis of follicular thyroid carcinoma (FTC), where a translocation with PAX8 has been reported in some 50% of tumors in three small series. The resultant fusion protein inhibits normal PPARgamma function by a dominant-negative mechanism. In a series of 19 FTCs, we identified this translocation in only two tumors (10.5%). However, microarray analysis and semiquantitative RT-PCR demonstrated greatly reduced PPARgamma expression in 13 of 17 (76%) nontranslocation tumors. Immunohistochemical analysis of 142 thyroid tumors showed a statistically significant reduction in PPARgamma immunoreactive protein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas. This suggests that while the overall frequency of the PAX8-PPARgamma translocation in FTCs may be lower than previously thought, functional downregulation of PPARgamma is a key event in multiple types of thyroid neoplasia and is a possible target for therapeutic intervention.	Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Univ Halle Wittenberg, Dept Surg, Halle Saale, Germany; Univ Halle Wittenberg, Inst Pathol, Halle Saale, Germany; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Leicester, Div Med Genet, Leicester, Leics, England; Univ Cambridge, Canc Res UK, Human Canc Genet Res Grp, Cambridge, England	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University System of Ohio; Ohio State University; University of Leicester; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Human Canc Genet Program, 420 W 12th Ave,Ste 690 TMRF, Columbus, OH 43210 USA.			Eng, Charis/0000-0002-3693-5145	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Clay CE, 2000, PROSTAG OTH LIPID M, V62, P23, DOI 10.1016/S0090-6980(00)00073-3; Dahia PLM, 1997, CANCER RES, V57, P4710; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Grebe SKG, 1997, J CLIN ENDOCR METAB, V82, P3684, DOI 10.1210/jc.82.11.3684; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Oriola J, 2001, EUR J CANCER, V37, P2470, DOI 10.1016/S0959-8049(01)00302-1; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; Trovato M, 1999, J CLIN ENDOCR METAB, V84, P3235, DOI 10.1210/jcem.84.9.5986; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758; Zhou XP, 2000, J MED GENET, V37, P410, DOI 10.1136/jmg.37.6.410	19	48	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3412	3416		10.1038/sj.onc.1206400	http://dx.doi.org/10.1038/sj.onc.1206400			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776192				2022-12-28	WOS:000183128500007
J	An, JB; Sun, YP; Sun, R; Rettig, MB				An, JB; Sun, YP; Sun, R; Rettig, MB			Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappa B and JNK/AP1 pathways	ONCOGENE			English	Article						KSHV; vFLIP; interleukin-6; NF-kappa B; jun N-terminal kinase; AP1	MULTICENTRIC CASTLEMANS-DISEASE; INTERLEUKIN-6 GENE-EXPRESSION; C-JUN; DNA-SEQUENCES; TERMINAL KINASE; NUCLEAR ANTIGEN; GROWTH-FACTOR; UP-REGULATION; ACTIVATION; HUMAN-HERPESVIRUS-8	The Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a FADD-like interferon converting enzyme or caspase 8 (FLICE) inhibitory protein (vFLIP) that prevents death receptor-mediated apoptosis by inhibiting the recruitment and activation of FLICE. Since vFLIP physically interacts with tumor necrosis factor receptor associated factor 2 (TRAF2) and TRAF2 mediates activation of the jun NH2-terminal kinase (JNK)/activation protein 1 (AP1) pathway, we hypothesized that vFLIP might also activate this pathway. To evaluate this hypothesis, we transiently and stably transfected a vFLIP expression construct and performed several complementary assays to document that vFLIP activates the JNK/AP1 pathway and does so in a TRAF-dependent fashion. As vFLIP also activates the nuclear factor kappaB (NF-kappaB) signaling pathway and the NF-kappaB and JNK/AP1 pathways both modulate cellular interleukin-6 (cIL-6) expression, we postulated that vFLIP induces expression of this cytokine. We show that vFLIP induces cIL-6 expression and activates the cIL-6 promoter, and maximal activation of the cIL-6 promoter by vFLIP requires NF-kappaB and AP1 activation. In addition, vFLIP and latency-associated nuclear antigen (LANA), another KSHV-encoded latent protein, potentiate each other's ability to activate the cIL-6 promoter. Gene silencing experiments by RNA interference demonstrate that vFLIP in BCBL-1 endogenously infected primary effusion lymphoma (PEL) cells mediates JNK/AP1 activation and cIL-6 expression. Thus, we conclude that vFLIP, in addition to its known effects on NF-kappaB activation, also modulates the JNK/AP1 pathway and induces gene expression from the cIL-6 promoter in a JNK/AP1-dependent fashion.	VA Greater Los Angeles Healthcare Syst W LA, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), VA Greater Los Angeles Healthcare Syst W LA, Dept Med, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA.	matthew.rettig@med.va.gov			NCI NIH HHS [1R01CA80004-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2002, BLOOD, V99, P649, DOI 10.1182/blood.V99.2.649; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BLACK EJ, 1991, ONCOGENE, V6, P1949; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Foussat A, 1999, EUR CYTOKINE NETW, V10, P501; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Glykofrydes D, 2000, J VIROL, V74, P11919, DOI 10.1128/JVI.74.24.11919-11927.2000; Grandadam M, 1997, J INFECT DIS, V175, P1198, DOI 10.1086/593567; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Hu SM, 1997, J BIOL CHEM, V272, P9621; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keller SA, 2000, BLOOD, V96, P2537; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Panyutich EA, 1998, AIDS, V12, P467, DOI 10.1097/00002030-199805000-00007; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; THORNE M, 1997, NATURE, V386, P517	46	101	105	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3371	3385		10.1038/sj.onc.1206407	http://dx.doi.org/10.1038/sj.onc.1206407			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776188	Bronze			2022-12-28	WOS:000183128500003
J	Medrano, EE				Medrano, EE			Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis	ONCOGENE			English	Article						melanocytes; melanoma; Ski; c-ski; Smad2; Smad3; RB; p21(Waf-1); SnoN	TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; TUMOR SUPPRESSIVE FUNCTIONS; ANAPHASE-PROMOTING COMPLEX; DEATH-ASSOCIATED PROTEINS; PROTOONCOGENE C-SKI; TRANSCRIPTIONAL REPRESSION; SMAD PROTEINS; V-SKI; MALIGNANT-MELANOMA	Transforming growth factor-beta (TGF-beta) has dual and paradoxical functions as a tumor suppressor and promoter of tumor progression and metastasis. TGF-beta-mediated growth inhibition is gradually lost during melanoma tumor progression, but there are no measurable defects at the receptor level. Furthermore, melanoma cells release high levels of TGF-beta to the microenvironment, which upon activation induces matrix deposition, angiogenesis, survival, and transition to more aggressive phenotypes. The SKI and SnoN protein family associate with and repress the activity of Smad2, Smad3, and Smad4, three members of the TGF-beta signaling pathway. SKI also facilitates cell-cycle progression by targeting the RB pathway by at least two ways: it directly associates with RB and represses its activity when expressed at high levels, and indirectly, it represses Smad-mediated induction of p21(Waf-1). This results in increased CDK2 activity, RB phosphorylation, and inactivation. Therefore, high levels of SKI result in lesions to the RB pathway in a manner similar to p16(INK4a) loss. SKI mRNA and protein levels dramatically increase during human melanoma tumor progression. In addition, the SKI protein shifts from nuclear localization in intraepidermal melanoma cells to nuclear and cytoplasmic in invasive and metastatic melanomas. Here, I discuss the basis for repression of intracellular TGF-beta signaling by SKI, some additional activities of this protein, and propose that by disrupting multiple tumor suppressor pathways, SKI functions as a melanoma oncogene.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Medrano, EE (corresponding author), Baylor Coll Med, Huffington Ctr Aging, 1 Baylor Plaza M320, Houston, TX 77030 USA.							Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Amaravadi LS, 1997, DEV BIOL, V192, P392, DOI 10.1006/dbio.1997.8780; [Anonymous], GENOME BIOL; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; BARKAS A, 1986, THESIS NEW YORK U NE; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Berking C, 2001, CANCER RES, V61, P8306; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Cohen SB, 1999, NUCLEIC ACIDS RES, V27, P1006, DOI 10.1093/nar/27.4.1006; Colmenares C, 2002, NAT GENET, V30, P106, DOI 10.1038/ng770; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Ichikawa K, 1997, BIOCHEM J, V328, P607, DOI 10.1042/bj3280607; JANG CW, 2001, NAT CELL BIOL; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaufman CD, 2000, MECH DEVELOP, V95, P147, DOI 10.1016/S0925-4773(00)00351-8; Kelder B, 1997, GENE, V202, P15, DOI 10.1016/S0378-1119(97)00439-3; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Krasagakis K, 1999, J CELL PHYSIOL, V178, P179, DOI 10.1002/(SICI)1097-4652(199902)178:2<179::AID-JCP7>3.0.CO;2-5; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; LYONS GE, 1994, DEV DYNAM, V201, P354, DOI 10.1002/aja.1002010407; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; NAMCIU S, 1994, ONCOGENE, V9, P1407; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; REED JA, 1994, AM J PATHOL, V145, P97; Reed JA, 2001, CANCER RES, V61, P8074; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RODECK U, 1994, CANCER RES, V54, P575; Rooke HM, 2001, PATHOLOGY, V33, P73; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; SOBBALLE PW, 1994, MELANOMA RES, V4, P213; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stone JG, 1997, J CELL SCI, V110, P1673; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Tietze MK, 2000, MOL MED TODAY, V6, P408, DOI 10.1016/S1357-4310(00)01781-0; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wong SF, 2001, PATHOLOGY, V33, P85; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	82	73	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3123	3129		10.1038/sj.onc.1206452	http://dx.doi.org/10.1038/sj.onc.1206452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12793438				2022-12-28	WOS:000183096600014
J	Mollaaghababa, R; Pavan, WJ				Mollaaghababa, R; Pavan, WJ			The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia	ONCOGENE			English	Article						SOX10; neural crest; glia; melanocytes; differentiation; transcription factor	TRANSCRIPTION FACTOR SOX10; CENTRAL-NERVOUS-SYSTEM; SRY-RELATED GENE; WAARDENBURG-SYNDROME; HIRSCHSPRUNG-DISEASE; DOMINANT MEGACOLON; MOUSE DEVELOPMENT; STEM-CELLS; EXPRESSION; FAMILY	SOX10(+) is a member of the high-mobility group-domain SOX family of transcription factors, which are ubiquitously found in the animal kingdom. Disruption of neural crest development in the Dominant megacolon (Dom) mice is associated with a Sox10 mutation. Mutations in human Sox10(+) gene have also been linked with the occurrence of neurocristopathies in the Waardenburg-Shah syndrome type IV (WS-IV), for which the Sox10(Dom) mice serve as a murine model. The neural crest disorders in the Sox10(Dom) mice and WS-IV patients consist of hypopigmentation, cochlear neurosensory deafness, and enteric aganglionosis. Consistent with these observations, a critical role for SOX10 in the proper differentiation of neural crest-derived melanocytes and glia has been demonstrated. Emerging data also show an important role for SOX10 in promoting the survival of neural crest precursor cells prior to lineage commitment. Several genes whose regulation is dependent on SOX10 function have been identified in the peripheral nervous system and in melanocytes, helping to begin the identification of the multiple pathways that appear to be modulated by SOX10 activity. In this review, we will discuss the biological relevance of these target genes to neural crest development and the properties of Sox10 as a transcription factor.	NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Pavan, WJ (corresponding author), NHGRI, NIH, 49 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000070, ZIAHG000136, ZIAHG000070, Z01HG000136] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; BADNER JA, 1990, AM J MED GENET, V35, P100, DOI 10.1002/ajmg.1320350119; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bondurand N, 1999, HUM MOL GENET, V8, P1785, DOI 10.1093/hmg/8.9.1785; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Bondurand N, 1998, FEBS LETT, V432, P168, DOI 10.1016/S0014-5793(98)00843-6; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Cheng YC, 2000, DEV BRAIN RES, V121, P233, DOI 10.1016/S0165-3806(00)00049-3; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Dutton KA, 2001, DEVELOPMENT, V128, P4113; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; Goding CR, 2000, GENE DEV, V14, P1712; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Inoue K, 1999, ANN NEUROL, V46, P313, DOI 10.1002/1531-8249(199909)46:3<313::AID-ANA6>3.0.CO;2-7; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kapur RP, 1996, DEV BIOL, V174, P360, DOI 10.1006/dbio.1996.0080; Kapur RP, 1999, PEDIATR DEVEL PATHOL, V2, P559, DOI 10.1007/s100249900162; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Korsch E, 2001, EUR J PEDIATR, V160, P68, DOI 10.1007/s004310000624; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LaBonne C, 1998, J NEUROBIOL, V36, P175, DOI 10.1002/(SICI)1097-4695(199808)36:2<175::AID-NEU6>3.0.CO;2-Z; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Le Douarin NM, 1999, NEURAL CREST, V2; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Liu Q, 1999, J NEUROSCI, V19, P9747; Loftus SK, 1999, P NATL ACAD SCI USA, V96, P9277, DOI 10.1073/pnas.96.16.9277; Loh SHY, 2000, MECH DEVELOP, V93, P185, DOI 10.1016/S0925-4773(00)00258-6; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; Melnikova IN, 2000, EUR J PHARMACOL, V393, P75, DOI 10.1016/S0014-2999(99)00884-5; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Meyer J, 1996, CYTOGENET CELL GENET, V72, P246, DOI 10.1159/000134200; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; Paratore C, 2001, DEVELOPMENT, V128, P3949; Parisi MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 2000, ANN NEUROL, V48, P671, DOI 10.1002/1531-8249(200010)48:4<671::AID-ANA17>3.3.CO;2-#; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Potterf SB, 2001, DEV BIOL, V237, P245, DOI 10.1006/dbio.2001.0372; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; Pusch C, 1998, HUM GENET, V103, P115, DOI 10.1007/s004390050793; Read AP, 2000, ADV OTO-RHINO-LARYNG, V56, P32; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Scherer SS, 1995, J NEUROSCI, V15, P8281; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Shah NM, 1997, P NATL ACAD SCI USA, V94, P11369, DOI 10.1073/pnas.94.21.11369; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Sham MH, 2001, J MED GENET, V38, DOI 10.1136/jmg.38.9.e30; Sham MH, 2001, GUT, V49, P220, DOI 10.1136/gut.49.2.220; Sonnenberg-Riethmacher E, 2001, MECH DEVELOP, V109, P253, DOI 10.1016/S0925-4773(01)00547-0; Southard-Smith EM, 1999, MAMM GENOME, V10, P744, DOI 10.1007/s003359901083; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Southard-Smith EM, 1999, GENOME RES, V9, P215; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; SUTER U, 1995, ANNU REV NEUROSCI, V18, P45, DOI 10.1146/annurev.ne.18.030195.000401; Touraine RL, 2000, AM J HUM GENET, V66, P1496, DOI 10.1086/302895; Uchikawa M, 1999, MECH DEVELOP, V84, P103, DOI 10.1016/S0925-4773(99)00083-0; VANDEWETERING M, 1993, NUCLEIC ACIDS RES, V21, P1669, DOI 10.1093/nar/21.7.1669; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe K, 2000, MOL BRAIN RES, V84, P141, DOI 10.1016/S0169-328X(00)00236-9; Watanabe KI, 2002, PIGM CELL RES, V15, P201, DOI 10.1034/j.1600-0749.2002.01080.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	87	159	166	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3024	3034		10.1038/sj.onc.1206442	http://dx.doi.org/10.1038/sj.onc.1206442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789277				2022-12-28	WOS:000183096600002
J	Soengas, MS; Lowe, SW				Soengas, MS; Lowe, SW			Apoptosis and melanoma chemoresistance	ONCOGENE			English	Review						skin cancer; drug resistance; apoptosis; cancer therapy; chemotherapeutic targets	NF-KAPPA-B; HUMAN METASTATIC MELANOMA; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; WILD-TYPE P53; DIFFERENTIATION-ASSOCIATED GENE-7; SMALL-MOLECULE INHIBITORS; PROTEIN-KINASE-B; MALIGNANT-MELANOMA; IN-VIVO	Melanoma is the most aggressive form of skin cancer and is notoriously resistant to all current modalities of cancer therapy. A large set of genetic, functional and biochemical studies suggest that melanoma cells become 'bullet proof' against a variety of chemotherapeutic drugs by exploiting their intrinsic resistance to apoptosis and by reprogramming their proliferation and survival pathways during melanoma progression. In recent years, the identification of molecules involved in the regulation and execution of apoptosis, and their alteration in melanoma, have provided new insights into the molecular basis for melanoma chemoresistance. With this knowledge in hand, the challenge is now to devise strategies potent enough to compensate or bypass these cell death defects and improve the actual poor prognosis of patients at late stages of the disease.	Univ Michigan, Ctr Comprehens Canc, Dept Dermatol, Melanoma Program, Ann Arbor, MI USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Michigan System; University of Michigan; Cold Spring Harbor Laboratory	Soengas, MS (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Dermatol, Melanoma Program, Ann Arbor, MI USA.	soengas@umich.edu	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ATKINS MB, 2002, ASCO ED BOOK, P175; Aviles A, 2002, EUR J HAEMATOL, V68, P144, DOI 10.1034/j.1600-0609.2002.01542.x; Bakker TR, 1999, INT J CANCER, V80, P320; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Bennett DC, 2002, PIGM CELL RES, V15, P242, DOI 10.1034/j.1600-0749.2002.02036.x; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Borner C, 1999, MELANOMA RES, V9, P347, DOI 10.1097/00008390-199908000-00002; Brown JM, 1999, CANCER RES, V59, P1391; Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Campain JA, 1995, SOMAT CELL MOLEC GEN, V21, P451, DOI 10.1007/BF02310211; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; CEHAN D, 2002, MOL CELL, V9, P423; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dong YB, 2002, CANCER RES, V62, P1776; Dressel R, 1998, MELANOMA RES, V8, P482, DOI 10.1097/00008390-199812000-00002; Dummer R, 2000, CANCER GENE THER, V7, P1069, DOI 10.1038/sj.cgt.7700214; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Guldberg P, 1997, CANCER RES, V57, P3660; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Haake A R, 1998, J Investig Dermatol Symp Proc, V3, P28; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1997, CANCER RES, V57, P362; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; Kawaguchi Y, 2001, J INVEST DERMATOL, V116, P920, DOI 10.1046/j.0022-202x.2001.01370.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khayat D, 2002, J CLIN ONCOL, V20, P2411, DOI 10.1200/JCO.2002.20.10.2411; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Klatzmann D, 1998, HUM GENE THER, V9, P2585, DOI 10.1089/hum.1998.9.17-2585; Korabiowska M, 2000, MELANOMA RES, V10, P537, DOI 10.1097/00008390-200012000-00005; Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109; Kramer DL, 1999, CANCER RES, V59, P1278; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Lage H, 2000, BRIT J CANCER, V82, P488, DOI 10.1054/bjoc.1999.0947; Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li G, 2001, CANCER RES, V61, P3819; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; McNulty SE, 2001, PIGM CELL RES, V14, P456, DOI 10.1034/j.1600-0749.2001.140606.x; Megahed M, 2002, LANCET, V359, P1921, DOI 10.1016/S0140-6736(02)08741-X; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Meyskens FL, 1999, CLIN CANCER RES, V5, P1197; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miller LK, 1997, J CELL PHYSIOL, V173, P178, DOI 10.1002/(SICI)1097-4652(199711)173:2<178::AID-JCP17>3.3.CO;2-Z; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Niu GL, 1999, CANCER RES, V59, P5059; Ohta Y, 1996, J INVEST DERMATOL, V106, P275, DOI 10.1111/1523-1747.ep12340688; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Park KC, 2000, ARCH DERMATOL RES, V292, P482, DOI 10.1007/s004030000173; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pennati M, 2002, J CLIN INVEST, V109, P285; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Putney SD, 1999, ANTISENSE NUCLEIC A, V9, P451, DOI 10.1089/oli.1.1999.9.451; Rass K, 2001, HISTOCHEM J, V33, P459, DOI 10.1023/A:1014472314354; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Reed JC, 2000, CURR OPIN BIOTECH, V11, P586, DOI 10.1016/S0958-1669(00)00148-8; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; Rieber M, 1998, DNA CELL BIOL, V17, P399, DOI 10.1089/dna.1998.17.399; Rieber M, 1998, INT J CANCER, V76, P757, DOI 10.1002/(SICI)1097-0215(19980529)76:5<757::AID-IJC22>3.3.CO;2-F; Rieber MS, 2001, CLIN CANCER RES, V7, P1446; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Satherley K, 2000, J PATHOL, V192, P174, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH677>3.0.CO;2-H; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; Satyamoorthy K, 2000, PIGM CELL RES, V13, P87, DOI 10.1034/j.1600-0749.13.s8.16.x; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Sauter ER, 2002, CANCER GENE THER, V9, P807, DOI 10.1038/sj.cgt.7700492; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Serrone L, 2000, J EXP CLIN CANC RES, V19, P21; Sikic Branimir I., 1997, P667; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sotomayor Maria G, 2002, Cancer Control, V9, P39; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; STAUNTON MJ, 1995, AM J CLIN PATHOL, V103, P300, DOI 10.1093/ajcp/103.3.300; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; te Poele RH, 2002, CANCER RES, V62, P1876; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRON VA, 1995, AM J PATHOL, V146, P643; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Ugurel S, 1999, INT J CANCER, V82, P727, DOI 10.1002/(SICI)1097-0215(19990827)82:5<727::AID-IJC17>3.0.CO;2-E; Vijuk G, 1998, ANN ONCOL, V9, P419, DOI 10.1023/A:1008201931959; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Waldmann V, 2002, MELANOMA RES, V12, P45, DOI 10.1097/00008390-200202000-00007; Waldmann V, 2001, ARCH DERMATOL RES, V293, P368, DOI 10.1007/s004030100236; Wang XD, 2001, GENE DEV, V15, P2922; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Wellbrock C, 1999, EXP CELL RES, V251, P340, DOI 10.1006/excr.1999.4580; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Withoff S, 1996, ANTICANCER RES, V16, P1867; Wolchok JD, 2001, LANCET ONCOL, V2, P205, DOI 10.1016/S1470-2045(00)00290-4; Yamamura K, 1996, CANCER RES, V56, P3546; Yang JM, 2001, CANCER RES, V61, P4901; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Zalaudek I, 2002, LANCET, V359, P1999, DOI 10.1016/S0140-6736(02)08834-7; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143; Zhang K, 1998, INT J ONCOL, V12, P871; Zhang XD, 1999, CANCER RES, V59, P2747; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	182	656	681	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3138	3151		10.1038/sj.onc.1206454	http://dx.doi.org/10.1038/sj.onc.1206454			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789290				2022-12-28	WOS:000183096600016
J	Iizuka, N; Oka, M; Yamada-Okabe, H; Mori, N; Tamesa, T; Okada, T; Takemoto, N; Hashimoto, K; Tangoku, A; Hamada, K; Nakayama, H; Miyamoto, T; Uchimura, S; Hamamoto, Y				Iizuka, N; Oka, M; Yamada-Okabe, H; Mori, N; Tamesa, T; Okada, T; Takemoto, N; Hashimoto, K; Tangoku, A; Hamada, K; Nakayama, H; Miyamoto, T; Uchimura, S; Hamamoto, Y			Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis	ONCOGENE			English	Article						DNA chip; gene expression profiles; HCC; HBV; liver cirrhosis	HEPATITIS-B; CDNA MICROARRAY; CANCER; IDENTIFICATION; APOPTOSIS; PROFILES; CARCINOGENESIS; PROGRESSION; INTERACTS; BINDING	Using oligonucleotide microarray data of 45 hepatocellular carcinoma (HCC) samples, we evaluated gene expression in hepatitis B virus-positive and hepatitis C virus-positive HCCs (HBV- and HCV-HCCs) for an association with liver cirrhosis (LC). In all, 89 genes were expressed differentially between HBV-HCCs associated with LC and those not associated with LC. Among them, tumors from LC patients showed significantly lower expression levels of 72 genes and significantly higher levels of 17 genes than the levels found in tumors from non-LC patients. The former included genes responsible for signal transduction, transcription, metabolism, and cell growth. The latter included a tumor suppressor gene and a cell-growth-related gene. Only eight genes were expressed differentially between HCV-HCCs associated with and without LC. Our findings provide as a framework for clarifying the role of LC in HBV- and HCV-related hepatocarcinogenesis.	Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Bioregulat Funct, Yamaguchi 7558505, Japan; Nippon Roche Res Ctr, Dept Oncol, Kanagawa 2478530, Japan; Yamaguchi Univ, Fac Engn, Dept Comp Sci & Syst Engn, Yamaguchi 7558611, Japan	Yamaguchi University; Yamaguchi University; Roche Holding; Yamaguchi University	Oka, M (corresponding author), Yamaguchi Univ, Sch Med, Dept Surg 2, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.							Bode BP, 1999, JPEN-PARENTER ENTER, V23, pS33, DOI 10.1177/014860719902300509; Delpuech O, 2002, ONCOGENE, V21, P2926, DOI 10.1038/sj.onc.1205392; Goldenberg D, 2002, MOL CARCINOGEN, V33, P113, DOI 10.1002/mc.10027.abs; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Huang CJ, 2000, J BIOMED SCI, V7, P160, DOI 10.1159/000025442; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; IIZUKA N, 1995, CANCER RES, V55, P652; Iizuka N, 2002, INT J CANCER, V99, P286, DOI 10.1002/ijc.10338; Iizuka N, 2002, CANCER RES, V62, P3939; Kao JH, 2000, GASTROENTEROLOGY, V118, P554, DOI 10.1016/S0016-5085(00)70261-7; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kim JS, 2002, CANCER RES, V62, P2744; Koike K, 2002, ONCOLOGY-BASEL, V62, P29, DOI 10.1159/000048273; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lau WY, 2000, ONCOL RES, V12, P59; Luo J, 2001, CANCER RES, V61, P4683; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith TAD, 1999, BRIT J BIOMED SCI, V56, P285; Sobin L, 2002, TNM CLASSIFICATION M, P81; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; Xu L, 2001, CANCER RES, V61, P3176; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398	26	77	86	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					3007	3014		10.1038/sj.onc.1206401	http://dx.doi.org/10.1038/sj.onc.1206401			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771952				2022-12-28	WOS:000182824800016
J	Boya, P; Morales, MC; Gonzalez-Polo, RA; Andreau, K; Gourdier, I; Perfettini, JL; Larochette, N; Deniaud, A; Baran-Marszak, F; Fagard, R; Feuillard, J; Asumendi, A; Raphael, M; Pau, B; Brenner, C; Kroemer, G				Boya, P; Morales, MC; Gonzalez-Polo, RA; Andreau, K; Gourdier, I; Perfettini, JL; Larochette, N; Deniaud, A; Baran-Marszak, F; Fagard, R; Feuillard, J; Asumendi, A; Raphael, M; Pau, B; Brenner, C; Kroemer, G			The chemopreventive agent N-(4-hydroxyphenyl) retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family	ONCOGENE			English	Article						4-hydroxyphenylretinamide; Bax; Bcl-2; cell death; chemoprevention; mitochondria	PERMEABILITY TRANSITION PORE; CERAMIDE-INDUCED APOPTOSIS; CELL-DEATH; ENDOPLASMIC-RETICULUM; CANCER-CELLS; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; LOCALIZED INHIBITOR; GD3 GANGLIOSIDE; KAPPA-B	N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction. 4-HPR induces a loss of the mitochondrial transmembrane potential and the mitochondrial release of cytochrome c before caspase activation. Inhibition of mitochondrial membrane permeabilization (MMP) by transfection with Bcl-2 or the Cytomegalovirus UL37 gene product vMIA prevented caspase activation and cell death. In contrast to other retinoid derivatives, 4-HPR has no direct MMP-inducing effects when added to isolated mitochondria or when added to proteoliposomes containing the MMP-regulatory permeability transition pore complex ( PTPC). Moreover, although reactive oxygen species (ROS) overproduction appears to be instrumental for 4-HPR-induced MMP and apoptosis, inhibition of the NF-kappaB or p53-mediated signal transduction pathways failed to modulate 4-HPR-induced apoptosis. 4-HPR was found to cause an antioxidant-inhibitable conformational change of both Bax and Bak, leading to the exposure of their N- termini and to the mitochondrial relocalization of Bax. Cells with a Bax(-/-) Bak(-/-) genotype were resistant against the 4-HPR-induced MMP, overproduction of ROS and cell death. Altogether, these data indicate that 4-HPR induce s MMP through an ROS-mediated pathway that involves the obligatory contribution of the proapopotic Bcl-2 family members Bax and/or Bak.	Inst Gustave Roussy, CNRS, UMR8125, Villejuif, France; Univ Versailles, CNRS, FRE 2445, F-78000 Versailles, France; CHU Kremlin Bicetre, Serv Hematol Biol, U473, Le Kremlin Bicetre, France; Univ Paris 13, APHP, Hop Avicenne, Biochim Lab, Bobigny, France; Univ Paris 13, EA 3406, Bobigny, France; CHU Dupuytren, Hematol Lab, Limoges, France; Univ Basque Country, Sch Med & Dent, Dept Cell Biol & Histol, Leioa 48940, Bizkaia, Spain; CNRS, UMR 5094, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite Paris 13; CHU Limoges; University of Basque Country; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	LAROCHETTE, Nathanael/R-4298-2017; brenner, catherine/AAE-8632-2020; Boya, Patricia/P-8345-2019; PERFETTINI, Jean-Luc/N-4699-2017; Morales, Maria Celia/AAB-5085-2020; Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; Asumendi, Aintzane/ABF-7001-2021; González-Polo, Rosa A./I-6076-2016; Kroemer, Guido/AAY-9859-2020; Boya, Patricia/K-2911-2014; Feuillard, Jean/O-8587-2016	LAROCHETTE, Nathanael/0000-0002-7936-678X; Boya, Patricia/0000-0003-3045-951X; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Morales, Maria Celia/0000-0001-5423-3684; KROEMER, Guido/0000-0002-9334-4405; González-Polo, Rosa A./0000-0002-0163-2953; Boya, Patricia/0000-0003-3045-951X; Andreau, Karine/0000-0002-9773-0733; Asumendi, Aintzane/0000-0002-2156-2323; Feuillard, Jean/0000-0001-6223-2454				Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levi MS, 2001, CURR MED CHEM, V8, P1349, DOI 10.2174/0929867013372229; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lim SJ, 2002, INT J CANCER, V101, P243, DOI 10.1002/ijc.10596; Lovat PE, 2002, CANCER RES, V62, P5158; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marchetti P, 1999, CANCER RES, V59, P6257; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Raffaghello L, 2003, INT J CANCER, V104, P559, DOI 10.1002/ijc.10991; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaker MR, 2001, CLIN EXP METASTAS, V18, P429, DOI 10.1023/A:1010905309570; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; Singletary SE, 2002, CLIN CANCER RES, V8, P2835; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Wang HT, 2001, CANCER RES, V61, P5102; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zou CP, 2002, CANCER LETT, V180, P131, DOI 10.1016/S0304-3835(01)00864-3	65	80	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6220	6230		10.1038/sj.onc.1206827	http://dx.doi.org/10.1038/sj.onc.1206827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679861				2022-12-28	WOS:000185506200012
J	Usami, N; Sekido, Y; Maeda, O; Yamamoto, K; Minna, JD; Hasegawa, Y; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K				Usami, N; Sekido, Y; Maeda, O; Yamamoto, K; Minna, JD; Hasegawa, Y; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K			beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion	ONCOGENE			English	Article						beta-catenin; malignant mesothelioma; chromosome 3; homozygous deletion	HUMAN LUNG-CANCER; HEPATOCELLULAR CARCINOMAS; EPIGENETIC INACTIVATION; ALLELIC LOSS; GENE; ACTIVATION; MUTATIONS; SITES; APOPTOSIS; MULTIPLE	We have found that a malignant mesothelioma cell line, NCI-H28, had a chromosome 3p21.3 homozygous deletion containing the beta-catenin gene (CTNNB1), which suggested that the deletion of beta-catenin might have a growth advantage in the development of this tumor. To determine whether beta-catenin has a growth-inhibitory activity, we transfected wild-type beta-catenin, Ser37Cys mutant beta-catenin as an activated type, and C-terminus deletion mutant beta-catenin that lacks the transcription activity, into the NCI-H28 cells. A non-small cell lung cancer cell line, NCI-H1299, which expressed endogenous beta-catenin, was also studied. We tested the localization of exogenous beta-catenin in the NCI-H28 cells with immunofluorescence, and found that the wild-type beta-catenin and the C-terminus deletion mutant were more strongly expressed in the plasma membrane and cytoplasm than in the nucleus, while the Ser37Cys mutant was more in the nucleus than in the cytoplasm. By using luciferase-reporter assay, the beta-catenin/T-cell factor 4-mediated transactivity of the Ser37Cys mutant was shown to be higher than that of the wild-type beta-catenin in both cell lines. However, the transactivity of the C-terminus deletion mutant was strongly reduced in both. Colony formation of the NCI-H28 cells was reduced by 50% after transfection with the wild-type beta-catenin, and 60% with the Ser37Cys mutant, but only 20% with the C-terminus deletion mutant compared to the vector control. Inhibition of colony formation in NCI-H28 cells was because of apoptosis, manifested by positive staining of Annexin V and TUNEL assays in transfected cells. In contrast, when transfected with the wild-type beta-catenin, no significant reduction in colony formation was seen in beta-catenin wildtype NCI-H1299 cells. In conclusion, our data indicate that inactivation of beta-catenin by a 3p21.3 homozygous deletion might be a crucial event in the development of the mesothelioma NCI-H28 cells. Thus, while beta-catenin is well known to be a positive growth-stimulating factor for many human cancers, it can also act as a potential growth suppressor in some types of human cancer cells.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol 2, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	Nagoya University; Nagoya University; Nagoya University; Nagoya University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.	ysekido@med.nagoya-u.ac.jp	Hasegawa, Yoshinori/I-1277-2012; Takahashi, Masahide/AAN-4770-2020; Sekido, Yoshitaka/P-9756-2015; Maeda, Osamu/Q-1016-2015; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Maeda, Osamu/0000-0003-4700-6541; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bell DW, 1997, CANCER RES, V57, P4057; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CHEN JY, 1993, ONCOGENE, V8, P2159; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; Fukuchi T, 1998, CANCER RES, V58, P3526; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hasegawa S, 2002, P NATL ACAD SCI USA, V99, P297, DOI 10.1073/pnas.012264999; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Iwao K, 1998, CANCER RES, V58, P1021; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee WC, 1996, CANCER RES, V56, P4297; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; POPESCU NC, 1988, CANCER RES, V48, P142; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; TAGUCHI T, 1993, CANCER RES, V53, P4349; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TIAINEN M, 1988, CANCER GENET CYTOGEN, V33, P251, DOI 10.1016/0165-4608(88)90035-0; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Wistuba II, 2000, CANCER RES, V60, P1949; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	44	24	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7922	7930		10.1038/sj.onc.1206533	http://dx.doi.org/10.1038/sj.onc.1206533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970740				2022-12-28	WOS:000185388200007
J	Kain, KH; Gooch, S; Klemke, RL				Kain, KH; Gooch, S; Klemke, RL			Cytoplasmic c-Abl provides a molecular 'rheostat' controlling carcinoma cell survival and invasion	ONCOGENE			English	Article						c-Abl kinase; Crk; invasion; survival; metastasis	FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; ADAPTER PROTEIN; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCED ACTIVATION; FACTOR RECEPTOR; F-ACTIN; IN-VIVO	Tumor cell metastasis involves the coordinated activation of migration and survival mechanisms necessary for cell invasion of foreign tissues. Here, we report that cytoplasmic c-Abl tyrosine kinase determines whether a cell invades the ECM or commits suicide. c-Abl phosphorylates the cytoskeleton-associated adaptor protein, Crk, at tyrosine 221, causing disassociation of Crk from the Crk-associated substrate (CAS) and disassembly of Crk/CAS complexes. c-Abl-induced disruption of Crk/CAS complexes inhibits cell migration and promotes apoptosis in normal cells, and is deregulated in highly invasive carcinoma cells. c-Abl-mediated disassembly of Crk/CAS complexes and induction of death occur via disruption of the cytoskeleton, which is distinct from nuclear c-Abl-induced apoptosis in response to DNA-damaging agents. Inhibition of c-Abl kinase activity or Crk binding to Abl's polyproline region prevents Crk phosphorylation and apoptosis, leading to increased cell survival and invasion of the extracellular matrix. Together, these data illustrate that c-Abl prevents aberrant motility and survival through Crk 221 phosphorylation and modulation of Crk/CAS complexes, and that deregulation of this pathway contributes to cell metastasis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,SP 231, La Jolla, CA 92037 USA.	klemke@scripps.edu			NATIONAL CANCER INSTITUTE [R29CA078493, R01CA097022] Funding Source: NIH RePORTER; NCI NIH HHS [CA97022, CA78493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gong JG, 1999, NATURE, V399, P806; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith JM, 2002, FRONT BIOSCI, V7, pD31; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang BL, 1996, ONCOGENE, V13, P1379; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	52	38	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6071	6080		10.1038/sj.onc.1206930	http://dx.doi.org/10.1038/sj.onc.1206930			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955086				2022-12-28	WOS:000185137800016
J	Iliakis, G; Wang, Y; Guan, J; Wang, HC				Iliakis, G; Wang, Y; Guan, J; Wang, HC			DNA damage checkpoint control in cells exposed to ionizing radiation	ONCOGENE			English	Review						checkpoints; DNA repair; DNA double-strand breaks; ionizing radiation	DEPENDENT PROTEIN-KINASE; S-PHASE CHECKPOINT; DOUBLE-STRAND BREAKS; TELANGIECTASIA GENE-PRODUCT; POLO-LIKE KINASE-1; HUMAN CYCLIN-A; ATAXIA-TELANGIECTASIA; HOMOLOGOUS RECOMBINATION; INDUCED PHOSPHORYLATION; FISSION YEAST	Damage induced in the DNA after exposure of cells to ionizing radiation activates checkpoint pathways that inhibit progression of cells through the G1 and G2 phases and induce a transient delay in the progression through S phase. Checkpoints together with repair and apoptosis are integrated in a circuitry that determines the ultimate response of a cell to DNA damage. Checkpoint activation typically requires sensors and mediators of DNA damage, signal transducers and effectors. Here, we review the current state of knowledge regarding mechanisms of checkpoint activation and proteins involved in the different steps of the process. Emphasis is placed on the role of ATM and ATR, as well on CHK1 and CHK2 kinases in checkpoint response. The roles of downstream effectors, such as P53 and the CDC25 family of proteins, are also described, and connections between repair and checkpoint activation are attempted. The role of checkpoints in genomic stability and the potential of improving the treatment of cancer by DNA damage inducing agents through checkpoint abrogation are also briefly outlined.	Univ Essen Med Sch, Inst Med Radiat Biol, D-45122 Essen, Germany; Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of Duisburg Essen; Jefferson University	Iliakis, G (corresponding author), Univ Essen Med Sch, Inst Med Radiat Biol, Hufelanstr 55, D-45122 Essen, Germany.	Georg.Iliakis@uni-essen.de			NCI NIH HHS [2P01 CA56690, CA42026, CA56706, CA76203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056690, R29CA076203, R01CA056706, R01CA042026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bernhard EJ, 1999, CANCER J SCI AM, V5, P194; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2000, GENE DEV, V14, P397; BRUSH GS, 1996, MECH REPLICATION DNA; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; DeSimone JN, 2003, RADIAT RES, V159, P72, DOI 10.1667/0033-7587(2003)159[0072:COTMOI]2.0.CO;2; Dibiase SJ, 2000, CANCER RES, V60, P1245; Donaldson AD, 2001, CURR BIOL, V11, pR979, DOI 10.1016/S0960-9822(01)00579-6; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; EISENMAN RN, 1995, NATURE, V378, P438, DOI 10.1038/378438a0; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Guo CY, 1999, RADIAT RES, V151, P125, DOI 10.2307/3579762; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARPER JW, 1993, CELL, V75, P805; Harris EER, 1998, CANC TREAT, V93, P169; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HWANG A, 1995, J BIOL CHEM, V270, P28419; Iliakis G, 1997, SEMIN ONCOL, V24, P602; ILIAKIS G, 1988, INT J RADIAT BIOL, V53, P541, DOI 10.1080/09553008814550901; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kao GD, 1999, J BIOL CHEM, V274, P34779, DOI 10.1074/jbc.274.49.34779; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Larner JM, 1997, CANCER SURV, V29, P25; Larson JS, 1997, CANCER RES, V57, P3351; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; LUCKEHUHLE C, 1982, RADIAT RES, V89, P298, DOI 10.2307/3575776; Lukas C, 2001, CANCER RES, V61, P4990; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Maity A, 1996, ONCOGENE, V13, P1647; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1995, 37 ANN M AM SOC THER; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; METZGER L, 1991, INT J RADIAT BIOL, V59, P1325, DOI 10.1080/09553009114551201; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Paciotti V, 2000, GENE DEV, V14, P2046; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; POWELL SN, 1995, CANCER RES, V55, P1643; Rhind N, 2000, J CELL SCI, V113, P3889; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Sampath D, 2001, CURR OPIN ONCOL, V13, P484, DOI 10.1097/00001622-200111000-00011; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sillje HHW, 2003, SCIENCE, V299, P1190; SMEETS MFMA, 1994, RADIAT RES, V140, P153, DOI 10.2307/3578897; Smith A, 2001, J ASSOC PERS SEVERE, V26, P180, DOI 10.2511/rpsd.26.3.180; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; SU LN, 1993, RADIAT RES, V133, P73, DOI 10.2307/3578259; Suganuma M, 1999, CANCER RES, V59, P5887; Takai H, 2000, GENE DEV, V14, P1439; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang HC, 2003, RADIAT RES, V159, P420, DOI 10.1667/0033-7587(2003)159[0420:CCNESH]2.0.CO;2; Wang HC, 2001, CANCER RES, V61, P270; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; WANG X, 2003, IN PRESS RAD RES; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Wang Y, 2000, GENE DEV, V14, P927; WANG Y, 1995, RADIAT RES, V142, P169, DOI 10.2307/3579025; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, CANCER RES, V62, P1598; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	230	378	407	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5834	5847		10.1038/sj.onc.1206682	http://dx.doi.org/10.1038/sj.onc.1206682			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947390				2022-12-28	WOS:000185086100010
J	Galderisi, U; Jori, FP; Giordano, A				Galderisi, U; Jori, FP; Giordano, A			Cell cycle regulation and neural differentiation	ONCOGENE			English	Review						neurogenesis; cyclin-dependent kinases; cyclin kinase inhibitors; Rb family; p53; N-Myc	LOOP-HELIX PROTEINS; RETINOBLASTOMA FAMILY PROTEINS; KINASE INHIBITOR P27(KIP1); BRAIN-SPECIFIC ACTIVATOR; N-MYC GENE; NEURONAL DIFFERENTIATION; TUMOR-SUPPRESSOR; NERVOUS-SYSTEM; DEPENDENT KINASE-5; MICE LACKING	The general mechanisms that control the cell cycle in mammalian cells have been studied in depth and several proteins that are involved in the tight regulation of cell cycle progression have been identified. However, the analysis of which molecules participate in cell cycle exit of specific cell lineages is not exhaustive yet. Moreover, the strict relation between cell cycle exit and induction of differentiation has not been fully understood and seems to depend on the cell type. Several in vivo and in vitro studies have been performed in the last few years to address these issues in cells of the nervous system. In this review, we focus our attention on cyclin-cyclin-dependent kinase complexes, cyclin kinase inhibitors, genes of the retinoblastoma family, p53 and N-Myc, and we aim to summarize the latest evidence indicating their involvement in the control of the cell cycle and induction of differentiation in different cell types of the peripheral and central nervous systems. Studies on nervous system tumors and a possible contributory role in tumorigenesis of polyomavirus T antigen are reported to point out the critical contribution of some cell cycle regulators to normal neural and glial development.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; Univ Naples 2, Dept Expt Med, Sect Biotechnol & Mol Biol, Sch Med, Naples, Italy; Univ Naples 2, Dept Neurol Sci, Sch Med, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	Giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; GALDERISI, Umberto/0000-0003-0909-7403				Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BAYER SA, 1991, J COMP NEUROL, V307, P499, DOI 10.1002/cne.903070312; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; Coskun V, 2001, J NEUROSCI, V21, P3092, DOI 10.1523/JNEUROSCI.21-09-03092.2001; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Del Valle L, 2002, NEUROLOGY, V58, P895, DOI 10.1212/WNL.58.6.895; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Flaegstad T, 1999, CANCER RES, V59, P1160; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloster A, 1999, J COMP NEUROL, V405, P45, DOI 10.1002/(SICI)1096-9861(19990301)405:1<45::AID-CNE4>3.0.CO;2-M; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Gordon J, 1998, DEV BIOL STAND, V94, P93; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYES TE, 1991, NEW BIOL, V3, P259; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; Horsfield J, 1998, DEVELOPMENT, V125, P5069; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jori FP, 2001, BIOCHEM J, V360, P569, DOI 10.1042/0264-6021:3600569; Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Norton JD, 2000, J CELL SCI, V113, P3897; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Piette J, 1997, EXP CELL RES, V234, P193, DOI 10.1006/excr.1997.3588; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Puduvalli VK, 2000, INT J ONCOL, V17, P963; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Rathore A, 1999, Pathol Oncol Res, V5, P21, DOI 10.1053/paor.1999.0021; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Schwab MH, 2000, J NEUROSCI, V20, P3714, DOI 10.1523/JNEUROSCI.20-10-03714.2000; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Stiegler P, 1998, J CELL BIOCHEM, P30; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAMARU T, 1993, NEUROSCI LETT, V153, P169, DOI 10.1016/0304-3940(93)90314-B; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tikoo R, 1997, J BIOL CHEM, V272, P442; Tokumoto YM, 2001, EMBO J, V20, P5261, DOI 10.1093/emboj/20.18.5261; Toma JG, 2000, J NEUROSCI, V20, P7648; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ueki K, 1996, CANCER RES, V56, P150; vanGrunsven LA, 1996, ONCOGENE, V12, P855; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	127	192	210	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5208	5219		10.1038/sj.onc.1206558	http://dx.doi.org/10.1038/sj.onc.1206558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910258				2022-12-28	WOS:000184615100012
J	Casteran, N; De Sepulveda, P; Beslu, N; Aoubala, M; Letard, S; Lecocq, E; Rottapel, R; Dubreuil, P				Casteran, N; De Sepulveda, P; Beslu, N; Aoubala, M; Letard, S; Lecocq, E; Rottapel, R; Dubreuil, P			Signal transduction by several KIT juxtamembrane domain mutations	ONCOGENE			English	Article						receptor; mutation; STI571; GIST	RECEPTOR TYROSINE KINASE; ACUTE MYELOID-LEUKEMIA; PROTOONCOGENE C-KIT; CELL LUNG-CANCER; CONSTITUTIVELY ACTIVATING MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; LIGAND-INDEPENDENT ACTIVATION; MAST-CELLS; CATALYTIC DOMAIN; POINT MUTATION	Mutations of KIT receptor tyrosine kinase are found in the majority of patients with mastocytosis and in most gastrointestinal stromal tumors. Oncogenic KIT mutations in GISTs are located in the KIT juxtamembrane domain (JMD), while codon 816 in the KIT kinase domain is mutated in systemic mastocytosis. We describe and characterize a mutation in the KIT-JMD named KDelta27. We show that KDelta27 mutant is constitutively dimerized and phosphorylated. KDelta27 ectopic expression renders both the Ba/F3 cell line and primary cultures of bone marrow mast cells independent of cytokines for proliferation and cell survival. The classical signaling pathways activated by wild-type KIT upon ligand stimulation are constitutively activated by KDelta27 and other JMD mutations. However, a side-to-side comparison revealed differences between the wild-type and JMD mutations. First, in vitro kinase assays reveal a change in peptide substrate specificity. Second, STAT proteins are preferentially phosphorylated by KIT mutants. Third, inhibitors of KIT kinase are more efficient on JMD mutations than on WT KIT. We conclude that KDelta27 is a new oncogenic KIT mutation showing constitutive activation of downstream signaling pathways, and suggest that specific pathways are activated by oncogenic KIT.	INSERM, U119, Mol & Funct Hematopoiesis Lab, F-13009 Marseille, France; Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; University Health Network Toronto	De Sepulveda, P (corresponding author), INSERM, U119, Mol & Funct Hematopoiesis Lab, 27 Bd Lei Roure, F-13009 Marseille, France.		De sepulveda, paulo/K-6043-2015; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	De sepulveda, paulo/0000-0001-8295-5414; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; LETARD, Sebastien/0000-0002-6508-7376; Rottapel, Robert/0000-0002-6024-5558				Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beghini A, 1998, BLOOD CELL MOL DIS, V24, P262, DOI 10.1006/bcmd.1998.0191; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Casteran N, 1998, LEUKEMIA, V12, P1089, DOI 10.1038/sj.leu.2401057; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; DASTYCH J, 1994, J IMMUNOL, V152, P213; Frost MJ, 2002, MOL CANCER THER, V1, P1115; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HERBST R, 1995, ONCOGENE, V10, P369; HIBI K, 1991, ONCOGENE, V6, P2291; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; KINASHI T, 1994, BLOOD, V83, P1033; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1997, CANCER RES, V57, P2203; Leslie NR, 1998, BLOOD, V92, P4798, DOI 10.1182/blood.V92.12.4798.424k12_4798_4807; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; London CA, 1999, EXP HEMATOL, V27, P689, DOI 10.1016/S0301-472X(98)00075-7; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Ma YS, 1999, J INVEST DERMATOL, V112, P165, DOI 10.1046/j.1523-1747.1999.00488.x; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakao M, 1996, LEUKEMIA, V10, P1911; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sperr WR, 1998, BRIT J HAEMATOL, V103, P740; Taniguchi M, 1999, CANCER RES, V59, P4297; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; TSUJIMURA T, 1994, BLOOD, V83, P2619; Tsujimura T, 1996, BLOOD, V87, P273; Tsujimura Tohru, 1997, Leukemia (Basingstoke), V11, P396; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	53	61	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4710	4722		10.1038/sj.onc.1206587	http://dx.doi.org/10.1038/sj.onc.1206587			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879016				2022-12-28	WOS:000184157000012
J	Jansson, AK; Emterling, AM; Arbman, G; Sun, XF				Jansson, AK; Emterling, AM; Arbman, G; Sun, XF			Noxa in colorectal cancer: a study on DNA, mRNA and protein expression	ONCOGENE			English	Article						Noxa; colorectal cancer; DNA sequencing; real-time PCR; immunohistochemistry	P53-DEPENDENT APOPTOSIS; BAX; P53; TRANSFORMATION; MUTATIONS; MEDIATOR; DEATH; CELLS; TUMOR; PUMA	Noxa is a BH3-only member of the Bcl-2 family, upregulated by p53 as a response to DNA damage. Mutations in the BH3-only region of other BH3-only members lead to an inactive protein. We have investigated the mRNA expression of Noxa with real-time PCR in 94 unselected colorectal adenocarcinomas and the corresponding normal mucosa. Among them, Noxa protein expression was investigated with immunohistochemistry in 16 tumors and six corresponding normal mucosa samples. Further, we searched for Noxa mutations in all the cases using single-stranded conformation polymorphism and DNA sequencing. The mRNA expression of Noxa was weak in 9% and strong in 2% of the tumors, and decreased in 9% and increased in 16% of the tumors compared with the normal mucosa; however, these changes did not have any clinical or pathological significance. The protein level in most of the cases investigated was correlated with the mRNA level. We did not find any mutations in the Noxa gene. Thus, we suggest that Noxa may not be of importance in the development of colorectal cancer.	Linkoping Univ, Dept Biomed & Surg, Div Oncol, S-58185 Linkoping, Sweden; Vrinnevi Hosp, Dept Surg, Norrkoping, Sweden	Linkoping University	Jansson, AK (corresponding author), Linkoping Univ, Dept Biomed & Surg, Div Oncol, S-58185 Linkoping, Sweden.	agnja@ibk.liu.se						Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jansson A, 2002, J CLIN ONCOL, V20, P811, DOI 10.1200/JCO.20.3.811; Jansson A, 2001, INT J CANCER, V92, P338, DOI 10.1002/ijc.1189; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Wei MC, 2000, GENE DEV, V14, P2060; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	18	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4675	4678		10.1038/sj.onc.1206655	http://dx.doi.org/10.1038/sj.onc.1206655			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879012				2022-12-28	WOS:000184157000008
J	Takino, T; Koshikawa, N; Miyamori, H; Tanaka, M; Sasaki, T; Okada, Y; Seiki, M; Sato, H				Takino, T; Koshikawa, N; Miyamori, H; Tanaka, M; Sasaki, T; Okada, Y; Seiki, M; Sato, H			Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases	ONCOGENE			English	Article						MMP; KiSS-1; cleavage	PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR; PROMOTES ACTIVATION; EXPRESSION; IDENTIFICATION; INVASION; BINDING; PEPTIDE; CELLS; ALPHA	A human placenta cDNA library was screened by the expression cloning method for gene products that interact with matrix metalloproteinases (MMPs), and we isolated a cDNA whose product formed a stable complex with pro-MMP-2 and pro-MMP-9. The cDNA encoded the metastasis suppressor gene KiSS-1. KiSS-1 protein was shown to form a complex with pro-MMP. KiSS-1 protein is known to be processed to peptide ligand of a G-protein-coupled receptor (hOT7T175) named metastin, and suppresses metastasis of tumors expressing the receptor. Active MMP-2, MMP-9, MT1-MMP, MT3-MMP and MT5-MMP cleaved the Gly(118)-Leu(119) peptide bond of not only full-length KiSS-1 protein but also metastin decapeptide. Metastin decapeptide induced formation of focal adhesion and actin stress fibers in cells expressing the receptor, and digestion of metastin decapeptide by MMP abolished its ligand activity. Migration of HT1080 cells expressing hOT7T175 that harbor a high-level MMP activity was only slightly suppressed by either metastin decapeptide or MMP inhibitor BB-94 alone, but the combination of metastin decapeptide and BB-94 showed a synergistic effect in blocking cell migration. We propose that metastin could be used as an antimetastatic agent in combination with MMP inhibitor, or MMP-resistant forms of metastin could be developed and may also be efficacious.	Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Tokyo 1088639, Japan; Kanazawa Univ, Canc Res Inst, Dept Chemotherapy, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Keio Univ, Sch Med, Dept Pathol, Tokyo 1608582, Japan	Kanazawa University; University of Tokyo; Kanazawa University; Kanazawa University; Keio University	Sato, H (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015; TAKINO, Takahisa/D-8460-2015; Koshikawa, Naohiko/S-7306-2017; Okada, Yasunori/B-5550-2014	Koshikawa, Naohiko/0000-0002-4539-888X; Okada, Yasunori/0000-0001-9208-4755				BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Jaworski DM, 2000, BRAIN RES, V860, P174, DOI 10.1016/S0006-8993(00)02035-7; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Llano E, 1999, CANCER RES, V59, P2570; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Murray MJ, 1999, SEMIN REPROD ENDOCR, V17, P275, DOI 10.1055/s-2007-1016235; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 2001, CANCER RES, V61, P8896; NOMURA H, 1995, CANCER RES, V55, P3263; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shirasaki F, 2001, CANCER RES, V61, P7422; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Ueno H, 1997, CANCER RES, V57, P2055; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Velasco G, 2000, CANCER RES, V60, P877; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200	38	122	140	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4617	4626		10.1038/sj.onc.1206542	http://dx.doi.org/10.1038/sj.onc.1206542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879005	Green Submitted			2022-12-28	WOS:000184157000001
J	Li, YF; Pei, J; Xia, H; Ke, HN; Wang, HY; Tao, WF				Li, YF; Pei, J; Xia, H; Ke, HN; Wang, HY; Tao, WF			Lats2, a putative tumor suppressor, inhibits G1/S transition	ONCOGENE			English	Article						Lats2; tumor suppressor; G1/S transition; cell cycle	PROTEIN-KINASE; HUMAN HOMOLOG; DNA-DAMAGE; CHECKPOINT PATHWAY; DEPENDENT KINASES; MITOTIC APPARATUS; DROSOPHILA LATS; CDK REGULATION; GENE; CANCER	Lats2 is a new member of the Lats tumor suppressor family. The human LATS2 gene is located at chromosome 13q11-12, which has been shown to be a hot spot (67%) for LOH in nonsmall cell lung cancer. In order to understand the function of LATS2 in the control of tumor development, we ectopically expressed mouse Lats2 via retroviral infection in NIH3T3/v-ras cells to examine whether Lats2 plays a role in suppressing tumor development and regulating cell proliferation. We have found that ectopic expression of Lats2 in NIH3T3/nu-ras cells suppresses development of tumors in athymic nude mice and inhibits proliferation of NIH3T3/nu-ras cells in an in vitro assay. Cell cycle profile analysis demonstrated that ectopic expression of Lats2 inhibited the G1/S transition. Further mechanistic studies revealed that cyclin E/CDK2 kinase activity was downregulated in Lats2-transduced NIH3T3/nu-ras cells, while other cell cycle regulators controlling the G1/S transition were not affected. We have also shown that LATS2 kinase activity and two LATS conserved domains (LCDs) are required for Lats2 to suppress tumorigenicity and to inhibit cell growth. In addition, the LATS2 protein is cytoplasmic during interphase in NIH3T3 cells, while it becomes localized to the mitotic apparatus during mitosis. Finally, we propose a model in which a combination of mammalian Lats2 and Lats1 control cell proliferation by negatively regulating different cell cycle check points.	Univ Minnesota, Sch Med, Stem Cell Inst, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Tao, WF (corresponding author), Univ Minnesota, Sch Med, Stem Cell Inst, Div Hematol Oncol & Transplantat, MMC716,420 Delaware St SE, Minneapolis, MN 55455 USA.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Girard L, 2000, CANCER RES, V60, P4894; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morinaga N, 2000, INT J ONCOL, V17, P1125; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	29	161	173	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4398	4405		10.1038/sj.onc.1206603	http://dx.doi.org/10.1038/sj.onc.1206603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853976				2022-12-28	WOS:000183978900009
J	Anastasi, S; Fiorentino, L; Fiorini, M; Fraioli, R; Sala, G; Castellani, L; Alema, S; Alimandi, M; Segatto, O				Anastasi, S; Fiorentino, L; Fiorini, M; Fraioli, R; Sala, G; Castellani, L; Alema, S; Alimandi, M; Segatto, O			Feedback inhibition by RALT controls signal output by the ErbB network	ONCOGENE			English	Article						ErbB; feedback inhibition; Mig-6; negative signaling; RALT	EPIDERMAL-GROWTH-FACTOR; CELL-CYCLE PROGRESSION; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; TYROSINE KINASES; BREAST-CANCER; TRANSCRIPTION FACTORS; RECEPTOR FAMILY; HETERODIMERIZATION; PHOSPHORYLATION	The ErbB-2 interacting protein receptor-associated late transducer (RALT) was previously identified as a feedback inhibitor of ErbB-2 mitogenic signals. We now report that RALT binds to ligand-activated epidermal growth factor receptor (EGFR), ErbB-4 and ErbB-2.ErbB-3 dimers. When ectopically expressed in 32D cells reconstituted with the above ErbB receptor tyrosine kinases (RTKs) RALT behaved as a pan-ErbB inhibitor. Importantly, when tested in either cell proliferation assays or biochemical experiments measuring activation of ERK and AKT, RALT affected the signalling activity of distinct ErbB dimers with different relative potencies. RALT DeltaEBR, a mutant unable to bind to ErbB RTKs, did not inhibit ErbB-dependent activation of ERK and AKT, consistent with RALT exerting its suppressive activity towards these pathways at a receptor-proximal level. Remarkably, RALT DeltaEBR retained the ability to suppress largely the proliferative activity of ErbB-2.ErbB-3 dimers over a wide range of ligand concentrations, indicating that RALT can intercept ErbB-2.ErbB-3 mitogenic signals also at a receptor-distal level. A suppressive function of RALT DeltaEBR towards the mitogenic activity of EGFR and ErbB-4 was detected at low levels of receptor occupancy, but was completely overcome by saturating concentrations of ligand. We propose that quantitative and qualitative aspects of RALT signalling concur in defining identity, strength and duration of signals generated by the ErbB network.	Regina Elena Inst Canc Res, I-00158 Rome, Italy; Univ Cassino, Cassino, Italy; Univ Roma Tor Vergata, INFM, Sez B, Rome, Italy; CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Cassino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Segatto, O (corresponding author), Regina Elena Inst Canc Res, Via Delle Messi Oro 156, I-00158 Rome, Italy.		Rocco, Fraioli/J-2638-2017; Sala, Gianluca/C-2056-2017; anastasi, sergio/AAB-9585-2020; Alimandi, Maurizio/AAG-9246-2019	Rocco, Fraioli/0000-0001-7906-6077; Sala, Gianluca/0000-0002-4494-915X; anastasi, sergio/0000-0003-1009-6117; Alimandi, Maurizio/0000-0002-1409-6803; Castellani, Loriana/0000-0002-8519-3504; Segatto, Oreste/0000-0003-2561-1142; Alema, Stefano/0000-0002-9869-6354				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ALIMANDI M, 1995, ONCOGENE, V10, P1813; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Cook SJ, 1999, MOL CELL BIOL, V19, P330; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LONARDO F, 1990, New Biologist, V2, P992; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Tang CK, 1998, CANCER RES, V58, P3415; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	92	97	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4221	4234		10.1038/sj.onc.1206516	http://dx.doi.org/10.1038/sj.onc.1206516			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833145				2022-12-28	WOS:000183979800009
J	Oien, KA; Vass, JK; Downie, I; Fullarton, G; Keith, WN				Oien, KA; Vass, JK; Downie, I; Fullarton, G; Keith, WN			Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach	ONCOGENE			English	Article						stomach; stomach neoplasms; adenocarcinoma; gene expression profiling; serial analysis of gene expression (SAGE)	SERIAL ANALYSIS; CANCER-CELLS; DIFFERENTIAL DISPLAY; TREFOIL PEPTIDES; BREAST-CANCER; IDENTIFICATION; PROTEIN; TRANSCRIPTOMES; ADENOCARCINOMA; DISCOVERY	Gastric carcinoma is the fourth most common cause of cancer death worldwide but its molecular biology is poorly understood. We catalogued the genes expressed in two gastric adenocarcinomas and normal stomach, using serial analysis of gene expression (SAGE), and compared the profiles on-line with other glandular epithelia. Candidates were validated by Northern blotting and immunohistochemistry. A total of 29480 transcripts, derived from 10 866 genes, were identified. In all, 1% of the genes were differentially expressed (greater than or equal tofivefold difference plus P-value less than or equal to0.01) between cancers and normal stomach. The most abundant transcripts included ribosomal and mitochondrial proteins, of which most were upregulated in the tumours, as were other widely expressed genes including transcription factors, signalling molecules (serine/threonine protein kinases), thymosin beta 10 and collagenase I. Transcripts abundant in normal stomach were functionally important, including gastrin, immunoglobulin alpha, lysozyme, MUC5, pS2 and pepsinogens, which were among 55 gastric-specific genes. Many transcripts were minimally characterized or new, some cancer-associated genes reflected their intestinal morphology, and some normal gastric genes had previously been considered as pancreatic carcinoma markers. The gastric carcinoma profiles resembled other tumours', supporting the existence of common cancer-associated targets. These data provide a catalogue from which to develop markers for better diagnosis and therapy of gastric carcinoma.	Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Glasgow Royal Infirm, Univ Dept Pathol, Glasgow G4 0SF, Lanark, Scotland; Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Gartnavel Royal Hosp, Dept Surg, Glasgow G12 0YN, Lanark, Scotland	Beatson Institute; Cancer Research UK; University of Glasgow; University of Glasgow; Beatson Institute; Cancer Research UK; Gartnavel Royal Hospital	Oien, KA (corresponding author), Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.oien@beatson.gla.ac.uk	Oien, Karin/AAH-3849-2019; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				Argani P, 2001, CANCER RES, V61, P4320; Bahrenberg G, 2000, BIOCHEM BIOPH RES CO, V275, P783, DOI 10.1006/bbrc.2000.3393; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; BERNER A, 1991, HISTOL HISTOPATHOL, V6, P317; Blok P, 1997, QJM-INT J MED, V90, P735; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Breitwieser GE, 1997, AM J PHYSIOL-CELL PH, V272, pC957, DOI 10.1152/ajpcell.1997.272.3.C957; Carulli JP, 1998, J CELL BIOCHEM, P286; Chan AOO, 1999, J GASTROEN HEPATOL, V14, P1150, DOI 10.1046/j.1440-1746.1999.02000.x; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; de Waard V, 1999, GENE, V226, P1, DOI 10.1016/S0378-1119(98)00577-0; Ebert MPA, 2000, CANCER RES, V60, P1995; El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RM, 2000, LIFE SCI, V67, P2051, DOI 10.1016/S0024-3205(00)00791-8; Harris V, 1998, CANC REGISTRATION ST, P182; Hibi K, 1998, CANCER RES, V58, P5690; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Hough CD, 2000, CANCER RES, V60, P6281; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; ISAACSON P, 1982, GUT, V23, P578, DOI 10.1136/gut.23.7.578; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Lal A, 1999, CANCER RES, V59, P5403; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Ma TH, 1999, J PHYSIOL-LONDON, V517, P317, DOI 10.1111/j.1469-7793.1999.0317t.x; Machado JC, 2000, J PATHOL, V190, P437; Mitani M, 2000, WORLD J SURG, V24, P455, DOI 10.1007/s002689910072; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Nacht M, 1999, CANCER RES, V59, P5464; Norton JD, 2000, J CELL SCI, V113, P3897; OWEN DA, 1986, AM J SURG PATHOL, V10, P48, DOI 10.1097/00000478-198601000-00006; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Roukos DH, 2000, CANCER TREAT REV, V26, P243, DOI 10.1053/ctrv.2000.0164; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Scheurle D, 2000, CANCER RES, V60, P4037; SESSA F, 1990, GASTROENTEROLOGY, V98, P1655, DOI 10.1016/0016-5085(90)91104-E; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Waghray A, 2001, CANCER RES, V61, P4283; Wang G, 2001, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V18, P43; Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	54	58	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4287	4300		10.1038/sj.onc.1206615	http://dx.doi.org/10.1038/sj.onc.1206615			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833151	Green Published			2022-12-28	WOS:000183979800015
J	Perez-Losada, J; Sanchez-Martin, M; Perez-Caro, M; Perez-Mancera, PA; Sanchez-Garcia, I				Perez-Losada, J; Sanchez-Martin, M; Perez-Caro, M; Perez-Mancera, PA; Sanchez-Garcia, I			The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug	ONCOGENE			English	Article						growth factors; hematopoietic development; transcription factor; radioresistance	STEM-CELL FACTOR; GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE RECEPTOR; PROTOONCOGENE C-KIT; GROWTH-FACTOR; W-LOCUS; BREAST CARCINOMAS; PROTO-ONCOGENE; E-CADHERIN; SI-LOCUS	Radiation-induced destruction of the hematopoietic system is the primary cause of death based on the findings that transfer of normal bone marrow cells prevents death from lethal irradiation. The stem cell factor-c-kit signaling pathway (SCF/c-kit) has been previously implicated in the hematopoietic recovery which prevents death from lethal irradiation, but the molecular mechanisms that mediate this biological effect are unknown. Since mutations on SCF, c-kit and Slug genes have a similar phenotype in mice, we examined if Slug could complement the radiosensitivity of kit-deficient mice. In this report, we show that Slug acts as a radioprotection agent as lack of Slug results in increased radiosensitivity. This effect cannot be recovered by activating SCF/c-kit in lethally irradiated Slug-deficient mice, as SCF-treated mice did not demonstrate stimulation of hematopoietic recovery leading to survival of the Slug-deficient mice. We found that we could complement the hematopoietic failure in lethally irradiated c-kit-deficient mice by transducing them with a TAT-Slug protein. We conclude that the zinc-finger transcription factor Slug is absolutely necessary for survival from lethal irradiation and identify Slug as the molecular target that mediates the radioprotection through SCF/c-kit. These results indicate that Slug may be a molecular component conferring radioresistance to cancer cells.	Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Unamuno, Salamanca 37007, Spain.		Pérez-Losada, Jesús/A-5883-2019; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Sanchez-Martin, Manuel/N-5327-2016	Pérez-Losada, Jesús/0000-0003-2400-624X; Sanchez-Martin, Manuel/0000-0001-8370-1336; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Hajra KM, 2002, CANCER RES, V62, P1613; HARRISON DE, 1972, BRIT J HAEMATOL, V22, P155, DOI 10.1111/j.1365-2141.1972.tb08797.x; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; INOUE M, 1994, CANCER RES, V54, P3049; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; KACZMAREK L, 1988, INT J RADIAT BIOL, V53, P703, DOI 10.1080/09553008814551071; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; LEE JM, 1994, ONCOGENE, V9, P3731; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA R, 1993, AM J PATHOL, V142, P339; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NETA R, 1993, BLOOD, V81, P324; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Silvers W.K., 1979, COAT COLORS MICE, P206; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZSEBO KM, 1992, P NATL ACAD SCI USA, V89, P9464, DOI 10.1073/pnas.89.20.9464	38	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4205	4211		10.1038/sj.onc.1206467	http://dx.doi.org/10.1038/sj.onc.1206467			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833143				2022-12-28	WOS:000183979800007
J	Achison, M; Hupp, TR				Achison, M; Hupp, TR			Hypoxia attenuates the p53 response to cellular damage	ONCOGENE			English	Article						p53; hypoxia; CK2; HIF-1; apoptosis	DNA-BINDING FUNCTION; RNA-POLYMERASE-II; P53-DEPENDENT TRANSCRIPTION; TUMOR-SUPPRESSOR; PHOSPHORYLATION; CANCER; PROTEIN; KINASE; CELLS; MDM2	The tumour suppressor activity of p53 in vivo can be subject to pressure from the physiological stress of hypoxia and we report on the development of a cell system to define the p53-dependent stages in the adaptation of cells to hypoxia. p53(+/+) cells exposed to hypoxia exhibited a transient arrest in G2/M, but escaped from this checkpoint and entered a long-term G(0)/G(1) arrest. By contrast, isogenic p53-null cells exposed to hypoxic conditions exhibited a 6-10-fold higher level of apoptosis, suggesting that p53 acts as a survival factor under limiting oxygen concentrations. Surprisingly, hypoxia-dependent growth arrest in p53(+/+) cells did not result in either p21(WAF1) or HIF-1 protein stabilization, but rather promoted a significant decrease in Ser(392)-site phosphorylation at the CK2/FACT site. However, chemically induced anoxia induced Ser(392)-site phosphorylation as well as stabilization of both p53 and HIF-1 proteins. In contrast to hypoxia, 5-flourouracil (5-FU)-induced p53-dependent cell death correlated with enhanced Ser(392) phosphorylation of p53 and elevated p21(WAF1) protein levels. Hypoxia inhibited 5-FU-induced p53-dependent cell death and attenuated p53 phosphorylation at the ATM and CK2/FACT phosphorylation sites. Although anoxia activates the p53 response, hypoxia silences the p53 transactivation pathway and identifies a physiological signalling model to study mechanisms of p53 inactivation under hypoxic conditions.	Univ Dundee, Dept Mol & Cellular Pathol, Canc Res UK Labs, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dept Mol & Cellular Pathol, Canc Res UK Labs, Dundee DD1 9SY, Scotland.	t.r.hupp@dundee.ac.uk						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHAN DA, 2002, J BIOL CHEM, V16, P16; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Hupp TR, 2000, METH MOL B, V99, P465; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kotala V, 2001, CELL MOL LIFE SCI, V58, P1333, DOI 10.1007/PL00000944; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Maxwell PH, 2002, CLIN MED, V2, P356, DOI 10.7861/clinmedicine.2-4-356; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Shieh SY, 2000, GENE DEV, V14, P289; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WENG H, 2002, MOL MED, V16, P1151; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zhao RB, 2000, GENE DEV, V14, P981	57	82	92	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3431	3440		10.1038/sj.onc.1206434	http://dx.doi.org/10.1038/sj.onc.1206434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776195				2022-12-28	WOS:000183128500010
J	Polsky, D; Cordon-Cardo, C				Polsky, D; Cordon-Cardo, C			Oncogenes in melanoma	ONCOGENE			English	Article						melanoma; oncogenes; review; proliferation; transformation	CUTANEOUS MALIGNANT-MELANOMA; HDM2 PROTEIN OVEREXPRESSION; GENE AMPLIFICATION; C-MYC; N-RAS; GERMLINE MUTATIONS; GROWTH-FACTORS; IN-VIVO; CDK4; EXPRESSION	Transformation of normal melanocytes into melanoma cells is accomplished by the activation of growth stimulatory pathways, typically leading to cellular proliferation, and the inactivation of apoptotic and tumor suppressor pathways. Small molecule inhibitors of proteins in the growth stimulatory pathways are under active investigation, and their application to melanoma patients would represent a new treatement strategy to inhibit cell proliferation or induce cell death. We provide a general overview of the mechanisms of oncogene activation and the functions of oncogenes. Lastly, we review oncogenic events in melanoma.	NYU, Med Ctr, Dept Dermatol, Skin & Canc Unit,Oncol Sect, New York, NY 10016 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, Div Mol Pathol, New York, NY 10021 USA	New York University; Memorial Sloan Kettering Cancer Center	Polsky, D (corresponding author), NYU, Med Ctr, Dept Dermatol, Skin & Canc Unit,Oncol Sect, 550 1St Ave, New York, NY 10016 USA.		Polsky, David/AAO-6254-2020	Polsky, David/0000-0001-9554-5289				Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Berking C, 2001, CANCER RES, V61, P8306; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Boni R, 1998, DERMATOLOGY, V196, P288, DOI 10.1159/000017922; Chana JS, 2001, ANN PLAS SURG, V47, P172, DOI 10.1097/00000637-200108000-00011; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1991, CANCER METAST REV, V10, P129, DOI 10.1007/BF00049410; Hayashi S, 1997, J CLIN INVEST, V99, P2581, DOI 10.1172/JCI119446; HODGSON SV, 1997, PRACTICAL GUIDE HUMA; Innominato PF, 2001, J PATHOL, V194, P95, DOI 10.1002/path.861; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Leiter U, 2000, ARCH DERMATOL RES, V292, P225, DOI 10.1007/s004030050479; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mertens F, 1997, CANCER RES, V57, P2765; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OOI A, 1994, INT J ONCOL, V4, P85; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Papp T, 1999, J MED GENET, V36, P610; PASTERNAK JJ, 1999, INTRO HUMAN MOL GENE; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Polsky D, 2002, J NATL CANCER I, V94, P1803; Polsky D, 2001, CANCER RES, V61, P7642; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; RICHMOND A, 1983, CANCER RES, V43, P2106; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rubie H, 1997, J CLIN ONCOL, V15, P1171, DOI 10.1200/JCO.1997.15.3.1171; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Sauter ER, 2002, CANCER RES, V62, P3200; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; vanElsas A, 1996, AM J PATHOL, V149, P883; VARMUS HE, 1985, CANCER-AM CANCER SOC, V55, P2324, DOI 10.1002/1097-0142(19850515)55:10<2324::AID-CNCR2820551004>3.0.CO;2-A; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Willis R.A., 1952, SPREAD TUMORS HUMAN; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	48	95	96	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3087	3091		10.1038/sj.onc.1206449	http://dx.doi.org/10.1038/sj.onc.1206449			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789285				2022-12-28	WOS:000183096600010
J	Aboulkassim, TO; LaRue, H; Lemieux, P; Rousseau, F; Fradet, Y				Aboulkassim, TO; LaRue, H; Lemieux, P; Rousseau, F; Fradet, Y			Alteration of the PATCHED locus in superficial bladder cancer	ONCOGENE			English	Article						chromosome 9; LOH; bladder cancer tumour-suppressor gene; PATCHED gene; RT-PCR	BASAL-CELL CARCINOMAS; FANCONI-ANEMIA POLYPEPTIDE; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; SIGNALING PATHWAY; SONIC HEDGEHOG; GENE; CANDIDATE; CHROMOSOME-9; MICE	Chromosome 9 alterations are the most frequently encountered cytologic anomalies in urothelial carcinoma (UC). We previously screened 139 low-stage UCs for loss of heterozygosity on chromosome 9, and identified five distinct regions likely to harbour tumour-suppressor genes. The present study focused on deletion mapping in the 9q22 region with 11 additional microsatellite markers. New deletions in the 9q22 region were found in five tumours. Deletion mapping allowed us to identify a 0.5 CM common minimal region of deletion between markers D9S280 and D9S1809, encompassing PATCHED (PTC), a gene identified as a tumour suppressor in basal cell carcinoma and in medulloblastoma. A marker located in the first intron of this gene showed the highest percentage of deletion (45%). cDNA sequencing in 15 tumours with deletion of PTC showed no mutation in the remaining allele. However, average expression of PTC mRNA measured by semiquantitative RT-PCR was significantly decreased in tumours with LOH in the 9q22 region, compared to normal urothelium (P = 0.04), while it showed marked fluctuations in tumours without deletion. Our results suggest that the PTC gene is a putative suppressor at the 9q22 locus and that haploinsufficiency of this gene may be an early event in the development of papillary bladder tumours.	Univ Laval, Hotel Dieu, Ctr Rech & Cancerol, Quebec City, PQ G1K 7P4, Canada; CHU Quebec, Hop St Francois Assise, Unite Rech Genet Humaine & Mol, Quebec City, PQ, Canada	Laval University; Laval University	Fradet, Y (corresponding author), Univ Laval, Hotel Dieu, Ctr Rech & Cancerol, Quebec City, PQ G1K 7P4, Canada.			Fradet, Yves/0000-0002-7581-2500				Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, CANCER RES, V53, P1230; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Simoneau M, 2000, ONCOGENE, V19, P6317, DOI 10.1038/sj.onc.1204022; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANAKA M, 1995, CANCER RES, V55, P3228; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; Velickovic M, 2002, MODERN PATHOL, V15, P479, DOI 10.1038/modpathol.3880551; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; Xie JW, 1997, CANCER RES, V57, P2369; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	35	49	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2967	2971		10.1038/sj.onc.1206513	http://dx.doi.org/10.1038/sj.onc.1206513			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771948				2022-12-28	WOS:000182824800012
J	Gridelli, C; Rossi, A; Maione, P				Gridelli, C; Rossi, A; Maione, P			Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents	ONCOGENE			English	Review						NSCLC; chemotherapy; new biologic agents; targeted therapy	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHASE-III; SELECTIVE CYCLOOXYGENASE-2; MOLECULAR HETEROGENEITY; MONOCLONAL-ANTIBODY; INHIBITOR ZD1839; STAGE-II; IN-VITRO; CHEMOTHERAPY	Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a plateau of effectiveness in improving the survival of NSCLC patients. Although neoadjuvant and adjuvant therapies in early stages are under investigation and some progress has been achieved in the management of locally advanced and advanced disease, treatment outcomes for NSCLC are still to be considered dismal. The majority of patients affected from NSCLC experience metastatic disease and optimization of chemotherapy is unlikely to produce further substantial survival improvement, with symptom relief and quality of life still being the primary goal of treatment. Based on this background, clinical investigation of novel treatment strategies is mandatory. As our understanding of tumor cell biology has increased and several molecular targets for NSCLC have been identified, a number of new biologic agents have been developed. Targeted therapy describes treatment strategies that focus on cell signaling and other biologic pathways involved in tumorigenesis. Several targeted agents have been introduced in clinical trials in NSCLC, the majority in advanced disease, and some phase III studies have already produced definitive results. Currently, the minority of these new agents offer promise of improved outcomes and negative results are more common to be reported than positive ones. However, important lessons can be learned from this first generation of clinical trials that should be considered the first step of clinical research in this field.	SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy	San Giuseppe Moscati Hospital	Gridelli, C (corresponding author), SG Moscati Hosp, Div Med Oncol, Via Circumvallaz, I-83100 Avellino, Italy.	cgridelli@libero.it	Gridelli, Cesare/AAA-8621-2019; Gridelli, Cesare/K-7909-2016; Rossi, Antonio/K-7054-2016	Rossi, Antonio/0000-0003-3295-0345				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; ALBERTI W, 1995, BRIT MED J, V311, P899; ALTORKI NK, 2002, P AN M AM SOC CLIN, V21, pA26; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BASSER R, 2001, P AN M AM SOC CLIN, V20, pA100; Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.3.CO;2-I; Betensky RA, 2002, J CLIN ONCOL, V20, P2495, DOI 10.1200/JCO.2002.06.140; Bunn PA, 2001, CLIN CANCER RES, V7, P3239; Burdett S, 1998, LANCET, V352, P257; BURKES RL, 1992, J CLIN ONCOL, V10, P580, DOI 10.1200/JCO.1992.10.4.580; CARBONE D, 2002, P AN M AM SOC CLIN, V21, P1270; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Cox G, 2001, INT J CANCER, V92, P480, DOI 10.1002/ijc.1214; Curran WJ, 2000, P AN M AM SOC CLIN, V19, p484a; DANG T, 2001, P AN M AM SOC CLIN, V20, pA332; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; FALCEY J, 1997, P AN M AM SOC CLIN, V16, pA383; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; FRANQOIS B, 2001, P AN M AM SOC CLIN, V20, pB277; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Furuse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692; GADGEEL SM, 2003, P AN M AM SOC CLIN, V22, P684; GATZEMEIER U, 2002, P AN M AM SOC CLIN, V21, pA297; Georgoulias V, 2001, LANCET, V357, P1478, DOI 10.1016/S0140-6736(00)04644-4; Giaccone G, 2002, ANN ONCOL, V13, P217, DOI 10.1093/annonc/mdf663; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362; Gridelli C, 2002, CURR MED CHEM, V9, P1487, DOI 10.2174/0929867023369565; GRIDELLI C, 2002, P AN M AM SOC CLIN, V21, P1165; GUPTA E, 2001, P AN M AM SOC CLIN, V20, pA76; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 1998, ANTICANCER RES, V18, P775; Hida T, 2000, CLIN CANCER RES, V6, P2006; JOHNSON DH, 2003, P AN M AM SOC CLIN, V22, P640; JOHNSON DH, 2002, ANN ONCOL, V13, P127; Johnson DH, 2001, P AN M AM SOC CLIN, V20, p315a; KATO H, 2003, P AN M AM SOC CLIN, V22, P621; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; KELLY K, 2003, P AN M AM SOC CLIN, V22, P644; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; KHURI FR, 2000, P AN M AM SOC CLIN, V19, pA205; KIM ES, 2003, P AN M AM SOC CLIN, V22, P642; Korn EL, 2001, J CLIN ONCOL, V19, P265, DOI 10.1200/JCO.2001.19.1.265; Kris MG, 2002, P AN M AM SOC CLIN, V21, p292a; KRUG LM, 2001, P AN M AM SOC CLIN, V20, pA333; Kuenen BC, 2002, J CLIN ONCOL, V20, P1657, DOI 10.1200/JCO.20.6.1657; LANGER CJ, 2001, P AN M AM SOC CLIN, V20, pA315; LECHEVALIER T, 2003, P AN M AM SOC CLIN, V22, P2; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Lynch TJ, 2003, P AM SOC CLIN ONCOL, V22, P623; MININBERG ED, 2003, P AN M AM SOC CLIN, V22, P627; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, pA310; PICCARTGEBHART MJ, 2001, P AN M AM SOC CLIN, V20, pA80; Pyo H, 2001, CLIN CANCER RES, V7, P2998; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Rioux N, 1998, CARCINOGENESIS, V19, P1393, DOI 10.1093/carcin/19.8.1393; ROBERT F, 2003, P AN M AM SOC CLIN, V22, P643; Rosell R, 1999, LUNG CANCER, V26, P7, DOI 10.1016/S0169-5002(99)00045-8; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sanchez-Alcazar JA, 2003, LUNG CANCER-J IASLC, V40, P33, DOI 10.1016/S0169-5002(02)00530-5; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SHIN DM, 2001, P AN M AM SOC CLIN, V20, pA82; SMYLIE M, 2001, P AN M AM SOC CLIN, V20, pA307; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TONATO M, 2002, P AN M AM SOC CLIN, V21, pA290; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Van Meerbeeck JP, 2001, P AN M AM SOC CLIN, V20, p308a; Wakeling AE, 2002, CANCER RES, V62, P5749; Wedge SR, 2002, CANCER RES, V62, P4645; WEDGE SR, 2000, P AM ASSOC CANC RES, V41, P3610; Wolff H, 1998, CANCER RES, V58, P4997; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; YUEN A, 2001, P AN M AM SOC CLIN, V20, pA309; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; ZINNER GR, 2001, P AN M AM SOC CLIN, V20, pA328	89	88	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6629	6638		10.1038/sj.onc.1206957	http://dx.doi.org/10.1038/sj.onc.1206957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528288				2022-12-28	WOS:000185700700020
J	Rahmani, M; Yu, CR; Reese, E; Ahmed, W; Hirsch, K; Dent, P; Grant, S				Rahmani, M; Yu, CR; Reese, E; Ahmed, W; Hirsch, K; Dent, P; Grant, S			Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition	ONCOGENE			English	Article						sodium butyrate; LY294002; apoptosis; AKT; MEK/ERK; p21(CIP1/WAF1)	GLYCOGEN-SYNTHASE KINASE-3; BREAST-CANCER CELLS; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; SODIUM-BUTYRATE; SIGNALING PATHWAY; GRANULOCYTIC DIFFERENTIATION; DEPSIPEPTIDE FR901228; RECEPTOR-GAMMA; UP-REGULATION	Effects of the PI-3 kinase inhibitor LY294002 (LY) have been examined in relation to responses of human leukemia cells to histone deacetylase inhibitors (HDIs). Coexposure of U937 cells for 24 h to marginally toxic concentrations of LY294002 (e.g., 30 mum) and sodium butyrate (SB; 1 mM) resulted in a marked increase in mitochondrial damage (e.g., cytochrome c and Smac/DIABLO release, loss of DeltaPsi(m)), caspase activation, and apoptosis. Similar results were observed in Jurkat, HL-60, and K562 leukemic cells and with other HDIs (e.g., SAHA, MS-275). Exposure of cells to SB/LY was associated with Bcl-2 and Bid cleavage, XIAP and Mcl-1 downregulation, and diminished CD11b expression. While LY blocked SB-mediated Akt activation, enforced expression of a constitutively active (myristolated) Akt failed to attenuate SB/LY-mediated lethality. Unexpectedly, treatment of cells with SB+/-LY resulted in a marked reduction in phosphorylation ( activation) of p44/42 mitogen-activated protein ( MAP) kinase. Moreover, enforced expression of a constitutively active MEK1 construct partially but significantly attenuated SB/LY-induced apoptosis. Lastly, cotreatment with LY blocked SB-mediated induction of p21(CIP1/WAF1); moreover, enforced expression of p21(CIP1/WAF1) significantly reduced SB/LY-mediated apoptosis. Together, these findings indicate that LY promotes SB-mediated apoptosis through an AKT-independent process that involves MEK/MAP kinase inactivation and interference with p21(CIP1/WAF1) induction.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, MCV Stn Box 230, Richmond, VA 23298 USA.			Hirsch, Karen/0000-0002-5474-3243; Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R55CA093798, R01CA093798, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93798, CA 63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; Cartee L, 2001, CANCER RES, V61, P2583; Cataldi A, 2000, CELL SIGNAL, V12, P667, DOI 10.1016/S0898-6568(00)00109-1; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUM JR, 1987, J BIOL CHEM, V262, P1092; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; Lee BI, 2001, CANCER RES, V61, P931; Lewandowski D, 2002, BRIT J HAEMATOL, V118, P535, DOI 10.1046/j.1365-2141.2002.03601.x; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nakashio A, 2000, CANCER RES, V60, P5303; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Page C, 2000, ANTICANCER RES, V20, P407; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Park SJ, 2002, IMMUNOPHARM IMMUNOT, V24, P211, DOI 10.1081/IPH-120003751; Rahmani M, 2002, EXP CELL RES, V277, P31, DOI 10.1006/excr.2002.5548; Rane SG, 2002, BLOOD, V100, P2753, DOI 10.1182/blood.V100.8.2753; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosato RR, 2002, MOL CANCER THER, V1, P253; Rosato RR, 2001, INT J ONCOL, V19, P181; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sidhu JS, 2001, MOL PHARMACOL, V59, P1138, DOI 10.1124/mol.59.5.1138; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang QD, 2002, CLIN CANCER RES, V8, P1940; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu CR, 2003, CANCER RES, V63, P1822; Yu XD, 2002, J NATL CANCER I, V94, P504; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200	61	89	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6231	6242		10.1038/sj.onc.1206646	http://dx.doi.org/10.1038/sj.onc.1206646			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679862				2022-12-28	WOS:000185506200013
J	Butz, K; Ristriani, T; Hengstermann, A; Denk, C; Scheffner, M; Hoppe-Seyler, F				Butz, K; Ristriani, T; Hengstermann, A; Denk, C; Scheffner, M; Hoppe-Seyler, F			siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells	ONCOGENE			English	Article						RNA interference; human papillomavirus; apoptosis; tumour virus; tumour therapy	INDUCED APOPTOSIS; RNA INTERFERENCE; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNA; P53 PROTEIN; E7; INHIBITION; PEPTIDES; TYPE-16	The targeted inhibition of antiapoptotic factors in tumour cells may provide a rational approach towards the development of novel anticancer therapies. Using human papillomavirus (HPV)-transformed cells as a model system, we investigated if RNA interference (RNAi)-mediated gene silencing can be employed in order to overcome the apoptosis resistance of cancer cells. We found that both vector-borne and synthetic small interfering (si)RNAs, specifically directed against the antiapoptotic HPV E6 oncogene, restored dormant tumour suppressor pathways in HPV-positive cancer cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive apoptotic cell death, selectively in HPV-positive tumour cells. These findings show that RNAi provides a powerful molecular strategy to inactivate intracellular E6 function efficiently. Moreover, they define E6 as a most promising therapeutic target to eliminate HPV-positive tumour cells specifically by RNAi. Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Cologne, Fak Med, Zentrum Biochem, D-50931 Cologne, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Hoppe-Seyler, Felix/0000-0002-1864-300X				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Hoppe-Seyler F, 1999, ANTICANCER RES, V19, P4747; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	46	267	303	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5938	5945		10.1038/sj.onc.1206894	http://dx.doi.org/10.1038/sj.onc.1206894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955072				2022-12-28	WOS:000185137800002
J	Chen, LH; Chen, JD				Chen, LH; Chen, JD			MDM2-ARF complex regulates p53 sumoylation	ONCOGENE			English	Article						p53; mdm2; ARF; sumoylation	NUCLEOLAR-LOCALIZATION; NUCLEAR EXPORT; SUMO-1; MDM-2; UBIQUITINATION; ACTIVATION; P14(ARF); PIAS	The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and degradation. Ubiquitination of p53 is regulated by ARF, which binds to MDM2 and inhibits its E3 ligase function. P53 is also subjected to modification by conjugation of SUMO-1. We found that a p53 mutant deficient for MDM2 binding (p53(14Q19S)) is poorly sumoylated in vivo compared to wild-type p53. Overexpression of MDM2 increases the level of p53 sumoylation, which is further stimulated by expression of ARE Stimulation of p53 sumoylation requires a highly conserved region (102-116) encoded by exon 2 of ARF and correlates with the ability of ARF to target p53 to the nucleolus. An MDM2 deletion mutant (MDM2(Delta222-437)) with activated cryptic nucleolar localization signal also targets p53 to the nucleolus and efficiently promotes p53 sumoylation in the absence of ARE Direct targeting of p53 to the nucleolus enhances its sumoylation in an MDM2- and ARF-dependent fashion. These results show that p53 sumoylation is regulated by MDM2- and ARF-mediated nucleolar targeting.	H Lee Moffit Comprehens Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA		Chen, JD (corresponding author), H Lee Moffit Comprehens Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu						CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZIRODIMAS D, 2002, ONCOGENE, V20, P4972	31	104	109	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5348	5357		10.1038/sj.onc.1206851	http://dx.doi.org/10.1038/sj.onc.1206851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917636				2022-12-28	WOS:000184734900014
J	Schavinsky-Khrapunsky, Y; Huleihel, M; Aboud, M; Torgeman, A				Schavinsky-Khrapunsky, Y; Huleihel, M; Aboud, M; Torgeman, A			Role of protein kinase C and the Sp1-p53 complex in activation of p21(WAF-1) expression by 12-O-tetradecanoylphorbol-13-acetate in human T cells	ONCOGENE			English	Article						p21(WAF-1); TPA; PKC; Sp1-p53 complex	LONG TERMINAL REPEAT; VIRUS TYPE-I; TRANSCRIPTION FACTOR SP1; CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR-BETA; INHIBITOR P21(WAF1/CIP1); CARCINOMA CELLS; DNA-REPLICATION; FAMILY-MEMBERS; CDK INHIBITORS	Previous reports have shown that, in certain cell types, p21(WAF-1), which plays a central role in cell proliferation, can be activated by HTLV-I Tax protein and by TPA. Tax and TPA are also known to stimulate HTLV-I gene expression. Since cell proliferation has a major impact on HTLV-I replication, it was of interest to investigate their effect on p21(WAF-1) in human T cells, which are the main target of HTLV-I in human infection. This study demonstrates that p21(WAF-1) is activated in such cells by both factors, each acting through a different mechanism that does not influence the other. The effect of TPA is shown to require PKC activity. Notably, however, examination of different PKC isoforms revealed that PKC-alpha: and PKC-epsilon stimulated p21(WAF-1) expression, whereas PKC-eta was rather inhibitory and PKC-beta1 and beta2 were ineffective. All these isoforms were found to be activated by TPA in the employed T cells, but this apparent paradox was resolved by the observation that when coexpressed together in these cells, the stimulatory PKCs override the inhibitory isoform. Further experiments demonstrated that the PKC-induced p21(WAF-1) activation was mediated by binding of Sp1-p53 complex to the second most upstream of the six Sp1 recognition sites present in its promoter and that this effect did not require the cooperation of an p53-binding site.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, Canc Res Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Inst Appl Biosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Aboud, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, Canc Res Ctr, IL-84105 Beer Sheva, Israel.	aboud@bgumail.bgu.ac.il	HULEIHEL, MAHMOUD/F-1837-2012					Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4; Boulaire J, 2000, PATHOL BIOL, V48, P190; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gorospe M, 1999, GENE EXPRESSION, V7, P377; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Isonishi S, 2000, BRIT J CANCER, V82, P34, DOI 10.1054/bjoc.1999.0873; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Livneh E, 1996, ONCOGENE, V12, P1545; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NAMBA H, 1995, CANCER RES, V55, P2075; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Revazova T, 1995, CELL MOL BIOL RES, V41, P377; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Torgeman A, 1999, VIROLOGY, V254, P279, DOI 10.1006/viro.1998.9556; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; YANG S, 2003, TRENDS GENET, V19, P9; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	58	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5315	5324		10.1038/sj.onc.1206782	http://dx.doi.org/10.1038/sj.onc.1206782			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917633	Bronze			2022-12-28	WOS:000184734900011
J	Augenlicht, L; Shi, L; Mariadason, J; Laboisse, C; Velcich, A				Augenlicht, L; Shi, L; Mariadason, J; Laboisse, C; Velcich, A			Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation	ONCOGENE			English	Article						human MUC2 gene; MUC2 expression; sodium butyrate and differentiation; goblet cell lineage	CHAIN FATTY-ACIDS; COLON-CARCINOMA-CELLS; SODIUM-BUTYRATE; CARCINOEMBRYONIC ANTIGEN; HISTONE ACETYLATION; PROTEIN PHOSPHATASE; TRICHOSTATIN-A; MESSENGER-RNA; DIFFERENTIATION; APOPTOSIS	Sodium butyrate (NaB) inhibits proliferation, stimulates apoptosis, and promotes differentiation of human colon cancer cells along the absorptive phenotype. In vitro, butyrate induces a switch from cells with a secretory to an absorptive phenotype. Here, we report that NaB specifically represses the expression of the MUC2 gene, a differentiation marker of the secretory goblet cell lineage, in forskolin- and 12-O-tetradecanoylphorbol 13-acetate-induced HT29 cells, and Cl.16E cells, a clonal derivative of HT29 cells that spontaneously differentiates into goblet cells. Thus, NaB repression is independent of the nature of the stimulus that triggers MUC2 expression. Further, repression was independent of new protein synthesis. Our results suggest that inhibition of MUC2 is linked to the ability of butyrate to repress histone deacetylase activity, since trichostatin A, another inhibitor of histone deacetylases, also inhibited MUC2 expression in induced HT29 cells. Finally, we demonstrate that the NaB effect is specific for this marker of the secretory cell lineage, since carcinoembryonic antigen, which is expressed in both the secretory and absorptive cells, is induced by NaB. Thus, the NaB repression of a definitive function of the secretory cell lineage is a further mechanism, in addition to the effects on proliferation and apoptotic pathways, through which butyrate can regulate intestinal homeostasis.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Fac Med, INSERM, U539, F-44035 Nantes, France	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm)	Velcich, A (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.		Mariadason, John/N-2003-2013	Mariadason, John/0000-0001-9123-7684	NATIONAL CANCER INSTITUTE [R01CA090808, R01CA068965, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA-13330, CA-68965, CA-90808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen A, 1998, INT J BIOCHEM CELL B, V30, P797, DOI 10.1016/S1357-2725(98)00028-4; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; Augenlicht LH, 1999, CANCER RES, V59, P6005; AUGERON C, 1984, CANCER RES, V44, P3961; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; Csordas A., 1995, ROLE GUT BACTERIA HU, P105; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DeRubertis F, 1996, NATURE, V384, P589; Espinos E, 1999, MOL CELL BIOL, V19, P3474; GUM JR, 1987, J BIOL CHEM, V262, P1092; Hague A, 1997, GASTROENTEROLOGY, V112, P1036, DOI 10.1053/gast.1997.v112.agast971036; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; HEERDT BG, 1994, CANCER RES, V54, P3288; HILL MJ, 1995, EUR J CANCER PREV, V4, P353, DOI 10.1097/00008469-199510000-00004; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Ilantzis C, 1997, LAB INVEST, V76, P703; JARRY A, 1994, EUR J PHARM-MOLEC PH, V267, P95, DOI 10.1016/0922-4106(94)90229-1; Laboisse C. L., 1989, CELL MOL BIOL COLON, P27; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Mariadason JM, 2000, CANCER RES, V60, P4561; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; NAP M, 1988, TUMOR BIOL, V9, P145, DOI 10.1159/000217555; PAULUS U, 1993, J CELL SCI, V106, P473; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; ROWE WA, 1992, GASTROENTEROLOGY, V103, P336, DOI 10.1016/0016-5085(92)91133-O; SCHEPPACH W, 1994, GUT, V35, pS35, DOI 10.1136/gut.35.1_Suppl.S35; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; TRAN C, 1998, AM J PHYSIOL, pG85; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; VELCICH A, 1993, J BIOL CHEM, V268, P13956; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Weiss AA, 1996, J HISTOCHEM CYTOCHEM, V44, P1161, DOI 10.1177/44.10.8813081; Wu JT, 2001, AM J PHYSIOL-GASTR L, V280, pG482, DOI 10.1152/ajpgi.2001.280.3.G482; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	44	53	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4983	4992		10.1038/sj.onc.1206521	http://dx.doi.org/10.1038/sj.onc.1206521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902981				2022-12-28	WOS:000184578900006
J	Gutmann, DH; Winkeler, E; Kabbarah, O; Hedrick, N; Dudley, S; Goodfellow, PJ; Liskay, RM				Gutmann, DH; Winkeler, E; Kabbarah, O; Hedrick, N; Dudley, S; Goodfellow, PJ; Liskay, RM			Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice	ONCOGENE			English	Article						tumor suppressor gene; mismatch repair; leukemia; neurofibromin	DNA MISMATCH REPAIR; JUVENILE MYELOMONOCYTIC LEUKEMIA; ENDOMETRIAL TUMORIGENESIS; HEMATOLOGICAL MALIGNANCY; BONE-MARROW; GENE; TYPE-1; CHILDREN; CELL; MUTATION	Defects in DNA mismatch repair (MMR) have been implicated in the genesis of a diverse set of human cancers. Recent studies have suggested that one of the targets of MMR is the neurofibromatosis 1 (NF1) gene. To evaluate the contribution of Mlh1 MMR deficiency to Nf1 tumorigenesis, Mlh1 - / -; Nfl + / - mice were generated. All Mlh1 - / -; Nfl +/- mice (n = 21) were dead by 260 days compared to none of the Nf1 + / - mice. In all, 50% of the Mlh1 - / -; Nfl +/- mice were dead at 150 days compared to 252 days for Mlh1 - / - mice. Nine of the Mlh1 - / -; Nf1 + / - mice were found to harbor intrathoracic NOS2-immunoreactive myeloid leukemias similar to the hematopoietic malignancies observed in older Nfl + / - mice. As expected, significant microsatellite instability was observed in six of six tumors and neurofibromin expression was lost in all tumors analysed. These results suggest that MMR deficiency can accelerate myeloid leukemogenesis in Nfl + / - mice, presumably by inactivating Nf1 gene expression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Washington University (WUSTL); Washington University (WUSTL); Oregon Health & Science University	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Dudley, Samuel C/A-7085-2009	Gutmann, David/0000-0002-3127-5045	NIGMS NIH HHS [R37 GM32741] Funding Source: Medline; NINDS NIH HHS [NS36996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; Boland CR, 1998, CANCER RES, V58, P5248; Buermeyer AB, 1999, CANCER RES, V59, P538; Cohn DE, 2001, GENE CHROMOSOME CANC, V32, P295, DOI 10.1002/gcc.1194; Cooper LJN, 2000, BLOOD, V96, P2310; Edelmann W, 1999, CANCER RES, V59, P1301; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Ingram DA, 2002, BLOOD, V100, P3656, DOI 10.1182/blood-2002-03-0734; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kim TJ, 2002, MOL IMMUNOL, V38, P701, DOI 10.1016/S0161-5890(01)00101-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; Li Y, 1996, CANCER RES, V56, P2872; Mahgoub N, 1999, BLOOD, V93, P3617, DOI 10.1182/blood.V93.11.3617.411a49_3617_3623; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Ricciardone MD, 1999, CANCER RES, V59, P290; Shannon KM, 2001, SEMIN CANCER BIOL, V11, P191, DOI 10.1006/scbi.2001.0372; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Wang H, 2002, AM J PATHOL, V160, P1481, DOI 10.1016/S0002-9440(10)62573-4; Wang Q, 1999, CANCER RES, V59, P294; Wang Q, 2003, HUM GENET, V112, P117, DOI 10.1007/s00439-002-0858-4; Whiteside D, 2002, CANCER RES, V62, P359; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	31	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4581	4585		10.1038/sj.onc.1206768	http://dx.doi.org/10.1038/sj.onc.1206768			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881715				2022-12-28	WOS:000184054700014
J	Spahn, L; Siligan, C; Bachmaier, R; Schmid, JA; Aryee, DNT; Kovar, H				Spahn, L; Siligan, C; Bachmaier, R; Schmid, JA; Aryee, DNT; Kovar, H			Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein	ONCOGENE			English	Article						EWS; FLI1; Ewing's sarcoma; dimerization; protein interaction	RESONANCE ENERGY-TRANSFER; RNA-POLYMERASE-II; EWINGS-SARCOMA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TYROSINE KINASE; ETS-FAMILY; TERNARY COMPLEXES; IQ DOMAIN; GENE	In Ewing's sarcoma family tumors, the ets transcription factor gene FLI1 is rearranged with one EWS allele resulting in coexpression of germline EWS and chimeric EWS-FLI1 proteins. Here, we investigated the potential of germline EWS, FLI1 and EWS-FLI1 to oligomerize. In two functional in vivo tests, fluorescence resonance energy transfer (FRET) and the mammalian two-hybrid (MTH) assay, self-association of EWS and EWS-FLI1, but not of FLI1 was detected. In addition, interaction of EWS-FLI1 with EWS and FLI1 was observed. GST pull-down assays and immunoprecipitation experiments largely confirmed these results. The EWS N-terminal domain present in both EWS and EWS-FLI1 was found to contribute to homotypic and heterotypic interactions of these proteins. However, in the context of germline EWS, the presence of the whole or part of the C-terminal RNA-binding domain greatly supported the self-association potential of the protein. Involvement of an RNA component in EWS oligomerization was confirmed by sensitivity of the corresponding GST pull-down assay to RNaseA treatment. In contrast, EWS-FLI1 was able to self-associate and also bind to FLI1 via its C-terminal domain, which comprises the FLI1 DNA-binding motif. Accordingly, the EWS-FLI1 interaction was not disrupted by RNaseA treatment. Despite its potential to oligomerize, EWS-FLI1 bound to a tandem ets-binding site of the TGFbeta type II receptor promoter as a monomer. Therefore, the functional consequences of homo- and hetero-oligomerization of EWS and EWS-FLI1 proteins remain to be elucidated.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Competence Ctr Biomol Therapeut, A-1235 Vienna, Austria	Saint Anna Children's Hospital; University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.		Schmid, Johannes A./C-7659-2009	Schmid, Johannes A./0000-0002-6586-3507; Kovar, Heinrich/0000-0001-6873-9109				Arvand A, 2001, CANCER RES, V61, P5311; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chansky HA, 2001, CANCER RES, V61, P3586; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Feng L, 2001, ONCOGENE, V20, P4161, DOI 10.1038/sj.onc.1204522; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kovar H, 2001, CANCER RES, V61, P5992; LADANYI M, 1994, CANCER RES, V54, P2837; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lin PP, 1999, CANCER RES, V59, P1428; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5859; Olsen RJ, 2001, ONCOGENE, V20, P1756, DOI 10.1038/sj.onc.1204268; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RAO VN, 1993, ONCOGENE, V8, P2167; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Spahn L, 2002, CANCER RES, V62, P4583; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	52	33	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6819	6829		10.1038/sj.onc.1206810	http://dx.doi.org/10.1038/sj.onc.1206810			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534527				2022-12-28	WOS:000185843400001
J	Koshikawa, N; Iyozumi, A; Gassmann, M; Takenaga, K				Koshikawa, N; Iyozumi, A; Gassmann, M; Takenaga, K			Constitutive upregulation of hypoxia-inducible factor-1 alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure	ONCOGENE			English	Article						VEGF; HIF-1 alpha; hypoxia; angiogenesis; metastasis	C6 GLIOMA-CELLS; FACTOR 1-ALPHA; TUMOR-GROWTH; FACTOR GENE; UNFAVORABLE PROGNOSIS; FACTOR EXPRESSION; POOR-PROGNOSIS; HIF-ALPHA; FACTOR-I; ANGIOGENESIS	Neoangiogenesis is crucial for tumor growth and metastasis and is regulated by various angiogenic factors including vascular endothelial growth factor ( VEGF). However, little is known whether highly metastatic cells express higher level of VEGF in response to various stimuli, thereby increasing neoangiogenesis compared to low-metastatic cells. Here we report that hypoxia markedly induced the expression of VEGF mRNA in the cell lines with high-metastatic potential (A11 and D6 cells) compared to the cell lines with low-metastatic potential (P29 and P34 cells) established from Lewis lung carcinoma. A11 cells exhibited higher VEGF gene-promoter activity, produced a larger amount of VEGF and showed higher activity to induce neoangiogenesis than P29 cells. Although the degradation rate of VEGF mRNA under hypoxic conditions was similar in both cell lines, hypoxia-inducible factor-1alpha (HIF-1alpha) mRNA, but not HIF-1beta mRNA, was found to be constitutively upregulated in A11 cells compared to P29 cells. Accordingly, the level of HIF-1alpha protein in response to hypoxia was higher in A11 cells than in P29 cells. Upregulation of HIF-1alpha mRNA was also observed in D6 cells but not in P34 cells. Thus, the high-metastatic cells produced a larger amount of VEGF under hypoxic conditions through constitutive HIF-1alpha mRNA upregulation compared to the low-metastatic cells, thereby leading to extensive neoangiogenesis.	Chiba Canc Ctr, Res Inst, Div Chemotherapy, Chuoh Ku, Chiba 2608717, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba 2608717, Japan; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	Chiba Cancer Center; Chiba Cancer Center; University of Zurich	Takenaga, K (corresponding author), Chiba Canc Ctr, Res Inst, Div Chemotherapy, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.			Gassmann, Max/0000-0003-2750-8878				ASANO M, 1995, CANCER RES, V55, P5296; Birner P, 2000, CANCER RES, V60, P4693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Hofer T, 2002, PFLUG ARCH EUR J PHY, V443, P503, DOI 10.1007/s00424-001-0759-8; Hopfl G, 2002, CANCER RES, V62, P2962; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kaya M, 2000, CLIN CANCER RES, V6, P572; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kondo Y, 2000, CLIN CANCER RES, V6, P622; Koshikawa N, 2000, CANCER RES, V60, P2936; Lee JC, 2000, EUR J CANCER, V36, P748, DOI 10.1016/S0959-8049(00)00003-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mori A, 1999, INT J CANCER, V80, P738, DOI 10.1002/(SICI)1097-0215(19990301)80:5<738::AID-IJC18>3.3.CO;2-Z; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Ravi R, 2000, GENE DEV, V14, P34; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Saleh M, 1996, CANCER RES, V56, P393; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Seo Y, 2000, CANCER, V88, P2239, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V; Takasu M, 1999, CLIN EXP METASTAS, V17, P409, DOI 10.1023/A:1006632819086; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1997, BIOL CHEM, V378, P609; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213; Zhong H, 1999, CANCER RES, V59, P5830	39	60	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6717	6724		10.1038/sj.onc.1206765	http://dx.doi.org/10.1038/sj.onc.1206765			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555985				2022-12-28	WOS:000185799300007
J	Kretschmer, A; Moepert, K; Dames, S; Sternberger, M; Kaufmann, J; Klippel, A				Kretschmer, A; Moepert, K; Dames, S; Sternberger, M; Kaufmann, J; Klippel, A			Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4	ONCOGENE			English	Article						Smad; TGF-beta; tumor suppressor; microarray	GROWTH-FACTOR-BETA; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; TARGETED DISRUPTION; DOWN-REGULATION; CELLS; EXPRESSION; REPRESSION; INHIBITOR; ARREST	Smad transcription factors mediate the growth inhibitory effect of transforming growth factor-beta (TGF-beta) in many cell types. Mutational inactivation of Smads has been correlated with loss of responsiveness to TGF-beta-mediated signal transduction. In this study, we compare the contribution of individual Smads to TGF-beta-induced growth inhibition and endogenous gene expression in isogenic cellular backgrounds. Smad2, Smad3 and Smad4 expression were selectively inhibited in differentiation-competent cells by using improved antisense molecules. We found that TGF-beta mediates its inhibitory effect on HaCaT keratinocyte cell growth predominantly through Smad3. Inhibition of Smad3 expression was sufficient to interfere with TGF-beta-induced cell cycle arrest and to induce or suppress endogenous cell cycle regulators. Inhibition of Smad4 expression exhibited a partial effect, whereas inhibition of Smad2 expression had no effect. By gene expression pro. ling, we identified TGF-beta-dependent genes that are differentially regulated by Smad2 and Smad3 under regular growth conditions on a genome-wide scale. We show that Smad2, Smad3 and Smad4 contribute to the regulation of TGF-beta responses to varying extents, and demonstrate, in addition, that these Smads exhibit distinct roles in different cell types.	Atugen AG, D-13125 Berlin, Germany		Klippel, A (corresponding author), Atugen AG, Robert Roessle Str 10,Otto Warburg Hause 80, D-13125 Berlin, Germany.	klippel@atugen.com						Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cerezo A, 2002, J CELL SCI, V115, P1305; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FRITZ HJ, 1978, BIOCHEMISTRY-US, V17, P1257, DOI 10.1021/bi00600a020; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill CS, 1999, INT J BIOCHEM CELL B, V31, P1249, DOI 10.1016/S1357-2725(99)00093-X; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Iavarone A, 1997, NATURE, V387, P417; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nicolas FJ, 2003, J BIOL CHEM, V278, P3251, DOI 10.1074/jbc.M209019200; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Robertson G, 2001, UASGCP REP, V2001, P43; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOULE HD, 1990, CANCER RES, V50, P6075; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Werner S, 2000, EXP CELL RES, V254, P80, DOI 10.1006/excr.1999.4726; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; WRANA JL, 2000, SCI STKE, pRE1; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xu GX, 2003, BIOCHEM BIOPH RES CO, V300, P383, DOI 10.1016/S0006-291X(02)02845-0; Xu GX, 2001, BIOCHEM BIOPH RES CO, V287, P47, DOI 10.1006/bbrc.2001.5533; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	62	118	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6748	6763		10.1038/sj.onc.1206791	http://dx.doi.org/10.1038/sj.onc.1206791			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555988				2022-12-28	WOS:000185799300010
J	Takahashi, M; Yang, XMJ; Sugimura, J; Backdahl, J; Tretiakova, M; Qian, CN; Gray, SG; Knapp, R; Anema, J; Kahnoski, R; Nicol, D; Vogelzang, NJ; Furge, KA; Kanyama, H; Kagawa, S; Teh, BT				Takahashi, M; Yang, XMJ; Sugimura, J; Backdahl, J; Tretiakova, M; Qian, CN; Gray, SG; Knapp, R; Anema, J; Kahnoski, R; Nicol, D; Vogelzang, NJ; Furge, KA; Kanyama, H; Kagawa, S; Teh, BT			Molecular subclassification of kidney tumors and the discovery of new diagnostic markers	ONCOGENE			English	Article						kidney tumor; microarray; gene expression profiling; molecular classification; diagnosis	RENAL-CELL CARCINOMA; DIFFERENTIALLY EXPRESSED GENES; II-DEFICIENT MICE; PROSTATE-CANCER; CDNA MICROARRAY; IDENTIFICATION; CLASSIFICATION; CARCINOGENESIS; RACEMASE; SURVIVAL	We analysed the expression profiles of 70 kidney tumors of different histological subtypes to determine if these subgroups can be distinguished by their gene expression profiles, and to gain insights into the molecular mechanisms underlying each subtype. In all, 39 clear cell renal cell carcinomas (RCC), seven primary and one metastatic papillary RCC, six granular RCC from old classification, five chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis and five Wilms' tumors were compared with noncancerous kidney tissues using microarrays containing 19 968 cDNAs. Based on global gene clustering of 3560 selected cDNAs, we found distinct molecular signatures in clear cell, papillary, chromophobe RCC/ oncocytoma, TCC and Wilms' subtypes. The close clustering in each of these subtypes points to different tumorigenic pathways as reflected by their histological characteristics. In the clear cell RCC clustering, two subgroups emerged that correlated with clinical outcomes, confirming the potential use of gene expression signatures as a predictor of survival. In the so-called granular cell RCC ( terminology for a subtype that is no longer preferred), none of the six cases clusters together, supporting the current view that they do not represent a single entity. Blinded histological re-evaluation of four cases of 'granular RCC' led to their reassignment to other existing histological subtypes, each compatible with our molecular classification. Finally, we found gene sets specific to each subtype. In order to establish the use of some of these genes as novel subtype markers, we selected four genes and performed immunohistochemical analysis on 40 cases of primary kidney tumors. The results were consistent with the gene expression microarray data: glutathione S-transferase alpha was highly expressed in clear cell RCC, a methylacyl racemase in papillary RCC, carbonic anhydrase II in chromophobe RCC and K19 in TCC. In conclusion, we demonstrated that molecular profiles of kidney cancers closely correlated with their histological subtypes. We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications.	Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Univ Tokushima, Sch Med, Dept Urol, Tokushima 7708503, Japan; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Urol Surg, Chicago, IL 60637 USA; Spectrum Hlth Hosp, Dept Pathol, Grand Rapids, MI 49503 USA; Spectrum Hlth Hosp, Div Urol, Grand Rapids, MI 49503 USA; Princess Alexandra Hosp, Dept Urol, Brisbane, Qld 4102, Australia; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Van Andel Res Inst, Bioinforamt Program, Grand Rapids, MI 49503 USA; Univ Tokushima, Sch Med, Dept Urol, Tokushima 7708503, Japan; Iwate Med Univ, Sch Med, Dept Urol, Morioka, Iwate 0208505, Japan	Van Andel Institute; Tokushima University; University of Chicago; University of Chicago; University of Chicago; Van Andel Institute; Tokushima University; Iwate Medical University	Teh, BT (corresponding author), Van Andel Res Inst, Canc Genet Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.		Tretiakova, Maria/U-3320-2019; Nicol, David L/M-6809-2016; Gray, Steven G./I-3081-2019	Nicol, David L/0000-0002-5623-7467; Gray, Steven G./0000-0002-5850-6392; Teh, Bin Tean/0000-0003-1514-1124; Sugimura, Jun/0000-0003-3587-5395; Nicol, David/0000-0003-0107-6990				Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; BRECHUE WF, 1991, BIOCHIM BIOPHYS ACTA, V1066, P201, DOI 10.1016/0005-2736(91)90187-D; Bugert P, 1996, AM J PATHOL, V149, P2081; Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRIGNON DJ, 1994, MODERN PATHOL, V7, P186; HADDAD R, 2002, APPL GENOM PROTEOM, V1, P51; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Lai LW, 1998, J CLIN INVEST, V101, P1320, DOI 10.1172/JCI1694; LEWIS SE, 1988, P NATL ACAD SCI USA, V85, P1962, DOI 10.1073/pnas.85.6.1962; Luo J, 2002, CANCER RES, V62, P2220; MOSTFI FK, 1998, WHO INT HISTOLOGICAL; Motzer RJ, 2002, J CLIN ONCOL, V20, P2376, DOI 10.1200/JCO.2002.11.123; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Presti JC, 1996, GENE CHROMOSOME CANC, V17, P199, DOI 10.1002/(SICI)1098-2264(199612)17:4<199::AID-GCC1>3.0.CO;2-Z; Rhodes DR, 2002, BIOINFORMATICS, V18, P205, DOI 10.1093/bioinformatics/18.1.205; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Sobin, 2009, UICC TNM CLASSIFICAT; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; VANMUIJEN GNP, 1987, EXP CELL RES, V171, P331, DOI 10.1016/0014-4827(87)90166-2; Xu JC, 2000, CANCER RES, V60, P1677; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	29	168	177	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6810	6818		10.1038/sj.onc.1206869	http://dx.doi.org/10.1038/sj.onc.1206869			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555994				2022-12-28	WOS:000185799300016
J	Reiss, K; Khalili, K				Reiss, K; Khalili, K			Viruses and cancer: lessons from the human polyomavirus, JCV	ONCOGENE			English	Review						tumorigenesis; T-antigen; oncogene; JC virus; PML	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN NEUROTROPIC POLYOMAVIRUS; INSULIN-RECEPTOR SUBSTRATE-1; HUMAN PAPOVAVIRUS JC; SMALL TUMOR-ANTIGEN; PROTEIN T-ANTIGEN; TRANSGENIC MICE; BETA-CATENIN; SIMIAN VIRUS-40; BRAIN-TUMORS	The possible role of eucaryotic viruses in the development of cancer has been the subject of intense investigation during the past 50 years. Thus far, a strong link between some RNA and DNA viruses and various cancers in humans has been established and the transforming activity of several of the viruses in cell culture and their oncogenecity in experimental animals has been well documented. Perhaps, one of the most common themes among the oncogenic viruses rests in the ability of one or more of the viral proteins to deregulate pathways involved in the control of cell proliferation. For example, inactivation of tumor suppressors through their association with viral transforming proteins, and/or impairment of signal transduction pathways upon viral infection and expression of viral proteins are among the key biological events that can either trigger and/or contribute to the process of cancer. In recent years, more attention has been paid to human polyomaviruses, particularly JC virus (JCV), which infects greater than 80% of the human population, due to the ability of this virus to induce a fatal demyelinating disease in the brain, its presence in various tumors of central nervous system (CNS) and non-CNS origin, and the oncogenic potential of this virus in several laboratory animal models. Here, we will focus our attention on JCV and describe several pathways employed by the virus to contribute to and/or accelerate cancer development.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA.							Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Berger JR, 1998, ANN NEUROL, V44, P341, DOI 10.1002/ana.410440309; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Bofill-Mas S, 2001, J VIROL, V75, P10290, DOI 10.1128/JVI.75.21.10290-10299.2001; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; CARSWELL S, 1986, J VIROL, V60, P1055, DOI 10.1128/JVI.60.3.1055-1061.1986; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Enam S, 2002, CANCER RES, V62, P7093; FAREED GC, 1978, MICROBIOLOGY 1978, P427; Franks RR, 1996, ONCOGENE, V12, P2573; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Gallia GL, 1998, J BIOL CHEM, V273, P32662, DOI 10.1074/jbc.273.49.32662; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; KHALILI K, 1988, P NATL ACAD SCI USA, V85, P354, DOI 10.1073/pnas.85.2.354; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; London W T, 1983, Prog Clin Biol Res, V105, P227; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Monaco MCG, 1996, J VIROL, V70, P7004, DOI 10.1128/JVI.70.10.7004-7012.1996; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; Patti R, 2000, INT J ONCOL, V16, P577; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Polakis P, 2000, GENE DEV, V14, P1837; Prins C, 2001, J NEUROVIROL, V7, P250; RAJ GV, 1995, INT J ONCOL, V7, P801; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; RESNICK J, 1986, J VIROL, V60, P1098, DOI 10.1128/JVI.60.3.1098-1106.1986; Ricciardiello L, 2000, GASTROENTEROLOGY, V119, P1228, DOI 10.1053/gast.2000.19269; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RICHARDSON E, 1961, NEW ENGL J MED, V265, P815, DOI 10.1056/NEJM196110262651701; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shintaku M, 2000, J NEUROPATH EXP NEUR, V59, P921, DOI 10.1093/jnen/59.10.921; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WALKER DL, 1978, MICROBIOLOGY, P432; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZURHEIN GM, 1979, NATL CANCER I MONOGR, V51, P205	67	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 29	2003	22	42					6517	6523		10.1038/sj.onc.1206959	http://dx.doi.org/10.1038/sj.onc.1206959			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528276				2022-12-28	WOS:000185700700008
J	Lynch, J; Keller, M; Guo, RJ; Yang, D; Traber, P				Lynch, J; Keller, M; Guo, RJ; Yang, D; Traber, P			Cdx1 inhibits the proliferation of human colon cancer cells by reducing cyclin D1 gene expression	ONCOGENE			English	Article						homeobox; cyclin D1; antiproliferative; colon cancer	HOMEODOMAIN PROTEIN CDX2; INTESTINAL EPITHELIAL-CELLS; HOMEOBOX GENE; COLORECTAL-CANCER; DOWN-REGULATION; CARCINOMA CELLS; DIFFERENTIATION; TRANSCRIPTION; TRANSACTIVATION; LINE	The transcription factor Cdx1 regulates intestine-specific gene expression and enterocyte differentiation. It has been hypothesized to play a role in regulating intestinal cell proliferation; however, the mechanism for this effect remains elusive. In a prior study, we demonstrated that Cdx1 expression reduced the proliferation of a nontransformed intestinal cell line. This study tests the hypothesis that Cdx1 expression inhibits colon cancer cell proliferation by reducing cyclin D1 gene expression. Cdx1 expression markedly reduced cancer cell proliferation and DNA synthesis and induced an accumulation of cells in G0/G1. A transcriptionally inactive Cdx1 mutant could not elicit this effect, suggesting that it required Cdx1 transcriptional activity. Cdx1 expression increased the hypophosphorylation of the retinoblastoma (pRb) and p130 proteins. Reductions in G1 cyclin-dependant kinase (cdk) activity accompanied this effect. Cyclin D1 mRNA and protein levels were diminished by Cdx1 expression. Restoration of cyclin D1 expression reversed the G0/G1 block and induced pRb hyperphosphorylation. Lastly, Cdx1 expression did not alter cyclin D1 mRNA stability but did reduce cyclin D1 promoter activity, suggesting that Cdx1 acts to diminish cyclin D1 gene transcription. We conclude that Cdx1 reduces the proliferation of human colon cancer cells by reducing cyclin D1 gene transcription.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Lynch, J (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 415 Curie Blvd,660 CRB, Philadelphia, PA 19104 USA.	lynchj@mail.med.upenn.edu		Keller, Matthew/0000-0003-1884-487X	NIDDK NIH HHS [P01-DK49210, DK02695-02, P30-DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, P01DK049210, K08DK002695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Lynch JP, 2002, HEMATOL ONCOL CLIN N, V16, P775, DOI 10.1016/S0889-8588(02)00029-1; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mariadason JM, 2001, CANCER RES, V61, P3465; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Naishiro Y, 2001, CANCER RES, V61, P2751; Oh EJ, 2002, INT J ONCOL, V20, P23; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; Sherr CJ, 2000, CANCER RES, V60, P3689; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Akker E, 2002, DEVELOPMENT, V129, P2181; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	51	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6395	6407		10.1038/sj.onc.1206770	http://dx.doi.org/10.1038/sj.onc.1206770			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508520				2022-12-28	WOS:000185535300010
J	Chauhan, D; Li, GL; Sattler, M; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Hideshima, T; Anderson, KC				Chauhan, D; Li, GL; Sattler, M; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Hideshima, T; Anderson, KC			Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; apoptosis; superoxide; cytochrome c; Smac (second mitochondrial activator of caspases); 2-methoxyestradiol; dexamethasone	MEDIATED APOPTOSIS; CANCER-CELLS; CYTOCHROME-C; ACTIVATION; RESISTANCE; INDUCTION; MECHANISM; PROTEIN; SMAC	Superoxide (O-2(-)) radicals have been linked to apoptosis. Here, we show that 2-methoxyestradiol (2ME2)-induced apoptosis in multiple myeloma ( MM) cells is associated with O-2(-) generation, whereas dexamethasone (Dex)induced apoptosis occurs without concurrent increase in O-2(-). In contrast, both these agents decrease mitochondrial transmembrane potential (Deltapsi(m)). Treatment of MM cells with an antioxidant N-acetyl-L-cysteine blocks 2ME2, but not Dex-induced apoptosis as well as release of mitochondrial proteins cytochrome c (cyto c) and Smac. Taken together, these results demonstrate that there are at least two distinct apoptotic pathways: one dependent on O-2(-), which is induced by 2ME2 and is associated with release of cyto c and Smac; and the other an independent of O-2(-), which is triggered by Dex and associated with Smac release.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NCI NIH HHS [CA 78373] Funding Source: Medline; PHS HHS [50947] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Poot M, 1999, CYTOMETRY, V35, P311, DOI 10.1002/(SICI)1097-0320(19990401)35:4<311::AID-CYTO3>3.3.CO;2-5; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang ZL, 1999, CANCER RES, V59, P1259; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	23	49	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6296	6300		10.1038/sj.onc.1206734	http://dx.doi.org/10.1038/sj.onc.1206734			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679868				2022-12-28	WOS:000185506200019
J	Aasen, T; Hodgins, MB; Edward, M; Graham, SV				Aasen, T; Hodgins, MB; Edward, M; Graham, SV			The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression	ONCOGENE			English	Article						gap junctions; connexins; cell-cell communication; papillomavirus; tumourigenesis; organotypic culture	HUMAN-PAPILLOMAVIRUS TYPE-16; CELL-CELL COMMUNICATION; INTERCELLULAR COMMUNICATION; GROWTH-CONTROL; HUMAN KERATINOCYTES; CARCINOMA CELLS; DOWN-REGULATION; HUMAN BREAST; E-CADHERIN; EXPRESSION	Disruption of gap junctional intercellular communication (GJIC) and/or connexins (gap junction proteins) is frequently reported in malignant cell lines and tumours. Certain human papillomaviruses (HPV) associated with the development of cancers, especially of the cervix, have previously been reported to downregulate GJIC in vitro. There is also evidence for reduced gap junctions in cervical dysplasia. However, many squamous hyperproliferative conditions, including HPV-induced warts, often show extensive upregulation of certain connexins. The association between HPV and GJIC, and the mechanism and consequence of deregulated GJIC in cervical tumour progression, remains unclear. Therefore, using a variety of nonmalignant and malignant cell lines and an organotypic raft-culture system, we investigated the relationship between HPV, gap junctions and tumour progression. Established cervical tumour cell lines carrying HPV were unable to communicate via gap junctions (when assayed by dye-transfer techniques). This correlated with lack of connexin protein expression, while transfection with connexins 26 or 43 led to functional gap junction membrane plaques. On the other hand, immortal but nonmalignant cell lines that contained episomal or integrated HPV-16, but required feeder-layer and growth-factor support, were consistently well coupled, and expressed multiple connexins at membrane junctions. In vitro selection of feeder-layer and growth-factor-independent variants eventually lead to loss of GJIC, which correlated with loss of membrane and increased cytoplasmic connexin 43 localization. However, this was preceded by loss of differentiation and stromal invasion, as assayed on the organotypic raft-culture model. Using this model, a comparison between noncoupled, well-coupled and connexin-transfected cell lines revealed no firm correlation between GJIC and dysplasia, but GJIC appeared to favour increased stratification. These findings demonstrate that loss of GJIC is frequent, but appears to occur more as a consequence of, rather than being the cause of, epithelial dysplasia, and may be influenced by, but is not directly attributable to, HPV.	Univ Glasgow, Div Canc Sci & Mol Pathol, Sect Squamous Cell Biol & Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Div Virol, IBLS, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow; University of Glasgow	Hodgins, MB (corresponding author), Univ Glasgow, Div Canc Sci & Mol Pathol, Sect Squamous Cell Biol & Dermatol, Robertson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	m.b.hodgins@clinmed.gla.ac.uk	Aasen, Trond/B-5279-2013	Aasen, Trond/0000-0003-0763-2695; Graham, Sheila/0000-0002-7140-8279	Wellcome Trust [064140] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Bhattacharyya T, 1998, MED MYCOL, V36, P15, DOI 10.1080/02681219880000031; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; Budunova IV, 1996, MOL CARCINOGEN, V15, P202; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Eiberger J, 2001, CELL COMMUN ADHES, V8, P163, DOI 10.3109/15419060109080717; ENNAJI MM, 1995, CELL MOL BIOL, V41, P481; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1993, J CELL SCI, V106, P463; FITZGERALD DJ, 1994, CARCINOGENESIS, V15, P1859, DOI 10.1093/carcin/15.9.1859; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Graeber SHM, 1998, EXP CELL RES, V243, P142, DOI 10.1006/excr.1998.4130; Habermann H, 2002, J UROLOGY, V167, P655, DOI 10.1016/S0022-5347(01)69118-3; Hernandez-Blazquez FJ, 2001, EXP CELL RES, V270, P235, DOI 10.1006/excr.2001.5342; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Holden PR, 1997, CARCINOGENESIS, V18, P15, DOI 10.1093/carcin/18.1.15; Huang RP, 1998, CANCER RES, V58, P5089; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2000, CARCINOGENESIS, V21, P311; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laird DW, 1999, CANCER RES, V59, P4104; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lesueur F, 2002, BIOCHEM BIOPH RES CO, V294, P108, DOI 10.1016/S0006-291X(02)00451-5; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Lucke T, 1999, J INVEST DERMATOL, V112, P354, DOI 10.1046/j.1523-1747.1999.00512.x; Manthey D, 2001, J MEMBRANE BIOL, V181, P137, DOI 10.1007/s00232-001-0017-1; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Martin PEM, 2001, J CELL SCI, V114, P3845; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; MCNUTT NS, 1971, J CELL BIOL, V51, P805, DOI 10.1083/jcb.51.3.805; MCNUTT NS, 1969, SCIENCE, V165, P597, DOI 10.1126/science.165.3893.597; MESNIL M, 1995, CANCER RES, V55, P629; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Naus CCG, 1999, ADV EXP MED BIOL, V468, P373; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Omori Y, 2001, MUTAT RES-FUND MOL M, V477, P191, DOI 10.1016/S0027-5107(01)00120-8; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Piechocki MP, 1999, CARCINOGENESIS, V20, P401, DOI 10.1093/carcin/20.3.401; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Richard G, 2002, AM J HUM GENET, V70, P1341, DOI 10.1086/339986; Risek B, 1998, J CELL SCI, V111, P1395; Saito T, 1998, ONCOGENE, V17, P1673, DOI 10.1038/sj.onc.1202092; Saito T, 2001, INT J CANCER, V93, P317, DOI 10.1002/ijc.1350; Saitoh M, 1997, CARCINOGENESIS, V18, P1319, DOI 10.1093/carcin/18.7.1319; Saunders MM, 2001, CANCER RES, V61, P1765; Sawey MJ, 1996, MOL CARCINOGEN, V17, P49, DOI 10.1002/(SICI)1098-2744(199610)17:2<49::AID-MC1>3.3.CO;2-8; Shore L, 2001, BIOCHEM J, V357, P489, DOI 10.1042/0264-6021:3570489; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tomakidi P, 2000, CELL TISSUE RES, V301, P323, DOI 10.1007/s004410000231; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Van Geel M, 2002, BRIT J DERMATOL, V146, P938, DOI 10.1046/j.1365-2133.2002.04893.x; VESSEY CJ, 1995, J PATHOL, V176, P151, DOI 10.1002/path.1711760208; Wiszniewski L, 2001, CELL COMMUN ADHES, V8, P409, DOI 10.3109/15419060109080762; Yamakage K, 1998, MOL CARCINOGEN, V23, P121, DOI 10.1002/(SICI)1098-2744(199810)23:2<121::AID-MC9>3.0.CO;2-P; Yamakage K, 2000, J INVEST DERMATOL, V114, P289, DOI 10.1046/j.1523-1747.2000.00873.x; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	81	51	56	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7969	7980		10.1038/sj.onc.1206709	http://dx.doi.org/10.1038/sj.onc.1206709			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970745				2022-12-28	WOS:000185388200012
J	Fagman, H; Larsson, F; Arvidsson, Y; Meuller, J; Nordling, M; Martinson, T; Helmbrecht, K; Brabant, G; Nilsson, M				Fagman, H; Larsson, F; Arvidsson, Y; Meuller, J; Nordling, M; Martinson, T; Helmbrecht, K; Brabant, G; Nilsson, M			Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation	ONCOGENE			English	Article						APQ beta-catenin; cell-cell adhesion; proliferation; nuclear transport	APC GENE-PRODUCT; BETA-CATENIN; SUPPRESSOR PROTEIN; SUBCELLULAR-LOCALIZATION; CYCLE PROGRESSION; COLORECTAL-CANCER; EPITHELIAL-CELLS; PHOSPHATASE 2A; S-PHASE; MUTATIONS	The adenomatous polyposis coli (APC) tumor suppressor is a nucleocytoplasmic protein. The nuclear accumulation of APC was recently found to vary depending on cell density, suggesting that putative APC function(s) in the nucleus is controlled by the establishment of cell contacts. We report here that the density-dependent redistribution of APC between nucleus and cytoplasm prevails in 6/6 thyroid and colorectal carcinoma cell lines. Moreover, mutated APC lacking known nuclear localization sequences had the similar distribution pattern as the full-length protein. APC invariably accumulated in the nuclei of Ki-67 expressing cells, but was largely cytoplasmic when cell cycle exit was induced by serum starvation or at high cell density. APC colocalized with beta-catenin in the nucleus only in one cell line (SW480). Also, APC maintained a predominantly nuclear position in early confluent states when cytoplasmic beta-catenin was recruited to newly formed adherens-like junctions. The results indicate that nuclear targeting of APC is driven by cell cycle entry rather than altered cell-cell contact. The ability of C-terminally truncated APC to accumulate in the nucleus suggests that nuclear import signals other than NLS1(APC) and NLS2(APC) are functionally important. Residual function(s) of N-terminal APC fragments in tumor cells carrying APC mutations might be beneficial to tumor growth and survival.	Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Univ Hosp E, Dept Clin Genet, SE-41685 Gothenburg, Sweden; Hannover Med Sch, Dept Clin Endocrinol, D-30625 Hannover, Germany	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Hannover Medical School	Fagman, H (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	henrik.fagman@anatcell.gu.se	Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123; Fagman, Henrik/0000-0001-5853-6295; Nordling, Margareta/0000-0002-4047-4994; Larsson, Fredrik/0000-0002-7888-6863				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Cetta F, 1998, WORLD J SURG, V22, P1231, DOI 10.1007/s002689900550; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; GERDES J, 1984, J IMMUNOL, V133, P1710; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Homma MK, 2002, P NATL ACAD SCI USA, V99, P5959, DOI 10.1073/pnas.092143199; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PROSSER J, 1994, BRIT J CANCER, V70, P841, DOI 10.1038/bjc.1994.408; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Senda T, 1996, BIOCHEM BIOPH RES CO, V223, P329, DOI 10.1006/bbrc.1996.0894; Sieber OM, 2000, MOL MED TODAY, V6, P462; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; vanderLuijt RB, 1997, HUM MUTAT, V9, P7, DOI 10.1002/(SICI)1098-1004(1997)9:1<7::AID-HUMU2>3.0.CO;2-8; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	52	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6013	6022		10.1038/sj.onc.1206731	http://dx.doi.org/10.1038/sj.onc.1206731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955080				2022-12-28	WOS:000185137800010
J	Mirzayans, R; Pollock, S; Scott, A; Gao, CQ; Murray, D				Mirzayans, R; Pollock, S; Scott, A; Gao, CQ; Murray, D			Metabolic labeling of human cells with tritiated nucleosides results in activation of the ATM-dependent p53 signaling pathway and acceleration of DNA repair	ONCOGENE			English	Article						radiolabeled nucleosides; growth arrest; nucleotide excision repair; CPDs; UV; p53; p21(WAF1)	NUCLEOTIDE EXCISION-REPAIR; NORMAL HUMAN FIBROBLASTS; GLOBAL GENOMIC REPAIR; LI-FRAUMENI SYNDROME; WILD-TYPE P53; ULTRAVIOLET-LIGHT; GROWTH ARREST; PYRIMIDINE DIMERS; PROTEIN-LEVELS; EXPRESSION	We investigated the effects of metabolic labeling with [H-3]thymidine, [H-3]uridine, and [C-14]thymidine on human cells in terms of cell growth, p53 signaling, and nucleotide excision repair. Labeling with [H-3] nucleosides resulted in growth inhibition by both p53-dependent and -independent mechanisms. Tritium labeling also led to nuclear accumulation of p53 and induction of the p53-regulated gene p2(WAF1) and its encoded protein (p21). ATM-deficient cells, however, did not increase their p53 and p21 protein levels in response to radiolabeling. Thus, labeling of human cells with tritiated nucleosides activates the radiation-responsive, ATM-dependent, DNA-damage surveillance network. Labeling of normal cells with [H-3]thymidine significantly accelerated the repair of ultraviolet (UV) light-induced cyclobutane pyrimidine dimers, as monitored by a sensitive immunofluorescence assay. Unlike [(3H]) labeling, [C-14] labeling did not produce any impact on proliferation, p53 signaling, or DNA repair. In the light of these findings, the validity of results obtained with nucleic acid synthesis and DNA repair assays that involve [H-3] and [C-14] labeling is discussed. Our immunofluorescence approach detected pyrimidine dimers after exposure to UV fluences as low as 1 J/m(2) (the lowest fluence examined). This approach may prove particularly useful for monitoring DNA damage and its repair following exposure to extremely low levels of genotoxic agents.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Mirzayans, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; BICKAR D, 1992, ANAL BIOCHEM, V203, P109, DOI 10.1016/0003-2697(92)90049-D; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; DOVER R, 1994, J CELL SCI, V107, P1181; Enns L, 2000, PHOTOCHEM PHOTOBIOL, V72, P562, DOI 10.1562/0031-8655(2000)072<0562:LOCBDS>2.0.CO;2; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Gaitonde SV, 2001, CELL GROWTH DIFFER, V12, P19; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; MIRZAYANS R, 1992, INT J RADIAT BIOL, V62, P417, DOI 10.1080/09553009214552301; Mirzayans R, 1999, CARCINOGENESIS, V20, P941, DOI 10.1093/carcin/20.6.941; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	18	18	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5562	5571		10.1038/sj.onc.1206514	http://dx.doi.org/10.1038/sj.onc.1206514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944903				2022-12-28	WOS:000184865900004
J	Henriksen, J; Aagesen, TH; Maelandsmo, GM; Lothe, RA; Myklebost, O; Forus, A				Henriksen, J; Aagesen, TH; Maelandsmo, GM; Lothe, RA; Myklebost, O; Forus, A			Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation	ONCOGENE			English	Article						COP9 signalosome; chromosome 17; mdm2; sarcoma; CSN3; CGH	COMPARATIVE GENOMIC HYBRIDIZATION; MDM2 GENE AMPLIFICATION; SMITH-MAGENIS-SYNDROME; ADIPOSE-TISSUE TUMORS; HUMAN SARCOMAS; CYTOGENETIC FINDINGS; SIGNAL-TRANSDUCTION; DNA-SEQUENCES; REGION; IDENTIFICATION	In sarcomas, the TP53 tumour suppressor pathway may be altered either by TP53 mutations or by amplification of MDM2, encoding a protein that inhibits TP53 and targets it for 26S-proteasome degradation. However, in the majority of the analysed clinical samples, neither of these types of aberrations are found, suggesting that additional mechanisms are involved. The present study shows that COPS3, located in 17p11 and encoding a component of the proteasome pathway, is more frequently amplified in osteosarcomas (OS) than is MDM2. We present detailed analysis of TP53 mutations and MDM2 and COPS3 expression levels in a set of 23 OS. Our results show that none of the tumours with COPS3 amplification had MDM2 amplification nor TP53 mutations, consistent with the hypothesis that one of the three aberrations is sufficient. The results suggest that inactivation of otherwise intact TP53 by aberrations in the proteasome pathway may contribute to the characteristic aneuploidy observed in OS.	Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway	University of Oslo; University of Oslo	Myklebost, O (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway.	olam@radium.uio.no	Myklebost, Ola/E-9335-2010	Myklebost, Ola/0000-0002-2866-3223; Lothe, Ragnhild A./0000-0002-1693-1032				Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bridge JA, 1997, CANCER GENET CYTOGEN, V95, P74, DOI 10.1016/S0165-4608(96)00306-8; Bridge JA, 1994, CYTOGENETICS BONE SO; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Elsea SH, 1999, AM J MED GENET, V87, P342, DOI 10.1002/(SICI)1096-8628(19991203)87:4<342::AID-AJMG12>3.3.CO;2-1; FLETCHER JA, 1994, CANCER GENET CYTOGEN, V77, P81, DOI 10.1016/0165-4608(94)90154-6; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Hansen DV, 2002, ONCOGENE, V21, P6209, DOI 10.1038/sj.onc.1205824; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; Hulsebos TJM, 1997, GENE CHROMOSOME CANC, V18, P279, DOI 10.1002/(SICI)1098-2264(199704)18:4<279::AID-GCC5>3.0.CO;2-Y; LADANYI M, 1993, CANCER RES, V53, P16; LINK MP, 1993, CANC PRINCIPLES PRAC, P1534; Lothe RA, 2001, GENE CHROMOSOME CANC, V30, P202, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1079>3.3.CO;2-X; MERTENS F, 1993, INT J CANCER, V55, P44, DOI 10.1002/ijc.2910550109; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Potocki L, 1999, GENOMICS, V57, P180, DOI 10.1006/geno.1998.5748; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; TARKKANEN M, 1993, CANCER GENET CYTOGEN, V68, P1, DOI 10.1016/0165-4608(93)90068-W; TARKKANEN M, 1995, CANCER RES, V55, P1334; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; Wolf M, 1999, INT J CANCER, V82, P329, DOI 10.1002/(SICI)1097-0215(19990730)82:3<329::AID-IJC4>3.0.CO;2-1	31	43	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5358	5361		10.1038/sj.onc.1206671	http://dx.doi.org/10.1038/sj.onc.1206671			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917637				2022-12-28	WOS:000184734900015
J	Ma, CL; Lin, H; Leonard, SS; Shi, XL; Ye, JP; Luo, J				Ma, CL; Lin, H; Leonard, SS; Shi, XL; Ye, JP; Luo, J			Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro	ONCOGENE			English	Article						alcohol; growth factors; metastasis; reactive oxygen species; signal transduction	N-TERMINAL KINASE; RECEPTOR TYROSINE KINASES; EPIDERMAL-GROWTH-FACTOR; ALCOHOL-CONSUMPTION; ESTROGEN-RECEPTOR; PC12 CELLS; REGULATED KINASE; OXIDATIVE STRESS; CARCINOMA-CELLS; RAT HEPATOCYTES	Both epidemiological and experimental studies indicate that ethanol is a tumor promoter and may promote metastasis of breast cancer. However, the molecular mechanisms underlying ethanol-mediated tumor promotion remain unknown. Overexpression of ErbB proteins in breast cancer patients is generally associated with poor prognosis. The ErbB proteins are a family of receptor kinases that include four closely related members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. Particularly, ErbB2 plays a pivotal role in ErbB-mediated activities. Here we demonstrated that amplification of ErbB2 expression sensitized a specific cellular response to ethanol. Human breast cancer cells or mammary epithelial cells with a high expression of ErbB2 exhibited an enhanced response to ethanol-stimulated cell invasion in vitro. Ethanol also stimulated cell proliferation; however, this stimulation was independent of ErbB2 levels. Ethanol triggered divergent intracellular signaling among cells expressing different ErbB2 levels. In the cells overexpressing ErbB2, ethanol was more effective in the activation of c-Jun NH2 terminal protein kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK) as well as the induction of reactive oxygen species (ROS) than the cells with normal ErbB2 expression. Blockage of either JNKs or p38 MAPK activation eliminated ethanol-mediated cell invasion. In contrast, the reduction of hydrogen peroxide concentration by catalase exposure had little effect on ethanol-induced cell invasion. These results indicated that ethanol-induced cell invasion was primarily mediated by JNKs and p38 MAPK, whereas the involvement of ROS formation might be minimal. Our study suggests that overexpression of ErbB2 may augment ethanol-elicited signaling and promote ethanol-stimulated tumor metastasis.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	West Virginia University; Air Force Military Medical University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.		Ye, Jianping/N-1998-2017; Shi, Xianglin/B-8588-2012; Luo, Jia/E-4674-2012	Ye, Jianping/0000-0003-3875-365X; Luo, Jia/0000-0002-6968-3618	NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER; NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alford D, 1998, J CELL SCI, V111, P521; Bailey SM, 1998, HEPATOLOGY, V28, P1318, DOI 10.1002/hep.510280521; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Castro GD, 2001, TOXICOLOGY, V160, P11, DOI 10.1016/S0300-483X(00)00433-9; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Doll R, 1981, J NATL CANCER I, V66, P1192; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Fan SJ, 2000, CANCER RES, V60, P5635; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hauck CR, 2001, CANCER RES, V61, P7079; HIATT RA, 1990, MED ONCOL TUMOR PHAR, V7, P143; Hoek JB, 2002, ALCOHOL, V27, P63, DOI 10.1016/S0741-8329(02)00215-X; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Izevbigie EB, 2002, EXP BIOL MED, V227, P260, DOI 10.1177/153537020222700406; Jurgensmeier JM, 1997, INT J CANCER, V70, P587; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Kuper H, 2000, BRIT J CANCER, V83, P949, DOI 10.1054/bjoc.2000.1360; LACROIX H, 1989, ONCOGENE, V4, P145; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Li YX, 2001, FREE RADICAL BIO MED, V30, P389, DOI 10.1016/S0891-5849(00)00484-6; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 2003, J BIOL CHEM, V278, P4542, DOI 10.1074/jbc.M208295200; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1186, DOI 10.1111/j.1530-0277.1997.tb04436.x; Luo J, 1999, ALCOHOL CLIN EXP RES, V23, P644, DOI 10.1111/j.1530-0277.1999.tb04166.x; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCANN A, 1989, IRISH J MED SCI, V158, P137, DOI 10.1007/BF02943053; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; MUFTI SI, 1993, J CANCER RES CLIN, V119, P304, DOI 10.1007/BF01212730; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Park MJ, 2002, J NEUROSURG, V97, P112, DOI 10.3171/jns.2002.97.1.0112; PATERSON MC, 1991, CANCER RES, V51, P556; PLANT ML, 1992, INT J ADDICT, V27, P107, DOI 10.3109/10826089209068733; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Reinke LA, 2002, FREE RADICAL BIO MED, V32, P953, DOI 10.1016/S0891-5849(02)00795-5; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SHI XL, 1991, ARCH BIOCHEM BIOPHYS, V289, P355, DOI 10.1016/0003-9861(91)90423-G; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Singletary K, 1997, ALCOHOL CLIN EXP RES, V21, P334; Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143; Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; Talvensaari-Mattila A, 1998, CANCER-AM CANCER SOC, V83, P1153, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4; Tan M, 1997, CANCER RES, V57, P1199; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vaeth PAC, 1998, ALCOHOL CLIN EXP RES, V22, P928; Verma M, 1999, Cancer Biochem Biophys, V17, P1; Watabiki T, 2000, ALCOHOL CLIN EXP RES, V24, p117S, DOI 10.1111/j.1530-0277.2000.tb00025.x; Weiss HA, 1996, BRIT J CANCER, V73, P1298, DOI 10.1038/bjc.1996.248; Wright RM, 1999, FREE RADICAL BIO MED, V26, P348, DOI 10.1016/S0891-5849(98)00204-4; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Zhu YF, 2001, BREAST CANCER RES TR, V69, P29, DOI 10.1023/A:1012293507534; Zhu YF, 2001, INT J ONCOL, V18, P1299	76	47	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5281	5290		10.1038/sj.onc.1206675	http://dx.doi.org/10.1038/sj.onc.1206675			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917629				2022-12-28	WOS:000184734900007
J	Narayan, G; Pulido, HA; Koul, S; Lu, XY; Harris, CP; Yeh, YA; Vargas, H; Posso, H; Terry, MB; Gissmann, L; Schneider, A; Mansukhani, M; Rao, PH; Murty, VVVS				Narayan, G; Pulido, HA; Koul, S; Lu, XY; Harris, CP; Yeh, YA; Vargas, H; Posso, H; Terry, MB; Gissmann, L; Schneider, A; Mansukhani, M; Rao, PH; Murty, VVVS			Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression	ONCOGENE			English	Article						cervical carcinoma; chromosome 2; CGH; gene amplification; LOH; cervical intraepithelial neoplasia	SQUAMOUS-CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; UTERINE CERVIX; CHROMOSOMAL-ABERRATIONS; PRECANCEROUS LESIONS; INTRAEPITHELIAL NEOPLASIA; CHILDHOOD NEUROBLASTOMAS; RECURRENT PATTERN; E7 ONCOPROTEINS; OVARIAN-CANCER	We performed comparative genomic hybridization (CGH) and high-resolution deletion mapping of the long arm of chromosome 2 (2q) in invasive cervical carcinoma (CC). The CGH analyses on 52 CCs identified genetic losses at 2q33-q36, gain of 3q26-q29, and frequent chromosomal amplifications. Characterization of 2q deletions by loss of heterozygosity (LOH) in 60 primary tumors identified two sites of minimal deleted regions at 2q35-q36.1 and 2q36.3-q37.1. To delineate the stage at which these genetic alterations occur in CC progression, we analysed 33 cervical intraepithelial neoplasia (CIN) for LOH. We found that 89% of high-grade (CINII and CINIII) and 40% of low-grade (CINI) CINs exhibited LOH at 2q. To identify the target tumor suppressor gene (TSG), we performed an extensive genetic and epigenetic analyses of a number of candidate genes mapped to the deleted regions. We did not find inactivating mutations in CASP10, BARD1, XRCC5, or PPP1R7 genes mapped to the deleted regions. However, we did find evidence of downregulated gene expression in CFLAR, CASP10 and PPPIR7 in CC cell lines. We also found reactivated gene expression in CC cell lines in vitro after exposure to demethylating and histone deacetylase (HDAC) inhibiting agents. Thus, these data identify frequent chromosomal amplifications in CC, and sites of TSGs at 2q35-q36.1 and 2q36.3-q37.1 that are critical in CC development.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Inst Nacl Canerol, Dept Genet, Santa Fe De Bogota, Colombia; Inst Nacl Canerol, Dept Pathol, Santa Fe De Bogota, Colombia; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; Univ Jena, Dept Obstet & Gynecol, D-6900 Jena, Germany	Columbia University; Columbia University; Baylor College of Medicine; Texas Children's Cancer Center; Columbia University; Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Schiller University of Jena	Murty, VVVS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.		Gissmann, Lutz/H-4688-2011; Arias-Pulido, Hugo/AEN-1741-2022	Arias-Pulido, Hugo/0000-0003-4941-1110; Terry, Mary Beth/0000-0002-4106-5033				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Chatterjee A, 2001, CANCER RES, V61, P2119; Dellas A, 1999, CANCER RES, V59, P3475; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Hidalgo A, 2000, EUR J CANCER, V36, P542, DOI 10.1016/S0959-8049(99)00323-8; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Kersemaekers AMF, 1999, GENE CHROMOSOME CANC, V26, P346, DOI 10.1002/(SICI)1098-2264(199912)26:4<346::AID-GCC9>3.0.CO;2-D; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; KURZROCK R, 1995, CANCER-AM CANCER SOC, V75, P584, DOI 10.1002/1097-0142(19950115)75:2<584::AID-CNCR2820750223>3.0.CO;2-P; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MITRA AB, 1994, CANCER RES, V54, P637; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MUNGER K, 1992, CANCER SURV, V12, P197; MURTHY NS, 1990, BRIT J CANCER, V61, P732, DOI 10.1038/bjc.1990.164; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Pulido HA, 2000, CANCER RES, V60, P6677; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; Ransom DT, 1998, HEAD NECK-J SCI SPEC, V20, P404; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Singh B, 2001, CANCER RES, V61, P4506; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Uejima H, 1998, MOL CARCINOGEN, V22, P34, DOI 10.1002/(SICI)1098-2744(199805)22:1<34::AID-MC5>3.0.CO;2-L; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071; 1996, CERVICAL CANC, V14, P1	51	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3489	3499		10.1038/sj.onc.1206432	http://dx.doi.org/10.1038/sj.onc.1206432			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776201	Green Published			2022-12-28	WOS:000183128500016
J	Bennett, DC				Bennett, DC			Human melanocyte senescence and melanoma susceptibility genes	ONCOGENE			English	Article						melanoma; senescence; genetics; progression; p16INK4A; CDK4	TELOMERASE ACTIVITY; CELLULAR SENESCENCE; TUMOR SUPPRESSION; INK4A LOCUS; IN-VITRO; P16(INK4A); RAS; DIFFERENTIATION; ACTIVATION; MECHANISMS	The molecular mechanisms and biology of cellular senescence in human melanocytes are discussed, including similarities to and differences from senescence in fibroblasts and other cell lineages. Special reference is made to the fact that the known melanoma susceptibility genes in the human, Inhibitor A of [cyclin-dependent] kinase 4-alternative reading frame (INK4A-ARF) and cyclin-dependent kinase 4, are involved in the regulation of cellular senescence, and possible reasons why this should be so. Based on the evidence including growth and survival kinetics of human and mouse melanocytes carrying germline deficiencies in the INK4A sequence, it is suggested that an 'MO' or p16/RB-dependent form of senescence may be particularly important in melanocytes. A speculative model is proposed, relating current concepts of early melanoma progression to the processes of cellular senescence and immortalization. This includes the suggestion that moles or nevi are senescent clones of melanocytes.	St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England	St Georges University London	Bennett, DC (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England.	dbennett@sghms.ac.uk	Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Bartkova J, 1996, CANCER RES, V56, P5475; Bastiaens M, 2001, HUM MOL GENET, V10, P1701, DOI 10.1093/hmg/10.16.1701; BENNETT DC, 1985, J CELL SCI, V77, P167; Bennett DC, 2002, PIGM CELL RES, V15, P242, DOI 10.1034/j.1600-0749.2002.02036.x; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; GILCHREST BA, 1984, J INVEST DERMATOL, V83, P370, DOI 10.1111/1523-1747.ep12264638; Glaessl A, 1999, ARCH DERMATOL RES, V291, P81, DOI 10.1007/s004030050387; Goding CR, 2000, GENE DEV, V14, P1712; GRAEVEN U, 1992, J IMMUNOTHER, V12, P199, DOI 10.1097/00002371-199210000-00012; Haddad M M, 1998, J Investig Dermatol Symp Proc, V3, P36; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Halachmi S, 2001, CURR OPIN ONCOL, V13, P129, DOI 10.1097/00001622-200103000-00008; Hayward N, 2000, Curr Oncol Rep, V2, P300, DOI 10.1007/s11912-000-0022-z; HERLYN M, 1985, CANCER RES, V45, P5670; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Keller-Melchior R, 1998, J INVEST DERMATOL, V110, P932, DOI 10.1046/j.1523-1747.1998.00211.x; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Le Poole IC, 2000, IN VITRO CELL DEV-AN, V36, P309; MEDRANO EE, 1994, MOL BIOL CELL, V5, P497, DOI 10.1091/mbc.5.4.497; MOOI W, 1992, BIOPSY PATHOLOGY MEL; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Papp T, 1999, J MED GENET, V36, P610; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rudolph P, 2000, AM J PATHOL, V156, P1425, DOI 10.1016/S0002-9440(10)65011-0; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Smalley KSM, 2002, MELANOMA RES, V12, P187, DOI 10.1097/00008390-200206000-00001; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; SVIDERSKAYA EV, 2003, IN PRESS J NATL CANC, V95; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YAVUZER U, 1995, ONCOGENE, V10, P123; ZEPTER K, 1995, J INVEST DERMATOL, V104, P755, DOI 10.1111/1523-1747.ep12606981	57	159	166	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3063	3069		10.1038/sj.onc.1206446	http://dx.doi.org/10.1038/sj.onc.1206446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789281				2022-12-28	WOS:000183096600006
J	Suzuki, K; Ojima, M; Kodama, S; Watanabe, M				Suzuki, K; Ojima, M; Kodama, S; Watanabe, M			Radiation-induced DNA damage and delayed induced genomic instability	ONCOGENE			English	Article						genomic instability; DNA damage; repair; p53 and chromatin	DOUBLE-STRAND BREAKS; CHROMOSOMAL INSTABILITY; REPRODUCTIVE DEATH; LETHAL MUTATIONS; GENETIC INSTABILITY; PLATING EFFICIENCY; OXIDATIVE STRESS; MAMMALIAN-CELLS; ALPHA-PARTICLES; X-IRRADIATION	Ionizing radiation induces genomic instability, which is transmitted over many generations after irradiation through the progeny of surviving cells. Induced genomic instability is manifested as the expression of the following delayed effects: delayed reproductive death or lethal mutation, chromosomal instability, and mutagenesis. Since induced genomic instability accumulates gene mutations (actually genomic instability is the process whereby gene mutation increases subtle difference) and gross chromosomal rearrangements, it has been thought to play a role in radiation-induced carcinogenesis. Radiation-induced genomic instability exerts its effects for prolonged periods of time, suggesting the presence of a mechanism by which the initial DNA damage in the surviving cells is memorized. Recent studies have shown that such memory transmission causes delayed DNA breakage, which in turn plays a role in the induction of delayed phenotypes. Although radiation-induced genomic instability has been studied for years, many questions remain to be answered. This review summarizes the current data on radiation-induced genomic instability. In particular, the mechanism(s) involved in the initiation and perpetuation of radiation-induced genomic instability, and a role of delayed activation of p53 protein are discussed.	Nagasaki Univ, Grad Sch Biomed Sci, Course Life Sci & Radiat Res, Dept Radiol & Radiat Biol,Div Radiat Biol, Nagasaki 8528521, Japan	Nagasaki University	Suzuki, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Course Life Sci & Radiat Res, Dept Radiol & Radiat Biol,Div Radiat Biol, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	kzsuzuki@net.nagasaki-u.ac.jp						Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; CHONG SY, 1995, BBA-GENE STRUCT EXPR, V1264, P103, DOI 10.1016/0167-4781(95)00133-2; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Cremer M, 2001, CHROMOSOME RES, V9, P541, DOI 10.1023/A:1012495201697; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Desmaze C, 1999, CYTOGENET CELL GENET, V86, P288, DOI 10.1159/000015321; Figgitt M, 1999, INT J RADIAT BIOL, V75, P811, DOI 10.1080/095530099139863; FITZEK M, 1993, RADIAT ENVIRON BIOPH, V32, P33, DOI 10.1007/BF01213128; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; Harper K, 1997, EXP HEMATOL, V25, P263; HOLMBERG K, 1993, MUTAT RES, V286, P321, DOI 10.1016/0027-5107(93)90197-N; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kadhim MA, 1996, INT J RADIAT BIOL, V69, P167, DOI 10.1080/095530096145995; Kaplan MI, 1998, RADIAT RES, V150, P382, DOI 10.2307/3579656; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kiefer J, 1999, MUTAT RES-FUND MOL M, V431, P429, DOI 10.1016/S0027-5107(99)00184-0; Li CY, 2001, CANCER RES, V61, P428; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P4048; Limoli CL, 1997, CANCER RES, V57, P5557; Limoli CL, 1999, RADIAT RES, V151, P677, DOI 10.2307/3580206; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; Lo AWI, 2002, MOL CELL BIOL, V22, P4836, DOI 10.1128/MCB.22.13.4836-4850.2002; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Marshall WF, 2002, CURR BIOL, V12, pR185, DOI 10.1016/S0960-9822(02)00724-8; MENDONCA MS, 1989, RADIAT RES, V119, P387, DOI 10.2307/3577629; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 1998, MUTAGENESIS, V13, P421, DOI 10.1093/mutage/13.5.421; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Narayanan PK, 1997, CANCER RES, V57, P3963; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; OLGA A, 2002, RADIAT RES, V158, P486; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Parada LA, 2002, TRENDS CELL BIOL, V12, P425, DOI 10.1016/S0962-8924(02)02351-6; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Ponnaiya B, 1997, RADIAT RES, V147, P288, DOI 10.2307/3579335; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Roy K, 1999, J RADIAT RES, V40, P311, DOI 10.1269/jrr.40.311; Roy K, 2000, RADIAT RES, V154, P659, DOI 10.1667/0033-7587(2000)154[0659:HRXRID]2.0.CO;2; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SINCLAIR WK, 1964, RADIAT RES, V21, P584, DOI 10.2307/3571653; Singleton BK, 2002, CANCER RES, V62, P6263; Smith LE, 1998, MUTAGENESIS, V13, P435, DOI 10.1093/mutage/13.5.435; Suzuki K, 1998, RADIAT RES, V150, P375, DOI 10.2307/3579655; Suzuki K, 2003, CANCER RES, V63, P936; Suzuki K, 1997, J RADIAT RES, V38, P55, DOI 10.1269/jrr.38.55; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Tanabe H, 2002, MUTAT RES-FUND MOL M, V504, P37, DOI 10.1016/S0027-5107(02)00077-5; Trott KR, 1998, INT J RADIAT BIOL, V74, P787, DOI 10.1080/095530098141078; Trott KR, 2000, RADIAT ENVIRON BIOPH, V39, P79, DOI 10.1007/s004110000047; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang P, 1997, P NATL ACAD SCI USA, V94, P12018, DOI 10.1073/pnas.94.22.12018; Wang P, 2002, NUCLEIC ACIDS RES, V30, P2639, DOI 10.1093/nar/gkf369; Yamada Y, 1996, RADIAT RES, V145, P481, DOI 10.2307/3579070; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	82	123	133	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					6988	6993		10.1038/sj.onc.1206881	http://dx.doi.org/10.1038/sj.onc.1206881			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557802				2022-12-28	WOS:000185903900002
J	Bellan, C; De Falco, G; Lazzi, S; Leoncini, L				Bellan, C; De Falco, G; Lazzi, S; Leoncini, L			Pathologic aspects of AIDS malignancies	ONCOGENE			English	Review						AIDS; HIV; neoplasm; pathology	HUMAN-IMMUNODEFICIENCY-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; EPSTEIN-BARR-VIRUS; TYPE-1 TAT PROTEIN; MULTICENTRIC CASTLEMANS-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; PRIMARY EFFUSION LYMPHOMA; GROWTH-FACTOR RECEPTOR-3; HIV-I TAT; KAPOSIS-SARCOMA	Since the emergence of the HIV pandemic, a close association between HIV infection and the development of a selected group of cancers has been acknowledged. The introduction of highly active antiretroviral therapy, however, has had a dramatic impact on the incidences of several AIDS-defining malignancies. This suggests the possibility of a direct and indirect role of HIV in HIV-related tumor genesis. The aim of this paper is to review the pathology of AIDS-related malignancies, taking into account the pathogenetic mechanisms and their potential for improving the treatment of these tumors.	Univ Siena, Dept Human Pathol & Oncol, Nuovo Policlin Le Scotte, I-53100 Siena, Italy	University of Siena	Leoncini, L (corresponding author), Univ Siena, Dept Human Pathol & Oncol, Nuovo Policlin Le Scotte, Via Scotte 6, I-53100 Siena, Italy.	leoncinil@unisi.it	leoncini, lorenzo/P-8361-2018; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; Lazzi, Stefano/P-8265-2018; BELLAN, CRISTIANA/L-3903-2013	leoncini, lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; Lazzi, Stefano/0000-0002-2218-3771; BELLAN, CRISTIANA/0000-0001-6119-9007				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Altavilla G, 1999, AM J PATHOL, V154, P1231, DOI 10.1016/S0002-9440(10)65375-8; Ambinder RF, 2001, EUR J CANCER, V37, P1209, DOI 10.1016/S0959-8049(01)00123-X; Ambrosino C, 2002, J BIOL CHEM, V277, P31448, DOI 10.1074/jbc.M112398200; Babcock GJ, 2000, P NATL ACAD SCI USA, V97, P12250, DOI 10.1073/pnas.200366597; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Boccalon M, 1996, EUR J CANCER, V32A, P2212, DOI 10.1016/S0959-8049(96)00416-9; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Cannon M, 2000, SEMIN ONCOL, V27, P409; Carbone A, 2003, LANCET ONCOL, V4, P22, DOI 10.1016/S1470-2045(03)00957-4; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Clarke B, 2002, J CLIN PATHOL-MOL PA, V55, P19, DOI 10.1136/mp.55.1.19; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CLIN CANCER RES, V6, P754; CORALLINI A, 1993, CANCER RES, V53, P5569; D'OLIVEIRA J J G, 1972, Cancer, V30, P553, DOI 10.1002/1097-0142(197208)30:2<553::AID-CNCR2820300236>3.0.CO;2-W; Dal Maso L, 2001, EUR J CANCER, V37, P1188, DOI 10.1016/S0959-8049(01)00120-4; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; DEFALCO G, 2003, IN PRESS ONCOGENE; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Du MQ, 2001, BLOOD, V97, P2130, DOI 10.1182/blood.V97.7.2130; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fiorelli V, 1998, BLOOD, V91, P956; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Gaidano G, 1998, AM J PATHOL, V152, P623; GAIDANO G, 2003, BLOOD           0424; Gates AE, 2002, ONCOLOGY-NY, V16, P657; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hengge UR, 2002, LANCET INFECT DIS, V2, P344, DOI 10.1016/S1473-3099(02)00288-8; Jussila L, 1998, CANCER RES, V58, P1599; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kersemaekers AMF, 1998, BRIT J CANCER, V77, P192, DOI 10.1038/bjc.1998.33; KIM CM, 1992, ONCOGENE, V7, P1525; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Knowles DM, 1999, MODERN PATHOL, V12, P200; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Muliokandov MR, 1996, CANCER RES, V56, P197; Noonan D, 2000, Adv Pharmacol, V48, P229; Olweny C L, 1984, IARC Sci Publ, P543; Prakash O, 2000, JNCI-J NATL CANCER I, V92, P721, DOI 10.1093/jnci/92.9.721; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Rabkin CS, 2001, EUR J CANCER, V37, P1316, DOI 10.1016/S0959-8049(01)00104-6; ROTH WK, 1992, AIDS, V6, P895, DOI 10.1097/00002030-199209000-00001; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; Schulz TF, 2002, VIRUS RES, V82, P115; Schulz TF, 2001, EUR J CANCER, V37, P1217, DOI 10.1016/S0959-8049(01)00115-0; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Stiegler P, 1998, J CELL BIOCHEM, P30; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tirelli U, 2002, CRIT REV ONCOL HEMAT, V41, P299, DOI 10.1016/S1040-8428(01)00165-2; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wallace SVF, 2001, INT J STD AIDS, V12, P283, DOI 10.1258/0956462011923039; Wistuba II, 1999, GYNECOL ONCOL, V74, P519, DOI 10.1006/gyno.1999.5485; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823	76	27	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6639	6645		10.1038/sj.onc.1206815	http://dx.doi.org/10.1038/sj.onc.1206815			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528289				2022-12-28	WOS:000185700700021
J	Lavia, P; Mileo, AM; Giordano, A; Paggi, MG				Lavia, P; Mileo, AM; Giordano, A; Paggi, MG			Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability	ONCOGENE			English	Review						E1A; E7; mitosis; genomic instability; cellular transformation	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASE; LARGE T-ANTIGEN; CENTROSOME DUPLICATION; ADENOVIRUS E1A; RAN-GTPASE; MITOTIC SPINDLE; MAMMALIAN-CELLS; AURORA-A	The small DNA virus proteins E1A and E1B from human Adenovirus, E6 and E7 from human papillomavirus, and large T and small T antigens from SV40, are multifaceted molecular tools that can carry out an impressive number of tasks in the host cell. These viral factors, collectively termed 'oncoproteins' for their ability to induce cancer, can be viewed as paradigmatic oncogenic factors which can disrupt checkpoint controls at multiple levels - they interfere with both 'gatekeeper' cellular functions, including major control pathways of cell cycle and apoptosis, and with 'caretaker' functions, thereby inducing mitotic abnormalities and increasing genomic instability. Both E1A and E7 have been recently found to interact physically with the Ran GTPase. This interaction is key in uncoupling the centrosome cycle from the cell cycle, highlighting a direct link between viral infection and the induction of genomic instability. Further expanding our current knowledge in this field will be crucial to elucidate viral strategies leading to cellular transformation and cancer progression, as well as design novel preventive or therapeutic approaches to human cancer.	Regina Elena Inst Canc Res, Ctr Expt Res, I-00158 Rome, Italy; CNR, Natl Res Council, Inst Mol Biol & Pathol, Rome, Italy; Temple Univ, Dept Biotechnol, Philadelphia, PA 19122 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Ctr Expt Res, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ccd.inemm.cnr.it	Mileo, Anna Maria/J-3667-2016; Lavia, Patrizia/J-5793-2019; Giordano, Antonio/F-1927-2010; Lavia, Patrizia/AAL-3982-2021; Paggi, Marco G./K-3494-2018	Mileo, Anna Maria/0000-0002-1970-3297; Lavia, Patrizia/0000-0003-3310-6701; Giordano, Antonio/0000-0002-5959-016X; 				Alazawi W, 2002, CANCER RES, V62, P6959; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086; Berger AJ, 2002, AM J PATHOL, V161, P603, DOI 10.1016/S0002-9440(10)64215-0; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2000, J CELL BIOCHEM, V76, P189, DOI 10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; CLAUDIO PP, 1994, CANCER RES, V54, P5556; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; De Luca A, 2003, CANCER RES, V63, P1430; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DIFIORE B, 2003, IN PRESS J CELL SCI; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, CANCER RES, V61, P2356; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Frank SA, 2003, CURR BIOL, V13, pR261, DOI 10.1016/S0960-9822(03)00195-7; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Goepfert TM, 2002, CANCER RES, V62, P4115; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Haase SB, 2001, NAT CELL BIOL, V3, P38, DOI 10.1038/35050543; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hubberstey AV, 2002, CANCER GENE THER, V9, P321, DOI 10.1038/sj.cgt.7700436; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lavia P, 1999, BIOESSAYS, V21, P221; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; Leung D, 2003, NAT BIOTECHNOL, V21, P687, DOI 10.1038/nbt826; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAYOL X, 1993, ONCOGENE, V8, P2561; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Moore WJ, 2002, CURR BIOL, V12, P1442, DOI 10.1016/S0960-9822(02)01076-X; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nishimoto T, 2000, BIOL CHEM, V381, P397, DOI 10.1515/BC.2000.052; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paggi MG, 2001, CANCER RES, V61, P4651; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pihan GA, 1998, CANCER RES, V58, P3974; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHMEICHEL KL, 2002, BREAST CANCER RES, V5, P59; Severino Anna, 2003, P297; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SHENK T, 1991, ADV CANCER RES, V57, P47; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Snaith HA, 1996, J CELL SCI, V109, P3001; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Stiegler P, 1998, J CELL BIOCHEM, P30; Stiegler P, 1998, CANCER RES, V58, P5049; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; TEODORO JG, 1995, ONCOGENE, V11, P467; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; Zatsepina OV, 1999, J CELL SCI, V112, P455; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1	122	54	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6508	6516		10.1038/sj.onc.1206861	http://dx.doi.org/10.1038/sj.onc.1206861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528275				2022-12-28	WOS:000185700700007
J	Motiwala, T; Ghoshal, K; Das, A; Majumder, S; Weichenhan, D; Wu, YZ; Holman, K; James, SJ; Jacob, ST; Plass, C				Motiwala, T; Ghoshal, K; Das, A; Majumder, S; Weichenhan, D; Wu, YZ; Holman, K; James, SJ; Jacob, ST; Plass, C			Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas	ONCOGENE			English	Article						DNA methylation; DNA amplification; folate deficiency; hepatocellular carcinoma; PTPRO; 5-azacytidine	ACUTE MYELOID-LEUKEMIA; RNA POLYMERASE-I; RAT HEPATOMA; P53 GENE; DNA; CANCER; EXPRESSION; DEFICIENT; FOLATE; METHYLTRANSFERASE	A diet lacking folic acid and choline and low in methionine (folate/methyl deficient diet, FMD diet) fed to rats is known to produce preneoplastic nodules (PNNs) after 36 weeks and hepatocellular carcinomas (tumors) after 54 weeks. FMD diet-induced tumors exhibit global hypomethylation and regional hypermethylation. Restriction landmark genome scanning analysis with methylation-sensitive enzyme NotI (RLGS-M) of genomic DNA isolated from control livers, PNNs and tumor tissues was performed to identify the genes that are differentially methylated or amplified during multistage hepatocarcinogenesis. Out of the 1250 genes analysed, 2 to 5 genes were methylated in the PNNs, whereas 5 to 45 genes were partially or completely methylated in the tumors. This analysis also showed amplification of 3 to 12 genes in the primary tumors. As a first step towards identifying the genes methylated in the PNNs and primary hepatomas, we generated a rat NotI-EcoRV genomic library in the pBluescriptKS vector. Here, we describe identification of one methylated and downregulated gene as the rat protein tyrosine phosphatase receptor type O ( PTPRO) and one amplified gene as rat C-MYC. Methylation of PTPRO at the NotI site located immediate upstream of the trancription start site in the PNNs and tumors, and amplification of C-MYC gene in the tumors were confirmed by Southern blot analyses. Bisulfite genomic sequencing of the CpG island encompassing exon 1 of the PTPRO gene revealed dense methylation in the PNNs and tumors, whereas it was methylation free in the livers of animals on normal diet. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed significant decrease in the expression of PTPRO in the tumors and in a transplanted rat hepatoma. The expression of PTPRO mRNA in the transplanted hepatoma after demethylation with 5-azacytidine, a potent inhibitor of DNA methyltransferases, further confirmed the role of methylation in PTPRO gene expression. These results demonstrate alteration in methylation pro. le and expression of specific genes during tumor progression in the livers of rats in response to folate/methyl deficiency, and further implicate the potential role of PTPRO as a novel growth regulatory gene at least in the hepatocellular carcinomas.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Med Univ Lubeck, Inst Biol, D-23538 Lubeck, Germany; Ohio State Univ, Coll Med, Div Human Canc Genet, Columbus, OH 43210 USA; US FDA, Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA	University System of Ohio; Ohio State University; University of Lubeck; University System of Ohio; Ohio State University; US Food & Drug Administration (FDA)	Jacob, ST (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	jacob.42@osu.edu	Motiwala, Tasneem/AAB-9067-2021; Das, Anindita/K-8003-2013; Plass, Christoph/H-7192-2014; Jacob, Samson/H-3135-2011	Das, Anindita/0000-0003-4422-7277; 	NCI NIH HHS [CA86978, R01 CA086978-01A2, R01 CA086978] Funding Source: Medline; NIEHS NIH HHS [ES10874, R01 ES010874-01, R01 ES010874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; BUTTERWORTH C, 1991, AM J CLIN NUTR, V94, P2; Canzian F, 1996, CANCER RES, V56, P3331; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CRAVO ML, 1992, CANCER RES, V52, P5002; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; GHOSHAL AK, 1987, CANCER LETT, V36, P289, DOI 10.1016/0304-3835(87)90022-X; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; HAYASHI K, 1984, JPN J CANCER RES, V75, P475; HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145; HAYASHIZAKI Y, 1992, GENOMICS, V14, P733, DOI 10.1016/S0888-7543(05)80176-4; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; JAMES SJ, 1989, CARCINOGENESIS, V10, P1209, DOI 10.1093/carcin/10.7.1209; JAMES SJ, 1992, CARCINOGENESIS, V13, P2471, DOI 10.1093/carcin/13.12.2471; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Melnyk S, 1999, CANCER LETT, V146, P35, DOI 10.1016/S0304-3835(99)00213-X; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; ROGERS AE, 1993, CARCINOGENESIS, V14, P2205, DOI 10.1093/carcin/14.11.2205; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; ROSE KM, 1981, J BIOL CHEM, V256, P7468; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; ROSENBERG IH, 1989, GASTROENTEROLOGY, V97, P502, DOI 10.1016/0016-5085(89)90091-7; Rush LJ, 2002, BLOOD, V99, P1874, DOI 10.1182/blood.V99.5.1874; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SEIMIYA H, 1995, ONCOGENE, V10, P1731; Seimiya H, 1998, J BIOL CHEM, V273, P21187, DOI 10.1074/jbc.273.33.21187; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; SUCHY BK, 1989, CANCER RES, V49, P6781; Tagawa M, 1997, BIOCHEM J, V321, P865, DOI 10.1042/bj3210865; Takeuchi S, 1996, CANCER RES, V56, P738; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAINFAN E, 1992, CANCER RES, V52, pS2071; WAINFAN E, 1988, CARCINOGENESIS, V9, P861, DOI 10.1093/carcin/9.5.861; WAINFAN E, 1989, CANCER RES, V49, P4094; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Wilkens L, 2000, AM J CLIN PATHOL, V114, P867, DOI 10.1309/BMTT-JBPD-D13H-1UVD; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	70	95	104	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6319	6331		10.1038/sj.onc.1206750	http://dx.doi.org/10.1038/sj.onc.1206750			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508512	Green Accepted			2022-12-28	WOS:000185535300002
J	Obungu, VH; Burns, AL; Agarwal, SK; Chandrasekharapa, SC; Adelstein, RS; Marx, SJ				Obungu, VH; Burns, AL; Agarwal, SK; Chandrasekharapa, SC; Adelstein, RS; Marx, SJ			Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain	ONCOGENE			English	Article						MEN1; menin; TAP; nonmuscle myosin; cytokinesis	ENDOCRINE NEOPLASIA TYPE-1; MOLD PHYSARUM-POLYCEPHALUM; MESSENGER-RNAS; NONHISTONE PROTEINS; NUCLEAR-ENVELOPE; GENE-PRODUCT; EXPRESSION; INTERACTS; DROSOPHILA; MORPHOGENESIS	MEN1 is a likely tumor suppressor gene that encodes a novel protein, menin. Menin is a 610 amino-acid residue protein with as yet unknown function(s). We have used tandem affinity purification and mass spectroscopy to isolate and identify proteins associating with menin from cultured HeLa cell extracts. This strategy has resulted in the isolation and identification of nonmuscle myosin type II-A heavy chain (NMHC II-A) as a menin interacting protein. This interaction was confirmed by glutathione-S-transferase pulldown assays, by coimmunoprecipitation, and by actin selection of myosin. We have further identified the amino-terminal region of menin and the head domain of NMHC II-A to be regions required for this interaction. Moreover menin was seen to colocalize with this myosin isoform in the cleavage furrow of dividing cells by indirect immunofluoresence. These data indicate that menin through binding to NMHC II-A could participate in cell division and in other processes that involve NMHC II-A.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Obungu, VH (corresponding author), Eli Lilly & Co, Lilly Res Lab, Lilly Corp Ctr, DC 1505, Indianapolis, IN 46285 USA.	Obunguvi@lilly.com	Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004218, Z01HL004218] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAYR SM, 1992, SHORT PROTOCOLS MOL; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUVAS AS, 1975, P NATL ACAD SCI USA, V72, P3902, DOI 10.1073/pnas.72.10.3902; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Huang SC, 1999, LAB INVEST, V79, P301; JOCKUSCH BM, 1971, J BACTERIOL, V108, P705, DOI 10.1128/JB.108.2.705-714.1971; JOCKUSCH BM, 1970, J BACTERIOL, V103, P356, DOI 10.1128/JB.103.2.356-363.1970; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LESTOURGEON WM, 1975, BIOCHIM BIOPHYS ACTA, V379, P529, DOI 10.1016/0005-2795(75)90160-9; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marx SJ, 2001, METABOLIC MOL BASES, P943; MAUPIN P, 1994, J CELL SCI, V107, P3077; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; OHNISHI T, 1963, J BIOCHEM, V54, P298, DOI 10.1093/oxfordjournals.jbchem.a127789; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Seri M, 2000, NAT GENET, V26, P103; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; STRAND D, 1995, ONCOGENE, V11, P291; Sukhodolets KE, 2003, MOL CELL BIOL, V23, P493, DOI 10.1128/MCB.23.2.493-509.2003; Suphapeetiporn K, 2001, AM J HUM GENET, V69, P206; Tonini R, 1999, FASEB J, V13, P1395, DOI 10.1096/fasebj.13.11.1395; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	55	37	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6347	6358		10.1038/sj.onc.1206658	http://dx.doi.org/10.1038/sj.onc.1206658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508515				2022-12-28	WOS:000185535300005
J	Totzke, G; Schulze-Osthoff, K; Janicke, RU				Totzke, G; Schulze-Osthoff, K; Janicke, RU			Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition	ONCOGENE			English	Article						NS-398; nimesulide; COX-2; death receptor; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER CELLS; ANTICANCER AGENTS; HUMAN COLON; KAPPA-B; EXPRESSION; CELECOXIB; GROWTH; SUPPRESSION; INDUCTION	Cyclooxygenase-2 (COX-2) is involved in diverse processes such as inflammation, carcinogenesis and apoptosis. As COX-2 inhibitors interfere with these processes, inhibition of COX-2 has been suggested as a promising anticancer treatment. However, the role of COX-2 in modulation of apoptosis as well as the death pathways affected by COX-2 inhibitors are poorly characterized. Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E-2 (PGE(2)) production, only in H21 cells. TNF did also not induce PGE(2) production in MCF-7/casp-3 cells stably expressing COX-2; however, nimesulide strongly enhanced TNF-induced apoptosis in these cells. Furthermore, COX-2 activity in HeLa H21 cells could be inhibited by NS-398 concentrations that were 10000-fold lower compared to those required for the induction of cell death. Most intriguingly, sensibilization to apoptosis was specifically observed in response to activation of death receptors. Not only TNF-induced cell death but also apoptosis triggered by the CD95 and TRAIL receptors was enhanced by nimesulide. In contrast, apoptosis induced by the anticancer drugs doxorubicine and etoposide that target the mitochondrial death pathway remained unaffected. Together, our data suggest that COX-2 inhibitors overcome apoptosis resistance and selectively sensitize tumor cells to the extrinsic death receptor-induced apoptotic pathway independently of COX-2.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Callejas NA, 2002, HEPATOLOGY, V35, P341, DOI 10.1053/jhep.2002.31163; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; GUPTA RA, 2000, ANN NY ACAD SCI, V10, P196; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang Y, 2001, CANCER RES, V61, P6918; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JENDROSSEK V, 2003, IN PRESS FASSEB J; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Liu XH, 1998, CANCER RES, V58, P4245; Masferrer JL, 2000, CANCER RES, V60, P1306; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Nzeako UC, 2002, HEPATOLOGY, V35, P552, DOI 10.1053/jhep.2002.31774; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ravi R, 2002, CANCER RES, V62, P4180; Ricchi P, 2002, BRIT J CANCER, V86, P1501, DOI 10.1038/sj.bjc.6600289; Ristimaki A, 1997, CANCER RES, V57, P1276; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shureiqi I, 2000, CANCER RES, V60, P6846; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Song XQ, 2002, J NATL CANCER I, V94, P585; Souza RF, 2000, CANCER RES, V60, P5767; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stier S, 2000, FEBS LETT, V467, P299, DOI 10.1016/S0014-5793(00)01177-7; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Tang XM, 2002, CANCER RES, V62, P4903; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tucker ON, 1999, CANCER RES, V59, P987; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Waskewich C, 2002, CANCER RES, V62, P2029; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wong BCY, 2003, ONCOGENE, V22, P1189, DOI 10.1038/sj.onc.1206234; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zimmermann KC, 1999, CANCER RES, V59, P198	58	73	77	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8021	8030		10.1038/sj.onc.1206837	http://dx.doi.org/10.1038/sj.onc.1206837			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970750				2022-12-28	WOS:000185388200017
J	Denko, NC; Fontana, LA; Hudson, KM; Sutphin, PD; Raychaudhuri, S; Altman, R; Giaccia, AJ				Denko, NC; Fontana, LA; Hudson, KM; Sutphin, PD; Raychaudhuri, S; Altman, R; Giaccia, AJ			Investigating hypoxic tumor physiology through gene expression patterns	ONCOGENE			English	Article						hypoxic gene induction; HIF-1; VHL	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; MESSENGER-RNA; TRANSCRIPTION FACTOR; OXYGENATION PREDICTS; PROLYL HYDROXYLATION; ERYTHROPOIETIN GENE; GLYCOLYTIC-ENZYMES; FIBRIN DEPOSITION; CARCINOMA CELLS	Clinical evidence shows that tumor hypoxia is an independent prognostic indicator of poor patient outcome. Hypoxic tumors have altered physiologic processes, including increased regions of angiogenesis, increased local invasion, increased distant metastasis and altered apoptotic programs. Since hypoxia is a potent controller of gene expression, identifying hypoxia-regulated genes is a means to investigate the molecular response to hypoxic stress. Traditional experimental approaches have identified physiologic changes in hypoxic cells. Recent studies have identified hypoxia-responsive genes that may define the mechanism(s) underlying these physiologic changes. For example, the regulation of glycolytic genes by hypoxia can explain some characteristics of the Warburg effect. The converse of this logic is also true. By identifying new classes of hypoxia-regulated gene(s), we can infer the physiologic pressures that require the induction of these genes and their protein products. Furthermore, these physiologically driven hypoxic gene expression changes give us insight as to the poor outcome of patients with hypoxic tumors. Approximately 1-1.5% of the genome is transcriptionally responsive to hypoxia. However, there is significant heterogeneity in the transcriptional response to hypoxia between different cell types. Moreover, the coordinated change in the expression of families of genes supports the model of physiologic pressure leading to expression changes. Understanding the evolutionary pressure to develop a 'hypoxic response' provides a framework to investigate the biology of the hypoxic tumor microenvironment.	Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Denko, NC (corresponding author), Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA.	ndenko@stanford.edu	denko, nicholas/F-8444-2010	Raychaudhuri, Soumya/0000-0002-1901-8265	NCI NIH HHS [CA67166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Brizel DM, 1996, CANCER RES, V56, P941; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; BRUICK RK, 2001, SCIENCE, V11, P11; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Chen EY, 1999, TERATOLOGY, V60, P215; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; De Jaeger K, 2001, BRIT J CANCER, V84, P1280; Denko N, 2003, J BIOL CHEM, V278, P5744, DOI 10.1074/jbc.M212534200; Denko N, 2000, CLIN CANCER RES, V6, P480; Denko NC, 2001, CANCER RES, V61, P795; Denko NC, 2000, EXP CELL RES, V258, P82, DOI 10.1006/excr.2000.4928; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ebert BL, 1996, BIOCHEM J, V313, P809, DOI 10.1042/bj3130809; Elson DA, 2000, CANCER RES, V60, P6189; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; FANDREY J, 1993, BLOOD, V81, P617; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham CH, 1998, BLOOD, V91, P3300, DOI 10.1182/blood.V91.9.3300.3300_3300_3307; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Grunstein J, 1999, CANCER RES, V59, P1592; Hockel M, 1996, CANCER RES, V56, P4509; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; IMAGAWA S, 1991, BLOOD, V77, P278; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koong AC, 2000, CANCER RES, V60, P883; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Laderoute KR, 2000, CLIN CANCER RES, V6, P2941; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Millhorn DE, 1996, ADV EXP MED BIOL, V410, P135; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Niitsu Y, 1999, MOL BRAIN RES, V74, P26, DOI 10.1016/S0169-328X(99)00245-4; Nordsmark M, 1996, RADIOTHER ONCOL, V41, P31, DOI 10.1016/S0167-8140(96)91811-3; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; Ozawa K, 2001, CANCER RES, V61, P4206; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; PLATE KH, 1993, CANCER RES, V53, P5822; Postovit LM, 2002, J BIOL CHEM, V277, P35730, DOI 10.1074/jbc.M204529200; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Scandurro AB, 2001, INT J ONCOL, V19, P129; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sowter HM, 2001, CANCER RES, V61, P6669; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Ten Vadim S, 2002, Curr Opin Crit Care, V8, P242, DOI 10.1097/00075198-200206000-00008; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Wang CG, 2000, DNA CELL BIOL, V19, P71, DOI 10.1089/104454900314582; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Warren SM, 2001, J SURG RES, V99, P147, DOI 10.1006/jsre.2001.6128; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71	86	253	267	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5907	5914		10.1038/sj.onc.1206703	http://dx.doi.org/10.1038/sj.onc.1206703			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947397				2022-12-28	WOS:000185086100017
J	Valerie, K; Povirk, LF				Valerie, K; Povirk, LF			Regulation and mechanisms of mammalian double-strand break repair	ONCOGENE			English	Review						ATM; DNA-PK; homologous recombination; nonhomologous end-joining; P53; signal transduction	DEPENDENT PROTEIN-KINASE; S-PHASE CHECKPOINT; TELANGIECTASIA-MUTATED ATM; WERNER-SYNDROME PROTEIN; DNA-LIGASE-IV; INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; RADIATION-INDUCED APOPTOSIS; HUMAN CELL-EXTRACTS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION	The double-strand break (DSB) is believed to be one of the most severe types of DNA damage, and if left unrepaired is lethal to the cell. Several different types of repair act on the DSB. The most important in mammalian cells are nonhomologous end-joining (NHEJ) and homologous recombination repair (HRR). NHEJ is the predominant type of DSB repair in mammalian cells, as opposed to lower eucaryotes, but HRR has recently been implicated in critical cell signaling and regulatory functions that are essential for cell viability. Whereas NHEJ repair appears constitutive, HRR is regulated by the cell cycle and inducible signal transduction pathways. More is known about the molecular details of NHEJ than HRR in mammalian cells. This review focuses on the mechanisms and regulation of DSB repair in mammalian cells, the signaling pathways that regulate these processes and the potential crosstalk between NHEJ and HRR, and between repair and other stress-induced pathways with emphasis on the regulatory circuitry associated with the ataxia telangiectasia mutated (ATM) protein.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Valerie, K (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.	KVALERIE@MAIL2.VCU.EDU	Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [P01CA72955, CA40615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072955, R01CA040615] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Achanta G, 2001, CANCER RES, V61, P8723; Adair GR, 2000, EMBO J, V19, P5552, DOI 10.1093/emboj/19.20.5552; Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; AllalunisTurner J, 1997, RADIAT RES, V147, P284, DOI 10.2307/3579334; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bill CA, 1997, MUTAT RES-DNA REPAIR, V385, P21, DOI 10.1016/S0921-8777(97)00040-2; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brown EJ, 2000, GENE DEV, V14, P397; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cheong N, 1999, INT J RADIAT BIOL, V75, P67, DOI 10.1080/095530099140825; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Daboussi F, 2002, CELL SIGNAL, V14, P969, DOI 10.1016/S0898-6568(02)00052-9; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; DiBiase SJ, 1999, INT J RADIAT ONCOL, V45, P743, DOI 10.1016/S0360-3016(99)00229-1; Donahue SL, 2002, J BIOL CHEM, V277, P46243, DOI 10.1074/jbc.M207937200; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Evans JW, 1996, RADIAT RES, V145, P39, DOI 10.2307/3579193; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gottlich B, 1998, EUR J BIOCHEM, V258, P387, DOI 10.1046/j.1432-1327.1998.2580387.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Gu XY, 1998, BIOCHEMISTRY-US, V37, P9827, DOI 10.1021/bi980198o; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hallahan DE, 1996, INT J RADIAT ONCOL, V36, P355, DOI 10.1016/S0360-3016(96)00327-6; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hickson ID, 2001, BIOCHEM SOC T, V29, P201, DOI 10.1042/0300-5127:0290201; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; ILIAKIS G, 1983, INT J RADIAT BIOL, V43, P649, DOI 10.1080/09553008314550741; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; ISILDAR M, 1981, INT J RADIAT BIOL, V40, P347, DOI 10.1080/09553008114551301; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Jones JM, 2002, EMBO J, V21, P4162, DOI 10.1093/emboj/cdf394; Jones JM, 2001, STRUCTURE, V9, P881, DOI 10.1016/S0969-2126(01)00658-X; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kabotyanski EB, 1998, NUCLEIC ACIDS RES, V26, P5333, DOI 10.1093/nar/26.23.5333; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Labhart P, 1999, MOL CELL BIOL, V19, P2585; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee JW, 2003, CANCER RES, V63, P22; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2002, NUCLEIC ACIDS RES, V30, P3653, DOI 10.1093/nar/gkf488; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Martensson S, 2002, J BIOL CHEM, V277, P3020, DOI 10.1074/jbc.M106711200; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; MIMORI T, 1986, J BIOL CHEM, V261, P375; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Oshima J, 2002, CANCER RES, V62, P547; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; Pang DL, 1997, CANCER RES, V57, P1412; Park SJ, 2001, DNA CELL BIOL, V20, P637, DOI 10.1089/104454901753340622; Pastwa E, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.16.e78; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; Pluth JM, 2001, CANCER RES, V61, P2649; POST S, 2001, P NATL ACAD SCI USA, V30, P30; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; POVIRK LF, 1994, J MOL BIOL, V243, P216; POWELL SN, 1995, CANCER RES, V55, P1643; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rathmell WK, 1997, CANCER RES, V57, P68; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Rothkamm K, 2001, CANCER RES, V61, P3886; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sargent RG, 2000, NUCLEIC ACIDS RES, V28, P3771, DOI 10.1093/nar/28.19.3771; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tang W, 1999, CANCER RES, V59, P2562; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; THACKER J, 1992, NUCLEIC ACIDS RES, V20, P6183, DOI 10.1093/nar/20.23.6183; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tong X, 2000, INT J RADIAT BIOL, V76, P1387, DOI 10.1080/09553000050151664; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 2001, EMBO REP, V2, P905, DOI 10.1093/embo-reports/kve201; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang HC, 2001, CANCER RES, V61, P270; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wang HY, 2001, CANCER RES, V61, P8554; Wang P, 1997, P NATL ACAD SCI USA, V94, P12018, DOI 10.1073/pnas.94.22.12018; Wang P, 2002, NUCLEIC ACIDS RES, V30, P2639, DOI 10.1093/nar/gkf369; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wiese C, 2002, CANCER RES, V62, P1279; Wiesmuller L, 1996, J VIROL, V70, P737; WINEGAR RA, 1992, MUTAGENESIS, V7, P439, DOI 10.1093/mutage/7.6.439; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 2002, J BIOL CHEM, V277, P36787, DOI 10.1074/jbc.M205350200; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yuan SSF, 1999, CANCER RES, V59, P3547; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, ONCOGENE, V21, P6377, DOI 10.1038/sj.onc.1205782	313	435	474	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5792	5812		10.1038/sj.onc.1206679	http://dx.doi.org/10.1038/sj.onc.1206679			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947387				2022-12-28	WOS:000185086100007
J	Waltermann, A; Kartasheva, NN; Dobbelstein, M				Waltermann, A; Kartasheva, NN; Dobbelstein, M			Differential regulation of p63 and p73 expression	ONCOGENE			English	Article						p53; p63; p73; E2F; TGF beta; cell density	GROWTH-FACTOR-BETA; P53 HOMOLOG P63; LARGE T-ANTIGEN; CELL-DENSITY; TRANSCRIPTION ANALYSES; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS; SPONTANEOUS TUMORS; E1B 55-KILODALTON; E4ORF6 PROTEINS	Two homologs of the tumor suppressor p53, named p63 and p 73, are each expressed from at least two start sites of mRNA synthesis, yielding full-length, transactivating (TA) isoforms, and also aminoterminally truncated (DeltaN) isoforms that act as antagonists to p53. The expression of TAp73-transcripts is induced by E2F and negatively regulated by transforming growth factor beta (TGFbeta). The DeltaNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity. Here, we have analysed the expression of p63 in comparison with p73. In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels. Accordingly, the 3' promoter of p73, but not that of p63, was activated by p53 in reporter assays. DeltaNp73 mRNA and DeltaNp73 protein, but not the p63 gene products, also accumulated when HaCat cells (lacking functional p53) were grown to high density. TAp73, but not TAp63, expression was suppressed by TGFbeta in these cells, and the TAp73, but not the TAp63, promoter was induced by E2F-1. Thus, in contrast to the functional similarities of their respective products, the expression levels of p63 and p 73 are regulated by different mechanisms. This might be responsible for the discordant biological roles of p63 and p73 in development, as well as their deviant expression characteristics in cancer.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cviko A, 2000, HUM PATHOL, V31, P740, DOI 10.1053/hupa.2000.8232; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; Koch P, 2001, CANCER RES, V61, P5941; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liefer KM, 2000, CANCER RES, V60, P4016; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nishi H, 1999, INT J ONCOL, V15, P1149; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Prabhu NS, 1998, INT J ONCOL, V13, P5; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Roth J, 1997, J VIROL, V71, P8933, DOI 10.1128/JVI.71.11.8933-8939.1997; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	61	50	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5686	5693		10.1038/sj.onc.1206859	http://dx.doi.org/10.1038/sj.onc.1206859			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944917				2022-12-28	WOS:000184865900018
J	Snijders, AM; Fridlyand, J; Mans, DA; Segraves, R; Jain, AN; Pinkel, D; Albertson, DG				Snijders, AM; Fridlyand, J; Mans, DA; Segraves, R; Jain, AN; Pinkel, D; Albertson, DG			Shaping of tumor and drug-resistant genomes by instability and selection	ONCOGENE			English	Article						genetic instability; amplification; array CGH; mismatch repair	DNA MISMATCH REPAIR; FOLYLPOLYGLUTAMATE SYNTHETASE GENE; FRAGILE SITES; DIHYDROFOLATE-REDUCTASE; IN-SITU; AMPLIFICATION; METHOTREXATE; CELLS; EXPRESSION; CANCER	Tumors with defects in mismatch repair (MMR) show fewer chromosomal changes by cytogenetic analyses than most solid tumors, suggesting that a greater proportion of the alterations required for malignancy occur in genes with nucleotide sequences susceptible to errors normally corrected by MMR. Here, we used genome-wide microarray comparative genomic hybridization to carry out a higher resolution evaluation of the effect of MMR competence on genomic alterations occurring in 20 cell lines and to determine if characteristic aberrations arise in MMR-proficient and -deficient HCT116 cells undergoing selection for methotrexate resistance. We observed different spectra of aberrations in MMR-proficient compared to -deficient cell lines, as well as among cell lines with different types of MMR-deficiency. We also observed different genetic routes to drug resistance. Resistant MMR-deficient cells most frequently displayed no copy number alterations (16/29 cell pools), whereas all MMR-proficient cells had unique abnormalities involving chromosome 5, including amplicons centered on the target gene, DHFR and/or a neighboring novel locus (7/13 pools). These observations support the concept that tumor genomes are shaped by selection for alterations that promote survival and growth advantage, as well as by the particular dysfunctions in genes responsible for maintenance of genetic integrity.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA083040, R33CA094407] Funding Source: NIH RePORTER; NCI NIH HHS [CA83040, CA94407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; Chen ZS, 2002, CANCER RES, V62, P3144; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Cole PD, 2001, CANCER RES, V61, P4599; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Duval A, 2002, CANCER RES, V62, P2447; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fink D, 1998, INT J CANCER, V77, P741, DOI 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4; Frouin I, 2001, EUR J CANCER, V37, P1173, DOI 10.1016/S0959-8049(01)00095-8; Guan XY, 1996, CANCER RES, V56, P3446; HAWN MT, 1995, CANCER RES, V55, P3721; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KOI M, 1994, CANCER RES, V54, P4308; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; Lin CT, 2001, NUCLEIC ACIDS RES, V29, P3304, DOI 10.1093/nar/29.16.3304; Loeb LA, 2001, CANCER RES, V61, P3230; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P223, DOI 10.1002/gcc.2870140312; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Soulie P, 1999, CANCER GENET CYTOGEN, V115, P118, DOI 10.1016/S0165-4608(99)00073-4; Srimatkandada S, 2000, ONCOL RES, V12, P11; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Takemura Y, 1999, ANTI-CANCER DRUG, V10, P677, DOI 10.1097/00001813-199908000-00008; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; Waldman FM, 2000, JNCI-J NATL CANCER I, V92, P313, DOI 10.1093/jnci/92.4.313; Zeng H, 2001, CANCER RES, V61, P7225; Zhang L, 2001, CANCER RES, V61, P3801; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5; Zimonjic D, 2001, CANCER RES, V61, P8838	50	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4370	4379		10.1038/sj.onc.1206482	http://dx.doi.org/10.1038/sj.onc.1206482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853973				2022-12-28	WOS:000183978900006
J	Sommer, KW; Schamberger, CJ; Schmidt, GE; Sasgary, S; Cerni, C				Sommer, KW; Schamberger, CJ; Schmidt, GE; Sasgary, S; Cerni, C			Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras	ONCOGENE			English	Article						survivin; c-H-ras; PI3-K; MEK1; HaCat; rat cell lines; apoptosis; transformation	WILD-TYPE P53; PHOSPHATIDYLINOSITOL-3-OH KINASE; SP1 PHOSPHORYLATION; ENDOTHELIAL-CELLS; CDK INHIBITORS; IN-VIVO; PATHWAY; GENE; EXPRESSION; CANCER	Among the inhibitors of apoptosis proteins (IAPs), survivin has attracted special attention through its involvement in human cancer. The mechanism underlying tumour-associated survivin re-expression is not known. We found a correlation between exogenous c-H-Ras oncoprotein and endogenous survivin in a series of rat cell lines, which expressed defined oncogenes. Moreover, human HaCat cells, transfected with a constitutively activated c-H-ras gene, had significantly increased survivin levels. To study the interdependence of the two proteins, we generated a rat cell line that expressed a dexamethasone-inducible c-H-ras construct. Induction of c-H-Ras expression was followed by rapid upregulation of survivin. Conversely, downregulation of the oncoprotein resulted in prompt reduction of survivin to baseline value. c-H-Ras-induced survivin was expressed constitutively and independent of cell cycle progression or proliferation. Compromising Ras-stimulated PI3-K activity and MEK1 by chemicals abolished survivin expression and was associated with apoptotic cell death. Upregulation of survivin appeared to be an important activity of c-H-Ras oncoprotein, since cotransfection of a survivin-antisense construct into c-myc/c-H-ras-transfected primary rat embryo cells resulted in profound reduction of transformed clones. It is tempted to speculate that the frequent presence of survivin in human cancer cells might be a consequence of activated Ras-signalling pathways.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@univie.ac.at						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bao RD, 2002, J NATL CANCER I, V94, P522; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CERNI C, 1986, CURR TOP MICROBIOL, V132, P193; CERNI C, 1995, ONCOGENE, V11, P587; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Fuhrmann G, 2001, ONCOGENE, V20, P4542, DOI 10.1038/sj.onc.1204499; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; Notarbartolo M, 2002, CANCER LETT, V180, P91, DOI 10.1016/S0304-3835(01)00834-5; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simonitsch I, 2001, FASEB J, V15, P1416, DOI 10.1096/fj.00-0678fje; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	67	83	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4266	4280		10.1038/sj.onc.1206509	http://dx.doi.org/10.1038/sj.onc.1206509			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833149				2022-12-28	WOS:000183979800013
J	Han, SH; Jeon, JH; Ju, HR; Jung, U; Kim, KY; Sook, H; Yoo, HS; Lee, YH; Song, KS; Hwang, HM; Na, YS; Yang, Y; Lee, KN; Choi, I				Han, SH; Jeon, JH; Ju, HR; Jung, U; Kim, KY; Sook, H; Yoo, HS; Lee, YH; Song, KS; Hwang, HM; Na, YS; Yang, Y; Lee, KN; Choi, I			VDUP1 upregulated by TGF-beta 1 and 1,25-dihydorxyvitamin D-3 inhibits tumor cell growth by blocking cell-cycle progression	ONCOGENE			English	Article						VDUP1; tumor; TGF-beta 1; cell cycle; PLZF	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; PML-RAR-ALPHA; HISTONE DEACETYLASE; MONOCYTIC DIFFERENTIATION; THIOREDOXIN FUNCTION; HL-60 CELLS; GENE; PLZF; EXPRESSION	Vitamin D-3 upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) upregulated protein, and it is induced by various stresses. In human tumor tissues, VDUP1 expression was downregulated. Upon stimulation by growth-inhibitory signals such as TGF-beta1 and 1,25(OH)(2)D-3, its expression was rapidly upregulated as the cell growth was retarded. The transfection of VDUP1 in tumor cells reduced cell growth. The VDUP1 expression was also increased when the cell-cycle progression was arrested. Transfection of VDUP1 induced cell-cycle arrest at the G0/G1 phase, indicating that VDUP1 possesses a tumor-suppressive activity. In addition, it was found that VDUP1 interacted with promyelocytic leukemia zinc-finger, Fanconi anemia zinc-finger, and histone deacetylase 1, which are known to be transcriptional corepressors. VDUP1 itself suppressed IL-3 receptor and cyclin A2 promoter activity. Taken together, these results suggest that VDUP1 is a novel antitumor gene which forms a transcriptional repressor complex.	Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Genome Res Ctr, Taejon 305333, South Korea; Chungnam Natl Univ, Coll Med, Dept Pathol, Dept Anat, Taejon 301131, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University	Choi, I (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea.			Yang, Young/0000-0003-4239-0804				BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Bocchia M, 1997, LEUKEMIA RES, V21, P439, DOI 10.1016/S0145-2126(96)00085-9; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kirshenbaum LA, 2001, CIRC RES, V88, P978, DOI 10.1161/hh1001.091865; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ludwig DL, 2001, GENE, V269, P103, DOI 10.1016/S0378-1119(01)00455-3; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Olsson I, 1996, EUR J HAEMATOL, V57, P1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Piek JMJ, 2001, HISTOPATHOLOGY, V38, P481, DOI 10.1046/j.1365-2559.2001.1163c.x; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sainty D, 2000, BLOOD, V96, P1287; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 2000, CANCER RES, V60, P3689; Takahashi Y, 2002, ONCOL REP, V9, P75; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang XN, 2001, J CELL BIOCHEM, V80, P471, DOI 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	37	229	241	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4035	4046		10.1038/sj.onc.1206610	http://dx.doi.org/10.1038/sj.onc.1206610			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821938				2022-12-28	WOS:000183707600007
J	Pedersen, TX; Leethanakul, C; Patel, V; Mitola, D; Lund, LR; Dano, K; Johnsen, M; Gutkind, JS; Bugge, TH				Pedersen, TX; Leethanakul, C; Patel, V; Mitola, D; Lund, LR; Dano, K; Johnsen, M; Gutkind, JS; Bugge, TH			Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma	ONCOGENE			English	Review						cDNA arrays; gene expression; keratinocytes; laser capture microdissection; squamous cell carcinoma; wound healing	GAP-JUNCTION PROTEINS; HUMAN EPIDERMAL-KERATINOCYTES; INTERFERON-GAMMA RECEPTORS; MOUSE SKIN CARCINOGENESIS; HEAT-SHOCK PROTEINS; NF-KAPPA-B; GROWTH-FACTOR; GENE-EXPRESSION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	Keratinocytes undergo a dramatic phenotypic conversion during reepithelialization of skin wounds to become hyperproliferative, migratory, and invasive. This transient healing response phenotypically resembles malignant transformation of keratinocytes during squamous cell carcinoma progression. Here we present the first analysis of global changes in keratinocyte gene expression during skin wound healing in vivo, and compare these changes to changes in gene expression during malignant conversion of keratinized epithelium. Laser capture microdissection was used to isolate RNA from wound keratinocytes from incisional mouse skin wounds and adjacent normal skin keratinocytes. Changes in gene expression were determined by comparative cDNA array analyses, and the approach was validated by in situ hybridization. The analyses identified 48 candidate genes not previously associated with wound reepithelialization. Furthermore, the analyses revealed that the phenotypic resemblance of wound keratinocytes to squamous cell carcinoma is mimicked at the level of gene expression, but notable differences between the two tissue-remodeling processes were also observed. The combination of laser capture microdissection and cDNA array analysis provides a powerful new tool to unravel the complex changes in gene expression that underlie physiological and pathological remodeling of keratinized epithelium.	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark; Natl Inst Dent & Craniofacial Res, Mol Carcinogenesis Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Rigshospitalet; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.		Johnsen, Morten/L-8016-2014; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Johnsen, Morten/0000-0003-3763-2362; Gutkind, J. Silvio/0000-0002-5150-4482; Pedersen, Tanja Xenia/0000-0003-2515-3022	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Balasubramanian S, 1998, BIOCHEM BIOPH RES CO, V243, P744, DOI 10.1006/bbrc.1998.8172; BARRA RM, 1994, J INVEST DERMATOL, V102, P61, DOI 10.1111/1523-1747.ep12371733; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; BUTTERWECK A, 1994, EUR J CELL BIOL, V65, P152; Cao TY, 1996, DEV GENET, V19, P309, DOI 10.1002/(SICI)1520-6408(1996)19:4<309::AID-DVG4>3.3.CO;2-1; Cao ZY, 2002, J BIOL CHEM, V277, P42299, DOI 10.1074/jbc.M200981200; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Codd JD, 1999, J PATHOL, V187, P549; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; CURINO A, 2002, IN PRESS ONCOGENE; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; De Panfilis G, 2002, BRIT J DERMATOL, V147, P7, DOI 10.1046/j.1365-2133.2002.04746.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEYERLE KL, 1992, J IMMUNOL, V149, P1657; Dick T, 1996, MOL CELL BIOL, V16, P1966; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; Dong G, 2001, CANCER RES, V61, P4797; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; ELLER MS, 1994, J INVEST DERMATOL, V103, P785, DOI 10.1111/1523-1747.ep12413037; ELLER MS, 1995, J CELL SCI, V108, P2741; Engelholm LH, 2001, LAB INVEST, V81, P1403, DOI 10.1038/labinvest.3780354; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FEINGOLD KR, 1995, J INVEST DERMATOL, V104, P246, DOI 10.1111/1523-1747.ep12612790; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GIMENEZCONTI IB, 1990, CANCER RES, V50, P4441; Gold LI, 1997, AM J PATHOL, V150, P209; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; Grehan S, 2001, J INVEST DERMATOL, V116, P77, DOI 10.1046/j.1523-1747.2001.00213.x; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIRAI Y, 1989, DEVELOPMENT, V105, P271; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Huh CG, 1999, J CLIN PATHOL-MOL PA, V52, P332, DOI 10.1136/mp.52.6.332; Ivell R, 2001, EXP PHYSIOL, V86, P289, DOI 10.1113/eph8602185; Jansen BJH, 2001, J INVEST DERMATOL, V116, P12, DOI 10.1046/j.1523-1747.2001.00218.x; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kaneto H, 1997, J BIOL CHEM, V272, P29137, DOI 10.1074/jbc.272.46.29137; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Kim SH, 2002, AUDIOL NEURO-OTOL, V7, P348, DOI 10.1159/000066159; KIMURA T, 1994, EUR J ENDOCRINOL, V131, P385, DOI 10.1530/eje.0.1310385; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kiriyama MT, 2001, BIOL PHARM BULL, V24, P197, DOI 10.1248/bpb.24.197; Kitayoshi H, 1999, ARCH DERMATOL RES, V291, P333, DOI 10.1007/s004030050418; Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6; Knoepfel L, 1996, BIOL CHEM H-S, V377, P139, DOI 10.1515/bchm3.1996.377.2.139; Kooy AJW, 1998, J PATHOL, V184, P169; KopfMaier P, 1996, ACTA ANAT, V155, P1; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; Kubo M, 2001, BRIT J DERMATOL, V145, P840, DOI 10.1046/j.1365-2133.2001.04480.x; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lansdown ABG, 1999, J ANAT, V195, P375, DOI 10.1046/j.1469-7580.1999.19530375.x; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee SH, 1998, APMIS, V106, P1035, DOI 10.1111/j.1699-0463.1998.tb00255.x; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Lu Q, 2002, J NEUROSCI RES, V67, P618, DOI 10.1002/jnr.10151; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; Mian IS, 1998, BLOOD CELL MOL DIS, V24, P83, DOI 10.1006/bcmd.1998.9998; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moll J, 1996, HISTOCHEM J, V28, P45, DOI 10.1007/BF02331426; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OISHI M, 1994, ARCH DERMATOL RES, V286, P396, DOI 10.1007/BF00371800; Okura T, 1996, J IMMUNOL, V157, P4277; OLKKONEN VM, 1994, GENE, V138, P207, DOI 10.1016/0378-1119(94)90809-5; Ono S, 2000, ACTA NEUROL SCAND, V102, P47, DOI 10.1034/j.1600-0404.2000.102001047.x; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Richard G, 2000, EXP DERMATOL, V9, P77, DOI 10.1034/j.1600-0625.2000.009002077.x; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.0.CO;2-3; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Sadano H, 2000, BIOCHEM BIOPH RES CO, V267, P418, DOI 10.1006/bbrc.1999.1969; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Schmitt J, 1996, GENOMICS, V32, P358, DOI 10.1006/geno.1996.0130; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Semina EV, 1998, HUM MOL GENET, V7, P415, DOI 10.1093/hmg/7.3.415; Shimeld SM, 1996, MECH DEVELOP, V55, P201, DOI 10.1016/0925-4773(96)00505-9; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Thelu J, 1998, J INVEST DERMATOL, V111, P903, DOI 10.1046/j.1523-1747.1998.00372.x; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; van Ruissen F, 2002, GENOMICS, V79, P671, DOI 10.1006/geno.2002.6756; VANDENOORD JJ, 1995, PATHOL RES PRACT, V191, P530, DOI 10.1016/S0344-0338(11)80872-1; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Westergaard M, 2001, J INVEST DERMATOL, V116, P702, DOI 10.1046/j.1523-1747.2001.01329.x; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wu WG, 2002, CLIN EXP METASTAS, V19, P319, DOI 10.1023/A:1015515119300; Xiao JH, 1999, EMBO J, V18, P1539, DOI 10.1093/emboj/18.6.1539; Yamamoto S, 2000, BBA-GENE STRUCT EXPR, V1490, P121, DOI 10.1016/S0167-4781(99)00217-1; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; YU S, 1995, CELL STRUCT FUNCT, V20, P263, DOI 10.1247/csf.20.263; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	137	68	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3964	3976		10.1038/sj.onc.1206614	http://dx.doi.org/10.1038/sj.onc.1206614			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813470				2022-12-28	WOS:000183612000016
J	Zhu, G; Reynolds, L; Crnogorac-Jurcevic, T; Gillett, CE; Dublin, EA; Marshall, JF; Barnes, D; D'Arrigo, C; Van Trappen, PO; Lemoine, NR; Hart, IR				Zhu, G; Reynolds, L; Crnogorac-Jurcevic, T; Gillett, CE; Dublin, EA; Marshall, JF; Barnes, D; D'Arrigo, C; Van Trappen, PO; Lemoine, NR; Hart, IR			Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer	ONCOGENE			English	Article						breast cancer; invasion; microarrays; microdissection	LASER CAPTURE MICRODISSECTION; BINDING PROTEIN; INVASION; PROGRESSION; METASTASIS; PATTERNS; ADENOCARCINOMA; GROWTH; ALPHA; CDNA	Comparison of gene expression changes between cancer cells at the periphery and in the centre of breast cancers was performed using a combination of microdissection and microarray analysis. Cancer cells from the two areas were pooled separately from five patients with ductal carcinoma in situ and separately from five patients with frankly invasive cancer. Limited total RNA, 100-200 ng, from this microdissected tissue required use of the Atlas SMART(TM) Probe Amplification Kit to synthesize and amplify cDNA and make P-33-labelled probes. Probes were then hybridized to Atlas Human Cancer 1.2 Arrays containing 1176 known genes. Triplicate analysis revealed that 22 genes changed their expression levels in the periphery relative to the central region: 15 upregulated and seven down-regulated (arbitrary threshold of 1.5-fold or greater). Differences in RNA levels were confirmed by quantitative real-time PCR for two of the genes and by changes in protein levels, detected by immunohistochemistry, for a couple of representative gene products. Thus, changes in gene expression associated with variation in microanatomical location of neoplastic cells can be detected within even small developing tumour masses.	St Thomas Hosp, Canc Res UK Lab, Richard Dimbleby Dept Canc Res, GKT Sch Med, London SE1 7EH, England; St Thomas Hosp, Rayne Inst, Canc Res UK, Cell Adhes & Dis Lab, London SE1 7EH, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK, London, England; Guys Hosp, Clin Oncol Dept, Hedley Atkins Breast Pathol Lab, London, England; St Bartholomews Hosp, Sch Med, Canc Res UK, Translat Oncol Lab,Queen Mary Coll, London, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; University of London; Queen Mary University London	Hart, IR (corresponding author), St Thomas Hosp, Canc Res UK Lab, Richard Dimbleby Dept Canc Res, GKT Sch Med, 4th Floor,Lambeth Wing, London SE1 7EH, England.		Van Trappen, Philippe/ABF-7431-2021	Van Trappen, Philippe/0000-0002-9784-7974; Marshall, John/0000-0002-0494-2295				Assmann V, 2001, J PATHOL, V195, P191, DOI 10.1002/path.941; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DeRisi J, 1996, NAT GENET, V14, P457; Edmonds BT, 1996, J CELL SCI, V109, P2705; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HALL PA, 1994, BRIT J CANCER, V70, P244, DOI 10.1038/bjc.1994.287; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Luzzi V, 2001, AM J PATHOL, V158, P2005, DOI 10.1016/S0002-9440(10)64672-X; Mariani L, 2001, CANCER RES, V61, P4190; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Scheidl SJ, 2002, AM J PATHOL, V160, P801, DOI 10.1016/S0002-9440(10)64903-6; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schutze K, 1998, CELL MOL BIOL, V44, P735; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Van Trappen PO, 2001, LANCET, V357, P15, DOI 10.1016/S0140-6736(00)03566-2; Zhumabayeva B, 2001, BIOTECHNIQUES, V30, P158, DOI 10.2144/01301pf01	24	58	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3742	3748		10.1038/sj.onc.1206428	http://dx.doi.org/10.1038/sj.onc.1206428			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802281				2022-12-28	WOS:000183551000008
J	Wilhelmsson, U; Eliasson, C; Bjerkvig, R; Pekny, M				Wilhelmsson, U; Eliasson, C; Bjerkvig, R; Pekny, M			Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression	ONCOGENE			English	Article						glial fibrillary acidic protein; astrocytoma; intermediate filaments; gene targeting; p53	FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; HUMAN GLIOMAS; INTERMEDIATE FILAMENTS; PHOSPHORYLATION SITES; COMPLEMENTARY-DNA; BRAIN-TUMORS; IN-VITRO; CELLS; GROWTH	In astrocytic neoplasms, the number of cells expressing glial fibrillary acidic protein (GFAP) is inversely proportional to the extent of anaplasia. The loss of GFAP expression, the principal marker of astroglial cells, in these tumors has been proposed to constitute a step in their development and progression. To test this hypothesis, we crossed p53-negative (p53(-/-)) mice, which frequently develop astrocytomas after intrauterine exposure to ethylnitrosourea, with GFAP-negative (GFAP(-/-)) mice or GFAP(+/+) controls. Brain tumors of glial origin were found in 12 of 35 GFAP(+/+) p53(-/-) mice (34%) and in I I of 27 GFAP(-/-) p53(-/-) mice (41%). The two groups did not differ in the age at which tumors were detected or in tumor histology or progression. Thus, the loss of GFAP expression frequently seen in high-grade astrocytomas does not constitute a step in tumor development. Rather, it may represent the undifferentiated state of these cells.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Univ Bergen, Dept Anat & Cell Biol, Bergen, Norway	University of Gothenburg; University of Bergen	Pekny, M (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.			Wilhelmsson, Ulrika/0000-0003-3227-2687				BIGNER SH, 1998, GENETIC BASIS HUMAN, P661; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECK JHN, 1978, ACTA NEUROPATHOL, V42, P183, DOI 10.1007/BF00690355; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Engebraaten O, 1999, J NEUROSURG, V90, P125, DOI 10.3171/jns.1999.90.1.0125; HARA A, 1991, SURG NEUROL, V36, P190, DOI 10.1016/0090-3019(91)90111-L; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JACQUE CM, 1979, J NATL CANCER I, V62, P479, DOI 10.1093/jnci/62.3.479; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; KAJIWARA K, 1992, BRAIN RES, V572, P314, DOI 10.1016/0006-8993(92)90492-R; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Leonard JR, 2001, ONCOGENE, V20, P8281, DOI 10.1038/sj.onc.1205024; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Oda H, 1997, CANCER RES, V57, P646; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Pekny M, 2001, Prog Brain Res, V132, P23; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TASCOS NA, 1982, HUM PATHOL, V13, P454, DOI 10.1016/S0046-8177(82)80028-2; TODA M, 1994, J NEUROCHEM, V63, P1975; Toda M, 1999, NEUROCHEM RES, V24, P339, DOI 10.1023/A:1022538810581; TSUJIMURA K, 1994, J BIOCHEM, V116, P426, DOI 10.1093/oxfordjournals.jbchem.a124542; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; Wechsler W, 1979, Natl Cancer Inst Monogr, P219; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; YONG VW, 1992, J NEUROL SCI, V111, P92; ZHOU Y, 2002, NAT REV CANCER, V8, P616	38	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3407	3411		10.1038/sj.onc.1206372	http://dx.doi.org/10.1038/sj.onc.1206372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776191				2022-12-28	WOS:000183128500006
J	Li, G; Satyamoorthy, K; Meier, F; Berking, C; Bogenrieder, T; Herlyn, M				Li, G; Satyamoorthy, K; Meier, F; Berking, C; Bogenrieder, T; Herlyn, M			Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil	ONCOGENE			English	Review						melanoma; stromal fibroblast; tumor progression; adherens junction; gap junction; stem cell	HEPATOCYTE GROWTH-FACTOR; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; NORMAL HUMAN MELANOCYTES; EPITHELIAL TUMOR-CELLS; SKIN EQUIVALENT MODEL; PROSTATE-CANCER CELLS; FACTOR SCATTER FACTOR; N-CADHERIN; MALIGNANT-MELANOMA	Melanoma development and progression not only involve genetic and epigenetic changes that take place within the melanocytic cells, but also involve processes that are determined collectively by contextual factors including intercellular adhesions and communications. In this review, we focus on melanoma-stromal fibroblast crosstalk by direct cell-cell contact and by growth factors/ cytokines/chemokines interacting with their respective receptors. The interactions between melanoma cells and stromal fibroblasts create a context that promotes tumor growth, migration/invasion, and angiogenesis. An understanding of this process and developing new experimental and screening models are of great importance for the development of effective therapeutical strategies to treat melanoma.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Program, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Satyamoorthy, Kapaettu/0000-0002-2368-5490	NCI NIH HHS [CA-47159, CA-10815, CA-76674, CA-25874, CA-80999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, P30CA010815, R01CA080999, R01CA076674, R01CA047159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Y, 1998, CANCER RES, V58, P4008; AlAlousi S, 1996, J CUTAN PATHOL, V23, P506, DOI 10.1111/j.1600-0560.1996.tb01442.x; AlAlousi S, 1996, J CUTAN PATHOL, V23, P118, DOI 10.1111/j.1600-0560.1996.tb01284.x; ALBINO AP, 1991, CANCER RES, V51, P4815; ARCHAMBAULT M, 1995, J INVEST DERMATOL, V104, P859, DOI 10.1111/1523-1747.ep12607034; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bechetoille N, 2000, MELANOMA RES, V10, P427, DOI 10.1097/00008390-200010000-00004; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Berking C, 2001, CANCER RES, V61, P8306; Bermont L, 2000, INT J CANCER, V85, P117, DOI 10.1002/(SICI)1097-0215(20000101)85:1<117::AID-IJC21>3.3.CO;2-O; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bissell MJ, 1999, CANCER RES, V59, p1757S; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Danen EHJ, 1996, MELANOMA RES, V6, P127, DOI 10.1097/00008390-199604000-00007; Davies G, 2001, CLIN CANCER RES, V7, P3289; DeLuca SM, 1999, EXP CELL RES, V251, P3, DOI 10.1006/excr.1999.4577; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Eves P, 2000, BRIT J DERMATOL, V142, P210, DOI 10.1046/j.1365-2133.2000.03287.x; FORSBERG K, 1993, INT J CANCER, V53, P556, DOI 10.1002/ijc.2910530405; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Gabbiani G, 1996, PATHOL RES PRACT, V192, P708, DOI 10.1016/S0344-0338(96)80092-6; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hajra KM, 2002, CANCER RES, V62, P1613; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Herlyn M, 2002, MELANOMA RES, V12, P3, DOI 10.1097/00008390-200202000-00002; HERLYN M, 1987, CANCER RES, V47, P3057; HERLYN M, 1994, PIGM CELL RES, V7, P81, DOI 10.1111/j.1600-0749.1994.tb00025.x; HERLYN M, 1985, CANCER RES, V45, P5670; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Javaherian A, 1998, CANCER RES, V58, P2200; Jouneau A, 2000, PIGM CELL RES, V13, P260, DOI 10.1034/j.1600-0749.2000.130408.x; Kanter-Lewensohn L, 1998, MELANOMA RES, V8, P389, DOI 10.1097/00008390-199810000-00002; Kawamura-Kodama K, 1999, J INVEST DERMATOL, V112, P62, DOI 10.1046/j.1523-1747.1999.00479.x; Krasagakis K, 1999, J CELL PHYSIOL, V178, P179, DOI 10.1002/(SICI)1097-4652(199902)178:2<179::AID-JCP7>3.0.CO;2-5; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Li G, 2001, CANCER RES, V61, P3819; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; Miura H, 2001, UROLOGY, V58, P1064, DOI 10.1016/S0090-4295(01)01427-3; Moinfar F, 2000, CANCER RES, V60, P2562; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakazawa K, 1997, PIGM CELL RES, V10, P382, DOI 10.1111/j.1600-0749.1997.tb00696.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nishimura EK, 1999, DEV BIOL, V215, P155, DOI 10.1006/dbio.1999.9478; Olumi AF, 1999, CANCER RES, V59, P5002; ONO I, 1995, J DERMATOL SCI, V10, P241, DOI 10.1016/0923-1811(95)00454-Z; Otsuka T, 1998, CANCER RES, V58, P5157; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Perris R, 1997, TRENDS NEUROSCI, V20, P23, DOI 10.1016/S0166-2236(96)10063-1; PIERCE GF, 1995, J CLIN INVEST, V96, P1336, DOI 10.1172/JCI118169; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; POSER I, 2001, J BIOL CHEM, V25, P25; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; REED JA, 1994, AM J PATHOL, V145, P97; RODECK U, 1994, CANCER RES, V54, P575; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Rusciano D, 1998, TUMOR BIOL, V19, P335, DOI 10.1159/000030026; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Satyamoorthy K, 2002, CELL GROWTH DIFFER, V13, P87; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sefton M, 1998, DEVELOPMENT, V125, P3111; Shih Ie-Ming, 1994, In Vivo (Attiki), V8, P113; SHIH IM, 1994, AM J PATHOL, V145, P837; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TANG A, 1994, J CELL SCI, V107, P983; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; TODD C, 1993, ARCH DERMATOL RES, V285, P455, DOI 10.1007/BF00376817; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Vaccariello M, 1999, J INVEST DERMATOL, V113, P384, DOI 10.1046/j.1523-1747.1999.00701.x; VALYINAGY IT, 1993, LAB INVEST, V69, P152; VanBelle P, 1996, AM J PATHOL, V148, P1887; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Washington C, 2000, AM J PATHOL, V157, P323, DOI 10.1016/S0002-9440(10)64543-9; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2	115	131	137	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3162	3171		10.1038/sj.onc.1206455	http://dx.doi.org/10.1038/sj.onc.1206455			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789292				2022-12-28	WOS:000183096600018
J	Starczynowski, DT; Reynolds, JG; Gilmore, TD				Starczynowski, DT; Reynolds, JG; Gilmore, TD			Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; malignant transformation; lymphoma	KAPPA-B-ALPHA; V-REL; LYMPHOMA; ACTIVATION; EXPRESSION; PROTEIN; ONCOPROTEIN; AMPLIFICATION; DOMAIN; GAINS	The REL gene is amplified in many human B-cell lymphomas and we have previously shown that expression of REL from a retroviral vector can malignantly transform chicken spleen cells in vitro. To identify REL protein functions necessary for malignant transformation, we have performed deletion analysis on REL sequences encoding residues of two C-terminal subdomains that are involved in transcriptional activation. We find that deletion of both C-terminal transactivation subdomains abolishes the ability of REL to transform chicken spleen cells in vitro. In contrast, deletion of either transactivation subdomain alone, which reduces the transactivation ability of REL, enhances the transforming activity of REL. Transforming REL mutants missing C-terminal sequences can also be selected at a low frequency in vitro. The REL transactivation domain can be functionally replaced in transformation assays by a portion of the VP16 transactivation domain that activates at a level similar to REL-transforming mutants. We also find that deletion of 29 C-terminal amino acids causes the subcellular localization of REL to change from cytoplasmic to nuclear in chicken embryo fibroblasts. In contrast, wild-type REL and all transforming REL mutants are located primarily in the cytoplasm of transformed spleen cells. Nevertheless, treatment of transformed spleen cells with leptomycin B causes wild-type REL and two REL mutants to relocalize to the nucleus, and nuclear extracts from these transformed cells contain REL DNA-binding activity. Taken together, these results suggest the following: ( 1) that REL must activate transcription to transform cells in vitro; ( 2) that a reduced level of transactivation enhances the oncogenicity of REL; ( 3) that REL shuttles from the cytoplasm to the nucleus in transformed chicken spleen cells; and ( 4) that mutations in REL, in addition to amplifications, could activate its oncogenicity in human lymphomas.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Chen CL, 1999, MOL CELL BIOL, V19, P307; Donnelly GB, 2001, BLOOD, V98, p302A; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Epinat JC, 2000, ONCOGENE, V19, P3131, DOI 10.1038/sj.onc.1203651; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; LU D, 1991, ONCOGENE, V6, P1235; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nagy M, 2000, LEUKEMIA, V14, P2142, DOI 10.1038/sj.leu.2401978; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIF S, 1993, ONCOGENE, V8, P2501; SMARDOVA J, 1995, ONCOGENE, V10, P2017; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891	51	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6928	6936		10.1038/sj.onc.1206801	http://dx.doi.org/10.1038/sj.onc.1206801			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534540				2022-12-28	WOS:000185843400014
J	Chen, SJ; Paul, P; Price, BD				Chen, SJ; Paul, P; Price, BD			ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response	ONCOGENE			English	Article						leucine zipper; ATM; kinase; radiosensitivity; ataxia telangiectasia	ATAXIA-TELANGIECTASIA GENE; S-PHASE CHECKPOINT; FUNCTIONAL-LINK; BREAST-CANCER; DEPENDENT PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; MISSENSE MUTATIONS; ALLELIC VARIANTS; P53; RADIATION	The ATM protein kinase regulates the DNA damage response by phosphorylating proteins involved in cell cycle checkpoints and DNA repair. We report here on the function of the predicted leucine zipper (LZ) motif, and sequences adjacent to this, in regulating ATM activity. The predicted LZ sequence was deleted from ATM, generating ATMDeltaLZ, and expressed in an ATM-negative AT cell line. ATM increased cell survival following exposure to ionizing radiation, whereas expression of ATMDeltaLZ failed to increase cell survival. ATMDeltaLZ retained in vitro kinase activity, but was unable to phosphorylate p53 in vivo. Leucine zippers mediate homo- and heterodimerization of proteins. However, the predicted LZ of ATM did not mediate the formation of ATM dimers. We examined if the predicted LZ of ATM was a dominant-negative inhibitor of ATM function in SW480 cells. Expression of amino acids 769-1436 of ATM, including the predicted LZ, sensitized SW480 cells to ionizing radiation, but did not inhibit ATM's kinase activity or its ability to phosphorylate Brca1. Further, this dominant-negative activity was not dependent on the predicted LZ domain. The central region of the ATM protein therefore contains multiple sequences which regulate cell survival following DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,JF513, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA093602, R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA93602, CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; Price BD, 1996, CANCER RES, V56, P246; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Wang Y, 2000, GENE DEV, V14, P927; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	39	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6332	6339		10.1038/sj.onc.1206760	http://dx.doi.org/10.1038/sj.onc.1206760			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508513				2022-12-28	WOS:000185535300003
J	Holmes, WF; Soprano, DR; Soprano, KJ				Holmes, WF; Soprano, DR; Soprano, KJ			Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway	ONCOGENE			English	Article						retinoids; apoptosis; CD437; MAP kinase; TR3; MEF-2	SYNTHETIC RETINOID CD437; ACID RECEPTOR-GAMMA; LUNG-CANCER CELLS; CYTOCHROME-C RELEASE; PROTEIN-KINASE; CASPASE ACTIVATION; TRANSCRIPTION FACTORS; INDEPENDENT PATHWAY; SELECTIVE RETINOIDS; MELANOMA-CELLS	Retinoids have great potential in the areas of cancer therapy and chemoprevention. 6-[3-(1-admantyl)]-4-hydroxyphenyl]2-naphthalene carboxylic acid (CD437) is a conformationally restricted synthetic retinoid that has been reported to induce growth arrest and apoptosis in ovarian tumor cell lines but the entire mechanism for apoptotic induction has not been fully defined. We set out to identify the early events of CD437-induced apoptosis of the CA-OV-3 cell line and determine if these occur in a CA-OV-3 cell line resistant to CD437 (CA-CD437R). Using inhibitors for the MAP kinase cascade, we determined that MEK and p38 inhibitors could block CD437-induced apoptosis of the CA-OV-3 cell line. Moreover, treatment of CA-OV-3 and CA-CD437R cells with CD437 resulted in increased phosphorylation and activity of p38 independent of caspase-3 activation. Furthermore, p38 induced the phosphorylation of MEF2 in both CA-OV-3 and CA-CD437R cells after CD437 treatment. Finally, GFP-TR3 protein translocated to the cytosol and associated with mitochondria in both cell lines in response to CD437 treatment. This leads to depolarization of mitochondria and subsequent induction of apoptosis only in CA-OV-3 cells. These results identify a number of initial molecular events in the induction of apoptosis by CD437 in CA-OV-3 cells and demonstrate that the alteration in CA-CD437R cells, which results in resistance to CD437 maps downstream of these early events after TR3 translocation but prior to mitochondrial depolarization.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIAID NIH HHS [AI 07101] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Bild AH, 2002, ONCOGENE, V21, P6649, DOI 10.1038/sj.onc.1205819; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Dawson MI, 2001, CANCER RES, V61, P4723; DE LUCA LM, 1991, FASEB J, V5, P2924; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gudas Lorraine J., 1994, P443; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kumar A, 2001, CANCER RES, V61, P7552; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Moon Richard C., 1994, P573; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 2002, CANCER RES, V62, P2430; Sun SY, 1997, CANCER RES, V57, P4931; Sun SY, 2000, CANCER RES, V60, P7149; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; Widschwendter M, 1997, INT J CANCER, V71, P497; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917; Zhao M, 2000, ACTA BIOCH BIOPH SIN, V32, P258; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	56	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6377	6386		10.1038/sj.onc.1206694	http://dx.doi.org/10.1038/sj.onc.1206694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508518				2022-12-28	WOS:000185535300008
J	Melnikova, VO; Santamaria, AB; Bolshakov, SV; Ananthaswamy, HN				Melnikova, VO; Santamaria, AB; Bolshakov, SV; Ananthaswamy, HN			Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase	ONCOGENE			English	Article						mutant p53; phosphorylation; serine 15; stabilization; ERK; skin tumor; UV	WILD-TYPE P53; DAMAGE-INDUCED PHOSPHORYLATION; NUCLEAR EXPORT SIGNAL; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; ENHANCED PHOSPHORYLATION; P38 KINASE; PROTEIN; MUTATIONS; GROWTH	Upon DNA damage, phosphorylation and nuclear translocation of wild-type p53 tumor suppressor protein signals its functional activation. However, very little is known about phosphorylation and localization of mutant p53. We found that mutant p53 protein in UV-induced murine primary skin tumors and cultured cell tines was constitutively phosphorylated at serine 15 residue and localized in the cell's nuclei. To investigate the mechanism of constitutive phosphorylation of mutant p53, we tested the involvement of a wide range of protein kinases and found that ERK1/2 mitogen-activated protein kinase was physically associated with mutant p53 in the nucleus. Addition of active recombinant ERK2 kinase protein in vitro to immunoprecipitated mutant p53 resulted in increased phosphorylation at serine 15. Furthermore, ERK1/2 activity was higher in tumor cells than normal cells, suggesting that phosphorylation of mutant p53 at serine 15 depends on the level of ERK1/2 activation. Interestingly, accumulation of mutant p53 in tumor cells was paralleled by low levels of Murine Double Minute 2 protein (MDM2) expression. However, when MDM2 was overexpressed, the fraction of mutant p53 that was phosphorylated at serine 15 resisted degradation, whereas the level of total p53 decreased, suggesting that phosphorylation at serine 15 and downregulation of MDM2 protein may both contribute to stabilization of mutant p53 in tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd,Box 178, Houston, TX 77030 USA.	hanantha@mdanderson.org			NCI NIH HHS [CA 16672, CA 46523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA046523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Araki R, 1999, CANCER RES, V59, P3543; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brown DR, 2001, INT J ONCOL, V18, P449; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KANJILAL S, 1993, CANCER RES, V53, P2961; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; PIERCEALL WE, 1992, CANCER RES, V52, P3946; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1999, GENE DEV, V13, P152; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigal A, 2000, CANCER RES, V60, P6788; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	54	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5958	5966		10.1038/sj.onc.1206595	http://dx.doi.org/10.1038/sj.onc.1206595			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955074				2022-12-28	WOS:000185137800004
J	Gearhart, PJ				Gearhart, PJ			B cells pay a price	ONCOGENE			English	Editorial Material							CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; DNA DEAMINATION; GENES		NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Gearhart, PJ (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	gearhartp@grc.nia.nih.gov	Gearhart, Patricia/Y-7227-2019		NATIONAL INSTITUTE ON AGING [ZIAAG000732, Z01AG000732] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2003, ONCOGENE, V22, P5381, DOI 10.1038/sj.onc.1206860; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	17	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5379	5380		10.1038/sj.onc.1206874	http://dx.doi.org/10.1038/sj.onc.1206874			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934096				2022-12-28	WOS:000184735000001
J	Grassme, H; Cremesti, A; Kolesnick, R; Gulbins, E				Grassme, H; Cremesti, A; Kolesnick, R; Gulbins, E			Ceramide-mediated clustering is required for CD95-DISC formation	ONCOGENE			English	Article						receptor aggregation; ceramide; acid sphingomyelinase; CD95; apoptosis	FAS-INDUCED APOPTOSIS; RICH MEMBRANE RAFTS; ACID SPHINGOMYELINASE; T-LYMPHOCYTES; CELL-DEATH; SIGNALING PATHWAY; CD95; ACTIVATION; RECEPTOR; FADD	Early events required for induction of apoptosis by CD95 are preassociation of CD95, the formation of the death-inducing signaling complex (DISC) and clustering of CD95 in distinct membrane domains. Here, we identify the molecular ordering of these events and show that the acid sphingomyelinase (ASM) functions upstream of the DISC to mediate CD95 clustering in ceramide-enriched membrane platforms, an event that is required for DISC formation. Experiments in ASM-deficient cells revealed that CD95 ligation, in the absence of ceramide generation, triggers <1% of full caspase 8 activation at the receptor. This event, however, is both necessary and sufficient to trigger translocation of ASM onto the outer leaflet of the plasma membrane, ASM activation and ceramide release, but insufficient for apoptosis induction. Ceramide-mediated CD95 clustering then amplifies the primary CD95 signaling and drives the second step of CD95 signaling, that is, formation of the DISC yielding 100% caspase activity and apoptosis. These studies suggest that the most parsimonious interpretation of the molecular ordering of the earliest events in CD95 signaling, at least in some cells, is: CD95 ligation&RARR;1% of maximum caspase 8 activation&RARR;ASM translocation&RARR;ceramide generation&RARR;CD95 clustering&RARR;DISC formation&RARR;100% of maximum caspase 8 activation&RARR;apoptosis.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University of Duisburg Essen; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.		Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342	NCI NIH HHS [CA 21765, CA 85704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085704, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Altman A, 1994, Semin Immunol, V6, P9, DOI 10.1006/smim.1994.1003; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; FANZO JC, 2003, UNPUB MCB; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudner J, 2001, J CELL SCI, V114, P4161; Sakata K, 1998, EUR J IMMUNOL, V28, P2648, DOI 10.1002/(SICI)1521-4141(199809)28:09<2648::AID-IMMU2648>3.0.CO;2-M; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; Sawada M, 2002, EXP CELL RES, V273, P157, DOI 10.1006/excr.2001.5437; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267	45	217	225	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5457	5470		10.1038/sj.onc.1206540	http://dx.doi.org/10.1038/sj.onc.1206540			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934106				2022-12-28	WOS:000184735000011
J	Sanchez-Carbayo, M; Schwarz, K; Charytonowicz, E; Cordon-Cardo, C; Mundel, P				Sanchez-Carbayo, M; Schwarz, K; Charytonowicz, E; Cordon-Cardo, C; Mundel, P			Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome	ONCOGENE			English	Article						bladder cancer; tissue microarrays; myopodin; cell-cycle	GENETIC ALTERATIONS; PARTIAL ALLELOTYPE; PROTEIN; ACTIN; P53; SYNAPTOPODIN; CARCINOMA; PATHWAY; ZYXIN	Myopodin is a dual compartment protein that displays actin-bundling activity and redistributes between the nucleus and the cytoplasm in a differentiation-dependent and stress-induced fashion. We evaluated myopodin expression in initiation and progression of bladder cancer. Normal urothelium expresses myopodin in the cytoplasm and nuclei. Invasive bladder tumors showed decreased nuclear myopodin expression as compared to superficial lesions. This loss of nuclear myopodin expression was significantly associated with histopathological stage, tumor grade and overall patient survival in bladder tumors contained in tissue microarrays. We identified a differential nuclear expression for myopodin among bladder cancer cell lines during cell-cycle. Myopodin was present in the nucleus during G1/S in cells derived from superficial and low-grade lesions but not in those derived from invasive tumors. Loss of nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on their histopathology. Most importantly, patients with preserved nuclear myopodin expression showed a longer survival. Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer.	Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Memorial Sloan Kettering Cancer Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Sanchez-Carbayo, M (corresponding author), Mem Sloan Kettering Canc Ctr, Div Mol Pathol, 1270 York Ave, New York, NY 10021 USA.		Schwarz, Karin/AAO-2819-2020	Schwarz, Karin/0000-0002-7328-1427				*AM JOINT COMM CAN, 1988, MAN STAG CANC, P194; American Cancer Society, 2000, CANC FACTS FIG; CordonCardo C, 1997, CANCER RES, V57, P1217; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5; Giroldi LA, 1999, INT J CANCER, V82, P70, DOI 10.1002/(SICI)1097-0215(19990702)82:1<70::AID-IJC13>3.0.CO;2-#; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Lin F, 2001, AM J PATHOL, V159, P1603, DOI 10.1016/S0002-9440(10)63006-4; Lu ML, 2002, CLIN CANCER RES, V8, P171; Markl IDC, 1998, CANCER RES, V58, P5348; McShane LM, 2000, CLIN CANCER RES, V6, P1854; Mostofi FK, 1973, HISTOLOGICAL TYPING; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Popov Z, 2000, BRIT J CANCER, V83, P209; REUTER VE, 1989, DIAGNOSTIC SURG PATH, P1355; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROSIN MP, 1995, CANCER RES, V55, P5213; SAHLAS DJ, 1993, J CELL SCI, V105, P347; Shaw ME, 1999, INT J CANCER, V80, P656, DOI 10.1002/(SICI)1097-0215(19990301)80:5&lt;656::AID-IJC4&gt;3.0.CO;2-A; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 1998, J PATHOL, V185, P345; WANG Y, 2000, BIOCHIM BIOPHYS ACTA, V1538, P260; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039	27	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5298	5305		10.1038/sj.onc.1206616	http://dx.doi.org/10.1038/sj.onc.1206616			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917631				2022-12-28	WOS:000184734900009
J	Spicer, J; Rayter, S; Young, N; Elliott, R; Ashworth, A; Smith, D				Spicer, J; Rayter, S; Young, N; Elliott, R; Ashworth, A; Smith, D			Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1	ONCOGENE			English	Article						cancer susceptibility; Peutz-Jeghers syndrome; Wnt signalling; colorectal cancer; protein kinase	PROTEIN-KINASES; KNOCKOUT MICE; BETA-CATENIN; CARCINOMA; POLARITY; ENCODES; INACTIVATION; POLYPOSIS; ASYMMETRY; PAR-1	Loss-of-function mutations in the LKB1 (STK11) serine-threonine kinase gene cause Peutz-Jeghers syndrome, which is associated with inherited susceptibility to colorectal and other cancers. No downstream targets of LKB1 kinase activity have been identified. Here we show that LKB1 can direct the phosphorylation of the serine-threonine kinase PAR1A. The amino-acid residues phosphorylated as a result of LKB1 activity have been identified and phosphorylation at these residues is required for PAR1A kinase activity. PAR1A has previously been implicated as a positive regulator of the Wnt-betacatenin signalling pathway. We show here that LKB1 can modify transcription driven by the Wnt-regulated TCF response element, implicating LKB1 in a pathway known to play a key role in human colorectal tumorigenesis.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.			Spicer, James/0000-0003-3732-8491				Back W, 1999, J CLIN PATHOL, V52, P345, DOI 10.1136/jcp.52.5.345; Bosman FT, 1999, J PATHOL, V188, P1, DOI 10.1002/(SICI)1096-9896(199905)188:1<1::AID-PATH327>3.0.CO;2-J; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; PARSA I, 1988, CANCER RES, V48, P2265; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Watts JL, 2000, DEVELOPMENT, V127, P1467; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	26	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4752	4756		10.1038/sj.onc.1206669	http://dx.doi.org/10.1038/sj.onc.1206669			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879020				2022-12-28	WOS:000184157000016
J	Sasaki, S; Kitagawa, Y; Sekido, Y; Minna, JD; Kuwano, H; Yokota, J; Kohno, T				Sasaki, S; Kitagawa, Y; Sekido, Y; Minna, JD; Kuwano, H; Yokota, J; Kohno, T			Molecular processes of chromosome 9p21 deletions in human cancers	ONCOGENE			English	Article						9p21 deletion; p16/CDKN2A; lung cancer; DNA double-strand break; nonhomologous end joining	DOUBLE-STRAND BREAK; FRAGILE REGION; GENE; RECOMBINATION; MECHANISM; SEQUENCE; REPAIR; DAMAGE; P15	Interstitial deletions of the chromosome 9p21 segment encoding the p16/CDKN2A tumor suppressor gene (i.e., 9p21 deletions) are frequently observed in a variety of human cancers. A majority of these deletions in lymphoid leukemia have been indicated to be mediated by illegitimate V(D)J recombination. In the present study, to elucidate the molecular processes of 9p21 deletions in nonlymphocytic malignancies, breakpoints for these deletions were analysed in 21 lung cancer cell lines and 32 nonlymphocytic cancer cell lines of nine other histological types. In all, 32 breakpoints in 21 lung cancer cell lines and 56 breakpoints in 32 nonlung cancer cell lines were mapped in a 450-kb segment encompassing the CDKN2A locus with a 10-kb resolution. The largest number of breakpoints (i.e., seven breakpoints in lung cancer and 12 breakpoints in noulung cancers) was mapped in a 10-kb region containing the CDKN2A gene. More precise mapping of these seven and 12 breakpoints revealed that none of these breakpoints were located within 50-bp intervals to each other in this 10kb region. Cloning and sequencing of breakpoints in 18 representative cell lines (six lung and 12 nonlung cancers) further revealed that there were no significant homologies among breakpoints in these 18 cell lines. In 11 (61%) cell lines, 1-5-bp nucleotides were overlapped at breakpoint junctions. These results indicate that DNA double-strand breaks triggering 9p21 deletions do not occur at specific DNA sequences, although they preferentially occur in or near the CDKN2A locus. It was also indicated that two broken DNA ends are rejoined by nonhomologous end-joining repair, preferentially utilizing microhomologies of DNA ends, in the occurrence of 9p21 deletions.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Sch Med, Dept Surg 1, Maebashi, Gumma 3718511, Japan; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	National Cancer Center - Japan; Gunma University; Nagoya University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp	Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OCHMAN H, 1988, GENETICS, V120, P621; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sherr CJ, 2000, CANCER RES, V60, P3689; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Smith J, 2001, NUCLEIC ACIDS RES, V29, P4783, DOI 10.1093/nar/29.23.4783; Tanaka H, 1997, INT J CANCER, V70, P437, DOI 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.3.CO;2-I; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	29	59	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3792	3798		10.1038/sj.onc.1206589	http://dx.doi.org/10.1038/sj.onc.1206589			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802286				2022-12-28	WOS:000183551000013
J	Marionnet, C; Lalou, C; Mollier, K; Chazal, M; Delestaing, G; Compan, D; Verola, O; Vilmer, C; Cuminet, J; Dubertret, L; Basset-Seguin, N				Marionnet, C; Lalou, C; Mollier, K; Chazal, M; Delestaing, G; Compan, D; Verola, O; Vilmer, C; Cuminet, J; Dubertret, L; Basset-Seguin, N			Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development	ONCOGENE			English	Article						DNA macroarray; basal cell carcinoma; squamous cell carcinoma	EXPRESSION; CANCER; PATHWAY; CARCINOGENESIS; MUTATIONS; EMMPRIN; RHOC	Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are skin tumors with different invasive potential. In this work, we analysed mRNA differential expression between seven BCC and five SCC and their normal skin counterparts using 1176 cDNA macroarrays and verification by RT-PCR to identify genes modulated in each tumor type. We identified 37 genes commonly modulated in both tumors and four genes specifically modulated in SCC. Among these latter RhoC and EMMPRIN genes seem to be of particular interest and could participate in SCC aggressivity.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Hop St Louis, IRP, Serv Stat, F-75010 Paris, France; Hop St Louis, Serv Anat Pathol, F-75010 Paris, France; Hop St Louis, Serv Chirurg Plast, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Basset-Seguin, N (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	nbs@chu-stlouis.fr		LALOU, Claude/0000-0002-5271-7439				Asch PH, 1999, AM J DERMATOPATH, V21, P146, DOI 10.1097/00000372-199904000-00006; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; BISWAS C, 1995, CANCER RES, V55, P434; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Harris CC, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P115; Kallassy M, 1997, CANCER RES, V57, P4731; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Matsuyoshi N, 1997, J INVEST DERMATOL, V108, P908, DOI 10.1111/1523-1747.ep12292703; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; PERKINS W, 1992, J CUTAN PATHOL, V19, P476, DOI 10.1111/j.1600-0560.1992.tb01600.x; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; QUINN AG, 1994, CANCER RES, V54, P4756; Ren ZP, 1996, ONCOGENE, V12, P765; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; van Golen KL, 2000, CANCER RES, V60, P5832; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	21	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3500	3505		10.1038/sj.onc.1206571	http://dx.doi.org/10.1038/sj.onc.1206571			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776202				2022-12-28	WOS:000183128500017
J	Jhappan, C; Noonan, FP; Merlino, G				Jhappan, C; Noonan, FP; Merlino, G			Ultraviolet radiation and cutaneous malignant melanoma	ONCOGENE			English	Review						cell cycle arrest; DNA damage response; DNA repair; melanoma; transgenic mice; UV radiation	NORMAL HUMAN MELANOCYTES; COMPARATIVE GENOMIC HYBRIDIZATION; MELANOCORTIN-1 RECEPTOR VARIANTS; CYCLOBUTANE PYRIMIDINE DIMERS; INDUCED SIGNAL-TRANSDUCTION; HUMAN-SKIN FIBROBLASTS; FACTOR SCATTER FACTOR; CELL-CYCLE ARREST; STIMULATING HORMONE; DNA-REPAIR	Recent years have seen a steady rise in the incidence of cutaneous malignant melanoma worldwide. Although it is now appreciated that the key to understanding the process by which melanocytes are transformed into malignant melanoma lies in the interplay between genetic factors and the ultraviolet (UV) spectrum of sunlight, the nature of this relation has remained obscure. Recently, prospects for elucidating the molecular mechanisms underlying such gene-environment interactions have brightened considerably through the development of UV-responsive experimental animal models of melanoma. Genetically engineered mice and human skin xenografts constitute novel platforms upon which to build studies designed to elucidate the pathogenesis of UV-induced melanomagenesis. The future refinement of these in vivo models should provide a wealth of information on the cellular and genetic targets of UV, the pathways responsible for the repair of UV-induced DNA damage, and the molecular interactions between melanocytes and other skin cells in response to UV. It is anticipated that exploitation of these model systems will contribute significantly toward the development of effective approaches to the prevention and treatment of melanoma.	NCI, Mol Biol Lab, Mol Genet Sect, Bethesda, MD 20892 USA; George Washington Univ, Sch Med, Sch Publ Hlth & Hlth Serv, Dept Environm & Occupat Hlth,Lab Photobil & Photo, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Merlino, G (corresponding author), NCI, Mol Biol Lab, Mol Genet Sect, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		Noonan, Frances/0000-0002-3302-7280				Abdel-Malek Z, 1999, ANN NY ACAD SCI, V885, P117; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ADIMOOLAM S, 2002, P NATL ACAD SCI USA, V19, P19; ALBINO AP, 1992, PIGM CELL RES, P199; AMSTAD P, 1994, MOL CARCINOGEN, V10, P181, DOI 10.1002/mc.2940100402; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; Ao Y, 1998, EXP CELL RES, V244, P117, DOI 10.1006/excr.1998.4086; APPLEGATE LA, 1987, PHOTOCHEM PHOTOBIOL, V45, P241, DOI 10.1111/j.1751-1097.1987.tb05371.x; ARCHAMBAULT M, 1995, J INVEST DERMATOL, V104, P859, DOI 10.1111/1523-1747.ep12607034; Armstrong B K, 1997, Australas J Dermatol, V38 Suppl 1, pS1; ARMSTRONG BK, 1988, J DERMATOL SURG ONC, V14, P835, DOI 10.1111/j.1524-4725.1988.tb03588.x; ARMSTRONG BK, 1995, DERMATOL CLIN, V13, P583, DOI 10.1016/S0733-8635(18)30064-0; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; Autier P, 1998, INT J CANCER, V77, P533, DOI 10.1002/(SICI)1097-0215(19980812)77:4<533::AID-IJC10>3.0.CO;2-7; Bardeesy N, 2000, ADV CANCER RES, V79, P123, DOI 10.1016/S0065-230X(00)79004-X; BARNHILL RL, 1993, SEMIN DIAGN PATHOL, V10, P47; Bastian BC, 1998, CANCER RES, V58, P2170; BENNETT JP, 1994, ANN ROY COLL SURG, V76, P373; Berking C, 2002, CARCINOGENESIS, V23, P181, DOI 10.1093/carcin/23.1.181; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; BOLOGNIA J, 1989, J INVEST DERMATOL, V92, P651, DOI 10.1111/1523-1747.ep12696836; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V39, P63, DOI 10.1111/j.1751-1097.1984.tb03405.x; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cadet J, 1997, BIOL CHEM, V378, P1275; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CHAKRABORTY A, 1995, J INVEST DERMATOL, V105, P655, DOI 10.1111/1523-1747.ep12324134; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Decraene D, 2001, J PHOTOCH PHOTOBIO B, V63, P78, DOI 10.1016/S1011-1344(01)00204-4; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDER DE, 1987, PATHOBIOLOGY MALIGNA; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; EPSTEIN JH, 1967, J NATL CANCER I, V38, P19; EVANS RD, 1988, J DERMATOL SURG ONC, V14, P393, DOI 10.1111/j.1524-4725.1988.tb03373.x; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Funasaka Y, 1998, BRIT J DERMATOL, V139, P216; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; Gause PR, 1997, MOL CARCINOGEN, V20, P78, DOI 10.1002/(SICI)1098-2744(199709)20:1<78::AID-MC9>3.0.CO;2-E; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Goldstein AM, 2001, ARCH DERMATOL, V137, P1493; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Halaban R, 1996, SEMIN ONCOL, V23, P673; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Healy E, 2000, LANCET, V355, P1072, DOI 10.1016/S0140-6736(00)02042-0; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HERZINGER T, 1995, ONCOGENE, V11, P2151; HIROBE T, 1984, ANAT REC, V208, P589, DOI 10.1002/ar.1092080414; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Hollander MC, 2001, CANCER RES, V61, P2487; HOLMAN CDJ, 1983, JNCI-J NATL CANCER I, V71, P651; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; HUNT G, 1995, J INVEST DERMATOL, V104, P83, DOI 10.1111/1523-1747.ep12613565; HUSAIN Z, 1991, CANCER RES, V51, P4964; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Insinga R P, 2001, WMJ, V100, P27; IRWIN C, 1993, PHOTOCHEM PHOTOBIOL, V57, P504, DOI 10.1111/j.1751-1097.1993.tb02326.x; ISLAS AL, 1995, CANCER RES, V55, P336; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jiang WD, 2001, P NATL ACAD SCI USA, V98, P9790, DOI 10.1073/pnas.171066498; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jung E G, 1986, Curr Probl Dermatol, V15, P117; KAIDBEY KH, 1979, J INVEST DERMATOL, V72, P253, DOI 10.1111/1523-1747.ep12531710; KAMADA S, 1995, CANCER RES, V55, P354; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kaskel P, 2001, BRIT J DERMATOL, V145, P602, DOI 10.1046/j.1365-2133.2001.04432.x; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Kato M, 2000, J INVEST DERMATOL, V115, P1157, DOI 10.1046/j.1523-1747.2000.0202a-2.x; Kawada Akira, 1994, Journal of Dermatology (Tokyo), V21, P571; Kazianis S, 1998, GENE CHROMOSOME CANC, V22, P210, DOI 10.1002/(SICI)1098-2264(199807)22:3<210::AID-GCC6>3.0.CO;2-Z; Kelsall SR, 1998, CANCER RES, V58, P4061; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; KLEINPARKER HA, 1994, J CUTAN PATHOL, V21, P297, DOI 10.1111/j.1600-0560.1994.tb00703.x; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAEMER KH, 1994, JPN J CANC RES, V85; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Kusewitt DF, 1996, CANCER SURV, V26, P35; Landi MT, 2002, JNCI-J NATL CANCER I, V94, P94, DOI 10.1093/jnci/94.2.94; Langley RGB, 1997, CANCER INVEST, V15, P561, DOI 10.3109/07357909709047598; LARUE L, 1992, P NATL ACAD SCI USA, V89, P9534, DOI 10.1073/pnas.89.20.9534; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; LEY RD, 1987, PHOTODERMATOLOGY, V4, P173; Ley RD, 2002, FRONT BIOSCI, V7, pD1531, DOI 10.2741/ley; LEY RD, 1988, MUTAT RES, V194, P49, DOI 10.1016/0167-8817(88)90055-7; Ley RD, 2001, PHOTOCHEM PHOTOBIOL, V73, P20, DOI 10.1562/0031-8655(2001)073<0020:DRFURA>2.0.CO;2; Li G, 1998, BRIT J DERMATOL, V139, P3; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; Linge C, 1996, CANCER SURV, V26, P71; LIU SCC, 1982, J INVEST DERMATOL, V79, P330, DOI 10.1111/1523-1747.ep12500087; MacKie RM, 1998, EUR J CANCER, V34, pS3; MALITSCHEK B, 1995, BIOESSAYS, V17, P1017, DOI 10.1002/bies.950171205; Marks R, 2000, CLIN EXP DERMATOL, V25, P459, DOI 10.1046/j.1365-2230.2000.00693.x; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; McGOVERN V J, 1952, Med J Aust, V1, P139; MCLANE JA, 1988, BIOCHEMISTRY-US, V27, P3743, DOI 10.1021/bi00410a033; MEDRANO EE, 1995, CANCER RES, V55, P4047; Mildner M, 1999, J INVEST DERMATOL, V113, P1136, DOI 10.1046/j.1523-1747.1999.00815.x; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Nairn RS, 1996, P NATL ACAD SCI USA, V93, P13042, DOI 10.1073/pnas.93.23.13042; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; Noonan FP, 2000, CANCER RES, V60, P3738; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Norris W., 1857, 8 CASES MELANOSIS PA; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ortonne JP, 2002, BRIT J DERMATOL, V146, P7, DOI 10.1046/j.1365-2133.146.s61.3.x; Otsuka T, 1998, CANCER RES, V58, P5157; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pavey S, 2002, CANCER RES, V62, P875; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Recio JA, 2002, CANCER RES, V62, P6724; Reedy MV, 1998, DEV DYNAM, V213, P476, DOI 10.1002/(SICI)1097-0177(199812)213:4<476::AID-AJA12>3.0.CO;2-R; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rigel DS, 2000, CA-CANCER J CLIN, V50, P215, DOI 10.3322/canjclin.50.4.215; Romerdahl C A, 1989, Cancer Commun, V1, P209; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUNGER TM, 1995, J INVEST DERMATOL, V104, P68, DOI 10.1111/1523-1747.ep12613504; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schaffer JV, 2001, ARCH DERMATOL, V137, P1477; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHARTL A, 1995, CANCER RES, V55, P159; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Scott MC, 2002, J CELL SCI, V115, P2349; SETLOW RB, 1994, MUTAT RES, V307, P365, DOI 10.1016/0027-5107(94)90310-7; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shih Ie-Ming, 1994, In Vivo (Attiki), V8, P113; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Suzuki I, 1999, J INVEST DERM SYMP P, V4, P29, DOI 10.1038/sj.jidsp.5640177; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; Takahashi S, 2001, CANCER RES, V61, P1187; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Taylor SC, 2002, J AM ACAD DERMATOL, V46, pS41, DOI 10.1067/mjd.2002.120790; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; Thody AJ, 1999, ANN NY ACAD SCI, V885, P217, DOI 10.1111/j.1749-6632.1999.tb08679.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TUCKER MA, 1983, J PEDIATR-US, V103, P65, DOI 10.1016/S0022-3476(83)80777-X; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; Wan YS, 2001, INT J ONCOL, V18, P461; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P767, DOI 10.1067/mjd.2001.112384; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; WILTSHIRE RN, 1995, CANCER RES, V55, P3954; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WONG G, 1974, NATURE, V248, P351, DOI 10.1038/248351a0; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yaar M, 2001, CLIN EXP DERMATOL, V26, P583, DOI 10.1046/j.1365-2230.2001.00895.x; Yamamura K, 1996, CANCER RES, V56, P3546; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	196	170	176	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3099	3112		10.1038/sj.onc.1206450	http://dx.doi.org/10.1038/sj.onc.1206450			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789287				2022-12-28	WOS:000183096600012
J	Morris, MR; Hesson, LB; Wagner, KJ; Morgan, NV; Astuti, D; Lees, RD; Cooper, WN; Lee, JA; Gentle, D; Macdonald, F; Kishida, T; Grundy, R; Yao, M; Latif, F; Maher, ER				Morris, MR; Hesson, LB; Wagner, KJ; Morgan, NV; Astuti, D; Lees, RD; Cooper, WN; Lee, JA; Gentle, D; Macdonald, F; Kishida, T; Grundy, R; Yao, M; Latif, F; Maher, ER			Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma	ONCOGENE			English	Article						Wilms' tumour; renal cell carcimona; methylation; profile; epigenetics	ABERRANT PROMOTER METHYLATION; E-CADHERIN GENE; HYPERMETHYLATION-ASSOCIATED INACTIVATION; HYPOXIA-INDUCIBLE FACTORS; FAMILIAL GASTRIC-CANCER; RECEPTOR-BETA GENE; SUPPRESSOR GENE; CPG ISLAND; COLORECTAL-CANCER; DNA METHYLATION	To investigate the role of epigenetic gene silencing in the pathogenesis of Wilms' tumour and renal cell carcinoma (RCC), we determined their methylation pro. le using a candidate gene approach. Thus, 40 Wilms' tumours and up to 49 adult RCC were analysed by methylation-specific PCR for promoter methylation at CASP8, CDH1, CDH13, DAPK, MGMT, NORE1A, p14(ARF) and RARB2 in primary Wilms' tumours and CASP8, CDH1, CDH13, CRBP1, DAPK, MGMT, MT1G, NORE1A, p16(INK4a), SDHB and RARB2 in primary RCC. Both tumour sample sets had previously been analysed for RASSF1A promoter methylation, and p16(INK4a) methylation results were also available for the Wilms' tumour samples. Wilms' tumours demonstrated a high incidence of methylation at CASP8 (43%) and MGMT (30%), intermediate frequencies at NORE1A (15%), p14(ARF) (15%), p16(INK4a) (10%), DAPK (11%) and CRBP1 (9%), but promoter methylation was rare or absent at RARB2 (0%), CDH13 ( 0%) and CDH1 (3%). No association was detected between methylation of RASSF1A, CASP8 or MGMT in individual tumours. The frequency of MGMT methylation was higher in stage 1 and 2 tumours (50%) than in stage 3 and 4 tumours (17%) but this did not reach statistical significance ( P = 0.06). RCC were most frequently methylated at DAPK (24%), MT1G ( 20%), NORE1A (19%), CDH1 (16%) and MGMT ( 9%) and not or rarely at SDHB (4%), RARB2 ( 0%), p16(INK4a) ( 0%) and CDH13 ( 3%). There were no associations between methylation of RASSF1A, DAPK and CDH1 in individual tumours. Papillary RCC demonstrated a higher frequency of DAPK methylation ( 43%) than clear cell tumours ( 19%) ( P = 0.14). We have demonstrated that de novo promoter methylation is frequent in Wilms' tumour and RCC, and these data enable methylation profiles to be constructed for each tumour type. Thus, combining our results with data published previously, it appears that promoter methylation occurs frequently (greater than or equal to20% of primary tumours) at CASP8, SLIT2 and RASSF1A in Wilms' tumour and at RASSF1A, TIMP3, DAPK, SLIT2, MT1G and GSTP1 in RCC.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Canc Res UK Renal Mol Oncol Grp, Birmingham B15 2TT, W Midlands, England; Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; Birmingham Childrens Hosp, Dept Paediat Oncol, Birmingham, W Midlands, England; Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan	University of Birmingham; University of Birmingham; Birmingham Women's Hospital; University of Birmingham; Yokohama City University	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		Morgan, Neil V/A-5475-2009; Morris, Mark/C-6413-2008; Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008	Morgan, Neil V/0000-0001-6433-5692; MAHER, EAMONN R/0000-0002-6226-6918; Morris, Mark/0000-0002-0700-355X; Astuti, Dewi/0000-0003-4205-6160				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Burrow CR, 2000, EXP NEPHROL, V8, P219; Caca K, 2002, INT J CANCER, V97, P481, DOI 10.1002/ijc.1639; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eggert A, 2001, CANCER RES, V61, P1314; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Grundy P, 1996, MED PEDIATR ONCOL, V27, P429, DOI 10.1002/(SICI)1096-911X(199611)27:5<429::AID-MPO7>3.0.CO;2-O; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; Harada K, 2002, CANCER RES, V62, P5897; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kawakami M, 1999, INT J ONCOL, V15, P715; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morrissey C, 2001, CANCER RES, V61, P7277; Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Schulz S, 2000, J PATHOL, V191, P162; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Skotnicka-Klonowicz G, 2000, EUR J SURG ONCOL, V26, P61, DOI 10.1053/ejso.1999.0742; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STORKEL S, 1995, WORLD J UROL, V13, P153; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2002, CANCER RES, V62, P3382; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Turner KJ, 2002, CANCER RES, V62, P2957; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van der Velden PA, 2001, CANCER RES, V61, P5303; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zbar B, 2000, SEMIN CANCER BIOL, V10, P313, DOI 10.1006/scbi.2000.0151; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	77	85	90	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6794	6801		10.1038/sj.onc.1206914	http://dx.doi.org/10.1038/sj.onc.1206914			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555992				2022-12-28	WOS:000185799300014
J	Soung, YH; Lee, JW; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Park, YG; Nam, SW; Jeong, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Soung, YH; Lee, JW; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Park, YG; Nam, SW; Jeong, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			Inactivating mutations of CASPASE-7 gene in human cancers	ONCOGENE			English	Article						CASPASE-7; mutation; solid cancer; apoptosis; caspases	FAS APO-1/CD95 GENE; INDUCED APOPTOSIS; CELL-DEATH; MAMMALIAN HOMOLOG; CYSTEINE PROTEASE; CARCINOMA; DISTINCT; CLEAVES; CASCADE; CED-3	Caspase-7 is a caspase involved in the execution phase of apoptosis. To explore the possibility that the genetic alterations of CASPASE-7 might be involved in the development of human cancers, we analysed the entire coding region and all splice sites of human CASPASE-7 gene for the detection of somatic mutations in a series of human solid cancers, including carcinomas from stomach, colon, head/neck, esophagus, urinary bladder and lung. Overall, we detected CASPASE-7 mutations in two of 98 colon carcinomas (2.0%), one of 50 esophageal carcinomas (2.0%) and one of 33 head/neck carcinomas (3.0%). We expressed the tumor-derived caspase-7 mutants in 293 T cells and found that the apoptosis was reduced compared to the wild-type caspase-7. This is the first report on the CASPASE-7 gene, mutations in human malignancies, and our data suggest that the inactivating mutations of the CASPASE-7 gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human solid cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biostat, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.		kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022					Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kurokawa H, 1999, ONCOL REP, V6, P33; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mollenhauer J, 2001, CANCER RES, V61, P8880; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Schwartz S, 1999, CANCER RES, V59, P2995; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; ZORNIG M, 1995, ONCOGENE, V10, P2397	26	75	76	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8048	8052		10.1038/sj.onc.1206727	http://dx.doi.org/10.1038/sj.onc.1206727			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970753				2022-12-28	WOS:000185388200020
J	Suriano, G; Mulholland, D; de Wever, O; Ferreira, P; Mateus, AR; Bruyneel, E; Nelson, CC; Mareel, MM; Yokota, J; Huntsman, D; Seruca, R				Suriano, G; Mulholland, D; de Wever, O; Ferreira, P; Mateus, AR; Bruyneel, E; Nelson, CC; Mareel, MM; Yokota, J; Huntsman, D; Seruca, R			The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion	ONCOGENE			English	Article						E-cadherin; hereditary diffuse gastric cancer; mutations; cell-cell adhesion; invasion; TCF-LEF	GASTRIC-CANCER FAMILIES	E-cadherin germline missense mutations have been shown to be responsible for significant loss of protein activity. A new cytoplasmic E-cadherin germline missense mutation (V832 M) was recently identified in a hereditary diffuse gastric cancer (HDGC) Japanese family. This E-cadherin mutant was cloned in a Chinese hamster ovary cell model system and functionally characterized, in terms of aggregation and invasion. Cells expressing the germline V832M mutant fail to aggregate and invade into collagen, supporting the pathogenic role of this germline missense mutation in gastric cancer. We also tested the ability of this mutation to activate the TCF-LEF trascriptional activity, in comparison with three other E-cadherin missense mutations (T340A, A634V and A617T), associated to loss of E-cadherin function. All the E-cadherin mutants reduced TCF-LEF activation to a similar extent as the wild-type protein, suggesting that the oncogenic effect of the E-cadherin mutants is unlikely to be transmitted through a beta-catenin-dependent activation of the WNT pathway.	Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200 Oporto, Portugal; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; UZG, Expt Cancerol Lab, B-9000 Ghent, Belgium; Natl Canc Ctr, Res Inst, Tokyo 104, Japan; Hosp Sao Joao, Fac Med, P-4200 Oporto, Portugal	Universidade do Porto; University of British Columbia; National Cancer Center - Japan; Sao Joao Hospital; Universidade do Porto	Seruca, R (corresponding author), Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200 Oporto, Portugal.	rseruca@ipatimup.pt	de wever, olivier/J-3094-2013; Huntsman, David/ABE-6082-2020; seruca, raquel/F-8187-2011	de wever, olivier/0000-0002-5453-760X; Seruca, Raquel/0000-0002-8851-4166				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BECKER KF, 1994, CANCER RES, V54, P3845; Becker KF, 1999, AM J PATHOL, V155, P1803, DOI 10.1016/S0002-9440(10)65497-1; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BOTERBERG T, 2000, METASTASIS RES PROTO, P35; BRACKE ME, 2000, METASTASIS RES PROTO, P81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Chen HY, 1997, J CELL SCI, V110, P345; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Handschuh G, 2001, J MOL BIOL, V314, P445, DOI 10.1006/jmbi.2001.5143; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234; Oliveira C, 2003, EXPERT REV MOL DIAGN, V3, P201; Oliveira C, 2002, HUM MUTAT, V19, P510, DOI 10.1002/humu.10068; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Polakis P, 2000, GENE DEV, V14, P1837; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Suriano G, 2003, HUM MOL GENET, V12, P575, DOI 10.1093/hmg/ddg048; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; van de Wetering M, 2001, CANCER RES, V61, P278; Vecsey-Semjen B, 2002, ONCOGENE, V21, P4646, DOI 10.1038/sj.onc.1205577; Yabuta T, 2002, INT J CANCER, V101, P434, DOI 10.1002/ijc.10633	31	65	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5716	5719		10.1038/sj.onc.1206672	http://dx.doi.org/10.1038/sj.onc.1206672			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944922				2022-12-28	WOS:000184865900023
J	Ludwig, L; Kessler, H; Hoang-Vu, C; Dralle, H; Adler, G; Boehm, BO; Schmid, RM				Ludwig, L; Kessler, H; Hoang-Vu, C; Dralle, H; Adler, G; Boehm, BO; Schmid, RM			Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling	ONCOGENE			English	Article						RET; Grb2-related adaptors; mitogenic signaling	CELL-LINE; CARCINOMA; PROTOONCOGENE; SYSTEM; SLP-76; GADS	Signal transduction of the RET receptor tyrosine kinase is involved in developmental processes as well as in neoplastic transformation. Activation of RET initiates receptor autophosphorylation on specific tyrosines that act as docking sites for downstream signaling molecules. Using the cytoplasmatic part of RET as bait in a yeast two-hybrid screen, we identified a novel SH2 and SH3 domain containing adaptor protein previously termed Grap-2/Grf40/GrpL/GRID) and its murine homologue as Gads/Mona, respectively. This protein, predominantly expressed in cells of hematopoietic origin, is involved in signaling downstream of the T-cell receptor and the receptor for monocyte colony-stimulating factor. Here, we show that Grap-2 is also expressed in neuroendocrine tumors and cell lines known to bear mutated forms of RET. Endogenously expressed RET and Grap-2 coimmunoprecipitate from lysates of a medullary thyroid carcinoma cell line. Grap-2 directly associates with RET in pull-down experiments using in vitro translated proteins. Overexpression of Grap-2 inhibits RET-induced NF-kappaB activation, and cotransfection of Grap-2 significantly reduces focus formation induced by oncogenic RET in NIH 3T3 cells. Taken together, these results suggest that besides being involved in tyrosine kinase signaling in hematopoietic cells, Grap-2 plays a tissue-specific role as an inhibitor of RET mitogenic signaling.	Tech Univ Munich, Klinikum Rechts Isar, Med Klin, D-81675 Munich, Germany; Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Halle Wittenberg, Dept Surg 1, D-06097 Halle Saale, Germany	Technical University of Munich; Ulm University; Martin Luther University Halle Wittenberg	Schmid, RM (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin, Ismaninger Str 22, D-81675 Munich, Germany.		Boehm, Bernhard Otto/F-8750-2015					Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; CARLOMAGNO F, 1995, BIOCHEM BIOPH RES CO, V207, P1022, DOI 10.1006/bbrc.1995.1287; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Ludwig L, 2001, CANCER RES, V61, P4526; LUNDQVIST M, 1991, EUR J CANCER, V27, P1663, DOI 10.1016/0277-5379(91)90441-F; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Taraviras S, 1999, CURR OPIN GENET DEV, V9, P321, DOI 10.1016/S0959-437X(99)80048-3; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176	14	8	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5362	5366		10.1038/sj.onc.1206517	http://dx.doi.org/10.1038/sj.onc.1206517			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917638				2022-12-28	WOS:000184734900016
J	Harvey, AJ; Crompton, MR				Harvey, AJ; Crompton, MR			Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation	ONCOGENE			English	Article						protein-tyrosine kinase; breast cancer; RNA interference; small interfering RNA; proliferation	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; EPIDERMAL-GROWTH-FACTOR; GASTROINTESTINAL-TRACT; EXPRESSION; 3-KINASE; PROTEIN; FAMILY; TUMORS; SIK	Brk (PTK6) is a nonreceptor protein tyrosine kinase, which is expressed in over 60% of breast carcinoma tissue samples and breast tumour cell lines, but not normal mammary tissue or benign lesions. Since experimental Brk expression in nontransformed mammary epithelial cells enhances their mitogenic response to epidermal growth factor, it was important to determine the role Brk plays in the proliferation of breast carcinoma cells and validate it as a therapeutic target. We have used RNA interference to efficiently and specifically downregulate Brk protein levels in breast carcinoma cells, and determined that this results in a significant suppression of their proliferation. Additionally, through the expression of a kinase-inactive mutant, we have determined that Brk can mediate promotion of proliferation via a kinase-independent mechanism, potentially functioning as an 'adapter'. These data identify Brk as a novel target for antiproliferative therapy in the majority of breast cancers, and illustrate the power of RNA interference for rapidly validating candidate therapeutic targets.	Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Crompton, MR (corresponding author), Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.							Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Lee HY, 1998, MOL CELLS, V8, P401; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; QUI H, 2002, J BIOL CHEM, V277, P34634; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	21	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5006	5010		10.1038/sj.onc.1206577	http://dx.doi.org/10.1038/sj.onc.1206577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902983				2022-12-28	WOS:000184578900008
J	Jin, BF; He, K; Wang, HX; Wang, J; Zhou, T; Lan, Y; Hu, MR; Wei, KH; Yang, SC; Shen, BF; Zhang, XM				Jin, BF; He, K; Wang, HX; Wang, J; Zhou, T; Lan, Y; Hu, MR; Wei, KH; Yang, SC; Shen, BF; Zhang, XM			Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A	ONCOGENE			English	Article						proteomics; ubiquitin-proteasome; matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; apoptosis; leukemic cell	HYPUSINE MODIFICATION; CELL-PROLIFERATION; APOPTOSIS; PROTEINS; EIF-5A; PHOSPHORYLATION; PATHWAY; RNA; DEOXYHYPUSINE; LOCALIZATION	The global effect of ubiquitin-proteasome (UP) inhibitors on leukemic cell proteome was analysed. A total of 39 protein spots, affected by UP inhibitors, were identified, including 11 new apoptosis-associated proteins. They are involved in different cellular functions and four were associated with caspase-3 activation. Eukaryotic initiation factor 5A (eIF-5A) was identified in two spots; however, the peptide mass-fingerprinting for the accumulated one included a peptide with lysine(50), indicating that hypusine formation was suppressed during UP inhibitor-induced apoptosis. Hypusine modification ensues immediately following translation of eIF-5A precursor, unless cells are treated with the modification inhibitors diaminoheptane. However, UP inhibitors induced a much stronger accumulation of unmodified eIF-5A compared to the effect of diaminoheptane. We further showed the unmodified eIF-5A was regulated in a proteasome-dependent manner. Inhibition of hypusine formation by diaminoheptane triggered apoptosis, but of particular interest is the finding that eIF-5A expression inhibition by antisense oligodeoxynucleotides significantly enhanced the stimulating effect of GM-CSF on cell growth. Therefore, the eIF-5A accumulation played important roles in the apoptosis induced by UP inhibitors. Moreover, hypusine inhibition in apoptosis was further revealed to be associated with the subcellular localization of eIF-5A. Our data pave the way to a better understanding of the mechanisms by which UP system has been linked to apoptosis.	Natl Ctr Biomed Anal, Inst Basic Med Sci, Beijing 100850, Peoples R China		Zhang, XM (corresponding author), Natl Ctr Biomed Anal, Inst Basic Med Sci, 27 Tai Ping Rd, Beijing 100850, Peoples R China.		Lan, Yu/AAV-2236-2021	Lan, Yu/0000-0002-4731-5945				Caraglia M, 2001, AMINO ACIDS, V20, P91, DOI 10.1007/s007260170050; Chen KY, 1999, J CHIN CHEM SOC-TAIP, V46, P727, DOI 10.1002/jccs.199900100; Chen KY, 1997, BIOL SIGNAL, V6, P105; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Gamble SC, 2000, CANCER RES, V60, P2146; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HERSHEY JWB, 1990, BIOCHIM BIOPHYS ACTA, V1050, P160, DOI 10.1016/0167-4781(90)90159-Y; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; JAKUS J, 1993, J BIOL CHEM, V268, P13131; Jao DLE, 2002, J CELL BIOCHEM, V86, P590, DOI 10.1002/jcb.10235; KANG HA, 1994, J BIOL CHEM, V269, P3934; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Liu YP, 1997, BIOL SIGNAL, V6, P166; Lovric J, 1998, J BIOL CHEM, V273, P22848; Melhem R, 1997, LEUKEMIA, V11, P1690, DOI 10.1038/sj.leu.2400792; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1991, J BIOL CHEM, V266, P7988; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rosorius O, 1999, J CELL SCI, V112, P2369; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Shen EC, 2000, J BIOL CHEM, V275, P23718, DOI 10.1074/jbc.M002312200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi XP, 1996, EXP CELL RES, V225, P348, DOI 10.1006/excr.1996.0185; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Tome ME, 1997, BIOCHEM J, V328, P847; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wang HX, 2002, ACTA BIOCH BIOPH SIN, V34, P630; Witke W, 2001, P NATL ACAD SCI USA, V98, P3832, DOI 10.1073/pnas.051515498; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6; Zhang XM, 1999, BIOCHEM J, V340, P127, DOI 10.1042/0264-6021:3400127	36	66	70	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4819	4830		10.1038/sj.onc.1206738	http://dx.doi.org/10.1038/sj.onc.1206738			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894223				2022-12-28	WOS:000184344600005
J	Rose-Hellekant, TA; Arendt, LM; Schroeder, MD; Gilchrist, K; Sandgren, EP; Schuler, LA				Rose-Hellekant, TA; Arendt, LM; Schroeder, MD; Gilchrist, K; Sandgren, EP; Schuler, LA			Prolactin induces ER alpha-positive and ER alpha-negative mammary cancer in transgenic mice	ONCOGENE			English	Article						mammary cancer; prolactin; ER alpha; transgenic mice	ESTROGEN-RECEPTOR-ALPHA; GLAND DEVELOPMENT; GROWTH-HORMONE; PROGESTERONE-RECEPTOR; CELL-PROLIFERATION; BREAST-CANCER; EPITHELIAL-CELLS; EXPRESSION; TUMORS; DISRUPTION	The role of prolactin in human breast cancer has been controversial. However, it is now apparent that human mammary epithelial cells can synthesize prolactin endogenously, permitting autocrine/paracrine actions within the mammary gland that are independent of pituitary prolactin. To model this local mammary production of prolactin (PRL), we have generated mice that overexpress prolactin within mammary epithelial cells under the control of a hormonally nonresponsive promoter, neurelated lipocalin (NRL). In each of the two examined NRL-PRL transgenic mouse lineages, female virgin mice display mammary developmental abnormalities, mammary intraepithelial neoplasias, and invasive neoplasms. Prolactin increases proliferation in morphologically normal alveoli and ducts, as well as in lesions. The tumors are of varied histotype, but papillary adenocarcinomas and adenosquamous neoplasms predominate. Neoplasms can be separated into two populations: one is estrogen receptor alpha (ERalpha) positive (greater than 15% of the cells stain for ERalpha), and the other is ERalpha- ( < 3%). ER alpha expression does not correlate with tumor histotype, or proliferative or apoptotic indices. These studies provide a mouse model of hormonally dependent breast cancer, and, perhaps most strikingly, a model in which some neoplasms retain ERa, as occurs in the human disease.	Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu		Arendt, Lisa/0000-0002-7954-3635	NATIONAL CANCER INSTITUTE [R01CA064843, R01CA078312] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312, R01-CA64843, R01 CA78312] Funding Source: Medline; NCRR NIH HHS [K01 RR00145] Funding Source: Medline; NIA NIH HHS [T32 AG000265, T32-AG00265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BERA TK, 1994, MOL CELL BIOCHEM, V132, P145, DOI 10.1007/BF00926923; BOOT LM, 1962, GEN COMP ENDOCR, V2, P601; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Camarillo IG, 2001, J ENDOCRINOL, V171, P85, DOI 10.1677/joe.0.1710085; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; Christov KT, 1996, CARCINOGENESIS, V17, P1741, DOI 10.1093/carcin/17.8.1741; Clarke RB, 1997, CANCER RES, V57, P4987; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; DEOME KB, 1959, CANCER RES, V19, P515; EDERY M, 1985, ENDOCRINOLOGY, V116, P105, DOI 10.1210/endo-116-1-105; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; GOUT PW, 1980, CANCER RES, V40, P2433; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; HUSEBY RA, 1985, ENDOCRINOLOGY, V116, P1440, DOI 10.1210/endo-116-4-1440; Imagawa W, 2002, J STEROID BIOCHEM, V80, P213, DOI 10.1016/S0960-0760(01)00188-1; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7; Mertani HC, 1998, INT J CANCER, V79, P202; MULDOON TG, 1987, ENDOCRINOLOGY, V121, P141, DOI 10.1210/endo-121-1-141; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Qin W, 1999, J VIROL, V73, P368, DOI 10.1128/JVI.73.1.368-376.1999; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Schroeder MD, 2001, MOL CELL ENDOCRINOL, V175, P173, DOI 10.1016/S0303-7207(01)00385-9; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SHAFIE S, 1977, CANCER RES, V37, P792; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Shyamala G, 2002, J STEROID BIOCHEM, V80, P137, DOI 10.1016/S0960-0760(01)00182-0; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Stoesz SP, 1995, ONCOGENE, V11, P2233; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; WELSCH CW, 1977, CANCER RES, V37, P951; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Yarus S, 1996, Genet Eng (N Y), V18, P57; Yoshidome K, 2000, CANCER RES, V60, P6901; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x	66	148	148	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4664	4674		10.1038/sj.onc.1206619	http://dx.doi.org/10.1038/sj.onc.1206619			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879011	Green Accepted			2022-12-28	WOS:000184157000007
J	Dunn, JR; Risk, JM; Langan, JE; Marlee, D; Ellis, A; Campbell, F; Watson, AJM; Field, JK				Dunn, JR; Risk, JM; Langan, JE; Marlee, D; Ellis, A; Campbell, F; Watson, AJM; Field, JK			Physical and transcript map of the minimally deleted region III on 17p implicated in the early development of Barrett's oesophageal adenocarcinoma	ONCOGENE			English	Article						chromosome 17; Barrett's oesophageal adenocarcinoma; transcript map; tumour suppressor gene; gene prediction programmes	CANDIDATE TUMOR-SUPPRESSOR; TARGET SITES; GENE; EXPRESSION; HETEROZYGOSITY; IDENTIFICATION; CHROMOSOME-17; DISCOVERY	Allelic imbalance (AI) studies on chromosome 17 (C17) in Barrett's oesophageal adenocarcinoma (BOA) tumours strongly suggest that a minimally deleted region on C17p harbours a BOA-associated gene with tumour suppressor function. This deleted region, designated minimal region III (MRIII), lies between the two microsatellite markers D17S1852 and D17S954. Computational sequence analysis techniques, BLAST and NIX, were used to assemble a physical map of MRIII, consisting of three overlapping bacterial artificial chromosome (BAC) clones, 297N7, 963H4 and 795F17, from the RPCI-11 library. The 270 kb genomic sequence of MRIII was analysed using the computational gene prediction methods NIX and TAP to identify putative BOA genes. A transcript map of MRIII has been generated and contains 25 candidate BOA genes, four of which are the named genes MYH3, SCO1, x006 and MAGOH-LIKE. The other candidates consist of seven genes predicted by TAP with associated ESTs identified by NIX, two genes predicted by TAP alone and 12 genes/ESTs (or pairs of ESTs) identified by NIX alone. No disease-specific mutations were identified in x006 or MAGOH-LIKE, although expression analysis of these genes suggests that they may show alternative splicing or be altered epigenetically or in regulatory regions in oesophageal cancer.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England; Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool L69 3BX, Merseyside, England; Royal Liverpool Univ Hosp, Dept Pathol, Liverpool, Merseyside, England; Royal Liverpool Univ Hosp, Dept Med, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Field, JK (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England.	J.K.Field@liv.ac.uk	Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				Bruening W, 1999, CANCER RES, V59, P4973; Dolan K, 1998, BRIT J CANCER, V78, P950, DOI 10.1038/bjc.1998.607; Dunn J, 1999, ONCOGENE, V18, P987, DOI 10.1038/sj.onc.1202371; Dunn JR, 2000, CLIN CANCER RES, V6, P4033; GISH W, 1996, WU BLASTN2; Harada H, 2001, J HUM GENET, V46, P90, DOI 10.1007/s100380170115; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Holscher AH, 1997, BRIT J SURG, V84, P1470, DOI 10.1111/j.1365-2168.1997.02800.x; Huang J, 2000, CARCINOGENESIS, V21, P2019, DOI 10.1093/carcin/21.11.2019; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Marchese A, 1999, GENOMICS, V56, P12, DOI 10.1006/geno.1998.5655; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Phillips NJ, 1996, CANCER RES, V56, P606; RANKIN SC, 2000, OESOPHAGEAL CANC STA; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; Russell SEH, 2000, CANCER RES, V60, P4729; Schultz DC, 1996, CANCER RES, V56, P1997; Soenen V, 1998, BLOOD, V91, P1008, DOI 10.1182/blood.V91.3.1008.1008_1008_1015; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; Zhao XF, 1998, GENOMICS, V47, P319, DOI 10.1006/geno.1997.5126	25	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4134	4142		10.1038/sj.onc.1206466	http://dx.doi.org/10.1038/sj.onc.1206466			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821948				2022-12-28	WOS:000183707600017
J	Jing, Y; Xia, LJ; Lu, M; Waxman, S				Jing, Y; Xia, LJ; Lu, M; Waxman, S			The cleavage product Delta PML-RAR alpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells	ONCOGENE			English	Article						acute promyelocytic leukemia; PML-RAR alpha; all-trans retinoic acid	RESISTANT NB4 CELLS; PML/RAR-ALPHA; HISTONE DEACETYLASE; IN-VITRO; PROTEASOME PATHWAY; ARSENIC TRIOXIDE; NUCLEAR-BODIES; FUSION PROTEIN; CHIMERIC GENE; NEW-YORK	PML-RARalpha protein, the leukemogenic product of t(15,17) in acute promyelocytic leukemia, is cleaved into a truncated form termed DeltaPML-RARalpha during all-trans retinoic acid (ATRA)-induced differentiation of NB4 cells. DeltaPML-RARalpha is not formed in ATRA differentiation resistant NB4 subclones. As2O3 inhibits DeltaPML-RARalpha formation and differentiation-induction when given in combination with ATRA. Treatment with hexamethylene bisacetamide (HMBA) combined with ATRA enhances ATRA-induced differentiation in ATRA-insensitive NB4-CI and arsenic-resistant NB4/As cells, and is associated with stabilization of PML-RARalpha protein and increased DeltaPML-RARalpha formation. Unlike forced expression of PML-RARalpha, forced DPML-RARalpha expression based on an estimated deletion of the N-terminal PML portion does not repress RARE-tk-luc reporter activity mediated by endogenous retinoic acid receptors. The cleavage of PML-RARalpha is blocked by RARalpha antagonist Ro-41-5253 and cycloheximide and therefore requires a RARalpha transactivation-dependent pathway. Proteasome inhibitor MG-132 and caspase inhibitor Z-VAD-FMK do not block ATRA-induced PML-RARalpha cleavage and differentiation. These data suggest that (a) ATRA treatment induces PML-RARalpha cleavage by induction of unknown enzymes independent of proteasome- and caspase-mediated pathways; (b) DeltaPML-RARalpha might function differently from both PML-RARalpha and RARalpha; (c) failure to cleave PML-RARalpha and form DeltaPML-RARalpha after ATRA treatment may contribute to ATRA resistance in APL cells.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Jing, Y (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1178,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA93533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castaigne Sylvie, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P515; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DEGOS L, 1990, LANCET, V336, P1440, DOI 10.1016/0140-6736(90)93135-C; DELVA L, 1993, BLOOD, V82, P2175; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1996, ONCOGENE, V12, P2451; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jing YK, 2002, BLOOD, V100, P1008, DOI 10.1182/blood.V100.3.1008; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LANOTTE M, 1991, BLOOD, V77, P1080; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Nervi C, 1998, BLOOD, V92, P2244; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; Takayama N, 2001, EXP HEMATOL, V29, P864, DOI 10.1016/S0301-472X(01)00651-8; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, pS33; Yoshida H, 1996, CANCER RES, V56, P2945; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	48	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4083	4091		10.1038/sj.onc.1206568	http://dx.doi.org/10.1038/sj.onc.1206568			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821942				2022-12-28	WOS:000183707600011
J	Sharpless, NE; Chin, L				Sharpless, NE; Chin, L			The INK4a/ARF locus and melanoma	ONCOGENE			English	Article						p19(ARF); cell cycle; cdk4; cdk6; ultraviolet light	TUMOR-SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS; ULTRAVIOLET-RADIATION; G(1) ARREST; CYCLIN-E; P16(INK4A); P53; SENESCENCE; EXPRESSION; MUTATIONS	Inactivation of the INK4a/ARF (or CDKN2a) locus is a common and critical genetic event in the development of human and mouse melanoma. This locus engages the Rb and p53 tumor suppressor pathways through its capacity to encode two distinct gene products, p16(INK4a) and p14(ARF). This review highlights the body of evidence supporting a role for both p16(INK4a) and p14(ARF) in the suppression of melanoma, and speculates as to why this locus is preferentially targeted in this tumor type. In addition, the potential importance of these two pathways in mediating UV-induced melanoma genesis will be addressed via genetic and molecular evidence in the mouse.	Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute	Chin, L (corresponding author), Harvard Univ, Sch Med, Dept Dermatol, 44 Binney St M413, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu		Sharpless, Norman/0000-0001-7078-9455				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berking C, 2002, CARCINOGENESIS, V23, P181, DOI 10.1093/carcin/23.1.181; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONAWHO CK, 1991, CANCER RES, V51, P4176; DURO D, 1995, ONCOGENE, V11, P21; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Flores JF, 1996, CANCER RES, V56, P5023; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; GLENDENING JM, 1995, CANCER RES, V55, P5531; HARRISON SL, 1994, LANCET, V344, P1529, DOI 10.1016/S0140-6736(94)90348-4; Herlyn M, 1996, AM J PATHOL, V149, P739; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jamal S, 2002, J CLIN INVEST, V110, P443, DOI 10.1172/JCI200213729; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU L, 1995, ONCOGENE, V11, P405; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; MAO L, 1995, CANCER RES, V55, P2995; Nairn RS, 1996, P NATL ACAD SCI USA, V93, P13042, DOI 10.1073/pnas.93.23.13042; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sharpless NE, 2002, CANCER RES, V62, P2761; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tang L, 1999, MELANOMA RES, V9, P148, DOI 10.1097/00008390-199904000-00006; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	76	176	183	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3092	3098		10.1038/sj.onc.1206461	http://dx.doi.org/10.1038/sj.onc.1206461			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789286				2022-12-28	WOS:000183096600011
J	Tokumaru, Y; Nomoto, S; Jeronimo, C; Henrique, R; Harden, S; Trink, B; Sidransky, D				Tokumaru, Y; Nomoto, S; Jeronimo, C; Henrique, R; Harden, S; Trink, B; Sidransky, D			Biallelic inactivation of the RIZ1 gene in human gastric cancer	ONCOGENE			English	Article						hypermethylation; RIZ1; gastric cancer tumor suppressor gene; gene silencing	TUMOR-SUPPRESSOR GENE; METHYLTRANSFERASE SUPERFAMILY/; HYPERMETHYLATION; METHYLATION; PROTEIN; INSTABILITY; MEMBER; SERUM; DNA	The distal short arm of chromosome 1 is commonly deleted in a variety of human neoplasms including gastrointestinal cancer. Genetic alterations of the retinoblastoma protein-interacting zing-finger gene (RIZ)1 including loss of heterozygosity (LOH) at 1p36, frame-shift mutations, and promoter hypermethylation were reported previously in several cancers. In this study, we evaluated RIZ1 in 30 primary gastric cancers and found frameshift mutations in two cases (6.7%). Moreover, using real-time quantitative methylation-specific PCR, methylation of the RIZ1 promoter was detected in 11 (37%) cases. In all 11 cases with methylation, inactivation of the second allele occurred through frameshift mutation, LOH or promoter methylation. Our results suggest that RIZ1 is a specific target of inactivation in human gastric cancer.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA; Portuguese Inst Oncol, Dept Genet, P-4200072 Oporto, Portugal; Portuguese Inst Oncol, Dept Pathol, P-4200072 Oporto, Portugal	Johns Hopkins University; Universidade de Coimbra; Universidade de Coimbra	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, 818 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Henrique, Rui Manuel Ferreira/I-2757-2013; Jerónimo, Carmen/H-3284-2013	Henrique, Rui Manuel Ferreira/0000-0003-3171-4666; Jerónimo, Carmen/0000-0003-4186-5345; Harden, Susan Victoria/0000-0001-6067-7177	NCI NIH HHS [1 U01 CA84986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, J CLIN PATHOL; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2001, CANCER RES, V61, P3225; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.3.CO;2-B; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Piao Z, 2000, CANCER RES, V60, P4701; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Usadel H, 2002, CANCER RES, V62, P371; Weith A, 1996, CYTOGENET CELL GENET, V72, P114	20	48	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6954	6958		10.1038/sj.onc.1206403	http://dx.doi.org/10.1038/sj.onc.1206403			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534544				2022-12-28	WOS:000185843400018
J	Tolg, C; Poon, R; Fodde, R; Turley, EA; Alman, BA				Tolg, C; Poon, R; Fodde, R; Turley, EA; Alman, BA			Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive. bromatosis (desmoid tumor)	ONCOGENE			English	Article						aggressive fibromatosis; Rhamm; beta-catenin; transgenic mice; adenomatous polyposis coli; density-dependent proliferation; hyaladherin	ACTIVATED PROTEIN-KINASE; BINDING-PROTEIN; BETA-CATENIN; ADHESION MOLECULES; BREAST-CANCER; MOUSE MODEL; EXPRESSION; FIBROMATOSIS; CELLS; CD44	Aggressive. bromatosis (desmoid tumor) is a locally invasive soft tissue neoplasm associated with mutations resulting in beta-catenin-mediated transcriptional activation. This tumor is composed of cells with histological and molecular characteristics common to proliferating mesenchymal cells of dermal wounds. Using immunohistochemistry and RT-PCR, we show that Rhamm, a protein with an important role in wound healing and neoplastic progression, is also expressed at high levels in aggressive. bromatosis. A mouse harboring a targeted deletion in Rhamm was generated, resulting in viable Rhamm-/- animals. Rhamm-/- mice were crossed with Apc/Apc1638N mice, which harbor a targeted mutation in the Apc gene predisposing animals to gastrointestinal and aggressive. bromatosis tumors. Rhamm deficiency significantly decreased the number of aggressive. bromatosis tumors formed, but did not alter the number of gastrointestinal polyps. Cell culture studies show that Rhamm regulates cell proliferation in both fibroblasts and. bromatosis cells under conditions of low density, but not high density. These results suggest that Rhamm regulates proliferation of cells with sparse cell-cell contacts, such as occurs in aggressive. bromatosis; provides the first genetic evidence implicating Rhamm in tumor pathology; and suggest Rhamm blockade as a potential therapeutic target for this otherwise difficult-to-treat neoplasm.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Western Ontario, Dept Oncol, London, ON N6A 3K7, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 3K7, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Leiden Univ, Med Ctr, MGC Human & Clin Genet, NL-2333 AL Leiden, Netherlands; Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Alman, BA (corresponding author), Hosp Sick Children, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca	Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324				Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Assmann V, 1999, J CELL SCI, V112, P3943; Assmann V, 2001, J PATHOL, V195, P191, DOI 10.1002/path.941; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Cheung WF, 1999, BIOCHEM SOC T, V27, P135, DOI 10.1042/bst0270135; Crainie M, 1999, BLOOD, V93, P1684, DOI 10.1182/blood.V93.5.1684.405k22_1684_1696; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gares S L, 2000, Dev Immunol, V7, P209, DOI 10.1155/2000/94616; Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x; Gutierrez-Ruiz MC, 2002, ARCH MED RES, V33, P595, DOI 10.1016/S0188-4409(02)00408-3; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Hall CL, 1996, ONCOGENE, V13, P2213; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; Kong QY, 2003, ONCOL REP, V10, P51; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Li H, 2000, INT J ONCOL, V17, P927; Line A, 2002, CANCER IMMUNOL IMMUN, V51, P574, DOI 10.1007/s00262-002-0322-2; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; Lovvorn HN, 1998, J PEDIATR SURG, V33, P1062, DOI 10.1016/S0022-3468(98)90532-2; Lynn BD, 2001, J COMP NEUROL, V439, P315, DOI 10.1002/cne.1353; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Naor D, 1998, CURR TOP MICROBIOL, V231, P143; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PILARSKI LM, 1994, LEUKEMIA LYMPHOMA, V14, P363, DOI 10.3109/10428199409049691; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; SPICER AP, 1995, GENOMICS, V30, P115, DOI 10.1006/geno.1995.0022; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tejpar S, 2001, BRIT J CANCER, V85, P98, DOI 10.1054/bjoc.2001.1857; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TURLEY E, 1989, EXP CELL RES, V182, P340, DOI 10.1016/0014-4827(89)90239-5; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1985, J CELL SCI, V78, P133; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1982, BIOCHEM BIOPH RES CO, V108, P1016, DOI 10.1016/0006-291X(82)92101-5; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Wang C, 1998, CLIN CANCER RES, V4, P567; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; Zhou RX, 2002, J NEURO-ONCOL, V59, P15, DOI 10.1023/A:1016373015569	56	79	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6873	6882		10.1038/sj.onc.1206811	http://dx.doi.org/10.1038/sj.onc.1206811			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534534				2022-12-28	WOS:000185843400008
J	Lee, MW; Hirai, I; Wang, HG				Lee, MW; Hirai, I; Wang, HG			Caspase-3-mediated cleavage of Rad9 during apoptosis	ONCOGENE			English	Article						caspase-3; Rad9; DNA damage; cell-cycle checkpoint; apoptosis	DNA-DAMAGE; CHECKPOINT COMPLEX; CELL-DEATH; PROTEIN; HRAD9; BCL-2; PHOSPHORYLATION; ACTIVATION; INTERACTS; EVOLUTION	The activation of caspases is a critical event for the execution phase of programmed cell death. Caspases are highly specific in their ability to activate or inhibit many crucial proteins in the cell via cleavage. In this study, we report the identification of several caspase-3-like cleavage sites in the cell-cycle checkpoint protein Rad9. We demonstrate that human Rad9 can be specifically cleaved in cells induced to enter apoptosis by both DNA damage and staurosporine treatment. Indeed, we show that human Rad9 can be effectively cleaved both in vitro and in vivo, which can be inhibited by either a pan-caspase inhibitor or a caspase-3-specific inhibitor. Additionally, no cleavage of Rad9 can be seen in the caspase-3-deficient cell line MCF-7. Site-directed mutagenesis of three of the most conserved cleavage sites dramatically abrogates cleavage of Rad9 by caspase-3 in vitro, and in intact cells after DNA damage. Expression of the cleavage-resistant mutant Rad9 DDD/AAA appears to protect the cell from DNA damage-induced apoptosis. Immunofluorescence studies of Rad9 localization before and after induction of apoptosis show a translocation of Rad9 from the nucleus to the cytosol, concomitant to the appearance of apoptotic morphology. Furthermore, analysis of a truncated Rad9 mutant that corresponds to a putative N-terminal cleavage fragment shows that the N-terminal portion of Rad9 localizes in the cytosol, binds to Bcl-XL, and induces apoptosis. These results support a dual role for cleavage of Rad9: ( 1) the liberation and translocation of the BH3 domain-containing N-terminus of Rad9 to the cytosol, as a means of promoting apoptosis via antagonism of Bcl-XL, and ( 2) the disruption of the Rad9-Rad1-Hus1 DNA damage checkpoint complex.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA082197, R01CA090315] Funding Source: NIH RePORTER; NCI NIH HHS [CA82197, CA90315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2002, CURR BIOL, V12, pR105, DOI 10.1016/S0960-9822(02)00673-5; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hayashi K, 2002, PATHOBIOLOGY, V70, P40, DOI 10.1159/000066002; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Komatsu K, 2000, FEBS LETT, V481, P122, DOI 10.1016/S0014-5793(00)01975-X; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	27	27	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6340	6346		10.1038/sj.onc.1206729	http://dx.doi.org/10.1038/sj.onc.1206729			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508514				2022-12-28	WOS:000185535300004
J	Gondi, CS; Lakka, SS; Yanamandra, N; Siddique, K; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Gondi, CS; Lakka, SS; Yanamandra, N; Siddique, K; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis	ONCOGENE			English	Article						adenovirus; antisense; glioma; invasion; uPA and uPAR	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; UROKINASE RECEPTOR; MEDIATED DELIVERY; MONOCLONAL-ANTIBODY; ACTIN CYTOSKELETON; SURFACE UROKINASE; IN-VITRO; CANCER; MICE	Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in the invasiveness of gliomas and other infiltrative tumors. In glioma cell lines and tumors, high grade correlates with increased expression of uPAR and uPA. We report here the downregulation of uPAR and uPA by delivery of antisense sequences of uPAR and uPA in a single adenoviral vector, Ad-uPAR-uPA (Ad, adenovirus). The bicistronic construct (Ad-uPAR-uPA) infected glioblastoma cell line had significantly reduced levels of uPAR, uPA enzymatic activity and immunoreactivity for these proteins when compared to controls. The Ad-uPAR-uPA infected cells showed a markedly lower level of invasion in the Matrigel invasion assays, and their spheroids failed to invade the fetal rat brain aggregates in the coculture system. Intracranial injection of SNB19 cells with the Ad-uPAR-uPA antisense bicistronic construct showed inhibited invasiveness and tumorigenicity. Subcutaneous injections of bicistronic antisense constructs into established tumors (U87 MG) caused regression of those tumors. Our results support the therapeutic potential of targeting the individual components of the uPAR-uPA system by using a single adenovirus construct for the treatment of glioma and other invasive cancers.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Pathol, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [CA 75557] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Adachi Y, 2002, ONCOGENE, V21, P87, DOI 10.1038/sj.onc.1204999; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Fibbi G, 1998, LAB INVEST, V78, P1109; FOEKENS JA, 1995, J NATL CANCER I, V87, P751, DOI 10.1093/jnci/87.10.751; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gutierrez LS, 2000, CANCER RES, V60, P5839; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOBAYASHI H, 1993, JPN J CANCER RES, V84, P633, DOI 10.1111/j.1349-7006.1993.tb02023.x; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LAFRENIE RM, 1992, CANCER RES, V52, P2202; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Min HY, 1996, CANCER RES, V56, P2428; Mohan PM, 1999, CANCER RES, V59, P3369; MOHANAM S, 1993, CANCER RES, V53, P4143; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; Park IK, 1997, INT J CANCER, V71, P867, DOI 10.1002/(SICI)1097-0215(19970529)71:5<867::AID-IJC27>3.0.CO;2-3; SAPPINO AP, 1987, CANCER RES, V47, P4043; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; Sieuwerts AM, 2002, THROMB HAEMOSTASIS, V87, P674; Sturge J, 2002, J CELL SCI, V115, P699; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	37	82	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5967	5975		10.1038/sj.onc.1206535	http://dx.doi.org/10.1038/sj.onc.1206535			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955075				2022-12-28	WOS:000185137800005
J	Yu, WM; Hawley, TS; Hawley, RG; Qu, CK				Yu, WM; Hawley, TS; Hawley, RG; Qu, CK			Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling	ONCOGENE			English	Article						SHP-2; tyrosine phosphatase; IL-3; hematopoietic cell proliferation and differentiation	COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELL DEVELOPMENT; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; BETA-SUBUNIT; SHC-PTB; T-CELL; PROTEIN; ACTIVATION; KINASE	SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells, however, the function of SHP-2 in hematopoietic cell signaling is not well understood. Here we focus on the role of SHP-2 phosphatase in the signal transduction of interleukin (IL)-3, a cytokine involved in hematopoietic cell survival, proliferation, and differentiation. We established immortalized SHP-2(-/-) hematopoietic cell pools and showed that IL-3-induced proliferative response was diminished in SHP-2(-/-) cells. Moreover, inhibition of the catalytic activity of SHP-2 in wild-type (WT) bone marrow hematopoietic progenitor cells and Ba/F3 cells by overexpression of catalytically inactive SHP-2 mutant suppressed their differentiative and proliferative responses to IL-3, demonstrating an important positive role for SHP-2 in IL-3 signal transduction. Further biochemical analyses revealed that IL-3-induced Jak/Stat, Erk, and PI3 kinase pathways in SHP-2(-/-) cells were impaired and reintroduction of WT SHP-2 into mutant cells partially restored IL-3 signaling. Interestingly, in catalytically inactive SHP-2-overexpressing Ba/F3 cells, although IL-3-induced activation of Jak2 and Erk kinases was reduced and shortened, PI3 kinase activation remained unaltered. Taken together, these results suggest that SHP-2 tyrosine phosphatase plays multiple roles in IL-3 signal transduction, functioning in both catalytic-dependent and -independent manners in the Jak/Stat, Erk, and PI3 kinase pathways.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Flow Cytometry Facil, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	quc@usa.redcross.org		Hawley, Robert/0000-0003-3512-5818	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066305, R01HL068212] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL66305, R01HL68212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAWLEY RG, 1994, ONCOGENE, V9, P1; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Manes S, 1999, MOL CELL BIOL, V19, P3125; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Okuda K, 1999, ANN NY ACAD SCI, V872, P305, DOI 10.1111/j.1749-6632.1999.tb08474.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yu WM, 2002, BLOOD, V100, P3828, DOI 10.1182/blood-2002-03-0937; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	43	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5995	6004		10.1038/sj.onc.1206846	http://dx.doi.org/10.1038/sj.onc.1206846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955078				2022-12-28	WOS:000185137800008
J	Kasid, U; Dritschilo, A				Kasid, U; Dritschilo, A			RAF antisense oligonucleotide as a tumor radiosensitizer	ONCOGENE			English	Review						radioresistance; RAF-1; radiation response; antisense; liposomal oligonucleotide drug; in vivo potency; clinical relevance	ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; FACTOR-KAPPA-B; PHASE-I TRIAL; IONIZING-RADIATION; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ISIS 5132; GENE-EXPRESSION	The RAF-1 serine-threonine kinase plays a central role in signal transduction pathways involved in cell survival and proliferation. The concept of RAF-1-targeted disruption of cell signaling for therapeutic purposes was first advanced in 1989 with the demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous carcinoma cells transfected with a vector expressing antisense cDNA. However, the clinical application of antisense strategies has awaited the development of improved antisense oligonucleotide technologies and drug delivery methods. Nuclease-resistant phosphorothioated antisense oligonucleotides have been the focus of pharmaceutical industry attention. In vivo delivery of nuclease-sensitive, natural backbone/phosphodiester oligonucleotides has remained a formidable challenge. Liposomal encapsulation of antisense oligonucleotides protects them from degradation and enhances drug delivery. Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide.	Georgetown Univ, Dept Radiat Med, Lombardi Canc Ctr, Med Ctr, Washington, DC 20007 USA	Georgetown University	Dritschilo, A (corresponding author), Georgetown Univ, Dept Radiat Med, Lombardi Canc Ctr, Med Ctr, E202,Res Bldg, Washington, DC 20007 USA.	dritscha@georgetown.edu			NCI NIH HHS [CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1999, ANTISENSE NUCLEIC A, V9, P371; Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Aplin AE, 1998, PHARMACOL REV, V50, P197; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AWADA A, 2001, P AACR NCI EORTC INT, P116; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Bianco C, 2002, CLIN CANCER RES, V8, P3250; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; Dai Y, 2001, CANCER RES, V61, P5106; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DEL PL, 1997, SCIENCE, V278, P687; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; DRITSCHILO A, 2002, P AN M AM SOC CLIN, V21, pA28; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Fuhrmann G, 2001, ONCOGENE, V20, P4542, DOI 10.1038/sj.onc.1204499; Garcia-Chaumont C, 2000, PHARMACOL THERAPEUT, V87, P255, DOI 10.1016/S0163-7258(00)00062-0; Geng L, 2001, CANCER RES, V61, P2413; Gokhale PC, 2002, CLIN CANCER RES, V8, P3611; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Gokhale PC, 1997, GENE THER, V4, P1289, DOI 10.1038/sj.gt.3300543; Gorski DH, 1999, CANCER RES, V59, P3374; Grana TM, 2002, CANCER RES, V62, P4142; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HALLAHAN DE, 1991, CANCER RES, V51, P4565; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; HOLMLUND J, 1998, P AN M AM SOC CLIN, V17, P811; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huang SM, 1999, CANCER RES, V59, P1935; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Janosch P, 2000, FASEB J, V14, P2008, DOI 10.1096/fj.99-0883com; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASID U, 1991, INT C RAD RES, V1, P242; Kasid Usha, 1998, P85; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; Khatib AM, 2002, CANCER RES, V62, P5393; Khodarev NN, 2001, P NATL ACAD SCI USA, V98, P12665, DOI 10.1073/pnas.211443698; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Koller E, 2000, TRENDS PHARMACOL SCI, V21, P142, DOI 10.1016/S0165-6147(00)01448-6; Kozin SV, 2001, CANCER RES, V61, P39; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lammering G, 2001, CLIN CANCER RES, V7, P682; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; Leonetti C, 2001, CANCER GENE THER, V8, P459, DOI 10.1038/sj.cgt.7700326; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Milas L, 2000, CLIN CANCER RES, V6, P701; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Monia BP, 2000, CANCER INVEST, V18, P635, DOI 10.3109/07357900009032830; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Monteith DK, 1998, TOXICOL SCI, V46, P365, DOI 10.1093/toxsci/46.2.365; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; Pagnan G, 2000, J NATL CANCER I, V92, P253, DOI 10.1093/jnci/92.3.253; Pandey SK, 1999, BIOCHEMISTRY-US, V38, P14667, DOI 10.1021/bi9911886; Patel S, 1997, MOL MED, V3, P674, DOI 10.1007/BF03401706; PETERS LJ, 1982, INT J RADIAT ONCOL, V8, P101, DOI 10.1016/0360-3016(82)90392-3; Pfeifer A, 1998, BIOCHEM BIOPH RES CO, V252, P481, DOI 10.1006/bbrc.1998.9660; Pirollo KF, 1997, BIOCHEM BIOPH RES CO, V230, P196, DOI 10.1006/bbrc.1996.5922; PIROLLO KF, 1989, INT J RADIAT BIOL, V55, P783, DOI 10.1080/09553008914550831; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Poggi MM, 2001, CURR PROB CANCER, V25, P334, DOI 10.1067/mcn.2001.120122; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; RUDIN C, 2002, P AN M AM SOC CLIN, V21, pB9; RUDIN C, 2001, P AN M AM SOC CLIN, V20, pA322; Rudin CM, 2001, CLIN CANCER RES, V7, P1214; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; SKORSKI T, 1995, CANCER RES, V55, P2275; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; Stevenson JP, 1999, J CLIN ONCOL, V17, P2227, DOI 10.1200/JCO.1999.17.7.2227; STRUMBERG D, 2001, P AN M AM SOC CLIN, V20, pA83; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Tari AM, 1998, J LIPOSOME RES, V8, P251, DOI 10.3109/08982109809035530; Tenzer A, 2001, CANCER RES, V61, P8203; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; Veikkola T, 2000, CANCER RES, V60, P203; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu XXS, 1998, J BIOL CHEM, V273, P33230, DOI 10.1074/jbc.273.50.33230; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zhong J, 2001, ONCOGENE, V20, P4807, DOI 10.1038/sj.onc.1204614; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	142	45	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5876	5884		10.1038/sj.onc.1206700	http://dx.doi.org/10.1038/sj.onc.1206700			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947394				2022-12-28	WOS:000185086100014
J	Frese, S; Pirnia, F; Miescher, D; Krajewski, S; Borner, MM; Reed, JC; Schmid, RA				Frese, S; Pirnia, F; Miescher, D; Krajewski, S; Borner, MM; Reed, JC; Schmid, RA			PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2	ONCOGENE			English	Article						lung cancer; resistance to apoptosis; tumor necrosis factor-related apoptosis-inducing ligand; mitogen-activated protein kinase; primary culture	TRAIL-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASE; MAP KINASE; IN-VIVO; TRAIL/APO2L-INDUCED APOPTOSIS; CHEMOTHERAPEUTIC-AGENTS; INHIBITORY PROTEIN; ANTITUMOR-ACTIVITY; TUMOR-CELLS; LIGAND	Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to the family of programmed cell death-inducing cytokines. Apo2L/TRAIL induces apoptosis in a wide variety of tumor cells. Tumor cells that are resistant to Apo2L/TRAIL-induced apoptosis can be sensitized by chemotherapeutic drugs and other agents via an unknown mechanism. Here we report that PG490 (triptolide), a diterpene triepoxide extracted from the Chinese herb Tripterygium wilfordii and used in traditional Chinese medicine, sensitizes lung cancer but not normal human bronchial epithelial cells to Apo2L/TRAIL-induced apoptosis. Sensitization was accompanied by caspase-3 and caspase-8 activation, whereas no cleavage of caspase-9 was observed. Determination of cell surface receptors by flow cytometry demonstrated no difference in Apo2L/TRAIL-R1 and -R2 expression, the two receptors with functional death domains, between resistant and sensitized cells. In cells treated with the combination of Apo2L/TRAIL and PG490, we observed activation of ERK2, a member of the mitogen-activated protein kinase family. Furthermore, sensitization could be blocked by the ERK inhibitor U0126 but not the p38 inhibitor SB203580, suggesting that activation of ERK2 is required for this effect. In addition, sensitization of lung cancer cells was also seen in ex vivo culture of lung cancer tissue from four patients who underwent surgery. Immunohistochemical staining showed a clear reduction in proliferation cell nuclear antigen (PCNA) in tissue treated with Apo2L/TRAIL and PG490. In conclusion, apoptosis induced by the combination of Apo2L/TRAIL and PG490 warrants further evaluation as a potential new strategy for the treatment of lung cancer.	Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Burnham Inst, La Jolla, CA 92037 USA	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Sanford Burnham Prebys Medical Discovery Institute	Frese, S (corresponding author), Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, Murtenstr 35,Room C807, CH-3010 Bern, Switzerland.	steffen.frese@email.de	Borner, Markus/B-7583-2011; Frese, Steffen/AAL-4573-2021	Schmid, Ralph Alexander/0000-0003-0699-079X	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Cottom J, 2003, J BIOL CHEM, V278, P7167, DOI 10.1074/jbc.M203901200; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Evdokiou A, 2002, INT J CANCER, V99, P491, DOI 10.1002/ijc.10376; Faul JL, 2000, AM J RESP CRIT CARE, V162, P2252, DOI 10.1164/ajrccm.162.6.2002018; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gliniak B, 1999, CANCER RES, V59, P6153; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith TS, 2002, CANCER RES, V62, P3093; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Huynh PN, 2000, J ANDROL, V21, P689; Ishiwata N, 2000, ANTICANCER RES, V20, P1445; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krajewska M, 1997, CANCER RES, V57, P1605; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee MW, 2002, FEBS LETT, V512, P313, DOI 10.1016/S0014-5793(02)02225-1; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Leverkus M, 2000, CANCER RES, V60, P553; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; McCullagh P, 1989, MONOGRAPHS STAT APPL, V2nd; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stadheim TA, 2001, CANCER RES, V61, P1533; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; Zhang XD, 1999, CANCER RES, V59, P2747	40	84	96	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5427	5435		10.1038/sj.onc.1206842	http://dx.doi.org/10.1038/sj.onc.1206842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934102				2022-12-28	WOS:000184735000007
J	Nilsen, H; Stamp, G; Andersen, S; Hrivnak, G; Krokan, HE; Lindahl, T; Barnes, DE				Nilsen, H; Stamp, G; Andersen, S; Hrivnak, G; Krokan, HE; Lindahl, T; Barnes, DE			Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas	ONCOGENE			English	Article						uracil-DNA glycosylase; B-cell lymphoma; gene-targeted mice; antibody diversity	BASE EXCISION-REPAIR; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; DEFICIENCY CAUSES; MISINCORPORATION; MUTATIONS; TUMORIGENESIS; ACCUMULATION; SUPPRESSION	Mice deficient in the Ung uracil-DNA glycosylase have an increased level of uracil in their genome, consistent with a major role of Ung counteracting U:A base pairs arising by misincorporation of dUMP during DNA replication. A complementary uracil-excising activity apparently acts on premutagenic U:G lesions resulting from deamination of cytosine throughout the genome. However, Ung specifically processes U:G lesions targeted to immunoglobulin variable (V) genes during somatic hypermutation and class-switch recombination. Gene-targeted Ung(-/-) null mice remained tumour-free and showed no overt pathological phenotype up to similar to12 months of age. We have monitored a large cohort of ageing Ung(-/-) mice and, beyond 18 months of age, they had a higher morbidity than Ung(+/+) controls. Post-mortem analyses revealed pathological changes in lymphoid organs, abnormal lymphoproliferation, and a greatly increased incidence of B-cell lymphomas in older Ung-deficient mice. These are the first data reporting the development of spontaneous malignancies in mice due to deficiency in a DNA glycosylase. Furthermore, they support a specific role for Ung in the immune system, with lymphomagenesis being related to perturbed processing of antibody genes in germinal centre B cells.	Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England; Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, Fac Med, London W12 0NN, England; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Fac Med, N-7489 Trondheim, Norway	Cancer Research UK; Imperial College London; Norwegian University of Science & Technology (NTNU)	Lindahl, T (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England.	lindahl@cancer.org.uk	Nilsen, Hilde/F-6432-2014	Nilsen, Hilde/0000-0003-2115-2663				Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; Elder RH, 2002, J BIOL CHEM, V277, P50487, DOI 10.1074/jbc.M208153200; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Kvaloy K, 2001, MUTAT RES-DNA REPAIR, V461, P325, DOI 10.1016/S0921-8777(00)00063-X; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; MCDONALD JP, 2003, IN PRESS J EXP MED; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sakumi K, 2003, CANCER RES, V63, P902; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Stevenson FK, 2001, ADV CANCER RES, V83, P81, DOI 10.1016/S0065-230X(01)83004-9; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299; Wright BE, 2002, CANCER RES, V62, P5641	35	122	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5381	5386		10.1038/sj.onc.1206860	http://dx.doi.org/10.1038/sj.onc.1206860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934097				2022-12-28	WOS:000184735000002
J	Prosser, S; Sorokina, E; Pratt, P; Sorokin, A				Prosser, S; Sorokina, E; Pratt, P; Sorokin, A			CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins	ONCOGENE			English	Article						CrkII; CrkIII; adaptor protein; ERK; MAP kinase	INSULIN-RECEPTOR SUBSTRATE-1; V-CRK; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; SIGNALING PATHWAYS; SH3 DOMAIN; PC12 CELLS; SRC; RAS; BINDS	As the role for adaptor proteins constantly proliferates, appreciation of their importance has never been higher. The Crk family of adaptor proteins is no exception. Currently comprising four members, v-Crk, CrkI, CrkII and Crk-like protein, we have introduced a fifth member, CrkIII. Cloned by the CORT technique, CrkIII is identical in sequence to CrkII until the second of its two SH3 domains, which is disrupted partway through and results in a nonfunctional domain and a unique C-terminal sequence. We have demonstrated the existence of native CrkIII at the message level using RT-PCR and RNAse protection assays, and at the protein level in mouse fibroblasts. We show that CrkII overexpression is capable of enhancing insulin-stimulated ERK activity, whereas CrkIII is not, thus partially characterizing a novel member of the Crk family and elucidating important effects mediated by the c-terminal SH3 domain.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	sorokin@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL10165-01, HL22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010165, R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKUI Y, 1989, ONCOGENE RES, V4, P283; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith JJ, 2000, J CELL BIOL, V151, P1391, DOI 10.1083/jcb.151.7.1391; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Sraer JD, 1996, KIDNEY INT, V49, P267, DOI 10.1038/ki.1996.38; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VRIESSMITS AMM, 1992, NATURE, V357, P602; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	27	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4799	4806		10.1038/sj.onc.1206714	http://dx.doi.org/10.1038/sj.onc.1206714			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894221				2022-12-28	WOS:000184344600003
J	Almholt, K; Nielsen, BS; Frandsen, TL; Brunner, N; Dano, K; Johnsen, M				Almholt, K; Nielsen, BS; Frandsen, TL; Brunner, N; Dano, K; Johnsen, M			Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice	ONCOGENE			English	Article						plasminogen activator inhibitor-1 (PAI-1); metastasis; breast cancer; angiogenesis	MATRIX-DEGRADING PROTEASES; UROKINASE-TYPE; MESSENGER-RNA; EXTRACELLULAR PROTEOLYSIS; IMMUNOHISTOCHEMICAL LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; CELL-ADHESION; TUMOR-GROWTH; PAI-1; INVASION	The plasminogen activator inhibitor-1 (PAI-1) blocks the activation of plasmin(ogen), an extracellular protease vital to cancer invasion. PAI-1 is like the corresponding plasminogen activator uPA (urokinase-type plasminogen activator) consistently expressed in human breast cancer. Paradoxically, high levels of PAI-1 as well as uPA are equally associated with poor prognosis in cancer patients. PAI-1 is thought to play a vital role for the controlled extracellular proteolysis during tumor neovascularization. We have studied the effect of PAI-1 deficiency in a transgenic mouse model of metastasizing breast cancer. In these tumors, the expression pattern of uPA and PAI-1 resembles that of human ductal breast cancer and plasminogen is required for efficient metastasis. In a cohort of 63 transgenic mice that were either PAI-1-deficient or wild-type sibling controls, primary tumor growth and vascular density were unaffected by PAI-1 status. PAI-1 deficiency also did not significantly affect the lung metastatic burden. These results agree with the virtual lack of spontaneous phenotype in PAI-1-deficient mice and humans and may reflect that the plasminogen activation reaction is not rate limiting for tumor vascularization and metastasis, or that there is a functional redundancy between PAI-1 and other inhibitors of the uPA/plasmin system, masking the effect of PAI-1 deficiency.	Rigshosp, Finsen Lab, Dept 8621, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Almholt, K (corresponding author), Rigshosp, Finsen Lab, Dept 8621, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	kasper@finsenlab.dk	Frandsen, Thomas L/H-7784-2017; Almholt, Kasper/D-6133-2013; Johnsen, Morten/L-8016-2014	Frandsen, Thomas L/0000-0001-8495-5274; Johnsen, Morten/0000-0003-3763-2362; Almholt, Kasper/0000-0002-9250-514X				ALMHOLT K, IN PRESS RECENT RESU, V162; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BIANCHI E, 1995, INT J CANCER, V60, P597, DOI 10.1002/ijc.2910600505; BIANCHI E, 1994, CANCER RES, V54, P861; Biliran H, 2001, CANCER RES, V61, P8676; BROWN T, 1997, CURRENT PROTOCOLS MO, V1; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; DANO K, 1993, PORTL PR P, P239; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Fay WP, 1997, BLOOD, V90, P204; Feng Q, 2001, PLACENTA, V22, P186, DOI 10.1053/plac.2000.0607; Frandsen TL, 2001, CANCER RES, V61, P532; Garlanda C, 1997, EUR J CELL BIOL, V73, P368; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Gutierrez LS, 2000, CANCER RES, V60, P5839; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HACKEL C, 1995, ANAT EMBRYOL, V192, P363, DOI 10.1007/BF00710105; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HOFMANN GE, 1994, AM J OBSTET GYNECOL, V170, P671, DOI 10.1016/S0002-9378(94)70246-2; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; KRISTENSEN P, 1990, HISTOCHEMISTRY, V93, P559, DOI 10.1007/BF00272198; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Lund LR, 2000, DEVELOPMENT, V127, P4481; Maglione JE, 2001, CANCER RES, V61, P8298; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Montemurro P, 1999, BRIT J HAEMATOL, V107, P294, DOI 10.1046/j.1365-2141.1999.01698.x; NEKARDA H, 1994, CANCER RES, V54, P2900; Nielsen BS, 1996, LAB INVEST, V74, P168; Nielsen BS, 2001, LAB INVEST, V81, P1485, DOI 10.1038/labinvest.3780363; Nielsen BS, 2001, AM J PATHOL, V158, P1997, DOI 10.1016/S0002-9440(10)64671-8; Parfyonova YV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P119, DOI 10.1023/A:1013964517211; PEDERSEN H, 1994, CANCER RES, V54, P120; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1993, CANCER RES, V53, P1911; Riisbro R, 2002, CLIN CANCER RES, V8, P1132; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tapiovaara H, 1996, ADV CANCER RES, V69, P101, DOI 10.1016/S0065-230X(08)60861-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	74	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4389	4397		10.1038/sj.onc.1206601	http://dx.doi.org/10.1038/sj.onc.1206601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853975				2022-12-28	WOS:000183978900008
J	Nicolas, FJ; Hill, CS				Nicolas, FJ; Hill, CS			Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest	ONCOGENE			English	Article						TGF-beta; Smad; signal duration; pancreatic tumor cells; cell cycle arrest	PLASMINOGEN-ACTIVATOR INHIBITOR; TRANSCRIPTIONAL ACTIVATION; ACTIVIN RECEPTOR; CDK INHIBITORS; CYCLE ARREST; CANCER CELLS; C-MYC; REPRESSION; EXPRESSION; GENE	We have investigated the mechanism whereby tumor cells become resistant to the antiproliferative effects of transforming growth factor (TGF)-beta, while maintaining other responses that can lead to increased malignancy and invasiveness. TGF-beta signaling results in nuclear accumulation of active Smad complexes which regulate transcription of target genes. Here we show that in two pancreatic carcinoma cell lines, PT45 and Panc-1, that are resistant to TGF-beta-induced growth arrest, the TGF-beta-Smad signaling pathway is attenuated compared with epithelial cells that are sensitive to the antiproliferative effects of TGF-beta (HaCaT and Colo-357). In PT45 and Panc-1 cells, active Smad complexes remain nuclear for only 1-2 It compared with more than 6 h in HaCaT and Colo-357 cells. The attenuated pathway in PT45 and Panc-1 cells correlates with low levels of TGF-beta type I receptor and results in an altered expression profile of TGF-beta-inducible genes required for cell cycle arrest. Most significantly, expression of the CDK inhibitor, p21(Cip1/WAF1), which is required for TGF-beta-induced growth arrest in these cells, is not maintained. Moreover, we show that artificially attenuating the TGF-beta-Smad signaling pathway in HaCaT cells is sufficient to prevent TGF-beta-induced growth arrest. Our results demonstrate that the duration of TGF-beta-Smad signaling is a critical determinant of the specificity of the TGF-beta response.	Canc Res UK, London Res Inst, Lab Dev Signalling, London WC2A 3PX, England	Cancer Research UK	Hill, CS (corresponding author), Canc Res UK, London Res Inst, Lab Dev Signalling, 44 Lincolns Inn Fields, London WC2A 3PX, England.	caroline.hill@cancer.org.uk	Nicolás, Francisco José/H-9422-2019	Nicolás, Francisco José/0000-0002-3969-1430; Hill, Caroline/0000-0002-8632-0480				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; Faure S, 2000, DEVELOPMENT, V127, P2917; Fink SP, 2001, CANCER RES, V61, P256; Florenes VA, 1996, ONCOGENE, V13, P2447; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Goggins M, 1998, CANCER RES, V58, P5329; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay ED, 1995, ACTA ANAT, V154, P8; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Iavarone A, 1997, NATURE, V387, P417; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jonson T, 2001, INT J ONCOL, V19, P71; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAVARONE A, 1999, MOL CELL BIOL, V19, P916; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P6791, DOI 10.1073/pnas.96.12.6791; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wells RG, 1997, J BIOL CHEM, V272, P11444; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wong C, 1999, MOL CELL BIOL, V19, P1821	67	114	126	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3698	3711		10.1038/sj.onc.1206420	http://dx.doi.org/10.1038/sj.onc.1206420			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802277				2022-12-28	WOS:000183551000004
J	Macaluso, M; Cinti, C; Russo, G; Russo, A; Giordano, A				Macaluso, M; Cinti, C; Russo, G; Russo, A; Giordano, A			PRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer	ONCOGENE			English	Article						pRb2/p130; chromatin-modifying enzymes; estrogen receptor-alpha; breast carcinoma	HISTONE DEACETYLASE INHIBITION; CHROMATIN-REMODELING COMPLEXES; CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; REPRESSES TRANSCRIPTION; GENE-EXPRESSION; DNA METHYLATION; METHYLTRANSFERASE; RECRUITMENT; ACETYLATION	The estrogen receptor-alpha (ER) plays a crucial role in normal breast development and is also linked to development and progression of mammary carcinoma. The transcriptional repression of ER-alpha gene in breast cancer is an area of active investigation with potential clinical significance. However, the molecular mechanisms that regulate the ER-alpha gene expression are not fully understood. Here we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells. We investigated in vivo occupancy of ER-alpha promoter by pRb2/p130-E2F4/5-HDAC1-SUV39 H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 complexes, and provided a link between pRb2/p130 and chromatin-modifying enzymes in the regulation of ER-alpha transcription in a physiological setting. These findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Palermo, Dept Oncol, Sect Mol Oncol, Reg Reference Ctr Biomol Characterizat Neoplasms, Palermo, Italy; CNR, ITOI, Inst Normal & Pathol Cytomorphol, I-40126 Bologna, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Siena	Macaluso, M (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369				Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Davis T, 2000, CLIN CANCER RES, V6, P4334; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1998, CANCER RES, V58, P2515; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Parl F.F., 2000, ESTROGENS ESTROGEN R; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Stiegler P, 1998, CANCER RES, V58, P5049; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WEIGEL RJ, 1993, CANCER RES, V53, P3472; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890	34	114	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3511	3517		10.1038/sj.onc.1206578	http://dx.doi.org/10.1038/sj.onc.1206578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789259				2022-12-28	WOS:000183399200001
J	Puccetti, E; Beissert, T; Guller, S; Li, JE; Hoelzer, D; Ottmann, OG; Ruthardt, M				Puccetti, E; Beissert, T; Guller, S; Li, JE; Hoelzer, D; Ottmann, OG; Ruthardt, M			Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis	ONCOGENE			English	Article						PML; arsenic; RAS; CML; APL; AML	ACUTE PROMYELOCYTIC LEUKEMIA; NF-KAPPA-B; TRIOXIDE-INDUCED APOPTOSIS; ALPHA FUSION PROTEIN; RETINOIC ACID; PREMATURE SENESCENCE; NUCLEAR-BODIES; MYELOID-LEUKEMIA; ONCOGENIC RAS; BCR-ABL	Since the 19th century, arsenic (As2O3) has been used in the treatment of chronic myelogenous leukemia (CML) characterized by the t(9;22) translocation. As2O3 induces complete remissions in patients with acute promyelocytic leukemia. The response to As2O3 is genetically determined by the t(15;17)- or the t(9;22)-specific fusion proteins PML/RARalpha or BCR/ABL. The PML portion of PML/RARalpha is crucial for the sensitivity to As2O3. PML is nearly entirely contained in PML/RARalpha. PML is upregulated by oncogenic RAS in primary fibroblasts. The aberrant kinase activity of BCR/ABL leads to constitutive activation of RAS. Therefore, we hypothesized that BCR/ABL could increase sensitivity to As2O2-induced apoptosis by modifying PML expression. To disclose the mechanism of As2O3-induced apoptosis in PML/RARalpha- and BCR/ABL-expressing cells, we focused on the role of PML for As2O3-induced cell death. Here we report that (i) sensitivity to As2O3-induced apoptosis of U937 cells can be increased either by overexpression of PML, or by conditional expression of activated RAS; (ii) also the expression of the t(8;21)-related AML-1/ETO increased sensitivity to As2O3-induced apoptosis; (iii) both BCR/ABL and AML-1/ETO activated RAS and modified the PML expression pattern; (iv) the expression of either BCR/ABL or AML-1/ETO rendered U937 cells sensitive to interferon alpha-induced apoptosis. In summary, these data suggest a crucial role of factors able to upregulate PML for As2O2-induced cell death.	Univ Frankfurt, Med Klin 3, Hamatol Abt, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Ruthardt, M (corresponding author), Univ Frankfurt Klinikum, Med Klin 3, Hamatol Abt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Ottmann, Oliver G/D-5007-2016	Ottmann, Oliver G/0000-0001-9559-1330; Ruthardt, Martin/0000-0003-1021-3811				Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Forkner CE, 1931, J AMER MED ASSOC, V97, P0003, DOI 10.1001/jama.1931.02730010007002; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lee RK, 1999, CANCER RES, V59, P5514; LISSAUER H, 1865, KLIN WOCHENSCHR, V2, P403; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182/blood.V98.13.3762; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.3.CO;2-2; Miller WH, 2002, CANCER RES, V62, P3893; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Puccetti E, 2000, CANCER RES, V60, P3409; Puccetti E, 2002, CANCER RES, V62, P7050; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SEARS DA, 1988, AM J MED SCI, V296, P85, DOI 10.1097/00000441-198808000-00001; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; STUURMAN N, 1992, J CELL SCI, V101, P773; VALENTINER W, 1865, BERL KLIN WOCHENSCHR, V2, P320; Villa E, 2001, AM J GASTROENTEROL, V96, P2973; Visani G, 2000, LEUKEMIA, V14, P22, DOI 10.1038/sj.leu.2401641; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	37	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6900	6908		10.1038/sj.onc.1206747	http://dx.doi.org/10.1038/sj.onc.1206747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534537				2022-12-28	WOS:000185843400011
J	De Falco, G; Bellan, C; Lazzi, S; Claudio, P; La Sala, D; Cinti, C; Tosi, P; Giordano, A; Leoncini, L				De Falco, G; Bellan, C; Lazzi, S; Claudio, P; La Sala, D; Cinti, C; Tosi, P; Giordano, A; Leoncini, L			Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms	ONCOGENE			English	Article						pRb2/p130; Tat; HIV; lymphoma; cell cycle	HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA PATHOGENESIS; LARGE T-ANTIGEN; TRANSGENIC MICE; CELL-CYCLE; GENE-EXPRESSION; GROWTH-FACTOR; IN-VIVO; PROTEIN; TYPE-1	Tat protein is an early nonstructural protein necessary for virus replication, which is secreted by infected cells and taken up by uninfected cells. Extensive evidence indicates that Tat may be a cofactor in the development of AIDS-related neoplasms. The molecular mechanism underlying Tat's oncogenic activity may include deregulation of cellular genes. Among these genes, it has recently been shown that pRb2/p130 oncosuppressor protein is one of the targets in the interaction between HIV gene product Tat and host proteins. However, whether the HIV-1 gene product Tat may inactivate the oncosuppressive function of pRb2/p130 has not yet been elucidated. Here, we show that mRNA levels of pRb2/p130 increase in the presence of Tat, whereas no change in the phosphorylation status of pRb2/p130 is observed. In addition, Tat can inhibit the growth control activity exerted by pRb2/p130 in the T98G cell line. Finally, Tat does not compete with E2F-4 in binding to pRb2/p130. The interaction between Tat and pRb2/p130 seems to result in the deregulation of the control exerted by pRb2/p130 on the cell cycle. Taken together, these results open a window on the role of pRb2/ p130 in AIDS-related oncogenesis.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; CNR, ITOI, Bologna Unit, I-40126 Bologna, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	leoncini, lorenzo/P-8361-2018; BELLAN, CRISTIANA/L-3903-2013; Giordano, Antonio/F-1927-2010; Lazzi, Stefano/P-8265-2018; BELLAN, CRISTIANA/ABG-4750-2021; Claudio, Pier Paolo/AAW-7282-2021; LEONCINI, Lorenzo/U-4413-2019	leoncini, lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007; Giordano, Antonio/0000-0002-5959-016X; Lazzi, Stefano/0000-0002-2218-3771; BELLAN, CRISTIANA/0000-0001-6119-9007; Claudio, Pier Paolo/0000-0001-7790-1622; LEONCINI, Lorenzo/0000-0002-7457-300X; Cinti, Caterina/0000-0001-8049-0369	NCI NIH HHS [R21-CA099955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA099955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Altavilla G, 1999, AM J PATHOL, V154, P1231, DOI 10.1016/S0002-9440(10)65375-8; Ambrosino C, 2002, J BIOL CHEM, V277, P31448, DOI 10.1074/jbc.M112398200; BARILLARI G, 1992, J IMMUNOL, V149, P3727; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Cinti C, 2000, CANCER RES, V60, P383; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Claudio PP, 2001, CANCER RES, V61, P462; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fiorelli V, 1999, J IMMUNOL, V162, P1165; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gaidano G, 1998, AM J PATHOL, V152, P623; Gatignol A, 2000, Adv Pharmacol, V48, P209; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; KIM CM, 1992, ONCOGENE, V7, P1525; Knowles DM, 1999, MODERN PATHOL, V12, P200; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736-1743.2001; Noonan D, 2000, Adv Pharmacol, V48, P229; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STEIN GS, 1999, MOL BASIS CELL CYCLE; Stiegler P, 1998, J CELL BIOCHEM, P30; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Vene R, 2001, CLIN EXP METASTAS, V18, P533, DOI 10.1023/A:1011991906685; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wu A, 1999, CANCER, V86, P2038, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2038::AID-CNCR22>3.0.CO;2-A; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823	48	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6214	6219		10.1038/sj.onc.1206637	http://dx.doi.org/10.1038/sj.onc.1206637			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679860				2022-12-28	WOS:000185506200011
J	Stoica, GE; Franke, TF; Moroni, M; Mueller, S; Morgan, E; Iann, MC; Winder, AD; Reiter, R; Wellstein, A; Martin, MB; Stoica, A				Stoica, GE; Franke, TF; Moroni, M; Mueller, S; Morgan, E; Iann, MC; Winder, AD; Reiter, R; Wellstein, A; Martin, MB; Stoica, A			Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway	ONCOGENE			English	Article						estradiol; estrogen receptor-alpha; ErbB2; Akt	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER-CELLS; SIGNAL-TRANSDUCTION PATHWAYS; STEROID-HORMONE RECEPTORS; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MCF-7 CELLS; TYROSINE KINASE; BINDING-SITES; TAMOXIFEN RESISTANCE	Epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), and heregulin-beta1 (HRG-beta1), can modulate the expression and activity of the estrogen receptor-alpha (ER-alpha) via the phosphatidylinositol 3-kinase (PI 3-K)/Akt pathway in the ER-alpha-positive breast cancer cell line, MCF-7. Estradiol can also rapidly activate PI 3-K/Akt in these cells (nongenomic effect). The recent study examines whether Akt is involved in the ER-alpha regulation by estradiol (genomic effect). Stable transfection of parental MCF-7 cells with a dominant-negative Akt mutant, as well as the PI 3-K inhibitors wortmannin and LY 294,002, blocked the effect of estradiol on ER-alpha expression and activity by 70-80 and 55-63%, respectively. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of estradiol. The changes in ER-alpha expression and activity were abrogated in response to estradiol by an arginine to cysteine mutation in the pleckstrin homology (PH) domain of Akt (R25C), suggesting the involvement of this amino acid in the interaction between Akt and ER-alpha. Experiments employing selective ErbB inhibitors demonstrate that the effect of estradiol on ER-a expression and activity is mediated by ErbB2 and not by EGFR. Moreover, anchorage-dependent and -independent growth assays, cell cycle and membrane ruffling analyses showed that Akt exerts estrogen-like activity on cell growth and membrane ruffling and that a selective ErbB2 inhibitor, but not anti-ErbB2 antibodies directed to the extracellular domain, can block these effects. In the presence of constitutively active Akt, tamoxifen only partially inhibits cell growth. In contrast, in cells stably transfected with either a dominant-negative Akt or with R25C-Akt, as well as in parental cells in the presence of a selective ErbB2 inhibitor, the effect of estradiol on anchorage-dependent and -independent cell growth was inhibited by 50-75 and 100%, respectively. Dominant-negative Akt inhibited membrane ruffling by 54%; however, R25C-Akt did not have any effect, suggesting that kinase activity plays an important role in this process. Scatchard analysis demonstrated a 67% reduction in estrogen-binding capacity in cells transfected with constitutively active Akt. No change in binding affinity of estradiol to the receptor was observed upon transfection with either Akt mutant. Taken together, our results suggest that estradiol treatment results in binding to membrane ER-alpha and interaction with a heterodimer containing ErbB2, leading to tyrosine phosphorylation. This results in the activation of PI 3-K and Akt. Akt, in turn, may interact with nuclear ER-alpha, altering its expression and activity.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Georgetown University; Georgetown University; Columbia University	Stoica, A (corresponding author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.			Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P30CA051008, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-51008, P50-CA-58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; Bacus SS, 1996, AM J PATHOL, V148, P549; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GUIOCHONMANTEL A, 1996, J STEROID BIOCHEM, V56, P1; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIM HH, 1994, J BIOL CHEM, V269, P24747; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; Normanno N, 1997, J MAMMARY GLAND BIOL, V2, P143, DOI 10.1023/A:1026351730785; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; REDDY KB, 1992, CANCER RES, V52, P3636; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; Salomon D S, 1988, Cancer Treat Res, V40, P363; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; SAPINO A, 1986, CANCER RES, V46, P2526; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P209; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vasudevan N, 2001, P NATL ACAD SCI USA, V98, P12267, DOI 10.1073/pnas.221449798; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Wen Y, 2000, CANCER RES, V60, P6841; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; WRIGHT C, 1992, J CLIN PATHOL, V45, P459, DOI 10.1136/jcp.45.5.459-b; ZEILLINGER R, 1989, ONCOGENE, V4, P109; Zhang K, 1996, J BIOL CHEM, V271, P3884	91	131	140	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7998	8011		10.1038/sj.onc.1206769	http://dx.doi.org/10.1038/sj.onc.1206769			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970748				2022-12-28	WOS:000185388200015
J	Iwahara, T; Akagi, T; Shishido, T; Hanafusa, H				Iwahara, T; Akagi, T; Shishido, T; Hanafusa, H			CrkII induces serum response factor activation and cellular transformation through its function in Rho activation	ONCOGENE			English	Article						CrkII; Rho; transformation	BINDING PROTEIN-RHO; HETEROTRIMERIC G-PROTEINS; GROWTH-FACTOR RECEPTOR; C-FOS PROMOTER; HTLV-I TAX; ADAPTER PROTEIN; V-CRK; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION	CrkII belongs to the adaptor protein family that plays a crucial role in signal transduction. In order to better understand the biological functions of CrkII, we focused on the regulation of gene expression by CrkII. Various transcriptional control elements were examined for their activation by CrkII-expression, and we found that CrkII selectively activates the serum response element (SRE), a transcriptional control element of immediate-early genes. This SRE activation induced by CrkII-overexpression was mediated by the serum response factor (SRF) via Rho. Indeed, we confirmed that the amount of activated Rho was increased in the CrkII-expressing cells. Moreover, we showed that when overexpressed, CrkII induces the cellular transformation of NIH 3T3 cells and that a dominant negative mutant of Rho suppresses this transformation, strongly suggesting that activation of Rho is essential for the transforming activity by CrkII. Furthermore, we also found that CrkII and Galpha12, a member of the heterotrimeric G proteins, synergistically activates Rho as well as the SRF, and that an SH3 mutant of CrkII can inhibit the Galpha12-induced activation of SRF. These results strongly suggest that CrkII is involved in the activation of Rho and SRF by Galpha12. Our study provides strong evidence that Rho activation plays a crucial role in CrkII-mediated signals to induce gene expression and cellular transformation.	Osaka Biosci Inst, Mol Oncol Lab, Osaka 5650874, Japan		Hanafusa, H (corresponding author), Osaka Biosci Inst, Mol Oncol Lab, 6-2-4 Furuedai, Osaka 5650874, Japan.	saburo@obisun1.obi.or.jp						Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; ALLEY MC, 1991, CANCER RES, V51, P1247; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; FUJII M, 1995, ONCOGENE, V11, P7; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Haskell MD, 2001, J CELL SCI, V114, P1699; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Posern G, 2000, ONCOGENE, V19, P6361, DOI 10.1038/sj.onc.1204027; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Stam JC, 2001, J BIOL CHEM, V276, P25176, DOI 10.1074/jbc.M009825200; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	82	15	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5946	5957		10.1038/sj.onc.1206633	http://dx.doi.org/10.1038/sj.onc.1206633			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955073				2022-12-28	WOS:000185137800003
J	Mikkelsen, RB; Wardman, P				Mikkelsen, RB; Wardman, P			Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms	ONCOGENE			English	Review						reactive oxygen; reactive nitrogen; nitric oxide radiation; signal transduction; redox	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; MITOCHONDRIAL PERMEABILITY TRANSITION; DNA-BINDING ACTIVITY; FLUORESCENT DYE 2'-7'-DICHLOROFLUORESCEIN; FREE-RADICAL FORMATION; SMOOTH-MUSCLE-CELLS; IONIZING-RADIATION; OXIDATIVE STRESS	In the past few years, nuclear DNA damage-sensing mechanisms activated by ionizing radiation have been identified, including ATM/ATR and the DNA-dependent protein kinase. Less is known about sensing mechanisms for cytoplasmic ionization events and how these events influence nuclear processes. Several studies have demonstrated the importance of cytoplasmic signaling pathways in cytoprotection and mutagenesis. For cytoplasmic signaling, radiation-stimulated reactive oxygen species (ROS) and reactive nitrogen species (RNS) are essential activators of these pathways. This review summarizes recent studies on the chemistry of radiation-induced ROS/RNS generation and emphasizes interactions between ROS and RNS and the relative roles of cellular ROS/RNS generators as amplifiers of the initial ionization events. Cellular mechanisms for regulating ROS/RNS levels are discussed. The mechanisms by which cells sense ROS/RNS are examined in terms of how ROS/RNS modify protein structure and function, for example, interactions with metal-thiol clusters, protein tyrosine nitration, protein cysteine oxidation, S-thiolation and S-nitrosylation. We propose that radiation-induced ROS are the initiators and that nitric oxide (NO.) or derivatives are the effectors activating these signal transduction pathways. In responding to cellular ionization events, the cell converts an oxidative signal to a nitrosative one because ROS are too reactive and unspecific in their reactions for regulatory purposes and the cell is equipped to precisely modulate NO. levels.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England	Virginia Commonwealth University; University of Oxford	Mikkelsen, RB (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, 401 Coll St, Richmond, VA 23298 USA.	rmikkels@vcu.edu			NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896, R25CA089055] Funding Source: NIH RePORTER; NCI NIH HHS [CA72955, CA65896, CA89055] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Balafanova Z, 2002, J BIOL CHEM, V277, P15021, DOI 10.1074/jbc.M112451200; Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BECIKMAN JS, 1996, AM J PHYSIOL, V271, pC1424; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Brune B, 2001, CELL SIGNAL, V13, P525, DOI 10.1016/S0898-6568(01)00175-9; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Cairo G, 2002, BIOCHEMISTRY-US, V41, P7435, DOI 10.1021/bi025756k; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Cordelier P, 1999, FASEB J, V13, P2037, DOI 10.1096/fasebj.13.14.2037; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Fitzhugh AL, 2000, FREE RADICAL BIO MED, V28, P1463, DOI 10.1016/S0891-5849(00)00251-3; Ford E, 2002, FREE RADICAL BIO MED, V32, P1314, DOI 10.1016/S0891-5849(02)00850-X; Ford E, 2002, J BIOL CHEM, V277, P2430, DOI 10.1074/jbc.M109310200; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Freeman SL, 2000, AM J PHYSIOL-GASTR L, V278, pG243, DOI 10.1152/ajpgi.2000.278.2.G243; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Gertzberg N, 2000, AM J RESP CELL MOL, V22, P105, DOI 10.1165/ajrcmb.22.1.3801; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Goda N, 1996, AM J PHYSIOL-HEART C, V271, pH1893, DOI 10.1152/ajpheart.1996.271.5.H1893; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Gudi T, 1996, J BIOL CHEM, V271, P4597; GUDZ TI, 1994, RADIAT RES, V138, P219; Gunther MR, 2002, TOXICOLOGY, V177, P1, DOI 10.1016/S0300-483X(02)00191-9; HABY C, 1994, J NEUROCHEM, V62, P496; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HASHIMOTO S, 1982, INT J RADIAT BIOL, V41, P303, DOI 10.1080/09553008214551761; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; Howe CJ, 2002, J BIOL CHEM, V277, P30469, DOI 10.1074/jbc.M205036200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; Janssens MY, 1998, CANCER RES, V58, P5646; JIN FM, 1993, J CHEM SOC PERK T 2, P1583, DOI 10.1039/p29930001583; Jourd'Heuil D, 2002, FREE RADICAL BIO MED, V33, P676, DOI 10.1016/S0891-5849(02)00955-3; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kettle AJ, 1997, REDOX REP, V3, P257, DOI 10.1080/13510002.1997.11747120; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kietzmann T, 2000, NEWS PHYSIOL SCI, V15, P202; Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kirsch M, 2002, BIOL CHEM, V383, P389, DOI 10.1515/BC.2002.043; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Kojima H, 2001, ANAL CHEM, V73, P1967, DOI 10.1021/ac001136i; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Lal M, 1997, J AM CHEM SOC, V119, P5735, DOI 10.1021/ja970744l; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Leach JK, 2001, CANCER RES, V61, P3894; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LONG CA, 1980, J PHYS CHEM-US, V84, P555, DOI 10.1021/j100442a023; Luxford C, 2000, CHEM RES TOXICOL, V13, P665, DOI 10.1021/tx000053u; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; LYMAR SV, 2001, MCGRAWHILL YB SCI TE, P263; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marchesi E, 1999, FREE RADICAL BIO MED, V26, P148, DOI 10.1016/S0891-5849(98)00174-9; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEISTER A, 1994, CANCER RES, V54, pS1969; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Narayanan PK, 1997, CANCER RES, V57, P3963; Nauser T, 2002, J PHYS CHEM A, V106, P4084, DOI 10.1021/jp025518z; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Niu XF, 1996, CIRC RES, V79, P992, DOI 10.1161/01.RES.79.5.992; Noble DR, 2000, NITRIC OXIDE-BIOL CH, V4, P392, DOI 10.1006/niox.2000.0291; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Patel KB, 2002, FREE RADICAL BIO MED, V32, P203, DOI 10.1016/S0891-5849(01)00777-8; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Pearce LL, 2002, J BIOL CHEM, V277, P13556, DOI 10.1074/jbc.M109838200; Pearce LL, 2001, NITRIC OXIDE-BIOL CH, V5, P128, DOI 10.1006/niox.2001.0338; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Phoa N, 2002, CARCINOGENESIS, V23, P469, DOI 10.1093/carcin/23.3.469; Phung YT, 1999, IUBMB LIFE, V48, P333, DOI 10.1080/152165499307062; Pineda-Molina E, 2001, BIOFACTORS, V15, P113, DOI 10.1002/biof.5520150213; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; Romashko DN, 1998, P NATL ACAD SCI USA, V95, P1618, DOI 10.1073/pnas.95.4.1618; ROOTS R, 1975, RADIAT RES, V64, P306, DOI 10.2307/3574267; ROSS AB, 1998, NDRL NIST SOLUTION K; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Schmidt K, 1997, N-S ARCH PHARMACOL, V355, P457, DOI 10.1007/PL00004969; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; St Croix CM, 2002, AM J PHYSIOL-LUNG C, V282, pL185, DOI 10.1152/ajplung.00267.2001; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STEVENSON MA, 1994, CANCER RES, V54, P12; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TODD DG, 1994, CANCER RES, V54, P5224; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tuttle S, 1998, INT J RADIAT ONCOL, V42, P833, DOI 10.1016/S0360-3016(98)00331-9; Uppu RM, 1999, J AM CHEM SOC, V121, P9738, DOI 10.1021/ja9921165; Vercesi AE, 1997, BIOSCIENCE REP, V17, P43, DOI 10.1023/A:1027335217774; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; von Sonntag C., 1997, PEROXYL RADICALS, P173; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; WARD JF, 1994, RADIAT RES, V138, pS85, DOI 10.2307/3578769; Ward Paul, 1995, P1; Wardman P, 2002, J FLUORESC, V12, P65, DOI 10.1023/A:1015363220266; Wardman P, 1998, CHEM FREE RADICALS, P155; Wardman P, 1999, CHEM FREE RADICALS, P289; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Williams D. L. H., 1988, NITROSATION; Williams DLH, 1997, NITRIC OXIDE-BIOL CH, V1, P522, DOI 10.1006/niox.1997.0159; WILLSON RL, 1977, CIBA F S, V51, P331; WILSON I, 1986, BIOCHEM PHARMACOL, V35, P21, DOI 10.1016/0006-2952(86)90547-2; Wink DA, 1995, TOXICOL LETT, V82-3, P221, DOI 10.1016/0378-4274(95)03557-5; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoo JC, 2000, FREE RADICAL BIO MED, V28, P390, DOI 10.1016/S0891-5849(99)00252-X; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2000, BIOCHEM PHARMACOL, V59, P1, DOI 10.1016/S0006-2952(99)00289-0; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	232	440	456	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5734	5754		10.1038/sj.onc.1206663	http://dx.doi.org/10.1038/sj.onc.1206663			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947383				2022-12-28	WOS:000185086100003
J	Ota, J; Yamashita, Y; Okawa, K; Kisanuki, H; Fujiwara, S; Ishikawa, M; Choi, YL; Ueno, S; Ohki, R; Koinuma, K; Wada, T; Compton, D; Kadoya, T; Mano, H				Ota, J; Yamashita, Y; Okawa, K; Kisanuki, H; Fujiwara, S; Ishikawa, M; Choi, YL; Ueno, S; Ohki, R; Koinuma, K; Wada, T; Compton, D; Kadoya, T; Mano, H			Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders	ONCOGENE			English	Article						acute myeloid leukemia; proteome; AC133; NuMA	MYELOID DIFFERENTIATION PROGRAM; DNA MICROARRAY ANALYSIS; S-TRANSFERASE-PI; GENE-EXPRESSION; CANCER-CELLS; PROTEINS; NUMA; IDENTIFICATION; PARKINSONISM; ORGANIZATION	DNA microarray analysis has been applied to identify molecular markers of human hematological malignancies. However, the relatively low correlation between the abundance of a given mRNA and that of the encoded protein makes it important to characterize the protein profile directly, or 'proteome,' of malignant cells in addition to the 'transcriptome.' To identify proteins specifically expressed in leukemias, here we isolated AC133(+) hematopoietic stem cell-like fractions from the bone marrow of 13 individuals with various leukemic disorders, and compared their protein profiles by two-dimensional electrophoresis. A total of 11 differentially expressed protein spots corresponding to 10 independent proteins were detected, and peptide fingerprinting combined with mass spectrometry of these proteins revealed them to include NuMA (nuclear protein that associates with the mitotic apparatus), heat shock proteins, and redox regulators. The abundance of NuMA in the leukemic blasts was significantly related to the presence of complex karyotype anomalies. Conditional expression of NuMA in a mouse myeloid cell line resulted in the induction of aneuploidy, cell cycle arrest in G(2)-M phases, and apoptosis. These results demonstrate the potential of proteome analysis with background-matched cell fractions obtained from fresh clinical specimens to provide insight into the mechanism of human leukemogenesis.	Jichi Med Sch, Div Funct Genom, Tochigi 3290498, Japan; Kirin Brewery Co Ltd, Div Pharmaceut, Pharmaceut Res Labs, Takasaki, Gumma 3701925, Japan; Jichi Med Sch, Div Hematol, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Tochigi 3290498, Japan; Jichi Med Sch, Dept Surg, Tochigi 3290498, Japan; Jichi Med Sch, Dept Gynecol, Tochigi 3290498, Japan; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Kirin Brewery Co Ltd, Div Pharmaceut, Prod Dept, R&D Ctr, Maebashi, Gumma 3710853, Japan	Jichi Medical University; Kirin Brewery Company Limited; Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Dartmouth College; Kirin Brewery Company Limited	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Tochigi 3290498, Japan.	hmano@jichi.ac.jp		Compton, Duane/0000-0002-4445-9118				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaul SC, 1998, ONCOGENE, V17, P907, DOI 10.1038/sj.onc.1202017; KAUL SC, 1995, FEBS LETT, V361, P269, DOI 10.1016/0014-5793(95)00177-B; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Makishima H, 2002, BRIT J HAEMATOL, V118, P462, DOI 10.1046/j.1365-2141.2002.03646.x; Matsumine H, 1997, AM J HUM GENET, V60, P588; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; OKUYAMA T, 1994, CANCER, V74, P1230, DOI 10.1002/1097-0142(19940815)74:4<1230::AID-CNCR2820740409>3.0.CO;2-0; Pang XP, 1997, ONCOL RES, V9, P623; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; ShimodaMatsubayashi S, 1997, NEUROLOGY, V49, P1257, DOI 10.1212/WNL.49.5.1257; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VOLM M, 1992, CANCER, V70, P764, DOI 10.1002/1097-0142(19920815)70:4<764::AID-CNCR2820700408>3.0.CO;2-M; Watarai H, 2000, ELECTROPHORESIS, V21, P460, DOI 10.1002/(SICI)1522-2683(20000101)21:2<460::AID-ELPS460>3.0.CO;2-P; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x	29	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5720	5728		10.1038/sj.onc.1206855	http://dx.doi.org/10.1038/sj.onc.1206855			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944923				2022-12-28	WOS:000184865900024
J	Ohira, M; Morohashi, A; Inuzuka, H; Shishikura, T; Kawamoto, T; Kageyama, H; Nakamura, Y; Isogai, E; Takayasu, H; Sakiyama, S; Suzuki, Y; Sugano, S; Goto, T; Sato, S; Nakagawara, A				Ohira, M; Morohashi, A; Inuzuka, H; Shishikura, T; Kawamoto, T; Kageyama, H; Nakamura, Y; Isogai, E; Takayasu, H; Sakiyama, S; Suzuki, Y; Sugano, S; Goto, T; Sato, S; Nakagawara, A			Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets	ONCOGENE			English	Article						neuroblastoma; expression profile; oligo-capping cDNA library; differentiation; regression; MYCN	N-MYC AMPLIFICATION; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; NEURO-BLASTOMA; RNA; ASSOCIATION; PROTEINS; LOCUS; GAIN; ONCOGENE	Neuroblastoma (NBL), one of the most common childhood solid tumors, has a distinct nature in different prognostic subgroups: NBL in patients under I year of age usually regresses spontaneously, whereas that in patients over 1 year of age often grows aggressively and eventually kills the patient. To understand the molecular mechanism of biology and tumorigenesis of NBL, we decided to perform a comprehensive approach to unveil the gene expression profiles among the NBL subsets. We constructed the subset-specific oligo-capping cDNA libraries from the primary NBL tissues with favorable (F: stage 1, high expression of TrkA and a single copy of MYCN) and unfavorable (UF: stage 3 or 4, decreased expression of TrkA and MYCN amplification) characteristics and randomly cloned 4654 cDNAs. Among 4243 cDNAs sequenced successfully, 1799 (42.4%) were the genes with unknown function. Excluding the housekeeping genes, an expression profile of each subset was extremely different. To determine the genes expressed differentially between F and UF subsets, we performed semiquantitative reverse transcriptase (RT)-PCR for each of the 1842 independent genes using RNA obtained from 16 F and 16 UF NBLs as template. This revealed that 278 genes were highly expressed in the F subset as compared to the UF one, while, surprisingly, only 27 genes were expressed at higher levels in the UF rather than the F subset. These differentially expressed genes included 194 genes with unknown function. Many of the genes expressed at high levels in the F subset were related to catecholamine biosynthesis, small GTPases, synapse formation, synaptic vesicle transport, and transcription factors regulating differentiation of the neural crest-derived cells. On the other hand, the genes expressed at high levels in the UF subset included transcription factors and/or receptors that might regulate neuronal growth and differentiation. The chromosomal mapping of those genes showed some clusters. Thus, our mass-identification and characterization of the differentially expressed genes between the subsets may become a powerful tool for finding the important genes of NBL as well as developing new diagnostic and therapeutic strategies against aggressive NBL.	Chiba Canc Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Tokyo, Dept Canc Virol, Inst Med Sci, Tokyo 1088639, Japan; Hisamitsu Co Inc, Chiyoda Ku, Tokyo 100622, Japan	Chiba Cancer Center; University of Tokyo	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							Abe A, 1999, J CLIN MICROBIOL, V37, P2899, DOI 10.1128/JCM.37.9.2899-2903.1999; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hishiki T, 1998, CANCER RES, V58, P2158; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Inoue K, 1999, J HEPATOL, V30, P801, DOI 10.1016/S0168-8278(99)80132-9; Kawamoto T, 2003, INT J ONCOL, V22, P815; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MARUYAMA K, 1994, GENE, V138, P171; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; NAKAGAWARA A, 1987, J PEDIATR SURG, V22, P895, DOI 10.1016/S0022-3468(87)80583-3; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1988, J PEDIATR SURG, V23, P346, DOI 10.1016/S0022-3468(88)80204-5; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NAKAGAWARA A, 1990, SURGERY, V107, P43; Nakagawara A, 1998, Hum Cell, V11, P115; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okutsu T, 2000, J BIOCHEM-TOKYO, V127, P475, DOI 10.1093/oxfordjournals.jbchem.a022630; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Plantaz D, 1997, AM J PATHOL, V150, P81; SAWADA T, 1984, LANCET, V2, P271; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAVC I, 1990, CANCER RES, V50, P1459; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Takita J, 1997, CANCER RES, V57, P907; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4	46	64	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5525	5536		10.1038/sj.onc.1206853	http://dx.doi.org/10.1038/sj.onc.1206853			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934113				2022-12-28	WOS:000184735000018
J	Carbone, M; Pass, HI; Miele, L; Bocchetta, M				Carbone, M; Pass, HI; Miele, L; Bocchetta, M			New developments about the association of SV40 with human mesothelioma	ONCOGENE			English	Article						SV40; mesothelioma; human cancer	LARGE T-ANTIGEN; HUMAN PLEURAL MESOTHELIOMA; DNA-SEQUENCES; HUMAN TUMORS; MALIGNANT MESOTHELIOMA; MOLECULAR-MECHANISMS; ABERRANT METHYLATION; GENE FAMILY; SIMIAN-VIRUS-40; CELL	Simian virus 40 (SV40) has been detected in human tumors in over 40 different laboratories. Many of these reports linked SV40 to human mesotheliomas. The Vaccine Safety Committee of the Institute of Medicine (IOM), National Academy of Sciences, USA, recently reviewed the evidence associating polio vaccines and/or SV40 with human tumors. The IOM conclusions about polio vaccines and human cancer were: (1) 'the evidence is inadequate to accept or reject a causal relation between SV40-containing polio vaccines and cancer' because the 'epidemiological studies are sufficiently flawed'; (2) 'the biological evidence is of moderate strength that SV40 exposure from the polio vaccines is related to SV40 infection in humans'. The epidemiological studies were considered flawed because it was not possible to distinguish reliably among exposed and nonexposed cohorts. Concerning SV40, the IOM concluded that (1) 'the evidence is strong that SV40 is a transforming virus; (2) the evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions' (IOM, 2002). Similar conclusions were reached at an International consensus meeting on SV40 and human tumors held at the University of Chicago in 2001. G Klein and C Croce, who chaired the final panel that reviewed all the published evidence linking SV40 to human tumors, stated that 'the presence of SV40 in human tumors has been convincingly demonstrated' (Klein et al, 2002). In addition, a workshop organized by the Biological Carcinogenesis Branch of the National Cancer Institute, Bethesda, MD, chaired by J Pagano, has reached similar conclusions (Wong et aL, 2002). Therefore, three independent scientific panels have all agreed that there is compelling evidence that SV40 is present in some human cancers and that SV40 could contribute to the pathogenesis of some of them. It should be noted that the presence of SV40 in mesothelioma and other human tumor types has been challenged by a research team that has consistently reported negative findings (Strickler et aL, 2001). However, a member of this research team has recently acknowledged - in sworn testimony -sensitivity problems and possible irregularities that raise concerns about these negative reports (MacLachlan, 2002). These revelations, together with the conclusions of the three independent panels mentioned above, appear to bring to an end the apparent controversy about the presence of SV40 in human mesotheliomas and brain tumors.	Loyola Univ, Dept Pathol, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Maywood, IL 60153 USA; Wayne State Univ, Sch Med, Karmanos Canc Ctr, Detroit, MI USA; Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL USA	Loyola University Chicago; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Carbone, M (corresponding author), Loyola Univ, Dept Pathol, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Room 205,2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		Miele, Lucio/0000-0002-5853-7287; Pass, Harvey/0000-0003-3222-3471				BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; CARBONE M, 2003, IN PRESS INT J CANC; Carroll-Pankhurst C, 2001, BRIT J CANCER, V85, P1295, DOI 10.1054/bjoc.2001.2065; De Rienzo A, 2002, J CELL BIOCHEM, V84, P455, DOI 10.1002/jcb.10058.abs; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Dhaene K, 1999, VIRCHOWS ARCH, V435, P1, DOI 10.1007/s004280050387; Emri S, 2000, ANTICANCER RES, V20, P891; Engels EA, 2002, INT J CANCER, V101, P348, DOI 10.1002/ijc.10621; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fisher SG, 1999, ANTICANCER RES, V19, P2173; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gordon GJ, 2002, ONCOL REP, V9, P631; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; Heinsohn S, 2000, ANTICANCER RES, V20, P4539; Hirvonen A, 1999, MOL CARCINOGEN, V26, P93, DOI 10.1002/(SICI)1098-2744(199910)26:2<93::AID-MC4>3.0.CO;2-Z; Hubner R, 2002, CANCER CAUSE CONTROL, V13, P121, DOI 10.1023/A:1014321729038; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; *IOM, 2002, IMM SAF REV SV40 CON; Jasani B, 1999, THORAX, V54, P750, DOI 10.1136/thx.54.8.750b; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; JENSEN F, 1964, J NATL CANCER I, V32, P917; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Leithner A, 2002, CANCER BIOL THER, V1, P375; MacLachlan DS, 2002, ANTICANCER RES, V22, P3495; MARK EJ, 1991, ANN NY ACAD SCI, V643, P196, DOI 10.1111/j.1749-6632.1991.tb24463.x; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; Mulatero C, 1999, THORAX, V54, P60, DOI 10.1136/thx.54.1.60; Olin P, 1998, DEV BIOL STAND, V94, P227; Pass HI, 1996, CANCER RES, V56, P4044; Ramael M, 1999, EUR RESPIR J, V14, P1381, DOI 10.1183/09031936.99.14613819; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Salewski H, 1999, CANCER RES, V59, P1980; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; Strickler HD, 2001, CANCER EPIDEM BIOMAR, V10, P523; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Testa JR, 1998, CANCER RES, V58, P4505; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; Toyooka S, 2001, CANCER RES, V61, P5727; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; Waheed I, 1999, CANCER RES, V59, P6068; Weggen S, 2000, BRAIN PATHOL, V10, P85; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	58	71	83	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5173	5180		10.1038/sj.onc.1206552	http://dx.doi.org/10.1038/sj.onc.1206552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910254				2022-12-28	WOS:000184615100008
J	Clancy, JL; Henderson, MJ; Russell, AJ; Anderson, DW; Bova, RJ; Campbell, IG; Choong, DYH; Macdonald, GA; Mann, GJ; Nolan, T; Brady, G; Olopade, OI; Woollatt, E; Davies, MJ; Segara, D; Hacker, NF; Henshall, SM; Sutherland, RL; Watts, CKW				Clancy, JL; Henderson, MJ; Russell, AJ; Anderson, DW; Bova, RJ; Campbell, IG; Choong, DYH; Macdonald, GA; Mann, GJ; Nolan, T; Brady, G; Olopade, OI; Woollatt, E; Davies, MJ; Segara, D; Hacker, NF; Henshall, SM; Sutherland, RL; Watts, CKW			EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer	ONCOGENE			English	Article						allelic imbalance; amplification; human neoplasms; gene expression; mutation	COMPARATIVE-GENOMIC-HYBRIDIZATION; POSTERIOR UVEAL MELANOMA; SQUAMOUS-CELL CARCINOMA; DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; OVARIAN-TUMORS; COPY NUMBER; FREQUENT MULTIPLICATION; CYTOGENETIC ANALYSIS	EDD (E3 isolated by differential display), located at chromosome 8q22.3, is the human orthologue of the Drosophila melanogaster tumour suppressor gene 'hyperplastic discs' and encodes a HECT domain E3 ubiquitin protein-ligase. To investigate the possible involvement of EDD in human cancer, several cancers from diverse tissue sites were analysed for allelic gain or loss (allelic imbalance, AI) at the EDD locus using an EDD-specific microsatellite, CEDD, and other polymorphic microsatellites mapped in the vicinity of the 8q22.3 locus. Of 143 cancers studied, 38 had AI at CEDD (42% of 90 informative cases). In 14 of these cases, discrete regions of imbalance encompassing 8q22.3 were present, while the remainder had more extensive 8q aberrations. AI of CEDD was most frequent in ovarian cancer (22/47 informative cases, 47%), particularly in the serous subtype (16/22, 73%), but was rare in benign and borderline ovarian tumours. AI was also common in breast cancer (31%), hepatocellular carcinoma (46%), squamous cell carcinoma of the tongue (50%) and metastatic melanoma (18%). AI is likely to represent amplification of the EDD gene locus rather than loss of heterozygosity, as quantitative RT-PCR and immunohistochemistry showed that EDD mRNA and protein are frequently overexpressed in breast and ovarian cancers, while among breast cancer cell lines EDD overexpression and increased gene copy number were correlated. These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; NIDCD, Mol Genet Lab, NIH, Rockville, MD USA; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia; Univ Queensland, Populat & Clin Sci Div, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Queensland, Dept Med, Brisbane, Qld, Australia; Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA; Womens & Childrens Hosp, Ctr Med Genet, Adelaide, SA, Australia; Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Peter Maccallum Cancer Center; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Sydney; Westmead Institute for Medical Research; University of Manchester; University of Chicago; University of Chicago Medical Center; Womens & Childrens Hospital Australia	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		campbell, Ian G/F-6006-2011; Sutherland, Robert L/A-8378-2008; henderson, Michelle/G-6657-2012; Mann, Graham J/G-4758-2014; Macdonald, Graeme A/K-4167-2013	Mann, Graham J/0000-0003-1301-405X; Macdonald, Graeme A/0000-0003-0929-110X; Campbell, Ian/0000-0002-7773-4155; Hacker, Neville/0000-0002-1445-2302				Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO;2-R; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Bova RJ, 1999, CLIN CANCER RES, V5, P2810; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Dahiya R, 1998, INT J ONCOL, V12, P811; Diebold J, 1996, LAB INVEST, V75, P473; ElNaggar AK, 1997, AM J SURG PATHOL, V21, P691, DOI 10.1097/00000478-199706000-00009; Fejzo MS, 1998, GENE CHROMOSOME CANC, V22, P105; Forozan F, 2000, CANCER RES, V60, P4519; FUJIWARA Y, 1993, CANCER RES, V53, P857; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hermsen MAJA, 1997, ORAL ONCOL, V33, P414, DOI 10.1016/S0964-1955(97)00031-6; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Indsto JO, 1998, CANCER GENET CYTOGEN, V100, P68, DOI 10.1016/S0165-4608(97)00016-2; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Knuutila S, 1998, AM J PATHOL, V152, P1107; Lee JD, 2002, DEVELOPMENT, V129, P5697, DOI 10.1242/dev.00159; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Mark HFL, 1997, PATHOBIOLOGY, V65, P184, DOI 10.1159/000164121; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; Mori Y, 2002, CANCER RES, V62, P3641; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NAWROZ H, 1994, CANCER RES, V54, P1152; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nogradi A, 1998, AM J PATHOL, V153, P1, DOI 10.1016/S0002-9440(10)65537-X; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Obata K, 1998, CANCER RES, V58, P2095; Orntoft TF, 2002, MOL CELL PROTEOMICS, V1, P37, DOI 10.1074/mcp.M100019-MCP200; Parrella P, 1999, CANCER RES, V59, P3032; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Pieretti M, 1995, INT J CANCER, V64, P434, DOI 10.1002/ijc.2910640614; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Seute A, 2001, INT J CANCER, V93, P80, DOI 10.1002/ijc.1296; Sisley K, 1997, GENE CHROMOSOME CANC, V19, P22, DOI 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2; Sutherland R.L., 1999, HUMAN CELL CULTURE, P79; Tsuneizumi M, 2001, CLIN CANCER RES, V7, P3526; vanDekken H, 1997, HISTOCHEM CELL BIOL, V108, P419, DOI 10.1007/s004180050182; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yokota T, 1999, CANCER LETT, V139, P7, DOI 10.1016/S0304-3835(98)00329-2	53	79	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5070	5081		10.1038/sj.onc.1206775	http://dx.doi.org/10.1038/sj.onc.1206775			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902990				2022-12-28	WOS:000184578900015
J	Kothari, S; Cizeau, J; McMillan-Ward, E; Israels, SJ; Bailes, M; Ens, K; Kirshenbaum, LA; Gibson, SB				Kothari, S; Cizeau, J; McMillan-Ward, E; Israels, SJ; Bailes, M; Ens, K; Kirshenbaum, LA; Gibson, SB			BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF	ONCOGENE			English	Article						hypoxia; cell death; tumor; BNIP3; EGF; IGF	MITOCHONDRIAL PERMEABILITY TRANSITION; ADVANCED BREAST-CANCER; TUMOR ANGIOGENESIS; INDUCED APOPTOSIS; PROTEIN BNIP3; BH3 DOMAIN; FACTOR-I; EXPRESSION; NIP3; HERCEPTIN	Hypoxic regions within solid tumors are often resistant to chemotherapy and radiation. BNIP3 (Bcl-2/E1B 19 kDa interacting protein) is a proapoptotic member of the Bcl-2 family that is expressed in hypoxic regions of tumors. During hypoxia, BNIP3 expression is increased in many cell types and upon forced overexpression BNIP3 induces cell death. Herein, we have demonstrated that blockage of hypoxia-induced BNIP3 expression using antisense oligonucleotides against BNIP3 or blockage of BNIP3 function through expression of a mutant form of BNIP3 inhibits hypoxia-induced cell death in human embryonic kidney 293 cells. We have also determined that hypoxia-mediated BNIP3 expression is regulated by the transcription factor, hypoxia-inducible factor-1alpha (HIF-1alpha) in human epithelial cell lines. Furthermore, HIF-1alpha directly binds to a consensus HIF-1alpha-responsive element (HRE) in the human BNIP3 promoter that upon mutation of this HRE site eliminates the hypoxic responsiveness of the promoter. Since BNIP3 is expressed in hypoxic regions of tumors but fails to induce cell death, we determined whether growth factors block BNIP3-induced cell death. Treatment of the breast cancer cell line MCF-7 cells with epidermal growth factor (EGF) or insulin-like growth factor effectively protected these cells from BNIP3-induced cell death. Furthermore, inhibiting EGF receptor signaling using antibodies against ErbB2 (Herceptin) resulted in increased hypoxia-induced cell death in MCF-7 cells. Taken together, BNIP3 plays a role in hypoxia-induced cell death in human epithelial cells that could be circumvented by growth factor signaling.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Biochem & Med Genet, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB, Canada.		Kirshenbaum, Lorrie A./F-5742-2014; Israels, Sara/ABC-3684-2021	Israels, Sara/0000-0002-1849-4825; Ryplanski, Kairee/0000-0002-3737-7181; Gibson, Spencer/0000-0003-0119-732X				Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burris HA, 2000, SEMIN ONCOL, V27, P19; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Farooq M, 2001, EXP MOL MED, V33, P169, DOI 10.1038/emm.2001.29; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Giatromanolaki A, 2001, ANTICANCER RES, V21, P4317; Gibson EM, 2002, CANCER RES, V62, P488; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Goonewardene TI, 2002, MICROSC RES TECHNIQ, V59, P41, DOI 10.1002/jemt.10175; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellermann JP, 2002, AM J MED, V113, P324, DOI 10.1016/S0002-9343(02)01185-3; Hochachka PW, 2002, BIOESSAYS, V24, P749, DOI 10.1002/bies.10131; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hung MC, 1999, SEMIN ONCOL, V26, P51; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314; Koukourakis MI, 2001, ANTICANCER RES, V21, P4285; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leek RD, 2002, CANCER RES, V62, P1326; Miura M, 2000, METHOD ENZYMOL, V322, P480; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Mrsic M, 2001, ANN ONCOL, V12, P95, DOI 10.1023/A:1011116224931; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Seigel G, 2000, MOL VIS, V6, P157; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Sowter HM, 2001, CANCER RES, V61, P6669; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	45	168	179	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4734	4744		10.1038/sj.onc.1206666	http://dx.doi.org/10.1038/sj.onc.1206666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879018				2022-12-28	WOS:000184157000014
J	Peller, S; Frenkel, J; Lapidot, T; Kahn, J; Rahimi-Levene, N; Yona, R; Nissim, L; Goldfinger, N; Sherman, DJ; Rotter, V				Peller, S; Frenkel, J; Lapidot, T; Kahn, J; Rahimi-Levene, N; Yona, R; Nissim, L; Goldfinger, N; Sherman, DJ; Rotter, V			The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts	ONCOGENE			English	Article						p53; erythropoiesis; differentiation; apoptosis	WILD-TYPE P53; ERYTHROID PRECURSORS; CASPASE ACTIVATION; DNA-DAMAGE; PROTEIN; EXPRESSION; CELLS; ERYTHROPOIETIN; DEATH; GENE	The p53 tumor suppressor gene was found to play a role in the differentiation of several tissue types. We report here that p53-dependent apoptosis plays a role in the final stages of physiological differentiation of normoblasts, resulting in nuclear condensation and expulsion without cell death. Blood samples of healthy newborns, cord blood as well as bone marrow, were analysed for apoptosis by TUNEL and p53 expression by immunostaining. While some samples exhibited simultaneously several distinct patterns of apoptosis, such as perinuclear, diffused nuclear or nuclear apoptotic bodies, others presented a single defined pattern. Overexpression of p53 protein was detected in normoblasts exhibiting either perinuclear or diffused nuclear p53, corresponding to the nuclear apoptotic pattern in the same sample. Similar results were also evident with colonies cultivated for 12-14 days in culture. Differentiated erythroid colonies exhibited overexpression of p53 and positive TUNEL staining only in the normoblasts. We further examined the state of caspase 3/7 and observed a decrease of this activated enzyme during erythroid differentiation in culture. This study suggests a novel role for apoptosis in normoblast differentiation where nuclear degradation occurs with a delay in the actual cell death. A pivotal role for the p53-dependent apoptosis in the erythroid lineage development is implied. However, this apoptotic process is not fully executed because of the exhaustion in caspase 3/7 and thus cells are diverted towards final stages of differentiation.	Assaf Harofeh Med Ctr, Dept Hematol, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Obstet & Gynecol, IL-70300 Zerifin, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Weizmann Institute of Science; Weizmann Institute of Science	Peller, S (corresponding author), Assaf Harofeh Med Ctr, Dept Hematol, IL-70300 Zerifin, Israel.	SPELLER@asaf.health.gov.il	Lapidot, Tsvee/A-1812-2010	Nissim, Lior/0000-0001-6495-4741				Aljurf M, 1996, BLOOD, V87, P2049; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BETKE K, 1967, NATURE, V214, P188, DOI 10.1038/214188a0; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KASTAN MB, 1991, CANCER RES, V51, P4279; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; KELLEY LL, 1993, BLOOD, V82, P2340; KELLY RM, 1994, WOMEN POLIT, V14, P3; Kollet O, 1999, BLOOD, V94, P923, DOI 10.1182/blood.V94.3.923.415k08_923_931; Koury MJ, 1997, BLOOD, V89, P4617, DOI 10.1182/blood.V89.12.4617; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; Mahdi T, 1996, EXP HEMATOL, V24, P702; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1998, NEW ENGL J MED, V338, P564, DOI 10.1056/NEJM199802263380902; WINTROBE, 1999, WINTROBES CLIN HEMAT; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN J, 1993, BLOOD, V82, P374, DOI 10.1182/blood.V82.2.374.bloodjournal822374; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	37	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4648	4655		10.1038/sj.onc.1206541	http://dx.doi.org/10.1038/sj.onc.1206541			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879009				2022-12-28	WOS:000184157000005
J	Yam, JWP; Chan, KW; Hsiao, WLW				Yam, JWP; Chan, KW; Hsiao, WLW			Transcriptional regulation of the promoter of the rat frizzled related protein gene by CREB	ONCOGENE			English	Article						rat frizzled related protein (rFrp); transcriptional regulation; CREB	BETA-CATENIN; MOLECULAR-CLONING; SPEMANN ORGANIZER; COLON-CARCINOMA; BREAST-TUMORS; CYCLIN D1; C-MYC; BINDING; EXPRESSION; APOPTOSIS	Frizzled related proteins (Frps) are secreted proteins structurally similar to frizzled receptors; they bind Wnt via the cysteine-rich domain and antagonize the Wnt signaling pathway. In this study, we have investigated the mechanisms regulating the transcriptional regulation of rat Frp (rFrp) promoter. From previous findings, we know that the transcriptional activation domain of rFrp resides in the region -202 to -144 relative to the transcription start site, and that it is essential for efficient promoter activity. The study presented here was designed to identify trans-acting factors that bind to this critical domain of the rFrp promoter and to elucidate the pathway involved in the regulation of rFrp expression. Electrophoretic mobility shift assay (EMSA) demonstrated that specific DNA protein binding activities fall into two adjacent core sequences with (CTTTGGGGG) at -197 to -189 and (AGATGATGTAA) at -151 to -141 of the rFrp promoter. Reporter assay showed that these core sequences are both required for the activation of rFrp promoter. Mutation within either one or both core sequence drastically reduced the promoter activity. Southwestern blotting showed that the estimated molecular mass of the distinct binding protein to the (AGATGATGTAA) domain is about 43 kDa. Further EMSA suggested CREB as the trans-acting factor in the DNA-protein complex, which was out competed by CREB consensus oligonucleotides and supershifted by anti-CREB antibody. Overexpression of PKA and CREB also transactivated rFrp promoter, and dominant-negative CREB inhibited the promoter activity in transient reporter assays. More importantly, CREB, phosphorylated CREB and the adaptor protein CBP were found binding to the endogenous rFrp promoter using chromatin immunoprecipitation assay. Collectively, our results demonstrate the induction of rFrp promoter activity by PKA and CREB in vitro, and the binding of CREB and CBP to the rFrp promoter core motif in vivo.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Hsiao, WLW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.		; Yam, Judy Wai Ping/C-4454-2009	Hsiao, W.L.Wendy/0000-0002-9113-8819; Yam, Judy Wai Ping/0000-0002-5637-121X				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Bui TD, 1997, GENE, V189, P25, DOI 10.1016/S0378-1119(96)00808-6; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Dennis S, 1999, J CELL SCI, V112, P3815; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; James IE, 2000, OSTEOARTHR CARTILAGE, V8, P452, DOI 10.1053/joca.1999.0321; Katoh M, 2001, BIOCHEM BIOPH RES CO, V282, P116, DOI 10.1006/bbrc.2001.4551; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LeGros L, 2001, J BIOL CHEM, V276, P24918, DOI 10.1074/jbc.M102816200; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Preiherr J, 2000, ANTICANCER RES, V20, P2255; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schumann H, 2000, CARDIOVASC RES, V45, P720, DOI 10.1016/S0008-6363(99)00376-4; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Xu LF, 2000, GENE DEV, V14, P585; Yam JWP, 2001, BIOCHEM BIOPH RES CO, V286, P94, DOI 10.1006/bbrc.2001.5349; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	50	4	4	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3901	3910		10.1038/sj.onc.1206489	http://dx.doi.org/10.1038/sj.onc.1206489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813463				2022-12-28	WOS:000183612000009
